PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Geanacopoulos, M; Adhya, S				Geanacopoulos, M; Adhya, S			Genetic analysis of GalR tetramerization in DNA looping during repressosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MUTAGENESIS; REPRESSION; HU	The Gal repressosome is a nucleoprotein complex consisting of 2 GalR dimers, 1 HU, and 1 DNA loop, which represses the transcription of the gal operon. We have adopted a structure-based genetic approach to complement ongoing physical studies of the complex. Homology-based and subsequent alanine-scanning mutageneses suggest that five residues in the DNA-distal subdomain of GalR dimer are important for repressosome formation. A further analysis of these and intragenic suppressors of looping-defective GalR mutants as well as gain-of-function mutants that permit repressosome assembly in the absence of HU show that GalR dimers contact each other in the repressosome in a partially stacked configuration.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Adhya, S (corresponding author), NCI, Mol Biol Lab, NIH, 37 Convent Dr,MSC 4264,Rm 5138, Bethesda, MD 20892 USA.							ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; Aki T, 1997, EMBO J, V16, P3666, DOI 10.1093/emboj/16.12.3666; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; Choy HE, 1997, J MOL BIOL, V272, P293, DOI 10.1006/jmbi.1997.1221; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Geanacopoulos M, 1999, GENE DEV, V13, P1251, DOI 10.1101/gad.13.10.1251; Geanacopoulos M, 2001, NAT STRUCT BIOL, V8, P432, DOI 10.1038/87595; Kar S, 2001, GENE DEV, V15, P2273, DOI 10.1101/gad.920301; Lewis DEA, 1999, MOL MICROBIOL, V31, P451, DOI 10.1046/j.1365-2958.1999.01186.x; Milsom SE, 2001, J MOL BIOL, V311, P515, DOI 10.1006/jmbi.2001.4893; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Tsodikov OV, 1999, J MOL BIOL, V294, P639, DOI 10.1006/jmbi.1999.3283; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X	15	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33148	33152		10.1074/jbc.M202445200	http://dx.doi.org/10.1074/jbc.M202445200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12065579	hybrid			2022-12-25	WOS:000177859000097
J	Josse, D; Ebel, C; Stroebel, D; Fontaine, A; Borges, F; Echalier, A; Baud, D; Renault, F; le Maire, M; Chabrieres, E; Masson, P				Josse, D; Ebel, C; Stroebel, D; Fontaine, A; Borges, F; Echalier, A; Baud, D; Renault, F; le Maire, M; Chabrieres, E; Masson, P			Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ESTER TRANSFER PROTEIN; THIOL CROSS-LINKING; A-I; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; HUMAN-PLASMA; PURIFICATION; DIMERIZATION; BINDING	Human plasma paraoxonase (HuPON1) is a high density lipoprotein (HDL)-bound enzyme exhibiting anti-atherogenic properties. The molecular basis for the binding specificity of HuPON1 to HDL has not been established. Isolation of HuPON1 from HDL requires the use of detergents. We have determined the activity, dispersity, and oligomeric states of HuPON1 in solutions containing mild detergents using nondenaturing electrophoresis, size exclusion chromatography, and crosslinking. HuPON1 was active whatever its oligomeric state. In nonmicellar solutions, HuPON1 was polydisperse. In contrast, HuPON1 exhibited apparent homogeneity in micellar solutions, except with CHAPS. The enzyme apparent hydrodynamic radius varied with the type of detergent and protein concentration. In C12E8 micellar solutions, from sedimentation velocity, equilibrium analytical ultracentrifugation, and radioactive detergent binding, HuPON1 was described as monomers and dimers in equilibrium. A decrease of the detergent concentration shifted this equilibrium toward the formation of dimers. About 100 detergent molecules were associated per monomer and dimer. The assembly of amphiphilic molecules, phospholipids in vivo, in sufficiently large aggregates could be a prerequisite for anchoring of HuPON1 and then allowing stabilization of the enzyme activity. Changes of HDL size and shape could strongly affect the binding affinity and stability of HuPON1 and result in reduced antioxidative capacity of the lipoprotein.	Ctr Rech Serv Sante Armees, Unite Enzymol, F-38702 La Tronche, France; UJF, UMR 5075 CNRS, CEA,Lab Biol Mol, Inst Biol Struct JP Ebel, F-38027 Grenoble 01, France; Univ Paris 11, CEA, URA CNRS 2096, SBFM,DBJC, F-91191 Gif Sur Yvette, France; Univ Paris 11, CEA, LRA17V, F-91191 Gif Sur Yvette, France; Univ Nancy 1, LCM3B, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Universite de Lorraine	Josse, D (corresponding author), USA, Med Res Inst Chem Def, 3100 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010 USA.		Masson, Patrick/AAA-7213-2019; Borges, Frédéric/A-7012-2012; Masson, Patrick YM/J-3964-2013	Masson, Patrick/0000-0002-7837-3662; Masson, Patrick YM/0000-0002-7837-3662; Ebel, Christine/0000-0002-6912-500X; Borges, Frederic/0000-0002-6159-5509				Ahmed Z, 2001, J BIOL CHEM, V276, P24473, DOI 10.1074/jbc.M010459200; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P6450; Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; BRUCE C, 1995, J BIOL CHEM, V270, P11532, DOI 10.1074/jbc.270.19.11532; Brushia RJ, 2001, J LIPID RES, V42, P951; Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Deakin S, 2002, J BIOL CHEM, V277, P4301, DOI 10.1074/jbc.M107440200; Dekker N, 1997, J BIOL CHEM, V272, P3179, DOI 10.1074/jbc.272.6.3179; Ferretti G, 2001, ACTA DIABETOL, V38, P163, DOI 10.1007/s592-001-8074-z; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; FURLONG CE, 1991, BIOCHEMISTRY-US, V30, P10133, DOI 10.1021/bi00106a009; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; GELDMACHERVONMALLINCKRODT M, 1988, TOXICOL ENVIRON CHEM, V18, P79, DOI 10.1080/02772248809357310; HARLAN JE, 1995, ANAL BIOCHEM, V224, P557, DOI 10.1006/abio.1995.1087; HESLER CB, 1987, J BIOL CHEM, V262, P2275; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; James RW, 1998, ATHEROSCLEROSIS, V139, P77, DOI 10.1016/S0021-9150(98)00058-6; Jin LH, 1997, J LIPID RES, V38, P1085; Josse D, 1999, BIOCHEMISTRY-US, V38, P2816, DOI 10.1021/bi982281h; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P832, DOI 10.1021/bi00169a026; KUO CL, 1995, DRUG METAB DISPOS, V23, P935; Kwaw I, 2000, BIOCHEMISTRY-US, V39, P3134, DOI 10.1021/bi992509g; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; Mackness B, 2002, EUR J CLIN INVEST, V32, P259, DOI 10.1046/j.1365-2362.2002.00977.x; Mackness MI, 2000, CURR OPIN LIPIDOL, V11, P383, DOI 10.1097/00041433-200008000-00007; MARGOLIS J, 1968, ANAL BIOCHEM, V25, P347, DOI 10.1016/0003-2697(68)90109-7; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; Musatov A, 2002, BIOCHEMISTRY-US, V41, P4371, DOI 10.1021/bi016080g; Nagy JK, 2000, BIOCHEMISTRY-US, V39, P4154, DOI 10.1021/bi991781n; Navab M, 2000, J LIPID RES, V41, P1495; Ng CJ, 2001, J BIOL CHEM, V276, P44444, DOI 10.1074/jbc.M105660200; Noto H, 2001, BIOCHEM BIOPH RES CO, V289, P395, DOI 10.1006/bbrc.2001.5985; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Reddy ST, 2001, ARTERIOSCL THROM VAS, V21, P542, DOI 10.1161/01.ATV.21.4.542; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Rudel L L, 1986, Methods Enzymol, V129, P45; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SEIGNEURET M, 1991, J BIOL CHEM, V266, P10066; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; TANFORD C, 1974, J PHYS CHEM-US, V78, P2469, DOI 10.1021/j100617a012; TANFORD C, 1969, J MOL BIOL, V39, P539, DOI 10.1016/0022-2836(69)90143-0; TANFORD C, 1991, HYDROPHOBIC EFFECT F, P149; Valabhji J, 2001, CLIN SCI, V101, P659, DOI 10.1042/CS20010111; WYMAN J, 1964, ADVANCES PROTEIN CHE, V19, P224	55	59	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33386	33397		10.1074/jbc.M200108200	http://dx.doi.org/10.1074/jbc.M200108200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080042	hybrid			2022-12-25	WOS:000177859000128
J	Kottra, G; Stamfort, A; Daniel, H				Kottra, G; Stamfort, A; Daniel, H			PEPT1 as a paradigm for membrane carriers that mediate electrogenic bidirectional transport of anionic, cationic, and neutral substrates.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED OLIGOPEPTIDE TRANSPORTER; XENOPUS-LAEVIS OOCYTES; RECOGNITION; AFFINITY; STOICHIOMETRY; COTRANSPORTER; ANTIBIOTICS; DIPEPTIDES; INHIBITOR; SYMMETRY	The capability for electrogenic inward transport of substrates that carry different net charge is a phenomenon observed in a variety of membrane-solute transporters but is not yet understood. We employed the two-electrode voltage clamp technique combined with intracellular pH recordings and the giant patch technique to assess the selectivity for bidirectional transport and the underlying stoichiometries in proton to substrate flux coupling for electrogenic transfer of selected anionic, cationic, and neutral dipeptides by the intestinal peptide transporter PEPT1. Anionic dipeptides such as Gly-Asp and Asp-Gly are transported in their neutral and negatively charged forms with high and low affinities, respectively. The positive transport current obtained with monoanionic substrates results from the cotransport of two protons. Cationic dipeptides can be transported in neutral and positively charged form, resulting in an excess transport current as compared with neutral substrates. However, binding and transport of cationic dipeptides shows a pronounced selectivity for the position of charged side chains demonstrating that the binding domain of PEPT1 is asymmetric, both in its inward and outward facing conformation. The simultaneous presence of identically charged substrates on both membrane surfaces generates outward and, unexpectedly, enhanced inward transport currents probably by increasing the turnover rate.	Tech Univ Munich, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Kottra, G (corresponding author), Tech Univ Munich, Mol Nutr Unit, Hochfeldweg 2, D-85356 Freising Weihenstephan, Germany.		Daniel, Hannelore/B-8982-2009					Amasheh S, 1997, J MEMBRANE BIOL, V155, P247, DOI 10.1007/s002329900177; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; Fei YJ, 1999, BBA-BIOMEMBRANES, V1418, P344, DOI 10.1016/S0005-2736(99)00046-2; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; Knutter I, 2001, BIOCHEMISTRY-US, V40, P4454, DOI 10.1021/bi0026371; Kottra G, 2001, J PHYSIOL-LONDON, V536, P495, DOI 10.1111/j.1469-7793.2001.0495c.xd; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mackenzie B, 1996, BBA-BIOMEMBRANES, V1284, P125, DOI 10.1016/S0005-2736(96)00170-8; Meredith D, 1998, J PHYSIOL-LONDON, V512, P629, DOI 10.1111/j.1469-7793.1998.629bd.x; Nussberger S, 1997, J BIOL CHEM, V272, P7777, DOI 10.1074/jbc.272.12.7777; Sawada K, 1999, J PHARMACOL EXP THER, V291, P705; SEKI G, 1993, PFLUG ARCH EUR J PHY, V425, P409, DOI 10.1007/BF00374866; SOBER HA, 1970, CRC HDB BIOCHEM SELE, P486; Steel A, 1997, J PHYSIOL-LONDON, V498, P563, DOI 10.1113/jphysiol.1997.sp021883; Takahashi K, 1998, J PHARMACOL EXP THER, V286, P1037; Tateoka R, 2001, BIOCONJUGATE CHEM, V12, P485, DOI 10.1021/bc000135u; Temple CS, 1998, J BIOL CHEM, V273, P20, DOI 10.1074/jbc.273.1.20; Terada T, 2000, PFLUG ARCH EUR J PHY, V440, P679, DOI 10.1007/s004240000339; Theis S, 2002, MOL PHARMACOL, V61, P214, DOI 10.1124/mol.61.1.214; Wenzel U, 1996, J PHARMACOL EXP THER, V277, P831	21	52	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32683	32691		10.1074/jbc.M204192200	http://dx.doi.org/10.1074/jbc.M204192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082113	hybrid			2022-12-25	WOS:000177859000038
J	Li, YM; Syvitski, RT; Auclair, K; Wilks, A; de Montellano, PRO; La Mar, GN				Li, YM; Syvitski, RT; Auclair, K; Wilks, A; de Montellano, PRO; La Mar, GN			Solution NMR characterization of an unusual distal H-bond network in the active site of the cyanide-inhibited, human heme oxygenase complex of the symmetric substrate, 2,4-dimethyldeuterohemin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ELECTRONIC CONTROL; RESONANCE RAMAN; CATALYTIC SITE; HMU O; DEGRADATION; ORIENTATION; MECHANISM; PROTEIN; EXPRESSION	The presence of variable static hemin orientational disorder about the alpha-gamma-meso axis in the substrate complexes of mammalian heme oxygenase, together with the incomplete averaging of a second, dynamic disorder, for each hemin orientation, has led to NMR spectra with severe spectral overlap and loss of key two-dimensional correlations that seriously interfere with structural characterization in solution. We demonstrate that the symmetric substrate, 2,4-dimethyldeuterohemin, yields a single solution species for which the dynamic disorder is sufficiently rapid to allow effective and informative H-1 NMR structural characterization. A much more extensive, effective, and definitive NMR characterization of the cyanide-inhibited, symmetric heme complex of human heme oxygenase shows that the active site structure, with some minor differences, is essentially the same as that for the native protohemin in solution and crystal. A unique distal network that involves particularly strong hydrogen bonds, as well as inter-aromatic contacts, is described that is proposed to stabilize the position of the catalytically critical distal helix Asp-140 carboxylate (Liu, Y., Koenigs Lightning, L., Huang, H., Moenne-Loccoz, P., Schuller, D. J., Poulos, T. L., Loehr, T. M., and Ortiz de Montellano, P. R. (2000) J. Biol. Chem. 275,34501-34507). The potential role of this network in placing a water molecule to stabilize the hydroperoxy species and as a template for the condensation of the distal helix upon substrate binding are discussed.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California Davis; University of California System; University of California San Francisco	La Mar, GN (corresponding author), Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA.	lamar@indigo.ucdavis.edu			NHLBI NIH HHS [HL 16087] Funding Source: Medline; NIDDK NIH HHS [DK 30297] Funding Source: Medline; NIGMS NIH HHS [GM 62380] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016087, R01HL016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; Bertini I, 1996, COORDIN CHEM REV, V151, P145, DOI 10.1016/S0010-8545(96)90203-9; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; CROSS KJ, 1985, J MAGN RESON, V64, P220, DOI 10.1016/0022-2364(85)90346-4; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; GRIESINGER C, 1988, J AM CHEM SOC, V65, P355; Harris TK, 1999, PROTEINS, V35, P275, DOI 10.1002/(SICI)1097-0134(19990515)35:3<275::AID-PROT1>3.0.CO;2-V; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jeffery G.A., 1997, INTRO HYDROGEN BONDI; La Mar GN, 2001, J BIOL CHEM, V276, P15676, DOI 10.1074/jbc.M009974200; LAMAR GN, 1986, J AM CHEM SOC, V108, P5568, DOI 10.1021/ja00278a033; LEMAR GN, 1999, PORPHYRIN HDB, V5, P185; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P34501, DOI 10.1074/jbc.M004245200; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1992, HEMEOXYGENASE CLIN A; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Nguyen BD, 1999, J AM CHEM SOC, V121, P208, DOI 10.1021/ja982555o; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; SCHULLER DJ, 2001, HDB METALLOPROTEINS, V1, P317; Shokhirev NV, 1998, J BIOL INORG CHEM, V3, P581, DOI 10.1007/s007750050271; SMITH KM, 1983, J CHEM SOC PERK T 1, P2329, DOI 10.1039/p19830002329; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Torpey J, 1997, J BIOL CHEM, V272, P22008, DOI 10.1074/jbc.272.35.22008; Torpey J, 1996, J BIOL CHEM, V271, P26067, DOI 10.1074/jbc.271.42.26067; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; WILLIAMS G, 1985, J MOL BIOL, V183, P447, DOI 10.1016/0022-2836(85)90013-0; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WUTHRICH K, 1983, NMR PROTEINS NUCL AC, P130; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	51	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33018	33031		10.1074/jbc.M204216200	http://dx.doi.org/10.1074/jbc.M204216200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12070167	hybrid			2022-12-25	WOS:000177859000082
J	Modrof, J; Muhlberger, E; Klenk, HD; Becker, S				Modrof, J; Muhlberger, E; Klenk, HD; Becker, S			Phosphorylation of VP30 impairs Ebola virus transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; BACTERIOPHAGE-T7 RNA-POLYMERASE; PROTEIN PHOSPHATASE 2A; OKADAIC ACID; MARBURG-VIRUS; M2-1 PROTEIN; NUCLEOPROTEIN; INCLUSIONS; PROMOTER; CELLS	Transcription of the highly pathogenic Ebola virus (EBOV) is dependent on VP30, a constituent of the viral nucleocapsid complex. Here we present evidence that phosphorylation of VP30, which takes place at six N-terminal serine residues and one threonine residue, is of functional significance. Replacement of the phosphoserines by alanines resulted in an only slightly phosphorylated VP30 (VP30(6A)) that is still able to activate EBOV-specific transcription in a plasmid-based minigenome system. VP30(6A), however, did not bind to inclusions that are induced by the major nucleocapsid protein NP. Three intracellular phosphatases (PP1, PP2A, and PP2C) have been determined to dephosphorylate VP30. The presence of okadaic acid (OA), an inhibitor of PP1 and PP2A, had the same negative effect on transcription activation by VP30 as the substitution of the six phosphoserines for aspartate residues. OA, however, did not impair transcription when VP30 was replaced by VP30(6A). In EBOV-infected cells, OA blocked virus growth dose-dependently. The block was mediated by the extensive phosphorylation of VP30, which is evidenced by the result that expression of VP30(6A), in trans, led to the progression of EBOV infection in the presence of OA. In conclusion, phosphorylation of VP30 was shown to regulate negatively transcription activation and positively binding to the NP inclusions.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Becker, S (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.	becker@mailer.uni-marburg.de	Modrof, Jens/AAQ-8751-2020; Modrof, Jens/AAU-4681-2020; Muhlberger, Elke/AAD-6924-2019	Modrof, Jens/0000-0001-8416-7681; Muhlberger, Elke/0000-0003-3547-9376				[Anonymous], 2001, Wkly Epidemiol Rec, V76, P41; BECKER S, 1992, MED MICROBIOL IMMUN, V181, P43, DOI 10.1007/BF00193395; Benndorf R, 2001, J BIOL CHEM, V276, P26753, DOI 10.1074/jbc.M103001200; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; BOWEN ETW, 1977, LANCET, V1, P571; Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999; Cartee TL, 2001, J VIROL, V75, P12188, DOI 10.1128/JVI.75.24.12188-12197.2001; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Collins PL, 1996, P NATL ACAD SCI USA, V93, P81, DOI 10.1073/pnas.93.1.81; Conzelmann KK, 1998, ANNU REV GENET, V32, P123, DOI 10.1146/annurev.genet.32.1.123; Cuesta I, 2000, J VIROL, V74, P9858, DOI 10.1128/JVI.74.21.9858-9867.2000; ELLIOTT LH, 1985, VIROLOGY, V147, P169, DOI 10.1016/0042-6822(85)90236-3; Faulkner NE, 2001, J BIOL CHEM, V276, P25804, DOI 10.1074/jbc.M006454200; Fearns R, 1999, J VIROL, V73, P5852, DOI 10.1128/JVI.73.7.5852-5864.1999; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Garcia A, 2000, MICROBES INFECT, V2, P401, DOI 10.1016/S1286-4579(00)00327-0; GARCIA J, 1993, VIROLOGY, V195, P243, DOI 10.1006/viro.1993.1366; Geisbert TW, 1995, VIRUS RES, V39, P129, DOI 10.1016/0168-1702(95)00080-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hardy RW, 2000, J VIROL, V74, P5880, DOI 10.1128/JVI.74.13.5880-5885.2000; Hardy RW, 1998, J VIROL, V72, P520, DOI 10.1128/JVI.72.1.520-526.1998; Kolesnikova L, 2000, J VIROL, V74, P3899, DOI 10.1128/JVI.74.8.3899-3904.2000; Kuntziger T, 2001, MOL BIOL CELL, V12, P437, DOI 10.1091/mbc.12.2.437; Lenard J, 1999, PHARMACOL THERAPEUT, V83, P39, DOI 10.1016/S0163-7258(99)00016-9; Matias WG, 1996, J TOXICOL ENV HEALTH, V48, P309, DOI 10.1080/009841096161357; Modrof J, 2001, VIROLOGY, V287, P171, DOI 10.1006/viro.2001.1027; Muhlberger E, 1999, J VIROL, V73, P2333; Nagao M, 1995, MUTAT RES-FUND MOL M, V333, P173, DOI 10.1016/0027-5107(95)00143-3; Pushko P, 2000, VACCINE, V19, P142, DOI 10.1016/S0264-410X(00)00113-4; SANCHEZ A, 1989, VIROLOGY, V170, P81, DOI 10.1016/0042-6822(89)90354-1; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; *WHO, 1995, EPIDEMIOL B, V16, P16; *WHO, 1999, WKLY EPIDEMIOL REC, V74, P145; Yang Y, 1999, J VIROL, V73, P1661, DOI 10.1128/JVI.73.2.1661-1664.1999	39	99	106	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33099	33104		10.1074/jbc.M203775200	http://dx.doi.org/10.1074/jbc.M203775200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12052831	hybrid			2022-12-25	WOS:000177859000091
J	Singh, SK; Kurnasov, OV; Chen, BZ; Robinson, H; Grishin, NV; Osterman, AL; Zhang, H				Singh, SK; Kurnasov, OV; Chen, BZ; Robinson, H; Grishin, NV; Osterman, AL; Zhang, H			Crystal structure of Haemophilus influenzae NadR protein - A bifunctional enzyme endowed with NMN adenylyltransferase and ribosylnicotinamide kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; ADENYLATE KINASE; ESCHERICHIA-COLI; NAD(+) SYNTHESIS; BIOSYNTHESIS; CATALYSIS; BINDING; PARAINFLUENZAE; CONFORMATION	Haemophilus influenzae NadR protein (hiNadR) has been shown to be a bifunctional enzyme possessing both NMN adenylytransferase (NMNAT; EC 2.7.7.1) and ribosylnicotinamide kinase (RNK; EC 2.7.1.22) activities. Its function is essential for the growth and survival of H. influenzae and thus may present a new highly specific anti-infectious drug target. We have solved the crystal structure of hiNadR complexed with NAD using the selenomethionine MAD phasing method. The structure reveals the presence of two distinct domains. The N-terminal domain that hosts the NMNAT activity is closely related to archaeal NMNAT, whereas the C-terminal domain, which has been experimentally demonstrated to possess ribosylnicotinamide kinase activity, is structurally similar to yeast thymidylate kinase and several other P-loop-containing kinases. There appears to be no cross-talk between the two active sites. The bound NAD at the active site of the NMNAT domain reveals several critical interactions between NAD and the protein. There is also a second non-active-site NAD molecule associated with the C-terminal RNK domain that adopts a highly folded conformation with the nicotinamide ring stacking over the adenine base. Whereas the RNK domain of the hiNadR structure presented here is the first structural characterization of a ribosylnicotinamide kinase from any organism, the NMNAT domain of hiNadR defines yet another member of the pyridine nucleotide adenylyltransferase family.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Integrated Genom Inc, Chicago, IL 60612 USA; Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory	Zhang, H (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065243] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65243] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Begley TP, 2001, VITAM HORM, V61, P103; Bell CE, 1997, PROTEIN SCI, V6, P2084; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CYNAMON MH, 1988, J GEN MICROBIOL, V134, P2789; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; Daugherty M, 2002, J BIOL CHEM, V277, P21431, DOI 10.1074/jbc.M201708200; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; EVANS NM, 1974, J MED MICROBIOL, V7, P359, DOI 10.1099/00222615-7-3-359; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOSTER JW, 1987, MOL GEN GENET, V208, P279, DOI 10.1007/BF00330454; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Gingrich W, 1944, J BACTERIOL, V47, P535, DOI 10.1128/JB.47.6.535-550.1944; GODEK CP, 1990, ANTIMICROB AGENTS CH, V34, P1473, DOI 10.1128/AAC.34.8.1473; GRISHIN VN, 2002, IN PRESS BIOINFORMAT; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kemmer G, 2001, J BACTERIOL, V183, P3974, DOI 10.1128/JB.183.13.3974-3981.2001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lavie A, 1998, BIOCHEMISTRY-US, V37, P3677, DOI 10.1021/bi9720787; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Penfound T, 1999, J BACTERIOL, V181, P648, DOI 10.1128/JB.181.2.648-655.1999; Raffaelli N, 1997, J BACTERIOL, V179, P7718, DOI 10.1128/jb.179.24.7718-7723.1997; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Raffaelli N, 1999, J BACTERIOL, V181, P5509, DOI 10.1128/JB.181.17.5509-5511.1999; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; SARMA RH, 1968, BIOCHEMISTRY-US, V7, P3052, DOI 10.1021/bi00849a005; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; SHIFRINE M, 1960, NATURE, V187, P623, DOI 10.1038/187623a0; Smith PE, 1999, J AM CHEM SOC, V121, P8637, DOI 10.1021/ja991624b; Tanner JJ, 1999, PROTEIN SCI, V8, P1725, DOI 10.1110/ps.8.9.1725; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Werner E, 2002, FEBS LETT, V516, P239, DOI 10.1016/S0014-5793(02)02556-5; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4; Zhang H, 2002, STRUCTURE, V10, P69, DOI 10.1016/S0969-2126(01)00693-1; Zhou TJ, 2002, J BIOL CHEM, V277, P13148, DOI 10.1074/jbc.M111469200; ZHU N, 1991, J BACTERIOL, V173, P1311, DOI 10.1128/jb.173.3.1311-1320.1991	47	46	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33291	33299		10.1074/jbc.M204368200	http://dx.doi.org/10.1074/jbc.M204368200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12068016	hybrid			2022-12-25	WOS:000177859000115
J	Tsakraklides, V; Solomon, MJ				Tsakraklides, V; Solomon, MJ			Comparison of Cak1p-like cyclin-dependent kinase-activating kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER PROTEIN; RNA-POLYMERASE-II; FISSION YEAST; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; CATALYTIC SUBUNIT; TERMINAL DOMAIN; CAK ACTIVITY; PHOSPHORYLATION	Cyclin-dependent kinases (cdks) coordinate progression through the eukaryotic cell cycle and require phosphorylation by a cdk-activating kinase (CAK) for full activity. In most eukaryotes Cdk7 is the catalytic subunit of a heterotrimeric CAK (Cdk7-cyclin H-Mat1) that is also involved in transcription as part of the transcription factor IIH complex. The Saccharomyces cerevisiae CAK, Cak1p, is a monomeric protein kinase with an atypical sequence and unusual biochemical properties compared with trimeric CAKs and other protein kinases. We sought to determine whether these properties were shared by a small group of monomeric CAKs that can function in place of CAK1 in S. cerevisiae. We found that Schizosaccharomyces pombe Csk1, Candida albicans Cak1, and Arabidopsis thaliana Cak1At, like Cak1p, all displayed a preference for cyclin-free cdk substrates, were insensitive to the protein kinase inhibitor 5'-fluorosulfonylbenzoyladenosine (FSBA), and were insensitive to mutation of a highly conserved lysine residue found in the nucleotide binding pocket of all protein kinases. The S. pombe and C. albicans kinases also resembled Cak1p in their kinetics of nucleotide and protein substrate utilization. Conservation of these unusual properties in fungi and plants points to shared evolutionary requirements not met by Cdk7 and raises the possibility of developing antifungal agents targeting CAKs.	Yale Univ, Dept Mol Biophys & Biochem, Sch Med, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol, Sch Med, New Haven, CT 06520 USA	Yale University; Yale University	Solomon, MJ (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.	mark.solomon@yale.edu		Tsakraklides, Vasiliki/0000-0003-1998-1075	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Chun KT, 1997, MOL GEN GENET, V256, P365, DOI 10.1007/s004380050580; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DARBON JM, 1994, ONCOGENE, V9, P3127; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FAYE G, 1999, Patent No. 9801788; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hermand D, 1998, EMBO J, V17, P7230, DOI 10.1093/emboj/17.24.7230; Hermand D, 2001, EMBO J, V20, P82, DOI 10.1093/emboj/20.1.82; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jordan P, 1997, MOL BIOL CELL, V8, P1207, DOI 10.1091/mbc.8.7.1207; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, J CELL SCI, V111, P3585; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; KALDIS P, 2001, CDK ACTIVATING KINAS; Lee KM, 1999, CURR BIOL, V9, P441, DOI 10.1016/S0960-9822(99)80194-8; Liu J, 2000, MOL BIOL EVOL, V17, P1061, DOI 10.1093/oxfordjournals.molbev.a026387; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; Moore DD, 1995, GLOB MOB SURV; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Pagano M., 1998, CELL CYCLE CONTROL, P79; Ross KE, 2000, MOL BIOL CELL, V11, P1597, DOI 10.1091/mbc.11.5.1597; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Russo AA, 1997, METHOD ENZYMOL, V283, P3; Schaber M, 2002, MOL CELL BIOL, V22, P57, DOI 10.1128/MCB.22.1.57-68.2002; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; THURET JY, 1999, Patent No. 9907836; Umeda M, 1998, P NATL ACAD SCI USA, V95, P5021, DOI 10.1073/pnas.95.9.5021; UMEDA M, 2001, CDK ACTIVATING KINAS; Wagner M, 1997, EMBO J, V16, P1305, DOI 10.1093/emboj/16.6.1305; Yamaguchi M, 1998, PLANT J, V16, P613, DOI 10.1046/j.1365-313x.1998.00338.x	52	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33482	33489		10.1074/jbc.M205537200	http://dx.doi.org/10.1074/jbc.M205537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084729	hybrid			2022-12-25	WOS:000177859000138
J	Burgess, JW; Kiss, RS; Zheng, H; Zachariah, S; Marcel, YL				Burgess, JW; Kiss, RS; Zheng, H; Zachariah, S; Marcel, YL			Trypsin-sensitive and lipid-containing sites of the macrophage extracellular matrix bind apolipoprotein A-I and participate in ABCA1-dependent cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FIBROBLAST GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR INHIBITOR; CELLULAR CHOLESTEROL; CASSETTE TRANSPORTER; TANGIER-DISEASE; PLASMA-MEMBRANE; ENDOTHELIAL-CELLS; ATHEROGENIC LIPOPROTEINS; ATHEROSCLEROTIC LESIONS	A unique property of the extracellular matrix of J774 and THP-1 cells has been identified, which contributes to the ability of these cells to promote cholesterol efflux. We demonstrate high level apolipoprotein (apo) A-I binding to macrophage cells (THP-1 and J774) and to their extracellular matrix (ECM). However, high level apoA-I binding is not observed on fibroblasts, HepG2 cells, or U937 cells (a macrophage cell line that does not efflux cholesterol to apoA-I or bind apoA-I on their respective ECM). Binding to the ECM of THP-1 or J774 macrophages depends on the presence of apoA-I C-terminal helices and is markedly reduced with a mutant lacking residues 187-243 (apoA-IDelta(187-243)), suggesting that the hydrophobic C terminus forms a hydrophobic interaction with the ECM ApoA-I binding is lost upon trypsin treatment or with Triton X-100, a preparation method that de-lipidates the ECM However, binding is recovered with re-lipidation, and is preserved with ECM prepared using cytochalasin B, which conserves the endogenous phospholipid levels of the ECM We also demonstrate that specific cholesterol efflux to apoA-I is much reduced in cells released from their native ECM, but fully restored when ECM-depleted cells are added back to ECM in the presence of apoA-I. The apoA-I-mediated efflux is deficient in plated or suspension U937 macrophages, but is restored to high levels when the suspension U937 cells are reconstituted with the ECM of J774 cells. The ECM-dependent activity was much reduced in the presence of glyburide, indicating participation of ABCA1 (ATP-binding cassette transporter 1) in the efflux mechanism. These studies establish a novel binding site for apoA-I on the macrophage ECM that may function together with ABCA1 in promoting cholesterol efflux.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Fac Med, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, 40 Ruskins St, Ottawa, ON K1Y 4W7, Canada.							AMEIS D, 1990, J BIOL CHEM, V265, P6552; Arispe N, 1996, BIOPHYS J, V71, P1764, DOI 10.1016/S0006-3495(96)79377-3; BARSHAVIT R, 1989, J CLIN INVEST, V84, P1096, DOI 10.1172/JCI114272; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BEDOSSA P, 1989, ARCH PATHOL LAB MED, V113, P777; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Bissell M J, 1987, Prog Clin Biol Res, V249, P251; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Burgess JW, 1998, J BIOL CHEM, V273, P5645, DOI 10.1074/jbc.273.10.5645; Buton X, 1999, J BIOL CHEM, V274, P32112, DOI 10.1074/jbc.274.45.32112; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Cohen M P, 1988, J Diabet Complications, V2, P214, DOI 10.1016/S0891-6632(88)80012-6; Diakonova M, 1997, J CELL SCI, V110, P1199; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Frank PG, 1997, BIOCHEMISTRY-US, V36, P1798, DOI 10.1021/bi962118r; GENGE BR, 1991, J BIOL CHEM, V266, P10678; GETZENBERG RH, 1990, ENDOCR REV, V11, P399, DOI 10.1210/edrv-11-3-399; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HALE JE, 1987, J BIOL CHEM, V262, P1916; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HARA H, 1991, J BIOL CHEM, V266, P3080; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; HOFF HF, 1975, CIRC RES, V37, P72, DOI 10.1161/01.RES.37.1.72; Jacob MP, 2001, PATHOL BIOL, V49, P326, DOI 10.1016/S0369-8114(01)00151-1; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; John Anitha, 2001, Pathology and Oncology Research, V7, P14; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Ju HS, 1996, CAN J CARDIOL, V12, P1259; Kouwenhoven M, 2001, J AUTOIMMUN, V16, P463, DOI 10.1006/jaut.2001.0505; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Lijnen HR, 2001, THROMB HAEMOSTASIS, V86, P324; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAI S, 1984, EXP CELL RES, V152, P500, DOI 10.1016/0014-4827(84)90652-9; Marathe S, 1999, ARTERIOSCL THROM VAS, V19, P2648, DOI 10.1161/01.ATV.19.11.2648; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTINEZHERNANDEZ A, 1993, VIRCHOWS ARCH A, V423, P77, DOI 10.1007/BF01606580; MIMURO J, 1987, BLOOD, V70, P721; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Oorni K, 1998, J BIOL CHEM, V273, P29127, DOI 10.1074/jbc.273.44.29127; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1996, J LIPID RES, V37, P2473; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; Paradis V, 1996, HEPATOLOGY, V23, P1232; Paradis V, 1996, CELL MOL BIOL, V42, P525; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RANDOLPH RK, 1986, J LIPID RES, V27, P307; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Sobel RA, 2001, BRAZ J MED BIOL RES, V34, P603, DOI 10.1590/S0100-879X2001000500007; Storey E, 1996, BRAIN RES, V735, P59; TABAS I, 1993, J BIOL CHEM, V268, P20419; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Turley EA, 2001, CIRC RES, V88, P2, DOI 10.1161/01.RES.88.1.2; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; WUTHIER RE, 1976, FED PROC, V35, P117; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200	80	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31318	31326		10.1074/jbc.M204200200	http://dx.doi.org/10.1074/jbc.M204200200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12050168	hybrid			2022-12-25	WOS:000177718700007
J	Jacob, R; Purschel, B; Naim, HY				Jacob, R; Purschel, B; Naim, HY			Sucrase is an intramolecular chaperone located at the C-terminal end of the sucrase-isomaltase enzyme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; CELL ANTIGEN RECEPTOR; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; PROTEIN; TRANSPORT; SUBUNIT; BIOSYNTHESIS; PROPEPTIDE; ASSOCIATION	The sucrase-isomaltase enzyme complex (pro-SI) is a type II integral membrane glycoprotein of the intestinal brush border membrane. Its synthesis commences with the isomaltase (IM) subunit and ends with sucrase (SUC). Both domains reveal striking structural similarities, suggesting a pseudo-dimeric assembly of a correctly folded and an enzymatically active pro-SI. The impact of each domain on the folding and function of pro-SI has been analyzed by individual expression and coexpression of the individual subunits. SUC acquires correct folding, enzymatic activity and transport competence and is secreted into the external milieu independent of the presence of IM. By contrast, IM persists as a mannose-rich polypeptide that interacts with the endoplasmic reticulum resident molecular chaperone calnexin. This interaction is disrupted when SUC is co-expressed with IM, indicating that SUC competes with calnexin for binding of IM. The interaction between SUC and the membrane-anchored IM leads to maturation of IM and blocks the secretion of SUC into the external milieu. We conclude that SUC plays a role as an intramolecular chaperone in the context of the pro-SI protein. To our knowledge all intramolecular chaperones so far identified are located at the N-terminal end. SUC is therefore the first C-terminally located intramolecular chaperone in mammalian cells.	Hannover Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Hannover Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011					Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Cigic B, 2000, BIOCHEMISTRY-US, V39, P12382, DOI 10.1021/bi0008837; Conesa A, 2001, FEBS LETT, V503, P117, DOI 10.1016/S0014-5793(01)02698-9; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; FEHLMANN M, 1985, BIOCHIMIE, V67, P1155, DOI 10.1016/S0300-9084(85)80114-0; Feller G, 1998, J BIOL CHEM, V273, P12109, DOI 10.1074/jbc.273.20.12109; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Gething MJ, 1997, NATURE, V388, P329, DOI 10.1038/40979; GORGA JC, 1992, CRIT REV IMMUNOL, V11, P305; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HAURI HP, 1982, J BIOL CHEM, V257, P4522; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2000, J CLIN INVEST, V106, P281, DOI 10.1172/JCI9677; Jacob R, 2002, J BIOL CHEM, V277, P8217, DOI 10.1074/jbc.M111500200; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; Luisiri P, 1996, J BIOL CHEM, V271, P5158; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAIM HY, 1992, BIOCHEM J, V286, P451, DOI 10.1042/bj2860451; NAIM HY, 1988, J BIOL CHEM, V263, P7242; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; NAIM HY, 1994, J BIOL CHEM, V269, P26933; Naim HY, 1996, EUR J CELL BIOL, V70, P198; Nichols BL, 1998, J BIOL CHEM, V273, P3076, DOI 10.1074/jbc.273.5.3076; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; Spodsberg N, 2001, J BIOL CHEM, V276, P23506, DOI 10.1074/jbc.C100219200; STEINER DF, 1984, J CELL BIOCHEM, V24, P121, DOI 10.1002/jcb.240240204; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang ZZ, 1996, J CELL BIOL, V135, P809, DOI 10.1083/jcb.135.3.809; WILSON JM, 1987, J CELL BIOL, V105, P691, DOI 10.1083/jcb.105.2.691; Xu WF, 1996, J BIOL CHEM, V271, P27948, DOI 10.1074/jbc.271.44.27948; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	45	11	19	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32141	32148		10.1074/jbc.M204116200	http://dx.doi.org/10.1074/jbc.M204116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12055199	hybrid			2022-12-25	WOS:000177718700105
J	Krishnan, P; Liou, JY; Cheng, YC				Krishnan, P; Liou, JY; Cheng, YC			Phosphorylation of pyrimidine (L)-deoxynucleoside analog diphosphates - Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE PHOSPHOGLYCERATE KINASE; ANGSTROM RESOLUTION STRUCTURE; L-DIOXOLANE-CYTIDINE; VIRUS-REPLICATION; METABOLISM; INHIBITION; 3-PHOSPHO-D-GLYCERATE; NUCLEOTIDE; REDUCTASE; PROTEINS	Anticancer and antiviral D- and L-nucleoside analogs are phosphorylated stepwise in the cells to the pharmacologically active triphosphate metabolites. We recently reported that in the last step, L-deoxynucleoside analog diphosphates are phosphorylated by 3-phosphoglycerate kinase (PGK). To explain the preference of PGK for L- over D-deoxynucleoside analog diphosphates, the kinetics of their phosphorylation were compared with the dephosphorylation of the respective triphosphates using recombinant human PGK. The results attributed favorable phosphorylation of L-deoxynucleoside analog diphosphates by PGK to differences in kappa(cat),which were consequences of varied orientations of the sugar and diphosphates in the catalytic site of PGK. The amino acids involved in the catalytic reaction of PGK (including GlU(344), Lys(220), and Asn(337)) were therefore mutated. The impact of mutations on the phosphorylation Of L- and D-deoxynucleoside analog diphosphates was different from those on dephosphorylation of the respective triphosphates. This suggested that the interactions of the nucleoside analogs with amino acids during the transition state are different in the phosphorylation and dephosphorylation. reactions. Thus, reversible action of the enzyme may not involve the same configuration of the active site. Furthermore, the amino acid determinants of the action of PGK for L-deoxynucleotides were not the same as for the D-deoxynucleotides. This study also suggests the potential impact of nucleoside analog diphosphates and triphosphates on the multiple cellular functions of PGK which may contribute to the action of the analogs.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,SHM B313, New Haven, CT 06520 USA.				NCI NIH HHS [CA-63477] Funding Source: Medline; NIAID NIH HHS [AI-38204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063477, R01CA063477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; BLAKLEY RL, 1989, MOL PHARMACOL, V37, P328; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHENG YC, 2001, CANC LETT, V162, pS35; Cheng Yung-Chi, 2001, Antiviral Chemistry and Chemotherapy, V12, P5; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; Dutschman GE, 1998, ANTIMICROB AGENTS CH, V42, P1799, DOI 10.1128/AAC.42.7.1799; Foudraine NA, 1998, AIDS, V12, P1513, DOI 10.1097/00002030-199812000-00014; Giles FJ, 2001, J CLIN ONCOL, V19, P762, DOI 10.1200/JCO.2001.19.3.762; GROVE KL, 1995, CANCER RES, V55, P3008; HARLOS K, 1992, PROTEINS, V12, P133, DOI 10.1002/prot.340120207; JOHNSON PE, 1976, BIOCHEMISTRY-US, V15, P2893, DOI 10.1021/bi00658a030; KHADIM SA, 1997, CANCER RES, V57, P4803; Krishnan P, 2002, J BIOL CHEM, V277, P5453, DOI 10.1074/jbc.M109025200; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Lay AJ, 2002, J BIOL CHEM, V277, P9062, DOI 10.1074/jbc.M111531200; Le Guerhier F, 2000, ANTIMICROB AGENTS CH, V44, P111, DOI 10.1128/AAC.44.1.111-122.2000; Le Guerhier F, 2001, ANTIMICROB AGENTS CH, V45, P1065, DOI 10.1128/AAC.45.4.1065-1077.2001; May A, 1996, PROTEINS, V24, P292; Merli A, 2002, BIOCHEMISTRY-US, V41, P111, DOI 10.1021/bi0115380; Moore LE, 1997, CANCER CHEMOTH PHARM, V39, P532, DOI 10.1007/s002800050609; MORI N, 1986, FEBS LETT, V204, P313, DOI 10.1016/0014-5793(86)80835-3; Ogino T, 1999, J BIOL CHEM, V274, P35999, DOI 10.1074/jbc.274.50.35999; PIZZORNO GHR, 2000, PYRIMIDINE PURINE AN, P625; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; RUTH JL, 1981, MOL PHARMACOL, V20, P415; Schneider B, 1998, J BIOL CHEM, V273, P11491, DOI 10.1074/jbc.273.19.11491; Schneider B, 2000, MOL PHARMACOL, V57, P948; Schneider B, 1999, NUCLEOS NUCLEOT, V18, P829, DOI 10.1080/15257779908041571; SHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Szilagyi AN, 2001, J MOL BIOL, V306, P499, DOI 10.1006/jmbi.2000.4294; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; Yao GQ, 1996, BIOCHEM PHARMACOL, V51, P941, DOI 10.1016/0006-2952(96)00049-4; Zemlicka J, 2000, PHARMACOL THERAPEUT, V85, P251, DOI 10.1016/S0163-7258(99)00062-5; Zhu YL, 1998, ANTIMICROB AGENTS CH, V42, P1805, DOI 10.1128/AAC.42.7.1805	38	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31593	31600		10.1074/jbc.M205115200	http://dx.doi.org/10.1074/jbc.M205115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080078	hybrid			2022-12-25	WOS:000177718700039
J	Zhou, B; Wang, ZX; Zhao, Y; Brautigan, DL; Zhang, ZY				Zhou, B; Wang, ZX; Zhao, Y; Brautigan, DL; Zhang, ZY			The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE-PHOSPHATASE; MAP KINASE; SUBSTRATE-SPECIFICITY; DIFFERENTIAL REGULATION; DUAL PHOSPHORYLATION; STRUCTURAL BASIS; PTP-SL; ACTIVATION; MECHANISM	The extracellular signal-regulated protein kinase 2 (ERK2) is the founding member of a family of mitogen. activated protein kinases (MAPKs) that are central components of signal transduction pathways for cell proliferation, stress responses, and differentiation. The MAPKs are unique among the Ser/Thr protein kinases in that they require both Thr and Tyr phosphorylation for full activation. The dual phosphorylation of Thr-183 and Tyr-185 in ERK2 is catalyzed by MAPK/ERK kinase 1 (MEK1). However, the identity and relative activity of protein phosphatases that inactivate ERK2 are less well established. In this study, we performed a kinetic analysis of ERK2 dephosphorylation by protein phosphatases using a continuous spectrophotometric enzyme-coupled assay that measures the inorganic phosphate produced in the reaction. Eleven different protein phosphatases, many previously suggested to be involved in ERK2 regulation, were compared, including tyrosine-specific phosphatases (PTP1B, CD45, and HePTP), dual specificity MAPK phosphatases (VHR, MKP3, and MKP5), and Ser/Thr protein phosphatases (PP1, PP2A, PP2B, PP2Calpha, and lambdaPP). The results provide biochemical evidence that protein phosphatases display exquisite specificity in their substrate recognition and implicate HePTP, MKP3, and PP2A as ERK2 phosphatases. The fact that ERK2 inactivation could be carried out by multiple specific phosphatases shows that signals can be integrated into the pathway at the phosphatase level to determine the cellular response to external stimuli. Important insights into the roles of various protein phosphatases in ERK2 kinase signaling are obtained, and further analysis of the mechanism by which different protein phosphatases recognize and inactivate MAPKs will increase our understanding of how this kinase family is regulated.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Virginia, Ctr Cell Signalling, Charlottesville, VA 22908 USA	Yeshiva University; Albert Einstein College of Medicine; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Virginia	Zhang, ZY (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu						Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Barford D, 1999, BIOCHEM SOC T, V27, P751, DOI 10.1042/bst0270751; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen PTW, 1994, ADV PROTEIN PHOSPHAT, V8, P371; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Karim FD, 1999, MOL CELL, V3, P741, DOI 10.1016/S1097-2765(01)80006-X; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Killilea SD, 1998, METH MOL B, V93, P23; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; SEGEL IH, 1975, ENZYME KINETICS, P73; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; USUI H, 1983, J BIOL CHEM, V258, P455; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wilsbacher JL, 2001, METHOD ENZYMOL, V332, P387; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	67	177	185	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31818	31825		10.1074/jbc.M203969200	http://dx.doi.org/10.1074/jbc.M203969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12082107	hybrid			2022-12-25	WOS:000177718700065
J	Janelle, ME; Gravel, A; Gosselin, J; Tremblay, MJ; Flamand, L				Janelle, ME; Gravel, A; Gosselin, J; Tremblay, MJ; Flamand, L			Activation of monocyte cyclooxygenase-2 gene expression by human herpesvirus 6 - Role for cyclic AMP-responsive element-binding protein and activator protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; NUCLEAR FACTOR; HUMAN CYTOMEGALOVIRUS; CYCLOSPORINE-A; GROWTH-FACTOR; T-CELLS; PHOSPHATASE-ACTIVITY	Prostaglandin E-2 (PGE(2)) is an arachidonic acid metabolite mainly produced by activated monocytes/macrophages (Mo/Mphi) that display broad immunomodulatory activities. Several viruses capable of infecting Mo/Mphi modulate PGE(2) synthesis in a way that favors the infection processes and the spread of virions. In the present work, we studied the effect of human herpesvirus 6 (HHV-6) infection of Mo/Mphi on PGE(2) synthesis. Our results indicate that HHV-6 induces COX-2 gene expression and PGE(2) synthesis within a few hours of infection. We mapped the different promoter elements associated with COX-2 gene activation by HHV-6 to two cis-acting elements: a cyclic AMP-responsive element and an activator protein-1 element. HHV-6 immediate-early protein 2 was identified as a modulator of COX-2 gene expression in Mo/Mphi. Finally, addition of PGE(2) to HHV-6-infected peripheral blood mononuclear cells cultures was found to increase significantly viral replication. Overall, these results further contribute to the immunomodulatory properties of HHV-6 and highlight a potential role for eicosanoids in the replication process of this virus.	Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada; CHU Laval, Res Ctr, Virol Lab, Quebec City, PQ G1V 4G2, Canada; CHU Laval, Res Ctr, Rheumatol & Immunol Res Ctr, Lab Viral Immunol, Quebec City, PQ G1V 4G2, Canada; CHU Laval, Res Ctr, Res Ctr Infect Dis, Lab Human Immunoretrovirol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University; Laval University	Flamand, L (corresponding author), Rheumatol & Immunol Res Ctr, Local T1-49,2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.			Flamand, Louis/0000-0001-5010-4586; Gravel, Annie/0000-0001-5229-5750				ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BenHur T, 1996, J NEUROVIROL, V2, P279, DOI 10.3109/13550289609146891; BETZ M, 1991, J IMMUNOL, V146, P108; BIEGALKE BJ, 1991, VIROLOGY, V183, P381, DOI 10.1016/0042-6822(91)90151-Z; BONNEFOY JY, 1989, J IMMUNOL, V143, P864; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; Chen N, 2000, VIROLOGY, V276, P44, DOI 10.1006/viro.2000.0562; Cheng HF, 2000, J CLIN INVEST, V106, P681, DOI 10.1172/JCI10318; CHOUAIB S, 1985, J IMMUNOL, V135, P1172; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENHOLM EM, 1991, J IMMUNOL METHODS, V144, P247, DOI 10.1016/0022-1759(91)90092-T; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; Dominguez G, 1999, J VIROL, V73, P8040, DOI 10.1128/JVI.73.10.8040-8052.1999; Doniger J, 1999, CLIN MICROBIOL REV, V12, P367, DOI 10.1128/CMR.12.3.367; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dumais N, 1998, J BIOL CHEM, V273, P27306, DOI 10.1074/jbc.273.42.27306; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Flamand L, 1998, J VIROL, V72, P8797, DOI 10.1128/JVI.72.11.8797-8805.1998; Flamand L, 1996, J CLIN INVEST, V97, P1373, DOI 10.1172/JCI118557; FLAMAND L, 1995, BLOOD, V85, P1263, DOI 10.1182/blood.V85.5.1263.bloodjournal8551263; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; Flodstrom M, 2001, VIROLOGY, V281, P205, DOI 10.1006/viro.2000.0801; FOLEY P, 1992, IMMUNOLOGY, V75, P391; Fortin JF, 2001, BLOOD, V97, P2390, DOI 10.1182/blood.V97.8.2390; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GHAZAL P, 1991, J VIROL, V65, P6735, DOI 10.1128/JVI.65.12.6735-6742.1991; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; GOSSELIN J, 1992, J IMMUNOL, V149, P181; Gravel A, 2002, J BIOL CHEM, V277, P19679, DOI 10.1074/jbc.M200836200; Guidotti LG, 2000, J EXP MED, V191, P1247, DOI 10.1084/jem.191.7.1247; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; HASLER F, 1983, J IMMUNOL, V131, P768; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HORVAT RT, 1993, J INFECT DIS, V167, P1274, DOI 10.1093/infdis/167.6.1274; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Isegawa Y, 1999, J VIROL, V73, P8053, DOI 10.1128/JVI.73.10.8053-8063.1999; JOSEPHS SF, 1991, J VIROL, V65, P5597, DOI 10.1128/JVI.65.10.5597-5604.1991; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Kempf W, 1997, P NATL ACAD SCI USA, V94, P7600, DOI 10.1073/pnas.94.14.7600; KHYATTI M, 1990, ANTIVIR RES, V14, P161, DOI 10.1016/0166-3542(90)90032-3; Kline JN, 1998, EXP LUNG RES, V24, P3, DOI 10.3109/01902149809046050; KONDO K, 1991, J GEN VIROL, V72, P1401, DOI 10.1099/0022-1317-72-6-1401; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LUSSO P, 1993, NATURE, V362, P458, DOI 10.1038/362458a0; Lusso P, 1996, ANTIVIR RES, V31, P1, DOI 10.1016/0166-3542(96)00949-7; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MARTIN MED, 1991, J VIROL, V65, P5381, DOI 10.1128/JVI.65.10.5381-5390.1991; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Moriuchi M, 2001, J VIROL, V75, P192, DOI 10.1128/JVI.75.1.192-198.2001; Noda S, 2001, J IMMUNOL, V166, P3533, DOI 10.4049/jimmunol.166.5.3533; Nokta MA, 1996, J CLIN INVEST, V97, P2635, DOI 10.1172/JCI118713; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Robida AM, 2000, MOL PHARMACOL, V58, P701, DOI 10.1124/mol.58.4.701; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Savard M, 2000, J IMMUNOL, V164, P6467, DOI 10.4049/jimmunol.164.12.6467; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; Speir E, 1998, CIRC RES, V83, P210, DOI 10.1161/01.RES.83.2.210; Steube KG, 1997, LEUKEMIA RES, V21, P327, DOI 10.1016/S0145-2126(96)00129-4; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAMANISHI K, 1988, LANCET, V1, P1065; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; YEUNG KC, 1993, VIROLOGY, V195, P786, DOI 10.1006/viro.1993.1431; Zhu H, 2002, P NATL ACAD SCI USA, V99, P3932, DOI 10.1073/pnas.052713799	99	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30665	30674		10.1074/jbc.M203041200	http://dx.doi.org/10.1074/jbc.M203041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12068008	hybrid			2022-12-25	WOS:000177579800035
J	Marmorstein, LY; McLaughlin, PJ; Stanton, JB; Yan, L; Crabb, JW; Marmorstein, AD				Marmorstein, LY; McLaughlin, PJ; Stanton, JB; Yan, L; Crabb, JW; Marmorstein, AD			Bestrophin interacts physically and functionally with protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITELLIFORM MACULAR DYSTROPHY; RETINAL-PIGMENT EPITHELIUM; BEST-DISEASE; VMD2 GENE; PLASMA-MEMBRANE; LIGHT PEAK; DEGENERATION; MUTATIONS; COMPONENT; PRODUCT	Bestrophin is a 68-kDa basolateral plasma membrane protein expressed in retinal pigment epithelial cells (RPE). It is encoded by the VMD2 gene, which is mutated in Best macular dystrophy, a disease characterized by a depressed light peak in the electrooculogram. Recently it was proposed that bestrophin is a chloride channel responsible for generating the light peak. To investigate its function further, we immunoaffinity purified a bestrophin complex from RPE lysates and identified bestrophin and the beta-catalytic subunit of protein phosphatase 2A (PP2A) as members of the complex by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Protein-protein interaction between bestrophin and PP2Ac and the structural subunit of PP2A, PR65, was confirmed by reciprocal immunoprecipitation. The C-terminal cytoplasmic domain of bestrophin was sufficient for the interaction with PP2A as demonstrated by a pulldown assay using a fusion of this domain with glutathione S-transferase. Bestrophin was phosphorylated when expressed in RPE-J cells and this phosphorylation was sensitive to okadaic acid. Purified PP2A effectively dephosphorylated bestrophin in vitro. These data suggest that bestrophin is in the signal transduction pathway that modulates the light peak of the electrooculogram, that it is regulated by phosphorylation, and that phosphorylation of bestrophin is in turn regulated by PP2A.	Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Marmorstein, AD (corresponding author), Cleveland Clin Fdn, Cole Eye Inst I31, Dept Ophthalm Res, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL EYE INSTITUTE [R01EY013160, R01EY006603] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 13160, R01 EY 06603] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986; Bakall B, 1999, HUM GENET, V104, P383, DOI 10.1007/s004390050972; BARD LA, 1976, T AM ACAD OPHTHALMOL, V79, pOP865; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Caldwell GM, 1999, GENOMICS, V58, P98, DOI 10.1006/geno.1999.5808; CROSS HE, 1974, AM J OPHTHALMOL, V77, P46, DOI 10.1016/0002-9394(74)90603-5; Eksandh L, 2001, Ophthalmic Genet, V22, P107, DOI 10.1076/opge.22.2.107.2226; GALLEMORE RP, 1993, J NEUROPHYSIOL, V70, P1669, DOI 10.1152/jn.1993.70.4.1669; GALLEMORE RP, 1989, J NEUROSCI, V9, P1977; GALLEMORE RP, 1998, RETINAL PIGMENT EPIT, P175; GASS DJM, 1997, STEREOSCOPIC ATLAS M, V1, P303; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; Harlow E, 1988, ANTIBODIES LABORATOR, P521; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447; Kutuzov MA, 1996, EUR J BIOCHEM, V238, P613, DOI 10.1111/j.1432-1033.1996.0613w.x; Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291; MALONEY WF, 1977, ARCH OPHTHALMOL-CHIC, V95, P979, DOI 10.1001/archopht.1977.04450060065003; Marchant D, 2001, Hum Mutat, V17, P235, DOI 10.1002/humu.9; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; Marmorstein AD, 1996, J CELL SCI, V109, P3025; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; NABI IR, 1993, J CELL SCI, V104, P37; OGORMAN S, 1988, ARCH OPHTHALMOL-CHIC, V106, P1261; Palomba G, 2000, AM J OPHTHALMOL, V129, P260, DOI 10.1016/S0002-9394(99)00327-X; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108; West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058	33	64	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30591	30597		10.1074/jbc.M204269200	http://dx.doi.org/10.1074/jbc.M204269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12058047	hybrid			2022-12-25	WOS:000177579800026
J	Rao, KVN; Chen, L; Gnanasekar, M; Ramaswamy, K				Rao, KVN; Chen, L; Gnanasekar, M; Ramaswamy, K			Cloning and characterization of a calcium-binding, histamine-releasing protein from Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CHEMOTACTIC FACTOR; HOST RESPONSE; IN-VITRO; TUMOR; HOMOLOG; IDENTIFICATION; MODULATION; IMMUNE; MICE; SKIN	A homologue of the mammalian translationally controlled tumor protein (TCTP) was cloned from the human parasite Schistosoma mansoni (SmTCTP). Sequence analysis showed that SmTCTP differed from other reported TCTPs in having only one signature sequence. Subsequently, SmTCTP was cloned in a T7 expression system and expressed as a histidine-tagged fusion protein. Recombinant SmTCTP (rSmTCTP) has a molecular mass of similar to23 kDa with the histidine tag. Further analysis showed that SmTCTP transcripts and protein are expressed in all life cycle stages of the parasite within the vertebrate hosts. Interestingly, antibodies to SmTCTP were present in the sera of mice 9 weeks after infection with S. mansoni. Characterization studies showed that rSmTCTP is a calcium-binding protein that can cause histamine release from basophil/mast cells and induce eosinophil infiltration. These findings suggest that SmTCTP may have an important role in the development of allergic inflammatory responses associated with schistosomiasis and may be a target for new drug development.	Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Rockford	Ramaswamy, K (corresponding author), Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA.	ramswamy@uic.edu	Rao, Kola Koteswara/ABE-7163-2021	Rao, Kola Koteswara/0000-0001-6176-7828	NIAID NIH HHS [N01 AI 55270, R01 AI039066-08, R29 AI039066, R01 AI039066, R01 AI039066-06A2, AI 39066] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI055270, R29AI039066, R01AI039066] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BARSOUM IS, 1984, J IMMUNOL, V133, P1576; Bheekha-Escura R, 2000, BLOOD, V96, P2191; Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192; Bhisutthibhan J, 2001, ANTIMICROB AGENTS CH, V45, P2397, DOI 10.1128/AAC.45.8.2397-2399.2001; BOHM H, 1989, BIOCHEM INT, V19, P277; CAPRON M, 1992, MEM I OSWALDO CRUZ, V87, P167, DOI 10.1590/S0074-02761992000800025; CATTO BA, 1980, AM J TROP MED HYG, V29, P886, DOI 10.4269/ajtmh.1980.29.886; el-Hawey A M, 1970, J Egypt Med Assoc, V53, P530; ELDIN AHS, 1983, ANN ALLERGY, V50, P190; ERCOLI N, 1985, EXP PARASITOL, V59, P204, DOI 10.1016/0014-4894(85)90074-8; Falcone FH, 1996, EUR J IMMUNOL, V26, P1147, DOI 10.1002/eji.1830260528; Gachet Y, 1999, J CELL SCI, V112, P1257; GERKEN SE, 1984, BRAZ J MED BIOL RES, V17, P301; Gnanasekar M, 2002, MOL BIOCHEM PARASIT, V121, P107, DOI 10.1016/S0166-6851(02)00027-0; Hamdan FF, 2002, MOL BIOCHEM PARASIT, V119, P75, DOI 10.1016/S0166-6851(01)00400-5; HARRIS WG, 1973, IMMUNOLOGY, V24, P567; HOFSTETTER M, 1983, J IMMUNOL, V130, P1376; HORII Y, 1990, PARASITOL RES, V76, P602, DOI 10.1007/BF00932570; KHALIFE J, 1994, PARASITOLOGY, V108, P527, DOI 10.1017/S0031182000077398; Kim M, 2000, ARCH PHARM RES, V23, P633, DOI 10.1007/BF02975253; LICHTENBERG FV, 1976, AM J PATHOL, V84, P479; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MacDonald SM, 2001, P NATL ACAD SCI USA, V98, P10829, DOI 10.1073/pnas.201191498; MacDonald SM, 1997, INT ARCH ALLERGY IMM, V113, P187, DOI 10.1159/000237542; NIAK CH, 2001, PARASITOLOGY, V123, P293; Owhashi M, 1996, INT J PARASITOL, V26, P705, DOI 10.1016/0020-7519(96)00054-9; PAY A, 1992, PLANT MOL BIOL, V19, P501, DOI 10.1007/BF00023399; RAM D, 1994, PARASITOLOGY, V108, P289, DOI 10.1017/S0031182000076137; Ramaswamy K, 1997, EXP PARASITOL, V86, P118, DOI 10.1006/expr.1997.4178; Ramaswamy K, 1996, J INFLAMM, V46, P13; Sabin EA, 1996, J EXP MED, V184, P1871, DOI 10.1084/jem.184.5.1871; Sanchez JC, 1997, ELECTROPHORESIS, V18, P150, DOI 10.1002/elps.1150180127; Satti MZ, 1996, TROP MED INT HEALTH, V1, P655; SCHOENBE.MJ, 1968, P SOC EXP BIOL MED, V127, P601, DOI 10.3181/00379727-127-32752; Schroeder JT, 1996, J EXP MED, V183, P1265, DOI 10.1084/jem.183.3.1265; Sturzenbaum SR, 1998, BBA-GENE STRUCT EXPR, V1398, P294, DOI 10.1016/S0167-4781(98)00077-3; Teshima S, 1998, J IMMUNOL, V161, P6356; WEINSTOCK JV, 1983, J IMMUNOL, V130, P423; Xiao SH, 2002, ACTA TROP, V82, P175, DOI 10.1016/S0001-706X(02)00009-8; Yan L, 2000, DEV GENES EVOL, V210, P507, DOI 10.1007/s004270000088; Yoon T, 2000, ARCH BIOCHEM BIOPHYS, V384, P379, DOI 10.1006/abbi.2000.2108	42	81	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31207	31213		10.1074/jbc.M204114200	http://dx.doi.org/10.1074/jbc.M204114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12050167	Green Accepted, hybrid			2022-12-25	WOS:000177579800101
J	Zhong, XP; Hainey, EA; Olenchock, BA; Zhao, H; Topham, MK; Koretzky, GA				Zhong, XP; Hainey, EA; Olenchock, BA; Zhao, H; Topham, MK; Koretzky, GA			Regulation of T cell receptor-induced activation of the Ras-ERK pathway by diacylglycerol kinase zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA-1 PLC-GAMMA-1; SEVERE COMBINED IMMUNODEFICIENCY; KAPPA-B ACTIVATION; ANTIGEN RECEPTOR; PROTEIN-KINASE; MOLECULAR-CLONING; TYROSINE KINASE; NUCLEAR-LOCALIZATION; MEDIATED ACTIVATION; PROMOTER ACTIVITY	T cell development in the thymus and activation of mature T cells in the periphery depend on signals stimulated by engagement of the T cell antigen receptor (TCR). Among the second messenger cascades initiated by TCR ligation include the phosphatidylinositol pathway where the membrane phospholipid, phosphatidylinositol 4,5-bisphosphate, is hydrolyzed to inositol 1,4,5-trisphosphate and diacylglycerol (DAG). Inositol 1,4,5-trisphosphate signals a rise in intracellular free calcium, leading to translocation of nuclear factor of activated T cells into the nucleus. DAG activates RasGRP and protein kinase C theta. Because both RasGRP and protein kinase C theta are essential for thymocyte and T cell function, it is critical to understand how DAG is regulated. In this report, we demonstrate expression of DAG kinase zeta (DGKzeta, the enzyme that catalyzes the conversion of DAG to phosphatidic acid) in multiple lymphoid organs, with highest expression observed within the T cell compartment. Overexpression studies in Jurkat T cells indicate that DGKzeta interferes with TCR-induced Ras and ERK activation, AP-1 induction, and expression of the activation marker CD69. In contrast, TCR-stimulated calcium influx is not altered. Mutational analysis indicates that the kinase and DAG binding domains, but not the ankyrin repeats of DGKzeta, are required for its inhibitory effects. Collectively these studies demonstrate a potential role of DGKzeta to function as a selective negative regulator of DAG signaling on T cell activation and provide the first structure/function analysis of this enzyme in T cells.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Signal Transduct Program, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Grad Program Immunol, Philadelphia, PA 19104 USA; Rigel Inc, San Francisco, CA 94080 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Koretzky, GA (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Signal Transduct Program, 415 BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.		Koretzky, Gary/AAU-5381-2021					ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; Berg LJ, 2001, CURR OPIN IMMUNOL, V13, P232, DOI 10.1016/S0952-7915(00)00209-0; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Castellanos MD, 1997, J IMMUNOL, V159, P5463; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Ding L, 1998, FEBS LETT, V429, P109, DOI 10.1016/S0014-5793(98)00490-6; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu YC, 2002, TRENDS IMMUNOL, V23, P140, DOI 10.1016/S1471-4906(01)02157-3; Liu ZT, 2001, J BIOL CHEM, V276, P5900, DOI 10.1074/jbc.M007311200; MIKOSHIBA K, 2000, SCI STKE; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Seminario MC, 2002, SEMIN IMMUNOL, V14, P27, DOI 10.1006/smim.2001.0339; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	72	91	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31089	31098		10.1074/jbc.M203818200	http://dx.doi.org/10.1074/jbc.M203818200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070163	hybrid			2022-12-25	WOS:000177579800088
J	Liu, BL; Peng, D; Lu, Y; Jin, WD; Fan, Z				Liu, BL; Peng, D; Lu, Y; Jin, WD; Fan, Z			A novel single amino acid deletion caspase-8 mutant in cancer cells that lost proapoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; CYTOCHROME-C; CD95 FAS/APO-1; DEATH DOMAIN; ACTIVATION; INDUCTION; PROTEASE; FADD; GENE	Caspase-8 is an important initiation caspase that activates the caspase cascade during death receptor-mediated apoptosis. We here report a novel caspase-8 mutant with a naturally occurring deletion of leucine 62 (DeltaLeu62casp-8). DeltaLeu62casp-8 has a shorter half-life than its wild-type counterpart. Unlike wild-type caspase-8, DeltaLeu62casp-8 failed to interact with wild-type caspase-8 or with the adaptor protein FADD. DeltaLeu62casp-8 lost its proapoptotic activity in mammalian cells. The leucine 62 therefore is critical for caspase-8 function, and the mutation may be one of the mechanisms through which some types of cancer cells escape from programmed cell death.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 036, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beltinger C, 1998, BLOOD, V91, P3943; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Liu B, 2000, BRIT J CANCER, V82, P1991; Liu BL, 2001, ONCOGENE, V20, P3726, DOI 10.1038/sj.onc.1204490; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ozoren N, 2000, INT J ONCOL, V16, P917; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Tamiya S, 1998, BLOOD, V91, P3935; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30159	30164		10.1074/jbc.M203566200	http://dx.doi.org/10.1074/jbc.M203566200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12055196	hybrid			2022-12-25	WOS:000177509300100
J	Neve, RM; Holbro, T; Hynes, NE				Neve, RM; Holbro, T; Hynes, NE			Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells	ONCOGENE			English	Article						ErbB2; p27(kip1); p38MAPK; PI3K; MAPK; heregulin	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; DOWN-REGULATION; CDK INHIBITORS; ERBB RECEPTORS; MYC; PROLIFERATION; NEUREGULIN	Addition of the ErbB-ligand, Heregulinbeta1 (HRG), to breast tumour-derived T47D cells promotes D-cyclin expression, p21(cip1) synthesis, cyclin-dependent kinase (CDK) activation through re-disiribution of p27(kip1) and DNA synthesis. In contrast EGF has no effect on T47D cell cycle progression. By comparing these two ligands and the use of specific inhibitors for phosphatidylinositol-3 kinase (PI3K), mitogen-activated protein kinase (MAPK) and p38MAPK, we have identified several molecular mechanisms required for ErbB receptor-mediated proliferation. The PI3K, MAPK and p38MAPK pathways each displayed distinct activation profiles in response to either HRG or EGF, with obvious differences in both the intensity and duration of signal output. Through inhibition of each of these pathways it is apparent that each pathway is necessary, yet insufficient alone, to stimulate proliferation. Each pathway regulates distinct subsets of essential cell cycle regulators and integration of these signal networks is required for the timely expression of these components, which culminates in cell cycle progression. Significantly, the mechanisms controlling ligand-stimulated proliferation through ErbB2 are strikingly similar to the mechanisms through which overexpressed, constitutively activated, ErbB2 orchestrates uncontrolled proliferation in cancer cells. This suggests that downstream effectors of ErbB receptors represent good therapeutic targets for breast cancer.	Novartis Forsch Stiftung Zweigniederlassung, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Buck Inst, Novato, CA 94945 USA; UCSF, Dept Hematol Oncol, San Francisco, CA USA	Friedrich Miescher Institute for Biomedical Research; Novartis; Buck Institute for Research on Aging; University of California System; University of California San Francisco	Neve, RM (corresponding author), Novartis Forsch Stiftung Zweigniederlassung, Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	rneve@buckinstitute.org						Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hijazi MM, 2000, INT J ONCOL, V17, P629; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; JONGEWARD GD, 1995, GENETICS, V139, P1553; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sellers LA, 2000, MOL CELL BIOL, V20, P5974, DOI 10.1128/MCB.20.16.5974-5985.2000; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SORKIN A, 1993, ONCOGENE, V8, P3021; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woldeyesus MT, 1999, GENE DEV, V13, P2538, DOI 10.1101/gad.13.19.2538; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, EUR J CANCER, V37, pS3	62	92	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4567	4576		10.1038/sj.onc.1205555	http://dx.doi.org/10.1038/sj.onc.1205555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085235				2022-12-25	WOS:000176476700011
J	Toyooka, S; Carbone, M; Toyooka, K; Bocchetta, M; Shivapurkar, N; Minna, JD; Gazdar, AF				Toyooka, S; Carbone, M; Toyooka, K; Bocchetta, M; Shivapurkar, N; Minna, JD; Gazdar, AF			Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells	ONCOGENE			English	Article						SV40; methylation; RASSF1A; mesothelial cell; mesothelioma	HUMAN PLEURAL MESOTHELIOMA; LARGE-T-ANTIGEN; EPIGENETIC INACTIVATION; PROMOTER HYPERMETHYLATION; MALIGNANT MESOTHELIOMA; DNA METHYLATION; LUNG CARCINOMAS; CPG ISLANDS; SIMIAN-VIRUS-40; 3P21.3	Mesotheliomas are tumors arising from mesothelial cells and are associated with asbestos exposure and approximately 50% contain simian virus 40 (SV40) DNA sequences. SV40 infection of human mesothelial cells (HM) causes early cellular immortalization and late transformation. Aberrant methylation is a major mechanism for loss of function of tumor suppressor genes (TSGs). We recently reported that of seven genes frequently methylated in epithelial tumors, only RASSF1A gene was frequently methylated in mesotheliomas, and its methylation was correlated with loss of RASSF1A expression and the presence of SV40. We studied whether SV40 infection of normal HM induces aberrant methylation of the genes previously studied in mesotheliomas. Of six infected foci examined at early passages (passages 8-30) there was no methylation of the seven genes examined. Of two foci examined at late passages (passages 51-86) after the appearance of morphological changes suggestive of transformation, methylation and loss of expression of RASSF1A was detected. Sequencing of the CpG dense region around the transcription start site and semi-quantitative real-time methylation specific PCR (MSP) assay for RASSF1A methylation demonstrated progressive methylation during late passages. Exposure to the demethylating agent 5-aza-2'-deoxycytidine restored RASSF1A expression, while exposure to the histone deacetylation inhibitor trichostatin A had no effect. These data, together with our previous findings, support a causal relationship between SV40 infection, progressive RASSF1A methylation and its silencing, and the pathogenesis of mesothelioma.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Maywood, IL 60153 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Loyola University Chicago	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Adi.GAZDAR@UTSouthwestern.edu			NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618, U01CA084971] Funding Source: NIH RePORTER; NCI NIH HHS [5U01CA8497102, R01 CA2657, R01 CA 71618, P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Antman K, 2001, CANC PRINCIPLES PRAC, P1943; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2000, CANCER RES, V60, P2368; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Klein G, 2000, P NATL ACAD SCI USA, V97, P9830, DOI 10.1073/pnas.190325697; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morrissey C, 2001, CANCER RES, V61, P7277; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Testa JR, 2001, CANC PRINCIPLES PRAC, P1937; Toyooka S, 2001, CANCER RES, V61, P5727; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Waheed I, 1999, CANCER RES, V59, P6068	28	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4340	4344		10.1038/sj.onc.1205381	http://dx.doi.org/10.1038/sj.onc.1205381			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082623				2022-12-25	WOS:000176174200018
J	Pierce, A; Spooncer, E; Ainsworth, S; Whetton, AD				Pierce, A; Spooncer, E; Ainsworth, S; Whetton, AD			BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor	ONCOGENE			English	Article						BCR-ABL; c-kit; CML; differentiation; haemopoietic	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; TRANSGENIC MICE; PHILADELPHIA-CHROMOSOME; PROGENITOR CELLS; CD34(+) CELLS; KIT-LIGAND; LINE	Chronic myeloid leukaemia (CML), a hematopoietic stem cell disorder is characterized by the expression of BCR-ABL. To investigate the effects of BCR-ABL on multipotent hematopoietic cells, a temperature sensitive BCR-ABL tyrosine kinase was expressed in the cell line, FDCP-Mix. BCR-ABL mediated an increase in c-kit expression that correlated with an enhanced mitogenic response to SCF. This was not observed in the absence of Ber-Abl kinase activity or presence of the BCR-ABL inhibitor STI571, which also inhibits c-kit. When cultured in a combination of SCF plus G-CSF the FDCP-Mix cells undergo neutrophilic differentiation over a 7-10 day period. When BCR-ABL was active there was a marked inhibition of cell maturation compared to control cells in which BCR-ABL was either inactive or not present. However, BCR-ABL did not block differentiation as the cells eventually undergo terminal maturation. These data argue that BCR-ABL is directly responsible for the enhanced response to SCF reported in CML progenitor cells. Furthermore, although the primary effect of STI571 is via direct inhibition of BCR-ABL, STI571 additionally reduces the enhanced response to SCF. Thus there are two sites of STI571 action of potential importance in Bcr-Abl expressing cells.	Univ Manchester, Dept Biomol Sci, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England	University of Manchester	Whetton, AD (corresponding author), Univ Manchester, Dept Biomol Sci, Leukaemia Res Fund Cellular Dev Unit, Sackville St, Manchester M60 1QD, Lancs, England.	Tony.Whetton@Umist.ac.uk		WHETTON, ANTHONY D/0000-0002-1098-3878; Pierce, Andrew/0000-0001-5995-2469				AGARWAL R, 1995, BLOOD, V85, P1306, DOI 10.1182/blood.V85.5.1306.bloodjournal8551306; Al-Taher A, 2000, YEAST, V17, P201, DOI 10.1002/1097-0061(20000930)17:3<201::AID-YEA30>3.0.CO;2-R; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Darley RL, 1999, EXP HEMATOL, V27, P1599, DOI 10.1016/S0301-472X(99)00100-9; Eaves A C, 1998, Stem Cells, V16 Suppl 1, P77; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Moore S, 1998, BLOOD, V92, P2461, DOI 10.1182/blood.V92.7.2461.2461_2461_2470; Pierce A, 1998, J CELL SCI, V111, P815; Pierce A, 2000, ONCOGENE, V19, P5487, DOI 10.1038/sj.onc.1203940; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; WANG J Y J, 1992, Current Biology, V2, P70, DOI 10.1016/0960-9822(92)90198-J; Wisniewski D, 1996, LEUKEMIA, V10, P229	32	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3068	3075		10.1038/sj.onc.1205424	http://dx.doi.org/10.1038/sj.onc.1205424			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082538				2022-12-25	WOS:000175262700015
J	Filali, M; Cheng, NL; Abbott, D; Leontiev, V; Engelhardt, JF				Filali, M; Cheng, NL; Abbott, D; Leontiev, V; Engelhardt, JF			Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; WNT-3A; INDUCTION; ISOFORMS; PATHWAY; AXIN	Members of the Wnt family of secreted molecules have been established as key factors in determining cell fate and morphogenic signaling. It has long been recognized that Wnt induces morphogenic signaling through the Tcf/LEF-1 cascade by regulating free intracellular levels of beta-catenin, a co-factor for Tcf/LEF-1 transcription factors. In the present study, we have demonstrated that Wnt-3A can also directly induce transcription from the LEF-1 promoter. This induction was dependent on glycogen synthase kinase 3beta inactivation, a rise in free intracellular beta-catenin, and a short 110-bp Wnt-responsive element (W-RE) in the LEF-1 promoter. Linear and internal deletion of this WRE led to a dramatic increase in constitutive LEF-1 promoter activity and loss of Wnt-3A responsiveness. In isolation, the 110-bp WRE conferred context-independent Wnt-3A or beta-catenin(S37A) responsiveness to a heterologous SV40 promoter. Studies expressing dominant active and negative forms of LEF-1, beta-catenin, GSK-3beta, and beta-catenin/LEF-1 fusions suggest that Wnt-3A activates the LEF-1 promoter through a beta-catenin-dependent and LEF-1-independent process. Wnt-3A expression also induced multiple changes in the binding of factors to the WRE and suggests that regulatory mechanisms may involve modulation of a multiprotein complex. In summary, these results provide evidence for transcriptional regulation of the LEF-1 promoter by Wnt and enhance the mechanistic understanding of Wnt/beta-catenin signaling in the regulation of LEF-1-dependent developmental processes.	Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Engelhardt, JF (corresponding author), Univ Iowa, Dept Anat & Cell Biol, Rm 1-111 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.			Engelhardt, John/0000-0003-2389-9277	NIDDK NIH HHS [R01 DK47967, R01 DK047967] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047967] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; Hovanes K, 2000, NUCLEIC ACIDS RES, V28, P1994, DOI 10.1093/nar/28.9.1994; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Millar SE, 1999, DEV BIOL, V207, P133, DOI 10.1006/dbio.1998.9140; Poss KD, 2000, DEV DYNAM, V219, P282, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1045>3.3.CO;2-3; RANISH JA, 1991, J BIOL CHEM, V266, P19320; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shibamoto S, 1998, GENES CELLS, V3, P659; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	21	204	207	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33398	33410		10.1074/jbc.M107977200	http://dx.doi.org/10.1074/jbc.M107977200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12052822	hybrid			2022-12-25	WOS:000177859000129
J	Krohn, NM; Yanagisawa, S; Grasser, KD				Krohn, NM; Yanagisawa, S; Grasser, KD			Specificity of the stimulatory interaction between chromosomal HMGB proteins and the transcription factor Dof2 and its negative regulation by protein kinase CK2-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; MOBILITY GROUP PROTEIN-1; NUCLEOPROTEIN COMPLEXES; ARCHITECTURAL ELEMENTS; DOMAIN PROTEINS; SSRP1 PROTEINS; HIGHER-PLANTS; MAIZE HMGA; IN-VITRO; CHROMATIN	The high mobility group (HMG) proteins of the HMGB family are chromatin-associated proteins that can contribute to transcriptional control by interaction with certain transcription factors. Using the transcription factor Dof2 and five different maize HMGB proteins, we have examined the specificity of the HMGB-transcription factor interaction. The HMG-box DNA binding domain of HMGB1 is sufficient for the interaction with Dof2. Although all tested HMGB proteins can interact with Dof2, the various HMGB proteins stimulate the binding of Dof2 to its DNA target site with different efficiencies. The HMGB5 protein is clearly the most potent facilitator of Dof2 DNA binding. Maximal stimulation of the DNA binding by the HMGB proteins requires association of HMGB and Dof2 prior to DNA binding. HMGB5 and Dof2 form a ternary complex with the DNA, but within the protein-DNA complex the interaction of EMGB5 and Dof2 is different from that in solution, as in contrast to the proteins in solution, they cannot be cross-linked with glutaraldehyde when bound to DNA. Phosphorylation of HMGB1 by protein kinase CK2 abolishes the interaction with Dof2 and the stimulation of Dof2 DNA binding. These findings indicate that transcription factors may recruit certain members of the HMGB family as assistant factors.	Univ Aalborg, Inst Life Sci, Dept Biotechnol, DK-9000 Aalborg, Denmark; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan	Aalborg University; University of Tokyo	Grasser, KD (corresponding author), Univ Aalborg, Inst Life Sci, Dept Biotechnol, Sohngaardsholmsvej 49, DK-9000 Aalborg, Denmark.							ALONSO JC, 1995, MOL MICROBIOL, V18, P471, DOI 10.1111/j.1365-2958.1995.mmi_18030471.x; Baumann K, 1999, PLANT CELL, V11, P323, DOI 10.1105/tpc.11.3.323; Beckett D, 2001, J MOL BIOL, V314, P335, DOI 10.1006/jmbi.2001.5134; BIANCHI ME, 1994, MOL MICROBIOL, V14, P1, DOI 10.1111/j.1365-2958.1994.tb01261.x; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; Das D, 2001, J BIOL CHEM, V276, P32597, DOI 10.1074/jbc.M011792200; Decoville M, 2000, NUCLEIC ACIDS RES, V28, P454, DOI 10.1093/nar/28.2.454; Dintilhac A, 2002, J BIOL CHEM, V277, P7021, DOI 10.1074/jbc.M108417200; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; Ellwood KB, 2000, MOL CELL BIOL, V20, P4359, DOI 10.1128/MCB.20.12.4359-4370.2000; GE H, 1994, J BIOL CHEM, V269, P17136; Grasser KD, 1998, TRENDS PLANT SCI, V3, P260, DOI 10.1016/S1360-1385(98)01259-X; Grasser KD, 1996, J BIOL CHEM, V271, P32900, DOI 10.1074/jbc.271.51.32900; Grasser KD, 2000, PHYSIOL PLANTARUM, V110, P427, DOI 10.1111/j.1399-3054.2000.1100401.x; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kang HG, 2000, PLANT J, V21, P329, DOI 10.1046/j.1365-313x.2000.00678.x; LANDSMAN D, 1991, MOL CELL BIOL, V11, P4483, DOI 10.1128/MCB.11.9.4483; Lichota J, 2001, BIOCHEMISTRY-US, V40, P7860, DOI 10.1021/bi010548y; Mena M, 1998, PLANT J, V16, P53, DOI 10.1046/j.1365-313x.1998.00275.x; Moreira JMA, 2000, EMBO J, V19, P6804, DOI 10.1093/emboj/19.24.6804; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; Ritt C, 1998, BIOCHEMISTRY-US, V37, P2673, DOI 10.1021/bi972620r; Ritt C, 1998, PLANT J, V14, P623, DOI 10.1046/j.1365-313X.1998.00154.x; Schultz TF, 1996, J BIOL CHEM, V271, P25742, DOI 10.1074/jbc.271.42.25742; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; SPIKER S, 1988, PHYSIOL PLANTARUM, V74, P200, DOI 10.1111/j.1399-3054.1988.tb04964.x; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; Stemmer C, 1999, PLANT MOL BIOL, V41, P351, DOI 10.1023/A:1006311121717; Stemmer C, 2002, J BIOL CHEM, V277, P1092, DOI 10.1074/jbc.M109503200; Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Travers A, 2000, CURR OPIN STRUC BIOL, V10, P102, DOI 10.1016/S0959-440X(99)00056-1; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; Washio K, 2001, BBA-GENE STRUCT EXPR, V1520, P54, DOI 10.1016/S0167-4781(01)00251-2; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; Yanagisawa S, 1999, PLANT J, V17, P209, DOI 10.1046/j.1365-313X.1999.00363.x; Yanagisawa S, 1996, TRENDS PLANT SCI, V1, P213; Yanagisawa S, 1998, PLANT CELL, V10, P75, DOI 10.1105/tpc.10.1.75; Yanagisawa S, 1997, EUR J BIOCHEM, V250, P403, DOI 10.1111/j.1432-1033.1997.0403a.x; Yanagisawa S, 2000, PLANT J, V21, P281, DOI 10.1046/j.1365-313x.2000.00685.x; Yanagisawa S, 2001, PLANT CELL PHYSIOL, V42, P813, DOI 10.1093/pcp/pce105; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; Zhang B, 1995, PLANT CELL, V7, P2241, DOI 10.1105/tpc.7.12.2241; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	56	60	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32438	32444		10.1074/jbc.M203814200	http://dx.doi.org/10.1074/jbc.M203814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12065590	hybrid			2022-12-25	WOS:000177859000007
J	Morimoto, S; Cassell, MD; Sigmund, CD				Morimoto, S; Cassell, MD; Sigmund, CD			Glia- and neuron-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; TRANSGENIC MICE; MESSENGER-RNA; DOG BRAIN; RESPONSES; LOCALIZATION; INITIATION; CAPTOPRIL; PROMOTER; APPETITE	The purpose of this study is to examine the regulation of blood pressure and fluid and electrolyte homeostasis in mice overexpressing angiotensin II (Ang-II) in the brain and to determine whether there are significant physiologic differences in Ang-II production in neurons or glia. Therefore, we generated and characterized transgenic mice overexpressing human renin (hREN) under the control of the glial fibrillary acidic protein (GFAP) promoter (GFAP-hREN) and synapsin-I promoter (SYN-hREN) and bred them with mice expressing human angiotensinogen (hAGT) under the control of the same promoters (GFAP-hAGT and SYN-hAGT). Both GFAP-hREN and SYN-hREN mice exhibited the highest hREN mRNA expression in the brain and had undetectable levels of hREN protein in the systemic circulation. In the brain of GFAP-hREN and SYN-hREN mice, hREN protein was observed almost exclusively in astrocytes and neurons, respectively. Transgenic mice overexpressing both hREN and hAGT transgenes in either glia or neurons were moderately hypertensive. In the glia-targeted mice, blood pressure could be corrected by intracerebroventricular injection of the Ang-II type 1 receptor antagonist losartan, and intravenous injection of a ganglion blocking agent, but not an arginine vasopressin V1 receptor antagonist, lowered blood pressure. These data suggest that stimulation of Ang-II type 1 receptors in the brain by Ang-II derived from local synthesis of renin and angiotensinogen can cause an elevation in blood pressure via a mechanism involving enhanced sympathetic outflow. Glia- and neuron-targeted mice also exhibited an increase in drinking volume and salt preference, suggesting that chronic overexpression of renin and angiotensinogen locally in the brain can result in hypertension and alterations in fluid homeostasis.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Med Educ & Biomed Res Facil 3181B, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Sigmund, CD (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Med Educ & Biomed Res Facil 3181B, Iowa City, IA 52242 USA.		Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NHLBI NIH HHS [HL58048, HL55006, HL61446] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006, R01HL061446] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bader J, 2001, J MOL MED, V79, P76, DOI 10.1007/s001090100210; BICKERTON R, 1961, P SOC EXP BIOL MED, V106, P834; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; BUCKLEY JP, 1984, J PHYSIOL-PARIS, V79, P485; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; Cook JL, 2001, CIRC RES, V89, P1138, DOI 10.1161/hh2401.101270; Davisson RL, 1998, CIRC RES, V83, P1047, DOI 10.1161/01.RES.83.10.1047; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; FISCHERFERRARO C, 1971, J EXP MED, V133, P353, DOI 10.1084/jem.133.2.353; FITTS DA, 1990, BEHAV NEUROSCI, V104, P818, DOI 10.1037/0735-7044.104.5.818; FITTS DA, 1990, BEHAV NEUROSCI, V104, P643, DOI 10.1037/0735-7044.104.4.643; FUXE K, 1980, NEUROSCI LETT, V18, P245, DOI 10.1016/0304-3940(80)90292-X; GANTEN D, 1971, AM J PHYSIOL, V221, P1733, DOI 10.1152/ajplegacy.1971.221.6.1733; GENAIN CP, 1985, J CLIN INVEST, V76, P1939, DOI 10.1172/JCI112191; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; HOESCHE C, 1993, J BIOL CHEM, V268, P26494; IMBODEN H, 1987, BRAIN RES, V410, P74, DOI 10.1016/S0006-8993(87)80022-7; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V185, P688, DOI 10.1016/0006-291X(92)91680-O; KAWASAKI H, 1987, EUR J PHARMACOL, V138, P351, DOI 10.1016/0014-2999(87)90473-0; LARK LA, 1992, EUR J PHARMACOL, V222, P33, DOI 10.1016/0014-2999(92)90459-H; Lee-Kirsch MA, 1999, CIRC RES, V84, P240, DOI 10.1161/01.RES.84.2.240; MENDELSOHN FAO, 1984, J HYPERTENSION S3, V2, P41; Merrill DC, 1996, J CLIN INVEST, V97, P1047, DOI 10.1172/JCI118497; Morimoto S, 2002, PHYSIOL GENOMICS, V9, P113, DOI 10.1152/physiolgenomics.00007.2002; Morimoto S, 2002, CIRC RES, V90, P80, DOI 10.1161/hh0102.102272; Morimoto S, 2001, CIRC RES, V89, P365, DOI 10.1161/hh1601.094988; PHILLIPS MI, 1977, NATURE, V270, P445, DOI 10.1038/270445a0; POCHIERO M, 1983, PHARMACOL RES COMMUN, V15, P173, DOI 10.1016/S0031-6989(83)80059-9; Prescott G, 2000, PHYSIOL GENOMICS, V4, P67, DOI 10.1152/physiolgenomics.2000.4.1.67; ROWE BP, 1990, EUR J PHARMACOL, V186, P339, DOI 10.1016/0014-2999(90)90457-H; Ryan MJ, 2002, ARTERIOSCL THROM VAS, V22, P42, DOI 10.1161/hq0102.101098; SCHELLING P, 1982, NEUROPHARMACOLOGY, V21, P455, DOI 10.1016/0028-3908(82)90031-4; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; Sinn PL, 2000, PHYSIOL GENOMICS, V3, P25, DOI 10.1152/physiolgenomics.2000.3.1.25; Sinn PL, 1999, J BIOL CHEM, V274, P35785, DOI 10.1074/jbc.274.50.35785; SLATER EE, 1980, P NATL ACAD SCI-BIOL, V77, P5458, DOI 10.1073/pnas.77.9.5458; Stec DE, 2001, BIOTECHNIQUES, V31, P256, DOI 10.2144/01312bm03; STORNETTA RL, 1988, SCIENCE, V242, P1444, DOI 10.1126/science.3201232; THOMAS WG, 1988, NEUROSCIENCE, V25, P319, DOI 10.1016/0306-4522(88)90029-2; Thompson MW, 1996, HYPERTENSION, V28, P290, DOI 10.1161/01.HYP.28.2.290; WRIGHT JW, 1992, BRAIN RES REV, V17, P227, DOI 10.1016/0165-0173(92)90018-H; YONGUE BG, 1991, HYPERTENSION, V17, P485, DOI 10.1161/01.HYP.17.4.485	42	93	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33235	33241		10.1074/jbc.M204309200	http://dx.doi.org/10.1074/jbc.M204309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080069	hybrid			2022-12-25	WOS:000177859000108
J	Reischl, S; Wiegert, T; Schumann, W				Reischl, S; Wiegert, T; Schumann, W			Isolation and analysis of mutant alleles of the Bacillus subtilis HrcA repressor with reduced dependency on GroE function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; CHAPERONIN GROEL; DNAK OPERON; NEGATIVE REGULATION; IN-VITRO; CLONING; CIRCE; GENES; IDENTIFICATION	The hrcA gene of Bacillus subtilis codes for a transcriptional repressor protein that negatively regulates expression of the heptacistronic dnaK and the bicistronic groE operon by binding to an operator-element called CIRCE. Recently, we have published data suggesting that the activity of HrcA is modulated by the GroE chaperonin system. Biochemical analyses of the HrcA protein have been hampered so far by its strong tendency to aggregate. Here, a genetic method was used to isolate mutant forms of HrcA with increased activity under conditions of decreased GroE function. One of these mutant forms (HrcA114) containing five amino acid replacements exhibited enhanced solubility when overexpressed. HrcA114 purified under native conditions produced two retarded CIRCE-containing DNA fragments in band shift experiments. The amount of the larger fragment increased after addition of GroEL, GroES, and ATP but decreased when ATP was replaced by the nonhydrolyzable ATP analog ATRyS. DNase I footprinting experiments exhibited full protection of the CIRCE element and neighboring nucleotides in an asymmetric way. An in vitro binding assay using affinity chromatography showed direct and specific interaction between HrcA114 and GroEL. All these experimental data are in full agreement with our previously published model that HrcA needs the GroE chaperonin system for activation.	Univ Bayreuth, Inst Genet, D-95440 Bayreuth, Germany	University of Bayreuth	Wiegert, T (corresponding author), Univ Bayreuth, Inst Genet, Univ Str 30, D-95440 Bayreuth, Germany.							Ahmad S, 1999, INT J SYST BACTERIOL, V49, P1387, DOI 10.1099/00207713-49-4-1387; BANUETT F, 1986, J MOL BIOL, V187, P213, DOI 10.1016/0022-2836(86)90229-9; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CARRILLO N, 1992, J BIOL CHEM, V267, P15537; Enz S, 2000, J BACTERIOL, V182, P637, DOI 10.1128/JB.182.3.637-646.2000; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hecker M, 1996, MOL MICROBIOL, V19, P417, DOI 10.1046/j.1365-2958.1996.396932.x; HIRATA H, 1986, J BACTERIOL, V166, P722, DOI 10.1128/jb.166.3.722-727.1986; Homuth G, 1997, J BACTERIOL, V179, P1153, DOI 10.1128/jb.179.4.1153-1164.1997; Homuth G, 1996, MICROBIOL-UK, V142, P1641, DOI 10.1099/13500872-142-7-1641; Homuth G, 1999, MOL MICROBIOL, V32, P1183, DOI 10.1046/j.1365-2958.1999.01428.x; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Kim L, 1996, GENE, V181, P71, DOI 10.1016/S0378-1119(96)00466-0; Kim SN, 2001, MOL CELLS, V11, P360; Koch B, 1998, J BACTERIOL, V180, P3873, DOI 10.1128/JB.180.15.3873-3881.1998; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Martin A, 2001, J MOL BIOL, V309, P717, DOI 10.1006/jmbi.2001.4698; Martirani L, 2001, FEMS MICROBIOL LETT, V198, P177, DOI 10.1016/S0378-1097(01)00142-2; Maxam A M, 1980, Methods Enzymol, V65, P499; Minder AC, 2000, J BACTERIOL, V182, P14, DOI 10.1128/JB.182.1.14-22.2000; Mogk A, 1997, EMBO J, V16, P4579, DOI 10.1093/emboj/16.15.4579; Mogk A, 1998, J BACTERIOL, V180, P2895, DOI 10.1128/JB.180.11.2895-2900.1998; Mogk A, 1996, GENE, V182, P33, DOI 10.1016/S0378-1119(96)00447-7; Narberhaus F, 1999, MOL MICROBIOL, V31, P1, DOI 10.1046/j.1365-2958.1999.01166.x; Rungeling E, 1999, FEMS MICROBIOL LETT, V170, P119; SAITO H, 1979, MOL GEN GENET, V170, P117, DOI 10.1007/BF00337785; SCHMIDT A, 1992, J BACTERIOL, V174, P3993, DOI 10.1128/jb.174.12.3993-3999.1992; SCHULZ A, 1995, MOL MICROBIOL, V15, P421, DOI 10.1111/j.1365-2958.1995.tb02256.x; SCHUMANN W, 2001, BACILLUS SUBTILIS IT; Segal G, 1996, FEMS MICROBIOL LETT, V138, P1; Servant P, 2001, ARCH MICROBIOL, V176, P237, DOI 10.1007/s002030100321; Storz G., 2000, BACTERIAL STRESS RES; Watanabe K, 2001, J BACTERIOL, V183, P155, DOI 10.1128/JB.183.1.155-161.2001; WETZSTEIN M, 1992, J BACTERIOL, V174, P3300, DOI 10.1128/jb.174.10.3300-3310.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yura T, 2000, BACTERIAL STRESS RESPONSES, P3; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZUBER U, 1994, J BACTERIOL, V176, P1359, DOI 10.1128/jb.176.5.1359-1363.1994	40	44	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32659	32667		10.1074/jbc.M201372200	http://dx.doi.org/10.1074/jbc.M201372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082092	hybrid			2022-12-25	WOS:000177859000035
J	Sato, A; Sasakura, Y; Sugiyama, S; Sagami, I; Shimizu, T; Mizutani, Y; Kitagawa, T				Sato, A; Sasakura, Y; Sugiyama, S; Sagami, I; Shimizu, T; Mizutani, Y; Kitagawa, T			Stationary and time-resolved resonance Raman spectra of His(77) and Met(95) mutants of the isolated heme domain of a direct oxygen sensor from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR COOA; SOLUBLE GUANYLATE-CYCLASE; CYTOCHROME-C PEROXIDASE; LIGAND-BINDING; RHIZOBIUM-MELILOTI; CARBON-MONOXIDE; RHODOSPIRILLUM-RUBRUM; POCKET STRUCTURE; PROXIMAL LIGAND; KINASE-ACTIVITY	The heme environments of Met(95) and HiS(77) mutants of the isolated heme-bound PAS domain (Escherichia coli DOS PAS) of a direct oxygen sensing protein from E. coli (E. coli DOS) were investigated with resonance Raman (RR) spectroscopy and compared with the wild type (WT) enzyme. The RR spectra of both the reduced and oxidized WT enzyme were characteristic of six-coordinate low spin heme complexes from pH 4 to 10. The time-resolved RR spectra of the photodissociated CO-WT complex had an iron-His stretching band (upsilon(Fe-His)) at 214 cm(-1), and the upsilon(Fe-Co) versus upsilon(Co) plot of CO-WT E. coli DOS PAS fell on the line of His-coordinate heme proteins. The photodissociated CO-H77A mutant complex did not yield the upsilon(Fe-His) band but gave a upsilon(Fe-Im) band in the presence of imidazole. The RR spectrum of the oxidized M95A mutant was that of a six-coordinate low spin complex (i.e. the same as that of the WT enzyme), whereas the reduced mutant appeared to contain a five-coordinate heme complex. Taken together, we suggest that the heme of the reduced WT enzyme is coordinated by His(77) and Met(95), and that Met(95) is displaced by CO and O-2. Presumably, the protein conformational change that occurs upon exchange of an unknown ligand for Met(95) following heme reduction may lead to activation of the phosphodiesterase domain of E. coli DOS.	Grad Univ Adv Studies, Sch Adv Sci, Hayama, Kanagawa 2400193, Japan; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Kobe Univ, Mol Photosci Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan; Okazaki Natl Res Inst, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan	Graduate University for Advanced Studies - Japan; Tohoku University; Kobe University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB)	Kitagawa, T (corresponding author), Grad Univ Adv Studies, Sch Adv Sci, Shonan Village, Hayama, Kanagawa 2400193, Japan.	teizo@ims.ac.jp	Mizutani, Yasuhisa/B-3809-2009	Shimizu, Toru/0000-0002-3950-5554				Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; HASHIMOTO S, 1986, J BIOL CHEM, V261, P1110; He YP, 1999, J BIOL CHEM, V274, P10840, DOI 10.1074/jbc.274.16.10840; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; KITAGAWA T, 1975, J BIOCHEM-TOKYO, V78, P719, DOI 10.1093/oxfordjournals.jbchem.a130960; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kushkuley B, 1996, BIOPHYS J, V70, P1214, DOI 10.1016/S0006-3495(96)79680-7; Lahiri S, 2000, OXYGEN SENSING MOL M; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; MATSUKAWA S, 1985, J AM CHEM SOC, V107, P1108, DOI 10.1021/ja00291a004; Miyatake H, 2000, J MOL BIOL, V301, P415, DOI 10.1006/jmbi.2000.3954; Miyatake H, 1999, J BIOL CHEM, V274, P23176, DOI 10.1074/jbc.274.33.23176; Mizutani Y, 1997, SCIENCE, V278, P443, DOI 10.1126/science.278.5337.443; Mizutani Y, 2001, J PHYS CHEM B, V105, P10992, DOI 10.1021/jp010923w; Mukai M, 2000, BIOCHEMISTRY-US, V39, P13810, DOI 10.1021/bi001184x; NAGAI M, 1991, BIOCHEMISTRY-US, V30, P6495, DOI 10.1021/bi00240a021; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROGERS KR, 1999, CURR OPIN CHEM BIOL, V3, P158; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1132, DOI 10.1021/bi00535a004; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uesugi Y, 1997, REV SCI INSTRUM, V68, P4001, DOI 10.1063/1.1148373; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m	60	59	60	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32650	32658		10.1074/jbc.M204559200	http://dx.doi.org/10.1074/jbc.M204559200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080073	hybrid			2022-12-25	WOS:000177859000034
J	Boulkroun, S; Fay, M; Zennaro, MC; Escoubet, B; Jaisser, F; Blot-Chabaud, M; Farman, N; Courtois-Coutry, N				Boulkroun, S; Fay, M; Zennaro, MC; Escoubet, B; Jaisser, F; Blot-Chabaud, M; Farman, N; Courtois-Coutry, N			Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCT CELL-LINE; COLLECTING DUCT; MESSENGER-RNA; INDUCED PROTEIN; INDUCED KINASE; NA+ CHANNEL; ALDOSTERONE; DIFFERENTIATION; EXPRESSION; TRANSCRIPTION	The early phase of the stimulatory action of aldosterone on sodium reabsorption in tight epithelia involves hormone-regulated genes that remain to be identified. Using a subtractive hybridization technique on isolated renal cortical collecting ducts from rats injected with a physiological dose of aldosterone, we have identified an early response cDNA highly homologous to human and murine NDRG2 (N-Myc downstream regulated gene 2), which consists of four isoforms and belongs to a new family of differentiation-related genes. NDRG2 mRNA was expressed in classical aldosterone target epithelia, and in the kidney, it was specifically located in the collecting duct, the site of aldosterone-regulated sodium absorption. NDRG2 mRNA was increased within 45 min by aldosterone in the kidney and distal colon, whereas it was unaffected in the heart. In the RCCD2 collecting duct cell line, NDRG2 mRNA was enhanced as early as 15 min after aldosterone addition by transcription-dependent effects. NDRG2 was induced by aldosterone concentrations as low as 10(-9) m, and a maximal effect was observed at 10(-8) m. In contrast, the glucocorticoid dexamethasone was ineffective in NDRG2 expression, whereas the glucocorticoid-regulated gene sgk was induced. Taken together, these results indicate that NDRG2 regulation by aldosterone is an early mineralocorticoid-specific effect. Interestingly, NDRG2 is homologous to Drosophila MESK2, a component of the Ras pathway, suggesting that activation of the Ras cascade may play a significant role in mineralocorticoid signaling.	Univ Paris 07, INSERM, U478, Fac Med Xavier Bichat, F-75870 Paris 18, France; Univ Paris 07, INSERM, U426, Fac Med Xavier Bichat, F-75870 Paris 18, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Courtois-Coutry, N (corresponding author), Univ Paris 07, INSERM, U478, Fac Med Xavier Bichat, 16 rue Henri Huchard,BP 416, F-75870 Paris 18, France.	courtois@bichat.inserm.fr	Blot-Chabaud, Marcel/D-4064-2017; Boulkroun, Sheerazed/AAX-8348-2021; Jaisser, Frederic/P-4287-2017; Boulkroun, Sheerazed/M-4459-2017; Zennaro, Maria-Christina/G-2841-2013; COUTRY, Nathalie/O-9352-2017	Boulkroun, Sheerazed/0000-0002-8796-7534; Jaisser, Frederic/0000-0001-9051-1901; Boulkroun, Sheerazed/0000-0002-8796-7534; Zennaro, Maria-Christina/0000-0001-5449-9191; COUTRY, Nathalie/0000-0001-5830-4013				Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; BlotChabaud M, 1996, KIDNEY INT, V50, P367, DOI 10.1038/ki.1996.325; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Brennan FE, 2000, MOL CELL ENDOCRINOL, V166, P129, DOI 10.1016/S0303-7207(00)00274-4; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Capurro C, 1996, AM J PHYSIOL-CELL PH, V271, pC753, DOI 10.1152/ajpcell.1996.271.3.C753; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Denault DL, 1996, AM J PHYSIOL-CELL PH, V271, pC423, DOI 10.1152/ajpcell.1996.271.1.C423; Djelidi S, 2001, J AM SOC NEPHROL, V12, P1805, DOI 10.1681/ASN.V1291805; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Escoubet B, 1997, AM J PHYSIOL-CELL PH, V272, pC1482, DOI 10.1152/ajpcell.1997.272.5.C1482; Farman N, 1999, CURR OPIN NEPHROL HY, V8, P45, DOI 10.1097/00041552-199901000-00008; Farman N, 2001, AM J PHYSIOL-RENAL, V280, pF181, DOI 10.1152/ajprenal.2001.280.2.F181; FARMAN N, 1992, AM J PHYSIOL, V263, pC810, DOI 10.1152/ajpcell.1992.263.4.C810; Funder JW, 1997, CLIN EXP HYPERTENS, V19, P885, DOI 10.3109/10641969709083193; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Guang RJ, 2000, CANCER RES, V60, P749; Hellal-Levy C, 1999, FEBS LETT, V464, P9, DOI 10.1016/S0014-5793(99)01667-1; HORISBERGER JD, 1983, AM J PHYSIOL, V245, pF89, DOI 10.1152/ajprenal.1983.245.1.F89; Huang AM, 2000, GENETICS, V156, P1219; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lin TM, 1997, P NATL ACAD SCI USA, V94, P4988, DOI 10.1073/pnas.94.10.4988; Mastroberardino L, 1998, MOL BIOL CELL, V9, P3417, DOI 10.1091/mbc.9.12.3417; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Penfornis P, 2000, AM J PHYSIOL-ENDOC M, V279, pE386, DOI 10.1152/ajpendo.2000.279.2.E386; Piquemal D, 1999, BBA-MOL CELL RES, V1450, P364, DOI 10.1016/S0167-4889(99)00056-7; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; Salnikow K, 2000, CANCER RES, V60, P38; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; Shigaev A, 2000, AM J PHYSIOL-RENAL, V278, pF613, DOI 10.1152/ajprenal.2000.278.4.F613; Shimono A, 1999, MECH DEVELOP, V83, P39, DOI 10.1016/S0925-4773(99)00025-8; Spindler B, 1999, AM J PHYSIOL-CELL PH, V276, pC1154, DOI 10.1152/ajpcell.1999.276.5.C1154; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; vanBelzen N, 1997, LAB INVEST, V77, P85; Verrey F, 2000, KIDNEY INT, V57, P1277, DOI 10.1046/j.1523-1755.2000.00962.x; Xu B, 1999, BIOL REPROD, V61, P681, DOI 10.1095/biolreprod61.3.681; Yamauchi Y, 1999, MOL BRAIN RES, V68, P149, DOI 10.1016/S0169-328X(99)00084-4; Zhou DJ, 1998, CANCER RES, V58, P2182; Zhou RH, 2001, GENOMICS, V73, P86, DOI 10.1006/geno.2000.6496	45	118	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31506	31515		10.1074/jbc.M200272200	http://dx.doi.org/10.1074/jbc.M200272200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12072429	hybrid			2022-12-25	WOS:000177718700029
J	Chao, W; Shen, Y; Li, L; Rosenzweig, A				Chao, W; Shen, Y; Li, L; Rosenzweig, A			Importance of FADD signaling in serum deprivation - and hypoxia-induced cardiomyocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CARDIAC MYOCYTES; IN-VIVO; ACTIVATION; CASPASE-8; PATHWAY; GLUCOSE; SYSTEM; MITOCHONDRIA; INVOLVEMENT	Although cardiomyocyte (CM) apoptosis has been well described in both in vitro and in vivo models of ischemic heart disease, the intracellular pathways leading to CM death have not been fully characterized. To define the role of death receptor signaling in CM apoptosis, we constructed recombinant adenoviral vectors carrying wild-type (wt) or dominant negative (dn) forms of the death receptor adaptor protein FADD (Fas-associated death domain protein) and used these vectors to transduce rat neonatal CMs in models of hypoxia- and serum deprivation (SD)-induced apoptosis. The combination of SD and hypoxia induced rapid activation of caspase-3 and -8 as well as DNA fragmentation, reaching a plateau within 4-8 h. Adenoviral expression of FADD-dn inhibited caspase-8 activation as well as hypoxia/SD-induced apoptosis at 24 h in an moi (multiplicity of infection)-dependent manner. In contrast, adenoviral expression of FADD-wt increased apoptosis and caspase-3 activity in CMs under both normoxic and hypoxic conditions. Surprisingly, FADD-dn, as well as the specific caspase-8 inhibitor benzyloxycarbonyl-IETD-fluoromethylketone also inhibited the activation of caspase-9 and -3 in CMs subjected to hypoxia/SD. These data suggest a primary role for FADD/caspase-8 signaling that is necessary and sufficient for apoptosis of CMs subjected to hypoxia/SD.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Program Cardiovasc Gene Therapy,Cardiovasc Res Ct, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Rosenzweig, A (corresponding author), Massachusetts Gen Hosp East, Program Cardiovasc Gene therapy, 114 16th St,Rm 2600, Charlestown, MA 02129 USA.			Chao, Wei/0000-0002-2505-1360	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059521, K08HL004336, R01HL061557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-04336, HL-59521, HL-61557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jeremias I, 2000, CIRCULATION, V102, P915; Kajstura J, 1996, LAB INVEST, V74, P86; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Malhotra R, 2001, AM J PHYSIOL-CELL PH, V281, pC1596, DOI 10.1152/ajpcell.2001.281.5.C1596; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wollert KC, 2000, CIRCULATION, V101, P1172, DOI 10.1161/01.CIR.101.10.1172; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	32	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31639	31645		10.1074/jbc.M204104200	http://dx.doi.org/10.1074/jbc.M204104200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12063258	hybrid			2022-12-25	WOS:000177718700044
J	Corbin, AS; Buchdunger, E; Pascal, F; Druker, BJ				Corbin, AS; Buchdunger, E; Pascal, F; Druker, BJ			Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; CLINICAL RESISTANCE; GROWTH; GENE	STI571, a selective inhibitor of Ber-Abl, has been a successful therapeutic agent in clinical trials for chronic myelogenous leukemia. Chronic phase chronic myelogenous leukemia patients treated with STI571 have durable responses; however, most responding blast phase patients relapse despite continued therapy. Co-crystallization studies of Abl kinase and an STI571-related compound identify specific amino acid residues as critical to STI571 binding, one of which, T315, has been characterized as an acquired Thr to Ile mutation in relapsed patients. Other studies, however, suggest that mutations other than these predicted contact points are capable of conferring STI571 resistance in relapsed patients. Using a variety of models of STI571 binding to the Abl kinase, we have performed an extensive mutational analysis of sites that might alter the sensitivity of the Abl kinase to STI571. Although mutation of many of the predicted contact points between Abl and STI571 result in a kinase-inactive protein, additional mutations that render the Abl kinase less sensitive to STI571 demonstrate a broad range of possibilities for clinical resistance that are now becoming evident.	Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; Novartis Pharma AG, CH-4002 Basel, Switzerland	Oregon Health & Science University; Novartis	Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	drukerb@ohsu.edu		Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [K24CA082445, R01CA065823] Funding Source: NIH RePORTER; NCI NIH HHS [K24 CA82445, 1R01 CA65823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hochhaus A, 2001, SCIENCE, V293, P2163; HOCHHAUS A, 2001, AM SOC HEM ANN M ORL; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	14	136	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32214	32219		10.1074/jbc.M111525200	http://dx.doi.org/10.1074/jbc.M111525200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077114	hybrid			2022-12-25	WOS:000177718700114
J	Santiago, C; Bjorling, E; Stehle, T; Casasnovas, JM				Santiago, C; Bjorling, E; Stehle, T; Casasnovas, JM			Distinct kinetics for binding of the CD46 and SLAM receptors to overlapping sites in the measles virus hemagglutinin protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR RECEPTOR; CRYSTAL-STRUCTURE; AFFINITY; RECOGNITION; RHINOVIRUS; SUFFICIENT; FRAGMENTS; EPITOPES; REVEALS; SURFACE	Measles virus (MV) is a human pathogen using two distinct cell surface receptors for entry into host cells. We present here a comparative analysis for binding of the MV receptors CD46 and SLAM to the measles virus hemagglutinin protein (MVH, Edmonston strain). Soluble monomeric and dimeric MM variants were prepared in mammalian cells and their conformation assessed using a panel of monoclonal antibodies. The two receptor molecules specifically bound to the MVH protein with distinct binding modes. The association rate (k(a)) for SLAM binding to MVH was very low (similar to3000 M-1 s(-1)), about 20 times lower that the k(a) determined for CD46 binding. However, SLAM bound tighter to the virus protein than CD46, as revealed by a 5-fold lower dissociation rate (k(d), similar to1.5 x 10(-3) s(-1)). These data suggest that the SLAM receptor binds to a less accessible and more hydrophobic surface on MVH than the CD46 receptor, as illustrated in a binding model. Despite the differences in kinetics, receptor competition binding experiments revealed that they recognize overlapping sites in MVH. Indeed, a panel of anti-MVH monoclonal antibodies equally inhibited binding of both receptor molecules. The similar immune reactivity of the two receptor binding sites suggests that the shift in receptor usage by MV may not be driven by immune responses.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Karolinska Inst, Microbiol & Tumor Biol Ctr, S-17177 Stockholm, Sweden; Karolinska Inst, South Hosp, Res Ctr, S-11883 Stockholm, Sweden; Massachusetts Gen Hosp, Lab Dev Immunol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Casasnovas, JM (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	jose.casasnovas@cbt.ki.se	Casasnovas, Jose M/L-6299-2014; Santiago, César/K-4240-2014	Casasnovas, Jose M/0000-0002-2873-6410; Santiago, César/0000-0002-5149-1722	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045716] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45716] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baranowski E, 2001, SCIENCE, V292, P1102, DOI 10.1126/science.1058613; Buckland R, 1997, VIRUS RES, V48, P1, DOI 10.1016/S0168-1702(96)01421-9; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; Christiansen D, 2000, J VIROL, V74, P4672, DOI 10.1128/JVI.74.10.4672-4678.2000; CLEMENTS CJ, 1995, CURR TOP MICROBIOL, V191, P13; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Crennell S, 2000, NAT STRUCT BIOL, V7, P1068; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; GRIFFIN DE, 1996, FIELDS VIROLOGY, V1, P1267; Hsu EC, 2001, VIROLOGY, V279, P9, DOI 10.1006/viro.2000.0711; Hsu EC, 1998, J VIROL, V72, P2905, DOI 10.1128/JVI.72.4.2905-2916.1998; HU AZ, 1993, VIROLOGY, V192, P351, DOI 10.1006/viro.1993.1042; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Krummenacher C, 1999, J VIROL, V73, P8127, DOI 10.1128/JVI.73.10.8127-8137.1999; Langedijk JPM, 1997, J VIROL, V71, P6155, DOI 10.1128/JVI.71.8.6155-6167.1997; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Lecouturier V, 1996, J VIROL, V70, P4200, DOI 10.1128/JVI.70.7.4200-4204.1996; Manchester M, 2000, J VIROL, V74, P3967, DOI 10.1128/JVI.74.9.3967-3974.2000; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; Nicacio CD, 2002, J VIROL, V76, P251, DOI 10.1128/JVI.76.1.251-258.2002; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; Oldstone MBA, 1999, CELL, V98, P629, DOI 10.1016/S0092-8674(00)80050-1; Ono N, 2001, J VIROL, V75, P1594, DOI 10.1128/JVI.75.4.1594-1600.2001; Plemper RK, 2000, J VIROL, V74, P6485, DOI 10.1128/JVI.74.14.6485-6493.2000; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SATO TA, 1995, J VIROL, V69, P513, DOI 10.1128/JVI.69.1.513-516.1995; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; SHESHBERADARAN H, 1986, VIROLOGY, V152, P58, DOI 10.1016/0042-6822(86)90371-5; Tanaka K, 1998, ARCH VIROL, V143, P213, DOI 10.1007/s007050050281; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Xing L, 2000, EMBO J, V19, P1207, DOI 10.1093/emboj/19.6.1207	36	62	66	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32294	32301		10.1074/jbc.M202973200	http://dx.doi.org/10.1074/jbc.M202973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12065582	hybrid			2022-12-25	WOS:000177718700124
J	Dorion, S; Lambert, H; Landry, J				Dorion, S; Lambert, H; Landry, J			Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S-transferase Mu from Ask1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATING KINASE 1; PROTEIN-KINASE; CYTOCHROME-C; MOLECULAR CHAPERONES; CELL-DEATH; MAP KINASE; APOPTOSIS; STRESS; PHOSPHORYLATION; MECHANISM	Despite the importance of the stress-activated protein kinase pathways in cell death and survival, it is unclear how stressful stimuli lead to their activation. In the case of heat shock, the existence of a specific mechanism of activation has been evidenced, but the molecular nature of this pathway is undefined. Here, we found that Ask1 (apoptosis signal-regulating kinase 1), an upstream activator of the stress-activated protein kinase p38 during exposure to oxidative stress and other stressful stimuli, was also activated by heat shock. Ask1 activity was required for p38 activation since overexpression of a kinase dead mutant of Ask1, Ask1(K709M), inhibited heat shock-induced p38 activation. The activation of Ask1 by oxidative stress involves the oxidation of thioredoxin, an endogenous inhibitor of Ask1. A different activation mechanism takes place during heat shock. In contrast to p38 induction by H2O2, induction by heat shock was not antagonized by pretreatment with the antioxidant N-acetyl-L-cysteine or by overexpressing thioredoxin and was not accompanied by the dissociation of thioredoxin from Ask1. Instead, heat shock caused the dissociation of glutathione S-transferase Mul-1 (GSTM1-1) from Ask1 and overexpression of GSTM1-1 -inhibited induction of p38 by heat shock. We concluded that because of an alternative regulation by the two distinct repressors thioredoxin and GSTM1-1, Ask1 constitutes the converging point of the heat shock and oxidative stress-sensing pathways that lead to p38 activation.	Univ Laval, Hotel Dieu, Ctr Hosp Univ Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Landry, J (corresponding author), Univ Laval, Hotel Dieu, Ctr Hosp Univ Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada.	jacques.landry@med.ulaval.ca						Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Dorion S, 1999, J BIOL CHEM, V274, P37591, DOI 10.1074/jbc.274.53.37591; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guay J, 1997, J CELL SCI, V110, P357; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Hung JJ, 1998, J BIOL CHEM, V273, P31924, DOI 10.1074/jbc.273.48.31924; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Ko YG, 2001, J BIOL CHEM, V276, P6030, DOI 10.1074/jbc.M006189200; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Landry J, 1999, BIOCHEM SOC SYMP, P79; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ogura M, 1998, J IMMUNOL, V161, P3569; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; Scott PH, 1998, AM J RESP CRIT CARE, V158, P958, DOI 10.1164/ajrccm.158.3.9712130; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Whelan R D, 1989, Cancer Commun, V1, P359; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	55	120	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30792	30797		10.1074/jbc.M203642200	http://dx.doi.org/10.1074/jbc.M203642200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12077134	hybrid			2022-12-25	WOS:000177579800051
J	Marc, F; Sandman, K; Lurz, R; Reeve, JN				Marc, F; Sandman, K; Lurz, R; Reeve, JN			Archaeal histone tetramerization determines DNA affinity and the direction of DNA supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; METHANOTHERMUS-FERVIDUS; (H3-H4)(2) TETRAMER; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CENP-A; PROTEIN; BINDING; HMF; FOLD	DNA binding and the topology of DNA have been determined in complexes formed by >20 archaeal histone variants and archaeal histone dimer fusions with residue replacements at sites responsible for histone fold dimendimer interactions. Almost all of these variants have decreased affinity for DNA. They have also lost the flexibility of the wild type archaeal histones to wrap DNA into a negative or positive supercoil depending on the salt environment; they wrap DNA into positive supercoils under all salt conditions. The histone folds of the archaeal histones, HMfA and HMfB, from Methanothermus fervidus are almost identical, but (HMfA)(2) and (HMfB), homodimers assemble into tetramers with sequence-dependent differences in DNA affinity. By construction and mutagenesis of HMfA+HMfB and HMfB+HMfA histone dimer fusions, the structure formed at the histone dimendimer interface within an archaeal histone tetramer has been shown to determine this difference in DNA affinity. Therefore, by regulating the assembly of different archaeal histone dimers into tetramers that have different sequence affinities, the assembly of archaeal histone-DNA complexes could be localized and used to regulate gene expression.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	University System of Ohio; Ohio State University; Max Planck Society	Reeve, JN (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.			Sandman, Kathleen/0000-0002-5222-5864	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alilat M, 1999, J MOL BIOL, V291, P815, DOI 10.1006/jmbi.1999.2988; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; Bailey KA, 1999, NUCLEIC ACIDS RES, V27, P532, DOI 10.1093/nar/27.2.532; Bailey KA, 2000, J MOL BIOL, V303, P25, DOI 10.1006/jmbi.2000.4128; Bailey KA, 2002, J BIOL CHEM, V277, P9293, DOI 10.1074/jbc.M110029200; CAMERINIOTERO RD, 1977, NUCLEIC ACIDS RES, V4, P1159, DOI 10.1093/nar/4.5.1159-a; Corona DFV, 2000, EMBO J, V19, P3049, DOI 10.1093/emboj/19.12.3049; Decanniere K, 2000, J MOL BIOL, V303, P35, DOI 10.1006/jmbi.2000.4104; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gangloff YG, 2001, MOL CELL BIOL, V21, P1841, DOI 10.1128/MCB.21.5.1841-1853.2001; Glowczewski L, 2000, MOL CELL BIOL, V20, P5700, DOI 10.1128/MCB.20.15.5700-5711.2000; Grayling RA, 1996, ADV PROTEIN CHEM, V48, P437; Grayling RA, 1997, EXTREMOPHILES, V1, P79, DOI 10.1007/s007920050018; Hamiche A, 1998, J BIOL CHEM, V273, P9261, DOI 10.1074/jbc.273.15.9261; Hamiche A, 1996, P NATL ACAD SCI USA, V93, P7588, DOI 10.1073/pnas.93.15.7588; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; Henikoff S, 2001, SCIENCE, V293, P1098, DOI 10.1126/science.1062939; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD MT, 1992, J BACTERIOL, V174, P7864, DOI 10.1128/JB.174.23.7864-7867.1992; Keith KC, 2000, GENETICS, V156, P973; Keith KC, 1999, MOL CELL BIOL, V19, P6130; Li WT, 1998, BIOCHEMISTRY-US, V37, P10563, DOI 10.1021/bi973006i; Liberati C, 1999, J MOL BIOL, V285, P1441, DOI 10.1006/jmbi.1998.2384; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Malik HS, 2002, P NATL ACAD SCI USA, V99, P1449, DOI 10.1073/pnas.032664299; Musgrave D, 2000, MOL MICROBIOL, V35, P341, DOI 10.1046/j.1365-2958.2000.01689.x; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Pereira SL, 1999, J MOL BIOL, V289, P675, DOI 10.1006/jmbi.1999.2812; Pereira SL, 1997, P NATL ACAD SCI USA, V94, P12633, DOI 10.1073/pnas.94.23.12633; SANDMAN K, 1995, BIO-TECHNOL, V13, P504, DOI 10.1038/nbt0595-504; SANDMAN K, 1990, P NATL ACAD SCI USA, V87, P5788, DOI 10.1073/pnas.87.15.5788; SANDMAN K, 1994, P NATL ACAD SCI USA, V91, P12624, DOI 10.1073/pnas.91.26.12624; Sandman K, 2001, METHOD ENZYMOL, V334, P116; Sandman K, 2000, ARCH MICROBIOL, V173, P165, DOI 10.1007/s002039900122; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Skarstad K, 2000, MOL MICROBIOL, V36, P1319, DOI 10.1046/j.1365-2958.2000.01943.x; Soares DJ, 2000, J MOL BIOL, V297, P39, DOI 10.1006/jmbi.2000.3546; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Sullivan S, 2002, NUCLEIC ACIDS RES, V30, P341, DOI 10.1093/nar/30.1.341; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Tomschik M, 2001, STRUCTURE, V9, P1201, DOI 10.1016/S0969-2126(01)00682-7; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yoda K, 2000, P NATL ACAD SCI USA, V97, P7266, DOI 10.1073/pnas.130189697	47	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30879	30886		10.1074/jbc.M203674200	http://dx.doi.org/10.1074/jbc.M203674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12058041	hybrid			2022-12-25	WOS:000177579800062
J	Rosen, H; Crowley, JR; Heinecke, JW				Rosen, H; Crowley, JR; Heinecke, JW			Human neutrophils use the myeloperoxidase-hydrogen peroxide-chloride system to chlorinate but not nitrate bacterial proteins during phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC QUANTIFICATION; POLYMORPHONUCLEAR LEUKOCYTES; HYPOCHLOROUS ACID; ANTIMICROBIAL ACTIVITY; CATALYZED OXIDATION; ESCHERICHIA-COLI; OXIDANTS; NITRITE; CYTOCHROME-B558; REACTIVITY	The generation of extracellular oxidants by neutrophils has been widely investigated, but knowledge about the chemical reactions that occur in the phagolysosome, the cellular compartment that kills pathogens, is more limited. One important pathway may involve the production of potent halogenating agents such as hypochlorous acid (HOCl) by the myeloperoxidase-hydrogen peroxide-halide system. However, explorations of the oxidation chemistry of phagolysosomes have been hampered by the organelle's inaccessibility. To overcome this limitation, we recovered Escherichia coli that had been internalized by human neutrophils. We then analyzed the bacterial proteins for 3-chlorotyrosine, a stable marker of damage by HOCI. Mass spectrometric analysis revealed that levels of 3-chlorotyrosine in E. coli proteins increased markedly after the bacteria were internalized by human neutrophils. This increase failed to occur in E. coli exposed to neutrophils deficient in NADPH oxidase or myeloperoxidase, implicating H2O2 and myeloperoxidase in the halogenation reaction. The extent of protein chlorination by normal neutrophils paralleled bacterial killing. Our observations support the view that the phagolysosome of human neutrophils uses the myeloperoxidase-hydrogen peroxide-chloride system to chlorinate bacterial proteins. In striking contrast, human neutrophils failed to nitrate bacterial proteins unless the medium was supplemented with 1 mm nitrite, and the level of nitration was low. Protein chlorination associated with bacterial killing was unaffected by the presence of nitrite in the medium. Nitration required NADPH oxidase but appeared to be independent of myeloperoxidase, suggesting that neutrophils can nitrate proteins through a pathway that requires nitrite but is independent of myeloperoxidase.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL); Washington University (WUSTL)	Rosen, H (corresponding author), Univ Washington, Dept Med, Box 356420, Seattle, WA 98195 USA.				NCRR NIH HHS [RR 00954] Funding Source: Medline; NHLBI NIH HHS [HL 64344] Funding Source: Medline; NIAID NIH HHS [AI 25606] Funding Source: Medline; NIA NIH HHS [AG 15013, AG 021191] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025606, R37AI025606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015013, R01AG021191] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAEHNER RL, 1970, J CLIN INVEST, V49, P865, DOI 10.1172/JCI106305; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; Chapman ALP, 2002, J BIOL CHEM, V277, P9757, DOI 10.1074/jbc.M106134200; Crowley JR, 1998, ANAL BIOCHEM, V259, P127, DOI 10.1006/abio.1998.2635; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; DULARAY B, 1991, ANN RHEUM DIS, V50, P383, DOI 10.1136/ard.50.6.383; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; Heinecke JW, 1999, FASEB J, V13, P1113, DOI 10.1096/fasebj.13.10.1113; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; HURST JK, 1991, J BIOL CHEM, V266, P1627; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; Jiang Q, 1997, CHEM RES TOXICOL, V10, P1080, DOI 10.1021/tx9700984; KETTLE AJ, 1991, FREE RADICAL RES COM, V12-3, P47, DOI 10.3109/10715769109145766; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KLEBANOFF SJ, 1967, J EXP MED, V126, P1063, DOI 10.1084/jem.126.6.1063; KLEBANOFF SJ, 1978, NEUTROPHIL; Kouoh F, 1999, FARMACO, V54, P695, DOI 10.1016/S0014-827X(99)00082-8; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1998, CHEM RES TOXICOL, V11, P714, DOI 10.1021/tx980076x; LYMAR SV, 1995, CHEM RES TOXICOL, V8, P833, DOI 10.1021/tx00048a003; Rosen H, 1997, INFECT IMMUN, V65, P4173, DOI 10.1128/IAI.65.10.4173-4178.1997; ROSEN H, 1976, J CLIN INVEST, V58, P50, DOI 10.1172/JCI108458; ROSEN H, 1991, J IMMUNOL METHODS, V144, P117, DOI 10.1016/0022-1759(91)90237-A; ROZENBERGARSKA M, 1985, INFECT IMMUN, V50, P852, DOI 10.1128/IAI.50.3.852-859.1985; STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WASIL M, 1987, BIOCHEM J, V243, P219, DOI 10.1042/bj2430219	42	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30463	30468		10.1074/jbc.M202331200	http://dx.doi.org/10.1074/jbc.M202331200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060654	hybrid			2022-12-25	WOS:000177579800010
J	Nielsen, AL; Holm, IE; Johansen, M; Bonven, B; Jorgensen, P; Jorgensen, AL				Nielsen, AL; Holm, IE; Johansen, M; Bonven, B; Jorgensen, P; Jorgensen, AL			A new splice variant of glial fibrillary acidic protein, GFAP epsilon, interacts with the presenilin proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENTS; ALZHEIMERS-DISEASE; CELL-LINES; EXPRESSION; GENE; CYTOSKELETON; TRANSCRIPTION; ASSOCIATION; ASTROCYTES; MUTATIONS	We describe a new human isoform, GFAPepsilon, of the intermediary filament protein GFAP (glial fibrillary acidic protein). GFAPepsilon mRNA is the result of alternative splicing and a new polyadenylation signal, and thus GFAPepsilon has a new C-terminal protein sequence. This provides GFAPepsilon with the capacity for specific binding of presenilin proteins in yeast and in vitro. Our observations suggest a direct link between the presenilins and the cytoskeleton where GFAPepsilon is incorporated. Mutations in GFAP and presenilins are associated with Alexander disease and Alzheimer's disease, respectively. Accordingly, GFAPepsilon should be taken into consideration when studying neurodegenerative diseases.	Aarhus Univ, Dept Biol Mol, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University	Nielsen, AL (corresponding author), Aarhus Univ, Dept Human Genet, Bartholin Bldg, DK-8000 Aarhus C, Denmark.		Nielsen, Anders Lade L/Q-9604-2016	Nielsen, Anders Lade L/0000-0003-4372-9961				Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; BESNARD F, 1991, J BIOL CHEM, V266, P18877; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN WJ, 1994, J CELL SCI, V107, P2299; Condorelli DF, 1999, J NEUROSCI RES, V56, P219, DOI 10.1002/(SICI)1097-4547(19990501)56:3<219::AID-JNR1>3.0.CO;2-2; FEINSTEIN DL, 1992, J NEUROSCI RES, V32, P1, DOI 10.1002/jnr.490320102; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GALEA E, 1995, J NEUROSCI RES, V41, P452, DOI 10.1002/jnr.490410404; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Isaacs A, 1998, GENOMICS, V51, P152, DOI 10.1006/geno.1998.5360; Johnsingh AA, 2000, FEBS LETT, V465, P53, DOI 10.1016/S0014-5793(99)01664-6; KANEKO R, 1993, P NATL ACAD SCI USA, V90, P4698, DOI 10.1073/pnas.90.10.4698; KANEKO R, 1994, P NATL ACAD SCI USA, V91, P4529, DOI 10.1073/pnas.91.10.4529; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Miake H, 1999, ACTA NEUROPATHOL, V98, P337, DOI 10.1007/s004010051090; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; REEVES SA, 1989, P NATL ACAD SCI USA, V86, P5178, DOI 10.1073/pnas.86.13.5178; Rose MD., 1990, METHODS YEAST GENETI; Sych M, 2000, NEUROREPORT, V11, P3091, DOI 10.1097/00001756-200009280-00011; Tandon Anurag, 2000, Current Opinion in Neurology, V13, P377, DOI 10.1097/00019052-200008000-00003; Thinakaran G, 1999, J CLIN INVEST, V104, P1321, DOI 10.1172/JCI8728; Weggen S, 1998, NEUROREPORT, V9, P3279; ZELENIKA D, 1995, MOL BRAIN RES, V30, P251, DOI 10.1016/0169-328X(95)00010-P; Zhang WJ, 1998, J NEUROSCI, V18, P914	29	84	88	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29983	29991		10.1074/jbc.M112121200	http://dx.doi.org/10.1074/jbc.M112121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058025	hybrid			2022-12-25	WOS:000177509300079
J	Song, A; Patel, A; Thamatrakoln, K; Liu, C; Feng, DD; Clayberger, C; Krensky, AM				Song, A; Patel, A; Thamatrakoln, K; Liu, C; Feng, DD; Clayberger, C; Krensky, AM			Functional domains and DNA-binding sequences of RFLAT-1/KLF13, a Kruppel-like transcription factor of activated T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NUCLEAR-LOCALIZATION; RANTES CHEMOKINE; MAMMALIAN-CELLS; PROMOTER; TRANSACTIVATION; REPRESSION; EXPRESSION; CONTAINS; FAMILY	RFLAT-1/KLF13, a member of the Kruppel-like family of transcription factors, was identified as a transcription factor expressed 3-5 days after T lymphocyte activation. It binds to the promoter of the chemokine gene RANTES (regulated on activation normal T cell expressed and secreted) and regulates its "late" expression in activated T-cells. In this study, a series of experiments to define the functional domains of RFLAT-1/KLF13 were undertaken to further advance the understanding of the molecular mechanisms underlying transcriptional regulation by this factor. Using the GAL4 fusion system, distinct transcriptional activation and repression domains were identified. The RFLAT-1 minimum activation domain is localized to amino acids 1-35, whereas the repression domain resides in amino acids 67-168. Deletion analysis on the RFLAT-1 protein further supports these domain functions. The RFLAT-1 activation domain is similar to that of its closest family member, basic transcription element-binding protein 1. This domain is highly hydrophobic, and site-directed mutagenesis demonstrated that both negatively charged and hydrophobic residues are important for transactivation. The nuclear localization signal of RFLAT-1 was also identified using the RFLAT-1/green fluorescence protein fusion approach. RFLAT-1 contains two potent, independent nuclear localization signals; one is immediately upstream of the zinc finger DNA-binding domain, and the other is within the zinc fingers. Using mutational analysis, we also determined that the critical binding sequence of RFLAT-1 is CTCCC. The intact CTCCC box on the RANTES promoter is necessary for RFLAT-1-mediated RANTES transcription and is also required for the synergy between RFLAT-1 and NF-kappaB proteins.	Stanford Univ, Sch Med, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cardiothorac Surg, Stanford, CA 94305 USA	Stanford University; Stanford University	Song, A (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Div Immunol & Transplantat Biol, CCSR Room 2105C,300 Pasteur Dr, Stanford, CA 94305 USA.			Thamatrakoln, Kimberlee/0000-0002-8029-5026	NIDDK NIH HHS [DK35008] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035008, R01DK035008] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Asano H, 2000, BLOOD, V95, P3578, DOI 10.1182/blood.V95.11.3578.011k48_3578_3584; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; Chen XY, 2001, MOL CELL BIOL, V21, P3118, DOI 10.1128/MCB.21.9.3118-3125.2001; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; Conley A., 2000, Pancreas, V21, P437; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P7558, DOI 10.1073/pnas.121635798; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Imhof A, 1999, MOL CELL BIOL, V19, P194; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOBAYASHI A, 1995, J BIOCHEM-TOKYO, V117, P91, DOI 10.1093/oxfordjournals.jbchem.a124727; Kojima S, 1997, J BIOCHEM, V121, P389; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; MATHENY C, 1994, J BIOL CHEM, V269, P8176; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moriuchi H, 1997, J IMMUNOL, V158, P3483; NELSON PJ, 1993, J IMMUNOL, V151, P2601; Nelson PJ, 1996, J IMMUNOL, V157, P1139; Pandya K, 2002, J BIOL CHEM, V277, P16304, DOI 10.1074/jbc.M200866200; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Yang ML, 1999, J BIOL CHEM, V274, P27399, DOI 10.1074/jbc.274.39.27399; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	40	47	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30055	30065		10.1074/jbc.M204278200	http://dx.doi.org/10.1074/jbc.M204278200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050170	hybrid			2022-12-25	WOS:000177509300088
J	Sturany, S; Van Lint, J; Gilchrist, A; Vandenheede, JR; Adler, G; Seufferlein, T				Sturany, S; Van Lint, J; Gilchrist, A; Vandenheede, JR; Adler, G; Seufferlein, T			Mechanism of activation of protein kinase D2(PKD2) by the CCKB/gastrin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; EPSILON; GASTRIN; DOMAIN; ZETA; PKD; CCK	Recently, we cloned a novel serine/threonine kinase termed protein kinase D2 (PKD2). PKD2 can be activated by phorbol esters both in vivo and in vitro but also by gastrin via the cholecystokinin/CCKB receptor in human gastric cancer cells stably transfected with the CCKB/gastrin receptor (AGS-B cells). Here we identify the mechanisms of gastrin-induced PKD2 activation in AGS-B cells. PKD2 phosphorylation in response to gastrin was rapid, reaching a maximum after 10 min of incubation. Our data demonstrate that gastrin-stimulated PKD2 activation involves a heterotrimeric Galpha(q) protein as well as the activation of phospholipase C. Furthermore, we show that PKD2 can be activated by classical and novel members of the protein kinase C (PKC) family such as PKCalpha, PKCepsilon, and PKCeta. These PKCs are activated by gastrin in AGS-B cells. Thus, PKD2 is likely to be a novel downstream target of specific PKCs upon the stimulation of AGS-B cells with gastrin. Our data suggest a two-step mechanism of activation of PKD2 via endogenously produced diacylglycerol and the activation of PKCs.	Med Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Katholieke Univ Leuven, Afdeling Biochem, B-3000 Louvain, Belgium; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA	Ulm University; KU Leuven; Northwestern University	Seufferlein, T (corresponding author), Univ Ulm, Med Klin, Innere Med Abt 1, Robert Koch Str 8, D-89081 Ulm, Germany.	thomas.seufferlein@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018; Van Lint, Johan/P-9073-2019; Gilchrist, Annette/I-4465-2014	Gilchrist, Annette/0000-0003-2386-7646				Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hartwich A, 2001, INT J COLORECTAL DIS, V16, P202, DOI 10.1007/s003840100288; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Paulssen RH, 2000, BIOCHEM PHARMACOL, V60, P865, DOI 10.1016/S0006-2952(00)00383-X; POWIS G, 1992, CANCER RES, V52, P2835; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	26	46	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29431	29436		10.1074/jbc.M200934200	http://dx.doi.org/10.1074/jbc.M200934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058027	hybrid			2022-12-25	WOS:000177509300012
J	Miyamoto, Y; Machida, K; Mizunuma, M; Emoto, Y; Sato, N; Miyahara, K; Hirata, D; Usui, T; Takahashi, H; Osada, H; Miyakawa, T				Miyamoto, Y; Machida, K; Mizunuma, M; Emoto, Y; Sato, N; Miyahara, K; Hirata, D; Usui, T; Takahashi, H; Osada, H; Miyakawa, T			Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G(1)-specific inhibitor reveromycin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID BIOSYNTHESIS; TRANSFER RNA-SYNTHETASES; MULTIDRUG-RESISTANCE; GENERAL CONTROL; YEAST; INITIATION; MECHANISMS; SEQUENCE; GROWTH	To dissect the action mechanism of reveromycin A (RM-A), a G(1)-specific inhibitor, a Saccharomyces cerevisiae dominant mutant specifically resistant to RM-A, was isolated from a strain in which the genes implicated in nonspecific multidrug resistance had been deleted. The mutant gene (YRR2-1) responsible for the resistance was identified as an allele of the ILS1 gene encoding tRNA(Ile) synthetase (MeRS). The activity of HeRS, but not several other aminoacyl-tRNA synthetases examined in wild type cell extract, was highly sensitive to RM-A (IC50 = 8 ng/ml). The IleRS activity of the YRR2-1 mutant was 4-fold more resistant to the inhibitor compared with that of wild type. The mutation IleRS(N660D), near the KMSKS consensus sequence commonly found in the class I aminoacyl transferases, was found to be responsible for RM-A resistance. Moreover, overexpression of the ILS1 gene from a high-copy plasmid conferred RM-A resistance. These results indicated that IleRS is a target of RM-A in vivo. A defect of the GCN2 gene led to decreased RM-A resistance. IleRS inhibition by RM-A led to transcriptional activation of the ILS1 gene via the Gcn2-Gcn4 general amino acid control pathway, and this autoregulation seemed to contribute to RM-A resistance.	Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398530, Japan; RIKEN, Antibiot Lab, Saitama 3510198, Japan	Hiroshima University; RIKEN	Miyakawa, T (corresponding author), Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398530, Japan.		Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020; Mizunuma, Masaki/V-2941-2017	Mizunuma, Masaki/0000-0002-1531-1763; Usui, Takeo/0000-0003-2377-7499				BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CIRAKOGLU B, 1985, EUR J BIOCHEM, V149, P353; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DELFORGE J, 1975, EUR J BIOCHEM, V57, P231, DOI 10.1111/j.1432-1033.1975.tb02295.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; MARTINDALE DW, 1989, CURR GENET, V15, P99, DOI 10.1007/BF00435455; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; NICHOLS RC, 1995, GENE, V155, P299, DOI 10.1016/0378-1119(94)00634-5; TAKAHASHI H, 1992, J ANTIBIOT, V45, P1414, DOI 10.7164/antibiotics.45.1414; UNGER MW, 1976, P NATL ACAD SCI USA, V73, P1664, DOI 10.1073/pnas.73.5.1664; Wendler F, 1997, J BIOL CHEM, V272, P27091, DOI 10.1074/jbc.272.43.27091; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	22	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28810	28814		10.1074/jbc.M203827200	http://dx.doi.org/10.1074/jbc.M203827200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12050165	hybrid			2022-12-25	WOS:000177342600061
J	Renstrom, E; Ivarsson, R; Shears, SB				Renstrom, E; Ivarsson, R; Shears, SB			Inositol 3,4,5,6-tetrakisphosphate inhibits insulin granule acidification and fusogenic potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; CHLORIDE CHANNELS; CYSTIC-FIBROSIS; CALCIUM; SECRETION; INS(3,4,5,6)P-4; CONDUCTANCE; EXOCYTOSIS; GLUCOSE	CIC Cl- channels in endosomes, synaptosomes, lysosomes, and beta-cell insulin granules provide charge neutralization support for the functionally indispensable acidification of the luminal interior by electrogenic H+-ATPases (Jentsch, T. J., Stein, V., Weinreich, F., and Zdebik, A. A. (2002) Physiol Rev. 82,503-568). Regulation of CIC activity is, therefore, of widespread biological significance (Forgac, M. (1999) J. Biol Chem. 274,1295112954). We now ascribe just such a regulatory function to the increases in cellular levels of inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4) that inevitably accompany activation of the ubiquitous Ins(1,4,5)P-3 signaling pathway. We used confocal. imaging to record insulin granule acidification in single mouse pancreatic beta-cells. Granule acidification was reduced by perfusion of single cells with 10 muM lns(3,4,5,6)P-4 (the concentration following receptor activation), whereas at 1 pm ("resting" levels), Ins(3,4,5,6)P-4 was ineffective. This response to lns(3,4,5,6)P-4 was not mimicked by 100 muM lns(1,4,5,6)P4 or by 100 muM Ins(1,3,4,5,6)P-5. Ins(3,4,5,6)P-4 did not affect granular H+-ATPase activity or H+ leak, indicating that Ins(3,4,5,6)P4 instead inhibited charge neutralization by CIC. The lns(3,4,5,6)P-4-mediated inhibition of vesicle acidification reduced exocytic release of insulin as determined by whole-cell capacitance recordings. This may impinge upon type 2 diabetes etiology. Regulatory control over vesicle acidification by this negative signaling pathway in other cell types should be considered.	Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden; NIEHS, Inositide Signaling Grp, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Lund University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Renstrom, E (corresponding author), Lund Univ, Dept Physiol Sci, BMC F11, SE-22184 Lund, Sweden.		Shears, Stephen B/C-6335-2019; Tuluc, Petronel/C-2527-2011	Shears, Stephen B/0000-0001-7309-8916; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAWQATI Q, 1992, J EXP BIOL, V172, P245; Barg S, 2001, J CELL SCI, V114, P2145; Barg S, 1999, P NATL ACAD SCI USA, V96, P5539, DOI 10.1073/pnas.96.10.5539; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; Carew MA, 2000, J BIOL CHEM, V275, P26906; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; Ho MWY, 2002, CURR BIOL, V12, P477, DOI 10.1016/S0960-9822(02)00713-3; Ho MWY, 2001, J BIOL CHEM, V276, P18673, DOI 10.1074/jbc.M101128200; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V254, P77, DOI 10.1006/bbrc.1998.9468; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Jonas JC, 1998, DIABETES, V47, P1266, DOI 10.2337/diabetes.47.8.1266; Kilpatrick ED, 1998, DIABETES, V47, P606, DOI 10.2337/diabetes.47.4.606; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; Meyer J, 2002, AM J PHYSIOL-ENDOC M, V282, pE917, DOI 10.1152/ajpendo.00427.2001; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; Renstrom E, 1996, J PHYSIOL-LONDON, V494, P41, DOI 10.1113/jphysiol.1996.sp021474; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Zawalich WS, 1996, PFLUG ARCH EUR J PHY, V432, P589, DOI 10.1007/s004240050174; ZHANG H, 2001, PEDIAT PULM S, V21, pA88	27	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26717	26720		10.1074/jbc.C200314200	http://dx.doi.org/10.1074/jbc.C200314200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12055181	hybrid			2022-12-25	WOS:000177055900002
J	Ding, ZH; Zhou, JY; Wei, WZ; Baker, VV; Wu, GS				Ding, ZH; Zhou, JY; Wei, WZ; Baker, VV; Wu, GS			Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines	ONCOGENE			English	Article						XK469; apoptosis; caspases; DN-caspase 9; Bcl2; Bax	CYTOCHROME-C RELEASE; P53-DEPENDENT APOPTOSIS; BCL-2 PROTEIN; MITOCHONDRIA; BAX; CLEAVAGE; DEATH; CASPASE; FAMILY; CHEMOSENSITIVITY	XK469, a synthetic quinoxaline phenoxypropionic acid derivative, has been found to have selective activity against a broad panel of solid tumors including several drug-resistant cell lines and has been approved for phase I clinical evaluation. Recent studies suggested that XK469 is a selective topoisomerase IIbeta inhibitor, but the mechanism of XK469-induced cell death remains unknown. Here we investigate the ability of XK469 to induce apoptosis of human cancer cells. In the human ovarian cancer cell line PA1, XK469 caused the release of cytochrome e, activation of caspases including caspases 9, 7 and 3, cleavage of PARP, and subsequently cell death. Moreover, 1362 and Bax were cleaved in XK469 treated cells. PA1 cells expressing the dominant negative-caspase 9 were less sensitive to XK469. Importantly, in these PA1 cells expressing DN-casp 9, the activation of caspases including caspases 3, 7 and 9, and cleavage of Bax and Bcl2 were inhibited, suggesting that the activation of the mitochondrial pathway is required for XK469-induced anticancer activity. These results indicate that the induction of apoptosis by XK469 may account for its anti-tumor activity and such activity is required for the activation of the mitochondrial pathway. Thus, our study defines a possible mechanism, at least in part, underlying XK469-induced anti-cancer activity.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Immunol Microbiol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Obstet & Gynecol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Wu, GS (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.	wug@karmanos.org						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Blagosklonny MV, 1999, LEUKEMIA, V13, P1028, DOI 10.1038/sj.leu.2401449; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Corbett TH, 1998, INVEST NEW DRUG, V16, P129, DOI 10.1023/A:1006174622061; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ding ZH, 2001, CLIN CANCER RES, V7, P3336; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gao HL, 1999, P NATL ACAD SCI USA, V96, P12168, DOI 10.1073/pnas.96.21.12168; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LoRusso PM, 1999, INVEST NEW DRUG, V16, P287; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Snapka RM, 2001, BIOCHEM BIOPH RES CO, V280, P1155, DOI 10.1006/bbrc.2001.4249; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	35	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4530	4538		10.1038/sj.onc.1205545	http://dx.doi.org/10.1038/sj.onc.1205545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085231				2022-12-25	WOS:000176476700007
J	Tilghman, RW; Hoover, RL				Tilghman, RW; Hoover, RL			The Src-cortactin pathway is required for clustering of E-selectin and ICAM-1 in endothelial cells	FASEB JOURNAL			English	Article						adhesion; tyrosine phosphorylation; inflammation; leukocyte; cytoskeleton	TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; LYMPHOCYTE MIGRATION; ADHESION MOLECULES; FOCAL ADHESIONS; ARP2/3 COMPLEX; ACTIN; CYTOSKELETON; ACTIVATION	Adhesion molecules such as E-selectin and intercellular adhesion molecule-1 (ICAM-1) expressed on endothelial cells (ECs) at sites of inflammation play an important role in the recruitment of leukocytes from the bloodstream into extravascular tissue. However, little is known about the signaling pathways that are initiated in ECs following adhesion molecule engagement. Here, we report that an 85-kDa protein becomes tyrosine phosphorylated in human ECs following leukocyte adhesion or upon antibody-induced clustering of E-selectin or ICAM-1. Through immunoprecipitation experiments, this protein was identified as cortactin, a cytoskeleton-binding molecule and prominent src substrate involved in cell adhesion. Following adhesion molecule clustering, cortactin phosphorylation was inhibited by the src family kinase inhibitor PP2. Both src and tyrosine-phosphorylated cortactin were found to be associated with E-selectin and ICAM-1 following adhesion of antibody-coated beads to ECs. PP2 did not inhibit the association of cortactin with E-selectin and ICAM-1; however, PP2 inhibited adhesion between paraformaldehyde-fixed THP-1 cells and ECs. This decrease in adhesion correlated with inhibition of adhesion molecule clustering on PP2-treated ECs at sites of THP-1 attachment. These findings implicate src and cortactin as mediators of leukocyte/EC interactions at sites of inflammation by regulating adhesion molecule clustering on ECs.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University	Hoover, RL (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, U4202 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	richard.hoover@mcmail.vanderbilt.edu						Adamson P, 1999, J IMMUNOL, V162, P2964; Aplin AE, 1998, PHARMACOL REV, V50, P197; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; MAA MC, 1992, ONCOGENE, V7, P2429; MACIAG T, 1982, J BIOL CHEM, V257, P5333; Malik AB, 1996, PHARMACOL REV, V48, P213; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PATCH LA, 1995, J CELL SCI, V108, P1371; ROMER LH, 1992, COLD SPRING HARB SYM, V57, P193, DOI 10.1101/SQB.1992.057.01.024; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yoshida M, 1998, J IMMUNOL, V161, P933; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; ZHAN X, 1993, J BIOL CHEM, V268, P24427	33	71	73	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1257	+		10.1096/fj.01-0969fje	http://dx.doi.org/10.1096/fj.01-0969fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060669				2022-12-25	WOS:000176683900034
J	Ae, K; Kobayashi, N; Sakuma, R; Ogata, T; Kuroda, H; Kawaguchi, N; Shinomiya, K; Kitamura, Y				Ae, K; Kobayashi, N; Sakuma, R; Ogata, T; Kuroda, H; Kawaguchi, N; Shinomiya, K; Kitamura, Y			Chromatin remodeling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-deficient cells	ONCOGENE			English	Article						INI1/SNF5; SWI/SNF complex; tumor suppressor; G1 arrest; apoptosis	SWI-SNF COMPLEX; MALIGNANT RHABDOID TUMOR; SINGLE-CHAIN ANTIBODY; SWI/SNF COMPLEX; VIRAL INTEGRASE; TRANSCRIPTION; MUTATIONS; PROTEINS; LINES; GENE	Ini1/hsnf5 gene encodes INI1 protein, a chromatin remodeling factor associated with the SWI/SNF complex. In yeast, this complex modifies chromatin condensation to coactivate various transcriptional factors. However, in human, little is known about the SWI/SNF complex and INI1. To elucidate cellular functions of ini1, we constructed a recombinant adenovirus (AdexHA-INI1) capable of overexpressing INI1 in ini1-deficient cells. AdexHA-INI1 produced intranuclear INI1 in three ini1-deficient cell lines, changed their morphology, and decreased the proportion of viable cells. Flow cytometry and a BrdU incorporation assay showed that after the infection, growth of these cells was partially arrested at G1. In two of the three ini1-deficient cell lines, apoptosis was found to occur after the infection, as detected by the presence of cleaved poly (ADP-ribose) polymerase. To determine functional domains of INI1, we constructed plasmids expressing INI1 and its deletion mutants, which were used for a colony formation assay. Repeats I and 2 of INI1 were found to be required to suppress the growth of the three ini1-deficient cell lines. The results support the hypothesis that ini1 is a tumor suppressor gene and suggest a novel link between human SWI/SNF chromatin remodeling complex and apoptosis.	Univ Tokyo, Inst Med Sci, Div Infect Dis, Adv Clin Res Ctr, Tokyo 1038639, Japan; Natl Inst Infect Dis, Div Mol Genet, Tokyo 2080011, Japan; Tokyo Med & Dent Univ, Sect Orthoped Spinal Surg, Dept Frontier Surg Therapeut, Div Adv Therapeut Sci,Grad Sch, Tokyo 1138519, Japan; Japanese Fdn Canc Res, Dept Orthoped Oncol, Canc Inst Hosp, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research	Kitamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Div Infect Dis, Adv Clin Res Ctr, 4-6-1 Shirokanedai, Tokyo 1038639, Japan.							Biegel JA, 1999, CANCER RES, V59, P74; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brand A, 2001, GYNECOL ONCOL, V80, P99, DOI 10.1006/gyno.2000.6032; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GRAHAM FL, 1977, J GEN VIROL, V36, P9; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kitamura Y, 1999, J ACQ IMMUN DEF SYND, V20, P105, DOI 10.1097/00042560-199902010-00001; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Okui N, 1998, J VIROL, V72, P6960, DOI 10.1128/JVI.72.8.6960-6964.1998; OTA S, 1993, CANCER-AM CANCER SOC, V71, P2862, DOI 10.1002/1097-0142(19930501)71:9<2862::AID-CNCR2820710930>3.0.CO;2-D; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; SEKIGUCHI M, 1985, BIOMED PHARMACOTHER, V39, P372; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Whitehouse I, 2000, BIOCHEM SOC T, V28, P376, DOI 10.1042/0300-5127:0280376; Wong AKC, 2000, CANCER RES, V60, P6171; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000	32	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3112	3120		10.1038/sj.onc.1205414	http://dx.doi.org/10.1038/sj.onc.1205414			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082626				2022-12-25	WOS:000175373600002
J	Hemmati, PG; Gillissen, B; von Haefen, C; Wendt, J; Starck, L; Guner, D; Dorken, B; Daniel, PT				Hemmati, PG; Gillissen, B; von Haefen, C; Wendt, J; Starck, L; Guner, D; Dorken, B; Daniel, PT			Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis	ONCOGENE			English	Article						p14(ARF); p53; Bax; mitochondria; apoptosis	DRUG-INDUCED APOPTOSIS; P19(ARF) TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; HUMAN ARF PROTEIN; BREAST-CANCER; CYTOCHROME-C; INK4A LOCUS; P53-DEPENDENT APOPTOSIS; METASTATIC MELANOMA; BCL-2 PROTEIN	The human INK4a gene locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF), which are frequently inactivated in human cancer. Whereas p16(INK4a) acts through engagement of the Rb-cdk4/6-cyclin D pathway, both the pro-apoptotic and cell cycle-regulatory functions of p14(ARF) were shown to be primarily dependent on the presence of functional p53. Recent reports have also implicated p14(ARF) in p53-independent mechanisms of cell cycle regulation and apoptosis induction, respectively. To further explore the pro-apoptotic function of p14(ARF) in relation to functional cellular p53, we constructed a replication-deficient adenoviral vector for overexpression of p14(ARF) (Ad-p14(ARF)). As expected, Ad-p14(ARF) efficiently induced apoptosis in p53/Rb wild-type U-2OS osteosarcoma cells at low multiplicities of infection. Interestingly, Ad-p14(ARF) also induced apoptosis in both p53-deleted SAOS-2 osteosarcoma cells and HCT116 colon cancer cells with a bi-allelic knock-out of p53 (HCT116-p53(-/-)). Similarly, adenovirus-mediated overexpression of p14(ARF) induced apoptosis in p53/Bax-mutated DU145 prostate cancer cells as well as in HCT116 cells devoid of functional Bax (HCT116-Bax(-/-)). Restoration of Bax expression by retroviral gene transfer in DU145 cells did not further enhance p14(ARF)-triggered cell death. Infection with Ad-p14(ARF) induced activation of mitochondrial permeability shift transition, caspase activation and apoptotic DNA fragmentation irrespective of the presence or absence of either Bax or functional cellular p53. Nevertheless, overexpression of the anti-apoptotic Bcl-2 homolog Bcl-x(L) markedly inhibited p14(ARF)-induced apoptosis. This may indicate that p14(ARF) triggers a so far unknown activator of mitochondrial apoptosis which can be inhibited by Bcl-2 but which acts either independently or downstream of Bax. Taken together, this report demonstrates the participation of signaling pathways apart from the p53/Mdm-2 rheostat and Bax in p14(ARF)-mediated apoptosis.	Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite, D-13125 Berlin, Germany; Charite, Dept Radiat Oncol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.			Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BOSANQUET, 2002, IN PRESS LEUKEMIA, V16; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Groth A, 2000, J BIOL CHEM, V275, P27473; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Inoue R, 1999, ANTICANCER RES, V19, P2939; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Krajewska M, 1996, CANCER RES, V56, P2422; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Nakamura M, 2001, BRAIN PATHOL, V11, P159; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2000, CANCER RES, V60, P3689; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weinmann P, 1997, EUR J IMMUNOL, V27, P2466, DOI 10.1002/eji.1830270947; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	64	95	98	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3149	3161		10.1038/sj.onc.1205458	http://dx.doi.org/10.1038/sj.onc.1205458			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082630				2022-12-25	WOS:000175373600006
J	Hemmeryckx, B; Reichert, A; Watanabe, M; Kaartinen, V; de Jong, R; Pattengale, PK; Groffen, J; Heisterkamp, N				Hemmeryckx, B; Reichert, A; Watanabe, M; Kaartinen, V; de Jong, R; Pattengale, PK; Groffen, J; Heisterkamp, N			BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl	ONCOGENE			English	Article						Bcr/Abl P190; Crkl; Ph-positive; acute lymphoblastic leukemia; null mutant	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL TRANSFORMATION; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; LEUKEMOGENESIS; CELLS; GENE; PROLIFERATION; PEPTIDES	The Bcr/Abl fusion protein directly causes chronic myelogenous leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Multiple independent studies have implicated Crkl, a small adapter protein, in transduction of oncogenic signals of Bcr/Abl and CrkI tyro sine-phosphorylation is used as a diagnostic tool for Philadelphia-positive leukemia. To evaluate the contribution of CrkI to this type of leukemia, we generated mutant mice that lack CrkI expression. We found that the overall survival of P190 BCR/ABL crkl-/- mice was comparable to that of genetically matched P190 BCR/ABL crkl +/+ mice. Both genotypes developed lymphoid lineage leukemia/lymphoma. Western blot analysis of -/- and +/+ lymphomas showed that the related Crk protein was tyrosine phosphorylated and could be found complexed with Bcr-Abl P190. These data indicate that possible therapeutic approaches that target CrkI may be complicated by the presence of pathways that compensate for lack of CrkI function.	Childrens Hosp Los Angeles, Res Inst, Sect Mol Carcinogenesis, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Sect Mol Carcinogenesis, Div Hematol Oncol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Res Inst, Dept Pathol, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California	Heisterkamp, N (corresponding author), Childrens Hosp Los Angeles, Res Inst, Sect Mol Carcinogenesis, Div Hematol Oncol, MS 54,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Kaartinen, Vesa/AAU-5396-2021; Hemmeryckx, Bianca/AAR-2360-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NCI NIH HHS [CA 90321, CA 50248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050248, R01CA090321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hemmeryckx B, 2001, CANCER RES, V61, P1398; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kardinal C, 2001, BLOOD, V98, P1773, DOI 10.1182/blood.V98.6.1773; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Voncken JW, 1998, ONCOGENE, V16, P2029, DOI 10.1038/sj.onc.1201730; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1992, CANCER RES, V52, P4534; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; VOSS J, 2001, SIGNAL TRANSDUCTION, V1, P1	36	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3225	3231		10.1038/sj.onc.1205452	http://dx.doi.org/10.1038/sj.onc.1205452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082638				2022-12-25	WOS:000175373600014
J	Zhang, SW; Cai, MM; Zhang, S; Xu, SL; Chen, S; Chen, XN; Chen, C; Gu, JX				Zhang, SW; Cai, MM; Zhang, S; Xu, SL; Chen, S; Chen, XN; Chen, C; Gu, JX			Interaction of p58(PITSLRE), a G(2)/M-specific protein kinase, with cyclin D3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DEPENDENT KINASES; MAMMALIAN-CELLS; GENE-COMPLEX; EXPRESSION; APOPTOSIS; ACTIVATION; ISOFORMS; 1P36; D1	The p58(PITSLRE) is a p34(cdc2)-related protein kinase that plays an important role in normal cell cycle progression. Elevated expression of p58(PITSLRE) in eukaryotic cells prevents them from undergoing normal cytokinesis and appears to delay them in late telophase. To investigate the molecular mechanism of p58(PITSLRE) action, we used the yeast two-hybrid system, screened a human fetal liver cDNA library, and identified cyclin D3 as an interacting partner of p58(PITSLRE). In vitro binding assay, in vivo coimmunoprecipitation, and immunofluorescence cell staining further confirmed the association of p58(PITSLRE) with cyclin D3. This binding was observed only in the G(2)/M phase but not in the G(1)/S phase of the cell cycle; meanwhile, no interaction between p110(PITSLRE) and cyclin D3 was observed in all the cell cycle. The overexpression of cyclin D3 in 7721 cells leads to an exclusively accumulation of p58(PITSLRE) in the nuclear region, affecting its cellular distribution. Histone H1 kinase activity of p58(PITSLRE) was greatly enhanced upon interaction with cyclin D3. Furthermore, kinase activity of p58(PITSLRE) was found to increase greatly in the presence of cyclin D3 using a specific substrate, beta-1,4-galactosyltransferase 1. These data provide a new clue to our understanding of the cellular function of p58(PITSLRE) and cyclin D3.	Fudan Univ, Med Ctr, Ctr Gene Res, Shanghai 200032, Peoples R China	Fudan University	Gu, JX (corresponding author), Fudan Univ, Med Ctr, Ctr Gene Res, Shanghai 200032, Peoples R China.	Jxgu@shmu.edu.cn	zhang, si/AAG-9094-2021	zhang, Si/0000-0002-5682-4995				Ariza ME, 1999, J BIOL CHEM, V274, P28505, DOI 10.1074/jbc.274.40.28505; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; BUNNELL BA, 1990, BIOCHEM BIOPH RES CO, V171, P196, DOI 10.1016/0006-291X(90)91376-4; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Dave BJ, 1999, CANCER GENET CYTOGEN, V108, P120, DOI 10.1016/S0165-4608(98)00138-1; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Furukawa K, 1999, BBA-GEN SUBJECTS, V1473, P54, DOI 10.1016/S0304-4165(99)00169-5; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANA X, 1995, ONCOGENE, V11, P211; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; Hirai H, 1996, MOL CELL BIOL, V16, P6457; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LI HM, 1995, GENE, V153, P237, DOI 10.1016/0378-1119(94)00801-X; Loyer P, 1998, J CELL SCI, V111, P1495; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; Nelson MA, 1999, CANCER GENET CYTOGEN, V108, P91, DOI 10.1016/S0165-4608(98)00122-8; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Reed S I, 1996, Prog Cell Cycle Res, V2, P15; Reed SI, 1997, CANCER SURV, V29, P7; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Sauer K, 1996, MOL BIOL CELL, V7, P1759, DOI 10.1091/mbc.7.11.1759; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shur BD, 1998, GLYCOCONJUGATE J, V15, P537, DOI 10.1023/A:1006951407168; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; XIANG JL, 1994, J BIOL CHEM, V269, P15786; Zhang SW, 2001, MOL CELL BIOCHEM, V221, P161, DOI 10.1023/A:1010932211745; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	44	61	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35314	35322		10.1074/jbc.M202179200	http://dx.doi.org/10.1074/jbc.M202179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12082095	hybrid			2022-12-25	WOS:000178117000085
J	Chalabi, S; Easton, RL; Patankar, MS; Lattanzio, FA; Morrison, JC; Panico, M; Morris, HR; Dell, A; Clark, GF				Chalabi, S; Easton, RL; Patankar, MS; Lattanzio, FA; Morrison, JC; Panico, M; Morris, HR; Dell, A; Clark, GF			The expression of free oligosaccharides in human seminal plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MILK; MASS-SPECTROMETRY; SEMEN; INFECTION; MUCINS; CERVIX	Human seminal plasma is a complex mixture of proteins, glycoproteins, peptides, glycopeptides, and prostaglandins secreted by organs of the male reproductive tract. The components of this fluid have been implicated in the suppression of immune response, agonistic effects on sperm-egg binding, and promotion of successful implantation of the human embryo. Fractionation followed by biophysical analyses revealed that free oligosaccharides constitute a major component of the total glycoconjugates within seminal plasma. Significant findings of our analyses include the following: (i) the concentration of free oligosaccharides is 0.3-0.4 mg/ml; (ii) mono and difucosylated forms of the disaccharide lactose are major components; (iii) many of the remaining oligosaccharides are also rich in fucose and carry Lewis(x) and/or Lewis(y) epitopes; (iv) a subset of the oligosaccharides express the reducing end sequence (GlcNAcbeta1-3/4Glc) not reported in human milk oligosaccharides; (v) oligosaccharides in seminal plasma exclusively express type 2 (Galbeta1-4GlcNAc) but not the type 1 sequences (Ga1beta1-3GlcNAc) that predominate in human milk glycans; and (vi) the structural diversity of seminal plasma oligosaccharides is far less than human milk oligosaccharides. The agonistic effect of both fucose and fucosylated glycoconjugates on human sperm-egg binding in vitro suggests that fucosylated oligosaccharides may also promote fertilization in the female reproductive tract.	Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AY, England; Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23501 USA	Imperial College London; Eastern Virginia Medical School	Morris, HR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AY, England.	h.morris@ic.ac.uk; a.dell@ic.ac.uk; clarkgf@evms.edu			NICHD NIH HHS [HD35652] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035652] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AITKEN RJ, 1995, HUM REPROD, V10, P1736, DOI 10.1093/oxfordjournals.humrep.a136165; ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BOLTON AE, 1987, LANCET, V1, P593; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1966, J BIOL CHEM, V241, P762; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; Denison FC, 1999, MOL HUM REPROD, V5, P220, DOI 10.1093/molehr/5.3.220; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Eriksen GV, 1998, FERTIL STERIL, V70, P350, DOI 10.1016/S0015-0282(98)00158-7; Gipson IK, 2001, FRONT BIOSCI-LANDMRK, V6, pD1245, DOI 10.2741/Gipson; GROLLMAN EF, 1969, J CLIN INVEST, V48, P1489, DOI 10.1172/JCI106115; HAMILTON DW, 1981, BIOL REPROD, V25, P385, DOI 10.1095/biolreprod25.2.385; Kelly RW, 1997, HUM REPROD, V12, P2200; Kunz C, 2000, ANNU REV NUTR, V20, P699, DOI 10.1146/annurev.nutr.20.1.699; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; NAGASAWA T, 1971, J DAIRY SCI, V54, P835, DOI 10.3168/jds.S0022-0302(71)85928-3; Newburg D, 1995, HDB MILK COMPOSITION, P273; Newburg DS, 1999, CURR MED CHEM, V6, P117; OEHNINGER S, 1990, FERTIL STERIL, V53, P143; Patankar MS, 1997, MOL HUM REPROD, V3, P501, DOI 10.1093/molehr/3.6.501; Robertson SA, 2001, SEMIN IMMUNOL, V13, P243, DOI 10.1006/smim.2000.0320; RONQUIST G, 1984, UROL RES, V12, P243; RONQUIST G, 1987, UROL INT, V42, P143, DOI 10.1159/000281874; RONQUIST G, 1985, UROL INT, V40, P269, DOI 10.1159/000281097; ROSS P, 1993, J REPROD FERTIL, V98, P129; Saez F, 1998, MOL HUM REPROD, V4, P667, DOI 10.1093/molehr/4.7.667; SETCHELL BP, 1980, PERSPECTIVES MALE RE, P753; SMITH DF, 1978, ANAL BIOCHEM, V85, P602, DOI 10.1016/0003-2697(78)90261-0; SOBRERO AJ, 1962, FERTIL STERIL, V13, P184; STAHL B, 1994, ANAL BIOCHEM, V223, P218, DOI 10.1006/abio.1994.1577; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TADOLINI B, 1977, ADV ENZYME REGUL, V15, P319, DOI 10.1016/0065-2571(77)90023-1; THOMPSON LA, 1992, AM J REPROD IMMUNOL, V28, P85, DOI 10.1111/j.1600-0897.1992.tb00765.x; Tulsiani DRP, 1998, J REPROD FERTIL, P85; USHIJIMA H, 1992, RES VIROLOGY, V143, P97, DOI 10.1016/S0923-2516(06)80087-7; WOLFF H, 1995, FERTIL STERIL, V63, P1143; YUREWICZ EC, 1982, J BIOL CHEM, V257, P2314; Zacharopoulos VR, 1997, MICROB PATHOGENESIS, V23, P225, DOI 10.1006/mpat.1997.0151	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32562	32570		10.1074/jbc.M205152200	http://dx.doi.org/10.1074/jbc.M205152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12063266	hybrid			2022-12-25	WOS:000177859000024
J	Angelova, K; Fanelli, F; Puett, D				Angelova, K; Fanelli, F; Puett, D			A model for constitutive lutropin receptor activation based on molecular simulation and engineered mutations in transmembrane helices 6 and 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE-RECEPTOR; ALPHA(1B)-ADRENERGIC RECEPTOR; INACTIVE CONFORMATION; CHORIOGONADOTROPIN RECEPTOR; CHORIONIC-GONADOTROPIN; CRYSTAL-STRUCTURE; IONIC LOCK; AMINO-ACID; PROTEIN; RHODOPSIN	Many naturally occurring and engineered mutations lead to constitutive activation of the G protein-coupled lutropin receptor (LHR), some of which also result in reduced ligand responsiveness. To elucidate the nature of interhelical interactions in this heptahelical receptor and changes thereof accompanying activation, we have utilized site-directed mutagenesis on transmembrane helices 6 and 7 of rat LHR to prepare and characterize a number of single, double, and triple mutants. The potent constitutively activating mutants, D556(6.44)H and D556(6.44)Q, were combined with weaker activating mutants, N593(7.45)R and N597(7.49)Q, and the loss-of-responsiveness mutant, N593(7.45)A. The engineered mutants have also been simulated using a new receptor model based on the crystal structure of rhodopsin. The results suggest that constitutive LHR activation by mutations at Asp-556(6.44) is triggered by the breakage or weakening of the interaction found in the wild type receptor between Asp-556(6.44) and Asn-593(7.45). Whereas this perturbation is unique to the activating mutations at Asp-556(6.44), common features to all of the most active LHR mutants are the breakage of the charge-reinforced H-bonding interaction between Arg-442(3.50) and Asp-542(6.30) and the increase in solvent accessibility of the cytosolic extensions of helices 3 and 6, which probably participate in the receptor-G protein interface. Asn-593(7.45) and Asn-597(7.49) also seem to be necessary for the high constitutive activities of D556(6.44)H and D556(6.44)Q and for full ligand responsiveness. The new theoretical model provides a foundation for further experimental work on the molecular mechanism(s) of receptor activation.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Modena, Dept Chem, I-41100 Modena, Italy	University System of Georgia; University of Georgia; Universita di Modena e Reggio Emilia	Puett, D (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, B129 Life Sci Bldg,120 Green St, Athens, GA 30602 USA.	puett@bmb.uga.edu	Fanelli, Francesca/O-8807-2014	Fanelli, Francesca/0000-0002-7620-6895	NIDDK NIH HHS [DK33973] Funding Source: Medline; Telethon [TCP00068] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033973] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angelova K, 2000, MOL ENDOCRINOL, V14, P459, DOI 10.1210/me.14.4.459; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chan WY, 1998, MOL GENET METAB, V63, P75, DOI 10.1006/mgme.1997.2650; Chen SH, 1999, J BIOL CHEM, V274, P16320, DOI 10.1074/jbc.274.23.16320; Chen SH, 2002, BIOCHEMISTRY-US, V41, P588, DOI 10.1021/bi011868k; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Fanelli F, 2000, J MOL BIOL, V296, P1333, DOI 10.1006/jmbi.2000.3516; Fanelli F, 2001, IUBMB LIFE, V51, P149, DOI 10.1080/152165401753544214; Fernandez LM, 1996, BIOCHEMISTRY-US, V35, P3986, DOI 10.1021/bi952421c; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; Greasley PJ, 2002, MOL PHARMACOL, V61, P1025, DOI 10.1124/mol.61.5.1025; Greasley PJ, 2001, J BIOL CHEM, V276, P46485, DOI 10.1074/jbc.M105791200; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; Kim JM, 1997, P NATL ACAD SCI USA, V94, P14273, DOI 10.1073/pnas.94.26.14273; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kosugi S, 1998, MOL PHARMACOL, V53, P894; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; KOSUGI S, 1997, 79 ANN M END SOC, P171; KRAAIJ R, 1995, J CLIN ENDOCR METAB, V80, P3168, DOI 10.1210/jc.80.11.3168; Latronico AC, 1999, AM J HUM GENET, V65, P949, DOI 10.1086/302602; Latronico AC, 1996, NEW ENGL J MED, V334, P507, DOI 10.1056/NEJM199602223340805; Laue LL, 1996, MOL ENDOCRINOL, V10, P987, DOI 10.1210/me.10.8.987; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; Neumann S, 2001, MOL ENDOCRINOL, V15, P1294, DOI 10.1210/me.15.8.1294; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; Schulz A, 2000, J BIOL CHEM, V275, P37860, DOI 10.1074/jbc.M006709200; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Shenker Andrew, 1998, V6, P139; Simon JP, 2002, PROTEIN PEPTIDE LETT, V9, P153, DOI 10.2174/0929866023408896; Themmen APN, 1998, MOL CELL ENDOCRINOL, V145, P137, DOI 10.1016/S0303-7207(98)00180-4; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Visiers I, 2002, INT J QUANTUM CHEM, V88, P65, DOI 10.1002/qua.10078	47	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32202	32213		10.1074/jbc.M203272200	http://dx.doi.org/10.1074/jbc.M203272200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070159	hybrid			2022-12-25	WOS:000177718700113
J	Eftmova, T; Deucher, A; Kuroki, T; Ohba, M; Eckert, RL				Eftmova, T; Deucher, A; Kuroki, T; Ohba, M; Eckert, RL			Novel protein kinase C isoforms regulate human keratinocyte differentiation by activating a p38 delta mitogen-activated protein kinase cascade that targets CCAAT/enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVOLUCRIN PROMOTER ACTIVITY; SIGNAL-TRANSDUCTION PATHWAY; TRANSCRIPTION FACTORS C/EBP; P38 MAP KINASE; PHORBOL ESTER; GENE-EXPRESSION; CELL-DIFFERENTIATION; SELECTIVE ACTIVATION; GROWTH ARREST; CHOP GADD153	The novel protein kinase C (nPKC) isoforms are important regulators of human involucrin (hINV) gene expression during keratinocyte differentiation (Efimova, T., and Eckert, R. L. (2000) J. Biol. Chem. 275, 1601-1607). Although the regulatory mechanism involves mitogenactivated protein kinase (MAPK) activation, the role of individual MAPK isoforms has not been elucidated. We therefore examined the effects of individual nPKCs on MAPK activation. We observe unique changes whereby nPKC expression simultaneously increases p38 activity and decreases ERK1 and ERK2 activity. Although p38alpha, p38beta, and p38delta are expressed in keratinocytes, only a single isoform, p38delta, accounts for the increased p38 activity. Parallel studies indicate that this isoform is also activated by treatment with the keratinocyte regulatory agents, 12-O-tetradecanoylphorbol-13-acetate, calcium, and okadaic acid. These changes in MAPK activity are associated with increased C/EBPalpha transcription factor expression and DNA binding to the hINV promoter and increased hINV gene expression. Expression of PKCdelta, PKCepsilon, or PKCeta causes a 10-fold increase in hINV promoter activity, whereas C/EBPa expression produces a 25-fold increase. However, simultaneous expression of both proteins causes a synergistic 100-fold increase in promoter activity. These responses are eliminated by the dominant-negative C/EBP isoform, GADD153, and are also inhibited by dominant-negative forms of Ras, MEKK1, MEK3, and p38. These results suggest that the nPKC isoforms produce a unique shift in MAPK activity via a Ras, MEKK1, MEK3 pathway, to increase p38delta and inhibit ERK1/2 and ultimately increase C/EBPa binding to the hINV promoter and hINV gene expression.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA; Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Pharmaceut Sci, Shinagawa Ku, Tokyo 1428555, Japan	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Showa University; Showa University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351; Efimova, Tatiana/0000-0002-9869-1545	NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; Balasubramanian S, 2000, BIOCHEM J, V350, P791, DOI 10.1042/0264-6021:3500791; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Deucher A, 2002, J BIOL CHEM, V277, P17032, DOI 10.1074/jbc.M109076200; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; GHERZI R, 1992, BIOCHEM BIOPH RES CO, V184, P283, DOI 10.1016/0006-291X(92)91190-2; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Maytin EV, 1998, J INVEST DERMATOL, V110, P493; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; OSADA S, 1990, J BIOL CHEM, V265, P22434; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Wang H, 1996, J VIROL, V70, P4839, DOI 10.1128/JVI.70.7.4839-4844.1996; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	53	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31753	31760		10.1074/jbc.M205098200	http://dx.doi.org/10.1074/jbc.M205098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080077	hybrid			2022-12-25	WOS:000177718700056
J	Hong, JJ; Yankee, TM; Harrison, ML; Geahlen, RL				Hong, JJ; Yankee, TM; Harrison, ML; Geahlen, RL			Regulation of signaling in B cells through the phosphorylation of Syk on linker region tyrosines - A mechanism for negative signaling by the Lyn tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; LYMPHOCYTE ANTIGEN RECEPTORS; PHOSPHOLIPASE C-GAMMA-2; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; DEFICIENT MICE; ACTIVATION; PROTEIN; BLNK; CBL	The B cell antigen receptor (BCR) is coupled to the mobilization of Ca2+ by the protein-tyrosine kinase, Syk. Syk, recruited to the clustered BCR, becomes phosphorylated on three tyrosines (Tyr-317, Tyr-342, and Tyr-346) located within the linker region that separates the C-terminal catalytic domain from the N-terminal tandem Src homology 2 domains. Phosphorylation within the linker region can be either activating or inhibitory to Ca2+ mobilization depending on the sites that are modified. Syk that is not phosphorylated on linker region tyrosines couples the BCR to Ca2+ mobilization through a phosphoinositide 3-kinase-dependent pathway. The phosphorylation of Tyr-342 and -346 enhances the phosphorylation and activation of phospholipase C-gamma and the early phase of Ca2+ mobilization via a phosphoinositide 3-kinase-independent pathway. The phosphorylation of Tyr-317 strongly dampens the Ca2+ signal. In cells that lack the Src family kinase, Lyn, the phosphorylation of the inhibitory Tyr-317 is suppressed leading to elevated production of inositol 1,4,5-trisphosphate and an amplified Ca2+ signal. This provides a novel mechanism by which Lyn functions as an inhibitor of BCR-stimulated signaling. Thus, Syk and Lyn combine to determine the pathway through which the BCR is coupled to Ca2+ mobilization as well as the magnitude and duration of the Ca2+ flux.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Geahlen, RL (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Hansen Life Sci Res Bldg, W Lafayette, IN 47907 USA.			Yankee, Thomas/0000-0002-3907-4838; Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372, T32CA009634] Funding Source: NIH RePORTER; NCI NIH HHS [CA09634, CA37372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Baba Y, 2001, P NATL ACAD SCI USA, V98, P2582, DOI 10.1073/pnas.051626198; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Fujimoto M, 2001, J BIOL CHEM, V276, P44820, DOI 10.1074/jbc.M107559200; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Ishiai M, 1999, J IMMUNOL, V163, P1746; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Law CL, 1996, MOL CELL BIOL, V16, P1305; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Peters JD, 1996, J BIOL CHEM, V271, P4755; Quek LS, 2000, BLOOD, V96, P4246; Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; SUSA M, 1992, J BIOL CHEM, V267, P22951; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tsubata T, 1999, CURR OPIN IMMUNOL, V11, P249, DOI 10.1016/S0952-7915(99)80041-7; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613; Yankee TM, 1999, J IMMUNOL, V163, P5827	51	69	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31703	31714		10.1074/jbc.M201362200	http://dx.doi.org/10.1074/jbc.M201362200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077122	hybrid			2022-12-25	WOS:000177718700051
J	Ramana, KV; Chandra, D; Srivastava, S; Bhatnagar, A; Aggarwal, BB; Srivastava, SK				Ramana, KV; Chandra, D; Srivastava, S; Bhatnagar, A; Aggarwal, BB; Srivastava, SK			Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIPID-PEROXIDATION PRODUCT; GENE-EXPRESSION; ENDOTHELIAL-CELLS; LESION FORMATION; BINDING PROTEIN; KETO REDUCTASE; END-PRODUCTS; GROWTH; ACTIVATION	Abnormal vascular smooth muscle cell (VSMC) proliferation is a key feature of atherosclerosis and restenosis; however, the mechanisms regulating growth remain unclear. Herein we show that inhibition of the aldehyde-metabolizing enzyme aldose reductase (AR) inhibits NF-kappaB activation during restenosis of balloon-injured rat carotid arteries as well as VSMC proliferation due to tumor necrosis factor alpha (TNF-alpha) stimulation. Inhibition of VSMC growth by AR inhibitors was not accompanied by increase in cell death or apoptosis. Inhibition of AR led to a decrease in the activity of the transcription factor NF-kappaB in culture and in the neointima of rat carotid arteries after balloon injury. Inhibition of AR in VSMC also prevented the activation of NF-kappaB by basic fibroblast growth factor (bFGF), angiotensin-II (Ang-II), and platelet-derived growth factor (PDGF-AB). The VSMC treated with AR inhibitors showed decreased nuclear translocation of NF-kappaB and diminished phosphorylation and proteolytic degradation of IkappaB-alpha. Under identical conditions, treatment with AR inhibitors also prevented the activation of protein kinase C (PKC) by TNF-alpha, bFGF, Ang-II, and PDGF-AB but not phorbol esters, indicating that AR inhibitors prevent PKC stimulation or the availability of its activator but not PKC itself. Treatment with antisense AR, which decreased the AR activity by >80%, attenuated PKC activation in TNF-alpha, bFGF, Ang-II, and PDGF-AB-stimulated VSMC and prevented TNF-alpha-induced proliferation. Collectively, these data suggest that inhibition of NF-kappaB may be a significant cause of the antimitogenic effects of AR inhibition and that this may be related to disruption of PKC-associated signaling in the AR-inhibited cells.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Louisville, Dept Med, Div Cardiol, Louisville, KY 40202 USA; Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Bioimmunotherapy, Houston, TX 77030 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Louisville; University of Texas System; UTMD Anderson Cancer Center	Srivastava, SK (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Rm 6-644,Basic Sci Bldg, Galveston, TX 77555 USA.	ssrivast@utmb.edu	Ramana, Kota/C-5460-2012; Bhatnagar, Aruni/H-7791-2013; Aggarwal, Bharat B/G-3388-2013; Srivastava, Sanjay/D-3921-2012	Ramana, Kota/0000-0001-6502-7800	NHLBI NIH HHS [HL55477, HL59378] Funding Source: Medline; NIDDK NIH HHS [DK 36118] Funding Source: Medline; NIEHS NIH HHS [R01 ES017260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059378, R01HL055477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES017260] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barisani D, 2000, FEBS LETT, V469, P208, DOI 10.1016/S0014-5793(00)01280-1; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BHATNAGAR A, 1990, BIOCHEM PHARMACOL, V39, P1115, DOI 10.1016/0006-2952(90)90292-S; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Bours V, 2000, TOXICOLOGY, V153, P27, DOI 10.1016/S0300-483X(00)00302-4; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; DONOHUE PJ, 1994, J BIOL CHEM, V269, P8604; Golovchenko I, 2000, CIRC RES, V87, P746, DOI 10.1161/01.RES.87.9.746; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Henry DN, 1999, AM J PHYSIOL-RENAL, V277, pF97, DOI 10.1152/ajprenal.1999.277.1.F97; Ho E, 1999, P SOC EXP BIOL MED, V222, P205, DOI 10.1046/j.1525-1373.1999.d01-137.x; Hoshi S, 2000, J BIOL CHEM, V275, P883, DOI 10.1074/jbc.275.2.883; Hsu DKW, 1997, BIOCHEM J, V328, P593, DOI 10.1042/bj3280593; JacquinBecker C, 1997, GLIA, V20, P135, DOI 10.1002/(SICI)1098-1136(199706)20:2<135::AID-GLIA5>3.0.CO;2-8; JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117; Jourd'heuil D, 1997, J CLIN GASTROENTEROL, V25, pS61, DOI 10.1097/00004836-199700001-00011; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Nakamura N, 2000, FREE RADICAL BIO MED, V29, P17, DOI 10.1016/S0891-5849(00)00286-0; Niemann-Jonsson A, 2001, ARTERIOSCL THROM VAS, V21, P1909, DOI 10.1161/hq1201.100222; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Rectenwald JE, 2000, CIRCULATION, V102, P1697, DOI 10.1161/01.CIR.102.14.1697; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; Selzman CH, 1999, CIRC RES, V84, P867; SELZMAN CH, 1999, CIRC RES, V508, P360; Seo HG, 2000, MOL PHARMACOL, V57, P709, DOI 10.1124/mol.57.4.709; Shinmura K, 2000, CIRCULATION, V102, P120; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Srivastava S, 1998, BIOCHEMISTRY-US, V37, P12909, DOI 10.1021/bi9804333; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; Wang ZB, 2001, FEBS LETT, V508, P360, DOI 10.1016/S0014-5793(01)03109-X; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21; Yang JC, 2000, CIRCULATION, V102, P3046	42	89	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32063	32070		10.1074/jbc.M202126200	http://dx.doi.org/10.1074/jbc.M202126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12063254	hybrid			2022-12-25	WOS:000177718700095
J	Welti, R; Li, WQ; Li, MY; Sang, YM; Biesiada, H; Zhou, HE; Rajashekar, CB; Williams, TD; Wang, XM				Welti, R; Li, WQ; Li, MY; Sang, YM; Biesiada, H; Zhou, HE; Rajashekar, CB; Williams, TD; Wang, XM			Profiling membrane lipids in plant stress responses - Role of phospholipase D alpha in freezing-induced lipid changes in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; PLASMA-MEMBRANE; COLD-ACCLIMATION; QUANTITATIVE-ANALYSIS; PANCREATIC-ISLETS; INSULINOMA CELLS; ACID; TOLERANCE; IDENTIFICATION; LEAVES	A sensitive approach based on electrospray ionization tandem mass spectrometry has been employed to profile membrane lipid molecular species in Arabidopsis undergoing cold and freezing stresses. Freezing at a sublethal temperature induced a decline in many molecular species of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylglycerol (PG) but induced an increase in phosphatidic acid (PA) and lysophospholipids. To probe the metabolic steps generating these changes, lipids of Arabidopsis deficient in the most abundant phospholipase D, PLDalpha, were analyzed. The PC content dropped only half as much, and PA levels rose only half as high in the PLDalpha-deficient plants as in wild-type plants. In contrast, neither PE nor PG levels decreased significantly more in wild-type plants than in PLDa-deficient plants. These data suggest that PC, rather than PE and PG, is the major in vivo substrate of PLDalpha The action of PLDalpha during freezing is of special interest because Arabidopsis plants that are deficient in PLDalpha have improved tolerance to freezing. The greater loss of PC and increase in PA in wild-type plants as compared with PLDalpha-deficient plants may be responsible for destabilizing membrane bilayer structure, resulting in a greater propensity toward membrane fusion and cell death in wild-type plants.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA; Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Univ Kansas, Mass Spectrometry Lab, Lawrence, KS 66045 USA; Kansas State Univ, Div Hort, Manhattan, KS 66506 USA	Kansas State University; Kansas State University; University of Kansas; Kansas State University	Welti, R (corresponding author), Kansas State Univ, Div Biol, Ackert Hall, Manhattan, KS 66506 USA.		Wang, Xuemin/M-2853-2013	Welti, Ruth/0000-0003-4373-2538; wang, xuemin/0000-0002-6251-6745; Li, Maoyin/0000-0002-9976-1349				ALBERDI M, 1990, PHYTOCHEMISTRY, V29, P2467, DOI 10.1016/0031-9422(90)85168-F; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Blom TS, 2001, BIOCHEMISTRY-US, V40, P14635, DOI 10.1021/bi0156714; Browse J, 2001, CURR OPIN PLANT BIOL, V4, P241, DOI 10.1016/S1369-5266(00)00167-9; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Fan L, 1997, PLANT CELL, V9, P2183, DOI 10.1105/tpc.9.12.2183; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; FUJIKAWA S, 1990, Cryobiology, V27, P665; Han XL, 1996, BIOCHEMISTRY-US, V35, P5822, DOI 10.1021/bi952927v; Hsu FF, 2000, J BIOL CHEM, V275, P16579, DOI 10.1074/jbc.M908342199; Kim YH, 1999, ANAL BIOCHEM, V267, P260, DOI 10.1006/abio.1998.3041; LYNCH DV, 1987, PLANT PHYSIOL, V83, P761, DOI 10.1104/pp.83.4.761; Miquel M, 1998, PLANT PHYSIOL, V117, P923, DOI 10.1104/pp.117.3.923; MURPHY RC, 1993, MASS SPECTROMETRY LI, V7, P223; NOVITSKAYA GV, 1983, APPL BIOCHEM MICROB, V18, P471; Pappan K, 1999, ARCH BIOCHEM BIOPHYS, V368, P347, DOI 10.1006/abbi.1999.1325; Pappan K, 1998, ARCH BIOCHEM BIOPHYS, V353, P131, DOI 10.1006/abbi.1998.0640; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; Qin CB, 2002, PLANT PHYSIOL, V128, P1057, DOI 10.1104/pp.010928; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Ramanadham S, 2000, BBA-MOL CELL BIOL L, V1484, P251, DOI 10.1016/S1388-1981(00)00022-6; SHOEMAKER DP, 1974, EXPT PHYSICAL CHEM, P34; Steponkus P., 1992, WATER LIFE, P338; Steponkus P.L., 1993, ADV LOW TEMPERATURE, V2, P211; STEPONKUS PL, 1984, ANNU REV PLANT PHYS, V35, P543, DOI 10.1146/annurev.pp.35.060184.002551; Steponkus PL, 1998, P NATL ACAD SCI USA, V95, P14570, DOI 10.1073/pnas.95.24.14570; Steponkus PL, 1995, PERMEABILITY STABILI, P77; SUGAWARA Y, 1990, Cryobiology, V27, P667; Thomashow MF, 1998, PLANT PHYSIOL, V118, P1, DOI 10.1104/pp.118.1.1; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; UEMURA M, 1995, PLANT PHYSIOL, V109, P15, DOI 10.1104/pp.109.1.15; UEMURA M, 1994, PLANT PHYSIOL, V104, P479, DOI 10.1104/pp.104.2.479; VERLEIJ AJ, 1982, BIOCHIM BIOPHYS ACTA, V684, P255; Wang CX, 2001, PLANT PHYSIOL, V127, P1102, DOI 10.1104/pp.010444; Wang CX, 2000, PLANT CELL, V12, P2237, DOI 10.1105/tpc.12.11.2237; Williams SD, 2000, J LIPID RES, V41, P1585; YOSHIDA S, 1974, PLANT PHYSIOL, V53, P509, DOI 10.1104/pp.53.3.509; YOSHIDA S, 1974, CONTR LOW TEMP SCI B, V18, P1; Zien CA, 2001, BBA-MOL CELL BIOL L, V1530, P236, DOI 10.1016/S1388-1981(01)00091-9	42	776	850	7	115	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31994	32002		10.1074/jbc.M205375200	http://dx.doi.org/10.1074/jbc.M205375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077151	hybrid			2022-12-25	WOS:000177718700087
J	Huttenrauch, F; Nitzki, A; Lin, FT; Honing, S; Oppermann, M				Huttenrauch, F; Nitzki, A; Lin, FT; Honing, S; Oppermann, M			beta-arrestin binding to CC chemokine receptor 5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 3RD INTRACELLULAR LOOP; CRYSTAL-STRUCTURE; VISUAL ARRESTIN; ALPHA(1B)-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; ADRENERGIC-RECEPTOR; CARBOXYL-TERMINUS; CLATHRIN ADAPTER	Agonist binding to the CC chemokine receptor 5 (CCR5) induces the phosphorylation of four distinct serine residues that are located in the CCR5 C terminus. We established a series of clonal RBL-2H3 cell lines expressing CCR5 with alanine mutations of Ser(336), Ser(337), Ser(342), and Ser(349) in various combinations and explored the significance of phosphorylation sites for the ability of the receptor to interact with beta-arrestins and to undergo desensitization and internalization upon ligand binding. Receptor mutants that lack any two phosphorylation sites retained their ability to recruit endogenous beta-arrestins to the cell membrane and were normally sequestered, whereas alanine mutation of any three C-terminal serine residues abolished both beta-arrestin binding and rapid agonist-induced internalization. In contrast, RANTES (regulated on activation normal T cell expressed and secreted) stimulation of a S336A/S349A mutant triggered a sustained calcium response and enhanced granular enzyme release. This mutational analysis implies that CCR5 internalization largely depends on a beta-arrestin-mediated mechanism that requires the presence of any two phosphorylation sites, whereas receptor desensitization is independently regulated by the phosphorylation of distinct serine residues. Surface plasmon resonance analysis further demonstrated that purified beta-arrestin 1 binds to phosphorylated and nonphosphorylated C-tail peptides with similar affinities, suggesting that beta-arrestins use additional receptor sites to discriminate between nonactivated and activated receptors. Surface plasmon resonance analysis revealed beta-arrestin 1 binding to the second intracellular loop of CCR5, which required an intact Asp-Arg-Tyr triplet. These results suggest that a conserved sequence motif within the second intracellular loop of CCR5 that is known to be involved in G protein activation plays a significant role in P-arrestin binding to CCR5.	Univ Gottingen, Dept Immunol, D-37075 Gottingen, Germany; Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Gottingen, Dept Biochem, D-37075 Gottingen, Germany	University of Gottingen; Duke University; Howard Hughes Medical Institute; Duke University; University of Gottingen	Oppermann, M (corresponding author), Univ Gottingen, Dept Immunol, Kreuzbergring 57, D-37075 Gottingen, Germany.							ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Fahmy K, 2000, BIOCHEMISTRY-US, V39, P10607, DOI 10.1021/bi000912d; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gelber EI, 1999, J NEUROCHEM, V72, P2206, DOI 10.1046/j.1471-4159.1999.0722206.x; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; McDowell JH, 2001, INVEST OPHTH VIS SCI, V42, P1439; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; MONTZ H, 1990, CELL IMMUNOL, V127, P337, DOI 10.1016/0008-8749(90)90137-G; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Murphy PM, 2000, PHARMACOL REV, V52, P145; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Potter RM, 2002, J BIOL CHEM, V277, P8970, DOI 10.1074/jbc.M111086200; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Qian HW, 2001, MOL ENDOCRINOL, V15, P1706, DOI 10.1210/me.15.10.1706; Santini F, 2000, J CELL SCI, V113, P2463; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Scheer A, 2000, MOL PHARMACOL, V57, P219; Shi W, 1998, BIOCHEMISTRY-US, V37, P4869, DOI 10.1021/bi9731100; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Smith WC, 1999, BIOCHEMISTRY-US, V38, P2752, DOI 10.1021/bi982643l; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836	53	84	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30769	30777		10.1074/jbc.M204033200	http://dx.doi.org/10.1074/jbc.M204033200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12065593	hybrid			2022-12-25	WOS:000177579800048
J	Mukhopadhyay, A; Shishodia, S; Suttles, J; Brittingham, K; Lamothe, B; Nimmanapalli, R; Bhalla, KN; Aggarwal, BB				Mukhopadhyay, A; Shishodia, S; Suttles, J; Brittingham, K; Lamothe, B; Nimmanapalli, R; Bhalla, KN; Aggarwal, BB			Ectopic expression of protein-tyrosine kinase bcr-abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and I kappa B alpha phosphorylation - Relationship with down-regulation of TNF receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; GROWTH-FACTOR-BETA; CELL-LINE; 2 FORMS; APOPTOSIS; GENE; RESISTANCE; INHIBITION; TRANSITION; INDUCTION	Bcr-Abl, the product of the protooncogene bcr-abl, is a constitutively active protein-tyrosine kinase that is highly expressed in chronic myelogenous leukemia and in acute myeloid leukemia cells. Because Bcr-Abl is known to provide mitogenic signals through suppression of apoptosis, we investigated the effect of this oncogene product on signaling by tumor necrosis factor (TNF), a proapoptotic cytokine. We used a bcr-abl-deficient human megakaryocytic leukemia cell line MO7E and an isogenic MBA cell line stably transfected with bcr-abl. Electrophoretic mobility shift assay revealed that TNF activated the nuclear transcription factor NF-kappaB in MO7E cells but not in MBA cells. The impaired NF-kappaB activation in Bcr-Abl-expressing cells was not due to absence of the NF-kappaB proteins p65, p50, or p100 or Of lkappaBalpha or IkappaBbeta. Okadaic acid-induced NF-kappaB activation was unaffected by Bcr-Abl expression. TNF induced IkappaBalpha phosphorylation and degradation in MO7E cells but not in MBA cells. The suppression of TNF-induced NF-kappaB activation by Bcr-Abl was not restricted to MBA cells, because ectopic expression of Bcr-Abl in human acute myeloid leukemia HL-60 cells also blocked TNF-induced NF-kappaB activation. When examined for the TNF receptors by the radioreceptor assay, flow cytometry, or Western blot analysis, we found that Bcr-Abl expression down-regulated the expression of the TNF receptors. The RNase protection assay and Northern blot analysis revealed the transcriptional down-regulation of the TNF receptor by Ber-Abl protein. Overall, these results indicate that ectopic expression of Bcr-Abl interferes with the TNF signaling pathway through the down-regulation of TNF receptors.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	University of Texas System; UTMD Anderson Cancer Center; University of Louisville; H Lee Moffitt Cancer Center & Research Institute	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@utmdacc.mda.uth.tmc.edu	Aggarwal, Bharat B/G-3388-2013	Bhalla, Kapil/0000-0001-5209-5126				AGGARWAL BB, 1993, LYMPHOKINE CYTOK RES, V12, P149; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; ARTEAGA CL, 1988, CANCER RES, V48, P3898; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; EVANS CA, 1993, CANCER RES, V53, P1735; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; KELLER JR, 1989, J CELL BIOCHEM, V39, P175, DOI 10.1002/jcb.240390209; Kumar A, 1999, METHOD ENZYMOL, V300, P339; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1994, CANCER RES, V54, P1360; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; ONOZAKI K, 1989, CANCER RES, V49, P3602; POIRIER GG, 1995, CELL, V81, P801; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ROBERTS AB, 1988, BRIT J CANCER, V57, P594, DOI 10.1038/bjc.1988.135; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Shi CS, 1999, BLOOD, V93, P1338, DOI 10.1182/blood.V93.4.1338.404k27_1338_1345; SIRARD C, 1994, BLOOD, V83, P1575; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WADA H, 1995, CANCER RES, V55, P3192; WilsonRawls J, 1996, CANCER RES, V56, P3426; Zeng Q, 1998, ANAL BIOCHEM, V259, P187, DOI 10.1006/abio.1998.2645	43	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30622	30628		10.1074/jbc.M204748200	http://dx.doi.org/10.1074/jbc.M204748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060665	Green Submitted, hybrid			2022-12-25	WOS:000177579800030
J	Wang, X; Li, MX; Sykes, BD				Wang, X; Li, MX; Sykes, BD			Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULSED-FIELD GRADIENT; MUSCLE-CONTRACTION; SKELETAL-MUSCLE; IMPROVED SENSITIVITY; ANGSTROM RESOLUTION; CALCIUM SENSITIZERS; NMR-SPECTROSCOPY; TERMINAL DOMAIN; BINDING; PROTEINS	Cardiac troponin C (cTnC) is the Ca2+-dependent switch for contraction in heart muscle and a potential target for drugs in the therapy of heart failure. Ca2+ binding to the regulatory domain of cTnC (cNTnC) induces little structural change but sets the stage for cTnI binding. A large "closed" to "open" conformational transition occurs in the regulatory domain upon binding cTnI(147-163) or bepridil. This raises the question of whether cTnI(147-163) and bepridil compete for cNTnC.Ca2+. In this work, we used two-dimensional H-1,N-15-heteronuclear single quantum coherence (HSQC) NAIR spectroscopy to examine the binding of bepridil to cNTnC.Ca2+ in the absence and presence of cTnI(147-163) and of cTnI(147-163) to cNTnC.Ca2+ in the absence and presence of bepridil. The results show that bepridil and cTnI147-163 bind cNTnC.Ca2+ simultaneously but with negative cooperativity. The affinity of cTnI(147-163) for cNTnC.Ca2+ is reduced similar to 3.5-fold by bepridil and vice versa. Using multinuclear and multidimensional NMR spectroscopy, we have determined the structure of the cNTnC.Ca2+ cTnI(147-163).bepridil ternary complex. The structure reveals a binding site for cTnI(147-163) primarily located on the A/B interhelical interface and a binding site for bepridil in the hydrophobic pocket of cNTnC.Ca2+. In the structure, the N terminus of the peptide clashes with part of the bepridil molecule, which explains the negative cooperativity between cTnI(147-163) and bepridil for cNTnC.Ca2+. This structure provides insights into the features that are important for the design of cTnC-specific cardiotonic drugs, which may be used to modulate the Ca2+ sensitivity of the myofilaments in heart muscle contraction.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada	University of Alberta	Sykes, BD (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.							Abusamhadneh E, 2001, FEBS LETT, V506, P51, DOI 10.1016/S0014-5793(01)02790-9; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; Chapelle JP, 1999, CLIN CHEM LAB MED, V37, P11, DOI 10.1515/CCLM.1999.002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GILL A, 1992, AM J CARDIOL, V69, pD11; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; ITOH H, 1984, J PHARMACOL EXP THER, V230, P737; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kischel P, 2000, BRIT J PHARMACOL, V131, P1496, DOI 10.1038/sj.bjp.0703727; Kleerekoper Q, 1998, J BIOL CHEM, V273, P8153, DOI 10.1074/jbc.273.14.8153; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li MX, 2000, BIOCHEMISTRY-US, V39, P8782, DOI 10.1021/bi000473i; Li MX, 1997, BIOCHEMISTRY-US, V36, P12519, DOI 10.1021/bi971222l; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Li Y, 2000, P NATL ACAD SCI USA, V97, P5140, DOI 10.1073/pnas.090098997; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; McKay RT, 2000, BIOCHEMISTRY-US, V39, P12731, DOI 10.1021/bi001240u; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; NielsenKudsk JE, 1995, J CARDIOVASC PHARM, V26, pS77; Ogura K, 1996, J BIOMOL NMR, V8, P492, DOI 10.1007/BF00228150; PARMACEK MS, 1991, CIRCULATION, V84, P991, DOI 10.1161/01.CIR.84.3.991; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Redwood CS, 1999, CARDIOVASC RES, V44, P20, DOI 10.1016/S0008-6363(99)00213-8; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SOLARO RJ, 1986, J PHARMACOL EXP THER, V238, P502; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Spyracopoulos L, 2000, BIOPHYS J, V78, p434A; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; Takeda S, 2002, BIOPHYS J, V82, p170A; Varro A, 1995, J CARDIOVASC PHARM, V26, pS32; Wang X, 2001, J BIOL CHEM, V276, P25456, DOI 10.1074/jbc.M102418200; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Zakhary DR, 1999, CIRCULATION, V99, P505, DOI 10.1161/01.CIR.99.4.505; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	53	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31124	31133		10.1074/jbc.M203896200	http://dx.doi.org/10.1074/jbc.M203896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060657	hybrid			2022-12-25	WOS:000177579800092
J	Chen, YR; Deterding, LJ; Sturgeon, BE; Tomer, KB; Mason, RP				Chen, YR; Deterding, LJ; Sturgeon, BE; Tomer, KB; Mason, RP			Protein oxidation of cytochrome c by reactive halogen species enhances its peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; HYPOCHLOROUS ACID; HYDROGEN-PEROXIDE; HUMAN-NEUTROPHILS; METHIONINE OXIDATION; OXIDIZED METHIONINE; ENDOTHELIAL-CELLS; HYPOHALOUS ACIDS; MYELOPEROXIDASE; GLUTATHIONE	Reactive halogen species (RHS; X-2 and HOX, where X represents Cl, Br, or I) are metabolites mediated by neutrophil activation and its accompanying respiratory burst. We have investigated the interaction between RHS and mitochondrial cytochrome c (cyt c) by using electrospray mass spectrometry and electron spin resonance (ESR). When the purified cyt c was reacted with an excess amount of hypochlorous acid (HOC1) at pH 7.4, the peroxidase activity of cyt c was increased by 4.5-, 6.9-, and 8.6-fold at molar ratios (HOCl/cyt c) of 2, 4, and 8, respectively. In comparison with native cyt c, the mass spectra obtained from the HOCl-treated cyt c revealed that oxygen is covalently incorporated into the protein as indicated by molecular ions of m/z = 12,360 (cyt c), 12,376 (cyt c + O), and 12,392 (cyt c + 20). Using tandem mass spectrometry, a peptide (obtained from the tryptic digests of HOCl-treated cyt c) corresponding to the amino acid sequence MIFAGIK, which contains the methionine that binds to the heme, was identified to be involved in the oxygen incorporation. The location of the oxygen incorporation was unequivocally determined to be the methionine residue, suggesting that the oxidation of heme ligand (Met-80) by HOCl results in the enhancement of peroxidase activity of cyt c. ESR spectroscopy of HOCl-oxidized cyt c, when reacted with H2O2 in the presence of the nitroso spin trap 2-methyl-2-nitrosopropane (MNP), yielded more immobilized MNP/tyrosyl adduct than native cyt c. In the presence of H2O2, the peroxidase activity of HOCl-oxidized cyt c exhibited an increasing ability to oxidize tyrosine to tyrosyl radical as measured directly by fast flow ESR. Titration of both native cyt c and HOCl-oxidized cyt c with various amounts of H2O2 indicated that the latter has a decreased apparent K-m for H2O2, implicating that protein oxidation of cyt c increases its accessibility to H2O2. HOCl-oxidized cyt c also displayed an impaired ability to support oxygen consumption by the purified mitochondrial cytochrome c oxidase, suggesting that protein oxidation of cyt c may break the electron transport chain and inhibit energy transduction in mitochondria.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Struct Biol, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Deterding, LJ (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Mason, Ronald P/G-5967-2019; Tomer, Kenneth B/E-8018-2013	Mason, Ronald P/0000-0002-1859-9109; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050139, ZIAES050171, Z01ES050167, ZIAES050167, Z01ES050171, ZIAES050139, Z01ES050153] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BARRETTE WC, 1989, BIOCHEMISTRY-US, V28, P9172, DOI 10.1021/bi00449a032; BECKSPEIER I, 1988, FEBS LETT, V227, P1, DOI 10.1016/0014-5793(88)81401-7; BERNOFSKY C, 1991, FASEB J, V5, P295, DOI 10.1096/fasebj.5.3.1848195; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BORREGAARD N, 1988, RESPIRATORY BURST IT, P1; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; CLARK RA, 1982, J IMMUNOL, V128, P1507; Dickerson R., 1975, ENZYMES, V11, P397; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Dunforb HB, 1999, HEME PEROXIDASES, P349; FEINBERG BA, 1986, BIOCHIM BIOPHYS ACTA, V851, P157, DOI 10.1016/0005-2728(86)90121-0; FLISS H, 1983, P NATL ACAD SCI-BIOL, V80, P7160, DOI 10.1073/pnas.80.23.7160; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Gunther MR, 1998, BIOCHEM J, V330, P1293; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Heinecke JW, 2002, FREE RADICAL BIO MED, V32, P1090, DOI 10.1016/S0891-5849(02)00792-X; Heinecke JW, 1999, FASEB J, V13, P1113, DOI 10.1096/fasebj.13.10.1113; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; IVANETICH KM, 1976, BIOCHEMISTRY-US, V15, P1144, DOI 10.1021/bi00650a029; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; Kotiaho T, 2000, J AM SOC MASS SPECTR, V11, P526, DOI 10.1016/S1044-0305(00)00116-1; LADINOIS OM, 2000, BIOCHEM BIOPH RES CO, V270, P199; Lagerwerf FM, 1996, RAPID COMMUN MASS SP, V10, P1905, DOI 10.1002/(SICI)1097-0231(199612)10:15<1905::AID-RCM755>3.0.CO;2-9; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOU BS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P403, DOI 10.1016/0005-2728(93)90127-2; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Prutz WA, 2001, ARCH BIOCHEM BIOPHYS, V389, P110, DOI 10.1006/abbi.2001.2321; Prutz WA, 2000, ARCH BIOCHEM BIOPHYS, V380, P181, DOI 10.1006/abbi.2000.1914; Pullar JM, 2001, J BIOL CHEM, V276, P22120, DOI 10.1074/jbc.M102088200; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSEN H, 1982, J BIOL CHEM, V257, P13731; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Sturgeon BE, 2001, J BIOL CHEM, V276, P45516, DOI 10.1074/jbc.M106835200; Vissers MCM, 1999, BIOCHEM J, V344, P443, DOI 10.1042/0264-6021:3440443; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WINTERBOURN CC, 2001, BIOASSAYS OXIDATIVE, P163; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZGLICZYNSKI JM, 1988, RESP BURST ITS PHYSL, P315	59	101	101	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29781	29791		10.1074/jbc.M200709200	http://dx.doi.org/10.1074/jbc.M200709200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050149	hybrid			2022-12-25	WOS:000177509300056
J	Konstas, AA; Shearwin-Whyatt, LM; Fotia, AB; Degger, B; Riccardi, D; Cook, DI; Korbmacher, C; Kumar, S				Konstas, AA; Shearwin-Whyatt, LM; Fotia, AB; Degger, B; Riccardi, D; Cook, DI; Korbmacher, C; Kumar, S			Regulation of the epithelial sodium channel by N4WBP5A, a novel Nedd4/Nedd4-2-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OOCYTE EXPRESSION SYSTEM; NA+ CHANNEL; LIDDLES-SYNDROME; WW DOMAINS; SURFACE EXPRESSION; XENOPUS-LAEVIS; CYTOSOLIC NA+; BETA-SUBUNIT; DUCT CELLS; NEDD4	The amiloride-sensitive epithelial sodium channel (ENaC) plays a critical role in fluid and electrolyte homeostasis and consists of alpha, beta, and gamma subunits. The carboxyl terminus of each ENaC subunit contains a PPXY motif that is believed to be important for interaction with the WW domains of the ubiquitin-protein ligases, Nedd4 and Nedd4-2. Disruption of this interaction, as in Liddle's syndrome where mutations delete or alter the PPXY motif of either the beta or gamma subunits, has been shown to result in increased ENaC activity and arterial hypertension. Here we present evidence that N4WBP5A, a novel Nedd4/Nedd4-2-binding protein, is a potential regulator of ENaC. In Xenopus laevis oocytes N4WBP5A increases surface expression of ENaC by reducing the rate of ENaC retrieval. We further demonstrate that N4WBP5A prevents sodium feedback inhibition of ENaC possibly by interfering with the xNedd4-2-mediated regulation of ENaC. As N4WBP5A binds Nedd4/Nedd4-2 via PPXY motif/WW domain interactions and appears to be associated with specific intracellular vesicles, we propose that N4WBP5A functions by regulating Nedd4/Nedd4-2 availability and trafficking. Because N4WBP5A is highly expressed in native renal collecting duct and other tissues that express ENaC, it is a likely candidate to modulate ENaC function an vivo.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia	University of Oxford; Institute Medical & Veterinary Science Australia; University of Adelaide; University of Manchester; University of Sydney	Korbmacher, C (corresponding author), Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, Waldstr 6, D-91054 Erlangen, Germany.		Shearwin, Linda/AAD-5594-2020; Riccardi, Daniela/A-4674-2010; Kumar, Sharad/AAX-7787-2020	Shearwin, Linda/0000-0002-4504-6534; Riccardi, Daniela/0000-0002-7322-3163; Kumar, Sharad/0000-0001-7126-9814; Degger, Brian/0000-0002-3930-8569				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Devuyst O, 1996, AM J PHYSIOL-RENAL, V271, pF723, DOI 10.1152/ajprenal.1996.271.3.F723; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Komwatana P, 1996, P NATL ACAD SCI USA, V93, P8107, DOI 10.1073/pnas.93.15.8107; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; KONSTAS AA, 2002, J BIOL CHEM; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Letz B, 1997, AM J PHYSIOL-CELL PH, V272, pC657, DOI 10.1152/ajpcell.1997.272.2.C657; LETZ B, 1995, J MEMBRANE BIOL, V148, P127; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Rebhun JF, 1998, DNA SEQUENCE, V9, P295, DOI 10.3109/10425179809008468; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; ToddTurla KM, 1996, AM J PHYSIOL-RENAL, V270, pF237, DOI 10.1152/ajprenal.1996.270.1.F237; Wagner CA, 2001, CELL PHYSIOL BIOCHEM, V11, P209, DOI 10.1159/000051935; Wang WH, 1999, AM J PHYSIOL-RENAL, V277, pF826, DOI 10.1152/ajprenal.1999.277.6.F826; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	44	80	84	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29406	29416		10.1074/jbc.M203018200	http://dx.doi.org/10.1074/jbc.M203018200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050153	hybrid			2022-12-25	WOS:000177509300009
J	Strezoska, Z; Pestov, DG; Lau, LF				Strezoska, Z; Pestov, DG; Lau, LF			Functional inactivation of the mouse nucleolar protein bop1 inhibits multiple steps in pre-rRNA processing and blocks cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTERNAL TRANSCRIBED SPACER; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; YEAST; 5.8S; BIOGENESIS; PRECURSOR; GROWTH; 28S; 25S	Bop1 is a conserved nucleolar protein involved in rRNA processing and ribosome assembly in eukaryotes. Expression of its dominant-negative mutant Bop1Delta in mouse cells blocks rRNA maturation and synthesis of large ribosomal subunits and induces a reversible, p53-dependent cell cycle arrest. In this study, we have conducted a deletion analysis of Bop1 and identified a new mutant, Bop1N2, that also acts as a potent inhibitor of cell cycle progression. Bop1N2 and Bop1Delta are C-terminal and N-terminal deletion mutants, respectively, and share only 72 amino acid residues. Both mutant proteins are localized to the nucleolus and strongly inhibit rRNA processing, suggesting that activation of a cell cycle checkpoint by Bop1 mutants is linked to their inhibitory effects on rRNA and ribosome synthesis. By using these dominant-negative mutants as well as antisense oligonucleotides to interfere with endogenous Bop1, we identified specific rRNA processing steps that require Bop1 function in mammalian cells. Our data demonstrate that Bop1 is required for proper processing at four distinct sites located within the internal transcribed spacers ITS1 and ITS2 and the 3' external spacer. We propose a model in which Bop1 serves as an essential factor in ribosome formation that coordinates processing of the spacer regions in pre-rRNA.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	LFLau@uic.edu		Lau, Lester/0000-0002-4364-2914; Pestov, Dimitri/0000-0002-1425-9879	NATIONAL CANCER INSTITUTE [R01CA095267] Funding Source: NIH RePORTER; NCI NIH HHS [CA95267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allmang C, 1998, J MOL BIOL, V278, P67, DOI 10.1006/jmbi.1998.1693; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cote CA, 2001, NUCLEIC ACIDS RES, V29, P2106, DOI 10.1093/nar/29.10.2106; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; Geerlings TH, 2000, RNA, V6, P1698, DOI 10.1017/S1355838200001540; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GURNEY T, 1985, NUCLEIC ACIDS RES, V13, P4905, DOI 10.1093/nar/13.13.4905; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Hitchen J, 1997, J MOL BIOL, V274, P481, DOI 10.1006/jmbi.1997.1376; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Liang WQ, 1997, P NATL ACAD SCI USA, V94, P2864, DOI 10.1073/pnas.94.7.2864; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; Pestov DG, 1998, ONCOGENE, V17, P3187, DOI 10.1038/sj.onc.1202260; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pestov DG, 2001, NUCLEIC ACIDS RES, V29, P3621, DOI 10.1093/nar/29.17.3621; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; Sambrook J., 2002, MOL CLONING LAB MANU; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; TIOLLAIS P, 1971, P NATL ACAD SCI USA, V68, P1117, DOI 10.1073/pnas.68.6.1117; VANNUES RW, 1994, NUCLEIC ACIDS RES, V22, P912, DOI 10.1093/nar/22.6.912; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	31	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29617	29625		10.1074/jbc.M204381200	http://dx.doi.org/10.1074/jbc.M204381200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048210	hybrid			2022-12-25	WOS:000177509300036
J	Gebhardt, C; Breitenbach, U; Tuckermann, JP; Dittrich, BT; Richter, KH; Angel, P				Gebhardt, C; Breitenbach, U; Tuckermann, JP; Dittrich, BT; Richter, KH; Angel, P			Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis	ONCOGENE			English	Article						AP-1; epidermis; inflammation; papilloma; tumor promoter	CALCIUM-BINDING PROTEINS; MALIGNANT PROGRESSION; MOUSE KERATINOCYTES; EXPRESSION; RECEPTOR; GENE; TRANSCRIPTION; DIFFERENTIATION; MRP14; AP-1	The two calgranulins S100A8 and S100A9 were found to be differentially expressed at sites of acute and chronic inflammation. Here we have employed the phorbol ester-induced multistage skin carcinogenesis protocol in mice to determine the expression of both genes in inflamed skin and in skin tumors. We show that expression is coordinately induced by the phorbol ester TPA in epithelial cells as well as infiltrating leukocytes. By comparing S100A8 and S100A9 mRNA levels in wild type and c-Fos deficient mice (c-fos(-/-)) we found that expression is negatively regulated by c-Fos/AP-1. Glucocorticoids, which exhibit potent anti-inflammatory and anti-tumor promoting activities repressed TPA-mediated S100A8 and S100A9 induction in wild type, cfos(-/-) mice, thus identifying both genes as but not in the first examples of AP-1 target genes whose repression of TPA-induced transcription by glucocorticoids depends on c-Fos. Finally, we show that enhanced expression is not restricted to the initial TPA-induced inflammatory response but is observed at all stages of skin carcinogenesis. These data identify S100A8 and S100A9 as novel, tumor-associated genes and may point to an as yet unrecognized function of both genes in the development of epithelial skin tumors.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.angel@dkfz-heidelberg.de	Gebhardt, Christoffer/F-8170-2015; Gebhardt, Christoffer/B-5713-2009	Gebhardt, Christoffer/0000-0001-7090-9584; 				Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; BELMAN S, 1972, CANCER RES, V32, P450; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BRANDTZAEG P, 1987, AM J CLIN PATHOL, V87, P700, DOI 10.1093/ajcp/87.6.700; Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; DiSepio D, 1997, J BIOL CHEM, V272, P25555, DOI 10.1074/jbc.272.41.25555; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FISHER C, 1991, DEVELOPMENT, V111, P253; FURSTENBERGER G, 1995, CARCINOGENESIS, V16, P61, DOI 10.1093/carcin/16.1.61; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Klempt M, 1999, J CELL BIOCHEM, V73, P49, DOI 10.1002/(SICI)1097-4644(19990401)73:1<49::AID-JCB6>3.0.CO;2-2; LAGASSE E, 1992, BLOOD, V79, P1907; LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; Melkonyan H, 1998, J BIOL CHEM, V273, P27026, DOI 10.1074/jbc.273.41.27026; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Nacken W, 1996, BBA-MOL BASIS DIS, V1315, P1, DOI 10.1016/0925-4439(95)00108-5; Nacken W, 2001, J CELL BIOCHEM, V80, P606, DOI 10.1002/1097-4644(20010315)80:4<606::AID-JCB1015>3.3.CO;2-B; Newton RA, 1998, J IMMUNOL, V160, P1427; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Passey RJ, 1999, J LEUKOCYTE BIOL, V66, P549, DOI 10.1002/jlb.66.4.549; Passey RJ, 1999, J IMMUNOL, V163, P2209; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Rammes A, 1997, J BIOL CHEM, V272, P9496; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Rennecke J, 2000, BBA-MOL CELL RES, V1497, P289, DOI 10.1016/S0167-4889(00)00067-7; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; SCHNARR B, 2000, INT J CANCER, V88, P345; SCHONTHAL A, 1989, ONCOGENE, V4, P629; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Wang HQ, 1999, J CELL SCI, V112, P3497; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WILKINSON MM, 1988, J CELL SCI, V91, P221; WINTER H, 1983, ARCH DERMATOL RES, V275, P27, DOI 10.1007/BF00516551; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	57	104	114	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4266	4276		10.1038/sj.onc.1205521	http://dx.doi.org/10.1038/sj.onc.1205521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082614	Bronze			2022-12-25	WOS:000176174200009
J	Oswald, RE; Suchyna, TM; McFeeters, R; Gottlieb, P; Sachs, F				Oswald, RE; Suchyna, TM; McFeeters, R; Gottlieb, P; Sachs, F			Solution structure of peptide toxins that block mechanosensitive ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; NUCLEAR-MAGNETIC-RESONANCE; GATING MODIFIER TOXINS; DEPENDENT K+ CHANNELS; CHEMICAL-SHIFT INDEX; BACKBONE DYNAMICS; CALCIUM-CHANNEL; SPIDER VENOM; NMR; SPECTROSCOPY	Mechanosensitive channels (MSCs) play key roles in sensory processing and have been implicated as primary transducers for a variety of cellular responses ranging from osmosensing to gene expression. This paper presents the first structures of any kind known to interact specifically with MSCs. GsMTx-4 and GsMtx-2 are inhibitor cysteine knot peptides isolated from venom of the tarantula, Grammostola spatulata (Suchyna, T. M., Johnson, J. H., Hamer, K., Leykam, J. F., Gage, D. A., Clemo, H. F., Baumgarten, C. M., and Sachs, F. (2000) J. Gen. Physiol. 115, 583-598). Inhibition of cationic MSCs by the higher affinity GsMtx-4 (K-D similar to500 nM) reduced cell size in swollen and hypertrophic heart cells, swelling-activated currents in astrocytes, and stretch-induced arrhythmias in the heart. Despite the relatively low affinity, no cross-reactivity has been found with other channels. Using two-dimensional NAIR spectroscopy, we determined the solution structure of GsMTx-4 and a lower affinity (GsMTx-2; K-D similar to6 muM) peptide from the same venom. The dominant feature of the two structures is a hydrophobic patch, utilizing most of the aromatic residues and surrounded with charged residues. The spatial arrangement of charged residues that are unique to GsMTx-4 and GsMTx-2 may underlie the selectivity of these peptides.	Cornell Univ, Dept Mol Med, Vet Med Ctr C3 167, Ithaca, NY 14853 USA; SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Oswald, RE (corresponding author), Cornell Univ, Dept Mol Med, Vet Med Ctr C3 167, Ithaca, NY 14853 USA.	reo1@cornell.edu	Gottlieb, Philip/C-3113-2019	Gottlieb, Philip/0000-0003-3764-9885	PHS HHS [R01 012042] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BASCUR L, 1980, TOXICON, V18, P224, DOI 10.1016/0041-0101(80)90078-1; Bode F, 2001, NATURE, V409, P35, DOI 10.1038/35051165; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1996, XPLOR MANUAL VERSION; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demchenko AP, 2001, J MOL RECOGNIT, V14, P42, DOI 10.1002/1099-1352(200101/02)14:1<42::AID-JMR518>3.0.CO;2-8; Ermakov YA, 2001, BIOPHYS J, V80, P1851, DOI 10.1016/S0006-3495(01)76155-3; Ermakov YuA, 1998, Membr Cell Biol, V12, P411; Ermakov YuA, 1997, Membr Cell Biol, V11, P539; Gizachew D, 2001, BIOCHEMISTRY-US, V40, P14368, DOI 10.1021/bi010989h; Goddard TD., SPARKY VERSION 3; Goldenberg DP, 2001, PROTEIN SCI, V10, P538, DOI 10.1110/ps.30701; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HACKNEY CM, 1995, AM J PHYSIOL-CELL PH, V268, pC1, DOI 10.1152/ajpcell.1995.268.1.C1; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hamill OP, 1996, PHARMACOL REV, V48, P231; KAISER II, 1994, TOXICON, V32, P1083, DOI 10.1016/0041-0101(94)90392-1; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAMPE RA, 1993, MOL PHARMACOL, V44, P451; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li-Smerin Y, 1998, P NATL ACAD SCI USA, V95, P8585, DOI 10.1073/pnas.95.15.8585; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; Li-Smerin Y, 2000, J GEN PHYSIOL, V115, P673, DOI 10.1085/jgp.115.6.673; Loh AP, 1999, BIOCHEMISTRY-US, V38, P12547, DOI 10.1021/bi9913707; Luque I, 2000, PROTEINS, P63; McNulty JC, 2001, BIOCHEMISTRY-US, V40, P15520, DOI 10.1021/bi0117192; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Newcomb R, 1998, BIOCHEMISTRY-US, V37, P15353, DOI 10.1021/bi981255g; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; Pallaghy PK, 1999, J PEPT RES, V53, P343, DOI 10.1034/j.1399-3011.1999.00040.x; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; RUSCH A, 1994, J PHYSIOL-LONDON, V474, P75; Sachs F, 1998, REV PHYSIOL BIOCH P, V132, P1, DOI 10.1007/BFb0004985; SMALL DL, 1995, BRIT J PHARMACOL, V114, P180, DOI 10.1111/j.1476-5381.1995.tb14923.x; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Takahashi H, 2000, J MOL BIOL, V297, P771, DOI 10.1006/jmbi.2000.3609; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Winterfield JR, 2000, J GEN PHYSIOL, V116, P637, DOI 10.1085/jgp.116.5.637; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	60	83	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34443	34450		10.1074/jbc.M202715200	http://dx.doi.org/10.1074/jbc.M202715200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12082099	hybrid			2022-12-25	WOS:000177959100117
J	Ashcroft, AE; Brinker, A; Coyle, JE; Weber, F; Kaiser, M; Moroder, L; Parsons, MR; Jager, J; Hartl, UF; Hayer-Hartl, M; Radford, SE				Ashcroft, AE; Brinker, A; Coyle, JE; Weber, F; Kaiser, M; Moroder, L; Parsons, MR; Jager, J; Hartl, UF; Hayer-Hartl, M; Radford, SE			Structural plasticity and noncovalent substrate binding in the GroEL apical domain - A study using electrospray ionization mass spectrometry and fluorescence binding studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHAPERONIN GROEL; CRYSTAL-STRUCTURE; POLYPEPTIDE BINDING; ATPASE CYCLE; PROTEIN; MINICHAPERONE; IDENTIFICATION; REFINEMENT; COMPLEXES; MECHANISM	Advances in understanding how GroEL binds to non-native proteins are reported. Conformational flexibility in the GroEL apical domain, which could account for the variety of substrates that GroEL binds, is illustrated by comparison of several independent crystallographic structures of apical domain constructs that show conformational plasticity in helices H and I. Additionally, ESI-MS indicates that apical domain constructs have co-populated conformations at neutral pH. To assess the ability of different apical domain conformers to bind cochaperone and substrate, model peptides corresponding to the mobile loop of GroES and to helix D from rhodanese were studied. Analysis of apical domain-peptide complexes by ESI-MS indicates that only the folded or partially folded apical domain conformations form complexes that survive gas phase conditions. Fluorescence binding studies show that the apical domain can fully bind both peptides independently. No competition for binding was observed, suggesting the peptides have distinct apical domain-binding sites. Blocking the GroES-apical domain-binding site in GroEL rendered the chaperonin inactive in binding GroES and in assisting the folding of denatured rhodanese, but still capable of binding non-native proteins, supporting the conclusion that GroES and substrate proteins have, at least partially, distinct binding sites even in the intact GroEL tetradecamer.	Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS3 9JT, W Yorkshire, England; Univ Leeds, Sch Biochem & Mol Sci, Leeds LS3 9JT, W Yorkshire, England; Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Bioorgan Chem, D-82152 Martinsried, Germany	University of Leeds; University of Leeds; Max Planck Society; Max Planck Society	Radford, SE (corresponding author), Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS3 9JT, W Yorkshire, England.	s.e.radford@leeds.ac.uk	Hayer-Hartl, Manajit/V-8078-2017	Hayer-Hartl, Manajit/0000-0001-8213-6742; Radford, Sheena/0000-0002-3079-8039; Moroder, Luis/0000-0001-9570-5713				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Brinker A, 2001, CELL, V107, P223, DOI 10.1016/S0092-8674(01)00517-7; Brocchieri L, 2000, PROTEIN SCI, V9, P476; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chatellier J, 1999, J MOL BIOL, V292, P163, DOI 10.1006/jmbi.1999.3040; Chatellier J, 2000, J MOL BIOL, V304, P883, DOI 10.1006/jmbi.2000.4277; Chatellier J, 2000, J MOL BIOL, V304, P897, DOI 10.1006/jmbi.2000.4278; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; DESSAUER CW, 1994, J BIOL CHEM, V269, P19766; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Feltham JL, 2000, CELL, V100, P193, DOI 10.1016/S0092-8674(00)81557-3; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; Grallert H, 2001, J STRUCT BIOL, V135, P95, DOI 10.1006/jsbi.2001.4387; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Hutchinson JP, 1997, J CHEM SOC PERK T 2, P279, DOI 10.1039/a604880c; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi N, 1999, J MOL BIOL, V292, P181, DOI 10.1006/jmbi.1999.3042; Konermann L, 1997, BIOCHEMISTRY-US, V36, P12296, DOI 10.1021/bi971266u; Kraunsoe JAE, 1996, FEBS LETT, V396, P108, DOI 10.1016/0014-5793(96)01081-2; Kusmierczyk AR, 2001, MOL BIOTECHNOL, V19, P141, DOI 10.1385/MB:19:2:141; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LESLIE AGW, 1992, JOINT CCP4 ESP EACMB, V26; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Ma JP, 2000, J MOL BIOL, V302, P303, DOI 10.1006/jmbi.2000.4014; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PFLUGRATH JW, 1984, NEW GENERATION GRAPH; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Raftery MJ, 1998, J AM SOC MASS SPECTR, V9, P533, DOI 10.1016/S1044-0305(98)00020-8; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Robinson CV, 1996, J AM CHEM SOC, V118, P8646, DOI 10.1021/ja960211x; ROMANO R, 1993, BIOCHIM BIOPHYS ACTA, V1151, P111, DOI 10.1016/0005-2736(93)90093-F; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Smith RD, 1997, CHEM SOC REV, V26, P191, DOI 10.1039/cs9972600191; Smoot AL, 2001, BIOCHEMISTRY-US, V40, P4484, DOI 10.1021/bi001822b; Tanaka N, 1999, J MOL BIOL, V292, P173, DOI 10.1006/jmbi.1999.3041; Wang QH, 2000, J MOL BIOL, V304, P873, DOI 10.1006/jmbi.2000.4276; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; Weber F, 1999, NAT STRUCT BIOL, V6, P200, DOI 10.1038/5894; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	62	30	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33115	33126		10.1074/jbc.M203398200	http://dx.doi.org/10.1074/jbc.M203398200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12065585	hybrid			2022-12-25	WOS:000177859000093
J	Besch, R; Giovannangeli, C; Kammerbauer, C; Degitz, K				Besch, R; Giovannangeli, C; Kammerbauer, C; Degitz, K			Specific inhibition of ICAM-1 expression mediated by gene targeting with triplex-forming oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; INTERFERON-GAMMA; ANTISENSE OLIGONUCLEOTIDES; DNA; CELLS; OLIGODEOXYNUCLEOTIDES; MODULATION; INDUCTION; RADIATION; CLONING	Selected sequences in the DNA double helix can be specifically recognized by oligonucleotides via hydrogen bonding interactions. The resulting triple helix can modulate DNA metabolism and especially interfere with transcription in a gene-specific manner. To explore the potential of triplex-forming oligonucleotides (TFOs) as gene repressors, a TFO was designed to target a 16-bp sequence within the third intron of the human intercellular-adhesion molecule-1 (ICAM-1) gene, which plays a key role in initiating inflammation. TFO binding to its ICAM-1 target sequence was characterized in vitro and also demonstrated in cell nuclei with the set-up of a novel magnetic capture assay, which represents a general experimental approach to the detection of specific TFO binding and to the determination of the accessibility of a given genomic DNA locus. In a human keratinocyte cell line (A431), we observed that: (i) the ICAM-1 target sequence in the chromatin context within the nuclei is still available for triplex formation and (ii) TFO inhibits sequence and gene-specific interferon-gamma-induced ICAM-1 surface expression. Collectively, the data demonstrate effective and specific inhibition of ICAM-1 expression by TFO treatment and support the view that triplex-mediated gene targeting might be a valuable technique for anti-inflammatory or anticancer strategies.	Univ Munich, Dept Dermatol, D-80337 Munich, Germany; Museum Natl Hist Nat, Biophys Lab, CNRS,UMR8646, INSERM U565, Paris, France	University of Munich; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN)	Degitz, K (corresponding author), Univ Munich, Dept Dermatol, Frauenlobstr 9-11, D-80337 Munich, Germany.	Klaus.Degitz@lrz.uni-muenchen.de						Bailey C, 2000, NUCLEIC ACIDS RES, V28, P1154, DOI 10.1093/nar/28.5.1154; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; BEHRENDS U, 1994, J INVEST DERMATOL, V103, P726, DOI 10.1111/1523-1747.ep12398607; Belousov ES, 1998, NUCLEIC ACIDS RES, V26, P1324, DOI 10.1093/nar/26.5.1324; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; CAUGHMAN SW, 1990, J INVEST DERMATOL, V94, pS22, DOI 10.1111/1523-1747.ep12875005; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Faria M, 2001, J GENE MED, V3, P299, DOI 10.1002/jgm.192; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; Giovannangeli C, 2000, CURR OPIN MOL THER, V2, P288; GIOVANNANGELI C, 1992, NUCLEIC ACIDS RES, V20, P4275, DOI 10.1093/nar/20.16.4275; Giovannangeli C, 1997, P NATL ACAD SCI USA, V94, P79, DOI 10.1073/pnas.94.1.79; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; Lebedeva I, 2001, ANNU REV PHARMACOL, V41, P403, DOI 10.1146/annurev.pharmtox.41.1.403; Luo ZJ, 2000, P NATL ACAD SCI USA, V97, P9003, DOI 10.1073/pnas.160004997; Marschall C, 1999, J INVEST DERMATOL, V113, P69, DOI 10.1046/j.1523-1747.1999.00631.x; NOONBERG SB, 1995, NUCLEIC ACIDS RES, V23, P1956, DOI 10.1093/nar/23.11.1956; NORRIS DA, 1990, J INVEST DERMATOL, V95, P132, DOI 10.1111/1523-1747.ep12477877; Oh DH, 1999, NUCLEIC ACIDS RES, V27, P4734, DOI 10.1093/nar/27.24.4734; POBER JS, 1986, J IMMUNOL, V137, P1893; RAMANATHAN M, 1994, J BIOL CHEM, V269, P24564; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; Schreiber S, 2001, GASTROENTEROLOGY, V120, P1339, DOI 10.1053/gast.2001.24015; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SRINIVASAN SK, 1995, J CLIN LAB ANAL, V9, P129, DOI 10.1002/jcla.1860090210; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Stepkowski SM, 2000, CURR OPIN MOL THER, V2, P304; Takebayashi Y, 2001, NAT MED, V7, P961, DOI 10.1038/91008; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Vasquez KM, 1999, NUCLEIC ACIDS RES, V27, P1176, DOI 10.1093/nar/27.4.1176; Vasquez KM, 2001, J BIOL CHEM, V276, P38536, DOI 10.1074/jbc.M101797200; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wraight CJ, 2001, PHARMACOL THERAPEUT, V90, P89, DOI 10.1016/S0163-7258(01)00133-4; Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4	38	32	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32473	32479		10.1074/jbc.M203311200	http://dx.doi.org/10.1074/jbc.M203311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080053	hybrid			2022-12-25	WOS:000177859000012
J	Doelling, JH; Walker, JM; Friedman, EM; Thompson, AR; Vierstra, RD				Doelling, JH; Walker, JM; Friedman, EM; Thompson, AR; Vierstra, RD			The APG8/12-activating enzyme APG7 is required for proper nutrient recycling and senescence in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONJUGATION SYSTEM; AUTOPHAGY; VACUOLE; YEAST; GENES; DEGRADATION; CELLS; CHLOROPLASTS; EXPRESSION; CYTOPLASM	The vacuole/lysosome serves an important recycling function during starvation and senescence in eukaryotes via a process called autophagy. Here bulk cytosolic constituents and organelles become sequestered in specialized autophagic vesicles, which then deliver their cargo to the vacuole for degradation. In yeasts, genetic screens have identified two novel post-translational modification pathways remarkably similar to ubiquitination that are required for autophagy. From searches of the Arabidopsis genome, we have identified gene families encoding proteins related to both the APG8 and -12 polypeptide tags and orthologs for all components required for their attachment. A single APG7 gene encodes the ATP-dependent activating enzyme that initiates both conjugation pathways. Phenotypic analysis of an APG7 disruption indicates that it is not essential for normal growth and development in Arabidopsis. However, the apg7-1 mutant is hypersensitive to nutrient limiting conditions and displays premature leaf senescence. mRNAs for both APG7 and APG8 preferentially accumulate as leaves senesce, suggesting that both conjugation pathways are up-regulated during the senescence syndrome. These findings show that the APG8/12 conjugation pathways have been conserved in plants and may have important roles in autophagic recycling, especially during situations that require substantial nitrogen and carbon mobilization.	Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Hort, 1575 Linden Dr, Madison, WI 53706 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aubert S, 1996, J CELL BIOL, V133, P1251, DOI 10.1083/jcb.133.6.1251; BUETOW DE, 1988, PHOTOSYNTH RES, V18, P61, DOI 10.1007/BF00042980; Callis J, 2000, CURR OPIN PLANT BIOL, V3, P381, DOI 10.1016/S1369-5266(00)00100-X; CALLIS J, 1995, PLANT CELL, V7, P845, DOI 10.1105/tpc.7.7.845; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; Di Sansebastiano GP, 1998, PLANT J, V15, P449, DOI 10.1046/j.1365-313X.1998.00210.x; Di Sansebastiano GP, 2001, PLANT PHYSIOL, V126, P78, DOI 10.1104/pp.126.1.78; Doelling JH, 2001, PLANT J, V27, P393, DOI 10.1046/j.1365-313X.2001.01106.x; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Fobert PR, 1996, PLANT CELL, V8, P1465, DOI 10.1105/tpc.8.9.1465; Fu HY, 1999, PLANT J, V18, P529, DOI 10.1046/j.1365-313X.1999.00479.x; Fu HY, 1998, GENETICS, V149, P677; Guo RB, 1998, PLANT PHYSIOL, V116, P605, DOI 10.1104/pp.116.2.605; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; HERMAN EM, 1981, EUR J CELL BIOL, V24, P226; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; Kurepa J, 1997, PLANT CELL PHYSIOL, V38, P463, DOI 10.1093/oxfordjournals.pcp.a029190; Marty F, 1999, PLANT CELL, V11, P587, DOI 10.1105/tpc.11.4.587; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; MOK DWS, 1994, CYTOKINS CHEM ACTIVI; Moriyasu Y, 1996, PLANT PHYSIOL, V111, P1233, DOI 10.1104/pp.111.4.1233; Nakabayashi K, 1999, PLANT CELL PHYSIOL, V40, P504, DOI 10.1093/oxfordjournals.pcp.a029571; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; ONO K, 1995, PLANT CELL PHYSIOL, V36, P9; Quirino BF, 2000, TRENDS PLANT SCI, V5, P278, DOI 10.1016/S1360-1385(00)01655-1; Rojo E, 2001, DEV CELL, V1, P303, DOI 10.1016/S1534-5807(01)00024-7; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Smalle J, 2002, PLANT CELL, V14, P17, DOI 10.1105/tpc.010381; Swanson SJ, 1998, PLANT CELL, V10, P685, DOI 10.1105/tpc.10.5.685; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Toyooka K, 2001, J CELL BIOL, V154, P973, DOI 10.1083/jcb.200105096; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; VANDERWILDEN W, 1980, P NATL ACAD SCI-BIOL, V77, P428; Vierstra RD, 1999, PLANT MOL BIOL, V41, P435, DOI 10.1023/A:1006323317890; Vierstra RD, 1996, PLANT MOL BIOL, V32, P275, DOI 10.1007/BF00039386; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Weaver LM, 1998, PLANT MOL BIOL, V37, P455, DOI 10.1023/A:1005934428906; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; WITTENBACH VA, 1982, PLANT PHYSIOL, V69, P98, DOI 10.1104/pp.69.1.98; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	55	445	475	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33105	33114		10.1074/jbc.M204630200	http://dx.doi.org/10.1074/jbc.M204630200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12070171	hybrid			2022-12-25	WOS:000177859000092
J	Magalhaes, AC; Silva, JA; Lee, KS; Martins, VR; Prado, VF; Ferguson, SSG; Gomez, MV; Brentani, RR; Prado, MAM				Magalhaes, AC; Silva, JA; Lee, KS; Martins, VR; Prado, VF; Ferguson, SSG; Gomez, MV; Brentani, RR; Prado, MAM			Endocytic intermediates involved with the intracellular trafficking of a fluorescent cellular prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR ACETYLCHOLINE TRANSPORTER; SCRAPIE-ASSOCIATED FORM; SPONGIFORM ENCEPHALOPATHIES; DEPENDENT RETENTION; COPPER-BINDING; CELLS; SURFACE; RECEPTOR; LOCALIZATION; EXPRESSION	We have investigated the intracellular traffic of PrPc, a glycosylphosphatidylinositol (GPI)-anchored protein implicated in spongiform encephalopathies. A fluorescent functional green fluorescent protein (GFP)-tagged version of PrPc is found at the cell surface and in intracellular compartments in SN56 cells. Confocal microscopy and organelle-specific markers suggest that the protein is found in both the Golgi and the recycling endosomal compartment. Perturbation of endocytosis with a dynamin I-K44A dominant-negative mutant altered the steady-state distribution of the GFP-PrPc, leading to the accumulation of fluorescence in unfissioned endocytic intermediates. These pre-endocytic intermediates did not seem to accumulate GFP-GPI, a minimum GPI-anchored protein, suggesting that PrPc trafficking does not depend solely on the GPI anchor. We found that internalized GFP-PrPc accumulates in Rab5-positive endosomes and that a Rab5 mutant alters the steady-state distribution of GFP-PrPc but not that of GFP-GPI between the plasma membrane and early endosomes. Therefore, we conclude that PrPc internalizes via a dynamin-dependent endocytic pathway and that the protein is targeted to the recycling endosomal compartment via Rab5-positive early endosomes. These observations indicate that traffic of GFP-PrPc is not determined predominantly by the GPI anchor and that, different from other GPI-anchored proteins, PrPc is delivered to classic endosomes after internalization.	Univ Fed Minas Gerais, Lab Neurofarmacol, Dept Farmacol, Inst Ciencias Biol, BR-31270910 Belo Horizonte, MG, Brazil; Univ Fed Minas Gerais, Dept Bioquim, Inst Ciencias Biol, BR-31270910 Belo Horizonte, MG, Brazil; Ludwig Inst Canc Res, Sao Paulo Branch, BR-01509010 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01509010 Sao Paulo, Brazil; Univ Western Ontario, Dept Physiol, London, ON N6A 5K8, Canada; Univ Western Ontario, JP Robarts Res Inst, London, ON N6A 5K8, Canada	Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Ludwig Institute for Cancer Research; Universidade de Sao Paulo; Western University (University of Western Ontario); Western University (University of Western Ontario)	Prado, MAM (corresponding author), Univ Fed Minas Gerais, Lab Neurofarmacol, Dept Farmacol, Inst Ciencias Biol, Av Antonio Carlos 6627, BR-31270910 Belo Horizonte, MG, Brazil.		Lee, Kil S/D-3678-2012; Prado, Marco Antonio Maximo/K-7638-2013; Prado, Vania Ferreira/K-7630-2013; Lee, Kil Sun/AAL-8564-2020; Gomez, Marcus Vinicius/I-4081-2012; Martins, Vilma/N-5446-2019; Martins, Vilma R/E-2547-2012	Lee, Kil S/0000-0002-2390-2774; Prado, Marco Antonio Maximo/0000-0002-3028-5778; Prado, Vania Ferreira/0000-0003-4994-6393; Gomez, Marcus Vinicius/0000-0002-6082-930X; Martins, Vilma R/0000-0002-2909-8502				Aguzzi A, 2001, NAT REV NEUROSCI, V2, P745, DOI 10.1038/35094590; Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Barbosa J, 1999, J NEUROCHEM, V73, P1881; BARBOSA J, 2002, IN PRESS J NEUROCHEM; BLUSZTAJN JK, 1992, J NEUROSCI, V12, P793; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; Graner E, 2000, FEBS LETT, V482, P257, DOI 10.1016/S0014-5793(00)02070-6; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; Herms JW, 2000, J NEUROCHEM, V75, P1487, DOI 10.1046/j.1471-4159.2000.0751487.x; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Klamt F, 2001, FREE RADICAL BIO MED, V30, P1137; Kushmerick C, 2001, BRAIN RES, V916, P199, DOI 10.1016/S0006-8993(01)02898-0; Laine J, 2001, EUR J NEUROSCI, V14, P47, DOI 10.1046/j.0953-816x.2001.01621.x; Lee KS, 2001, J NEUROCHEM, V79, P79, DOI 10.1046/j.1471-4159.2001.00529.x; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; MARTIN N, 1997, HDB ORGANIC CONDUCTI, V1, P1; Martins VR, 2002, FEBS LETT, V512, P25, DOI 10.1016/S0014-5793(02)02291-3; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Negro A, 2001, MOL CELL NEUROSCI, V17, P521, DOI 10.1006/mcne.2000.0953; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PICCARDO P, 1990, NEUROLOGY, V40, P518, DOI 10.1212/WNL.40.3_Part_1.518; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ricci V, 2000, MOL BIOL CELL, V11, P3897, DOI 10.1091/mbc.11.11.3897; Rijnboutt S, 1996, J CELL BIOL, V132, P35, DOI 10.1083/jcb.132.1.35; Santos MS, 2001, J NEUROCHEM, V78, P1104, DOI 10.1046/j.1471-4159.2001.00494.x; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; Skretting G, 1999, J CELL SCI, V112, P3899; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Whittal RM, 2000, PROTEIN SCI, V9, P332; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	58	102	105	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33311	33318		10.1074/jbc.M203661200	http://dx.doi.org/10.1074/jbc.M203661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12070160	hybrid, Green Published			2022-12-25	WOS:000177859000117
J	Martin, LT; Marth, JD; Varki, A; Varki, NM				Martin, LT; Marth, JD; Varki, A; Varki, NM			Genetically altered mice with different sialyltransferase deficiencies show tissue-specific alterations in sialylation and sialic acid 9-O-acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; MAACKIA-AMURENSIS; GOLGI-APPARATUS; RAT-LIVER; ALPHA-2->6 SIALYLTRANSFERASE; ERYTHRINA-CORALLODENDRON; LINKED OLIGOSACCHARIDES; O-ACETYLTRANSFERASE; MOLECULAR-CLONING; BOVINE COLOSTRUM	Glycan chains on glycoconjugates traversing the Golgi apparatus are often terminated by sialic acid residues, which can also be 9-O-acetylated. This process involves competition between multiple Golgi enzymes. Expression levels of Golgi enzyme mRNAs do not always correlate with enzyme activity, which in turn cannot accurately predict glycan sequences found on cell surfaces. Here we examine the cell type-specific expression of terminal glycans in tissues of normal mice in comparison with animals deficient in ST6Gal-I (transfers alpha2-6-linked sialic acid to Galbeta1-4GlcNAc) or ST3Gal-I (transfers alpha2-3-linked sialic acid to GaLbeta1-3GaLNAc. Tissues of ST6Gal-I null mice showed minimal binding of an alpha2-6-sialic acid-specific lectin, indicating that no other enzyme generates Siaalpha2-6Galbeta1-4GlcNAc and that Siaalpha2-6GalNAc (sialyl-Tn) is rare in mice. However, exposed Galbeta1-4GlcNAc termini were only moderately increased, indicating that these can be partially capped by other enzymes. Indeed, Galalpha1-3Galbeta1-4GlcNAc and Fucalpha1-2Galbeta1-4GlcNAc termini were enhanced in some tissues. Many tissues of ST3Gal-I null animals showed increases in Galbeta1-3GalNAc termini, and some increases in poly-N-acetyllactosamines. However, overall expression of alpha2-3-linked sialic acid was selectively reduced only in a few instances, indicating that other ST3Gal enzymes can generate this linkage in most tissues. Highly selective losses of 9-O-acetylation of sialic acid residues were also observed, with ST6Gal-I deficiency causing loss on endothelium and ST3Gal-I deficiency giving a marked decrease on CD4(+) lymphocytes. These data demonstrate selective regulation of sialylation and 9-O-acetylation, point to cell types with potential physiological defects in null animals, and show in vivo evidence for competition between Golgi enzymes.	Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Varki, NM (corresponding author), Univ Calif San Diego, CMM E, Rm 1058,Mail Code 0687, La Jolla, CA 92093 USA.				NHLBI NIH HHS [P01-HL57345] Funding Source: Medline; NIGMS NIH HHS [GM32373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373, R37GM032373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Bai XM, 2001, GLYCOBIOLOGY, V11, P621, DOI 10.1093/glycob/11.8.621; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BHATTACHARYYA L, 1989, GLYCOCONJUGATE J, V6, P141, DOI 10.1007/BF01047896; Brinkman-Van der Linden ECM, 2002, ANAL BIOCHEM, V303, P98, DOI 10.1006/abio.2001.5539; Brockhausen I, 1998, ACTA ANAT, V161, P36; Chammas R, 1996, MOL BIOL CELL, V7, P1691, DOI 10.1091/mbc.7.11.1691; Chen R, 2001, J AM SOC MASS SPECTR, V12, P55, DOI 10.1016/S1044-0305(00)00200-2; Cines DB, 1998, BLOOD, V91, P3527; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DIAZ S, 1989, J BIOL CHEM, V264, P19416; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Furukawa Kiyoshi, 1992, Current Opinion in Biotechnology, V3, P554, DOI 10.1016/0958-1669(92)90085-W; Hakomori S, 1996, CANCER RES, V56, P5309; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X; Iwersen M, 1998, GLYCOCONJUGATE J, V15, P895, DOI 10.1023/A:1006911100081; Johansson L, 1999, ANAL BIOCHEM, V267, P239, DOI 10.1006/abio.1998.2982; JOZIASSE DH, 1987, J BIOL CHEM, V262, P2025; KAKU H, 1993, J BIOL CHEM, V268, P13237; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KOBAYASHI H, 1992, J CLIN ONCOL, V10, P95, DOI 10.1200/JCO.1992.10.1.95; Kono M, 2000, BIOCHEM BIOPH RES CO, V272, P94, DOI 10.1006/bbrc.2000.2745; Krishna M, 1997, J EXP MED, V185, P1997, DOI 10.1084/jem.185.11.1997; Kurosawa N, 2000, J BIOCHEM-TOKYO, V127, P845, DOI 10.1093/oxfordjournals.jbchem.a022678; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; MATTOX S, 1992, ANAL BIOCHEM, V206, P430, DOI 10.1016/0003-2697(92)90389-O; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Moreno E, 1997, BIOCHEMISTRY-US, V36, P4429, DOI 10.1021/bi962231h; Ogawa H, 1996, GYNECOL OBSTET INVES, V41, P278, DOI 10.1159/000292284; Orntoft TF, 1999, ELECTROPHORESIS, V20, P362, DOI 10.1002/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.3.CO;2-M; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; POWELL LD, 1994, J BIOL CHEM, V269, P10628; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; REARICK JI, 1979, J BIOL CHEM, V254, P4444; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; SCHAUER R, 1988, GLYCOCONJUGATE J, V5, P257, DOI 10.1007/BF01049086; Schauer R, 1982, SIALIC ACIDS CHEM ME, V10; Sharon N, 1998, PROTEIN SCI, V7, P2042, DOI 10.1002/pro.5560070922; Shi WX, 1996, J BIOL CHEM, V271, P15130, DOI 10.1074/jbc.271.25.15130; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; Shi WX, 1996, J BIOL CHEM, V271, P31517, DOI 10.1074/jbc.271.49.31517; Shi WX, 1998, GLYCOBIOLOGY, V8, P199, DOI 10.1093/glycob/8.2.199; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; TENEBERG S, 1994, J BIOL CHEM, V269, P8554; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; Varki Ajit, 1995, Seminars in Developmental Biology, V6, P127, DOI 10.1016/S1044-5781(06)80022-8; WANG WC, 1988, J BIOL CHEM, V263, P4576; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; Wu WY, 1997, GLYCOBIOLOGY, V7, P349, DOI 10.1093/glycob/7.3.349; Wu WY, 1996, J EXP MED, V184, P759, DOI 10.1084/jem.184.2.759; Yeh JC, 1996, ANAL BIOCHEM, V236, P126, DOI 10.1006/abio.1996.0140	67	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32930	32938		10.1074/jbc.M203362200	http://dx.doi.org/10.1074/jbc.M203362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12068010	hybrid			2022-12-25	WOS:000177859000071
J	Park, H; Kaushik, VK; Constant, S; Prentki, M; Przybytkowski, E; Ruderman, NB; Saha, AK				Park, H; Kaushik, VK; Constant, S; Prentki, M; Przybytkowski, E; Ruderman, NB; Saha, AK			Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; CARNITINE PALMITOYLTRANSFERASE-I; SKELETAL-MUSCLE; LIVER; EXPRESSION; METABOLISM; CONTRACTION; HEXOKINASE; GLUT-4; HUMANS	Changes in the concentration of malonyl-CoA in many tissues have been related to alterations in the activity of acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in its formation. In contrast, little is known about the physiological role of malonyl-CoA decarboxylase (MCD), an enzyme responsible for malonyl-CoA catabolism. In this study, we examined the effects of voluntary exercise on MCD activity in rat liver, skeletal muscle, and adipose tissue. In addition, the activity of sn-glycerol-3-phosphate acyltransferase (GPAT), which like MCD and ACC can be regulated by AMP-activated protein kinase (AMPK), was assayed. Thirty min after the completion of a treadmill run, MCD activity was increased similar to2-fold, malonyl-CoA levels were reduced, and ACC and GPAT activities were diminished by 50% in muscle and liver. These events appeared to be mediated via activation of AMPK since: 1) AMPK activity was concurrently increased by exercise in both tissues; 2) similar findings were observed after the injection of 5-amino 4 imidazole carboxamide, an AMPK activator; 3) changes in the activity of GPAT and ACC paralleled that of MCD; and 4) the increase in MCD activity in muscle was reversed in vitro by incubating immunoprecipitated enzyme from the exercised muscle with protein phosphatase 2A, and it was reproduced by incubating immunopurified MCD from resting muscle with purified AMPK. An unexpected finding was that exercise caused similar changes in the activities of ACC, MCD, GPAT, and AMPK and the concentration of malonyl-CoA in adipose tissue. In conclusion: MCD, GPAT, and ACC are coordinately regulated by AMPK in liver and adipose tissue in response to exercise, and except for GPAT, also in muscle. The results suggest that AMPK activation plays a major role in regulating lipid metabolism in many cells following exercise. They also suggest that in each of them, it acts to increase fatty acid oxidation and decrease its esterification.	Boston Univ, Med Ctr, Diabet & Metab Unit, Sect Endocrinol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Physiol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Biochem, Boston, MA 02118 USA; Univ Montreal, Mol Nutr Unit, Dept Nutr, Montreal, PQ H2L 4M1, Canada	Boston University; Boston University; Boston University; Boston University; Universite de Montreal	Saha, AK (corresponding author), Boston Univ, Med Ctr, Diabet & Metab Unit, Sect Endocrinol, 650 Albany St,EBRC-827, Boston, MA 02118 USA.			Ruderman, Neil/0000-0002-6589-6587; Saha, Asish/0000-0003-1001-5110	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019514, R01DK049147] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49147, DK19514] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlson CL, 1999, J APPL PHYSIOL, V86, P669, DOI 10.1152/jappl.1999.86.2.669; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; CHRISTENSEN NJ, 1979, DIABETES, V28, P58, DOI 10.2337/diab.28.1.S58; DEAN DJ, 2001, DIABETES, V50, P222; DENTON RM, 1966, BIOCHEM J, V100, P420, DOI 10.1042/bj1000420; Dyck JRB, 2000, BIOCHEM J, V350, P599, DOI 10.1042/0264-6021:3500599; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; Habinowski SA, 2001, ARCH BIOCHEM BIOPHYS, V396, P71, DOI 10.1006/abbi.2001.2589; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Kaushik VK, 2001, AM J PHYSIOL-ENDOC M, V281, pE335, DOI 10.1152/ajpendo.2001.281.2.E335; Lowry OH, 1972, FLEXIBLE SYSTEM ENZY, P174; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1995, BIOCHEM SOC T, V23, P321, DOI 10.1042/bst0230321; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072; SAHA AK, 1995, AM J PHYSIOL-ENDOC M, V269, pE283, DOI 10.1152/ajpendo.1995.269.2.E283; Saha AK, 2000, J BIOL CHEM, V275, P24279, DOI 10.1074/jbc.C000291200; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Velasco G, 1998, FEBS LETT, V439, P317, DOI 10.1016/S0014-5793(98)01400-8; Voilley N, 1999, BIOCHEM J, V340, P213, DOI 10.1042/0264-6021:3400213; WAHRENBERG H, 1987, AM J PHYSIOL, V253, pE383, DOI 10.1152/ajpendo.1987.253.4.E383; WINDER WW, 1990, AM J PHYSIOL, V259, pE266, DOI 10.1152/ajpendo.1990.259.2.E266; WINDER WW, 1989, J APPL PHYSIOL, V67, P2230, DOI 10.1152/jappl.1989.67.6.2230; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; WINDER WW, 1995, J APPL PHYSIOL, V78, P578, DOI 10.1152/jappl.1995.78.2.578; WOLFE RR, 1990, AM J PHYSIOL, V258, pE382, DOI 10.1152/ajpendo.1990.258.2.E382; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	34	294	309	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32571	32577		10.1074/jbc.M201692200	http://dx.doi.org/10.1074/jbc.M201692200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12065578	hybrid			2022-12-25	WOS:000177859000025
J	Wilcox, LJ; Balderes, DA; Wharton, B; Tinkelenberg, AH; Rao, G; Sturley, SL				Wilcox, LJ; Balderes, DA; Wharton, B; Tinkelenberg, AH; Rao, G; Sturley, SL			Transcriptional profiling identifies two members of the ATP-binding cassette transporter superfamily required for sterol uptake in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TANGIER-DISEASE; CHOLESTEROL ABSORPTION; DIETARY-CHOLESTEROL; MANNOPROTEIN GENES; ABC TRANSPORTERS; REPRESSION; MUTATIONS; EXPRESSION; METABOLISM	In contrast to lipoprotein-mediated sterol uptake, free sterol influx by eukaryotic cells is poorly understood. To identify components of non-lipoprotein-mediated sterol uptake, we utilized strains of Saccharomyces cerevisiae that accumulate exogenous sterol due to a neomorphic mutation in the transcription factor, UPC2. Two congenic upc2-1 strains, differing quantitatively in aerobic sterol uptake due to a modifying mutation in the HAP1 transcription factor, were compared using DNA microarrays. We identified 9 genes as responsive to UPC2 that were also induced under anaerobiosis, when sterol uptake is essential. Deletion mutants in these genes were assessed for sterol influx in the upc2-1 background. UPC2 itself was up-regulated under these conditions and was required for aerobic sterol influx. Deletion of the ATP-binding cassette transporters YOR011w (AUS1) or PDR11, or a putative cell wall protein encoded by DAN1, significantly reduced sterol influx. Sodium azide and vanadate inhibited sterol uptake, consistent with the participation of ATP-binding cassette transporters. We hypothesized that the physiological role of Aus1p and Pdr11p is to mediate sterol uptake when sterol biosynthesis is compromised. Accordingly, expression of AUS1 or PDR11 was required for anaerobic growth and sterol uptake. We proposed similar molecules may be important components of sterol uptake in all eukaryotes.	Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Affymetrix Inc, Santa Clara, CA 95051 USA	Columbia University; Columbia University; Affymetrix	Sturley, SL (corresponding author), Columbia Univ Coll Phys & Surg, Inst Human Nutr, 650 W 168th St, New York, NY 10032 USA.				NIDDK NIH HHS [DK54320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramova NE, 2001, GENETICS, V157, P1169; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Burke D., 2000, METHODS YEAST GENETI; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Cohen BD, 2001, NUCLEIC ACIDS RES, V29, P799, DOI 10.1093/nar/29.3.799; Crowley JH, 1998, J BACTERIOL, V180, P4177, DOI 10.1128/JB.180.16.4177-4183.1998; DECKERT J, 1995, GENETICS, V139, P1149; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Detmers PA, 2000, BBA-MOL CELL BIOL L, V1486, P243, DOI 10.1016/S1388-1981(00)00068-8; Erdeniz N, 1997, GENOME RES, V7, P1174, DOI 10.1101/gr.7.12.1174; Gaisne M, 1999, CURR GENET, V36, P195, DOI 10.1007/s002940050490; GOLLUB EG, 1974, BIOCHEM BIOPH RES CO, V56, P471, DOI 10.1016/0006-291X(74)90866-3; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; Hernandez M, 2000, BBA-MOL CELL BIOL L, V1486, P232, DOI 10.1016/S1388-1981(00)00067-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JIANG B, 1994, YEAST, V10, P341, DOI 10.1002/yea.320100307; KEESLER GA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P127, DOI 10.1016/0005-2760(92)90102-2; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; LEWIS TL, 1988, YEAST, V4, P93, DOI 10.1002/yea.320040203; LORENZ RT, 1991, LIPIDS, V26, P598, DOI 10.1007/BF02536423; LORENZ RT, 1986, J BACTERIOL, V167, P981, DOI 10.1128/jb.167.3.981-985.1986; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; Sturley SL, 1998, CURR OPIN LIPIDOL, V9, P85, DOI 10.1097/00041433-199804000-00002; Sturley SL, 2000, BBA-MOL CELL BIOL L, V1529, P155, DOI 10.1016/S1388-1981(00)00145-1; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; YOUINGS A, 1989, Yeast, V5, pS459	37	197	207	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32466	32472		10.1074/jbc.M204707200	http://dx.doi.org/10.1074/jbc.M204707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077145	hybrid			2022-12-25	WOS:000177859000011
J	Ambrosino, C; Palmieri, C; Puca, A; Trimboli, F; Schiavone, M; Olimpico, F; Ruocco, MR; di Leva, F; Toriello, M; Quinto, I; Venuta, S; Scala, G				Ambrosino, C; Palmieri, C; Puca, A; Trimboli, F; Schiavone, M; Olimpico, F; Ruocco, MR; di Leva, F; Toriello, M; Quinto, I; Venuta, S; Scala, G			Physical and functional interaction of HIV-1 tat with E2F-4, a transcriptional regulator of mammalian cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; TRANS-ACTIVATOR GENE; LONG TERMINAL REPEAT; CREB-BINDING-PROTEIN; RNA-POLYMERASE-II; TYPE-1 TAT; RETINOBLASTOMA PROTEIN; DISTINCT MECHANISMS; IN-VITRO	Tat protein of the human immunodeficiency virus type-1 (HIV-1) plays a critical role in the regulation of viral transcription and replication. In addition, Tat regulates the expression of a variety of cellular genes and could account for AIDS-associated diseases including Kaposi's Sarcoma and non-Hodgkin's lymphoma by interfering with cellular processes such as proliferation, differentiation, and apoptosis. The molecular mechanisms underlying the pleiotropic activities of Tat may include the generation of functional heterodimers of Tat with cellular proteins. By screening a human B-lymphoblastoid cDNA library in the yeast two-hybrid system, we identified E2F-4, a member of E2F family of transcription factors, as a Tat-binding protein. The interaction between Tat and E2F-4 was confirmed by GST pulldown experiments performed with cellular extracts as well as with in vitro translated E2F-4. The physical association of Tat and E2F-4 was confirmed by in vivo binding experiments where Tat-E2F-4 heterodimers were recovered from Jurkat cells by immunoprecipitation and immunoblotting. By using plasmids expressing mutant forms of Tat and E2F-4, the domains involved in Tat-E2F-4 interaction were identified as the regions encompassing amino acids 1-49 of Tat and amino acids 1-184 of E2F-4. Tat-E2F-4 complexes were shown to bind to E2F cis-regions with increased efficiency compared with E2F-4 alone and to mediate the activity of E2F-dependent promoters including HIV-1 long terminal repeat and cyclin A. The data point to Tat as an adaptor protein that recruits cellular factors such as E2F-4 to exert its multiple biological activities.	Univ Catanzaro, Sch Med, Dept Clin & Expt Med, I-88100 Catanzaro, Italy; Univ Naples Federico II, Sch Med, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy	Magna Graecia University of Catanzaro; University of Naples Federico II	Scala, G (corresponding author), Univ Catanzaro, Sch Med, Dept Clin & Expt Med, I-88100 Catanzaro, Italy.		SCALA, GIUSEPPE/A-3280-2009; toriello, mario/AAA-4255-2022; Trimboli, Francesca/Y-1143-2019; Palmieri, Camillo/A-3195-2009	Trimboli, Francesca/0000-0002-1766-9179; Schiavone, Marco/0000-0002-8566-5559; Palmieri, Camillo/0000-0001-6707-4723; QUINTO, Ileana/0000-0001-8212-8515; DI LEVA, Francesca/0000-0002-6167-0679				Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Allen KE, 1997, J CELL SCI, V110, P2819; Ambrosino C, 1997, J BIOL CHEM, V272, P14883, DOI 10.1074/jbc.272.23.14883; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Baranger AM, 1998, CURR OPIN CHEM BIOL, V2, P18, DOI 10.1016/S1367-5931(98)80031-8; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; delaLuna S, 1996, J CELL SCI, V109, P2443; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; HARPER JW, 1993, CELL, V75, P805; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LEVINE AM, 1992, BLOOD, V80, P8; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Liu WM, 2001, NAT IMMUNOL, V2, P939, DOI 10.1038/ni1001-939; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; Mallardo M, 1996, J BIOL CHEM, V271, P20820, DOI 10.1074/jbc.271.34.20820; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mayol X, 1996, ONCOGENE, V13, P237; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUBEN S, 1989, J VIROL, V63, P1; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SIDEROVSKI DP, 1992, NUCLEIC ACIDS RES, V20, P5311, DOI 10.1093/nar/20.20.5311; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; WUBAER F, 1995, P NATL ACAD SCI USA, V92, P7153, DOI 10.1073/pnas.92.16.7153; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	82	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31448	31458		10.1074/jbc.M112398200	http://dx.doi.org/10.1074/jbc.M112398200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12055184	hybrid			2022-12-25	WOS:000177718700022
J	Gao, TY; Newton, AC				Gao, TY; Newton, AC			The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; BETA-II; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA; DEPHOSPHORYLATION; HSP90; STRESS; AUTOPHOSPHORYLATION; ACTIVATION; MECHANISM	Heat shock proteins play central roles in ensuring the correct folding and maturation of cellular proteins. Here we show that the heat shock protein Hsp70 has a novel role in prolonging the lifetime of activated protein kinase C. We identified Hsp70 in a screen for binding partners for the carboxyl terminus of protein kinase C. Co-immunoprecipitation experiments revealed that Hsp70 specifically binds the unphosphorylated turn motif (Thr(641) in protein kinase C betaII), one of three priming sites phosphorylated during the maturation of protein kinase C family members. The interaction of Hsp70 with protein kinase C can be abolished in vivo by co-expression of fusion proteins encoding the carboxyl terminus of protein kinase C or the carboxyl terminus of Hsp70. Pulse-chase experiments reveal that Hsp70 does not regulate the maturation of protein kinase C: the rate of processing by phosphorylation. is the same in the presence or absence of disrupting constructs. Rather, Hsp70 prolongs the lifetime of mature protein kinase Q disruption of the interaction promotes the accumulation of matured and then dephosphorylated protein kinase C in the detergent-insoluble fraction of cells. Furthermore, studies with K562 cells reveal that disruption of the interaction with Hsp70 slows the protein kinase C betaII-mediated recovery of cells from PMA-induced growth arrest. Last, we show that other members of the AGC superfamily (Akt/protein kinase B and protein kinase A) also bind Hsp70 via their unphosphorylated turn motifs. Our data are consistent with a model in which Hsp70 binds the dephosphorylated carboxyl terminus of mature protein kinase C, thus stabilizing the protein and allowing re-phosphorylation of the enzyme. Disruption of this interaction prevents re-phosphorylation and targets the enzyme for down-regulation.	Univ Calif, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK54441] Funding Source: Medline; NIGMS NIH HHS [R01 GM43154] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Di YP, 1997, J CELL PHYSIOL, V172, P44, DOI 10.1002/(SICI)1097-4652(199707)172:1<44::AID-JCP5>3.0.CO;2-D; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; Gysin S, 1997, EUR J BIOCHEM, V249, P156, DOI 10.1111/j.1432-1033.1997.t01-2-00156.x; Gysin S, 1996, EUR J BIOCHEM, V240, P747, DOI 10.1111/j.1432-1033.1996.0747h.x; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Holmberg CI, 1998, J CELL SCI, V111, P3357; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Ma N, 2001, INT J RADIAT ONCOL, V50, P1041, DOI 10.1016/S0360-3016(01)01596-6; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; PARISSENTI AM, 1993, MOL CELL ENDOCRINOL, V98, P9, DOI 10.1016/0303-7207(93)90230-H; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; SU L, 1992, RECEPTOR CHANNEL, V1, P1; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	37	110	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31585	31592		10.1074/jbc.M204335200	http://dx.doi.org/10.1074/jbc.M204335200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080070	hybrid			2022-12-25	WOS:000177718700038
J	Pitcher, RS; Cheesman, MR; Watmough, NJ				Pitcher, RS; Cheesman, MR; Watmough, NJ			Molecular and spectroscopic analysis of the cytochrome cbb(3) oxidase from Pseudomonas stutzeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-CIRCULAR-DICHROISM; COMPLETE GENOME SEQUENCE; C-OXIDASE; ESCHERICHIA-COLI; NITRIC-OXIDE; BRADYRHIZOBIUM-JAPONICUM; RHODOBACTER-SPHAEROIDES; ACTIVE-SITE; TERMINAL OXIDASES; DINUCLEAR CENTER	Cytochrome cbb(3) oxidase, a member of the heme-copper oxidase superfamily, is characterized by its high affinity for oxygen while retaining the ability to pump protons. These attributes are central to its proposed role in the microaerobic metabolism of proteobacteria. We have completed the first detailed spectroscopic characterization of a cytochrome cbb(3) oxidase, the enzyme purified from Pseudomonas stutzeri. A combination of UV-visible and magnetic CD spectroscopies clearly identified four low-spin hemes and the high-spin heme of the active site. This heme complement is in good agreement with our analysis of the primary sequence of the ccoNOPQ operon and biochemical analysis of the complex. Near-IR magnetic CD spectroscopy revealed the unexpected presence of a low-spin bishistidine-coordinated c-type heme in the complex. This was shown to be one of two c-type hemes in the CcoP subunit by separately expressing the subunit in Escherichia coli. Separate expression of CcoP also allowed us to unambiguously assign each of the signals associated with low-spin ferric hemes present in the X-band EPR spectrum of the oxidized enzyme. This work both underpins future mechanistic studies on this distinctive class of bacterial oxidases and raises questions concerning the role of CcoP in electron delivery to the catalytic subunit.	Univ E Anglia, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of East Anglia; University of East Anglia	Watmough, NJ (corresponding author), Univ E Anglia, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	n.watmough@uea.ac.uk	Watmough, Nicholas J/A-6643-2010	Watmough, Nicholas J/0000-0001-5901-6750				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Arslan E, 2000, FEBS LETT, V470, P7, DOI 10.1016/S0014-5793(00)01277-1; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BELL LC, 1992, J GEN MICROBIOL, V138, P437, DOI 10.1099/00221287-138-3-437; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHEESMAN MR, 1994, EUR J BIOCHEM, V219, P595, DOI 10.1111/j.1432-1033.1994.tb19975.x; CHEESMAN MR, 1991, ADV INORG CHEM, V36, P201, DOI 10.1016/S0898-8838(08)60040-9; CHEESMAN MR, 1993, BIOCHEM J, V289, P709, DOI 10.1042/bj2890709; CUYPERS H, 1993, J BACTERIOL, V175, P7236, DOI 10.1128/JB.175.22.7236-7246.1993; deGier JWL, 1996, MOL MICROBIOL, V20, P1247; Eraso JM, 2000, BIOCHEMISTRY-US, V39, P2052, DOI 10.1021/bi9923858; Field SJ, 2002, J BIOL CHEM, V277, P20146, DOI 10.1074/jbc.M112202200; GADSBY PMA, 1989, BIOCHIM BIOPHYS ACTA, V994, P37, DOI 10.1016/0167-4838(89)90059-9; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; Gronberg KLC, 1999, BIOCHEMISTRY-US, V38, P13780, DOI 10.1021/bi9916426; HILL BC, 1993, J BIOENERG BIOMEMBR, V25, P115, DOI 10.1007/BF00762853; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Koch HG, 1998, J BACTERIOL, V180, P969, DOI 10.1128/JB.180.4.969-978.1998; Koch HG, 2000, J MOL BIOL, V297, P49, DOI 10.1006/jmbi.2000.3555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; Moody AJ, 1996, BBA-BIOENERGETICS, V1276, P6; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Myllykallio H, 2000, TRENDS MICROBIOL, V8, P542, DOI 10.1016/S0966-842X(00)91831-6; Oganesyan VS, 1998, J AM CHEM SOC, V120, P4232, DOI 10.1021/ja974050o; Oh JI, 1999, BIOCHEMISTRY-US, V38, P2688, DOI 10.1021/bi9825100; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Pereira MM, 2001, BBA-BIOENERGETICS, V1505, P185, DOI 10.1016/S0005-2728(01)00169-4; Preisig O, 1996, J BACTERIOL, V178, P1532, DOI 10.1128/JB.178.6.1532-1538.1996; PREISIG O, 1993, P NATL ACAD SCI USA, V90, P3309, DOI 10.1073/pnas.90.8.3309; RAITIO M, 1994, BBA-BIOENERGETICS, V1186, P100, DOI 10.1016/0005-2728(94)90140-6; Reincke B, 1999, BBA-BIOENERGETICS, V1411, P114, DOI 10.1016/S0005-2728(99)00037-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; SPINNER F, 1995, BIOCHEM J, V308, P641, DOI 10.1042/bj3080641; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; ThonyMeyer L, 1996, EUR J BIOCHEM, V235, P754, DOI 10.1111/j.1432-1033.1996.00754.x; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Urbani A, 2001, FEBS LETT, V508, P29, DOI 10.1016/S0014-5793(01)03006-X; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; Vollack KU, 1998, MICROBIOL-SGM, V144, P441, DOI 10.1099/00221287-144-2-441; Walker FA, 1999, COORDIN CHEM REV, V185-6, P471, DOI 10.1016/S0010-8545(99)00029-6; Watmough NJ, 1998, J BIOENERG BIOMEMBR, V30, P55, DOI 10.1023/A:1020507511285; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8; WATMOUGH NJ, 1993, FEBS LETT, V319, P151, DOI 10.1016/0014-5793(93)80056-Z; Zufferey R, 1998, J BIOL CHEM, V273, P6452, DOI 10.1074/jbc.273.11.6452; Zufferey R, 1996, J BIOL CHEM, V271, P9114, DOI 10.1074/jbc.271.15.9114	56	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31474	31483		10.1074/jbc.M204103200	http://dx.doi.org/10.1074/jbc.M204103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070166	hybrid			2022-12-25	WOS:000177718700025
J	Vallur, AC; Feller, JA; Abner, CW; Tran, RK; Bloom, LB				Vallur, AC; Feller, JA; Abner, CW; Tran, RK; Bloom, LB			Effects of hydrogen bonding within a damaged base pair on the activity of wild type and DNA-intercalating mutants of human alkyladenine DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXCISION-REPAIR; CRYSTAL-STRUCTURE; 3-METHYLADENINE; SUBSTRATE; 1,N-6-ETHENOADENINE; HYPOXANTHINE; MECHANISMS; MOUSE; SPECIFICITY	Human alkyladenine DNA glycosylase "flips" damaged DNA bases into its active site where excision occurs. Tyrosine 162 is inserted into the DNA helix in place of the damaged base and may assist in nucleotide flipping by "pushing" it. Mutating this DNA-intercalating Tyr to Ser reduces the DNA binding and base excision activities of alkyladenine DNA glycosylase to undetectable levels demonstrating that Tyr-162 is critical for both activities. Mutation of Tyr-162 to Phe reduces the single turnover excision rate of hypoxanthine by a factor of 4 when paired with thymine. Interestingly, when the base pairing partner for hypoxanthine is changed to difluorotoluene, which cannot hydrogen bond to hypoxanthine, single turnover excision rates increase by a factor of 2 for the wild type enzyme and about 3 to 4 for the Phe mutant. In assays with DNA substrates containing 1,N-6-ethenoadenine, which does not form hydrogen bonds with either thymine or difluorotoluene, base excision rates for both the wild type and Phe mutant were unaffected. These results are consistent with a role for Tyr-162 in pushing the damaged base to assist in nucleotide flipping and indicate that a nucleotide flipping step may be rate-limiting for excision of hypoxanthine.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Bloom, LB (corresponding author), Univ Florida, Dept Biochem & Mol Biol, 1600 SW Archer Rd,JHMHC Rm,R3-234, Gainesville, FL 32610 USA.		Bloom, Linda B/F-3684-2014					Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; Asaeda A, 2000, BIOCHEMISTRY-US, V39, P1959, DOI 10.1021/bi9917075; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P710; CRUSE WBT, 1989, NUCLEIC ACIDS RES, V17, P55, DOI 10.1093/nar/17.1.55; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11866, DOI 10.1021/bi9910878; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; Guckian KM, 1998, NAT STRUCT BIOL, V5, P954, DOI 10.1038/2930; Handa P, 2001, J BIOL CHEM, V276, P17324, DOI 10.1074/jbc.M011166200; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; Jarman RG, 1999, VIROLOGY, V262, P384, DOI 10.1006/viro.1999.9861; Jiang YL, 2001, J BIOL CHEM, V276, P42347, DOI 10.1074/jbc.M106594200; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Roy R, 1996, CARCINOGENESIS, V17, P2177, DOI 10.1093/carcin/17.10.2177; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Wyatt MD, 2000, CARCINOGENESIS, V21, P901, DOI 10.1093/carcin/21.5.901; XUAN JC, 1992, NUCLEIC ACIDS RES, V20, P5457, DOI 10.1093/nar/20.20.5457	34	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31673	31678		10.1074/jbc.M204475200	http://dx.doi.org/10.1074/jbc.M204475200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077143	hybrid			2022-12-25	WOS:000177718700048
J	Ding, L; Donate, F; Parry, GCN; Guan, XJ; Maher, P; Levin, EG				Ding, L; Donate, F; Parry, GCN; Guan, XJ; Maher, P; Levin, EG			Inhibition of cell migration and angiogenesis by the aminoterminal fragment of 24kD basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOTHELIAL-CELLS; DNA-SYNTHESIS; PROLIFERATION; PURIFICATION; APOPTOSIS	The 24-kDa form of basic fibroblast growth factor inhibits the migration of endothelial cells and mammary carcinoma cells while continuing to promote cell proliferation. This molecule consists of the 18-kDa fibroblast growth factor sequence plus an additional 55 amino acids at the amino-terminal end. Antibody neutralization studies suggested that the inhibition of migration is associated with these 55 amino acids, whereas the promotion of proliferation localizes to the 18-kDa domain. To determine whether 24kD basic fibroblast growth factor could be modified to eliminate its effect on cell proliferation but retain its inhibition of migration, portions of the carboxyl-terminal end of 24kD fibroblast growth factor were deleted, and the products were tested on MCF-7 and endothelial cells. A protein consisting of the 55 amino acids of the amino-terminal end and the first 31 amino acids of 18kD basic fibroblast growth factor (ATE+31) inhibited migration by 80% but did not promote cell growth. Arginine to alanine substitutions within the first 21 amino acids of the carboxyl-terminal end substantially reduced the efficacy of ATE+31, whereas substitutions in the remaining part of the molecule had no effect. Competition binding experiments showed that ATE+31 does not compete with 24kD basic fibroblast growth factor for binding to fibroblast growth factor receptor 1. In an in vivo matrigel plug assay, 150 nm ATE+31 peptide reduced angiogenesis by 80%. These studies demonstrate that the amino-terminal end of 24kD basic fibroblast growth factor is responsible for an activity that inhibits the migration rates of cultured cells as well as the angiogenic response in vivo.	La Jolla Inst Mol Med, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Attenuon LLC, San Diego, CA 92121 USA	Scripps Research Institute	Levin, EG (corresponding author), La Jolla Inst Mol Med, San Diego, CA 92121 USA.				NATIONAL CANCER INSTITUTE [R01CA081209] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056775] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81209] Funding Source: Medline; NHLBI NIH HHS [HL 56775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MOSCATELLI D, 1988, BIOCHIMIE, V70, P83, DOI 10.1016/0300-9084(88)90162-9; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; Nazar Ross N, 2002, Methods Mol Biol, V182, P117; PEPPER MS, 1992, J CELL PHYSIOL, V153, P196, DOI 10.1002/jcp.1041530124; Piotrowicz RS, 1999, J CELL PHYSIOL, V178, P144, DOI 10.1002/(SICI)1097-4652(199902)178:2<144::AID-JCP3>3.0.CO;2-Z; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Piotrowicz RS, 2001, J BIOL CHEM, V276, P3963, DOI 10.1074/jbc.M004868200; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; PRESTA M, 1988, J CELL PHYSIOL, V137, P593, DOI 10.1002/jcp.1041370329; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SLAVIN J, 1995, CELL BIOL INT, V19, P431, DOI 10.1006/cbir.1995.1087; Yang WD, 1997, FEBS LETT, V403, P139, DOI 10.1016/S0014-5793(96)01486-X	18	19	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31056	31061		10.1074/jbc.M203658200	http://dx.doi.org/10.1074/jbc.M203658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063256	hybrid			2022-12-25	WOS:000177579800084
J	Kim, YM; Benovic, JL				Kim, YM; Benovic, JL			Differential roles of arrestin-2 interaction with clathrin and adaptor protein 2 in G protein-coupled receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; ARRESTIN/CLATHRIN INTERACTION; CRYSTAL-STRUCTURE; VISUAL ARRESTIN; 48-KDA PROTEIN; ENDOCYTOSIS; BINDING; ACTIVATION; INTERNALIZATION	The non-visual arrestins, arrestin-2 and arrestin-3, play a critical role in regulating the signaling and trafficking of many G protein-coupled receptors (GPCRs). Molecular insight into the role of arrestins in GPCR trafficking has suggested that arrestin interaction with clathrin, beta(2)-adaptin (the beta-subunit of the adaptor protein AP2), and phosphoinositides contributes to this process. In the present study, we have attempted to better define the molecular basis and functional role of arrestin-2 interaction with clathrin and beta(2)-adaptin. Site-directed mutagenesis revealed that the C-terminal region of arrestin-2 mediated beta(2)-adaptin and clathrin interaction with Phe-391 and Arg-395 having an essential role in beta(2)-adaptin binding and LIELD (residues 376-380) having an essential role in clathrin binding. Interestingly, arrestin-2-R169E, an activated form of arrestin that binds to GPCRs in a phosphorylation-independent manner, has significantly enhanced binding to beta(2)-adaptin and clathrin. This suggests that receptor-induced conformational changes in the C-terminal tail of arrestin-2 will likely play a major role in mediating arrestin interaction with clathrin-coated pits. In an effort to clarify the role of these interactions in GPCR trafficking we generated arrestin mutants that were completely and selectively defective in either clathrin (arrestin-2-DeltaLIELD) or beta(2)-adaptin (arrestin-2-F391A) interaction. Analysis of these mutants in COS-1 cells revealed that arrestin/clathrin interaction was essential for agonist-promoted internalization of the beta(2)-adrenergic receptor, while arrestin/beta(2)-adaptin interaction appeared less critical. Arrestin-2 mutants defective in both clathrin and beta(2)-adaptin binding functioned as effective dominant negatives in HEK293 cells and significantly attenuated beta(2)-adrenergic receptor internalization. These mutants should prove useful in better defining the role of arrestins in mediating receptor trafficking.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.		Kim, You-Me/I-5553-2013	Kim, You-Me/0000-0001-8780-704X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067663, P50HL067663] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67663] Funding Source: Medline; NIGMS NIH HHS [GM 47419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	36	61	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30760	30768		10.1074/jbc.M204528200	http://dx.doi.org/10.1074/jbc.M204528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070169	hybrid			2022-12-25	WOS:000177579800047
J	Obaya, AJ; Kotenko, L; Cole, MD; Sedivy, JM				Obaya, AJ; Kotenko, L; Cole, MD; Sedivy, JM			The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor P27(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; CELL-PROLIFERATION; NEGATIVE REGULATION; MAMMALIAN-CELLS; GROWTH ARREST; EXPRESSION; GENE; G1; TRANSCRIPTION; COMPLEXES	Progression through the early G(1) phase of the cell cycle requires mitogenic stimulation, which ultimately leads to the activation of cyclin-dependent kinases 4 and 6 (Cdk4/6). Cdk4/6 activity is promoted by D-type cyclins and opposed by Cdk inhibitor proteins. Loss of c-myc proto-oncogene function results in a defect in the activation of Cdk4/6. c-myc(-/-) cells express elevated levels of the Cdk inhibitor p27(Kip1) and reduced levels of Cdk7, the catalytic subunit of Cdk-activating kinase. We show here that in normal (c-myc(+/+)) cells, the majority of cyclin D-Cdk4/6 complexes are assembled with p27 and remain inactive during cell cycle progression; their function is presumably to sequester p27 from Cdk2 complexes. A small fraction of Cdk4/6 protein was found in lower molecular mass catalytically active complexes. Conditional overexpression of p27 in c-myc(+/+) cells caused inhibition of Cdk4/6 activity and elicited defects in G(0)-to-S phase progression very similar to those seen in c-myc(-/-) cells. Overexpression of cyclin D1 in c-myc(-/-) cells rescued the defect in Cdk4/6 activity, indicating that the limiting factor is the number of cyclin D-Cdk4/6 complexes. Cdk-activating kinase did not rescue Cdk4/6 activity. We propose that the defect in Cdk4/6 activity in c-myc(-/-) cells is caused by the elevated levels of p27, which convert the low abundance activable cyclin D-Cdk4/6 complexes into unactivable complexes containing higher stoichiometries of p27. These observations establish p27 as a physiologically relevant regulator of cyclin D-Cdk4/6 activity as well as mechanistically a target of c-Myc action and provide a model by which c-Myc influences the early-to-mid G(1) phase transition.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, JW Wilson Lab, Providence, RI 02912 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Brown University; Princeton University	Sedivy, JM (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, JW Wilson Lab, Rm 223,69 Brown St, Providence, RI 02912 USA.	john_sedivy@brown.edu	Obaya, Alvaro J./AAQ-6115-2021	Obaya, Alvaro J./0000-0002-4163-2173	NCI NIH HHS [CA 80320] Funding Source: Medline; NIGMS NIH HHS [GM 41690] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Holzel M, 2001, EMBO REP, V2, P1125, DOI 10.1093/embo-reports/kve251; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lu KK, 1998, CELL GROWTH DIFFER, V9, P367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Lyons AB, 1999, IMMUNOL CELL BIOL, V77, P509, DOI 10.1046/j.1440-1711.1999.00864.x; Lyons AB, 2001, METHOD CELL BIOL, V63, P375; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Nikiforov MA, 2000, ONCOGENE, V19, P4828, DOI 10.1038/sj.onc.1203880; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Parry D, 1999, MOL CELL BIOL, V19, P1775; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WATERS CM, 1991, ONCOGENE, V6, P797; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	43	76	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31263	31269		10.1074/jbc.M202528200	http://dx.doi.org/10.1074/jbc.M202528200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070150	hybrid			2022-12-25	WOS:000177579800109
J	Isaacs, JS; Jung, YJ; Mimnaugh, EG; Martinez, A; Cuttitta, F; Neckers, LM				Isaacs, JS; Jung, YJ; Mimnaugh, EG; Martinez, A; Cuttitta, F; Neckers, LM			Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HEAT-SHOCK PROTEIN; TUMOR-SUPPRESSOR PROTEIN; HELIX-LOOP-HELIX; CELL GLUCOCORTICOID RECEPTOR; HUMAN ERYTHROPOIETIN GENE; PROLYL HYDROXYLATION; SIGNAL-TRANSDUCTION; DIOXIN RECEPTOR; FACTOR 1-ALPHA	HIF-1alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1alpha protein levels, efficiently targets HIF-1alpha for rapid proteasome-dependent degradation under normoxia, HIF-1alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1alpha point mutations that block VHL association did not protect HIF-1alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.	NCI, Ctr Canc Res, Cell & Canc Biol Branch, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neckers, LM (corresponding author), NCI, Ctr Canc Res, Cell & Canc Biol Branch, NIH, 9610 Med Ctr Dr,Ste 300, Rockville, MD 20850 USA.		Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044				Adams J, 1999, CANCER RES, V59, P2615; Agnew EB, 2001, J CHROMATOGR B, V755, P237, DOI 10.1016/S0378-4347(01)00113-X; Akakura N, 2001, CANCER RES, V61, P6548; An WG, 2000, CELL GROWTH DIFFER, V11, P355; ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Birner P, 2000, CANCER RES, V60, P4693; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Bonvini P, 2002, CANCER RES, V62, P1559; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chapman JD, 1998, RADIOTHER ONCOL, V46, P229, DOI 10.1016/S0167-8140(97)00186-2; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Griffiths JR, 2002, CANCER RES, V62, P688; Hockel M, 1999, CANCER RES, V59, P4525; Hostein I, 2001, CANCER RES, V61, P4003; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kruger EA, 2001, CLIN CANCER RES, V7, P1867; Kurebayashi J, 2001, JPN J CANCER RES, V92, P1342, DOI 10.1111/j.1349-7006.2001.tb02159.x; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Nguyen DM, 2000, ANN THORAC SURG, V70, P1853, DOI 10.1016/S0003-4975(00)01810-5; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TAKAHASHI A, 1994, CANCER RES, V54, P4233; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITESELL L, 1992, CANCER RES, V52, P1721; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wiesener MS, 2001, CANCER RES, V61, P5215; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Zhong H, 1999, CANCER RES, V59, P5830	80	564	585	4	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29936	29944		10.1074/jbc.M204733200	http://dx.doi.org/10.1074/jbc.M204733200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12052835	hybrid			2022-12-25	WOS:000177509300074
J	Abdelrahim, M; Samudio, I; Smith, R; Burghardt, R; Safe, S				Abdelrahim, M; Samudio, I; Smith, R; Burghardt, R; Safe, S			Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; NF-Y; GROWTH-FACTOR; RECEPTOR SP1; RETINOIC ACID; ACTIVATION; 17-BETA-ESTRADIOL; BINDING; PROMOTER; INTERFERENCE	Small interfering RNA duplexes containing 21-22 nucleotides that mediate sequence-specific mRNA degradation and inhibitory RNA (iRNA) for Sp1 mRNA were used in this study to investigate the role of Sp1 on basal and hormone-induced growth and transactivation in MCF-7 and ZR-75 human breast cancer cells. Transfection of Sp1 iRNA in MCF-7 or ZR-75 cells for 36-44 h decreased Sp1 protein (50-70%) in nuclear extracts, and immunohistochemical analysis showed that the Sp1 protein in transfected MCF-7 cells was barely detectable. In cell cycle progression studies in MCF-7 cells, decreased Spl protein was accompanied by a decrease in cells in the S phase and an increase in cells in G(0)/G(1), and estrogen-induced G(0)/G(1) --> S phase progression was inhibited in cells treated with iRNA for Spl. Spl iRNA also specifically blocked basal and estrogen-induced transactivation in cells transfected with a GC-rich construct linked to a luciferase reporter gene (pSp1(3)), and this was accompanied by decreased Spl binding to this GC-rich promoter as determined in gel mobility shift and chromatin immunoprecipitation assays. These results clearly demonstrate the key role of the Spl protein in basal and estrogen-induced growth and gene expression in breast cancer cells.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Vet Pathobiol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Anat & Publ Hlth, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU,Vet Res Bldg 409, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Smith III, Roger/C-8685-2013; Burghardt, Robert C./AAF-4847-2021; Samudio, Ismael/D-3581-2013	Burghardt, Robert C./0000-0003-1021-8444; Samudio, Ismael/0000-0001-8676-1035; Smith, Roger/0000-0001-5645-8422	NCI NIH HHS [CA96676] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Harborth J, 2001, J CELL SCI, V114, P4557; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Ishibashi H, 2000, CANCER RES, V60, P6531; Kyo S, 1999, CANCER RES, V59, P5917; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Salvatori L, 2000, ENDOCRINOLOGY, V141, P2266, DOI 10.1210/en.141.6.2266; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shimada J, 2001, MOL ENDOCRINOL, V15, P1677, DOI 10.1210/me.15.10.1677; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200; Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.0.CO;2-R; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Xie W, 2000, ENDOCRINOLOGY, V141, P2439, DOI 10.1210/en.141.7.2439; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197	46	103	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28815	28822		10.1074/jbc.M203828200	http://dx.doi.org/10.1074/jbc.M203828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12052832	hybrid			2022-12-25	WOS:000177342600062
J	Bettuzzi, S; Scorcioni, F; Astancolle, S; Davalli, P; Scaltriti, M; Corti, A				Bettuzzi, S; Scorcioni, F; Astancolle, S; Davalli, P; Scaltriti, M; Corti, A			Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression	ONCOGENE			English	Article						cell cycle; clusterin; ODC; PNT2; prostate cancer; SV40	HUMAN DERMAL FIBROBLASTS; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; VENTRAL PROSTATE; SULFATED GLYCOPROTEIN-2; POLYAMINE METABOLISM; GENE-EXPRESSION; ANDROGEN RECEPTOR; HUMAN HOMOLOG; CANCER	Clusterin is a highly conserved, widely distributed glycoprotein whose biological significance is still debated. Involved in many biological processes and disease states, clusterin is induced by cell injury and tissue regression, but is repressed during cell proliferation. We have previously reported that clusterin mRNA induction is associated with epithelial cell atrophy in the rat prostate and both clusterin transcript and protein accumulated in quiescent normal human skin fibroblasts. Here we show that transient clusterin overexpression, in SV40-immortalized human prostate epithelial cells (PNT2), resulted in increased accumulation of cells in the G(0)/G(1) phases of the cell cycle, accompanied by slowdown of cell cycle progression and decrease of DNA synthesis. The activities of ornithine decarboxylase (ODC) and S-andenosylmethionine decarboxylase (AdoMetDC), and the level of histone H3 mRNA (markers of cell proliferation) concomitantly decreased, while Gas1 mRNA (a marker of cell quiescence) accumulated. Thus it appears that clusterin, by opposing the effect of SV40 on the proliferation rate of PNT2 cells, acts as an antioncogene in the prostate, suggesting a role for this gene in controlling proliferation of normal and transformed prostate epithelial cells.	Univ Parma, Dipartimento Med Sperimentale, I-43100 Parma, Italy; Univ Modena, Dipartimento Sci Biomed, I-41100 Modena, Italy	University of Parma; Universita di Modena e Reggio Emilia	Bettuzzi, S (corresponding author), Univ Parma, Dipartimento Med Sperimentale, Via Volturno 39, I-43100 Parma, Italy.	saverio.bettuzzi@unipr.it	Bettuzzi, Saverio/B-2609-2009	Bettuzzi, Saverio/0000-0003-2080-6979				Astancolle S, 2000, J ENDOCRINOL, V167, P197, DOI 10.1677/joe.0.1670197; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bettuzzi S, 2000, CANCER RES, V60, P1472; Bettuzzi S, 1995, FEBS LETT, V377, P321, DOI 10.1016/0014-5793(95)01359-8; BETTUZZI S, 1992, J ENDOCRINOL, V132, P361, DOI 10.1677/joe.0.1320361; Bettuzzi S, 1999, FEBS LETT, V448, P297, DOI 10.1016/S0014-5793(99)00375-0; Bettuzzi S, 1999, FEBS LETT, V446, P18, DOI 10.1016/S0014-5793(99)00182-9; BETTUZZI S, 1994, FEBS LETT, V348, P255, DOI 10.1016/0014-5793(94)00609-1; BETTUZZI S, 1989, BIOCHEM J, V257, P293, DOI 10.1042/bj2570293; Blanchere M, 1998, J STEROID BIOCHEM, V66, P319, DOI 10.1016/S0960-0760(98)00056-9; BUCK MRE, 1995, CANCER RES, V55, P2959; BURKEY BF, 1991, J LIPID RES, V32, P1039; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CANELLAKIS ZN, 1989, YALE J BIOL MED, V62, P481; CUSSENOT O, 1991, J UROLOGY, V146, P881, DOI 10.1016/S0022-5347(17)37953-3; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; FINK TM, 1993, GENOMICS, V16, P526, DOI 10.1006/geno.1993.1222; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948; GRASSILLI E, 1991, BIOCHEM BIOPH RES CO, V180, P59, DOI 10.1016/S0006-291X(05)81254-9; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; Huang HFS, 1997, J ANDROL, V18, P250; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; Koch-Brandt C, 1996, Prog Mol Subcell Biol, V16, P130; Konishi H, 1996, CANCER RES, V56, P434; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Latil A, 1996, J UROLOGY, V156, P2079, DOI 10.1016/S0022-5347(01)65439-9; LOWE NJ, 1980, ARCH DERMATOL, V116, P822, DOI 10.1001/archderm.116.7.822; LUK GD, 1987, ADV ENZYME REGUL, V26, P91, DOI 10.1016/0065-2571(87)90007-0; MARINELLI M, 1994, BIOCHEM CELL BIOL, V72, P515, DOI 10.1139/o94-069; Miyake H, 2000, CANCER RES, V60, P170; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; PEARSE MJ, 1992, INT IMMUNOL, V4, P1225, DOI 10.1093/intimm/4.11.1225; PEGG AE, 1988, CANCER RES, V48, P759; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; PURRELLO M, 1991, GENOMICS, V10, P151, DOI 10.1016/0888-7543(91)90495-Z; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Scorcioni F, 2001, BIOCHEM J, V354, P217, DOI 10.1042/0264-6021:3540217; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x	45	75	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4328	4334		10.1038/sj.onc.1205594	http://dx.doi.org/10.1038/sj.onc.1205594			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082621				2022-12-25	WOS:000176174200016
J	de Molina, AR; Gutierrez, R; Ramos, MA; Silva, JM; Silva, J; Bonilla, F; Sanchez, JJ; Lacal, JC				de Molina, AR; Gutierrez, R; Ramos, MA; Silva, JM; Silva, J; Bonilla, F; Sanchez, JJ; Lacal, JC			Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy	ONCOGENE			English	Article						choline kinase; breast carcinomas; anticancer drugs; estrogen receptors	CANCER; INHIBITORS; TAMOXIFEN; PROGNOSIS; ANTIBODY; THERAPY; PROTEIN; MARKER	Choline kinase (ChoK) and its product, phosphocholine (PCho), have been implicated in human carcinogenesis. Inhibition of this enzyme has been shown to be an efficient antitumor strategy in viro. The aim of this study was to assess the relationship between the regulation of ChoK and clinical features in patients with breast cancer. To that end, normal and tumoral tissues from 53 patients with breast carcinomas were analysed for ChoK activity and expression, and compared to some clinical parameters. We report a relevant increase in ChoK activity in 38.5% of the tumoral tissues analysed when compared to the normal levels in healthy tissues. Furthermore, some clinical features were found significant versus ChoK status. First, an association of choline enzymatic activity with histological tumor grade was observed (P<0.001). In addition, increased ChoK activity was also associated with ER-negative breast carcinomas (P=0.037). A significant association between ChoK overexpression and both high histologic tumor grade (P=0.017) and ER-negative tumors (P=0.003) was found. Finally, ChoK overexpression was found in 17% of the samples and all corresponded with those that display the highest increase in ChoK activity (P<0.004). Here we provide evidence that ChoK may e related to the development of human breast cancer, suggesting that this finding may constitute the basis for the development of a novel antitumoral strategy for these patients.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, E-28029 Madrid, Spain; Hosp Puerta Hierro, Med Oncol Serv, Madrid, Spain; Univ Autonoma Madrid, Dept Estadist, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Arturo Duperier 4, E-28029 Madrid, Spain.	jclacal@iib.uam.es	Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				Dominguez G, 2000, BREAST CANCER RES TR, V63, P17, DOI 10.1023/A:1006446709715; Fentiman IS, 2000, EUR J CANCER, V36, P1085, DOI 10.1016/S0959-8049(00)00088-5; Ferlay J, 2001, 5 IARC; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Kumar R, 2000, SEMIN ONCOL, V27, P84, DOI 10.1053/sonc.2000.19893; Lacal J C, 2001, IDrugs, V4, P419; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Powles T, 1998, LANCET, V352, P98; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; SALAZAR JM, 2001, REV ONCOLOGIA, V3, P171; Schneider J, 2000, ANTICANCER RES, V20, P4373; SLUYSER M, 1990, Anti-Cancer Drugs, V1, P127, DOI 10.1097/00001813-199012000-00003; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Tripathy D, 1992, Cancer Treat Res, V63, P15; VELASCO FB, 2001, REV ONCOLOGIA, V3, P130	20	203	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4317	4322		10.1038/sj.onc.1205556	http://dx.doi.org/10.1038/sj.onc.1205556			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082619				2022-12-25	WOS:000176174200014
J	Mainard, JL; Morel, V; Fourgeaud, M; Cremniter, J; Blanot, D; Legrand, R; Frehel, C; Arthur, M; van Heijenoort, J; Gutmann, L				Mainard, JL; Morel, V; Fourgeaud, M; Cremniter, J; Blanot, D; Legrand, R; Frehel, C; Arthur, M; van Heijenoort, J; Gutmann, L			Balance between two transpeptidation mechanisms determines the expression of beta-lactam resistance in Enterococcus faecium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEIN; ESCHERICHIA-COLI; PEPTIDOGLYCAN STRUCTURE; DD-CARBOXYPEPTIDASE; STREPTOCOCCUS-FAECALIS; MUREIN SACCULUS; CELL-WALL; VANCOMYCIN; GROWTH; STAPHYLOCOCCI	The D,D-transpeptidase activity of high molecular weight penicillin-binding proteins (PBPs) is essential to maintain cell wall integrity as it catalyzes the final cross-linking step of bacterial peptidoglycan synthesis. We investigated a novel beta-lactam resistance mechanism involving by-pass of the essential PBP's by L,D-transpeptidation in Enterococcus faecium. Determination of the peptidoglycan structure by reverse phase high performance liquid chromatography coupled to mass spectrometry revealed that stepwise selection for ampicillin resistance led to the gradual replacement of the usual cross-links generated by the PBPs (D-Ala(4) --> D-Asx-Lys(3) by cross-links resulting from L,D-transpeptidation (L-Lys(3) --> D-Asx-Lys,). This was associated with no modification of the level of production of the PBPs or of their affinity for beta-lactams, indicating that altered PBP activity was not required for ampicillin resistance. A beta-lactam-insensitive L,D-transpeptidase was detected in membrane preparations of the parental susceptible strain. Acquisition of resistance was not because of variation of this activity. Instead, selection led to production of a beta-lactam-insensitive D,D-carboxypeptidase that cleaved the C-terminal D-Ala residue of pentapeptide stems in vitro and caused massive accumulation of cytoplasmic precursors containing a tetrapeptide stem in vivo. The parallel dramatic increase in the proportion of L-Lyw(3) --> D-Asx-Lys(3) crosslinks showed that the enzyme was activating the resistance pathway by generating the substrate for the L,D-transpeptidase.	Univ Paris 06, INSERM EMI U0004, Lab Rech Mol Antibiot, UFR Broussais Hotel Dieu, F-75270 Paris, France; CNRS, UMR 8619, F-91405 Orsay, France; Hoechst Marion Roussel, Dept Phys, F-93235 Romainville, France; Fac Med Necker Enfants Malad, INSERM U411, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Sanofi-Aventis; Sanofi France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mainard, JL (corresponding author), Univ Paris 06, INSERM EMI U0004, Lab Rech Mol Antibiot, UFR Broussais Hotel Dieu, 15 Rue Ecole Med, F-75270 Paris, France.		Arthur, Michel/G-3680-2013	Arthur, Michel/0000-0003-1007-636X; cremniter, julie/0000-0002-2249-8394				Arthur M, 1998, MOL MICROBIOL, V30, P819, DOI 10.1046/j.1365-2958.1998.01114.x; BELIVEAU C, 1991, J BACTERIOL, V173, P5619, DOI 10.1128/jb.173.18.5619-5623.1991; BillotKlein D, 1997, J BACTERIOL, V179, P6208, DOI 10.1128/jb.179.19.6208-6212.1997; BillotKlein D, 1996, BIOCHEM J, V313, P711, DOI 10.1042/bj3130711; BillotKlein D, 1997, J BACTERIOL, V179, P4684, DOI 10.1128/jb.179.15.4684-4688.1997; BILLOTKLEIN D, 1992, ANTIMICROB AGENTS CH, V36, P1487, DOI 10.1128/AAC.36.7.1487; BLASCO B, 1988, J BACTERIOL, V170, P5224, DOI 10.1128/jb.170.11.5224-5228.1988; CORNETT JB, 1978, J BACTERIOL, V133, P631, DOI 10.1128/JB.133.2.631-640.1978; COYETTE J, 1974, EUR J BIOCHEM, V44, P459, DOI 10.1111/j.1432-1033.1974.tb03504.x; deJonge BLM, 1996, MICROB DRUG RESIST, V2, P225, DOI 10.1089/mdr.1996.2.225; DRIEHUIS F, 1987, J BACTERIOL, V169, P97, DOI 10.1128/jb.169.1.97-101.1987; FONTANA R, 1983, J BACTERIOL, V155, P1343, DOI 10.1128/JB.155.3.1343-1350.1983; Ghuysen Jean-Marie, 1994, Trends in Microbiology, V2, P372, DOI 10.1016/0966-842X(94)90614-9; Ghuysen JM, 1973, BACTERIAL MEMBRANES, P37; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; HOLTJE JV, 1990, RES MICROBIOL, V141, P75, DOI 10.1016/0923-2508(90)90100-5; Kimura Y, 1999, J BACTERIOL, V181, P4696, DOI 10.1128/JB.181.15.4696-4699.1999; KLARE I, 1992, ANTIMICROB AGENTS CH, V36, P783, DOI 10.1128/AAC.36.4.783; LondonoVallejo JA, 1997, MOL MICROBIOL, V24, P29, DOI 10.1046/j.1365-2958.1997.3181680.x; MAINARDI JL, 1995, ANTIMICROB AGENTS CH, V39, P1984, DOI 10.1128/AAC.39.9.1984; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; Pinho MG, 2001, P NATL ACAD SCI USA, V98, P10886, DOI 10.1073/pnas.191260798; PISABARRO AG, 1985, J BACTERIOL, V161, P238, DOI 10.1128/JB.161.1.238-242.1985; Reynolds PE, 2001, MICROBIOL-SGM, V147, P2571, DOI 10.1099/00221287-147-9-2571; Rybkine T, 1998, J INFECT DIS, V178, P159, DOI 10.1086/515605; SANDRIN E, 1963, HELV CHIM ACTA, V46, P1637, DOI 10.1002/hlca.19630460518; Sifaoui F, 2001, ANTIMICROB AGENTS CH, V45, P2594, DOI 10.1128/AAC.45.9.2594-2597.2001; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; WILLIAMSON R, 1985, J GEN MICROBIOL, V131, P1933; WRIGHT GD, 1992, ANTIMICROB AGENTS CH, V36, P1514, DOI 10.1128/AAC.36.7.1514; Zorzi W, 1996, J BACTERIOL, V178, P4948, DOI 10.1128/jb.178.16.4948-4957.1996	35	64	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35801	35807		10.1074/jbc.M204319200	http://dx.doi.org/10.1074/jbc.M204319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12077139	hybrid			2022-12-25	WOS:000178275100006
J	Lee, C; Prakash, S; Matouschek, A				Lee, C; Prakash, S; Matouschek, A			Concurrent translocation of multiple polypeptide chains through the proteasomal degradation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOA4 DEUBIQUITINATING ENZYME; END RULE; 20S PROTEASOME; TRANSCRIPTION FACTOR; PROTEIN STABILITY; LYSINE RESIDUES; CORE PARTICLE; SIGNAL; UBIQUITINATION	The proteasome can actively unfold proteins by sequentially unraveling their substrates from the attachment point of the degradation signal. To investigate the steric constraints imposed on substrate proteins during their degradation by the proteasome, we constructed a model protein in which specific parts of the polypeptide chain were covalently connected through disulfide bridges. The cross-linked model proteins were fully degraded by the proteasome, but two or more cross-links retarded the degradation slightly. These results suggest that the pore of the proteasome allows the concurrent passage of at least three stretches of a polypeptide chain. A degradation channel that can tolerate some steric bulk may reconcile the two opposing needs for degradation that is compartmentalized to avoid aberrant proteolysis yet able to handle a range of substrates of various sizes.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Matouschek, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.		Prakash, Sumit/B-2679-2009; Matouschek, Andreas/L-9379-2013	Prakash, Sumit/0000-0002-0608-3420; Matouschek, Andreas/0000-0001-6016-2341				Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CLARKE J, 1995, J MOL BIOL, V253, P493, DOI 10.1006/jmbi.1995.0568; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARTLEY RW, 1975, BIOCHEMISTRY-US, V14, P2367, DOI 10.1021/bi00682a015; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; REISS Y, 1988, J BIOL CHEM, V263, P2693; Rodriguez MS, 1996, ONCOGENE, V12, P2425; ROOD JI, 1980, GENE, V8, P255, DOI 10.1016/0378-1119(80)90003-7; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwartz MP, 1999, P NATL ACAD SCI USA, V96, P13086, DOI 10.1073/pnas.96.23.13086; Schwartz MP, 1999, J BIOL CHEM, V274, P12759, DOI 10.1074/jbc.274.18.12759; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Stroschein SL, 2001, GENE DEV, V15, P2822; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Yamano H, 1998, EMBO J, V17, P5670, DOI 10.1093/emboj/17.19.5670; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	47	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34760	34765		10.1074/jbc.M204750200	http://dx.doi.org/10.1074/jbc.M204750200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12080075	hybrid			2022-12-25	WOS:000178117000016
J	Leys, D; Meyer, TE; Tsapin, AS; Nealson, KH; Cusanovich, MA; Van Beeumen, JJ				Leys, D; Meyer, TE; Tsapin, AS; Nealson, KH; Cusanovich, MA; Van Beeumen, JJ			Crystal structures at atomic resolution reveal the novel concept of "electron-harvesting" as a role for the small tetraheme cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHEWANELLA-FRIGIDIMARINA; FLAVOCYTOCHROME-C; IDENTIFICATION; C(3); REFINEMENT; MECHANISMS; REDUCTASE; MODEL	The genus Shewanella produces a unique small tetraheme cytochrome c that is implicated in the iron oxide respiration pathway. It is similar in heme content and redox potential to the well known cytochromes c(3) but related in structure to the cytochrome c domain of soluble fumarate reductases from Shewanella sp. We report the crystal structure of the small tetraheme cytochrome c from Shewanella oneidensis MR-1 in two crystal forms and two redox states. The overall fold and heme core are surprisingly different from the soluble fumarate reductase structures. The high resolution obtained for an oxidized orthorhombic crystal (0.97 Angstrom) revealed several flexible regions. Comparison of the six monomers in the oxidized monoclinic space group (1.55 Angstrom) indicates flexibility in the C-terminal region containing heme IV. The reduced orthorhombic crystal structure (1.02 Angstrom) revealed subtle differences in the position of several residues, resulting in decreased solvent accessibility of hemes and the withdrawal of a positive charge from the molecular surface. The packing between monomers indicates that intermolecular electron transfer between any heme pair is possible. This suggests there is no unique site of electron transfer on the surface of the protein and that electron transfer partners may interact with any of the hemes, a process termed "electron-harvesting." This optimizes the efficiency of intermolecular electron transfer by maximizing chances of productive collision with redox partners.	Dept Biochem Physiol & Microbiol, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona	Leys, D (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	dl37@le.ac.uk						Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Beliaev AS, 2001, MOL MICROBIOL, V39, P722, DOI 10.1046/j.1365-2958.2001.02257.x; Brige A, 2002, BIOCHEMISTRY-US, V41, P4827, DOI 10.1021/bi012144b; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Gordon EHJ, 2000, BIOCHEM J, V349, P153, DOI 10.1042/0264-6021:3490153; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Igarashi N, 1997, NAT STRUCT BIOL, V4, P276, DOI 10.1038/nsb0497-276; Isaacs NW, 1995, CURR OPIN STRUC BIOL, V5, P794, DOI 10.1016/0959-440X(95)80013-1; Iverson TM, 1998, NAT STRUCT BIOL, V5, P1005, DOI 10.1038/2975; Jeuken LJC, 2002, J AM CHEM SOC, V124, P5702, DOI 10.1021/ja012638w; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Leys D, 1999, NAT STRUCT BIOL, V6, P1113; Matias PM, 1997, J BIOL INORG CHEM, V2, P507, DOI 10.1007/s007750050162; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Norager S, 1999, J MOL BIOL, V290, P881, DOI 10.1006/jmbi.1999.2917; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pessanha M, 2001, FEBS LETT, V489, P8, DOI 10.1016/S0014-5793(00)02383-8; SHELDRICK GM, 1997, SHELX 97 CRYSTALLOGR; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; Tsapin AI, 1996, J BACTERIOL, V178, P6386, DOI 10.1128/jb.178.21.6386-6388.1996; Tsapin AI, 2001, APPL ENVIRON MICROB, V67, P3236, DOI 10.1128/AEM.67.7.3236-3244.2001	25	79	81	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35703	35711		10.1074/jbc.M203866200	http://dx.doi.org/10.1074/jbc.M203866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12080059	hybrid			2022-12-25	WOS:000178117000132
J	Russo, C; Dolcini, V; Salis, S; Venezia, V; Zambrano, N; Russo, T; Schettini, G				Russo, C; Dolcini, V; Salis, S; Venezia, V; Zambrano, N; Russo, T; Schettini, G			Signal transduction through tyrosine-phosphorylated C-terminal fragments of amyloid precursor protein via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; BETA-PROTEIN; SERINE PROTEASES; MAMMALIAN BRAIN; RAT-BRAIN; CELLS; EXPRESSION; FE65; ACCUMULATION; APP	The proteolytic processing of amyloid precursor protein (APP) through the formation of membrane-bound C-terminal fragments (CTFs) and of soluble beta-amyloid peptides likely influences the development of Alzheimer's disease (AD). We show that in human brain a subset of CTFs are tyrosine-phosphorylated and form stable complexes with the adaptor protein ShcA. Grb2 is also part of these complexes, which are present in higher amounts in AD than in control brains. ShcA immunoreactivity is also greatly enhanced in patients with AD and occurs at reactive astrocytes surrounding cerebral vessels and amyloid plaques. A higher amount of phospho-ERK1,2, likely as result of the ShcA activation, is present in AD brains. In vitro experiments show that the ShcA-CTFs interaction is strictly confined to glial cells when treated with thrombin, which is a well known ShcA and ERK1,2 activator and a regulator of APP cleavage. In untreated cells SheA does not interact with either APP or CTFs, although they are normally generated. Altogether these data suggest that CTFs are implicated in cell signaling via She transduction machinery, likely influencing MAPK activity and glial reaction in AD patients.	Ctr Biotecnol Avanzate, IST, Dipartimento Farmacol & Neurosci, I-16132 Genoa, Italy; Univ Genoa, Dipartimento Oncol Biol & Genet, Sez Farmacol, I-16132 Genoa, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Genoa; University of Naples Federico II	Schettini, G (corresponding author), Ctr Biotecnol Avanzate, IST, Dipartimento Farmacol & Neurosci, Largo R Benzi 10, I-16132 Genoa, Italy.		Russo, Claudio/AIA-1429-2022; Zambrano, Nicola/B-9352-2014; Russo, Tommaso/K-1331-2016	Zambrano, Nicola/0000-0001-9395-3481; Russo, Tommaso/0000-0003-4426-0106; russo, claudio/0000-0002-2520-2958	Telethon [E.1144] Funding Source: Medline	Telethon(Fondazione Telethon)		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Berger-Sweeney J, 1999, MOL BRAIN RES, V66, P150, DOI 10.1016/S0169-328X(99)00014-5; BHAT NR, 1995, J CELL PHYSIOL, V165, P417, DOI 10.1002/jcp.1041650223; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Cocks TM, 2000, TRENDS PHARMACOL SCI, V21, P103, DOI 10.1016/S0165-6147(99)01440-6; Conti L, 1997, P NATL ACAD SCI USA, V94, P8185, DOI 10.1073/pnas.94.15.8185; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; GALASKO D, 1995, NEUROLOGY, V45, P1451, DOI 10.1212/WNL.45.8.1451; GANDY SE, 1992, J NEUROCHEM, V58, P383, DOI 10.1111/j.1471-4159.1992.tb09322.x; GHISO J, 1994, NEUROSCI LETT, V171, P213, DOI 10.1016/0304-3940(94)90642-4; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Howell BW, 1999, MOL CELL BIOL, V19, P5179; HYMAN BT, 1994, AM J PATHOL, V144, P565; KNOPS J, 1992, J BIOL CHEM, V267, P16022; Kubo Y, 2000, J NEUROTRAUM, V17, P163, DOI 10.1089/neu.2000.17.163; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; LI QX, 1995, J BIOL CHEM, V270, P14140, DOI 10.1074/jbc.270.23.14140; Li SC, 1996, J BIOL CHEM, V271, P31855, DOI 10.1074/jbc.271.50.31855; MAHDI F, 1995, J BIOL CHEM, V270, P23468, DOI 10.1074/jbc.270.40.23468; Matsuda S, 2001, J NEUROSCI, V21, P6597; McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Ricketts WA, 1999, MOL ENDOCRINOL, V13, P1988, DOI 10.1210/me.13.12.1988; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Russo C, 2001, NEUROBIOL DIS, V8, P173, DOI 10.1006/nbdi.2000.0357; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; SAPORITOIRWIN SM, 1995, J BIOL CHEM, V270, P26265, DOI 10.1074/jbc.270.44.26265; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simons M, 1996, J NEUROSCI, V16, P899; Storey E, 1996, BRAIN RES, V735, P217, DOI 10.1016/0006-8993(96)00608-7; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Thellung S, 2000, INT J DEV NEUROSCI, V18, P481, DOI 10.1016/S0736-5748(00)00005-8; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; Turgeon VL, 1997, BRAIN RES REV, V25, P85, DOI 10.1016/S0165-0173(97)00015-5; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	45	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35282	35288		10.1074/jbc.M110785200	http://dx.doi.org/10.1074/jbc.M110785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12084708	hybrid			2022-12-25	WOS:000178117000081
J	Ambrosini, G; Nath, AK; Sierra-Honigmann, MR; Flores-Riveros, J				Ambrosini, G; Nath, AK; Sierra-Honigmann, MR; Flores-Riveros, J			Transcriptional activation of the human leptin gene in response to hypoxia - Involvement of hypoxia-inducible factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE-A; MEDIATES ANGIOGENIC ACTIVITY; HUMAN ERYTHROPOIETIN GENE; BINDING PROTEIN-ALPHA; MOUSE OBESE GENE; MOLECULAR-BIOLOGY; SKIN REPAIR; OB GENE; EXPRESSION; ENHANCER	In addition to having a major role in energy homeostasis, leptin is emerging as a pleiotropic cytokine with multiple physiological effector functions. The recently discovered proangiogenic activity of leptin suggested the hypothesis that its production might be regulated by hypoxia, as are other angiogenic factors. To examine this proposal, the expression of leptin protein and mRNA was measured and found to be markedly up-regulated in response to ambient or chemical hypoxia (upon exposure to desferrioxamine or cobalt chloride), an effect that requires intact RNA synthesis, suggesting a transcriptional mechanism. Transient transfection of cultured cells with deletion constructs of the leptin gene promoter linked to a reporter gene revealed a functional hypoxia response element (HRE) located at position -116 within the proximal upstream region. This putative HRE harbors a characteristic 5'-RCGTG-3' core motif, a hallmark of hypoxia-sensitive genes and recognized by the hypoxia-inducible factor 1 (HIF1), which consists of a HIF1alpha/HIFbeta heterodimer. Constructs harboring this -116/HRE supported reporter gene expression in response to hypoxia but not when mutated. Expression of HIF1alpha cDNA in normoxic cells mimicked hypoxia-induced reporter gene expression in cells cotransfected with the wild type leptin -116/HRE construct but not with the mutant. Gel shift assays with a P-32-labeled leptin promoter -116/HRE probe and nuclear extracts from hypoxia-treated cells indicated binding of the HIF1alpha/beta heterodimer, which was blocked with an excess of unlabeled -116/HRE probe or a HIF1-binding probe from the erythropoietin gene enhancer. Taken together, these observations demonstrate that the leptin gene is actively engaged by hypoxia through a transcriptional pathway commonly utilized by hypoxia-sensitive genes.	Inst Diabet Discovery, Dept Mol Biol, Branford, CT 06405 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ So Calif, Div Plast Surg, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA	Yale University; University of Southern California; Cedars Sinai Medical Center	Flores-Riveros, J (corresponding author), Inst Diabet Discovery, Dept Mol Biol, 23 Business Pk Dr, Branford, CT 06405 USA.							Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; BECK I, 1991, J BIOL CHEM, V266, P15563; Bi S, 1997, J BIOL CHEM, V272, P30583, DOI 10.1074/jbc.272.48.30583; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Chaconas G, 1980, Methods Enzymol, V65, P75; CHANG N, 1983, ANN SURG, V197, P470, DOI 10.1097/00000658-198304000-00017; delaBrousse FC, 1996, P NATL ACAD SCI USA, V93, P4096, DOI 10.1073/pnas.93.9.4096; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ebihara K, 1997, BIOCHEM BIOPH RES CO, V241, P658, DOI 10.1006/bbrc.1997.7869; FAURA J, 1969, BLOOD-J HEMATOL, V33, P668, DOI 10.1182/blood.V33.5.668.668; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Frank S, 2000, J CLIN INVEST, V106, P501, DOI 10.1172/JCI9148; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gong DW, 1996, J BIOL CHEM, V271, P3971; Grosfeld A, 2001, FEBS LETT, V502, P122, DOI 10.1016/S0014-5793(01)02673-4; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; HOM DB, 1992, ANN OTO RHINOL LARYN, V101, P349, DOI 10.1177/000348949210100411; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; JONSSON K, 1991, ANN SURG, V214, P605, DOI 10.1097/00000658-199111000-00011; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Mise H, 1998, J CLIN ENDOCR METAB, V83, P3225, DOI 10.1210/jc.83.9.3225; Nissen NN, 1998, AM J PATHOL, V152, P1445; Nissen NN, 1996, SURGERY, V119, P457, DOI 10.1016/S0039-6060(96)80148-6; RATCLIFFE PJ, 1993, KIDNEY INT, V44, P887, DOI 10.1038/ki.1993.327; Reynolds LP, 2001, BIOL REPROD, V64, P1033, DOI 10.1095/biolreprod64.4.1033; ROBIN ED, 1984, J CELL PHYSIOL, V118, P287, DOI 10.1002/jcp.1041180311; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 1998, CHEST, V114, p40S, DOI 10.1378/chest.114.1_Supplement.40S; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Stallmeyer B, 2001, J INVEST DERMATOL, V117, P98, DOI 10.1046/j.0022-202x.2001.01387.x; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yan SF, 1997, J BIOL CHEM, V272, P4287, DOI 10.1074/jbc.272.7.4287; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463	55	155	162	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34601	34609		10.1074/jbc.M205172200	http://dx.doi.org/10.1074/jbc.M205172200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12084725	hybrid			2022-12-25	WOS:000177959100134
J	Bailey, EC; Milenkovic, L; Scott, MP; Collawn, JF; Johnson, RL				Bailey, EC; Milenkovic, L; Scott, MP; Collawn, JF; Johnson, RL			Several PATCHED1 missense mutations display activity in patched1-deficient fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMA; CENTRAL-NERVOUS-SYSTEM; SONIC-HEDGEHOG; HUMAN HOMOLOG; SIGNALING PATHWAY; NEURAL-TUBE; FLOOR PLATE; MEMBRANE-PROTEIN; DEVELOPING LIMB; NEVUS SYNDROME	Mutations in mouse and human patched1 (ptc1) genes are associated with birth defects and cancer. Ptc1 is a receptor for Hedgehog (Hh) signaling proteins. Hh proteins activate transcription of target genes, including ptc1, and Ptc1 represses those genes, both by regulating the activity of Gli transcription factors. We have established mammalian cell lines with reduced Ptc1 function and a lacZ reporter to investigate Hh signal transduction. Embryonic fibroblasts were derived from mice, heterozygous or homozygous for a ptc1 mutation that inserts lacZ under the control of the ptc1 promoter (ptc1-lacZ). In heterozygous ptc1 cells, ptc1-lacZ was expressed at low levels but could be induced by Sonic Hedgehog (Shh) and Gli-1. Homozygous ptc1 cells expressed high levels of ptc1-lacZ without Hh stimulation. ptc1-lacZ expression was dependent on cell density in ptc1 homozygotes and Hh-stimulated heterozygotes but was independent of density when Gli1 was used to activate ptc1-lacZ. A wild-type ptc1 transgene introduced into homozygous ptc1 cells greatly reduced ptc1-lacZ expression. Expression of either half of Ptc1 alone resulted in improper maturation of the protein and a failure to complement the ptc1(-/-) cells. When co-expressed, both Ptc1 halves matured and had an activity similar to that of the intact protein. Three missense PTCH1 mutations exhibited significant functions in homozygous ptc1 cells. The missense mutants retained activity when expressed at about 10-fold lower levels and appeared as stable as wild-type Ptc1. These studies suggest that some tumors and disease phenotypes may arise from small reductions in PTCH1 activity.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Stanford, CA 94305 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Johnson, RL (corresponding author), Human Genome Sci, 9410 Key W Ave, Rockville, MD 20850 USA.			Collawn, James/0000-0002-2528-2759	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037505] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NICHD NIH HHS [1R01 HD 37505-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chidambaram A, 1996, CANCER RES, V56, P4599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Concordet JP, 1996, DEVELOPMENT, V122, P2835; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Gailani M R, 1999, Adv Dermatol, V14, P261; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; Graubert TA, 1998, NUCLEIC ACIDS RES, V26, P2849, DOI 10.1093/nar/26.12.2849; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; Hasenpusch-Theil K, 1998, Hum Mutat, V11, P480, DOI 10.1002/(SICI)1098-1004(1998)11:6<480::AID-HUMU9>3.0.CO;2-4; HAWLEY RG, 1994, GENE THER, V1, P136; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1997, COLD SPRING HARB SYM, V62, P205; Johnson RL, 2000, MOL CELL, V6, P467, DOI 10.1016/S1097-2765(00)00045-9; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lee J, 1997, DEVELOPMENT, V124, P2537; Lewis KE, 1999, DEV BIOL, V208, P14, DOI 10.1006/dbio.1998.9169; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; Matise MP, 1998, DEVELOPMENT, V125, P2759; Milenkovic L, 1999, DEVELOPMENT, V126, P4431; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Motoyama J, 1998, MECH DEVELOP, V78, P81, DOI 10.1016/S0925-4773(98)00149-X; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; Park HL, 2000, DEVELOPMENT, V127, P1593; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Raffel C, 1997, CANCER RES, V57, P842; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; Ruttledge MH, 1996, AM J HUM GENET, V59, P331; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; WARD CL, 1994, J BIOL CHEM, V269, P25710; Wetmore C, 2000, CANCER RES, V60, P2239; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wicking C, 1997, AM J HUM GENET, V60, P21; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	72	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33632	33640		10.1074/jbc.M202203200	http://dx.doi.org/10.1074/jbc.M202203200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12072433	hybrid			2022-12-25	WOS:000177959100015
J	Woodmansee, AN; Imlay, JA				Woodmansee, AN; Imlay, JA			Reduced flavins promote oxidative DNA damage in non-respiring Escherichia coli by delivering electrons to intracellular free iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; SUPEROXIDE-DISMUTASE; RIBONUCLEOTIDE REDUCTASE; DEOXYRIBONUCLEIC-ACID; RESPIRATORY-CHAIN; SULFITE REDUCTASE; HYDROXYL RADICALS; STRAND SCISSION; OXYGEN RADICALS; OXIDOREDUCTASE	When cells are exposed to external H2O2, the H2O2 rapidly diffuses inside and oxidizes ferrous iron, thereby forming hydroxyl radicals that damage DNA. Thus the process of oxidative DNA damage requires only H2O2, free iron, and an as-yet unidentified electron donor that reduces ferric iron to the ferrous state. Previous work showed that H2O2 kills Escherichia coli especially rapidly when respiration is inhibited either by cyanide or by genetic defects in respiratory enzymes. In this study we established that these respiratory blocks accelerate the rate of DNA damage. The respiratory blocks did not substantially affect the amounts of intracellular free iron or H2O2, indicating that that they accelerated damage because they increased the availability of the electron donor. The goal of this work was to identify that donor. As expected, the respiratory inhibitors caused a large increase in the amount of intracellular NADH. However, NADH itself was a poor reductant of free iron in vitro. This suggests that in non-respiring cells electrons are transferred from NADH to another carrier that directly reduces the iron. Genetic manipulations of the amounts of intracellular glutathione, NADPH, alpha-ketoacids, ferredoxin, and thioredoxin indicated that none of these was the direct electron donor. However, cells were protected from cyanide-stimulated DNA damage if they lacked flavin reductase, an enzyme that transfers electrons from NADH to free FAD. The K. value of this enzyme for NADH is much higher than the usual intracellular NADH concentration, which explains why its flux increased when NADH levels rose during respiratory inhibition. Flavins that were reduced by purified flavin reductase rapidly transferred electrons to free iron and drove a DNA-damaging Fenton system in vitro. Thus the rate of oxidative DNA damage can be limited by the rate at which electron donors reduce free iron, and reduced flavins become the predominant donors in E. coli when respiration is blocked. It remains unclear whether flavins or other reductants drive Fenton chemistry in respiring cells.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Imlay, JA (corresponding author), Univ Illinois, Dept Microbiol, 131 Burrill Hall, Urbana, IL 61801 USA.	jimlay@uiuc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059030] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR 01811] Funding Source: Medline; NIGMS NIH HHS [GM 59030] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; AU DCT, 1984, J BACTERIOL, V157, P122, DOI 10.1128/JB.157.1.122-125.1984; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BRAWN K, 1981, ARCH BIOCHEM BIOPHYS, V206, P414, DOI 10.1016/0003-9861(81)90108-9; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CARLSON BW, 1984, J AM CHEM SOC, V106, P7233, DOI 10.1021/ja00335a062; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; DEMPLE B, 1983, J BACTERIOL, V153, P1079, DOI 10.1128/JB.153.2.1079-1082.1983; Eichhorn E, 1999, J BIOL CHEM, V274, P26639, DOI 10.1074/jbc.274.38.26639; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1994, BIOMETALS, V7, P3; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HANSON RL, 1980, J BACTERIOL, V141, P401, DOI 10.1128/JB.141.1.401-404.1980; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1986, J BACTERIOL, V166, P519, DOI 10.1128/jb.166.2.519-527.1986; Jeffers CE, 2001, BIOCHEMISTRY-US, V40, P1749, DOI 10.1021/bi0024310; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KOPPENOL WH, 1993, FREE RADICAL BIO MED, V14, P91, DOI 10.1016/0891-5849(93)90513-T; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAWLEY PD, 1970, BIOCHEM J, V116, P693, DOI 10.1042/bj1160693; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; Lei BF, 1996, J BACTERIOL, V178, P5699, DOI 10.1128/jb.178.19.5699-5705.1996; LESKO SA, 1980, BIOCHEMISTRY-US, V19, P3023, DOI 10.1021/bi00554a029; LINN S, 1987, J CELL SCI, P289; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MEGANATHAN R, 1996, AM SOC MICROBIOLOGY, P642; MEISEL D, 1975, J PHYS CHEM-US, V79, P2459, DOI 10.1021/j100590a002; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; MULLER F, 1987, FREE RADICAL BIO MED, V3, P215, DOI 10.1016/0891-5849(87)90009-8; NASCIMENTO ALTO, 1995, CARCINOGENESIS, V16, P1335, DOI 10.1093/carcin/16.6.1335; Niviere V, 1999, J BIOL CHEM, V274, P18252, DOI 10.1074/jbc.274.26.18252; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; Poon WW, 2000, J BACTERIOL, V182, P5139, DOI 10.1128/JB.182.18.5139-5146.2000; ROWLEY DA, 1982, FEBS LETT, V142, P39, DOI 10.1016/0014-5793(82)80214-7; RUSH JD, 1990, METHOD ENZYMOL, V186, P148; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seaver LC, 2001, J BACTERIOL, V183, P7182, DOI 10.1128/JB.183.24.7182-7189.2001; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WINTERBOURN CC, 1979, BIOCHEM J, V182, P625, DOI 10.1042/bj1820625; Witschel M, 1997, J BACTERIOL, V179, P6937, DOI 10.1128/jb.179.22.6937-6943.1997; WOLF RE, 1979, J BACTERIOL, V139, P1093, DOI 10.1128/JB.139.3.1093-1096.1979; Xu YR, 1997, J BACTERIOL, V179, P1112, DOI 10.1128/jb.179.4.1112-1116.1997; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q; Zhu BZ, 2002, FREE RADICAL BIO MED, V32, P465, DOI 10.1016/S0891-5849(01)00824-3	66	111	115	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34055	34066		10.1074/jbc.M203977200	http://dx.doi.org/10.1074/jbc.M203977200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12080063	hybrid			2022-12-25	WOS:000177959100072
J	Bishop, JD; Moon, BC; Harrow, F; Ratner, D; Gomer, RH; Dottin, JP; Brazill, DT				Bishop, JD; Moon, BC; Harrow, F; Ratner, D; Gomer, RH; Dottin, JP; Brazill, DT			A second UDP-glucose pyrophosphorylase is required for differentiation and development in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION PATHWAYS; SUBSTRATE-BINDING SITE; CELL-CELL INTERACTIONS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; GENE-EXPRESSION; POTATO-TUBER; CDNA; COMPLEMENTATION; INHIBITION	Uridine diphosphoglucose pyrophosphorylase (UDPGP) is a developmentally regulated enzyme in Dictyostelium discoideum, which is involved in trehalose, cellulose, and glycogen synthesis. Two independent UDPGP proteins are believed to be responsible for this activity. To determine the relative contributions of each protein, the genes encoding them were disrupted individually. Cells lacking the udpgp1 gene exhibit normal growth and development and make normal levels of cellulose. In agreement with these phenotypes, udpgp1(-) cells still have UDPGP activity, although at a reduced level. This supports the importance of the second UDPGP gene. This newly identified gene, ugpB, encodes an active UDPGP as determined by complementation in Escherichia coli. When this gene is disrupted, cells undergo aberrant differentiation and development ending with small, gnarled fruiting bodies. These cells also have decreased spore viability and decreased levels of glycogen, whose production requires UDPGP activity. These phenotypes suggest that UgpB constitutes the major UDPGP activity produced during development. Sequence analysis of the two UDPGP genes shows that UgpB has higher homology to other eukaryotic UDPGPs than does UDPGP1. This includes the presence of 5 conserved lysine residues. Udpgp1 only has 1 of these lysines.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Rice Univ, Howard Hughes Med Inst, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Amherst Coll, Dept Biol, Amherst, MA 01002 USA	City University of New York (CUNY) System; Hunter College (CUNY); Howard Hughes Medical Institute; Rice University; Amherst College	Brazill, DT (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.			Gomer, Richard/0000-0003-2361-4307	NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [S06-GM606564, S06 GM060654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTON TH, 1977, DEV BIOL, V60, P180, DOI 10.1016/0012-1606(77)90118-X; ASHWORTH JM, 1967, J BIOL CHEM, V242, P1696; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; Daran JM, 1997, FEMS MICROBIOL LETT, V153, P89, DOI 10.1016/S0378-1097(97)00240-1; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DIMOND RL, 1976, DEV BIOL, V50, P169, DOI 10.1016/0012-1606(76)90075-0; DOTTIN RP, 1991, DEV GENET, V12, P2, DOI 10.1002/dvg.1020120103; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; DYNES JL, 1994, GENE DEV, V8, P948, DOI 10.1101/gad.8.8.948; Eimert K, 1996, GENE, V170, P227, DOI 10.1016/0378-1119(95)00873-X; EMYANITOFF RG, 1979, J BACTERIOL, V140, P1008, DOI 10.1128/JB.140.3.1008-1012.1979; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FISHEL BR, 1985, DEV BIOL, V110, P369, DOI 10.1016/0012-1606(85)90096-X; GOMER RH, 1991, DEVELOPMENT, V112, P269; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; HARIBABU B, 1991, DEV GENET, V12, P35, DOI 10.1002/dvg.1020120108; HARIBABU B, 1986, DEV BIOL, V113, P436, DOI 10.1016/0012-1606(86)90178-8; HARIBABU B, 1986, MOL CELL BIOL, V6, P2402, DOI 10.1128/MCB.6.7.2402; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; KATSUBE T, 1991, BIOCHEMISTRY-US, V30, P8546, DOI 10.1021/bi00099a008; KAZUTA Y, 1991, BIOCHEMISTRY-US, V30, P8541, DOI 10.1021/bi00099a007; KLEIN G, 1990, EUR J BIOCHEM, V193, P135, DOI 10.1111/j.1432-1033.1990.tb19314.x; KONISHI Y, 1993, J BIOCHEM-TOKYO, V114, P61, DOI 10.1093/oxfordjournals.jbchem.a124141; KUSPA A, 1994, GENETICS, V138, P665; LOOMIS WF, 1993, CURR TOP DEV BIOL, V28, P1, DOI 10.1016/S0070-2153(08)60208-2; LOOMIS WF, 1975, DICTYOSTELIUM DISCOI, P47; MANROW RE, 1982, ANAL BIOCHEM, V120, P181, DOI 10.1016/0003-2697(82)90334-7; PANNBACK.RG, 1967, BIOCHEMISTRY-US, V6, P1283, DOI 10.1021/bi00857a008; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; RAGHEB JA, 1987, NUCLEIC ACIDS RES, V15, P3891, DOI 10.1093/nar/15.9.3891; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; SUSSMAN MA, 1964, P NATL ACAD SCI USA, V52, P503; UPDEGRAFF DM, 1969, ANAL BIOCHEM, V32, P420, DOI 10.1016/S0003-2697(69)80009-6; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; Wood SA, 1996, DEVELOPMENT, V122, P3677; WRIGHT BE, 1967, BIOCHEMISTRY-US, V6, P2074, DOI 10.1021/bi00859a026; ZRENNER R, 1993, PLANTA, V190, P247, DOI 10.1007/BF00196618	39	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32430	32437		10.1074/jbc.M204245200	http://dx.doi.org/10.1074/jbc.M204245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12060658	hybrid			2022-12-25	WOS:000177859000006
J	Lacana, E; Maceyka, M; Milstein, S; Spiegel, S				Lacana, E; Maceyka, M; Milstein, S; Spiegel, S			Cloning and characterization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GROWTH-FACTOR; INTRACELLULAR SPHINGOSINE-1-PHOSPHATE; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; 2ND MESSENGER; RECEPTOR; ACTIVATION; APOPTOSIS; 1-PHOSPHATE	Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that has novel dual actions. S1P is the ligand for a family of G protein-coupled receptors known as S1PRs that mediate various physiological functions. Growth factors rapidly activate sphingosine kinase type 1 (SPHK1) resulting in phosphorylation of sphingosine to form S1P, which plays important roles in cell growth regulation and protection from apoptosis. However, little is known of the mechanism(s) by which SPHK activity is regulated. Using a yeast two-hybrid screening approach, we cloned a 3-kb cDNA encoding a SPHK1-interacting protein (SKIP). BLAST analysis revealed that SKIP corresponded to the C-terminal region of a larger (similar to7 kb) cDNA that encoded a protein with a high degree of similarity to a family of protein kinase A anchor proteins (AKAP). In confirmation of the yeast two-hybrid assay, glutathione S-transferase (GST)-SPHK1 specifically pulled down SKIP, whereas GST did not. Moreover, immunoprecipitation of in vitro translated SPHK1 and SKIP revealed that SKIP and SPHK1 are tightly associated. Furthermore, SKIP overexpression in NIH 3T3 fibroblasts reduced SPHK1 activity and interfered with its biological functions. The apoptotic-sparing effect of SPHK1 against serum deprivation was reduced when co-transfected with SKIP. In addition, SPHK1-enhanced cell proliferation was also abolished by SKIP, with a corresponding decrease in activation of ERK. Taken together, these results indicate that SKIP is a novel protein likely to play a regulatory role in the modulation of SPHK1 activity.	Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Virginia Commonwealth University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Med Coll Virginia Campus, Richmond, VA 23298 USA.		Maceyka, Michael/B-9277-2008		NCI NIH HHS [R01 CA61774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Diviani D, 2001, J CELL SCI, V114, P1431; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Edsall LC, 1997, J NEUROSCI, V17, P6952; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Heringdorf DM, 1999, FEBS LETT, V461, P217, DOI 10.1016/S0014-5793(99)01463-5; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Kleuser B, 1998, CANCER RES, V58, P1817; Kleuser B, 2001, FEBS LETT, V503, P85, DOI 10.1016/S0014-5793(01)02697-7; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Nagase T, 2000, DNA RES, V7, P347, DOI 10.1093/dnares/7.6.347; Nava VE, 2000, CANCER RES, V60, P4468; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Reinton N, 2000, DEV BIOL, V223, P194, DOI 10.1006/dbio.2000.9725; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; van Koppen CJ, 2001, LIFE SCI, V68, P2535, DOI 10.1016/S0024-3205(01)01049-9; Vann LR, 2002, J BIOL CHEM, V277, P12649, DOI 10.1074/jbc.M109111200; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Vijayaraghavan S, 1999, MOL ENDOCRINOL, V13, P705, DOI 10.1210/me.13.5.705; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499	59	65	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32947	32953		10.1074/jbc.M202841200	http://dx.doi.org/10.1074/jbc.M202841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080051	hybrid			2022-12-25	WOS:000177859000073
J	Williams, SJ; Senaratne, RH; Mougous, JD; Riley, LW; Bertozzi, CR				Williams, SJ; Senaratne, RH; Mougous, JD; Riley, LW; Bertozzi, CR			5 '-adenosinephosphosulfate lies at a metabolic branch point in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-PHOSPHOSULFATE REDUCTASE; SULFATE ASSIMILATION; HIGHER-PLANTS; PENICILLIUM-CHRYSOGENUM; CYSTEINE BIOSYNTHESIS; APS REDUCTASE; TUBERCULOSIS; EXPRESSION; ADENOSINE-5'-PHOSPHOSULFATE; SULFOTRANSFERASE	Bacterial sulfate assimilation pathways provide for activation of inorganic sulfur for the biosynthesis of cysteine and methionine, through either adenosine 5% phosphosulfate (A-PS) or 3'-phosphoadenosine 5'-phosphosulfate (PAPS) as intermediates. PAPS is also the substrate for sulfotransferases that produce sulfolipids, putative virulence factors, in Mycobacterium tuberculosis such as SL-1. In this report, genetic complementation using Escherichia coli mutant strains deficient in APS kinase and PAPS reductase was used to define the M. tuberculosis and Mycobacterium smegmatis CysH enzymes as APS reductases. Consequently, the sulfate assimilation pathway of M. tuberculosis proceeds from sulfate through APS, which is acted on by APS reductase in the first committed step toward cysteine and methionine. Thus, M. tuberculosis most likely produces PAPS for the sole use of this organism's sulfotransferases. Deletion of CysH from M. smegmatis afforded a cysteine and methionine auxotroph consistent with a metabolic branch point centered on APS. In addition, we have redefined the substrate specificity of the R subtilis CysH, formerly designated a PAPS reductase, as an APS reductase, based on its ability to complement a mutant E. coli strain deficient in APS kinase. Together, these studies show that two conserved sequence motifs, CCXXRKXXPL and SXGCXXCT, found in the C termini of all APS reductases, but not in PAPS reductases, may be used to predict the substrate specificity of these enzymes. A functional domain of the M. tuberculosis CysC protein was cloned and expressed in E. coli, confirming the ability of this organism to make PAPS. The expression of recombinant M. tuberculosis APS kinase provides a means for the discovery of inhibitors of this enzyme and thus of the biosynthesis of SL-1.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	bertozzi@cchem.berkeley.edu	Williams, Spencer/C-3545-2009	Williams, Spencer/0000-0001-6341-4364	NIAID NIH HHS [AI51622] Funding Source: Medline; NIGMS NIH HHS [GM59907] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059907] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abola AP, 1999, J BACTERIOL, V181, P5280, DOI 10.1128/JB.181.17.5280-5287.1999; Bick JA, 2000, J BACTERIOL, V182, P135, DOI 10.1128/JB.182.1.135-142.2000; Bick JA, 1998, CURR OPIN PLANT BIOL, V1, P240, DOI 10.1016/S1369-5266(98)80111-8; Bick JA, 1998, P NATL ACAD SCI USA, V95, P8404, DOI 10.1073/pnas.95.14.8404; Bowman KG, 1999, CHEM BIOL, V6, pR9, DOI 10.1016/S1074-5521(99)80014-3; Brennan PJ, 2001, LEPROSY REV, V72, P415; BURNELL JN, 1975, ANAL BIOCHEM, V68, P281, DOI 10.1016/0003-2697(75)90706-X; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Gao Y, 2000, PLANT PHYSIOL, V123, P1087, DOI 10.1104/pp.123.3.1087; Glascock CB, 1998, GENE, V223, P221, DOI 10.1016/S0378-1119(98)00240-6; Glickman MS, 2001, CELL, V104, P477, DOI 10.1016/S0092-8674(01)00236-7; GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P116, DOI 10.1016/0005-2760(70)90067-6; GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P127, DOI 10.1016/0005-2760(70)90068-8; GOREN MB, 1974, INFECT IMMUN, V9, P142, DOI 10.1128/IAI.9.1.142-149.1974; GREENE RC, 1996, ESCHERICHIA COLI SAL, P542; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; Jeevan A, 2002, INFECT IMMUN, V70, P1245, DOI 10.1128/IAI.70.3.1245-1253.2002; Khoo KH, 1999, J BIOL CHEM, V274, P9778, DOI 10.1074/jbc.274.14.9778; Kopriva S, 2002, J BIOL CHEM, V277, P21786, DOI 10.1074/jbc.M202152200; Kopriva S, 2001, J BIOL CHEM, V276, P42881, DOI 10.1074/jbc.M107424200; Kredich N.M., 1996, ESCHERICHIA COLI SAL, P514; LEATHERBARROW RJ, 2001, GRAFIT VERSION 4 0; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LIU CX, 1994, BIOCHEMISTRY-US, V33, P7309, DOI 10.1021/bi00189a036; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; Mansilla MC, 1997, J BACTERIOL, V179, P976, DOI 10.1128/jb.179.3.976-981.1997; MARIN LML, 1992, BIOCHEMISTRY-US, V31, P11106, DOI 10.1021/bi00160a021; MIDDLEBROOK G, 1959, P NATL ACAD SCI USA, V45, P1801, DOI 10.1073/pnas.45.12.1801; Parish T, 2000, MICROBIOL-SGM, V146, P1969, DOI 10.1099/00221287-146-8-1969; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; Rivera-Marrero CA, 2002, MICROBIOL-SGM, V148, P783, DOI 10.1099/00221287-148-3-783; Rothschild BM, 2001, CLIN INFECT DIS, V33, P305, DOI 10.1086/321886; Satishchandran C, 2000, ARCH BIOCHEM BIOPHYS, V378, P210, DOI 10.1006/abbi.2000.1841; Setya A, 1996, P NATL ACAD SCI USA, V93, P13383, DOI 10.1073/pnas.93.23.13383; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Suter M, 2000, J BIOL CHEM, V275, P930, DOI 10.1074/jbc.275.2.930; Weber M, 2000, EUR J BIOCHEM, V267, P3647, DOI 10.1046/j.1432-1327.2000.01394.x; Wei J, 2000, BIOCHEMISTRY-US, V39, P4704, DOI 10.1021/bi992210y; Wray JL, 1998, CHEM-BIOL INTERACT, V109, P153, DOI 10.1016/S0009-2797(97)00130-0; Zink A, 2001, J MED MICROBIOL, V50, P355, DOI 10.1099/0022-1317-50-4-355	41	73	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32606	32615		10.1074/jbc.M204613200	http://dx.doi.org/10.1074/jbc.M204613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12072441	hybrid			2022-12-25	WOS:000177859000029
J	Bellamy, TC; Griffiths, C; Garthwaite, J				Bellamy, TC; Griffiths, C; Garthwaite, J			Differential sensitivity of guanylyl cyclase and mitochondrial respiration to nitric oxide measured using clamped concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-OXIDASE; INHIBITION; ACTIVATION; RAT; NO; CEREBELLUM; MESSENGER; DYNAMICS; KINETICS; RECEPTOR	Nitric oxide (NO) signal transduction may involve at least two targets: the guanylyl cyclase-coupled NO receptor (NOGCR), which catalyzes cGMP formation, and cytochrome c oxidase, which is responsible for mitochondrial O-2 consumption and which is inhibited by NO in competition with O-2. Current evidence indicates that the two targets may be similarly sensitive to NO, but quantitative comparison has been difficult because of an inability to administer NO in known, constant concentrations. We addressed this deficiency and found that purified NOGCR was about 100-fold more sensitive to NO than reported previously, 50% of maximal activity requiring only 4 nm NO. Conversely, at physiological O-2 concentrations (20-30 muM), mitochondrial respiration was 2-10-fold less sensitive to NO than estimated beforehand. The two concentration-response curves showed minimal overlap. Accordingly, an NO concentration maximally active on the NOGCR (20 nm) inhibited respiration only when the O-2 concentration was pathologically low (50% inhibition at 5 muM O-2). Studies on brain slices under conditions of maximal stimulation of endogenous NO synthesis suggested that the local NO concentration did not rise above 4 nm. It is concluded that under physiological conditions, at least in brain, NO is constrained to target the NOGCR without inhibiting mitochondrial respiration.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Garthwaite, J (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	john.garthwaite@ucl.ac.uk		Bellamy, Tomas/0000-0003-0204-7366				Artz JD, 2001, BIOCHEMISTRY-US, V40, P9256, DOI 10.1021/bi002885x; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; Bellamy TC, 2002, P NATL ACAD SCI USA, V99, P507, DOI 10.1073/pnas.012368499; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; De Visscher G, 2002, J CEREBR BLOOD F MET, V22, P515, DOI 10.1097/00004647-200205000-00002; DEVENTE J, 1990, EUR J NEUROSCI, V2, P845; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Griffiths C, 2001, J PHYSIOL-LONDON, V536, P855, DOI 10.1111/j.1469-7793.2001.00855.x; Griffiths C, 2002, EUR J NEUROSCI, V15, P962, DOI 10.1046/j.1460-9568.2002.01930.x; Griffiths C, 2002, BIOCHEM J, V362, P459, DOI 10.1042/0264-6021:3620459; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; Koivisto A, 1997, FEBS LETT, V417, P75, DOI 10.1016/S0014-5793(97)01258-1; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Parkinson SJ, 1999, BIOCHEMISTRY-US, V38, P6441, DOI 10.1021/bi990154v; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Schrammel A, 1996, MOL PHARMACOL, V50, P1; SOUTHAM E, 1991, J NEUROCHEM, V56, P2072, DOI 10.1111/j.1471-4159.1991.tb03468.x; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.98.1.355; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1; WOOD PL, 1991, PHARMACOL REV, V43, P1; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhelyaskov VR, 1999, NITRIC OXIDE-BIOL CH, V3, P419, DOI 10.1006/niox.1999.0253	37	106	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31801	31807		10.1074/jbc.M205936200	http://dx.doi.org/10.1074/jbc.M205936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080082	hybrid			2022-12-25	WOS:000177718700063
J	Kim, JT; Joo, CK				Kim, JT; Joo, CK			Involvement of cell-cell interactions in the rapid stimulation of Cas tyrosine phosphorylation and Src kinase activity by transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR; E-CADHERIN; DIRECT BINDING; ACTIN ORGANIZATION; V-SRC; P130(CAS); PROTEIN; ACTIVATION; CRK	Transforming growth factor-beta (TGF-beta) regulates a wide range of physiological and pathological cellular processes, including cell migration, mesenchymal transition, extracellular matrix synthesis, and cell death. Cas (Crk-associated substrate, 130 kDa), an adaptor protein localized at focal adhesions and stress fibers, is also known to have important functions in cell migration and the induction of immediate-early gene expression. Here, we report that a rapid and transient tyrosine phosphorylation of Cas is induced by TGF-beta1 and that E-cadherin-mediated cell-cell interaction and the Src kinase pathway are involved in this early TGF-beta signaling. The addition of TGF-beta1 to epithelial cells rapidly induced tyrosine phosphorylation of Cas and promoted the formation of complexes between focal adhesion molecules. Cas phosphorylation required the integrity of the actin cytoskeleton but was not dependent on cell adhesion, implying that Cas-dependent signaling may be distinct from integrin signaling. TGF-beta1 also stimulated Src kinase activity, and specific inhibitors of Src completely blocked the induction of Cas phosphorylation by TGF-beta1. The Cas phosphorylation and Src kinase activation seen in our results were induced in an epithelial phenotype-specific manner. Stable transfection of E-cadherin to L929 cells and L cells as well as E-cadherin blocking assay revealed that E-cadherin-mediated cell-cell interactions were essential for both Cas phosphorylation and Src kinase activation. Taken together, our data suggest that rapid Cas phosphorylation and Src kinase activation may play a novel role in TGF-beta signal transduction.	Catholic Univ Korea, Coll Med, Lab Ophthalmol & Visual Sci, Seocho Ku, Seoul, South Korea; Catholic Res Inst Med Sci, Seoul 137040, South Korea	Catholic University of Korea; Catholic University of Korea	Joo, CK (corresponding author), Catholic Univ Korea, Coll Med, Lab Ophthalmol & Visual Sci, Seocho Ku, 505 Banpo Dong, Seoul, South Korea.	ckjoo@catholic.ac.kr						ALEXANDROW MG, 1995, CANCER RES, V55, P3928; Astier A, 1997, J BIOL CHEM, V272, P228; ATFI A, 1994, J BIOL CHEM, V269, P30688; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Boland S, 1996, J CELL SCI, V109, P2207; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen HY, 1997, J CELL SCI, V110, P345; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fukuda K, 1998, ONCOGENE, V16, P3349, DOI 10.1038/sj.onc.1201896; Fukuda K, 1998, HEPATOLOGY, V28, P796, DOI 10.1002/hep.510280329; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Jester JV, 1999, INVEST OPHTH VIS SCI, V40, P1959; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Johansson N, 2000, J CELL SCI, V113, P227; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; ROZENGURT E, 1995, CANCER SURV, V24, P81; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369	74	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31938	31948		10.1074/jbc.M201178200	http://dx.doi.org/10.1074/jbc.M201178200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12065577	hybrid			2022-12-25	WOS:000177718700080
J	Lartigue, A; Campanacci, V; Roussel, A; Larsson, AM; Jones, TA; Tegoni, M; Cambillau, C				Lartigue, A; Campanacci, V; Roussel, A; Larsson, AM; Jones, TA; Tegoni, M; Cambillau, C			X-ray structure and ligand binding study of a moth chemosensory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; PHEROMONE-BINDING; 3-DIMENSIONAL STRUCTURE; MAMESTRA-BRASSICAE; ANTHERAEA-POLYPHEMUS; CRYSTAL-STRUCTURE; SEQUENCE; LOCALIZATION; PURIFICATION; CLONING	Chemosensory proteins (CSPs) are believed to be involved in chemical communication and perception. Such proteins, of M-r 13,000, have been isolated from several sensory organs of a wide range of insect species. Several CSPs have been identified in the antennae and proboscis of the moth Mamestra brassicae. One of them, CSPMbraA6, a 112-amino acid antennal protein, has been expressed in large quantities and is soluble in the Escherichia coli periplasm. X-ray structure determination has been performed in parallel with ligand binding assays using tryptophan fluorescence quenching. The protein has overall dimensions of 25 x 30 x 32 Angstrom and exhibits a novel type of alpha-helical fold with six helices connected by alpha-alpha loops. A narrow channel extends within the protein hydrophobic core. Fluorescence quenching with brominated alkyl alcohols or fatty acids and modeling studies indicates that CSPMbraA6 is able to bind such compounds with C12-18 alkyl chains. These ubiquitous proteins might have the role of extracting hydrophobic linear compounds (pheromones, odors, or fatty acids) dispersed in the phospholipid membrane and transporting them to their receptor.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Uppsala University	Cambillau, C (corresponding author), CNRS, UMR 6098, 31 Chemin J Aiguier, F-13402 Marseille 20, France.	tegoni@afmb.cnrs-mrs.fr; cambillau@afmb.cnrs-mrs.fr		Campanacci, Valerie/0000-0001-6407-6395				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Angeli S, 1999, EUR J BIOCHEM, V262, P745, DOI 10.1046/j.1432-1327.1999.00438.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balendiran GK, 2000, J BIOL CHEM, V275, P27045; Bette S, 2002, INSECT BIOCHEM MOLEC, V32, P241, DOI 10.1016/S0965-1748(01)00171-0; Bohbot J, 1998, BIOCHEM BIOPH RES CO, V253, P489, DOI 10.1006/bbrc.1998.9806; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campanacci V, 2001, J BIOL CHEM, V276, P20078, DOI 10.1074/jbc.M100713200; Campanacci V, 2001, EUR J BIOCHEM, V268, P4731, DOI 10.1046/j.1432-1327.2001.02398.x; Campanacci V, 2001, ACTA CRYSTALLOGR D, V57, P137, DOI 10.1107/S0907444900013822; CHRISTOPHER JA, 1998, SPOCK MANUAL; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; deForesta B, 1996, EUR J BIOCHEM, V241, P343; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; DYANOV HM, 1995, BIOTECHNIQUES, V18, P822; Flower DR, 1996, BIOCHEM J, V318, P1; GINCEL E, 1994, EUR J BIOCHEM, V226, P413, DOI 10.1111/j.1432-1033.1994.tb20066.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horst R, 2001, P NATL ACAD SCI USA, V98, P14374, DOI 10.1073/pnas.251532998; Jacquin-Joly E, 2001, CHEM SENSES, V26, P833, DOI 10.1093/chemse/26.7.833; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maleszka R, 1997, GENE, V202, P39, DOI 10.1016/S0378-1119(97)00448-4; Marchese S, 2000, INSECT BIOCHEM MOLEC, V30, P1091, DOI 10.1016/S0965-1748(00)00084-9; Nagnan-Le Meillour P, 2000, CHEM SENSES, V25, P541, DOI 10.1093/chemse/25.5.541; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NOMURA A, 1992, INT J DEV BIOL, V36, P391; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAESEN GC, 1995, INSECT BIOCHEM MOLEC, V25, P401, DOI 10.1016/0965-1748(94)00085-V; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Picimbon JF, 2000, INSECT BIOCHEM MOLEC, V30, P233, DOI 10.1016/S0965-1748(99)00121-6; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; Ramon R, 2001, J BIOL CHEM, V276, P7150, DOI 10.1074/jbc.M010368200; Ravelli RBG, 1997, J APPL CRYSTALLOGR, V30, P551, DOI 10.1107/S0021889897003543; Robertson HM, 1999, INSECT MOL BIOL, V8, P501, DOI 10.1046/j.1365-2583.1999.00146.x; Rothemund S, 1999, STRUCT FOLD DES, V7, P1325, DOI 10.1016/S0969-2126(00)80022-2; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V81, P77; Sandler BH, 2000, CHEM BIOL, V7, P143, DOI 10.1016/S1074-5521(00)00078-8; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; STEINBRECHT RA, 1995, CELL TISSUE RES, V282, P203, DOI 10.1007/BF00319112; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	43	126	157	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32094	32098		10.1074/jbc.M204371200	http://dx.doi.org/10.1074/jbc.M204371200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12068017	hybrid			2022-12-25	WOS:000177718700099
J	Marsche, G; Hammer, A; Oskolkova, O; Kozarsky, KF; Sattler, W; Malle, E				Marsche, G; Hammer, A; Oskolkova, O; Kozarsky, KF; Sattler, W; Malle, E			Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN ATHEROSCLEROTIC LESIONS; MODIFIED PROTEINS; SR-BI; GENERATED HYPOCHLORITE; CELLULAR CHOLESTEROL; ENDOTHELIAL-CELLS; OXIDIZED LDL; RAT-LIVER; EFFLUX	Hypochlorous acid/hypochlorite (HOCl/OCl-), a potent oxidant generated in vivo by the myeloperoxidase-H2O2-chloride system of activated phagocytes, alters the physiological properties of high density lipoprotein (HDL) by generating a proatherogenic lipoprotein particle. On endothelial cells lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) and scavenger receptor class B, type I (SR-BI), act in concert by mediating the holoparticle of and selective cholesteryl ester uptake from HOCl-HDL. We therefore investigated the ligand specificity of HOCl-HDL to SR-BI-overexpressing Chinese hamster ovary cells. Binding of HOCl-HDL was saturable, and the degree of HOCl modification was the determining factor for increased binding affinity to SR-BI. Competition experiments further confirmed that HOCl-HDL binds with increased affinity to the same or overlapping domain(s) of SR-BI as does native HDL. Furthermore, SR-BI-mediated selective HDL-cholesteryl ester association as well as time- and concentration-dependent cholesterol efflux from SR-BI overexpressing Chinese hamster ovary cells were, depending on the degree of HOCl modification of HDL, markedly impaired. The most significant findings of this study were that the presence of very low concentrations of HOCl-HDL severely impaired SR-BI-mediated bidirectional cholesterol flux mediated by native HDL. The colocalization of immunoreactive HOCl-modified epitopes with apolipoprotein A-I along with deposits of lipids in serial sections of human atheroma shown here indicates that the myeloperoxidase-H2O2-halide system contributes to oxidative damage of HDL in vivo.	Karl Franzens Univ Graz, Inst Med Biochem & Mol Biol, A-8010 Graz, Austria; Karl Franzens Univ Graz, Inst Histol & Embryol, A-8010 Graz, Austria; Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria; GlaxoSmithKline, King Of Prussia, PA 19406 USA	University of Graz; University of Graz; Graz University of Technology; GlaxoSmithKline	Malle, E (corresponding author), Karl Franzens Univ Graz, Inst Med Biochem & Mol Biol, Harrachgasse 21, A-8010 Graz, Austria.	ernst.malle@kfunigraz.ac.at	Malle, Ernst/D-3071-2013	Oskolkova, Olga/0000-0001-9443-8705; Marsche, Gunther/0000-0002-2422-5381				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; BANKA CL, 1994, J BIOL CHEM, V269, P10288; Bergt C, 1999, FEBS LETT, V452, P295, DOI 10.1016/S0014-5793(99)00677-8; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Bonnefont-Rousselot D, 1999, CLIN CHEM LAB MED, V37, P939, DOI 10.1515/CCLM.1999.139; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BRAESEN JH, 2002, IN PRESS ATHEROSCLER; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; Brown KE, 2001, AM J PATHOL, V159, P2081, DOI 10.1016/S0002-9440(10)63059-3; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; de Beer MC, 2001, J LIPID RES, V42, P309; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; Fluiter K, 1999, J BIOL CHEM, V274, P8893, DOI 10.1074/jbc.274.13.8893; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Grone HJ, 2002, LAB INVEST, V82, P5, DOI 10.1038/labinvest.3780390; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Hammer A, 2001, LAB INVEST, V81, P543, DOI 10.1038/labinvest.3780263; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hirano K, 1999, CIRC RES, V85, P108; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P167, DOI 10.1016/0005-2760(92)90287-6; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KATRANTZIS M, 1991, FREE RADICAL BIO MED, V10, P101, DOI 10.1016/0891-5849(91)90003-L; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Kopprasch S, 1998, ATHEROSCLEROSIS, V136, P315, DOI 10.1016/S0021-9150(97)00233-5; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LIAO LX, 1995, ARTERIOSCL THROM VAS, V15, P2305, DOI 10.1161/01.ATV.15.12.2305; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCHOOMUN J, 1994, BBA-LIPID LIPID MET, V1212, P319, DOI 10.1016/0005-2760(94)90206-2; Malerod L, 2002, CELL TISSUE RES, V307, P173, DOI 10.1007/s00441-001-0476-9; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; Malle E, 1997, AM J PATHOL, V150, P603; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Malle E, 2001, BIOCHEM BIOPH RES CO, V289, P894, DOI 10.1006/bbrc.2001.6074; Marcinkiewicz J, 1997, IMMUNOL TODAY, V18, P577, DOI 10.1016/S0167-5699(97)01161-4; Marsche G, 2001, FASEB J, V15, P1095, DOI 10.1096/fj.00-0532fje; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; Opper C, 1998, PLATELETS, V9, P339, DOI 10.1080/09537109876582; Panzenboeck U, 1997, J BIOL CHEM, V272, P29711, DOI 10.1074/jbc.272.47.29711; PETTY MA, 1990, EUR J PHARMACOL, V180, P119, DOI 10.1016/0014-2999(90)90599-2; Rothblat GH, 1999, J LIPID RES, V40, P781; Sas B, 1999, J CHROMATOGR A, V864, P179, DOI 10.1016/S0021-9673(99)01025-0; Sattler W, 1996, LIPIDS, V31, P1303, DOI 10.1007/BF02587917; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SATTLER W, 1991, ANAL BIOCHEM, V198, P184, DOI 10.1016/0003-2697(91)90526-Y; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Scheuer H, 2000, AM J PHYSIOL-RENAL, V278, pF63, DOI 10.1152/ajprenal.2000.278.1.F63; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; SINN HJ, 1988, ANAL BIOCHEM, V170, P186, DOI 10.1016/0003-2697(88)90107-8; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Stein O, 1999, ATHEROSCLEROSIS, V144, P285, DOI 10.1016/S0021-9150(99)00065-9; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; Thomas E L, 1986, Methods Enzymol, V132, P585; UMEDA Y, 1995, AM J PHYSIOL-GASTR L, V268, pG709, DOI 10.1152/ajpgi.1995.268.4.G709; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Woenckhaus C, 1998, CLIN IMMUNOL IMMUNOP, V86, P27, DOI 10.1006/clin.1997.4453; Zabe M, 1999, CELL CALCIUM, V26, P281, DOI 10.1054/ceca.1999.0081	67	99	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32172	32179		10.1074/jbc.M200503200	http://dx.doi.org/10.1074/jbc.M200503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070141	hybrid			2022-12-25	WOS:000177718700109
J	Pathak, HB; Ghosh, SKB; Roberts, AW; Sharma, SD; Yoder, JD; Arnold, JJ; Gohara, DW; Barton, DJ; Paul, AV; Cameron, CE				Pathak, HB; Ghosh, SKB; Roberts, AW; Sharma, SD; Yoder, JD; Arnold, JJ; Gohara, DW; Barton, DJ; Paul, AV; Cameron, CE			Structure-function relationships of the RNA-dependent RNA polymerase from poliovirus (3Dpol) - A surface of the primary oligomerization domain functions in capsid precursor processing and VPg uridylylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTING REPLICATION ELEMENT; IN-VITRO; 3D(POL); IDENTIFICATION; INITIATION; COMPLEX; CIS; TEMPLATE; REQUIRES; CLEAVAGE	The primary oligomerization domain of poliovirus polymerase, 3Dpol, is stabilized by the interaction of the back of the thumb subdomain of one molecule with the back of the palm subdomain of a second molecule, thus permitting the head-to-tail assembly of 3Dpol monomers into long fibers. The interaction of Arg-455 and Arg-456 of the thumb with Asp-339, Ser-341, and Asp-349 of the palm is key to the stability of this interface. We show that mutations predicted to completely disrupt this interface do not produce equivalent growth phenotypes. Virus encoding a polymerase with changes of both residues of the thumb to alanine is not viable; however, virus encoding a polymerase with changes of all three residues of the palm to alanine is viable. Biochemical analysis of 3Dpol derivatives containing the thumb or palm substitutions revealed that these derivatives are both incapable of forming long fibers, suggesting that polymerase fibers are not essential for virus viability. The RNA binding activity, polymerase activity, and thermal stability of these derivatives were equivalent to that of the wild-type enzyme. The two significant differences observed for the thumb mutant were a modest reduction in the ability of the altered 3CD proteinase to process the VP0/VP3 capsid precursor and a substantial reduction in the ability of the altered 3Dpol to catalyze oriI-templated uridylylation of VPg. The defect to uridylylation was a result of the inability of 3CD to stimulate this reaction. Because 3C alone can substitute for 3CD in this reaction, we conclude that the lethal replication phenotype associated with the thumb mutant is caused, in part, by the disruption of an interaction between the back of the thumb of 3Dpol and some undefined domain of 3C. We speculate that this interaction may also be critical for assembly of other complexes required for poliovirus genome replication.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.		SHARMA, Suresh/C-4431-2008; Ghosh, Saikat/AAD-1176-2022; SHARMA, Suresh D./AAD-7723-2022	SHARMA, Suresh/0000-0002-8633-4145; SHARMA, Suresh D./0000-0002-8633-4145; Gohara, David/0000-0001-8799-9125	NCI NIH HHS [CA75118] Funding Source: Medline; NIAID NIH HHS [AI42189, AI45818] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042189, R56AI042189, R21AI042189, R01AI045818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Arnold JJ, 1999, J BIOL CHEM, V274, P2706, DOI 10.1074/jbc.274.5.2706; Barton DJ, 1997, J VIROL, V71, P8482, DOI 10.1128/JVI.71.11.8482-8489.1997; Barton DJ, 1996, METHOD ENZYMOL, V275, P35; Barton DJ, 2001, EMBO J, V20, P1439, DOI 10.1093/emboj/20.6.1439; Beckman MTL, 1998, J BIOL CHEM, V273, P6724, DOI 10.1074/jbc.273.12.6724; BLAIR WS, 1993, J VIROL, V67, P2336, DOI 10.1128/JVI.67.4.2336-2343.1993; Carroll SS, 1996, METHOD ENZYMOL, V275, P365; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Gerber K, 2001, J VIROL, V75, P10979, DOI 10.1128/JVI.75.22.10979-10990.2001; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; Hobson SD, 2001, EMBO J, V20, P1153, DOI 10.1093/emboj/20.5.1153; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JARVIS TC, 1992, EMBO J, V11, P3135, DOI 10.1002/j.1460-2075.1992.tb05386.x; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; KRAUSSLICH HG, 1990, J VIROL, V64, P2433; Lyons T, 2001, J VIROL, V75, P10696, DOI 10.1128/JVI.75.22.10696-10708.2001; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; PATA JD, 1995, RNA, V1, P466; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Rieder E, 2000, J VIROL, V74, P10371, DOI 10.1128/JVI.74.22.10371-10380.2000; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Xiang WK, 1997, SEMIN VIROL, V8, P256, DOI 10.1006/smvy.1997.0128; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998	39	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31551	31562		10.1074/jbc.M204408200	http://dx.doi.org/10.1074/jbc.M204408200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077141	hybrid			2022-12-25	WOS:000177718700034
J	Prisco, M; Santini, F; Baffa, R; Liu, ML; Drakas, R; Wu, A; Baserga, R				Prisco, M; Santini, F; Baffa, R; Liu, ML; Drakas, R; Wu, A; Baserga, R			Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAINS; ID2 GENE-EXPRESSION; LARGE TUMOR-ANTIGEN; PLECKSTRIN HOMOLOGY; POSTNATAL-GROWTH; CELL; PROTEIN; APOPTOSIS; LOCALIZATION	32D cells are a murine hemopoietic cell line that undergoes apoptosis upon withdrawal of interleukin-3 (IL-3) from the medium. 32D cells have low levels of the type 1 insulin-like growth factor (IGF-I) receptor and do not express insulin receptor substrate-1 (IRS-1) or IRS-2. Ectopic expression of IRS-1 delays apoptosis but cannot rescue 32D cells from IL-3 dependence. In 32D/IRS-1 cells, IRS-1 is detectable, as expected, in the cytosol/membrane compartment. The SV40 large T antigen is a nuclear protein that, by itself, also fails to protect 32D cells from apoptosis. Co-expression of IRS-1 with the SV40 T antigen in 32D cells results in nuclear translocation of IRS-1 and survival after IL-3 withdrawal. Expression of a human IGF-I receptor in 32D/IRS-1 cells also results in nuclear translocation of IRS-1 and IL-3 independence. The phosphotyrosine-binding domain, but not the pleckstrin domain, is necessary for IRS-1 nuclear translocation. Nuclear translocation of IRS-1 was confirmed in mouse embryo fibroblasts. These results suggest possible new roles for nuclear IRS-1 in IGF-I-mediated growth and anti-apoptotic signaling.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	R_baserga@lac.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA089640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020956] Funding Source: NIH RePORTER; NCI NIH HHS [CA089640] Funding Source: Medline; NIA NIH HHS [AG20956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASKEW DS, 1991, ONCOGENE, V6, P1915; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; COHEN LS, 1967, J CELL PHYSIOL, V69, P331, DOI 10.1002/jcp.1040690309; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; FUKUDA M, 1953, J BIOCHEM, V40, P95, DOI 10.1093/oxfordjournals.jbchem.a126356; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; Jacobs AR, 2001, J BIOL CHEM, V276, P40795, DOI 10.1074/jbc.M105194200; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Kabuta T, 2002, J BIOL CHEM, V277, P6846, DOI 10.1074/jbc.M107058200; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Navarro M, 2001, ENDOCRINOLOGY, V142, P5149, DOI 10.1210/en.142.12.5149; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Prisco M, 2001, MOL CELL BIOL, V21, P5447, DOI 10.1128/MCB.21.16.5447-5458.2001; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; SANTOS M, 1982, J CELL BIOCHEM, V19, P127, DOI 10.1002/jcb.240190204; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Winnay JN, 2000, J BIOL CHEM, V275, P10545, DOI 10.1074/jbc.275.14.10545; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	59	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32078	32085		10.1074/jbc.M204658200	http://dx.doi.org/10.1074/jbc.M204658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12063262	hybrid			2022-12-25	WOS:000177718700097
J	Suetomi, K; Rojo, D; Navarro, J				Suetomi, K; Rojo, D; Navarro, J			Identification of a signal transduction switch in the chemokine receptor CXCR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-8 RECEPTOR; AMINO TERMINUS; BINDING SITES; ACTIVATION; DISEASE; MECHANISMS; CELLS; HIV-1; ROLES; IL-8	Chemokine receptors belong to the superfamily of G protein-coupled receptors, which regulate the trafficking and activation of leukocytes, and operate as coreceptors in the entry of HIV-1. To investigate the early steps in the signal transmission from the chemokinebinding site to the G protein-coupling region we engineered metal ion-binding sites at putative extracellular sites in the chemokine receptor CXCR1. We introduced histidines into sites located in the second and third putative extracellular loops of CXCR1, creating single, double, and triple mutant receptors: R199H, R203H, D265H, R199H/R203H, R199H/D265H, R203H/D265H, R203H/H207Q, and R199H/R203H/D265H. Cells expressing the double mutants R199H/D265H and R203H/D265H and the triple mutant R199H/R203H/D265H failed to trigger interleukin 8-dependent calcium responses. Interestingly, calcium responses mediated by the single mutant R203H and the double mutants R199H/R203H and R203H/H207Q were blocked by Zn(II), indicating the creation of a functional metal ion-binding site. On the other hand, cells expressing all single, double, or triple histidine-substituted CXCR1 demonstrated high affinity binding to interleukin 8 in the presence and absence of metal ions. These findings indicate that occupation of the engineered metal-binding site uncouples the chemokine-binding site from the activation mechanism in CXCR1. Most importantly, we identify for the first time elements of an early signal transduction switch of chemokine receptors before the activation of cytoplasmic G proteins.	Univ Texas, Med Branch, Membrane Prot Lab, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Navarro, J (corresponding author), Univ Texas, Med Branch, Membrane Prot Lab, Dept Physiol & Biophys, Galveston, TX 77555 USA.			Navarro, Javier/0000-0001-7098-4373	NIAID NIH HHS [AI34031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034031] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; Guo ZH, 2000, SCIENCE, V288, P2042, DOI 10.1126/science.288.5473.2042; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; Kunkel SL, 1996, J LEUKOCYTE BIOL, V59, P6, DOI 10.1002/jlb.59.1.6; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Shao WP, 1998, BIOCHEMISTRY-US, V37, P8303, DOI 10.1021/bi980112r; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Siveke JT, 1998, J IMMUNOL, V160, P550; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; STRADER CD, 1988, J BIOL CHEM, V263, P10267; Suetomi K, 1999, J BIOL CHEM, V274, P11768, DOI 10.1074/jbc.274.17.11768; SUZUKI H, 1994, J BIOL CHEM, V269, P18263; Teran LM, 2000, IMMUNOL TODAY, V21, P235, DOI 10.1016/S0167-5699(00)01634-0; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; Wells TNC, 1999, INFLAMM RES, V48, P353, DOI 10.1007/s000110050472; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202	30	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31563	31566		10.1074/jbc.M204713200	http://dx.doi.org/10.1074/jbc.M204713200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077146	hybrid			2022-12-25	WOS:000177718700035
J	Uramoto, H; Izumi, H; Ise, T; Tada, M; Uchiumi, T; Kuwano, M; Yasumoto, K; Funa, K; Kohno, K				Uramoto, H; Izumi, H; Ise, T; Tada, M; Uchiumi, T; Kuwano, M; Yasumoto, K; Funa, K; Kohno, K			p73 interacts with c-Myc to regulate Y-box-binding protein-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGING AGENTS; TRANSCRIPTIONAL ACTIVATION; APOPTOTIC RESPONSE; CELL-PROLIFERATION; P53; GENE; FAMILY; MAX; P73-ALPHA; CISPLATIN	YB-1 is a member of the cold shock domain family of proteins that is important for signaling DNA damage and cell proliferation. YB-1 is induced by DNA damage and can also recognize cisplatin-modified DNA. In this study we observed a 6-fold increase in the steady-state level of YB-1 mRNA in response to cisplatin exposure in cells of the human cancer cell line KB. We present evidence from cotransfection experiments for a critical role of c-Myc and p73 in the transactivation of the YB-1 promoter. p73 transactivated the YB-1 promoter in experiments with Saos-2 cells, which express c-Myc, but not with HO15.19 cells, which lack c-Myc. In turn, c-Myc transactivated an intact YB-1 promoter but not a YB-1 promoter with a mutant E-box, indicating that the E-box is necessary for the response of the promoter to cisplatin. We also found that p73 interacts with c-Myc in vitro and in vivo. Using deletion mutants we showed that the DNA-binding domain of p,73 and the C-terminal region of c-Myc are required for the interaction. Furthermore, p73 stimulated the interaction of Max with c-Myc and promoted binding of the c-Myc-Max complex to its target DNA. Our data suggest that p73 stimulates the transcription of the YB-1 promoter by enhancing recruitment of the c-Myc-Max complex to the E-box.	Univ Occupat & Environm Hlth, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Hokkaido Univ, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Kyushu Univ, Dept Med Biochem, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan; Univ Occupat & Environm Hlth, Dept Surg 2, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Gothenburg, Dept Cell Biol, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden	University of Occupational & Environmental Health - Japan; Hokkaido University; Kyushu University; University of Occupational & Environmental Health - Japan; University of Gothenburg	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.		Nagata, Satoshi/B-5781-2008					Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Agami R, 1999, NATURE, V399, P809; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Eastman A., 1999, CISPLATIN CHEM BIOCH, P111, DOI [DOI 10.1002/9783906390420.CH4, 10.1002/9783906390420.ch4]; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gong JG, 1999, NATURE, V399, P806; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ise T, 1999, CANCER RES, V59, P342; Izumi H, 2001, J CELL SCI, V114, P1533; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Levenson VV, 2000, CANCER RES, V60, P5027; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Makino Y, 1996, NUCLEIC ACIDS RES, V24, P1873, DOI 10.1093/nar/24.10.1873; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Oren M., 1996, BIOCHIM BIOPHYS ACTA, V1288, P13, DOI DOI 10.1016/S0304-419X(96)00030-3; Ozaki T, 1999, CANCER RES, V59, P5902; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Takayama M, 2000, FEBS LETT, V477, P43, DOI 10.1016/S0014-5793(00)01756-7; Vikhanskaya F, 2001, CANCER RES, V61, P935; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200	51	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31694	31702		10.1074/jbc.M200266200	http://dx.doi.org/10.1074/jbc.M200266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080043	hybrid			2022-12-25	WOS:000177718700050
J	Carr, HS; George, GN; Winge, DR				Carr, HS; George, GN; Winge, DR			Yeast Cox11, a protein essential for cytochrome c oxidase assembly, is a Cu(I)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL ACTIVATOR; SUPEROXIDE-DISMUTASE; COPPER-METABOLISM; HEME-O; METALLOCHAPERONE; CLONING; IDENTIFICATION; MEMBRANE; PRODUCT	Cox11 is a protein essential for respiratory growth and has been implicated in the assembly of the Cu-B site of cytochrome c oxidase. In the present study, we demonstrate that Cox11 is a copper-binding protein. The soluble C-terminal domain of Cox11 forms a dimer that coordinates one Cu(I) per monomer via three thiolate ligands. The two Cu(I) ions in the dimer exist in a binuclear cluster and appear to be ligated by three conserved Cys residues. Mutation of any of these Cys residues reduces Cu(I) binding and confers respiratory incompetence. Cytochrome c oxidase activity is reduced in these mutants. Thus, the residues important for Cu(I) binding correlate with in vivo function, suggesting that Cu(I) binding is important in Cox11 function.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Utah System of Higher Education; University of Utah; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.		Winge, Dennis/G-3611-2010; George, Graham N/E-3290-2013	George, Graham/0000-0002-0420-7493	NIEHS NIH HHS [ES 03817] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; CHADHA RK, 1988, POLYHEDRON, V7, P1121, DOI 10.1016/S0277-5387(00)86404-9; Church C, 1996, J BIOL CHEM, V271, P18499, DOI 10.1074/jbc.271.31.18499; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DANCE IG, 1983, POLYHEDRON, V2, P1031, DOI 10.1016/S0277-5387(00)81450-3; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Green-Willms NS, 2001, J BIOL CHEM, V276, P6392, DOI 10.1074/jbc.M009856200; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hell K, 2000, J BIOL CHEM, V275, P4571, DOI 10.1074/jbc.275.7.4571; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Laue T, 1992, ULTRACENTRIFUGATION, P90; MCMULLIN TW, 1993, J BIOL CHEM, V268, P11737; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; Musatov A, 2002, BIOCHEMISTRY-US, V41, P4371, DOI 10.1021/bi016080g; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NITTIS T, 2001, MICROBIAL TRANSPORT, P419; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; REHR JJ, 1992, PHYS REV LETT, V69, P3397, DOI 10.1103/PhysRevLett.69.3397; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Saveanu C, 2001, J BIOL CHEM, V276, P15861, DOI 10.1074/jbc.M010864200; Souza RL, 2000, J BIOL CHEM, V275, P14898, DOI 10.1074/jbc.275.20.14898; Torres AS, 2001, J BIOL CHEM, V276, P38410, DOI 10.1074/jbc.M104790200; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Winge D R, 1994, Adv Inorg Biochem, V10, P1	36	128	132	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31237	31242		10.1074/jbc.M204854200	http://dx.doi.org/10.1074/jbc.M204854200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063264	hybrid			2022-12-25	WOS:000177579800105
J	Garcia-Barrio, M; Dong, JS; Cherkasova, VA; Zhang, XL; Zhang, F; Ufano, S; Lai, R; Qin, J; Hinnebusch, AG				Garcia-Barrio, M; Dong, JS; Cherkasova, VA; Zhang, XL; Zhang, F; Ufano, S; Lai, R; Qin, J; Hinnebusch, AG			Serine 577 is phosphorylated and negatively affects the tRNA binding and eIF2 alpha kinase activities of GCN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; PROTEIN-KINASE; TRANSLATIONAL ACTIVATION; YEAST; DOMAIN; GENE; ASSOCIATION; EXPRESSION; IDENTIFICATION; DIMERIZATION	Protein kinase GCN2 regulates translation initiation by phosphorylating eukaryotic initiation factor 2alpha (eIF2alpha), impeding general protein synthesis but specifically inducing translation of GCN4, a transcriptional activator of amino acid biosynthetic genes in Saccharomyces cerevisiae. GCN2 activity is stimulated in amino acid-deprived cells through binding of uncharged tRNA to a domain related to histidyl tRNA synthetase. We show that GCN2 is phosphorylated by another kinase on serine 577, located N-terminal to the kinase domain. Mutation of Ser-577 to alanine produced partial activation of GCN2 in nonstarved cells, increasing the level of phosphorylated eIF2alpha, derepressing GCN4 expression, and elevating the cellular levels of tryptophan and histidine. The Ala-577 mutation also increased the tRNA binding affinity of purified GCN2, which can account for the elevated kinase activity of GCN2-S577A in nonstarved cells where uncharged tRNA levels are low. Whereas Ser-577 remains phosphorylated in amino acid-starved cells, its dephosphorylation could mediate GCN2 activation in other stress or starvation conditions by lowering the threshold of uncharged tRNA required to activate the protein.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hinnebusch, AG (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 6A,Rm B1A13, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Berlanga JJ, 1998, J BIOL CHEM, V273, P32340, DOI 10.1074/jbc.273.48.32340; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DIALLINAS G, 1994, GENE, V143, P21, DOI 10.1016/0378-1119(94)90599-1; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; Goossens A, 2001, J BIOL CHEM, V276, P30753, DOI 10.1074/jbc.M102960200; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; Jia MH, 2000, PHYSIOL GENOMICS, V3, P83, DOI 10.1152/physiolgenomics.2000.3.2.83; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kubota H, 2001, J BIOL CHEM, V276, P17591, DOI 10.1074/jbc.M011793200; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Parent S A, 1985, Yeast, V1, P83, DOI 10.1002/yea.320010202; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Qiu H, 2001, EMBO J, V20, P1425, DOI 10.1093/emboj/20.6.1425; Qiu HF, 2002, GENE DEV, V16, P1271, DOI 10.1101/gad.979402; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; SHERMAN F, 1974, METHODS YEAST GENETI, P61; SIKORSKI RS, 1989, GENETICS, V122, P19; Sood R, 2000, GENETICS, V154, P787; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	45	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30675	30683		10.1074/jbc.M203187200	http://dx.doi.org/10.1074/jbc.M203187200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070158	hybrid			2022-12-25	WOS:000177579800036
J	Howe, CJ; LaHair, MM; Maxwell, JA; Lee, JT; Robinson, PJ; Rodriguez-Mora, O; McCubrey, JA; Franklin, RA				Howe, CJ; LaHair, MM; Maxwell, JA; Lee, JT; Robinson, PJ; Rodriguez-Mora, O; McCubrey, JA; Franklin, RA			Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced I kappa B phosphorylation in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; RAS/RAF-1/MEK/MAPK CASCADE; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; TNF-ALPHA; ACTIVATION; CALMODULIN; COMPLEX	NF-kappaB is an important transcription factor that has a role in a variety of responses such as inflammation, oncogenesis, apoptosis, and viral replication. Oxidative stress is well known to induce the activation of NF-kappaB. Cells can be exposed to either endogenously produced oxidants or oxidants produced by surrounding cells. In addition, ischemia reperfusion and certain cancer therapies such as chemotherapy and photodynamic therapy are thought to result in oxygen radical production. Because of the important role that NF-kappaB has in multiple responses, it is critical to determine the mechanisms by which oxidative stress induces NF-kappaB activity. We report that the calmodulin antagonist W-7 and the calcium/calmodulin-dependent (CaM) kinase inhibitors KN-93 and K252a, can block oxidative stress-induced IkappaB phosphorylation in Jurkat T lymphocytes. Furthermore, KN-93 but not KN-92 can block hydrogen peroxide-induced Akt and IKK phosphorylation. In addition, we found that expression of a kinase-dead CaM-KIV construct in two cell lines inhibits IkappaB phosphorylation or degradation and that expression of CaM-KIV augments hydrogen peroxide-induced IkappaB phosphorylation and degradation. Although the CaM kinases appear to be required for this response, increases in intracellular calcium do not appear to be required. These results identify the CaM kinases as potential targets that can be used to minimize NF-kappaB activation in response to oxidative stress.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Franklin, RA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Brody Bldg, Greenville, NC 27858 USA.	franklinr@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156; Franklin, Richard A./0000-0003-0299-9578	NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 51025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Atherfold PA, 1999, MOL IMMUNOL, V36, P543, DOI 10.1016/S0161-5890(99)00076-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; Bogumil R, 2000, EUR J BIOCHEM, V267, P1407, DOI 10.1046/j.1432-1327.2000.01133.x; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Carballo M, 1999, J BIOL CHEM, V274, P93, DOI 10.1074/jbc.274.1.93; Chatila T, 1997, J VIROL, V71, P6560, DOI 10.1128/JVI.71.9.6560-6567.1997; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Corti C, 1999, EUR J BIOCHEM, V262, P790, DOI 10.1046/j.1432-1327.1999.00441.x; Cruise L, 2000, NEUROREPORT, V11, P395, DOI 10.1097/00001756-200002070-00034; FRANKLIN RA, 1994, J IMMUNOL, V153, P4890; Franklin RA, 1999, BIOCHEM BIOPH RES CO, V259, P283, DOI 10.1006/bbrc.1999.0778; FRANKLIN RA, 1994, J CLIN INVEST, V93, P2134, DOI 10.1172/JCI117209; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; GRANDISON L, 1994, MOL CELL ENDOCRINOL, V106, P9; HALLIWELL B, 1988, FASEB J, V2, P2867, DOI 10.1096/fasebj.2.13.2844616; Hayashi M, 2000, HYPERTENS RES, V23, P521, DOI 10.1291/hypres.23.521; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; Lyakh LA, 2000, J IMMUNOL, V165, P3647, DOI 10.4049/jimmunol.165.7.3647; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; Okuno S, 2000, J BIOCHEM-TOKYO, V127, P965, DOI 10.1093/oxfordjournals.jbchem.a022712; Quadroni M, 1998, BIOCHEMISTRY-US, V37, P6523, DOI 10.1021/bi972930+; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWINZER R, 1994, EUR J IMMUNOL, V24, P1391, DOI 10.1002/eji.1830240623; SCHWINZER R, 1992, J IMMUNOL, V148, P1322; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Sommer D, 2000, EUR J BIOCHEM, V267, P2312, DOI 10.1046/j.1432-1327.2000.01240.x; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TORDAI A, 1994, J BIOL CHEM, V269, P7538; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; Valen G, 1999, FREE RADICAL RES, V31, P503, DOI 10.1080/10715769900301071; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	57	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30469	30476		10.1074/jbc.M205036200	http://dx.doi.org/10.1074/jbc.M205036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063265	hybrid			2022-12-25	WOS:000177579800011
J	Hu, CJ; Bai, C; Zheng, XD; Wang, YM; Wang, Y				Hu, CJ; Bai, C; Zheng, XD; Wang, YM; Wang, Y			Characterization and functional analysis of the siderophore-iron transporter CaArn1p in Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PATHOGENIC BACTERIA; FILAMENTOUS GROWTH; DNA-BINDING; YEAST; IDENTIFICATION; ACQUISITION; GENE; FERRICHROME; REPRESSOR	Siderophores are small organic compounds with high affinity for ferric iron. Microorganisms commonly acquire iron via siderophore secretion and uptake. Here we report the characterization of the siderophore transporter CaArn1p in the fungal pathogen Candida albicans. Deletion of CaARN1 reduced the ability of C. albicans to use iron bound to the hydroxamate-type siderophore ferrichrome and abolished it when two high-affinity iron permease genes (CaFTR1 and CaFTR2) were also deleted, indicating a role of CaArn1p as well as the permeases in ferrichrome-iron uptake. Caarn1Delta (but not Caftr1DeltaCaftr2Delta) assimilated iron from another hydroxamate-type siderophore, ferrioxamine B, suggesting that iron uptake from this compound depends on the permeases, but not on CaArn1p. Northern blot analysis revealed that the transcription repressor CaTup1p repressed CaARN1 expression under iron-replete conditions via the DNA-binding protein Rfg1p. Green fluorescent protein-tagged CaArn1p was observed predominantly in the plasma membrane, with some in the cytoplasm as distinct spots. The number of these spots increased with the increase in ferrichrome concentration, suggesting that CaArn1p internalization might be a mechanism for ferrichrome-iron uptake or for recycling the transporter. Caarn1Delta did not show reduced virulence when injected into the blood stream of mice, implying that CaArn1p is not required for iron uptake along this route of infection.	Inst Mol & Cell Biol, Microbial Collect & Screening Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Wang, Y (corresponding author), Inst Mol & Cell Biol, Microbial Collect & Screening Lab, 30 Med Dr, Singapore 117609, Singapore.		Wang, Yue/H-2107-2011; zheng, xinde/F-9527-2014; Wang, Yue/AGN-6053-2022	Wang, Yue/0000-0002-1211-2822; 				Ardon O, 2001, J BIOL CHEM, V276, P43049, DOI 10.1074/jbc.M108701200; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Braun BR, 2000, GENETICS, V156, P31; Braun BR, 1997, SCIENCE, V277, P105, DOI 10.1126/science.277.5322.105; Braun BR, 2001, EMBO J, V20, P4753, DOI 10.1093/emboj/20.17.4753; Brem D, 2001, MICROBIOL-SGM, V147, P1115, DOI 10.1099/00221287-147-5-1115; BYERS BR, 1991, EXPERIENTIA, V47, P416; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; FONZI WA, 1993, GENETICS, V134, P717; Girishkumar H, 1999, POSTGRAD MED J, V75, P151, DOI 10.1136/pgmj.75.881.151; Hammacott JE, 2000, MICROBIOL-SGM, V146, P869, DOI 10.1099/00221287-146-4-869; Hazan I, 2002, MOL BIOL CELL, V13, P134, DOI 10.1091/mbc.01-03-0116; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Howard DH, 1999, CLIN MICROBIOL REV, V12, P394, DOI 10.1128/CMR.12.3.394; ISMAIL A, 1985, BIOCHEM BIOPH RES CO, V132, P1160, DOI 10.1016/0006-291X(85)91928-X; ISMAIL A, 1986, MYCOPATHOLOGIA, V96, P109, DOI 10.1007/BF00436669; Kadosh D, 2001, MOL CELL BIOL, V21, P2496, DOI 10.1128/MCB.21.7.2496-2505.2001; Khalaf RA, 2001, GENETICS, V157, P1503; Knight SAB, 2002, MICROBIOL-SGM, V148, P29, DOI 10.1099/00221287-148-1-29; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Lesuisse E, 2002, YEAST, V19, P329, DOI 10.1002/yea.840; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Lewis LA, 1997, MOL MICROBIOL, V23, P737, DOI 10.1046/j.1365-2958.1997.2501619.x; MANNS JM, 1994, INFECT IMMUN, V62, P5154, DOI 10.1128/IAI.62.11.5154-5156.1994; MINNICK AA, 1991, ANAL BIOCHEM, V194, P223, DOI 10.1016/0003-2697(91)90171-O; MOORS MA, 1992, J EXP MED, V175, P1643, DOI 10.1084/jem.175.6.1643; Murad AMA, 2000, YEAST, V16, P325, DOI 10.1002/1097-0061(20000315)16:4&lt;325::AID-YEA538&gt;3.0.CO;2-#; Murad AMA, 2001, EMBO J, V20, P4742, DOI 10.1093/emboj/20.17.4742; Murad AMA, 2001, MOL MICROBIOL, V42, P981, DOI 10.1046/j.1365-2958.2001.02713.x; Nicholson ML, 1999, MICROBIOL-UK, V145, P2453, DOI 10.1099/00221287-145-9-2453; PATNE SM, 1993, TRENDS MICROBIOL, V1, P66; Ramanan N, 2000, SCIENCE, V288, P1062, DOI 10.1126/science.288.5468.1062; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Rozalska Barbara, 1998, Acta Microbiologica Polonica, V47, P185; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10691, DOI 10.1073/pnas.200318797; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	49	66	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30598	30605		10.1074/jbc.M204545200	http://dx.doi.org/10.1074/jbc.M204545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060662	hybrid			2022-12-25	WOS:000177579800027
J	Iams, K; Larson, ED; Drummond, JT				Iams, K; Larson, ED; Drummond, JT			DNA template requirements for human mismatch repair in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; XENOPUS EGG EXTRACTS; GENETIC-RECOMBINATION; RECOGNITION COMPLEX; SLIDING CLAMP; HMUTS-ALPHA; TUMOR-CELLS; IN-VITRO; CANCER; PCNA	The human mismatch repair pathway is competent to correct DNA mismatches in a strand-specific manner. At present, only nicks are known to support strand discrimination, although the DNA end within the active site of replication is often proposed to serve this role. We therefore tested the competence of DNA ends or gaps to direct mismatch correction. Eight G-T templates were constructed which contained a nick or gap of 4, 28, or similar to200 nucleotides situated similar to330 lip away in either orientation. A competition was established in which the mismatch repair machinery had to compete with gap-filling replication and ligation activities for access to the strand discontinuity. Gaps of 4 or 28 nucleotides were the most effective strand discrimination signals for mismatch repair, whereas double strand breaks did not direct repair to either strand. To define the minimal spatial requirements for access to either the strand signal or mismatch site, the nicked templates were linearized close to either site and assayed. As few as 14 bp beyond the nick supported mismatch excision, although repair synthesis failed using 5'-nicked templates. Finally, asymmetric G-T templates with a remote nick and a nearby DNA end were repaired efficiently.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Drummond, JT (corresponding author), Indiana Univ, Dept Biol, 1001 E 3rd St, Bloomington, IN 47405 USA.				NCI NIH HHS [R01 CA 79906] Funding Source: Medline; NIGMS NIH HHS [GM 07751-21] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AU KG, 1992, J BIOL CHEM, V267, P12142; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Drotschmann K, 2001, J BIOL CHEM, V276, P46225, DOI 10.1074/jbc.C100450200; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 2001, NUCLEIC ACIDS RES, V29, P2234, DOI 10.1093/nar/29.11.2234; Evans E, 2000, MOL CELL BIOL, V20, P7839, DOI 10.1128/MCB.20.21.7839-7844.2000; FANG WH, 1993, J BIOL CHEM, V268, P11838; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HOLDEN JA, 1985, J BIOL CHEM, V260, P4491; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; Larson ED, 2001, J BIOL CHEM, V276, P9775, DOI 10.1074/jbc.M006390200; Li GM, 1999, ONCOL RES, V11, P393; Maniatis T., 1982, MOL CLONING LAB MANU; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petranovic M, 2000, NEOPLASMA, V47, P375; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Varlet I, 1996, P NATL ACAD SCI USA, V93, P10156, DOI 10.1073/pnas.93.19.10156; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605	43	21	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30805	30814		10.1074/jbc.M200846200	http://dx.doi.org/10.1074/jbc.M200846200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12077119	hybrid			2022-12-25	WOS:000177579800053
J	Kilts, JD; Akazawa, T; Richardson, MD; Kwatra, MM				Kilts, JD; Akazawa, T; Richardson, MD; Kwatra, MM			Age increases cardiac G alpha(i2) expression, resulting in enhanced coupling to G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MYOCARDIAL ADENYLATE-CYCLASE; RAT VENTRICULAR MYOCYTES; SENSITIVE G-PROTEINS; FAILING HUMAN-HEART; SIGNAL-TRANSDUCTION; BETA(2)-ADRENERGIC RECEPTORS; ADRENOCEPTOR SENSITIVITY; AGING RESEARCH; TROPONIN-I	Cardiac G protein-coupled receptors that function through stimulatory G protein Galpha(s), such as beta(1)- and beta(2)-adrenergic receptors (beta(1)ARs and beta(2)ARs), play a key role in cardiac contractility. Recent data indicate that several Galpha(s)-coupled receptors in heart also activate Galpha(i), including beta(2)ARs (but not beta(1)ARs). Coupling of cardiac beta(2)ARs to Galpha(i) inhibits adenylyl cyclase and opposes beta(1)AR-mediated apoptosis. Dual coupling of beta(2)AR to both Galpha(s) and Galpha(i) is likely to alter beta(2)AR function in disease, such as congestive heart failure in which Galpha(i) levels are increased. Indeed, heart failure is characterized by reduced responsiveness of betaARs. Cardiac betaAR-responsiveness is also decreased with aging. However, whether age increases cardiac Galpha(i) has been controversial, with some studies reporting an increase and others reporting no change. The present study examines Galpha(i) in left ventricular membranes from young and old Fisher 344 rats by employing a comprehensive battery of biochemical assays. Immunoblotting reveals significant increases with age in left ventricular Galpha(i2), but no changes in Galpha(i), Galpha(o), Galpha(s), Gbeta(1), or Gbeta(2). Aging also increases ADP-ribosylation of pertussis toxin-sensitive G proteins. Consistent with these results, basal as well as receptor-mediated incorporation of photoaffinity label [P-32] azidoanilido-GTP indicates higher amounts of Galpha(i2) in older left ventricular membranes. Moreover, both basal and receptor-mediated adenylyl cyclase activities are lower in left ventricular membranes from older rats, and disabling of Galpha(i) with pertussis toxin increases both basal and receptor-stimulated adenylyl cyclase activity. Finally, age produces small but significant increases in muscarinic potency for the inhibition of both beta(1)AR- and beta(2)AR-stimulated adenylyl cyclase activity. The present study establishes that Galpha(i2) increases with age and provides data indicating that this increase dampens adenylyl cyclase activity.	Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Kwatra, MM (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, 146 Sands Bldg,Box 3094, Durham, NC 27710 USA.	kwatr001@mc.duke.edu	Kwatra, Madan/ABD-2008-2020; soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108	NIA NIH HHS [AG 15817, 5T32 AG 00024] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015817] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTSCHULD RA, 1995, CIRCULATION, V92, P1612, DOI 10.1161/01.CIR.92.6.1612; ANVERSA P, 1990, CIRC RES, V67, P871, DOI 10.1161/01.RES.67.4.871; BAZAN A, 1994, BIOCHEM PHARMACOL, V48, P479, DOI 10.1016/0006-2952(94)90277-1; BOHM M, 1993, AM J PHYSIOL, V264, pH805, DOI 10.1152/ajpheart.1993.264.3.H805; BOHM M, 1995, MOL CELL BIOCHEM, V147, P147, DOI 10.1007/BF00944795; BOREA PA, 1992, J MOL CELL CARDIOL, V24, P753, DOI 10.1016/0022-2828(92)93389-2; BRISTOW MR, 1992, BASIC RES CARDIOL, V87, P15; BRODDE OE, 1995, J CARDIOVASC PHARM, V26, P20, DOI 10.1097/00005344-199507000-00004; BRODDE OE, 1995, CARDIOVASC RES, V30, P570, DOI 10.1016/S0008-6363(95)00152-2; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Chin JH, 1996, MECH AGEING DEV, V86, P11, DOI 10.1016/0047-6374(95)01676-7; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; Derweesh IH, 2000, J PHARMACOL EXP THER, V294, P969; FAN THM, 1985, GERONTOLOGY, V31, P373, DOI 10.1159/000212726; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; Ferrara N, 1997, J MOL CELL CARDIOL, V29, P439, DOI 10.1006/jmcc.1996.0397; Gao EH, 1997, J MOL CELL CARDIOL, V29, P593, DOI 10.1006/jmcc.1996.0302; GILMAN AG, 1984, J CLIN INVEST, V73, P1, DOI 10.1172/JCI111179; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Jain M, 2001, AM J PHYSIOL-HEART C, V280, pH569, DOI 10.1152/ajpheart.2001.280.2.H569; Jiang TR, 1997, AM J PHYSIOL-HEART C, V273, pH1044, DOI 10.1152/ajpheart.1997.273.2.H1044; JOHNSON MD, 1995, J GERONTOL A-BIOL, V50, pB14, DOI 10.1093/gerona/50A.1.B14; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; Kaumann A, 1999, CIRCULATION, V99, P65, DOI 10.1161/01.CIR.99.1.65; Kaumann AJ, 1996, MOL CELL BIOCHEM, V164, P113, DOI 10.1007/BF00408647; KELLY J, 1984, CLIN SCI, V66, P509, DOI 10.1042/cs0660509; Kilts JD, 2000, CIRC RES, V87, P705, DOI 10.1161/01.RES.87.8.705; KUSOMOTO FM, 1994, AM J PHYSIOL, V266, pH1408; Lakatta Edward G., 2000, Am J Geriatr Cardiol, V9, P251, DOI 10.1111/j.1076-7460.2000.80047.x; Lakatta EG, 1999, J AM GERIATR SOC, V47, P613, DOI 10.1111/j.1532-5415.1999.tb02579.x; LEFKOWITZ RJ, 1995, NEW ENGL J MED, V332, P186, DOI 10.1056/NEJM199501193320312; LEMOINE H, 1991, N-S ARCH PHARMACOL, V344, P56; MADER SL, 1991, J APPL PHYSIOL, V71, P2094, DOI 10.1152/jappl.1991.71.6.2094; Mazzeo RS, 1995, MECH AGEING DEV, V84, P157, DOI 10.1016/0047-6374(95)01643-0; MIYAMOTO A, 1994, EUR J PHARM-MOLEC PH, V266, P147, DOI 10.1016/0922-4106(94)90104-X; Molenaar P, 2000, CIRCULATION, V102, P1814, DOI 10.1161/01.cir.102.15.1814; MOSS J, 1984, J RECEPTOR RES, V4, P459, DOI 10.3109/10799898409042567; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Niroomand F, 1996, N-S ARCH PHARMACOL, V354, P643; OCONNOR SW, 1983, MECH AGEING DEV, V21, P357, DOI 10.1016/0047-6374(83)90052-0; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; OPIE LH, 1998, HEART PHYSL CELL CIR, P173; Ping PP, 1999, CIRC RES, V84, P587, DOI 10.1161/01.RES.84.5.587; ROBISHAW JD, 1994, ALCOHOL CLIN EXP RES, V18, P115, DOI 10.1111/j.1530-0277.1994.tb00890.x; Roka F, 2000, EXP GERONTOL, V35, P133, DOI 10.1016/S0531-5565(99)00092-3; Roth DA, 1998, J APPL PHYSIOL, V84, P177, DOI 10.1152/jappl.1998.84.1.177; Roush ED, 1998, FEBS LETT, V428, P291, DOI 10.1016/S0014-5793(98)00553-5; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCARPACE PJ, 1988, J GERONTOL, V43, pB163, DOI 10.1093/geronj/43.6.B163; SCARPACE PJ, 1990, MECH AGEING DEV, V52, P169, DOI 10.1016/0047-6374(90)90122-V; SCARPACE PJ, 1992, EXP GERONTOL, V27, P169, DOI 10.1016/0531-5565(92)90041-W; SCARPACE PJ, 1994, J APPL PHYSIOL, V77, P737, DOI 10.1152/jappl.1994.77.2.737; SHU Y, 1994, J CARDIOVASC PHARM, V23, P188, DOI 10.1097/00005344-199402000-00003; Slotkin TA, 1996, J PHARMACOL EXP THER, V279, P478; TUMER N, 1990, J GERONTOL, V45, pB48; URASAWA K, 1991, JPN CIRC J, V55, P676, DOI 10.1253/jcj.55.676; VESTAL RE, 1979, CLIN PHARMACOL THER, V26, P181; Wang YG, 2002, J GEN PHYSIOL, V119, P69, DOI 10.1085/jgp.119.1.69; WEINDRUCH R, 1991, J GERONTOL, V46, pB87, DOI 10.1093/geronj/46.3.B87; WHITE M, 1994, CIRCULATION, V90, P1225, DOI 10.1161/01.CIR.90.3.1225; Xiao RP, 1998, J CLIN INVEST, V101, P1273, DOI 10.1172/JCI1335; XIAO RP, 1994, J BIOL CHEM, V269, P19151; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	72	33	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31257	31262		10.1074/jbc.M203640200	http://dx.doi.org/10.1074/jbc.M203640200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12065589	hybrid			2022-12-25	WOS:000177579800108
J	Vainauskas, S; Maeda, Y; Kurniawan, H; Kinoshita, T; Menon, AK				Vainauskas, S; Maeda, Y; Kurniawan, H; Kinoshita, T; Menon, AK			Structural requirements for the recruitment of Gaa1 into a functional glycosylphosphatidylinositol transamidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI ANCHOR ATTACHMENT; CELL-FREE SYSTEM; ENDOPLASMIC-RETICULUM PROTEINS; MEMBRANE-PROTEINS; TERMINAL SIGNAL; IN-VITRO; BIOSYNTHESIS; SUBCOMPARTMENT; SUBSTRATE; CLEAVAGE	Glycosylphosphatidylinositol (GPI)-anchored proteins are synthesized on membrane-bound ribosomes, translocated across the endoplasmic reticulum. membrane, and GPI-anchored by GPI transamidase (GPIT). GPIT is a minimally heterotetrameric membrane protein complex composed of Gaa1, Gpi8, PIG-S and PIG-T. We describe structure-function analyses of Gaa1, the most hydrophobic of the GPIT subunits, with the aim of assigning a functional role to the different sequence domains of the protein. We generated epitope-tagged Gaa1 mutants and analyzed their membrane topology, subcellular distribution, complex-forming capability, and ability to restore GPIT activity in Gaa1-deficient cells. We show that (i) detergent-extracted, Gaa1-containing GPIT complexes sediment unexpectedly rapidly at similar to17 S, (ii) Gaa1 is an endoplasmic reticulum-localized membrane glycoprotein with a cytoplasmically oriented N terminus and a lumenally oriented C terminus, (iii) elimination of C-terminal transmembrane segments allows Gaa1 to interact with other GPIT subunits but renders the resulting GPIT complex nonfunctional, (iv) interaction between Gaa1 and other GPIT subunits occurs via the large lumenal domain of Gaa1 located between the first and second transmembrane segments, and (v) the cytoplasmic N terminus of Gaa1 is not required for formation of a functional GPIT complex but may act as a membrane-sorting determinant directing Gaa1 and associated GPIT subunits to an endoplasmic reticulum. membrane domain.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, Suita, Osaka 5650871, Japan	University of Wisconsin System; University of Wisconsin Madison; Osaka University	Vainauskas, S (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		Kinoshita, Taroh/C-7353-2009	Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM 55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Doering TL, 1997, BIOCHEM J, V328, P669; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; Eisenhaber B, 2001, PROTEIN ENG, V14, P17, DOI 10.1093/protein/14.1.17; FIELD MC, 1994, J BIOL CHEM, V269, P10830; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; Hilley JD, 2000, MOL BIOL CELL, V11, P1183, DOI 10.1091/mbc.11.4.1183; HOLDER AA, 1983, BIOCHEM J, V209, P261, DOI 10.1042/bj2090261; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KODUKULA K, 1995, METHOD ENZYMOL, V250, P536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma JY, 1999, J BIOL CHEM, V274, P8046, DOI 10.1074/jbc.274.12.8046; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Sharma DK, 2000, BIOCHEM J, V351, P717, DOI 10.1042/0264-6021:3510717; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Spurway TD, 2001, J BIOL CHEM, V276, P15975, DOI 10.1074/jbc.M010128200; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; Vidugiriene J, 2001, EUR J BIOCHEM, V268, P2290, DOI 10.1046/j.1432-1327.2001.02106.x; WADA I, 1991, J BIOL CHEM, V266, P19599; WASSLER M, 1993, J CELL BIOL, V123, P285, DOI 10.1083/jcb.123.2.285; Yan W, 1998, J MOL BIOL, V275, P25, DOI 10.1006/jmbi.1997.1447; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	40	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30535	30542		10.1074/jbc.M205402200	http://dx.doi.org/10.1074/jbc.M205402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12052837	hybrid			2022-12-25	WOS:000177579800019
J	Wong, SC; Chew, WK; Tan, JEL; Melendez, AJ; Francis, F; Lam, KP				Wong, SC; Chew, WK; Tan, JEL; Melendez, AJ; Francis, F; Lam, KP			Peritoneal CD5(+) B-1 cells have signaling properties similar to tolerant B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BRUTONS TYROSINE KINASE; RECOGNIZE PHOSPHATIDYL CHOLINE; ACTIVATED PROTEIN-KINASE; ANTIGEN-RECEPTOR; IN-VIVO; BCL-X; TRANSCRIPTION FACTORS; REGULATED KINASE; CYCLIN D1	CD5(+) B (or B-1) cells are the normal precursors of B cell chronic lymphocytic leukemia. They differ from conventional B (B-2) cells with respect to their phenotype and mitogenic responses and are often secretors of the natural polyreactive antibodies in the serum. The origin of B-1 cells remains controversial, and the relationship between B-1 cells and autoreactive B cells is unclear. Here, we compare the signaling pathways that are activated by the engagement of the B cell antigen receptor (BCR) in B-1 and B-2 cells. Stimulation of the BCR leads to the induced activation of the three major classes of mitogen-activated protein kinases (MAPKs), ERK, JNK, and p38 MAPK, as well as the Akt kinase and the transcription factors nuclear factor of activated T cells (NF-AT) and NF-kappaB in B-2 cells. In contrast, B-1 cells have constitutive activation of ERK and NF-AT but exhibit delayed JNK and lack p38 MAPK and NF-kappaB induction upon BCR cross-linking. The lack of NF-kappaB activation in B-1 cells may be due to a lack of Akt activation in these cells. Furthermore, our study using specific inhibitors reveals that the extended survival of B-1 cells in culture is not due to the constitutive activation of ERK; nor is it due to Akt signaling or Bcl-x(L) up-regulation, since these are not induced in B-1 cells. The current findings of altered MAPK and NF-AT activation and lack of NF-kappaB induction in B-1 cells indicate that these cells have signaling properties similar to tolerant B cells that are chronically exposed to self-antigens. Indeed, BCR stimulation of B-1 cells does not lead to their full activation as indicated by their lack of maximal up-regulation of specific markers such as CD25, CD69, and CD86.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Lam, KP (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcblamkp@imcb.nus.edu.sg	Lam, Kong-Peng/G-5374-2012	Lam, Kong-Peng/0000-0002-1316-4333				Arnold LW, 2000, J IMMUNOL, V164, P2924, DOI 10.4049/jimmunol.164.6.2924; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Berland R, 1998, J IMMUNOL, V161, P277; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; Bondada S, 2000, CURR TOP MICROBIOL, V252, P141; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chumley MJ, 2000, J IMMUNOL, V164, P4586, DOI 10.4049/jimmunol.164.9.4586; Clarke SH, 1998, J EXP MED, V187, P1325, DOI 10.1084/jem.187.8.1325; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Gold MR, 1999, J IMMUNOL, V163, P1894; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAUGHTON G, 1993, IMMUNOL TODAY, V14, P84, DOI 10.1016/0167-5699(93)90064-R; Hayakawa K, 1999, SCIENCE, V285, P113, DOI 10.1126/science.285.5424.113; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HERZENBERG LA, 1993, IMMUNOL TODAY, V14, P79, DOI 10.1016/0167-5699(93)90063-Q; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hippen KL, 2000, J EXP MED, V191, P883, DOI 10.1084/jem.191.5.883; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; Karras JG, 1997, J EXP MED, V185, P1035, DOI 10.1084/jem.185.6.1035; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; Lam KP, 1999, J EXP MED, V190, P471, DOI 10.1084/jem.190.4.471; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIU JL, 1991, J IMMUNOL, V146, P1685; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Melendez AJ, 1999, IMMUNOLOGY, V98, P1; MERCOLINO TJ, 1989, J EXP MED, V169, P1869, DOI 10.1084/jem.169.6.1869; MERCOLINO TJ, 1988, J EXP MED, V168, P687, DOI 10.1084/jem.168.2.687; MONROE JG, 1985, J IMMUNOL, V135, P1674; MORRIS DL, 1993, J EXP MED, V177, P857, DOI 10.1084/jem.177.3.857; NORVELL A, 1995, J IMMUNOL, V154, P4404; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Ozes ON, 1999, NATURE, V401, P82; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; Qian Y, 2001, J IMMUNOL, V166, P2412, DOI 10.4049/jimmunol.166.4.2412; RAJEWSKY K, 1989, COLD SPRING HARB SYM, V54, P209; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROTHSTEIN TL, 1988, J IMMUNOL, V140, P2880; ROTHSTEIN TL, 1988, J IMMUNOL, V141, P4089; Schuh K, 1996, LEUKEMIA LYMPHOMA, V23, P583, DOI 10.3109/10428199609054868; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; Sutherland CL, 1996, J IMMUNOL, V157, P3381; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397	65	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30707	30715		10.1074/jbc.M202460200	http://dx.doi.org/10.1074/jbc.M202460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070149	hybrid			2022-12-25	WOS:000177579800040
J	Xia, L; Wang, LJ; Chung, AS; Ivanov, SS; Ling, MY; Dragoi, AM; Platt, A; Gilmer, TM; Fu, XY; Chin, YE				Xia, L; Wang, LJ; Chung, AS; Ivanov, SS; Ling, MY; Dragoi, AM; Platt, A; Gilmer, TM; Fu, XY; Chin, YE			Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; EGF RECEPTOR; MOUSE-LIVER; INTERFERON-GAMMA; APOPTOSIS; PROTEIN; SH2; PROLIFERATION; ASSOCIATION; INDUCTION	The cytoplasmic region of human epidermal growth factor receptor (EGFR) contains an intrinsic tyrosine kinase (697-955) followed by a 231-residue-long COOH-terminal tail (C-tail), which contains multiple tyrosine residues. To examine the role of the EGFR C-tail in signal transducer and activator of transcription (STAT) activation, a series of EGFR C-tail truncations were constructed. Transient transfection of 293 cells with EGFR lacking the C-tail, i.e. Y974DeltaEGFR or Y992DeltaEGFR, led to EGF-independent or constitutive STAT activation, whereas EGF-dependent STAT activation was restored with truncations made COOH-terminal to the next tyrosine residue, i.e. EGFR-Y1045Delta. Transfection with the truncated form EGFR-Y954Delta resulted in the loss of STAT activation, suggesting that the sequence between Tyr(974) and Tyr(954) is essential for STAT activation. Phosphopeptide competition analysis revealed multiple tyrosine residues within the C-tail that can act as the docking sites for both Stat1 and Stat3. A region that negatively regulated STAT activation was also identified, extending from Tyr(1114) to Glu(1172), consistent with the ability of this region to recruit a suppressor of cytokine signaling factors SOCS1 and SOCS3. When cotransfected with the full-length EGFR, but not Y992DeltaEGFR, SOCS1 or SOCS3 inhibited STAT activation by EGF in 293 cells. This suggests that both SOCS1 and SOCS3 can negatively regulate EGFR activation, presumably by inducing ubiquitination-dependent EGFR degradation upon ligand binding. These findings may therefore offer clues to how the EGF receptor C-tail regulates STAT activity.	Brown Univ, Sch Med, Dept Pathol & Lab Med, Providence, RI 02912 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Glaxo Wellcome Inc, Res Inst, Dept Cell Biol, Res Triangle Pk, NC 27709 USA	Brown University; Yale University; GlaxoSmithKline	Chin, YE (corresponding author), Brown Univ, Sch Med, Dept Pathol & Lab Med, Providence, RI 02912 USA.	Y_Eugene_Chin@Brown.edu	Ivanov, Stanimir/J-4289-2019	Ivanov, Stanimir/0000-0002-3294-7595; Platt, Adam/0000-0002-3455-1789	NATIONAL CANCER INSTITUTE [R01CA082549] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 82549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; de Melker AA, 2001, J CELL SCI, V114, P2167; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Iwamoto Y, 1998, J BIOL CHEM, V273, P18198, DOI 10.1074/jbc.273.29.18198; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	90	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30716	30723		10.1074/jbc.M202823200	http://dx.doi.org/10.1074/jbc.M202823200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070153	hybrid			2022-12-25	WOS:000177579800041
J	Bhat, NR; Feinstein, DL; Shen, Q; Bhat, AN				Bhat, NR; Feinstein, DL; Shen, Q; Bhat, AN			p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells - Roles of nuclear factors, nuclear factor kappa B, cAMP response element-binding protein, ccaat/enhancer-binding protein-beta, and activating transcription factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SIGNAL-TRANSDUCTION PATHWAY; INTERFERON-GAMMA; GENE-EXPRESSION; MOLECULAR-CLONING; KINASE PATHWAYS; MESANGIAL CELLS; FACTOR ATF2; INDUCTION; DISEASES	Previous studies have shown that mitogen-activated protein kinase (MAPK) cascades signal the induction of inducible nitric-oxide synthase (iNOS) in glial cells (Bhat, N. R., Zhang, P., Lee, J. C., and Hogan E. L. (1998) J. Neurosci. 18, 1633-1641; Bhat, N. R., Zhang, P., and Bhat, A. N. (1999) J. Neurochem. 72,472-478). This study further investigates the role of p38 MAPK in the transcriptional activation of the iNOS gene by transient transfection with constitutively active upstream kinases in the pathway (i.e. MAPK kinase 3 (MKK3b(E)) and MAPK kinase 6 (MKK6b(E)). Expression in C-6 glial cells of either MKK3b(E) or MKK6b(E) resulted in an induction of the activity of a cotransfected rat iNOS promoter-reporter (iNOS-luciferase (Luc)) gene and an enhancement of cytokine-induced expression of iNOS mRNA, both of which were inhibitable by the p38 MAPK inhibitor SB203580. The MKK constructs also induced CAMP response element-mediated (CRE-Luc) and nuclear factor kappaB-dependent (nuclear factor kappaB-Luc) transcriptional activities. Transfection with dominant negative (dn) forms of CRE-binding protein (CREB) and CCAAT/enhancer-binding protein (C/EBP), the two CRE-binding transcription factors targeted by the p38 MAPK pathway, resulted in opposite effects; dnCREB enhanced and dnC/EBP inhibited iNOS-Luc parallel to their effects on CRE-Luc. In addition, the induction, by MKK3b(E) and MKK6b(E), of iNOS promoter activity was enhanced by a wild-type activating transcription factor (ATF-2), whereas a phosphorylation-defective form of ATF-2 had a suppressive effect. The results of these molecular studies provide evidence for an important role for the p38 MAPK pathway in the transcriptional activation of the iNOS gene in rat glial cells involving the transcription factors nuclear factor kappaB, C/EBP, and ATF-2.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA	Medical University of South Carolina; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bhat, NR (corresponding author), Med Univ S Carolina, Dept Neurol, 171 Ashley Ave, Charleston, SC 29425 USA.		Bhat, Anjana/AAE-9656-2019; feinstein, doug/M-9414-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031556, R01NS041035] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS041035, NS31556, NS41035] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bhat NR, 1999, J NEUROCHEM, V72, P472, DOI 10.1046/j.1471-4159.1999.0720472.x; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Brosnan CF, 1997, BIOCHEM SOC T, V25, P679, DOI 10.1042/bst0250679; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen CC, 1999, MOL PHARMACOL, V55, P481; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Dawson VL, 1996, P SOC EXP BIOL MED, V211, P33; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gavrilyuk V, 2001, J NEUROCHEM, V78, P129, DOI 10.1046/j.1471-4159.2001.00375.x; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Guan ZH, 1999, J BIOL CHEM, V274, P36200, DOI 10.1074/jbc.274.51.36200; Gupta AK, 1999, AM J PHYSIOL-RENAL, V276, pF599, DOI 10.1152/ajprenal.1999.276.4.F599; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Kinugawa K, 1997, CIRC RES, V81, P911; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; KRUETZBERG GW, 1996, TRENDS NEUROSCI, V19, P312; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MUCKE L, 1993, FASEB J, V7, P1226, DOI 10.1096/fasebj.7.13.8405808; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAY BK, 1994, EUR J BIOCHEM, V222, P891, DOI 10.1111/j.1432-1033.1994.tb18937.x; Routes JM, 2000, BIOCHEM J, V352, P335, DOI 10.1042/0264-6021:3520335; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stasiolek M, 2000, J BIOL CHEM, V275, P24847, DOI 10.1074/jbc.M910284199; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Zamora R, 2000, MOL MED, V6, P347, DOI 10.1007/BF03401781; Zhang HF, 1998, BIOCHEM PHARMACOL, V55, P1873, DOI 10.1016/S0006-2952(98)00078-1; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	58	150	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29584	29592		10.1074/jbc.M204994200	http://dx.doi.org/10.1074/jbc.M204994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048217	hybrid			2022-12-25	WOS:000177509300032
J	Borrelly, GPM; Harrison, MD; Robinson, AK; Cox, SG; Robinson, NJ; Whitehall, SK				Borrelly, GPM; Harrison, MD; Robinson, AK; Cox, SG; Robinson, NJ; Whitehall, SK			Surplus zinc is handled by Zym1 metallothionein and Zhf endoplasmic reticulum transporter in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FISSION YEAST; CONFERS RESISTANCE; EXPRESSION; PROTEIN; GENE; TRANSCRIPTION; KINASE; DETOXIFICATION; SENSITIVITY	Homeostatic mechanisms prevent the accumulation of free zinc in the cytoplasm, raising questions regarding where surplus zinc is stored and how it is delivered to and from these stores. A genetic screen for zinc hypersensitivity in Schizosaccharomyces pombe identified a missense mutation truncating Zhf, an endoplasmic reticulum transporter. These cells were similar to5-fold more zinc-sensitive than other independent mutants. The targeted disruption of zhf prevented growth on low zinc medium and caused hypersensitivity to elevated zinc/cobalt but resistance to cadmium. The exposure to elevated zinc but not copper also promotes the accumulation of transcripts encoding a metallothionein designated Zym1. The Sty1 pathway is required for maximal zym1 expression but is not obligatory for zinc perception. The targeted disruption of zym1 impaired cadmium tolerance but only slightly impaired zinc tolerance, whereas zym1 overexpression substantially rescued zinc hypersensitivity of zhf(-) cells. Four equivalents of zinc were displaced from Zym1 by up to 12 equivalents of p-(hydroxymercuri)phenylsulphonate. Zym1 thiols react rapidly with 5,5'-dithiobis-(2-nitrobenzoic acid) compared with bacterial zinc metallothionein (6.8 and 0.2 x 10(-4) s(-1), respectively). Zym1 is unlike known fungal metallothioneins that are induced by and sequester copper but not zinc. Less zinc but normal cadmium was accumulated by zym1Delta, consistent with zinc sequestration by Zym1 in vivo.	Newcastle Univ, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Whitehall, SK (corresponding author), Newcastle Univ, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	N.J.Robinson@ncl.ac.uk; S.K.Whitehall@ncl.ac.uk	Robinson, Nigel J/J-6363-2012	Robinson, Nigel J/0000-0001-5586-1092; Harrison, Mark/0000-0002-0220-1565				ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Blindauer CA, 2001, P NATL ACAD SCI USA, V98, P9593, DOI 10.1073/pnas.171120098; Clemens S, 2002, J BIOL CHEM, V277, P18215, DOI 10.1074/jbc.M201031200; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; CONKLIN DS, 1994, MOL GEN GENET, V244, P303, DOI 10.1007/BF00285458; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; Daniels MJ, 1998, J BIOL CHEM, V273, P22957, DOI 10.1074/jbc.273.36.22957; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Jang YK, 1996, GENE, V169, P125, DOI 10.1016/0378-1119(96)83099-X; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; Jiang LJ, 2000, P NATL ACAD SCI USA, V97, P2503, DOI 10.1073/pnas.97.6.2503; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Kanoh J, 1996, GENES CELLS, V1, P391, DOI 10.1046/j.1365-2443.1996.d01-247.x; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; Kelly EJ, 1996, J NUTR, V126, P1782; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; McMahon RJ, 1998, J NUTR, V128, P667, DOI 10.1093/jn/128.4.667; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURASUGI A, 1984, J BIOCHEM-TOKYO, V96, P1375, DOI 10.1093/oxfordjournals.jbchem.a134965; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PALMITER RD, 1995, TOXICOL APPL PHARM, V135, P139, DOI 10.1006/taap.1995.1216; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; SHAW CF, 1991, METHOD ENZYMOL, V205, P401; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; WHITE C, 1987, J GEN MICROBIOL, V133, P727; Whitehall S, 1999, MOL BIOL CELL, V10, P3705, DOI 10.1091/mbc.10.11.3705; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	49	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30394	30400		10.1074/jbc.M203145200	http://dx.doi.org/10.1074/jbc.M203145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050156	Green Published, hybrid			2022-12-25	WOS:000177509300127
J	Faisal, A; El-Shemerly, M; Hess, D; Nagamine, Y				Faisal, A; El-Shemerly, M; Hess, D; Nagamine, Y			Serine/threonine phosphorylation of ShcA - Regulation of protein-tyrosine phosphatase-pest binding and involvement in insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; SERINE PHOSPHORYLATION; SH3 DOMAIN; MASS-SPECTROMETRY; PATHWAY UPSTREAM; KINASE PATHWAY; PTP-PEST; ACTIVATION; RECEPTOR; ASSOCIATION	Serine phosphorylation of the ShcA signaling molecule has been reported recently. In this work, we have identified 12-O-tetradecanoylphorbol-13-acetate (TPA)- and growth factor-induced serine/threonine phosphorylation sites in p52(Shc) and p66(Shc). Among them, Ser(29) in p52(Shc) (equivalent to Ser(138) in p66(Shc)) was phosphorylated only after TPA stimulation. Phosphorylation of this site together with the intact phosphotyrosine-binding domain was essential for ShcA binding to the protein-tyrosine phosphatase PTP-PEST. TPA-induced ShcA phosphorylation at this site (and hence, its association with PTP-PEST) was inhibited by a protein kinase C-specific inhibitor and was induced by overexpression of constitutively active mutants of protein kinase Calpha, -epsilon, and -delta isoforms. Insulin also induced ShcA/PTP-PEST association, although to a lesser extent than TPA. Overexpression of a PTP-PEST binding-defective mutant of P52(Shc) (S29A) enhanced insulin-induced ERK activation in insulin receptor-overexpressing HIRc-B cells. Consistent with this, p52(Shc) S29A was more tyrosine-phosphorylated than wild-type p,52 She after insulin stimulation. Thus, we have identified a new mechanism whereby serine phosphorylation of ShcA controls the ability of its phosphotyrosine-binding domain to bind PTP-PEST, which is responsible for the dephosphorylation and down-regulation of ShcA after insulin stimulation.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Nagamine, Y (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Faisal, Amir/AAE-8992-2020	Faisal, Amir/0000-0002-7376-8286				BALDARI CT, 1995, ONCOGENE, V10, P1141; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Besser D, 1995, ONCOGENE, V11, P2383; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; Foschi M, 2001, J BIOL CHEM, V276, P26640, DOI 10.1074/jbc.M102008200; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; HABIB T, 1994, J BIOL CHEM, V269, P25243; HOFSTETTER P, 1987, MOL CELL BIOL, V7, P4535, DOI 10.1128/MCB.7.12.4535; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ishihara H, 1997, J BIOL CHEM, V272, P9581; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Lai KMV, 2000, GENE DEV, V14, P1132; Le S, 2001, J BIOL CHEM, V276, P48332, DOI 10.1074/jbc.M106612200; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Park C, 1998, MOL CELLS, V8, P518; Pawson T, 2000, GENE DEV, V14, P1027; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Sato H, 2000, ONCOGENE, V19, P2904, DOI 10.1038/sj.onc.1203615; Scholler JK, 2000, EUR J IMMUNOL, V30, P2378, DOI 10.1002/1521-4141(2000)30:8<2378::AID-IMMU2378>3.0.CO;2-E; SEGER R, 1995, J BIOL CHEM, V270, P28325; Shevchenko A, 1997, J PROTEIN CHEM, V16, P481, DOI 10.1023/A:1026361427575; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; Wasiak S, 2001, J BIOL CHEM, V276, P26622, DOI 10.1074/jbc.M100591200; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Yang CPH, 2000, CANCER RES, V60, P5171; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	59	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30144	30152		10.1074/jbc.M203229200	http://dx.doi.org/10.1074/jbc.M203229200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12052829	hybrid			2022-12-25	WOS:000177509300098
J	Sakamoto, K; Yamaguchi, S; Ando, R; Miyawaki, A; Kabasawa, Y; Takagi, M; Li, CL; Perbal, B; Katsube, K				Sakamoto, K; Yamaguchi, S; Ando, R; Miyawaki, A; Kabasawa, Y; Takagi, M; Li, CL; Perbal, B; Katsube, K			The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; NOV GENE; DOWN-REGULATION; CELL-ADHESION; EGF-LIKE; EXPRESSION; FAMILY; DELTA; NEUROGENESIS; ACTIVATION	We demonstrate a novel interaction of the nephroblastoma overexpressed gene (NOV), a member of the CCN gene family, with the Notch signaling pathway. NOV associates with the epidermal growth factor-like repeats of Notch1 by the CT (C-terminal cysteine knot) domain. The promoters of HES1 and HES5, which are the downstream transducers of Notch signaling, were activated by NOV. Expressions of NOV and Notch1 were concomitant in the presomitic mesoderm and later in the myocytes and chondrocytes, suggesting their synergistic effects in mesenchymal cell differentiation. In C2/4 myogenic cells, elevated expression of NOV led to down-regulation of MyoD and myogenin, resulting in inhibition of myotube formation. These results indicate that NOV-Notch1 association exerts a positive effect on Notch signaling and consequently suppresses myogenesis.	Tokyo Med & Dent Univ, Grad Sch, Dept Mol Pathol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Oral Surg, Bunkyo Ku, Tokyo 1138549, Japan; RIKEN, Brain Sci Inst, Adv Technol Dev Ctr, Lab Cell Funct & Dynam, Wako, Saitama 3510198, Japan; Univ Paris 07, UFR Biochim, Lab Oncol Virale & Mol, F-75005 Paris, France	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); RIKEN; UDICE-French Research Universities; Universite Paris Cite	Katsube, K (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Mol Pathol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	katsube.mpa@tmd.ac.jp	Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ayer-Lelievre C., 2001, Molecular Pathology, V54, P105, DOI 10.1136/mp.54.2.105; Babic AM, 1999, MOL CELL BIOL, V19, P2958; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Burren CP, 1999, J CLIN ENDOCR METAB, V84, P1096; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chevalier G, 1998, AM J PATHOL, V152, P1563; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Crowe R, 1999, DEVELOPMENT, V126, P987; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Delmolino LM, 1997, J CELL PHYSIOL, V173, P371; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Glukhova L, 2001, CANCER GENET CYTOGEN, V130, P105, DOI 10.1016/S0165-4608(01)00477-0; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Henry CA, 2001, DEV BIOL, V240, P474, DOI 10.1006/dbio.2001.0467; Hirsinger E, 2001, DEVELOPMENT, V128, P107; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; Katsube K, 2001, Brain Res Gene Expr Patterns, V1, P61; Katsumi A, 2000, J BIOL CHEM, V275, P25585, DOI 10.1074/jbc.M002654200; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; Kocialkowski S, 2001, ANAT EMBRYOL, V203, P417, DOI 10.1007/s004290100177; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; LYMAN D, 1993, P NATL ACAD SCI USA, V90, P10395, DOI 10.1073/pnas.90.21.10395; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Natarajan D, 2000, DEV DYNAM, V219, P417, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1058>3.0.CO;2-2; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Noguchi S, 1999, BIOCHEM BIOPH RES CO, V262, P88, DOI 10.1006/bbrc.1999.1163; NYE JS, 1994, DEVELOPMENT, V120, P2421; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; PERBAL B, 1994, CRIT REV ONCOGENESIS, V5, P589; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Perbal B, 1999, J CLIN PATHOL-MOL PA, V52, P84, DOI 10.1136/mp.52.2.84; Powell PA, 2001, NATURE, V409, P626, DOI 10.1038/35054566; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Sakamoto K, 1998, FEBS LETT, V426, P337, DOI 10.1016/S0014-5793(98)00369-X; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Snaith MR, 1996, GENOMICS, V38, P425, DOI 10.1006/geno.1996.0647; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Su BY, 1998, CR ACAD SCI III-VIE, V321, P883, DOI 10.1016/S0764-4469(99)80002-X; Su BY, 2001, J CLIN PATHOL-MOL PA, V54, P184, DOI 10.1136/mp.54.3.184; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Sun X, 1996, DEVELOPMENT, V122, P2465; Takagi J, 2001, P NATL ACAD SCI USA, V98, P11175, DOI 10.1073/pnas.201420198; Tanaka S, 2001, ONCOGENE, V20, P5525, DOI 10.1038/sj.onc.1204723; Thomopoulos G. N., 2001, Journal of Submicroscopic Cytology and Pathology, V33, P251; Wesley CS, 1999, MOL CELL BIOL, V19, P5743; XU T, 1992, DEVELOPMENT, V115, P913; Ying ZT, 1996, GENE, V171, P243, DOI 10.1016/0378-1119(95)00891-8; Yoshida N, 1998, J CELL SCI, V111, P769; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	77	162	172	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29399	29405		10.1074/jbc.M203727200	http://dx.doi.org/10.1074/jbc.M203727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050162	hybrid			2022-12-25	WOS:000177509300008
J	Noujaim, D; van Golen, CM; van Golen, KL; Grauman, A; Feldman, EL				Noujaim, D; van Golen, CM; van Golen, KL; Grauman, A; Feldman, EL			N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; N-Myc; Bcl-2; MMP; invasion; tumorigenesis	MATRIX-METALLOPROTEINASE INHIBITORS; AMYOTROPHIC-LATERAL-SCLEROSIS; SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; MATRIX-METALLOPROTEINASE-9 EXPRESSION; IV COLLAGENASE; TUMOR-CELLS; BREAST-CANCER; IGF-I; INVASION	Neuroblastoma is a peripheral nervous system tumor that accounts for 8-10% of all solid childhood tumors. N-Myc is the most reliable prognostic indicator for neuroblastoma. Bcl-2 is detected in 40-60% of primary neuroblastoma tumors and demonstrates anti-apoptotic action by conferring resistance to chemotherapy and radiation treatment. In neuroblastoma cell lines, the coexpression of N-Myc and Bcl-2 leads to increased tumorigenic properties. Matrix metalloproteinases (MMPs) are endopeptidases that degrade a wide range of basement membrane components, a process important for tumor invasion. This study investigates the effect of N-Myc and Bcl-2 on MMP expression and activation. MMP-2 expression and secretion are increased in SHEP neuroblastoma cells expressing Bcl-2 alone (SHEP/Bcl-2 cells) or both N-Myc and Bcl-2 (SHEP/N-Myc/Bcl-2 cells). MMP-2 activity is increased in the SHEP/N-Myc/Bcl-2 cells yet remains unchanged in SHEP/Bcl-2 cells. TIMP-2 expression is high in SHEP/Bcl-2 cells, which likely inhibits MMP-2 activity, and absent in SHEP/N-Myc/Bcl-2 cells, allowing MMP-2 activity. Invasion is increased in SHEP/N-Myc/Bcl-2 cells and prevented by the use of a pharmacologic MMP-2 inhibitor. These data imply that N-Myc and Bcl-2 cooperate to increase the expression, secretion, and activation of MMP-2, which likely leads to a more tumorigenic phenotype due to increased MMP-2 mediated invasion.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge 3,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007222, R01NS036778] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS36778, T32 NS07222] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ara T, 1998, J PEDIATR SURG, V33, P1272, DOI 10.1016/S0022-3468(98)90167-1; Ara T, 2000, J PEDIATR SURG, V35, P432, DOI 10.1016/S0022-3468(00)90208-2; Barille S, 1999, J IMMUNOL, V163, P5723; Beuche W, 2000, NEUROREPORT, V11, P3419, DOI 10.1097/00001756-200011090-00003; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Bjornland K, 2001, J PEDIATR SURG, V36, P1040, DOI 10.1053/jpsu.2001.24735; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Butler AA, 1998, CANCER RES, V58, P3021; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; Crowe DL, 2001, NEOPLASIA, V3, P27, DOI 10.1038/sj.neo.7900135; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; DEVEAS RG, 1995, J CANCER RES CLIN, V121, P275, DOI 10.1007/BF01209593; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Easton RM, 1998, MOL CELL NEUROSCI, V11, P334, DOI 10.1006/mcne.1998.0690; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Elliott S, 2001, DRUG AGING, V18, P87, DOI 10.2165/00002512-200118020-00002; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; George SJ, 2000, EXPERT OPIN INV DRUG, V9, P993, DOI 10.1517/13543784.9.5.993; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kanayama Hiro-omi, 2001, Journal of Medical Investigation, V48, P31; Kelly T, 2000, LEUKEMIA LYMPHOMA, V37, P273, DOI 10.3109/10428190009089428; Khasigov PZ, 2001, BIOCHEMISTRY-MOSCOW+, V66, P130, DOI 10.1023/A:1002879128392; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; Leventhal Phillip S., 1999, V17, P425; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Lim GP, 1996, J NEUROCHEM, V67, P251; Long L, 1998, CANCER RES, V58, P3243; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McLennan SV, 2000, KIDNEY INT, V58, pS81, DOI 10.1046/j.1523-1755.2000.07713.x; Mitsiades N, 2001, CANCER RES, V61, P577; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1998, Cell Res, V8, P179; PHILIP T, 1992, AM J PEDIAT HEMATOL, V14, P97; Ravanti L, 2000, INT J MOL MED, V6, P391; Ribatti D, 1998, INT J CANCER, V77, P449; Ribatti D, 2001, LIFE SCI, V68, P1161, DOI 10.1016/S0024-3205(00)01030-4; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Singleton JR, 1996, CANCER RES, V56, P4522; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Sugiura Y, 1998, CANCER RES, V58, P2209; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Taguchi K, 1997, JPN J CANCER RES, V88, P394, DOI 10.1111/j.1349-7006.1997.tb00395.x; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	62	47	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4549	4557		10.1038/sj.onc.1205552	http://dx.doi.org/10.1038/sj.onc.1205552			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085233				2022-12-25	WOS:000176476700009
J	Busuttil, V; Bottero, V; Frelin, C; Imbert, V; Ricci, JE; Auberger, P; Peyron, JF				Busuttil, V; Bottero, V; Frelin, C; Imbert, V; Ricci, JE; Auberger, P; Peyron, JF			Blocking NF-kappa B activation in Jurkat leukemic T cells converts the survival agent and tumor promoter PMA into an apoptotic effector	ONCOGENE			English	Article						NF-kappa B; tumor promoter PMA; Jurkat; leukemic cells; survival; apoptosis	PROTEIN-KINASE-C; SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; MEDIATED APOPTOSIS; INCONTINENTIA PIGMENTI; EMBRYONIC LETHALITY; ALPHA PROTEOLYSIS; PHORBOL ESTER; IKK; PHOSPHORYLATION	The transcription factor NF-kappaB promotes cell survival. Using a variant of Jurkat leukemic T cells expressing IkappaB-alphaDeltaN, a super-repressor of NF-kappaB activation we first show that the tumor promoter PMA could prevent Fas-induced apoptosis via activation of NF-kappaB. Moreover, we demonstrate that in the absence of NF-kappaB activation, PNIA became a strong inducer of apoptosis through stimulation of the upstream caspases 8 and 9 as well as of the effector caspase 3. A RNase-protection analysis showed that PNIA stimulated the expression of several known anti-apoptotic genes (TRAF1, TRAF4, c-IAP-1, c-IAP-2, Bfl-1, Bcl-xl). In the absence of NF-kappaB activation, these survival influences were strongly lowered revealing the apoptotic effect of PMA. These results suggest that NF-kappaB activation could be an important step in the tumor promoting effect of PMA.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Fac Med Pasteur, INSERM, U526, IFR 50 Genet & Signalisat Mol, F-06107 Nice 02, France	La Jolla Institute for Immunology; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Peyron, JF (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Peyron, Jean-Francois/M-5682-2016; AUBERGER, Patrick/G-1491-2013; RICCI, Jean Ehrland/AAS-4379-2020; Ricci, Jean Ehrland/I-7117-2016; Imbert, Véronique/I-6093-2016; Jean-Francois, Peyron/AAA-9496-2022	Peyron, Jean-Francois/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; RICCI, Jean Ehrland/0000-0003-1585-8117; Ricci, Jean Ehrland/0000-0003-1585-8117; Imbert, Véronique/0000-0003-2103-6718; Jean-Francois, Peyron/0000-0001-6113-916X				Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	49	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3213	3224		10.1038/sj.onc.1205433	http://dx.doi.org/10.1038/sj.onc.1205433			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082637				2022-12-25	WOS:000175373600013
J	Hsieh, SC; Lo, PK; Wang, FF				Hsieh, SC; Lo, PK; Wang, FF			Mouse DDA3 gene is a direct transcriptional target of p53 and p73	ONCOGENE			English	Article						DDA3; p53; p73; intronic response element	CELL-CYCLE ARREST; KINASE C-ABL; APOPTOTIC RESPONSE; CANDIDATE MEDIATOR; PROTEIN; DNA; INHIBITOR; FAMILY; IDENTIFICATION; ACCUMULATION	The p53 tumor suppressor is a transcription factor that activates the expression of many target genes. We hake previously reported the identification of a p53-regulated mouse gene DDA3. The 5' upstream genomic region of the mouse DDA3 was cloned, and sequence analysis revealed the presence of a potential p53 response element (RE2) residing at nucleotides +390similar to +409 relative to the first translation start site. When fused upstream to a luciferase reporter gene, 5' genomic regions of the DDA3 gene containing RE2 were shown to be responsive to the wild-type, but not mutant p53, in a transient transfection assay. RE2 was sufficient to confer the transactivation responsiveness to p53. Furthermore, gel mobility shift analysis showed that RE2 formed specific complexes with wild-type p53. Induction of DDA3 was found in adriamycin treated normal mouse embryonic fibroblast cells (MEF), but not in p53 knockout (p53(-/-)) MEF. Overexpression of p73 induced DDA3 mRNA expression, and luciferase reporter analysis indicated that RE2 was responsive to transactivation by members of the p73 family proteins. Consistent with these findings, elevated expression of p73 protein and DDA3 mRNA were observed concomitantly in the p53(-/-) MEF cells treated with cisplatin. These results together demonstrated that DDA3 is a transcriptional target gene of p53 and its related-protein p73.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	ffwang@ym.edu.tw		HSIEH, SHU-CHEN/0000-0002-0844-7435				Agami R, 1999, NATURE, V399, P809; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Gong JG, 1999, NATURE, V399, P806; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; STEWART N, 1995, ONCOGENE, V10, P109; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tang PP, 2000, LEUKEMIA, V14, P1292, DOI 10.1038/sj.leu.2401823; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, CANCER RES, V58, P5061	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3050	3057		10.1038/sj.onc.1205417	http://dx.doi.org/10.1038/sj.onc.1205417			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082536				2022-12-25	WOS:000175262700013
J	Cottet, S; Corthesy-Theulaz, I; Spertini, F; Corthesy, B				Cottet, S; Corthesy-Theulaz, I; Spertini, F; Corthesy, B			Microaerophilic conditions permit to mimic in vitro events occurring during in vivo Helicobacter pylori infection and to identify Rho/Ras-associated proteins in cellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; NF-KAPPA-B; TYROSINE PHOSPHORYLATION; HOST-CELL; INTERLEUKIN-8 PRODUCTION; UREASE; CAGA; EXPRESSION; ADHESION; ACID	Molecular dissection of the mechanisms underlying Helicobacter pylori infection suffers from the lack of in vitro systems mimicking in vivo observations. A system was developed whereby human epithelial cells (Caco-2) grown as polarized monolayers and bacteria can communicate with each other under culture conditions optimal for each partner. Caco-2 cells grown on filter supports were inserted in a vertical position into diffusion chambers equilibrated with air and 5% CO2 at their basolateral surface (aerophilic conditions) and 5% CO2, 5% O-2, 90% N-2 (microaerophilic conditions) in the apical compartment. Remarkably, the epithelial polarized layer was stable under these asymmetric culture conditions for at least 24 h, and the presence of Caco-2 cells was necessary to maintain H. pylori growth. In contrast to previous studies conducted with non-polarized Caco-2 cells and other cell lines kept under aerophilic conditions, we found H. pylori-dependent stimulation of cytokine secretion (MCP-1 (monocyte chemoattractant protein-1), GRO-alpha (growth-regulated oncogene-alpha), RANTES (regulated on activation normal T cell expressed and secreted)). This correlated with nuclear translocation of NF-kappaB p50 and p65 subunits. Tyrosine phosphorylation of nine cellular proteins was induced or enhanced; we identified p120(RasGAP), p190(RhoGAP), p62dok (downstream of tyrosine kinases), and cortactin as H. pylori-inducible targets. Moreover, reduction of H. pylori urease expression was observed in adherent bacteria as compared with bacteria in suspension. In addition to mimicking several observations seen in the inflamed gastric mucosa, the novel in vitro system was allowed to underscore complex cellular events not seen in classical in vitro analyses of microaerophilic bacteria-epithelial cell cross-talk.	CHU Vaudois, R&D Lab, Div Immunol & Allergy, CH-1005 Lausanne, Switzerland; Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Nestle SA	Corthesy, B (corresponding author), Hop Orthoped, R&D Lab, Div Immunol & Allergy, Ave Pierre Decker 4, CH-1005 Lausanne, Switzerland.	blaise.corthesy@chuv.hospvd.ch						Aihara M, 1997, INFECT IMMUN, V65, P3218, DOI 10.1128/IAI.65.8.3218-3224.1997; Akada JK, 2000, MOL MICROBIOL, V36, P1071, DOI 10.1046/j.1365-2958.2000.01918.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Campbell N, 1999, IMMUNOL REV, V172, P315, DOI 10.1111/j.1600-065X.1999.tb01375.x; CATRENICH CE, 1991, SCAND J GASTROENTERO, V26, P58, DOI 10.3109/00365529109093209; CELLINI L, 1994, MICROBIOL IMMUNOL, V38, P25, DOI 10.1111/j.1348-0421.1994.tb01740.x; CHANTRET I, 1988, CANCER RES, V48, P1936; Clyne M, 1996, INFECT IMMUN, V64, P2817, DOI 10.1128/IAI.64.7.2817-2820.1996; Cole SP, 1997, INFECT IMMUN, V65, P843, DOI 10.1128/IAI.65.2.843-846.1997; CorthesyTheulaz I, 1996, INFECT IMMUN, V64, P3827; Covacci A, 2000, J EXP MED, V191, P587, DOI 10.1084/jem.191.4.587; Covacci A, 1998, CURR OPIN MICROBIOL, V1, P96, DOI 10.1016/S1369-5274(98)80148-3; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; Dunn BE, 1998, YALE J BIOL MED, V71, P63; DYTOC M, 1993, INFECT IMMUN, V61, P448, DOI 10.1128/IAI.61.2.448-456.1993; ELDER JB, 1980, SCAND J GASTROENTERO, V15, P19; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; Fan XJ, 2000, J IMMUNOL, V165, P1918, DOI 10.4049/jimmunol.165.4.1918; GRASS GM, 1988, PHARMACEUT RES, V5, P372, DOI 10.1023/A:1015911712079; GRASSET E, 1984, AM J PHYSIOL, V247, pC260, DOI 10.1152/ajpcell.1984.247.3.C260; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Hamlet A, 1999, GASTROENTEROLOGY, V116, P259, DOI 10.1016/S0016-5085(99)70121-6; Hofman V, 2000, INFECT IMMUN, V68, P5225, DOI 10.1128/IAI.68.9.5225-5233.2000; Houimel M, 2001, TUMOR BIOL, V22, P36, DOI 10.1159/000030153; HUANG JZ, 1995, INFECT IMMUN, V63, P1732, DOI 10.1128/IAI.63.5.1732-1738.1995; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kamisago S, 1996, INFECT IMMUN, V64, P624, DOI 10.1128/IAI.64.2.624-628.1996; Kampik D, 2000, INFECT IMMUN, V68, P2484, DOI 10.1128/IAI.68.5.2484-2492.2000; Karita M, 1996, INFECT IMMUN, V64, P4501, DOI 10.1128/IAI.64.11.4501-4507.1996; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li SDD, 1999, INFECT IMMUN, V67, P3893, DOI 10.1128/IAI.67.8.3893-3899.1999; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MCCOLM AA, 1993, GUT, V34, P181, DOI 10.1136/gut.34.2.181; McGee DJ, 1999, CURR TOP MICROBIOL, V241, P155; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; NOACH LA, 1994, J CLIN PATHOL, V47, P699, DOI 10.1136/jcp.47.8.699; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ootani A, 2000, BIOCHEM BIOPH RES CO, V271, P741, DOI 10.1006/bbrc.2000.2673; Papini E, 1998, J CLIN INVEST, V102, P813, DOI 10.1172/JCI2764; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; REYNOLDS DJ, 1994, MICROBIOL-UK, V140, P2649, DOI 10.1099/00221287-140-10-2649; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; Sachs G, 1996, YALE J BIOL MED, V69, P301; SAMBROOK J, 1989, MOL CLONING, pB32; Scott DR, 1998, GASTROENTEROLOGY, V114, P58, DOI 10.1016/S0016-5085(98)70633-X; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Sharma SA, 1998, J IMMUNOL, V160, P2401; Shimoyama T, 1998, J CLIN PATHOL, V51, P765, DOI 10.1136/jcp.51.10.765; SMOOT DT, 1993, INFECT IMMUN, V61, P350, DOI 10.1128/IAI.61.1.350-355.1993; Stubbe H, 2000, J IMMUNOL, V164, P1952, DOI 10.4049/jimmunol.164.4.1952; TANG P, 1994, MOL BIOL CELL, V5, P455, DOI 10.1091/mbc.5.4.455; TAYLOR WG, 1982, J CELL PHYSIOL, V111, P21, DOI 10.1002/jcp.1041110105; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Warhurst AC, 1998, GUT, V42, P208, DOI 10.1136/gut.42.2.208; Yakabi K, 2000, J GASTROEN HEPATOL, V15, P263, DOI 10.1046/j.1440-1746.2000.02130.x	66	43	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33978	33986		10.1074/jbc.M201726200	http://dx.doi.org/10.1074/jbc.M201726200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12058029	hybrid			2022-12-25	WOS:000177959100061
J	Glynne, PA; Darling, KEA; Picot, J; Evans, TJ				Glynne, PA; Darling, KEA; Picot, J; Evans, TJ			Epithelial inducible nitric-oxide synthase is an apical EBP50-binding protein that directs vectorial nitric oxide output	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PDZ-DOMAIN; NA+/H+-EXCHANGER; BETA(2)-ADRENERGIC RECEPTOR; BINDING PROTEIN; EXPRESSION; ASSOCIATION; EBP50; IDENTIFICATION; CLONING	Nitric oxide (NO), produced via inducible NO synthase (iNOS), can modulate polarized epithelial processes such as solute transport. Given the high reactivity of NO, we hypothesized that optimal NO regulation of polarized epithelial functions is achieved through compartmentalization of iNOS, allowing local NO delivery to its molecular targets. Here, we show that iNOS localizes to the apical domain of epithelial cells within a submembranous protein complex tightly bound to cortical actin. We further show that iNOS can bind to the apical PDZ protein, EBP50 (ezrin-radixin-moesin-binding phosphoprotein 50), an interaction that is dependent on the last three COOH-terminal amino acids of iNOS, SAL, but requires the presence of additional unknown cellular proteins. Mutation of these three COOH-terminal residues abolishes the iNOS-EBP50 interaction and disrupts the apical association of iNOS in transfected cells, showing that this COOH-terminal motif is essential for the correct localization of iNOS in epithelial cells. Apically localized iNOS directs vectorial NO production at the apical proximal tubule epithelial cell surface. These studies define human epithelial iNOS as an apical EBP50-binding protein and suggest that the physical association of iNOS with EBP50 might allow precise NO modulation of EBP50-associated protein functions.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Infect Dis, London W12 0NN, England	Imperial College London	Evans, TJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Infect Dis, London W12 0NN, England.	tom.evans@ic.ac.uk		Darling, Katharine/0000-0003-1449-3873; Picot, Joanna/0000-0001-5987-996X				ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; DONG YJ, 1995, EMBO J, V14, P2700, DOI 10.1002/j.1460-2075.1995.tb07270.x; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Glynne PA, 2000, METH MOLEC MED, V36, P197, DOI 10.1385/1-59259-216-3:197; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; Ingraffea J, 2002, EUR J CELL BIOL, V81, P61, DOI 10.1078/0171-9335-00218; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; Liang MY, 2000, AM J PHYSIOL-REG I, V278, pR1117, DOI 10.1152/ajpregu.2000.278.5.R1117; MARKEWITZ BA, 1993, J CLIN INVEST, V91, P2138, DOI 10.1172/JCI116439; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Meng QH, 2000, J PATHOL, V190, P126, DOI 10.1002/(SICI)1096-9896(200002)190:2<126::AID-PATH500>3.0.CO;2-#; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pestonjamasp KN, 1997, J CELL BIOL, V139, P1255, DOI 10.1083/jcb.139.5.1255; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Webb JL, 2001, INFECT IMMUN, V69, P6391, DOI 10.1128/IAI.69.10.6391-6400.2001; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	36	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33132	33138		10.1074/jbc.M205764200	http://dx.doi.org/10.1074/jbc.M205764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080081	hybrid			2022-12-25	WOS:000177859000095
J	Grishkovskaya, I; Avvakumov, GV; Hammond, GL; Catalano, MG; Muller, YA				Grishkovskaya, I; Avvakumov, GV; Hammond, GL; Catalano, MG; Muller, YA			Steroid ligands bind human sex hormone-binding globulin in specific orientations and produce distinct changes in protein conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAY-DIFFRACTION DATA; HUMAN-PLASMA; DIMERIZATION DOMAINS; ESTRADIOL; SHBG; CRYSTALLOGRAPHY; TESTOSTERONE; DERIVATIVES; RESOLUTION	The amino-terminal laminin G-like domain of human sex hormone-binding globulin (SHBG) contains a single high affinity steroid-binding site. Crystal structures of this domain in complex with several different steroid ligands have revealed that estradiol occupies the SHBG steroid-binding site in an opposite orientation when compared with 5alpha-dihydrotestosterone or C19 androgen metabolites (5alpha-androstan-3beta,17beta-diol and 5alpha-androstan-3beta,17beta-diol) or the synthetic progestin levonorgestrel. Substitution of specific residues within the SHBG steroid-binding site confirmed that Ser(42) plays a key role in determining high affinity interactions by hydrogen bonding to functional groups at C3 of the androstanediols and levonorgestrel and the hydroxyl at C17 of estradiol. Among residues participating in the hydrogen bond network with hydroxy groups at C17 of C19 steroids or C3 of estradiol, Asp(65) appears to be the most important. The different binding mode of estradiol is associated with a difference in the position/orientation of residues (Leu(131) and Lys(134)) in the loop segment (Leu(131)-His(136)) that covers the steroid-binding site as well as others (Leu(171)-Lys(173) and Trp(84)) on the surface of human SHBG and may provide a basis for ligand-dependent interactions between SHBG and other macromolecules. These new crystal structures have also enabled us to construct a simple space-filling model that can be used to predict the characteristics of novel SHBG ligands.	Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England; Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canadian Inst Hlth, Res Grp Fetal & Neonatal Hlth & Dev, London, ON N6A 4L6, Canada; Free Univ Berlin, Fachbereich Biol Chem Pharm, Grad Sch, D-14195 Berlin, Germany; Max Delbruck Ctr Mol Med, Forschungsgrp Kristallog, D-13092 Berlin, Germany	University of Sussex; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Muller, YA (corresponding author), Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.		Catalano, Maria Graziella/J-4320-2016; Muller, Yves A/R-5397-2016	Catalano, Maria Graziella/0000-0002-1170-8245; Muller, Yves A/0000-0003-0519-8928; Hammond, Geoffrey/0000-0002-4639-7336; Grishkovskaya, Irina/0000-0003-0164-9373				Avvakumov GV, 2000, J BIOL CHEM, V275, P25920, DOI 10.1074/jbc.M004484200; AVVAKUMOV GV, 1986, BIOCHIM BIOPHYS ACTA, V881, P489, DOI 10.1016/0304-4165(86)90043-7; Avvakumov GV, 2001, J BIOL CHEM, V276, P34453, DOI 10.1074/jbc.M106274200; BOCCHINFUSO WP, 1994, BIOCHEMISTRY-US, V33, P10622, DOI 10.1021/bi00201a008; BOCCHINFUSO WP, 1992, FEBS LETT, V301, P227, DOI 10.1016/0014-5793(92)81253-I; BOCCHINFUSO WP, 1992, ENDOCRINOLOGY, V131, P2331, DOI 10.1210/en.131.5.2331; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chambon C, 2001, BIOCHEMISTRY-US, V40, P15424, DOI 10.1021/bi011504s; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; FORTUNATI N, 1993, J STEROID BIOCHEM, V45, P435, DOI 10.1016/0960-0760(93)90012-L; GRENOT C, 1992, BIOCHEMISTRY-US, V31, P7609, DOI 10.1021/bi00148a024; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; Grishkovskaya I, 2002, J MOL BIOL, V318, P621, DOI 10.1016/S0022-2836(02)00169-9; Grishkovskaya I, 1999, ACTA CRYSTALLOGR D, V55, P2053, DOI 10.1107/S0907444999012883; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1985, J STEROID BIOCHEM, V23, P451, DOI 10.1016/0022-4731(85)90192-X; HAMMOND GL, 1993, STEROID HORMONE ACTI, P1; HILDEBRAND C, 1995, BIOCHEMISTRY-US, V34, P3231, DOI 10.1021/bi00010a012; HRYB DJ, 1990, J BIOL CHEM, V265, P6048; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jury HH, 2000, J STEROID BIOCHEM, V75, P167, DOI 10.1016/S0960-0760(00)00168-0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAMKUNG PC, 1990, J BIOL CHEM, V265, P18345; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petra PH, 2001, PROTEIN SCI, V10, P1811, DOI 10.1110/ps.02301; PETRA PH, 1991, J STEROID BIOCHEM, V40, P735, DOI 10.1016/0960-0760(91)90299-K; PUGEAT MM, 1981, J CLIN ENDOCR METAB, V53, P69, DOI 10.1210/jcem-53-1-69; RENOIR JM, 1980, P NATL ACAD SCI-BIOL, V77, P4578, DOI 10.1073/pnas.77.8.4578; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; WESTPHAL U, 1986, STEROID PROTEIN INTE, V2	35	54	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32086	32093		10.1074/jbc.M203999200	http://dx.doi.org/10.1074/jbc.M203999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12065592	hybrid			2022-12-25	WOS:000177718700098
J	Kobayashi, T; Beuchat, MH; Chevallier, J; Makino, A; Mayran, N; Escola, JM; Lebrand, C; Cosson, P; Kobayashi, T; Gruenberg, J				Kobayashi, T; Beuchat, MH; Chevallier, J; Makino, A; Mayran, N; Escola, JM; Lebrand, C; Cosson, P; Kobayashi, T; Gruenberg, J			Separation and characterization of late endosomal membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIVESICULAR ENDOSOMES; ENDOCYTIC PATHWAY; LIPIDS; TRANSPORT; PROTEINS; ACID; CRYOSECTIONS; COMPLEXES; VESICLES; RECEPTOR	Very little is known about the biophysical properties and the lipid or protein composition of membrane domains presumably present in endocytic and biosynthetic organelles. Here we analyzed the membrane composition of late endosomes by suborganellar fractionation in the absence of detergent. We found that the internal membranes of this multivesicular organelle can be separated from the limiting membrane and that each membrane population exhibited a defined composition. Our data also indicated that internal membranes may consist of at least two populations, containing primarily phosphatidylcholine or lysobisphosphatidic acid as major phospholipid, arguing for the existence of significant microheterogeneity within late endosomal membranes. We also found that lysobisphosphatidic acid exhibited unique pH-dependent fusogenic properties, and we speculated that this lipid is an ideal candidate to regulate the dynamic properties of this internal membrane mosaic.	Univ Geneva, Dept Biochem Sci 2, CH-1211 Geneva 4, Switzerland; RIKEN, Supra Biomol Res Grp, Inst Phys & Chem Res, Frontier Res Syst, Wako, Saitama 3510198, Japan; Inst Natl Sci Appl, INSERM, U352, F-69621 Villeurbanne, France; Ctr Med Univ Geneva, Dept Morphol, CH-1211 Geneva 4, Switzerland; Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 113, Japan	University of Geneva; RIKEN; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; University of Geneva; Ochanomizu University	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem Sci 2, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.	jean.gruenberg@biochem.unige.ch	Kobayashi, Toshihide/B-6298-2015; KOBAYASHI, TOSHIHIDE/S-8313-2019; Lebrand, Cecile/G-1394-2015	Kobayashi, Toshihide/0000-0002-4811-7270; KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Lebrand, Cecile/0000-0002-2750-3164				ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BROTHERUS J, 1974, CHEM PHYS LIPIDS, V13, P178, DOI 10.1016/0009-3084(74)90034-6; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chevallier J, 2000, ORG LETT, V2, P1859, DOI 10.1021/ol0059246; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; FEWSTER ME, 1969, J CHROMATOGR, V43, P120, DOI 10.1016/S0021-9673(00)99173-8; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fivaz M, 1999, TRENDS CELL BIOL, V9, P212, DOI 10.1016/S0962-8924(99)01567-6; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Galve-de Rochemonteix B, 2000, ARTERIOSCL THROM VAS, V20, P563; Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5758, DOI 10.1073/pnas.84.16.5758; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2001, BIOL CHEM, V382, P483, DOI 10.1515/BC.2001.059; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Luquain C, 2000, BIOCHEM J, V351, P795, DOI 10.1042/0264-6021:3510795; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; MCDOWALL A, 1989, EUR J CELL BIOL, V49, P281; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; PALTAUF F, 1978, LIPIDS, V13, P165, DOI 10.1007/BF02533261; Robinson LJ, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P248; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simonsen A, 2001, NAT CELL BIOL, V3, pE179, DOI 10.1038/35087112; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; WHERRETT JR, 1973, LIPIDS, V8, P531, DOI 10.1007/BF02531989; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271	40	282	284	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32157	32164		10.1074/jbc.M202838200	http://dx.doi.org/10.1074/jbc.M202838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12065580	hybrid			2022-12-25	WOS:000177718700107
J	Chughtai, N; Schimchowitsch, S; Lebrun, JJ; Ali, S				Chughtai, N; Schimchowitsch, S; Lebrun, JJ; Ali, S			Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-HORMONE; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION; TERMINAL TYROSINE; PRL RECEPTOR; DNA-BINDING; SH2 DOMAIN; ACTIVATION; KINASE	The Src homology 2 (SH2) domain containing protein-tyrosine phosphatase SHP-2 contributes to prolactin receptor (PRLR) signal transduction to beta-casein gene promoter activation. We report for the first time that SHP-2 physically associates with the signal transducer and activator of transcription-5a (Stat5a), an important mediator of PRLR signaling to milk protein gene activation, in the mouse mammary HC11 and the human breast cancer T47D cells when stimulated with prolactin (PRL) and human growth hormone, respectively. In addition, overexpression studies indicate that the carboxyl-terminal SH2 domain of SHP-2 is required to maintain tyrosine phosphorylation of Stat5 and its interaction with SHP-2. Furthermore, we demonstrate by nuclear co-immunoprecipitation and indirect immunofluorescence studies that PRL stimulation of mammary cells leads to the nuclear translocation of SHP-2 as a complex with Stat5a. This process was found to involve the catalytic activity of the phosphatase. Finally, using the Stat5 GAS (gamma-activated sequence) element of the beta-casein gene promoter in electrophoretic mobility shift assays, we demonstrate that PRL induces the SHP-2-Stat5a complex to bind to DNA. The presence of the phosphatase in the protein-bound DNA complex was verified by using polyclonal antisera to SHP-2. Our studies indicate a tight physical and functional interaction between SHP2 and Stat5 required for regulation and perpetuation of PRL-mediated signaling in mammary cells and suggest a potential role for SHP-2 in the nucleus.	McGill Univ, Ctr Hlth, Royal Victoria Hosp, Mol Oncol Grp,Dept Med,Div Hematol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Royal Victoria Hosp, Dept Med,Div Mol Endocrinol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Ali, S (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Mol Oncol Grp,Dept Med,Div Hematol, H5-81,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	Suhad.Ali@muhc.mcgill.ca	Lebrun, Jean-Jacques/GNP-5222-2022					Ali S, 2000, J BIOL CHEM, V275, P39073, DOI 10.1074/jbc.M007478200; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Das R, 1996, BREAST CANCER RES TR, V40, P141, DOI 10.1007/BF01806209; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Ozaki K, 1998, BLOOD, V92, P4652; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pircher TJ, 1999, MOL ENDOCRINOL, V13, P555, DOI 10.1210/mend.13.4.0263; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rosen JM, 1999, ANNU REV NUTR, V19, P407, DOI 10.1146/annurev.nutr.19.1.407; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	38	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31107	31114		10.1074/jbc.M200156200	http://dx.doi.org/10.1074/jbc.M200156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060651	hybrid			2022-12-25	WOS:000177579800090
J	Lei, M; Cheng, IH; Roberts, LA; McAlear, MA; Tye, BK				Lei, M; Cheng, IH; Roberts, LA; McAlear, MA; Tye, BK			Two mcm3 mutations affect different steps in the initiation of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC7 PROTEIN-KINASE; S-PHASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; SCHIZOSACCHAROMYCES-POMBE; MCM2-7 PROTEINS; CROSS-LINKING; COMPLEX; ORIGINS	Mcm3 is a subunit of the hexameric MCM2-7 complex required for the initiation and elongation of DNA replication in eukaryotes. We have characterized two mutant alleles, mcm3-1 and mcm3-10, in Saccharomyces cerevisiae and showed that they are defective at different steps of the replication initiation process. Mcm3-10 contains a P118L substitution that compromises its interaction with Mcm5 and the recruitment of Mcm3 and Mcm7 to a replication origin. P118 is conserved between Mcm3, Mcm4, Mcm5, and Mcm7. An identical substitution of this conserved residue in Mcm5 (P83L of mcm5-bobl) strengthens the interaction between Mcm3 and Mcm5 and allows cells to enter S phase independent of Cdc7-Dbf4 kinase (Hardy, C. F., Dryga, O., Pahl, P. M. B., and Sclafani, R. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3151-3155). Mem3-1 contains a G246E mutation that diminishes the efficiency of replication initiation (Yan, H., Merchant, A. M., and Tye, B. K. (1993) Genes Dev. 7, 2149-2160) but not its interaction with Mcm5 or recruitment of the MCM2-7 complex to replication origin. These observations indicate that Mcm3-10 is defective in a step before, and Mcm3-1 is defective in a step after the recruitment of the MCM2-7 complex to replication origins.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA	Medical College of Wisconsin; Cornell University; Wesleyan University	Lei, M (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA.	mlei@mcw.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034190, R01GM062649] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34190, GM 62649-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FITCH MJ, 2001, THESIS CORNELL U ITH; Geraghty DS, 2000, J BIOL CHEM, V275, P18011, DOI 10.1074/jbc.M909787199; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Hecht A, 1999, METH MOL B, V119, P469; Homesley L, 2000, GENE DEV, V14, P913; HUTTER KJ, 1978, A VAN LEEUW J MICROB, V44, P269, DOI 10.1007/BF00394305; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; JOHNSTON LH, 1982, MOL GEN GENET, V186, P445, DOI 10.1007/BF00729467; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, J BIOL CHEM, V275, P8426, DOI 10.1074/jbc.275.12.8426; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Pasero P, 1997, GENE DEV, V11, P1504, DOI 10.1101/gad.11.12.1504; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Prokhorova TA, 2000, J BIOL CHEM, V275, P2491, DOI 10.1074/jbc.275.4.2491; ROBERTS LA, 1999, THESIS CORNELL U ITH; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Sclafani RA, 2002, GENETICS, V161, P47; Sclafani RA, 2000, J CELL SCI, V113, P2111; Seki T, 2000, P NATL ACAD SCI USA, V97, P14115, DOI 10.1073/pnas.97.26.14115; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; SHERMAN F, 1991, METHOD ENZYMOL, V194, P38; SHORTLE D, 1984, P NATL ACAD SCI-BIOL, V81, P4889, DOI 10.1073/pnas.81.15.4889; Stern BM, 2001, CURR BIOL, V11, P1462, DOI 10.1016/S0960-9822(01)00451-1; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TOYN JH, 1995, MOL CELL BIOL, V15, P5312; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	64	11	12	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30824	30831		10.1074/jbc.M201816200	http://dx.doi.org/10.1074/jbc.M201816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060653	hybrid			2022-12-25	WOS:000177579800055
J	Maiya, R; Buck, KJ; Harris, RA; Mayfield, RD				Maiya, R; Buck, KJ; Harris, RA; Mayfield, RD			Ethanol-sensitive sites on the human dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL REGULATION; STRUCTURAL DOMAINS; EXPRESSION CLONING; TRAFFICKING; RECEPTORS; ALCOHOL; BINDING; INTERNALIZATION; NOREPINEPHRINE; INHIBITION	Previous studies have shown that ethanol enhanced [H-3]dopamine uptake in Xenopus oocytes expressing the dopamine transporter (DAT). This increase in DAT activity was mirrored by an increase in the number of transporters expressed at the cell surface. In the present study, ethanol potentiated the function of DAT expressed in HeLa cells but inhibited the function of the related norepinephrine transporter (NET). Chimeras generated between DAT and NET were examined for ethanol sensitivity and demonstrated that a 76-amino acid region spanning transmembrane domains (TMD) 2 and 3 was essential for ethanol potentiation of DAT function. The second intracellular loop between TMD 2 and 3 of DAT, which differs from that of NET by four amino acids, was explored for possible sites of ethanol action. Site-directed mutagenesis was used to replace each of these residues in DAT with the corresponding residue in NET, and the resulting cRNA were expressed in Xenopus oocytes. We found that mutations G130T or I137F abolished ethanol potentiation of DAT function, whereas the mutations F123Y and L138F had no significant effect. These results identify novel sites in the second intracellular loop that are important for ethanol modulation of DAT activity.	Univ Texas, Waggoner Ctr Alcohol & Addict Res, Austin, TX 78712 USA; Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97201 USA; Dept Vet Affairs Med Ctr, Portland, OR 97201 USA	University of Texas System; University of Texas Austin; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System	Mayfield, RD (corresponding author), Univ Texas, Waggoner Ctr Alcohol & Addict Res, MBB1-124,2500 Speedway, Austin, TX 78712 USA.	Dayne.Mayfield@mail.utexas.edu			NIAAA NIH HHS [P60 AA010760, AA 06399, AA 10760] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA010760, R37AA006399, R01AA006399, P60AA010760] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALEXI T, 1991, BRAIN RES, V544, P243, DOI 10.1016/0006-8993(91)90060-9; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Brodie MS, 1998, ALCOHOL CLIN EXP RES, V22, P236, DOI 10.1111/j.1530-0277.1998.tb03644.x; BRODIE MS, 1990, BRAIN RES, V508, P65, DOI 10.1016/0006-8993(90)91118-Z; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; BUCK KJ, 1996, NATL I DRUG ABUSE RE; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Harris RA, 1999, ALCOHOL CLIN EXP RES, V23, P1563, DOI 10.1097/00000374-199910000-00001; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lewohl JM, 1999, NAT NEUROSCI, V2, P1084, DOI 10.1038/16012; LIN AMY, 1993, NEUROSCI LETT, V164, P71, DOI 10.1016/0304-3940(93)90860-N; Little KY, 2002, MOL PHARMACOL, V61, P436, DOI 10.1124/mol.61.2.436; Mayfield RD, 2001, MOL PHARMACOL, V59, P113, DOI 10.1124/mol.59.1.113; Mayfield RD, 2001, J NEUROCHEM, V79, P1070, DOI 10.1046/j.1471-4159.2001.00656.x; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Minami K, 1998, MOL PHARMACOL, V53, P148, DOI 10.1124/mol.53.1.148; Nelson N, 1998, J NEUROCHEM, V71, P1785; Nunez E, 2000, BRIT J PHARMACOL, V129, P802, DOI 10.1038/sj.bjp.0703100; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Quick MW, 1997, J NEUROSCI, V17, P2967; REITH MEA, 1993, J NEUROCHEM, V61, P167, DOI 10.1111/j.1471-4159.1993.tb03552.x; Ronald KM, 2001, J BIOL CHEM, V276, P44729, DOI 10.1074/jbc.M102800200; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; WEISS F, 1993, J PHARMACOL EXP THER, V267, P250; Whitworth TL, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0003.2002; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	36	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30724	30729		10.1074/jbc.M204914200	http://dx.doi.org/10.1074/jbc.M204914200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070173	hybrid			2022-12-25	WOS:000177579800042
J	Wang, H; Eto, M; Steers, WD; Somlyo, AP; Somlyo, AV				Wang, H; Eto, M; Steers, WD; Somlyo, AP; Somlyo, AV			RhoA-mediated Ca2+ sensitization in erectile function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; GRAND MASTER LECTURES; PROTEIN-KINASE-C; SMOOTH-MUSCLE; SIGNAL-TRANSDUCTION; MYOSIN PHOSPHATASE; CALCIUM SENSITIZATION; PENILE ERECTION; ANGIOTENSIN-II; INHIBITION	A Rho-kinase inhibitor increases corpus cavernosum (CC) pressure in an in vivo rat model (Chitaley, K., Wingard, C. J., Webb, R. C., Branam, H., Stopper, V. S., Lewis, R. W., and Mills, T. M. (2001) Nat. Med. 7,119-122) suggesting that Rho-mediated Ca2+ sensitization of CC smooth muscle maintains the flaccid (contracted) state. We directly demonstrate Ca2+ sensitization of permeabilized rabbit and human CC and identify a highly expressed molecular component of this pathway. Ca2+ sensitization of force induced by endothelin or GTPgammaS was significantly greater in CC than in rabbit ileum smooth muscle and was accompanied by a 17-fold higher RhoA content. Pull-down assays with the RhoA binding domain of mDia showed the high RhoA content of CC to be available for activation by GTPgammaS. Ca2+ sensitization induced by endothelin, phenylephrine, or GTPgammaS was completely relaxed by the Rho kinase inhibitor Y-27632. Human and rabbit CC both express the phosphatase inhibitor CPI-17, the myosin phosphatase regulatory (MYPT-1) and catalytic (PP1delta) subunits, and two isoforms of Rho kinase. We suggest that high expression of RhoA contributes, through RhoA-mediated Ca2+ sensitization, to the flaccid state of CC that can be reversed by a water-soluble, orally active Rho kinase inhibitor suitable for therapy of erectile dysfunction.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Dept Urol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Somlyo, AV (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.	avs5u@virginia.edu	Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836				ANDERSSON KE, 1995, PHYSIOL REV, V75, P191, DOI 10.1152/physrev.1995.75.1.191; Becker AJ, 2001, UROLOGY, V57, P193, DOI 10.1016/S0090-4295(00)00881-5; Berger R, 2001, INT J IMPOT RES, V13, pS39; BURNETT AL, 1995, BIOL REPROD, V52, P485, DOI 10.1095/biolreprod52.3.485; Cellek S, 1997, P NATL ACAD SCI USA, V94, P8226, DOI 10.1073/pnas.94.15.8226; Chitaley K, 2001, INT J IMPOT RES, V13, P67, DOI 10.1038/sj.ijir.3900647; Chitaley K, 2001, NAT MED, V7, P119, DOI 10.1038/83258; CHRIST GJ, 1997, MOL UROL, V1, P45; Dai Y, 2000, AM J PHYSIOL-REG I, V279, pR25, DOI 10.1152/ajpregu.2000.279.1.R25; Dey J, 2002, MAYO CLIN PROC, V77, P276, DOI 10.4065/77.3.276; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Eto M, 2000, CELL MOTIL CYTOSKEL, V46, P222, DOI 10.1002/1097-0169(200007)46:3<222::AID-CM6>3.3.CO;2-2; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Fu XH, 1998, FEBS LETT, V440, P183, DOI 10.1016/S0014-5793(98)01455-0; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; Gong MC, 2001, AM J PHYSIOL-CELL PH, V281, pC257, DOI 10.1152/ajpcell.2001.281.1.C257; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; GONG MC, 1992, J BIOL CHEM, V267, P14662; Guiliano F, 1997, Prog Urol, V7, P24; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hedlund P, 2000, P NATL ACAD SCI USA, V97, P2349, DOI 10.1073/pnas.030419997; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; ITO M, 1989, J BIOL CHEM, V264, P13971; Kifor I, 1997, J UROLOGY, V157, P1920, DOI 10.1016/S0022-5347(01)64901-2; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mills TM, 2001, INT J IMPOT RES, V13, pS29, DOI 10.1038/sj.ijir.3900774; Mills TM, 2002, EUR J PHARMACOL, V439, P173, DOI 10.1016/S0014-2999(02)01408-5; Mills TM, 2001, J APPL PHYSIOL, V91, P1269, DOI 10.1152/jappl.2001.91.3.1269; Moreland RB, 2001, J PHARMACOL EXP THER, V296, P225; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Rees RW, 2001, BRIT J PHARMACOL, V133, P455, DOI 10.1038/sj.bjp.0704124; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; Steers WD, 1999, UROLOGY, V54, P12, DOI 10.1016/S0090-4295(99)00133-8; Traish A, 2000, INT J IMPOT RES, V12, pS48, DOI 10.1038/sj.ijir.3900506; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Walker LA, 2002, BIOPHYS J, V82, p273A; Walker LA, 2001, J BIOL CHEM, V276, P24519, DOI 10.1074/jbc.M103560200; Wingard CJ, 2001, INT J IMPOT RES, V13, P212, DOI 10.1038/sj.ijir.3900688; Woodsome TP, 2001, J PHYSIOL-LONDON, V535, P553, DOI 10.1111/j.1469-7793.2001.t01-1-00553.x; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; Yamawaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1040, DOI 10.1006/bbrc.2001.5290	58	125	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30614	30621		10.1074/jbc.M204262200	http://dx.doi.org/10.1074/jbc.M204262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060659	hybrid			2022-12-25	WOS:000177579800029
J	Han, BH; Xu, DG; Choi, JJ; Han, YX; Xanthoudakis, S; Roy, S; Tam, J; Vaillancourt, J; Colucci, J; Siman, R; Giroux, A; Robertson, GS; Zamboni, R; Nicholson, DW; Holtzman, DM				Han, BH; Xu, DG; Choi, JJ; Han, YX; Xanthoudakis, S; Roy, S; Tam, J; Vaillancourt, J; Colucci, J; Siman, R; Giroux, A; Robertson, GS; Zamboni, R; Nicholson, DW; Holtzman, DM			Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DELAYED NEURONAL DEATH; CYTOCHROME-C RELEASE; INFANT RAT-BRAIN; CALPAIN ACTIVATION; CYSTEINE PROTEASES; CEREBRAL-ISCHEMIA; FAMILY PROTEASES; APOPTOSIS; DAMAGE	Hypoxia-ischemia (H-I) in the developing brain results in brain injury with prominent features of both apoptosis and necrosis. A peptide-based pan-caspase inhibitor is neuroprotective against neonatal H-I brain injury, suggesting a central role of caspases in brain injury. Because previously studied peptide-based caspase inhibitors are not potent and are only partially selective, the exact contribution of specific caspases and other proteases to injury after H-I is not clear. In this study, we explored the neuroprotective effects of a small, reversible caspase-3 inhibitor M826. M826 selectively and potently inhibited both caspase-3 enzymatic activity and apoptosis in cultured cells in vitro. In a rat model of neonatal H-I, M826 blocked caspase-3 activation and cleavage of its substrates, which begins 6 h and peaks 24 h after H-I. Although M826 significantly reduced DNA fragmentation and brain tissue loss, it did not prevent calpain activation in the cortex. This activation, which is associated with excitotoxic/necrotic cell injury, occurred within 30 min to 2 h after H-I even in the presence of M826. Similar to calpain activation, we found evidence of caspase-2 processing within 30 min to 2 h after H-I that was not affected by M826. Caspase-2 processing appeared to be secondary to calpain-mediated cleavage and was not associated with caspase-2 activation. These data suggest that caspase-3 specifically contributes to delayed cell death and brain injury after neonatal H-I and that calpain activation is associated with and likely a marker for the early component of excitotoxic/necrotic brain injury previously demonstrated in this model.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Penn, Dept Pharmacol, Med Ctr, Philadelphia, PA 19104 USA; Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Pennsylvania; Merck & Company	Holtzman, DM (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.			Robertson, George/0000-0001-8411-7721	NINDS NIH HHS [NS35902] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS035902] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamec E, 2001, BRAIN RES PROTOC, V7, P193, DOI 10.1016/S1385-299X(01)00072-1; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Chen J, 1998, J NEUROSCI, V18, P4914; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Droin N, 2000, CANCER RES, V60, P7039; FERRIERO DM, 1988, ANN NEUROL, V24, P670, DOI 10.1002/ana.410240512; Gao G, 2000, J CELL BIOCHEM, V80, P53; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gibson ME, 2001, MOL MED, V7, P644, DOI 10.1007/BF03401871; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Han BH, 2000, NEUROBIOL DIS, V7, P38; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Henshall DC, 2001, J NEUROCHEM, V77, P886, DOI 10.1046/j.1471-4159.2001.00291.x; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; IKONOMIDOU C, 1989, J NEUROSCI, V9, P1693; JOHNSTON MV, 1983, ANN NEUROL, V13, P511, DOI 10.1002/ana.410130507; Juan TSC, 1997, GENOMICS, V40, P86, DOI 10.1006/geno.1996.4548; Ko SCW, 2000, BIOCHEM BIOPH RES CO, V270, P1009, DOI 10.1006/bbrc.2000.2565; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEVINE S, 1960, AM J PATHOL, V36, P1; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakajima W, 2000, J NEUROSCI, V20, P7994; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 2000, METH MOL B, V144, P219; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; OLNEY JW, 1989, J NEUROSCI, V9, P1701; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; Pulera MR, 1998, STROKE, V29, P2622, DOI 10.1161/01.STR.29.12.2622; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Salgame P, 1997, NUCLEIC ACIDS RES, V25, P680, DOI 10.1093/nar/25.3.680; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Tu S, 2001, J BIOL CHEM, V276, P19656, DOI 10.1074/jbc.M009838200; VANNUCCI RC, 1990, PEDIATR RES, V27, P317, DOI 10.1203/00006450-199004000-00001; Volpe J., 1995, NEUROLOGY NEWBORN; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	69	147	156	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30128	30136		10.1074/jbc.M202931200	http://dx.doi.org/10.1074/jbc.M202931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058036	hybrid			2022-12-25	WOS:000177509300096
J	Meng, FY; Liu, L; Chin, PC; D'Mello, SR				Meng, FY; Liu, L; Chin, PC; D'Mello, SR			Akt is a downstream target of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CYCLIN D1; APOPTOSIS; ACTIVATION; KINASE; GROWTH; CELLS; PHOSPHORYLATION	The ubiquitously expressed transcription factor NF-kappaB and the serine-threonine kinase Akt both are involved in the promotion of cell survival. Although initially believed to operate as components of distinct signaling pathways, several studies have demonstrated that the NF-kappaB and Akt signaling pathways can converge. Indeed, IkappaB kinase, the kinase involved in NF-kappaB activation, is a substrate of Akt, and activation of Akt therefore stimulates NF-kappaB activity. Although these results place Akt upstream of NF-kappaB activation in the sequence of signaling events, we report that this may not necessarily be the case and that Akt is a downstream target of NF-kappaB. Treatment of NIH3T3 cells with the NF-kappaB activators, tumor necrosis factor (TNF) alpha and lipopolysaccharide, results in the stimulation of Akt phosphorylation. The stimulation of Akt is, however, detected only after IkappaB-alpha degradation is induced by these agents. The nuclear translocation of p65 and increased DNA binding activity of NF-kappaB also precede Akt phosphorylation. Treatment with two pharmacological inhibitors of NF-kappaB, SN50 and N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), blocks TNF-induced Akt activation. On the other hand TNF-mediated NF-kappaB activation is not reduced by the phosphoinositide-3 kinase inhibitors wortmannin and LY294002, although these inhibitors completely block the activation of Akt. These results suggest that NF-kappaB is required for TNF-mediated Akt activation and that it lies upstream of the stimulation of Akt. Consistent with this conclusion is the finding that overexpression of p65/RelA leads to Akt phosphorylation in the absence of extracellular stimulatory factors, whereas overexpression of IkappaB-alpha reduces Akt phosphorylation below basal levels. Interestingly, in addition to stimulating the phosphorylation of Akt, overexpression of p65 causes an increase in the expression of Akt mRNA and protein.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	D'Mello, SR (corresponding author), Univ Texas, Dept Mol & Cell Biol, 2601 N Floyd Rd, Richardson, TX 75083 USA.	dmello@utdallas.edu	Eckhardt, Erik/G-1567-2010; Chin, Paul C/AAF-4055-2020; D'Mello, Santosh/AAO-7192-2020; D'Mello, Santosh/AAM-3644-2020	D'Mello, Santosh/0000-0002-7652-1334; Chin, Paul/0000-0001-8035-2193	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040408] Funding Source: NIH RePORTER; NINDS NIH HHS [NS40408] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Burow ME, 2000, BIOCHEM BIOPH RES CO, V271, P342, DOI 10.1006/bbrc.2000.2626; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Huxford T, 1999, COLD SPRING HARB SYM, V64, P533, DOI 10.1101/sqb.1999.64.533; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kumari S, 2001, MOL BRAIN RES, V96, P157, DOI 10.1016/S0006-8993(01)03045-1; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; Ozes ON, 1999, NATURE, V401, P82; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Rauch BH, 2000, FEBS LETT, V481, P3, DOI 10.1016/S0014-5793(00)01957-8; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200	32	163	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29674	29680		10.1074/jbc.M112464200	http://dx.doi.org/10.1074/jbc.M112464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12052823	hybrid			2022-12-25	WOS:000177509300043
J	Yazgan, O; Pfarr, CM				Yazgan, O; Pfarr, CM			Regulation of two JunD Isoforms by Jun N-terminal kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCRINE NEOPLASIA TYPE-1; C-JUN; DNA-BINDING; MAP KINASES; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; MOUSE DEVELOPMENT; PROTEIN-KINASE; FOS	The JunD transcription factor is one member of the Jun family of proteins that also includes c-Jun and JunB. Although c-Jun can function to promote cell proliferation and can cooperate with other oncogenes to transform cells, JunD slows proliferation of fibroblasts and antagonizes transformation by activated ras. Two isoforms of JunD, a full-length isoform containing 341 amino acids (JunD-FL) and a truncated isoform lacking 48 amino acids at the N terminus (DeltaJunD), are generated through utilization of two translation start sites within a single mRNA. Here we show that both isoforms of JunD are phosphorylated by Jun N-terminal kinases (JNKs) at three identical residues and that both contain a docking domain that specifically binds JNKs. The JunD-FL isoform binds to and is phosphorylated by JNK more efficiently than DeltaJunD in vitro; correspondingly, JunD-FL is a more potent transcriptional activator than DeltaJunD. Although increased JNK signaling can activate both JunD isoforms, mutating either the JNK docking domain or the target JNK phosphorylation sites blocks this activation. These results identify two distinct isoforms of JunD with differential responses to JNK signaling pathways.	Texas Tech Univ, Hlth Sci Ctr, Med Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Med Ctr, SW Canc Ctr, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Pfarr, CM (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Med Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.	curt.pfarr@ttmc.ttuhsc.edu	Pfarr, Curt/HHD-1410-2022					ADLER V, 1994, J BIOL CHEM, V269, P11186; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI S-I, 1989, New Biologist, V1, P181; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Knapp JI, 2000, ONCOGENE, V19, P4706, DOI 10.1038/sj.onc.1203832; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RYSECK RP, 1991, ONCOGENE, V6, P533; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; van Drogen F, 2002, CURR BIOL, V12, pR53, DOI 10.1016/S0960-9822(01)00672-8; Wang HL, 1996, ONCOGENE, V13, P2639; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yazgan O, 2001, CANCER RES, V61, P916; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	51	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29710	29718		10.1074/jbc.M204552200	http://dx.doi.org/10.1074/jbc.M204552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12052834	hybrid			2022-12-25	WOS:000177509300047
J	Saeki, T; Mhashilkar, A; Swanson, X; Zou-Yang, XH; Sieger, K; Kawabe, S; Branch, CD; Zumstein, L; Meyn, RE; Roth, JA; Chada, S; Ramesh, R				Saeki, T; Mhashilkar, A; Swanson, X; Zou-Yang, XH; Sieger, K; Kawabe, S; Branch, CD; Zumstein, L; Meyn, RE; Roth, JA; Chada, S; Ramesh, R			Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo	ONCOGENE			English	Article						MDA-7; TRAIL; CD31; apoptosis; gene therapy; antiangiogenesis	DIFFERENTIATION-ASSOCIATED GENE; MELANOMA DIFFERENTIATION; TUMOR-GROWTH; APOPTOSIS; CELLS; VEGF	Overexpression of the melanoma differentiation associated gene-7 (mda-7) in vitro results in suppression of lung cancer cell proliferation. However, the ability of MDA-7 to suppress lung cancer in vivo has not been previously demonstrated. In this study, we investigated the possibility of inducing overexpression of the mda-7 gene in human non-small cell lung carcinoma cells in vivo and its effects on tumor growth. Adenovirus-mediated overexpression of MDA-7 in p53-wild-type A549 and p53-null H1299 subcutaneous tumors resulted in significant tumor growth inhibition through induction of apoptosis. In addition, decreased CD31/PECAM expression and upregulation of APO2/TRAIL were observed in tumors expressing MDA-7. In vivo studies correlated well with in vitro inhibition of lung tumor cell proliferation and endothelial cell differentiation mediated by Ad-mda7. These data demonstrate that Ad-mda7 functions as a multi-modality anti-cancer agent, possessing both, pro-apoptotic and anti-angiogenic properties. We demonstrate for the first time the potential therapeutic effects of Ad-mda7 in human lung cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ramesh, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd,Box 45, Houston, TX 77030 USA.	rramesh@mdanderson.org			NCI NIH HHS [R43 CA86587, P01CA78778-01A1, P50-CA70907, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672, P50CA070907, R43CA086587] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; GEORGES RN, 1993, CANCER RES, V53, P1743; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kagawa S, 2001, CANCER RES, V61, P3330; Kundu N, 1998, INT J CANCER, V76, P713, DOI 10.1002/(SICI)1097-0215(19980529)76:5<713::AID-IJC17>3.0.CO;2-4; Madireddi MT, 2000, J CELL PHYSIOL, V185, P36, DOI 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Nishizaki M, 1999, CLIN CANCER RES, V5, P1015; Orre M, 1999, INT J CANCER, V84, P101, DOI 10.1002/(SICI)1097-0215(19990420)84:2<101::AID-IJC2>3.0.CO;2-5; Ramesh R, 2001, MOL THER, V3, P337, DOI 10.1006/mthe.2001.0266; ROBERTS AB, 1989, AM REV RESPIR DIS, V140, P1126, DOI 10.1164/ajrccm/140.4.1126; Rowe DH, 2000, J PEDIATR SURG, V35, P30, DOI 10.1016/S0022-3468(00)80008-1; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	20	142	175	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4558	4566		10.1038/sj.onc.1205553	http://dx.doi.org/10.1038/sj.onc.1205553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085234				2022-12-25	WOS:000176476700010
J	Imai, S; Sakane, F; Kanoh, H				Imai, S; Sakane, F; Kanoh, H			Phorbol ester-regulated oligomerization of diacylglycerol kinase delta linked to its phosphorylation and translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; SAM DOMAIN; TYROSINE KINASES; ALPHA; ACTIVATION; COMPLEXES; CLONING; STERILE; BINDING	Diacylglycerol kinase (DGK) plays an important role in signal transduction through modulating the balance between two signaling lipids, diacylglycerol and phosphatidic acid. In yeast two-hybrid screening, we unexpectedly found a self-association of the C-terminal part of DGKdelta containing a sterile alpha-motif (SAM) domain. We then bacterially expressed the SAM domain fused with maltose-binding protein and confirmed the formation of dimeric and tetrameric structures. Moreover, gel filtration and co-immunoprecipitation analyses demonstrated that DGKdelta formed homo-oligomeric structures in intact cells and that the SAM domain was critically involved in the oligomerization. Interestingly, phorbol ester stimulation induced dissociation of the oligomeric structures with concomitant phosphorylation of DGKdelta. Furthermore, we found that DGKdelta was translocated from cytoplasmic vesicles to the plasma membrane upon phorbol ester stimulation. In this case, DGKdelta mutants lacking the ability of self-association were localized at the plasma membranes even in the absence of phorbol ester. A protein kinase C inhibitor, staurosporine, blocked all of the effects of phorbol ester, i.e. oligomer dissociation, phosphorylation, and translocation. We confirmed that tumor-promoting phorbol esters did not directly bind to DGKdelta. The present studies demonstrated that the formation and dissociation of oligomers serve as the regulatory mechanisms of DGKdelta and that DGKdelta is a novel downstream effector of phorbol ester/protein kinase C signaling pathway.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Sakane, F (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.	sakane@sapmed.ac.jp	Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377				Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hurley JH, 1997, PROTEIN SCI, V6, P477; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1989, BIOCHEM J, V258, P455, DOI 10.1042/bj2580455; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; Schultz J, 1997, PROTEIN SCI, V6, P249; SHARKEY NA, 1985, CANCER RES, V45, P19; Shindo M, 2001, BIOCHEM BIOPH RES CO, V289, P451, DOI 10.1006/bbrc.2001.5935; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Tanaka M, 1999, BIOCHEM BIOPH RES CO, V255, P169, DOI 10.1006/bbrc.1999.0162; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Thanos CD, 1999, J BIOL CHEM, V274, P37301, DOI 10.1074/jbc.274.52.37301; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3	36	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35323	35332		10.1074/jbc.M202035200	http://dx.doi.org/10.1074/jbc.M202035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12084710	hybrid			2022-12-25	WOS:000178117000086
J	Adachi, H; Tsujimoto, M				Adachi, H; Tsujimoto, M			FEEL-1, a novel scavenger receptor with in vitro bacteria-binding and angiogenesis-modulating activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; EPIDERMAL GROWTH-FACTOR; HUMAN-ENDOTHELIAL-CELLS; EXPRESSION CLONING; BASEMENT-MEMBRANE; FACTOR-BETA; IDENTIFICATION; ATHEROSCLEROSIS; METABOLISM; ADHESION	Employing the expression cloning technique, we cloned a novel scavenger receptor that is structurally unrelated to other scavenger receptors. The cloned receptor contained fasciclin (Fas-1), epidermal growth factor (EGF)-like, laminin-type EGF-like, and link domains. Based on the domain structures, we temporarily named it FEEL-1 (fasciclin, EGF-like, laminin-type EGF-like, and link domain-containing scavenger receptor-1). A data base search suggested the presence of a paralogous gene of FEEL-1, the full-length cDNA of this gene was also cloned, and its nucleotide sequence was determined. The deduced amino acid sequence of the clone indicated that its domain organization is similar to FEEL-1, and we named this clone FEEL-2. The effect of monoclonal antibodies against FEEL-1 indicated that FEEL-1 is the major receptor for 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbo-cyanine perchlorate (DiI)-labeled acetylated low density lipoprotein (DiI-Ac-LDL) in human umbilical vein endothelial cells. Reverse transcription and PCR analysis revealed that both FEEL-1 and FEEL-2 were expressed in several tissues and expressed highly in the spleen and lymph node. On the other hand, only FEEL-1 was expressed in mononuclear cells, particularly resting CD14(+) cells. The transient expression of FEEL-1 and FEEL-2 in Chinese hamster ovary cells demonstrated that both FEELs could bind to Dil-Ac-LDL. Both receptors were also found to bind to Gram-negative and Gram-positive bacteria. These results suggest that FEELs play important roles in the defense mechanisms against bacterial infection. Finally, the phenotypic effect of the inhibition of FEEL-1 on vascular remodeling was tested in vitro using the Matrigel tube formation assay, and we found a marked reduction in the degree of cell-cell interaction in anti-FEEL-1 monoclonal antibody-treated cells, suggesting the role of this receptor in angiogenesis.	RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	RIKEN	Adachi, H (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; ADACHI H, 1990, J BIOL CHEM, V265, P3992; AMARAVADI L, 1994, BIOTECHNIQUES, V16, P98; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; CALVO D, 1993, J BIOL CHEM, V268, P18929; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; GENTZ R, 1992, EUR J BIOCHEM, V210, P545, DOI 10.1111/j.1432-1033.1992.tb17453.x; GOERDT S, 1991, J CELL BIOL, V113, P1425, DOI 10.1083/jcb.113.6.1425; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kodelja V, 1997, IMMUNOBIOLOGY, V197, P478, DOI 10.1016/S0171-2985(97)80080-0; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 2001, J CLIN INVEST, V108, P645, DOI 10.1172/JCI13932; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; OZMEN L, 1993, J IMMUNOL, V150, P2698; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; POLITZ O, 2002, BIOCHEM J, V15, P155; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shimaoka T, 2001, J IMMUNOL, V166, P5108, DOI 10.4049/jimmunol.166.8.5108; VANHINSBERGH VWM, 1983, ARTERIOSCLEROSIS, V3, P547, DOI 10.1161/01.ATV.3.6.547; WUILMART C, 1976, J IMMUNOGENET, V3, P1; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	37	133	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34264	34270		10.1074/jbc.M204277200	http://dx.doi.org/10.1074/jbc.M204277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12077138	hybrid			2022-12-25	WOS:000177959100096
J	Kohl, R; Antoine, M; Reimers, K; Kiefer, P				Kohl, R; Antoine, M; Reimers, K; Kiefer, P			FGF3 attached to a phosholipid membrane anchor gains a high transforming capacity - Implications of microdomains for FGF3 cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE; TARGETED EXPRESSION; RECEPTOR; BINDING; GLYPICAN-1; COMPLEX; SIGNAL; MOUSE; FIBROBLAST-GROWTH-FACTOR-3	NIH3T3 cells transformed by mouse FGF3-cDNA (DMI cells) selected for their ability to grow as anchorage-independent colonies in soft agar and in defined medium lacking growth factors exhibit a highly transformed phenotype. We have used dominant negative (DN) fibroblast growth factor (FGF) receptor 2 (FGFR2) isoforms to block the FGF response in DMI cells. When the DN-FGFR was expressed in DMI cells, their transformed phenotype can be reverted. The truncated FGFR2(IIIb), the high affinity FGFR for FGF3, is significantly more efficient at reverting the transformed phenotype as the IIIc isoform, reaffirming the notion that the affinity of the ligand to the DN-FGFR2 isoform determines the effect. Heparin or heparan sulfate displaces FGF3 from binding sites on the cell surface inhibiting the growth of DMI cells and reverts the transformed phenotype (1). However, the presence of heparin is necessary to induce a mitogenic response in NIH3T3 cells when stimulated with soluble purified mouse FGF3. We have investigated the importance of cell surface binding of FGF3 for its ability to transform NIH3T3 cells by creating an FGF3 mutant anchored to the membrane via glycosylphosphatidylinositol (GPI). The GPI anchor renders the cell surface association of FGF3 independent from binding to heparan sulfate-proteoglycan of the cell surface membrane. Attachment of a GPI anchor to FGF3 also confers a much higher transforming potential to the growth factor. Even more, the purified GPI-attached FGF3 is as much transforming as the secreted protein acting in an autocrine mode. Because NIH3T3 cells do not express the high affinity tyrosine kinase FGF receptors for FGF3, these findings suggest that FGF3 attached to GPI-linked heparan sulfate-proteoglycan may have a broader biological activity as when bound to transmembrane or soluble heparan sulfate-proteoglycan.	Univ Dusseldorf, Fak Med, Inst Hamostaseol & Transfusionsmed, Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Kiefer, P (corresponding author), Univ Dusseldorf, Fak Med, Inst Hamostaseol & Transfusionsmed, Moorenstr 5, Dusseldorf, Germany.	kiefer@med.uni-duesseldorf.de						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Citores L, 1999, MOL BIOL CELL, V10, P3835, DOI 10.1091/mbc.10.11.3835; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GOLDFARB M, 1991, ONCOGENE, V6, P65; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; HUANG JH, 1994, IMMUNITY, V1, P607, DOI 10.1016/1074-7613(94)90050-7; Jackson D, 1997, J CELL SCI, V110, P1261; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kiefer P, 1996, ONCOGENE, V12, P1503; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KIEFER P, 1993, MOL CELL BIOL, V13, P5781, DOI 10.1128/MCB.13.9.5781; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Kleeff J, 1999, PANCREAS, V19, P281, DOI 10.1097/00006676-199910000-00009; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Reimers K, 2001, MOL CELL BIOL, V21, P4996, DOI 10.1128/MCB.21.15.4996-5007.2001; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Szebenyi G, 1999, INT REV CYTOL, V185, P45; UENO H, 1992, J BIOL CHEM, V267, P1470; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x	40	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32760	32767		10.1074/jbc.M204661200	http://dx.doi.org/10.1074/jbc.M204661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084721	hybrid			2022-12-25	WOS:000177859000048
J	de Diego, I; Schwartz, F; Siegfried, H; Dauterstedt, P; Heeren, J; Beisiegel, U; Enrich, C; Grewal, T				de Diego, I; Schwartz, F; Siegfried, H; Dauterstedt, P; Heeren, J; Beisiegel, U; Enrich, C; Grewal, T			Cholesterol modulates the membrane binding and intracellular distribution of annexin 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SUBCELLULAR-DISTRIBUTION; RAT-LIVER; ENDOCYTIC COMPARTMENT; PHOSPHOLIPID-BINDING; PLASMA-MEMBRANE; VI; CALCIUM; ASSOCIATION; PROTEIN	Annexins are Ca2+- and phospholipid-binding proteins that are widely expressed in mammalian tissues and that bind to different cellular membranes. In recent years its role in membrane traffic has emerged as one of its predominant functions, but the regulation of its intracellular distribution still remains unclear. We demonstrated that annexin 6 translocates to the late endocytic compartment in low density lipoprotein-loaded CHO cells. This prompted us to investigate whether cholesterol, one of the major constituents of low density lipoprotein, could influence the membrane binding affinity and intracellular distribution of annexin 6. Treatment of crude membranes or early and late endosomal fractions with digitonin, a cholesterol-sequestering agent, displayed a strong reduction in the binding affinity of a novel EDTA-resistant and cholesterol-sensitive pool of annexin 6 proteins. In addition, U18666A-induced accumulation of cholesterol in the late endosomal compartment resulted in a significant increase of annexin 6 in these vesicles in vivo. This translocation/recruitment correlates with an increased membrane binding affinity of GST-annexin 6 to late endosomes of U18666A-treated cells in vitro. In conclusion, the present study shows that changes in the intracellular distribution and concentration of cholesterol in different subcellular compartments participate in the reorganization of intracellular pools of Ca2+-dependent and -independent annexin 6.	Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Dept Mol Cell Biol, D-20246 Hamburg, Germany; Univ Barcelona, Fac Med, IDIBAPS, Inst Biomed August Pi I Sunyer,Dept Biol Cellular, Barcelona 0836, Spain	University of Hamburg; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Grewal, T (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Dept Mol Cell Biol, Martinistr 52, D-20246 Hamburg, Germany.	grewal@uke.uni-hamburg.de	de Diego Martinez, Iñaki/AAB-4712-2019	de Diego Martinez, Iñaki/0000-0002-6156-4032; Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				Avila-Sakar AJ, 1998, BBA-PROTEIN STRUCT M, V1387, P103, DOI 10.1016/S0167-4838(98)00111-3; Ayala-Sanmartin J, 2001, BIOCHEM BIOPH RES CO, V283, P72, DOI 10.1006/bbrc.2001.4748; Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; BANDOROWICZ J, 1992, BIOCHIM BIOPHYS ACTA, V1105, P201, DOI 10.1016/0005-2736(92)90195-R; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Cuervo AM, 2000, J BIOL CHEM, V275, P33329, DOI 10.1074/jbc.M005655200; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; DRUST DS, 1991, J NEUROCHEM, V56, P469, DOI 10.1111/j.1471-4159.1991.tb08174.x; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FISCHER HD, 1980, J BIOL CHEM, V255, P9608; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Golczak M, 2001, BIOCHEM BIOPH RES CO, V284, P785, DOI 10.1006/bbrc.2001.5051; Golczak M, 2001, FEBS LETT, V496, P49, DOI 10.1016/S0014-5793(01)02402-4; GOLCZAK M, 2001, FASEB J, V6, P1083; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; GREWAL T, 2002, IN PRESS ANNEXINS BI; Gu F, 2000, J BIOL CHEM, V275, P8154, DOI 10.1074/jbc.275.11.8154; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Hoyal CR, 1996, J BIOL CHEM, V271, P29205, DOI 10.1074/jbc.271.46.29205; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Jost M, 1997, J CELL SCI, V110, P221; Kamal A, 1998, J CELL BIOL, V142, P937, DOI 10.1083/jcb.142.4.937; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Konig J, 2000, BBA-MOL CELL RES, V1498, P174, DOI 10.1016/S0167-4889(00)00094-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Massey-Harroche D, 1998, J CELL SCI, V111, P3007; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; Michaely P, 1999, J BIOL CHEM, V274, P35908, DOI 10.1074/jbc.274.50.35908; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; Ortega D, 1998, J CELL SCI, V111, P261; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; Pons M, 2000, EXP CELL RES, V257, P33, DOI 10.1006/excr.2000.4861; Pons M, 2001, EXP CELL RES, V269, P13, DOI 10.1006/excr.2001.5268; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Raynal P, 1996, BIOCHEM BIOPH RES CO, V225, P116, DOI 10.1006/bbrc.1996.1139; Rosengarth A, 1998, FEBS LETT, V438, P279, DOI 10.1016/S0014-5793(98)01318-0; TAGOE CE, 1994, BBA-BIOMEMBRANES, V1192, P272, DOI 10.1016/0005-2736(94)90128-7; Turpin E, 1998, BBA-MOL CELL RES, V1402, P115, DOI 10.1016/S0167-4889(97)00151-1; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; WEINMAN JS, 1994, CELL TISSUE RES, V278, P389, DOI 10.1007/BF00414181; Zanotti G, 1998, BIOCHEM J, V329, P101, DOI 10.1042/bj3290101	50	86	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32187	32194		10.1074/jbc.M205499200	http://dx.doi.org/10.1074/jbc.M205499200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070178	hybrid			2022-12-25	WOS:000177718700111
J	Lu, AP; Zhang, F; Gupta, A; Liu, JW				Lu, AP; Zhang, F; Gupta, A; Liu, JW			Blockade of AP1 transactivation abrogates the abnormal expression of breast cancer-specific gene 1 in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-1; SYNUCLEIN-GAMMA; ONCOSTATIN-M; IDENTIFICATION; RECEPTOR; AP-1; TRANSFORMATION; TRANSCRIPTION; STIMULATION; MECHANISMS	Breast cancer-specific gene 1 (BCSG1) is not expressed innormal breast tissue but is highly expressed in the vast majority of invasive and metastatic breast carcinomas. When over-expressed, BCSG1 significantly stimulates the proliferation and invasion of breast cancer cells. The accumulated evidence suggests that the aberrant expression of BCSG1 in breast carcinomas is caused by transcriptional activation of the BCSG1 gene. However, the transcription factors that activate BCSG1 transcription have not been identified. In this study, we extensively investigated the role of AP1 in BCSG1 expression in breast cancer cells. We demonstrate that there are two closely located AP1 binding sites residing in the first intron of the BCSG1 gene. Mutation of either AP1 motif on the BCSG1 promoter constructs markedly reduces the promoter activity. We further show that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases BCSG1 mRNA expression and up-regulates BCSG1 promoter activity through the intronic AP1 sites. The effect of TPA on BCSG1 transcription is also demonstrated under in vivo conditions in intact cells by using chromatin immunoprecipitation assays that show the TPA-induced binding of c-Jun to the chromatin region encompassing the intronic AP1 sites. Finally, to examine the direct effect of AP1 transactivation on BCSG1 expression, we established stable cell lines of T47D that express the dominant negative mutant of c-Jun, TAM67. RT-PCR and Western blot analyses demonstrated that levels of BCSG1 mRNA and protein in TAM67 transfectants were drastically reduced as compared with mock-transfected cells. Furthermore, inhibition of BCSG1 expression by blocking AP1. transactivation produced a similar repressive effect on cell growth as that by expressing BCSG1 antisense mRNA. We show that the anchorage-independent growth of T47D cells expressing either TAM67 or BCSG1 antisense mRNA is significantly inhibited. Taken together, we provide strong evidence that AP1 plays an overriding role in the transcription of the BCSG1 gene and that blockade of AP1 transactivation down-regulates BCSG1 expression and suppresses tumor phenotype.	Dept Vet Affairs, Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Liu, JW (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.				NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA83648-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD KE, 1998, MOL CELL BIOL, V20, P9203; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Grundker C, 2001, EUR J ENDOCRINOL, V145, P651, DOI 10.1530/eje.0.1450651; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Li SL, 2001, J BIOL CHEM, V276, P39368, DOI 10.1074/jbc.M106111200; Liu HF, 1999, WORLD J GASTROENTERO, V5, P15; Liu JW, 1997, J LIPID RES, V38, P2035; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Melkonyan H, 1998, J BIOL CHEM, V273, P27026, DOI 10.1074/jbc.273.41.27026; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Przybyszewski J, 2001, CARCINOGENESIS, V22, P1421, DOI 10.1093/carcin/22.9.1421; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Song MS, 2001, CANCER RES, V61, P8322; Steinmuller L, 2001, BIOCHEM J, V360, P599, DOI 10.1042/0264-6021:3600599	24	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31364	31372		10.1074/jbc.M201060200	http://dx.doi.org/10.1074/jbc.M201060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12072430	hybrid			2022-12-25	WOS:000177718700012
J	Marsin, AS; Bouzin, C; Bertrand, L; Hue, L				Marsin, AS; Bouzin, C; Bertrand, L; Hue, L			The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FRUCTOSE 2,6-BISPHOSPHATE; HEART 6-PHOSPHOFRUCTO-2-KINASE; PHOSPHORYLATION; GLUCOSE; MACROPHAGES; EXPRESSION; CELL; TRANSLOCATION; PATHOGENESIS	The activation of monocytes involves a stimulation of glycolysis, release of potent inflammatory mediators, and alterations in gene expression. All of these processes are known to be further increased under hypoxic conditions. The activated monocytes express inducible 6-phosphofructo-2-kinase (iPFK-2), which synthesizes fructose 2,6-bisphosphate, a stimulator of glycolysis. During ischemia, AMP-activated protein kinase (AMPK) activates the homologous heart 6-phosphofructo-2-kinase isoform by phosphorylating its Ser-466. Here, we studied the involvement of AMPK and iPFK-2 in the stimulation of glycolysis in activated monocytes under hypoxia. iPFK-2 was phosphorylated on the homologous serine (Ser-461) and activated by AMPK in vitro. The activation of human monocytes by lipopolysaccharide induced iPFK-2 expression and increased fructose 2,6-bisphosphate content and glycolysis. The incubation of activated monocytes with oligomycin, an inhibitor of oxidative phosphorylation, or under hypoxic conditions activated AMPK and further increased iPFK-2 activity, fructose 2,6-bisphosphate content, and glycolysis. In cultured human embryonic kidney 293 cells, the expression of a dominant-negative AMPK prevented both the activation and phosphorylation of co-transfected iPFK-2 by oligomycin. It is concluded that the stimulation of glycolysis by hypoxia in activated monocytes requires the phosphorylation and activation of iPFK-2 by AMPK.	Univ Louvain, Sch Med, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Christian de Duve Int Inst Cellular & Mol Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Hue, L (corresponding author), ICP UCL 7529, HORM Unit, 7529 Ave Hippocrate 75, B-1200 Brussels, Belgium.			Bertrand, Luc/0000-0003-0655-7099				Bertrand L, 1999, J BIOL CHEM, V274, P30927, DOI 10.1074/jbc.274.43.30927; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; CREPIN KM, 1993, J BIOL CHEM, V268, P15277; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Guida E, 1998, CELL PHYSIOL BIOCHEM, V8, P75, DOI 10.1159/000016272; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hempel SL, 1996, AM J RESP CELL MOL, V14, P170, DOI 10.1165/ajrcmb.14.2.8630267; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1974, BIOCHEM BIOPH RES CO, V58, P532, DOI 10.1016/S0006-291X(74)80453-5; HUNT TK, 1984, SURGERY, V96, P48; Kawaguchi T, 2001, J BIOL CHEM, V276, P28554, DOI 10.1074/jbc.M101396200; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; LANG CH, 1985, AM J PHYSIOL, V248, pR471, DOI 10.1152/ajpregu.1985.248.4.R471; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; ORLINSKA U, 1993, J CELL PHYSIOL, V157, P201, DOI 10.1002/jcp.1041570126; REMENSNYDER JP, 1968, AM J PATHOL, V52, P301; RUSSELL AR, 1999, AM J PHYSIOL, V277, pH643; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Suzuki T, 2000, BLOOD, V96, P2584; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; WEST MA, 1994, J TRAUMA, V37, P82, DOI 10.1097/00005373-199407000-00015; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282	33	274	286	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30778	30783		10.1074/jbc.M205213200	http://dx.doi.org/10.1074/jbc.M205213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12065600	hybrid			2022-12-25	WOS:000177579800049
J	Pazy, Y; Kulik, T; Bayer, EA; Wilchek, M; Livnah, O				Pazy, Y; Kulik, T; Bayer, EA; Wilchek, M; Livnah, O			Ligand exchange between proteins - Exchange of biotin and biotin derivatives between avidin and streptavidin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; EGG-WHITE AVIDIN; CRYSTAL-STRUCTURE; Y-90 BIOTIN; COMPLEX; BINDING; TRYPTOPHAN; SYSTEM	We have studied the structural elements that affect ligand exchange between the two high affinity biotin-binding proteins, egg white avidin and its bacterial analogue, streptavidin. For this purpose, we have developed a simple assay based on the antipodal behavior of the two proteins toward hydrolysis of biotinyl p-nitrophenyl ester (BNP). The assay provided the experimental basis for these studies. It was found that biotin migrates unidirectionally from streptavidin to avidin. Conversely, the biotin derivative, BNP, is transferred in the opposite direction, from avidin to streptavidin. A previous crystallographic study (Huberman, T., Eisenberg-Domovich, Y., Gitlin, G., Kulik, T., Bayer, E. A., Wilchek, M., and Livnah, O. (2001) J. Bio. Chem. 276, 32031-32039) provided insight into a plausible explanation for these results. These data revealed that the non-hydrolyzable BNP analogue, biotinylp-nitroanilide, was almost completely sheltered in streptavidin as opposed to avidin in which the disordered conformation of a critical loop resulted in the loss of several hydrogen bonds and concomitant exposure of the analogue to the solvent. In order to determine the minimal modification of the biotin molecule required to cause the disordered loop conformation, the structures of avidin and streptavidin were determined with norbiotin, homobiotin, and a common long-chain biotin derivative, biotinyl epsilon-aminocaproic acid. Six new crystal structures of the avidin and streptavidin complexes with the latter biotin analogues and derivatives were thus elucidated. It was found that extending the biotin side chain by a single CH2 group (i.e. homobiotin) is sufficient to result in this remarkable conformational change in the loop of avidin. These results bear significant biotechnological importance, suggesting that complexes containing biotinylated probes with streptavidin would be more stable than those with avidin. These findings should be heeded when developing new drugs based on lead compounds because it is difficult to predict the structural and conformational consequences on the resultant protein-ligand interactions.	Hebrew Univ Jerusalem, Dept Biol Chem, Inst Life Sci, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Livnah, O (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Inst Life Sci, Wolfson Ctr Appl Struct Biol, Givat Ram, IL-91904 Jerusalem, Israel.							BAYER EA, 1995, APPL BIOCHEM BIOTECH, V53, P1, DOI 10.1007/BF02783477; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; Cremonesi M, 1999, EUR J NUCL MED, V26, P110, DOI 10.1007/s002590050366; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Freitag S, 1998, J MOL BIOL, V279, P211, DOI 10.1006/jmbi.1998.1735; Freitag S, 1997, PROTEIN SCI, V6, P1157, DOI 10.1002/pro.5560060604; GREEN N. M., 1970, Methods in Enzymology, V18A, P418, DOI 10.1016/0076-6879(71)18342-5; GREEN NM, 1963, BIOCHEM J, V89, P599, DOI 10.1042/bj0890599; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; GREEN NM, 1965, BIOCHEM J, V94, P23; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; Huberman T, 2001, J BIOL CHEM, V276, P32031, DOI 10.1074/jbc.M102018200; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katz BA, 1997, J BIOL CHEM, V272, P13220, DOI 10.1074/jbc.272.20.13220; Katz BA, 1997, J MOL BIOL, V274, P776, DOI 10.1006/jmbi.1997.1444; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURZBAN GP, 1989, BIOCHEMISTRY-US, V28, P8537, DOI 10.1021/bi00447a040; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; LIVNAH O, 1993, FEBS LETT, V328, P165, DOI 10.1016/0014-5793(93)80986-5; Magnani P, 2000, BRIT J CANCER, V82, P616; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGANELLI G, 1990, INT J CANCER, V45, P1184, DOI 10.1002/ijc.2910450632; Paganelli G, 1999, EUR J NUCL MED, V26, P348, DOI 10.1007/s002590050397; PIRAN U, 1990, J IMMUNOL METHODS, V133, P141, DOI 10.1016/0022-1759(90)90328-S; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; WEBER PC, 1992, BIOCHEMISTRY-US, V31, P9350, DOI 10.1021/bi00154a004; WILCHEK M, 1990, METHOD ENZYMOL, V184, P5	33	62	64	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30892	30900		10.1074/jbc.M202874200	http://dx.doi.org/10.1074/jbc.M202874200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12055191	hybrid			2022-12-25	WOS:000177579800064
J	Rechkoblit, O; Zhang, YB; Guo, DY; Wang, ZG; Amin, S; Krzeminsky, J; Louneva, N; Geacintov, NE				Rechkoblit, O; Zhang, YB; Guo, DY; Wang, ZG; Amin, S; Krzeminsky, J; Louneva, N; Geacintov, NE			trans-lesion synthesis past bulky benzo[a]pyrene diol epoxide N-2-dG and N-6-dA lesions catalyzed by DNA bypass polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; HUMAN DINB1 GENE; TEMPLATE-PRIMER JUNCTION; N-RAS CODON-61; ESCHERICHIA-COLI; ERROR-PRONE; CRYSTAL-STRUCTURE; TRANSLESIONAL SYNTHESIS; VITRO REPLICATION; COMPLEX-FORMATION	The effectiveness of in vitro primer elongation reactions catalyzed by human bypass DNA polymerases kappa (hDinB1), pol eta (hRad30A), pol iota (hRad30B), and yeast pol zeta (Rev3 and Rev7) in site-specifically modified template oligonucleotide strands were studied in vitro. The templates contained single bulky lesions derived from the trans-addition of the mutagenic (+)- or (-)-enantiomers of r7,t8-dihydroxy-t9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (a metabolite of the environmental carcinogen benzo[a]pyrene), to the exocyclic amino groups of guanine or adenine in oligonucleotide templates 33, or more, bases long. In "running start" primer extension reactions, pol kappa effectively bypassed both the stereoisomeric (+)- and (-)-trans-guanine adducts but not the analogous adenine adducts. In sharp contrast, pol eta, which exhibits considerable sequence homology with pol kappa (both belong to the group of Y family polymerases), is partially blocked by the guanine adducts and the (-)-trans-adenine adduct, although the stereoisomeric (+)-trans-adenine adduct is more successfully bypassed. Neither pol iota nor pol zeta, either alone or in combination, were effective in trans-lesion synthesis past the same adducts. In all cases, the fidelity of insertion is dependent on adduct stereochemistry and structure. Generally, error-free nucleotide insertion opposite the lesions tends to depend more on adduct stereochemistry than error-prone insertion. None of the polymerases tested are a universal bypass polymerase for the stereoisomeric bulky polycyclic aromatic hydrocarbon-DNA adducts derived from anti-BPDE.	NYU, Dept Chem, New York, NY 10003 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Amer Hlth Fdn, Valhalla, NY 10595 USA	New York University; University of Kentucky; American Health Foundation	Geacintov, NE (corresponding author), NYU, Dept Chem, 29 Washington Pl, New York, NY 10003 USA.	nicholas.geacintov@nyu.edu	Zhang, Yanbin/F-2998-2011	Zhang, Yanbin/0000-0002-7263-5510; Rechkoblit, Olga/0000-0003-4270-7242	NCI NIH HHS [CA 92768, CA 20851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA092768, R01CA020851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alekseyev YO, 2000, BIOCHEMISTRY-US, V39, P10431, DOI 10.1021/bi000552u; Alekseyev YO, 2001, BIOCHEMISTRY-US, V40, P2282, DOI 10.1021/bi002245u; Chary P, 1997, J BIOL CHEM, V272, P5805, DOI 10.1074/jbc.272.9.5805; CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; CHRISTNER DF, 1994, BIOCHEMISTRY-US, V33, P14297, DOI 10.1021/bi00251a043; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; COSMAN M, 1990, CARCINOGENESIS, V11, P1667, DOI 10.1093/carcin/11.9.1667; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Feng BB, 1997, BIOCHEMISTRY-US, V36, P13769, DOI 10.1021/bi970069s; Fernandes A, 1998, BIOCHEMISTRY-US, V37, P10164, DOI 10.1021/bi980401f; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; GEACINTOV NE, 1991, CARCINOGENESIS, V12, P2099, DOI 10.1093/carcin/12.11.2099; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Guo DY, 2001, NUCLEIC ACIDS RES, V29, P2875, DOI 10.1093/nar/29.13.2875; Hanrahan CJ, 1997, CHEM RES TOXICOL, V10, P369, DOI 10.1021/tx9601925; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Krzeminski J, 1999, POLYCYCL AROMAT COMP, V17, P1, DOI 10.1080/10406639908020596; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Lipinski LJ, 1998, INT J ONCOL, V13, P269; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 2001, PHILOS T R SOC B, V356, P53, DOI 10.1098/rstb.2000.0748; MCLAUGHLIN LW, 1984, OLIGONUCLEOTIDE SYNT, P117; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Page JE, 1999, CHEM RES TOXICOL, V12, P258, DOI 10.1021/tx980244l; Perlow RA, 2001, J MOL BIOL, V309, P519, DOI 10.1006/jmbi.2001.4674; Pradhan P, 2001, BIOCHEMISTRY-US, V40, P5870, DOI 10.1021/bi002896q; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; Rechkoblit O, 2001, BIOCHEMISTRY-US, V40, P5622, DOI 10.1021/bi002543r; RECHKOBLIT O, 2002, THESIS NEW YORK U; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; Shukla R, 1997, BIOCHEMISTRY-US, V36, P13263, DOI 10.1021/bi971195z; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P6212, DOI 10.1021/bi9524732; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0; Zhuang P, 2001, BIOCHEMISTRY-US, V40, P6660, DOI 10.1021/bi010005o	69	164	168	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30488	30494		10.1074/jbc.M201167200	http://dx.doi.org/10.1074/jbc.M201167200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063247	hybrid			2022-12-25	WOS:000177579800013
J	Saito, H; Yasumoto, K; Takeda, K; Takahashi, K; Fukuzaki, A; Orikasa, S; Shibahara, S				Saito, H; Yasumoto, K; Takeda, K; Takahashi, K; Fukuzaki, A; Orikasa, S; Shibahara, S			Melanocyte-specific microphthalmia-associated transcription factor isoform activates its own gene promoter through physical interaction with lymphoid-enhancing factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WAARDENBURG-SYNDROME; ALPHA-ENHANCER; HUMAN HOMOLOG; BETA-CATENIN; MITF GENE; CELL; MUTATIONS; SOX10; PROTEIN; PAX3	Waardenburg syndrome type 2 (WS2) is associated with heterozygous mutations in the gene encoding microphthalmia-associated transcription factor (MITF) and characterized by deafness and hypopigmentation due to lack of melanocytes in the inner ear and skin. Melanocyte-specific MITF isoform (MITF-M) is essential for melanocyte differentiation and is transcriptionally induced by Wnt signaling that is mediated by beta-catenin and LEF-1. Here we show that MITF-M transactivates its own promoter (M promoter) by interacting with LEF-1, as judged by transient expression assays and in vitro protein-protein binding assays, whereas no transactivation of the M promoter was detected with MITF-M alone or with the combination of MITF-M and dominant-negative LEF1 that lacks the beta-catenin-binding domain. This synergy depends on the three LEF-1-binding sites that are clustered in the proximal M promoter. Importantly, MITF-M recruited on the M promoter could function as a non-DNA-binding cofactor for LEF-1. Thus, MITF-M may function as a self-regulator of its own expression to maintain a threshold level of MITF-M that is required for melanocyte development. We suggest that MITF-M haploinsufficiency may impair the dosage-sensitive role of MITF-M or the correct assembly of multiple transcription factors, involving MITF-M, on the M promoter, which could account for dominant inheritance of WS2.	Tohoku Univ, Sch Med, Dept Mol Biol & Appl Physiol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Urol, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University	Shibahara, S (corresponding author), Tohoku Univ, Sch Med, Dept Mol Biol & Appl Physiol, Aoba Ku, Sendai, Miyagi 9808575, Japan.		Shibahara, Shigeki/M-3644-2014; Takahashi, Kazuhiro/A-4887-2010	Takahashi, Kazuhiro/0000-0001-8943-1875; Yasumoto, Ken-ichi/0000-0002-8090-1161				Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; FARRER LA, 1994, AM J HUM GENET, V55, P728; Fuse N, 1999, J BIOCHEM-TOKYO, V126, P1043, DOI 10.1093/oxfordjournals.jbchem.a022548; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; Mochii M, 1998, DEV BIOL, V193, P47, DOI 10.1006/dbio.1997.8800; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOTOHASHI H, 1994, HEARING RES, V80, P10, DOI 10.1016/0378-5955(94)90003-5; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Oboki K, 2002, BIOCHEM BIOPH RES CO, V290, P1250, DOI 10.1006/bbrc.2002.6332; Ogihara H, 2001, BLOOD, V97, P645, DOI 10.1182/blood.V97.3.645; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x; STEEL KP, 1992, DEVELOPMENT, V115, P1111; Steingrimsson E, 1996, EMBO J, V15, P6280, DOI 10.1002/j.1460-2075.1996.tb01018.x; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; Takeda K, 2002, BBA-GENE STRUCT EXPR, V1574, P15, DOI 10.1016/S0167-4781(01)00339-6; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Watanabe KI, 2002, PIGM CELL RES, V15, P201, DOI 10.1034/j.1600-0749.2002.01080.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; Yajima I, 1999, HUM MOL GENET, V8, P1431, DOI 10.1093/hmg/8.8.1431; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874; Yasumoto K, 1998, PIGM CELL RES, V11, P329, DOI 10.1111/j.1600-0749.1998.tb00491.x; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Yasumoto K, 1997, J BIOL CHEM, V272, P503; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YOKOYAMA K, 1994, J BIOL CHEM, V269, P27080; YOSHIDA Y, 2000, GENES GENET SYST, V75, P364	55	80	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28787	28794		10.1074/jbc.M203719200	http://dx.doi.org/10.1074/jbc.M203719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048204	hybrid			2022-12-25	WOS:000177342600058
J	Billecke, CA; Ljungman, ME; McKay, BC; Rehemtulla, A; Taneja, N; Ethier, SP				Billecke, CA; Ljungman, ME; McKay, BC; Rehemtulla, A; Taneja, N; Ethier, SP			Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells	ONCOGENE			English	Article						retinoblastoma protein; UV radiation; apoptosis; DNA damage repair	NUCLEOTIDE EXCISION-REPAIR; MAMMARY EPITHELIAL-CELLS; LIGHT-INDUCED APOPTOSIS; RNA-POLYMERASE-II; ULTRAVIOLET-IRRADIATION; RETINOBLASTOMA PROTEIN; IONIZING-RADIATION; CASPASE ACTIVATION; SUPPRESSOR GENES; E7 PROTEIN	Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells. We have previously demonstrated that a human breast cancer cell line, MDA-MB-468, which lacks the retinoblastoma protein (pRb), is particularly sensitive to low doses of ultraviolet (UV) radiation. These cells are 15-20-fold more sensitive to UV radiation than cells with wild-type pRb. In order to understand the mechanisms of the high apoptotic response of MDA-MB-468 cells to UV radiation, we examined the effects of UV on these cells with regards to both membrane-mediated events and DNA damage. We found that MDA-MB-468 cells were resistant to all ligand-induced death receptor signaling. In addition, although UV activated caspase 8 in MDA-MB-468 cells, a peptide inhibitor of caspase 8 failed to inhibit UV-induced apoptosis. We then tested the possibility that nuclear events mediated the enhanced sensitivity to UV-induced apoptosis in these cells. Unlike UV-resistant cells, MDA-MB-468 cells were unable to recover mRNA synthesis after 5 J/m(2) UVC. We also found that the pRb-null DU-145 cells similarly had attenuated recovery of mRNA synthesis after UV radiation. In UV-resistant cells with wild-type pRb, the inactivation of pRb with HPV-16 E7 resulted in significant inhibition in their ability to recover mRNA synthesis and increased levels of apoptosis following UV radiation. Furthermore, pRb-null cells were deficient in repair of UV radiation-induced DNA damage. These data suggest that the sensitivity of MDA-MB-468 cells to UV radiation is due to defects in repair of DNA damage and recovery of mRNA synthesis rather than to membrane death receptor pathways. Inactivation of pRb may contribute to an increased sensitivity to UV radiation by attenuating repair of DNA lesions and recovery of mRNA synthesis following UV radiation.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Radiol, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada	University of Michigan System; University of Michigan; University of Ottawa; Ottawa Hospital Research Institute	Ethier, SP (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA.	spethier@umich.edu	McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Addison CL, 1997, J GEN VIROL, V78, P1653, DOI 10.1099/0022-1317-78-7-1653; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Boyer SN, 1996, CANCER RES, V56, P4620; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carlson CA, 2000, RADIAT RES, V154, P590, DOI 10.1667/0033-7587(2000)154[0590:LORPCW]2.0.CO;2; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Conforti G, 2000, ONCOGENE, V19, P2714, DOI 10.1038/sj.onc.1203583; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Fan GS, 1997, J BIOL CHEM, V272, P19413, DOI 10.1074/jbc.272.31.19413; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Game JC, 1999, GENETICS, V151, P485; Havre PA, 1998, CANCER RES, V58, P4733; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; McDougall J K, 1994, Curr Top Microbiol Immunol, V186, P101; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sartor CI, 1997, CANCER RES, V57, P978; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Taneja N, 2001, ONCOGENE, V20, P167, DOI 10.1038/sj.onc.1204054; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492	43	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4481	4489		10.1038/sj.onc.1205546	http://dx.doi.org/10.1038/sj.onc.1205546			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085226				2022-12-25	WOS:000176476700002
J	Hasegawa, M; Nelson, HH; Peters, E; Ringstrom, E; Posner, M; Kelsey, KT				Hasegawa, M; Nelson, HH; Peters, E; Ringstrom, E; Posner, M; Kelsey, KT			Patterns of gene promoter methylation in squamous cell cancer of the head and neck	ONCOGENE			English	Article						p16(INK4a); DAP-kinase; RASSF1A; E-Cadherin; hypermethylation; oral cancer; head and neck cancer	TUMOR-SUPPRESSOR GENE; E-CADHERIN EXPRESSION; CPG ISLAND; EPIGENETIC INACTIVATION; LUNG-CANCER; DNA HYPERMETHYLATION; BREAST CANCERS; HIGH-FREQUENCY; CARCINOMAS; RASSF1A	Promoter methylation is an important pathway in transcriptional silencing of known and candidate tumor suppressor genes in Head and Neck Squamous Cell Carcinoma (HNSCC). In order to study the association of tumor suppressor gene promoter methylation in HNSCC with patient clinical characteristics, especially alcohol consumption and tobacco smoking, we examined promoter methylation of the p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A genes using methylation-specific PCR (MSP) in 80 patients. The prevalence of p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A promoter methylation was 26/80 (32.5%), 19/80 (23.8%), 29/80 (36.3%), 6/80 (7.5%) respectively. In 48 cases (60%), at least one of these promoters was methylated. There was a significant association of methylation of any of these genes and ever smoking (P=0.006). p16(INK4a), gene promoter methylation was associated with a younger age of smoking initiation (P<0.03); E-Cadherin promoter methylation was associated with an increased number of pack years smoked (P<0.03). We also found an association of methylation of any gene and T status (OR=2.7, P<0.05). Tumors with p16(INK4a) methylation were significantly less likely to show lymph node metastasis (P<0.001). DAP-kinase promoter methylation was significantly associated with lymph node metastasis and this relationship was dependent upon p16(INK4a) promoter methylation status. Our results suggest that, in HNSCC, promoter methylation of these four genes accumulates with increasing tumor size. This may reflect distinct pathways of somatic inactivation leading to cancer; additional larger studies are needed to further investigate this possibility. Tobacco smoking may play an important role in both the occurrence of promoter methylation as well as delineating the precise pathway that eventually results in a tumorigenic phenotype.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm Epidemiol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Dent & Oral Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Adult Oncol, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.		Peters, Edward S/H-1077-2015; Kelsey, Karl T/I-1252-2014	Peters, Edward S/0000-0003-4928-6532; Nelson, Heather/0000-0003-1901-9513	NCI NIH HHS [CA78609] Funding Source: Medline; NIDCR NIH HHS [1P01-DE12467-05] Funding Source: Medline; NIEHS NIH HHS [ES08357, ES00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, R01ES008357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Belinsky SA, 1995, TOXICOL LETT, V82-3, P335, DOI 10.1016/0378-4274(95)03486-2; BLOT WJ, 1988, CANCER RES, V48, P3282; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Califano J, 1996, CANCER RES, V56, P2488; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Eguchi K, 1997, CANCER RES, V57, P4913; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lo KW, 2001, CANCER RES, V61, P3877; MAESTRO R, 1993, CANCER RES, V53, P5775; Morrissey C, 2001, CANCER RES, V61, P7277; Nagai MA, 1999, BRAZ J MED BIOL RES, V32, P897, DOI 10.1590/S0100-879X1999000700015; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reed AL, 1996, CANCER RES, V56, P3630; Riese U, 1999, INT J MOL MED, V4, P61; Rosas SLB, 2001, CANCER RES, V61, P939; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SARACCI R, 1987, EPIDEMIOL REV, V9, P175, DOI 10.1093/oxfordjournals.epirev.a036301; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPITZ MR, 1999, HEAD NECK CANC MULTI, P11; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YARBROUGH WG, 1994, LARYNGOSCOPE, V104, P1337; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	41	165	173	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4231	4236		10.1038/sj.onc.1205528	http://dx.doi.org/10.1038/sj.onc.1205528			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082610				2022-12-25	WOS:000176174200005
J	Rigacci, S; Rovida, E; Dello Sbarba, P; Berti, A				Rigacci, S; Rovida, E; Dello Sbarba, P; Berti, A			Low M-r phosphotyrosine protein phosphatase associates and dephosphorylates p125 focal adhesion kinase, interfering with cell motility and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; MIGRATION; OVEREXPRESSION; STIMULATION; INTEGRIN; SRC; AUTOPHOSPHORYLATION	Low M-r phosphotyrosine protein phosphatase interferes in vivo with the activation of several growth factor receptors and is transiently redistributed, following cell stimulation with platelet-derived growth factor, from the cytosol to the cytoskeleton. We demonstrate here that this phosphatase also participates in the regulation of cell spreading and migration, pointing to its involvement in cytoskeleton organization. Low M-r phosphotyrosine protein phosphatase-overexpressing fibroblasts are, indeed, less spread than controls and display a significantly decreased number of focal adhesions and increased cell motility. Furthermore, p125 focal adhesion kinase is associated to, and dephosphorylated by, low M-r phosphotyrosine protein phosphatase both in vitro and in vivo. This event is consistent with an altered association of pp60(src) with focal adhesion kinase. The activation of extracellular signal-regulated kinase, another well known event downstream of the focal adhesion kinase, is also affected. On the other hand, cells overexpressing the dominant-negative form of low M-r phosphotyrosine protein phosphatase exhibit hyperphosphorylated focal adhesion kinase, reduced motility, and an increased number of focal adhesions, which are distributed all over the ventral cell surface. Taken together, the results reported here are in keeping with low M-r phosphotyrosine protein phosphatase participation in FAK-mediated focal adhesion remodeling.	Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy; Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy	University of Florence; University of Florence; University of Florence	Berti, A (corresponding author), Univ Florence, Dept Expt Pathol & Oncol, Viale Morgagni 50, I-50134 Florence, Italy.	berti_a@scibio.unifi.it	Rovida, Elisabetta/F-3565-2015; Dello Sbarba, Persio/AAX-9887-2020	Rovida, Elisabetta/0000-0002-5949-3239; 				Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Cary LA, 1996, J CELL SCI, V109, P1787; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; Chiarugi P, 2000, J BIOL CHEM, V275, P37619, DOI 10.1074/jbc.M006375200; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; ILLC D, 1995, NATURE, V377, P539; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; Ren XD, 2000, J CELL SCI, V113, P3673; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Rigacci S, 1998, FEBS LETT, V432, P145, DOI 10.1016/S0014-5793(98)00847-3; Rigacci S, 1999, FEBS LETT, V459, P191, DOI 10.1016/S0014-5793(99)01234-X; Rovida E, 1998, BIOCHEM BIOPH RES CO, V253, P300, DOI 10.1006/bbrc.1998.9736; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	33	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41631	41636		10.1074/jbc.M201709200	http://dx.doi.org/10.1074/jbc.M201709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12055185	Green Published, hybrid			2022-12-25	WOS:000178985300043
J	Shimada, M; Chen, X; Cvrk, T; Hilfiker, H; Parfenova, M; Segre, GV				Shimada, M; Chen, X; Cvrk, T; Hilfiker, H; Parfenova, M; Segre, GV			Purification and characterization of a receptor for human parathyroid hormone and parathyroid hormone-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PROTEIN-RECEPTOR; NMR SOLUTION STRUCTURE; BINDING DOMAIN; HUMORAL HYPERCALCEMIA; H-1-NMR SPECTROSCOPY; ADENYLATE-CYCLASE; TERMINAL REGION; AMINO-TERMINUS; FRAGMENT 1-34; TRANSMEMBRANE RESIDUES	The human parathyroid hormone (PTH) receptor (hPTH1R), containing a 9-amino, acid sequence of rhodopsin at its C terminus, was transiently expressed in COS-7 cells and solubilized with 0.25% n-dodecyl maltoside. Approximately 18 mug of hPTH1R were purified to homogeneity per mg of crude membranes by single-step affinity chromatography using 1D4, a monoclonal antibody to a rhodopsin epitope. The N terminus of the hPTH1R is Tyr(23), consistent with removal of the 22-amino acid signal peptide. Comparisons of hPTH1R by quantitative immunoblotting and Scatchard analysis revealed that 75% of the receptors in membrane preparations were functional; there was little, if any, loss of functional receptors during purification. The binding affinity of the purified hPTH1R was slightly lower than membrane-embedded hPTH1R (K-d = 16.5 +/- 1.3 versus 11.9 +/- 1.9 nm), and the purified receptors bound rat [Nle(8,21),Tyr(34)]PTH-(1-34)-NH2 (PTH-(1-34)), and rat [Ile(5)Trp(23),Tyr(36)]PTHrP-(5-36)-NH2 with indistinguishable affinity. Maximal displacement of I-125-PTH-(1-34) binding by rat [alpha-aminoisobutyric acid (Aib)(1,3),Nle(8),Gln(10),Har(11),Ala(12),Trp(14),Arg(19),Tyr(21)]PTH-(1-21)-NH2 and rat Aib(1,3),Gln(10),Ha(11),Ala(12),Trp(14)]PTH-(1-14)-NH2 of 80 and 10%, respectively, indicates that both N-terminal and juxtamembrane ligand binding determinants are functional in the purified hPTH1R. Finally, PTH stimulated [S-35]GTPgammaS incorporation into Galpha(s) in a time- and dose-dependent manner, when recombinant hPTH1R, Galpha(s)-, and betagamma-subunits were reconstituted in phospholipid vesicles. The methods described will enable structural studies of the hPTH1R, and they provide an efficient and general technique to purify proteins, particularly those of the class 11 G protein-coupled receptor family.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Segre, GV (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Wellman 501, Boston, MA 02114 USA.	segre@helix.mgh.harvard.edu			NIDDK NIH HHS [DK-47034, DK-11794] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Assil IQ, 2001, BIOCHEMISTRY-US, V40, P1187, DOI 10.1021/bi001758y; Barbier JR, 1997, J MED CHEM, V40, P1373, DOI 10.1021/jm960743o; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; Barden JA, 1997, J BIOL CHEM, V272, P29572, DOI 10.1074/jbc.272.47.29572; Barden JA, 1996, BIOCHEM BIOPH RES CO, V220, P431, DOI 10.1006/bbrc.1996.0390; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BARDEN JA, 1994, BIOCHIM BIOPHYS ACTA, V19, P256; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Beyermann M, 2000, J BIOL CHEM, V275, P5702, DOI 10.1074/jbc.275.8.5702; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BUNDI A, 1978, EUR J BIOCHEM, V91, P201, DOI 10.1111/j.1432-1033.1978.tb20952.x; BUNDI A, 1976, FEBS LETT, V64, P126, DOI 10.1016/0014-5793(76)80265-7; Chen ZG, 2000, BIOCHEMISTRY-US, V39, P12766, DOI 10.1021/bi000882e; CHOREV M, 2001, PRINCIPLES BONE BIOL, P423; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; EPAND RM, 1985, INT J PEPT PROT RES, V25, P594; Friedman PA, 1999, ENDOCRINOLOGY, V140, P301, DOI 10.1210/en.140.1.301; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Gronwald W, 1996, BIOL CHEM H-S, V377, P175, DOI 10.1515/bchm3.1996.377.3.175; Gronwald W, 1997, BIOL CHEM, V378, P1501, DOI 10.1515/bchm.1997.378.12.1501; Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; Inooka H, 2001, NAT STRUCT BIOL, V8, P161, DOI 10.1038/84159; Jin L, 2000, J BIOL CHEM, V275, P27238; Juarranz MG, 1999, MOL PHARMACOL, V56, P1280, DOI 10.1124/mol.56.6.1280; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kronenberg HM, 1998, RECENT PROG HORM RES, V53, P283; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEE SC, 1989, BIOPOLYMERS, V28, P1115, DOI 10.1002/bip.360280606; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; MALBON CC, 1975, BIOCHEM BIOPH RES CO, V66, P179, DOI 10.1016/S0006-291X(75)80311-1; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Maretto S, 1997, BIOCHEMISTRY-US, V36, P3300, DOI 10.1021/bi9619031; Marx UC, 1998, J BIOL CHEM, V273, P4308, DOI 10.1074/jbc.273.8.4308; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; Mierke DF, 1997, BIOCHEMISTRY-US, V36, P10372, DOI 10.1021/bi970771o; Mirzabekov T, 2000, NAT BIOTECHNOL, V18, P649, DOI 10.1038/76501; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; NISSENSON RA, 1986, ENDOCRINOLOGY, V118, P932, DOI 10.1210/endo-118-3-932; Ohtaki T, 1998, J BIOL CHEM, V273, P15464, DOI 10.1074/jbc.273.25.15464; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Pellegrini M, 1997, J MED CHEM, V40, P3025, DOI 10.1021/jm970181o; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Pellegrini M, 1996, BIOPOLYMERS, V40, P653, DOI 10.1002/(SICI)1097-0282(1996)40:6<653::AID-BIP5>3.0.CO;2-V; Piserchio A, 2000, BIOCHEMISTRY-US, V39, P8153, DOI 10.1021/bi000196f; RAY FR, 1993, EUR J BIOCHEM, V211, P205, DOI 10.1111/j.1432-1033.1993.tb19887.x; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SHIGENO C, 1988, J BIOL CHEM, V263, P3864; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Shimizu M, 2001, ENDOCRINOLOGY, V142, P3068, DOI 10.1210/en.142.7.3068; Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; TEITELBAUM AP, 1982, ENDOCRINOLOGY, V111, P1524, DOI 10.1210/endo-111-5-1524; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; UNENO S, 1992, CALCIFIED TISSUE INT, V51, P382, DOI 10.1007/BF00316884; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Weidler M, 1999, FEBS LETT, V444, P239, DOI 10.1016/S0014-5793(98)01658-5; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	89	26	31	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31774	31780		10.1074/jbc.M204166200	http://dx.doi.org/10.1074/jbc.M204166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080067	hybrid			2022-12-25	WOS:000177718700059
J	Fernandez, SBM; Hollo, Z; Kern, A; Bakos, E; Fischer, PA; Borst, P; Evers, R				Fernandez, SBM; Hollo, Z; Kern, A; Bakos, E; Fischer, PA; Borst, P; Evers, R			Role of the N-terminal transmembrane region of the multidrug resistance protein MRP2 in routing to the apical membrane in MDCKII cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; PDZ-INTERACTING DOMAIN; MONOCLONAL-ANTIBODIES; DRUG-RESISTANCE; LEUKOTRIENE C-4; EXPORT PUMP; CMOAT MRP2; GLUTATHIONE; GENE; LOCALIZATION	In polarized cells, the multidrug resistance protein MRP2 is localized in the apical plasma membrane, whereas MRP1, another multidrug resistance protein (MRP) family member, is localized in the basolateral membrane. MRP1 and MRP2 are thought to contain an N-terminal region of five transmembrane segments (TMDO) coupled to 2 times six transmembrane segments via an intracellular loop (L-0). We previously demonstrated for MRP1 that a mutant lacking TMD0 but still containing L-0, called L(0)DeltaMRP1, was functional and routed to the lateral plasma membrane. To investigate the role of the TMD0L0 region of MRP2 in routing to the apical membrane, we generated mutants similar to those made for MRP1. In contrast to L(0)DeltaMRP1, L(0)DeltaMRP2 was associated with an intracellular compartment, most likely endosomes. Co-expression with TMD0, however, resulted in apical localization of L(0)DeltaMRP2 and transport activity. Uptake experiments with vesicles containing L(0)DeltaMRP2 demonstrated that the molecule is able to transport LTC4. An MRP2 mutant without TMD0L0, DeltaMRP2, was only core-glycosylated and localized intracellularly. Co-expression of DeltaMRP2 with TMD0L0 resulted in an increased protein level of DeltaMRP2, full glycosylation of the protein, routing to the apical membrane, and transport activity. Our results suggest that the TMD0 region is required for routing to or stable association with the apical membrane.	Merck & Co Inc, Dept Drug Metab, Rahway, NJ 07065 USA; Merck & Co Inc, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Georg Speyer Haus, D-60596 Frankfurt, Germany; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary	Merck & Company; Merck & Company; Netherlands Cancer Institute; Netherlands Cancer Institute; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Evers, R (corresponding author), Merck & Co Inc, Dept Drug Metab, RY80E-200,POB 2000, Rahway, NJ 07065 USA.	Raymond_Evers@merck.com	Kern, Andras/F-2823-2014					ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BAKOS E, 1996, BIOCHEM J, V323, P777; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; ELFERINK RPJO, 1993, BIOCHEM J, V290, P759, DOI 10.1042/bj2900759; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Harris MJ, 2001, J BIOL CHEM, V276, P20876, DOI 10.1074/jbc.M010566200; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; Jedlitschky G, 1996, CANCER RES, V56, P988; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kleizen B, 2000, EUR J CELL BIOL, V79, P544, DOI 10.1078/0171-9335-00078; Kocher O, 1999, LAB INVEST, V79, P1161; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; KOOL M, 1997, CANCER RES, V57, P3527; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; LEIER I, 1994, J BIOL CHEM, V269, P27807; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Loe DW, 1998, CANCER RES, V58, P5130; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Milewski MI, 2001, J CELL SCI, V114, P719; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Rappa G, 1997, CANCER RES, V57, P5232; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Scheffer GL, 2000, CANCER RES, V60, P5269; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; Zeng H, 1999, CANCER RES, V59, P5964	45	61	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31048	31055		10.1074/jbc.M204267200	http://dx.doi.org/10.1074/jbc.M204267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060660	hybrid			2022-12-25	WOS:000177579800083
J	Liu, T; Lee, YN; Malbon, CC; Wang, HY				Liu, T; Lee, YN; Malbon, CC; Wang, HY			Activation of the beta-catenin/Lef-Tcf pathway is obligate for formation of primitive endoderm by mouse F9 totipotent teratocarcinoma cells in response to retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; FUNCTIONAL INTERACTION; PHOSPHOLIPASE-C; RAT FRIZZLED-1; AXIS FORMATION; WINGLESS; TRANSCRIPTION; COMPLEX; FAMILY; MEMBER	The morphogen retinoic acid promotes the formation of primitive endoderm in mouse F9 teratocarcinoma cells as does the stimulation of the Frizzled-1 pathway. We investigated whether the beta-catenin/Lef-Tef-sensitive transcriptional pathway activated by Frizzled-1 plays a role in the retinoic acid-induced pathway to primitive endoderm formation. An analysis of Lef-Tcf-sensitive transcription reveals increased transcription at 1 and 4 h post-treatment with retinoic acid. The stimulation of Lef-Tcf-sensitive transcription as well as the formation of primitive endoderm was accompanied by the stabilization of beta-catenin as observed in activation of the Frizzled-1 pathway. Transient transfection of F9 cells with an expression vector harboring a dominant-negative mutant of Tcf4 resulted in the attenuation of both the increase in Lef-Tef-sensitive transcription and formation of primitive endoderm in response to the morphogen. Clones stably transfected to express the dominant-negative Tcf4 displayed a block in retinoic acid-induced activation of Lef-Tcf-sensitive transcription and primitive endoderm formation. These data reveal the obligate role of the beta-catenin/Lef-Tcf transcriptional pathway in the action of the morphogen retinoic acid.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol, Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	wangh@pharm.sunysb.edu	malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32 DK 07521] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Cox RT, 1998, CURR BIOL, V8, pR140, DOI 10.1016/S0960-9822(98)70081-8; Durston AJ, 1998, CURR TOP DEV BIOL, V40, P111, DOI 10.1016/S0070-2153(08)60366-X; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	44	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30887	30891		10.1074/jbc.M203852200	http://dx.doi.org/10.1074/jbc.M203852200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063257	hybrid			2022-12-25	WOS:000177579800063
J	Roder, K; Latasa, MJ; Sul, HS				Roder, K; Latasa, MJ; Sul, HS			Silencing of the mouse H-rev107 gene encoding a class II tumor suppressor by CpG methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; BINDING-PROTEINS; CELL-LINES; TRANSCRIPTIONAL REPRESSION; EXPRESSION; CHROMATIN; CLONING; COMPLEX; FAMILY; IDENTIFICATION	H-rev107 is a tumor suppressor originally isolated in revertants of H-ras-transformed cell lines. The gene is ubiquitously expressed in normal tissues but down-regulated in primary carcinomas or in many cell lines derived from tumors, including WEHI 7.1 lymphoma cells. Here, we show that unlike in H-rev107-expressing cells or tissues the 5'-end of H-rev107 containing a CpG-rich region of 421 bp is highly methylated in WEHI 7.1 lymphoma cells, correlating with silencing of this gene. Repression of H-rev107 transcription in these cells could be relieved by chemically induced hypomethylation with 5-aza-dC. In addition, upon in vitro methylation, expression of the luciferase reporter gene driven by the H-rev107 promoter decreased by 80% in WEHI 7.1 and 293 cells. Furthermore, co-transfection of the methyl-CpG binding proteins, MeCP2 and MBD2, inhibited H-rev107 promoter activity up to 70% in SL2 cells when the promoter was methylated. By chromatin immunoprecipitation assays, we observed in vivo binding of MeCP2 and MBD2 to the 5'-end of H-rev107 in WEHI 7.1 cells, which was reduced to undetectable levels upon 5-aza-dC treatment, concluding that MeCP2 and MBD2 might be involved in silencing the methylated H-rev107 gene in lymphoma cells and probably certain tumors.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Morgan Hall,Rm 219, Berkeley, CA 94720 USA.		Latasa, Maria-Jesus/M-8704-2014; Han, Zaiqi/AAI-2233-2019	Latasa, Maria-Jesus/0000-0003-2840-8692; 	NIDDK NIH HHS [DK 50828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama H, 1999, J BIOL CHEM, V274, P32192, DOI 10.1074/jbc.274.45.32192; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cho JH, 2001, ENDOCRINOLOGY, V142, P3389, DOI 10.1210/en.142.8.3389; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; Feng Q, 2001, GENE DEV, V15, P827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gregory RI, 2001, MOL CELL BIOL, V21, P5426, DOI 10.1128/MCB.21.16.5426-5436.2001; HAJNAL A, 1994, ONCOGENE, V9, P479; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Quesnel B, 1999, LEUKEMIA LYMPHOMA, V35, P437, DOI 10.1080/10428199909169608; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Siegrist S, 2001, ONCOGENE, V20, P5155, DOI 10.1038/sj.onc.1204658; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	36	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30543	30550		10.1074/jbc.M111891200	http://dx.doi.org/10.1074/jbc.M111891200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12055182	hybrid			2022-12-25	WOS:000177579800020
J	Heyes, CD; El-Sayed, MA				Heyes, CD; El-Sayed, MA			The role of the native lipids and lattice structure in bacteriorhodopsin protein conformation and stability as studied by temperature-dependent Fourier transform-infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-BLUE TRANSITION; X-RAY-DIFFRACTION; METAL-ION-BINDING; PURPLE MEMBRANE; CATION-BINDING; CIRCULAR-DICHROISM; SECONDARY STRUCTURE; PHASE-TRANSITIONS; ABSORPTION; PH	We report the effect of partial delipidation and monomerization on the protein conformational changes of bacteriorhodopsin (bR) as a function of temperature. Removal of up to 75% of the lipids is known to have the lattice structure of the purple membrane, albeit as a smaller unit cell, whereas treatment by Triton monomerizes bR into micelles. The effects of these modifications on the protein secondary structure is analyzed by monitoring the protein amide I and amide II bands in the Fourier transform-infrared (FT-IR) spectra. It is found that removal of the first 75% of the lipids has only a slight effect on the secondary structure at physiological temperature, whereas monomerizing bR into micelles alters the secondary structure considerably. Upon heating, the bR monomer is found to have a very low thermal stability compared with the native bR with its melting point reduced from 97 to 65 degreesC, and the premelting transition in which the protein changes conformation in native bR at 80 degreesC could not be observed. Also, the N-H to N-D exchange of the amide II band is effectively complete at room temperature, suggesting that there are no hydrophobic regions that are protected from the aqueous medium, possibly explaining the low thermal stability of the monomer. On the other hand, 75% delipidated bR has its melting temperature close to that of the native bR and does have a pre-melting transition, although the pre-melting transition occurs at significantly higher temperature than that of the native bR (91 degreesC compared with 80 degreesC) and is still reversible. Furthermore, we have also observed that the reversibility of this pre-melting transition of both native and partially delipidated bR is time-dependent and becomes irreversible upon holding at 91 degreesC between 10 and 30 min. These results are discussed in terms of the lipid and lattice contribution to the protein thermal stability of native bR.	Georgia Inst Technol, Sch Chem & Biochem, Laser Dynam Lab, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	El-Sayed, MA (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Laser Dynam Lab, 770 State St, Atlanta, GA 30332 USA.	mostafa.el-sayed@chemistry.gatech.edu		Heyes, Colin/0000-0003-1124-9947				ARIKI M, 1986, J BIOL CHEM, V261, P8167; Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; BIRGE RR, 1981, ANNU REV BIOPHYS BIO, V10, P315, DOI 10.1146/annurev.bb.10.060181.001531; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; CHANG CH, 1986, BIOPHYS J, V49, P731, DOI 10.1016/S0006-3495(86)83699-2; CHANG CH, 1985, P NATL ACAD SCI USA, V82, P396, DOI 10.1073/pnas.82.2.396; CLADERA J, 1992, COLLOQ INSE, V221, P33; DENCHER NA, 1978, FEBS LETT, V96, P322, DOI 10.1016/0014-5793(78)80427-X; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; DRACHEV LA, 1974, NATURE, V249, P321, DOI 10.1038/249321a0; DUNACH M, 1989, BIOCHEMISTRY-US, V28, P8940, DOI 10.1021/bi00448a038; Eliash T, 1999, FEBS LETT, V447, P307, DOI 10.1016/S0014-5793(99)00289-6; ELSAYED MA, 1992, ACCOUNTS CHEM RES, V25, P279, DOI 10.1021/ar00019a002; ElSayed MA, 1995, ISR J CHEM, V35, P465; GIBSON NJ, 1989, BIOCHEMISTRY-US, V28, P2134, DOI 10.1021/bi00431a026; GLAESER RM, 1985, BIOPHYS J, V48, P775, DOI 10.1016/S0006-3495(85)83835-2; Griffiths JA, 1996, J PHYS CHEM-US, V100, P929, DOI 10.1021/jp952951i; Heyes CD, 2002, BIOPHYS J, V82, P1598, DOI 10.1016/S0006-3495(02)75511-2; Heyes CD, 2001, BIOCHEMISTRY-US, V40, P11819, DOI 10.1021/bi002594o; HIRAKI K, 1981, BIOCHIM BIOPHYS ACTA, V647, P18, DOI 10.1016/0005-2736(81)90291-1; HIRAKI K, 1981, PHOTOCHEM PHOTOBIOL, V33, P429, DOI 10.1111/j.1751-1097.1981.tb05442.x; HUANG KS, 1980, P NATL ACAD SCI-BIOL, V77, P323, DOI 10.1073/pnas.77.1.323; JACKSON MB, 1978, BIOCHEMISTRY-US, V17, P911, DOI 10.1021/bi00598a026; JANG DJ, 1988, P NATL ACAD SCI USA, V85, P5918, DOI 10.1073/pnas.85.16.5918; JONAS R, 1990, PHOTOCHEM PHOTOBIOL, V52, P1163, DOI 10.1111/j.1751-1097.1990.tb08455.x; Kawase Y, 2000, BIOCHEMISTRY-US, V39, P14472, DOI 10.1021/bi0015820; KIMURA Y, 1984, PHOTOCHEM PHOTOBIOL, V40, P641, DOI 10.1111/j.1751-1097.1984.tb05353.x; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; KRESHECK GC, 1990, J PHOTOCH PHOTOBIO B, V7, P289, DOI 10.1016/1011-1344(90)85163-Q; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; KUSHWAHA SC, 1975, CAN J BIOCHEM CELL B, V53, P284, DOI 10.1139/o75-040; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Lanyi JK, 1999, FEBS LETT, V464, P103, DOI 10.1016/S0014-5793(99)01685-3; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MASUDA S, 1995, J PHYS CHEM-US, V99, P7776, DOI 10.1021/j100019a066; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MOWERY PC, 1979, BIOCHEMISTRY-US, V18, P4100, DOI 10.1021/bi00586a007; Nollert P, 1999, FEBS LETT, V457, P205, DOI 10.1016/S0014-5793(99)01014-5; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; Oesterhelt D, 1974, Methods Enzymol, V31, P667; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; SUBRAMANIAM S, 1993, EMBO J, V12, P1; SZUNDI I, 1987, P NATL ACAD SCI USA, V84, P3681, DOI 10.1073/pnas.84.11.3681; SZUNDI I, 1989, BIOPHYS J, V56, P369, DOI 10.1016/S0006-3495(89)82683-9; SZUNDI I, 1988, BIOPHYS J, V54, P227, DOI 10.1016/S0006-3495(88)82951-5; TANEVA SG, 1995, FEBS LETT, V367, P297, DOI 10.1016/0014-5793(95)00570-Y; Torres J, 1995, BIOCHEMISTRY-US, V34, P16320, DOI 10.1021/bi00050a012; Tuzi S, 1996, BIOCHEMISTRY-US, V35, P7520, DOI 10.1021/bi960274s; TUZI S, 1994, BIOCHEMISTRY-US, V33, P15046, DOI 10.1021/bi00254a013; Varo G, 1999, BIOPHYS J, V76, P3219, DOI 10.1016/S0006-3495(99)77473-4; VOGEL H, 1987, J BIOL CHEM, V262, P11464; VSEVOLODOV NN, 1998, BIOMOLECULAR ELECT I; Wang JP, 1999, BIOPHYS J, V76, P2777, DOI 10.1016/S0006-3495(99)77431-X; Wang JP, 2002, J PHYS CHEM B, V106, P723, DOI 10.1021/jp013131a	56	29	29	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29437	29443		10.1074/jbc.M203435200	http://dx.doi.org/10.1074/jbc.M203435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058039	hybrid			2022-12-25	WOS:000177509300013
J	Lennon, AM; Ramauge, M; Dessouroux, A; Pierre, M				Lennon, AM; Ramauge, M; Dessouroux, A; Pierre, M			MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; PPAR-GAMMA; SIGNAL-TRANSDUCTION; ASTROGLIAL CELLS; OXIDATIVE STRESS; DIFFERENTIATION; PROSTAGLANDINS; IRRADIATION; REQUIREMENT; EXPRESSION	15-Deoxy-Delta(12-14)-prostaglandin J(2) (dPGJ2) and thiazolidinediones are known as ligands for the peroxisome proliferator activator receptor gamma (PPARgamma) a member of the nuclear receptor superfamily. Herein, we show that dPGJ2 activates, in cultured primary astrocytes, Erk, Jnk, p38 MAP kinase, and ASK1, a MAP kinase kinase kinase, which can be involved in the activation of Jnk and p38 MAP kinase. The activation kinetic is similar for the three MAP kinase. The activation of the MAP kinases is detectable around 0.5 h. The activation increases with dPGJ2 in a dose dependent manner (0-15 muLM). A scavenger of reactive oxygenated species; (ROS), N-acetylcysteine (NAC) at 20 mm, completely suppresses the activation of MAP kinases and ASK1, suggesting a role for oxidative stress in the activation mechanism. Other prostaglandin cyclopentenones than dPGJ2, A(2), and to a lesser degree, A(1) also stimulate the MAP kinases, although they do not bind to PPARgamma. Ciglitazone (20 muM), a thiazolidinedione that mimics several effects of dPGJ2 in different cell types, also activates the three MAP kinase families and ASK1 in cultured astrocytes. However the activation is more rapid (it is detectable at 0.25 h) and more sustained (it is still strong after 4 h). NAC prevents the activation of the three MAP kinase families by ciglitazone. Another thiazolidinedione that binds to PPARgamma, rosiglitazone, does not activate MAP kinases, indicating that the effect of ciglitazone on MAP kinases is independent of PPAR gamma. Ciglitazone and less strongly dPGJ2 activate Erk in undifferentiated cells of the adipocyte cell line 1B8. Ciglitazone also activates Jnk and p38 MAP kinase in these preadipocytes. Our findings suggest that a part of the biological effects of dPGJ2 and ciglitazone involve the activation of the three MAP kinase families probably through PPARgamma-independent mechanisms involving ROS.	INSERM Unite 488, Unite Rech Steroides & Syst Nerveux, F-94276 Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Pierre, M (corresponding author), INSERM Unite 488, Unite Rech Steroides & Syst Nerveux, 80 Ave Gen Leclerc, F-94276 Le Kremlin Bicetre, France.							Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; COURTIN F, 1988, ENDOCRINOLOGY, V123, P1577, DOI 10.1210/endo-123-3-1577; COURTIN F, 1991, J NEUROCHEM, V54, P1056; Duh JL, 1997, PHARMACEUT RES, V14, P186, DOI 10.1023/A:1012048626963; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; ESFANDIARI A, 1994, ENDOCRINOLOGY, V135, P2086, DOI 10.1210/en.135.5.2086; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAVARET J M, 1989, Developmental Brain Research, V45, P77, DOI 10.1016/0165-3806(89)90009-6; KLAUS S, 1994, J CELL SCI, V107, P313; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larose M, 1996, J BIOL CHEM, V271, P31533, DOI 10.1074/jbc.271.49.31533; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Lennon AM, 2002, BIOCHEM PHARMACOL, V63, P163, DOI 10.1016/S0006-2952(01)00826-7; MCKNIGHT SG, 1977, ANAL BIOCHEM, V78, P86; Murga C, 1999, TRENDS ENDOCRIN MET, V10, P122, DOI 10.1016/S1043-2760(98)00131-3; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; SANTORO MG, 1994, EXPERIENTIA, V50, P1039, DOI 10.1007/BF01923459; STEVENSON MA, 1994, CANCER RES, V54, P12; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wilmer WA, 2001, BIOCHEM BIOPH RES CO, V281, P57, DOI 10.1006/bbrc.2001.4301; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962	33	127	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29681	29685		10.1074/jbc.M201517200	http://dx.doi.org/10.1074/jbc.M201517200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12052825	hybrid			2022-12-25	WOS:000177509300044
J	Huang, M; Wang, YH; Collins, M; Gu, JJ; Mitchell, BS; Graves, LM				Huang, M; Wang, YH; Collins, M; Gu, JJ; Mitchell, BS; Graves, LM			Inhibition of nucleoside transport by p38 MAPK inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LEUKEMIA-CELLS; SELECTIVE INHIBITOR; MAMMALIAN-CELLS; T-CELLS; SITE; EXPRESSION; LINES	While investigating the ability of p38 MAPK to regulate cytarabine (Ara C)-dependent differentiation of erythroleukemia K562 cells, we observed effects that indicated that the imidazoline class of p38 MAPK inhibitors prevented nucleoside transport. Incubation of K562 cells with SB203580, SB203580-iodo, or SB202474, an analogue of SB203580 that does not inhibit p38 MAPK activity, inhibited the uptake of [H-3]Ara C or [H-3]uridine and the differentiation of K562 cells. Consistent with the effects of these compounds on the nitrobenzylthioinosine (NBMPR)-sensitive equilibrative nucleoside transporter (ENT1), incubation with SB203580 or SB203580-iodo eliminated the binding of [H-3]NBMPR to K562 cells or membranes isolated from human erythrocytes. Furthermore, using a uridine-dependent cell type (G9c), we observed that SB203580 or SB203580-iodo efficiently inhibited the salvage synthesis of pyrimidine nucleotides in vivo. Thus these studies demonstrate that the NBMPR-sensitive equilibrative nucleoside transporters are novel and unexpected targets for the p38 MAPK inhibitors at concentrations typically used to inhibit protein kinases.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Graves, LM (corresponding author), Univ N Carolina, Dept Pharmacol, 936 Mary Ellen Jones Bldg CB 7365, Chapel Hill, NC 27599 USA.		Graves, Lee/AAG-5470-2021		NCI NIH HHS [R01-CA34085] Funding Source: Medline; NIGMS NIH HHS [R01-GM59767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badger AM, 2000, ARTHRITIS RHEUM, V43, P175, DOI 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S; Banerjei LC, 1997, SOMAT CELL MOLEC GEN, V23, P37, DOI 10.1007/BF02679954; Boleti H, 1997, NEUROPHARMACOLOGY, V36, P1167, DOI 10.1016/S0028-3908(97)00136-6; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Cannons JL, 2000, J IMMUNOL, V165, P6193, DOI 10.4049/jimmunol.165.11.6193; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CLUMECK N, 1993, J ANTIMICROB CHEMOTH, V32, P133, DOI 10.1093/jac/32.suppl_A.133; Collis AJ, 2001, BIOORG MED CHEM LETT, V11, P693, DOI 10.1016/S0960-894X(01)00034-8; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Gati WP, 1997, BLOOD, V90, P346; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Hammond JR, 2000, N-S ARCH PHARMACOL, V361, P373, DOI 10.1007/s002100000214; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; Huang M, 2002, MOL PHARMACOL, V61, P569, DOI 10.1124/mol.61.3.569; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Koprak S, 1999, CELL IMMUNOL, V192, P87, DOI 10.1006/cimm.1998.1448; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; NAGY K, 1995, LEUKEMIA RES, V19, P203, DOI 10.1016/0145-2126(94)00138-Z; Pastor-Anglada M, 2001, MOL MEMBR BIOL, V18, P81, DOI 10.1080/096876800110033783; Schafer PH, 1999, J IMMUNOL, V162, P7110; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; ULLMAN B, 1989, ADV EXP MED BIOL, V253, P415; Wadsworth SA, 1999, J PHARMACOL EXP THER, V291, P680; Ward JL, 1999, BBA-BIOMEMBRANES, V1419, P15, DOI 10.1016/S0005-2736(99)00045-0; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	29	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28364	28367		10.1074/jbc.C200321200	http://dx.doi.org/10.1074/jbc.C200321200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12077112	Green Published, hybrid			2022-12-25	WOS:000177342600002
J	Velazquez, C; Vidavsky, I; van der Drift, K; Gross, ML; Unanue, ER				Velazquez, C; Vidavsky, I; van der Drift, K; Gross, ML; Unanue, ER			Chemical identification of a low abundance lysozyme peptide family bound to I-A(k) histocompatibility molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; MHC ANCHOR RESIDUE; T-CELL RECEPTOR; MASS-SPECTROMETRY; TYROSINE SULFATION; NEGATIVE SELECTION; COMPLEX; QUANTITATION; EPITOPE; MOTIFS	The processing by antigen-presenting cells (APC) of the protein hen egg-white lysozyme (HEL) results in the selection of a number of peptide families by the class II major histocompatibility complex (MHC) molecule, I-A(k). Some of these families are expressed in very small amounts, in the order of a few picomoles/10(9) APC. We detected these peptides from an extract of class II MHC molecules by using monoclonal anti-peptide antibodies to capture the MHC-bound peptides prior to their examination by HPLC tandem mass spectrometry. Here, we have identified several members of a family of peptides encompassing residues 20-35, which represent less than 1% of the total HEL peptides. Binding analysis indicated that the core segment of the family was represented by residues 24-32 (SLGNWVCAA). Asn-27 (shown in boldface) is the main MHC-binding residue, mapped as interacting with the P4 pocket of the I-A(k) molecule. Analysis of several T cell hybridomas indicated that three residues contacted the T cell receptor: Tyr-23 (P-1), Leu-25 (P3), and Trp-28 (P5). The HEL peptides isolated from the APC extract were sulfated on Tyr-23, but further analysis showed that this modification did not occur physiologically but took place during the peptide isolation.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Dept Chem, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Unanue, ER (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Velazquez, Carlos/0000-0002-3728-7848				Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Dadaglio G, 1997, IMMUNITY, V6, P727, DOI 10.1016/S1074-7613(00)80448-3; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; Gugasyan R, 1998, J IMMUNOL, V161, P6074; Gugasyan R, 2000, J IMMUNOL, V165, P3206, DOI 10.4049/jimmunol.165.6.3206; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; Kersh GJ, 2001, J IMMUNOL, V166, P3345, DOI 10.4049/jimmunol.166.5.3345; Latek RR, 1999, IMMUNOL REV, V172, P209, DOI 10.1111/j.1600-065X.1999.tb01367.x; Latek RR, 2000, P NATL ACAD SCI USA, V97, P11460, DOI 10.1073/pnas.210384197; Latek RR, 2000, IMMUNITY, V12, P699, DOI 10.1016/S1074-7613(00)80220-4; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LUESCHER IF, 1985, J IMMUNOL METHODS, V135, P233; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1992, P NATL ACAD SCI USA, V89, P7380, DOI 10.1073/pnas.89.16.7380; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; Nelson CA, 1997, P NATL ACAD SCI USA, V94, P628, DOI 10.1073/pnas.94.2.628; Nemeth-Cawley JF, 2001, J MASS SPECTROM, V36, P1301, DOI 10.1002/jms.235; Peterson DA, 1999, IMMUNITY, V11, P453, DOI 10.1016/S1074-7613(00)80120-X; Peterson DA, 2001, J IMMUNOL, V166, P5874, DOI 10.4049/jimmunol.166.10.5874; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; QIN J, 1997, ANAL CHEM, V69, P402; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Rappsilber J, 2001, J MASS SPECTROM, V36, P832, DOI 10.1002/jms.195; RUDENSKY AY, 1992, NATURE, V359, P429, DOI 10.1038/359429a0; Severs JC, 1999, RAPID COMMUN MASS SP, V13, P1016, DOI 10.1002/(SICI)1097-0231(19990615)13:11<1016::AID-RCM599>3.0.CO;2-5; Suri A, 2002, J IMMUNOL, V168, P1235, DOI 10.4049/jimmunol.168.3.1235; Velazquez C, 2001, J IMMUNOL, V166, P5488, DOI 10.4049/jimmunol.166.9.5488; VIGNALI DAA, 1993, EUR J IMMUNOL, V23, P1602, DOI 10.1002/eji.1830230731; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777	39	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42514	42522		10.1074/jbc.M202316200	http://dx.doi.org/10.1074/jbc.M202316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12055186	hybrid			2022-12-25	WOS:000179081200013
J	Mellet, P; Mely, Y; Hedstrom, L; Cahoon, M; Belorgey, D; Srividya, N; Rubin, H; Bieth, JG				Mellet, P; Mely, Y; Hedstrom, L; Cahoon, M; Belorgey, D; Srividya, N; Rubin, H; Bieth, JG			Comparative trajectories of active and S195A inactive trypsin upon binding to serpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL ELASTASE; RESONANCE ENERGY-TRANSFER; MAXIMUM-ENTROPY METHOD; INHIBITORY MECHANISM; PROTEASE COMPLEX; ALPHA(1)-PROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR; CONFORMATIONAL CHANGE; PROTEINASE COMPLEX; SERINE PROTEASES	Serpins inhibit proteinases through a complicated multistep mechanism. The precise nature of these steps and the order by which they occur are still debated. We compared the fate of active and S195A inactive rat trypsin upon binding to alpha(1)-antitrypsin and P-1-Arg-antichymotrypsin using stopped-flow kinetics with fluorescence resonance energy transfer detection and time-resolved fluorescence resonance energy transfer. We show that inhibition of active trypsin by these serpins leads to two irreversible complexes, one being compatible with the full insertion of the serpin-reactive site loop but not the other one. Binding of inactive trypsin to serpins triggers a large multistep reversible rearrangement leading to the migration of the proteinase to an intermediate position. Binding of inactive trypsin, unlike that of active trypsin, does not perturb the rhodamine fluorescence at position 150 on the helix F of the serpin. Thus, inactive proteinases do not migrate past helix F and do not trigger full serpin loop insertion.	Univ Strasbourg 1, Fac Pharm, INSERM, U392,Lab Enzymol, F-67400 Illkirch Graffenstaden, France; Univ Strasbourg 1, Fac Pharm Strasbourg, CNRS, UMR 7034, F-67401 Illkirch Graffenstaden, France; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Brandeis University; University of Pennsylvania; University of Pennsylvania	Bieth, JG (corresponding author), Univ Strasbourg 1, Fac Pharm, INSERM, U392,Lab Enzymol, 74 Route Rhin, F-67400 Illkirch Graffenstaden, France.		Srividya, Narayanan/AAV-6936-2021	Mellet, Philippe/0000-0001-5499-9735; Srividya, Narayanan/0000-0001-7934-7987				BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BROCHON JC, 1994, METHOD ENZYMOL, V240, P262; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; Duranton J, 2000, J BIOL CHEM, V275, P3787, DOI 10.1074/jbc.275.6.3787; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; FALLER B, 1990, BIOCHEM J, V270, P639, DOI 10.1042/bj2700639; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Hedstrom L, 1996, BIOCHEMISTRY-US, V35, P4515, DOI 10.1021/bi951928k; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lee KN, 1998, J BIOL CHEM, V273, P2509, DOI 10.1074/jbc.273.5.2509; Ludeman JP, 2001, BIOPHYS J, V80, P491, DOI 10.1016/S0006-3495(01)76031-6; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; Luo Y, 1999, J BIOL CHEM, V274, P17733, DOI 10.1074/jbc.274.25.17733; Mellet P, 1998, J BIOL CHEM, V273, P9119, DOI 10.1074/jbc.273.15.9119; Mellet P, 2000, J BIOL CHEM, V275, P10788, DOI 10.1074/jbc.275.15.10788; Mely Y, 1997, BIOCHEMISTRY-US, V36, P15624, DOI 10.1021/bi971029r; O'Malley KM, 2001, J BIOL CHEM, V276, P6631, DOI 10.1074/jbc.M008478200; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; Pasternak A, 2001, PROTEIN SCI, V10, P1331, DOI 10.1110/ps.44101; *PERS VIS DEV TEAM, 1999, POV RAY VERS 3 1; Peterson FC, 2000, BIOCHEMISTRY-US, V39, P11884, DOI 10.1021/bi001152+; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; Plotnick MI, 2002, BIOCHEMISTRY-US, V41, P334, DOI 10.1021/bi015650+; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Southan C, 2000, J PEPT SCI, V6, P453, DOI 10.1002/1099-1387(200009)6:9<453::AID-PSC284>3.0.CO;2-Z; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Tew DJ, 2001, FEBS LETT, V494, P30, DOI 10.1016/S0014-5793(01)02305-5; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979	44	9	9	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38901	38914		10.1074/jbc.M204090200	http://dx.doi.org/10.1074/jbc.M204090200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12077135				2022-12-25	WOS:000178529600113
J	Sarrett, P; Gendron, L; Kilian, P; Nguyen, HMK; Gallo-Payet, N; Payet, MD; Beaudet, A				Sarrett, P; Gendron, L; Kilian, P; Nguyen, HMK; Gallo-Payet, N; Payet, MD; Beaudet, A			Pharmacology and functional properties of NTS2 neurotensin receptors in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROPERTIES; MESSENGER-RNA; RAT-BRAIN; INTERNALIZATION; EXPRESSION; LOCALIZATION; ENDOCYTOSIS; ANTAGONIST; PROTEIN; IDENTIFICATION	The binding and signaling properties of neuronal NTS2 neurotensin (NT) receptors were examined in cultured rat cerebellar granule cells. As shown by reverse transcription-PCR, receptor autoradiography, and confocal microscopic localization of fluorescent NT, these cells selectively express the NTS2 receptor subtype. Accordingly, a single apparent class of I-125-NT-binding sites, with an affinity of 3.1 nM, was detected in cerebellar granule cell cultures. This binding was competed for with high affinity (IC50 = 5.7 nM) by the NTS2 ligand levocabastine and with low affinity (IC50 = 203 nM) by the NTS1 antagonist SR48692. Hypertonic acid stripping of surface-bound ligand and hyperosmolar sucrose treatment revealed that 64% of specifically bound I-125-NT was internalized at equilibrium via a clathrin-dependent pathway. In cells loaded with the Ca2+-sensitive fluorescent dye Fluo4, SR48692, but neither NT nor levocabastine, triggered a marked increase in cytosolic [Ca2+](i). By contrast, both NT and levocabastine, but not SR48692, induced a sustained (>60 min) activation of the mitogen-activated protein kinases, p42/p44, indicating functional coupling of NTS2 receptors. Complementary experiments carried out on synaptosomes from adult rat cerebellum demonstrated the presence of presynaptic NTS2 receptors. However, in contrast to perikaryal NTS2 sites, these presynaptic receptors did not internalize in response to NT stimulation. Taken together, the present results demonstrate that NTS2 receptors are present both presynaptically and postsynaptically in central neurons and that NT and levocabastine act as agonists on these receptors.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Sherbrooke, Dept Med, Serv Endocrinol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada	McGill University; University of Sherbrooke; University of Sherbrooke	Beaudet, A (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Unv St, Montreal, PQ H3A 2B4, Canada.	alain.beaudet@mcgill.ca		Sarret, Philippe/0000-0002-7627-701X; Gendron, Louis/0000-0002-2058-8863				Asselin ML, 2001, NEUROREPORT, V12, P1087, DOI 10.1097/00001756-200104170-00044; Botto JM, 1997, FEBS LETT, V400, P211, DOI 10.1016/S0014-5793(96)01391-9; Botto JM, 1997, NEUROSCI LETT, V223, P193, DOI 10.1016/S0304-3940(97)13437-1; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; CAMBRAYDEAKIN MA, 1995, NEURAL CELL CULTURE, P3; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; FAURE MP, 1995, J NEUROSCI, V15, P4140; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; GALLOPAYET N, 1986, ENDOCRINOLOGY, V119, P1042, DOI 10.1210/endo-119-3-1042; Gendron L, 1999, MOL ENDOCRINOL, V13, P1615, DOI 10.1210/me.13.9.1615; GONZALEZ B, 1992, P NATL ACAD SCI USA, V89, P9627, DOI 10.1073/pnas.89.20.9627; Grady EF, 1996, NEUROSCIENCE, V75, P1239, DOI 10.1016/0306-4522(96)00357-0; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; IRVING AJ, 1992, J PHYSIOL-LONDON, V456, P667, DOI 10.1113/jphysiol.1992.sp019360; KITABGI P, 1985, Reviews in Clinical and Basic Pharmacology, V5, P397; KITABGI P, 1987, EUR J PHARMACOL, V140, P285, DOI 10.1016/0014-2999(87)90285-8; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; Lepee-Lorgeoux I, 1999, DEV BRAIN RES, V113, P115, DOI 10.1016/S0165-3806(99)00009-7; Mazella J, 1996, J NEUROSCI, V16, P5613; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Navarro V, 2001, FEBS LETT, V495, P100, DOI 10.1016/S0014-5793(01)02367-5; NEMEROFF CB, 1980, BIOL PSYCHIAT, V15, P283; Nguyen HMK, 2002, NEUROPHARMACOLOGY, V42, P1089, DOI 10.1016/S0028-3908(02)00054-0; NICOT A, 1994, J COMP NEUROL, V341, P407, DOI 10.1002/cne.903410310; Nouel D, 1999, NEUROSCIENCE, V94, P1189, DOI 10.1016/S0306-4522(99)00354-1; Nouel D, 1997, J NEUROSCI, V17, P1795; Rostene WH, 1997, FRONT NEUROENDOCRIN, V18, P115, DOI 10.1006/frne.1996.0146; Sarret P, 1998, J COMP NEUROL, V394, P344; SCHOTTE A, 1986, N-S ARCH PHARMACOL, V333, P400, DOI 10.1007/BF00500016; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Vincent JP, 1995, CELL MOL NEUROBIOL, V15, P501, DOI 10.1007/BF02071313; Vita N, 1998, EUR J PHARMACOL, V360, P265, DOI 10.1016/S0014-2999(98)00678-5; Walker N, 1998, MOL BRAIN RES, V57, P193, DOI 10.1016/S0169-328X(98)00074-6; Yamada M, 1998, LIFE SCI, V62, pPL375; Yao CJ, 1999, J NEUROCHEM, V73, P457, DOI 10.1046/j.1471-4159.1999.0730457.x	41	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36233	36243		10.1074/jbc.M202586200	http://dx.doi.org/10.1074/jbc.M202586200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12084713	hybrid			2022-12-25	WOS:000178275100059
J	Lokeshwar, VB; Schroeder, GL; Carey, RI; Soloway, MS; Iida, N				Lokeshwar, VB; Schroeder, GL; Carey, RI; Soloway, MS; Iida, N			Regulation of hyaluronidase activity by alternative mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-DERIVED HYALURONIDASE; HAASE URINE TEST; BLADDER-CANCER; VENOM HYALURONIDASE; GLYCOSYL HYDROLASES; ENDOTHELIAL-CELLS; BEE VENOM; IN-VITRO; EXPRESSION; ACID	Hyaluronidase is a hyaluronic acid-degrading endoglycosidase that is present in many toxins and the levels of which are elevated in cancer. Increased concentration of HYAL1-type hyaluronidase correlates with tumor progression and is a marker for grade (G) 2 or 3 bladder cancer. Using bladder tissues and cells, prostate cancer cells, and kidney tissues and performing reverse transcription-PCR, cDNA cloning, DNA sequencing, and in vitro translation, we identified splice variants of HYAL1 and HYAL3. HYAL1v1 variant lacks a 30-amino acid (aa) sequence (301-330) present in HYAL1 protein. HYAL1v1, HYAL1v2 (aa 183-435 present in HYAL1 wild type), HYAL1v3 (aa 1-207), HYAL1v4 (aa 260-435), and HYAL1v5 (aa 340-435) are enzymatically inactive an are expressed in normal tissues/cells and G1 bladder tumor tissues. However, HYAL1 wild type is expressed in G2/G3 tumors and in invasive tumor cells. Stable transfection and HYAL1v1-specific antibody confirmed that the HYAL1 sequence from aa 301 to 330 is critical for hyaluronidase activity. All tumor cells and tissues mainly express HYAL3 variants. HYAL3vl lacks a 30-aa sequence (299-328) present in HYAL3 protein, that is homologous to the 30-aa HYAL1 sequence. HYAL3v1, HYAL3v2 (aa 251-417 present in HYAL3 wild type), and HYAL3v3 (aa 251-417, but lacking aa 299-328), are enzymatically inactive. Although splicing of a single independent exon generates HYAL1v1 and HYAL3vl, internal exon splicing generates the other HYAL1/HYAL3 variants. These results demonstrate that alternative mRNA splicing controls cellular expression of enzymatically active hyaluronidase and may explain the elevated hyaluronidase levels in bladder/prostate cancer.	Univ Miami, Sch Med, Dept Urol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami; University of Miami	Lokeshwar, VB (corresponding author), Univ Miami, Sch Med, Dept Urol, M-800,POB 016960, Miami, FL 33101 USA.	vlokeshw@med.miami.edu			NCI NIH HHS [CA 72821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072821, R01CA072821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arming S, 1997, EUR J BIOCHEM, V247, P810, DOI 10.1111/j.1432-1033.1997.t01-1-00810.x; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Cherr GN, 2001, MATRIX BIOL, V20, P515, DOI 10.1016/S0945-053X(01)00171-8; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Csoka TB, 1997, FEBS LETT, V417, P307, DOI 10.1016/S0014-5793(97)01309-4; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; DINNEY CPN, 1995, J UROLOGY, V154, P1532, DOI 10.1016/S0022-5347(01)66923-4; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Frost GI, 2000, ONCOGENE, V19, P870, DOI 10.1038/sj.onc.1203317; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; Hautmann SH, 2001, J UROLOGY, V165, P2068, DOI 10.1016/S0022-5347(05)66296-9; Hayen W, 1999, J CELL SCI, V112, P2241; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HOBARTH K, 1992, EUR UROL, V21, P206; Ji L, 2002, CANCER RES, V62, P2715; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; Lee R, 2000, UROL CLIN N AM, V27, P1, DOI 10.1016/S0094-0143(05)70229-9; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Liu DC, 1996, P NATL ACAD SCI USA, V93, P7832, DOI 10.1073/pnas.93.15.7832; Liu NF, 2001, CANCER RES, V61, P1022; Lokeshwar VB, 1998, CANCER LETT, V131, P21, DOI 10.1016/S0304-3835(98)00197-9; Lokeshwar VB, 2000, J UROLOGY, V163, P348, DOI 10.1016/S0022-5347(05)68050-0; Lokeshwar VB, 2002, CANCER-AM CANCER SOC, V95, P61, DOI 10.1002/cncr.10652; Lokeshwar VB, 1997, CANCER RES, V57, P773; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Lokeshwar VB, 2000, UROL CLIN N AM, V27, P53, DOI 10.1016/S0094-0143(05)70234-2; Lokeshwar VB, 1999, CANCER RES, V59, P4464; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Patel S, 2002, INT J CANCER, V97, P416, DOI 10.1002/ijc.1638; Pham HT, 1997, CANCER RES, V57, P778; Pirinen R, 2001, INT J CANCER, V95, P12, DOI 10.1002/1097-0215(20010120)95:1<12::AID-IJC1002>3.0.CO;2-E; RODEN L, 1989, CIBA F SYMP, V143, P60; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Ropponen K, 1998, CANCER RES, V58, P342; Setala LP, 1999, BRIT J CANCER, V79, P1133, DOI 10.1038/sj.bjc.6690180; Shuttleworth TL, 2002, J BIOL CHEM, V277, P23008, DOI 10.1074/jbc.M108991200; Slevin M, 1998, LAB INVEST, V78, P987; STERN M, 1992, MATRIX, V12, P397, DOI 10.1016/S0934-8832(11)80036-3; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Triggs-Raine B, 1999, P NATL ACAD SCI USA, V96, P6296, DOI 10.1073/pnas.96.11.6296; Trochon V, 1997, FEBS LETT, V418, P6, DOI 10.1016/S0014-5793(97)01337-9; TU AT, 1983, COMP BIOCHEM PHYS B, V76, P377, DOI 10.1016/0305-0491(83)90086-X; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vines CA, 2001, MOL REPROD DEV, V60, P542, DOI 10.1002/mrd.1119.abs; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x	50	76	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33654	33663		10.1074/jbc.M203821200	http://dx.doi.org/10.1074/jbc.M203821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12084718	hybrid			2022-12-25	WOS:000177959100018
J	Rim, JS; Kozak, LP				Rim, JS; Kozak, LP			Regulatory motifs for CREB-binding protein and Nfe212 transcription factors in the upstream enhancer of the mitochondrial uncoupling protein 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; BROWN ADIPOSE-TISSUE; ACTIVATED RECEPTOR-GAMMA; RNA-POLYMERASE-II; SOMATOSTATIN GENE; NUCLEAR-PROTEIN; RETINOIC ACID; ADAPTIVE THERMOGENESIS; MEDIATED EXPRESSION; TRANSGENIC MICE	Thermogenesis against cold exposure in mammals occurs in brown adipose tissue (BAT) through mitochondrial uncoupling protein (UCP1). Expression of the Ucp1 gene is unique in brown adipocytes and is regulated tightly. The 5'-flanking region of the mouse Ucp1 gene contains cis-acting elements including PPRE, TRE, and four half-site cAMP-responsive elements (CRE) with BAT-specific enhancer elements. In the course of analyzing how these half-site CREs are involved in Ucp1 expression, we found that a DNA regulatory element for NF-E2 overlaps CRE2. Electrophoretic mobility shift assay and competition assays with the CRE2 element indicates that nuclear proteins from BAT, inguinal fat, and retroperitoneal fat tissue interact with the CRE2 motif (CGTCA) in a specific manner. A supershift assay using an antibody against the CRE-binding protein (CREB) shows specific affinity to the complex from CRE2 and nuclear extract of BAT. Additionally, Western blot analysis for phospho-CREB/ATF1 shows an increase in phosphorylation of CREB/ATF1 in HIB-1B cells after norepinephrine treatment. Transient transfection assay using luciferase reporter constructs also indicates that the two half-site CREs are involved in transcriptional regulation of Ucp1 in response to norepinephrine and cAMP. We also show that a second DNA regulatory element for NF-E2 is located upstream of the CRE2 region. This element, which is found in a similar location in the 5'-flanking region of the human and rodent Ucp1 genes, shows specific binding to rat and human NF-E2 by electrophoretic mobility shift assay with nuclear extracts from brown fat. Co-transfections with an Nfe212 expression vector and a luciferase reporter construct of the Ucpl enhancer region provide additional evidence that Nfe212 is involved in the regulation of Ucp1 by cAMP-mediated signaling.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Kozak, LP (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	kozaklp@pbrc.edu			NICHD NIH HHS [HD 08431] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BIANCO AC, 1988, J BIOL CHEM, V263, P18168; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Crino P, 1998, P NATL ACAD SCI USA, V95, P2313, DOI 10.1073/pnas.95.5.2313; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Girardier L., 1986, BROWN ADIPOSE TISSUE, P122; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gonzalez-Barroso MD, 2000, J BIOL CHEM, V275, P31722, DOI 10.1074/jbc.M001678200; Guerra C, 1996, J BIOL CHEM, V271, P2076, DOI 10.1074/jbc.271.4.2076; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; HOUSTEK J, 1988, BIOCHIM BIOPHYS ACTA, V935, P19, DOI 10.1016/0005-2728(88)90103-X; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; KOZAK UC, 1992, MOL ENDOCRINOL, V6, P763, DOI 10.1210/me.6.5.763; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larose M, 1996, J BIOL CHEM, V271, P31533, DOI 10.1074/jbc.271.49.31533; Levine JA, 1999, SCIENCE, V283, P212, DOI 10.1126/science.283.5399.212; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWRY OH, 1964, J BIOL CHEM, V239, P18; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOHLER J, 1995, DEVELOPMENT, V121, P237; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Motohashi H, 1996, GENES CELLS, V1, P223, DOI 10.1046/j.1365-2443.1996.d01-230.x; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 1996, BIOCHEM J, V317, P827, DOI 10.1042/bj3170827; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; Rabelo R, 1997, ENDOCRINOLOGY, V138, P5325, DOI 10.1210/en.138.12.5325; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SHIBATA H, 1987, CAN J PHYSIOL PHARM, V65, P152, DOI 10.1139/y87-030; SMITH RE, 1969, PHYSIOL REV, V49, P330, DOI 10.1152/physrev.1969.49.2.330; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	71	68	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34589	34600		10.1074/jbc.M108866200	http://dx.doi.org/10.1074/jbc.M108866200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12084707	hybrid			2022-12-25	WOS:000177959100133
J	Chen, CW; Tsay, YG; Wu, HL; Lee, CH; Chen, DS; Chen, PJ				Chen, CW; Tsay, YG; Wu, HL; Lee, CH; Chen, DS; Chen, PJ			The double-stranded RNA-activated kinase, PKR, can phosphorylate hepatitis D virus small delta antigen at functional serine and threonine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; NUCLEAR-LOCALIZATION; BINDING ACTIVITY; VIRAL GENOME; LARGE FORM; IN-VITRO; REPLICATION; INTERFERON; IDENTIFICATION; TRANSCRIPTION	Hepatitis D virus (HDV) encodes two proteins, the 24-kDa small delta antigen (S-HDAg) and 27-kDa large delta antigen (L-HDAg) in its single open reading frame. Both of them had been identified as nuclear phosphoproteins. Moreover, the phosphorylated form of S-HDAg was shown to be important for HDV replication. However, the kinase responsible for S-HDAg phosphorylation remains unknown. Therefore, we employed an in-gel kinase assay to search candidate kinases and indeed identified a kinase with a molecular mass of about 68 kDa. Much evidence demonstrated this kinase to be the double-stranded RNA-activated kinase, PKR. The immunoprecipitated endogenous PKR was sufficient to catalyze S-HDAg phosphorylation, and the kinase activity disappeared in the PKR-depleted cell lysate. The S-HDAg and PKR could be co-immunoprecipitated together, and both of them co-located in the nucleolus. The LC/MS/MS analysis revealed that the serine 177, serine 180, and threonine 182 of S-HDAg were phosphorylated by PKR in vitro. This result was consistent with previous phosphoamino acid analysis indicating that serine and threonine were phosphorylation targets in S-HDAg. Furthermore, serine 177 was also shown to be the predominant phosphorylation site for S-HDAg purified the from cell line. In dominant negative PKR-transfected cells, the level of phosphorylated S-HDAg was suppressed, but replication of HDV was enhanced. Other than human immunodeficiency virus type I trans-activating protein (Tat), S-HDAg is another viral protein phosphorylated by PKR that may regulates HDV replication and viral response to interferon therapy.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10018, Taiwan; Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Chen, PJ (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10018, Taiwan.		Tsay, Yeou-Guang/HGE-2076-2022	Chen, Pei-Jer/0000-0001-8316-3785; Lee, Chi-Hua/0000-0002-9292-9639; CHEN, DING-SHINN/0000-0001-7791-6154				ARICO S, 1985, LANCET, V2, P356; BONINO F, 1986, J VIROL, V58, P945, DOI 10.1128/JVI.58.3.945-950.1986; BRANCH AD, 1989, SCIENCE, V243, P649, DOI 10.1126/science.2492676; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; CASEY JL, 1992, P NATL ACAD SCI USA, V89, P7149, DOI 10.1073/pnas.89.15.7149; CHANG FL, 1991, P NATL ACAD SCI USA, V88, P8490, DOI 10.1073/pnas.88.19.8490; CHANG MF, 1988, J VIROL, V62, P2403, DOI 10.1128/JVI.62.7.2403-2410.1988; CHANG MF, 1995, J VIROL, V69, P2508, DOI 10.1128/JVI.69.4.2508-2514.1995; CHANG MF, 1993, J VIROL, V67, P2529, DOI 10.1128/JVI.67.5.2529-2536.1993; CHANG MF, 1992, J VIROL, V66, P6019, DOI 10.1128/JVI.66.10.6019-6027.1992; CHEN PJ, 1990, P NATL ACAD SCI USA, V87, P5253, DOI 10.1073/pnas.87.14.5253; Chen PJ, 1997, J GASTROEN HEPATOL, V12, pS188, DOI 10.1111/j.1440-1746.1997.tb00500.x; Circle DA, 1997, RNA, V3, P438; COLIGAN JE, 1997, CURRENT PROTOCOLS PR, V2; COLIGAN JE, 1997, CURRENT PROTOCALS PR, V1; Craig AWB, 1996, J BIOL CHEM, V271, P24526, DOI 10.1074/jbc.271.40.24526; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GOVINDARAJAN S, 1986, BIOMED PHARMACOTHER, V40, P239; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; HWANG SB, 1992, VIROLOGY, V190, P413, DOI 10.1016/0042-6822(92)91227-L; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; KawagishiKobayashi M, 1997, MOL CELL BIOL, V17, P4146, DOI 10.1128/MCB.17.7.4146; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; Lam LL, 2002, J CLIN MICROBIOL, V40, P325, DOI 10.1128/JCM.40.02.325-329.2002; Lee CH, 2001, J BIOL CHEM, V276, P8142, DOI 10.1074/jbc.M004477200; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MCNAIR ANB, 1994, J GEN VIROL, V75, P1371, DOI 10.1099/0022-1317-75-6-1371; Mu JJ, 2001, J VIROL, V75, P9087, DOI 10.1128/JVI.75.19.9087-9095.2001; Mu JJ, 1999, J VIROL, V73, P10540, DOI 10.1128/JVI.73.12.10540-10545.1999; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Polson AG, 1998, MOL CELL BIOL, V18, P1919, DOI 10.1128/MCB.18.4.1919; Polson AG, 1996, NATURE, V380, P454; PONZETTO A, 1988, HEPATOLOGY, V8, P1655, DOI 10.1002/hep.1840080631; Rizzetto M, 1999, ITAL J GASTROENTEROL, V31, P781; RIZZETTO M, 1986, J HEPATOL, V3, pS229, DOI 10.1016/S0168-8278(86)80125-8; RIZZETTO M, 1985, J HEPATOL, V1, P187, DOI 10.1016/S0168-8278(85)80766-2; Robertson HD, 1996, J VIROL, V70, P5611, DOI 10.1128/JVI.70.8.5611-5617.1996; RYU WS, 1992, J VIROL, V66, P2310, DOI 10.1128/JVI.66.4.2310-2315.1992; Sheu GT, 2000, VIROLOGY, V278, P578, DOI 10.1006/viro.2000.0680; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; WANG HW, 1994, J VIROL, V68, P6363, DOI 10.1128/JVI.68.10.6363-6371.1994; Wang HW, 1997, VIROLOGY, V239, P119, DOI 10.1006/viro.1997.8818; WANG JG, 1993, J VIROL, V67, P446, DOI 10.1128/JVI.67.1.446-454.1993; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; XIA YP, 1992, J VIROL, V66, P6641, DOI 10.1128/JVI.66.11.6641-6648.1992; XIA YP, 1990, VIROLOGY, V178, P331, DOI 10.1016/0042-6822(90)90415-N; Yeh TS, 1996, J VIROL, V70, P6190, DOI 10.1128/JVI.70.9.6190-6198.1996	54	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33058	33067		10.1074/jbc.M200613200	http://dx.doi.org/10.1074/jbc.M200613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12060652	hybrid			2022-12-25	WOS:000177859000086
J	Hayashi, S; Okada, T; Igarashi, N; Fujita, T; Jahangeer, S; Nakamura, S				Hayashi, S; Okada, T; Igarashi, N; Fujita, T; Jahangeer, S; Nakamura, S			Identification and characterization of RPK118, a novel sphingosine kinase-1-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; SORTING NEXIN; SACCHAROMYCES-CEREVISIAE; PX DOMAINS; RECEPTORS; KINASE; SPHINGOSINE-1-PHOSPHATE; CELLS; 1-PHOSPHATE; WORTMANNIN	Sphingosine kinase (SPHK) is a key enzyme catalyzing the formation of sphingosine 1 phosphate (SPP), a lipid messenger that is implicated in the regulation of a wide variety of important cellular events through intracellular as well as extracellular mechanisms. However, the molecular mechanism of the intracellular actions of SPP remains unclear. Here we have cloned a novel sphingosine kinase-1 (SPHK1)-binding protein, RPK118, by yeast two-hybrid screening. RPK118 contains several functional domains whose sequences are homologous to other known proteins including the phox homology domain and pseudokinase 1 and 2 domains and is shown to be a member of an evolutionarily highly conserved gene family. The pseudokinase 2 domain of RPK118 is responsible for SPHK1 binding as judged by yeast two-hybrid screening and immunoprecipitation studies. RPK118 is also shown to co-localize with SPHK1 on early endosomes in COS7 cells expressing both recombinant proteins. Furthermore, RPK118 specifically binds to phosphatidylinositol 3-phosphate. These results strongly suggest that RPK118 is a novel SPHK1-binding protein that may be involved in transmitting SPP-mediated signaling into the cell.	Kobe Univ, Grad Sch Med, Div Biochem, Dept Mol & Cellular Biol, Kobe, Hyogo 6500017, Japan	Kobe University	Nakamura, S (corresponding author), Kobe Univ, Grad Sch Med, Div Biochem, Dept Mol & Cellular Biol, Kobe, Hyogo 6500017, Japan.							Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Choi OH, 1996, NATURE, V380, P634; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Gijsbers S, 2001, BBA-MOL CELL BIOL L, V1532, P37, DOI 10.1016/S1388-1981(01)00111-1; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Kjeken R, 2001, BIOCHEM J, V357, P497, DOI 10.1042/0264-6021:3570497; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Sarkar S, 2001, BIOCHEM J, V359, P599, DOI 10.1042/0264-6021:3590599; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; YANO H, 1993, J BIOL CHEM, V268, P25846; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zhang HL, 1999, GENOMICS, V61, P314, DOI 10.1006/geno.1999.5963; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	34	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33319	33324		10.1074/jbc.M201442200	http://dx.doi.org/10.1074/jbc.M201442200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077123	hybrid			2022-12-25	WOS:000177859000118
J	Ikari, A; Nakano, M; Kawano, K; Suketa, Y				Ikari, A; Nakano, M; Kawano, K; Suketa, Y			Up-regulation of sodium-dependent glucose transporter by interaction with heat shock protein 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/GLUCOSE COTRANSPORTER SGLT1; EPITHELIAL-CELL LINE; LLC-PK1 CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; MOLECULAR CHAPERONES; GLUT1 EXPRESSION; MESANGIAL CELLS; SUGAR-TRANSPORT; KIDNEY; BETA	Heat shock stress induces some heat shock proteins, including Hsp70, and activates sodium-dependent glucose transport in porcine renal LLC-PK1 cells, but its mechanisms have not been described in detail. We investigated whether sodium-dependent glucose transporter (SGLT1) interacts with Hsp70 to increase SGLT1 activity. Heat shock stress increased SGLT1 activity without changing SGLT1 expression. The increase of SGLT1 activity was completely inhibited by an antitransforming growth factor-beta1 (TGF-beta1) antibody. Instead of heat shock stress, TGF-beta1 increased SGLT1 activity dose- and time-dependently without changing SGLT1 expression. We found that the amount of Hsp70 immunoprecipitated from TGF-beta1-treated cells with an anti-SGLT1 antibody was higher than that of the control cells. Transfection of an anti-Hsp70 antibody into the cells inhibited the increase of SGLT1 activity. With confocal laser microscopy, both SGLT1 and Hsp70 was localized near the apical membrane in the TGF-beta1-treated cells, and an anti-Hsp70 antibody disturbed this localization. Furthermore, we clarified that an anti-Hsp70 antibody inhibited interaction of SGLT1 with Hsp70 in vitro. These results suggest that Hsp70 forms a complex with SGLT1 and increases the expression level of SGLT1 in the apical membrane, resulting in up-regulation of glucose uptake.	Univ Shizuoka, Sch Pharmaceut Sci, Dept Environm Biochem & Toxicol, Shizuoka 4228526, Japan	University of Shizuoka	Ikari, A (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Environm Biochem & Toxicol, 52-1 Yada, Shizuoka 4228526, Japan.							ANDERSON RJ, 1993, AM J PHYSIOL, V265, pF584, DOI 10.1152/ajprenal.1993.265.4.F584; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Beck FX, 2000, AM J PHYSIOL-RENAL, V279, pF203, DOI 10.1152/ajprenal.2000.279.2.F203; Bidmon B, 2000, KIDNEY INT, V58, P2400, DOI 10.1046/j.1523-1755.2000.00423.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cao Y, 1999, PFLUG ARCH EUR J PHY, V438, P239, DOI 10.1007/s004240050905; Choo-Kang LR, 2001, AM J PHYSIOL-LUNG C, V281, pL58, DOI 10.1152/ajplung.2001.281.1.L58; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; Heilig CW, 1997, DIABETES, V46, P1030, DOI 10.2337/diabetes.46.6.1030; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; Ikari A, 2001, BIOCHEM BIOPH RES CO, V287, P671, DOI 10.1006/bbrc.2001.5644; Inoki K, 1999, KIDNEY INT, V55, P1704, DOI 10.1046/j.1523-1755.1999.00438.x; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MULLIN JM, 1980, J CELL PHYSIOL, V104, P375, DOI 10.1002/jcp.1041040311; OIWA K, 1993, J BIOCHEM-TOKYO, V114, P28, DOI 10.1093/oxfordjournals.jbchem.a124134; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; Phillips AO, 1997, AM J PATHOL, V150, P1101; RABITO CA, 1980, J MEMBRANE BIOL, V54, P31, DOI 10.1007/BF01875374; Sarrio S, 2000, MOL CELL BIOL, V20, P5164, DOI 10.1128/MCB.20.14.5164-5174.2000; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; SHIODA T, 1994, P NATL ACAD SCI USA, V91, P11919, DOI 10.1073/pnas.91.25.11919; SILVA NLCL, 1995, BIOCHEMISTRY-US, V34, P10412, DOI 10.1021/bi00033a013; SUSSMAN CR, 1997, AM J PHYSIOL, V42, pF530; Takata Y, 1997, BIOCHEM BIOPH RES CO, V237, P345, DOI 10.1006/bbrc.1997.7116; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; TURNER RJ, 1982, AM J PHYSIOL, V242, P406; Vayro S, 1999, AM J PHYSIOL-CELL PH, V276, pC1053, DOI 10.1152/ajpcell.1999.276.5.C1053; Weber H, 2000, DIGEST DIS SCI, V45, P2252, DOI 10.1023/A:1026459001195; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315	31	40	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33338	33343		10.1074/jbc.M200310200	http://dx.doi.org/10.1074/jbc.M200310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082088	hybrid			2022-12-25	WOS:000177859000121
J	Mohajeri, MH; Saini, K; Schultz, JG; Wollmer, MA; Hock, C; Nitsch, RM				Mohajeri, MH; Saini, K; Schultz, JG; Wollmer, MA; Hock, C; Nitsch, RM			Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; A-BETA; CELL-DEATH; IN-VIVO; MUTANT PRESENILIN-1; HIPPOCAMPAL-NEURONS; PRECURSOR PROTEINS; APP MUTATIONS; BRAIN; A-BETA-42	To characterize the effects of the familial Alzheimer's disease-causing Swedish mutations of amyloid precursor protein (SwAPP) on the vulnerability of central nervous system neurons, we induced epileptic seizures in transgenic mice expressing SwAPP. The transgene expression did not change the seizure threshold, but consistently more neurons degenerated in brains of SwAPP mice as compared with wild-type littermates. The degenerating neurons were stained both by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling and by Gallyas silver impregnation. A susceptible population of neurons accumulated intracellular Abeta and immunoreacted with antibodies against activated caspase-3. To demonstrate that increased Abeta levels mediated the increased vulnerability, we infused antibodies against Abeta and found a significant reduction in neuronal loss that was paralleled by decreased brain levels of Abeta. Because the SwAPP mice exhibited no amyloid plaques at the age of these experiments, transgenic overproduction of Abeta in brain rendered neurons susceptible to damage much earlier than the onset of amyloid plaque formation. Our data underscore the possibility that Abeta is toxic, that it increases the vulnerability of neurons to excitotoxic events produced by seizures, and that lowering Abeta by passive immunization can protect neurons from Abeta-related toxicity.	Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland; Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	University of Zurich; University of Zurich	Mohajeri, MH (corresponding author), Univ Zurich, Div Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.	mohajeri@bli.unizh.ch	Wollmer, Marc A/B-5038-2009					Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Biagini G, 2001, J NEUROCHEM, V76, P1814, DOI 10.1046/j.1471-4159.2001.00163.x; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Drouet B, 1999, J NEUROCHEM, V73, P742, DOI 10.1046/j.1471-4159.1999.0730742.x; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Franklin K. B. J., 1996, MOUSE BRAIN STEREOTA; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P1; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Haass C, 2001, NAT NEUROSCI, V4, P859, DOI 10.1038/nn0901-859; Hardy J, 1999, NEUROBIOL AGING, V20, P85; Holcomb LA, 1999, BEHAV GENET, V29, P177, DOI 10.1023/A:1021691918517; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Janciauskiene S, 1999, NEUROPEPTIDES, V33, P510, DOI 10.1054/npep.1999.0771; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Katayama S, 2000, ACTA NEUROPATHOL, V100, P221, DOI 10.1007/s004019900156; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Longo VD, 2000, J NEUROCHEM, V75, P1977, DOI 10.1046/j.1471-4159.2000.0751977.x; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Masliah E, 2001, J NEUROPATH EXP NEUR, V60, P357, DOI 10.1093/jnen/60.4.357; McDonald DR, 1997, J NEUROSCI, V17, P2284; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; RACINE R, 1972, ELECTROEN CLIN NEURO, V32, P295, DOI 10.1016/0013-4694(72)90178-2; RACINE RJ, 1972, BRAIN RES, V47, P262, DOI 10.1016/0006-8993(72)90268-5; Rapoport M, 2000, J NEUROCHEM, V74, P125, DOI 10.1046/j.1471-4159.2000.0740125.x; Renolleau S, 1998, STROKE, V29, P1454, DOI 10.1161/01.STR.29.7.1454; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Sankar R, 1998, J NEUROSCI, V18, P8382; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; TEUCHERTNOODT G, 1991, DEV NEUROSCI-BASEL, V13, P151, DOI 10.1159/000112153; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wegiel J, 2001, NEUROBIOL AGING, V22, P49, DOI 10.1016/S0197-4580(00)00181-0; Weldon DT, 1998, J NEUROSCI, V18, P2161; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	55	56	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33012	33017		10.1074/jbc.M203193200	http://dx.doi.org/10.1074/jbc.M203193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12068009	hybrid			2022-12-25	WOS:000177859000081
J	Guha, M; Mackman, N				Guha, M; Mackman, N			The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; TISSUE FACTOR GENE; LYMPHOTOXIN-BETA-RECEPTOR; NITRIC-OXIDE SYNTHASE; FACTOR-ALPHA PROMOTER; PROTEIN-KINASE; INTERLEUKIN-1 RECEPTOR; RELA/P65 SUBUNIT; LPS INDUCTION	Monocytes and macrophages express cytokines and procoagulant molecules in various inflammatory diseases. In sepsis, lipopolysaccharide (LPS) from Gram-negative bacteria induces tumor necrosis factor-alpha (TNF-alpha) and tissue factor (TF) in monocytic cells via the activation of the transcription factors Egr-1, AP-1, and nuclear factor-kappaB. However, the signaling pathways that negatively regulate LPS-induced TNF-alpha and TF expression in monocytic cells are currently unknown. We report that inhibition of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway enhances LPS-induced activation of the mitogen-activated protein kinase pathways (ERK1/2, p38, and JNK) and the downstream targets AP-1 and Egr-1. In addition, inhibition of PI3K-Akt enhanced LPS-induced nuclear translocation of nuclear factor-kappaB and prevented Akt-dependent inactivation of glycogen synthase kinase-beta, which increased the trans-activational activity of p65. We propose that the activation of the PI3K-Akt pathway in human monocytes limits the LPS induction of TNF-alpha and TF expression. Our study provides new insight into the inhibitory mechanism by which the PI3K-Akt pathway ensures transient expression of these potent inflammatory mediators.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Mackman, N (corresponding author), Scripps Res Inst, Dept Immunol, C-204,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	nmackman@scripps.edu			NHLBI NIH HHS [HL 48872] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048872] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Blum S, 2001, J BIOL CHEM, V276, P33428, DOI 10.1074/jbc.M105474200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; Carl VS, 2002, J BIOL CHEM, V277, P17448, DOI 10.1074/jbc.M111847200; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hall AJ, 1999, J BIOL CHEM, V274, P376, DOI 10.1074/jbc.274.1.376; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Jones BW, 2001, ANN RHEUM DIS, V60, pIII6; Kim I, 2001, FASEB J, V15, P126, DOI 10.1096/fj.01-0556fje; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; LIU MK, 1994, J IMMUNOL, V153, P2642; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; Oeth P, 1997, ARTERIOSCL THROM VAS, V17, P365, DOI 10.1161/01.ATV.17.2.365; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Park YC, 1997, BIOCHEM BIOPH RES CO, V240, P692, DOI 10.1006/bbrc.1997.7722; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Scherle PA, 1998, J IMMUNOL, V161, P5681; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; STEINEMANN S, 1994, ARTERIOSCLER THROMB, V14, P1202, DOI 10.1161/01.ATV.14.7.1202; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Tengku-Muhammad TS, 1999, CYTOKINE, V11, P463, DOI 10.1006/cyto.1998.0460; Thomas KW, 2002, J BIOL CHEM, V277, P492, DOI 10.1074/jbc.M108107200; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	58	638	660	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32124	32132		10.1074/jbc.M203298200	http://dx.doi.org/10.1074/jbc.M203298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12052830	hybrid			2022-12-25	WOS:000177718700103
J	Yang, Q; Zhang, R; Wang, XW; Spillare, EA; Linke, SP; Subramanian, D; Griffith, JD; Li, JL; Hickson, ID; Shen, JC; Loeb, LA; Mazur, SJ; Appella, E; Brosh, RM; Karmakar, P; Bohr, VA; Harris, CC				Yang, Q; Zhang, R; Wang, XW; Spillare, EA; Linke, SP; Subramanian, D; Griffith, JD; Li, JL; Hickson, ID; Shen, JC; Loeb, LA; Mazur, SJ; Appella, E; Brosh, RM; Karmakar, P; Bohr, VA; Harris, CC			The processing of Holliday junctions by BLM and WRN helicases is regulated by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FUNCTION; TUMOR-SUPPRESSOR PROTEIN; WERNERS-SYNDROME PROTEIN; BLOOMS-SYNDROME HELICASE; HOMOLOGOUS RECOMBINATION; POSTTRANSLATIONAL MODIFICATIONS; EXONUCLEASE ACTIVITY; CRYSTAL-STRUCTURE; BRANCH MIGRATION; POLYMERASE-DELTA	BLM, WRN, and p53 are involved in the homologous DNA recombination pathway. The DNA structure-specific helicases, BLM and WRN, unwind Holliday junctions (HJ), an activity that could suppress inappropriate homologous recombination during DNA replication. Here, we show that purified, recombinant p53 binds to BLM and WRN helicases and attenuates their ability to unwind synthetic HJ in vitro. The p53 248W mutant reduces abilities of both to bind HJ and inhibit helicase activities, whereas the p53 273H mutant loses these abilities. Moreover, full-length p53 and a C-terminal polypeptide (residues 373-383) inhibit the BLM and WRN helicase activities, but phosphorylation at Ser(376) or Ser(378) completely abolishes this inhibition. Following blockage of DNA replication, Ser(15) phospho-p53, BLM, and RAD51 colocalize in nuclear foci at sites likely to contain DNA replication intermediates in cells. Our results are consistent with a novel mechanism for p53-mediated regulation of DNA recombinational repair that involves p53 post-translational modifications and functional protein-protein interactions with BLM and WRN DNA helicases.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK, Oxford OX3 9DS, England; Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; Cancer Research UK; University of Oxford; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Rm 2C05,37 Convent Dr, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009; Bohr, Vilhelm/AAP-5931-2020; Hickson, Ian/AAJ-7548-2020	Wang, Xin Wei/0000-0001-9735-606X; Hickson, Ian/0000-0002-0583-566X; Linke, Steven/0000-0001-8584-4947	NCI NIH HHS [CA70343] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS DE, 1995, MUTAT RES-DNA REPAIR, V337, P149, DOI 10.1016/0921-8777(95)00031-E; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; German J, 1996, CLIN GENET, V49, P223; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Mazur SJ, 1999, J MOL BIOL, V292, P241, DOI 10.1006/jmbi.1999.3064; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Milne DM, 1996, ONCOGENE, V13, P205; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Sharples GJ, 1999, J BACTERIOL, V181, P5543, DOI 10.1128/JB.181.18.5543-5550.1999; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wiesmuller L, 1996, J VIROL, V70, P737; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2001, SCIENCE, V292, P229, DOI 10.1126/science.1060832; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	58	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31980	31987		10.1074/jbc.M204111200	http://dx.doi.org/10.1074/jbc.M204111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080066	hybrid, Green Submitted, Green Published			2022-12-25	WOS:000177718700085
J	Tran, K; Thorne-Tjomsland, G; DeLong, CJ; Cui, Z; Shan, J; Burton, L; Jamieson, JC; Yao, ZM				Tran, K; Thorne-Tjomsland, G; DeLong, CJ; Cui, Z; Shan, J; Burton, L; Jamieson, JC; Yao, ZM			Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; SECRETORY PATHWAY; APO-B; HEPATOCYTES; LIPIDS; LIVER; PHOSPHATIDYLETHANOLAMINE	Previous studies with McA-RH7777 cells showed a 15-20-min temporal delay in the oleate treatment-induced assembly of very low density lipoproteins (VLDL) after apolipoprotein (apo) B100 translation, suggesting a post-translational process. Here, we determined whether the post-translational assembly of apoB100-VLDL occurred within the endoplasmic reticulum (ER) or in post-ER compartments using biochemical and microscopic techniques. At steady state, apoB100 distributed throughout ER and Golgi, which were fractionated by Nycodenz gradient centrifugation. Pulse-chase experiments showed that it took about 20 min for newly synthesized apoB100 to exit the ER and to accumulate in the cis/medial Golgi. At the end of a subsequent 20-min chase, a small fraction of apoB100 accumulated in the distal Golgi, and a large amount of apoB100 was secreted into the medium as VLDL. VLDL was not detected either in the lumen of ER or in that of cis/medial Golgi where apoB100 was membrane-associated and sensitive to endoglycosidase H treatment. In contrast, VLDL particles were found in the lumen of the distal Golgi where apoB100 was resistant to endoglycosidase H. Formation of lumenal VLDL almost coincided with the appearance of VLDL in the medium, suggesting that the site of VLDL assembly is proximal to the site of secretion. When microsomal triglyceride transfer protein activity was inactivated after apoB had exited the ER, VLDL formation in the distal Golgi and its subsequent secretion was unaffected. Lipid analysis by tandem mass spectrometry showed that oleate treatment increased the masses of membrane phosphatidylcholine (by 68%) and phosphatidylethanolamine (by 27%) and altered the membrane phospholipid profiles of ER and Golgi. Taken together, these results suggest that VLDL assembly in McA-RH7777 cells takes place in compartments at the distal end of the secretory pathway.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada; Canadian Food Inspect Agcy, Natl Ctr Foreign Anim Dis, Winnipeg, MB R3E 3M4, Canada; Univ Ottawa, Dept Pathol & Lab Med, Dept Biochem Microbiol & Mol Immunol, Ottawa, ON K1Y 4W7, Canada; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	University of Ottawa; University of Ottawa Heart Institute; University of Manitoba; Canadian Food Inspection Agency; University of Ottawa; Wake Forest University; Wake Forest Baptist Medical Center	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada.		Adiels, Martin/C-9278-2011	DeLong, Cynthia/0000-0002-6823-8619	NCI NIH HHS [CA 09422, R01 CA 79670] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079670, T32CA009422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CARTWRIGHT IJ, 1995, BIOCHEM J, V310, P897, DOI 10.1042/bj3100897; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; CHAN L, 1992, J BIOL CHEM, V267, P25621; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; HAMILTON RL, 1991, J LIPID RES, V32, P529; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hebbachi AM, 2001, J LIPID RES, V42, P1609; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; HIGGINS JA, 1984, J LIPID RES, V25, P1295; JANERO DR, 1983, J BIOL CHEM, V258, P4496; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; RICKWOOD D, 1982, ANAL BIOCHEM, V123, P23, DOI 10.1016/0003-2697(82)90618-2; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; SWIFT LL, 1995, J LIPID RES, V36, P395; Swift LL, 2001, J LIPID RES, V42, P218; Thorne-Tjomsland G, 1998, ANAT REC, V250, P381, DOI 10.1002/(SICI)1097-0185(199804)250:4<381::AID-AR1>3.0.CO;2-0; Tran K, 2000, J BIOL CHEM, V275, P25023, DOI 10.1074/jbc.M908971199; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WETTERAU JR, 1992, SCIENCE, V258, P999; WONG L, 1994, BIOCHEMISTRY-US, V33, P1923, DOI 10.1021/bi00173a040	36	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31187	31200		10.1074/jbc.M200249200	http://dx.doi.org/10.1074/jbc.M200249200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12065576	hybrid			2022-12-25	WOS:000177579800099
J	Tuo, JS; Jaruga, P; Rodriguez, H; Dizdaroglu, M; Bohr, VA				Tuo, JS; Jaruga, P; Rodriguez, H; Dizdaroglu, M; Bohr, VA			The Cockayne syndrome group B gene product is involved in cellular repair of 8-hydroxyadenine in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVELY DAMAGED DNA; TANDEM MASS-SPECTROMETRY; BASE EXCISION-REPAIR; COLI FPG PROTEIN; SUBSTRATE-SPECIFICITY; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GLYCOSYLASE ACTIVITY; IONIZING-RADIATION; PUTATIVE HELICASES	Cockayne syndrome (CS) is a human disease characterized by sensitivity to sunlight, severe neurological abnormalities, and accelerated aging. CS has two complementation groups, CS-A and CS-B. The CSB gene encodes the CSB protein with 1493 amino acids. We previously reported that the CSB protein is involved in cellular repair of 8-hydroxyguanine, an abundant lesion in oxidatively damaged DNA and that the putative helicase motif V/VI of the CSB may play a role in this process. The present study investigated the role of the CSB protein in cellular repair of 8-hydroxyadenine (8-OH-Ade), another abundant lesion in oxidatively damaged DNA. Extracts of CS-B-null cells and mutant cells with site-directed mutation in the motif VI of the putative helicase domain incised 8-hydroxyadenine in vitro less efficiently than wild type cells. Furthermore, CS-B-null and motif VI mutant cells accumulated more 8-hydroxyadenine in their genomic DNA than wild type cells after exposure to gamma-radiation at doses of 2 or 5 Gy. These results suggest that the CSB protein contributes to cellular repair of 8-OH-Ade and that the motif VI of the putative helicase domain of CSB is required for this activity.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institute of Standards & Technology (NIST) - USA	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Jaruga, Pawel/M-4378-2015	Jaruga, Pawel/0000-0001-9192-6084	NATIONAL INSTITUTE ON AGING [Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; CAVALIERI LF, 1950, J AM CHEM SOC, V72, P2587, DOI 10.1021/ja01162a067; Deutsch WA, 1997, J BIOL CHEM, V272, P32857, DOI 10.1074/jbc.272.52.32857; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dherin C, 2000, NUCLEIC ACIDS RES, V28, P4583, DOI 10.1093/nar/28.23.4583; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dizdaroglu M, 1998, FREE RADICAL RES, V29, P551, DOI 10.1080/10715769800300591; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DIZDAROGLU M, 2001, FREE RADICALS CHEM B, P58; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Frelon S, 2000, CHEM RES TOXICOL, V13, P1002, DOI 10.1021/tx000085h; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; Girard PM, 1998, CARCINOGENESIS, V19, P1299, DOI 10.1093/carcin/19.7.1299; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hua YS, 2001, J AM SOC MASS SPECTR, V12, P80, DOI 10.1016/S1044-0305(00)00191-4; Jaiswal M, 2001, CANCER RES, V61, P6388; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; Jaruga PW, 2001, FREE RADICAL BIO MED, V31, P336, DOI 10.1016/S0891-5849(01)00594-9; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; Karakaya A, 1997, NUCLEIC ACIDS RES, V25, P474, DOI 10.1093/nar/25.3.474; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; Muftuoglu M, 2002, GENE, V283, P27, DOI 10.1016/S0378-1119(01)00870-8; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Podmore ID, 2000, BIOCHEM BIOPH RES CO, V277, P764, DOI 10.1006/bbrc.2000.3752; Selzer RR, 2002, NUCLEIC ACIDS RES, V30, P782, DOI 10.1093/nar/30.3.782; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; Tan XZ, 1999, CARCINOGENESIS, V20, P2287, DOI 10.1093/carcin/20.12.2287; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Weimann A, 2001, FREE RADICAL BIO MED, V30, P757, DOI 10.1016/S0891-5849(01)00462-2; WOOD ML, 1992, NUCLEIC ACIDS RES, V20, P6023, DOI 10.1093/nar/20.22.6023; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	48	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30832	30837		10.1074/jbc.M204814200	http://dx.doi.org/10.1074/jbc.M204814200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060667	hybrid			2022-12-25	WOS:000177579800056
J	Hadjiargyrou, M; Lombardo, F; Zhao, SC; Ahrens, W; Joo, J; Ahn, H; Jurman, M; White, DW; Rubin, CT				Hadjiargyrou, M; Lombardo, F; Zhao, SC; Ahrens, W; Joo, J; Ahn, H; Jurman, M; White, DW; Rubin, CT			Transcriptional profiling of bone regeneration - Insight into the molecular complexity of wound repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; COLLAGEN GENES; MORPHOGENETIC PROTEINS; TEMPORAL EXPRESSION; MATRIX PROTEINS; FRACTURE REPAIR; SONIC HEDGEHOG; MESSENGER-RNA; GROWTH; IDENTIFICATION	The healing of skeletal fractures is essentially a replay of bone development, involving the closely regulated, interdependent processes of chondrogenesis and osteogenesis. Using a rat femur model of bone healing to determine the degree of transcriptional complexity of these processes, suppressive subtractive hybridization (SSH) was performed between RNA isolated from intact bone to that of callus from post-fracture (PF) days 3, 5, 7, and 10 as a means of identifying up-regulated genes in the regenerative process. Analysis of 3,635 cDNA clones revealed 588 known genes (65.8%, 2392 clones) and 821 expressed sequence tags (ESTs) (31%, 1,127). The remaining. 116 cDNAs (3.2%) yielded no homology and presumably represent novel genes. Microarrays were then constructed to confirm induction of expression and determine the temporal profile of all isolated cDNAs during fracture healing. These experiments confirmed that similar to90 and similar to80% of the subtracted known genes and ESTs are up-regulated (greater than or equal to2.5-fold) during the repair process, respectively. Clustering analysis revealed subsets of genes, both known and unknown, that exhibited distinct expression patterns over 21 days (PF), indicating distinct roles in the healing process. Additionally, this transcriptional profiling of bone repair revealed a host of activated signaling molecules and even pathways (i.e. Wnt). In summary, the data demonstrate, for the fist time, that the healing process is exceedingly complex, involves thousands of activated genes, and indicates that groups of genes rather than individual molecules should be considered if the regeneration of bone is to be accelerated exogenously.	SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Biotechnol, Stony Brook, NY 11794 USA; Millennium Pharmaceut Inc, Dept Metab Dis, Cambridge, MA 02139 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Hadjiargyrou, M (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Psychol A Bldg,3rd Floor, Stony Brook, NY 11794 USA.	michael.hadjiargyrou@sunysb.edu	Hadjiargyrou, Michael/H-7191-2018	Hadjiargyrou, Michael/0000-0001-8927-2333				ANDREW JG, 1993, CALCIFIED TISSUE INT, V53, P97, DOI 10.1007/BF01321886; Asaumi K, 2000, BONE, V26, P625, DOI 10.1016/S8756-3282(00)00281-7; Barnes GL, 1999, J BONE MINER RES, V14, P1805, DOI 10.1359/jbmr.1999.14.11.1805; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bland YS, 1999, HISTOCHEM J, V31, P797, DOI 10.1023/A:1003954104290; BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; BOURQUE WT, 1993, INT J DEV BIOL, V37, P573; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; Calinski T., 1974, COMMUNICATIONS STAT, V3, P1, DOI [DOI 10.1080/03610927408827101, 10.1080/03610927408827101]; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Diwan AD, 2000, J BONE MINER RES, V15, P342, DOI 10.1359/jbmr.2000.15.2.342; Duda R. O., 1973, PATTERN CLASSIFICATI; EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623-199506000-00016; Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7; EINHORN TA, 1995, J BONE MINER RES, V10, P1272; Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; Fujii H, 1999, HISTOCHEM CELL BIOL, V112, P131, DOI 10.1007/s004180050399; Hadjiargyrou M, 1998, BIOCHEM BIOPH RES CO, V249, P879, DOI 10.1006/bbrc.1998.9167; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; Hadjiargyrou M, 1998, CLIN ORTHOP RELAT R, pS216, DOI 10.1097/00003086-199810001-00022; HADJIARGYROU M, 2001, BONE NY, V9, P149; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; Hannouche D, 2001, J BONE JOINT SURG BR, V83B, P157, DOI 10.1302/0301-620X.83B2.12106; Hartmann C, 2000, DEVELOPMENT, V127, P3141; HILTUNEN A, 1995, FEBS LETT, V364, P171, DOI 10.1016/0014-5793(95)00384-L; HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551; Hu D, 1999, DEVELOPMENT, V126, P4873; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; HUGHES SS, 1995, J BONE MINER RES, V10, P533; JINGUSHI S, 1992, J BONE MINER RES, V7, P1045; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; KENWRIGHT J, 1998, CLIN ORTHOP S, V355, pS179; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; Matsui N, 1996, BIOCHEM BIOPH RES CO, V229, P571, DOI 10.1006/bbrc.1996.1845; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; Nakase T, 1998, ACTA HISTOCHEM, V100, P287, DOI 10.1016/S0065-1281(98)80015-9; OHTA S, 1991, FEBS LETT, V284, P42, DOI 10.1016/0014-5793(91)80757-T; Ohta S, 1999, J BONE MINER RES, V14, P1132, DOI 10.1359/jbmr.1999.14.7.1132; Oni OOA, 2000, INJURY, V31, P363, DOI 10.1016/S0020-1383(00)00004-8; Otter MW, 1998, CLIN ORTHOP RELAT R, pS90; Patapoutian A, 2000, CURR OPIN NEUROBIOL, V10, P392, DOI 10.1016/S0959-4388(00)00100-8; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; RHINELANDER FW, 1968, J BONE JOINT SURG AM, VA 50, P784, DOI 10.2106/00004623-196850040-00016; Rubin C, 2001, J BONE JOINT SURG AM, V83A, P259, DOI 10.2106/00004623-200102000-00015; Sakano S, 1999, J BONE MINER RES, V14, P1891, DOI 10.1359/jbmr.1999.14.11.1891; SANDBERG MM, 1993, CLIN ORTHOP RELAT R, P292; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Uusitalo H, 2001, J BONE MINER RES, V16, P1837, DOI 10.1359/jbmr.2001.16.10.1837; Uusitalo H, 2000, CALCIFIED TISSUE INT, V67, P382, DOI 10.1007/s002230001152; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Yamazaki M, 1997, J ORTHOPAED RES, V15, P757, DOI 10.1002/jor.1100150519; Yaoita H, 2000, J BONE MINER METAB, V18, P63, DOI 10.1007/s007740050013; Zehentner BK, 1999, J BONE MINER RES, V14, P1734, DOI 10.1359/jbmr.1999.14.10.1734; Zhi J, 2001, J BONE MINER RES, V16, P1994, DOI 10.1359/jbmr.2001.16.11.1994; Zhu W, 2001, J BONE MINER RES, V16, P535, DOI 10.1359/jbmr.2001.16.3.535	60	219	228	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30177	30182		10.1074/jbc.M203171200	http://dx.doi.org/10.1074/jbc.M203171200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12055193	hybrid			2022-12-25	WOS:000177509300102
J	Kotaja, N; Karvonen, U; Janne, OA; Palvimo, JJ				Kotaja, N; Karvonen, U; Janne, OA; Palvimo, JJ			The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER PROTEIN; ANDROGEN RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; STEROID-RECEPTORS; ESTROGEN-RECEPTOR; UBIQUITIN; BINDING; ACTIVATION; CONJUGATION; YEAST	The steroid receptor coactivator (SRC) proteins comprise a well-characterized family of nuclear receptor (NR) coactivators that increase transcriptional activation by NRs via covalent modification of chromatin proteins and recruitment of other coactivators. We have recently shown that the SRC family member GRIP1 interacts with a class of SUMO-1 (small ubiquitin-like modifier 1) E3 ligases, the PIAS proteins, and that the coactivator is subjected to SUMO-1 modifications (sumoylation). In this work, we demonstrate that lysine residues 239, 731, and 788 of GRIP1 serve as principal attachment sites for SUMO-1. Lys-731 and Lys-788 are located in the NR interaction domain (NID), and their substitution by arginines impairs the ability of GRIP1 to colocalize with androgen receptor (AR) in nuclei. Likewise, Lys-731 and Lys-788 mutants of GRIP1 have attenuated ability to enhance AR-dependent transcription and fail to synergize with PIASxbeta-mediated activation of AR function, indicating that sumoylation modifies the ability of GRIP1 to function as a steroid receptor coactivator. The Lys-731 sumoylation site is conserved in SRC-3 and SRC-1, and the NIDs of the latter coactivators harbor one or two additional sites matching with the consensus sites for SUMO-1 attachment, respectively, suggesting a more general role for the modification in the regulation of SRC protein activity.	Univ Helsinki, Biomedicum, Inst Biomed, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Palvimo, JJ (corresponding author), Univ Helsinki, Biomedicum, Inst Biomed, POB 63, FIN-00014 Helsinki, Finland.	jorma.palvimo@helsinki.fi		Kotaja, Noora/0000-0003-1503-9170; Palvimo, Jorma/0000-0003-2373-0578				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Glass CK, 2000, GENE DEV, V14, P121; Grobelny JV, 2000, J CELL SCI, V113, P4577; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Joseph J, 2002, J CELL BIOL, V156, P595, DOI 10.1083/jcb.200110109; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Ma H, 1999, MOL CELL BIOL, V19, P6164; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 2000, J CELL SCI, V113, P2991; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	48	116	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30283	30288		10.1074/jbc.M204768200	http://dx.doi.org/10.1074/jbc.M204768200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12060666	hybrid			2022-12-25	WOS:000177509300114
J	Quadro, L; Blaner, WS; Hamberger, L; Van Gelder, RN; Vogel, S; Piantedosi, R; Gouras, P; Colantuoni, V; Gottesman, ME				Quadro, L; Blaner, WS; Hamberger, L; Van Gelder, RN; Vogel, S; Piantedosi, R; Gouras, P; Colantuoni, V; Gottesman, ME			Muscle expression of human retinol-binding protein (RBP) - Suppression of the visual defect of RBP knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSTHYRETIN-DEFICIENT MICE; VITAMIN-A; PIGMENT EPITHELIUM; ACID RECEPTORS; METABOLISM; RAT; CELLS; MECHANISM; COMPLEX; LACKING	Mice lacking retinol-binding protein (RBP) have low circulating retinol levels. They have severe visual defects due to a low content of retinol or retinyl esters in the eye. A transgenic mouse strain that expresses human RBP under the control of the muscle creatine kinase promoter in the null background was generated. The exogenous protein bound retinol and transthyretin in the circulation and effectively delivered retinol to the eye. Thus, RBP expressed from an ectopic source suppresses the visual phenotype, and retinoids accumulate in the eye. No human RBP was found in the retinal pigment epithelium of the transgenic mice, indicating that retinol uptake by the eye does not entail endocytosis of the carrier RBP.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Res, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA; Univ Sannio, Fac Biol Sci, I-82100 Benevento, Italy; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Columbia University; Columbia University; Columbia University; University of Sannio; Washington University (WUSTL)	Blaner, WS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.		Van Gelder, Russell/ABB-4225-2021	Van Gelder, Russell/0000-0001-5368-3659	NEI NIH HHS [R01 EY12858] Funding Source: Medline; NIDDK NIH HHS [R01 DK52444] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052444] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler AJ, 2000, EXP EYE RES, V70, P227, DOI 10.1006/exer.1999.0780; Bellovino D, 1996, EXP CELL RES, V222, P77, DOI 10.1006/excr.1996.0010; BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; BLANER WS, 1987, J BIOL CHEM, V262, P53; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BROUWER A, 1988, CHEM-BIOL INTERACT, V68, P203, DOI 10.1016/0009-2797(88)90017-8; CHEN JD, 1995, NATURE, V377, P545; Clagett-Dame M, 1997, CRIT REV EUKAR GENE, V7, P299, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.20; COLANTUONI V, 1983, NUCLEIC ACIDS RES, V11, P7769, DOI 10.1093/nar/11.22.7769; DAS SR, 1988, BIOCHEM J, V250, P459, DOI 10.1042/bj2500459; FLOOD MT, 1983, INVEST OPHTH VIS SCI, V24, P1227; FLOOD MT, 1982, BIRTH DEFECTS-ORIG, V18, P53; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; Gudas Lorraine J., 1994, P443; HERBERT J, 1991, INVEST OPHTH VIS SCI, V32, P302; HOGAN B, 1986, MANIPULATING MOUSE E; HUANG HFS, 1983, BIOL REPROD, V28, P1163, DOI 10.1095/biolreprod28.5.1163; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTONE RL, 1988, BIOCHEM BIOPH RES CO, V157, P1078, DOI 10.1016/S0006-291X(88)80984-7; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; MUTO Y, 1972, J BIOL CHEM, V247, P2542; Napoli JL, 1996, CLIN IMMUNOL IMMUNOP, V80, pS52, DOI 10.1006/clin.1996.0142; NAVAB M, 1977, J BIOL CHEM, V252, P5100; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; ONG DE, 1994, BIOCHEMISTRY-US, V33, P1835, DOI 10.1021/bi00173a029; Pfahl M, 1996, ANNU REV NUTR, V16, P257, DOI 10.1146/annurev.nu.16.070196.001353; PFEFFER BA, 1986, INVEST OPHTH VIS SCI, V27, P1031; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; Sambrook J., 2002, MOL CLONING LAB MANU; SIVAPRASADARAO A, 1994, BIOCHEM J, V302, P245, DOI 10.1042/bj3020245; SMELAND S, 1995, BIOCHEM J, V305, P419, DOI 10.1042/bj3050419; Soprano Dianne Robert, 1994, P257; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; Thompson CL, 2001, P NATL ACAD SCI USA, V98, P11708, DOI 10.1073/pnas.201301498; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; UNNI E, 1983, INDIAN J EXP BIOL, V21, P180; van Bennekum AM, 2001, J BIOL CHEM, V276, P1107, DOI 10.1074/jbc.M008091200; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Ward SJ, 1997, BIOL REPROD, V57, P751, DOI 10.1095/biolreprod57.4.751; WEI SH, 1995, J BIOL CHEM, V270, P866, DOI 10.1074/jbc.270.2.866	46	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30191	30197		10.1074/jbc.M205046200	http://dx.doi.org/10.1074/jbc.M205046200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048218	hybrid			2022-12-25	WOS:000177509300104
J	Clark, PA; Llanos, S; Peters, G				Clark, PA; Llanos, S; Peters, G			Multiple interacting domains contribute to p14(ARF) mediated inhibition of MDM2	ONCOGENE			English	Article						p53; tumour suppressor; INK4a/ARF; MDM2; nucleolus	TUMOR-SUPPRESSOR; NUCLEOLAR LOCALIZATION; P53; ARF; MUTATIONS; LOCUS; DEGRADATION; P16(INK4A); PROMOTES; P19(ARF)	The small basic protein p14(Arf), encoded by one of the alternative transcripts from the human INK4A/ARF locus, interferes with MDM2-mediated ubiquitination of the p53 tumour suppressor protein. The resultant stabilization of p53 leads to increased expression of p53-regulated genes, such as MDM2 itself and the cyclin-dependent kinase inhibitor p21(CIP1). Here we relate physical interactions between p][4111 and MDM2, as determined using synthetic peptides and systematic deletions of p14(Arf), with consequential effects on p53 stabilization and transcriptional activity. The data imply that the amino terminal half of p14(Arf), encoded by the alternative first exon (exon 1beta) contacts MDM2 through multiple domains that can independently impede MDM2-mediated degradation of p53, provided that they are localized in the cell nucleus. As well as identifying previously unrecognized functional domains, our findings offer an explanation for the relative paucity of missense mutations in exon 1beta in human tumours.	London Res Inst, Canc Res UK, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), London Res Inst, Canc Res UK, Lincolns Inn Fields Labs, 61 Lincolns Inn Fields, London WC2A 3PX, England.	g.peters@cancer.org.uk	, Susana/AAA-9282-2019	Llanos, Susana/0000-0002-8555-9326				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BATES S, 1994, ONCOGENE, V9, P1633; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; DiGiammarino EL, 2001, BIOCHEMISTRY-US, V40, P2379, DOI 10.1021/bi0024005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	35	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4498	4507		10.1038/sj.onc.1205558	http://dx.doi.org/10.1038/sj.onc.1205558			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085228				2022-12-25	WOS:000176476700004
J	Deng, WG; Saunders, MA; Gilroy, DW; He, XZ; Yeh, H; Zhu, Y; Shtivelband, MI; Ruan, KH; Wu, KK				Deng, WG; Saunders, MA; Gilroy, DW; He, XZ; Yeh, H; Zhu, Y; Shtivelband, MI; Ruan, KH; Wu, KK			Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts	FASEB JOURNAL			English	Article						inhibitors of cyclooxygenase-2; inflammation; tumorigenesis	NITRIC-OXIDE SYNTHASE; EXPRESSION; GROWTH; CELLS; INHIBITION; INDUCTION; REPAIR	Cyclooxygenase-2 (COX-2) is an inducible enzyme that plays an important role in several pathophysiological processes, including inflammation, angiogenesis, and tumorigenesis. We have recently observed that COX-2 induction is restrained in proliferating fibroblasts. The mechanism by which this occurs is unclear. Here, we report the detection and isolation from the conditioned medium of proliferating fibroblasts a factor that suppressed COX-2 expression. This factor, which was named cytoguardin, suppressed COX-2 protein levels induced by phorbol 12-myristate 13-acetate, interleukin-1beta, tumor necrosis factor alpha, and lipopolysaccharide (LPS) in fibroblasts and LPS-induced COX-2 protein levels and promoter activities in human endothelial cells and murine RAW 264.7 cells in a comparable concentration-dependent manner. It inhibited COX-2 expression induced by angiogenic factors and endothelial tube formation induced by angiogenic factors and colon cancer cell medium. These findings provide evidence for the control of COX-2 transcription by an endogenous cellular factor.	Univ Texas, Houston Med Sch, Vasc Biol Res Ctr, Inst Mol Med, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Div Hematol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Wu, KK (corresponding author), Univ Texas, Houston Med Sch, Vasc Biol Res Ctr, Inst Mol Med, 6431 Fannin St, Houston, TX 77030 USA.	Kenneth.K.Wu@uth.tmc.edu	Gilroy, Derek/AAP-7227-2020; Wu, Kenneth Kun-Yu/B-1070-2010; Shtivelband, Mikhail/GXN-0194-2022; Gilroy, Derek W/C-2588-2009	Gilroy, Derek/0000-0003-3476-0844; Deng, wuguo/0000-0002-1193-1500				Bielas JH, 2000, P NATL ACAD SCI USA, V97, P11391, DOI 10.1073/pnas.190330997; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Ghosh AK, 2000, J PHARMACOL EXP THER, V295, P802; Gilroy DW, 2001, AM J PHYSIOL-CELL PH, V281, pC188, DOI 10.1152/ajpcell.2001.281.1.C188; Gilroy DW, 2001, FASEB J, V15, P288; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Jones MK, 1999, NAT MED, V5, P1418; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292	19	20	20	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1286	+		10.1096/fj.01-0844fje	http://dx.doi.org/10.1096/fj.01-0844fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060668				2022-12-25	WOS:000176683900030
J	Mattison, K; Oropeza, R; Kenney, LJ				Mattison, K; Oropeza, R; Kenney, LJ			The linker region plays an important role in the interdomain communication of the response regulator OmpR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ACTIVATOR PROTEIN; COLI POSITIVE REGULATOR; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; TERMINAL PHOSPHORYLATION; CRYSTAL-STRUCTURE; GENETIC-ANALYSIS; RECEIVER DOMAIN; 2-WAY STREET; DNA	OmpR is the response regulator of a two-component regulatory system that controls the expression of the porin genes ompF and ompC in Escherichia coli. This regulator consists of two domains joined by a flexible linker region. The amino-terminal domain is phosphorylated by the sensor kinase EnvZ, and the carboxyl-terminal domain binds DNA via a winged helix-turn-helix motif. In vitro studies have shown that amino-terminal phosphorylation enhances the DNA binding affinity of OmpR and, conversely, that DNA binding by the carboxyl terminus increases OmpR phosphorylation. In the present work, we demonstrate that the linker region contributes to this communication between the two domains of OmpR. Changing the specific amino acid composition of the linker alters OmpR function, as does increasing or decreasing its length. Three linker mutants give rise to an OmpF(+) OmpC(-) phenotype, but the defects are not due to a shared molecular mechanism. Currently, functional homology between response regulators is predicted based on similarities in the amino and carboxyl terminal domains. The results presented here indicate that linker length and composition should also be considered. Furthermore, classification of response regulators in the same subfamily does not necessarily imply that they share a common response mechanism.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA	Oregon Health & Science University	Kenney, LJ (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, L-220,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.				NIGMS NIH HHS [GM-58746] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058746] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1994, FEBS LETT, V351, P303, DOI 10.1016/0014-5793(94)00846-9; AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; AIBA H, 1990, FEBS LETT, V261, P19, DOI 10.1016/0014-5793(90)80626-T; Allen MP, 2001, J BACTERIOL, V183, P2204, DOI 10.1128/JB.183.7.2204-2211.2001; Ames SK, 1999, P NATL ACAD SCI USA, V96, P11792, DOI 10.1073/pnas.96.21.11792; ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; Bourret RB, 2002, J BACTERIOL, V184, P1, DOI 10.1128/JB.184.1.1-17.2002; Buckler DR, 2000, TRENDS MICROBIOL, V8, P153, DOI 10.1016/S0966-842X(00)01707-8; Buckler DR, 2002, STRUCTURE, V10, P153, DOI 10.1016/S0969-2126(01)00706-7; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; HALL MN, 1979, J BACTERIOL, V140, P342, DOI 10.1128/JB.140.2.342-350.1979; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; Head CG, 1998, J MOL BIOL, V281, P857, DOI 10.1006/jmbi.1998.1985; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Huang KJ, 1997, P NATL ACAD SCI USA, V94, P2828, DOI 10.1073/pnas.94.7.2828; KANAMARU K, 1992, J BIOCHEM-TOKYO, V111, P425, DOI 10.1093/oxfordjournals.jbchem.a123773; KATO M, 1989, FEBS LETT, V249, P168, DOI 10.1016/0014-5793(89)80617-9; Kenney LJ, 2000, TRENDS MICROBIOL, V8, P155, DOI 10.1016/S0966-842X(00)01708-X; Kenney LJ, 1997, ARCH BIOCHEM BIOPHYS, V346, P303, DOI 10.1006/abbi.1997.0315; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; Kenney LJ, 2002, CURR OPIN MICROBIOL, V5, P135, DOI 10.1016/S1369-5274(02)00310-7; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Mattison K, 2002, J MOL BIOL, V315, P497, DOI 10.1006/jmbi.2001.5222; Mattison K, 2002, J BIOL CHEM, V277, P11143, DOI 10.1074/jbc.M111128200; Qin L, 2001, P NATL ACAD SCI USA, V98, P908, DOI 10.1073/pnas.031383098; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; ROBERTS DL, 1994, J BIOL CHEM, V269, P8728; RUSSO FD, 1993, J MOL BIOL, V231, P261, DOI 10.1006/jmbi.1993.1281; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; TATE S, 1988, FEBS LETT, V242, P27, DOI 10.1016/0014-5793(88)80978-5; Tran VK, 2000, J MOL BIOL, V299, P1257, DOI 10.1006/jmbi.2000.3809; TSUZUKI M, 1994, J MOL BIOL, V242, P607, DOI 10.1006/jmbi.1994.1610; VANALPHEN W, 1977, J BACTERIOL, V131, P623; Webber CA, 1997, MOL MICROBIOL, V24, P1039, DOI 10.1046/j.1365-2958.1997.4021765.x; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; Yamamoto I, 1999, BBA-GENE STRUCT EXPR, V1447, P57, DOI 10.1016/S0167-4781(99)00121-9	41	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32714	32721		10.1074/jbc.M204122200	http://dx.doi.org/10.1074/jbc.M204122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077136	hybrid			2022-12-25	WOS:000177859000042
J	Sen, CK; Khanna, S; Babior, BM; Hunt, TK; Ellison, EC; Roy, S				Sen, CK; Khanna, S; Babior, BM; Hunt, TK; Ellison, EC; Roy, S			Oxidant-induced vascular endothelial growth factor expression in human keratinocytes and cutaneous wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; CELLS; RAC1; SUPEROXIDE; ACTIVATION; PROMOTER; FIBROBLASTS; INDUCTION; HYPOXIA; SKIN	Neutrophils and macrophages, recruited to the wound site, release reactive oxygen species by respiratory burst. It is commonly understood that oxidants serve mainly to kill bacteria and prevent wound infection. We tested the hypothesis that oxidants generated at the wound site promote dermal wound repair. We observed that H2O2 potently induces vascular endothelial growth factor (VEGF) expression in human keratinocytes. Deletion mutant studies with a VEGF promoter construct revealed that a GC-rich sequence from bp -194 to -50 of the VEGF promoter is responsible for the H2O2 response. It was established that at pm concentrations oxidant induces VEGF expression and that oxidant-induced VEGF expression is independent of hypoxia-inducible factor (HIF)-1 and dependent on Sp1 activation. To test the effect of NADPH oxidase-generated reactive oxygen species on wound healing in vivo, Rac1 gene transfer was performed to dermal excisional wounds left to heal by secondary intention. Rac1 gene transfer accelerated wound contraction and closure. Rac1 overexpression was associated with higher VEGF expression both in vivo as well in human keratinocytes. Interestingly, Rac1 gene therapy was associated with a more well defined hyperproliferative epithelial region, higher cell density, enhanced deposition of connective tissue, and improved histological architecture. Overall, the histological data indicated that Rac1 might be an important stimulator of various aspects of the repair process, eventually enhancing the wound-healing process as a whole. Taken together, the results of this study indicate that wound healing is subject to redox control.	Ohio State Univ, Med Ctr, Mol Med Lab,Ctr Minimally Invas Surg, Dorothy M Davis Heart & Lung Res Inst,Dept Surg, Columbus, OH 43210 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA	University System of Ohio; Ohio State University; Scripps Research Institute	Sen, CK (corresponding author), 512 Heart & Lung Res Inst, 473 W 12th Ave, Columbus, OH 43210 USA.		Khanna, Savita/E-3378-2011; Sen, Chandan K/A-8762-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM027345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 27345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Baeuerle PA, 1996, PATHOL BIOL, V44, P29; Bancroft G.D., 1996, THEORY PRACTICE PATH, V4th ed.; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brown S, 2001, BIOTECHNIQUES, V30, P38, DOI 10.2144/01301bm06; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; CHANDRAKASAN G, 1991, CELL MOL BIOL, V37, P751; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Cool RH, 1998, BIOCHEM J, V332, P5, DOI 10.1042/bj3320005; ECKERT JW, 1995, AM J SURG, V169, P320, DOI 10.1016/S0002-9610(99)80167-6; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Khanna S, 2001, FREE RADICAL BIO MED, V31, P38, DOI 10.1016/S0891-5849(01)00544-5; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Latijnhouwers MA, 1996, J PATHOL, V178, P30, DOI 10.1002/(SICI)1096-9896(199601)178:1<30::AID-PATH442>3.0.CO;2-7; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Moldovan L, 1999, ANTIOXID REDOX SIGN, V1, P29, DOI 10.1089/ars.1999.1.1-29; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Roy S, 2002, METHOD ENZYMOL, V352, P326; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Sen CK, 1999, METHOD ENZYMOL, V299, P239; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Sen CK, 2002, AM J PHYSIOL-HEART C, V282, pH1821, DOI 10.1152/ajpheart.01015.2001; Sen CK, 2000, ANTIOXIDANT REDOX RE; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WANG GL, 1993, J BIOL CHEM, V268, P21513; Yu WH, 1999, J INVEST DERMATOL, V112, P370, DOI 10.1046/j.1523-1747.1999.00513.x	42	226	235	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33284	33290		10.1074/jbc.M203391200	http://dx.doi.org/10.1074/jbc.M203391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12068011	hybrid, Green Published			2022-12-25	WOS:000177859000114
J	Kim, BC; Kim, HT; Mamura, M; Ambudkar, IS; Choi, KS; Kim, SJ				Kim, BC; Kim, HT; Mamura, M; Ambudkar, IS; Choi, KS; Kim, SJ			Tumor necrosis factor induces apoptosis in hepatoma cells by increasing Ca2+ release from the endoplasmic reticulum and suppressing Bcl-2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; TNF RECEPTOR-2; DEATH DOMAIN; ACTIVATION; PROTEIN; CASPASE; MECHANISM	Tumor necrosis factor (TNF) plays an import role in the control of apoptosis. The most well known apoptotic pathway regulated by TNF involves the TNFR1-associated death domain protein, Fas-associated death domain protein, and caspase-8. This study examines the mechanism of TNF-induced apoptosis in FaO rat hepatoma cells. TNF treatment significantly increased the percentage of apoptotic cells. TNF did not activate caspase-8 but activated caspase-3, -10, and -12. The effect of TNF on the expression of different members of the Bcl-2 family in these cells was studied. We observed no detectable changes in the steady-state levels of Bcl-X-L, Bax, and Bid, although TNF suppresses Bcl-2 expression. Dantrolene suppressed the inhibitory effect of TNF on Bcl-2 expression. TNF induced release of Ca2+ from the endoplasmic reticulum. (ER) that was blocked by dantrolene. Importantly, the expression of BcI-2 blocked TNF-induced apoptosis and decreased TNF-induced Ca2+ release. These results suggest that TNF induces apoptosis by a mechanism that involves increasing Ca2+ release from the ER and suppression of Bcl-2 expression.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Ajou Univ, Sch Med, Inst Med Sci, Med Genet Lab, Suwon 442749, South Korea; Ajou Univ, Sch Med, Lab Endocrinol, Paldal Gu, Suwon 442749, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ajou University; Ajou University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Rm B1106, Bethesda, MD 20892 USA.	Kims@mail.nih.gov		Choi, Kyeong Sook/0000-0003-2331-0856; Mamura, Mizuko/0000-0003-4531-0144	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Chevalier S, 1999, CARCINOGENESIS, V20, P1209, DOI 10.1093/carcin/20.7.1209; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; DUCHEN MR, 1999, J PHYSL, V16, P1; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Goll V, 2000, HUM EXP TOXICOL, V19, P193, DOI 10.1191/096032700678827753; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Guo H, 1998, EXP CELL RES, V245, P57, DOI 10.1006/excr.1998.4235; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Marin MC, 1996, ONCOGENE, V12, P2259; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; OKAMOTO Y, 1995, NEUROCHEM INT, V26, P233, DOI 10.1016/0197-0186(94)00130-M; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pollock J, 2002, NEUROPHARMACOLOGY, V42, P93, DOI 10.1016/S0028-3908(01)00163-0; Pozzan T, 2000, NAT CELL BIOL, V2, pE25, DOI 10.1038/35000095; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wei HF, 2000, J NEUROCHEM, V75, P81, DOI 10.1046/j.1471-4159.2000.0750081.x; Wei HF, 1996, J NEUROCHEM, V67, P2390; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	53	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31381	31389		10.1074/jbc.M203465200	http://dx.doi.org/10.1074/jbc.M203465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077131	hybrid, Green Published			2022-12-25	WOS:000177718700014
J	Kim, J; Eckhart, AD; Eguchi, S; Koch, WJ				Kim, J; Eckhart, AD; Eguchi, S; Koch, WJ			beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; ANGIOTENSIN-II; PROTEIN-KINASE; EGF RECEPTOR; TYROSINE KINASE; G(I) PROTEINS; C-SRC; STIMULATION; INHIBITOR; IDENTIFICATION	Cardiac hypertrophy often leads to heart failure and is associated with abnormal myocardial adrenergic signaling. This enlargement of myocardial mass can involve not only an increase in cardiomyocyte size, but increased proliferation of cardiac fibroblasts. A potential key player in the cardiac hypertrophic response is the ERK family of MAPKs. To gain mechanistic insight into adrenergic regulation of myocardial mitogenic signaling, we examined beta-adrenergic receptor (beta-AR) stimulation of ERK activation and DNA synthesis in cultured adult rat cardiac fibroblasts, including the involvement of tyrosine kinases in this signaling pathway. Addition of the beta-AR agonist isoproterenol (ISO) to serum-starved cells induced DNA synthesis in a dose-dependent manner, and this was inhibited by selective inhibitors of the epidermal growth factor receptor (EGFR). Importantly and in agreement with the involvement of MAPKs and the EGFR in this response in cardiac fibroblasts, the EGFR inhibitor AG1478 attenuated ISO-induced ERK phosphorylation. Moreover, pretreatment with PP2, a selective inhibitor of the Src tyrosine kinase, attenuated both ISO-mediated EGFR phosphorylation and ERK activation. Furthermore, studies in these cardiac fibroblasts showed that phosphatidylinositol 3-kinase contributed to beta-AR-mediated ERK activation, but not to EGFR activation. Finally, studies using selective inhibitors of matrix metalloproteases indicated that they and heparin-bound EGF shedding were involved in beta-AR-induced ERK activation and subsequent DNA synthesis in cardiac fibroblasts. Because these cells primarily express the beta(2)-AR subtype, our findings indicate that beta(2)-AR-mediated EGFR transactivation of intracellular tyrosine kinase signaling pathways is the major signaling pathway responsible for the adrenergic stimulation of mitogenesis of cardiac fibroblasts.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Duke University; Vanderbilt University	Koch, WJ (corresponding author), Duke Univ, Med Ctr, Dept Surg, Med Sci Res Bldg,Rm 479,POB 2606, Durham, NC 27710 USA.	koch0002@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056205, R01HL065360, R01HL059533] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65360, HL59533, HL56205] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOOZ GW, 1995, CARDIOVASC RES, V30, P537, DOI 10.1016/S0008-6363(96)88507-5; Colombo F, 2001, J MOL CELL CARDIOL, V33, P1091, DOI 10.1006/jmcc.2001.1381; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Dostal DE, 1996, MOL CELL BIOCHEM, V157, P15; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Esposito G, 2001, CIRCULATION, V103, P1453, DOI 10.1161/01.CIR.103.10.1453; Fujino T, 1998, CARDIOVASC RES, V38, P365, DOI 10.1016/S0008-6363(98)00010-8; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gustafsson AB, 2000, MOL PHARMACOL, V58, P1470, DOI 10.1124/mol.58.6.1470; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Leicht M, 2000, CARDIOVASC RES, V48, P274, DOI 10.1016/S0008-6363(00)00170-X; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Lovdahl C, 2000, J VASC RES, V37, P345, DOI 10.1159/000025750; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Manning BS, 2000, CIRCULATION, V102, P2751, DOI 10.1161/01.CIR.102.22.2751; Meszaros JG, 2000, AM J PHYSIOL-CELL PH, V278, pC154, DOI 10.1152/ajpcell.2000.278.1.C154; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Schluter KD, 1999, AM J PHYSIOL-HEART C, V276, pH1655, DOI 10.1152/ajpheart.1999.276.5.H1655; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; Shah AS, 2001, CIRCULATION, V103, P1311; VILLARREAL FJ, 1993, CIRCULATION, V88, P2849, DOI 10.1161/01.CIR.88.6.2849; Weber KT, 2000, CURR OPIN CARDIOL, V15, P264, DOI 10.1097/00001573-200007000-00010; Xiao RP, 1999, CIRC RES, V84, P43; Yamazaki T, 1997, CIRCULATION, V95, P1260; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	47	121	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32116	32123		10.1074/jbc.M204895200	http://dx.doi.org/10.1074/jbc.M204895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12048215	hybrid			2022-12-25	WOS:000177718700102
J	Koblinski, JE; Dosescu, J; Sameni, M; Moin, K; Clark, K; Sloane, BF				Koblinski, JE; Dosescu, J; Sameni, M; Moin, K; Clark, K; Sloane, BF			Interaction of human breast fibroblasts with collagen I increases secretion of procathepsin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-ASSOCIATED LAMININ; GROWTH-FACTOR-BETA; CATHEPSIN-B; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; EXPRESSION; CELLS; PROTEIN; CANCER; CARCINOMA	Interactions of stromal and tumor cells with the extracellular matrix may regulate expression of proteases including the lysosomal proteases cathepsins B and D. In the present study, we determined whether the expression of these two proteases in human breast fibroblasts was modulated by interactions with the extracellular matrix component, collagen I. Breast fibroblasts were isolated from non-malignant breast tissue as well as from tissue surrounding malignant human breast tumors. Growth of these fibroblasts on collagen I gels affected cell morphology, but not the intracellular localization of vesicles staining for cathepsin B or D. Cathepsins B and D levels (mRNA or intracellular protein) were not affected in fibroblasts growing on collagen I gels or plastic, nor was cathepsin D secreted from these cells. In contrast, protein expression and secretion of cathepsin B, primarily procathepsin B, was induced by growth on collagen I gels. The induced secretion appeared to be mediated by integrins binding to collagen I, as inhibitory antibodies against alpha(1), alpha(2), and beta(1) integrin subunits prevented procathepsin B secretion from fibroblasts grown on collagen. In addition, procathepsin B secretion was induced when cells were plated on beta(1) integrin antibodies. To our knowledge, this is the first examination of cathepsin B and D expression and localization in human breast fibroblasts and their regulation by a matrix protein. Secretion of the cysteine protease procathepsin B from breast fibroblasts may have physiological and pathological consequences, as proteases are required for normal development and for lactation of the mammary gland, yet can also initiate and accelerate the progression of breast cancer.	Wayne State Univ, Dept Pharmacol, Sch Med, Detroit, MI 48201 USA; Wayne State Univ, Barbara Ann Karmanos Ctr Inst, Sch Med, Detroit, MI 48201 USA; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Sloane, BF (corresponding author), Wayne State Univ, Dept Pharmacol, Sch Med, 540 E Canfield, Detroit, MI 48201 USA.	bsloane@med.wayne.edu	Sloane, Bonnie F/A-1050-2009		NATIONAL CANCER INSTITUTE [R01CA036481, P30CA022453, R01CA056586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NCI NIH HHS [CA36481, CA56586, P30CA22453] Funding Source: Medline; NIEHS NIH HHS [P30ES06639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Ahn K, 2002, TRAFFIC, V3, P147, DOI 10.1034/j.1600-0854.2002.030207.x; Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; BARICOS WH, 1988, BIOCHEM J, V252, P301, DOI 10.1042/bj2520301; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Bright RK, 1997, CANCER RES, V57, P995; BRIOZZO P, 1988, CANCER RES, V48, P3688; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAMPO E, 1994, AM J PATHOL, V145, P301; CASTIGLIONI T, 1994, HUM PATHOL, V25, P857, DOI 10.1016/0046-8177(94)90003-5; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christensen L, 1996, INT J CANCER, V66, P441; DOWNS TR, 1983, ANAL BIOCHEM, V131, P538, DOI 10.1016/0003-2697(83)90212-9; DOWRICK P, 1993, EUR J CELL BIOL, V61, P44; Eckes B, 2000, MATRIX BIOL, V19, P325, DOI 10.1016/S0945-053X(00)00077-9; Ermis A, 1998, J RHEUMATOL, V25, P208; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Guo M, 2002, J BIOL CHEM, V277, P14829, DOI 10.1074/jbc.M108180200; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; HONN KV, 1994, EXP CELL RES, V214, P120, DOI 10.1006/excr.1994.1240; HUMPHRIES MJ, 1983, NATURE, V305, P811, DOI 10.1038/305811a0; Ikeda Yuichi, 2000, Journal of Medical Investigation, V47, P61; Ishidoh K, 1999, J BIOCHEM-TOKYO, V125, P770, DOI 10.1093/oxfordjournals.jbchem.a022348; JOENSUU H, 1995, BRIT J CANCER, V71, P155, DOI 10.1038/bjc.1995.32; Kane S E, 1990, Semin Cancer Biol, V1, P127; KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3; Khan A, 1998, ARCH PATHOL LAB MED, V122, P172; Khan A, 1998, MODERN PATHOL, V11, P704; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Lah TT, 2000, CLIN CANCER RES, V6, P578; Lah TT, 2000, HUM PATHOL, V31, P149, DOI 10.1016/S0046-8177(00)80214-2; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; Mackay EA, 1997, EUR J BIOCHEM, V244, P414, DOI 10.1111/j.1432-1033.1997.00414.x; Maniatis T., 1982, MOL CLONING LAB MANU; MAUCH C, 1989, FEBS LETT, V250, P301, DOI 10.1016/0014-5793(89)80743-4; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; MORISSET M, 1986, BIOCHEM BIOPH RES CO, V138, P102, DOI 10.1016/0006-291X(86)90252-4; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo-129-6-3313; Pauley RJ, 2000, J CLIN ENDOCR METAB, V85, P837, DOI 10.1210/jc.85.2.837; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; ROZHIN J, 1994, CANCER RES, V54, P6517; Sado Y, 1998, EXTRACELLULAR MATRIX-CELL INTERACTION, P235; Sameni M, 2000, NEOPLASIA, V2, P496, DOI 10.1038/sj.neo.7900116; Sameni Mansoureh, 1995, Pathol Oncol Res, V1, P43; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; SILBERSTEIN GB, 1990, J CELL BIOL, V110, P2209, DOI 10.1083/jcb.110.6.2209; SLOANE BF, 1994, J CELL SCI, V107, P373; Stanton H, 1998, J CELL SCI, V111, P2789; SUKOH N, 1994, CANCER, V74, P46, DOI 10.1002/1097-0142(19940701)74:1<46::AID-CNCR2820740109>3.0.CO;2-G; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Uria JA, 1997, CANCER RES, V57, P4882; Vetvicka V, 1997, INT J CANCER, V73, P403, DOI 10.1002/(SICI)1097-0215(19971104)73:3<403::AID-IJC15>3.0.CO;2-D; VISSCHER DW, 1994, MODERN PATHOL, V7, P76; VISSCHER DW, 1993, PATHOL RES PRACT, V189, P867; WHEATER PR, 1987, FUNCTIONAL HISTOLOGY, P52; WILLINGHAM MC, 1990, FOCUS, V12, P62; Wolfe K, 2000, NAT REV GENET, V1, P7, DOI 10.1038/35049607; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YANO T, 1995, EUR J BIOCHEM, V234, P39, DOI 10.1111/j.1432-1033.1995.039_c.x	69	61	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32220	32227		10.1074/jbc.M204708200	http://dx.doi.org/10.1074/jbc.M204708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12072442	hybrid			2022-12-25	WOS:000177718700115
J	Yu, JH; Lo, JL; Huang, L; Zhao, A; Metzger, E; Adam, A; Meinke, PT; Wright, SD; Cui, JS				Yu, JH; Lo, JL; Huang, L; Zhao, A; Metzger, E; Adam, A; Meinke, PT; Wright, SD; Cui, JS			Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; PROTEIN GENE; IDENTIFICATION; LIVER; METABOLISM; PROMOTER; LIGANDS; ELEMENT; DRUG; FXR	Bile salt export pump (BSEP) is a major bile acid transporter in the liver. Mutations in BSEP result in progressive intrahepatic cholestasis, a severe liver disease that impairs bile flow and causes irreversible liver damage. BSEP is a target for inhibition and down-regulation by drugs and abnormal bile salt metabolites, and such inhibition and down-regulation may result in bile acid retention and intrahepatic cholestasis. In this study, we quantitatively analyzed the regulation of BSEP expression by FXR ligands in primary human hepatocytes and HepG2 cells. We demonstrate that BSEP expression is dramatically regulated by ligands of the nuclear receptor farnesoid X receptor (FXR). Both the endogenous FXR agonist chenodeoxycholate (CDCA) and synthetic FXR ligand GW4064 effectively increased BSEP mRNA in both cell types. This up-regulation was readily detectable at as early as 3 h, and the ligand potency for BSEP regulation correlates with the intrinsic activity on FXR. These results suggest BSEP as a direct target of FXR and support the recent report that the BSEP promoter is transactivated by FXR. In contrast to CDCA and GW4064, lithocholate (LCA), a hydrophobic bile acid and a potent inducer of cholestasis, strongly decreased BSEP expression. Previous studies did not identify LCA as an FXR antagonist ligand in cells, but we show here that LCA is an MAR antagonist with partial agonist activity in cells. In an in vitro coactivator association assay, LCA decreased CDCA- and GW4064-induced FXR activation with an IC50 of 1 mum. In HepG2 cells, LCA also effectively antagonized GW4064-enhanced FXR transactivation. These data suggest that the toxic and cholestatic effect of LCA in animals may result from its down-regulation of BSEP through FXR. Taken together, these observations indicate that FXR plays an important role in BSEP gene expression and that FXR ligands may be potential therapeutic drugs for intrahepatic cholestasis.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Cui, JS (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000,RY80W-107, Rahway, NJ 07065 USA.	jisong_cui@merck.com						Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; Fischer S, 1996, CLIN CHIM ACTA, V251, P173, DOI 10.1016/0009-8981(96)06305-X; FISHER MM, 1971, LAB INVEST, V25, P88; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Jansen PLM, 1999, GASTROENTEROLOGY, V117, P1370, DOI 10.1016/S0016-5085(99)70287-8; JAVITT NB, 1966, NATURE, V210, P1262, DOI 10.1038/2101262a0; Kikuchi Hideaki, 2002, Nihon Eiseigaku Zasshi, V56, P622; Kliewer SA, 2002, J LIPID RES, V43, P359; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Lecureur V, 2000, TOXICOLOGY, V153, P203, DOI 10.1016/S0300-483X(00)00315-2; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pascussi JM, 1999, BIOCHEM BIOPH RES CO, V260, P377, DOI 10.1006/bbrc.1999.0745; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Stieger B, 2000, GASTROENTEROLOGY, V118, P422, DOI 10.1016/S0016-5085(00)70224-1; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Warskulat U, 1999, BIOL CHEM, V380, P1273, DOI 10.1515/BC.1999.162; Willson TM, 2001, MED RES REV, V21, P513, DOI 10.1002/med.1023; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; Zhou GC, 2001, METHODS, V25, P54, DOI 10.1006/meth.2001.1215	34	141	145	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31441	31447		10.1074/jbc.M200474200	http://dx.doi.org/10.1074/jbc.M200474200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12052824	hybrid			2022-12-25	WOS:000177718700021
J	Bernard, D; Monte, D; Vandenbunder, B; Abbadie, C				Bernard, D; Monte, D; Vandenbunder, B; Abbadie, C			The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD	ONCOGENE			English	Article						NF-kappaB; apoptosis; MnSOD; reactive oxygen species	NF-KAPPA-B; MANGANESE SUPEROXIDE-DISMUTASE; SEVERE LIVER DEGENERATION; PROSTATE CARCINOMA-CELLS; ALPHA-INDUCED APOPTOSIS; MICE LACKING; DIHYDRORHODAMINE 123; HYDROGEN-PEROXIDE; DEFICIENT MICE; T-LYMPHOCYTES	Rel/NF-kappaB transcription factors are involved in several physiological processes, including the regulation of apoptosis. These factors were shown to exhibit pro- or anti-apoptotic activities in different cellular models, but at present, the mechanisms underlying these opposite effects are poorly understood. In this study, we show that the constitutive expression of a transcriptionally active member of the Rel/NF-kappaB family, c-Rel, first induces a resistance against TNFalpha-induced apoptosis and later increases the level of spontaneous apoptosis of HeLa cells. Both the anti- and pro-apoptotic effects increase with the level of c-Rel overexpression. The up-regulation by c-Rel of the manganese superoxide dismutase (MnSOD) could explain both the rapid anti-apoptotic effect and the delayed pro-apoptotic one. Indeed, the enzymatic activity of MnSOD is to transform the toxic O-2(.-) in H2O2. Hence, on one hand, its induction helps cells to resist against the apoptogenic burst of O-2 produced upon TNFalpha stimulation, but on the other hand, it leads to a progressive H2O2 accumulation that ultimately results in apoptosis. These results indicate that the anti- and pro-apoptotic effects of Rel/NF-kappaB factors are not necessarily alternative but can occur successively in the same cell, via the up-regulation of the same target gene.	Univ Lille 2, IPL, CNRS, FRE 2353,Inst Biol Lille, F-59021 Lille, France; Univ Lille 2, IPL, CNRS, UMR 8526,Inst Biol Lille, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Abbadie, C (corresponding author), Univ Lille 2, IPL, CNRS, FRE 2353,Inst Biol Lille, 1 Rue Calmette,BP 447, F-59021 Lille, France.	corinne.abbadie@ibl.fr	ABBADIE, Corinne/F-4949-2018; Bernard, David/D-6265-2018	ABBADIE, Corinne/0000-0002-8174-2393; monte, didier/0000-0002-0613-6203				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bernard D, 2001, CANCER RES, V61, P2656; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Cusack JC, 2000, CANCER RES, V60, P2323; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Gugasyan R, 2000, IMMUNOL REV, V176, P134; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang Y, 2000, CANCER RES, V60, P4426; Huguet C, 1997, CELL DEATH DIFFER, V4, P413, DOI 10.1038/sj.cdd.4400259; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1999, FREE RADICAL BIO MED, V26, P1554, DOI 10.1016/S0891-5849(99)00024-6; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Qin ZH, 1999, J NEUROSCI, V19, P4023; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rudolph D, 2000, GENE DEV, V14, P854; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sohur US, 2000, CANCER RES, V60, P1202; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	57	65	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4392	4402		10.1038/sj.onc.1205536	http://dx.doi.org/10.1038/sj.onc.1205536			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080470				2022-12-25	WOS:000176317100005
J	Hansen, M; Rusyn, EV; Hughes, PE; Ginsberg, MH; Cox, AD; Willumsen, BM				Hansen, M; Rusyn, EV; Hughes, PE; Ginsberg, MH; Cox, AD; Willumsen, BM			R-Ras C-terminal sequences are sufficient to confer R-Ras specificity to H-Ras	ONCOGENE			English	Article						H-Ras; R-Ras; structure-function; transformation; integrin affinity modulation	NUCLEOTIDE DISSOCIATION STIMULATOR; INTEGRIN CYTOPLASMIC DOMAINS; OUT SIGNAL-TRANSDUCTION; CELLULAR-TRANSFORMATION; PLASMA-MEMBRANE; EFFECTOR LOOP; ACTIVATION; CELLS; PATHWAY; PROTEIN	Activated versions of the similar GTPases, H-Ras and R-Ras, have differing effects on biological phenotypes: Activated H-Ras strongly transforms many fibroblast cell lines causing dramatic changes in cell shape and cytoskeletal organization. In contrast, R-Ras transforms fewer cell lines and the transformed cells display only some of the morphological changes associated with H-Ras transformation. H-Ras cells can survive in the absence of serum whereas R-Ras cells seem to die by an apoptotic-like mechanism in response to removal Of serum. H-Ras can suppress integrin activation and R-Ras specifically antagonizes this effect. To map sequences responsible for these differences we have generated and investigated a panel of H-Ras and R-Ras chimeras. We found that the C-terminal 53 amino acids of R-Ras were necessary and sufficient to specify the contrasting biological properties of R-Ras with respect to focus morphology, reactive oxygen species (ROS) production and reversal of H-Ras-induced integrin suppression. Surprisingly, we found chimeras in which the focus formation and integrin-mediated phenotypes were separated, suggesting that different effectors could be involved in mediating these responses. An integrin profile of H-Ras and R-Ras cell pools showed no significant differences; both activated H-Ras and R-Ras expressing cells were found to have reduced beta(1) activity, suggesting that the activity state of the beta(1) subunit is not sufficient to direct an H-Ras transformed cell morphology.	Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen K, Denmark; Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Copenhagen; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute	Willumsen, BM (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA 61951, CA 76092] Funding Source: Medline; NHLBI NIH HHS [HL 31950, HL 48728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076092, R29CA061951] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Chou CC, 1997, N-S ARCH PHARMACOL, V355, P177, DOI 10.1007/PL00004929; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUGHES PE, 2002, IN PRESS MOL CELL BI; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; Jasiulionis MG, 1996, CANCER RES, V56, P1682; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIN CS, 1993, CANCER RES, V53, P2950; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Oertli B, 2000, ONCOGENE, V19, P4961, DOI 10.1038/sj.onc.1203876; Osada M, 1999, MOL CELL BIOL, V19, P6333; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Ramos JW, 1996, J CELL BIOL, V134, P227, DOI 10.1083/jcb.134.1.227; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAEZ R, 1994, ONCOGENE, V9, P2977; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Self AJ, 2001, J CELL SCI, V114, P1357; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang YC, 1999, CLIN CANCER RES, V5, P129; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS G, 1999, DISCOVERY, V1, P11; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	62	16	17	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2002	21	28					4448	4461		10.1038/sj.onc.1205538	http://dx.doi.org/10.1038/sj.onc.1205538			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080475				2022-12-25	WOS:000176317100010
J	Mason, SL; Loughran, O; La Thangue, NB				Mason, SL; Loughran, O; La Thangue, NB			p14(ARF) regulates E2F activity	ONCOGENE			English	Article						E2F; p14(ARF); MDM2; p53	TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; NUCLEOLAR LOCALIZATION; GENE-PRODUCT; P53; MDM2; P19(ARF); DEGRADATION; INHIBITION; PATHWAY	The ARF protein product of the ink4a/arf locus is induced by a variety of oncogenic signals. ARF facilitates growth arrest through the p53 pathway by hindering the down-regulation of p53 activity mediated by MDM2, through the formation of a protein complex with MDM2. Here we have explored the possibility that human p14(LambdaRF) activity is integrated with growth regulating pathways other than p53, and report our results that p14(LambdaRF) can control the activity of the E217 transcription factor. p14(LambdaRF) regulates E2F activity in different cell-types, including p53(-/-)/mdm(-/-) MEFs, thus excluding that the effects of p14(LambdaRF) are indirectly caused through MDM2 modulation. p14(LambdaRF) down-regulates E2F-dependent transcription, and in cells undergoing E2F-dependent apoptosis prompts cell cycle arrest. p14(LambdaRF) possesses multiple binding domains for E2F-1, one of which resides within the N-terminal region and coincides with the regulation of E2F activity. A mutational analysis of p14(LambdaRF) indicates that the E2F-1 and MDM2 binding domains can be distinguished. These results highlight the potential interplay between p14(LambdaRF) and E2F, and establish p14(LambdaRF) as a pleiotrophic regulator of cell growth that acts by targetting at least two key pathways in the control of proliferation, namely E2F and p53.	Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	N.LaThangue@bio.gla.ac.uk			Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline; MRC [G9400953] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Botz J, 1996, MOL CELL BIOL, V16, P3401; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lomax M, 2001, ONCOGENE, V20, P4951, DOI 10.1038/sj.onc.1204717; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	46	55	61	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4220	4230		10.1038/sj.onc.1205524	http://dx.doi.org/10.1038/sj.onc.1205524			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082609				2022-12-25	WOS:000176174200004
J	Le Lay, S; Lefrere, I; Trautwein, C; Dugail, I; Krief, S				Le Lay, S; Lefrere, I; Trautwein, C; Dugail, I; Krief, S			Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes - Identification of CCAAT/enhancer-binding protein beta as an SREBP-1c target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR GENE; ACID SYNTHASE PROMOTER; ADIPOSE-TISSUE; MESSENGER-RNA; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TRANSCRIPTIONAL ACTIVATION; C/EBP-BETA; PPAR-GAMMA; DIFFERENTIATION; CELLS	We evaluated the hypothesis of sterol-regulatory element-binding protein (SREBP)-1c being a general mediator of the transcriptional effects of insulin, with a focus on adipocytes, in which insulin profoundly influences specific gene expression. Using real time quantitative reverse transcriptase-PCR to monitor changes in the expression of about 50 genes that cover a wide range of adipocyte functions, we have compared the impact of insulin treatment with that of adenoviral overexpression of either dominant positive or dominant negative SREBP-1c mutants in 3T3-L1 adipocytes. As expected, insulin up-regulated, dominant positive stimulated, and dominant negative decreased previously characterized direct SREBP targets (FAS, SCD-1, and low density lipoprotein receptor). We also identified three novel SREBP-1c transcriptional targets in adipocytes, which were confirmed by run-on assays: plasminogen activator inhibitor 1, CCAAT/enhancer-binding protein delta (C/EBPdelta), and C/EBPbeta. Because most insulin-regulated genes were also modulated by SREBP-1c mutants, our data establish that 1) SREBP-1c is an important mediator of insulin transcriptional effects in adipocytes, and 2) C/EBPbeta is under the direct control of SREBP-1c, as demonstrated by the ability of SREBP-1c to activate the transcription from C/EBPbeta promoter through canonical SREBP binding sites. Thus, some of the effects of insulin and/or SREBP-1c in mature fat cells might require C/EBPbeta or C/EBPdelta as transcriptional relays.	Ctr Rech Biomed Cordeliers, INSERM, U465, F-75270 Paris 06, France; GlaxoSmithKline Labs Pharmaceut, F-35762 St Gregoire, France; Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; GlaxoSmithKline; Hannover Medical School	Dugail, I (corresponding author), Ctr Rech Biomed Cordeliers, INSERM, U465, 15 Rue Ecole Med, F-75270 Paris 06, France.	idugail@bhdc.jussieu.fr; s.krief@bioprojet.com	Le Lay, Soazig/AAI-2442-2021; Dugail, Isabelle/L-1567-2017; Le Lay, Soazig/N-6862-2018	Le Lay, Soazig/0000-0003-2456-2422; Dugail, Isabelle/0000-0003-3631-2252; Krief, Stephane/0000-0002-5543-731X				ALEXANDER M, 1985, J BIOL CHEM, V260, P1978; ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BHANDARI B, 1991, MOL CELL ENDOCRINOL, V76, P71, DOI 10.1016/0303-7207(91)90261-P; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; DANI C, 1989, MOL CELL ENDOCRINOL, V63, P199, DOI 10.1016/0303-7207(89)90096-8; FEVE B, 1994, P NATL ACAD SCI USA, V91, P5677, DOI 10.1073/pnas.91.12.5677; Flier JS, 1999, P NATL ACAD SCI USA, V96, P14191, DOI 10.1073/pnas.96.25.14191; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; HAJDUCH EJ, 1992, J CELL BIOCHEM, V49, P251, DOI 10.1002/jcb.240490307; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; KRIEF S, 1994, J BIOL CHEM, V269, P6664; Lacasa D, 2001, J BIOL CHEM, V276, P11512, DOI 10.1074/jbc.M008556200; Li XL, 2001, ENDOCRINOLOGY, V142, P174, DOI 10.1210/en.142.1.174; Lopez D, 1999, ENDOCRINOLOGY, V140, P5669, DOI 10.1210/en.140.12.5669; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; *PERK ELM LIF SCI, 1999, REL QUAN GEN EXPR B, V2; ROLLAND V, 1995, J BIOL CHEM, V270, P1102, DOI 10.1074/jbc.270.3.1102; Rosen ED, 2000, GENE DEV, V14, P1293; Sakamoto T, 1999, AM J PHYSIOL-CELL PH, V276, pC1391, DOI 10.1152/ajpcell.1999.276.6.C1391; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sekar N, 2001, ENDOCRINOLOGY, V142, P2921, DOI 10.1210/en.142.7.2921; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; TODAKA M, 1994, J BIOL CHEM, V269, P29265; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WEINER FR, 1991, J BIOL CHEM, V266, P23525; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	57	114	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35625	35634		10.1074/jbc.M203913200	http://dx.doi.org/10.1074/jbc.M203913200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12048207	hybrid			2022-12-25	WOS:000178117000122
J	Allen, JWA; Tomlinson, EJ; Hong, L; Ferguson, SJ				Allen, JWA; Tomlinson, EJ; Hong, L; Ferguson, SJ			The Escherichia coli cytochrome c maturation (Ccm) system does not detectably attach heme to single cysteine variants of an apocytochrom c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; IN-VITRO; PROTEIN; GENES; PERIPLASM; BIOGENESIS; REDUCTASE; C(552); BIOSYNTHESIS; EXPRESSION	Cytochromes c are typically characterized by the covalent attachment of heme to polypeptide through two thioether bonds with the cysteine residues of a Cys-Xaa-Xaa-Cys-His peptide motif. In many Gram-negative bacteria, the heme is attached to the polypeptide by the periplasmically functioning cytochrome c maturation (Ccm) proteins. Exceptionally, Hydrogenobacter thermophilus cytochrome c(552), which has a normal CXXCH heme-binding motif, and variants with AXXCH, CXXAH, and AXXAH motifs, can be expressed as stable holocytochromes in the cytoplasm of Escherichia coli. By targeting these proteins to the periplasm using a signal peptide, with or without co-expression of the Cent proteins, we have assessed the ability of the Ccm system to attach heme to proteins with no, one, or two cysteine residues in the heme-binding motif. Only the wild-type protein, with two cysteines, was effectively processed and thus accumulated in the periplasm as a holocytochrome. This is strong evidence for disulfide bond formation involving the two cysteine residues of apocytochrome c as an intermediate in Ccm-type Gram-negative bacterial cytochrome c biogenesis and/or that only a pair of cysteines can be recognized by the heme attachment apparatus.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	ferguson@bioch.ox.ac.uk						Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Goldman BS, 1996, J BACTERIOL, V178, P6338, DOI 10.1128/jb.178.21.6338-6347.1996; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; Herbaud ML, 2000, BBA-PROTEIN STRUCT M, V1481, P18, DOI 10.1016/S0167-4838(00)00117-5; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; Igarashi N, 1997, NAT STRUCT BIOL, V4, P276, DOI 10.1038/nsb0497-276; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; JANSSON JAT, 1965, BIOCHIM BIOPHYS ACTA, V99, P171, DOI 10.1016/S0926-6593(65)80018-2; Karan EF, 2002, J BIOL INORG CHEM, V7, P260, DOI 10.1007/s007750100292; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Metheringham R, 1996, MOL GEN GENET, V253, P95; MOORE GR, 1990, CYTOCHROMES EVOLUTIO; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PAGE MD, 1989, MOL MICROBIOL, V3, P653, DOI 10.1111/j.1365-2958.1989.tb00213.x; PETTIGREW GW, 1975, BIOCHEM J, V147, P291, DOI 10.1042/bj1470291; PETTIGREW GW, 1987, CYTOCHROMES BIOL ASP; Potter LC, 1999, BIOCHEM J, V344, P69, DOI 10.1042/0264-6021:3440069; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; Pugsley AP, 2001, J BACTERIOL, V183, P1312, DOI 10.1128/JB.183.4.1312-1319.2001; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Reid E, 1998, FEMS MICROBIOL LETT, V166, P369, DOI 10.1016/S0378-1097(98)00357-7; Rios-Velazquez C, 2001, ARCH BIOCHEM BIOPHYS, V389, P234, DOI 10.1006/abbi.2001.2330; Rosell FI, 2002, BIOCHEMISTRY-US, V41, P7811, DOI 10.1021/bi016060e; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; SAMBONGI Y, 1994, FEBS LETT, V344, P207, DOI 10.1016/0014-5793(94)00399-8; Sanders C, 2001, MOL MICROBIOL, V41, P241, DOI 10.1046/j.1365-2958.2001.02514.x; SCOTT RA, 1995, CYTOCHROME MULTIDISC; Sinha N, 1998, FEMS MICROBIOL LETT, V161, P1; Spielewoy N, 2001, J BIOL CHEM, V276, P5491, DOI 10.1074/jbc.M008853200; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; ThroneHolst M, 1997, FEBS LETT, V410, P351, DOI 10.1016/S0014-5793(97)00656-X; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; Tomlinson EJ, 2000, J BIOL CHEM, V275, P32530, DOI 10.1074/jbc.M004022200; TROWER MK, 1993, BIOCHIM BIOPHYS ACTA, V1143, P109, DOI 10.1016/0005-2728(93)90223-3; Wain R, 2001, J BIOL CHEM, V276, P45813, DOI 10.1074/jbc.M107572200; Zhang Y, 1998, J FERMENT BIOENG, V85, P346, DOI 10.1016/S0922-338X(97)85688-7	47	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33559	33563		10.1074/jbc.M204963200	http://dx.doi.org/10.1074/jbc.M204963200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12048216	hybrid			2022-12-25	WOS:000177959100005
J	Gao, T; Ehrenman, K; Tang, L; Leippe, M; Brock, DA; Gomer, RH				Gao, T; Ehrenman, K; Tang, L; Leippe, M; Brock, DA; Gomer, RH			Cells respond to and bind countin, a component of a multisubunit cell number counting factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PHOSPHORYLATION; DENSITY-SENSING FACTOR; DICTYOSTELIUM MYOSIN-II; SIGNAL-TRANSDUCTION; CHEMOTACTIC STIMULATION; ENTAMOEBA-HISTOLYTICA; ADENYLYL-CYCLASE; GENE-EXPRESSION; HUMAN-MONOCYTES; MOLECULE GP80	In Dictyostelium discoideum counting factor (CF), a secreted similar to450-kDa complex of polypeptides, inhibits group and fruiting body size. When the gene encoding countin (a component of CF) was disrupted, cells formed large groups. We find that recombinant countin causes developing cells to form small groups, with an EC50 of similar to3 ng/ml, and affects cAMP signal transduction in the same manner as semipurified CF. Recombinant countin in. creases cell motility, decreases cell-cell adhesion, and regulates gene expression in a manner similar to the effect of CF. However, countin does not decrease adhesion or group size to the extent that semipurified CF does. A 1-min exposure of developing cells to countin causes an increase in F-actin polymerization and myosin phosphorylation and a decrease in myosin polymerization, suggesting that countin activates a rapid signal transduction pathway. I-125-Labeled countin has countin bioactivity, and binding experiments suggest that vegetative and developing cells have similar to53 cell-surface sites that bind countin with a K-D of similar to1.5 ng/ml or 60 pM. We hypothesize that countin regulates cell development through the same pathway as CF and that other proteins within the complex may modify the activity of countin and/or have independent size-regulating activities.	Rice Univ, Howard Hughes Med Inst, Houston, TX 77251 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX USA; Res Ctr Infect Dis, Mol Parasitol Grp, D-97070 Wurzburg, Germany	Howard Hughes Medical Institute; Rice University; Rice University; University of Wurzburg	Gomer, RH (corresponding author), Rice Univ, Howard Hughes Med Inst, MS-140,6100 S Main St, Houston, TX 77251 USA.		Leippe, Matthias/AAP-1677-2020	Gomer, Richard/0000-0003-2361-4307				BERLOT C, 1987, METHOD CELL BIOL, V28, P333; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BONNER JT, 1963, J EMBRYOL EXP MORPH, V11, P571; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Brock DA, 1996, DEVELOPMENT, V122, P2569; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Brock DA, 2002, DEVELOPMENT, V129, P3657; Bruhn H, 2001, ZOOL-ANAL COMPLEX SY, V104, P3, DOI 10.1078/0944-2006-00001; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; BYRNE PV, 1989, LEUKEMIA RES, V13, P117, DOI 10.1016/0145-2126(89)90135-5; Chaudoir BM, 1999, J CELL SCI, V112, P1611; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Clow PA, 1999, MOL BIOL CELL, V10, P1309, DOI 10.1091/mbc.10.5.1309; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; Day SJ, 2000, DEVELOPMENT, V127, P2977; Deery WJ, 1999, J BIOL CHEM, V274, P34476, DOI 10.1074/jbc.274.48.34476; DESBARATS L, 1994, J CELL SCI, V107, P1705; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; ELLIOTT MJ, 1989, BLOOD, V74, P2349; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; Firtel RA, 2000, CURR OPIN GENET DEV, V10, P421, DOI 10.1016/S0959-437X(00)00107-6; Giannopoulos A, 1997, J UROLOGY, V157, P79, DOI 10.1016/S0022-5347(01)65287-X; GOMER RH, 1983, J CELL BIOL, V96, P321, DOI 10.1083/jcb.96.2.321; GOMER RH, 1991, DEVELOPMENT, V112, P269; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; Gupta R, 1999, GLYCOBIOLOGY, V9, P1009, DOI 10.1093/glycob/9.10.1009; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HOLTER W, 1987, J IMMUNOL, V138, P2917; Ishihara C, 1997, CLIN EXP IMMUNOL, V110, P524, DOI 10.1046/j.1365-2249.1997.4511469.x; JAIN R, 1994, J BIOL CHEM, V269, P9128; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; KAMBOJ RK, 1990, CELL REGUL, V1, P715, DOI 10.1091/mbc.1.10.715; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; Liu X, 1998, P NATL ACAD SCI USA, V95, P14124, DOI 10.1073/pnas.95.24.14124; LOOMIS WF, 1993, CURR TOP DEV BIOL, V28, P1, DOI 10.1016/S0070-2153(08)60208-2; Loomis WF., 1975, DICTYOSTELIUM DISCOI; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Moniakis J, 2001, GENE DEV, V15, P687, DOI 10.1101/gad.871001; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; Noegel AA, 1995, EXPERIENTIA, V51, P1135, DOI 10.1007/BF01944731; OGIHARA S, 1988, DEV GENET, V9, P505, DOI 10.1002/dvg.1020090427; Okuwa T, 2001, DEV GROWTH DIFFER, V43, P735; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; RATHI A, 1992, MECH DEVELOP, V36, P173, DOI 10.1016/0925-4773(92)90068-U; Roisin-Bouffay C, 2000, MOL CELL, V6, P953, DOI 10.1016/S1097-2765(05)00082-1; Sabry JH, 1997, MOL BIOL CELL, V8, P2605, DOI 10.1091/mbc.8.12.2605; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SCHAAP P, 1991, MICROBIAL CELL CELL, P147; SHAFFER BM, 1957, Q J MICROSC SCI, V98, P393; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SREEDHARAN SP, 1989, J BIOL CHEM, V264, P949; Steimle PA, 2001, CURR BIOL, V11, P708, DOI 10.1016/S0960-9822(01)00182-8; Stites J, 1998, CELL MOTIL CYTOSKEL, V39, P31, DOI 10.1002/(SICI)1097-0169(1998)39:1<31::AID-CM4>3.0.CO;2-J; Tang L, 2002, P NATL ACAD SCI USA, V99, P1371, DOI 10.1073/pnas.022516099; Tang L, 2001, J BIOL CHEM, V276, P27663, DOI 10.1074/jbc.M102205200; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; vanHaastert PJM, 1997, FEBS LETT, V410, P25, DOI 10.1016/S0014-5793(97)00416-X; VanHaastert PJM, 1996, J CELL BIOL, V134, P1543, DOI 10.1083/jcb.134.6.1543; Wang B, 1999, DEV BIOL, V208, P1, DOI 10.1006/dbio.1998.9193; WESSELS D, 1989, J CELL BIOL, V109, P2841, DOI 10.1083/jcb.109.6.2841; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251; YUEN IS, 1994, J THEOR BIOL, V167, P273, DOI 10.1006/jtbi.1994.1069; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; Zhai YF, 2000, BBA-REV BIOMEMBRANES, V1469, P87, DOI 10.1016/S0304-4157(00)00003-4	83	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32596	32605		10.1074/jbc.M203075200	http://dx.doi.org/10.1074/jbc.M203075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12070154	hybrid			2022-12-25	WOS:000177859000028
J	Li, T; Dai, W; Lu, L				Li, T; Dai, W; Lu, L			Ultraviolet-induced junD activation and apoptosis in myeloblastic leukemia ML-1 cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-REGULATED KINASE; UV IRRADIATION; GENE-TRANSCRIPTION; GROWTH-FACTORS; FOS; PHOSPHORYLATION; AP-1; INDUCTION; PATHWAYS	The exposure of mammalian cells to UV irradiation induces the expression of immediate early genes such as c-jun and c-fos and activates the transcription factors AP-1 and NF-kappaB. JunD is one of the three members of the Jun family and shares some functional characteristics with c-Jun. In the present study, we found that the exposure of myeloblastic leukemia ML-1 cells to UV light (UVC) caused a significant increase in junD mRNA expression within 5 min that persisted for a period of 3 h. The activation of protein kinase C (PKC) with 12-O-tetradecaoylphorbol-13-acetate (TPA) also induced increases in junD expression similar to those of UV irradiation. In addition, UV irradiation- and TPA-induced increases in junD expression were completely abolished by GF-109203x, a PKC-specific inhibitor. UV irradiation activated intracellular signaling pathways including extracellular regulated kinase-2 (Erk-2), c-Jun N-terminal kinases-1 (JNK-1), and p38. However, TPA-induced activation of PKC affected only Erk-2 activity, and GF-109203x (a PKC inhibitor) markedly suppressed UV-induced Erk-2 activation. To further investigate the effect of UV-induced Erk-2 activation of the expression of junD mRNA, cDNA encoding mitogen-activated protein kinases kinase (MEK1) was overexpressed in ML-1 cells. The overexpression of MEK1 enhanced substantially junD expression in response to UV or TPA. In contrast, the suppression of Erk activation with PD98059, a specific inhibitor of MEK1, inhibited UV- and TPA-induced junD mRNA expression, UV-induced increases in caspase-3 activities, and cell death. In addition, the overexpression of junD enhanced the UV irradiation-induced increases in caspase-3 activity and cell death. We conclude that UV irradiation-induced increases in junD expression in ML-1 cells are mediated through activation of the PKC-coupled ERK-2 signaling pathway and play an important role in ML-1 cell apoptosis.	Univ Calif Los Angeles, Harbor Med Ctr, Sch Med, Div Mol Med, Torrance, CA 90502 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York Medical College	Lu, L (corresponding author), Univ Calif Los Angeles, Harbor Med Ctr, Sch Med, Div Mol Med, 1124 W Carson St C-2, Torrance, CA 90502 USA.				NATIONAL CANCER INSTITUTE [R01CA074229] Funding Source: NIH RePORTER; NCI NIH HHS [CA74229] Funding Source: Medline; NEI NIH HHS [EY10669] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Dosch J, 1996, ONCOGENE, V13, P1927; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fritz G, 1999, MOL CELL BIOL, V19, P1768; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HABY C, 1994, BIOCHEM PHARMACOL, V48, P819, DOI 10.1016/0006-2952(94)90061-2; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; STRONG DD, 1994, CALCIFIED TISSUE INT, V55, P311, DOI 10.1007/BF00310411; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Wang YL, 1998, GENE, V216, P293, DOI 10.1016/S0378-1119(98)00345-X; WILHELM D, 1995, IMMUNOBIOLOGY, V193, P143, DOI 10.1016/S0171-2985(11)80537-1; WILSON RE, 1993, ONCOGENE, V8, P3229; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xu DZ, 1999, BLOOD, V94, P139, DOI 10.1182/blood.V94.1.139.413k11_139_145; Zhuang SG, 1997, BIOCHEM BIOPH RES CO, V240, P273, DOI 10.1006/bbrc.1997.7474; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V278, pC102, DOI 10.1152/ajpcell.2000.278.1.C102	38	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32668	32676		10.1074/jbc.M203519200	http://dx.doi.org/10.1074/jbc.M203519200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082101	hybrid			2022-12-25	WOS:000177859000036
J	Matsumoto, TK; Ellsmore, AJ; Cessna, SG; Low, PS; Pardo, JM; Bressan, RA; Hasegawa, PM				Matsumoto, TK; Ellsmore, AJ; Cessna, SG; Low, PS; Pardo, JM; Bressan, RA; Hasegawa, PM			An osmotically induced cytosolic Ca2+ transient activates calcineurin signaling to mediate ion homeostasis and salt tolerance of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CALCIUM-CONCENTRATION; GENE-EXPRESSION; ABIOTIC STRESS; TOBACCO CELLS; MAP KINASE; YEAST; PROTEIN; CHANNELS; INFLUX	Hyperosmotic stress caused by NaCl, LiCl, or sorbitol induces an immediate and short duration (similar to 1 min) transient cytosolic Ca2+ ([Ca2+](cyt)) increase (Ca2+-dependent aequorin luminescence) in Saccharomyces cerevisiae cells. The amplitude of the osmotically induced [Ca2+] cyt transient was attenuated by the addition of chelating agents EGTA or BAPTA, cation channel pore blockers, competitive inhibitors of Ca2+ transport, or mutations (cch1Delta or mid1Delta) that reduce Ca2+ influx, indicating that Ca2+ is a source for the transient. An osmotic pre-treatment (30 min) administered by inoculating cells into media supplemented with either NaCl (0.4 or 0.5 m) or sorbitol (0.8 or 1.0 m) enhanced the subsequent growth of these cells in media containing 1 m NaCl or 2 m sorbitol. Inclusion of EGTA in the osmotic pretreatment media or the cch1Delta mutation reduced cellular capacity for NaCl but not hyperosmotic adaptation. The stress-adaptive effect of hyperosmotic pretreatment was mimicked by exposing cells briefly to 20 mm CaCl2. Thus, NaCl- or sorbitol-induced hyperosmotic shock causes a [Ca2+](cyt) transient that is facilitated by Ca2+ influx, which enhances ionic but not osmotic stress adaptation. NaCl-induced ENA1 expression was inhibited by EGTA, cch1Delta mutation, and FK506, indicating that the [Ca2+](cyt) transient activates calcineurin signaling to mediate ion homeostasis and salt tolerance.	Purdue Univ, Ctr Plant Environm Stress Physiol, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA; Eastern Mennonite Univ, Dept Biol, Harrisonburg, VA 22802 USA; Eastern Mennonite Univ, Dept Chem, Harrisonburg, VA 22802 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; CSIC, Inst Recursos Nat & Agrobiol, Seville 41012, Spain	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)	Hasegawa, PM (corresponding author), Purdue Univ, Ctr Plant Environm Stress Physiol, Dept Hort & Landscape Architecture, 1165 Hort Bldg, W Lafayette, IN 47907 USA.	paul.m.hasegawa.1@purdue.edu	Pardo, Jose M./B-4652-2009; Pardo, Jose M/AAB-5866-2022	Pardo, Jose M./0000-0003-4510-8624; Pardo, Jose M/0000-0003-4510-8624; Bressan, Ray/0000-0002-8754-606X; Low, Philip/0000-0001-9042-5528				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; AMZALLAG GN, 1990, J EXP BOT, V41, P29, DOI 10.1093/jxb/41.1.29; [Anonymous], [No title captured]; Balibrea ME, 1999, AUST J PLANT PHYSIOL, V26, P781, DOI 10.1071/PP99092; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BINZEL ML, 1985, PLANT PHYSIOL, V79, P118, DOI 10.1104/pp.79.1.118; Bressan RA, 1998, TRENDS PLANT SCI, V3, P411, DOI 10.1016/S1360-1385(98)01331-4; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; Cessna SG, 1998, J BIOL CHEM, V273, P27286, DOI 10.1074/jbc.273.42.27286; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DASCALU A, 1995, J PHYSIOL-LONDON, V486, P97, DOI 10.1113/jphysiol.1995.sp020793; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; *DIF LAB, 1998, DIF MAN; DING JP, 1993, PLANT J, V3, P83, DOI 10.1111/j.1365-313X.1993.tb00013.x; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ehlers MD, 1999, NATURE, V399, P105, DOI 10.1038/20079; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; Hasegawa M, 2000, TRENDS PLANT SCI, V5, P317, DOI 10.1016/S1360-1385(00)01692-7; Hobai IA, 2000, AM J PHYSIOL-HEART C, V279, pH692, DOI 10.1152/ajpheart.2000.279.2.H692; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Knight H, 2000, INT REV CYTOL, V195, P269; Knight H, 2001, TRENDS PLANT SCI, V6, P262, DOI 10.1016/S1360-1385(01)01946-X; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; Ko Jae Heung, 1995, Journal of Plant Biology, V38, P243; Kummer U, 2000, BIOPHYS J, V79, P1188, DOI 10.1016/S0006-3495(00)76373-9; LAUCHLI A, 1990, CUR TOP PL, V4, P26; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Miedema H, 2001, TRENDS PLANT SCI, V6, P514, DOI 10.1016/S1360-1385(01)02124-0; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; Mizoguchi T, 2000, RES PRO CEL, V27, P29; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; Randall A, 1999, MOL CELL NEUROSCI, V14, P255, DOI 10.1006/mcne.1999.0795; REID RJ, 1993, PLANT CELL ENVIRON, V16, P547, DOI 10.1111/j.1365-3040.1993.tb00902.x; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; REYNOLDS A, 1993, CURRENT PROTOCOLS MO; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Serrano R, 2001, CURR OPIN CELL BIOL, V13, P399, DOI 10.1016/S0955-0674(00)00227-1; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Tena G, 2001, CURR OPIN PLANT BIOL, V4, P392, DOI 10.1016/S1369-5266(00)00191-6; Torrecilla I, 2001, PLANT CELL ENVIRON, V24, P641, DOI 10.1046/j.0016-8025.2001.00708.x; Urao T, 2000, TRENDS PLANT SCI, V5, P67, DOI 10.1016/S1360-1385(99)01542-3; Varela JCS, 1996, MICROBIOL-SGM, V142, P721, DOI 10.1099/00221287-142-4-721; Wach A, 1998, METHOD MICROBIOL, V26, P67; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200; Zhu JK, 2001, CURR OPIN PLANT BIOL, V4, P401, DOI 10.1016/S1369-5266(00)00192-8; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0	71	118	125	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33075	33080		10.1074/jbc.M205037200	http://dx.doi.org/10.1074/jbc.M205037200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084723	hybrid			2022-12-25	WOS:000177859000088
J	Regeimbal, J; Bardwell, JCA				Regeimbal, J; Bardwell, JCA			DsbB catalyzes disulfide bond formation de novo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESPIRATORY-CHAIN; ELECTRON-TRANSFER; FORMATION PATHWAY; ACTIVE-SITE; CYSTEINES; SUBUNIT; SYSTEM; ROLES; BPTI	DsbA and DsbB are responsible for disulfide bond formation. DsbA is the direct donor of disulfides, and DsbB oxidizes DsbA. DsbB has the unique ability to generate disulfides by quinone reduction. It is thought that DsbB oxidizes DsbA via thiol disulfide exchange. In this mechanism, a disulfide is formed across the N-terminal pair of cysteines (Cys-41/Cys-44) in DsbB by quinone reduction. This disulfide is then transferred on to the second pair of cysteine residues in DsbB (Cys-104/Cys-130) and then finally transferred to DsbA. We have shown here the redox potential of the two disulfides in DsbB are -271 and -284 mV, respectively, and considerably less oxidizing than the disulfide of DsbA at -120. In addition, we have found the Cys-104/Cys-130 disulfide of DsbB to actually be a substrate for DsbA in vitro. These findings indicate that the disulfides in DsbB are unsuitable to function as the oxidant of DsbA. Furthermore, we have shown that mutants in DsbB that lack either pair or all of its cysteines are also capable of oxidizing DsbA. These unexpected findings raise the possibility that the oxidation of DsbA by DsbB does not occur via thiol disulfide exchange as is widely assumed but rather, directly via quinone reduction.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVEZOUX A, 1995, BIOCHEM J, V307, P735, DOI 10.1042/bj3070735; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; BERTRAND P, 1994, BIOCHIMIE, V76, P524, DOI 10.1016/0300-9084(94)90176-7; Brettel K, 2001, BBA-BIOENERGETICS, V1507, P100, DOI 10.1016/S0005-2728(01)00202-X; Bulaj G, 1999, PROTEIN SCI, V8, P1825, DOI 10.1110/ps.8.9.1825; Chen IP, 2000, BIOCHEMISTRY-US, V39, P3592, DOI 10.1021/bi992443p; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Hoshino K, 2002, BIOSCI BIOTECH BIOCH, V66, P344, DOI 10.1271/bbb.66.344; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; Kadokura H, 2000, P NATL ACAD SCI USA, V97, P10884, DOI 10.1073/pnas.97.20.10884; Kadokura H, 2002, EMBO J, V21, P2354, DOI 10.1093/emboj/21.10.2354; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 2001, MOL MICROBIOL, V39, P158, DOI 10.1046/j.1365-2958.2001.02229.x; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wong C, 2000, BIOTECHNIQUES, V28, P426, DOI 10.2144/00283bm07; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; Zander T, 1998, METHOD ENZYMOL, V290, P59, DOI 10.1016/S0076-6879(98)90007-6; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	27	46	47	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32706	32713		10.1074/jbc.M205433200	http://dx.doi.org/10.1074/jbc.M205433200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12072444	hybrid			2022-12-25	WOS:000177859000041
J	Arcus, VL; Langley, R; Proft, T; Fraser, JD; Baker, EN				Arcus, VL; Langley, R; Proft, T; Fraser, JD; Baker, EN			The three-dimensional structure of a superantigen-like protein, SET3, from a pathogenicity island of the Staphylococcus aureus genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-CLASS-II; ELECTRON-DENSITY MAPS; STREPTOCOCCUS-PYOGENES; CRYSTAL-STRUCTURE; HUMAN-DISEASE; CRYSTALLOGRAPHY; IDENTIFICATION; MOLECULES; SYSTEM; CELL	The staphylococcal enterotoxin-like toxins (SETS) are a family of proteins encoded within the Staphylococcus aureus genome that were identified by their similarity to the well described bacterial superantigens. The first crystal structure of a member of the SET family, SET3, has been determined to 1.9 (A) over circle (R = 0.205, R-free = 0.240) and reveals a fold characteristic of the superantigen family but with significant differences. The SET proteins are secreted at varying levels by staphylococcal isolates, and seroconversion studies of normal individuals indicate that they are strongly antigenic to humans. Recombinant SETs do not exhibit any of the properties expected of superantigens such as major histocompatibility complex class II binding or broad T-cell activation, suggesting they have an entirely different function. The fact that the whole gene family is clustered within the pathogenicity island SaIn2 of the S. aureus genome suggests that they are involved in host/pathogen interactions.	Univ Auckland, Sch Biol Sci, Auckland, New Zealand; Univ Auckland, Dept Mol Med, Auckland, New Zealand	University of Auckland; University of Auckland	Baker, EN (corresponding author), Univ Auckland, Sch Biol Sci, Private Bag 92-019, Auckland, New Zealand.		Proft, Thomas/H-4686-2019	Proft, Thomas/0000-0002-9275-5042; Langley, Ries/0000-0001-8606-2197; Baker, Edward/0000-0003-2456-7661				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Arcus VL, 2000, J MOL BIOL, V299, P157, DOI 10.1006/jmbi.2000.3725; Bernal A, 1999, J CLIN IMMUNOL, V19, P149, DOI 10.1023/A:1020547509410; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fraser J, 2000, MOL MED TODAY, V6, P125, DOI 10.1016/S1357-4310(99)01657-3; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Li HM, 1998, IMMUNOL REV, V163, P177, DOI 10.1111/j.1600-065X.1998.tb01196.x; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Proft T, 2000, J EXP MED, V191, P1765, DOI 10.1084/jem.191.10.1765; Proft T, 1999, J EXP MED, V189, P89, DOI 10.1084/jem.189.1.89; Roussel A, 1997, NAT STRUCT BIOL, V4, P635, DOI 10.1038/nsb0897-635; Sundberg EJ, 2002, CURR OPIN IMMUNOL, V14, P36, DOI 10.1016/S0952-7915(01)00296-5; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tiedemann RE, 1996, J IMMUNOL, V157, P3958; WALLACE FJ, 1995, VET IMMUNOL IMMUNOP, V48, P139, DOI 10.1016/0165-2427(95)05426-7; Williams RJ, 2000, INFECT IMMUN, V68, P4407, DOI 10.1128/IAI.68.8.4407-4415.2000	27	65	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32274	32281		10.1074/jbc.M203914200	http://dx.doi.org/10.1074/jbc.M203914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12082105	hybrid			2022-12-25	WOS:000177718700122
J	Ikegaya, Y; Matsuura, S; Ueno, S; Baba, A; Yamada, MK; Nishiyama, N; Matsuki, N				Ikegaya, Y; Matsuura, S; Ueno, S; Baba, A; Yamada, MK; Nishiyama, N; Matsuki, N			beta-amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; LONG-TERM POTENTIATION; FIBROBLAST-GROWTH-FACTOR; PROTEIN TRANSGENIC MICE; MOUSE SPINAL-CORD; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; HIPPOCAMPAL SLICES; MEMBRANE TRAFFICKING; TRANSPORTER EAAT4	Although amyloid beta-protein (Abeta) has long been implicated in the pathogenesis of Alzheimer's disease, little is known about the mechanism by which Abeta causes dementia. Abeta leads to neuronal cell death in vivo and in vitro, but recent evidence suggests that the property of the amnesic characteristic of Alzheimer's disease can be explained by a malfunction of synapses rather than a loss of neurons. Here we show that prolonged treatment with Abeta augments the glutamate clearance ability of cultured astrocytes and induces a dramatic decrease in glutamatergic synaptic activity of neurons cocultured with the astrocytes. Biotinylation assay revealed that the enhancement of glutamate uptake activity was associated with an increase in cell-surface expression of GLAST, a subtype of glial glutamate transporters, without apparent changes in the total amount of GLAST. This phenomenon was blocked efficiently by actin-disrupting agents. Thus, Abeta-induced actin-dependent GLAST redistribution and relevant synaptic malfunction may be a cellular basis for the amnesia of Alzheimer's disease.	Univ Tokyo, Chem Pharmacol Lab, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Ikegaya, Y (corresponding author), Univ Tokyo, Chem Pharmacol Lab, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ikegaya@tk.airnet.ne.jp	Yamada, Maki K./A-1573-2015; Yamada, Maki/U-5251-2019	Yamada, Maki K./0000-0002-1956-6069; Baba, Atsushi/0000-0002-6871-7249; Ikegaya, Yuji/0000-0003-2260-8191				Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; Barres BA, 2000, CURR OPIN NEUROBIOL, V10, P642, DOI 10.1016/S0959-4388(00)00134-3; Beckstrom H, 1999, J NEUROSCI RES, V55, P218, DOI 10.1002/(SICI)1097-4547(19990115)55:2<218::AID-JNR9>3.3.CO;2-C; Bergles DE, 1998, J NEUROSCI, V18, P7709; Brera B, 2000, NEUROBIOL DIS, V7, P395, DOI 10.1006/nbdi.2000.0313; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; CONRADT M, 1995, EUR J BIOCHEM, V229, P682, DOI 10.1111/j.1432-1033.1995.tb20514.x; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; Cullen WK, 1996, NEUROREPORT, V8, P87, DOI 10.1097/00001756-199612200-00018; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Duan SM, 1999, J NEUROSCI, V19, P10193; Emmerling MR, 2000, BBA-MOL BASIS DIS, V1502, P158, DOI 10.1016/S0925-4439(00)00042-9; Fitzjohn SM, 2001, J NEUROSCI, V21, P4691, DOI 10.1523/JNEUROSCI.21-13-04691.2001; Fukuda H, 1999, BIOORG MED CHEM LETT, V9, P953, DOI 10.1016/S0960-894X(99)00121-3; Furuta A, 1997, J NEUROSCI, V17, P8363; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Harris ME, 1996, J NEUROCHEM, V67, P277; Horn D, 1996, NEURAL COMPUT, V8, P1227, DOI 10.1162/neco.1996.8.6.1227; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Ikegaya Y, 2000, NEUROSCIENCE, V98, P647, DOI 10.1016/S0306-4522(00)00188-3; Itoh A, 1999, EUR J PHARMACOL, V382, P167, DOI 10.1016/S0014-2999(99)00601-9; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kar S, 1996, J NEUROSCI, V16, P1034; Larson J, 1999, BRAIN RES, V840, P23, DOI 10.1016/S0006-8993(99)01698-4; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Masliah E, 2000, EXP NEUROL, V163, P381, DOI 10.1006/exnr.2000.7386; Matsui K, 1998, J NEUROSCI, V18, P4500; Matsuura S, 2002, GLIA, V37, P178, DOI 10.1002/glia.10020; Melikian HE, 1999, J NEUROSCI, V19, P7699; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 1997, J NEUROSCI, V17, P2967; Robinson M B, 1997, Adv Pharmacol, V37, P69; Rogers SL, 2000, CURR OPIN CELL BIOL, V12, P57, DOI 10.1016/S0955-0674(99)00057-5; RUPPIN E, 1995, BRIT J PSYCHIAT, V166, P19, DOI 10.1192/bjp.166.1.19; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scott HL, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-03-j0004.2002; Shibata T, 1997, J NEUROSCI, V17, P9212; Shitaka Y, 1996, J NEUROSCI, V16, P6476; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Stephan A, 2001, J NEUROSCI, V21, P5703, DOI 10.1523/JNEUROSCI.21-15-05703.2001; Suzuki K, 2001, J CELL SCI, V114, P3717; Terry RD, 2000, J NEUROPATH EXP NEUR, V59, P1118, DOI 10.1093/jnen/59.12.1118; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Yamada K, 1998, J NEUROSCI, V18, P5706; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	59	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32180	32186		10.1074/jbc.M203764200	http://dx.doi.org/10.1074/jbc.M203764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070161	hybrid			2022-12-25	WOS:000177718700110
J	Yamada, S; Okada, Y; Ueno, M; Deepa, SS; Nishimura, S; Fujita, M; Van Die, I; Hirabayashi, Y; Sugahara, K				Yamada, S; Okada, Y; Ueno, M; Deepa, SS; Nishimura, S; Fujita, M; Van Die, I; Hirabayashi, Y; Sugahara, K			Determination of the glycosaminoglycan-protein linkage region oligosaccharide structures of proteoglycans from Drosophila melanogaster and Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; PORCINE INTESTINAL HEPARIN; N-LINKED OLIGOSACCHARIDES; SWARM RAT CHONDROSARCOMA; MOLECULAR-CLONING; TOUT-VELU; GLUCURONOSYLTRANSFERASE-I; EPITHELIAL-CELLS; GENE FAMILY; SQUID SKIN	Caenorhabditis elegans and Drosophila melanogaster are relevant models for studying the roles of glycosaminoglycans (GAG) during the development of multicellular organisms. The genome projects of these organisms have revealed the existence of multiple genes related to GAG-synthesizing enzymes. Although the putative genes encoding the enzymes that synthesize the GAG-protein linkage region have also been identified, there is no direct evidence that the GAG chains bind covalently to core proteins. This study aimed to clarify whether GAG chains in these organisms are linked to core proteins through the conventional linkage region tetrasaccharide sequence found in vertebrates and whether modifications by phosphorylation and sulfation reported for vertebrates are present also in invertebrates. The linkage region oligosaccharides were isolated from C. elegans chondroitin in addition to D. melanogaster heparan and chondroitin sulfate after digestion with the respective bacterial eliminases and were then derivatized with a fluorophore 2-aminobenzamide. Their structures were characterized by gel filtration and anion-exchange high performance liquid chromatography in conjunction with enzymatic digestion and matrix-assisted laser desorption ionization time-of-flight spectrometry, which demonstrated a uniform linkage tetrasaccharide structure of -GlcUA-Gal-Gal-Xyl- or -GlcUA-Gal-Gal-Xyl(2-O-phosphate)- for C. elegans chondroitin and D. melanogaster CS, respectively. In contrast, the unmodified and phosphorylated counterparts were demonstrated in heparan sulfate of adult flies at a molar ratio of 73:27, and in that of the immortalized D. melanogaster S2 cell line at a molar ratio of 7:93, which suggests that the linkage region in the fruit fly first becomes phosphorylated uniformly on the Xyl residue and then dephosphorylated. It has been established here that GAG chains in both C. elegans and D. melanogaster are synthesized on the core protein through the ubiquitous linkage region tetrasaccharide sequence, suggesting that indispensable functions of the linkage region in the GAG synthesis have been well conserved during evolution.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands; RIKEN, Brains Sci Inst, Neuronal Circuit Mech Res Grp, Wako, Saitama 35101, Japan	Kobe Pharmaceutical University; Vrije Universiteit Amsterdam; RIKEN	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.			Deepa, Sathyaseelan/0000-0002-3669-4820				Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; ANNO K, 1964, BIOCHIM BIOPHYS ACTA, V83, P348, DOI 10.1016/0926-6526(64)90013-8; Baeg GH, 2001, DEVELOPMENT, V128, P87; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; CAMBIAZO V, 1990, COMP BIOCHEM PHYS B, V97, P307, DOI 10.1016/0305-0491(90)90286-3; DAVIDSON EA, 1954, J BIOL CHEM, V211, P605; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HAKER U, 1997, DEVELOPMENT, V124, P3565; HEINEGAR.D, 1972, BIOCHIM BIOPHYS ACTA, V285, P193, DOI 10.1016/0005-2795(72)90191-2; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; KARAMANOS NK, 1990, EUR J BIOCHEM, V192, P33, DOI 10.1111/j.1432-1033.1990.tb19191.x; KARAMANOS NK, 1988, BIOCHIM BIOPHYS ACTA, V966, P36, DOI 10.1016/0304-4165(88)90126-2; Kendall FE, 1937, J BIOL CHEM, V118, P61; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Lin XH, 1999, DEVELOPMENT, V126, P3715; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Moses J, 1997, EUR J BIOCHEM, V248, P767, DOI 10.1111/j.1432-1033.1997.t01-1-00767.x; Moses J, 1999, EUR J BIOCHEM, V260, P879, DOI 10.1046/j.1432-1327.1999.00228.x; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; Mullen GP, 1999, MOL BIOL CELL, V10, P3205, DOI 10.1091/mbc.10.10.3205; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; NADER HB, 1984, J BIOL CHEM, V259, P1431; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Nilson LA, 1998, CELL, V93, P253, DOI 10.1016/S0092-8674(00)81576-7; NORGARDSUMNICHT KE, 1995, J BIOL CHEM, V270, P27634, DOI 10.1074/jbc.270.46.27634; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Plaas AH, 2001, J BIOL CHEM, V276, P39788, DOI 10.1074/jbc.M103227200; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RODRIGUEZ ML, 1988, EUR J BIOCHEM, V177, P117, DOI 10.1111/j.1432-1033.1988.tb14351.x; Rogalski TM, 2001, BIOCHEM SOC T, V29, P171, DOI 10.1042/BST0290171; Sakaguchi H, 2001, J BIOCHEM-TOKYO, V129, P107, DOI 10.1093/oxfordjournals.jbchem.a002820; Schimpf J, 1999, HISTOCHEM J, V31, P285, DOI 10.1023/A:1003761817109; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SUGAHARA K, 1995, J BIOL CHEM, V270, P22914, DOI 10.1074/jbc.270.39.22914; SUGAHARA K, 2002, IN PRESS IUBMB LIFE; Sugiyama E, 1997, GLYCOBIOLOGY, V7, P719, DOI 10.1093/glycob/7.5.719; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8890; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Tsuda H, 1999, EUR J BIOCHEM, V262, P127, DOI 10.1046/j.1432-1327.1999.00348.x; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7; YAMADA S, 1995, GLYCOBIOLOGY, V5, P335, DOI 10.1093/glycob/5.3.335; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975	76	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31877	31886		10.1074/jbc.M205078200	http://dx.doi.org/10.1074/jbc.M205078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12058048	hybrid			2022-12-25	WOS:000177718700073
J	Briknarova, K; Takayama, S; Homma, S; Baker, K; Cabezas, E; Hoyt, DW; Li, Z; Satterthwait, AC; Ely, KR				Briknarova, K; Takayama, S; Homma, S; Baker, K; Cabezas, E; Hoyt, DW; Li, Z; Satterthwait, AC; Ely, KR			BAG4/SODD protein contains a short BAG domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAINS; BCL-2-BINDING PROTEIN; CELL-DEATH; HSP70/HSC70; BCL-2; HOMOLOGY; SILENCER; COMPLEX; FAMILY; SCYTHE	BAG (Bcl-2-associated athanogene) proteins are molecular chaperone regulators that affect diverse cellular pathways. All members share a conserved motif, called the BAG domain (BD), which binds to Hsp70/Hsc70 family proteins and modulates their activity. We have determined the solution structure of BD from BAG4/SODD (silencer of death domains) by multidimensional nuclear magnetic resonance methods and compared it to the corresponding domain in BAG1 (Briknarovi, K., Takayama, S., Brive, L., Havert, M. L., Knee, D. A., Velasco, J., Homma, S., Cabezas, E., Stuart, J., Hoyt, D. W., Satterthwait, A. C., Llinas, M., Reed, J. C., and Ely, K. R. (2001) Nat. Struct. Biol. 8, 349-352). The difference between BDs from these two BAG proteins is striking, and the structural comparison defines two subfamilies of mammalian BD-containing proteins. One subfamily includes the closely related BAG3, BAG4, and BAG5 proteins, and the other is represented by BAG1, which contains a structurally and evolutionarily distinct BD. BDs from both BAG1 and BAG4 are three-helix bundles; however, in BAG4, each helix in this bundle is three to four turns shorter than its counterpart in BAG1, which reduces the length of the domain by one-third. BAG4 BD thus represents a prototype of the minimal functional fragment that is capable of binding to Hsc70 and modulating its chaperone activity.	Burnham Inst, La Jolla, CA 92037 USA; Pacific NW Natl Lab, Environm Mol Sci Lab, Richland, WA 99352 USA	Sanford Burnham Prebys Medical Discovery Institute; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Ely, KR (corresponding author), Burnham Inst, La Jolla, CA 92037 USA.		Hoyt, David/H-6295-2013	Hoyt, David/0000-0002-2857-719X; Homma, Sachiko/0000-0001-6563-8521; Baker, Kelly/0000-0002-3774-2628	NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabezas E, 1999, J AM CHEM SOC, V121, P3862, DOI 10.1021/ja983212t; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Moribe Y, 2001, EUR J BIOCHEM, V268, P3432, DOI 10.1046/j.1432-1327.2001.02244.x; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Thress K, 2001, EMBO J, V20, P1033, DOI 10.1093/emboj/20.5.1033; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032	28	51	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31172	31178		10.1074/jbc.M202792200	http://dx.doi.org/10.1074/jbc.M202792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12058034	hybrid			2022-12-25	WOS:000177579800097
J	Eloranta, JJ; Hurst, HC				Eloranta, JJ; Hurst, HC			Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; DNA-BINDING; GENE-EXPRESSION; COVALENT MODIFICATION; MAMMARY-CARCINOMA; MODIFIER-1 SUMO-1; BREAST-CANCER; ACTIVATION; P53	The members of the AP-2 family of transcription factors are developmentally regulated and have distinct yet overlapping functions in the regulation of many genes governing growth and differentiation. All AP-2 factors appear to be capable of binding very similar DNA recognition sites, and the determinants of functional specificity remain to be elucidated. AP-2 transcription factors have been shown to act both as transcriptional activators and repressors in a promoter-specific manner. Although several mediators of their activation function have been suggested, few mechanisms for the repression or down-regulation of transactivation have been described. In a two-hybrid screen for proteins interacting with AP-2 factors, we have identified the UBC9 gene that encodes the E2 (ubiquitin carrier protein)-conjugating enzyme for the small ubiquitin-like modifier, RUMO. The interaction domain resides in the C-terminal half of AP-2, which contains the conserved DNA binding and dimerization domains. We have detected sumolated forms of endogenous AP-2 in mammalian cells and have further mapped the in vivo sumolation site to conserved lysine 10. Transient transfection studies indicate that sumolation of AP-2 decreases its transcription activation potential, and we discuss the possible mechanisms for the observed suppression of AP-2 transactivation.	Hammersmith Hosp, Mol Oncol Unit, Canc Res United Kingdom, London W12 0NN, England	Cancer Research UK; Imperial College London; University of London; University College London	Hurst, HC (corresponding author), Hammersmith Hosp, Mol Oncol Unit, Canc Res United Kingdom, Du Cane Rd, London W12 0NN, England.	helen.hurst@cancer.org.uk						Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Garcia MA, 1999, FEBS LETT, V444, P27, DOI 10.1016/S0014-5793(99)00021-6; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; PARK K, 1993, J BIOL CHEM, V268, P17811; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Turner BC, 1998, CANCER RES, V58, P5466; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	50	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30798	30804		10.1074/jbc.M202780200	http://dx.doi.org/10.1074/jbc.M202780200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12072434	hybrid			2022-12-25	WOS:000177579800052
J	Nilius, B; Prenen, J; Hoenderop, JGJ; Vennekens, R; Hoefs, S; Weidema, AF; Droogmans, G; Bindels, RJM				Nilius, B; Prenen, J; Hoenderop, JGJ; Vennekens, R; Hoefs, S; Weidema, AF; Droogmans, G; Bindels, RJM			Fast and slow inactivation kinetics of the Ca2+ channels ECaC1 and ECaC2 (TRPV5 and TRPV6) - Role of the intracellular loop located between transmembrane segments 2 and 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CALCIUM-CHANNEL; MONOVALENT CATION CURRENTS; ALPHA(1C) SUBUNIT; MOLECULAR-CLONING; CALMODULIN; FACILITATION; MODULATION; PERMEATION; TERMINUS; KIDNEY	The Ca2+ channels ECaC1 and ECaC2 (TRPV5 and TRPV6) share several functional properties including permeation profile and Ca2+-dependent inactivation. However, the kinetics of ECaC2 currents notably differ from ECaC1 currents. The initial inactivation is much faster in ECaC2 than in ECaC1, and the kinetic differences between Ca2+ and Ba2+ currents are more pronounced for ECaC2 than ECaC1. Here, we identify the structural determinants for these functional differences. Chimeric proteins were expressed heterologously in HEK 293 cells and studied by patch clamp analysis. Both channels retained their phenotype after exchanging the complete N termini, the C termini, or even both N and C termini, i.e. ECaC1 with the ECaC2 N or C terminus still showed the ECaC1 phenotype and vice versa. The substitution of the intracellular loop between the transmembrane domains 2 and 3 of ECaC2 with that of ECaC1 induced a delay of inactivation. Three amino acid residues (Leu-409, Val-411 and Thr-412) present in this loop determine the fast inactivation behavior. When this intracellular loop between the transmembrane domains 2 and 3 of ECaC1 was exchanged with the TM2-TM3 loop of ECaC2, the ECaC1 kinetics were analogous to ECaC2. In conclusion, the TM2-TM3 loop is a critical determinant of the inactivation in ECaC1 and ECaC2.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Univ Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Physiol, NL-6500 Nijmegen, Netherlands	KU Leuven	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Bindels, René JM/B-9824-2013; Vennekens, Rudi/AAQ-1664-2020; Hoenderop, Joost G.J./H-8047-2014	Bindels, René JM/0000-0003-1167-1339; Vennekens, Rudi/0000-0002-2564-5150; Hoenderop, Joost G.J./0000-0002-1816-8544				Berjukow S, 2001, J BIOL CHEM, V276, P17076, DOI 10.1074/jbc.M010491200; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hoenderop JGJ, 2000, CURR OPIN NEPHROL HY, V9, P335, DOI 10.1097/00041552-200007000-00003; Kepplinger KJF, 2000, FEBS LETT, V477, P161, DOI 10.1016/S0014-5793(00)01791-9; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Marksteiner R, 2001, J PHYSIOL-LONDON, V537, P27, DOI 10.1111/j.1469-7793.2001.0027k.x; Muller D, 2000, GENOMICS, V67, P48, DOI 10.1006/geno.2000.6203; Muller D, 2000, BIOCHEM BIOPH RES CO, V275, P47, DOI 10.1006/bbrc.2000.3227; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Soldatov NM, 2000, J MEMBRANE BIOL, V177, P129, DOI 10.1007/s002320001106; Staes M, 2001, J PHYSIOL-LONDON, V530, P35, DOI 10.1111/j.1469-7793.2001.0035m.x; Suzuki M, 2000, BIOCHEM BIOPH RES CO, V274, P344, DOI 10.1006/bbrc.2000.3135; Vennekens R, 2001, J PHYSIOL-LONDON, V530, P183, DOI 10.1111/j.1469-7793.2001.0183l.x; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Weber K, 2001, BIOCHEM BIOPH RES CO, V289, P1287, DOI 10.1006/bbrc.2001.6121; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	29	66	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30852	30858		10.1074/jbc.M202418200	http://dx.doi.org/10.1074/jbc.M202418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12077127	Green Published, hybrid			2022-12-25	WOS:000177579800059
J	Kim, WJ; Park, EJ; Lee, HJ; Seong, RH; Park, SD				Kim, WJ; Park, EJ; Lee, HJ; Seong, RH; Park, SD			Physical interaction between recombinational proteins Rhp51 and Rad22 in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-BINDING-PROTEIN; YEAST RAD52 PROTEIN; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; REPAIR GENE; HOMOLOG; COMPLEX; RECA; ASSOCIATION	In eukaryotes, Rad51 and Rad52 are two key components of homologous recombination and recombinational repair. These two proteins interact with each other. Here we investigated the role of interaction between Rhp51 and Rad22, the fission yeast homologs of Rad51 and Rad52, respectively, on the function of each protein. We identified a direct association between the two proteins and their self-interactions both in vivo and in vitro. We also determined the binding domains of each protein that mediate these interactions. To characterize the role of Rhp51-Rad22 interaction, we used random mutagenesis to identify the mutants Rhp51 and Rad22, which cannot interact each other. Interestingly, we found that mutant Rhp51 protein, which cannot interact with either Rad22 or Rti1 (G282D), lost its DNA repair ability. In contrast, mutant Rad22 proteins, which cannot specifically bind to Rhp51 (S379L and P381L), maintained their DNA repair ability. These results suggest that the interaction between Rhp51 and Rad22 is crucial for the recombinational repair function of Rhp51. However, the significance of this interaction on the function of Rad22 remains to be characterized further.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Park, SD (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.			Seong, Rho/0000-0001-5699-0718				Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Alfa C., 1993, EXPT FISSION YEAST L, P133; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P302; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; JANG YK, 1994, GENE, V142, P207, DOI 10.1016/0378-1119(94)90262-3; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; KAISER C, 1994, METHODS YEAST GENETI, P167; Kanaar Roland, 1997, Genes and Function, V1, P165; Khasanov FK, 1999, GENETICS, V152, P1557; Kim WJ, 2001, NUCLEIC ACIDS RES, V29, P1724, DOI 10.1093/nar/29.8.1724; Kim WJ, 2000, J BIOL CHEM, V275, P35607, DOI 10.1074/jbc.M007060200; Klein HL, 1997, GENETICS, V147, P1533; Krejci L, 2001, MOL CELL BIOL, V21, P966, DOI 10.1128/MCB.21.3.966-976.2001; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Muris DFR, 1996, J CELL SCI, V109, P73; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; PAETKAU DW, 1994, GENE DEV, V8, P2035, DOI 10.1101/gad.8.17.2035; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Suto K, 1999, MOL BIOL CELL, V10, P3331, DOI 10.1091/mbc.10.10.3331; Tsutsui Y, 2001, GENETICS, V159, P91; Tsutsui Y, 2000, GENETICS, V154, P1451; van den Bosch M, 2001, MUTAT RES-DNA REPAIR, V461, P311, DOI 10.1016/S0921-8777(00)00060-4; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	42	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30264	30270		10.1074/jbc.M202517200	http://dx.doi.org/10.1074/jbc.M202517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050150	hybrid			2022-12-25	WOS:000177509300112
J	Gruber, A; Cantwell, AM; Di Cera, E; Hanson, SR				Gruber, A; Cantwell, AM; Di Cera, E; Hanson, SR			The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; BLOOD-COAGULATION; INHIBITION; PRIMATES; BABOON	Administration of the thrombin mutant W215A/E217A (WE), rationally designed for selective activation of the anticoagulant protein C, elicits safe and potent anticoagulant and antithrombotic effects in a baboon model of platelet-dependent thrombosis. The lowest dose of WE tested (0.011 mg/kg bolus) reduced platelet thrombus accumulation by 80% and was at least as effective as the direct administration of 40-fold more (0.45 mg/kg bolus) activated protein C. WE-treated animals showed no detectable hemorrhage or organ failure. No procoagulant activity could be detected for up to 1 week in baboon plasma obtained following WE administration. These results show that engineered thrombin derivatives that selectively activate protein C may represent useful therapeutic agents for the treatment of thrombotic disorders.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Emory Univ, Sch Med, Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA; Georgia Inst Technol, Atlanta, GA 30322 USA	Washington University (WUSTL); Emory University; Emory University; University System of Georgia; Georgia Institute of Technology	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.			Gruber, Andras/0000-0001-6212-2247	NCRR NIH HHS [RR00165] Funding Source: Medline; NHLBI NIH HHS [HL49413, HL31469, HL58141] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL058141, R01HL049413, R01HL031469] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 1998, TRENDS CARDIOVAS MED, V8, P340, DOI 10.1016/S1050-1738(98)00030-9; ESMON CT, 1989, J BIOL CHEM, V264, P4743; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; GRUBER A, 1989, BLOOD, V73, P639; HANSON SR, 1988, J CLIN INVEST, V81, P149, DOI 10.1172/JCI113286; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; HARKER LA, 1991, CIRCULATION, V83, P41; HEEB MJ, 1991, J BIOL CHEM, V266, P17606; Libby P, 1998, Vasc Med, V3, P225, DOI 10.1177/1358836X9800300309; MARTINOLI JL, 1986, THROMB RES, V43, P253, DOI 10.1016/0049-3848(86)90145-3; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902	15	62	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27581	27584		10.1074/jbc.C200237200	http://dx.doi.org/10.1074/jbc.C200237200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12070133	hybrid			2022-12-25	WOS:000177189800002
J	Smith, AJH; Xian, J; Richardson, M; Johnstone, KA; Rabbitts, PH				Smith, AJH; Xian, J; Richardson, M; Johnstone, KA; Rabbitts, PH			Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21.3 region of homozygous loss in human tumours	ONCOGENE			English	Article						Cre-loxP; Luca region; chromosome 3; deletion; breast cancer; lung cancer	EMBRYONIC STEM-CELLS; FREQUENT EPIGENETIC INACTIVATION; SUPPRESSOR GENE; LUNG-CANCER; ALLELE LOSS; RASSF1A; BREAST; MICE; RECOMBINATION; GENERATION	Chromosomal deletions are a common feature of epithelial tumours and when further defined by homozygous deletions, are often the location of tumour suppressor genes. Deletions within the short arm of chromosome 3 occur very frequently in human carcinomas: a minimal region of loss at 3p21.3 (the Luca) region has been defined by overlapping homozygous deletions in lung and breast cancer cell lines. Using a rapid strategy for Cre-loxP chromosome engineering, a deletion of approximately 370 kb was created in the mouse germline corresponding to the deleted region at 3p21.3. The deletion when homozygous is embryonic lethal. Heterozygotes develop normally despite being haplo-insufficient for twelve genes including the candidate tumour suppressor gene Rassf1. Because damage to 3p21.3 often occurs very early in the sequence of genetic changes that lead to malignancy, particularly in lung and breast cancer, further genetic damage to these mice will provide the opportunity to model multi-step tumorigenesis of these tumours.	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Cambridge, Ctr Mrc, Dept Oncol, Cambridge CB2 2QH, England	University of Edinburgh; University of Cambridge	Smith, AJH (corresponding author), Univ Edinburgh, Ctr Genome Res, W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.		Johnstone, Karen/E-2369-2011	Johnstone, Karen/0000-0002-3183-8397				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Chung GTY, 1995, ONCOGENE, V11, P2591; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Hesketh R., 1997, ONCOGENE TUMOUR SUPP; Justice MJ, 1997, METHODS, V13, P423, DOI 10.1006/meth.1997.0548; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Lee MG, 2001, CANCER RES, V61, P6688; LePage DF, 2000, P NATL ACAD SCI USA, V97, P10471, DOI 10.1073/pnas.97.19.10471; Lerman MI, 2000, CANCER RES, V60, P6116; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Mitelman F, 1991, CATALOGUE CHROMOSOME; Morrissey C, 2001, CANCER RES, V61, P7277; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Thomas JW, 1998, P NATL ACAD SCI USA, V95, P1114, DOI 10.1073/pnas.95.3.1114; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wistuba II, 2000, CANCER RES, V60, P1949; Zheng BH, 2000, MOL CELL BIOL, V20, P648, DOI 10.1128/MCB.20.2.648-655.2000; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	27	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4521	4529		10.1038/sj.onc.1205530	http://dx.doi.org/10.1038/sj.onc.1205530			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085230				2022-12-25	WOS:000176476700006
J	Alarcon-Vargas, D; Tansey, WP; Ronai, Z				Alarcon-Vargas, D; Tansey, WP; Ronai, Z			Regulation of c-myc stability by selective stress conditions and by MEKK1 requires aa 127-189 of c-myc	ONCOGENE			English	Article						c-myc; stress kinases; MEKK1; protein stability; cytokines; TNF alpha	RECEPTOR-INTERACTING PROTEIN; CELL-LINE; PHOSPHORYLATION; TRANSACTIVATION; STABILIZATION; EXPRESSION; DEGRADATION; ACTIVATION; KINASE; JNK	C-myc availability is central for its ability to serve as a regulator of cell growth and death. Here we study the regulation of c-myc protein stability and identify domains of c-myc that are important for its stabilization in response to stress kinases activated following selective stress conditions. UV-irradiation elicited an increase in c-myc protein levels, which could be attenuated by inhibitors of stress kinases but also by actinomycin D-inhibitor of transcription. Inhibition of protein synthesis results in a noticeable decrease in c-myc levels, further pointing to the short half-life of the protein. However, in combination with tumor necrosis factor-alpha (TNF-alpha), cycloheximide efficiently increases steady-state levels of C-myc, suggesting that selective stress conditions are required to increase c-myc protein stability. Expression of MEKK1, an upstream regulator of protein kinases that has been implicated in mediating the response to diverse stress conditions, also results in an efficient increase in the half-life of c-myc protein. To map c-myc domains that are responsive to stress kinases, we monitored changes in the level of c-myc deletion mutants following MEKK1 expression. Of the seven c-myc deletion mutants analysed, the domain spanning amino acids 127-189 was found to be required for MEKK1-dependent increase in c-myc stability. In all, the present study identifies a novel domain that is important for the regulation of c-myc stability by stress kinases in response to selective stress conditions.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Cold Spring Harbor Laboratory	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419, P01CA013106, F31CA085197] Funding Source: NIH RePORTER; NCI NIH HHS [CA85197, CA13106, CA78419] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Dang CV, 1999, MOL CELL BIOL, V19, P1; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Herbst A, 2000, MOL BIOL REP, V27, P203, DOI 10.1023/A:1011008018565; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Kim JW, 2001, J BIOL CHEM, V276, P27064, DOI 10.1074/jbc.M009364200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Park IC, 1998, CANCER LETT, V125, P17, DOI 10.1016/S0304-3835(97)00450-3; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; PULVERER BJ, 1994, ONCOGENE, V9, P59; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SETH A, 1991, J BIOL CHEM, V266, P23521; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; WATERS CM, 1991, ONCOGENE, V6, P797; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	45	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4384	4391		10.1038/sj.onc.1205543	http://dx.doi.org/10.1038/sj.onc.1205543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080469				2022-12-25	WOS:000176317100004
J	Tinhofer, I; Anether, G; Senfter, M; Pfaller, K; Bernhard, D; Hara, M; Greil, R				Tinhofer, I; Anether, G; Senfter, M; Pfaller, K; Bernhard, D; Hara, M; Greil, R			Stressful death of T-ALL tumor cells following treatment with the antitumor agent Tetrocarcin-A	FASEB JOURNAL			English	Article						ER-stress; heat shock protein; apoptosis	DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; BCL-2 GENE-EXPRESSION; HEAT-SHOCK PROTEINS; ENDOPLASMIC-RETICULUM; CHILDHOOD NEUROBLASTOMAS; CASPASE ACTIVATION; OCCURS DOWNSTREAM; CANCER-CELLS	The T-ALL cell lines CCRF-CEM and Jurkat were studied for their sensitivity toward apoptosis induced by tetrocarcin-A (TC-A), an antibacterial and antitumor agent isolated from the actinomycete Micromonospora. This substance promoted cell death via a mitochondrial signaling pathway, that is, by activation of Bid and Bax, loss of the mitochondrial transmembrane potential, release of cytochrome c, and activation of effector caspases, even under conditions of Bcl-2 overexpression. Furthermore, sensitivity to TC-A was not dependent on expression of wild-type caspase-8. In contrast, this apoptotic pathway was inhibited markedly by pretreatment of cells with cycloheximide, an inhibitor of de novo protein synthesis. cDNA microarray chip analysis revealed that TC-A induced a significant up-regulation of members of the heat shock protein family known to be involved in the endoplasmic reticulum (ER)-stress-induced apoptotic program. The activation of caspase-12, the central inducer caspase involved in ER-stress by TC-A treatment, is in concordance with this result. These results show that, in TALL cells, TC-A induces an apoptotic machinery via mitochondrial and ER signaling, which is not inhibited by aberrant expression/function of important regulators of death receptor- and drug-induced apoptosis.	Univ Innsbruck, Dept Hematol & Oncol, Lab Mol Cytol, A-6020 Innsbruck, Austria; Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Anat & Histol, A-6020 Innsbruck, Austria; Kyowa Hakko Kogyo Co Ltd, Pharmaceut Res Inst, Nagaizumi, Shizuoka 411, Japan	University of Innsbruck; University of Innsbruck; University of Innsbruck; Kyowa Kirin Ltd	Tinhofer, I (corresponding author), Univ Innsbruck, Dept Hematol & Oncol, Lab Mol Cytol, A-6020 Innsbruck, Austria.	Inge.Tinhofer@uibk.ac.at	Greil, Richard F/C-7673-2017	Greil, Richard F/0000-0002-4462-3694; Tinhofer, Ingeborg/0000-0002-0512-549X; Bernhard, David/0000-0002-2383-6607				Basu S, 2000, CELL STRESS CHAPERON, V5, P443, DOI 10.1379/1466-1268(2000)005<0443:HSPTFO>2.0.CO;2; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cotter Finbarr E., 1999, Seminars in Hematology, V36, P9; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gao G, 2000, J CELL BIOCHEM, V80, P53; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Konopleva M, 2000, BLOOD, V95, P3929; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Leung S, 2001, INT J CANCER, V91, P846, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1131>3.0.CO;2-Y; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Mano Y, 1999, EUR J CANCER, V35, P1214, DOI 10.1016/S0959-8049(99)00124-0; Marschitz I, 2000, AM J CLIN PATHOL, V113, P219, DOI 10.1309/491W-L1TN-UFQX-T61B; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORIMOTO M, 1982, J ANTIBIOT, V35, P1033, DOI 10.7164/antibiotics.35.1033; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakashima T, 2000, CANCER RES, V60, P1229; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pepper C, 1999, LEUKEMIA RES, V23, P1007, DOI 10.1016/S0145-2126(99)00122-8; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; REED JC, 1989, ONCOGENE RES, V4, P271; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Thomas A, 1996, ONCOGENE, V12, P1055; Tomiuk S, 2001, Brief Bioinform, V2, P329, DOI 10.1093/bib/2.4.329; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Villunger A, 1997, CANCER RES, V57, P3331; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wu GS, 1996, CLIN CANCER RES, V2, P623; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624	57	44	44	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1295	+		10.1096/fj.02-0020fje	http://dx.doi.org/10.1096/fj.02-0020fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060673				2022-12-25	WOS:000176683900035
J	Jacobsen, K; Groth, A; Willumsen, BM				Jacobsen, K; Groth, A; Willumsen, BM			Ras-inducible immortalized fibroblasts: focus formation without cell cycle deregulation	ONCOGENE			English	Article						oncogene; inducible ras; saturation density; reversible transformation	NIH 3T3 CELLS; MAMMALIAN-CELLS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSION; GENE-EXPRESSION; ONCOGENIC RAS; LAC OPERATOR; INK4A LOCUS; C-RASH; ACTIVATION	The Ras oncogene transforms cultured murine fibroblasts into malignant, focus-forming cells, whose lack of contact inhibition is evidenced by high saturation densities. In order to investigate the reversibility of Ras transformation, as well as the kinetics of Ras-induced changes, cell lines that conditionally express oncogenic Ras were constructed. Both focus formation and increased saturation density were inducible and fully reversible. In exponentially growing cells, oncogenic Ras-expression had no effect on proliferation rates, Erk phosphorylation, or the level of cyclin D1, and Ras-induction did not confer serum-independent growth. As expected, growth to high density in uninduced cells led to quiescence with a low level of cyclin D1 and no active Erk; in this setting, Ras induction prevented full downregulation of cyclin D1 and inactivation of Erk. Our results show that Ras expression to a level sufficient for transformation leads to relatively subtle effects on known downstream targets, and that the focus formation and increased saturation density growth induced by Ras is not a result of growth factor independence.	Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark	University of Copenhagen	Willumsen, BM (corresponding author), Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark.	bmw@biobase.dk	Willumsen, Berthe M/H-1903-2012; Groth, Anja/AAH-5386-2019	Willumsen, Berthe M/0000-0002-2277-6999; Groth, Anja/0000-0003-0577-1771				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHUNG HH, 1992, BIOCHIM BIOPHYS ACTA, V1129, P278, DOI 10.1016/0167-4781(92)90504-S; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FILMUS J, 1994, ONCOGENE, V9, P3627; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; Harvey J J, 1971, Int Rev Exp Pathol, V10, P265; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; JACOBSEN KD, 1995, J MOL BIOL, V252, P289, DOI 10.1006/jmbi.1995.0496; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; SIMONS PJ, 1967, NATURE, V214, P897, DOI 10.1038/214897a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; Villalonga P, 2000, ONCOGENE, V19, P690, DOI 10.1038/sj.onc.1203341; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269; Winston JT, 1996, ONCOGENE, V12, P127; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZAVADA J, 1970, NATURE, V225, P24, DOI 10.1038/225024a0; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	54	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3058	3067		10.1038/sj.onc.1205423	http://dx.doi.org/10.1038/sj.onc.1205423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082537				2022-12-25	WOS:000175262700014
J	Friedmann, E; Salzberg, Y; Weinberger, A; Shaltiel, S; Gerst, JE				Friedmann, E; Salzberg, Y; Weinberger, A; Shaltiel, S; Gerst, JE			YOS9, the putative yeast homolog of a gene amplified in osteosarcomas, is involved in the endoplasmic reticulum (ER)-Golgi transport of GPI-anchored proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; GOLGI-APPARATUS; MEMBRANE-PROTEINS; QUALITY-CONTROL; ER; COMPLEX; ENCODES	The OS-9 gene maps to a region (q13-15) of chromosome 12 that is highly amplified in human osteosarcomas and encodes a protein of unknown function. Here we have characterized a homolog designated as YOS9 (YDR057w) from Saccharomyces cerevisiae. The yeast protein (Yos9) is a membrane-associated glycoprotein that localizes to the endoplasmic reticulum (ER). YOS9 interacts genetically with genes involved in ER-Golgi transport, particularly SEC34, whose temperature-sensitive mutant is rescued by YOS9 overexpression. Interestingly, Yos9 appears to play a direct role in the transport of glycosylphosphatidylinositol (GPI)-anchored proteins to the Golgi apparatus. Yos9 binds directly to Gas1 and Mkc7 and accelerates Gas1 transport and processing in cells overexpressing YOS9. Correspondingly, Gas1 processing is slowed in cells bearing a deletion in YOS9. No effect upon the transport and processing of non-GPI-anchored proteins (e.g. invertase and carboxypeptidase Y) was detected in cells either lacking or overexpressing Yos9. As Yos9 is not a component of the Emp24 complex, it may act as a novel escort factor for GPI-anchored proteins in ER-Golgi transport in yeast and possibly in mammals.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Gerst, JE (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Salzberg, Yehuda/0000-0003-0605-8038				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Belden WJ, 2001, MOL BIOL CELL, V12, P957, DOI 10.1091/mbc.12.4.957; BORDIER C, 1981, J BIOL CHEM, V256, P1604; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; Lustgarten V, 1999, MOL CELL BIOL, V19, P4480; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Michalak M, 1998, BIOCHEM CELL BIOL, V76, P779, DOI 10.1139/bcb-76-5-779; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakayama T, 1999, FEBS LETT, V453, P77, DOI 10.1016/S0014-5793(99)00700-0; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Su YA, 1996, MOL CARCINOGEN, V15, P270, DOI 10.1002/(SICI)1098-2744(199604)15:4<270::AID-MC4>3.0.CO;2-K; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; Wuestehube LJ, 1996, GENETICS, V142, P393	47	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35274	35281		10.1074/jbc.M201044200	http://dx.doi.org/10.1074/jbc.M201044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12077121	hybrid			2022-12-25	WOS:000178117000080
J	Takeshita, A; Taguchi, M; Koibuchi, N; Ozawa, Y				Takeshita, A; Taguchi, M; Koibuchi, N; Ozawa, Y			Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; DNA-BINDING DOMAIN; HORMONE RECEPTORS; SIGNALING PATHWAY; RESPONSE ELEMENTS; DRUG-INTERACTIONS; CO-REPRESSOR; COREPRESSOR; COACTIVATOR; EXPRESSION	Cytochrome P450 monooxygenase 3A4 (CYP3A4) is responsible for the metabolism of endogenous steroids and drugs in liver. Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter. Conversely, it is not known whether SXR mediates the transcriptional repression. We thus examined transcriptional repression of SXR and its interaction with corepressors, NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid receptors) using reporter assays in the absence and presence of ligand. Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on the CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells. Interestingly, rifampicin also increased the interaction of SXR with SMRT as well as with coactivator SRC-1. On the other hand, the anti-fungal agent ketoconazole decreased SXR interaction with both SRC-1 and SMRT. Ketoconazole partially inhibited corticosterone-induced SXR-mediated transcription on the CYP3A4 promoter. Taken together, our results suggest that the differential interaction of coactivators and corepressors induced by various xenobiotics may alter SXR-mediated transcription. Further, the effects of ketoconazole on the CYP3A4 gene suppression may explain, in part, drug-induced inhibition of the CYP3A4 action at the transcriptional level.	Toranomon Gen Hosp, Div Endocrinol & Metab, Okinaka Mem Inst Med Res, Minato Ku, Tokyo 1058470, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Maebashi, Gumma 3718511, Japan	Toranomon Hospital; Japan Science & Technology Agency (JST)	Takeshita, A (corresponding author), Toranomon Gen Hosp, Div Endocrinol & Metab, Okinaka Mem Inst Med Res, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.			Koibuchi, Noriyuki/0000-0002-2247-9740				BECK DJ, 1989, BR J CLIN PHARM, V28, P166; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; HUANG YC, 1986, ANTIMICROB AGENTS CH, V30, P206, DOI 10.1128/AAC.30.2.206; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Liu Y, 1998, MOL ENDOCRINOL, V12, P34, DOI 10.1210/mend.12.1.0046; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; MAURICE M, 1992, FASEB J, V6, P752, DOI 10.1096/fasebj.6.2.1371482; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sumida A, 2000, BIOCHEM BIOPH RES CO, V267, P756, DOI 10.1006/bbrc.1999.2029; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 2001, EUR J ENDOCRINOL, V145, P513, DOI 10.1530/eje.0.1450513; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	35	101	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32453	32458		10.1074/jbc.M111245200	http://dx.doi.org/10.1074/jbc.M111245200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12072427	hybrid			2022-12-25	WOS:000177859000009
J	Avramovich, Y; Amit, T; Youdim, MBH				Avramovich, Y; Amit, T; Youdim, MBH			Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; MICROGLIAL CELLS; METALLOPROTEASE INHIBITORS; CONVERTING-ENZYME; SENILE PLAQUES; KINASE CASCADE; NITRIC-OXIDE; TNF-ALPHA	Chronic inflammatory processes are associated with the pathophysiology of Alzheimer's disease (AD), and it has been proposed that treatment with non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk for AD. Here we report that various NSAIDs, such as the cyclooxygenase inhibitors, nimesulide, ibuprofen and indomethacin, as well as thalidomide (Thal) and its nonteratogenic analogue, supidimide, significantly stimulated the secretion of the hon-amyloidogenic alpha-secretase form of the soluble amyloid precursor protein (sAPPalpha) into the conditioned media of SH-SY5Y neuroblastoma and PC12 cells. These NSAIDs markedly reduced the levels of the cellular APP holoprotein, further accelerating non-amyloidogenic processes. sAPPalpha release, induced by nimesulide and Thal, was modulated by inhibitors of protein kinase C and Erk mitogen-activated protein (MAP) kinase. Furthermore, in results complementary to the inhibitor studies, we show for the first time that NSAIDs can activate the Erk MAP kinase signaling cascade, thus identifying a novel pharmacology mechanism of NSAIDs. Our findings suggest that NSAIDs and Thal might prove useful to favor non-amyloidogenic APP processing by enhancing alpha-secretase activity, thereby reducing the formation of amyloidogenic derivatives, and therefore are of potential therapeutic value in AD.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf & Natl Parkinson Fdn Ctr Excellence Neur, IL-31096 Haifa, Israel; Interdepartmental Unit Biotechnol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.							ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CACABELOS R, 1994, METHOD FIND EXP CLIN, V16, P141; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; DAVIES B, 1993, CANCER RES, V53, P2087; De Strooper B, 2000, J CELL SCI, V113, P1857; DELACOURTE A, 1990, NEUROLOGY, V40, P33, DOI 10.1212/WNL.40.1.33; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFFY PE, 1980, NEUROLOGY, V30, P778, DOI 10.1212/WNL.30.7.778; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Forloni G, 1997, CYTOKINE, V9, P759, DOI 10.1006/cyto.1997.0232; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GITTER BD, 1995, P NATL ACAD SCI USA, V92, P10738, DOI 10.1073/pnas.92.23.10738; HAGA S, 1993, BRAIN RES, V601, P88, DOI 10.1016/0006-8993(93)91698-R; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Ho L, 1999, J NEUROSCI RES, V57, P295; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Ii M, 1996, BRAIN RES, V720, P93, DOI 10.1016/0006-8993(96)00156-4; ITAGAKI S, 1994, BRAIN RES, V645, P78, DOI 10.1016/0006-8993(94)91640-3; Kadoyama K, 2001, BIOCHEM BIOPH RES CO, V281, P483, DOI 10.1006/bbrc.2001.4357; KHOURY JE, 1996, NATURE, V382, P716; KINOUCHI T, 1995, BIOCHEM BIOPH RES CO, V209, P841, DOI 10.1006/bbrc.1995.1576; Klegeris A, 1997, J NEUROSCI RES, V49, P229, DOI 10.1002/(SICI)1097-4547(19970715)49:2<229::AID-JNR11>3.0.CO;2-W; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee RKK, 1999, J NEUROSCI, V19, P940; Lee RKK, 2000, ANN NY ACAD SCI, V920, P261; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; McGeer EG, 1999, CURR PHARM DESIGN, V5, P821; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MCGEER PL, 1992, DEMENTIA, V3; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Mills J, 1997, J NEUROSCI, V17, P9415; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Nitsch RM, 1997, J NEUROCHEM, V69, P704; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; Rossi F, 1996, BIOCHEM BIOPH RES CO, V225, P474, DOI 10.1006/bbrc.1996.1197; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SMALL DH, 1994, J NEUROSCI, V14, P2117; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Szczepanik AM, 2001, J NEUROCHEM, V77, P304, DOI 10.1046/j.1471-4159.2001.t01-1-00240.x; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	80	78	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31466	31473		10.1074/jbc.M201308200	http://dx.doi.org/10.1074/jbc.M201308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070143	hybrid			2022-12-25	WOS:000177718700024
J	Bernard-Pierrot, I; Delbe, J; Rouet, V; Vigny, M; Kerros, ME; Caruelle, D; Raulais, D; Barritault, D; Courty, J; Milhiet, PE				Bernard-Pierrot, I; Delbe, J; Rouet, V; Vigny, M; Kerros, ME; Caruelle, D; Raulais, D; Barritault, D; Courty, J; Milhiet, PE			Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR PLEIOTROPHIN; MOLECULE HB-GAM; ANAPLASTIC LYMPHOMA KINASE; ACTIVATED PROTEIN-KINASE; BIOLOGICAL-ACTIVITY; ZETA/RPTP-BETA; CELL-GROWTH; BINDING; RECEPTOR; CANCER	Heparin affin regulatory peptide (HARP) is an heparin-binding growth factor, highly expressed in several primary human tumors and considered as a rate-limiting angiogenic factor in tumor growth, invasion, and metastasis. Implication of this protein in carcinogenesis is linked to its mitogenic, angiogenic, and transforming activities. Recently, we have demonstrated that the C-terminal residues 111-136 of HARP are required for its mitogenic and transforming activities (Bernard-Pierrot, I., Delbe, J., Caruelle, D., Barritault, D., Courty, J., and Milhiet, P. E. (2001) J. Biol Chem. 276, 12228 -12234). In this paper, HARP deleted of its last 26 amino acids was shown to act as a dominant negative effector for its mitogenic, angiogenic, transforming, and tumor-formation activities by heterodimerizing with the wild type protein. Similarly, the synthetic corresponding peptide P111-136 displayed in vitro inhibition of wild type HARP activities, but in this case, the inhibition was mainly explained by the competition of the peptide with HARP for the binding to the extracellular domain of the high affinity ALK receptor.	Univ Paris 12, CNRS UPRES A 7053, Lab Rech Croissance Cellulaire Reparat & Regenera, F-94010 Creteil, France; UMR554 INSERM, Ctr Biochim Struct, F-34090 Montpellier, France; Univ Paris 06, INSERM U440, F-75005 Paris, France	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Courty, J (corresponding author), Univ Paris 12, CNRS UPRES A 7053, Lab Rech Croissance Cellulaire Reparat & Regenera, Ave Gen de Gaulle, F-94010 Creteil, France.	Courty@univ-paris12.fr	Delbe, Jean/R-3680-2018; Kerros, Marie-Emmanuelle/G-5394-2011; Courty, Jose/Q-3702-2018					Bernard-Pierrot I, 1999, BIOCHEM BIOPH RES CO, V266, P437, DOI 10.1006/bbrc.1999.1835; Bernard-Pierrot I, 2001, J BIOL CHEM, V276, P12228, DOI 10.1074/jbc.M010913200; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Choudhuri R, 1997, CANCER RES, V57, P1814; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Jager R, 1997, INT J CANCER, V73, P537; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V206, P468, DOI 10.1006/bbrc.1995.1066; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; Laaroubi Khalid, 1995, Progress in Growth Factor Research, V6, P25; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; Nakanishi T, 1997, OBSTET GYNECOL, V90, P285, DOI 10.1016/S0029-7844(97)00237-8; Papadimitriou E, 2000, BIOCHEM BIOPH RES CO, V274, P242, DOI 10.1006/bbrc.2000.3126; PASSANITI A, 1992, LAB INVEST, V67, P519; POWERS C, 2002, J BIOL CHEM, V23, P23; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Satyamoorthy K, 2000, PIGM CELL RES, V13, P87, DOI 10.1034/j.1600-0749.13.s8.16.x; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Soulie P, 2002, J IMMUNOASS IMMUNOCH, V23, P33, DOI 10.1081/IAS-120002273; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; Weber D, 2000, CANCER RES, V60, P5284; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733	36	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32071	32077		10.1074/jbc.M202747200	http://dx.doi.org/10.1074/jbc.M202747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070152	hybrid			2022-12-25	WOS:000177718700096
J	Petersen, C; Moller, LB; Valentin-Hansen, P				Petersen, C; Moller, LB; Valentin-Hansen, P			The cryptic adenine deaminase gene of Escherichia coli - Silencing by the nucleoid-associated DNA-binding protein, H-NS, and activation by insertion elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURVED DNA; TRANSCRIPTIONAL ACTIVATOR; BGL PROMOTER; EXPRESSION; OPERON; SITE; REPRESSION; SEQUENCE; CAMP; K-12	In Escherichia coli there are two pathways for conversion of adenine into guanine nucleotides, both involving the intermediary formation of IMP. The major pathway involves conversion of adenine into hypoxanthine in three steps via adenosine and inosine, with subsequent phosphoribosylation. of hypoxanthine to IMP. The minor pathway involves formation of ATP, which is converted via the histidine pathway to the purine intermediate 5-amino-4-imidazolecarboxamide ribonucleotide and, subsequently, to IMP. Here we describe E. coli mutants, in which a third pathway for conversion of adenine to IMP has been activated. This pathway was shown to involve direct deamination of adenine to hypoxanthine by a manganese-dependent adenine deaminase encoded by a cryptic gene, yicP, which we propose be renamed ade. Insertion elements, located from -145 to +13 bp relative to the transcription start site, activated the ade gene as did unlinked mutations in the hns gene, encoding the histone-like protein H-NS. Gene fusion analysis indicated that ade transcription is repressed more than 10-fold by H-NS and that a region of 231 bp including the ade promoter is sufficient for this regulation. The activating insertion elements essentially eliminated the H-NS-mediated silencing, and stimulated ade gene expression 2-3-fold independently of the H-NS protein.	Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, DK-1307 Copenhagen K, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; John F Kennedy Inst, DK-2600 Glostrup, Denmark	University of Copenhagen; University of Southern Denmark	Petersen, C (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, Solvade 83H, DK-1307 Copenhagen K, Denmark.	carstenpt@mermaid.molbio.ku.dk		Moller, Lisbeth/0000-0002-9524-4301				Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; Bustamante VH, 2001, MOL MICROBIOL, V39, P664, DOI 10.1046/j.1365-2958.2001.02209.x; Caramel A, 1998, J MOL BIOL, V284, P875, DOI 10.1006/jmbi.1998.2191; Clark RA, 2000, J ACQ IMMUN DEF SYND, V23, P99; DEELEY MC, 1992, J BACTERIOL, V174, P3102, DOI 10.1128/jb.174.10.3102-3110.1992; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; FORSMAN K, 1992, P NATL ACAD SCI USA, V89, P9880, DOI 10.1073/pnas.89.20.9880; Francetic O, 2000, MOL MICROBIOL, V35, P1506, DOI 10.1046/j.1365-2958.2000.01817.x; Free A, 2001, MOL MICROBIOL, V42, P903, DOI 10.1046/j.1365-2958.2001.02678.x; Govantes F, 2000, MOL MICROBIOL, V38, P1061, DOI 10.1046/j.1365-2958.2000.02215.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; JORDI BJAM, 1992, EMBO J, V11, P2627, DOI 10.1002/j.1460-2075.1992.tb05328.x; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; KOCHARIAN SM, 1982, GENETIKA+, V18, P906; Kruger MK, 1998, J MOL BIOL, V284, P621, DOI 10.1006/jmbi.1998.2196; LEUNG HB, 1980, J BIOL CHEM, V255, P867; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Maniatis T., 1982, MOL CLONING LAB MANU; Matsui H, 2001, BIOSCI BIOTECH BIOCH, V65, P1112, DOI 10.1271/bbb.65.1112; MELEFORS O, 1988, CELL, V52, P893, DOI 10.1016/0092-8674(88)90431-X; Miller J.H., 1972, EXPT MOL GENETICS; Mukerji M, 1997, MOL MICROBIOL, V24, P617, DOI 10.1046/j.1365-2958.1997.3621725.x; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; Nygaard P, 1996, J BACTERIOL, V178, P846, DOI 10.1128/jb.178.3.846-853.1996; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; Petersen C, 2000, GENE, V261, P289, DOI 10.1016/S0378-1119(00)00509-6; PETERSEN C, 1987, MOL GEN GENET, V209, P179, DOI 10.1007/BF00329856; Petersen C, 2001, J BIOL CHEM, V276, P884, DOI 10.1074/jbc.M008300200; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; REYNOLDS AE, 1986, J MOL BIOL, V191, P85, DOI 10.1016/0022-2836(86)90424-9; SCHNETZ K, 1992, P NATL ACAD SCI USA, V89, P1244, DOI 10.1073/pnas.89.4.1244; SCHNETZ K, 1995, EMBO J, V14, P2545, DOI 10.1002/j.1460-2075.1995.tb07252.x; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; Smyth CP, 2000, MOL MICROBIOL, V36, P962, DOI 10.1046/j.1365-2958.2000.01917.x; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; TANAKA K, 1991, MOL GEN GENET, V226, P367, DOI 10.1007/BF00260648; Timchenko T, 1996, EMBO J, V15, P3986, DOI 10.1002/j.1460-2075.1996.tb00772.x; TOBE T, 1993, J BACTERIOL, V175, P6142, DOI 10.1128/JB.175.19.6142-6149.1993; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Ueguchi C, 1996, J MOL BIOL, V263, P149, DOI 10.1006/jmbi.1996.0566; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; Westermark M, 2000, J BACTERIOL, V182, P6347, DOI 10.1128/JB.182.22.6347-6357.2000; WINKLER ME, 1996, ESCHERICHIA COLI SAL, V1, P485; ZALKIN H, 1996, ESCHERICHIA COLI SAL, V1, P561; ZUBER F, 1994, MOL MICROBIOL, V12, P231, DOI 10.1111/j.1365-2958.1994.tb01012.x	51	25	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31373	31380		10.1074/jbc.M204268200	http://dx.doi.org/10.1074/jbc.M204268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077137	hybrid			2022-12-25	WOS:000177718700013
J	Kedar, PS; Kim, SJ; Robertson, A; Hou, E; Prasad, R; Horton, JK; Wilson, SH				Kedar, PS; Kim, SJ; Robertson, A; Hou, E; Prasad, R; Horton, JK; Wilson, SH			Direct interaction between mammalian DNA polymerase beta and proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; PURIFIED HUMAN PROTEINS; NEGATIVE GROWTH-CONTROL; REPLICATION-FACTOR-C; LIGASE-I; POLY(ADP-RIBOSE) POLYMERASE-1; BOVINE TESTIS; FACTOR PCNA; BINDING; RECONSTITUTION	Proliferating cell nuclear antigen (PCNA) plays an essential role in nucleic acid metabolism as a component of the DNA replication and DNA repair machinery. As such, PCNA interacts with many proteins that have a sequence motif termed the PCNA interacting motif (PIM) and also with proteins lacking a PIM. Three regions in human and rat DNA polymerases beta (beta-pol) that resemble the consensus PIM were identified, and we show here that beta-polymerase and PCNA can form a complex both in vitro and in vivo. Immunoprecipitation experiments, yeast two-hybrid analysis, and overlay binding assays were used to examine the interaction between the two proteins. Competition experiments with synthetic PIM-containing peptides suggested the importance of a PIM in the interaction, and studies of a beta-polymerase PIM mutant, H222A/F223A, demonstrated that this alteration blocked the interaction with PCNA. The results indicate that at least one of the PIM-like sequences in beta-polymerase appears to be a functional PIM and was required in the interaction between beta-polymerase and PCNA.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050158, ZIAES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEARD WA, 1995, HIV PRACTICAL APPROA, V2, P15; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CHEN IT, 1995, ONCOGENE, V11, P1931; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HALL PA, 1995, ONCOGENE, V10, P2427; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; HUSAIN I, 1995, NUCLEIC ACIDS RES, V23, P1597, DOI 10.1093/nar/23.9.1597; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Ochs K, 1999, CANCER RES, V59, P1544; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Scott M, 2001, J CELL SCI, V114, P3455; Shi J, 2000, J BIOL CHEM, V275, P14910, DOI 10.1074/jbc.275.20.14910; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1996, BIOCHEMISTRY-US, V35, P3728, DOI 10.1021/bi952632h; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P16402, DOI 10.1074/jbc.270.27.16402; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Takasaki Y, 2001, J IMMUNOL, V166, P4780, DOI 10.4049/jimmunol.166.7.4780; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; Tomkinson AE, 2001, PROG NUCLEIC ACID RE, V68, P151; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869	63	108	114	3	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31115	31123		10.1074/jbc.M201497200	http://dx.doi.org/10.1074/jbc.M201497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063248	hybrid			2022-12-25	WOS:000177579800091
J	Tao, HM; Szeszel-Fedorowicz, W; Amir-Ahmady, B; Gibson, MA; Stabile, LP; Salati, LM				Tao, HM; Szeszel-Fedorowicz, W; Amir-Ahmady, B; Gibson, MA; Stabile, LP; Salati, LM			Inhibition of the splicing of glucose-6-phosphate dehydrogenase precursor mRNA by polyunsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POSTTRANSCRIPTIONAL MECHANISM; ACETYL-COA CARBOXYLASE; MESSENGER-RNA EXPORT; NUTRITIONAL REGULATION; GENE-TRANSCRIPTION; SYNTHASE GENE; RAT-LIVER; CHROMATIN STRUCTURE; 3T3-L1 ADIPOCYTES; SITE SELECTION	Polyunsaturated fatty acids inhibit the expression of hepatic glucose-6-phosphate dehydrogenase (G6PD) by changes in the amount of G6PD pre-mRNA in the nucleus in the absence of changes in the transcription rate of the gene. We have compared the nuclear accumulation of partially and fully spliced mRNA for G6PD in the livers of mice fed diets high versus low in polyunsaturated fat. Consumption of a diet high in polyunsaturated fat decreased the accumulation of partially spliced forms of the G6PD pre-mRNA. Examining the fate of multiple introns within the G6PD primary transcript indicated that in mice fed a high fat diet, G6PD pre-mRNA containing intron 11 accumulated within the nucleus, whereas G6PD mature mRNA abundance was inhibited 50% or more within the same livers. Transient transfection of RNA reporters into primary hepatocyte cultures was used to localize the cis-acting RNA element involved in this regulated splicing. Reporter RNA produced from constructs containing exon 12 were decreased in amount by arachidonic acid. The extent of this decrease paralleled that seen in the expression of the endogenous G6PD mRNA. The presence of both exon 12 and a neighboring intron within the G6PD reporter RNA was essential for regulation by polyunsaturated fatty acid. Inhibition was not dependent on the presence of the G6PD polyadenylation signal and the 3'-untranslated region, but substitution with the SV40 poly(A) signal attenuated the inhibition by arachidonic acid. Thus, exon 12 contains a putative splicing regulatory element involved in the inhibition of G6PD expression by polyunsaturated fat.	W Virginia Univ, Hlth Sci Ctr, Sch Med, Dept Mol Pharmacol & Biochem, Morgantown, WV 26506 USA	West Virginia University	Salati, LM (corresponding author), W Virginia Univ, Hlth Sci Ctr, Sch Med, Dept Mol Pharmacol & Biochem, POB 9142, Morgantown, WV 26506 USA.		Stabile, Laura/AAE-9235-2020		NIDDK NIH HHS [R01 DK046897, DK 46897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046897, R56DK046897, R01DK046897] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amir-Ahmady B, 2001, J BIOL CHEM, V276, P10514, DOI 10.1074/jbc.M010535200; Antoniou M, 1998, NUCLEIC ACIDS RES, V26, P721, DOI 10.1093/nar/26.3.721; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BURMEISTER LA, 1991, J BIOL CHEM, V266, P22905; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIEJEK EM, 1982, BIOCHEMISTRY-US, V21, P4945, DOI 10.1021/bi00263a018; Custodio N, 1999, EMBO J, V18, P2855, DOI 10.1093/emboj/18.10.2855; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Hillgartner FB, 1996, BIOCHEM J, V319, P263, DOI 10.1042/bj3190263; Hodge DL, 1997, ARCH BIOCHEM BIOPHYS, V348, P303, DOI 10.1006/abbi.1997.0373; JUMP DB, 1990, J BIOL CHEM, V265, P3474; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; Ke YB, 1996, MOL CELL BIOL, V16, P376; Kim VN, 2001, MOL CELLS, V12, P1; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; MA XJ, 1990, J BIOL CHEM, V265, P18435; McCracken S, 2002, MOL CELL BIOL, V22, P148, DOI 10.1128/MCB.22.1.148-160.2002; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; MOONEY RA, 1981, J BIOL CHEM, V256, P1724; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stabile LP, 1998, J LIPID RES, V39, P1951; Stabile LP, 1996, ARCH BIOCHEM BIOPHYS, V332, P269, DOI 10.1006/abbi.1996.0342; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; Walker JD, 1996, ENDOCRINOLOGY, V137, P2293, DOI 10.1210/en.137.6.2293; Wang J, 2002, J BIOL CHEM, V277, P18489, DOI 10.1074/jbc.M111781200; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111	45	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31270	31278		10.1074/jbc.M203196200	http://dx.doi.org/10.1074/jbc.M203196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12072438	Green Published, hybrid			2022-12-25	WOS:000177579800110
J	Mattiazzi, M; D'Aurelio, M; Gajewski, CD; Martushova, K; Kiaei, M; Beal, MF; Manfredi, G				Mattiazzi, M; D'Aurelio, M; Gajewski, CD; Martushova, K; Kiaei, M; Beal, MF; Manfredi, G			Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU/ZN SUPEROXIDE-DISMUTASE; MOTOR-NEURONS; CU,ZN-SUPEROXIDE DISMUTASE; ANIMAL-CELLS; MUTANT SOD1; RAT-LIVER; DAMAGE; MUTATIONS; ALS	A growing body of evidence suggests that impaired mitochondrial energy production and increased oxidative radical damage to the mitochondria could be causally involved in motor neuron death in amyotrophic lateral sclerosis (ALS) and in familial ALS associated with mutations of Cu,Zn superoxide dismutase (SOD1). For example, morphologically abnormal mitochondria and impaired mitochondrial histoenzymatic respiratory chain activities have been described in motor neurons of patients with sporadic ALS. To investigate further the role of mitochondrial alterations in the pathogenesis of ALS, we studied mitochondria from transgenic mice expressing wild type and G93A mutated hSOD1. We found that a significant proportion of enzymatically active SOD1 was localized in the intermembrane space of mitochondria. Mitochondrial respiration, electron transfer chain, and ATP synthesis were severely defective in G93A mice at the time of onset of the disease. We also found evidence of oxidative damage to mitochondrial proteins and lipids. On the other hand, presymptomatic G93A transgenic mice and mice expressing the wild type form of hSOD1 did not show significant mitochondrial abnormalities. Our findings suggest that G93A-mutated hSOD1 in mitochondria may cause mitochondrial defects, which contribute to precipitating the neurodegenerative process in motor neurons.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA	Cornell University	Manfredi, G (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 525 E 68th St,A-505, New York, NY 10021 USA.				NATIONAL INSTITUTE ON AGING [P01AG012992] Funding Source: NIH RePORTER; NIA NIH HHS [P01-AG12992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS RD, 1997, PRINCIPLES NEUROLOGY, P1089; Andreassen OA, 2001, EXP NEUROL, V168, P356, DOI 10.1006/exnr.2001.7627; Andrus PK, 1998, J NEUROCHEM, V71, P2041; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bendotti C, 2001, J NEUROL SCI, V191, P25, DOI 10.1016/S0022-510X(01)00627-X; Bogdanov M, 2000, FREE RADICAL BIO MED, V29, P652, DOI 10.1016/S0891-5849(00)00349-X; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Browne SE, 1998, J NEUROCHEM, V71, P281; ESTEBAN J, 1994, HUM MOL GENET, V3, P997, DOI 10.1093/hmg/3.6.997; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Fitzmaurice PS, 1996, MUSCLE NERVE, V19, P797; Greenawalt J W, 1974, Methods Enzymol, V31, P310; GREENAWALT JW, 1970, J CELL BIOL, V46, P173, DOI 10.1083/jcb.46.1.173; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; HIGGINS CMJ, 2001, SOC NEUR ABSTR, V31, P580; Jaarsma D, 2000, NEUROBIOL DIS, V7, P623, DOI 10.1006/nbdi.2000.0299; Jaarsma D, 2001, ACTA NEUROPATHOL, V102, P293; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kong JM, 1998, J NEUROSCI, V18, P3241; Kruman II, 1999, EXP NEUROL, V160, P28, DOI 10.1006/exnr.1999.7190; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Liu DX, 1999, FASEB J, V13, P2318, DOI 10.1096/fasebj.13.15.2318; Manfredi G, 2001, METHOD CELL BIOL, V65, P133, DOI 10.1016/S0091-679X(01)65008-8; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAPP PC, 1995, NEUROMUSCULAR DISORD, V5, P353, DOI 10.1016/0960-8966(95)00007-A; Shaw CE, 1998, ANN NEUROL, V43, P390, DOI 10.1002/ana.410430319; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TRITSCHLER HJ, 1991, NEUROLOGY, V41, P300, DOI 10.1212/WNL.41.2_Part_1.300; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	40	450	457	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29626	29633		10.1074/jbc.M203065200	http://dx.doi.org/10.1074/jbc.M203065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050154	hybrid			2022-12-25	WOS:000177509300037
J	Fusaro, G; Wang, S; Chellappan, S				Fusaro, G; Wang, S; Chellappan, S			Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis	ONCOGENE			English	Article						Rb; E2F; prohibitin; apoptosis; cell cycle	RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TRANSCRIPTIONAL ACTIVITY; REPRESS TRANSCRIPTION; CELL-LINES; E2F-1; P53; PHOSPHORYLATION; PROLIFERATION; RECEPTOR	Prohibitin, a potential tumor suppressor, is known to induce growth suppression and repress E2F-mediated transcription. These growth regulatory functions of prohibitin require a physical interaction with the Rb protein. We now find that prohibitin protects cells from apoptosis mediated by camptothecin, a topoisomerase I inhibitor. Camptothecin treatment of Ramos B cells leads to the degradation of Rb protein and phosphorylation of its family members, p107 and p130. This correlates with an increase in the levels of cyclin E as well as the kinase activity associated with it. Inactivation of Rb leads to the dissociation and release of free E2F. We find also that E2F activity is induced upon camptothecin treatment, but this increase is absent in prohibitin overexpressing cells. It thus appears that prohibitin may be inhibiting apoptosis by downregulating E2F activity when Rb family members are inactive.	H Lee Moffit Canc Ctr & Res Inst, Dept Interdiscilinary Oncol, Tampa, FL 33612 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University	Chellappan, S (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Dept Interdiscilinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER; NCI NIH HHS [CA77301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HSEIH JK, 1997, GENE DEV, V11, P1840; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JUPE ER, 1995, EXP CELL RES, V218, P577, DOI 10.1006/excr.1995.1194; KITAGAWA M, 1995, ONCOGENE, V10, P229; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Steglich G, 1999, MOL CELL BIOL, V19, P3435; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	40	85	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4539	4548		10.1038/sj.onc.1205551	http://dx.doi.org/10.1038/sj.onc.1205551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085232				2022-12-25	WOS:000176476700008
J	Degot, S; Regnier, CH; Wendling, C; Chenard, MP; Rio, MC; Tomasetto, C				Degot, S; Regnier, CH; Wendling, C; Chenard, MP; Rio, MC; Tomasetto, C			Metastatic Lymph Node 51, a novel nucleo-cytoplasmic protein overexpressed in breast cancer	ONCOGENE			English	Article						MLN51; breast cancer; SH2; SH3; NLS; coiled-coil	SIGNALING PROTEINS; SH3 DOMAINS; MAMMALIAN-CELLS; FACTOR RECEPTOR; COILED COILS; IDENTIFICATION; CARCINOMA; DNA; LOCALIZATION; PRECURSOR	Metastatic Lymph Node 51 (MLN51) cDNA was isolated by differential screening of a human breast cancer metastasis cDNA library. MLN51 cDNA encodes a novel human protein of 703 residues that shares no significant homology to any known protein. However MLN51 is well conserved between vertebrate and invertebrate species suggesting an important biological function. The amino terminal half of the protein contains a coiled-coil domain and two potential nuclear localization signals (NLS). The carboxy terminal half contains one SH2 and four SH3 binding motifs. The coiled-coil domain promotes MLN51 oligomerization in transfected cells. When transiently expressed, the MLN51 protein is mainly found in the cytoplasm with a weak nuclear staining. However, deletion of the carboxy terminal half of the protein allows the targeting of the protein to the nucleus, demonstrating that the NLSs are functional. MLN51 is ubiquitously expressed in normal tissues. Human breast carcinomas show MLN51 overexpression in malignant epithelial cells. The uncommon association of protein-protein interaction domains often found either in nuclear or in cytoplasmic signaling proteins raises a possible nucleo-cytoplasmic function for MLN51.	Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, F-67404 Illkirch Graffenstaden, CU De Strasbour, France; CHU Hautepierre, Serv Anat Pathol Gen, F-67098 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg	Tomasetto, C (corresponding author), Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, CU De Strasbour, France.	cat@igbmc.u-strasburg.fr	Chenard, Marie-Pierre/O-2373-2016; Tomasetto, Catherine Laure/J-2783-2014	Tomasetto, Catherine Laure/0000-0002-1811-5848; Regnier, Catherine/0000-0002-4386-1324				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Bieche I, 1996, CANCER RES, V56, P3886; Boyle P, 2000, INT J GYNECOL OBSTET, V70, P263, DOI 10.1016/S0020-7292(00)00298-8; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Klapper LN, 2000, ADV CANCER RES, V77, P25; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Liotta LA, 2001, NATURE, V410, P24, DOI 10.1038/35065180; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mayer BJ, 2001, J CELL SCI, V114, P1253; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; SHOEMAN RL, 1993, BIOESSAYS, V15, P605, DOI 10.1002/bies.950150906; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tanaka S, 1997, CANCER RES, V57, P28; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Yan YT, 2000, MOL CELL BIOL, V20, P661, DOI 10.1128/MCB.20.2.661-671.2000; Yu DL, 2000, CHINESE PHYS LETT, V17, P19, DOI 10.1088/0256-307X/17/1/007; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4422	4434		10.1038/sj.onc.1205611	http://dx.doi.org/10.1038/sj.onc.1205611			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080473				2022-12-25	WOS:000176317100008
J	Velazquez, OC; Snyder, R; Liu, ZJ; Fairman, RM; Herlyn, M				Velazquez, OC; Snyder, R; Liu, ZJ; Fairman, RM; Herlyn, M			Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like, three-dimensional networks	FASEB JOURNAL			English	Article						endothelium; angiogenesis; capillary networks; VEGF; angiopoietin-1	ANGIOGENESIS IN-VITRO; GROWTH-FACTORS; INDUCTION; SURVIVAL	An in vitro model has been developed to study migration, survival, proliferation, and capillary-like differentiation of human microvascular endothelial cells (HMVECs) in an environment that avoids tumor promoters and complex matrices. HMVEC monolayers were plated, then induced to form three-dimensional, capillary-like networks by overlaying with human type I collagen followed by a second overlay of collagen with embedded fibroblasts. Detachment and migration of endothelial cells into the matrix was triggered within hours by the overlaying collagen, and the fibroblasts stimulated survival and formation of cords, vacuoles, tubes, and, after 4 to 5 days, capillary networks. The differentiation into branching capillary-like structures was dependent on direct fibroblast-endothelial cell contact and was not achieved when fibroblasts were replaced by seven types of melanoma cells, which included radial and vertical growth phase primary and metastatic stages. Vascular endothelial growth factor (VEGF), when overexpressed in fibroblasts, stimulated endothelial cell proliferation and migration, whereas angiopoietin-1 (Ang-1) had only motogenic effects. Neutralizing antibodies against VEGF and blocking antibodies for VEGF-receptor 2 (VEGFR2) significantly inhibited but not completely obliterated capillary network formation, suggesting that the VEGF signaling pathway is important but not exclusive and that other fibroblast-derived soluble factors and fibroblast-endothelial cell contact are essential for endothelial cell survival and differentiation.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Surg, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu						Black AF, 1999, CELL BIOL TOXICOL, V15, P81, DOI 10.1023/A:1007541713398; Blau HM, 2001, NAT MED, V7, P532, DOI 10.1038/87850; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hicklin DJ, 2001, DRUG DISCOV TODAY, V6, P517, DOI 10.1016/S1359-6446(01)01759-7; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; Hoying JB, 1996, IN VITRO CELL DEV-AN, V32, P409; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; IMCKE E, 1991, ARCH DERMATOL RES, V283, P149, DOI 10.1007/BF00372054; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; JACKSON CJ, 1991, EXP CELL RES, V192, P319, DOI 10.1016/0014-4827(91)90194-Y; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LATERRA J, 1990, J CELL PHYSIOL, V144, P204, DOI 10.1002/jcp.1041440205; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1993, J CELL SCI, V105, P1013; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Pinney E, 2000, J CELL PHYSIOL, V183, P74, DOI 10.1002/(SICI)1097-4652(200004)183:1<74::AID-JCP9>3.0.CO;2-G; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7	33	106	117	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1316	+		10.1096/fj.01-1011fje	http://dx.doi.org/10.1096/fj.01-1011fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060671				2022-12-25	WOS:000176683900031
J	Blanco, MJ; Moreno-Bueno, G; Sarrio, D; Locascio, A; Cano, A; Palacios, J; Nieto, MA				Blanco, MJ; Moreno-Bueno, G; Sarrio, D; Locascio, A; Cano, A; Palacios, J; Nieto, MA			Correlation of Snail expression with histological grade and lymph node status in breast carcinomas	ONCOGENE			English	Article						Snail; E-cadherin; breast carcinoma; invasive ductal carcinomas; lobular carcinoma	E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; NEURAL CREST; IN-SITU; VERTEBRATE DEVELOPMENT; LOBULAR CARCINOMA; GENE-EXPRESSION; BETA-CATENIN; CHICK; TISSUE	Snail is a zinc finger transcription factor that triggers the epithelial-mesenchymal transition (EMT) by directly repressing E-cadherin expression. Snail is required for mesoderm and neural crest formation during embryonic development and has recently been implicated in the EMT associated with tumour progression. In a series of human breast carcinomas, we have analysed the expression of Snail and that of molecules of the E-cadherin/catenin complexes. We have also correlated these data with the pathological features of the tumours. We show that Snail expression inversely correlates with the grade of differentiation of the tumours and that it is expressed in all the infiltrating ductal carcinomas (IDC) presenting lymph node metastases that were analysed. In addition, Snail is expressed in some dedifferentiated tumours with a negative nodal status. Considering that Snail is involved in the induction of the invasive and migratory phenotype in epithelial cells, these results indicate that it is also involved in the progression of breast ductal tumours, where it could additionally serve as a marker of the metastatic potential.	CSIC, Inst Cajal, E-28002 Madrid, Spain; Ctr Nacl Invest Oncol, Programa Patol Mol, Madrid, Spain; Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Nieto, MA (corresponding author), CSIC, Inst Cajal, Doctor Arce 37, E-28002 Madrid, Spain.	anieto@cajal.csic.es	Locascio, Annamaria/E-8714-2015; Nieto, M. Angela/A-6531-2008; Palacios, Jose/AAV-3765-2020; Moreno-Bueno, Gema/K-9354-2016; SARRIO, DAVID/Y-8903-2019	Locascio, Annamaria/0000-0001-6956-2157; Nieto, M. Angela/0000-0002-3538-840X; Moreno-Bueno, Gema/0000-0002-5030-6687; Sarrio, David/0000-0003-4886-8290				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1996, ONCOGENE, V13, P1919; Bukholm IK, 2000, J PATHOL, V190, P15; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; GAMALLO C, 1993, AM J PATHOL, V142, P987; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; GRAU Y, 1984, GENETICS, V108, P347; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; KOHN EC, 1995, CANCER RES, V55, P1856; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; Locascio A, 2001, CURR OPIN GENET DEV, V11, P464, DOI 10.1016/S0959-437X(00)00218-5; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; PALACIOS J, 1995, AM J PATHOL, V146, P605; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Ros MA, 1997, DEVELOPMENT, V124, P1821; Sefton M, 1998, DEVELOPMENT, V125, P3111; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Van Diest PJ, 1999, J PATHOL, V187, P383, DOI 10.1002/(SICI)1096-9896(199903)187:4<383::AID-PATH299>3.0.CO;2-H; Vos CBJ, 1997, BRIT J CANCER, V76, P1131, DOI 10.1038/bjc.1997.523; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2	30	466	502	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3241	3246		10.1038/sj.onc.1205416	http://dx.doi.org/10.1038/sj.onc.1205416			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082640				2022-12-25	WOS:000175373600016
J	Caballero, OL; Resto, V; Patturajan, M; Meerzaman, D; Guo, MZ; Engles, J; Yochem, R; Ratovitski, E; Sidransky, D; Jen, J				Caballero, OL; Resto, V; Patturajan, M; Meerzaman, D; Guo, MZ; Engles, J; Yochem, R; Ratovitski, E; Sidransky, D; Jen, J			Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1)	ONCOGENE			English	Article						PGP9.5/UCH-L1; JAB1; p27(Kip1); lung cancer; nuclear localization; yeast two-hybrid system	DEUBIQUITINATING ENZYMES; CELL-CYCLE; CDK INHIBITOR; PROTEIN; P27; DEGRADATION; SPECIFICITY; EXPRESSION; PREDICTOR; COMPLEX	PGP9.5 (UCH-L1) is a member of the ubiquitin C-terminal hydrolase (UCH) family of proteins that is expressed in neuronal tissues. Our previous studies have shown that PGP9.5 was highly expressed in primary lung cancers and lung cancer cell lines. Additionally, the frequency of PGP9.5 over expression increases with tumor stage, indicating that PGP9.5 may play a role in lung cancer tumorigenesis. We used the yeast two-hybrid system to identify proteins that interact with PGP9.5. We show that PGP9.5 interacts with at least three proteins, one of which is JAB1, a Jun activation domain binding protein that can bind to p27(Kip1) and is involved in the cytoplasmic transportation of p27(Kip1) for its degradation. We also show that PGP9.5 is associated with JAB1 in vitro and in vivo; and that both proteins can be a part of a heteromeric complex containing p27(Kip1) in the nucleus in lung cancer cells. Furthermore, under serum-restimulation, nuclear translocation of both PGP9.5 and JAB1 coincides with a reduced level of P27(Kip1) in the nucleus. In contrast, when cells are contact inhibited, both PGP9.5 and JAB1 became more perinuclear and cytoplasmic in localization while p27(Kip1) was present only in the nucleus. Therefore, PGP9.5 may contribute to p27(Kip1) degradation via its interaction and nuclear translocation with JAB1.	NCI, Lab Populat Genet, Ctr Canc Res, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Jen, J (corresponding author), NCI, Lab Populat Genet, Ctr Canc Res, Bldg 41,Rm D702,41 Lib Dr, Bethesda, MD 20892 USA.	jenj@mail.nih.gov	Resto, Vicente/D-9891-2014		NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Ciechanover A, 2000, J CELL BIOCHEM, P40; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Hibi K, 1998, CANCER RES, V58, P5690; Hirano K, 2000, CANCER DETECT PREV, V24, P343; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hommura F, 2000, CLIN CANCER RES, V6, P4073; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; James P, 1996, GENETICS, V144, P1425; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yao J, 2000, INT J CANCER, V89, P213, DOI 10.1002/1097-0215(20000520)89:3<213::AID-IJC1>3.0.CO;2-L	33	95	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3003	3010		10.1038/sj.onc.1205390	http://dx.doi.org/10.1038/sj.onc.1205390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082530	Bronze			2022-12-25	WOS:000175262700007
J	Jullien, J; Guili, V; Reichardt, LF; Rudkin, BB				Jullien, J; Guili, V; Reichardt, LF; Rudkin, BB			Molecular kinetics of nerve growth factor receptor trafficking and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; TYROSINE KINASE; PC12 CELLS; NEUROTROPHIN RECEPTOR; TRK RECEPTORS; PHEOCHROMOCYTOMA CELLS; COMPARTMENTED CULTURES; RETROGRADE TRANSPORT; PLASMA-MEMBRANE; SENSORY NEURONS	A growing body of evidence indicates a close relationship between tyrosine kinase receptor trafficking and signaling. Biochemical and molecular analyses of the expression, fate, and kinetics of membrane trafficking of the nerve growth factor (NGF) receptor TrkA were performed in PC12 cells. Pulse-chase experiments indicate that TrkA is synthesized as a 110-kDa N-glycosylated precursor that leads to the mature 140-kDa form of the receptor with a half-life of conversion of similar to24 +/- 0.5 min. Neuraminidase digestion shows that modification of the carbohydrate moiety of the receptor by sialylation occurs during maturation. The 140-kDa form is rapidly translocated to the cell surface as assessed by cell surface biotinylation performed on intact PC12 cells. Mature receptor half-life is similar to138 +/- 4 min and is shortened to 86 +/- 8 min by NGF treatment. Flow cytometric analysis indicates that NGF induces clearing of this receptor from the cell surface within minutes of treatment. The addition of NGF decreases the half-life of cell surface gp140(TrkA) from 100 to 35 min and leads to enhanced lysosomal degradation of the receptor. The process of NGF-induced TrkA internalization is clearly affected by interfering with ligand binding to p75(NTR). An analysis of receptor activation kinetics also shows that receptor signaling primarily takes place from an intracellular location. Together, these data show that the primary effect of NGF treatment is a p75(NTR)-modulated decrease in TrkA transit time at the cell surface.	Ecole Normale Super Lyon, CNRS, Biol Cellulaire & Mol Lab, UMR 5665, F-69364 Lyon 07, France; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Howard Hughes Medical Institute; University of California System; University of California San Francisco	Rudkin, BB (corresponding author), Ecole Normale Super Lyon, CNRS, Biol Cellulaire & Mol Lab, UMR 5665, 46 Allee Italie, F-69364 Lyon 07, France.		jerome, jullien/K-5565-2019; jullien, jerome/AAC-1887-2022	jerome, jullien/0000-0002-7868-0021; RUDKIN, Brian B./0000-0003-3700-1982	NIMH NIH HHS [P50 MH048200-090005] Funding Source: Medline; NINDS NIH HHS [NS 16033] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016033, P01NS016033] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arenas MI, 2001, J ANDROL, V22, P79; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BEJCEK BE, 1993, BIOCHEM BIOPH RES CO, V196, P69, DOI 10.1006/bbrc.1993.2217; Bhattacharyya A, 1997, J NEUROSCI, V17, P7007; Burrone J, 2001, CURR BIOL, V11, pR274, DOI 10.1016/S0960-9822(01)00137-3; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; EHLERS MD, 1995, J CELL BIOL, V130, P149, DOI 10.1083/jcb.130.1.149; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; EVELETH DD, 1992, J CELL BIOL, V117, P291, DOI 10.1083/jcb.117.2.291; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; Gargano N, 1997, J NEUROSCI RES, V50, P1; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes ML, 1997, P NATL ACAD SCI USA, V94, P9909, DOI 10.1073/pnas.94.18.9909; Grimes ML, 1996, J NEUROSCI, V16, P7950; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; HUANG SS, 1990, J BIOL CHEM, V265, P3340; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; KAHLE P, 1994, J NEUROSCI RES, V38, P599, DOI 10.1002/jnr.490380512; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KEATING MT, 1987, J BIOL CHEM, V262, P7932; Keller P, 1997, J CELL SCI, V110, P3001; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kimpinski K, 1999, NEUROSCIENCE, V93, P253, DOI 10.1016/S0306-4522(99)00156-6; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Mischel PS, 2001, J BIOL CHEM, V276, P11294, DOI 10.1074/jbc.M005132200; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Patel TD, 2000, NEURON, V25, P345, DOI 10.1016/S0896-6273(00)80899-5; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Reynolds AJ, 2000, BRAIN RES REV, V33, P169, DOI 10.1016/S0165-0173(00)00028-X; Rohn WM, 2000, J CELL SCI, V113, P2093; Ross AH, 1996, J CELL BIOL, V132, P945, DOI 10.1083/jcb.132.5.945; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Senger DL, 1997, J CELL BIOL, V138, P411, DOI 10.1083/jcb.138.2.411; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; Supino-Rosin L, 1999, EUR J BIOCHEM, V263, P410, DOI 10.1046/j.1432-1327.1999.00516.x; Urdiales JL, 1998, J NEUROSCI, V18, P6767; Ure DR, 1997, J NEUROSCI, V17, P1282; van Weering DHJ, 1998, J BIOL CHEM, V273, P12077, DOI 10.1074/jbc.273.20.12077; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wolf DE, 1998, BIOCHEMISTRY-US, V37, P3178, DOI 10.1021/bi9719253; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000; ZHOU J, 1995, J NEUROCHEM, V65, P1146	66	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38700	38708		10.1074/jbc.M202348200	http://dx.doi.org/10.1074/jbc.M202348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12055187	Green Accepted, hybrid			2022-12-25	WOS:000178529600088
J	Monick, MM; Robeff, PK; Butler, NS; Flaherty, DM; Carter, AB; Peterson, MW; Hunninghake, GW				Monick, MM; Robeff, PK; Butler, NS; Flaherty, DM; Carter, AB; Peterson, MW; Hunninghake, GW			Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN ALVEOLAR MACROPHAGES; NF-KAPPA-B; PROSTAGLANDIN-H SYNTHASE-2; MESSENGER-RNA STABILITY; GENE-EXPRESSION; SIGNALING PATHWAY; CARCINOMA CELLS; TERMINAL KINASE; P38	Human alveolar macrophages have both lipopolysaccharide (LPS)-induced and constitutive phosphatidylinositol 3-kinase (PI3K) activity. We observed that blocking PI3K activity increased release of prostaglandin E2 after LPS exposure, and increasing PI3K activity (interleukin-13) decreased release of prostaglandin E2 after LPS exposure. This was not because of an effect of PI3K on phospholipase 2 activity. PI3K inhibition resulted in an increase in cyclooxygenase 2 (COX2) protein, mRNA, and mRNA stability. PI3K negatively regulated activation of the p38 pathway (p38, MKK3/6, and MAPKAP2), and an active p38 was necessary for COX2 production. The data suggest that PI3K inhibition of p38 modulates COX2 expression via destabilization of LPS-induced COX2 mRNA.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, EMRB, Iowa City, IA 52242 USA; Univ Iowa, Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Monick, MM (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, EMRB, Rm 100, Iowa City, IA 52242 USA.			Butler, Noah/0000-0002-1429-0796	NCRR NIH HHS [RR00059] Funding Source: Medline; NHLBI NIH HHS [HL-60316, HL-03860] Funding Source: Medline; NIEHS NIH HHS [ES-09607] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009607] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Berg DJ, 2001, J IMMUNOL, V166, P2674, DOI 10.4049/jimmunol.166.4.2674; Blum S, 2001, J BIOL CHEM, V276, P33428, DOI 10.1074/jbc.M105474200; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Carter AB, 2001, J BIOL CHEM, V276, P33826, DOI 10.1074/jbc.M100209200; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Hempel SL, 1996, AM J RESP CELL MOL, V14, P170, DOI 10.1165/ajrcmb.14.2.8630267; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HEMPEL SL, 1994, J BIOL CHEM, V269, P32979; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; MATHUR SN, 1985, BIOCHIM BIOPHYS ACTA, V837, P13, DOI 10.1016/0005-2760(85)90080-3; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; MONICK M, 1987, AM REV RESPIR DIS, V135, P72; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; Monick MM, 2001, J IMMUNOL, V166, P4713, DOI 10.4049/jimmunol.166.7.4713; Monick MM, 2001, J IMMUNOL, V167, P5977, DOI 10.4049/jimmunol.167.10.5977; Ozes ON, 1999, NATURE, V401, P82; Pahan K, 2000, J NEUROCHEM, V75, P576, DOI 10.1046/j.1471-4159.2000.0750576.x; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 2001, CANCER RES, V61, P2670; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Tang QB, 2001, CANCER RES, V61, P4329; Thomas KW, 2002, J BIOL CHEM, V277, P492, DOI 10.1074/jbc.M108107200; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weaver SA, 2001, GASTROENTEROLOGY, V120, P1117, DOI 10.1053/gast.2001.23257; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; Zhou JH, 2001, J IMMUNOL, V167, P4436, DOI 10.4049/jimmunol.167.8.4436	61	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32992	33000		10.1074/jbc.M203218200	http://dx.doi.org/10.1074/jbc.M203218200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12072439	hybrid			2022-12-25	WOS:000177859000079
J	Boudreau, F; Rings, EHHM; van Wering, HM; Kim, RK; Swain, GP; Krasinski, SD; Moffett, J; Grand, RJ; Suh, ER; Traber, PG				Boudreau, F; Rings, EHHM; van Wering, HM; Kim, RK; Swain, GP; Krasinski, SD; Moffett, J; Grand, RJ; Suh, ER; Traber, PG			Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription - Implication for the developmental regulation of the sucrose-isomaltase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART TUBE FORMATION; RAT SMALL-INTESTINE; CRYPT-VILLUS AXIS; EPITHELIAL-CELLS; VENTRAL MORPHOGENESIS; TRANSGENIC MICE; EXPRESSION; DIFFERENTIATION; HNF-1-ALPHA; ACTIVATION	Sucrase-isomaltase (SI), an intestine-specific gene, is induced in the differentiated small intestinal villous epithelium during the suckling-weaning transition in mice. We have previously identified cis-acting elements within a short evolutionarily conserved SI promoter. However, the nature and profile of expression of the interacting proteins have not been fully characterized during this developmental transition. Herein, we show that hepatocyte nuclear factor-1alpha (HNF-1alpha), GATA-4, and caudal related homeodomain proteins Cdx2 and Cdx1 are the primary transcription factors from the adult mouse intestinal epithelium to interact with the SIF3, GATA, and SIF1 elements of the SI promoter. We wanted to study whether HNF-1alpha, GATA-4, and Cdx2 can cooperate in the regulation of SI gene expression. Immunolocalization experiments revealed that HNF-1alpha is detected in rare epithelial cells of suckling mice and becomes progressively more expressed in the villous epithelial cells during the suckling-weaning transition. GATA-4 protein is expressed exclusively in villous differentiated epithelial cells of the proximal small intestine, decreases in expression in the ileum, and becomes undetectable in the colon. HNF-1alpha, GATA-4, and Cdx2 interact in vitro and in vivo. These factors activate SI promoter activity in cotransfection experiments where GATA-4 requires the presence of both HNF-1alpha and Cdx2. These findings imply a combinatory role of HNF-1alpha, Cdx2, and GATA-4 for the time- and position-dependent regulation of SI transcription during development.	Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Acad Hosp Groningen, Div Pediat Gastroenterol, Dept Pediat, NL-9700 RB Groningen, Netherlands; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Free Univ Amsterdam, Sch Med, NL-1081 HV Amsterdam, Netherlands	University of Pennsylvania; University of Groningen; Harvard University; Boston Children's Hospital; Harvard Medical School; Vrije Universiteit Amsterdam	Traber, PG (corresponding author), 709 Swedeland Rd,POB 1539, King Of Prussia, PA 19406 USA.		Rings, Edmond/ABE-5731-2021	Rings, Edmond/0000-0001-8195-4356	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032658, R01DK047437, P30DK050306, R01DK046704] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK32658-19, R01-DK46704, R01-DK47437, P30-DK50306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BOLL W, 1993, J BIOL CHEM, V268, P12901; Boudreau F, 1998, DNA CELL BIOL, V17, P669, DOI 10.1089/dna.1998.17.669; Boudreau F, 2002, MOL CELL BIOL, V22, P5467, DOI 10.1128/MCB.22.15.5467-5478.2002; Boudreau F, 2001, J BIOL CHEM, V276, P32122, DOI 10.1074/jbc.M102002200; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BURGLIN TR, 1994, COMPREHENSIVE CLASSI; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Fitzgerald K, 1998, AM J PHYSIOL-GASTR L, V274, pG314, DOI 10.1152/ajpgi.1998.274.2.G314; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Jacobsen CM, 2002, DEV BIOL, V241, P34, DOI 10.1006/dbio.2001.0424; JAMES R, 1994, J BIOL CHEM, V269, P15229; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; KRASINSKI SD, 1994, AM J PHYSIOL-GASTR L, V267, pG584, DOI 10.1152/ajpgi.1994.267.4.G584; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Montgomery RK, 1999, GASTROENTEROLOGY, V116, P702, DOI 10.1016/S0016-5085(99)70193-9; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Opitz OG, 2000, CANCER RES, V60, P2825; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Rhoads DB, 1998, J BIOL CHEM, V273, P9510, DOI 10.1074/jbc.273.16.9510; RINGS EHHM, 1994, GASTROENTEROLOGY, V106, P1223, DOI 10.1016/0016-5085(94)90013-2; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tamai Y, 1999, CANCER RES, V59, P2965; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Traber Peter G., 1995, P21; Traber PG, 1998, PHILOS T ROY SOC B, V353, P911, DOI 10.1098/rstb.1998.0255; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRABER PG, 1992, AM J PHYSIOL, V262, pG123, DOI 10.1152/ajpgi.1992.262.1.G123; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; WU GD, 1994, J BIOL CHEM, V269, P17080; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	60	199	203	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31909	31917		10.1074/jbc.M204622200	http://dx.doi.org/10.1074/jbc.M204622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12060663	hybrid			2022-12-25	WOS:000177718700077
J	Goerke, A; Sakai, N; Gutjahr, E; Schlapkohl, WA; Mushinski, JF; Haller, H; Kolch, W; Saito, N; Mischak, H				Goerke, A; Sakai, N; Gutjahr, E; Schlapkohl, WA; Mushinski, JF; Haller, H; Kolch, W; Saito, N; Mischak, H			Induction of apoptosis by protein kinase C delta is independent of its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; CYTOCHROME-C; PROTEOLYTIC ACTIVATION; NUCLEAR TRANSLOCATION; PKC-DELTA; CELLS; CASPASES; EPSILON; DIFFERENTIATION; PHOSPHORYLATION	Protein kinase C, a multigene family of phospholipid-dependent and diacylglycerol-activated Ser/Thr protein kinases, is a key component in many signal transduction pathways. The kinase activity was thought to be essential for a plethora of biological processes attributed to these enzymes. Here we show that at least one protein kinase C function, the induction of apoptosis by protein kinase Cdelta, is independent of the kinase activity. Stimulation of green fluorescent protein-protein kinase Cdelta fusion protein with phorbol ester or diacylglycerol led to its redistribution within seconds after the stimulus. Membrane blebbing, an early hallmark of apoptosis, was visible as early as 20 min after stimulation, and nuclear condensation was visible after 3-5 h. Apoptosis could be inhibited by expression of Bcl-2 but not by specific protein kinase C inhibitors. In addition, a kinase-negative mutant of protein kinase CS also induced apoptosis to the same extent as the wild type enzyme. Apoptosis was confined to the protein kinase Cdelta-overexpressing cells. Stimulation of overexpressed protein kinase Cepsilon did not result in increased apoptosis. Our results indicate that distinct protein kinase C isozymes induce apoptosis in vascular smooth muscle cells. More importantly, they show that some protein kinase C effector functions are independent of the catalytic activity.	Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany; Kobe Univ, Mol Pharmacol Lab, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; NCI, Genet Lab, NIH, Bethesda, MD 20892 USA; CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Hannover Medical School; Kobe University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Beatson Institute	Mischak, H (corresponding author), Hannover Med Sch, Dept Nephrol, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022; Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306; Kolch, Walter/0000-0001-5777-5016				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ASSENDER JW, 1994, FEBS LETT, V342, P76, DOI 10.1016/0014-5793(94)80588-1; CACACE AM, 1993, ONCOGENE, V8, P2095; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Hong F, 2000, BIOCHEM BIOPH RES CO, V279, P974, DOI 10.1006/bbrc.2000.4044; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Musashi M, 2000, INT J HEMATOL, V72, P12; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Romanova LY, 1996, BIOCHEMISTRY-US, V35, P9900, DOI 10.1021/bi9525886; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Ware Carl F., 1998, P549; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Webb PR, 2000, APOPTOSIS, V5, P451, DOI 10.1023/A:1009601220552; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175	47	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32054	32062		10.1074/jbc.M203734200	http://dx.doi.org/10.1074/jbc.M203734200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12055197	hybrid			2022-12-25	WOS:000177718700094
J	Quadrini, KJ; Bieker, JJ				Quadrini, KJ; Bieker, JJ			Kruppel-like zinc fingers bind to nuclear import proteins and are required for efficient nuclear localization of erythroid Kruppel-like Factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; TRANSCRIPTION FACTOR; FACTOR EKLF; ALPHA-SUBUNIT; NUCLEOCYTOPLASMIC TRANSPORT; GLUCOCORTICOID RECEPTOR; VIRUS NUCLEOPROTEIN; KARYOPHERIN-ALPHA; BETA-THALASSEMIA; T-ANTIGEN	Erythroid Kruppel-like Factor (EKLF/KLF-1) is an erythroid-specific transcription factor that contains three C2H2 zinc fingers and is required for correct chromatin structure and expression of the beta-globin locus. However, regions within the EKLF protein that serve as signals for its nuclear localization and the proteins that may enable it to become localized are unknown. Two approaches were used to address these issues. First, green fluorescent protein or pyruvate kinase was fused to EKLF domains, and localization was monitored and quantitated by confocal microscopy. Two necessary and sufficient nuclear localization signals (NLSs) were identified: one (NLS1) adjacent to the zinc finger DNA binding domain within a highly basic stretch of amino acids (275-296), and another more efficient signal (NLS2) within the zinc finger domain itself (amino acids 293376). Interestingly, each zinc finger contributes to the overall effectiveness of NLS2 and requires an intact finger structure. Second, each NLS was tested in vitro for binding to importin proteins. Surprisingly, both EKLF NLSs, but principally the zinc finger domain, bind importin a and importin beta. These findings demonstrate that two nuclear localization signals target EKLF to the nucleus and suggest this transport relies primarily on a novel zinc finger/importin protein interaction.	CUNY Mt Sinai Sch Med, Dept Cell Mol & Dev Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Bieker, JJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Cell Mol & Dev Biol, Box 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCRR NIH HHS [1 S10 RR0 9145-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK46865] Funding Source: Medline; NIGMS NIH HHS [T32 GM08553] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008553] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen XY, 2001, MOL CELL BIOL, V21, P3118, DOI 10.1128/MCB.21.9.3118-3125.2001; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Claussen M, 1999, J BIOL CHEM, V274, P33951, DOI 10.1074/jbc.274.48.33951; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DAVEY J, 1985, CELL, V40, P667, DOI 10.1016/0092-8674(85)90215-6; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; FENG WC, 1994, J BIOL CHEM, V269, P1493; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUIOCHONMANTEL A, 1992, J STEROID BIOCHEM, V41, P209; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kamei Y, 1999, J HISTOCHEM CYTOCHEM, V47, P363, DOI 10.1177/002215549904700310; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; MATHENY C, 1994, J BIOL CHEM, V269, P8176; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Prieve MG, 1998, MOL CELL BIOL, V18, P4819, DOI 10.1128/MCB.18.8.4819; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHMID W, 1995, J STEROID BIOCHEM, V53, P33, DOI 10.1016/0960-0760(95)00038-2; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Southwood CM, 1996, DEV DYNAM, V206, P248, DOI 10.1002/(SICI)1097-0177(199607)206:3<248::AID-AJA3>3.0.CO;2-I; Tsuji L, 1997, FEBS LETT, V416, P30, DOI 10.1016/S0014-5793(97)01092-2; Wang P, 1997, J VIROL, V71, P1850, DOI 10.1128/JVI.71.3.1850-1856.1997; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001	58	58	58	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32243	32252		10.1074/jbc.M205677200	http://dx.doi.org/10.1074/jbc.M205677200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12072445	hybrid			2022-12-25	WOS:000177718700118
J	Akal-Strader, A; Khare, S; Xu, D; Naider, F; Becker, JM				Akal-Strader, A; Khare, S; Xu, D; Naider, F; Becker, JM			Residues in the first extracellular loop of a G protein-coupled receptor play a role in signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; DOMINANT-NEGATIVE MUTATIONS; SITE-SPECIFIC MUTAGENESIS; AFFINITY HORMONE-BINDING; TRANSMEMBRANE DOMAIN 6; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; MATING PHEROMONE; DIRECT IDENTIFICATION; SCANNING MUTAGENESIS	The Saccharomyces cerevisiae pheromone, alpha-factor (WHWLQLKPGQPMY), and Ste2p, its G protein-coupled receptor, were used as a model system to study ligand-receptor interaction. Cys-scanning mutagenesis on each residue of EL1, the first extracellular loop of Ste2p, was used to generate a library of 36 mutants with a single Cys residue substitution. Mutation of most residues of EL1 had only negligible effects on ligand affinity and biological activity of the mutant receptors. However, five mutants were identified that were either partially (L102C and T114C) or severely (N105C, S108C, and Y111C) compromised in signaling but retained binding affinities similar to those of wild-type receptor. Three-dimensional modeling, secondary structure predictions, and subsequent circular dichroism studies on a synthetic peptide with amino acid sequence corresponding to EL1 suggested the presence of a helix corresponding to EL1 residues 106 to 114 followed by two short beta-strands (residues 126 to 135). The distinctive periodicity of the five residues with a signal-deficient phenotype combined with biophysical studies suggested a functional involvement in receptor activation of a face on a 3(10) helix in this region of EL1. These studies indicate that EL1 plays an important role in the conformational switch that activates the Ste2p receptor to initiate the mating pheromone signal transduction pathway.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA; Univ Tennessee, Oak Ridge Natl Lab, Genome Sci & Technol Grad Sch, Oak Ridge, TN 37830 USA; CUNY Grad Sch & Univ Ctr, Program Biochem & Chem, New York, NY 10016 USA	University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; College of Staten Island (CUNY); United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; City University of New York (CUNY) Graduate School	Becker, JM (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.	jbecker@utk.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM022086, R56GM022087, R01GM022086, R01GM022087] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22087, GM 22086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MG, 1998, BBA-MOL CELL RES, V1448, P12, DOI 10.1016/S0167-4889(98)00109-8; Abel MG, 1998, J PEPT RES, V52, P95; Audoly L, 1997, J BIOL CHEM, V272, P13475, DOI 10.1074/jbc.272.21.13475; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Banuett F, 1998, MICROBIOL MOL BIOL R, V62, P249, DOI 10.1128/MMBR.62.2.249-274.1998; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Blackhart BD, 2000, MOL PHARMACOL, V58, P1178, DOI 10.1124/mol.58.6.1178; BLUMER KJ, 1988, COLD SPRING HARB SYM, V53, P591, DOI 10.1101/SQB.1988.053.01.068; Boucard AA, 2000, BIOCHEMISTRY-US, V39, P9662, DOI 10.1021/bi000597v; Carpenter KA, 1999, BIOCHEMISTRY-US, V38, P15295, DOI 10.1021/bi991081i; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARK CD, 1994, J BIOL CHEM, V269, P8831; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; David NE, 1997, J BIOL CHEM, V272, P15553, DOI 10.1074/jbc.272.24.15553; Ding FX, 2001, BIOCHEMISTRY-US, V40, P1102, DOI 10.1021/bi0021535; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Dosil M, 2000, MOL CELL BIOL, V20, P5321, DOI 10.1128/MCB.20.14.5321-5329.2000; Dosil M, 1998, MOL CELL BIOL, V18, P5981, DOI 10.1128/MCB.18.10.5981; Dowell SJ, 2001, DRUG DISCOV TODAY, V6, P884, DOI 10.1016/S1359-6446(01)01936-5; Dube P, 1998, MOL CELL BIOL, V18, P7205, DOI 10.1128/MCB.18.12.7205; Dube P, 2000, J BIOL CHEM, V275, P26492, DOI 10.1074/jbc.M002767200; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Giragossian C, 2001, BIOCHEMISTRY-US, V40, P3804, DOI 10.1021/bi002659n; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Han KH, 1999, J BIOL CHEM, V274, P32055, DOI 10.1074/jbc.274.45.32055; Henry LK, 2002, BIOCHEMISTRY-US, V41, P6128, DOI 10.1021/bi015863z; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; Iwaki S, 2000, J BIOL CHEM, V275, P22704, DOI 10.1074/jbc.M910354199; Javitch JA, 1999, BIOCHEMISTRY-US, V38, P7961, DOI 10.1021/bi9905314; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; KONOPKA JB, 1992, ANTON LEEUW INT J G, V62, P95, DOI 10.1007/BF00584465; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; Leavitt LM, 1999, MOL GEN GENET, V261, P917, DOI 10.1007/s004380051039; Lee BK, 2001, J BIOL CHEM, V276, P37950; Lefkowitz RJ, 2000, NAT CELL BIOL, V2, pE133, DOI 10.1038/35017152; Liu S, 2000, J PEPT RES, V56, P24, DOI 10.1034/j.1399-3011.2000.00730.x; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Marshall GR, 2001, BIOPOLYMERS, V60, P246, DOI 10.1002/1097-0282(2001)60:3<246::AID-BIP10044>3.0.CO;2-V; Martin NP, 1999, BIOCHEMISTRY-US, V38, P682, DOI 10.1021/bi982062w; Martin NP, 2002, J MOL BIOL, V317, P765, DOI 10.1006/jmbi.2002.5444; Mentesana PE, 2001, BIOCHEMISTRY-US, V40, P9685, DOI 10.1021/bi0108507; Moro S, 1999, BIOCHEMISTRY-US, V38, P3498, DOI 10.1021/bi982369v; Mouledous L, 2000, J BIOL CHEM, V275, P29268, DOI 10.1074/jbc.M004971200; Nielsen SM, 2000, P NATL ACAD SCI USA, V97, P10277, DOI 10.1073/pnas.97.18.10277; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Piserchio A, 2000, BIOCHEMISTRY-US, V39, P8153, DOI 10.1021/bi000196f; RATHS SK, 1988, J BIOL CHEM, V263, P17333; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SCHREIER S, 2001, PEPTIDES WAVE FUTURE, P911; SCHWARTZ TW, 1996, TXB RECEPTOR PHARM, P65; SEN M, 1994, J BIOL CHEM, V269, P968; Sen M, 1997, CURR GENET, V31, P235, DOI 10.1007/s002940050200; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; SOMMERS CM, 1999, REC BIOCH M, P141; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Stillman BA, 1999, MOL PHARMACOL, V56, P545, DOI 10.1124/mol.56.3.545; Stillman BA, 1998, EUR J PHARMACOL, V357, P73, DOI 10.1016/S0014-2999(98)00522-6; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x; Wise A, 2002, DRUG DISCOV TODAY, V7, P235, DOI 10.1016/S1359-6446(01)02131-6; Xu Y, 2000, PROTEINS, V40, P343, DOI 10.1002/1097-0134(20000815)40:3<343::AID-PROT10>3.0.CO;2-S; Xu Y, 2002, STAT SINICA, V12, P159; Zhang L, 2002, BIOCHEMISTRY-US, V41, P61, DOI 10.1021/bi0117955	88	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30581	30590		10.1074/jbc.M204089200	http://dx.doi.org/10.1074/jbc.M204089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12058045	hybrid			2022-12-25	WOS:000177579800025
J	Bennett, CN; Ross, SE; Longo, KA; Bajnok, L; Hemati, N; Johnson, KW; Harrison, SD; MacDougald, OA				Bennett, CN; Ross, SE; Longo, KA; Bajnok, L; Hemati, N; Johnson, KW; Harrison, SD; MacDougald, OA			Regulation of Wnt signaling during adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-ALPHA; ADIPOCYTE DIFFERENTIATION; GENE-EXPRESSION; BETA-CATENIN; 3T3-L1 CELLS; GLUT4 GENE; C/EBP-BETA; ACTIVATION; INHIBITION; RECEPTOR	We have identified Wnt10b as a potent inhibitor of adipogenesis that must be suppressed for preadipocytes to differentiate in vitro. Here, we demonstrate that a specific inhibitor of glycogen synthase kinase 3, CHIR 99021, mimics Wnt signaling in preadipocytes. CHIR 99021 stabilizes free cytosolic beta-catenin and inhibits adipogenesis by blocking induction of CCAAT/enhancer-binding protein a and peroxisome proliferator-activated receptor gamma. Preadipocyte differentiation is inhibited when 3T3-L1 cells are exposed to CHIR 99021 for any 24 h period during the first 3 days of adipogenesis. Consistent with this time frame of inhibition, expression of Wnt10b mRNA is suppressed upon induction of differentiation, with a 50% decline by 6 h and complete inhibition by 36 h. Of the agents used to induce differentiation, exposure of 3T3-L1 cells to methyl-isobutylxanthine or cAMP is sufficient to suppress expression of Wnt10b mRNA. Inhibition of adipogenesis by Wnt10b is likely mediated by Wnt receptors, Frizzled 1, 2, and/or 5, and co-receptors low density lipoprotein receptor-related proteins 5 and 6. These receptors, like Wnt10b, are highly expressed in preadipocytes and stromal vascular cells. Finally, we demonstrate that disruption of extracellular Wnt signaling by expression of secreted Frizzled related proteins causes spontaneous adipocyte conversion.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Chiron Corp, Emeryville, CA 94608 USA	University of Michigan System; University of Michigan; Novartis	MacDougald, OA (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 7620 Med Sci 2,1301 E Catherine St, Ann Arbor, MI 48109 USA.		Longo, Kenneth A/A-5631-2010	MacDougald, Ormond/0000-0001-6907-7960	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51563] Funding Source: Medline; NIGMS NIH HHS [T323 GM 08322, T32 GM008322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bejsovec A, 2000, CURR BIOL, V10, pR919, DOI 10.1016/S0960-9822(00)00852-6; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen CL, 1997, OBES RES, V5, P146, DOI 10.1002/j.1550-8528.1997.tb00655.x; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; CUSHMAN SW, 1970, J CELL BIOL, V46, P326, DOI 10.1083/jcb.46.2.326; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; Kurebayashi S, 2001, ENDOCR J, V48, P249, DOI 10.1507/endocrj.48.249; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Malik TH, 2000, BIOCHEM J, V349, P829, DOI 10.1042/bj3490829; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Oderwald H, 1996, FEBS LETT, V382, P313, DOI 10.1016/0014-5793(96)00189-5; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; ROSS S, 2002, IN PRESS MOL CELL BI; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Saitoh T, 2001, INT J ONCOL, V19, P1187; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	43	568	608	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30998	31004		10.1074/jbc.M204527200	http://dx.doi.org/10.1074/jbc.M204527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12055200	hybrid			2022-12-25	WOS:000177579800077
J	Garcia-Ruiz, I; de la Torre, P; Diaz, T; Esteban, E; Fernandez, I; Munoz-Yague, T; Solis-Herruzo, JA				Garcia-Ruiz, I; de la Torre, P; Diaz, T; Esteban, E; Fernandez, I; Munoz-Yague, T; Solis-Herruzo, JA			Sp1 and Sp3 transcription factors mediate malondialdehyde-induced collagen alpha 1(I) gene expression in cultured hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; ALPHA-2(I) COLLAGEN; LIPID-PEROXIDATION; HUMAN-FIBROBLASTS; OXIDATIVE STRESS; PROTEIN ADDUCTS; PROMOTER; LIVER; ACTIVATION; ACETALDEHYDE	Malondialdehyde, the end product of lipid peroxidation, has been shown to stimulate collagen alpha1 (I) (Col1a1) gene expression. However, mechanisms of this effect are unclear. The purpose of this study was to clarify these mechanisms. Rat hepatic stellate cells were cultured in the presence of 200 pm malondialdehyde, and the effects on collagen gene expression and the binding of nuclear proteins to the col1a1 promoter were analyzed. Malondialdehyde treatment induced an increase in the cellular levels of col1a1 mRNA that was abrogated by pretreating cells with cycloheximide, p-hydroxymercuribenzoate, pyridoxal 5'-phosphate, and mithramycin. Transient transfections showed that malondialdehyde exerted its effect through regulatory elements located between -220 and -110 bp of the col1a1 promoter. Gel retardation assays demonstrated that malondialdehyde increased the binding of nuclear proteins to two elements located between -161 and -110 bp of the col1a1 promoter. These bindings were supershifted with Sp1 and Sp3 antibodies. Finally, malondialdehyde increased cellular levels of the Sp1 and Sp3 proteins and Sp1 mRNA. Our data indicated that treatment of hepatic stellate cells with malondialdehyde stimulated col1a1 gene expression by inducing the synthesis of Sp1 and Sp3 and their binding to two regulatory elements located between -161 and -110 bp of the col1a1 promoter.	Univ Complutense, Hosp Univ 12 Octubre, Serv Aparato Digest, Res Ctr,Dept Gastroenterol, Madrid 28041, Spain	Complutense University of Madrid; Hospital Universitario 12 de Octubre	Solis-Herruzo, JA (corresponding author), Univ Complutense, Hosp Univ 12 Octubre, Serv Aparato Digest, Res Ctr,Dept Gastroenterol, C Andalucia,Km 5400, Madrid 28041, Spain.	jasolis@h12o.es	García-Ruiz, Inmaculada/G-8204-2015	García-Ruiz, Inmaculada/0000-0003-4185-8524				Anania FA, 1996, ARCH BIOCHEM BIOPHYS, V331, P187, DOI 10.1006/abbi.1996.0297; BEDOSSA P, 1994, HEPATOLOGY, V19, P1262, DOI 10.1016/0270-9139(94)90876-1; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASINI A, 1993, J HEPATOL, V19, P385, DOI 10.1016/S0168-8278(05)80547-1; Chen AP, 2000, MOL CELL BIOL, V20, P2818, DOI 10.1128/MCB.20.8.2818-2826.2000; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; CHOJKIER M, 1989, J BIOL CHEM, V264, P16957; COLTON T, 1979, ESTADISTICA MED; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; Garcia Ruiz Inmaculada, 2000, DNA and Cell Biology, V19, P167; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Hernandez I, 2000, DNA CELL BIOL, V19, P341, DOI 10.1089/10445490050043317; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Houglum K, 1997, GASTROENTEROLOGY, V113, P1069, DOI 10.1053/gast.1997.v113.pm9322499; HOUGLUM K, 1990, J CLIN INVEST, V86, P1991, DOI 10.1172/JCI114934; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ihn H, 2000, J INVEST DERMATOL, V114, P1011, DOI 10.1046/j.1523-1747.2000.00956.x; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Maher JJ, 1997, HEPATOLOGY, V26, P618, DOI 10.1002/hep.510260313; MAHER JJ, 1994, ALCOHOL ALCOHOLISM, V29, P605; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NOMURA F, 1981, BIOCHEM BIOPH RES CO, V100, P131, DOI 10.1016/S0006-291X(81)80073-3; Ohhira M, 1998, ALCOHOL CLIN EXP RES, V22, p145S, DOI 10.1111/acer.1998.22.s3_part1.145s; Paradis V, 1997, HEPATOLOGY, V26, P135; PAROLA M, 1992, HEPATOLOGY, V16, P1014, DOI 10.1002/hep.1840160426; Parola M, 1996, BIOCHEM BIOPH RES CO, V222, P261, DOI 10.1006/bbrc.1996.0732; PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927; PIETRANGELO A, 1995, J CLIN INVEST, V95, P1824, DOI 10.1172/JCI117861; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RHODES K, 1994, MOL CELL BIOL, V14, P5950, DOI 10.1128/MCB.14.9.5950; RIPPE RA, 1990, MOL CELL BIOL, V10, P689, DOI 10.1128/MCB.10.2.689; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; Solis-Herruzo JA, 1999, J BIOL CHEM, V274, P30919, DOI 10.1074/jbc.274.43.30919; Solis-Herruzo JA, 1998, CELL SIGNAL, V10, P173, DOI 10.1016/S0898-6568(97)00036-3; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; TSUKAMOTO H, 1995, J GASTROEN HEPATOL, V10, pS50, DOI 10.1111/j.1440-1746.1995.tb01798.x; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; TSUKAMOTO H, 1993, ALCOHOL, V10, P465, DOI 10.1016/0741-8329(93)90066-W; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0	57	37	38	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30551	30558		10.1074/jbc.M203368200	http://dx.doi.org/10.1074/jbc.M203368200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12055194	hybrid			2022-12-25	WOS:000177579800021
J	Shiokawa, D; Kobayashi, T; Tanuma, S				Shiokawa, D; Kobayashi, T; Tanuma, S			Involvement of DNase gamma in apoptosis associated with myogenic differentiation of C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDONUCLEASE-G; EXPRESSION; CLONING; AKT; FRAGMENTATION; ACTIVATION; SURVIVAL; PROTEIN; GENE; PHOSPHORYLATION	Nucleosomal DNA fragmentation is detected in myoblasts only when apoptosis is induced under differentiating conditions. However, the molecular mechanisms and the DNase responsible for the differentiation-dependent apoptotic DNA laddering are poorly understood. Here we show that a Ca2+/Mg2+-dependent endonuclease, DNase gamma, is induced in C2C12 myoblasts during myogenic differentiation and catalyzes apoptotic DNA fragmentation in differentiating myoblasts. A Ca2+/Mg2+-dependent, Zn2+-sensitive endonuclease activity appears in C2C12 myoblasts during myogenic differentiation. The enzymatic properties of the inducible DNase were found to be quite similar to those of DNase I family of DNases. Reverse transcriptase-PCR analysis revealed that the induction of DNase gamma, a member of the DNase I family of DNases, is correlated with the appearance of inducible DNase activity. The induction of DNase gamma occurs simultaneously with myogenin induction but precedes the up-regulation of p21. A high level of DNase gamma expression was also detected in differentiated myotubes but not in skeletal muscle fibers in which DNase X is highly expressed. The role of DNase gamma in myoblast apoptosis was evaluated in the following experiments. Proliferating myoblasts acquire DNA ladder producing ability by the ectopic expression of DNase gamma, but not DNase X, suggesting that the expression level of DNase gamma is the determinant of the differentiation-dependent apoptotic DNA laddering observed in myoblasts. DNA fragmentation during differentiation-induced apoptosis is strongly suppressed by the antisense-mediated down-regulation of DNase gamma. Importantly, the extent of DNA laddering is well correlated with the level of endogenous DNase gamma activity. Our data demonstrate that DNase gamma is the endonuclease responsible for DNA fragmentation in apoptosis associated with myogenic differentiation.	Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Biochem, Shinjuku Ku, Tokyo 1620826, Japan; Tokyo Univ Sci, Genome & Drug Res Ctr, Chiba 2780022, Japan	Tokyo University of Science; Tokyo University of Science	Tanuma, S (corresponding author), Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Biochem, Shinjuku Ku, 12 Funagawara Machi,Ichigaya, Tokyo 1620826, Japan.	tanuma@ps.kagu.sut.ac.jp						Boulares AH, 2002, J BIOL CHEM, V277, P372, DOI 10.1074/jbc.M107738200; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; COHEN JJ, 1984, J IMMUNOL, V132, P38; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; Coy JF, 1996, CELL DEATH DIFFER, V3, P199; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fimia GM, 1996, J BIOL CHEM, V271, P15575, DOI 10.1074/jbc.271.26.15575; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Huppertz B, 2001, INT REV CYTOL, V205, P215, DOI 10.1016/S0074-7696(01)05005-7; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kaufmann SH, 2000, METHOD ENZYMOL, V322, P3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Krieser RJ, 1998, J BIOL CHEM, V273, P30909, DOI 10.1074/jbc.273.47.30909; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Los M, 2000, BIOCHEMISTRY-US, V39, P7365, DOI 10.1021/bi000158w; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; McArdle A, 1999, LAB INVEST, V79, P1069; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; NIKONOVA LV, 1982, BIOCHIM BIOPHYS ACTA, V699, P281, DOI 10.1016/0167-4781(82)90118-X; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; PARRISH JE, 1995, HUM MOL GENET, V4, P1557, DOI 10.1093/hmg/4.9.1557; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Pergolizzi R, 1996, GENE, V168, P267, DOI 10.1016/0378-1119(95)00741-5; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Rauch F, 1997, J CELL BIOL, V137, P909, DOI 10.1083/jcb.137.4.909; Rodriguez AM, 1997, GENOMICS, V42, P507, DOI 10.1006/geno.1997.4748; RUNDNICKI MA, 1995, BIOESSAYS, V17, P203; Sandri M, 1999, INT J BIOCHEM CELL B, V31, P1373, DOI 10.1016/S1357-2725(99)00063-1; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; Shiokawa D, 2001, BIOCHEMISTRY-US, V40, P143, DOI 10.1021/bi001041a; Shiokawa D, 1997, ARCH BIOCHEM BIOPHYS, V346, P15, DOI 10.1006/abbi.1997.0275; SHIOKAWA D, 1994, EUR J BIOCHEM, V226, P23, DOI 10.1111/j.1432-1033.1994.tb20022.x; Shiokawa D, 1998, BIOCHEM J, V332, P713, DOI 10.1042/bj3320713; Shiokawa D, 1998, APOPTOSIS, V3, P89, DOI 10.1023/A:1009692807692; Shiokawa D, 2000, BIOCHEM BIOPH RES CO, V275, P343, DOI 10.1006/bbrc.2000.3249; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Walsh K, 1997, Prog Cell Cycle Res, V3, P53; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Yakovlev AG, 1999, NUCLEIC ACIDS RES, V27, P1999, DOI 10.1093/nar/27.9.1999; Zhang JH, 2000, CELL RES, V10, P205, DOI 10.1038/sj.cr.7290049; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450	48	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31031	31037		10.1074/jbc.M204038200	http://dx.doi.org/10.1074/jbc.M204038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12050166	hybrid			2022-12-25	WOS:000177579800081
J	Rodova, M; Islam, MR; Maser, RL; Calvet, JP				Rodova, M; Islam, MR; Maser, RL; Calvet, JP			The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; TRANSGENIC MICE; PKD1 GENE; C-MYC; PROTOONCOGENE EXPRESSION; MOLECULAR-BASIS; CYST FORMATION; CPK MOUSE; ACTIVATION; DEFECTS	Polycystic kidney disease (PKD) results from loss-of-function mutations in the PKD1 gene. There are also reports showing abnormally high levels of PRD1 expression in cystic epithelial cells. At present, nothing is known about the molecular mechanisms regulating the normal expression of the PKD1 gene or whether transcriptional disregulation of the PKD1 gene has a role in cyst formation. We have analyzed a 3.3-kb 5'-proximal portion of the human PKD1 gene. Sequence analysis revealed the presence of consensus sequences for numerous transactivating factors, including four T-cell factor (TCF) binding elements (TBEs). Transcriptional activity of the 3.3-kb fragment and a series of deletion constructs was assayed in HEK293T cells. A 2.0-kb proximal promoter region containing one of the four TBEs (TBE1) was inducible up to 6-fold by cotransfection with beta-catenin. beta-catenin-mediated induction was inhibited by dominant-negative TCF and by deletion of the TBE1 sequence. 15- or 109-bp sequences containing the TBE1 site, when cloned upstream of a minimal promoter, were shown to respond to beta-catenin induction. Gel shift assays confirmed that the TBE1 site is capable of forming complexes with TCF and beta-catenin. To determine whether expression of the endogenous PKD1 gene responds to beta-catenin, HT1080 cells were treated with LiCl, and HeLa cells were stably transfected with beta-catenin. In both cases, endogenous PKD1 mRNA levels were elevated in response to these treatments. Taken together, these studies define an active PKD1 promoter region and suggest that the PKD1 gene is a target of the beta-catenin/TCF pathway.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Kidney Inst, Kansas City, KS 66160 USA; NW Missouri State Univ, Dept Chem Phys, Maryville, MO 64468 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Calvet, JP (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NIDDK NIH HHS [P50 DK57301, P01 DK53763] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053763, P50DK057301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Bogdanova N, 2001, GENOMICS, V74, P333, DOI 10.1006/geno.2001.6568; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; Charron AJ, 2000, J CELL BIOL, V149, P111, DOI 10.1083/jcb.149.1.111; Chauvet V, 2002, AM J PATHOL, V160, P973, DOI 10.1016/S0002-9440(10)64919-X; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; Grantham JJ, 2000, KIDNEY INT, V57, P339, DOI 10.1046/j.1523-1755.2000.00849.x; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; Guillaume R, 1999, DEV DYNAM, V214, P337, DOI 10.1002/(SICI)1097-0177(199904)214:4<337::AID-AJA6>3.0.CO;2-O; HARDING MA, 1992, KIDNEY INT, V41, P317, DOI 10.1038/ki.1992.44; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ilyas M, 1997, J PATHOL, V182, P128; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Koptides M, 2000, HUM MOL GENET, V9, P447, DOI 10.1093/hmg/9.3.447; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lanoix J, 1996, ONCOGENE, V13, P1153; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Lu WN, 2001, HUM MOL GENET, V10, P2385, DOI 10.1093/hmg/10.21.2385; Lu WN, 1999, NAT GENET, V21, P160, DOI 10.1038/5944; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ong ACM, 1999, KIDNEY INT, V56, P1324, DOI 10.1046/j.1523-1755.1999.00659.x; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; Perrone RD, 1997, AM J PHYSIOL-CELL PH, V272, pC1748, DOI 10.1152/ajpcell.1997.272.5.C1748; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; Qian F, 1997, AM J HUM GENET, V61, P1000, DOI 10.1086/301618; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Romagnolo B, 1999, CANCER RES, V59, P3875; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Surendran K, 2002, AM J PHYSIOL-RENAL, V282, pF431, DOI 10.1152/ajprenal.0009.2001; Trudel M, 1998, AM J PATHOL, V152, P219; van Adelsberg J, 2000, NEPHROL DIAL TRANSPL, V15, P1, DOI 10.1093/ndt/15.1.1; vanAdelsberg J, 1997, AM J PHYSIOL-RENAL, V272, pF602, DOI 10.1152/ajprenal.1997.272.5.F602; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; Watnick T, 2000, NAT GENET, V25, P143, DOI 10.1038/75981; Watnick T, 1999, SEMIN NEPHROL, V19, P327; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943	50	47	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29577	29583		10.1074/jbc.M203570200	http://dx.doi.org/10.1074/jbc.M203570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048202	hybrid			2022-12-25	WOS:000177509300031
J	Park, HO; Kang, PJ; Rachfal, AW				Park, HO; Kang, PJ; Rachfal, AW			Localization of the Rsr1/Bud1 GTPase involved in selection of a proper growth site in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR CDC24P; CELL POLARITY; BUD-SITE; SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; BUDDING YEAST; RAS; TRAFFICKING; BUD1/RSR1; MEMBRANE	Yeast cells organize their actin cytoskeleton in a highly polarized manner during vegetative growth. The Ras-like GTPase Rsr1/Bud1 and its regulators are required for selection of a specific site for growth. Here we showed that Rsr1/Bud1 was broadly distributed on the plasma membrane and highly concentrated at the incipient bud site and polarized growth sites. We also showed that localization of Cdc24, a guanine nucleotide exchange factor for the Cdc42 GTPase, to the proper bud site was dependent on Rsr1/Bud1. Surprisingly, Rsr1/ Bud1 also localized to intracellular membranes. A mutation in the lysine repeat in the hypervariable region of Rsr1/Bud1 specifically abolished its plasma membrane localization, whereas a mutation at the CAAX motif eliminated both plasma membrane and internal membrane association of Rsr1/Bud1. Thus the lysine repeat and the CAAK motif of Rsr1/Bud1 are important for its localization to the plasma membrane and to the polarized growth sites. This localization of Rsr1/Bud1 is essential for its function in proper bud site selection because both mutations resulted in random bud site selection.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Grad Program Mol Cellular & Dev Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Park, HO (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12Th Ave, Columbus, OH 43210 USA.	park.294@osu.edu		Park, Hay-Oak/0000-0001-5782-2257; Rachfal, Amy/0000-0001-6468-4737	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056997, R01GM076375] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056997-04, R01 GM 56997, R01 GM076375, R01 GM056997] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HICKS JB, 1977, GENETICS, V85, P373; Kang PJ, 2001, SCIENCE, V292, P1376, DOI 10.1126/science.1060360; Michelitch M, 1996, CURR BIOL, V6, P446, DOI 10.1016/S0960-9822(02)00512-2; Muller O, 2001, EMBO J, V20, P5657, DOI 10.1093/emboj/20.20.5657; Murray JM, 2001, J BIOL CHEM, V276, P3004, DOI 10.1074/jbc.M007389200; Nern A, 2000, J CELL BIOL, V148, P1115, DOI 10.1083/jcb.148.6.1115; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Park HO, 1999, GENE DEV, V13, P1912, DOI 10.1101/gad.13.15.1912; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; White WH, 1997, GENETICS, V147, P43; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626	27	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26721	26724		10.1074/jbc.C200245200	http://dx.doi.org/10.1074/jbc.C200245200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12058023	hybrid			2022-12-25	WOS:000177055900003
J	Wunderlich, M; Berberich, SJ				Wunderlich, M; Berberich, SJ			Mdm2 inhibition of p53 induces E2F1 transactivation via p2l	ONCOGENE			English	Article						Mdm2; E2F1; p53; p21	TRANSCRIPTION FACTOR E2F-1; RING-FINGER DOMAIN; P53-INDEPENDENT APOPTOSIS; DNA-DAMAGE; P53-MEDIATED TRANSACTIVATION; RETINOBLASTOMA PROTEIN; CELL-LINE; S-PHASE; EXPRESSION; DIFFERENTIATION	The transcription factor E2F1 functions as a key regulator for both cell-cycle progression and apoptosis. Mdm2, a major cellular regulator of the p53 tumor suppressor protein, is also closely involved in cell cycle and apoptosis. In addition to regulation of p53, Mdm2 has been reported to stimulate E2F1 transactivation by a mechanism that remains unclear. Here we examined how overexpression of Mdm2 alters E2F1/DP1 transactivation. Using a set of cell lines with differing p53 and Rb status we determined that Mdm2 induction of E2F1 transactivation was p53-dependent, resulting from release of repression by p53. While Mdm2 association with p53 was required to increase E2F1 transactivation, Mdm2 mediated degradation of p53 was not. p53 repression of E2F1 transactivation required a functional DNA binding and transactivation domain. Consistent with Mdm2 activation of E2F1 via an inhibition of p53 transactivation we demonstrate a concomitant reduction in p21 protein levels with Mdm2 overexpression. Furthermore, E2F1 repression by an Rb-phosphorylation mutant could not be reversed by Mdm2 overexpression. Mdm2 was also unable to enhance E2F1 transactivation in Mouse embryo fibroblasts lacking p21. Taken together, these results suggest that Mdm2 activation of E2F1 occurs through the repression of p53-dependent transcription of p21, a p53-target gene and cyclin dependent kinase inhibitor.	Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Berberich, SJ (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, 3640 Colonel Glenn Hywy, Dayton, OH 45435 USA.	steven.berberich@wright.edu			NATIONAL CANCER INSTITUTE [R01CA064430, R29CA064430] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA064430-09, R01 CA064430, CA64430] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; JACKSON MW, 2001, J BIOL CHEM, V10, P10; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lin JY, 2000, CANCER RES, V60, P5895; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	41	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4414	4421		10.1038/sj.onc.1205541	http://dx.doi.org/10.1038/sj.onc.1205541			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080472				2022-12-25	WOS:000176317100007
J	Harada, K; Toyooka, S; Maitra, A; Maruyama, R; Toyooka, KO; Timmons, CF; Tomlinson, GE; Mastrangelo, D; Hay, RJ; Minna, JD; Gazdar, AF				Harada, K; Toyooka, S; Maitra, A; Maruyama, R; Toyooka, KO; Timmons, CF; Tomlinson, GE; Mastrangelo, D; Hay, RJ; Minna, JD; Gazdar, AF			Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines	ONCOGENE			English	Article						epigenetic; tumor suppressor gene; pediatric tumor	LUNG-CANCER PATIENTS; CPG ISLAND; EPIGENETIC INACTIVATION; SUPPRESSOR GENE; HUMAN NEOPLASIA; BREAST CANCERS; HYPERMETHYLATION; 3P21.3; DNA; EXPRESSION	Aberrant promoter methylation of tumor suppressor genes has not been fully investigated in pediatric tumors. Therefore, we examined the methylation status of nine genes (p16(Ink4a), MGMT, GSTP1, RASSF1A, APC, DAPK, RARbeta, CDH1 and CDH13) in 175 primary pediatric tumors and 23 tumor cell lines using methylation-specific PCR. We studied the major forms of pediatric tumors - Wilms' tumor, neuroblastoma, hepatoblastoma, medulloblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, retinoblastoma and acute leukemia. The most frequently methylated gene in both primary tumors and cell lines was RASSF1A (40, 86%, respectively). However, the rates of RASSF1A methylation in individual tumor types varied from 0 to 88%. RASSF1A methylation was tumor specific and was absent in adjacent non-malignant tissues. Methylation of the other genes was relatively rare in tumors and nonmalignant tissues (less than 5%). Neuroblastoma patients with methylation of RASSF1A were significantly older than patients without methylation (P=0.008). There was no relationship between methylation status and other clinico-pathologic parameters. We treated six cell lines lacking RASSF1A mRNA with 5-aza-2'deoxycytidine to examine the relationship between methylation and transcriptional silencing. In five of six cell lines, restoration of RASSF1A mRNA was confirmed by RT-PCR. Our findings indicate that aberrant promoter methylation of RASSF1A may contribute to the pathogenesis of many different forms of pediatric tumors.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Childrens Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Amer Type Culture Collect, Manassas, VA 20110 USA; Univ Siena, Dept Ophthalmol, I-53100 Siena, Italy	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Siena	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd,NB8-206, Dallas, TX 75390 USA.		Tomlinson, Gail/AAR-9776-2020		NCI NIH HHS [U01CA8497102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen B, 1998, AM J PATHOL, V152, P1071; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davidoff A M, 2001, Semin Pediatr Surg, V10, P106, DOI 10.1053/spsu.2001.24700; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Loeb LA, 2001, CANCER RES, V61, P3230; Mares J, 2001, CANCER LETT, V166, P165, DOI 10.1016/S0304-3835(01)00402-5; Maruyama R, 2001, CANCER RES, V61, P8659; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Mollerup S, 1999, CANCER RES, V59, P3317; Morrissey C, 2001, CANCER RES, V61, P7277; Nakamura M, 1999, LEUKEMIA, V13, P884, DOI 10.1038/sj.leu.2401437; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790; Takita J, 2000, MED PEDIATR ONCOL, V35, P541, DOI 10.1002/1096-911X(20001201)35:6<541::AID-MPO9>3.0.CO;2-T; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2001, CANCER RES, V61, P5727; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	33	165	177	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4345	4349		10.1038/sj.onc.1205446	http://dx.doi.org/10.1038/sj.onc.1205446			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082624				2022-12-25	WOS:000176174200019
J	Yousafzai, FK; Eady, RR				Yousafzai, FK; Eady, RR			Dithionite reduction kinetics of the dissimilatory coppercontaining nitrite reductase of Alcalegenes xylosoxidans - The SO2 radical binds to the substrate binding type 2 copper site before the type 2 copper is reduced	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; X-RAY-STRUCTURE; ACHROMOBACTER-CYCLOCLASTES; ALCALIGENES-FAECALIS; MUTANT FORMS; BLUE; CU; ENDOR	We report here the first detailed study of the dithionite reduction kinetics of a copper-containing dissimilatory nitrite reductase (NiR). The reduction of the blue type 1 copper (T1Cu) center of NiR preparations that contained both type 1 and type 2 copper atoms, followed biphasic kinetics. In contrast, NiR that was deficient in type 2 copper (T2DNiR), followed monophasic kinetics with a second-order rate constant (T2D)k = 3.06 X 10(6) M-1 s(-1). In all cases the SO2radical anion radical rather than S2O42- was the effective reductant. The observed kinetics were compatible with a reaction mechanism in which the T1Cu of the fully loaded protein is reduced both directly by dithionite and indirectly by the type 2 Cu (T2Cu) site via intramolecular electron transfer. Reduction kinetics of the T2Cu were consistent with SO2radical anion binding first to the T2Cu center and then transferring electrons (112 s(-1)) to reduce it. As SO2radical anion is a homologue of NO2-, the NiR substrate, it is not unlikely that it binds to the catalytic T2Cu site. Effects on the catalytic activity of the enzyme using dithionite as a reducing agent are discussed. Reduction of the semireduced T1Cu(I)T2Cu(II) state followed either second-order kinetics with k(2) = 3.33 X 10(7) m(-1) s(-1) or first-order kinetics with 52.6 s(-1) < (T1red)k(1) < 112 s(-1). Values of formation constants of the T1Cu(II)T2Cu(II)-SO2radical anion and T1Cu(I)T2Cu(II)-SO2radical anion adducts showed that the redox state of T1Cu affected binding of SO2radical anion at the catalytic T2Cu center. Analysis of the kinetics required the development of a mathematical protocol that could be applied to a system with two intercommunicating sites but only one of which can be monitored. This novel protocol, reported for the first time, is of general application.	John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Yousafzai, FK (corresponding author), John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England.	faridoon.yousafzai@bbsrc.ac.uk						ABRAHAM ZHL, 1993, BIOCHEM J, V295, P587, DOI 10.1042/bj2950587; Abraham ZHL, 1997, BIOCHEM J, V324, P511, DOI 10.1042/bj3240511; ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; Dodd FE, 1997, ACTA CRYSTALLOGR D, V53, P406, DOI 10.1107/S0907444997002667; Dodd FE, 1998, J MOL BIOL, V282, P369, DOI 10.1006/jmbi.1998.2007; DODD FE, 1995, BIOCHEMISTRY-US, V34, P10180, DOI 10.1021/bi00032a011; Farver O, 1998, FEBS LETT, V436, P239, DOI 10.1016/S0014-5793(98)01120-X; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HOWES BD, 1994, BIOCHEMISTRY-US, V33, P3171, DOI 10.1021/bi00177a005; Inoue T, 1998, J BIOCHEM, V124, P876, DOI 10.1093/oxfordjournals.jbchem.a022201; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; Murphy LM, 2002, J MOL BIOL, V315, P859, DOI 10.1006/jmbi.2001.5253; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; MURPHY MEP, BIOCHEMISTRY, V34, P12107; Prudencio M, 2002, BIOCHEMISTRY-US, V41, P3430, DOI 10.1021/bi011955c; Strange RW, 1999, J MOL BIOL, V287, P1001, DOI 10.1006/jmbi.1999.2648; STRANGE RW, 1995, NAT STRUCT BIOL, V2, P287, DOI 10.1038/nsb0495-287; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; Suzuki S, 1997, J BIOL INORG CHEM, V2, P265, DOI 10.1007/s007750050132; Suzuki S, 2000, INORG REACT MECH, V2, P129; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; Veselov A, 1998, BIOCHEMISTRY-US, V37, P6095, DOI 10.1021/bi971604r; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	26	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34067	34073		10.1074/jbc.M204305200	http://dx.doi.org/10.1074/jbc.M204305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12082116	hybrid			2022-12-25	WOS:000177959100073
J	Susalka, SJ; Nikulina, K; Salata, MW; Vaughan, PS; King, SM; Vaughan, KT; Pfister, KK				Susalka, SJ; Nikulina, K; Salata, MW; Vaughan, PS; King, SM; Vaughan, KT; Pfister, KK			The roadblock light chain binds a novel region of the cytoplasmic dynein intermediate chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ARM DYNEIN; WD-REPEAT; DIFFERENTIAL EXPRESSION; SUBUNIT HETEROGENEITY; AXONAL-TRANSPORT; DYNACTIN COMPLEX; HEAVY-CHAIN; PROTEIN; FAMILY; IDENTIFICATION	Cytoplasmic dynein is the major minus-end directed microtubule-based motor in eukaryotic cells. It is composed of a number of different subunits including three light chain families: Tctex1, LC8, and roadblock. The incorporation of the roadblock light chains into the cytoplasmic dynein complex had not been determined. There are two roadblock genes in mammals, ROBL-1 and ROBL-2. We find that both members of the roadblock family bind directly to all of the intermediate chain isoforms of mammalian cytoplasmic dynein. This was determined with three complementary approaches. A yeast two-hybrid assay demonstrated that both roadblock light chains interact with intermediate chain isoforms from the IC74-1 and IC74-2 genes in vivo. This was confirmed in vitro with both a solid phase blot overlay assay and a solution-binding assay. The roadblock-binding domain on the intermediate chain was mapped to an similar to72 residue region. The binding domain is downstream of each of the two alternative splice sites in the intermediate chains. This location is consistent with the finding that both roadblock-1 and roadblock-2 show no binding specificity for a single IC74-1 or IC74-2 intermediate chain isoform. In addition, this roadblock-binding domain is significantly downstream from both the Tctex1-and LC8-binding sites, supporting the hypothesis that multiple light chain family members can bind to the same intermediate chain.	Univ Virginia, Dept Cell Biol, Sch Med, Charlottesville, VA 22908 USA; Gordon Coll, Div Math & Nat Sci, Barnesville, GA 30204 USA; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA; Univ Notre Dame, Dept Sci Biol, Notre Dame, IN 46556 USA	University of Virginia; University System of Georgia; Gordon State College; University of Connecticut; University of Notre Dame	Pfister, KK (corresponding author), Univ Virginia, Dept Cell Biol, Sch Med, POB 800732, Charlottesville, VA 22908 USA.	kkp9w@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060560, R01GM051293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029996] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60560, GM51293] Funding Source: Medline; NINDS NIH HHS [NS29996] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; Barbar E, 2001, BIOCHEMISTRY-US, V40, P1596, DOI 10.1021/bi002278+; Bowman AB, 1999, J CELL BIOL, V146, P165; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; DiBella LM, 2001, J BIOL CHEM, V276, P14366, DOI 10.1074/jbc.M011456200; Dillman JF, 1996, P NATL ACAD SCI USA, V93, P141, DOI 10.1073/pnas.93.1.141; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Gietz RD, 2001, BIOTECHNIQUES, V30, P816, DOI 10.2144/01304rv02; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; Harada A, 1998, J CELL BIOL, V141, P51, DOI 10.1083/jcb.141.1.51; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; HUGHES SM, 1995, J CELL SCI, V108, P17; Hurd DD, 1996, GENETICS, V144, P1075; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jiang JM, 2001, GENE, V281, P103, DOI 10.1016/S0378-1119(01)00787-9; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; King SJ, 2002, PROTEIN SCI, V11, P1239, DOI 10.1110/ps.2520102; KING SM, 1990, J BIOL CHEM, V265, P19807; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Koonin EV, 2000, CURR BIOL, V10, pR774, DOI 10.1016/S0960-9822(00)00774-0; Lawrence CJ, 2001, TRAFFIC, V2, P362, DOI 10.1034/j.1600-0854.2001.25020508.x; Leopold PL, 2000, HUM GENE THER, V11, P151, DOI 10.1089/10430340050016238; LIN SXH, 1992, J CELL SCI, V101, P125; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Ma S, 1999, J CELL BIOL, V147, P1261, DOI 10.1083/jcb.147.6.1261; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Mou T, 1998, FEBS LETT, V435, P275, DOI 10.1016/S0014-5793(98)01069-2; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; Porter ME, 1996, GENETICS, V144, P569; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Salata MW, 2001, J NEUROSCI RES, V65, P408, DOI 10.1002/jnr.1168; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Steffen W, 1996, J STRUCT BIOL, V117, P227, DOI 10.1006/jsbi.1996.0087; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Susalka SJ, 2000, BBA-MOL CELL RES, V1496, P76, DOI 10.1016/S0167-4889(00)00010-0; Susalka SJ, 2000, J NEUROCYTOL, V29, P819, DOI 10.1023/A:1010995408343; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; VALLEE RB, 1989, TRENDS NEUROSCI, V12, P66, DOI 10.1016/0166-2236(89)90138-0; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vaughan PS, 2001, J BIOL CHEM, V276, P26171, DOI 10.1074/jbc.M102649200; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; Wilson MJ, 2001, CELL MOTIL CYTOSKEL, V49, P229, DOI 10.1002/cm.1036; Yang PF, 1998, MOL BIOL CELL, V9, P3335, DOI 10.1091/mbc.9.12.3335; Ye FC, 2000, J BIOL CHEM, V275, P27172; Ye GJ, 2000, J VIROL, V74, P1355, DOI 10.1128/JVI.74.3.1355-1363.2000	65	56	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32939	32946		10.1074/jbc.M205510200	http://dx.doi.org/10.1074/jbc.M205510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077152	hybrid			2022-12-25	WOS:000177859000072
J	Duncan, JA; Gilman, AG				Duncan, JA; Gilman, AG			Characterization of Saccharomyces cerevisiae acyl-protein thioesterase 1, the enzyme responsible for G protein alpha subunit deacylation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITOYLATION-SITE; LIPID MODIFICATIONS; ADENYLYL-CYCLASE; BETA-GAMMA; PALMITATE; LYSOPHOSPHOLIPASE; PURIFICATION; ACTIVATION; G(S-ALPHA); INCREASES	Thioacylation is a reversible lipid modification of proteins that plays a role in the regulation of signal transduction. Acyl-protein thioesterase 1 (APT1) was identified as an enzyme capable of deacylating some thioacylated proteins in vitro. Saccharomyces cerevisiae open reading frame YLR118c encodes an enzyme homologous to Rattus norvegicus APT1. We demonstrate that the catalytic activity of the protein encoded by the yeast open reading frame is similar to that of rat APT1, and we designate the protein S. cerevisiae Apt1p. Yeasts bearing a disruption of the APT1 gene lack significant biochemically detectable acyl-protein thioesterase activity. They also fail to deacylate Gpa1p, the yeast Galpha subunit, in metabolic radiolabeling studies. We conclude that native APTI is the enzyme responsible for Ga subunit deacylation in S. cerevisiae and presumably other eukaryotes as well.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; CAMP LA, 1993, J BIOL CHEM, V268, P22566; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Guthrie C, 1991, GUIDE YEAST GENETICS; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE KS, 1994, J BIOL CHEM, V269, P19725; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sambrook J., 2002, MOL CLONING LAB MANU; SIKORSKI RS, 1989, GENETICS, V122, P19; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	35	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31740	31752		10.1074/jbc.M202505200	http://dx.doi.org/10.1074/jbc.M202505200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080046	hybrid			2022-12-25	WOS:000177718700055
J	Kordulakova, J; Gilleron, M; Mikusova, K; Puzo, G; Brennan, PJ; Gicquel, B; Jackson, M				Kordulakova, J; Gilleron, M; Mikusova, K; Puzo, G; Brennan, PJ; Gicquel, B; Jackson, M			Definition of the first mannosylation step in phosphatidylinositol mannoside synthesis - PimA is essential for growth of mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL ANCHOR; MULTIACYLATED FORMS; GENE REPLACEMENT; LIPOARABINOMANNAN; TUBERCULOSIS; BIOSYNTHESIS; SMEGMATIS; MANNOPHOSPHOLIPIDS; SELECTION; SEQUENCE	We examined the function of the pimA (Rv2610c) gene, located in the vicinity of the phosphatidylinositol synthase gene in the genomes of Mycobacterium tuberculosis and Mycobacterium smegmatis, which encodes a putative mannosyltransferase involved in the early steps of phosphatidylinositol mannoside synthesis. A cell-free assay was developed in which membranes from M. smegmatis overexpressing the pimA gene incorporate mannose from GDP-[(14)C]Man into di- and tri-acylated phosphatidylinositol mono-mannosides. Moreover, crude extracts from Escherichia coli producing a recombinant PimA protein synthesized diacylated phosphatidylinositol mono-mannoside from GDP-[(14)C]Man and bovine phosphatidylinositol. To determine whether PimA is an essential enzyme of mycobacteria, we constructed a pimA conditional mutant of M. smegmatis. The ability of this mutant to synthesize the PimA mannosyltransferase was dependent on the presence of a functional copy of the pimA gene carried on a temperature-sensitive rescue plasmid. We demonstrate here that the pimA mutant is unable to grow at the higher temperature at which the rescue plasmid is lost. Thus, the synthesis of phosphatidylinositol mono-mannosides and derived higher phosphatidylinositol mannosides in M. smegmatis appears to be dependent on PimA and essential for growth. This work provides the first direct evidence of the essentiality of phosphatidylinositol mannosides for the growth of mycobacteria.	Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Colorado State University; Comenius University Bratislava; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Jackson, M (corresponding author), Inst Pasteur, Unite Genet Mycobacterienne, 25 Rue Dr Roux, F-75724 Paris 15, France.	mjackson@pasteur.fr	Jackson, Mary/D-5345-2017; Kordulakova, Jana/I-3887-2014; Mikusova, Katarina/I-3622-2014	Jackson, Mary/0000-0002-9212-0258; Kordulakova, Jana/0000-0003-2834-0165; Mikusova, Katarina/0000-0002-0100-4877; GILLERON, Martine/0000-0002-2581-3302				Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; GILLERON M, 2001, IN PRESS GLYCANS CEL; GOREN MB, 1984, MYCOBACTERIA SOURCEB, V1, P379; GUILHOT C, 1994, J BACTERIOL, V176, P535, DOI 10.1128/JB.176.2.535-539.1994; HILL DL, 1966, J BIOL CHEM, V241, P895; Jackson M, 1997, INFECT IMMUN, V65, P2883, DOI 10.1128/IAI.65.7.2883-2889.1997; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; Jackson M, 2001, Methods Mol Med, V54, P59, DOI 10.1385/1-59259-147-7:059; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1111/j.1574-6968.1994.tb07194.x; Kang BK, 1998, INFECT IMMUN, V66, P2769, DOI 10.1128/IAI.66.6.2769-2777.1998; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; Parish T, 1997, J BACTERIOL, V179, P7827, DOI 10.1128/jb.179.24.7827-7833.1997; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TAKAYAMA K, 1969, BIOCHIM BIOPHYS ACTA, V176, P196, DOI 10.1016/0005-2760(69)90089-7; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149	30	149	155	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31335	31344		10.1074/jbc.M204060200	http://dx.doi.org/10.1074/jbc.M204060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12068013	hybrid			2022-12-25	WOS:000177718700009
J	Miura, S; Gan, JW; Brzostowski, J; Parisi, MJ; Schultz, CJ; Londos, C; Oliver, B; Kimmel, AR				Miura, S; Gan, JW; Brzostowski, J; Parisi, MJ; Schultz, CJ; Londos, C; Oliver, B; Kimmel, AR			Functional conservation for lipid storage droplet association among perilipin, ADRP, and TIP47 (PAT)-related proteins in mammals, Drosophila, and Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; ADIPOCYTES; EXPRESSION; GENE; LIPOLYSIS; CELLS; MEMBRANE; CAVEOLIN; OBESITY; BODIES	Intracellular neutral lipid storage droplets are essential organelles of eukaryotic cells, yet little is known about the proteins at their surfaces or about the amino acid sequences that target proteins to these storage droplets. The mammalian proteins Perilipin, ADRP, and TIP47 share extensive amino acid sequence similarity, suggesting a common function. However, while Perilipin and ADRP localize exclusively to neutral lipid storage droplets, an association of TIP47 with intracellular lipid droplets has been controversial. We now show that GFP-tagged TIP47 co-localizes with isolated intracellular lipid droplets. We have also detected a close juxtaposition of TIP47 with the surfaces of lipid storage droplets using antibodies that specifically recognize TIP47, further indicating that TIP47 associates with intracellular lipid storage droplets. Finally, we show that related proteins from species as diverse as Drosophila and Dictyostelium can also target mammalian or Drosophila lipid droplet surfaces in vivo. Thus, sequence and/or structural elements within this evolutionarily ancient protein family are necessary and sufficient to direct association to heterologous intracellular lipid droplet surfaces, strongly indicating that they have a common function for lipid deposition and/or mobilization.	NIDDK, Membrane Regulat Sect, NIH, Bethesda, MD 20992 USA; NIDDK, Dev Biochem Sect, NIH, Bethesda, MD 20992 USA; NIDDK, Mol Mechanisms Dev Sect, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20992 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Londos, C (corresponding author), NIDDK, Membrane Regulat Sect, NIH, 50 S Dr,50-3140, Bethesda, MD 20992 USA.		Miura, Shinji/K-6516-2013	Miura, Shinji/0000-0001-8806-9763	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK015600, Z01DK015503, Z01DK015505, Z01DK015600, ZIADK015505] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrews J, 1998, DEV GENES EVOL, V207, P482, DOI 10.1007/s004270050139; Barbero P, 2001, J BIOL CHEM, V276, P24348, DOI 10.1074/jbc.M102468200; Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; EISINGER DP, 1993, GENOMICS, V16, P638, DOI 10.1006/geno.1993.1241; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; Schultz CJ, 2002, AM J PHYSIOL-LUNG C, V283, pL288, DOI 10.1152/ajplung.00204.2001; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	33	302	315	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32253	32257		10.1074/jbc.M204410200	http://dx.doi.org/10.1074/jbc.M204410200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077142	hybrid			2022-12-25	WOS:000177718700119
J	Jin, YT; Zeng, SX; Dai, MS; Yang, XJ; Lu, H				Jin, YT; Zeng, SX; Dai, MS; Yang, XJ; Lu, H			MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; GAMMA-RADIATION; IN-VIVO; BINDING; DEGRADATION; PHOSPHORYLATION; CHECKPOINT	Our previous study shows that MDM2, a negative feedback regulator of the tumor suppressor p53, inhibits p300-mediated p53 acetylation. Because PCAF (p300/ CREB-binding protein-associated factor) also acetylates and activates p53 after DNA damage, in this study we have examined the effect of MDA12 on PCAF-mediated p53 acetylation. We have found that MDA12 inhibited p53 acetylation by PCAF in vitro. In addition, when overexpressed, MDM2 inhibited PCAF-mediated p53 acetylation in cells. MDA12 interacted with PCAF both in vitro and in cells, as assessed using GST fusion protein interaction and immunoprecipitation assays, respectively. Consistent with the above results, MDM2 significantly repressed the activation of p53 transcriptional activity by PCAF without apparently affecting the level of p53. In addition, MDM2 co-resided with p53 at the p53-responsive mdm2 and p21(waf1/cip1) promoters, inhibiting expression of the endogenous p21(waf1/cip1). These results demonstrate that MDM2 can inhibit PCAF-mediated p53 acetylation and activation.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; McGill Univ, Dept Med, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Oregon Health & Science University; McGill University	Lu, H (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chehab NH, 2000, GENE DEV, V14, P278; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAND RJA, 1995, VIROLOGY, V210, P323, DOI 10.1006/viro.1995.1349; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; JUVEN T, 1993, ONCOGENE, V8, P3411; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Liu YG, 2001, CANCER RES, V61, P5402; Lu H, 1994, Harvey Lect, V90, P81; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	53	65	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30838	30843		10.1074/jbc.M204078200	http://dx.doi.org/10.1074/jbc.M204078200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12068014	hybrid			2022-12-25	WOS:000177579800057
J	Masuda, M; Yageta, M; Fukuhara, H; Kuramochi, M; Maruyama, T; Nomoto, A; Murakami, Y				Masuda, M; Yageta, M; Fukuhara, H; Kuramochi, M; Maruyama, T; Nomoto, A; Murakami, Y			The tumor suppressor protein TSLC1 is involved in cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; N-CAM; MOLECULES; IDENTIFICATION; RECEPTOR; AFADIN; MEMBER	TSLC1 is a tumor suppressor gene encoding a member of the immunoglobulin (Ig) superfamily. The significant homology of its extracellular domain with those of other Ig superfamily cell adhesion molecules (IgCAMs) has raised the possibility that TSLC1 participates in cell-cell interactions. In this study, the physiological properties of TSLC1 were investigated in Madin-Darby canine kidney (MDCK) cells expressing TSLC1 tagged with green fluorescent protein (GFP) as well as in the cells that express endogenous TSLC1. Biochemical analysis has revealed that TSLC1 is an N-linked glycoprotein wit a molecular mass of 75 kDa and that it forms homodimers through cis interaction within the plane of the cell membranes. Confocal laser scanning microcopy of the cells expressing TSLC1 showed the localization patterns characteristic to adhesion molecules. At the beginning of cell attachment, TSLC1 accumulated in interdigitated structures at cell-cell boundaries, but, when cells reached a confluence, TSLC1 was distributed all along the cell membranes. In polarized cells, TSLC1 was recruited to the lateral membrane, implying trans interaction of TSLC1 between neighboring cells. In support of this notion, MDCK cells expressing TSLC1-GFP showed a significant level of cell aggregation in the absence or presence of Ca2+ and Mg2+. Taken together, these results indicate that TSLC1 mediates intracellular adhesion through homophilic interactions in a Ca2+/Mg2+-independent manner.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Projects, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Grad Sch Med, Dept Microbiol, Tokyo 1130033, Japan	National Cancer Center - Japan; University of Tokyo	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Projects, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ymurakam@gan2.ncc.go.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Benson DL, 2000, TRENDS CELL BIOL, V10, P473, DOI 10.1016/S0962-8924(00)01838-9; Braga V, 2001, NAT CELL BIOL, V3, pE168, DOI 10.1038/35083128; Brummendorf T, 2001, CURR OPIN CELL BIOL, V13, P611, DOI 10.1016/S0955-0674(00)00259-3; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; MIURA M, 1992, J BIOL CHEM, V267, P10752; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	24	137	148	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31014	31019		10.1074/jbc.M203620200	http://dx.doi.org/10.1074/jbc.M203620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12050160	hybrid			2022-12-25	WOS:000177579800079
J	Do, H; Lee, WS; Ghosh, P; Hollowell, T; Canfield, W; Kornfeld, S				Do, H; Lee, WS; Ghosh, P; Hollowell, T; Canfield, W; Kornfeld, S			Human mannose 6-phosphate-uncovering enzyme is synthesized as a proenzyme that is activated by the endoprotease furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-N-ACETYLGLUCOSAMINIDASE; CONSTITUTIVE SECRETORY PATHWAY; UNCOVERING ENZYME; CLEAVAGE SITE; PRECURSOR; PURIFICATION; EXPRESSION; SEQUENCE; BINDING; TOXIN	N-Acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase, also known as "uncovering" enzyme (UCE), is localized in the trans-Golgi network, where it removes a covering N-acetylglucosamine from the mannose 6-phosphate recognition marker on lysosomal acid hydrolases. Here we show that UCE is synthesized as an inactive proenzyme that is activated by the endoprotease furin, which cleaves an RARLPR down arrow D sequence to release a 24-amino acid propiece. As furin is localized in the trans-Golgi network, newly synthesized UCE is inactive until it reaches this terminal Golgi compartment. LoVo cells (derived from a human colon adenocarcinoma) lack furin activity and have extremely low UCE activity. Addition of furin to LoVo cell extracts restores UCE activity to normal levels, demonstrating that the UCE proenzyme is stable in this cell type. LoVo cells secrete acid hydrolases with phosphomannose diesters as a consequence of the deficient UCE activity. This demonstrates for the first time that UCE is the only enzyme in these cells capable of efficiently uncovering phosphomannose diesters. UCE also hydrolyzes UDP-GlcNAc, a sugar donor for Golgi N-acetylglucosaminyl-transferases. The fact that UCE is not activated until it reaches the trans-Golgi network may ensure that the pool of UDP-GlcNAc in the Golgi stack is not depleted, thereby maintaining proper oligosaccharide assembly.	Washington Univ, Sch Med, Div Hematol, Dept Internal Med, St Louis, MO 63110 USA; Novazyme Pharmaceut Inc, Oklahoma City, OK USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.							Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Chan M, 2001, EUR J BIOCHEM, V268, P3423, DOI 10.1046/j.1432-1327.2001.02241.x; Chiron MF, 1996, MOL MICROBIOL, V22, P769, DOI 10.1046/j.1365-2958.1996.d01-1721.x; DUGUAY SJ, 1995, J BIOL CHEM, V270, P17566, DOI 10.1074/jbc.270.29.17566; FAUST PL, 1989, J BIOL CHEM, V264, P479; GARRED O, 1995, J BIOL CHEM, V270, P10817; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; HORIMOTO T, 1994, J VIROL, V68, P6074, DOI 10.1128/JVI.68.9.6074-6078.1994; Kornfeld R, 1998, J BIOL CHEM, V273, P23203, DOI 10.1074/jbc.273.36.23203; Kornfeld R, 1999, J BIOL CHEM, V274, P32778, DOI 10.1074/jbc.274.46.32778; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEE JK, 1995, ARCH BIOCHEM BIOPHYS, V319, P413, DOI 10.1006/abbi.1995.1312; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Miranda L, 1996, P NATL ACAD SCI USA, V93, P7695, DOI 10.1073/pnas.93.15.7695; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; MULLIS KG, 1994, J BIOL CHEM, V269, P1718; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; Rohrer J, 2001, MOL BIOL CELL, V12, P1623, DOI 10.1091/mbc.12.6.1623; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TALKAD V, 1983, J BIOL CHEM, V258, P7345; VARKI A, 1981, J BIOL CHEM, V256, P9937; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1992, J BIOL CHEM, V267, P8270	29	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29737	29744		10.1074/jbc.M202369200	http://dx.doi.org/10.1074/jbc.M202369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058031	hybrid			2022-12-25	WOS:000177509300050
J	Robertson, JD; Enoksson, M; Suomela, M; Zhivotovsky, B; Orrenius, S				Robertson, JD; Enoksson, M; Suomela, M; Zhivotovsky, B; Orrenius, S			Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ADAPTER MOLECULE; PROTEIN; LOCALIZATION; ACTIVATION; RECEPTOR; BCL-2; INHIBITION; CASCADES; ISOFORM	DNA damage induced by the cancer chemotherapeutic drug etoposide triggers the onset of a series of intracellular events characteristic of apoptosis. Among the early changes observed is the release of cytochrome c from mitochondria, although the mechanism responsible for this effect is unclear. We demonstrate here a role for caspase-2 in etoposide-induced cytochrome c release. In particular, Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp-Val-Ala-Asp-fluoromethyl ketone (z-VDVAD-fmk), or stably transfected with pro-caspase-2 antisense (Carp-2/AS) are refractory to cytochrome c release stimulated by etoposide. Experiments performed using a reconstituted cell-free system indicate that etoposide-induced cytochrome c release by way of caspase-2 occurs independently of cytosolic factors, suggesting that the nuclear pool of pro-caspase-2 is critical to this process. Apart from inhibiting cytochrome c release, undermining caspase-2 activity results in an attenuation of downstream events, such as pro-caspase-9 and -3 activation, phosphatidylserine exposure on the plasma membrane, and DNA fragmentation. Taken together, our data indicate that caspase-2 provides an important link between etoposide-induced DNA damage and the engagement of the mitochondrial apoptotic pathway.	Karolinska Inst, Div Toxicol, Inst Environm Med, SE-17177 Stockholm, Sweden	Karolinska Institutet	Robertson, JD (corresponding author), Karolinska Inst, Div Toxicol, Inst Environm Med, Box 210, SE-17177 Stockholm, Sweden.		Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482	NATIONAL CANCER INSTITUTE [F32CA083273] Funding Source: NIH RePORTER; NCI NIH HHS [5 F32 CA83273] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Ahmad M, 1997, CANCER RES, V57, P615; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Jiang SN, 1997, CELL DEATH DIFFER, V4, P39, DOI 10.1038/sj.cdd.4400204; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stefanis L, 1998, J NEUROSCI, V18, P9204; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	35	335	343	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29803	29809		10.1074/jbc.M204185200	http://dx.doi.org/10.1074/jbc.M204185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12065594	hybrid			2022-12-25	WOS:000177509300058
J	Iijima, Y; Okuda, K; Tojo, A; Tri, NK; Setoyama, M; Sakaki, Y; Asano, S; Tokunaga, K; Kruh, GD; Sato, Y				Iijima, Y; Okuda, K; Tojo, A; Tri, NK; Setoyama, M; Sakaki, Y; Asano, S; Tokunaga, K; Kruh, GD; Sato, Y			Transformation of Ba/F3 cells and rat-1 cells by ETV6/ARG	ONCOGENE			English	Article						translocation; tyrosine kinase; ETV6/ARG; transforming activity	CHRONIC MYELOMONOCYTIC LEUKEMIA; PROTEIN-TYROSINE KINASE; ETV6-NTRK3 GENE FUSION; ABL-RELATED GENE; ENCODES; TEL; OLIGOMERIZATION; DOMAIN; BETA; BCR	ETV6/ARG, a novel fusion gene composed of the ETV6 HLH oligomerization domain and most of sequences of the ARG protein tyrosine, was recently identified in human leukemia cells. The presence of the ETV6/ARG translocation raises the possibility that the resulting fusion protein functions as an oncogene. However, the transforming activity of the ETV6/ARG protein has not been determined and its contribution to leukemogenesis is therefore unknown. Here we address this question by analysing the oncogenic activity of ETV6/ARG in hematopoietic and fibroblast cells. It is demonstrated that expression of ETV6/ARG confers IL3-independent growth to Ba/F3 cells and anchorage independent growth to Rat-1 fibroblasts. It is also shown that multiple signaling molecules, including PI3K, SHC, ras-GAP and CRK-L, are tyrosine phosphorylated in Ba/F3 cells that express ETV6/ARG. Analysis of four different types of ETV6/ARG transcripts previously identified in the AML-M3 leukemia cell line HT93A suggest that ETV6 HLH domain is required for oncogenic activity. Based upon these results it is concluded that ARG can be activated as an oncogene in human malignancy and that the ETV6/ARG oncoprotein triggers some of the same signaling pathways associated with activated ABL oncogenes.	Int Med Ctr Japan, Res Inst, Dept Clin Pathol, Div Mol Cytogenet,Shinjuku Ku, Tokyo 1620052, Japan; Kyoto Prefectural Univ Med, Dept Hyg, Kyoto 6020841, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Mol Therapy, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Funct Genomics, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Med, Sch Int Hlth, Dept Human Genet, Tokyo 1130033, Japan; Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	National Center for Global Health & Medicine - Japan; Kyoto Prefectural University of Medicine; University of Tokyo; University of Tokyo; University of Tokyo; Fox Chase Cancer Center	Sato, Y (corresponding author), Int Med Ctr Japan, Res Inst, Dept Clin Pathol, Div Mol Cytogenet,Shinjuku Ku, Toyama 1-21-1, Tokyo 1620052, Japan.	ysato@ri.imcj.go.jp			NCI NIH HHS [CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057273, R55CA057273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Iijima Y, 2000, BLOOD, V95, P2126; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Mysliwiec T, 1996, ONCOGENE, V12, P631; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Okuda K, 1996, ONCOGENE, V13, P1147; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PEREGO R, 1991, ONCOGENE, V6, P1899; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1996, ONCOGENE, V13, P1379; WANG N, 1993, FOCUS, V3, P3	23	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4374	4383		10.1038/sj.onc.1205544	http://dx.doi.org/10.1038/sj.onc.1205544			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080468				2022-12-25	WOS:000176317100003
J	Ure, DR; Rodriguez, M				Ure, DR; Rodriguez, M			Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease	FASEB JOURNAL			English	Article						multiple sclerosis autoantibodies; central nervous system disease	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HISTOCOMPATIBILITY COMPLEX-MOLECULES; LYSOLECITHIN-INDUCED DEMYELINATION; T-CELL LINES; MULTIPLE-SCLEROSIS; BASIC-PROTEIN; SYNTHETIC COPOLYMER-1; PROMISCUOUS BINDING; CNS REMYELINATION	Using a murine model of demyelinating disease, we demonstrate that remyelination of spinal cord axons is promoted by antibodies to glatiramer acetate (GA, Copolymer-1, Copaxone(R)), a therapeutic agent for multiple sclerosis (MS). Glatiramer acetate is a mixture of randomly synthesized peptides that induces both T cell activation and antibody production in all treated individuals. These observations prompted us to compare the independent effects of adoptively transferred GA-reactive T cells and antibodies in mice with chronic inflammatory demyelination induced by Theiler's virus. Transferred T cells had no effect on lesion load or the extent of remyelination. Purified polyclonal GA antibodies also did not alter lesion load, which suggests that neither GA T cells or antibodies were pathogenic. On the contrary, GA antibodies enhanced the normally low level of remyelination in chronic lesions. The antibodies, which were primarily immunoglobulin (Ig) G1 and IgG2, cross-reacted with oligodendrocytes, perivascular infiltrating cells, astrocytes, and neurons in spinal cord sections. In glial cultures they bound subsets of early lineage oligodendrocytes and microglia. Thus, several mechanisms may have contributed to the promotion of remyelination. These results support the hypothesis that the antibody response in GA-treated patients is beneficial by facilitating repair of demyelinated lesions.	Mayo Clin & Mayo Fdn, Mayo Med & Grad Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med & Grad Sch, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med & Grad Sch, Dept Immunol, 428 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.	ure.daren@mayo.edu; rodriguez.moses@mayo.edu		Rodriguez, Moses/0000-0001-6328-6497				Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; AHARONI R, 1993, EUR J IMMUNOL, V23, P17, DOI 10.1002/eji.1830230105; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Aharoni R, 1997, P NATL ACAD SCI USA, V94, P10821, DOI 10.1073/pnas.94.20.10821; Aharoni R, 2001, TRANSPLANTATION, V72, P598, DOI 10.1097/00007890-200108270-00007; Ballow M, 1997, J ALLERGY CLIN IMMUN, V100, P151, DOI 10.1016/S0091-6749(97)70217-3; Bartnik BL, 2000, MULT SCLER, V6, P37, DOI 10.1191/135245800678827400; BenNun A, 1996, J NEUROL, V243, pS14, DOI 10.1007/BF00873697; Brenner T, 2001, J NEUROIMMUNOL, V115, P152, DOI 10.1016/S0165-5728(01)00250-8; Comi G, 2001, ANN NEUROL, V49, P290, DOI 10.1002/ana.64; Deisenhammer F, 2001, J INTERF CYTOK RES, V21, P167, DOI 10.1089/107999001750133195; Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970; Farina C, 2001, BRAIN, V124, P705, DOI 10.1093/brain/124.4.705; Filippi M, 2001, NEUROLOGY, V57, P731, DOI 10.1212/WNL.57.4.731; Fridkis-Hareli M, 1998, J IMMUNOL, V160, P4386; Fridkis-Hareli M, 1998, P NATL ACAD SCI USA, V95, P12528, DOI 10.1073/pnas.95.21.12528; FRIDKISHARELI M, 1994, P NATL ACAD SCI USA, V91, P4872, DOI 10.1073/pnas.91.11.4872; Gran B, 2000, NEUROLOGY, V55, P1704, DOI 10.1212/WNL.55.11.1704; Hussien Y, 2001, J NEUROIMMUNOL, V121, P102, DOI 10.1016/S0165-5728(01)00432-5; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Johnson N, 2000, ORAL DIS, V6, P1; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Koh CS, 2000, J NEUROIMMUNOL, V108, P22, DOI 10.1016/S0165-5728(00)00282-4; Kotter MR, 2001, GLIA, V35, P204, DOI 10.1002/glia.1085; LIPTON HL, 1976, J NEUROL SCI, V30, P201, DOI 10.1016/0022-510X(76)90267-7; LISAK RP, 1983, J NEUROL SCI, V62, P281, DOI 10.1016/0022-510X(83)90205-8; Loughlin AJ, 1997, J NEUROSCI RES, V47, P384; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; McGavern DB, 1999, J NEUROSCI RES, V58, P492, DOI 10.1002/(SICI)1097-4547(19991115)58:4<492::AID-JNR3>3.0.CO;2-P; Miller A, 1998, J NEUROIMMUNOL, V92, P113, DOI 10.1016/S0165-5728(98)00191-X; MILLER DJ, 1995, J IMMUNOL, V154, P2460; MILLER DJ, 1994, J NEUROSCI, V14, P6230; Neuhaus O, 2000, P NATL ACAD SCI USA, V97, P7452, DOI 10.1073/pnas.97.13.7452; Pavelko KD, 1998, J NEUROSCI, V18, P2498; RACKE MK, 1992, J NEUROIMMUNOL, V37, P75, DOI 10.1016/0165-5728(92)90157-G; Rice G, 2001, ARCH NEUROL-CHICAGO, V58, P1297, DOI 10.1001/archneur.58.8.1297; Rodriguez M, 1996, NEUROLOGY, V46, P538, DOI 10.1212/WNL.46.2.538; RODRIGUEZ M, 1988, VIROLOGY, V166, P463, DOI 10.1016/0042-6822(88)90517-X; Schlegel PG, 1996, P NATL ACAD SCI USA, V93, P5061, DOI 10.1073/pnas.93.10.5061; Stangel M, 1998, J NEUROL SCI, V153, P203, DOI 10.1016/S0022-510X(97)00292-X; Teitelbaum D, 1996, J NEUROIMMUNOL, V64, P209, DOI 10.1016/0165-5728(95)00180-8; Teitelbaum D, 1999, P NATL ACAD SCI USA, V96, P3842, DOI 10.1073/pnas.96.7.3842; TEITELBAUM D, 1973, EUR J IMMUNOL, V3, P273, DOI 10.1002/eji.1830030505; TEITELBAUM D, 1971, European Journal of Immunology, V1, P242, DOI 10.1002/eji.1830010406; Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820; Zhang MF, 2000, J NEUROIMMUNOL, V103, P189, DOI 10.1016/S0165-5728(99)00239-8	46	46	53	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1260	+		10.1096/fj.01-1023fje	http://dx.doi.org/10.1096/fj.01-1023fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060672				2022-12-25	WOS:000176683900032
J	Benzing, T; Kottgen, M; Johnson, M; Schermer, B; Zentgraf, H; Walz, G; Kim, E				Benzing, T; Kottgen, M; Johnson, M; Schermer, B; Zentgraf, H; Walz, G; Kim, E			Interaction of 14-3-3 protein with regulator of G protein signaling 7 is dynamically regulated by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; RGS PROTEINS; K+ CHANNELS; ACUTE DESENSITIZATION; MEDIATED MODULATION; KINASE; PHOSPHORYLATION; BINDING; ACTIVATION; COMPLEXES	Regulators of G protein signaling (RGS) constitute a family of proteins with a conserved RGS domain of similar to 120 amino acids that accelerate the intrinsic GTP hydrolysis of activated Galpha(i) and Galpha(q) subunits. The phosphorylation-dependent interaction of 14-3-3 proteins with a subset of RGS proteins inhibits their GTPase-accelerating activity in vitro. The inhibitory interaction between 14-3-3 and RGS7 requires phosphorylation of serine 434 of RGS7. We now show that phosphorylation of serine 434 is dynamically regulated by TNF-alpha. Cellular stimulation by TNTF-alpha transiently decreased the phosphorylation of serine 434 of RGS7, abrogating the inhibitory interaction with 14-3-3. We examined the effect of 14-3-3 on RGS-mediated deactivation kinetics of G protein-coupled inwardly rectifying K+ channels (GIRKs) in Xenopus oocytes. 14-3-3 inhibited the function of wild-type RGS7, but not that of either RSG7(P436R) or RGS4, two proteins that do not bind 14-3-3. Our findings are the first evidence that extracellular signals can modulate the activity of RGS proteins by regulating their interaction with 14-3-3.	Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany; Univ Hosp Freiburg, Clin Res Ctr, D-79106 Freiburg, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Walz, G (corresponding author), Univ Hosp Freiburg, Div Renal, Hugstetterstr 55, D-79106 Freiburg, Germany.	walz@med1.ukl.uni-freiburg.de	Benzing, Thomas/X-5476-2019; Schermer, Bernhard/E-9972-2014	Schermer, Bernhard/0000-0002-5194-9000; Kottgen, Michael/0000-0003-2406-5039				Benzing T, 2000, J BIOL CHEM, V275, P28167; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Herlitze X, 1999, J PHYSIOL-LONDON, V517, P341, DOI 10.1111/j.1469-7793.1999.0341t.x; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Ulens C, 2000, LIFE SCI, V67, P2305, DOI 10.1016/S0024-3205(00)00820-1; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000	31	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32954	32962		10.1074/jbc.M200859200	http://dx.doi.org/10.1074/jbc.M200859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077120	hybrid			2022-12-25	WOS:000177859000074
J	Fitzgerald, ML; Morris, AL; Rhee, JS; Andersson, LP; Mendez, AJ; Freeman, MW				Fitzgerald, ML; Morris, AL; Rhee, JS; Andersson, LP; Mendez, AJ; Freeman, MW			Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN DEFICIENCY; HDL PARTICLE UPTAKE; CHOLESTEROL EFFLUX; TANGIER-DISEASE; CELLULAR CHOLESTEROL; PLASMA-MEMBRANE; BINDING; GENE; RECEPTOR; CELLS	The ABCA1 transporter contains two large domains into which many of the genetic mutations in individuals with Tangier disease fall. To investigate the structural requirements for the cellular cholesterol efflux mediated by ABCA1, we have determined the topology of these two domains and generated transporters harboring five naturally occurring missense mutations in them. These mutants, unlike wild type ABCA1, produced little or no apoA-I-stimulated cholesterol efflux when transfected into 293 cells, establishing their causality in Tangier disease. Because all five mutant proteins were well expressed and detectable on the plasma membrane, their interaction with the ABCA1 ligand, apolipoprotein (apo) A-I, was measured using bifunctional cross-linking agents. Four of five mutants had a marked decline in cross-linking to apoA-I, whereas one (W590S) retained full cross-linking activity. Cross-linking of apoA-I was temperature-dependent, rapid in onset, and detectable with both lipid-and water-soluble cross-linking agents. These results suggest that apoA-I-stimulated cholesterol efflux cannot occur without a direct interaction between the apoprotein and critical residues in two extracellular loops of ABCAI. The behavior of the W590S mutant indicates that although binding of apoA-I by ABCA1 may be necessary, it is not sufficient for stimulation of cholesterol efflux.	Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Miami, Sch Med, Diabet Res Inst, Miami, FL 33101 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Miami	Freeman, MW (corresponding author), Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA.	freeman@molbio.mgh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098, K08HL145098, R01HL068988, F32HL010398] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL10398, HL45098, HL68988] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; Bertolini S, 2001, ATHEROSCLEROSIS, V154, P599, DOI 10.1016/S0021-9150(00)00587-6; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Fitzgerald ML, 2002, J MOL MED, V80, P271, DOI 10.1007/s00109-001-0318-y; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Huang W, 2001, BBA-MOL BASIS DIS, V1537, P71, DOI 10.1016/S0925-4439(01)00058-8; Lapicka-Bodzioch K, 2001, BBA-MOL BASIS DIS, V1537, P42, DOI 10.1016/S0925-4439(01)00053-9; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Mendez AJ, 1997, J LIPID RES, V38, P1807; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983, DOI 10.1161/01.ATV.20.8.1983; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772	36	161	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33178	33187		10.1074/jbc.M204996200	http://dx.doi.org/10.1074/jbc.M204996200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084722	hybrid			2022-12-25	WOS:000177859000101
J	Pawliczak, R; Han, C; Huang, XL; Demetris, AJ; Shelhamer, JH; Wu, T				Pawliczak, R; Han, C; Huang, XL; Demetris, AJ; Shelhamer, JH; Wu, T			85-kDa cytosolic phospholipase A(2) mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; PPAR-GAMMA; NUCLEAR-ENVELOPE; GENE-EXPRESSION; MACROPHAGE ACTIVATION; DEPENDENT MECHANISM; SIGNAL-TRANSDUCTION; AIRWAY INFLAMMATION; GROWTH-FACTOR; DIFFERENTIATION	The 85-kDa cytosolic phospholipase A(2) (cPLA(2)) plays an important role in the control of arachidonic acid metabolism. This study was designed to investigate the possible contributions of cPLA(2) and group IIA secretory phospholipase A2 (sPLA(2)) in the regulation of peroxisome proliferator-activated receptor (PPAR)-mediated gene transcription in human airway epithelial cells. Primary normal human bronchial epithelial cells and human lung epithelial cell lines BEAS 2B, A549, and NCI-H292 all express PPARgamma and -beta. Overexpression of cPLA(2) in BEAS 213 cells and primary bronchial epithelial cells resulted in a significant increase of PPARgamma-mediated reporter activity. In contrast, overexpression of group IIA sPLA(2), had no effect on PPARgamma activation. The PPARgamma activity in A549 cells was significantly inhibited by the cPLA(2) inhibitor arachidonyltrifluoromethyl ketone but not by the sPLA2 inhibitor LY311727 and the iPLA(2) inhibitor HELSS. Activation of cPLA(2) by the calcium ionophore, A23187, induced a dose-dependent increase of PPAR activity in normal human bronchial epithelial cells and in the A549 cells. Electrophoretic mobility shift assays show that the binding between PPAR isolated from A549 cells and peroxisome proliferator response element (PPRE) is enhanced by A23187 but partially blocked by the cPLA2 inhibitors arachidonyltrifluoromethyl ketone and methyl arachidonyl fluorophosphate. Finally, NS 398, a COX-2 inhibitor, partially blocked the A23187 effect on PPAR activity and binding to the PPRE suggesting involvement of COX-2 metabolites in PPRE activation. The above results demonstrate a novel function of cPLA, in the control of PPARgamma activation in human lung epithelial cells.	Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; NIH, Ctr Clin, Dept Crit Care Med, Bethesda, MD 20892 USA; Med Univ Lodz, Dept Allergy & Clin Immunol, PL-92213 Lodz, Poland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Medical University Lodz	Wu, T (corresponding author), Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA.		Pawliczak, Rafal Tomasz/S-9649-2016; Pawliczak, Rafa/S-2021-2019	Pawliczak, Rafa/0000-0001-6784-453X				ADLER KB, 1990, J CLIN INVEST, V85, P75, DOI 10.1172/JCI114436; ADLER KB, 1992, AM J RESP CELL MOL, V6, P550, DOI 10.1165/ajrcmb/6.5.550; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; Alaoui-El-Azher M, 2002, MOL PHARMACOL, V61, P786, DOI 10.1124/mol.61.4.786; Alpert SE, 1995, AM J PHYSIOL-LUNG C, V269, pL734, DOI 10.1152/ajplung.1995.269.6.L734; Asano K, 1997, J CLIN INVEST, V99, P1057, DOI 10.1172/JCI119233; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Chang TH, 2000, CANCER RES, V60, P1129; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Dahlen SE, 2000, AM J RESP CRIT CARE, V161, pS1, DOI 10.1164/ajrccm.161.supplement_1.ltta-0; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Drazen JM, 1998, AM J RESP CRIT CARE, V158, pS193, DOI 10.1164/ajrccm.158.supplement_2.13tac180; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hill EM, 1996, AM J PHYSIOL-LUNG C, V270, pL854, DOI 10.1152/ajplung.1996.270.5.L854; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; HOLTZMAN MJ, 1992, ANNU REV PHYSIOL, V54, P303; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; Ikezono T, 1997, BBA-MOL CELL RES, V1355, P121, DOI 10.1016/S0167-4889(96)00122-X; Jiang YJ, 2001, J LIPID RES, V42, P716; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Matsuura H, 1999, MOL CELL ENDOCRINOL, V147, P85, DOI 10.1016/S0303-7207(98)00214-7; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; Micheal LF, 1997, ENDOCRINOLOGY, V138, P3695, DOI 10.1210/en.138.9.3695; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nettesheim P, 1996, TOXICOL LETT, V88, P35, DOI 10.1016/0378-4274(96)03715-0; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RIEVES RD, 1991, AM J PHYSIOL, V261, pL415, DOI 10.1152/ajplung.1991.261.6.L415; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Seeds MC, 1999, CLIN REV ALLERG IMMU, V17, P5, DOI 10.1007/BF02737594; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Serhan CN, 2001, AM J RESP CELL MOL, V24, P658, DOI 10.1165/ajrcmb.24.6.f210; SHELHAMER JH, 1995, ANN INTERN MED, V123, P288, DOI 10.7326/0003-4819-123-4-199508150-00008; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Suruga K, 1999, EUR J BIOCHEM, V262, P70, DOI 10.1046/j.1432-1327.1999.00330.x; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; WU T, 1993, AM J RESP CELL MOL, V8, P282, DOI 10.1165/ajrcmb/8.3.282; WU T, 1991, EXP LUNG RES, V17, P1079, DOI 10.3109/01902149109064336; Wu T, 1996, BBA-MOL CELL RES, V1310, P175, DOI 10.1016/0167-4889(95)00143-3; Wu T, 1997, AM J PHYSIOL-LUNG C, V273, pL331, DOI 10.1152/ajplung.1997.273.2.L331; Yoo HY, 1999, GENE, V234, P87, DOI 10.1016/S0378-1119(99)00176-6	65	62	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33153	33163		10.1074/jbc.M200246200	http://dx.doi.org/10.1074/jbc.M200246200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077117	hybrid			2022-12-25	WOS:000177859000098
J	Smith, DA; Toone, WM; Chen, DR; Bahler, J; Jones, N; Morgan, BA; Quinn, J				Smith, DA; Toone, WM; Chen, DR; Bahler, J; Jones, N; Morgan, BA; Quinn, J			The Srk1 protein kinase is a target for the Sty1 stress-activated MAPK in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATF1 TRANSCRIPTION FACTOR; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; BUDDING YEAST; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; SEXUAL DEVELOPMENT; MITOTIC REGULATOR; OXIDATIVE STRESS; HIGH OSMOLARITY	The fission yeast stress-activated Sty1/Spc1 MAPK pathway responds to a similar range of stresses as do the mammalian p38 and SAPK/JNK MAPK pathways. In addition, sty1(-) cells are sterile and exhibit a G(2) cell cycle delay, indicating additional roles of Sty1 in meiosis and cell cycle progression. To identify novel proteins involved in stress responses, a microarray analysis of the Schizosaccharomyces pombe genome was performed to find genes that are up-regulated following exposure to stress in a Sty1-dependent manner. One such gene identified, srk1(+) (Sty1-regulated kinase 1), encodes a putative serine/threonine kinase homologous to mammalian calmodulin kinases. At the C terminus of Srk1 is a putative MAPK binding motif similar to that in the p38 substrates, MAPK-activated protein kinases 2 and 3. Indeed, we find that Srk1 is present in a complex with the Sty1 MAPK and is directly phosphorylated by Sty1. Furthermore, upon stress, Srk1 translocates from the cytoplasm to the nucleus in a process that is dependent on the Sty1 MAPK. Finally, we show that Srk1 has a role in regulating meiosis in fission yeast; following nitrogen limitation, srk1(-) cells enter meiosis significantly faster than wild-type cells and overexpression of srk1(-) inhibits the nitrogen starvation-induced arrest in G(1).	Newcastle Univ, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK Cell Regulat Grp, Manchester M20 4BX, Lancs, England; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Newcastle University - UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Wellcome Trust Sanger Institute	Quinn, J (corresponding author), Newcastle Univ, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	janet.quinn@ncl.ac.uk	Bahler, Jurg/B-4572-2009; Quinn, Janet/AAR-9957-2021	Bahler, Jurg/0000-0003-4036-1532; 	Cancer Research UK [A6517] Funding Source: Medline; Wellcome Trust [077118] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		ALFA CE, 1993, METHOD CELL BIOL, V37, P201, DOI 10.1016/S0091-679X(08)60251-4; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; DAHLKVIST A, 1995, MOL GEN GENET, V246, P316, DOI 10.1007/BF00288604; Degols G, 1996, MOL CELL BIOL, V16, P2870; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Melcher ML, 1996, J BIOL CHEM, V271, P29958, DOI 10.1074/jbc.271.47.29958; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Ramne A, 2000, MOL GEN GENET, V263, P253, DOI 10.1007/s004380051166; RASMUSSEN C, 1994, MOL BIOL CELL, V5, P785, DOI 10.1091/mbc.5.7.785; Samejima I, 1997, EMBO J, V16, P6162, DOI 10.1093/emboj/16.20.6162; Samejima I, 1998, MOL BIOL CELL, V9, P2325, DOI 10.1091/mbc.9.8.2325; Shieh JC, 1998, MOL BIOL CELL, V9, P311, DOI 10.1091/mbc.9.2.311; Shieh JC, 1997, GENE DEV, V11, P1008, DOI 10.1101/gad.11.8.1008; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; Shiozaki K, 1998, MOL BIOL CELL, V9, P1339, DOI 10.1091/mbc.9.6.1339; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Teige M, 2001, P NATL ACAD SCI USA, V98, P5625, DOI 10.1073/pnas.091610798; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Yamada K, 1999, YEAST, V15, P1125, DOI 10.1002/(SICI)1097-0061(199908)15:11<1125::AID-YEA442>3.0.CO;2-Z	48	58	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33411	33421		10.1074/jbc.M204593200	http://dx.doi.org/10.1074/jbc.M204593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080074	hybrid			2022-12-25	WOS:000177859000130
J	Bodin, K; Andersson, U; Rystedt, E; Ellis, E; Norlin, M; Pikuleva, I; Eggertsen, G; Bjorkhem, I; Diczfalusy, U				Bodin, K; Andersson, U; Rystedt, E; Ellis, E; Norlin, M; Pikuleva, I; Eggertsen, G; Bjorkhem, I; Diczfalusy, U			Metabolism of 4 beta-hydroxycholesterol in Humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR LXR; CHOLESTEROL HOMEOSTASIS; BILE; IDENTIFICATION; OXYSTEROL; 24S-HYDROXYCHOLESTEROL; PATHWAY; BRAIN; ACID	One of the major oxysterols in the human circulation is 4beta-hydroxycholesterol formed from cholesterol by the drug-metabolizing enzyme cytochrome P450 3A4. Deuterium-labeled 4beta-hydroxycholesterol was injected into two healthy volunteers, and the apparent half-life was found to be 64 and 60 h, respectively. We have determined earlier the half-lives for 7alpha-, 27-, and 24-hydroxycholesterol to be similar to0.5, 0.75, and 14 h, respectively. Patients treated with certain antiepileptic drugs have up to 20-fold increased plasma concentrations of 4beta-hydroxycholesterol. The apparent half-life of deuteriumlabeled 4beta-hydroxycholesterol in such a patient was found to be 52 h, suggesting that the high plasma concentration was because of increased synthesis rather than impaired clearance. 4beta-Hydroxycholesterol was converted into acidic products at a much slower rate than 7alpha-hydroxycholesterol in primary human hepatocytes, and 4beta-hydroxycholesterol was 7alpha-hydroxylated at a slower rate than cholesterol by recombinant human CYP7A1. CYP7B1 and CYP39A1 had no activity toward 4beta-hydroxycholesterol. These results suggest that the high plasma concentration of 4beta-hydroxycholesterol is because of its exceptionally slow elimination, probably in part because of the low rate of 7alpha-hydroxylation of the steroid. The findings are discussed in relation to a potential role of 4beta-hydroxycholesterol as a ligand for the nuclear receptor LXR.	Huddinge Univ Hosp, Dept Med Lab Sci & Technol, Div Clin Chem, Karolinska Inst, SE-14186 Huddinge, Sweden; Huddinge Univ Hosp, Div Gastroenterol & Hepatol, Karolinska Inst, SE-14186 Huddinge, Sweden; Uppsala Univ, Div Biochem, Dept Pharmaceut Biosci, SE-75123 Uppsala, Sweden; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA	Karolinska Institutet; Karolinska Institutet; Uppsala University; University of Texas System; University of Texas Medical Branch Galveston	Diczfalusy, U (corresponding author), Huddinge Univ Hosp, Dept Med Lab Sci & Technol, Div Clin Chem, Karolinska Inst, SE-14186 Huddinge, Sweden.	ulf.diezfalusy@chemlab.hs.sll.se	Ellis, Ewa C S/D-5370-2014; Diczfalusy, Ulf/A-5336-2008	Ellis, Ewa C S/0000-0002-3057-5337; Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425; Norlin, Maria/0000-0003-4348-6269; Pikuleva, Irina/0000-0001-9742-6232; Diczfalusy, Ulf/0000-0001-6643-3763	NIGMS NIH HHS [GM62882] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062882] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200; BJORKHEM I, 1969, EUR J BIOCHEM, V8, P337, DOI 10.1111/j.1432-1033.1969.tb00533.x; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bodin K, 2001, J BIOL CHEM, V276, P38685, DOI 10.1074/jbc.M105127200; BREUER O, 1995, J LIPID RES, V36, P2275; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; DUMASWALA R, 1989, J LIPID RES, V30, P847; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Lasalvia M, 1998, J CHEM RES, P694; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LI AP, 1992, J TISSUE CULT METHOD, V14, P139; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Meaney S, 2001, J LIPID RES, V42, P70; Miettinen TA, 2000, ATHEROSCLEROSIS, V153, P241, DOI 10.1016/S0021-9150(00)00404-4; Murai T, 1997, J CHROMATOGR B, V691, P13, DOI 10.1016/S0378-4347(96)00384-2; Norlin M, 2000, J LIPID RES, V41, P1629; Pikuleva IA, 1998, J BIOL CHEM, V273, P18153, DOI 10.1074/jbc.273.29.18153; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995	19	136	136	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31534	31540		10.1074/jbc.M201712200	http://dx.doi.org/10.1074/jbc.M201712200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077124	hybrid			2022-12-25	WOS:000177718700032
J	Okazaki, K; Li, J; Yu, H; Fukui, NS; Sandell, LJ				Okazaki, K; Li, J; Yu, H; Fukui, NS; Sandell, LJ			CCAAT/enhancer-binding proteins beta and delta mediate the repression of gene transcription of cartilage-derived retinoic acid-sensitive protein induced by interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PRO-ALPHA-1(II) COLLAGEN GENE; CHONDROCYTE-SPECIFIC ENHANCER; C/EBP-BETA; ARTICULAR CHONDROCYTES; INHIBITORY PROTEIN; ACTIVATION DOMAIN; NUCLEAR FACTOR; MESSENGER-RNA; ACTIVITY MIA	Cartilage-derived retinoic acid-sensitive protein (CD-RAP) is a secreted protein expressed by chondrocytes; the expression is repressed by interleukin 1beta (IL-1beta). To investigate the transcriptional mechanism, by which CD-RAP expression is suppressed by IL-1beta, deletion constructs of the mouse CD-RAP promoter were transfected into rat chondrocytes treated with or without IL-1beta. The results revealed an IL-lbeta-responsive element located between -2138 and -2068 bp. As this element contains a CAAT/enhancer-binding protein (C/EBP) motif, the function of C/EBPbeta and C/EBPdelta was examined. IL-1beta stimulated the expression of C/EBP)3 and -delta, and the direct binding of C/EBPbeta to the C/EBP motif was confirmed. The -2251-bp CD-RAP promoter activity was down-regulated by co-transfection with C/EBP expression vectors. Mutation of the C/EBP motif abolished the inhibitory response to IL-1beta. Additionally, C/EBP expression vectors were found to down-regulate the construct containing the promoter and enhancer of the type II collagen gene. Finally, the enhancer factor, Sox9, was shown to bind adjacent to the C/EBP site competing with C/EBP binding. Taken together, these results suggest that C/EBPbeta and -delta may play an important role in the IL-1beta-induced repression of cartilage-specific proteins and that expression of matrix proteins will be influenced by the availability of positive and negative trans-acting factors.	Washington Univ, Sch Med, Dept Orthopaed Surg, Barnes Jewish Hosp, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, Barnes Jewish Hosp, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Sandell, LJ (corresponding author), Washington Univ, Sch Med, Dept Orthopaed Surg, Barnes Jewish Hosp, Mail Stop 90-34-674,216 S Kingshighway, St Louis, MO 63110 USA.	sandelll@msnotes.wustl.edu		Okazaki, Ken/0000-0003-1274-8406	NIAMS NIH HHS [R01AR45550, R01-AR36994] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994, R01AR045550] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Attard FA, 2000, ARCH BIOCHEM BIOPHYS, V378, P57, DOI 10.1006/abbi.2000.1803; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Bosserhoff AK, 1997, DEV DYNAM, V208, P516, DOI 10.1002/(SICI)1097-0177(199704)208:4<516::AID-AJA7>3.0.CO;2-L; Buck M, 2001, EMBO J, V20, P6712, DOI 10.1093/emboj/20.23.6712; Chansky H, 1998, J ORTHOPAED RES, V16, P521, DOI 10.1002/jor.1100160502; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Fukui N, 2001, Curr Rheumatol Rep, V3, P496, DOI 10.1007/s11926-001-0064-8; Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926-000-0021-y; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harrison JR, 2000, J BONE MINER RES, V15, P1138, DOI 10.1359/jbmr.2000.15.6.1138; He YW, 2002, J BIOL CHEM, V277, P23493, DOI 10.1074/jbc.M202629200; Hirai Y, 2001, J CELL BIOL, V153, P785, DOI 10.1083/jcb.153.4.785; Jain R, 1999, BIOCHEM J, V338, P737, DOI 10.1042/0264-6021:3380737; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kirfel J, 1997, P NATL ACAD SCI USA, V94, P2227, DOI 10.1073/pnas.94.6.2227; Kondo SJ, 2001, J ORTHOP RES, V19, P712, DOI 10.1016/S0736-0266(00)00068-1; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI J, 2002, 48 ANN M ORTH RES SO; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; Martel-Pelletier J, 1999, FRONT BIOSCI, V4, pD694; Massaad C, 2000, J BIOL CHEM, V275, P22686, DOI 10.1074/jbc.M001250200; Moser M, 2002, MOL CELL BIOL, V22, P1438, DOI 10.1128/MCB.22.5.1438-1445.2002; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; PURPLE CR, 2000, 46 ANN M ORTH RES SO; Robbins JR, 2000, ARTHRITIS RHEUM, V43, P2189, DOI 10.1002/1529-0131(200010)43:10<2189::AID-ANR6>3.0.CO;2-S; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711; Tetlow LC, 2001, ARTHRITIS RHEUM-US, V44, P585, DOI 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.0.CO;2-C; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Vidal NOA, 1997, J ENDOCRINOL, V155, P433, DOI 10.1677/joe.0.1550433; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Xie WF, 2000, MATRIX BIOL, V19, P501, DOI 10.1016/S0945-053X(00)00087-1; Xie WF, 1998, J BIOL CHEM, V273, P5026, DOI 10.1074/jbc.273.9.5026; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974; Zahnow CA, 2001, CANCER RES, V61, P261	55	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31526	31533		10.1074/jbc.M202815200	http://dx.doi.org/10.1074/jbc.M202815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12072435	hybrid			2022-12-25	WOS:000177718700031
J	Chen, Y; Derin, R; Petralia, RS; Li, M				Chen, Y; Derin, R; Petralia, RS; Li, M			Actinfilin, a brain-specific actin-binding protein in postsynaptic density	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; DENDRITIC SPINES; BTB DOMAIN; POZ-DOMAIN; KELCH; FAMILY; CELLS; MECHANISMS; COMPLEX; ENCODES	The dynamic assembly and disassembly of actin-based cytoskeleton is closely linked to the changes in the postsynaptic density in both number and shape, which is thought to be important in forming long-term memory. Thus, regulation of actin filaments may play a critical role in contributing to the formation of long-term memory. Here, we report the cloning of actinfilin, a brain-specific Kelch protein, which interacts with F-actin. Actinfilin contains an amino-terminal POZ/BTB domain and carboxyl positioned six tandem Kelch repeats that presumably form six blades of beta-propeller structure of the Kelch domain. Co-immunoprecipitation analyses showed that the amino-terminal POZ domain mediated actinfilin-actinfilin interaction. The recombinant Kelch domain alone was sufficient to mediate binding to F-actin. Immunohistochemistry studies of rat brain sections suggested that actinfilin is broadly expressed in neurons of most regions of the brain. The subcellular localization of actinfilin was studied by biochemical fractionation and immunogold labeling. The results showed the postsynaptic density distribution of actinfilin. Together, these results indicate that actinfilin may be a key player in the actin-based neuronal function.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; NIDCD, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Li, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, WBSB 216,725 N Wolfe St, Baltimore, MD 21205 USA.							Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Allison DW, 1998, J NEUROSCI, V18, P2423; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Bailly M, 2001, CURR BIOL, V11, P620, DOI 10.1016/S0960-9822(01)00152-X; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHANG FLF, 1984, BRAIN RES, V309, P35, DOI 10.1016/0006-8993(84)91008-4; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DESMOND NL, 1988, BRAIN RES, V453, P308, DOI 10.1016/0006-8993(88)90171-0; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; FIFKOVA E, 1977, J NEUROCYTOL, V6, P211, DOI 10.1007/BF01261506; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hernandez MC, 1997, J NEUROSCI, V17, P3038; James P, 1996, GENETICS, V144, P1425; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Petralia RS, 2001, EUR J NEUROSCI, V13, P1722, DOI 10.1046/j.0953-816x.2001.01553.x; PETRALIA RS, 1999, METHODS MOL BIOL NMD, P113; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	33	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30495	30501		10.1074/jbc.M202076200	http://dx.doi.org/10.1074/jbc.M202076200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063253	hybrid			2022-12-25	WOS:000177579800014
J	Guerardel, Y; Maes, E; Elass, E; Leroy, Y; Timmerman, P; Besra, GS; Locht, C; Strecker, G; Kremer, L				Guerardel, Y; Maes, E; Elass, E; Leroy, Y; Timmerman, P; Besra, GS; Locht, C; Strecker, G; Kremer, L			Structural study of lipomannan and lipoarabinomannan from Mycobacterium chelonae - Presence of unusual components with alpha 1,3-mannopyranose side chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL ANCHOR; MAGNETIC-RESONANCE SPECTROSCOPY; GAS-LIQUID-CHROMATOGRAPHY; BACILLUS-CALMETTE-GUERIN; TUMOR-NECROSIS-FACTOR; MASS-SPECTROMETRY; BOVIS BCG; PHOSPHATIDYLINOSITOL MANNOSIDES; MULTIACYLATED FORMS; NONREDUCING TERMINI	Lipomannan (LM) and lipoarabinomannan (LAM) are major glycolipids present in the mycobacterial cell wall that are able to modulate the host immune response. In this study, we have undertaken the structural determination of these important modulins in Mycobacterium chelonae, a fast growing pathogenic mycobacterial species. One-dimensional and two-dimensional NMR spectra were used to demonstrate that LM and LAM from M. chelonae, designated CheLM and CheLAM, respectively, possess structures that differ from the ones reported earlier in other mycobacterial species. Analysis by gas chromatography/mass spectrometry of the phosphatidyl-myo-inositol anchor, which is thought to play a role in the biological functions of these lipoglycans, pointed to a high degree of heterogeneity based on numerous combinations of acyl groups on the C-1 and C-2 positions of the glycerol moiety. Characterization of the mannan core of CheLM and CheLAM revealed the presence of novel alpha1,3-mannopyranosyl side chains. This motif, which reacted specifically with the lectin from Galanthus nivalis, was found to be unique among a panel of nine mycobacterial species. Then, CheLM and CheLAM were found to be devoid of both the mannooligosaccharide cap present in Mycobacterium tuberculosis and the inositol phosphate cap present in Mycobacterium smegmatis and other fast growing species. Tumor necrosis factor-a and interleukin-8 production were assessed from human macrophages with LAM preparations from different species. Our results suggest that the inositol phosphate capping may represent the major cytokine-inducing component of LAMs. This work not only underlines the diversity of LAM structures among various mycobacterial species but also provides new structures that could be useful to dissect the structure-function relationships of these complex molecules.	Inst Pasteur, IBL, INSERM, U447,Lab Mecanismes Mol Pathol Microbienne, F-59019 Lille, France; Univ Sci & Technol Lille, Lab Glycobiol Struct & Fonct, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; University of Birmingham	Kremer, L (corresponding author), Inst Pasteur, IBL, INSERM, U447,Lab Mecanismes Mol Pathol Microbienne, 1 Rue Pr Calmette,BP245, F-59019 Lille, France.	laurent.kremer@ibl.fr	Locht, Camille/L-3516-2018; Kremer, Laurent/M-4935-2017	Kremer, Laurent/0000-0002-6604-4458; elass, elisabeth/0000-0002-2573-2959; Besra, Gurdyal/0000-0002-5605-0395; Guerardel, Yann/0000-0003-4967-9512				Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; Ernst WA, 1998, IMMUNITY, V8, P331, DOI 10.1016/S1074-7613(00)80538-5; FRIEDMANN FF, 1903, ZBL BAKT           1, V34, P647; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 1997, J BIOL CHEM, V272, P117; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; INGRAM CW, 1993, CLIN INFECT DIS, V16, P463, DOI 10.1093/clind/16.4.463; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; Khoo HH, 2001, J BIOL CHEM, V276, P3863, DOI 10.1074/jbc.M004010200; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Kremer L, 2002, BIOCHEM J, V364, P423, DOI 10.1042/BJ20011628; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; MINNIKIN DE, 1982, J GEN MICROBIOL, V128, P817; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; ROACH TIA, 1993, J IMMUNOL, V150, P1886; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SIBLEY LD, 1990, CLIN EXP IMMUNOL, V80, P141; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VENISSE A, 1993, J BIOL CHEM, V268, P12401; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149; WALLACE RJ, 1992, J INFECT DIS, V166, P405, DOI 10.1093/infdis/166.2.405; WANG Y, 1995, ANAL BIOCHEM, V225, P242, DOI 10.1006/abio.1995.1149; WOLINSKY E, 1979, AM REV RESPIR DIS, V119, P107; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702	50	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30635	30648		10.1074/jbc.M204398200	http://dx.doi.org/10.1074/jbc.M204398200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063260	hybrid			2022-12-25	WOS:000177579800032
J	Johnsen, SA; Subramaniam, M; Monroe, DG; Janknecht, R; Spelsberg, TC				Johnsen, SA; Subramaniam, M; Monroe, DG; Janknecht, R; Spelsberg, TC			Modulation of transforming growth factor beta (TGF beta)/Smad transcriptional responses through targeted degradation of TGF beta-inducible early gene-1 by human seven in absentia homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DEGRADATION; MAMMALIAN HOMOLOGS; PROTEASOME PATHWAY; UBIQUITIN LIGASE; FINGER PROTEIN; RECEPTOR; SMAD7; TIEG; IDENTIFICATION; APOPTOSIS	Transforming growth factor beta (TGFbeta)-inducible early gene-1 (TIEG1) is a Kruppel-like transcription factor that is rapidly induced upon TGFbeta treatment. TIEG1 promotes TGFbeta/Smad signaling by down-regulating negative feedback through the inhibitory Smad7. In this report, we describe the identification of an E3 ubiquitin ligase, Seven in Absentia homologue-1 (SIAH1), as a TIEG1-interacting protein. We show that TIEG1 and SIAH1 interact through an amino-terminal domain of TIEG1. Co-expression of SIAH1 results in proteasomal degradation of TIEG1 but not of the related factor TIEG2. Importantly, co-expression of SIAH1 completely reverses repression of Smad7 promoter activity by TIEG1. Furthermore, overexpression of a dominant negative SIAH1 stabilizes TIEG1 and synergizes with TIEG1 to enhance TGFbeta/Smad-dependent transcriptional activation. These findings suggest a novel mechanism whereby the ability of TGFbeta to modulate gene transcription may be regulated by proteasomal degradation of the downstream effector TIEG1 through the SIAH pathway. In this manner, turnover of TIEG1 may serve to limit the duration and/or magnitude of TGFbeta responses.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Spelsberg, TC (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	spelsberg.thomas@mayo.edu	Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Janknecht, Ralf/0000-0003-1741-1562	NCI NIH HHS [CA 09441] Funding Source: Medline; NIDCR NIH HHS [1R01 DE 14036-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014036] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hefferan TE, 2000, J BIOL CHEM, V275, P20255, DOI 10.1074/jbc.C000135200; Hefferan TE, 2000, J CELL BIOCHEM, V78, P380, DOI 10.1002/1097-4644(20000901)78:3<380::AID-JCB4>3.0.CO;2-L; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1996, ONCOGENE, V12, P1961; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Subramaniam M, 1998, J CELL BIOCHEM, V68, P226, DOI 10.1002/(SICI)1097-4644(19980201)68:2<226::AID-JCB9>3.0.CO;2-X; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tanabe A, 2001, BIOL PHARM BULL, V24, P144, DOI 10.1248/bpb.24.144; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yajima S, 1997, J NEUROSCI, V17, P8657; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974	48	66	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30754	30759		10.1074/jbc.M204812200	http://dx.doi.org/10.1074/jbc.M204812200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12072443	hybrid			2022-12-25	WOS:000177579800046
J	Levites, Y; Amit, T; Youdim, MBH; Mandel, S				Levites, Y; Amit, T; Youdim, MBH; Mandel, S			Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACT EGB-761 PROTECTS; PRIMARY CORTICAL-NEURONS; LOW-DENSITY-LIPOPROTEIN; OXIDATIVE STRESS; NERVOUS-SYSTEM; SIGNAL-TRANSDUCTION; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS	Studies from our laboratory have demonstrated that the major green tea polyphenol, (-)-epigallocatechin 3-gallate (EGCG), exerts potent neuroprotective actions in the mice model of Parkinson's disease. These studies were extended to neuronal cell culture employing the parkinsonism-inducing neurotoxin, 6-hydroxydopamine (6-OHDA). Pretreatment with EGCG (0.1-10 mum) attenuated human neuroblastoma (NB) SH-SY5Y cell death, induced by a 24-h exposure to 6-OHDA (50 pm). Potential cell signaling candidates involved in this neuroprotective effect were further examined. EGCG restored the reduced protein kinase C (PKC) and extracellular signal-regulated kinases (ERK1/2) activities caused by 6-OHDA toxicity. However, the neuroproteetive effect of EGCG on cell survival was abolished by pretreatment with PKC inhibitor GF 109203X (1 mum). Because EGCG increased phosphorylated PKC, we suggest that PKC isoenzymes are involved in the neuroprotective action of EGCG against 6-OHDA. In addition, gene expression analysis revealed that EGCG prevented both the 6-OHDA-induced expression of several mRNAs, such as Bax, Bad, and Mdm2, and the decrease in Bcl-2, Bcl-w, and Bcl-x(L). These results suggest that the neuroprotective mechanism of EGCG against oxidative stress-induced cell death includes stimulation of PKC and modulation of cell survival/cell cycle genes.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Excellence Neurodegenerat Dis Res, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Pharmacol, USA Natl Parkinson Ctr Excellence Neurodegenerat, IL-31096 Haifa, Israel; Intradepartmental Unit Biotechnol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Excellence Neurodegenerat Dis Res, POB 9697, IL-31096 Haifa, Israel.	Youdim@Tx.Technion.ac.il						Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; Bastianetto S, 2000, J NEUROCHEM, V74, P2268, DOI 10.1046/j.1471-4159.2000.0742268.x; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BUSTO R, 1994, J NEUROCHEM, V63, P1095; CARDELL M, 1993, J NEUROCHEM, V61, P1308, DOI 10.1111/j.1471-4159.1993.tb13623.x; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Choi YT, 2001, LIFE SCI, V70, P603, DOI 10.1016/S0024-3205(01)01438-2; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Chung JY, 2001, FASEB J, V15, P2022, DOI 10.1096/fj.01-0031fje; COHEN G, 1974, J BIOL CHEM, V249, P2447; D'Onofrio M, 2001, J NEUROCHEM, V78, P435, DOI 10.1046/j.1471-4159.2001.00435.x; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; DEMPSEY EC, 2000, AM J PHYSIOL, V279, pL249; Durkin JP, 1997, J NEUROCHEM, V68, P1400; Gassen M, 1998, MOVEMENT DISORD, V13, P242, DOI 10.1002/mds.870130208; Gassen M, 1998, Adv Pharmacol, V42, P320; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GLINKA YY, 1995, EUR J PHARM-ENVIRON, V292, P329, DOI 10.1016/0926-6917(95)90040-3; Gressens P, 1998, J NEUROCHEM, V70, P2574; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Guo QN, 1996, BBA-LIPID LIPID MET, V1304, P210, DOI 10.1016/S0005-2760(96)00122-1; Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066; Haqqi TM, 1999, P NATL ACAD SCI USA, V96, P4524, DOI 10.1073/pnas.96.8.4524; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Joseph JA, 1999, J NEUROSCI, V19, P8114; Lee SR, 2000, NEUROSCI LETT, V287, P191, DOI 10.1016/S0304-3940(00)01159-9; Levites Y, 2002, BIOCHEM PHARMACOL, V63, P21, DOI 10.1016/S0006-2952(01)00813-9; Levites Y, 2001, J NEUROCHEM, V78, P1073, DOI 10.1046/j.1471-4159.2001.00490.x; Lin JK, 1999, BIOCHEM PHARMACOL, V58, P911, DOI 10.1016/S0006-2952(99)00112-4; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; MARUYAMA W, 2000, J NEURAL TRANSM-SUPP, V60, P147; Masuda M, 2001, CLIN CANCER RES, V7, P4220; MATSUOKA Y, 1995, J PHARMACOL EXP THER, V274, P602; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Nanjo F, 1996, FREE RADICAL BIO MED, V21, P895, DOI 10.1016/0891-5849(96)00237-7; Pan MH, 2000, BIOCHEM PHARMACOL, V59, P357, DOI 10.1016/S0006-2952(99)00335-4; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Samanta S, 1998, J NEUROCHEM, V70, P2082; Satoh T, 2000, NEUROSCI LETT, V288, P163, DOI 10.1016/S0304-3940(00)01229-5; Schroeter H, 2001, BIOCHEM J, V358, P547, DOI 10.1042/0264-6021:3580547; Schroeter H, 2000, FREE RADICAL BIO MED, V29, P1222, DOI 10.1016/S0891-5849(00)00415-9; Singer CA, 1999, J NEUROSCI, V19, P2455; Small DL, 1996, NEUROPHARMACOLOGY, V35, P1037, DOI 10.1016/S0028-3908(96)00028-7; STONER GD, 1995, J CELL BIOCHEM, P169; Tremblay R, 1999, J NEUROCHEM, V72, P102, DOI 10.1046/j.1471-4159.1999.0720102.x; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yu R, 1997, CARCINOGENESIS, V18, P451, DOI 10.1093/carcin/18.2.451; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4	60	327	361	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30574	30580		10.1074/jbc.M202832200	http://dx.doi.org/10.1074/jbc.M202832200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12058035	hybrid			2022-12-25	WOS:000177579800024
J	Pojasek, K; Raman, R; Kiley, P; Venkataraman, G; Sasisekharan, R				Pojasek, K; Raman, R; Kiley, P; Venkataraman, G; Sasisekharan, R			Biochemical characterization of the chondroitinase B active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOBACTERIUM-HEPARINUM; ENZYMATIC DEGRADATION; DERMATAN SULFATE; DIRECTED MUTAGENESIS; FORCE-FIELD; GLYCOSAMINOGLYCANS; LYASE; AC; OLIGOSACCHARIDES; IDENTIFICATION	Chondroitinase B from Flavobacterium heparinum is the only known lyase that cleaves the glycosaminoglycan, dermatan sulfate (DS), as its sole substrate. A recent co-crystal structure of chondroitinase B with a disaccharide product of DS depolymerization has provided some insight into the location of the active site and suggested potential roles of some active site residues in substrate binding and catalysis. However, this co-crystal structure was not representative of the actual enzyme-substrate complex, because the disaccharide product did not have the right length or the chemical structure of the minimal substrate (tetrasaccharide) involved in catalysis. Therefore, only a limited picture of the functional role of active site residues in DS depolymerization was presented in previous structural studies. In this study, by docking a DS tetrasaccharide into the proposed active site of the enzyme, we have identified novel roles of specific active site amino acids in the catalytic function of chondroitinase B. Our conformational analysis also revealed a unique, symmetrical arrangement of active site amino acids that may impinge on the catalytic mechanism of action of chondroitinase B. The catalytic residues Lys-250, Arg-271, His-272, and Glu-333 along with the substrate binding residues Arg-363 and Arg-364 were mutated using site-directed mutagenesis, and the kinetics and product profile of each mutant were compared with recombinant chondroitinase B. Mutating Lys-250 to alanine resulted in inactivation of the enzyme, potentially attributable to the role of the residue in stabilizing the carbanion intermediate formed during enzymatic catalysis. The His-272 and Glu-333 mutants showed diminished enzymatic activity that could be indicative of a possible role for one or both residues in the abstraction of the C-5 proton from the galactosamine. In addition, the Arg-364 mutant had an altered product profile after exhaustive digestion of DS, suggesting a role for this residue in defining the substrate specificity of chondroitinase B.	MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Bioengn & Environm Hlth, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073, R37GM057073, T32GM008334] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57073, 5T32 GM 08334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Daidouji K, 2002, DIGEST DIS SCI, V47, P331, DOI 10.1023/A:1013718021713; Denholm EM, 2001, EUR J PHARMACOL, V416, P213, DOI 10.1016/S0014-2999(01)00884-6; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; GACESA P, 1992, INT J BIOCHEM, V24, P545, DOI 10.1016/0020-711X(92)90325-U; Gandra M, 2000, GLYCOBIOLOGY, V10, P1333, DOI 10.1093/glycob/10.12.1333; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GU KN, 1995, BIOCHEM J, V312, P569, DOI 10.1042/bj3120569; HOMANS SW, 1990, BIOCHEMISTRY-US, V29, P9110, DOI 10.1021/bi00491a003; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; HUIGE CJM, 1995, J COMPUT CHEM, V16, P56, DOI 10.1002/jcc.540160106; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; Lin B, 1997, BIOCHEM BIOPH RES CO, V231, P379, DOI 10.1006/bbrc.1997.6107; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; Monagle P, 1998, J BIOL CHEM, V273, P33566, DOI 10.1074/jbc.273.50.33566; Nadanaka S, 1997, GLYCOBIOLOGY, V7, P253, DOI 10.1093/glycob/7.2.253; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Pojasek K, 2000, BIOCHEMISTRY-US, V39, P4012, DOI 10.1021/bi992514k; Pojasek K, 2001, BIOCHEM BIOPH RES CO, V286, P343, DOI 10.1006/bbrc.2001.5380; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; Sasisekharan R, 1996, J BIOL CHEM, V271, P3124, DOI 10.1074/jbc.271.6.3124; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Shriver Z, 1998, J BIOL CHEM, V273, P10160, DOI 10.1074/jbc.273.17.10160; Shriver Z, 1998, J BIOL CHEM, V273, P22904, DOI 10.1074/jbc.273.36.22904; Shriver Z, 2002, TRENDS CARDIOVAS MED, V12, P71, DOI 10.1016/S1050-1738(01)00150-5; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; VENKATARAMAN G, 1994, P NATL ACAD SCI USA, V91, P6171, DOI 10.1073/pnas.91.13.6171; Vicente CP, 2001, THROMB HAEMOSTASIS, V86, P1215, DOI 10.1055/s-0037-1616054	32	14	34	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31179	31186		10.1074/jbc.M201552200	http://dx.doi.org/10.1074/jbc.M201552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063249	hybrid			2022-12-25	WOS:000177579800098
J	Gale, AJ; Tsavaler, A; Griffin, JH				Gale, AJ; Tsavaler, A; Griffin, JH			Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; BLOOD-COAGULATION; ANTICOAGULANT; INHIBITION; PLASMA; INACTIVATION; MECHANISM; CLEAVAGE; DOMAIN	The anticoagulant human plasma serine protease, activated protein C (APC), inhibits blood coagulation by specific inactivation of the coagulation cofactors factor Va (FVa) and factor VIIIa. Site-directed mutagenesis of residues in three surface loops of a positive exosite located on APC was used to identify residues that play a significant role in binding to FVa. Eighteen different residues were mutated to alanine singly, in pairs, or in triple mutation combinations. Mutant APC proteins were purified and characterized for their inactivation of FVa. Three APC residues were identified that provide major contributions to FVa interactions: Lys(193), Arg(229), and Arg(230). In addition, four residues made significant minor contributions to FVa interactions: Lys(191), Lys(192), Asp(214), and Glu(215). All of these residues primarily contribute to APC cleavage at Arg(506) in FVa and play a small role in the interaction of APC with the Arg(306) cleavage site. In conjunction with previously published work, these results define an extensive FVa binding site in the positive exosite of APC that is primarily involved in binding and cleaving at Arg(506) on FVa.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Gale, AJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.	agale@scripps.edu		Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL052246, R01HL052246, R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21544, HL52246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; FISHER CL, 1994, PROTEIN SCI, V3, P588; Friedrich U, 2001, J BIOL CHEM, V276, P23105, DOI 10.1074/jbc.M103138200; Friedrich U, 2001, J BIOL CHEM, V276, P24122, DOI 10.1074/jbc.M011567200; Gale AJ, 2000, BLOOD, V96, P585; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; HEEB MJ, 1989, BLOOD, V73, P446; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARLAR RA, 1982, BLOOD, V59, P1067; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESTERS RM, 1993, PROTEIN SCI, V2, P1482, DOI 10.1002/pro.5560020912; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Pellequer JL, 2000, THROMB HAEMOSTASIS, V84, P849, DOI 10.1055/s-0037-1614127; Rintelen C, 2001, THROMB HAEMOSTASIS, V85, P274, DOI 10.1055/s-0037-1615694; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016	26	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28836	28840		10.1074/jbc.M204363200	http://dx.doi.org/10.1074/jbc.M204363200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12063259	hybrid			2022-12-25	WOS:000177342600065
J	Lin, HM; Zhao, L; Cheng, SY				Lin, HM; Zhao, L; Cheng, SY			Cyclin D1 is a ligand-independent co-repressor for thyroid hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; NUCLEAR RECEPTOR; N-COR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL REPRESSION; CELL-PROLIFERATION; CLASS-I; ACTIVATION; SMRT; ACETYLTRANSFERASE	Thyroid hormone receptors (TRs) are critical regulators of growth, differentiation, and homeostasis. TRs function by regulating the expression of thyroid hormone (T3) target genes in both ligand-dependent and -independent pathways. Distinct classes of co-regulatory proteins modulate these two pathways. We show here a novel role of cyclin D1 as a T3-independent corepressor for TRs. Cyclin D1 interacted with TR in vitro and in cells in a ligand-independent manner. Cyclin D1 acted to repress both the silencing activity of the unliganded TR and the transcriptional activity of the liganded TR. The repression was not due to the inhibition of the binding of TR to the thyroid hormone response element but by serving as a ligand-independent bridging factor to selectively recruit HDAC3 to form ternary complexes. The repression was augmented by increasing expression of HDAC3 but not by HDAC1 and was alleviated by trichostatin A. Thus, cyclin D1 is a novel ligand-independent co-repressor that opens a new paradigm to understand the molecular basis of the silencing action of TR.	NCI, Mol Biol Lab, NIH, Canc Res Ctr,Gene Regulat Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cheng, SY (corresponding author), NCI, Mol Biol Lab, NIH, Canc Res Ctr,Gene Regulat Sect, 37 Convent Dr,Rm 5128A2,MSC 4264, Bethesda, MD 20892 USA.							Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; BERNARDS R, 1999, BIOCHIM BIOPHYS ACTA, V1424, P17; BHAT MK, 1995, BIOCHEMISTRY-US, V34, P10591, DOI 10.1021/bi00033a034; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Jones PL, 2001, J BIOL CHEM, V276, P8807, DOI 10.1074/jbc.C000879200; Kao HY, 2000, GENE DEV, V14, P55; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhu XG, 1997, ENDOCRINOLOGY, V138, P1456, DOI 10.1210/en.138.4.1456; Zhu XG, 1997, J BIOL CHEM, V272, P9048; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	37	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28733	28741		10.1074/jbc.M203380200	http://dx.doi.org/10.1074/jbc.M203380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048199	hybrid			2022-12-25	WOS:000177342600051
J	Albertoni, M; Shaw, PH; Nozaki, M; Godard, S; Tenan, M; Hamou, MF; Fairlie, DW; Breit, SN; Paralkar, VM; de Tribolet, N; Van Meir, EG; Hegi, ME				Albertoni, M; Shaw, PH; Nozaki, M; Godard, S; Tenan, M; Hamou, MF; Fairlie, DW; Breit, SN; Paralkar, VM; de Tribolet, N; Van Meir, EG; Hegi, ME			Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1	ONCOGENE			English	Article						MIC-1; glioma; anoxia; p53; HIF-1	TGF-BETA SUPERFAMILY; GROWTH-FACTOR-BETA; WILD-TYPE P53; RECEPTOR NUCLEAR TRANSLOCATOR; BONE MORPHOGENETIC PROTEIN; TUMOR ANGIOGENESIS; GENE-EXPRESSION; MAMMALIAN-CELLS; MEMBER; HYPOXIA	Human astrocytic brain tumors select for mutations in the p53 tumor suppressor gene early in malignant progression. p53 is activated upon various kinds of cellular stress leading to apoptosis or cell cycle arrest, but is also implicated in complex biological processes such as inhibition of angiogenesis and metastasis. In an effort to shed light on consequences mediated by p53 inactivation in gliomas, we established the fet-On system for p53 in the LN-Z308 glioblastoma cell line. The macrophage inhibitory cytokine-1 (MIC-1) gene was identified as a most prominent p53 target gene upon gene expression profiling. Oxygen deprivation, an important cellular stress, revealed MIC-1 as an anoxia responsive gene in glioblastoma cell lines. MIC-1 up-regulation by anoxia is mediated through an alternative, p53 and hypoxia inducible factor 1 (HIF-1) independent pathway. Furthermore, ectopic expression of MIC-1 in LN-Z308 cell line completely abolished its inherent tumorigenicity in nude mice, while proliferation in vitro was not affected. In the present experimental model MIC-1 may exert its anti-tumorigenic properties via a paracrine mechanism mediated by host cells in vivo. Taken together, these data suggest that MIC-1 is an important downstream mediator of p53 function, while acting itself as an intercessor of cellular stress signaling and exerting anti-tumorigenic activities.	Univ Lausanne Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Univ Lausanne, Inst Pathol, Expt Oncol Lab, CH-1011 Lausanne, Switzerland; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ S Wales, Sydney, NSW 2010, Australia; Prizer Cent Res, Groton, CT USA; Emory Univ, Mol Neurooncol Lab, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; St Vincents Hospital Sydney; University of New South Wales Sydney; Emory University; Emory University	Hegi, ME (corresponding author), CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, BH19-110, CH-1011 Lausanne, Switzerland.		Fairlie, Walter/M-8401-2015; Hegi, Monika/O-4796-2015	Fairlie, Walter/0000-0002-2498-1160; Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; BONNEKOH B, 1989, ARCH DERMATOL RES, V281, P487, DOI 10.1007/BF00510085; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, GENE, V237, P105, DOI 10.1016/S0378-1119(99)00309-1; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Detmer K, 1999, BLOOD CELL MOL DIS, V25, P310, DOI 10.1006/bcmd.1999.0259; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Fairlie WD, 2001, BIOCHEMISTRY-US, V40, P65, DOI 10.1021/bi001064p; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Hsiao EC, 2000, MOL CELL BIOL, V20, P3742, DOI 10.1128/MCB.20.10.3742-3751.2000; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kessler R, 2000, CANCER RES, V60, P1403; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Schober A, 2001, J COMP NEUROL, V439, P32, DOI 10.1002/cne.1333; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Strelau J, 2000, J NEUROSCI, V20, P8597; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405	43	139	154	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4212	4219		10.1038/sj.onc.1205610	http://dx.doi.org/10.1038/sj.onc.1205610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082608				2022-12-25	WOS:000176174200003
J	Opi, S; Peloponese, JM; Esquieu, D; Campbell, G; de Mareuil, J; Walburger, A; Solomiac, M; Gregoire, C; Bouveret, E; Yirrell, DL; Loret, EP				Opi, S; Peloponese, JM; Esquieu, D; Campbell, G; de Mareuil, J; Walburger, A; Solomiac, M; Gregoire, C; Bouveret, E; Yirrell, DL; Loret, EP			Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; KAPOSIS-SARCOMA; AIDS VIRUS; T-CELLS; PROTEIN; TRANSCRIPTION; TRANSACTIVATOR; LYMPHOCYTES; VACCINATION; ASSIGNMENT	Clinical studies show that in the absence of anti-retroviral therapy an immune response against the human immunodeficiency virus type 1 (HIV-1), transacting transcriptional activator (Tat) protein correlates with long term non-progression. The purpose of this study is to try to understand what can trigger an effective immune response against Tat. We used five Tat variants from HIV strains identified in different parts of the world and showed that mutations of as much as 38% exist without any change in activity. Rabbit sera were raised against Tat variants identified in rapid-progressor patients (Tat HXB2, a European variant and Tat Eli, an African variant) and a long term non-progressor patient (Tat Oyi, an inactive African variant). Enzymelinked immunosorbent assay (ELISA) results showed that anti-Tat Oyi serum had the highest antibody titer and was the only one to have a broad antibody response against heterologous Tat variants. Surprisingly, Tat HXB2 was better recognized by anti-Tat Oyi serum compared with anti-Tat HXB2 serum. Western blots showed that non-homologous Tat variants were recognized by antibodies directed against conformational epitopes. This study suggests that the primary and tertiary structures of the Tat variant from the long term non-progressor patient are critical to the induction of a broad and effective antibody response against Tat.	Inst Biol Struct & Microbiol, Lab Ingn Syst Macromol, CNRS, UPR 9027, F-13402 Marseille, France; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Univ Edinburgh, Ctr HIV Res, Edinburgh EH9 3JN, Midlothian, Scotland; Uganda Virus Res Inst, Programme AIDS Uganda, MRC, Entebbe, Uganda	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Edinburgh; Uganda Virus Research Institute	Loret, EP (corresponding author), Inst Biol Struct & Microbiol, Lab Ingn Syst Macromol, CNRS, UPR 9027, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.	loret@ibsm.cnrs-mrs.fr	Campbell, Grant/C-9018-2011	Campbell, Grant/0000-0003-3927-1994; Peloponese, Jean-Marie/0000-0002-9677-9703; Bouveret, Emmanuelle/0000-0001-5511-6375				Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781; ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Cafaro A, 2001, VACCINE, V19, P2862, DOI 10.1016/S0264-410X(01)00002-0; Carr JK, 1996, J VIROL, V70, P5935, DOI 10.1128/JVI.70.9.5935-5943.1996; Cohen SS, 1999, P NATL ACAD SCI USA, V96, P10842, DOI 10.1073/pnas.96.19.10842; Delaporte E, 1996, AIDS, V10, P903, DOI 10.1097/00002030-199607000-00014; Demirhan I, 2000, J HUMAN VIROL, V3, P137; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996; Goldstein G, 2000, VACCINE, V18, P2789, DOI 10.1016/S0264-410X(00)00085-2; Gregoire C, 2001, BIOPOLYMERS, V62, P324, DOI 10.1002/bip.10000; HUET T, 1989, AIDS, V3, P707, DOI 10.1097/00002030-198911000-00004; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184, DOI 10.1097/00042560-200202010-00013; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; Peloponese JM, 1999, J BIOL CHEM, V274, P11473, DOI 10.1074/jbc.274.17.11473; Peloponese JM, 2000, CR ACAD SCI III-VIE, V323, P883, DOI 10.1016/S0764-4469(00)01228-2; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Re MC, 2001, J CLIN VIROL, V21, P81, DOI 10.1016/S1386-6532(00)00189-X; RODMAN TC, 1993, P NATL ACAD SCI USA, V90, P7719, DOI 10.1073/pnas.90.16.7719; Secchiero P, 1999, J IMMUNOL, V162, P2427; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Weiss JM, 1999, J IMMUNOL, V163, P2953; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Zagury J F, 1998, J Hum Virol, V1, P282	36	34	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35915	35919		10.1074/jbc.M204393200	http://dx.doi.org/10.1074/jbc.M204393200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12080071	hybrid			2022-12-25	WOS:000178275100021
J	Muto, M; Kanari, Y; Kubo, E; Takabe, T; Kurihara, T; Fujimori, A; Tatsumi, K				Muto, M; Kanari, Y; Kubo, E; Takabe, T; Kurihara, T; Fujimori, A; Tatsumi, K			Targeted disruption of Np95 gene renders murine embryonic stem cells hypersensitive to DNA damaging agents and DNA replication blocks.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA; NUCLEAR ANTIGEN; SCHIZOSACCHAROMYCES-POMBE; CHECKPOINT PATHWAYS; CHROMATID EXCHANGES; CYCLE CHECKPOINTS; MEIOTIC CELLS; S-PHASE; PROTEIN; REPAIR	NP95, which contains a ubiquitin-like domain, a cyclin A/E-Cdk2 phosphorylation site, a retinoblastoma (Rb) binding motif, and a ring finger domain, has been shown to be colocalized as foci with proliferating cell nuclear antigen in early and mid-S phase nuclei. We established Np95 nulligous embryonic stem cells by replacing the exons 2-7 of the Np95 gene with a neo cassette and by selecting out a spontaneously occurring homologous chromosome crossing over with a higher concentration of neomycin. Np95-null cells were more sensitive to x-rays, UV light, N-methyl-N"-nitro-N-nitrosoguanidine (MNNG), and hydroxyurea than embryonic stem wild type (Np95(+/+)) or heterozygously inactivated (Np95(+/-)) cells. Expression of transfected Np95 cDNA in Np95-null cells restored the resistance to x-rays, UV, MNNG, or hydroxyurea concurrently to a level similar to that of Np95(+/-) cells, although slightly below that of wild type (Np95(+/-)) cells. These findings suggest that NP95 plays a role in the repair of DNA damage incurred by these agents. The frequency of spontaneous sister chromatid exchange was significantly higher for Np95-null cells than for Np95(+/-) cells or Np95(+/-) cells (p < 0.001). We conclude that NP95 functions as a common component in the multiple response pathways against DNA damage and replication arrest and thereby contributes to genomic stability.	Natl Inst Radiol Sci, Res Ctr Radiat Safety, Inage Ku, Chiba 2638555, Japan; Kanazawa Med Univ, Med Res Inst, Div Basic Sci, Kanazawa, Ishikawa 9200293, Japan	National Institutes for Quantum Science & Technology; Kanazawa Medical University	Tatsumi, K (corresponding author), Natl Inst Radiol Sci, Res Ctr Radiat Safety, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.							ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Chen JJ, 2000, CANCER RES, V60, P5037; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cleaver JE, 1996, MUTAGENESIS, V11, P183, DOI 10.1093/mutage/11.2.183; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fujimori A, 1998, MAMM GENOME, V9, P1032, DOI 10.1007/s003359900920; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; German J, 1998, GENETIC BASIS HUMAN, P301; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUMBERT C, 1992, J CELL SCI, V103, P97; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KLEIJER WJ, 1994, INT J RADIAT BIOL, V66, pS167, DOI 10.1080/09553009414552001; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIHARA T, 1987, MUTAT RES, V184, P147, DOI 10.1016/0167-8817(87)90071-X; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liu QH, 2000, GENE DEV, V14, P1448; Miura M, 2001, EXP CELL RES, V263, P202, DOI 10.1006/excr.2000.5115; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Muto M, 1995, CELL PROLIFERAT, V28, P645, DOI 10.1111/j.1365-2184.1995.tb00051.x; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; Roy SK, 2000, CANCER GENET CYTOGEN, V118, P52, DOI 10.1016/S0165-4608(99)00191-0; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Takai H, 2000, GENE DEV, V14, P1439; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang Y, 2000, GENE DEV, V14, P927; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WIT JD, 1981, MUTAT RES, V80, P221; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	49	91	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34549	34555		10.1074/jbc.M205189200	http://dx.doi.org/10.1074/jbc.M205189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12084726	hybrid			2022-12-25	WOS:000177959100128
J	Damdimopoulos, AE; Miranda-Vizuete, A; Pelto-Huikko, M; Gustafsson, JA; Spyrou, G				Damdimopoulos, AE; Miranda-Vizuete, A; Pelto-Huikko, M; Gustafsson, JA; Spyrou, G			Human mitochondrial thioredoxin - Involvement in mitochondrial membrane potential and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DNA-BINDING ACTIVITY; PERMEABILITY TRANSITION; GAMMA-SUBUNIT; ATP SYNTHASE; APOPTOSIS; PROTEIN; EXPRESSION; REDUCTION; INDUCTION	Thioredoxins (Trx) are a class of small multifunctional redox-active proteins found in all organisms. Recently, we reported the cloning of a mitochondrial thioredoxin, Trx2, from rat heart. To investigate the biological role of Trx2 we have isolated the human homologue, hTrx2, and generated HEK-293 cells overexpressing Trx2 (HEK-Trx2). Here, we show that HEK-Trx2 cells are more resistant toward etoposide. In addition, HEK-Trx2 are more sensitive toward rotenone, an inhibitor of complex I of the respiratory chain. Finally, overexpression of Trx2 confers an increase in mitochondrial membrane potential, DeltaPsi(m). Treatment with oligomycin could both reverse the effect of rotenone and decrease the membrane potential suggesting that Trx2 interferes with the activity of ATP synthase. Taken together, these results suggest that Trx2 interacts with specific components of the mitochondrial respiratory chain and plays an important role in the regulation of the mitochondrial membrane potential.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Tampere Univ Hosp, Dept Dev Biol, FIN-33101 Tampere, Finland	Karolinska Institutet; Tampere University; Tampere University Hospital	Spyrou, G (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	giannis.spyrou@cbt.ki.se	IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Belogrudov GI, 2002, J BIOL CHEM, V277, P6097, DOI 10.1074/jbc.M111256200; Buckman JF, 2001, J NEUROSCI, V21, P5054, DOI 10.1523/JNEUROSCI.21-14-05054.2001; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; IRELAND RC, 1995, ARCH BIOCHEM BIOPHYS, V319, P470, DOI 10.1006/abbi.1995.1319; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Janke C, 2002, EMBO J, V21, P181, DOI 10.1093/emboj/21.1.181; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mantymaa P, 2000, BRIT J HAEMATOL, V108, P574, DOI 10.1046/j.1365-2141.2000.01852.x; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Rybnikova E, 2000, EUR J NEUROSCI, V12, P1669, DOI 10.1046/j.1460-9568.2000.00059.x; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Stefanelli C, 1997, BIOCHEM J, V322, P909, DOI 10.1042/bj3220909; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VALLE VGR, 1993, ARCH BIOCHEM BIOPHYS, V307, P1, DOI 10.1006/abbi.1993.1551; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; YAMAMOTO T, 1989, GENE, V80, P337; YU LM, 1988, J BIOL CHEM, V263, P19342; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	41	167	175	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33249	33257		10.1074/jbc.M203036200	http://dx.doi.org/10.1074/jbc.M203036200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080052	hybrid			2022-12-25	WOS:000177859000110
J	Epand, RF; Martinou, JC; Fornallaz-Mulhauser, M; Hughes, DW; Epand, RM				Epand, RF; Martinou, JC; Fornallaz-Mulhauser, M; Hughes, DW; Epand, RM			The apoptotic protein tBid promotes leakage by altering membrane curvature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CARDIOLIPIN-PHOSPHATIDYLCHOLINE VESICLES; HEXAGONAL PHASE-TRANSITION; MITOCHONDRIAL-MEMBRANE; CA-2+-INDUCED FUSION; BCL-2 FAMILY; OLIGOMERIZES BAK; CONTAINING MODEL; LIPID-MEMBRANES; CELL-DEATH	The apoptotic protein tBid is effective in promoting both leakage and lipid mixing in liposomes composed of cardiolipin and phosphatidylcholine at a molar ratio of 1:2 in the presence of calcium. When half of the phosphatidylcholine component of these liposomes is replaced with phosphatidylethanolamine, a lipid that promotes negative membrane curvature, the rates of both leakage and lipid mixing caused by tBid are substantially increased. Replacement of cardiolipin with phosphatidylglycerol, a lipid that is structurally similar to cardiolipin but does not promote negative membrane curvature in the presence of calcium, prevents the tBid from promoting leakage. The promotion of leakage by tBid is also inhibited by several substances that promote positive membrane curvature, including lysophosphatidylcholine, tritrpticin, a potent antimicrobial peptide, and cyclosporin A, a known inhibitor of cytochrome c release from mitochondria. We directly measured the effect of tBid on membrane curvature by P-31 NMR. We found that tBid promotes the formation of highly curved non-lamellar phases. All of these data are consistent with the hypothesis that tBid promotes negative curvature, and as a result it destabilizes bilayer membranes. Bcl-X-L inhibits leakage and lipid mixing induced by tBid. Bcl-X-L is anti-apoptotic. It reduces the promotion of non-bilayer phases by tBid, although by itself Bcl-X-L is capable of promoting their formation. Bcl-X-L has little effect on liposomal integrity. Our results suggest that the anti-apoptotic activity of Bcl-X-L is not a consequence of its interaction with membranes, but rather with other proteins, such as tBid.	McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Hlth Sci Ctr, Dept Chem, Hamilton, ON L8N 3Z5, Canada; Univ Geneva, Dept Biol Cellulaire, CH-1211 Geneva 4, Switzerland	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Geneva	Epand, RM (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.	epand@mcmaster.ca	, Richard/R-2316-2019	, Richard/0000-0002-9602-9558; martinou, Jean-claude/0000-0002-9847-2051				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDERSON DM, 1988, P NATL ACAD SCI USA, V85, P5364, DOI 10.1073/pnas.85.15.5364; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; CHERNOMORDIK L, 1995, BIOPHYS J, V69, P922, DOI 10.1016/S0006-3495(95)79966-0; CULLIS PR, 1980, BIOCHIM BIOPHYS ACTA, V600, P625, DOI 10.1016/0005-2736(80)90466-6; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V602, P477, DOI 10.1016/0005-2736(80)90327-2; Deng YR, 1999, J STRUCT BIOL, V127, P231, DOI 10.1006/jsbi.1999.4147; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7092, DOI 10.1021/bi00346a011; Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X; EPAND RM, 1987, J BIOL CHEM, V262, P1526; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; KELLER SL, 1993, BIOPHYS J, V65, P23, DOI 10.1016/S0006-3495(93)81040-3; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI L, 1995, CHEM PHYS LIPIDS, V76, P135, DOI 10.1016/0009-3084(95)02437-N; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Montes LR, 2002, J BIOL CHEM, V277, P11788, DOI 10.1074/jbc.M111568200; NICOLAY K, 1985, BIOCHIM BIOPHYS ACTA, V819, P55, DOI 10.1016/0005-2736(85)90195-6; Nielsen C, 2000, BIOPHYS J, V79, P2583, DOI 10.1016/S0006-3495(00)76498-8; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Ortiz A, 1999, BIOPHYS J, V77, P2003, DOI 10.1016/S0006-3495(99)77041-4; Polozov IV, 1997, BIOCHEMISTRY-US, V36, P9237, DOI 10.1021/bi970045l; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Van Loo G, 2002, CELL DEATH DIFFER, V9, P301, DOI 10.1038/sj.cdd.4400966; VANVENETIE R, 1982, BIOCHIM BIOPHYS ACTA, V692, P397, DOI 10.1016/0005-2736(82)90390-X; Vogel HJ, 2002, BIOCHEM CELL BIOL, V80, P49, DOI 10.1139/o01-213; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WILSCHUT J, 1982, BIOCHIM BIOPHYS ACTA, V690, P297, DOI 10.1016/0005-2736(82)90334-0; WILSCHUT J, 1985, BIOCHEMISTRY-US, V24, P4630, DOI 10.1021/bi00338a023; Wolkowicz P, 1988, Adv Exp Med Biol, V232, P131; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhai DY, 2001, EUR J BIOCHEM, V268, P48, DOI 10.1046/j.1432-1327.2001.01841.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	62	150	154	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32632	32639		10.1074/jbc.M202396200	http://dx.doi.org/10.1074/jbc.M202396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082098	hybrid			2022-12-25	WOS:000177859000032
J	Blais, A; Monte, D; Pouliot, F; Labrie, C				Blais, A; Monte, D; Pouliot, F; Labrie, C			Regulation of the human cyclin-dependent kinase inhibitor p18(INK4c) by the transcription factors E2F1 and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; PROTEIN FAMILY MEMBERS; CORE PROMOTER ELEMENT; BREAST-CANCER CELLS; N-TERMINAL REGION; RETINOBLASTOMA PROTEIN; REPRESS TRANSCRIPTION; DISTINCT MECHANISMS; GENE PROMOTER; TATA-BOX	The p18(INK4c) cyclin-dependent kinase inhibitor is an important regulator of cell cycle progression and cellular differentiation. We and others found that overexpressed E2F proteins up-regulate p18 expression. To better understand this phenomenon, we performed a functional analysis of the human p18 promoter. Deletion studies revealed that the E2F-responsive elements of the promoter are located within 131 bp upstream of the transcription start site. This region contains putative Sp1- and E2F-binding sites. Mutational inactivation of these elements revealed that the Sp1 sites were important for the basal activity of the promoter but could also mediate the effects of E2F1 on the p18 promoter. Moreover, we found that E2F1 and Sp1 can synergistically enhance the activity of the proximal p18 promoter. Gel shift analyses using p18 promoter-derived probes led to the identification of several multiprotein complexes that were found to contain different combinations of E2F proteins and/or Sp1. Recombinant E2F1 was also capable of binding to the E2F-binding sites. Chromatin immunoprecipitation experiments demonstrated that E2F1 and E2F4 associate with the p18 promoter in unperturbed cells. Based on these findings, we conclude that E2F proteins and Sp1 play an important role in the control of p18 expression.	CHU Laval, Mol Endocrinol & Oncol Res Ctr, Res Ctr, Ctr Hosp Univ Quebec, Ste Foy, PQ G1V 4G2, Canada; Inst Biol Lille, Format Rech Evolut 2527, F-59021 Lille, France	Laval University	Labrie, C (corresponding author), CHU Laval, Mol Endocrinol & Oncol Res Ctr, Res Ctr, Ctr Hosp Univ Quebec, Ste Foy, PQ G1V 4G2, Canada.	Claude.Labrie@crchul.ulaval.ca		Blais, Alexandre/0000-0003-2446-1883; monte, didier/0000-0002-0613-6203				Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Allen KE, 1997, J CELL SCI, V110, P2819; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Beck GR, 2001, CELL GROWTH DIFFER, V12, P61; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Blais A, 1998, BIOCHEM BIOPH RES CO, V247, P146, DOI 10.1006/bbrc.1998.8497; Botz J, 1996, MOL CELL BIOL, V16, P3401; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1998, COLD SPRING HARB SYM, V63, P75, DOI 10.1101/sqb.1998.63.75; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dong S, 2000, J CELL BIOCHEM, V77, P50, DOI 10.1002/(SICI)1097-4644(20000401)77:1<50::AID-JCB6>3.0.CO;2-C; DOU QP, 1994, J BIOL CHEM, V269, P1306; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Geng Y, 1996, ONCOGENE, V12, P1173; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jensen DE, 1997, J CELL BIOCHEM, V67, P24, DOI 10.1002/(SICI)1097-4644(19971001)67:1<24::AID-JCB3>3.0.CO;2-Y; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kovalev GI, 2001, J IMMUNOL, V167, P3285, DOI 10.4049/jimmunol.167.6.3285; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lapointe J, 1996, CANCER RES, V56, P4586; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Magae J, 1996, J CELL SCI, V109, P1717; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schrantz N, 2000, J IMMUNOL, V165, P4346, DOI 10.4049/jimmunol.165.8.4346; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Takahashi Y, 2000, GENE DEV, V14, P804; Tsihlias J, 1999, ANNU REV MED, V50, P401; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WALSH MJ, 1995, J BIOL CHEM, V270, P5289, DOI 10.1074/jbc.270.10.5289; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Zhou JN, 1996, ANTICANCER RES, V16, P1931; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139	78	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31679	31693		10.1074/jbc.M204554200	http://dx.doi.org/10.1074/jbc.M204554200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077144	hybrid			2022-12-25	WOS:000177718700049
J	Cheng, K; Li, Z; Fu, WY; Wang, JH; Fu, AKY; Ip, NY				Cheng, K; Li, Z; Fu, WY; Wang, JH; Fu, AKY; Ip, NY			Pctaire1 interacts with p35 and is a novel substrate for Cdk5/p35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MOUSE-BRAIN; IDENTIFICATION; ASSOCIATION; NEUREGULIN; EXPRESSION; ACTIVATOR; SUBUNIT; REGION; FAMILY	Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase that plays important roles during central nervous system development. Cdk5 kinase activity depends on its regulatory partners, p35 or p39, which are prominently expressed in the central nervous system. We have previously demonstrated the involvement of Cdk5 in the regulation of acetylcholine receptor expression at the neuromuscular junction, suggesting a novel functional role of Cdk5 at the synapse. Here we report the identification of Pctaire1, a member of the Cdk-related kinase family, as a p35-interacting protein in muscle. Binding of Pctaire1 to p35 can be demonstrated by in vitro binding assay and co-immunoprecipitation experiments. Pctaire1 is associated with p35 in cultured myotubes and skeletal muscle, and is concentrated at the neuromuscular junction. Furthermore, Pctaire1 can be phosphorylated by the Cdk5/p25 complex, and serine 95 is the major phosphorylation site. In brain and muscle of Cdk5 null mice, Pctaire1 activity is significantly reduced. Moreover, Pctaire1 activity is increased following preincubation with brain extracts and phosphorylation by the Cdk5/p25 complex. Taken together, our findings demonstrate that Pctaire1 interacts with p35, both in vitro and in vivo, and that phosphorylation. of Pctaire1 by Cdk5 enhances its kinase activity.	Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neuorsci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China.	BOIP@UST.HK		Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Fu, Kit Yu/0000-0003-4085-6201				Besset V, 1999, CELL GROWTH DIFFER, V10, P173; Charrasse S, 1999, CELL GROWTH DIFFER, V10, P611; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fu AKY, 1999, MOL CELL NEUROSCI, V14, P241, DOI 10.1006/mcne.1999.0784; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Fu WY, 2002, NEUROREPORT, V13, P243, DOI 10.1097/00001756-200202110-00014; Hirose T, 2000, EUR J BIOCHEM, V267, P2113, DOI 10.1046/j.1432-1327.2000.01218.x; Ip FCF, 2000, MOL CELL NEUROSCI, V16, P661, DOI 10.1006/mcne.2000.0892; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Le Boffant F, 1998, EUR J BIOCHEM, V257, P112, DOI 10.1046/j.1432-1327.1998.2570112.x; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li BS, 2001, P NATL ACAD SCI USA, V98, P12742, DOI 10.1073/pnas.211428098; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; OKUDA T, 1992, ONCOGENE, V7, P2249; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Qi Z, 1998, J BIOL CHEM, V273, P2329, DOI 10.1074/jbc.273.4.2329; Sladeczek F, 1997, MOL GEN GENET, V254, P571, DOI 10.1007/s004380050453; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wang XJ, 2000, J BIOL CHEM, V275, P31763, DOI 10.1074/jbc.M004358200; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	23	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31988	31993		10.1074/jbc.M201161200	http://dx.doi.org/10.1074/jbc.M201161200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12084709	hybrid			2022-12-25	WOS:000177718700086
J	Guan, E; Wang, JH; Roderiquez, G; Norcross, MA				Guan, E; Wang, JH; Roderiquez, G; Norcross, MA			Natural truncation of the chemokine MIP-1 beta/CCL4 affects receptor specificity but not Anti-HIV-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; C-C CHEMOKINES; CD8(+) T-CELLS; CD26/DIPEPTIDYL-PEPTIDASE IV; CHEMOTACTIC ACTIVITY; BETA-CHEMOKINES; FACTOR 1-ALPHA; HIV-1 ENTRY; RANTES; IDENTIFICATION	Activated lymphocytes synthesize and secrete substantial amounts of the beta-chemokines macrophage inflammatory protein (MIP)-1alpha/CCL3 and MIP-1beta/CCL4, both of which inhibit infection of cells with human immunodeficiency virus type 1 (HIV-1). The native form of MIP-1beta secreted by activated human peripheral blood lymphocytes (MIP-1beta(3-69)) lacks the two NH2-terminal amino acids of the full-length protein. This truncated form of MIP-1beta has now been affinity-purified from the culture supernatant of such cells, and its structure has been confirmed by mass spectrometry. Functional studies of the purified protein revealed that MIP-1beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T cells. Characterization of the chemokine receptor specificity of MIP-1beta(3-69) showed that the truncated protein not only shares the ability of intact MIP-1beta to induce Ca2+ signaling through CCR5, but unlike the full-length protein, it also triggers a Ca2+ response via CCR1 and CCR2b. These results demonstrate that NH2-terminally truncated MIP-1beta functions as a chemokine agonist with expanded receptor reactivity, which may represent an important mechanism for regulation of immune cell recruitment during inflammatory and antiviral responses.	US FDA, CBER, Div Therapeut Prot, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Guan, E (corresponding author), US FDA, CBER, Div Therapeut Prot, Bldg 29B,Rm 4E12,HFM 535,8800 Rockville Pike, Bethesda, MD 20892 USA.	guan@cber.fda.gov; norcross@cber.fda.gov						Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bystry RS, 2001, NAT IMMUNOL, V2, P1126, DOI 10.1038/ni735; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 2000, P NATL ACAD SCI USA, V97, P13812, DOI 10.1073/pnas.240469997; Cordero OJ, 2001, RHEUMATOL INT, V21, P69, DOI 10.1007/s002960100134; Cuchacovich M, 2001, CLIN EXP RHEUMATOL, V19, P673; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; DEMEESTER IA, 1995, J LEUKOCYTE BIOL, V58, P325, DOI 10.1002/jlb.58.3.325; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Garzino-Demo A, 1999, P NATL ACAD SCI USA, V96, P11986, DOI 10.1073/pnas.96.21.11986; Gerli R, 1996, CLIN IMMUNOL IMMUNOP, V80, P31, DOI 10.1006/clin.1996.0091; Guan E, 2001, J BIOL CHEM, V276, P12404, DOI 10.1074/jbc.M006327200; Kamin-Lewis R, 2001, P NATL ACAD SCI USA, V98, P9283, DOI 10.1073/pnas.161298998; Laurence JS, 1998, BIOCHEMISTRY-US, V37, P9346, DOI 10.1021/bi980329l; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Muller A, 2000, J PATHOL, V192, P113; Nufer O, 1999, BIOCHEMISTRY-US, V38, P636, DOI 10.1021/bi981294s; Ohtsuki T, 1998, FEBS LETT, V431, P236, DOI 10.1016/S0014-5793(98)00763-7; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Signoret N, 1998, J CELL SCI, V111, P2819; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Struyf S, 1999, J IMMUNOL, V162, P4903; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; Struyf S, 2001, EUR J IMMUNOL, V31, P2170, DOI 10.1002/1521-4141(200107)31:7<2170::AID-IMMU2170>3.0.CO;2-D; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; Wang JH, 1999, J IMMUNOL, V163, P5763; Wang JH, 2001, J BIOL CHEM, V276, P49236, DOI 10.1074/jbc.M108523200; Wang JH, 2001, J IMMUNOL, V167, P3360, DOI 10.4049/jimmunol.167.6.3360; Wang JH, 1998, J VIROL, V72, P7642, DOI 10.1128/JVI.72.9.7642-7647.1998; Xin XM, 1999, FEBS LETT, V457, P219, DOI 10.1016/S0014-5793(99)01035-2; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3857, DOI 10.1073/pnas.95.7.3857	41	50	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32348	32352		10.1074/jbc.M203077200	http://dx.doi.org/10.1074/jbc.M203077200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070155	hybrid			2022-12-25	WOS:000177718700130
J	Liu, FJ; Usui, I; Evans, LG; Austin, DA; Mellon, PL; Olefsky, JM; Webster, NJG				Liu, FJ; Usui, I; Evans, LG; Austin, DA; Mellon, PL; Olefsky, JM; Webster, NJG			Involvement of both G(q/11) and G(s) proteins in gonadotropin-releasing hormone receptor-mediated signaling in L beta T2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE G-PROTEINS; GNRH RECEPTOR; PHOSPHOLIPASE-C; INOSITOL PHOSPHATE; COUPLED RECEPTORS; TRANSCRIPTIONAL REGULATION; TRANSDUCTION PATHWAYS; LUTEINIZING-HORMONE; INTRACELLULAR LOOP; KINASE ACTIVATION	The hypothalamic hormone gonadotropin-releasing hormone (GnRH) stimulates the synthesis and release of the pituitary gonadotropins. GnRH acts through a plasma membrane receptor that is a member of the G protein-coupled receptor (GPCR) family. These receptors interact with heterotrimeric G proteins to initiate downstream signaling. In this study, we have investigated which G proteins are involved in GnRH receptor-mediated signaling in LbetaT2 pituitary gonadotrope cells. We have shown previously that GnRH activates ERK and induces the c-fos and LHbeta genes in these cells. Signaling via the G(i) subfamily of G proteins was excluded, as neither ERK activation nor c-Fos and LHbeta induction was impaired by treatment with pertussis toxin or a cell-permeable peptide that sequesters Gbetagamma-subunits. GnRH signaling was partially mimicked by adenoviral expression of a constitutively active mutant of Galpha(q) (Q209L) and was blocked by a cell-permeable peptide that uncouples Galpha(q) from GPCRs. Furthermore, chronic activation of Gaq signaling induced a state of GnRH resistance. A cell-permeable peptide that uncouples Galpha(s) from receptors was also able to inhibit ERK, c-Fos, and LHbeta, indicating that both G(q/11) and G(s) proteins are involved in signaling. Consistent with this, GnRH caused GTP loading on G(s) and G(q/11) and increased intracellular cAMP. Artificial elevation of cAMP with forskolin activated ERK and caused a partial induction of c-Fos. Finally, treatment of Galpha(q) (Q209L)-infected cells with forskolin enhanced the induction of c-Fos showing that the two pathways are independent and additive. Taken together, these results indicate that the GnRH receptor activates both G(q/11) and G(s) signaling to regulate gene expression in LbetaT2 cells.	Univ Calif San Diego, Dept Med 0673, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Reprod Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; San Diego Vet Healthcare Syst, San Diego, CA 92161 USA; Med Res Serv, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Webster, NJG (corresponding author), Univ Calif San Diego, Dept Med 0673, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Webster, Nick/AAI-8410-2021		NICHD NIH HHS [U54 HD-12303, U54 HD012303-23, U54 HD012303-230011, P50 HD012303, U54 HD012303] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P50HD012303, U54HD012303] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alarid ET, 1996, DEVELOPMENT, V122, P3319; Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; Ando H, 2001, COMP BIOCHEM PHYS B, V129, P525, DOI 10.1016/S1096-4959(01)00356-6; Arora KK, 1998, J BIOL CHEM, V273, P25581, DOI 10.1074/jbc.273.40.25581; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; BOURNE GA, 1987, AM J PHYSIOL, V253, pE296, DOI 10.1152/ajpendo.1987.253.3.E296; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dickenson JM, 1998, EUR J PHARMACOL, V355, P85, DOI 10.1016/S0014-2999(98)00468-3; Drissi H, 1998, J BIOL CHEM, V273, P20168, DOI 10.1074/jbc.273.32.20168; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Gur G, 2002, MOL CELL ENDOCRINOL, V189, P125, DOI 10.1016/S0303-7207(01)00724-9; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAMM HE, 1994, METHOD ENZYMOL, V237, P423; Han XB, 1999, ENDOCRINOLOGY, V140, P2241, DOI 10.1210/en.140.5.2241; HAWES BE, 1993, ENDOCRINOLOGY, V132, P2124, DOI 10.1210/en.132.5.2124; HAWES BE, 1992, ENDOCRINOLOGY, V130, P2465, DOI 10.1210/en.130.5.2465; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; Hur EM, 2002, CELL SIGNAL, V14, P397, DOI 10.1016/S0898-6568(01)00258-3; Imai A, 1996, J CLIN ENDOCR METAB, V81, P3249, DOI 10.1210/jc.81.9.3249; Imamura T, 1999, MOL CELL BIOL, V19, P6765; JANOVICK JA, 1994, ENDOCRINOLOGY, V135, P2214, DOI 10.1210/en.135.5.2214; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; Lin XW, 1998, ENDOCRINOLOGY, V139, P3896, DOI 10.1210/en.139.9.3896; Liu FJ, 2002, MOL ENDOCRINOL, V16, P419, DOI 10.1210/me.16.3.419; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Maya-Nunez G, 2001, BIOL REPROD, V65, P561, DOI 10.1095/biolreprod65.2.561; Maya-Nunez G, 1999, ENDOCRINOLOGY, V140, P3452, DOI 10.1210/en.140.8.3452; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; NEER EJ, 1994, PROTEIN SCI, V3, P3; Nishida M, 2002, J BIOL CHEM, V277, P9036, DOI 10.1074/jbc.M107392200; Rebers FEM, 2000, AM J PHYSIOL-REG I, V278, pR1572, DOI 10.1152/ajpregu.2000.278.6.R1572; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Romoser VA, 2001, MOL ENDOCRINOL, V15, P125, DOI 10.1210/me.15.1.125; Shacham S, 2001, VITAM HORM, V63, P63, DOI 10.1016/S0083-6729(01)63003-6; Shacham S, 1999, ANN ENDOCRINOL-PARIS, V60, P79; SHAH BH, 1994, MOL PHARMACOL, V46, P1; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Ulloa-Aguirre A, 1998, ENDOCRINOLOGY, V139, P2472, DOI 10.1210/en.139.5.2472; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	48	144	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32099	32108		10.1074/jbc.M203639200	http://dx.doi.org/10.1074/jbc.M203639200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12050161	hybrid, Green Accepted			2022-12-25	WOS:000177718700100
J	Reunanen, N; Li, SP; Ahonen, M; Foschi, M; Han, JH; Kahari, VM				Reunanen, N; Li, SP; Ahonen, M; Foschi, M; Han, JH; Kahari, VM			Activation of p38 alpha MAPK enhances collagenase-1 (Matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; PROTEIN-KINASE; GENE-EXPRESSION; I COLLAGEN; 3-DIMENSIONAL COLLAGEN; GROWTH-FACTOR; TRANSFORMATION; ACID; PROMOTER; CELLS	Here, we have examined the role of distinct MAPK pathways in the regulation of collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by human skin fibroblasts. Tumor necrosis factor-alpha rapidly and transiently activated ERK1/2 and JNK in fibroblasts, whereas the activation of p38 MAPK was more persistent. Inhibition of p38 activity by SB203580 markedly (by 80-90%) inhibited induction of MMP-1 and MMP-3 expression by tumor necrosis factor-alpha, whereas blocking the activation of ERK1/2 by PD98059 had no effect. Activation of endogenous ERK1/2 by adenovirus-mediated transfer of constitutively active MEK1 resulted in potent induction of MMP-1 and MMP-3 expression. Activation of endogenous or adenovirally expressed p38alpha by adenovirally delivered constitutively active MKK3b and MKK6b also enhanced MMP-1 and MMP-3 expression and augmented the up-regulatory effect of ERK1/2 activation on the expression of these MMPs. Activation of ERK1/2 resulted in induction of c-jun, junB, and c-fos expression, whereas activation of p38 alone had no effect. In contrast, activation of p38alpha resulted in marked stabilization of MMP-1 and MMP-3 mRNAs. These results identify two distinct and complementary signaling mechanisms mediating induction of MMP-1 and MMP-3 expression in dermal fibroblasts: AP-1-dependent transcriptional activation via the ERK1/2 pathway and AP-1-independent enhancement via p38alpha MAPK by mRNA stabilization. It is conceivable that both modes of action play an important role in controlling the proteolytic phenotype of fibroblasts, e.g. in wound repair and tumor invasion.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Dept Med, FIN-20520 Turku, Finland; Univ Turku, Dept Biochem & Dermatol, FIN-20520 Turku, Finland; Univ Florence, Dept Internal Med, I-50134 Florence, Italy; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Florence; Scripps Research Institute	Kahari, VM (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kähäri, Veli-Matti/E-5144-2011; Kahari, Veli-Matti/T-4925-2019; Han, J/G-4671-2010	Kähäri, Veli-Matti/0000-0003-2421-9368; Kahari, Veli-Matti/0000-0003-2421-9368; 				Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; JAHAN I, 1993, IN VITRO CELL DEV-AN, V29A, P763; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; Laine P, 2000, BIOCHEM J, V349, P19, DOI 10.1042/0264-6021:3490019; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Messent AJ, 1998, J CELL SCI, V111, P1127; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OKA H, 1995, CANCER RES, V55, P4182; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Planus E, 1999, J CELL SCI, V112, P243; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Reunanen N, 2000, J BIOL CHEM, V275, P34634, DOI 10.1074/jbc.C000175200; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Ridley SH, 1997, J IMMUNOL, V158, P3165; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAUS J, 1988, J BIOL CHEM, V263, P6742; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Simon C, 1998, CANCER RES, V58, P1135; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 2000, CANCER RES, V60, P7156; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437	55	187	194	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32360	32368		10.1074/jbc.M204296200	http://dx.doi.org/10.1074/jbc.M204296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12060661	hybrid			2022-12-25	WOS:000177718700132
J	Lecointe, F; Namy, O; Hatin, I; Simos, G; Rousset, JP; Grosjean, H				Lecointe, F; Namy, O; Hatin, I; Simos, G; Rousset, JP; Grosjean, H			Lack of pseudouridine 38/39 in the anticodon arm of yeast cytoplasmic tRNA decreases in vivo recoding efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENES; SUPPRESSOR TRANSFER-RNAS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; SUBSTRATE-SPECIFICITY; TRANSLATION TERMINATION; FRAME MAINTENANCE; MESSENGER-RNA; IN-VIVO	Many different modified nucleotides are found in naturally occurring tRNA, especially in the anticodon region. Their importance for the efficiency of the translational process begins to be well documented. Here we have analyzed the in vivo effect of deleting genes coding for yeast tRNA-modifying enzymes, namely Pus1p, Pus3p, Pus4p, or Trm4p, on termination readthrough and +1 frameshift events. To this end, we have transformed each of the yeast deletion strains with a lacZ-luc dual-reporter vector harboring selected programmed recoding sites. We have found that only deletion of the PUS3 gene, encoding the enzyme that introduces pseudouridines at position 38 or 39 in tRNA, has an effect on the efficiency of the translation process. In this mutant, we have observed a reduced readthrough efficiency of each stop codon by natural nonsense suppressor tRNAs. This effect is solely due to the absence of pseudouridine 38 or 39 in tRNA because the inactive mutant protein Pus3[D151A]p did not restore the level of natural readthrough. Our results also show that absence of pseudouridine 39 in the slippery tRNA(UAG)(Leu) reduces +1 frameshift efficiency. Therefore, the presence of pseudouridine 38 or 39 in the tRNA anticodon arm enhances misreading of certain codons by natural nonsense tRNAs as well as promotes frameshifting on slippery sequences in yeast.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 11, Inst Genet & Microbiol, F-91405 Orsay, France; Univ Thessaly, Sch Med, Biochem Lab, Larisa 41222, Greece	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; University of Thessaly	Grosjean, H (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse,Bat 34, F-91198 Gif Sur Yvette, France.		Namy, Olivier/ABD-4379-2020; Namy, olivier/B-8906-2008; Simos, George/AAH-2596-2021	Lecointe, Francois/0000-0002-9596-2514; Simos, George/0000-0001-5453-3185; Hatin, Isabelle/0000-0002-4428-3079; Namy, Olivier/0000-0002-1143-5961				Agris PF, 1996, PROG NUCLEIC ACID RE, V53, P79, DOI 10.1016/S0079-6603(08)60143-9; Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427; Ansmant I, 2001, J BIOL CHEM, V276, P34934, DOI 10.1074/jbc.M103131200; ARNEZ JG, 1994, BIOCHEMISTRY-US, V33, P7560, DOI 10.1021/bi00190a008; Auffinger P, 1998, Modification and Editing of RNA, P103, DOI [10.1128/9781555818296.ch6, DOI 10.1128/9781555818296.CH6]; Auffinger P, 1998, MODIFICATION EDITING, P569; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Beier H, 2001, NUCLEIC ACIDS RES, V29, P4767, DOI 10.1093/nar/29.23.4767; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; Bidou L, 2000, RNA, V6, P952, DOI 10.1017/S1355838200000443; Bjork GR, 1999, FEBS LETT, V452, P47, DOI 10.1016/S0014-5793(99)00528-1; BRENNER M, 1972, J BIOL CHEM, V247, P4333; CARBONE MLA, 1991, CURR GENET, V19, P1; Charette M, 2000, IUBMB LIFE, V49, P341; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P10249, DOI 10.1021/bi00089a047; Curran J. F., 1998, MODIFICATION EDITING, P493; Davis DR, 1995, NUCLEIC ACIDS RES, V23, P5020, DOI 10.1093/nar/23.24.5020; Davis DR, 1998, J BIOMOL STRUCT DYN, V15, P1121, DOI 10.1080/07391102.1998.10509006; Davis DR., 1998, MODIFICATION EDITING, P85; Del Campo M, 2001, RNA, V7, P1603; Drugeon G, 1997, NUCLEIC ACIDS RES, V25, P2254, DOI 10.1093/nar/25.12.2254; Farabaugh PJ, 2000, PROG NUCLEIC ACID RE, V64, P131, DOI 10.1016/S0079-6603(00)64004-7; FEARON K, 1994, J BIOL CHEM, V269, P17802; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Grosshans H, 2000, GENE DEV, V14, P830; Grosshans H, 2001, J BIOL CHEM, V276, P46333, DOI 10.1074/jbc.M107141200; Gutgsell N, 2000, RNA, V6, P1870, DOI 10.1017/S1355838200001588; Gutgsell NS, 2001, RNA, V7, P990, DOI 10.1017/S1355838201000243; HAGERVALL TG, 1990, BIOCHIM BIOPHYS ACTA, V1050, P263, DOI 10.1016/0167-4781(90)90178-5; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+; HUTTENHOFER A, 1990, EMBO J, V9, P551, DOI 10.1002/j.1460-2075.1990.tb08142.x; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiang HQ, 1997, NUCLEIC ACIDS RES, V25, P2694, DOI 10.1093/nar/25.14.2694; JOHNSON PF, 1983, NATURE, V302, P681, DOI 10.1038/302681a0; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFONTAINE D, 1995, GENE DEV, V9, P2470, DOI 10.1101/gad.9.20.2470; LAFONTAINE D, 1994, J MOL BIOL, V241, P492, DOI 10.1006/jmbi.1994.1525; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; Li JN, 1997, J MOL BIOL, V271, P209, DOI 10.1006/jmbi.1997.1176; Li ZR, 2001, RNA, V7, P275, DOI 10.1017/S135583820100190X; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Morris DK, 1997, CURR BIOL, V7, P969, DOI 10.1016/S0960-9822(06)00416-7; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; Namy O, 2001, EMBO REP, V2, P787, DOI 10.1093/embo-reports/kve176; Namy O, 2002, MOL MICROBIOL, V43, P641, DOI 10.1046/j.1365-2958.2002.02770.x; NURSE K, 1995, RNA, V1, P102; PARKER J, 1982, MOL GEN GENET, V187, P405, DOI 10.1007/BF00332619; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; SCHULTZ DW, 1994, J MOL BIOL, V235, P1381, DOI 10.1006/jmbi.1994.1095; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STAHL G, 1995, NUCLEIC ACIDS RES, V23, P1557, DOI 10.1093/nar/23.9.1557; STROBEL MC, 1986, MOL CELL BIOL, V6, P2663, DOI 10.1128/MCB.6.7.2663; SULLIVAN MA, 1985, J BACTERIOL, V161, P377, DOI 10.1128/JB.161.1.377-384.1985; Sundararajan A, 1999, MOL CELL, V4, P1005, DOI 10.1016/S1097-2765(00)80229-4; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; VIMALADITHAN A, 1994, MOL CELL BIOL, V14, P8107, DOI 10.1128/MCB.14.12.8107; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEISSENBACH J, 1977, FEBS LETT, V82, P71, DOI 10.1016/0014-5793(77)80888-0; Wrzesinski J, 2000, IUBMB LIFE, V50, P33; WRZESINSKI J, 1995, RNA, V1, P437; ZERFASS K, 1992, NUCLEIC ACIDS RES, V20, P5911, DOI 10.1093/nar/20.22.5911	69	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30445	30453		10.1074/jbc.M203456200	http://dx.doi.org/10.1074/jbc.M203456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12058040	hybrid, Green Published			2022-12-25	WOS:000177579800008
J	Atkinson, LL; Fischer, MA; Lopaschuk, GD				Atkinson, LL; Fischer, MA; Lopaschuk, GD			Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL TRIGLYCERIDE TURNOVER; RAT-LIVER; HEART; REPERFUSION; INHIBITION; METABOLISM; EXPRESSION; MECHANISM; PATHWAYS; MUSCLE	Leptin regulates fatty acid metabolism in liver, skeletal muscle, and pancreas by partitioning fatty acids into oxidation rather than triacylglycerol (TG) storage. Although leptin receptors are present in the heart, it is not known whether leptin also regulates cardiac fatty acid metabolism. To determine whether leptin directly regulates cardiac fatty acid metabolism, isolated working rat hearts were perfused with 0.8 mm [9,10-H-3]palmitate and 5 mm [1-C-14]glucose to measure palmitate and glucose oxidation rates. Leptin (60 ng/ml) significantly increased palmitate oxidation rates 60% above control hearts (p < 0.05) and decreased TG content by 33% (p < 0.05) over the 60-min perfusion period. In contrast, there was no difference in glucose oxidation rates between leptin-treated and control hearts. Although leptin did not affect cardiac work, oxygen consumption increased by 30% (p < 0.05) and cardiac efficiency was decreased by 42% (p < 0.05). AMP-activated protein kinase (AMPK) plays a major role in the regulation of cardiac fatty acid oxidation by inhibiting acetyl-CoA carboxylase (ACC) and reducing malonyl-CoA levels. Leptin has also been shown to increase fatty acid oxidation in skeletal muscle through the activation of AMPK. However, we demonstrate that leptin had no significant effect on AMPK activity, AMPK phosphorylation state, ACC activity, or malonyl-CoA levels. AMPK activity and its phosphorylation state were also unaffected after 5 and 10 min of perfusion in the presence of leptin. The addition of insulin (100 microunits/ml) to the perfusate reduced the ability of leptin to increase fatty acid oxidation and decrease cardiac TG content. These data demonstrate for the first time that leptin activates fatty acid oxidation and decreases TG content in the heart. We also show that the effects of leptin in the heart are independent of changes in the AMPK-ACC-malonyl-CoA axis.	Univ Alberta, Muttart Diabet Res & Training Ctr, Fac Med, Dept Pediat,Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada	University of Alberta	Lopaschuk, GD (corresponding author), Univ Alberta, Heritage Med Res Ctr 423, Edmonton, AB T6G 2S2, Canada.	gary.lopaschuk@ualberta.ca						Baile CA, 2000, ANNU REV NUTR, V20, P105, DOI 10.1146/annurev.nutr.20.1.105; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; Carvalheira JBC, 2001, FEBS LETT, V500, P119, DOI 10.1016/S0014-5793(01)02591-1; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; CORR PB, 1989, J CLIN INVEST, V83, P927, DOI 10.1172/JCI113978; DANNO H, 1992, J NUTR SCI VITAMINOL, V38, P517, DOI 10.3177/jnsv.38.517; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; Fiordaliso F, 1999, CIRCULATION, V100, P759; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hynes GR, 2001, CURR OPIN LIPIDOL, V12, P321, DOI 10.1097/00041433-200106000-00012; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; KING MT, 1985, ANAL BIOCHEM, V146, P173, DOI 10.1016/0003-2697(85)90412-9; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; Leyva F, 1998, ARTERIOSCL THROM VAS, V18, P928, DOI 10.1161/01.ATV.18.6.928; Liu Q, 2002, J AM COLL CARDIOL, V39, P718, DOI 10.1016/S0735-1097(01)01803-4; Lopaschuk GD, 1997, MOL CELL BIOCHEM, V172, P137, DOI 10.1023/A:1006875823561; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Muoio DM, 1999, AM J PHYSIOL-ENDOC M, V276, pE913, DOI 10.1152/ajpendo.1999.276.5.E913; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; REGAN TJ, 1992, J AM COLL CARDIOL, V19, P1165, DOI 10.1016/0735-1097(92)90318-H; SADDIK M, 1992, J BIOL CHEM, V267, P3825; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Steinberg GR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1374, DOI 10.1152/ajpendo.2000.279.6.E1374; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V282, pE593, DOI 10.1152/ajpendo.00303.2001; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; WITTERS LA, 1992, J BIOL CHEM, V267, P284; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Yamagishi SI, 2001, J BIOL CHEM, V276, P25096, DOI 10.1074/jbc.M007383200; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; ZONERAICH S, 1993, CAN J CARDIOL, V9, P293	46	145	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29424	29430		10.1074/jbc.M203813200	http://dx.doi.org/10.1074/jbc.M203813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058043	hybrid			2022-12-25	WOS:000177509300011
J	Dwivedi, PP; Hii, CST; Ferrante, A; Tan, J; Der, CJ; Omdahl, JL; Morris, HA; May, BK				Dwivedi, PP; Hii, CST; Ferrante, A; Tan, J; Der, CJ; Omdahl, JL; Morris, HA; May, BK			Role of MAP kinases in the 1,25-dihydroxyvitamin D-3-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter - Specific functions for ERK1/ERK2 and ERK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; VITAMIN-D-RECEPTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; C-JUN; TNF-ALPHA; IDENTIFICATION; TRANSCRIPTION; PHOSPHORYLATION; COACTIVATOR	The current study investigated the action of 1,25-dihydroxyvitamin D-3 (1,25D) at the genomic and signal transduction levels to induce rat cytochrome P450C24 (CYP24) gene expression. A rat CYP24 promoter containing two vitamin D response elements and an Ets-1 binding site was used to characterize the mechanism of actions for the 1,25D secosteroid hormone. The Ets-1 binding site was determined to function cooperatively with the most proximal vitamin D response element in a hormone-dependent fashion. Evidence was obtained for distinct roles of ERK1/ERK2 and ERK5 in the 1,25D-inductive actions. Specifically, 1,25D stimulated the activities of ERK1/ERK2 and ERK5 in a Ras-dependent manner. Promoter induction was inhibited by mitogen-activated protein (MAP) kinase inhibitors (PD98059 and U0126) and a dominant-negative Ras mutant (Ras17N). Induction of CYP24 by 1,25D was also inhibited by overexpression of dominant-negative mutants of ERK1 and MEK5 (ERK1K71R and MEK5(A)). The p38 and JNK MAP kinases were not required for the action of 1,25D. 9-cis retinoid X receptor a (RXRalpha) interacted with ERK2 but not ERK5 in intact cells, whereas Ets-1 interacted preferentially with ERK5. Increased phosphorylation of RXRa and Ets-1 was detected in response to 1,25D. Activated ERK2 and ERK5 specifically phosphorylated RXRalpha and Ets-1, respectively. Mutagenesis of Ets-1 (T38A) reduced CYP24 promoter activity to levels observed with the dominant-negative MEK5(A) and inhibited ERK5-directed phosphorylation. Mutated RXRalpha (S260A) inhibited 1,25D-induced CYP24 promoter activity and abolished phosphorylation by activated ERK2. The 1,25D-inductive action through ERK5 involved Ets-1 phosphorylation at threonine 38, whereas hormone stimulation of ERK1/ERK2 required RXRalpha phosphorylation on serine 260. The ERK1/ERK2 and ERK5 modules provide a novel mechanism for linking the rapid signal transduction and slower transcription actions of 1,25D to induce CYP24 gene expression.	Univ New Mexico, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA; Univ Adelaide, Dept Mol Biosci Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Pediat, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Physiol, Adelaide, SA 5005, Australia; Womens & Childrens Hosp, Dept Immunopathol, Adelaide, SA 5005, Australia; Univ S Australia, Sch Pharm Mol & Biomed Sci, Adelaide, SA 5001, Australia; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Hanson Inst, Adelaide, SA 5005, Australia	University of New Mexico; University of Adelaide; University of Adelaide; University of Adelaide; Womens & Childrens Hospital Australia; University of South Australia; University of North Carolina; University of North Carolina Chapel Hill; Hanson Institute	Omdahl, JL (corresponding author), Univ New Mexico, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA.	jomdahl@salud.unm.edu	Morris, Howard A/G-4564-2010; Morris, Howard/L-6272-2019	Der, Channing/0000-0002-7751-2747				Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; Buitrago C, 2000, J CELL BIOCHEM, V79, P274, DOI 10.1002/1097-4644(20001101)79:2<274::AID-JCB100>3.0.CO;2-R; Carlberg C, 1998, CRIT REV EUKAR GENE, V8, P19, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.20; Chan ED, 1999, J IMMUNOL, V162, P415; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Chen SL, 2000, GENE DEV, V14, P1209; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Christakos S, 1996, BIOCHEM J, V316, P361, DOI 10.1042/bj3160361; Dranitzki-Elhalel M, 1999, J BONE MINER RES, V14, P1822, DOI 10.1359/jbmr.1999.14.11.1822; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; Hewison M., 1997, Vitamin D., P447; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Issa LL, 1998, INFLAMM RES, V47, P451, DOI 10.1007/s000110050360; Janulis M, 2001, MOL CELL BIOL, V21, P2235, DOI 10.1128/MCB.21.6.2235-2247.2001; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; Norman A. W., 1997, Vitamin D., P233; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; Omdahl J., 1997, Vitamin D., P69; Omdahl JL, 2001, STEROIDS, V66, P381, DOI 10.1016/S0039-128X(00)00157-4; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SLATER SJ, 1995, J BIOL CHEM, V270, P6639, DOI 10.1074/jbc.270.12.6639; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; St-Arnaud R, 2000, ENDOCRINOLOGY, V141, P2658, DOI 10.1210/en.141.7.2658; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	52	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29643	29653		10.1074/jbc.M204561200	http://dx.doi.org/10.1074/jbc.M204561200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048211	hybrid			2022-12-25	WOS:000177509300039
J	Martinez, ED; Danielsen, M				Martinez, ED; Danielsen, M			Loss of androgen receptor transcriptional activity at the G(1)/S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; EPIDERMAL GROWTH-FACTOR; RAT VENTRAL PROSTATE; CELL-CYCLE; RESPONSE ELEMENTS; UP-REGULATION; PROGESTERONE-RECEPTOR; HISTONE ACETYLATION; CHROMATIN-STRUCTURE; BINDING DOMAIN	Androgens are essential for the differentiation, growth, and maintenance of male-specific organs. The effects of androgens in cells are mediated by the androgen receptor (AR), a member of the nuclear receptor superfamily of transcription factors. Recently, transient transfection studies have shown that overexpression of cell cycle regulatory proteins affects the transcriptional activity of the AR. In this report, we characterize the transcriptional activity of endogenous AR through the cell cycle. We demonstrate that in G0, AR enhances transcription from an integrated steroid-responsive mouse mammary tumor virus promoter and also from an integrated androgen-specific probasin promoter. This activity is strongly reduced or abolished at the G(1)/S boundary. In S phase, the receptor regains activity, indicating that there is a transient regulatory event that inactivates the AR at the G(1)/S transition. This regulation is specific for the AR, since the related glucocorticoid receptor is transcriptionally active at the G(1)/S boundary. Not all of the effects of androgens are blocked, however, since androgens retain the ability to increase AR protein levels. The transcriptional inactivity of the AR at the G(1)/S junction coincides with a decrease in AR protein level, although activity can be partly rescued without an increase in receptor. Inhibition of histone deacetylases brings about this partial restoration of AR activity at the G(1)/S boundary, demonstrating the involvement of acetylation pathways in the cell cycle regulation of AR transcriptional activity. Finally, a model is proposed that explains the inactivity of the AR at the G(1)/S transition by integrating receptor levels, the action of cell cycle regulators, and the contribution of histone acetyltransferase-containing coactivators.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Danielsen, M (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,Rm 355,3900 Reservoir Rd NW, Washington, DC 20007 USA.	dan@bc.georgetown.edu	danielsen, mark/AAE-9813-2020; Danielsen, Mark/B-1606-2008	danielsen, mark/0000-0002-0923-9945; Danielsen, Mark/0000-0002-0923-9945				AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; Beato M, 1996, J MOL MED, V74, P711, DOI 10.1007/s001090050076; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blanchere M, 1998, J STEROID BIOCHEM, V66, P319, DOI 10.1016/S0960-0760(98)00056-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Coffey D S, 1987, Prog Clin Biol Res, V239, P1; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; CULIG Z, 1994, CANCER RES, V54, P5474; Culig Z, 2000, UROL RES, V28, P211, DOI 10.1007/s002400000111; Dai JL, 1996, MOL ENDOCRINOL, V10, P1582, DOI 10.1210/me.10.12.1582; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; FANGER BO, 1986, ARCH BIOCHEM BIOPHYS, V249, P116, DOI 10.1016/0003-9861(86)90566-7; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Gregory CW, 2001, J ANDROL, V22, P537; HALL RE, 1992, INT J CANCER, V52, P778, DOI 10.1002/ijc.2910520518; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JUNGTESTAS I, 1985, EXP CLIN ENDOCRINOL, V86, P151, DOI 10.1055/s-0029-1210481; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Knudsen KE, 1999, CANCER RES, V59, P2297; Koivisto P, 1997, J PATHOL, V183, P51, DOI 10.1002/(SICI)1096-9896(199709)183:1<51::AID-PATH1092>3.0.CO;2-N; Leewansangtong Sunai, 1999, Journal of the Medical Association of Thailand, V82, P192; List HJ, 1999, EXP CELL RES, V252, P471, DOI 10.1006/excr.1999.4638; List HJ, 1999, EXP CELL RES, V250, P414, DOI 10.1006/excr.1999.4517; List HJ, 2000, EXP CELL RES, V260, P160, DOI 10.1006/excr.2000.5018; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Ma H, 1999, MOL CELL BIOL, V19, P6164; MARTIN D, 1969, P NATL ACAD SCI USA, V62, P248, DOI 10.1073/pnas.62.1.248; Martinez E, 1998, NUCLEIC ACIDS RES, V26, P239, DOI 10.1093/nar/26.1.239; Miyazaki Y, 2001, J BIOL CHEM, V276, P40528, DOI 10.1074/jbc.M103051200; MIZOKAMI A, 1992, ENDOCRINOL JAPON, V39, P235; Mora GR, 1996, J STEROID BIOCHEM, V58, P539, DOI 10.1016/0960-0760(96)00079-9; Mora GR, 1999, STEROIDS, V64, P587, DOI 10.1016/S0039-128X(99)00037-9; MYMRYK JS, 1995, GENE DEV, V9, P1366, DOI 10.1101/gad.9.11.1366; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OHARANEMOTO Y, 1988, J STEROID BIOCHEM, V31, P295; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; ROSSINI GP, 1991, BIOCHEM BIOPH RES CO, V181, P383, DOI 10.1016/S0006-291X(05)81430-5; Schoelch ML, 1999, ORAL ONCOL, V35, P333, DOI 10.1016/S1368-8375(98)00098-0; SCOTT WW, 1980, CANCER-AM CANCER SOC, V45, P1929, DOI 10.1002/cncr.1980.45.s7.1929; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SONG CS, 1995, ANN NY ACAD SCI, V761, P97, DOI 10.1111/j.1749-6632.1995.tb31372.x; Song CS, 1999, MOL ENDOCRINOL, V13, P1487, DOI 10.1210/me.13.9.1487; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; Supakar PC, 1996, BIOL SIGNAL, V5, P170; SYMS AJ, 1985, J BIOL CHEM, V260, P455; TRACHTENBERG J, 1987, ADENOCARCINOMA PROST, P173; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; Wolffe A P, 1997, Cell Res, V7, P127; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yata K, 2001, BRIT J HAEMATOL, V114, P591, DOI 10.1046/j.1365-2141.2001.02990.x; Ye Jianping, 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P275; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang SM, 2001, METH MOL B, V176, P297; ZHANG SM, 1995, ENDOCRINE, V3, P5, DOI 10.1007/BF02917442; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; Zhu X, 1997, MOL CELL ENDOCRINOL, V134, P9, DOI 10.1016/S0303-7207(97)00168-8	86	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29719	29729		10.1074/jbc.M112134200	http://dx.doi.org/10.1074/jbc.M112134200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12055183	hybrid			2022-12-25	WOS:000177509300048
J	Zhang, Y; Miki, T; Iwanaga, T; Koseki, Y; Okuno, M; Sunaga, Y; Ozaki, N; Yano, H; Koseki, H; Seino, S				Zhang, Y; Miki, T; Iwanaga, T; Koseki, Y; Okuno, M; Sunaga, Y; Ozaki, N; Yano, H; Koseki, H; Seino, S			Identification, tissue expression, and functional characterization of Otx3, a novel member of the Otx family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR NEUROECTODERM; TRANSCRIPTION FACTOR; BRAIN MORPHOGENESIS; ROSTRAL BRAIN; MICE LACKING; GENE; DROSOPHILA; HOMEODOMAIN; DOMAINS; PROTEIN	Transcription factors containing a homeodomain play an important role in the organogenesis of vertebrates. We have isolated a novel homeodomain transcription factor, Otx3, which is structurally and functionally related to Otx1 and Otx2, transcription factors that are critical in brain morphogenesis. Mouse Otx3 is a protein composed of 376 amino acids. Otx3 mRNA was expressed in mouse embryos from 10.5 to 13.5 days postcoitum (dpc) and in adult cerebellum as assessed by Northern blotting. Whole-mount in situ hybridization of mouse embryos from 9.5 to 11.5 dpc revealed strong expression of Otx3 mRNA in the diencephalon, mesencephalon, metencephalon, myelencephalon, and developing eye, indicating an expression pattern largely overlapping but distinct from those of Otx1 and Otx2. In addition, Otx3 was shown by electrophoretic mobility shift assay to bind to the TAATCC motif, the consensus binding sequence for Otx1, Otx2, and Crx. Results of a transcription reporter assay suggest that Otx3 functions as a transcription repressor by binding to this motif. These results suggest that Otx3 is a novel member of the Otx family and may be involved in the development of the central nervous system.	Chiba Univ, Dept Cellular & Mol Med, Chiba 2608670, Japan; Chiba Univ, Dept Mol Embryol, Grad Sch Med, Chiba 2608670, Japan; Chiba Univ, Ctr Gene Res, Chiba 2608670, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 0600818, Japan	Chiba University; Chiba University; Chiba University; Hokkaido University	Seino, S (corresponding author), Chiba Univ, Dept Cellular & Mol Med, Chiba 2608670, Japan.		Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854				ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Acampora D, 1998, DEVELOPMENT, V125, P1229; Acampora D, 2001, PROG NEUROBIOL, V64, P69, DOI 10.1016/S0301-0082(00)00042-3; Acampora D, 1997, DEVELOPMENT, V124, P3639; Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; Akasaka T, 2001, DEVELOPMENT, V128, P1587; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Chau KY, 2000, J BIOL CHEM, V275, P37264, DOI 10.1074/jbc.M002763200; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Goriely A, 1996, DEVELOPMENT, V122, P1641; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; Mailhos C, 1998, DEVELOPMENT, V125, P937; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Suda Y, 1997, MECH DEVELOP, V69, P125, DOI 10.1016/S0925-4773(97)00161-5; Suda Y, 1999, DEVELOPMENT, V126, P743; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; TREISMAN J, 1989, CELL, V59, P553; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	26	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28065	28069		10.1074/jbc.C100767200	http://dx.doi.org/10.1074/jbc.C100767200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12055180	hybrid			2022-12-25	WOS:000177189800062
J	Jahn, T; Seipel, P; Coutinho, S; Urschel, S; Schwarz, K; Miething, C; Serve, H; Peschel, C; Duyster, J				Jahn, T; Seipel, P; Coutinho, S; Urschel, S; Schwarz, K; Miething, C; Serve, H; Peschel, C; Duyster, J			Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain	ONCOGENE			English	Article						c-kit; EGFP; signal transduction; PI3-kinase; Src	STEM-CELL-FACTOR; GREEN FLUORESCENT PROTEIN; RESONANCE ENERGY-TRANSFER; RECEPTOR TYROSINE KINASE; SRC FAMILY KINASES; PHOSPHATIDYLINOSITOL 3'-KINASE; ADAPTER PROTEIN; LIPID RAFTS; MAST-CELLS; ACTIVATION	In order to investigate activation and internalization of e-kit we created a functional c-kit-EGFP chimera by inserting EYFP (enhanced yellow fluorescent protein) within the extracellular domain of e-kit immediately downstream of the signal sequence, SS-EYFP-kit. This location was chosen because the C-terminal fusion of EGFP to c-kit unexpectedly caused constitutive activation of the c-kit tyrosine kinase. As analysed in fixed cells and by real time imaging in vivo, SCF induced activation led to internalization of the fusion construct and translocation to punctate structures resembling vesicles. Analysis of the internalization process by time lapse imaging revealed high mobility and discontinuous movement of these vesicles and their predominantly radial tracks. Two subsets of vesicles were observed: Traffic of the majority of vesicles was directed from the periphery to the center of the cell and most likely represents the internalization of activated receptor molecules via the endosomal pathway. However, some vesicular structures were observed to move towards the periphery of the cell and probably contain newly synthesized protein to replace internalized receptor molecules. The calculated velocity of moving vesicles ranged from 0.05 to 0.2 mum per se. Vesicle formation upon SCF induced dimerization of the receptor was strictly dependent on kinase activity of e-kit. Treatment of cells with phenylarsine oxide, an agent blocking receptor internalization, prior to SCF stimulation resulted in abrogation of the translocation of the chimera to vesicles whereas accumulation of vesicles was observed when cells were treated with proteasome inhibitors. Cholesterol depletion of the cell membrane by methyl-beta-cyclodextrin resulted in dose dependent reduction of receptor internalization indicating that c-kit may be present in lipid rafts or that intact lipid rafts are required for efficient internalization of the receptor. Using the induction of vesicular structures as a sign of efficient internalization of the receptor analysis of mutant e-kit constructs deficient either in activation of PI3-Kinase or Src revealed that internalization of e-kit is dependent on recruitment of Src but not PI3-Kinase.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; Univ Munster, Dept Internal Med A, D-4400 Munster, Germany	Technical University of Munich; University of Munich; University of Munster	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismaningerstr 22, D-81675 Munich, Germany.		Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805				Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Broudy VC, 1999, BLOOD, V94, P1979; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; Coutinho S, 2000, BLOOD, V96, P618; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Feng YQ, 1999, BIOCHEMISTRY-US, V38, P4553, DOI 10.1021/bi982224o; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KANUKURA Y, 1994, LEUKEMIA S1, V8, pS18; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Krystal GW, 1998, CANCER RES, V58, P4660; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LANGLEY KE, 1993, BLOOD, V81, P656; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Li Q, 1996, CANCER RES, V56, P4343; LIU L, 1994, J BIOL CHEM, V269, P16774; Longley BJ, 1997, P NATL ACAD SCI USA, V94, P9017, DOI 10.1073/pnas.94.17.9017; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MIYAZAWA K, 1994, BLOOD, V83, P137; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Shimizu YJ, 1996, J IMMUNOL, V156, P3443; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YEE NS, 1994, J BIOL CHEM, V269, P31991	40	52	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4508	4520		10.1038/sj.onc.1205559	http://dx.doi.org/10.1038/sj.onc.1205559			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085229				2022-12-25	WOS:000176476700005
J	Guo, L; Wu, CY				Guo, L; Wu, CY			Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex	FASEB JOURNAL			English	Article						integrin-linked kinase; PINCH; CH-ILKBP; fibronectin	INTEGRIN-LINKED KINASE; FOCAL ADHESION PROTEIN; GLYCOGEN-SYNTHASE KINASE; EXTRACELLULAR-MATRIX; DIABETIC-NEPHROPATHY; CYTOPLASMIC DOMAIN; BINDING PROTEIN; GROWTH-FACTOR; LOCALIZATION; SITES	Alteration in renal glomerular mesangial cell growth and fibronectin matrix deposition is a hallmark of glomerulosclerosis, which ultimately leads to end-stage renal failure. We have previously shown that the expression of integrin-linked kinase (ILK), a cytoplasmic component of the cell-extracellular matrix contacts, is increased in mesangial cells in human patients with diabetic nephropathy. We show here that ILK forms a complex with PINCH and CH-ILKBP in primary mesangial cells, which are co-clustered at fibrillar adhesions, sites that are involved in fibronectin matrix deposition. To investigate functional significance of the PINCH-ILK-CH-ILKBP complex formation, we expressed the PINCH-binding N-terminal fragment and the CH-ILKBP-binding C-terminal fragment of ILK, respectively, in mesangial cells by using an adenoviral expression system. Overexpression of either the N-terminal fragment or the C-terminal fragment of ILK effectively inhibited the PINCH-ILK-CH-ILKBP complex formation. Inhibition of the PINCH-ILK-CH-ILKBP complex formation significantly reduced fibronectin matrix deposition and inhibited cell proliferation. These results indicate that the PINCH-ILK-CH-ILKBP complex is critically involved in the regulation of mesangial fibronectin matrix deposition and cell proliferation, and suggest that it may potentially serve as a useful target in the therapeutic control of progressive renal failure and other pathological processes involving abnormal cell proliferation and fibronectin matrix deposition.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	carywu@imap.pitt.edu						ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; ABRASS CK, 1995, WESTERN J MED, V162, P318; Adler S, 1997, KIDNEY INT, pS42; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Christopher RA, 1997, J CELL SCI, V110, P569; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark RAF, 1997, J CELL PHYSIOL, V170, P69; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GETTNER SN, 1995, J CELL BIOL, V129, P1127, DOI 10.1083/jcb.129.4.1127; Guo LD, 2001, AM J PATHOL, V159, P1735, DOI 10.1016/S0002-9440(10)63020-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kagami S, 2001, EXP CELL RES, V268, P274, DOI 10.1006/excr.2001.5279; Kagami S, 2000, KIDNEY INT, V58, P1088, DOI 10.1046/j.1523-1755.2000.00266.x; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; KERJASCHKI D, 1994, KIDNEY INT, V45, P300, DOI 10.1038/ki.1994.39; KREISBERG JI, 1993, KIDNEY INT, V43, P109, DOI 10.1038/ki.1993.18; Kretzler M, 2001, FASEB J, V15, P1843, DOI 10.1096/fj.00-0832fje; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LaFlamme SE, 1996, SEMIN CANCER BIOL, V7, P111, DOI 10.1006/scbi.1996.0016; Li FG, 1999, J CELL SCI, V112, P4589; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Olski TM, 2001, J CELL SCI, V114, P525; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; Phillips AO, 1999, KIDNEY BLOOD PRESS R, V22, P81, DOI 10.1159/000025912; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2001, J CELL SCI, V114, P2553; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sottile J, 1998, J CELL SCI, V111, P2933; STERZEL RB, 1993, KIDNEY INT, V43, pS26; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VIRCHOW R, 1958, DISEASE LIFE MAN, P71; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Wolf G, 2000, KIDNEY INT, V58, pS59, DOI 10.1046/j.1523-1755.2000.07710.x; Wu C, 1997, HISTOL HISTOPATHOL, V12, P233; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; WU CY, 1995, J CELL SCI, V108, P2511; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Wu CY, 2001, J CELL SCI, V114, P2549; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 1999, J CELL SCI, V112, P1655; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200	66	66	71	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1298	+		10.1096/fj.02-0089fje	http://dx.doi.org/10.1096/fj.02-0089fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060675				2022-12-25	WOS:000176683900037
J	Fedele, M; Battista, S; Kenyon, L; Baldassarre, G; Fidanza, V; Klein-Szanto, AJP; Parlow, AF; Visone, R; Pierantoni, GM; Outwater, E; Santoro, M; Croce, CM; Fusco, A				Fedele, M; Battista, S; Kenyon, L; Baldassarre, G; Fidanza, V; Klein-Szanto, AJP; Parlow, AF; Visone, R; Pierantoni, GM; Outwater, E; Santoro, M; Croce, CM; Fusco, A			Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas	ONCOGENE			English	Article						transgenic mice; HMGA2; pituitary adenomas; Pit-1; tumorigenesis	EXPRESS HIGH-LEVELS; GROUP PROTEIN GENE; NEOPLASTIC TRANSFORMATION; MESENCHYMAL TUMORS; HMGI(Y) PROTEINS; C GENE; CELLS; LIPOMAS; FAMILY; REARRANGEMENTS	Overexpression of the HMGA2 gene is a common feature of neoplastic cells both in experimental and human models. Intragenic and extragenic HMGA2 rearrangements responsible for HMGA2 gene overexpression have been frequently detected in human benign tumours of mesenchymal origin. To better understand the role of HMGA2 overexpression in human tumorigenesis, we have generated transgenic mice carrying the HMGA2 gene under the transcriptional control of the cytomegalovirus promoter. High expression of the transgene was demonstrated in all the mouse tissues analysed, whereas no expression of the endogenous HMGA2 gene was detected in the same tissues from wild-type mice. In this study, two indipendent lines of transgenic mice have been generated. By 6 months of age, 85% of female animals of both transgenic lines developed pituitary adenomas secreting prolactin and growth hormone. The transgenic males developed the same phenotype with a lower penetrance (40%) and a longer latency period (about 18 months). Therefore, these data demonstrate that the overexpression of HMGA2 leads to the onset of mixed growth hormone/prolactin cell pituitary adenomas. These transgenic mice may represent an important tool for the study of this kind of neoplasia.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg Napoli, Ctr Endocrinol & Oncol Sperimentale,CNR, I-80131 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Harbor UCLA Med Ctr, Natl Hormone & Pituitary Program, Torrance, CA 90509 USA; Thomas Jefferson Univ, Jefferson Med Coll, Image Ctr, Philadelphia, PA 19107 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Fac Med & Chirurg Catanzaro, Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; Jefferson University; Fox Chase Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Jefferson University; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg Napoli, Ctr Endocrinol & Oncol Sperimentale,CNR, Via Pansini 5, I-80131 Naples, Italy.		Fedele, Monica/C-1417-2015; visone, rosa/K-7910-2016; Battista, Sabrina/AAY-2981-2020; Pierantoni, Giovanna Maria/O-7527-2015; Young, Richard A/F-6495-2012; Baldassarre, Gustavo/K-1350-2016	Fedele, Monica/0000-0002-9171-1312; Battista, Sabrina/0000-0001-5899-9759; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Young, Richard A/0000-0001-8855-8647; Baldassarre, Gustavo/0000-0002-9750-8825; Fusco, Alfredo/0000-0003-3332-5197; Kenyon, Lawrence/0000-0002-3719-9565; VISONE, Rosa/0000-0002-4993-0220	NATIONAL CANCER INSTITUTE [P30CA056036, P01CA076259] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 56036, P01 CA 76259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BAUER K, 1990, ENDOCRINOLOGY, V127, P1224, DOI 10.1210/endo-127-3-1224; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bol S, 1996, CANCER GENET CYTOGEN, V90, P88, DOI 10.1016/0165-4608(96)00062-3; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; Fejzo MS, 1996, GENE CHROMOSOME CANC, V17, P1, DOI 10.1002/(SICI)1098-2264(199609)17:1<1::AID-GCC1>3.0.CO;2-0; Finelli P, 2000, INT J CANCER, V86, P344, DOI 10.1002/(SICI)1097-0215(20000501)86:3<344::AID-IJC7>3.0.CO;2-8; FINELLI P, 2002, IN PRESS CANC RES; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; PellegriniBouiller I, 1997, HORM RES, V47, P251, DOI 10.1159/000185472; Rogalla P, 1996, AM J PATHOL, V149, P775; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Spady TJ, 1999, ENDOCRINE, V11, P217, DOI 10.1385/ENDO:11:3:217; Staats B, 1996, BREAST CANCER RES TR, V38, P299, DOI 10.1007/BF01806149; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TSOKOS M, 1987, AM J PATHOL, V128, P484; Weil RJ, 1998, CANCER RES, V58, P4715; Wood LJ, 2000, CANCER RES, V60, P4256; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	36	173	178	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3190	3198		10.1038/sj.onc.1205428	http://dx.doi.org/10.1038/sj.onc.1205428			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082634				2022-12-25	WOS:000175373600010
J	Guan, BX; Yue, P; Lotan, R; Sun, SY				Guan, BX; Yue, P; Lotan, R; Sun, SY			Evidence that the human death receptor 4 is regulated by activator protein 1	ONCOGENE			English	Article						DR4; AP-1; death receptors; gene expression; apoptosis	APOPTOSIS-INDUCING LIGAND; LUNG-CARCINOMA CELLS; FAS LIGAND; IN-VIVO; TRAIL; AP-1; EXPRESSION; INDUCTION; CANCER; AGENTS	Death receptor 4 (DR4; also called TRAIL-RI), a member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that triggers the apoptotic machinery upon binding to its ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Although several chemotherapeutic agents were reported to induce DR4 expression, the mechanism of this effect remains largely unknown. To begin to understand its regulation, we cloned a 1.8 Kb 5'-flanking region of the human DR4 gene and identified several putative binding sites for transcription factors including activator protein I (AP-1). Among the three putative AP-1 binding sites, the site located at -350/-344 is functionally active as evidenced by a combination of electrophoretic mobility shift and luciferase reporter assays. The AP-1 activator phorbol 12-myristate 13-acetate (TPA) enhanced the binding of this DR4 AP-1 binding site to protein(s) in a nuclear extract from TPA-treated cells, increased luciferase activity of a reporter construct containing this site and induced DR4 expression at the transcription level. These results indicate that AP-1 regulates DR4 expression via the AP-1 binding site located at -350/-344. AP-1 has been implicated in many critical cellular processes including apoptosis, and is a major target of the c-Jun NH3-terminal kinase signaling pathway that is activated by many anticancer drugs. Therefore, our findings may increase the understanding of the mechanisms underlying AP-1-mediated apoptosis as well as drug-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Sun, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Fan MY, 2001, CANCER RES, V61, P4450; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Fricker J, 1999, MOL MED TODAY, V5, P374, DOI 10.1016/S1357-4310(99)01555-5; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kim JH, 2000, INTELL AUTOM SOFT CO, V6, P3, DOI 10.1080/10798587.2000.10768155; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nagane M, 2000, CANCER RES, V60, P847; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ozoren N, 2000, INT J ONCOL, V16, P917; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sambrook J., 1989, MOL CLONING LAB MANU, P79; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shin MS, 2001, CANCER RES, V61, P4942; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1997, CANCER RES, V57, P4931; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247	39	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3121	3129		10.1038/sj.onc.1205430	http://dx.doi.org/10.1038/sj.onc.1205430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082627				2022-12-25	WOS:000175373600003
J	Kleer, CG; Zhang, YH; Pan, Q; van Golen, KL; Wu, ZF; Livant, D; Merajver, SD				Kleer, CG; Zhang, YH; Pan, Q; van Golen, KL; Wu, ZF; Livant, D; Merajver, SD			WISP3 is a novel tumor suppressor gene of inflammatory breast cancer	ONCOGENE			English	Article						WISP3; breast cancer; tumor suppressor gene; angiogenesis	FACTOR-BINDING PROTEIN; IMMEDIATE-EARLY GENE; MAMMARY EPITHELIAL-CELLS; TISSUE GROWTH-FACTOR; RHOC GTPASE; IGF-I; FAMILY; CYR61; EXPRESSION; SENESCENCE	Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with a 5-year disease-free survival of less than 45%. Little is known about the genetic alterations that result in IBC. In our previous work, we found that WISP3 was specifically lost in human IBC tumors when compared to stage-matched, non-IBC tumors. We hypothesize that WISP3 has tumor suppressor function in the breast and that it may be a key genetic alteration that contributes to the unique IBC phenotype. The full-length WISP3 cDNA was sequenced and cloned into an expression vector. The resulting construct was introduced in to the SUM149 cell line that was derived from a patient with IBC and lacks WISP3 expression. In soft agar, stable WISP3 transfectants formed significantly fewer colonies than the controls. Stable WISP3 transfectants lost their ability to invade and had reduced angiogenic potential. WISP3 transfection was effective in suppressing in vivo tumor growth in nude mice. Mice bearing WISP3 expressing tumors had a significantly longer survival than those with vector-control transfectant tumors. Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis.	Univ Michigan, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kleer, CG (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Univ Hosp 2G332, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	kleer@umich.edu	Pan, Quintin/E-3808-2011		NATIONAL CANCER INSTITUTE [R01CA077612, P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 46592, R01 CA 77612] Funding Source: Medline; NCRR NIH HHS [M01 RR 00042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Byun D, 2001, J ENDOCRINOL, V169, P135, DOI 10.1677/joe.0.1690135; ETHIER SP, 1993, CANCER RES, V53, P627; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JAIYESIMI IA, 1992, J CLIN ONCOL, V10, P1014, DOI 10.1200/JCO.1992.10.6.1014; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Lee BJ, 1924, SURG GYNECOL OBSTET, V39, P580; Li WX, 1996, MOL PATHOL, V49, P91; LIVANT DL, 1995, CANCER RES, V55, P5085; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Merajver SD, 1997, J CLIN ONCOL, V15, P2873, DOI 10.1200/JCO.1997.15.8.2873; NISSANOV J, 1995, LAB INVEST, V73, P734; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sprenger CC, 1999, CANCER RES, V59, P2370; SWAIN SM, 1987, CANCER RES, V47, P3889; Tsugu A, 2000, AM J PATHOL, V157, P919, DOI 10.1016/S0002-9440(10)64605-6; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xu LF, 2000, GENE DEV, V14, P585	30	118	120	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3172	3180		10.1038/sj.onc.1205462	http://dx.doi.org/10.1038/sj.onc.1205462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082632				2022-12-25	WOS:000175373600008
J	Xia, L; Robinson, D; Ma, AH; Chen, HC; Wu, F; Qiu, Y; Kung, HJ				Xia, L; Robinson, D; Ma, AH; Chen, HC; Wu, F; Qiu, Y; Kung, HJ			Identification of human male germ cell-associated kinase, a kinase transcriptionally activated by androgen in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MOLECULAR-CLONING; TYROSINE KINASE; SERINE/THREONINE KINASE; RAPID AMPLIFICATION; RESPONSE ELEMENT; GASTRIC-CANCER; MAP KINASE; CDNA ENDS; RECEPTOR	Androgen is involved in both normal development and malignant transformation of prostate cells. The signal transduction pathways associated with these processes are not well understood. Using a novel kinase display approach, we have identified a protein kinase, human male germ cell-associated kinase (hMAK), which is transcriptionally induced by the androgenic hormone 5alpha-dihydrotestosterone (DHT). The kinetics of induction is rapid and dose-dependent, and the induction is not blocked by cycloheximide treatment. Real time reverse transcription-PCR studies demonstrated a 9-fold induction of hMAK by 10 nM DHT at 24 h post-stimulation. The expression levels of hMAK in prostate cancer cell lines are in general higher than those of normal prostate epithelial cells. A reverse transcription-PCR prouct encompassing the entire hMAK open reading frame was isolated. The results from sequencing analysis showed that the hMAK protein is 623 amino acids in length and contains a kinase catalytic domain at its N terminus, followed by a proline/glutamine-rich domain. The catalytic domain of this kinase contains sequence motifs related to both the cyclin-dependent kinase and the mitogen-activated protein kinase families. When expressed in COS1 cells, hMAK is kinase-active as demonstrated by autophosphorylation and phosphorylation of exogenous substrate and is localized in the nucleus. A 3.7-kilobase pair promoter of the hMAK locus was isolated from a human genomic DNA bacterial artificial chromosome clone and was shown to be activated by DHT. This activation can be blocked by an anti-androgen drug bicalutamide (Casodex), implicating the involvement of androgen receptor in this process. Taken together, these data suggest that hMAK is a protein kinase targeted by androgen that may participate in androgen-mediated signaling in prostate cancer cells.	Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; Natl Hlth Res Inst, Taipei 11529, Taiwan; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of California System; University of California Davis; University of California System; University of California Davis; National Health Research Institutes - Taiwan; University of Minnesota System; University of Minnesota Twin Cities	Kung, HJ (corresponding author), Univ Calif Davis, Ctr Canc, Res Bldg 3,Rm 2400B,4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA57179, CA82073, CA39207] Funding Source: Medline; NIDDK NIH HHS [DK52659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R37CA039207, R01CA082073, R01CA039207, R01CA057179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe S, 1995, ONCOGENE, V11, P2187; Bertioli D, 1997, Methods Mol Biol, V67, P233; BLADT F, 1993, DIFFERENTIATION, V53, P115, DOI 10.1111/j.1432-0436.1993.tb00651.x; Bostik P, 2001, J VIROL, V75, P11298, DOI 10.1128/JVI.75.23.11298-11306.2001; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Culig Z, 2000, UROL RES, V28, P211, DOI 10.1007/s002400000111; Gnanapragasam VJ, 2000, BJU INT, V86, P1001, DOI 10.1046/j.1464-410x.2000.00943.x; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Kassen AE, 2000, PROSTATE, V44, P124, DOI 10.1002/1097-0045(20000701)44:2<124::AID-PROS5>3.0.CO;2-S; Klotz Laurence, 2000, Cancer, V88, P3009, DOI 10.1002/1097-0142(20000615)88:12+<3009::AID-CNCR17>3.0.CO;2-E; Kokontis JM, 1999, VITAM HORM, V55, P219; Kung HJ, 1998, J BIOMED SCI, V5, P74, DOI 10.1007/BF02258359; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Lin BY, 2000, CANCER RES, V60, P858; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lin JS, 1998, J BIOMED SCI, V5, P101, DOI 10.1159/000025319; Lin WC, 2000, ONCOGENE, V19, P5680, DOI 10.1038/sj.onc.1203924; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; Lu S, 1997, CANCER RES, V57, P4511; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; Meric F, 2002, CLIN CANCER RES, V8, P361; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Mitchell SH, 2000, MOL CELL ENDOCRINOL, V168, P89, DOI 10.1016/S0303-7207(00)00319-1; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; MORAN TV, 1993, BIOCHIM BIOPHYS ACTA, V1216, P9, DOI 10.1016/0167-4781(93)90031-8; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Pilat MJP, 1998, CANCER METAST REV, V17, P373, DOI 10.1023/A:1006166511344; Qi H, 2002, CANCER RES, V62, P721; Qi H, 2001, MOL CELL ENDOCRINOL, V182, P181, DOI 10.1016/S0303-7207(01)00560-3; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Robinson D, 1998, J BIOMED SCI, V5, P93, DOI 10.1159/000025318; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Swinnen JV, 1997, CANCER RES, V57, P1086; Wen Y, 2000, CANCER RES, V60, P6841; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu JC, 2001, CANCER RES, V61, P1563; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOSHIDA M, 1990, MOL GEN GENET, V221, P176, DOI 10.1007/BF00261718; Zhang Y, 1997, Methods Mol Biol, V69, P61	49	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35422	35433		10.1074/jbc.M203940200	http://dx.doi.org/10.1074/jbc.M203940200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12084720	hybrid			2022-12-25	WOS:000178117000098
J	Valcourt, U; Gouttenoire, J; Moustakas, A; Herbage, D; Mallein-Gerin, F				Valcourt, U; Gouttenoire, J; Moustakas, A; Herbage, D; Mallein-Gerin, F			Functions of transforming growth factor-beta family type I receptors and smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; INHIBITS MYOGENIC DIFFERENTIATION; EARLY XENOPUS DEVELOPMENT; COLLAGEN MESSENGER-RNAS; MOUSE OSTEOCALCIN GENE; MAD-RELATED PROTEIN; SIGNALING PATHWAYS; CELL-LINE; TRANSCRIPTIONAL REGULATION; C2C12 MYOBLASTS	We investigated the effects of bone morphogenetic protein (BMP)-2, a member of the transforming growth factor-beta superfamily, on the regulation of the chondrocyte phenotype, and we identified signaling molecules involved in this regulation. BMP-2 triggers three concomitant responses in mouse primary chondrocytes and chondrocytic MC615 cells. First, BMP-2 stimulates expression or synthesis of type II collagen. Second, BMP-2 induces expression of molecular markers characteristic of pre- and hypertrophic chondrocytes, such as Indian hedgehog, parathyroid hormone/parathyroid hormone-related peptide receptor, type X collagen, and alkaline phosphatase. Third, BMP-2 induces osteocalcin expression, a specific trait of osteoblasts. Constitutively active forms of transforming growth factor-beta family type I receptors and Smad proteins were overexpressed to address their role in this process. Activin receptor-like kinase (ALK)-1, ALK-2, ALK-3, and ALK-6 were able to reproduce the hypertrophic maturation of chondrocytes induced by BMP-2. In addition, ALK-2 mimicked further the osteoblastic differentiation of chondrocytes induced by BMP-2. In the presence of BMP-2, Smad1, Smad5, and Smad8 potentiated the hypertrophic maturation of chondrocytes, but failed to induce osteocalcin expression. Smad6 and Smad7 impaired chondrocytic expression and osteoblastic differentiation induced by BMP-2. Thus, our results indicate that Smad-mediated pathways are essential for the regulation of the different steps of chondrocyte and osteoblast differentiation and suggest that additional Smad-independent pathways might be activated by ALK-2.	Univ Lyon 1, UMR 5086 CNRS, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ludwig Institute for Cancer Research	Mallein-Gerin, F (corresponding author), Univ Lyon 1, UMR 5086 CNRS, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.		VALCOURT, Ulrich/ABB-3943-2021; Gouttenoire, Jérôme/AAQ-8353-2020; Gouttenoire, Jérôme/G-7947-2017	VALCOURT, Ulrich/0000-0002-1727-4409; Gouttenoire, Jérôme/0000-0002-7715-1494; Gouttenoire, Jérôme/0000-0002-7715-1494				Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Aoki H, 2001, J CELL SCI, V114, P1483; APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; Armes NA, 1997, DEVELOPMENT, V124, P3797; Armes NA, 1999, J BIOL CHEM, V274, P7929, DOI 10.1074/jbc.274.12.7929; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bluteau G, 2001, BBA-GEN SUBJECTS, V1526, P147, DOI 10.1016/S0304-4165(01)00122-2; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Chung CY, 1999, BIOCHEM BIOPH RES CO, V265, P246, DOI 10.1006/bbrc.1999.1639; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; Cowles EA, 1998, CALCIFIED TISSUE INT, V62, P74, DOI 10.1007/s002239900397; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ebisawa T, 1999, J CELL SCI, V112, P3519; Enomoto-Iwamoto M, 1998, J CELL BIOL, V140, P409, DOI 10.1083/jcb.140.2.409; Fagenholz PJ, 2001, J CRANIOFAC SURG, V12, P183, DOI 10.1097/00001665-200103000-00016; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; GERSTENFELD LC, 1991, J CELL BIOL, V112, P501, DOI 10.1083/jcb.112.3.501; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kawai S, 2000, BIOCHEM BIOPH RES CO, V271, P682, DOI 10.1006/bbrc.2000.2704; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kokenyesi R, 1997, BIOCHEM J, V327, P831, DOI 10.1042/bj3270831; Kramer J, 2000, MECH DEVELOP, V92, P193, DOI 10.1016/S0925-4773(99)00339-1; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Leboy PS, 1997, J CELL BIOCHEM, V66, P394, DOI 10.1002/(SICI)1097-4644(19970901)66:3<394::AID-JCB11>3.0.CO;2-F; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LIU F, 1995, MOL CELL BIOL, V15, P3479; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; LUI VCH, 1995, DEV DYNAM, V203, P198, DOI 10.1002/aja.1002030208; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MALLEINGERIN F, 1993, P NATL ACAD SCI USA, V90, P3289, DOI 10.1073/pnas.90.8.3289; MALLEINGERIN F, 1995, EXP CELL RES, V219, P257, DOI 10.1006/excr.1995.1226; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MAYNE R, 1994, CONNECT TISSUE RES, V30, P1; METSARANTA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P241, DOI 10.1016/0167-4781(91)90014-D; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo-124-2-612; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; ROSEN V, 1994, J BONE MINER RES, V9, P1759; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Smith P, 2000, ARTHRITIS RHEUM-US, V43, P1156, DOI 10.1002/1529-0131(200005)43:5<1156::AID-ANR26>3.0.CO;2-M; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Valcourt U, 1999, EXP CELL RES, V251, P264, DOI 10.1006/excr.1999.4584; Visser JA, 2001, MOL ENDOCRINOL, V15, P936, DOI 10.1210/me.15.6.936; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; Wallis GA, 1996, CURR BIOL, V6, P1577, DOI 10.1016/S0960-9822(02)70776-8; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	86	120	129	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33545	33558		10.1074/jbc.M202086200	http://dx.doi.org/10.1074/jbc.M202086200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12082094	hybrid			2022-12-25	WOS:000177959100004
J	Longhurst, CM; Jacobs, JD; White, MM; Crossno, JT; Fitzgerald, DA; Bao, JX; Fitzgerald, TJ; Raghow, R; Jennings, LK				Longhurst, CM; Jacobs, JD; White, MM; Crossno, JT; Fitzgerald, DA; Bao, JX; Fitzgerald, TJ; Raghow, R; Jennings, LK			Chinese hamster ovary cell motility to fibronectin is modulated by the second extracellular loop of CD9 - Identification of a putative fibronectin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET P24/CD9; PROTEIN CD9; ASSOCIATION; EXPRESSION; SUPERFAMILY; INTEGRINS; MIGRATION; ADHESION; LAMININ; TETRASPANINS	CD9, a member of the tetraspanin family of proteins, is characterized by four transmembrane domains and two extracellular loops. Surface expression of CD9 on Chinese hamster ovary (CHO) cells dramatically enhances spreading and motility on fibronectin. To elucidate the mechanistic basis of CD9-fibronectin interaction, binding to fibronectin was investigated using purified and recombinant forms of CD9. The affinity of fibronectin for CD9 in enzyme-linked immunosorbent assay was 81 25 rim. The binding of fibronectin to immobilized CD9 was enhanced by Ca2+ ions. Protein binding and peptide competition studies demonstrated that peptide 6 derived from CD9 extracellular loop 2 (amino acids 168-192) contained part of the fibronectin-binding domain. Additionally, enhanced adhesion of CD9-CHO-beta2 cells to fibronectin was significantly reduced by peptide 6. CD9-CHO cells had a 5-fold increase in motility to fibronectin as compared with mock-transfected controls, an effect that correlated with CD9 cell surface density. Truncation of CD9 extracellular loop 2 and peptide 6 caused inhibition of CD9-CHO cell motility to fibronectin. Deletion of CD9 extracellular loop I had no significant effect on CHO cell motility. These findings demonstrate a critical role for CD9 extracellular loop 2 in cell motility to fibronectin and clarify the mechanism by which CD9-fibronectin interaction modulates cell adhesion and motility.	Univ Tennessee, Ctr Hlth Sci, Vasc Biol Ctr Excellence, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Vet Adm Med Ctr, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Jennings, LK (corresponding author), Univ Tennessee, Ctr Hlth Sci, Vasc Biol Ctr Excellence, 956 Court Ave,Rm H300, Memphis, TN 38163 USA.	ljennings@utmem.edu			NHLBI NIH HHS [HL53514] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053514] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTON ES, 1995, J NEUROSCI, V15, P584; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Chen MS, 1999, P NATL ACAD SCI USA, V96, P11830, DOI 10.1073/pnas.96.21.11830; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Cook GA, 1999, EXP CELL RES, V251, P356, DOI 10.1006/excr.1999.4596; CROSSNO JT, 1999, THESIS U TENNESSEE M; Hadjiargyrou M, 1996, J NEUROCHEM, V67, P2505; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hirano T, 1999, MOL HUM REPROD, V5, P168, DOI 10.1093/molehr/5.2.168; Hirano T, 1999, MOL HUM REPROD, V5, P162, DOI 10.1093/molehr/5.2.162; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Jennings LK, 1995, THROMB HAEMOSTASIS, V74, P1551; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; Klein-Soyer C, 2000, ARTERIOSCL THROM VAS, V20, P360, DOI 10.1161/01.ATV.20.2.360; LANZA F, 1991, J BIOL CHEM, V266, P10638; LAURIE GW, 1982, J CELL BIOL, V95, P340, DOI 10.1083/jcb.95.1.340; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Lijnen HR, 2000, THROMB HAEMOSTASIS, V83, P956; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Ono M, 1999, CANCER RES, V59, P2335; Park KR, 2000, MOL HUM REPROD, V6, P719, DOI 10.1093/molehr/6.8.719; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; TIMPL R, 1979, J BIOL CHEM, V254, P9933; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	34	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32445	32452		10.1074/jbc.M204420200	http://dx.doi.org/10.1074/jbc.M204420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12068019	hybrid			2022-12-25	WOS:000177859000008
J	Flood, C; Gustafsson, M; Richardson, PE; Harvey, SC; Segrest, JP; Boren, J				Flood, C; Gustafsson, M; Richardson, PE; Harvey, SC; Segrest, JP; Boren, J			Identification of the proteoglycan binding site in apolipoprotein B48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; POLYMORPHISM; RETENTION; TERMINUS; PROTEIN; LESIONS; MODEL; B100	An initial event in atherosclerosis is the retention of lipoproteins within the intima of the vessel wall. Previously we identified Site B (residues 3359-3369) in apolipoprotein (apo) B100 as the proteoglycan binding sequence in low density lipoproteins (LDLs) and showed that the atherogenicity of apoB-containing lipoproteins is linked to their affinity for artery wall proteoglycans. However, both apoB100- and apoB48-containing lipoproteins are equally atherogenic even though Site B lies in the carboxyl-terminal half of apoB100 and is absent in apoB48. If binding to proteoglycans is a key step in atherogenesis, apoB48-containing lipoproteins must bind to proteoglycans via other proteoglycan binding sites in the amino-terminal 48% of apoB. In vitro studies have identified five clusters of basic amino acids in delipidated apoB48 that bind negatively charged glycos-aminoglycans. To determine which of these sites is functional on LDL particles, we analyzed the proteoglycan binding activity of recombinant human LDLs from transgenic mice or rat hepatoma cells. Substitution of neutral amino acids for the basic amino acids in Site B-Ib (residues 84-94) abolished the proteoglycan binding activity of recombinant apoB53. Carboxyl-truncated apoB80 bound biglycan with higher affinity than apoB100 and apoB48. ApoB80 in which Site B was mutated had the same affinity for proteoglycans as apoB48. These data support the hypothesis that the carboxyl terminus of apoB100 "masks" Site B-Ib, the amino-terminal proteoglycan binding site, and that this site is exposed in carboxyl-truncated forms of apoB. The presence of a proteoglycan binding site in the amino-terminal region of apoB may explain why apoB48- and apoB100-containing lipoproteins are equally atherogenic.	Gothenburg Univ, Sahlgrenska Acad, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Atherosclerosis Res Unit, Birmingham, AL 35294 USA	University of Gothenburg; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Boren, J (corresponding author), Sahlgrens Univ Hosp, Wallenberg Lab, S-41345 Gothenburg, Sweden.	Jan.Boren@wlab.wall.gu.se	Adiels, Martin/C-9278-2011					Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BOREN J, 1994, J BIOL CHEM, V269, P25879; Boren J, 2001, J BIOL CHEM, V276, P9214, DOI 10.1074/jbc.M008890200; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; CHEN PF, 1988, EUR J BIOCHEM, V175, P111, DOI 10.1111/j.1432-1033.1988.tb14172.x; Goldberg IJ, 1998, J BIOL CHEM, V273, P35355, DOI 10.1074/jbc.273.52.35355; HIROSE N, 1987, BIOCHEMISTRY-US, V26, P5505, DOI 10.1021/bi00391a044; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; JI ZS, 1993, J BIOL CHEM, V268, P10160; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; McCormick SPA, 1997, J BIOL CHEM, V272, P23616, DOI 10.1074/jbc.272.38.23616; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Segrest JP, 1998, J LIPID RES, V39, P85; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; YAO ZM, 1992, J BIOL CHEM, V267, P1175; YOUNG SG, 1989, J LIPID RES, V30, P443; YOUNG SG, 1986, P NATL ACAD SCI USA, V83, P1101, DOI 10.1073/pnas.83.4.1101; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	34	85	90	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32228	32233		10.1074/jbc.M204053200	http://dx.doi.org/10.1074/jbc.M204053200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070165	hybrid			2022-12-25	WOS:000177718700116
J	Jawhari, A; Laine, JP; Dubaele, S; Lamour, V; Poterszman, A; Coin, F; Moras, D; Egly, JM				Jawhari, A; Laine, JP; Dubaele, S; Lamour, V; Poterszman, A; Coin, F; Moras, D; Egly, JM			p52 mediates XPB function within the transcription/repair factor TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; DNA-REPAIR; FACTOR-IIH; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; PROMOTER ESCAPE; SSL1 GENES; HELICASE; MUTATIONS	To further our understanding of the transcription/DNA repair factor TFIIH, we investigated the role of its p52 subunit in TFIIH function. Using a completely reconstituted in vitro transcription or nucleotide excision repair (NER) system, we show that deletion of the G terminal region of p52 results in a dramatic reduction of TFIIH NER and transcription activities. This mutation prevents promoter opening and has no effect on the other enzymatic activities of TFIIH. Moreover, we demonstrate that intact p52 is needed to anchor the XPB helicase within TFIIH, providing an explanation for the transcription and NER defects observed with the mutant p52. We show that these two subunits physically interact and map domains involved in the interface. Taken together, our results show that the p52/Tfb2 subunit of TFIIH regulates the function of XPB through pair-wise interactions as described previously for p44 and XPD.	Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Egly, JM (corresponding author), Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 10142, F-67404 Illkirch Graffenstaden, France.	egly@igbmc.u-strasbg.fr	Coin, Frédéric/F-5925-2013	Coin, Frédéric/0000-0002-5620-8519; JAWHARI, Anass/0000-0001-8170-0524; Lamour, Valerie/0000-0001-7793-4029; POTERSZMAN, Arnaud/0000-0002-6702-5777				Araujo SJ, 2000, GENE DEV, V14, P349; Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Chang WH, 2000, CELL, V102, P609, DOI 10.1016/S0092-8674(00)00083-0; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; Feaver WJ, 2000, J BIOL CHEM, V275, P5941, DOI 10.1074/jbc.275.8.5941; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; Jawhari A, 2002, PROTEIN EXPRES PURIF, V24, P513, DOI 10.1006/prep.2001.1597; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA LB, 1994, NUCLEIC ACIDS RES, V22, P4095, DOI 10.1093/nar/22.20.4095; Maines S, 1998, GENETICS, V150, P963; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; Poterszman A, 1997, TRENDS BIOCHEM SCI, V22, P418, DOI 10.1016/S0968-0004(97)01124-9; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Seroz T, 2000, J BIOL CHEM, V275, P33260, DOI 10.1074/jbc.M004764200; Shivji MKK, 1999, METH MOL B, V113, P373; Sweder KS, 1996, NUCLEIC ACIDS RES, V24, P1540, DOI 10.1093/nar/24.8.1540; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Tremeau-Bravard A, 2001, J BIOL CHEM, V276, P27693, DOI 10.1074/jbc.M102457200; Vermeulen W, 2001, NAT GENET, V27, P299, DOI 10.1038/85864; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; WEEDA G, 1991, GENOMICS, V10, P1035, DOI 10.1016/0888-7543(91)90195-K	38	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31761	31767		10.1074/jbc.M203792200	http://dx.doi.org/10.1074/jbc.M203792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080057	hybrid			2022-12-25	WOS:000177718700057
J	Perrais, M; Pigny, P; Copin, MC; Aubert, JP; Van Seuningen, I				Perrais, M; Pigny, P; Copin, MC; Aubert, JP; Van Seuningen, I			Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/Extracellular Signal-regulated Kinase cascade and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GENOMIC ORGANIZATION; 5'-FLANKING REGION; PROMOTER ACTIVITY; GASTRIN PROMOTER; SECRETORY MUCIN; FACTOR RECEPTOR; FACTOR-ALPHA; IDENTIFICATION; TRANSCRIPTION	The 11p15 mucin genes (MUC2, MUC5AC, MUC5B and MUC6) possess a cell-specific pattern of expression in normal lung that is altered during carcinogenesis. Growth factors of the epidermal growth factor family are known to target key genes that in turn may affect the homeostasis of lung mucosae. Our aim was to study the regulation of the 11p15 mucin genes both at the promoter and protein levels to assess whether their altered expression may represent a key event during lung carcinogenesis. Studies were performed in the mucoepidermoid NCI-H292 lung cancer cell line. Cell treatment with epidermal growth factor (EGF), transforming growth factor alpha (TGF-alpha), or tumor necrosis factor alpha (TNF-alpha) resulted in a dramatic increase of MUC2 and MUC5AC mRNAs levels, promoter activity, and apomucin expression, whereas those of MUC5B and MUC6 were unchanged. pGL3 deletion mutants of MUC2, MUC5AC, and MUC5B promoters were constructed and used in transient transfection assays to characterize EGF- and TGF-alpha-responsive regulatory regions within the promoters. They were located in the -2627/-2097 and -202/-1 regions of MUC2 and MUC5AC promoters, respectively. Finally, we demonstrate that transcription factor Spl not only binds and activates MUC2 and MUC5AC promoters but also participates to their EGF- and TGF-alpha-mediated up-regulation. We also show that Sp3 is a strong inhibitor of 11p15 mucin gene transcription. In conclusion, MUC2 and MUC5AC are two target genes of EGFR ligands in lung cancer cells, and up-regulation of these two genes goes through concomitant activation of the EGFR/Ras/Raf/Extracellular Signal-regulated Kinase-signaling pathway and Sp1 binding to their promoters.	INSERM, U560, F-59045 Lille, France; CHU Lille, Lab Biochim & Biol Mol, F-59037 Lille, France; CHU Lille, Endocrinol Hop Claude Huriez, F-59037 Lille, France; CHU Lille, Serv Anat & Cytol Pathol, Hop Calmette, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille	Van Seuningen, I (corresponding author), INSERM, U560, Pl Verdun, F-59045 Lille, France.	isabelvs@lille.inserm.fr	VAN SEUNINGEN, Isabelle/N-6176-2016; pigny, pascal/L-7059-2018	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; 				Aslam F, 2001, CANCER RES, V61, P570; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; Bartman AE, 1998, J PATHOL, V186, P398; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Berger JT, 1999, AM J RESP CELL MOL, V20, P500, DOI 10.1165/ajrcmb.20.3.3383; Buisine MP, 1998, BIOCHEM J, V332, P729, DOI 10.1042/bj3320729; Buisine MP, 1999, AM J RESP CELL MOL, V20, P209, DOI 10.1165/ajrcmb.20.2.3259; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; Copin MC, 2000, INT J CANCER, V86, P162, DOI 10.1002/(SICI)1097-0215(20000415)86:2<162::AID-IJC3>3.3.CO;2-I; Copin MC, 2001, FRONT BIOSCI, V6, pD1264, DOI 10.2741/Copin; Copin MC, 2001, HUM PATHOL, V32, P274, DOI 10.1053/hupa.2001.22752; Corfield AP, 2000, GUT, V47, P589, DOI 10.1136/gut.47.4.589; Davies DE, 1999, ALLERGY, V54, P771; Desseyn JL, 1998, J MOL EVOL, V46, P102, DOI 10.1007/PL00006276; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; Dong ZG, 1999, ANTICANCER RES, V19, P3743; FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hanski C, 1997, LAB INVEST, V77, P685; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; HO JJL, 1995, INT J ONCOL, V7, P913; HO SB, 1993, CANCER RES, V53, P641; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; Kim YD, 2000, BIOCHEM BIOPH RES CO, V274, P112, DOI 10.1006/bbrc.2000.3107; LESUFFLEUR T, 1994, CRIT REV ONCOL HEMAT, V17, P153, DOI 10.1016/1040-8428(94)90053-1; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Marchetti A, 1996, J PATHOL, V179, P254, DOI 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Nettesheim P, 2000, J AEROSOL MED, V13, P207, DOI 10.1089/jam.2000.13.207; Nogami H, 1997, GENE, V198, P191, DOI 10.1016/S0378-1119(97)00314-4; Nordman H, 2002, BIOCHEM J, V364, P191, DOI 10.1042/bj3640191; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; Porchet Nicole, 1999, Journal de la Societe de Biologie, V193, P85; Ruocco S, 1996, PEDIATR RES, V39, P448, DOI 10.1203/00006450-199603000-00012; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takeyama K, 2000, J IMMUNOL, V164, P1546, DOI 10.4049/jimmunol.164.3.1546; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511, DOI 10.1164/ajrccm.163.2.2001038; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398; Van Seuningen I, 2000, BIOCHEM J, V348, P675; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Velcich A, 1997, J BIOL CHEM, V272, P7968, DOI 10.1074/jbc.272.12.7968; Wickstrom C, 1998, BIOCHEM J, V334, P685, DOI 10.1042/bj3340685; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200	55	227	235	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32258	32267		10.1074/jbc.M204862200	http://dx.doi.org/10.1074/jbc.M204862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077147	hybrid, Green Published			2022-12-25	WOS:000177718700120
J	Berkowitz, O; Wirtz, M; Wolf, A; Kuhlmann, J; Hell, R				Berkowitz, O; Wirtz, M; Wolf, A; Kuhlmann, J; Hell, R			Use of biomolecular interaction analysis to elucidate the regulatory mechanism of the cysteine synthase complex from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLSERINE THIOL LYASE; PROTEIN-PROTEIN INTERACTIONS; SERINE ACETYLTRANSFERASE; SULFATE ASSIMILATION; ESCHERICHIA-COLI; HIGHER-PLANTS; BIOSYNTHESIS; SULFUR; PURIFICATION; TRANSPORTER	Real time biomolecular interaction analysis based on surface plasmon resonance has been proven useful for studying protein-protein interaction but has not been extended so far to investigate enzyme-enzyme interactions, especially as pertaining to regulation of metabolic activity. We have applied BIAcore technology to study the regulation of enzyme-enzyme interaction during mitochondrial cysteine biosynthesis in Arabidopsis thaliana. The association of the two enzyme subunits in the hetero-oligomeric cysteine synthase complex was investigated with respect to the reaction intermediate and putative effector O-acetylserine. We have determined an equilibrium dissociation constant of the cysteine synthase complex (K-D = 25 +/- 4 x 10(-9) M), based on a reliable A + B double left right arrow AB model of interaction. Analysis of dissociation kinetics in the presence of O-acetylserine revealed a half-maximal dissociation rate at 77 +/- 4 mum O-acetylserine and strong positive cooperativity for complex dissociation. The equilibrium of interaction was determined using an enzyme activity-based approach and yielded a K-m value of 58 +/- 7 muM O-acetylserine. Both effector concentrations are in the range of intracellular O-acetylserine fluctuations and support a functional model that integrates effector-driven cysteine synthase complex dissociation as a regulatory switch for the biosynthetic pathway. The results show that BIAcore technology can be applied to obtain quantitative kinetic data of a hetero-oligomeric protein complex with enzymatic and regulatory function.	Inst Plant Genet & Crop Plant Res, Dept Mol Cell Biol, D-06466 Gatersleben, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Max Planck Society	Hell, R (corresponding author), Inst Plant Genet & Crop Plant Res, Dept Mol Cell Biol, Corrensstr 3, D-06466 Gatersleben, Germany.		Hell, Ruediger/E-5436-2014; Berkowitz, Oliver/AAE-7979-2019; Berkowitz, Oliver/A-7854-2008; Wirtz, Markus/G-5917-2010	Berkowitz, Oliver/0000-0002-7671-6983; Berkowitz, Oliver/0000-0002-7671-6983; Wirtz, Markus/0000-0001-7790-4022; Hell, Ruediger/0000-0002-6238-4818				AWAZUHARA M, 2000, SULFUR NUTR SULFUR A, P331; Bogdanova N, 1997, PLANT J, V11, P251, DOI 10.1046/j.1365-313X.1997.11020251.x; BOGDANOVA N, 1995, FEBS LETT, V358, P43, DOI 10.1016/0014-5793(94)01392-E; Bowsher CG, 2001, J EXP BOT, V52, P513, DOI 10.1093/jexbot/52.356.513; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; COOK PF, 1977, ARCH BIOCHEM BIOPHYS, V178, P293, DOI 10.1016/0003-9861(77)90194-1; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; DROUX M, 1992, ARCH BIOCHEM BIOPHYS, V295, P379, DOI 10.1016/0003-9861(92)90531-Z; Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x; Gutierrez-Alcala G, 2000, P NATL ACAD SCI USA, V97, P11108, DOI 10.1073/pnas.190334497; HELL R, 1998, THESIS RUHR U BOCHUM, P23; Hesse H, 1999, AMINO ACIDS, V16, P113, DOI 10.1007/BF01321531; Hindson VJ, 2000, J BIOL CHEM, V275, P461, DOI 10.1074/jbc.275.1.461; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Jost R, 2000, GENE, V253, P237, DOI 10.1016/S0378-1119(00)00261-4; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kim H, 1999, PLANTA, V209, P282, DOI 10.1007/s004250050634; Koprivova A, 2000, PLANT PHYSIOL, V122, P737, DOI 10.1104/pp.122.3.737; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; Leustek T, 2000, ANNU REV PLANT PHYS, V51, P141, DOI 10.1146/annurev.arplant.51.1.141; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Mino K, 1999, BIOSCI BIOTECH BIOCH, V63, P168, DOI 10.1271/bbb.63.168; NEUENSCHWANDER U, 1991, PLANT PHYSIOL, V97, P253, DOI 10.1104/pp.97.1.253; Noji M, 1998, J BIOL CHEM, V273, P32739, DOI 10.1074/jbc.273.49.32739; Saito K, 2000, CURR OPIN PLANT BIOL, V3, P188, DOI 10.1016/S1369-5266(00)00063-7; Sambrook J., 2002, MOL CLONING LAB MANU; Smith FW, 1997, PLANT J, V12, P875, DOI 10.1046/j.1365-313X.1997.12040875.x; Takahashi H, 2000, PLANT J, V23, P171, DOI 10.1046/j.1365-313x.2000.00768.x; Takahashi H, 1997, P NATL ACAD SCI USA, V94, P11102, DOI 10.1073/pnas.94.20.11102; VANCOTT TC, 1992, J IMMUNOL METHODS, V146, P163, DOI 10.1016/0022-1759(92)90225-I; Warrilow AGS, 2000, J EXP BOT, V51, P985, DOI 10.1093/jexbot/51.347.985; Wirtz M, 2001, EUR J BIOCHEM, V268, P686, DOI 10.1046/j.1432-1327.2001.01920.x	33	87	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30629	30634		10.1074/jbc.M111632200	http://dx.doi.org/10.1074/jbc.M111632200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063244	hybrid			2022-12-25	WOS:000177579800031
J	Dixon, DP; Davis, BG; Edwards, R				Dixon, DP; Davis, BG; Edwards, R			Functional divergence in the glutathione transferase superfamily in plants - Identification of two classes with putative functions in redox homeostasis in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; DEHYDROASCORBATE REDUCTASE; CATALYTIC MECHANISM; MOLECULAR-CLONING; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE; ASCORBIC-ACID; GENE; THIOLTRANSFERASE; PURIFICATION	Searches with the human Omega glutathione transferase (GST) identified two outlying groups of the GST superfamily in Arabidopsis thaliana which differed from all other plant GSTs by containing a cysteine in place of a serine at the active site. One group consisted of four genes, three of which encoded active glutathione-dependent dehydroascorbate reductases (DHARs). Two DHARs were predicted to be cytosolic, whereas the other contained a chloroplast targeting peptide. The DELARs were also active as thiol transferases but had no glutathione conjugating activity. Unlike most other GSTs, DHARs were monomeric. The other class of GST comprised two genes termed the Lambda GSTs (GSTLs). The recombinant GSTLs were also monomeric and had glutathione-dependent thiol transferase activity. One GSTL was cytosolic, whereas the other was chloroplast-targeted. When incubated with oxidized glutathione, the putative active site cysteine of the GSTLs and cytosolic DHARs formed mixed disulfides with glutathione, whereas the plastidic DHAR formed an intramolecular disulfide. DHAR S-glutathionylation was consistent with a proposed catalytic mechanism for dehydroascorbate reduction. Roles for the cytosolic DHARs and GSTLs as antioxidant enzymes were also inferred from the induction of the respective genes following exposure to chemicals and oxidative stress.	Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Oxford, Dyson Perrins Lab, Dept Chem, Oxford OX1 3QY, England	Durham University; University of Oxford	Edwards, R (corresponding author), Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.	Robert.Edwards@durham.ac.uk	Dixon, David P/B-5413-2008; Davis, Benjamin G/C-5281-2011	Dixon, David P/0000-0003-4644-8399; Davis, Benjamin G/0000-0002-5056-407X; Edwards, Robert/0000-0003-0809-5991	Biotechnology and Biological Sciences Research Council [EGA17763] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		An YQ, 1996, PLANT CELL, V8, P15, DOI 10.1105/tpc.8.1.15; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; ASHBY EC, 1981, TETRAHEDRON LETT, V22, P4209, DOI 10.1016/S0040-4039(01)82106-7; ASHBY EC, 1985, J ORG CHEM, V50, P5184, DOI 10.1021/jo00225a041; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; Cummins I, 1999, PLANT J, V18, P285, DOI 10.1046/j.1365-313X.1999.00452.x; Davies J, 1998, PESTIC SCI, V52, P29, DOI 10.1002/(SICI)1096-9063(199801)52:1&lt;29::AID-PS659&gt;3.0.CO;2-J; Dixon DP, 1998, CURR OPIN PLANT BIOL, V1, P258, DOI 10.1016/S1369-5266(98)80114-3; Dixon DP, 1998, PLANT MOL BIOL, V36, P75, DOI 10.1023/A:1005958711207; Dixon DP, 2000, ARCH BIOCHEM BIOPHYS, V384, P407, DOI 10.1006/abbi.2000.2125; DOYLE MP, 1984, J ORG CHEM, V49, P1917, DOI 10.1021/jo00185a014; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; EDWARDS R, 2000, HERBICIDES THEIR MEC, P38; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FOYER CH, 1976, PLANTA, V133, P21, DOI 10.1007/BF00386001; Foyer CH, 1998, FEBS LETT, V425, P528, DOI 10.1016/S0014-5793(98)00281-6; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HERSHEY HP, 1991, PLANT MOL BIOL, V17, P679, DOI 10.1007/BF00037053; HOSSAIN MA, 1984, PLANT CELL PHYSIOL, V25, P85; Jung CH, 1998, ARCH BIOCHEM BIOPHYS, V355, P9, DOI 10.1006/abbi.1998.0713; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; KIYOSUE T, 1993, FEBS LETT, V335, P189, DOI 10.1016/0014-5793(93)80727-C; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Labrou NE, 2001, BIOCHEM J, V358, P101, DOI 10.1042/0264-6021:3580101; Loyall L, 2000, PLANT CELL, V12, P1939, DOI 10.1105/tpc.12.10.1939; Mannervik B, 1998, CHEM-BIOL INTERACT, V112, P15, DOI 10.1016/S0009-2797(97)00147-6; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; McGonigle B, 2000, PLANT PHYSIOL, V124, P1105, DOI 10.1104/pp.124.3.1105; Morell S, 1997, FEBS LETT, V414, P567, DOI 10.1016/S0014-5793(97)01074-0; Moutiez M, 1997, BIOCHEM J, V322, P43, DOI 10.1042/bj3220043; Mueller LA, 2000, PLANT PHYSIOL, V123, P1561, DOI 10.1104/pp.123.4.1561; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Noctor G, 1998, J EXP BOT, V49, P623, DOI 10.1093/jexbot/49.321.623; Reiter R. S., 1992, Methods in Arabidopsis research., P170; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Roxas VP, 1997, NAT BIOTECHNOL, V15, P988, DOI 10.1038/nbt1097-988; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shimaoka T, 2000, PLANT CELL PHYSIOL, V41, P1110, DOI 10.1093/pcp/pcd035; Theodoulou F. L., 1999, Plant Physiology, V119, P1567, DOI 10.1104/pp.119.4.1567; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Urano J, 2000, FEBS LETT, V466, P107, DOI 10.1016/S0014-5793(99)01768-8; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; vanderKop DAM, 1996, PLANT MOL BIOL, V30, P839, DOI 10.1007/BF00019016; VASUMATHI N, 1989, SULFUR LETT, V10, P15; Washburn MP, 1999, BIOCHEMISTRY-US, V38, P268, DOI 10.1021/bi980480v; Yang KY, 1998, PLANT CELL REP, V17, P700, DOI 10.1007/s002990050468; YANG YF, 1991, J BIOL CHEM, V266, P12759	51	310	355	3	48	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30859	30869		10.1074/jbc.M202919200	http://dx.doi.org/10.1074/jbc.M202919200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12077129	Green Submitted, hybrid			2022-12-25	WOS:000177579800060
J	Mizutani, H; Tada-Oikawa, S; Hiraku, Y; Oikawa, S; Kojima, M; Kawanishi, S				Mizutani, H; Tada-Oikawa, S; Hiraku, Y; Oikawa, S; Kojima, M; Kawanishi, S			Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICALLY-INDUCED APOPTOSIS; OXYGEN SPECIES PRODUCTION; ANTICANCER DRUG TAS-103; OXIDATIVE DNA-DAMAGE; NADPH OXIDASE; CYTOCHROME-C; MITOCHONDRIAL CONTROL; ANTITUMOR-ACTIVITY; BCL-2 FAMILY; ACTIVATION	TAS-103, a new anticancer drug, induces DNA cleavage by inhibiting the activities of topoisomerases I and II. We investigated the mechanism of TAS-103-induced apoptosis in human cell lines. Pulsed field gel electrophoresis revealed that in the leukemia cell line HL-60 and the H2O2-resistant subclone, HP100, TAS-103 induced DNA cleavage to form 1-2-Mb fragments at 1 h to a similar extent, indicating that the DNA cleavage was induced independently of H2O2. TAS-103-induced DNA ladder formation in HP100 cells was delayed compared with that seen at 4 h in HL-60 cells, suggesting the involvement of H2O2-mediated pathways in apoptosis. Flow cytometry revealed that H2O2 formation preceded increases in mitochondrial membrane potential (Deltapsim) and caspase-3 activation. Inhibitors of poly(ADP-ribose) polymerase (PARP) prevented both TAS-103-induced H2O2 generation and DNA ladder formation. The levels of NAD(+), a PARP substrate, were significantly decreased in HL-60 cells after a 3-h incubation with TAS-103. The decreases in NAD(+) levels preceded both increases in Deltapsim and DNA ladder formation. Inhibitors of NAD(P)H oxidase prevented TAS-103-induced apoptosis, suggesting that NAD(P)H oxidase is the primary enzyme mediating H2O2 formation. Expression of the antiapoptotic protein, Bcl-2, in BJAB cells drastically inhibited TAS-103-induced apoptosis, confirming that H2O2 generation occurs upstream of mitochondrial permeability transition. Therefore, these findings indicate that DNA cleavage by TAS-103 induces PARP hyperactivation and subsequent NAD(+) depletion, followed by the activation of NAD(P)H oxidase. This enzyme mediates O-2(-)-derived H2O2 generation, followed by the increase in Deltapsim and subsequent caspase-3 activation, leading to apoptosis.	Mie Univ, Sch Med, Dept Environm & Mol Med, Tsu, Mie 5148507, Japan; Mie Univ Hosp, Dept Pharm, Tsu, Mie 5148507, Japan	Mie University; Mie University	Kawanishi, S (corresponding author), Mie Univ, Sch Med, Dept Environm & Mol Med, Tsu, Mie 5148507, Japan.	kawanisi@doc.medic.mie-u.ac.jp						Aoyagi Y, 1999, JPN J CANCER RES, V90, P578, DOI 10.1111/j.1349-7006.1999.tb00786.x; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; Byl JAW, 1999, BIOCHEMISTRY-US, V38, P15573; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Decaudin D, 1997, CANCER RES, V57, P62; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Ewesuedo RB, 2001, J CLIN ONCOL, V19, P2084, DOI 10.1200/JCO.2001.19.7.2084; Fortune JM, 1999, BIOCHEMISTRY-US, V38, P15580, DOI 10.1021/bi991792g; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hiraku Y, 1996, CANCER RES, V56, P5172; Hiraoka W, 1998, J CLIN INVEST, V102, P1961, DOI 10.1172/JCI3437; Hishita T, 2001, CANCER RES, V61, P2878; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Ikeda K, 1999, BIOCHEM PHARMACOL, V57, P1361, DOI 10.1016/S0006-2952(99)00055-6; ITO K, 1992, BIOCHEMISTRY-US, V31, P11606, DOI 10.1021/bi00161a046; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Jones RD, 2000, FREE RADICAL BIO MED, V29, P416, DOI 10.1016/S0891-5849(00)00320-8; Kajiwara K, 2001, CELL MOL LIFE SCI, V58, P485, DOI 10.1007/PL00000872; KASUGAI I, 1992, LEUKEMIA RES, V16, P173, DOI 10.1016/0145-2126(92)90129-U; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluza J, 2000, CANCER RES, V60, P4077; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lakritz J, 1997, ANAL BIOCHEM, V247, P63, DOI 10.1006/abio.1997.2032; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LITT MR, 1989, ANAL BIOCHEM, V179, P34, DOI 10.1016/0003-2697(89)90196-6; Martin DS, 2000, CANCER RES, V60, P6776; Meyer JW, 2000, FEBS LETT, V472, P1, DOI 10.1016/S0014-5793(00)01397-1; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MohazzabH KM, 1997, CIRCULATION, V96, P614; Muller I, 1998, INT J MOL MED, V1, P491; Murata M, 2001, CHEM RES TOXICOL, V14, P678, DOI 10.1021/tx000209q; Ohyama T, 1999, JPN J CANCER RES, V90, P691, DOI 10.1111/j.1349-7006.1999.tb00802.x; Padget K, 2000, BIOCHEM PHARMACOL, V60, P817, DOI 10.1016/S0006-2952(00)00402-0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; STUBBERFIELD CR, 1989, BIOCHEM PHARMACOL, V38, P2631, DOI 10.1016/0006-2952(89)90548-0; Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014-5793(98)00228-2; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; Tada-Oikawa S, 1998, BIOCHEM BIOPH RES CO, V247, P693, DOI 10.1006/bbrc.1998.8869; Tammariello SP, 2000, J NEUROSCI, V20; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Toomey D, 1998, EUR J BIOCHEM, V251, P935, DOI 10.1046/j.1432-1327.1998.2510935.x; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Utsugi T, 1997, JPN J CANCER RES, V88, P992, DOI 10.1111/j.1349-7006.1997.tb00320.x; Van den Worm E, 2001, EUR J PHARMACOL, V433, P225, DOI 10.1016/S0014-2999(01)01516-3; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	57	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30684	30689		10.1074/jbc.M204353200	http://dx.doi.org/10.1074/jbc.M204353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12068015	hybrid			2022-12-25	WOS:000177579800037
J	Rashid, N; Imanaka, H; Kanai, T; Fukui, T; Atomi, H; Imanaka, T				Rashid, N; Imanaka, H; Kanai, T; Fukui, T; Atomi, H; Imanaka, T			A novel candidate for the true fructose-1,6-bisphosphatase in Archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; HYPERTHERMOPHILIC ARCHAEON; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; DEPENDENT PHOSPHOFRUCTOKINASE; ALLOSTERIC TRANSITION; PYROCOCCUS-FURIOSUS; GLUCOSE; GENE	Fructose-1,6-bisphosphatase (FBPase) is one of the key enzymes of the gluconeogenic pathway. Although enzyme activity had been detected in Archaea, the corresponding gene had not been identified until a presumable inositol monophosphatase gene from Methanococcus jannaschii was found to encode a protein with both inositol monophosphatase and FBPase activities. Here we display that a gene from the hyperthermophilic archaeon, Thermococcus kodakaraensis KOD1, which does not correspond to the inositol monophosphatase gene from M. jannaschii, displays high FBPase activity. The FBPase from strain KOD1 was partially purified, its N-terminal amino acid sequence was determined, and the gene (Tk-fbp) was cloned. Tk-fbp encoded a protein of 375 amino acid residues with a molecular mass of 41,658 Da. The recombinant Tk-Fbp was purified and characterized. Tk-Fbp catalyzed the conversion of fructose 1,6-bisphosphate to fructose 6-phosphate following Michaelis-Menten kinetics with a K-m value of 100 mum toward fructose 1,6-bisphosphate, and a k(cat) value of 17 s(-1) subunit(-1) at 95degreesC. Unlike the inositol monophosphatase from M. jannaschii, Tk-Fbp displayed strict substrate specificity for fructose 1,6-bisphosphate. Activity was enhanced by Mg2+ and dithioerythritol, and was slightly inhibited by fructose 2,6-bisphosphate. AMP did not inhibit the enzyme activity. We examined whether expression of Tk-fbp was regulated at the transcription level. High levels of Tk-fbp transcripts were detected in cells grown on pyruvate or amino acids, whereas no transcription was detected when starch was present in the medium. Orthologue genes corresponding to Tk-fbp with high similarity are present in all the complete genome sequences of thermophilic Archaea, including M. jannaschii, Pyrococcus furiosus, Sulfolobus solfataricus, and Archaeoglobus fulgidus, but are yet to be assigned any function. Taking into account the high FBPase activity of the protein, the strict substrate specificity, and its sugar-repressed gene expression, we propose that Tk-Fbp may represent the bona fide FBPase in Archaea.	Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Corp, Core Res Evolutional Sci & Technol Program, Kawaguchi, Saitama 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Imanaka, T (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.		Kanai, Tamotsu/I-5842-2012; Fukui, Toshiaki/S-6882-2019; Imanaka, Hiroyuki/J-5579-2015; 福居, 俊昭/K-5056-2012; Rashid, Naeem/AAD-7049-2021	Kanai, Tamotsu/0000-0003-3537-2114; Fukui, Toshiaki/0000-0003-4557-6284; Imanaka, Hiroyuki/0000-0001-6830-9934; 福居, 俊昭/0000-0003-4557-6284; Atomi, Haruyuki/0000-0001-9687-6426				BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; Carcamo JG, 2000, EUR J BIOCHEM, V267, P2242, DOI 10.1046/j.1432-1327.2000.01227.x; De la Rosa JM, 2000, CURR MICROBIOL, V41, P384, DOI 10.1007/s002840010154; Donahue JL, 2000, J BACTERIOL, V182, P5624, DOI 10.1128/JB.182.19.5624-5627.2000; Fraser CM, 2000, NATURE, V406, P799, DOI 10.1038/35021244; FUCHS G, 1983, ARCH MICROBIOL, V136, P160, DOI 10.1007/BF00404793; Fujita Y, 1998, J BACTERIOL, V180, P4309, DOI 10.1128/JB.180.16.4309-4313.1998; Hansen T, 2001, ARCH MICROBIOL, V177, P62, DOI 10.1007/s00203-001-0359-1; Kelley-Loughnane N, 2002, BBA-PROTEIN STRUCT M, V1594, P6, DOI 10.1016/S0167-4838(01)00261-8; Kelley-Loughnane N, 2001, PROTEINS, V44, P255, DOI 10.1002/prot.1090; MARCUS F, 1987, BIOCHEMISTRY-US, V26, P7029, DOI 10.1021/bi00396a026; Meijer MMC, 1998, J BIOL CHEM, V273, P24102, DOI 10.1074/jbc.273.37.24102; MORIKAWA M, 1994, APPL ENVIRON MICROB, V60, P4559, DOI 10.1128/AEM.60.12.4559-4566.1994; Nakatani M, 2000, J BACTERIOL, V182, P6424, DOI 10.1128/JB.182.22.6424-6433.2000; Nakatani M, 2002, EUR J BIOCHEM, V269, P650, DOI 10.1046/j.0014-2956.2001.02695.x; Nelson KE, 2000, NAT BIOTECHNOL, V18, P1049, DOI 10.1038/80235; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; Ronimus RS, 2001, FEMS MICROBIOL LETT, V202, P85, DOI 10.1111/j.1574-6968.2001.tb10784.x; Sakuraba H, 2002, J BIOL CHEM, V277, P12495, DOI 10.1074/jbc.C200059200; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; Shieh HL, 1998, J BIOL CHEM, V273, P3381, DOI 10.1074/jbc.273.6.3381; SHYUR LF, 1995, ARCH BIOCHEM BIOPHYS, V319, P123, DOI 10.1006/abbi.1995.1273; Skalecki K, 1999, ARCH BIOCHEM BIOPHYS, V365, P1, DOI 10.1006/abbi.1999.1120; Stec B, 2000, NAT STRUCT BIOL, V7, P1046, DOI 10.1038/80968; Tang GL, 2000, PROTEIN EXPRES PURIF, V19, P411, DOI 10.1006/prep.2000.1267; Tuininga JE, 1999, J BIOL CHEM, V274, P21023, DOI 10.1074/jbc.274.30.21023; YU JP, 1994, J BACTERIOL, V176, P325, DOI 10.1128/JB.176.2.325-332.1994; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	31	58	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30649	30655		10.1074/jbc.M202868200	http://dx.doi.org/10.1074/jbc.M202868200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12065581	hybrid			2022-12-25	WOS:000177579800033
J	Yoshimoto, H; Saltsman, K; Gasch, AP; Li, HX; Ogawa, N; Botstein, D; Brown, PO; Cyert, MS				Yoshimoto, H; Saltsman, K; Gasch, AP; Li, HX; Ogawa, N; Botstein, D; Brown, PO; Cyert, MS			Genome-wide analysis of gene expression regulated by the calcineurin/Crz1p signaling pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; TRANSCRIPTION FACTOR; ENVIRONMENTAL-CHANGES; CA2+ ATPASES; SALT STRESS; ION-PUMP; IDENTIFICATION; PROMOTER; PMR1; DEPHOSPHORYLATION	In Saccharomyces cerevisiae, the Ca2+/calmodulin-dependent protein phosphatase, calcineurin, is activated by specific environmental conditions, including exposure to Ca2+ and Na+, and induces gene expression by regulating the Crz1p/Tcn1p transcription factor. We used DNA microarrays to perform a comprehensive analysis of calcineurin/Crz1p-dependent gene expression following addition of Ca2+ (200 mM) or Na+ (0.8 M) to yeast. 163 genes exhibited increased expression that was reduced 50% or more by calcineurin inhibition. These calcineurin-dependent genes function in signaling pathways, ion/small molecule transport, cell wall maintenance, and vesicular transport, and include many open reading frames of previously unknown function. Three distinct gene classes were defined as follows: 28 genes displayed calcineurin-dependent induction in response to Ca2+ and Na+, 125 showed calcineurin-dependent expression following Ca2+ but not Na+ addition, and 10 were regulated by calcineurin in response to Na+ but not Ca2+. Analysis of crz1Delta cells established Crz1p as the major effector of calcineurin-regulated gene expression in yeast. We identified the Crz1p-binding site as 5'-GNGGC(G/T)CA-3' by in vitro site selection. A similar sequence, 5'-GAGGCTG-3', was identified as a common sequence motif in the upstream regions of calcineurin/Crz1p-dependent genes. This finding is consistent with direct regulation of these genes by Crz1p.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Cyert, MS (corresponding author), Stanford Univ, Dept Biol Sci, 371 Serra Mall, Stanford, CA 94305 USA.		Gasch, Audrey P./AAS-5924-2021; Yoshimoto, Hiroyuki/GPX-8697-2022	Gasch, Audrey P./0000-0002-8182-257X; Yoshimoto, Hiroyuki/0000-0003-2837-8446; Cyert, Martha/0000-0003-3825-7437	NCI NIH HHS [CA 77097] Funding Source: Medline; NHGRI NIH HHS [HG 00983] Funding Source: Medline; NIGMS NIH HHS [GM 48728, GM 46406] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046406, R01GM046406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; BAILEY TL, 1994, ISMB, V2, P28; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; Boustany LM, 2002, GENE DEV, V16, P608, DOI 10.1101/gad.967602; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Kingsbury TJ, 2000, GENE DEV, V14, P1595; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; Mendizabal I, 2001, MOL GENET GENOMICS, V265, P801, DOI 10.1007/s004380100474; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Polizotto RS, 2001, J CELL BIOL, V154, P951, DOI 10.1083/jcb.200104078; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	47	331	342	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31079	31088		10.1074/jbc.M202718200	http://dx.doi.org/10.1074/jbc.M202718200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12058033	hybrid			2022-12-25	WOS:000177579800087
J	Hutchison, S; LeBel, C; Blanchette, M; Chabot, B				Hutchison, S; LeBel, C; Blanchette, M; Chabot, B			Distinct sets of adjacent heterogeneous nuclear ribonucleoprotein (hnRNP) A1/A2 binding sites control 5 ' splice site selection in the hnRNP A1 mRNA precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA DOUBLESEX GENE; A/B PROTEINS; SR PROTEINS; IN-VIVO; SILENCER ELEMENT/; PREMESSENGER RNA; TELOMERIC DNA; EXON; ENHANCER; INCLUSION	In the heterogeneous nuclear ribonucleoprotein (hnRNP) A1 pre-mRNA, different regions in the introns flanking alternative exon 7B have been implicated in the production of the A1 and A1B mRNA splice isoforms. Among these, the CE1a and CE4 elements, located downstream of common exon 7 and alternative exon 7B, respectively, are bound by hnRNP A1 to promote skipping of exon 7B in vivo and distal 5' splice site selection in vitro. Here, we report that CE1a is flanked by an additional high affinity A1 binding site (CE1d). In a manner similar to CE1a, CE1d affects 5' splice site selection in vitro. Consistent with a role for hnRNP A1 in the activity of CE1d, a mutation that abrogates A1 binding abolishes distal 5' splice site activation. Moreover, the ability of CE1d to stimulate distal 5' splice site usage is lost in an HeLa extract depleted of hnRNP A/B proteins, and the addition of recombinant A1 restores the activity of CE1d. Notably, distal 5' splice site selection mediated by A1 binding sites is not compromised in an extract prepared from mouse cells that are severely deficient in hnRNP A1 proteins. In this case, we show that hnRNP A2 compensates for the A1 deficiency. Further studies with the CE4 element reveal that it also consists of two distinct portions (CE4m and CE4p), each one capable of promoting distal 5' splice site use in an hnRNP A1-dependent manner. The presence of multiple A1/A2 binding sites downstream of common exon 7 and alternative exon 7B probably plays an important role in maximizing the activity of hnRNP A1/A2 proteins.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infect, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Chabot, B (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infect, 3001,12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Benoit.Chabot@USherbrooke.ca	Chabot, Benoit/A-8943-2008	Chabot, Benoit/0000-0003-0994-0042				Ashiya M, 1997, RNA, V3, P996; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; CHABOT B, 2003, IN PRESS PROGR MOL S; Chabot B., 1994, RNA PROCESSING PRACT, VI, P1; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Cooper TA, 1998, MOL CELL BIOL, V18, P4519, DOI 10.1128/MCB.18.8.4519; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hammond LE, 1997, MOL CELL BIOL, V17, P7260, DOI 10.1128/MCB.17.12.7260; HUH GS, 1993, MOL CELL BIOL, V13, P5301, DOI 10.1128/MCB.13.9.5301; HUTCHISON S, 2000, RRD MOLEC CELL BIOL, V1, P117; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LIN CH, 1995, RNA, V1, P234; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Muhlemann O, 2000, MOL CELL BIOL, V20, P2317, DOI 10.1128/MCB.20.7.2317-2325.2000; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; Simard MJ, 2000, MOL CELL BIOL, V20, P7353, DOI 10.1128/MCB.20.19.7353-7362.2000; Simard MJ, 2002, MOL CELL BIOL, V22, P4001, DOI 10.1128/MCB.22.12.4001-4010.2002; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Southby J, 1999, MOL CELL BIOL, V19, P2699; Tange TO, 2001, EMBO J, V20, P5748; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	49	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29745	29752		10.1074/jbc.M203633200	http://dx.doi.org/10.1074/jbc.M203633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12060656	hybrid			2022-12-25	WOS:000177509300051
J	Vega, RB; Yang, J; Rothermel, BA; Bassel-Duby, R; Williams, RS				Vega, RB; Yang, J; Rothermel, BA; Bassel-Duby, R; Williams, RS			Multiple domains of MCIP1 contribute to inhibition of calcineurin activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; MUSCLE FIBER-TYPE; CYCLOSPORINE-A; DOWN-SYNDROME; PHOSPHATASE-ACTIVITY; CARDIAC-HYPERTROPHY; STRIATED MUSCLES; PROTEIN; FAMILY; IDENTIFICATION	Calcineurin is a serine/threonine protein phosphatase that plays a critical role in many physiologic processes such as T-cell activation, apoptosis, skeletal myocyte differentiation, and cardiac hypertrophy. Calcineurin-dependent signals are transduced to the nucleus by nuclear factor of activated T-cells (NFAT) transcription factors that undergo nuclear translocation upon dephosphorylation and promote transcriptional activation of target genes. Several endogenous proteins are capable of inhibiting the catalytic activity of calcineurin. Modulatory calcineurin interacting protein 1 (MCIP1) is unique among these proteins on the basis of its pattern of expression and its function in a negative feedback loop to regulate calcineurin activity. Here we show that MCIP1 can be phosphorylated by MAPK and glycogen synthase kinase-3 and that phosphorylated MCIP1 is a substrate for calcineurin. Peptides corresponding to the substrate domain competitively inhibit calcineurin activity in vitro. However, a detailed structure/function analysis of MCIP1 reveals that either of two additional domains of MCIP1 is sufficient for binding to calcineurin in vitro and for inhibition of calcineurin activity in vivo. We conclude that MCIP1 inhibits calcineurin through mechanisms that include, but are not limited to, competition with other substrates such as nuclear factor of activated T-cells.	Duke Univ, Med Ctr, Sch Med, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA	Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Duke Univ, Med Ctr, Sch Med, Box 2927,Davidson Bldg,Green Zone,Room 125, Durham, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296, T32HL007360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR040849, R01AR040849] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296, HLO7360] Funding Source: Medline; NIAMS NIH HHS [AR40849] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HAVERICH A, 1994, TRANSPLANT P, V26, P2713; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Strippoli P, 2000, GENE, V257, P223, DOI 10.1016/S0378-1119(00)00407-8; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61	34	122	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30401	30407		10.1074/jbc.M200123200	http://dx.doi.org/10.1074/jbc.M200123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12063245	hybrid			2022-12-25	WOS:000177509300128
J	Laghi, L; Orbetegli, O; Bianchi, P; Zerbi, A; Di Carlo, V; Boland, CR; Malesci, A				Laghi, L; Orbetegli, O; Bianchi, P; Zerbi, A; Di Carlo, V; Boland, CR; Malesci, A			Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers	ONCOGENE			English	Article						pancreatic cancer; bile duct cancer; K-RAS; pancreatic intraepithelial neoplasia	GENE-MUTATIONS; ONCOGENE ACTIVATION; ADENOCARCINOMA; PROGRESSION; CARCINOMAS; CODON-12; PATHWAYS	Recent studies on small series of pancreatic cancer (PC) with foci of pancreatic intraepithelial neoplasia (PanIN), a putative precursor lesion, have shown that multiple K-RAS mutations may coexist in the same neoplastic pancreas. To see whether mutant-K-RAS polyclonality is a common and specific feature of pancreatic carcinogenesis, we investigated a unselected series of periampullary cancers (41 pancreatic, 13 biliary and two ampullary adenocarcinomas). After hemi-nested polymerase chain reaction (PCR), mutations identified with single strand conformation polymorphism (SSCP) were confirmed by allele-specific PCR and sequencing. K-RAS codon 12 was mutated in 34 (83%) pancreatic cancers and in 11 (85%) biliary cancers. Multiple distinct K-RAS mutations were found in 16 PC (39% of all cases, 47% of those with mutated K-RAS) and in eight biliary cancers (62 and 72%, respectively). In PC, multiple K-RAS mutations were more frequent (P<0.001) in cancers with (nine of 12, 75%) than in those without detectable PanIN (seven of 29, 24%). Individual precursor lesions of the same neoplastic pancreas were found to harbor distinct mutations. Results show that multiple K-RAS mutations are frequent both in PC with associated PanIN and in biliary cancers, and indicate that clonally distinct precursor lesions of PC might variably contribute to tumor development.	Ist Clin Humanitas, Div Gastroenterol, I-20089 Milan, Italy; Univ Milan, Dept Internal Med, I-20121 Milan, Italy; Ist Clin Humanitas, Dept Pathol, Res Lab, I-20089 Milan, Italy; Osped San Raffaele, Dept Surg, I-20132 Milan, Italy; Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA	IRCCS Humanitas Research Hospital; University of Milan; IRCCS Humanitas Research Hospital; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California San Diego	Malesci, A (corresponding author), Ist Clin Humanitas, Div Gastroenterol, Via Manzoni 56, I-20089 Milan, Italy.		Bianchi, Paolo/E-7592-2013; Piemonti, Lorenzo/P-7605-2017; Laghi, Luigi/GZM-5831-2022	Bianchi, Paolo/0000-0001-5786-5644; Piemonti, Lorenzo/0000-0002-2172-2198; Laghi, Luigi/0000-0003-4187-1059; zerbi, alessandro/0000-0002-9176-0448				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; CALDAS C, 1994, CANCER RES, V54, P3568; CUBILLA AL, 1976, CANCER RES, V36, P2690; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Kern Scott E., 1998, Current Opinion in Oncology, V10, P74, DOI 10.1097/00001622-199801000-00012; LEVI S, 1991, CANCER RES, V51, P3497; Moskaluk CA, 1997, CANCER RES, V57, P2140; MOTOJIMA K, 1991, ANN SURG, V214, P657, DOI 10.1097/00000658-199112000-00003; Rozenblum E, 1997, CANCER RES, V57, P1731; Sherratt EJ, 1996, BIOTECHNIQUES, V20, P430; SUGANO K, 1993, LAB INVEST, V68, P361; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; TADA M, 1993, CANCER RES, V53, P2472; Urrutia R, 1996, GASTROENTEROLOGY, V110, P306, DOI 10.1053/gast.1996.v110.agast960306; WATANABE M, 1994, GASTROENTEROLOGY, V107, P1147, DOI 10.1016/0016-5085(94)90240-2; Yamano M, 2000, AM J PATHOL, V156, P2123, DOI 10.1016/S0002-9440(10)65083-3; YANAGISAWA A, 1993, CANCER RES, V53, P953; Yashiro M, 2001, CANCER RES, V61, P2676; Zhu D, 1997, CANCER RES, V57, P2485	23	56	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4301	4306		10.1038/sj.onc.1205533	http://dx.doi.org/10.1038/sj.onc.1205533			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082617				2022-12-25	WOS:000176174200012
J	Sarker, M; Ruiz-Ruiz, C; Robledo, G; Lopez-Rivas, A				Sarker, M; Ruiz-Ruiz, C; Robledo, G; Lopez-Rivas, A			Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells	ONCOGENE			English	Article						MAPK; TRAIL; apoptosis; MCF-7 cells; mitochondria	CYTOCHROME-C; TUMOR-CELLS; IN-VIVO; T-CELLS; DEATH; CASPASE-3; BCL-2; CHEMOTHERAPY; SENSITIVITY; LYMPHOCYTES	We studied the role of the mitogen-activated protein kinase (MAPK) pathway in the regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in breast tumor MCF-7 cells. We found that addition of a protein kinase C (PKC) activator to MCF-7 cultures prevented TRAIL-induced apoptosis, by inhibiting a step downstream of both caspase-8 activation and BID cleavage. TRAIL-induced translocation of Bax from cytosol to mitochondria, release of cytochrome c from mitochondria and activation of caspase-9 were all inhibited by PKC activation. PKC-mediated prevention of mitochondrial apoptotic events; and apoptosis was found to be dependent on the MAPK pathway. Since TRAIL is a ligand of potential use in antineoplastic clinical trials, our findings may provide relevant information in cancer therapy.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.		Ruiz-Ruiz, Carmen/I-8792-2017; Lopez-Rivas, Abelardo/E-5115-2015	Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Lopez-Rivas, Abelardo/0000-0002-9351-9690				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jarvis WD, 1999, INVEST NEW DRUG, V17, P227, DOI 10.1023/A:1006328303451; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	34	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4323	4327		10.1038/sj.onc.1205523	http://dx.doi.org/10.1038/sj.onc.1205523			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082620				2022-12-25	WOS:000176174200015
J	Aissouni, Y; Perez, C; Calmels, B; Benech, PD				Aissouni, Y; Perez, C; Calmels, B; Benech, PD			The cleavage/polyadenylation activity triggered by a U-rich motif sequence is differently required depending on the poly(A) site location at either the first or last 3 '-terminal exon of the 2 '-5 ' oligo(A) synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; LATE POLYADENYLATION SIGNAL; TRACT-BINDING PROTEIN; UPSTREAM EFFICIENCY ELEMENT; SNRNP-A PROTEIN; ACTIVATES POLYADENYLATION; TRANSCRIPTION UNITS; POLYMERASE-II; TAIL LENGTH; HUMAN-CELLS	Production of the two mRNAs encoding distinct forms of 2'-5'-oligoadenylate synthetase depends on processing that involves the recognition of alternative poly(A) sites and an internal 5'-splice site located within the first W-terminal exon. The resulting 1.6- and 1.8-kb mRNAs are expressed in fibroblast cell lines, whereas lymphoblastoid B cells, such as Daudi, produce only the 1.8-kb mRNA. In the present study, we have shown that the 3'-end processing at the last W-terminal exon occurs independently of the core poly(A) site sequence or the presence of regulatory elements. In contrast, in Daudi cells, the recognition of the poly(A) site at the first 3'-terminal exon is impaired because of an unfavorable sequence context. The X-end processing at this particular location requires a strong stabilization of the cleavage/polyadenylation factors, which can be achieved by the insertion of a 25-nucleotide long U-rich motif identified upstream of the last poly(A) site. Consequently, we speculate that in cells expressing the 1.6-kb mRNA, such as fibroblasts, direct or indirect participation of a specific mechanism or cell type-specific factors are required for an efficient polyadenylation at the first 3% terminal exon.	Inst Cancerol & Immunol, U119 INSERM, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Benech, PD (corresponding author), Inst Biol Dev Marseille, Case 907,Campus Luminy, F-13288 Marseille, France.	benech@ibdm.univ-mrs.fr	aissouni, youssef/K-2254-2015; calmels, boris/R-2538-2016	aissouni, youssef/0000-0002-9264-7690; calmels, boris/0000-0002-1684-6030				ADAMI G, 1988, EMBO J, V7, P2107, DOI 10.1002/j.1460-2075.1988.tb03050.x; Ashe MP, 1997, EMBO J, V16, P5752, DOI 10.1093/emboj/16.18.5752; BENECH P, 1985, NUCLEIC ACIDS RES, V13, P1267; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Brackenridge S, 1997, NUCLEIC ACIDS RES, V25, P2326, DOI 10.1093/nar/25.12.2326; Brackenridge S, 2000, MOL CELL BIOL, V20, P2660, DOI 10.1128/MCB.20.8.2660-2669.2000; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; CUSHLEY W, 1982, NATURE, V298, P77, DOI 10.1038/298077a0; DEZAZZO JD, 1989, MOL CELL BIOL, V9, P4951, DOI 10.1128/MCB.9.11.4951; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; FURTH PA, 1994, MOL CELL BIOL, V14, P5278, DOI 10.1128/MCB.14.8.5278; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GILMARTIN GM, 1995, GENE DEV, V9, P72, DOI 10.1101/gad.9.1.72; GILMARTIN GM, 1992, EMBO J, V11, P4419, DOI 10.1002/j.1460-2075.1992.tb05542.x; Gu HD, 1999, P NATL ACAD SCI USA, V96, P8943, DOI 10.1073/pnas.96.16.8943; GUISE JW, 1988, J IMMUNOL, V140, P3988; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; Hans H, 2000, MOL CELL BIOL, V20, P2926, DOI 10.1128/MCB.20.8.2926-2932.2000; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KHANNA KK, 1991, P NATL ACAD SCI USA, V88, P5852, DOI 10.1073/pnas.88.13.5852; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; Lou H, 1999, MOL CELL BIOL, V19, P78; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; MOREIRA A, 1995, EMBO J, V14, P3809, DOI 10.1002/j.1460-2075.1995.tb00050.x; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Penalva LOF, 2001, MOL CELL BIOL, V21, P1986, DOI 10.1128/MCB.21.6.1986-1996.2001; Phillips C, 1999, NUCLEIC ACIDS RES, V27, P429, DOI 10.1093/nar/27.2.429; Phillips C, 1997, NUCLEIC ACIDS RES, V25, P2344, DOI 10.1093/nar/25.12.2344; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; Ryan K, 2002, MOL CELL BIOL, V22, P1684, DOI 10.1128/MCB.22.6.1684-1692.2002; SCHEK N, 1992, MOL CELL BIOL, V12, P5386, DOI 10.1128/MCB.12.12.5386; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Vagner S, 2000, RNA, V6, P178, DOI 10.1017/S1355838200991854; Wahle E, 1997, PROG NUCLEIC ACID RE, V57, P41, DOI 10.1016/S0079-6603(08)60277-9; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Yonaha M, 1999, MOL CELL, V3, P593, DOI 10.1016/S1097-2765(00)80352-4; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	51	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35808	35814		10.1074/jbc.M200540200	http://dx.doi.org/10.1074/jbc.M200540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12082089	hybrid			2022-12-25	WOS:000178275100007
J	Pinheiro, P; Scarlett, G; Rodger, A; Rodger, PM; Murray, A; Brown, T; Newbury, SF; McClellan, JA				Pinheiro, P; Scarlett, G; Rodger, A; Rodger, PM; Murray, A; Brown, T; Newbury, SF; McClellan, JA			Structures of CUG repeats in RNA - Potential implications for human genetic diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; CIRCULAR-DICHROISM SPECTROSCOPY; HUMAN HEREDITARY-DISEASES; SINGLE-STRANDED-DNA; CTG TRIPLET REPEATS; TRINUCLEOTIDE REPEAT; MYOTONIC-DYSTROPHY; ESCHERICHIA-COLI; IN-VITRO; CONFORMATIONAL-CHANGES	Triplet repeats that cause human genetic diseases have been shown to exhibit unusual compact structures in DNA, and in this paper we show that similar structures exist in shorter "normal length" CNG RNA. CUG and control RNAs were made chemically and by in vitro transcription. We find that "normal" short CUG RNAs migrate anomalously fast on non-denaturing gels, compared with control oligos of similar base composition. By contrast, longer tracts approaching clinically relevant lengths appear to form higher order structures. The CD spectrum of shorter tracts is similar to triplex and pseudoknot nucleic acid structures and different from classical hairpin spectra. A model is outlined that enables the base stacking features of poly(r(G-C))(2).poly(r(U)) or poly(d(G-C))(2).poly(d(T)) triplexes to be achieved, even by a single 15-mer.	Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; Univ Portsmouth, Sch Biol Sci, Biophys Labs, Portsmouth PO1 2DT, Hants, England; Salisbury Dist Hosp, Salisbury Hlth Care Natl Hlth Serv Trust, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Warwick; University of Portsmouth; Salisbury District Hospital; University of Southampton; University of Oxford	Rodger, A (corresponding author), Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.	A.Rodger@warwick.ac.uk	Rodger, Alison/A-1063-2009; Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Rodger, Alison/0000-0002-7111-3024; Brown, Tom/0000-0003-4683-1873; Murray, Anna/0000-0002-2351-2522; Brown, Tom/0000-0002-6538-3036; Scarlett, Garry/0000-0001-8338-2398				BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CAUSLEY GC, 1982, BIOPOLYMERS, V21, P1763, DOI 10.1002/bip.360210907; CHASTAIN M, 1992, NUCLEIC ACIDS RES, V20, P315, DOI 10.1093/nar/20.2.315; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; DARLOW JM, 1995, GENETICS, V141, P825; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Djian P, 1996, P NATL ACAD SCI USA, V93, P417, DOI 10.1073/pnas.93.1.417; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1995, CELL, V81, P533; GLUICK TC, 1994, J MOL BIOL, V241, P246, DOI 10.1006/jmbi.1994.1493; GOLDBERG YP, 1995, HUM MOL GENET, V4, P1911, DOI 10.1093/hmg/4.10.1911; GRAY DM, 1992, METHOD ENZYMOL, V211, P389; GRAY DM, 1981, BIOPOLYMERS, V20, P1337, DOI 10.1002/bip.1981.360200702; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; GU YH, 1994, HUM MOL GENET, V3, P1705, DOI 10.1093/hmg/3.9.1705; Hamshere MG, 1996, TRENDS GENET, V12, P332, DOI 10.1016/S0168-9525(96)80002-3; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; JOHNSON KH, 1992, J BIOMOL STRUCT DYN, V9, P733, DOI 10.1080/07391102.1992.10507952; JOHNSON KH, 1991, BIOPOLYMERS, V31, P385, DOI 10.1002/bip.360310404; JOHNSON KH, 1990, BIOPOLYMERS, V29, P325, DOI 10.1002/bip.360290205; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KOHWI Y, 1993, NUCLEIC ACIDS RES, V21, P5651; Kooy RF, 2000, MOL MED TODAY, V6, P193, DOI 10.1016/S1357-4310(00)01674-9; KURYAVYI VV, 1995, NAT GENET, V9, P339, DOI 10.1038/ng0495-339; LAING LG, 1994, J MOL BIOL, V237, P560, DOI 10.1006/jmbi.1994.1255; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; LUGENBEEL KA, 1995, NAT GENET, V10, P483, DOI 10.1038/ng0895-483; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P784, DOI 10.1093/nar/24.4.784; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; McClellan J, 1996, NATURE, V379, P396, DOI 10.1038/379396a0; MCCLELLAN JA, 1986, NUCLEIC ACIDS RES, V14, P9291, DOI 10.1093/nar/14.23.9291; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; Murray A, 1996, HUM MOL GENET, V5, P727, DOI 10.1093/hmg/5.6.727; Newbury SF, 1996, ANAL COMMUN, V33, P117, DOI 10.1039/ac9963300117; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; PARK YW, 1992, P NATL ACAD SCI USA, V89, P6653, DOI 10.1073/pnas.89.14.6653; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; Sarkar M, 1996, BIOCHEMISTRY-US, V35, P4678, DOI 10.1021/bi9523466; SCARIA PV, 1991, J BIOL CHEM, V266, P5417; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHWEISGUTH DC, 1994, NUCLEIC ACIDS RES, V22, P604, DOI 10.1093/nar/22.4.604; Shi PY, 1996, BIOCHEMISTRY-US, V35, P4222, DOI 10.1021/bi952398v; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; SMITH SS, 1994, J MOL BIOL, V243, P143, DOI 10.1006/jmbi.1994.1640; SPEDDING G, 1993, J MOL BIOL, V229, P609, DOI 10.1006/jmbi.1993.1067; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; TROTTIER Y, 1994, AM J MED GENET, V51, P454, DOI 10.1002/ajmg.1320510431; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; YANOYANAGISAWA H, 1995, NUCLEIC ACIDS RES, V23, P2654, DOI 10.1093/nar/23.14.2654	57	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35183	35190		10.1074/jbc.M202235200	http://dx.doi.org/10.1074/jbc.M202235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12077125	hybrid			2022-12-25	WOS:000178117000068
J	Madison, BB; Dunbar, L; Qiao, XTT; Braunstein, K; Braunstein, E; Gumucio, DL				Madison, BB; Dunbar, L; Qiao, XTT; Braunstein, K; Braunstein, E; Gumucio, DL			cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; REGULATORY SEQUENCES; VISCERAL ENDODERM; TRANSGENIC MICE; GLOBIN GENE; MOUSE; MORPHOGENESIS; CELLS; EPITHELIUM; CHROMATIN	Villin, an actin bundling protein found in the apical brush border of absorptive tissues, is one of the first structural genes to be transcriptionally activated in the embryonic intestinal endoderm. In the adult, villin is broadly expressed in every cell of the intestinal epithelium on both the vertical axis (crypt to villus tip) and the horizontal axis (duodenum through colon) of the intestine. Here, we document that a 12.4-kilobase region of the mouse villin gene drives high level expression of two different reporter genes (LacZ and Cre recombinase) within the entire intestinal epithelium of transgenic mice. Deletion of a portion of this transgene results in reduction of beta-galactosidase activity in restricted domains of the small intestine (duodenum) and large intestine (cecum). In addition, expression is reduced in the crypt compartment throughout the intestine. Thus, the global expression pattern of villin in the intestine is apparently the consequence of an amalgam of distinct and individual domain-specific control processes. That is, expression of villin in the duodenum and cecum requires different regulatory sequences than the rest of the intestine, and the expression of villin in crypts is regulated by different circuitry than expression of villin on villus tips.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Gumucio, DL (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, 5704 Med Sci 2, Ann Arbor, MI 48109 USA.				NHLBI NIH HHS [T32HL07505] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bieker J J, 1998, Curr Opin Hematol, V5, P145; Braunstein EM, 2002, DEV DYNAM, V224, P90, DOI 10.1002/dvdy.10091; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; Dusing MR, 1997, J BIOL CHEM, V272, P26634, DOI 10.1074/jbc.272.42.26634; Dusing MR, 2001, J BIOL CHEM, V276, P14434, DOI 10.1074/jbc.M009249200; Dusing MR, 2000, AM J PHYSIOL-GASTR L, V279, pG1080, DOI 10.1152/ajpgi.2000.279.5.G1080; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; KAUFMAN MH, 1994, ATLAS MOUSE DEV, P95; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; ROBINE S, 1993, J BIOL CHEM, V268, P11426; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; Sackerson C, 1999, DEV BIOL, V211, P39, DOI 10.1006/dbio.1999.9301; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stamatoyannopoulos JA, 1997, MOL CELL BIOL, V17, P240, DOI 10.1128/MCB.17.1.240; Su YH, 2000, J BIOL CHEM, V275, P7902, DOI 10.1074/jbc.275.11.7902; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3	26	535	544	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33275	33283		10.1074/jbc.M204935200	http://dx.doi.org/10.1074/jbc.M204935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12065599	hybrid			2022-12-25	WOS:000177859000113
J	Mood, K; Friesel, R; Daar, IO				Mood, K; Friesel, R; Daar, IO			SNT1/FRS2 mediates germinal vesicle breakdown induced by an activated FGF receptor1 in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; CYCLIC-AMP PHOSPHODIESTERASE; MAP KINASE ACTIVATION; MOS PROTO-ONCOGENE; PHOSPHATIDYLINOSITOL 3-KINASE; MESODERM INDUCTION; TYROSINE KINASE; MEIOTIC MATURATION; ADENYLATE-CYCLASE	The docking protein SNT1/FRS2 (fibroblast growth factor receptor substrate 2) is implicated in the transmission of extracellular signals from the fibroblast growth factor receptor (FGFR), which plays vital roles during embryogenesis. Activating FGFR mutations cause several craniosynostoses and dwarfism syndromes in humans. Here we show that the Xenopus homolog of mammalian FRS-2 (XFRS2) is essential for the induction of oocyte maturation by an XFGFR1 harboring an activating mutation (XFGFR1act). Using a dominant-negative form of kinase suppressor of Ras, we show the Mek activity is required for germinal vesicle breakdown (GVBD) induced by co-expression of XFGFR1act and XFRS2, but this activity is not required for progesterone-induced GVBD. Furthermore, Mek/MAPK activity is critical for the induction and/or maintenance of H1 kinase activity at metaphase of meiosis II in progesterone-treated oocytes. An activated XFGFR1 containing a mutation in the phospholipase Cgamma binding site (XFGFR1actY672F) displayed a reduced ability to induce cell-cycle progression in oocytes, suggesting phospholipase Cgamma may not be necessary but that it augments XFGFR signaling in this system. Oocytes co-expressing XFGFR1act and XFRS2 showed substantial H1 kinase activity, but this activity was blocked when the oocytes were treated with the phosphatidylinositol 3-kinase inhibitor LY294002. Although phosphatidylinositol 3-kinase activity is essential for XFGFR1act/XFRS2-induced oocyte maturation, this activity is not required for maturation induced by progesterone. Finally, ectopic expression of Xspry2, a negative regulator of XFGFR signaling, greatly reduced MAPK activation and GVBD induced by the expression of either XFGFR1act plus XFRS2 or activated Ras (H-RasV12). In contrast, Xspry2 did not prevent GVBD induced by an activated form of Raf1, suggesting that Xspry2 exerts its inhibitory function upstream or parallel to Raf and downstream of Ras.	NCI, Regulat Cell Growth Lab, NIH, Frederick, MD 21702 USA; Maine Med Ctr, Inst Res, Ctr Mol Med, Portland, ME 04106 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Maine Medical Center	Daar, IO (corresponding author), NCI, Regulat Cell Growth Lab, NIH, Bldg 560,Rm 22-3, Frederick, MD 21702 USA.			Daar, Ira/0000-0003-2657-526X	NCRR NIH HHS [RR15555] Funding Source: Medline; NHLBI NIH HHS [HL65301] Funding Source: Medline; NIDCR NIH HHS [DE13234] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013234] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akagi K, 2002, DEV DYNAM, V223, P216, DOI 10.1002/dvdy.10048; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; Bagowski CP, 2001, J BIOL CHEM, V276, P37708, DOI 10.1074/jbc.M104582200; Browaeys-Poly E, 2000, EUR J BIOCHEM, V267, P6256, DOI 10.1046/j.1432-1327.2000.01710.x; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Carballada R, 2001, DEVELOPMENT, V128, P35; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Christen B, 1999, DEVELOPMENT, V126, P119; Colvin JS, 2001, DEVELOPMENT, V128, P2095; Curran KL, 2000, DEV BIOL, V228, P41, DOI 10.1006/dbio.2000.9917; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; Easton JB, 1999, J BIOL CHEM, V274, P11321, DOI 10.1074/jbc.274.16.11321; ELETR M, 1979, SCIENCE, V205, P1397, DOI 10.1126/science.472755; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Gavin AC, 1999, MOL BIOL CELL, V10, P2971, DOI 10.1091/mbc.10.9.2971; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GRIECO D, 1995, ONCOGENE, V11, P113; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Gross SD, 2001, J BIOL CHEM, V276, P46099, DOI 10.1074/jbc.C100496200; Gupta RW, 1998, ONCOGENE, V17, P2155, DOI 10.1038/sj.onc.1202158; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; Kannan K, 2000, IUBMB LIFE, V49, P197; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Kusakabe M, 2001, EMBO REP, V2, P727, DOI 10.1093/embo-reports/kve152; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; Lopez-Hernandez E, 1999, FEBS LETT, V451, P284, DOI 10.1016/S0014-5793(99)00595-5; MALLER JL, 1981, DEV BIOL, V85, P309, DOI 10.1016/0012-1606(81)90262-1; Maller JL, 2001, BIOL CELL, V93, P27, DOI 10.1016/S0248-4900(01)01127-3; Maller JL, 2001, P NATL ACAD SCI USA, V98, P8, DOI 10.1073/pnas.98.1.8; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; Partanen J, 1998, GENE DEV, V12, P2332, DOI 10.1101/gad.12.15.2332; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Reich A, 1999, DEVELOPMENT, V126, P4139; ROBBIE EP, 1995, DEVELOPMENT, V121, P1775; SADLER SE, 1989, J BIOL CHEM, V264, P856; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SADLER SE, 1985, ADV CYCLIC NUCL PROT, V19, P179; SADLER SE, 1983, J BIOL CHEM, V258, P7935; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Sun X, 1999, GENE DEV, V13, P1834, DOI 10.1101/gad.13.14.1834; Tan C, 2001, DEVELOPMENT, V128, P3665; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Wang JK, 1996, ONCOGENE, V13, P721; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu XL, 1998, DEVELOPMENT, V125, P753; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	86	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33196	33204		10.1074/jbc.M203894200	http://dx.doi.org/10.1074/jbc.M203894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082104	hybrid			2022-12-25	WOS:000177859000103
J	Zhang, M; Liu, P; Dwyer, NK; Christenson, LK; Fujimoto, T; Martinez, F; Comly, M; Hanover, JA; Blanchette-Mackie, EJ; Strauss, JF				Zhang, M; Liu, P; Dwyer, NK; Christenson, LK; Fujimoto, T; Martinez, F; Comly, M; Hanover, JA; Blanchette-Mackie, EJ; Strauss, JF			MLN64 mediates mobilization of lysosomal cholesterol to steroidogenic mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; PICK C1 PROTEIN; DOMAIN; CELLS; STAR; TRAFFICKING; GENE; COMPARTMENT; TRANSPORT; HOMOLOGY	This study demonstrates that the steroidogenic acute regulatory protein-related lipid transfer (START) domain-containing protein, MLN64, participates in intra. cellular cholesterol trafficking. Analysis of the intracellular itinerary of MLN64 and MLN64 mutants tagged with green fluorescent protein showed that the N-terminal transmembrane domains mediate endocytosis of MLN64 from the plasma membrane to late endocytic compartments. MLN64 constitutively traffics via dynamic NPC1-containing late endosomal tubules in normal cells; this dynamic movement was inhibited in cholesterol-loaded cells, and MLN64 is trapped at the periphery of cholesterol-laden lysosomes. The MLN64 START domain stimulated free cholesterol transfer from donor to acceptor mitochondrial membranes and enhanced steroidogenesis by placental mitochondria. Expression of a truncated form of MLN64 (DeltaSTART-AULN64), which contains N-terminal transmembrane domains but lacks the START domain, caused free cholesterol accumulation in lysosomes and inhibited late endocytic dynamics. The DeltaSTART-MLN64 dominant negative protein was located at the surface of the cholesterol-laden lysosomes. This dominant negative mutant suppressed steroidogenesis in COS cells expressing the mitochondrial cholesterol side chain cleavage system. We conclude that MLN64 participates in mobilization and utilization of lysosomal cholesterol by virtue of the START domain's role in cholesterol transport.	NIDDK, Lipid Cell Biol Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Cell Biochem Sect, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA; Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Pennsylvania; Pennsylvania Medicine	Strauss, JF (corresponding author), NIDDK, Lipid Cell Biol Sect, NIH, Bldg 8,Rm 427,MSC 0851,8 Ctr Dr, Bethesda, MD 20892 USA.	jfs3@mail.med.upenn.edu	Christenson, Lane K/G-6435-2013		FIC NIH HHS [D43-TW-00671] Funding Source: Medline; NICHD NIH HHS [HD06274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000, Z01DK060003, ZIADK060003] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; Martinez F, 1997, ENDOCRINOLOGY, V138, P2172, DOI 10.1210/en.138.5.2172; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; SOTO E, 1984, J CLIN ENDOCR METAB, V58, P831, DOI 10.1210/jcem-58-5-831; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; Tong HY, 2000, J BIOL CHEM, V275, P11981, DOI 10.1074/jbc.275.16.11981; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; Watari H, 2000, EXP CELL RES, V255, P56, DOI 10.1006/excr.1999.4774; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	26	123	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33300	33310		10.1074/jbc.M200003200	http://dx.doi.org/10.1074/jbc.M200003200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12070139	hybrid			2022-12-25	WOS:000177859000116
J	Cai, C; Coleman, SK; Niemi, K; Keinanen, K				Cai, C; Coleman, SK; Niemi, K; Keinanen, K			Selective binding of synapse-associated protein 97 to GluR-A alpha-amino-5-hydroxy-3-methyl-4-isoxazole propionate receptor subunit is determined by a novel sequence motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ DOMAIN; POSTSYNAPTIC DENSITY; STRUCTURAL BASIS; PSD-95 FAMILY; SAP97; RECOGNITION; HOMOLOG; COMPLEX	A family of four closely related PDZ domain-containing membrane-associated guanylate kinase homologues (MAGUKs) is involved in the regulation of the amount and functional state of ionotropic glutamate receptors in excitatory synapses. To understand the mechanisms that determine the specificity of these interactions, we examined the structural basis of the highly selective association between the ionotropic GluR subunit GluR-A and synapse-associated protein 97 (SAP97). The C terminus of GluR-A bound to the PDZ domains of SAP97, but not to those of three related MAGUKs, PSD-93, PSD-95, and SAP102. Experiments with single PDZ domains indicated that the strongest contribution was by the second PDZ domain. Unexpectedly, mutation analysis of the GluR-A C terminus revealed that a tripeptide sequence SSG at position -9 to -11 plays an essential role in this binding, in addition to a C-terminal type I PDZ binding motif (leucine at C terminus and threonine at the -2 position). Analysis of the in vitro MAGUK-binding properties of a GluR-D mutant with a one-residue deletion at the C terminus provides further support for the view that an SSG sequence located N-terminally from a type I PDZ binding motif can mediate selective binding to SAP97 and suggest the existence of a novel variation of the PDZ domain-peptide interaction.	Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Viiki Bioctr, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Keinanen, K (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, POB 56,Viikinkaari 5D, FIN-00014 Helsinki, Finland.	kari.keinanen@helsinki.fi	Keinanen, Kari/E-9122-2010	Coleman, Sarah/0000-0002-1066-8296				Bassand P, 1999, EUR J NEUROSCI, V11, P2031, DOI 10.1046/j.1460-9568.1999.00611.x; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Imamura F, 2002, J BIOL CHEM, V277, P3640, DOI 10.1074/jbc.M106940200; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mehta S, 2001, J BIOL CHEM, V276, P16092, DOI 10.1074/jbc.M100643200; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x	29	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31484	31490		10.1074/jbc.M204354200	http://dx.doi.org/10.1074/jbc.M204354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070168	Green Published, hybrid			2022-12-25	WOS:000177718700026
J	Deery, WJ; Gao, T; Ammann, R; Gomer, RH				Deery, WJ; Gao, T; Ammann, R; Gomer, RH			A single cell density-sensing factor stimulates distinct signal transduction pathways through two different receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE CAMP RECEPTORS; DICTYOSTELIUM-DISCOIDEUM; G-PROTEIN; GENE-EXPRESSION; GUANINE-NUCLEOTIDES; CHEMOATTRACTANT RECEPTORS; ADENYLATE-CYCLASE; DECOY RECEPTORS; BODY-WEIGHT; CHEMOTAXIS	In Dictyostelium discoideum, cell density is monitored by levels of a secreted protein, conditioned medium factor (CMF). CMFR1 is a putative CMF receptor necessary for CMF-induced G protein-independent accumulation of the SP70 prespore protein but not for CMF-induced G protein-dependent inositol 1,4,5-trisphosphate production. Using recombinant fragments of CMF, we find that stimulation of the inositol 1,4,5-trisphosphate pathway requires amino acids 170-180, whereas SP70 accumulation does not, corroborating a two-receptor model. Cells lacking CMFR1 do not aggregate, due to the lack of expression of several important early developmentally regulated genes, including gp80. Although many aspects of early developmental cAMP-stimulated signal transduction are mediated by CMF, CMFR1 is not essential for cAMP-stimulated cAMP and cGMP production or Ca2+ uptake, suggesting the involvement of a second CMF receptor. Exogenous application of antibodies against either the region between a first and second or a second and third possible transmembrane domain of CMFR1 induces SP70 accumulation. Antibody- and CMF-induced gene expression can be inhibited by recombinant CMFR1 corresponding to the region between the first and third potential transmembrane domains, indicating that this region is extracellular and probably contains the CMF binding site. These observations support a model where a one- or two-transmembrane CMFR1 regulates gene expression and a G protein-coupled CMF receptor mediates cAR1 signal transduction.	Rice Univ, Dept Biochem & Cell Biol, Howard Hughes Med Inst, Houston, TX 77005 USA	Howard Hughes Medical Institute; Rice University	Gomer, RH (corresponding author), Rice Univ, Dept Biochem & Cell Biol, Howard Hughes Med Inst, MS-140,6100 S Main St, Houston, TX 77005 USA.			Gomer, Richard/0000-0003-2361-4307				ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Brazill DT, 1997, FEBS LETT, V404, P100, DOI 10.1016/S0014-5793(97)00104-X; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Clarke M, 1995, EXPERIENTIA, V51, P1124, DOI 10.1007/BF01944730; Deery WJ, 1999, J BIOL CHEM, V274, P34476, DOI 10.1074/jbc.274.48.34476; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; Firtel RA, 2000, CURR OPIN GENET DEV, V10, P421, DOI 10.1016/S0959-437X(00)00107-6; GARVEY JS, 1977, METHOD IMMUNOL, P218; GOMER RH, 1994, CURR BIOL, V4, P734, DOI 10.1016/S0960-9822(00)00163-9; GOMER RH, 1991, DEVELOPMENT, V112, P269; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; GOMER RH, 1987, METHOD CELL BIOL, P471; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; Gupta R, 1999, GLYCOBIOLOGY, V9, P1009, DOI 10.1093/glycob/9.10.1009; JAIN R, 1994, J BIOL CHEM, V269, P9128; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Jequier E, 1999, PHYSIOL REV, V79, P451, DOI 10.1152/physrev.1999.79.2.451; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOOMIS WF, 1988, DEV GENET, V9, P549, DOI 10.1002/dvg.1020090431; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MAEDA Y, 1997, DICTYOSTELIUM MODEL, P207; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; MILNE JL, 1993, MOL BIOL CELL, V4, P283, DOI 10.1091/mbc.4.3.283; MILNE JLS, 1995, J BIOL CHEM, V270, P5926, DOI 10.1074/jbc.270.11.5926; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; Pan SH, 2000, BIOTECHNIQUES, V29, P1234, DOI 10.2144/00296st03; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PODGORSKI GJ, 1986, J GEN MICROBIOL, V132, P1043; ROWEKAMP W, 1980, CELL, V20, P495, DOI 10.1016/0092-8674(80)90636-4; Sansom DM, 2000, IMMUNOLOGY, V101, P169, DOI 10.1046/j.1365-2567.2000.00121.x; SAXE SA, 1988, DEV GENET, V9, P259, DOI 10.1002/dvg.1020090408; Schaloske R, 1997, BIOCHEM J, V327, P233, DOI 10.1042/bj3270233; Secko DM, 2001, EXP CELL RES, V266, P135, DOI 10.1006/excr.2001.5216; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Siu C.-H., 1997, DICTYOSTELIUM CELL D, P111; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; Sonnemann J, 1998, FEBS LETT, V436, P271, DOI 10.1016/S0014-5793(98)01139-9; Sower LE, 1999, EXP CELL RES, V247, P422, DOI 10.1006/excr.1998.4372; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; Stock J, 1996, SCIENCE, V274, P370, DOI 10.1126/science.274.5286.370; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANHAASTERT PJM, 1989, ANAL BIOCHEM, V177, P115, DOI 10.1016/0003-2697(89)90024-9; vanHaastert PJM, 1997, FEBS LETT, V410, P25, DOI 10.1016/S0014-5793(97)00416-X; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1987, EUR J BIOCHEM, V162, P251; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VanHaastert PJM, 1996, J CELL BIOL, V134, P1543, DOI 10.1083/jcb.134.6.1543; Wang B, 1999, DEV BIOL, V208, P1, DOI 10.1006/dbio.1998.9193; Wang N, 1999, MOL CELL BIOL, V19, P4750; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251; YUEN IS, 1994, J THEOR BIOL, V167, P273, DOI 10.1006/jtbi.1994.1069; YUEN IS, 1991, DEVELOPMENT, V113, P1375	68	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31972	31979		10.1074/jbc.M204539200	http://dx.doi.org/10.1074/jbc.M204539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070170	hybrid			2022-12-25	WOS:000177718700084
J	Joet, T; Genty, B; Josse, EM; Kuntz, M; Cournac, L; Peltier, G				Joet, T; Genty, B; Josse, EM; Kuntz, M; Cournac, L; Peltier, G			Involvement of a plastid terminal oxidase in plastoquinone oxidation as evidenced by expression of the Arabidopsis thaliana enzyme in tobacco	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; NADH-SPECIFIC DEHYDROGENASE; HIGHER-PLANT CHLOROPLASTS; PHOTOSYSTEM-I; ALTERNATIVE OXIDASE; NDH GENES; NAD(P)H-PLASTOQUINONE OXIDOREDUCTASE; NONPHOTOCHEMICAL REDUCTION; CHLOROPHYLL FLUORESCENCE; CHLORORESPIRATION	Chlororespiration has been defined as a respiratory electron transport chain in interaction with photosynthetic electron transport involving both non-photochemical reduction and oxidation of plastoquinones. Different enzymatic activities, including a plastid-encoded NADH dehydrogenase complex, have been reported to be involved in the non-photochemical reduction of plastoquinones. However, the enzyme responsible for plasquinol oxidation has not yet been clearly identified. In order to determine whether the newly discovered plastid oxidase (PTOX) involved in carotenoid biosynthesis acts as a plastoquinol oxidase in higher plant chloroplasts, the Arabidopsis thaliana PTOX gene (At-PTOX) was expressed in tobacco under the control of a strong constitutive promoter. We showed that AtPTOX is functional in tobacco chloroplasts and strongly accelerates the non-photochemical reoxidation of plastoquinols; this effect was inhibited by propyl gallate, a known inhibitor of PTOX. During the dark to light induction phase of photosynthesis at low irradiances, At-PTOX drives significant electron flow to O-2, thus avoiding over-reduction of plastoquinones, when photosynthetic CO2 assimilation was not fully induced. We proposed that PTOX, by modulating the redox state of intersystem electron carriers, may participate in the regulation of cyclic electron flow around photosystem I.	Univ Mediterranee, Direct Sci Vivant, Dept Ecophysiol Vegetale & Microbiol,CEA Cadarach, Lab Ecophysiol Photosynth,UMR 163,CNRS,CEA, F-13108 St Paul Les Durance, France; Univ Grenoble 1, Lab Genet Mol Plantes, F-38041 Grenoble 9, France; CNRS, UMR 5575, F-38041 Grenoble 9, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Peltier, G (corresponding author), Univ Mediterranee, Direct Sci Vivant, Dept Ecophysiol Vegetale & Microbiol,CEA Cadarach, Lab Ecophysiol Photosynth,UMR 163,CNRS,CEA, CEA 1000, F-13108 St Paul Les Durance, France.		JOËT, Thierry/A-9070-2011; Cournac, Laurent/G-2564-2010; PELTIER, Gilles/ABD-4484-2021	JOËT, Thierry/0000-0002-0531-5146; Josse, Eve-Marie/0000-0002-3286-8264; Peltier, Gilles/0000-0002-2226-3931				Aluru MR, 2001, PLANT PHYSIOL, V127, P67, DOI 10.1104/pp.127.1.67; BENDALL DS, 1995, BBA-BIOENERGETICS, V1229, P23, DOI 10.1016/0005-2728(94)00195-B; BENNOUN P, 1982, P NATL ACAD SCI-BIOL, V79, P4352, DOI 10.1073/pnas.79.14.4352; BENNOUN P, 1994, BBA-BIOENERGETICS, V1186, P59, DOI 10.1016/0005-2728(94)90135-X; Bennoun P., 1998, MOL BIOL CHLOROPLAST, P675; BERGER S, 1993, PLANTA, V190, P25, DOI 10.1007/BF00195671; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Carol P, 1999, PLANT CELL, V11, P57, DOI 10.1105/tpc.11.1.57; Carol P, 2001, TRENDS PLANT SCI, V6, P31, DOI 10.1016/S1360-1385(00)01811-2; Casano LM, 2000, J BIOL CHEM, V275, P942, DOI 10.1074/jbc.275.2.942; CLELAND RE, 1992, PHOTOSYNTH RES, V34, P409, DOI 10.1007/BF00029815; Corneille S, 1998, BBA-BIOENERGETICS, V1363, P59, DOI 10.1016/S0005-2728(97)00074-1; Cournac L, 2000, J BIOL CHEM, V275, P17256, DOI 10.1074/jbc.M908732199; Cournac L, 2000, PHILOS T ROY SOC B, V355, P1447, DOI 10.1098/rstb.2000.0705; Cournac L, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1877; COURNAC L, 2002, IN PRESS PLANT PHYSL; CUELLO J, 1995, PLANT CELL PHYSIOL, V36, P265, DOI 10.1093/oxfordjournals.pcp.a078758; DELOSME R, 1967, BIOCHIM BIOPHYS ACTA, V143, P108, DOI 10.1016/0005-2728(67)90115-6; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Feild TS, 1998, PLANT PHYSIOL, V116, P1209, DOI 10.1104/pp.116.4.1209; GARAB G, 1989, PLANTA, V179, P349, DOI 10.1007/BF00391080; GENTY B, 1989, BIOCHIM BIOPHYS ACTA, V990, P87, DOI 10.1016/S0304-4165(89)80016-9; GROOM QJ, 1993, PHOTOSYNTH RES, V36, P205, DOI 10.1007/BF00033039; Guedeney G, 1996, FEBS LETT, V378, P277, DOI 10.1016/0014-5793(95)01473-X; HARRIS GC, 1993, PLANT PHYSIOL, V101, P1169, DOI 10.1104/pp.101.4.1169; Hibberd JM, 2002, NATURE, V415, P451, DOI 10.1038/415451a; Hoefnagel MHN, 1998, BBA-BIOENERGETICS, V1366, P235, DOI 10.1016/S0005-2728(98)00126-1; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Horvath EM, 2000, PLANT PHYSIOL, V123, P1337, DOI 10.1104/pp.123.4.1337; Joet T, 2002, PLANT PHYSIOL, V128, P760, DOI 10.1104/pp.010775; Joet T, 2001, PLANT PHYSIOL, V125, P1919, DOI 10.1104/pp.125.4.1919; Josse EM, 2000, PLANT PHYSIOL, V123, P1427, DOI 10.1104/pp.123.4.1427; KAUTSKY H, 1960, BIOCHEM Z, V332, P277; Kubicki A, 1996, PLANTA, V199, P276, DOI 10.1007/BF00196569; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENTHALER H. K., 1983, BIOCHEM SOC T, V11, P591, DOI [DOI 10.1042/BST0110591, 10.1042/BST0110591]; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; MILLS WR, 1980, PLANTA, V148, P75, DOI 10.1007/BF00385445; Nixon PJ, 2000, PHILOS T R SOC B, V355, P1541, DOI 10.1098/rstb.2000.0714; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PELTIER G, 1987, BIOCHIM BIOPHYS ACTA, V893, P83, DOI 10.1016/0005-2728(87)90151-4; Peltier G, 2002, ANNU REV PLANT BIOL, V53, P523, DOI 10.1146/annurev.arplant.53.100301.135242; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; Rumeau D, 1996, PLANTA, V199, P79, DOI 10.1007/BF00196884; Sazanov LA, 1996, BIOCHEM SOC T, V24, P739, DOI 10.1042/bst0240739; Sazanov LA, 1998, P NATL ACAD SCI USA, V95, P1319, DOI 10.1073/pnas.95.3.1319; SCHERER S, 1990, TRENDS BIOCHEM SCI, V15, P458, DOI 10.1016/0968-0004(90)90296-N; Shikanai T, 1998, P NATL ACAD SCI USA, V95, P9705, DOI 10.1073/pnas.95.16.9705; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; Wu DY, 1999, PLANT CELL, V11, P43, DOI 10.1105/tpc.11.1.43; ZIEMHANCK U, 1980, BIOCHIM BIOPHYS ACTA, V591, P266, DOI 10.1016/0005-2728(80)90158-9	51	130	138	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31623	31630		10.1074/jbc.M203538200	http://dx.doi.org/10.1074/jbc.M203538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12050159	hybrid			2022-12-25	WOS:000177718700042
J	Maeda, N; Kanai, T; Atomi, H; Imanaka, T				Maeda, N; Kanai, T; Atomi, H; Imanaka, T			The unique pentagonal structure of an archaeal Rubisco is essential for its high thermostability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; CRYSTAL-STRUCTURE; HYPERTHERMOPHILIC ARCHAEON; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; BISPHOSPHATE CARBOXYLASE/OXYGENASE; TRIOSEPHOSPHATE ISOMERASE; THERMOTOGA-MARITIMA; RESOLUTION; OXYGENASE; TIM	We have previously determined the crystal structure of a novel pentagonal ribulose 1,5-bisphosphate carboxylase/oxygenase (Rubisco) from the hyperthermophilic archaeon, Thermococcus kodakaraensis KOD1 Here we have carried out biochemical studies to identify the necessities and/or advantages of this intriguing pentagonal structure. The structure indicated the presence of three neighboring residues (Glu-63, Arg-66, and Asp-69), participating in ionic interactions within unique dimer-dimer interfaces. We constructed three single mutant proteins (E63S, R66S, and D69S) and one triple mutant protein (E63S/R66S/D69S) by replacing the charged residues with serine. The wild type (WT) and all mutant proteins were purified and subjected to gel permeation chromatography at various temperatures. WT and D69S proteins were decameric at all temperatures examined between 30 and 90 degreesC. The majority of E63S and R66S were decamers at 30 degreesC but were found to gradually disassemble with the elevation in temperature. E63S/ R66S/D69S was found in a dimeric form even at 30 degreesC. An interesting correlation was found between the subunit assembly and thermostability of the proteins. Circular dichroism and differential scanning calorimetry analyses indicated that the denaturation temperatures of dimeric enzymes (ENS, R66S, and E63S/R66S/D69S) were similar to95 degreesC, whereas those of the enzymes retaining a decameric structure (WT and D69S) were similar to 110 degreesC. Disassembly into tetramer or dimer units did not alter the slopes of the Arrhenius plots, indicating that the decameric structure had no effect on catalytic performance per se. The results indicate that the decameric assembly of Tk-Rubisco contributes to enhance the thermostability of the enzyme. Taking into account the growth temperature of strain KOD1 (65-100 degreesC), the decameric structure of Tk-Rubisco can be considered essential for the stable presence of the enzyme in the host cells. This study provides an interesting example in which the thermostability of a protein can be enhanced by formation of a unique quaternary structure not found in mesophilic enzymes.	Kyoto Univ, Dept Synthet Chem & Biol Chem, Grad Sch Engn, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol Program, Kawaguchi 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Imanaka, T (corresponding author), Kyoto Univ, Dept Synthet Chem & Biol Chem, Grad Sch Engn, Sakyo Ku, Kyoto 6068501, Japan.	imanaka@sbchem.kyoto-u.ac.jp	Kanai, Tamotsu/I-5842-2012	Kanai, Tamotsu/0000-0003-3537-2114; Atomi, Haruyuki/0000-0001-9687-6426				Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; Atomi H, 2001, METHOD ENZYMOL, V331, P353; Dams T, 2000, J MOL BIOL, V297, P659, DOI 10.1006/jmbi.2000.3570; DELBONI LF, 1995, PROTEIN SCI, V4, P2594, DOI 10.1002/pro.5560041217; Duff AP, 2000, J MOL BIOL, V298, P903, DOI 10.1006/jmbi.2000.3724; Ezaki S, 1999, J BIOL CHEM, V274, P5078, DOI 10.1074/jbc.274.8.5078; Grabarse W, 1999, STRUCTURE, V7, P1257, DOI 10.1016/S0969-2126(00)80059-3; Hansen S, 1999, J MOL BIOL, V288, P609, DOI 10.1006/jmbi.1999.2701; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Hashimoto H, 1999, J MOL BIOL, V292, P707, DOI 10.1006/jmbi.1999.3100; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; Kitano K, 2001, STRUCTURE, V9, P473, DOI 10.1016/S0969-2126(01)00608-6; Maeda N, 1999, J MOL BIOL, V293, P57, DOI 10.1006/jmbi.1999.3145; Maes D, 1999, PROTEINS, V37, P441, DOI 10.1002/(SICI)1097-0134(19991115)37:3<441::AID-PROT11>3.3.CO;2-Z; MORIKAWA M, 1994, APPL ENVIRON MICROB, V60, P4559, DOI 10.1128/AEM.60.12.4559-4566.1994; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; SAMBROOK J, 2000, MOL CLONING LAB MANU; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; SCHNEIDER G, 1992, ANNU REV BIOPH BIOM, V21, P119, DOI 10.1146/annurev.bb.21.060192.001003; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; Shively JM, 1998, ANNU REV MICROBIOL, V52, P191, DOI 10.1146/annurev.micro.52.1.191; Sugawara H, 1999, J BIOL CHEM, V274, P15655, DOI 10.1074/jbc.274.22.15655; Thoma R, 2000, STRUCTURE, V8, P265, DOI 10.1016/S0969-2126(00)00106-4; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433; Watson GMF, 1997, FEMS MICROBIOL LETT, V146, P13, DOI 10.1016/S0378-1097(96)00417-X; Watson GMF, 1999, J BACTERIOL, V181, P1569, DOI 10.1128/JB.181.5.1569-1575.1999	27	53	58	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31656	31662		10.1074/jbc.M203117200	http://dx.doi.org/10.1074/jbc.M203117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070156	hybrid			2022-12-25	WOS:000177718700046
J	Straub, SV; Giovannucci, DR; Bruce, JIE; Yule, DI				Straub, SV; Giovannucci, DR; Bruce, JIE; Yule, DI			A role for phosphorylation of inositol 1,4,5-trisphosphate receptors in defining calcium signals induced by peptide agonists in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; RYANODINE RECEPTORS; MESSENGER PATHWAYS; EXOCRINE PANCREAS; WAVE-PROPAGATION; CA2+ SIGNALS; OSCILLATIONS; TRISPHOSPHATE; EXPRESSION; PROTEINS	Stimulation of pancreatic acinar cells with acetylcholine (ACh) and cholecystokinin (CCK) results in an elevation of cytosolic calcium ([Ca2+](c)) through activation of inositol 1,4,5-trisphosphate receptors (InsP(3)R). The global temporal pattern of the [Ca2+](c) changes produced by ACh or CCK stimulation differs significantly. The hypothesis was tested that CCK stimulation results in a protein kinase A (PKA)-mediated phosphorylation. of InsP(3)R and this event contributes to the generation of agonist-specific [Ca2+](c) signals. Physiological concentrations of CCK evoked phosphorylation of the type III InsP(3)R, which was blocked by pharmacological inhibition of PKA. Imaging of fura-2-loaded acinar cells revealed that the rate of [Ca2+](c) rise during CCK-evoked oscillations slows with each subsequent oscillation, consistent with a developing modulation of release, whereas the kinetics of ACh-evoked oscillations remain constant. Stimulation of cells with ACh following activation of PKA resulted in a slowing of the ACh-evoked [Ca2+](c) rise, which now resembled a time-matched CCK response. PKA activation also resulted in a slowing of [Ca2+](c) increases elicited by photolysis of caged InsP(3). Targeted, PKA-mediated phosphorylation of type III InsP(3)R is involved in a physiological CCK response, as disruption of the targeting of PKA with the peptide HT31 resulted in marked changes in the CCK-evoked [Ca2+](c) signal but had no effect on ACh-evoked responses. Stimulation of cells with bombesin, which evokes [Ca2+](c) oscillations indistinguishable from those produced by CCK, also results in PKA-mediated phosphorylation of type III InsP(3)R. Thus, we conclude that PKA-mediated phosphorylation of type III InsP(3)R is a general mechanism by which the patterns of [Ca2+](c) oscillations are shaped in pancreatic acinar cells.	Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Yule, DI (corresponding author), Univ Rochester, Dept Pharmacol & Physiol, 601 Elmwood Ave,Box 711, Rochester, NY 14642 USA.	david_yule@urmc.rochester.edu	Giovannucci, David R/A-5657-2018		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054568, R56DK054568] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54568] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Burdakov D, 2000, CURR BIOL, V10, P993, DOI 10.1016/S0960-9822(00)00649-7; Burdakov D, 2001, CELL CALCIUM, V29, P211, DOI 10.1054/ceca.2000.0188; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Giovannucci DR, 2000, J BIOL CHEM, V275, P33704, DOI 10.1074/jbc.M004278200; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; LeBeau AP, 1999, J GEN PHYSIOL, V113, P851, DOI 10.1085/jgp.113.6.851; Leite MF, 1999, BIOCHEM J, V337, P305, DOI 10.1042/0264-6021:3370305; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; LYNCH M, 1992, CELL CALCIUM, V13, P227, DOI 10.1016/0143-4160(92)90011-G; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHICK J, 1984, J CELL BIOL, V99, P1569, DOI 10.1083/jcb.99.5.1569; SCHNEFEL S, 1990, BIOCHEM J, V269, P483, DOI 10.1042/bj2690483; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Yule DI, 1999, AM J PHYSIOL-GASTR L, V276, pG271, DOI 10.1152/ajpgi.1999.276.1.G271; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; YULE DI, 1994, PHYSL GASTROINTESTIN	33	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31949	31956		10.1074/jbc.M204318200	http://dx.doi.org/10.1074/jbc.M204318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12065595	hybrid			2022-12-25	WOS:000177718700081
J	Wang, YL; Frauwirth, KA; Rangwala, SM; Lazar, MA; Thompson, CB				Wang, YL; Frauwirth, KA; Rangwala, SM; Lazar, MA; Thompson, CB			Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INDUCE APOPTOSIS; T-LYMPHOCYTES; GENE-EXPRESSION; IN-VITRO; GROWTH; AGONISTS; CANCER; TROGLITAZONE; INHIBITION	Thiazolidinediones (TZDs) are widely used for treatment of type 2 diabetes mellitus. Peroxisome proliferator-activated receptor gamma (PPARgamma) is the molecular target of TZDs and is believed to mediate the apoptotic effects of this class of drugs in a variety of cell types, including B and T lymphocytes. The finding that TZDs induce lymphocyte death has raised concerns regarding whether TZDs might further impair immune functions in diabetics. To address this issue, we investigated the roles of PPARgamma and TZDs in lymphocyte survival. PPARgamma was up-regulated upon T cell activation. As previously reported, PPARgamma agonists induced T cell death in a dose-dependent manner. However, the concentrations of TZD needed to cause T cell death were above those needed to induce PPARgamma-dependent transcription. Surprisingly, at concentrations that induce optimal transcriptional activation, TZD activation of PPARgamma protected cells from apoptosis following growth factor withdrawal. The survival-enhancing effects depended on both the presence and activation of PPARgamma. Measurements of mitochondrial potential revealed that PPARgamma activation enhanced the ability of cells to maintain their mitochondrial potential. These data indicate that activation of PPARgamma with TZDs can promote cell survival and suggest that PPARgamma activation may potentially augment the immune responses of diabetic patients.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, 421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019					Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Frauwirth KA, 2000, J IMMUNOL, V164, P2987, DOI 10.4049/jimmunol.164.6.2987; Goll V, 2000, HUM EXP TOXICOL, V19, P193, DOI 10.1191/096032700678827753; Greene M. E., 1995, Gene Expression, V4, P281; Harris SG, 2001, EUR J IMMUNOL, V31, P1098, DOI 10.1002/1521-4141(200104)31:4<1098::AID-IMMU1098>3.0.CO;2-I; Henry RR, 1997, ENDOCRIN METAB CLIN, V26, P553, DOI 10.1016/S0889-8529(05)70267-X; Izuishi K, 2000, CANCER RES, V60, P6201; Jones DC, 2002, J BIOL CHEM, V277, P6838, DOI 10.1074/jbc.M106908200; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Khaled AR, 2001, J BIOL CHEM, V276, P6453, DOI 10.1074/jbc.M006391200; Krauss S, 2001, IMMUNITY, V15, P497, DOI 10.1016/S1074-7613(01)00205-9; Lazar MA, 2001, NAT MED, V7, P23, DOI 10.1038/83301; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Okura T, 2000, EUR J PHARMACOL, V407, P227, DOI 10.1016/S0014-2999(00)00758-5; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sato H, 2000, BRIT J CANCER, V83, P1394, DOI 10.1054/bjoc.2000.1457; Spencer CM, 1997, DRUGS, V54, P89, DOI 10.2165/00003495-199754010-00010; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 1999, MOL CELL, V3, P159; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541	43	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31781	31788		10.1074/jbc.M204279200	http://dx.doi.org/10.1074/jbc.M204279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12082115	hybrid			2022-12-25	WOS:000177718700060
J	Portela, P; Howell, S; Moreno, S; Rossi, S				Portela, P; Howell, S; Moreno, S; Rossi, S			In vivo and in vitro phosphorylation of two Isoforms of yeast pyruvate kinase by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; ALLOSTERIC REGULATION; SENSING MECHANISMS; ACTIVATION; SUBUNIT; FRUCTOSE-1,6-BISPHOSPHATE; TRANSFORMATION; OVEREXPRESSION; IDENTIFICATION	Saccharomyces cerevisiae pyruvate kinase 1 (Pyk1) was demonstrated to be associated to an immunoprecipitate of yeast protein kinase A holoenzyme (HA-Tpk1.Bcy1) and to be phosphorylated in a cAMP-dependent process. Both glutathione S-transferase (GST)-Pyk1 and GST-Pyk2 were phosphorylated in vitro by the bovine heart protein kinase A (PKA) catalytic subunit and by immobilized yeast RA-Tpk1. The specificity constant for the phosphorylation of GST-Pyk1 and GST-Pyk2 by bovine catalytic subunit was in the range of the value for Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide). Both fusion proteins were phosphorylated in vivo, in intact cells overexpressing the protein, or in vitro using crude extracts, as source of protein kinase A, when a wild type strain was used but were not phosphorylated when using a strain with only one TPK gene with an attenuated mutation (tpk1(omega1)). The effect of phosphorylation on Pyk activity was assayed in partially purified preparations from three strains, containing different endogenous protein kinase A activity levels. Pyk1 activity was measured at different phosphoenolpyruvate concentrations in the absence or in the presence of the activator fructose 1,6-bisphosphate at 1.5 mm. Preliminary kinetic results derived from the comparison of Pyk1 obtained from extracts with the highest versus those from the lowest protein kinase A activity indicate that the enzyme is more active upon phosphorylation conditions; in the absence of the activator it shows a shift in the titration curve for phosphoenolpyruvate to the left and an increase in the Hill coefficient, whereas in the presence of fructose 1,6-bisphosphate it shows an n(H) value of 1.4, as compared with an n(H) of 2 for the Pyk1 obtained from extracts with almost null protein kinase A activity.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina; Natl Inst Med Res, Lab Prot Struct, London NW7 1AA, England	University of Buenos Aires; MRC National Institute for Medical Research	Rossi, S (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Ciudad Univ,Pabellon 2, RA-1428 Buenos Aires, DF, Argentina.	srossi@qb.fcen.uba.ar		Rossi, Silvia/0000-0001-6996-0622				Boles E, 1997, J BACTERIOL, V179, P2987, DOI 10.1128/jb.179.9.2987-2993.1997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brazill DT, 1997, J BACTERIOL, V179, P4415, DOI 10.1128/jb.179.13.4415-4418.1997; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; Cytrynska M, 2001, FEMS MICROBIOL LETT, V203, P223, DOI 10.1111/j.1574-6968.2001.tb10845.x; DENIS CL, 1991, J BIOL CHEM, V266, P17932; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DICKINSON JR, 1999, METABOLISM MOL PHYSL, P209; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P233; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; Fenton AW, 2002, ARCH BIOCHEM BIOPHYS, V397, P28, DOI 10.1006/abbi.2001.2634; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; Goncalves P, 1998, TRENDS MICROBIOL, V6, P314, DOI 10.1016/S0966-842X(98)01305-5; Goncalves PM, 1997, MOL MICROBIOL, V25, P483, DOI 10.1046/j.1365-2958.1997.4811847.x; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; Navas MA, 1996, J BACTERIOL, V178, P1809, DOI 10.1128/jb.178.7.1809-1812.1996; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PILKIS SJ, 1988, ADV SEC MESS PHOSPH, V22, P175; Portela P, 2001, MICROBIOL-SGM, V147, P1149, DOI 10.1099/00221287-147-5-1149; Rayner TF, 2002, J BIOL CHEM, V277, P16814, DOI 10.1074/jbc.M112349200; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sherman F., 1981, METHODS YEAST GENETI; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Sorol MR, 2001, EXP CELL RES, V271, P337, DOI 10.1006/excr.2001.5382; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Valentin G, 2000, J BIOL CHEM, V275, P18145, DOI 10.1074/jbc.M001870200; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Zaremberg V, 1996, EUR J BIOCHEM, V237, P136, DOI 10.1111/j.1432-1033.1996.0136n.x; Zaremberg V, 2000, ARCH BIOCHEM BIOPHYS, V381, P74, DOI 10.1006/abbi.2000.1948	40	44	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30477	30487		10.1074/jbc.M201094200	http://dx.doi.org/10.1074/jbc.M201094200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063246	hybrid, Green Published			2022-12-25	WOS:000177579800012
J	Zou, ZY; DiRusso, CC; Ctrnacta, V; Black, PN				Zou, ZY; DiRusso, CC; Ctrnacta, V; Black, PN			Fatty acid transport in Saccharomyces cerevisiae - Directed mutagenesis of Fat1 distinguishes the biochemical activities associated with Fat1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; TRANSCRIPTION FACTOR FADR; CELLULAR UPTAKE; BINDING PROTEIN; SHUTTLE VECTORS; CD36; GENE; EXPRESSION; YEAST	The fatty acid transport protein Fat1p functions as a component of the long-chain fatty acid transport apparatus in the yeast Saccharomyces cerevisiae. Fat1p has significant homologies to the mammalian fatty acid transport proteins (FATP) and the very long-chain acyl-CoA synthetases (VLACS). In order to further understand the functional roles intrinsic to Fat1p (fatty acid transport and VLACS activities), a series of 16 alleles carrying site-directed mutations within FAT1 were constructed and analyzed. Sites chosen for the construction of amino acid substitutions were based on conservation between Fat1p and the mammalian FATP orthologues and included the ATP/AMP and FATP/VLACS signature motifs. Centromeric and 2mu plasmids encoding mutant forms of Fat1p were transformed into a yeast strain containing a deletion in FAT1 (fat1Delta). For selected subsets of FAT1 mutant alleles, we observed differences between the wild type and mutants in 1) growth rates when fatty acid synthase was inhibited with 45 mum cerulenin in the presence of 100 muM oleate (C-18:1), 2) levels of fatty acid import monitored using the accumulation of the fluorescent fatty acid 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-S-indacene-3-dodecanoic acid and [H-3]oleate, 3) levels of lignoceryl (C-24:0) CoA synthetase activities, and 4) fatty acid profiles monitored using gas chromatography/mass spectrometry. In most cases, there was a correlation between growth on fatty acid/cerulenin plates, the levels of fatty acid accumulation, very long-chain fatty acyl-CoA synthetase activities, and the fatty acid profiles in the different FAT1 mutants. For several notable exceptions, the fatty acid transport and very long-chain fatty acyl-CoA synthetase activities were distinguishable. The characterization of these novel mutants provides a platform to more completely understand the role of Fat1p in the linkage between fatty acid import and activation to CoA thioesters.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College	Black, PN (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, 47 New Scotland Ave, Albany, NY 12208 USA.	blackp@mail.amc.edu	Korenková, Vlasta/G-6401-2014; DiRusso, Concetta C/M-1884-2014	Black, Paul/0000-0002-6272-6881; Korenkova, Vlasta/0000-0002-6289-5175	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056840] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56840] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abumrad N, 1999, BBA-MOL CELL BIOL L, V1441, P4, DOI 10.1016/S1388-1981(99)00137-7; ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; BERK PD, 1990, ANN NY ACAD SCI, V585, P379, DOI 10.1111/j.1749-6632.1990.tb28070.x; Berk PD, 1999, J BIOL CHEM, V274, P28626, DOI 10.1074/jbc.274.40.28626; Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; Berk PD, 1996, P SOC EXP BIOL MED, V212, P1; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; Binnert C, 2000, AM J PHYSIOL-ENDOC M, V279, pE1072, DOI 10.1152/ajpendo.2000.279.5.E1072; Black PN, 2000, J BIOL CHEM, V275, P38547, DOI 10.1074/jbc.M006413200; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cechetto JD, 2002, HISTOL HISTOPATHOL, V17, P353, DOI 10.14670/HH-17.353; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Choi JY, 1999, J BIOL CHEM, V274, P4671, DOI 10.1074/jbc.274.8.4671; COOPER R, 1987, BIOCHEMISTRY-US, V26, P5890, DOI 10.1021/bi00392a047; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Dutta-Roy AK, 2000, CELL MOL LIFE SCI, V57, P1360, DOI 10.1007/PL00000621; Faergeman NJ, 2001, J BIOL CHEM, V276, P37051, DOI 10.1074/jbc.M100884200; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Feng JW, 2000, J LIPID RES, V41, P688; Fuhrman B, 2002, ATHEROSCLEROSIS, V161, P307, DOI 10.1016/S0021-9150(01)00646-3; Gargiulo CE, 1999, J LIPID RES, V40, P881; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hamilton JA, 1998, J LIPID RES, V39, P467; Hamilton JA, 1999, PROSTAG LEUKOTR ESS, V60, P291, DOI 10.1016/S0952-3278(99)80002-7; Hamilton JA, 2001, J MOL NEUROSCI, V16, P99, DOI 10.1385/JMN:16:2-3:99; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Hertzel AV, 1998, MOL CELL BIOCHEM, V188, P33; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; KOHLWEIN SD, 1984, BIOCHIM BIOPHYS ACTA, V792, P310, DOI 10.1016/0005-2760(84)90198-X; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Magnetto S, 1998, CELL BIOCHEM FUNCT, V16, P211, DOI 10.1002/(SICI)1099-0844(199809)16:3<211::AID-CBF788>3.3.CO;2-Q; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; Miller LH, 2002, MOL BIOCHEM PARASIT, V120, P321, DOI 10.1016/S0166-6851(02)00011-7; Ohgami N, 2002, J DIABETES COMPLICAT, V16, P56, DOI 10.1016/S1056-8727(01)00208-2; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; Saier MH, 2001, GENET ENG P, V23, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Serghides L, 2002, LANCET, V359, P1404, DOI 10.1016/S0140-6736(02)08360-5; SIKORSKI RS, 1989, GENETICS, V122, P19; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Watkins PA, 2000, CELL BIOCHEM BIOPHYS, V32, P333, DOI 10.1385/CBB:32:1-3:333	55	97	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31062	31071		10.1074/jbc.M205034200	http://dx.doi.org/10.1074/jbc.M205034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12052836	hybrid			2022-12-25	WOS:000177579800085
J	Hu, JB; Meng, QJ; Roy, SK; Raha, A; Hu, JD; Zhang, J; Hashimoto, K; Kalvakolanu, DV				Hu, JB; Meng, QJ; Roy, SK; Raha, A; Hu, JD; Zhang, J; Hashimoto, K; Kalvakolanu, DV			A novel transactivating factor that regulates interferon-gamma-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; CLASS-II TRANSACTIVATOR; TRANSCRIPTION FACTOR; DNA-BINDING; IFN-GAMMA; REDOX REGULATION; FACTOR FAMILY; ALPHA-INTERFERON; BETA-INTERFERON; IN-VIVO	We have previously identified a novel interferon (IFN)-stimulated cis-acting enhancer element, gamma-IFN-activated transcriptional element (GATE). GATE differs from the known IFN-stimulated elements in its primary sequence. Preliminary analysis has indicated that the GATE-dependent transcriptional response requires the binding of novel transacting factors. A cDNA expression library derived from an IFN-gamma-stimulated murine macrophage cell line was screened with a P-32-labeled GATE probe to identify the potential GATE-binding factors. A cDNA coding for a novel transcription-activating factor was identified. Based on its discovery, we named it as GATE-binding factor-1 (GBF-1). GBF-1 homologs are present in mouse, human, monkey, and Drosophila. It activates transcription from reporter genes carrying GATE. It possesses a strong transactivating activity but has a weak DNA binding property. GBF-1 is expressed in most tissues with relatively higher steady-state levels in heart, liver, kidney, and brain. Its expression is induced by IFN-gamma treatment. GBF-1 is present in both cytosolic and nuclear compartments. These studies thus identify a novel transactivating factor in IFN signaling pathways.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA; Natl Inst Infect Dis, Div Genet Resources, Tokyo 1628640, Japan	University System of Maryland; University of Maryland Baltimore; National Institute of Infectious Diseases (NIID)	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, 655 W Baltimore St,BRB 9th Floor, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA071401, R01CA078282] Funding Source: NIH RePORTER; NCI NIH HHS [CA78282, CA71401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Bachmann A, 2002, J VIROL, V76, P280, DOI 10.1128/JVI.76.1.280-291.2002; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Contursi C, 2000, P NATL ACAD SCI USA, V97, P91, DOI 10.1073/pnas.97.1.91; Cremer I, 2002, FEBS LETT, V511, P41, DOI 10.1016/S0014-5793(01)03276-8; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Fontes JD, 1999, MICROBES INFECT, V1, P863, DOI 10.1016/S1286-4579(99)80529-2; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; GALANG CK, 1993, MOL CELL BIOL, V13, P4609, DOI 10.1128/MCB.13.8.4609; Giese NA, 1997, J EXP MED, V186, P1535, DOI 10.1084/jem.186.9.1535; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kalvakolanu DV, 1999, TRENDS MICROBIOL, V7, P166, DOI 10.1016/S0966-842X(99)01476-6; Kalvakolanu DV, 2001, MOL BASIS CANC, P503; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Levi BZ, 2002, J INTERF CYTOK RES, V22, P153, DOI 10.1089/107999002753452764; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEWIS JA, 1989, J VIROL, V63, P4569, DOI 10.1128/JVI.63.11.4569-4578.1989; Li SY, 1999, ONCOGENE, V18, P5727, DOI 10.1038/sj.onc.1202960; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; Read ML, 1997, FEBS LETT, V418, P68, DOI 10.1016/S0014-5793(97)01352-5; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SEN GC, 1997, TRANSCIPTIONAL REGUL; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tell G, 2002, J BIOL CHEM, V277, P14564, DOI 10.1074/jbc.M200582200; Vallejo AN, 1996, J BIOL CHEM, V271, P29813, DOI 10.1074/jbc.271.47.29813; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Xiao WH, 2001, J BIOL CHEM, V276, P23275, DOI 10.1074/jbc.M010047200; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103	67	14	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30253	30263		10.1074/jbc.M202679200	http://dx.doi.org/10.1074/jbc.M202679200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050152	hybrid			2022-12-25	WOS:000177509300111
J	Nice, DC; Sato, TK; Stromhaug, PE; Emr, SD; Klionsky, DJ				Nice, DC; Sato, TK; Stromhaug, PE; Emr, SD; Klionsky, DJ			Cooperative binding of the cytoplasm to vacuole targeting pathway proteins, Cvt13 and Cvt20, to phosphatidylinositol 3-phosphate at the pre-autophagosomal structure is required for selective autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PX DOMAINS; PEROXISOME DEGRADATION; ALKALINE-PHOSPHATASE; AMINOPEPTIDASE-I; YEAST; COMPLEX; 3-KINASE; KINASE; MACROAUTOPHAGY	Autophagy is a catabolic membrane-trafficking mechanism involved in cell maintenance and development. Most components of autophagy also function in the cytoplasm to vacuole targeting (Cvt) pathway, a constitutive biosynthetic pathway required for the transport of aminopeptidase I (Ape1). The protein components of autophagy and the Cvt pathway include a putative complex composed of Apg1 kinase and several interacting proteins that are specific for either the Cvt pathway or autophagy. A second required complex includes a phosphatidylinositol (PtdIns) 3-kinase and associated proteins that are involved in its activation and localization. The majority of proteins required for the Cvt and autophagy pathways localize to a perivacuolar pre-autophagosomal structure. We show that the Cvt13 and Cvt20 proteins are required for transport of precursor Ape1 through the Cvt pathway. Both proteins contain phox homology domains that bind PtdIns(3)P and are necessary for membrane localization to the pre-autophagosomal structure. Functional phox homology domains are required for Cvt pathway function. Cvt13 and Cvt20 interact with each other and with an autophagy-specific protein, Apg17, that interacts with Apg1 kinase. These results provide the first functional connection between the Apg1 and PtdIns 3-kinase complexes. The data suggest a role for PtdIns(3)P in the Cvt pathway and demonstrate that this lipid is required at the pre-autophagosomal structure.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Klionsky, DJ (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.		Klionsky, Daniel J./ABD-5189-2021	Klionsky, Daniel J./0000-0002-7828-8118	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [R01 GM053396-12, GM53396, R01 GM053396-13, R01 GM053396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hutchins MU, 1999, J CELL SCI, V112, P4079; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2000, INT REV CYTOL, V198, P153; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; MITCHELL JK, 1981, BIOCHIM BIOPHYS ACTA, V657, P482, DOI 10.1016/0005-2744(81)90333-8; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; Wang YX, 1996, MOL BIOL CELL, V7, P1375, DOI 10.1091/mbc.7.9.1375; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200	45	150	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30198	30207		10.1074/jbc.M204736200	http://dx.doi.org/10.1074/jbc.M204736200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048214	Green Accepted, hybrid			2022-12-25	WOS:000177509300105
J	Tanaka, T; Ito, T; Furuta, M; Eguchi, C; Toda, H; Wakabayashi-Takai, E; Kaneko, K				Tanaka, T; Ito, T; Furuta, M; Eguchi, C; Toda, H; Wakabayashi-Takai, E; Kaneko, K			In situ phage screening - A method for identification of subnanogram tissue components in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; DISPLAY TECHNOLOGY; PROTEINS; ANTIBODIES; MUSCLE	We have established a novel method, in situ phage screening (ISPS), to identify proteins in tissue microstructures. The method is based on the selection of repertoires of phage-displayed antibody fragments with small samples of tissues microdissected using a laser. Using a human muscle frozen section with an area of 4800 mum 2 as a model target, we successfully selected monoclonal antibody fragments directed against three major (myosin heavy chain, actin, and tropomyosin-alpha) and one minor (alpha-actinin 2) muscle constituent proteins. These proteins were present in the sample in amounts less than one nanogram, and the antibodies were used to visualize the proteins in situ. This shows that the use of ISPS can obtain monoclonal antibodies for histochemical and biochemical purposes against minute amounts of proteins from microstructures with no requirement for large amounts of samples or biochemical efforts.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Cort Funct Disorders, Kodaira, Tokyo 1878502, Japan; Yokohama City Univ, Sch Med, Dept Neurol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	National Center for Neurology & Psychiatry - Japan; Yokohama City University; Japan Science & Technology Agency (JST)	Kaneko, K (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Cort Funct Disorders, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.							Chaurand P, 1999, ANAL CHEM, V71, P5263, DOI 10.1021/ac990781q; Coomber David W J, 2002, Methods Mol Biol, V178, P133; Goletz S, 2002, J MOL BIOL, V315, P1087, DOI 10.1006/jmbi.2001.5314; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Hirabayashi T, 2000, ELECTROPHORESIS, V21, P446, DOI 10.1002/(SICI)1522-2683(20000101)21:2<446::AID-ELPS446>3.0.CO;2-9; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Jimenez CR, 1998, BIOCHEMISTRY-US, V37, P2070, DOI 10.1021/bi971848b; Kinumi T, 1997, EUR MASS SPECTROM, V3, P367, DOI 10.1255/ejms.169; Lehmann U, 2000, PATHOBIOLOGY, V68, P202, DOI 10.1159/000055924; MacCafferty J, 1990, NATURE, V348, P552; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; Sambrook J., 2002, MOL CLONING LAB MANU; Simone NL, 2000, MOL DIAGN, V5, P301, DOI 10.1054/modi.2000.19808a; Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573; VANDAM AP, 1990, J IMMUNOL METHODS, V129, P63, DOI 10.1016/0022-1759(90)90421-Q; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	19	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30382	30387		10.1074/jbc.M203547200	http://dx.doi.org/10.1074/jbc.M203547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048201	hybrid			2022-12-25	WOS:000177509300125
J	Morita, D; Miyoshi, K; Matsui, Y; Toh-e, A; Shinkawa, H; Miyakawa, T; Mizuta, K				Morita, D; Miyoshi, K; Matsui, Y; Toh-e, A; Shinkawa, H; Miyakawa, T; Mizuta, K			Rpf2p, an evolutionarily conserved protein, interacts with ribosomal protein L11 and is essential for the processing of 27 SB pre-rRNA to 25 S rRNA and the 60 S ribosomal subunit assembly in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST HOMOLOG; RNA SYNTHESIS; BIOGENESIS; GENES; TRANSCRIPTION; BIOSYNTHESIS; MUTATION; COMPLEX; ENCODES; PATHWAY	Saccharomyces cerevisiae Rrs1p is a nuclear protein that is essential for the maturation of 25 S rRNA and the 60 S ribosomal subunit assembly. In two-hybrid screening, using RRS1 as bait, we have cloned YKR081c/RPF2. Rpf2p, is essential for growth and is mainly localized in the nucleolus. The amino acid sequence of Rpf2p is highly conserved in eukaryotes from yeast to human. Similar to Rrs1p, Rpf2p shows physical interaction with ribosomal protein L11 and appears to associate with preribosomal subunits fairly tightly. Northern, methionine pulse-chase, and sucrose density gradient ultracentrifugation analyses reveal that the depletion of Rpf2p results in a delayed processing of pre-rRNA, a decrease of mature 25 S rRNA, and a shortage of 60 S subunits. An analysis of processing intermediates by primer extension shows that the Rpf2p depletion leads to an accumulation of 27 SB pre-rRNA, suggesting that Rpf2p is required for the processing of 27 SB into 25 S rRNA.	Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398528, Japan; Hiroshima Univ, Grad Sch Biosphere Sci, Dept Bioresource Sci & Technol, Higashihiroshima 7398528, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	Hiroshima University; Hiroshima University; University of Tokyo	Mizuta, K (corresponding author), Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Kagamiyama 1-4-4, Higashihiroshima 7398528, Japan.	kmizuta@hiroshima-u.ac.jp						Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BaudinBaillieu A, 1997, MOL CELL BIOL, V17, P5023, DOI 10.1128/MCB.17.9.5023; CHENSCHMEISSER U, 1977, FEBS LETT, V74, P287, DOI 10.1016/0014-5793(77)80866-1; Eisinger DP, 1997, MOL CELL BIOL, V17, P5146, DOI 10.1128/MCB.17.9.5146; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; HERRUER MH, 1987, NUCLEIC ACIDS RES, V15, P10133, DOI 10.1093/nar/15.24.10133; HERRUER MH, 1988, NUCLEIC ACIDS RES, V16, P7917, DOI 10.1093/nar/16.16.7917; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; KIEF DR, 1981, MOL CELL BIOL, V1, P1007, DOI 10.1128/MCB.1.11.1007; KIM CH, 1983, MOL CELL BIOL, V3, P457, DOI 10.1128/MCB.3.3.457; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Miyoshi K, 2002, J BIOL CHEM, V277, P18334, DOI 10.1074/jbc.M201667200; Miyoshi K, 2001, NUCLEIC ACIDS RES, V29, P3297, DOI 10.1093/nar/29.16.3297; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Schaper S, 2001, CURR BIOL, V11, P1885, DOI 10.1016/S0960-9822(01)00584-X; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; SIKORSKI RS, 1989, GENETICS, V122, P19; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; TSAY YF, 1994, J BIOL CHEM, V269, P7579; Tsujii R, 2000, GENES CELLS, V5, P543, DOI 10.1046/j.1365-2443.2000.00346.x; Tsuno A, 2000, MOL CELL BIOL, V20, P2066, DOI 10.1128/MCB.20.6.2066-2074.2000; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WARNER JR, 1978, NATURE, V275, P338, DOI 10.1038/275338a0; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Wehner KA, 2002, MOL CELL, V9, P329, DOI 10.1016/S1097-2765(02)00438-0; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587	39	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28780	28786		10.1074/jbc.M203399200	http://dx.doi.org/10.1074/jbc.M203399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048200				2022-12-25	WOS:000177342600057
J	Muller, P; Kietz, S; Gustafsson, JA; Strom, A				Muller, P; Kietz, S; Gustafsson, JA; Strom, A			The anti-estrogenic effect of all-trans-retinoic acid on the breast cancer cell line MCF-7 is dependent on HES-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELLS; CYCLE PROGRESSION; GROWTH ARREST; INHIBITION; PROLIFERATION; PROTEIN	All-trans-retinoic acid has been shown to have an antiproliferative effect in the estrogen receptor alpha-positive breast cancer cell line MCF-7. The mechanism of this effect is not well understood. We have previously shown that 17beta-estradiol down-regulates the basic helix-loop-helix factor Hairy and Enhancer of Split homologue-1 in MCF-7 and T47D cells (Strom, A., Arai, N., Leers, J., and Gustafsson, J. Angstrom. (2000) Oncogene 19, 5951-5953) and that this down-regulation is essential for proliferation in response to 17beta-estradiol. Treatment of the same cells with all-trans-retinoic acid prevented 17beta-estradiol-mediated down-regulation of the factor. The antiproliferative effect of all-trans-retinoic acid correlated well with the prevention of Hairy and Enhancer of Split homologue-1 down-regulation. Increasing concentrations of all-trans-retinoic acid, in the range of 1-1000 nm, produced a dose-dependent inhibition of proliferation and prevented 17beta-estradiol-mediated down-regulation of Hairy and Enhancer of Split homologue-1. By using a receptor-specific ligand we were able to show that the retinoic acid receptor a is important for regulation of the Hairy and Enhancer of Split homologue-1. Expression of a dominant negative form of Hairy and Enhancer of Split homologue-1 in MCF-7 cells abolished the growth-inhibitory effect of all-trans-retinoic acid in these cells. This finding indicates that Hairy and Enhancer of Split homologue-1 is a mediator of the antiproliferative effect of all-trans-retinoic acid in estrogen receptor a-positive breast cancer cell lines.	Karolinska Inst, Novum, Ctr Biotechnol, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Strom, A (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, S-14157 Huddinge, Sweden.							Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Cho YH, 1997, J CELL PHYSIOL, V172, P306, DOI 10.1002/(SICI)1097-4652(199709)172:3<306::AID-JCP4>3.0.CO;2-S; DiSepio D, 1999, Mol Cell Biol Res Commun, V1, P7, DOI 10.1006/mcbr.1999.0101; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; GULICK T, 1997, CURRENT PROTOCOLS MO; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; LOTAN R, 1990, METHOD ENZYMOL, V190, P100; MILLER WH, 1990, ONCOGENE, V5, P511; Raffo P, 2000, ANTICANCER RES, V20, P1535; Sapi E, 1999, CANCER RES, V59, P5578; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sriuranpong V, 2001, CANCER RES, V61, P3200; STOPERA SA, 1993, INT J CANCER, V53, P798, DOI 10.1002/ijc.2910530516; Strom A, 2000, ONCOGENE, V19, P5951, DOI 10.1038/sj.onc.1203990; Wang Q, 2000, CANCER RES, V60, P2040; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	20	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28376	28379		10.1074/jbc.C200340200	http://dx.doi.org/10.1074/jbc.C200340200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12080040	hybrid			2022-12-25	WOS:000177342600005
J	Kim, BY; Gaynor, RB; Song, K; Dritschilo, A; Jung, M				Kim, BY; Gaynor, RB; Song, K; Dritschilo, A; Jung, M			Constitutive activation of NF-kappa B in Ki-ras-transformed prostate epithelial cells	ONCOGENE			English	Article						Kirsten-ras (Ki-Ras); nuclear factor-kappa B; I-kappa B (I kappa,B); I kappa B kinase (IKK)	KINASE COMPLEX; IKK-ALPHA; TRANSCRIPTIONAL ACTIVITY; INCONTINENTIA PIGMENTI; LIVER DEGENERATION; DEFICIENT MICE; ERK ACTIVITY; BETA; ONCOGENE; PROTEIN	The signaling pathway responsible for the activation of nuclear factor-kappaB (NF-kappaB) by oncogenic forms of Ras remains unclear. Both, the transactivation and DNA binding activities of NF-kappaB, were increased in 267B1 human prostate epithelial cells transformed by viral Kirsten-ras (267B1/Ki-ras cells) compared with those in the parental cells. This increased NF-kappaB activity was attributed to a heterodimeric complex of p50 and p65 subunits. Although the abundance of the inhibitor protein IkappaBbeta was higher in 267B1/Ki-ras cells than in 267B1 cells, an electrophoretic mobility-shift assay suggested that IkappaBalpha is responsible for the activation of NF-kappaB in the former cells. Consistent with this notion, the phosphorylation of IkappaBalpha appeared increased in 267B1/Ki-ras cells, and the proteasome inhibitor I abolished the constitutive activation of NF-kappaB in these cells. The expression of dominant negative mutants of either NIK (NF-kappaB-inducing kinase) or IKKbeta (IkappaB kinase beta) inhibited the activity of NF-kappaB in 267B1/Ki-ras cells. Furthermore, chemical inhibitors specific for Ras activation, sulindac sulfide and farnesytranferase inhibitor 1, markedly reduced IkappaBalpha phosphorylation and NF-kappaB activation in the Ki-ras-transformed cells while transfection of these cells with NIK or IKKbeta counteracted the inhibitory effect on NF-kappaB activation. These results suggest that oncogenic Ki-Ras induces transactivation of NF-kappaB through the NIK-IKKbeta-IkappaBalpha pathway.	Georgetown Univ, Sch Med, Dept Radiat Med, Washington, DC 20007 USA; Univ Texas, SW Med Ctr, Dept Med, Harold Simmons Canc Ctr, Dallas, TX 75235 USA	Georgetown University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jung, M (corresponding author), Georgetown Univ, Sch Med, Dept Radiat Med, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [CA74175, CA45408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Janssen YMW, 1999, METHOD ENZYMOL, V300, P363; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin YB, 1998, INT J COMMUN SYST, V11, P1; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MILLS NE, 1995, CANCER RES, V55, P1444; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Ozes ON, 1999, NATURE, V401, P82; PARDA DS, 1993, PROSTATE, V23, P91, DOI 10.1002/pros.2990230202; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SUKUMAR S, 1991, MOL CARCINOGEN, V4, P362, DOI 10.1002/mc.2940040507; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4490	4497		10.1038/sj.onc.1205547	http://dx.doi.org/10.1038/sj.onc.1205547			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085227				2022-12-25	WOS:000176476700003
J	Silva, JM; Dominguez, G; Gonzalez-Sancho, JM; Garcia, JM; Silva, J; Garcia-Andrade, C; Navarro, A; Munoz, A; Bonilla, F				Silva, JM; Dominguez, G; Gonzalez-Sancho, JM; Garcia, JM; Silva, J; Garcia-Andrade, C; Navarro, A; Munoz, A; Bonilla, F			Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer	ONCOGENE			English	Article						erbA; thyroid receptor genes; thyroid hormone; breast cancer; mutation	MOUSE MAMMARY-GLANDS; C-ERBA-BETA; HEPATOCELLULAR-CARCINOMA; EPITHELIAL-CELLS; V-ERBA; ESTROGEN; TUMORS; AMPLIFICATION; MUTATIONS; PROMOTER	The relation between thyroid status and diseases and cancer is unclear. No detailed analysis of thyroid hormone receptor (TR) expression in human breast cancer has been reported. We have analysed the expression and mutational status of the TRalpha1, encoded by the c-erbA proto-oncogene, TRbeta1 and TRbeta2 isoforms in 70 sporadic breast cancers. Alterations in the RNA level of TRbeta1, TRalpha1, or both were found in a number of patients. No expression of TRbeta2 RNA was detected. Western blotting analysis confirmed the differences in expression at the protein level in those cases where sufficient tumor sample was available. Additionally, tumor-specific truncated TRbeta1 RNA was found in six patients. Strikingly, three transcripts shared the same breakpoint. Only one tumor carried the corresponding deletion at the genomic DNA level, suggesting that the remaining abnormal TR[11 transcripts are aberrant splicing products. Though no significant correlation was found between TRbeta1 alteration and any clinical parameter, it showed a tendency to associate with early age of onset (<50 years). Our results reveal specific alterations in the expression of TRbeta and TRalpha genes in a subset of breast cancer patients, suggesting that deregulation of thyroid hormone target genes may be involved in the generation of this neoplasia.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Clin Puerta Hierro, Dept Med Oncol, E-28035 Madrid, Spain; Hosp Santa Cristina, Dept Pathol, E-28009 Madrid, Spain; Clin Puerta Hierro, Dept Pathol, E-28035 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Bonilla, F (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.	felixbv@stnet.es	Munoz, Alberto/O-6393-2014; Gonzalez-Sancho, Jose/AAA-6010-2019	Munoz, Alberto/0000-0003-3890-4251; Gonzalez-Sancho, Jose/0000-0001-5875-1964				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALVARADOPISANI AR, 1986, ANTICANCER RES, V6, P1347; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARBUTHNOT P, 1989, ANTICANCER RES, V9, P885; Armitage P., 1987, STAT METHODS MED RES; Ballinger SW, 1996, CANCER RES, V56, P5692; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BURKE RE, 1978, CANCER RES, V38, P3769; Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; CERBON MA, 1981, CANCER RES, V41, P4167; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; CIDLOWSKI JA, 1975, ENDOCRINOLOGY, V97, P59, DOI 10.1210/endo-97-1-59; Collingwood TN, 1998, EMBO J, V17, P4760, DOI 10.1093/emboj/17.16.4760; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DOBROVIC A, 1988, CANCER RES, V48, P682; Dressel U., 2001, NUCL RECEPTORS DIS, P59; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; Fasco MJ, 2000, MOL CELL ENDOCRINOL, V166, P155, DOI 10.1016/S0303-7207(00)00328-2; FEI ZL, 1992, ENDOCRINOLOGY, V130, P1145; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; FUTREAL PA, 1994, CANCER RES, V54, P1791; FUTREAL PA, 1992, CANCER RES, V52, P2624; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gonzalez-Sancho JM, 1999, MOL CARCINOGEN, V24, P99, DOI 10.1002/(SICI)1098-2744(199902)24:2<99::AID-MC4>3.0.CO;2-#; GUERNSEY DL, 1993, CANCER J - FRANCE, V6, P253; HEDLEY AJ, 1981, LANCET, V1, P131; HOUDEBINE LM, 1978, BIOCHIMIE, V60, P809, DOI 10.1016/S0300-9084(78)80027-3; HuberGieseke T, 1997, ONCOLOGY, V54, P214; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; LOPEZBARAHONA M, 1995, EMBO J, V14, P1145, DOI 10.1002/j.1460-2075.1995.tb07098.x; Lukas J, 2001, CANCER RES, V61, P3212; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKOWITZ S, 1989, J CLIN INVEST, V84, P1683, DOI 10.1172/JCI114349; MARTINEZ L, 1995, EUR J ENDOCRINOL, V132, P673, DOI 10.1530/eje.0.1320673; Martinez MB, 2000, CANCER CHEMOTH PHARM, V45, P93, DOI 10.1007/s002800050016; McCabe CJ, 1999, J CLIN ENDOCR METAB, V84, P649, DOI 10.1210/jc.84.2.649; Munoz A, 1997, EUR J ENDOCRINOL, V137, P433, DOI 10.1530/eje.0.1370433; Nogueira CR, 1996, J STEROID BIOCHEM, V59, P271, DOI 10.1016/S0960-0760(96)00117-3; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; Puzianowska-Kuznicka M, 2000, CANCER LETT, V155, P145, DOI 10.1016/S0304-3835(00)00416-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SELLITTI DF, 1983, CANCER RES, V43, P1030; SINGH DV, 1969, J ENDOCRINOL, V45, P579, DOI 10.1677/joe.0.0450579; SMALLRIDGE RC, 1980, CLIN RES, V28, pA421; Smyth PPA, 1997, ANN MED, V29, P189, DOI 10.3109/07853899708999335; Smyth PPA, 1996, J CLIN ENDOCR METAB, V81, P937, DOI 10.1210/jc.81.3.937; Strain JJ, 1997, NUTR CANCER, V27, P48, DOI 10.1080/01635589709514500; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; Vasudevan N, 2001, MOL BRAIN RES, V95, P9, DOI 10.1016/S0169-328X(01)00165-6; Vasudevan N, 2001, J NEUROENDOCRINOL, V13, P779, DOI 10.1046/j.1365-2826.2001.00693.x; VONDERHAAR BK, 1979, ENDOCRINOLOGY, V104, P409, DOI 10.1210/endo-104-2-409; VONDERHAAR BK, 1986, ENDOCRINOLOGY, V119, P580, DOI 10.1210/endo-119-2-580; VONDERHAAR BK, 1977, ENDOCRINOLOGY, V100, P1423, DOI 10.1210/endo-100-5-1423; WALLIN G, 1992, THYROID, V2, P307, DOI 10.1089/thy.1992.2.307; Williams GR, 2000, MOL CELL BIOL, V20, P8329, DOI 10.1128/MCB.20.22.8329-8342.2000; Yokoe T, 1997, ANTICANCER RES, V17, P695; Zhu YS, 1996, P NATL ACAD SCI USA, V93, P12587, DOI 10.1073/pnas.93.22.12587	63	90	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4307	4316		10.1038/sj.onc.1205534	http://dx.doi.org/10.1038/sj.onc.1205534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082618				2022-12-25	WOS:000176174200013
J	Kim, JY; Kim, YH; Chang, I; Kim, S; Pak, YK; Oh, BH; Yagita, H; Jung, YK; Oh, YJ; Lee, MS				Kim, JY; Kim, YH; Chang, I; Kim, S; Pak, YK; Oh, BH; Yagita, H; Jung, YK; Oh, YJ; Lee, MS			Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis	ONCOGENE			English	Article						mitochondria; apoptosis; TRAIL; cytochrome c; Bax	FADD-DEPENDENT APOPTOSIS; CYTOCHROME-C; TUMORICIDAL ACTIVITY; CRYSTAL-STRUCTURE; NECROSIS; LIGAND; RECEPTOR; EXPRESSION; TRANSLOCATION; SENSITIVITY	Mitochondrion is one of the master players in both apoptosis and necrosis. We studied the role of mitochondrial function in TRAIL-induced apoptosis. TRAIL killed SK-Hep1 cells with characteristic features of apoptosis such as DNA fragmentation, sub-G1 ploidy peak and cytochrome c translocation. In contrast, mitochondrial DNA-deficient SK-Hep1 rho(0) cells were resistant to TRAIL. Dissipation of mitochondrial potential or cytochrome e translocation did not occur in rho(0) cells after TRAIL treatment. TRAIL induced translocation of Bax subsequent to the cleavage of Bid in parental cells. However, Bax translocation was absent in rho(0) cells, accounting for the failure of cytochrome c release in rho(0) cells. Forced expression of Bax induced caspase-3 activity in rho(0) cells. Incubation of rho(0) cells with ADP+Pi to increase intracellular ATP restored sensitivity to TRAIL. Despite different sensitivity to TRAIL, parental cells and rho(0) cells did not show significant difference in susceptibility to agonistic anti-Fas antibody, TNF-alpha or staurosporine. Our results indicate that TRAIL-induced apoptosis is dependent on intact mitochondrial function and susceptibility of mitochondrial DNA-deficient cells to apoptosis depends on the type of apoptotic stimuli. Tumor cells with mitochondrial mutations or dysfunction might have the ability to evade tumor surveillance imposed by TRAIL in vivo.	Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr,Kangnam Ku, Seoul 135710, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Natl Inst Hlth, Div Metab Dis, Dept Biomed Sci, Eunpyung Ku, Seoul 122710, South Korea; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Pohang University of Science & Technology (POSTECH); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; Juntendo University; Gwangju Institute of Science & Technology (GIST); Yonsei University	Lee, MS (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr,Kangnam Ku, 50 Irwon Dong, Seoul 135710, South Korea.	mslee@smc.samsung.co.kr	Pak, Youngmi Kim/AAI-1091-2020; Oh, Byung-Ha/C-2061-2011; Lee, Myung Shik/C-9606-2011	Pak, Youngmi Kim/0000-0001-7424-3484; Lee, Myung-Shik/0000-0003-3292-1720				ALBERTS B, 1994, GARLAND PUB INC NEW, V3, P568; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; DRGON T, 1991, FEBS LETT, V289, P159, DOI 10.1016/0014-5793(91)81059-H; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HIGUCHI Y, 1992, J EXP MED, V176, P1719, DOI 10.1084/jem.176.6.1719; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Kayagaki N, 1999, J IMMUNOL, V163, P1906; KERR JFR, 1995, METHOD CELL BIOL, V46, P1; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang BC, 1998, CELL DEATH DIFFER, V5, P694, DOI 10.1038/sj.cdd.4400401; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RUBIN BY, 1988, CANCER RES, V48, P6006; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, CANCER RES, V56, P2161; SKOWRONEK P, 1992, BIOCHEM BIOPH RES CO, V187, P991, DOI 10.1016/0006-291X(92)91295-2; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Thomas WD, 1998, J IMMUNOL, V161, P2195; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wuchter C, 2001, LEUKEMIA, V15, P921, DOI 10.1038/sj.leu.2402131; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	57	60	65	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3139	3148		10.1038/sj.onc.1205406	http://dx.doi.org/10.1038/sj.onc.1205406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082629				2022-12-25	WOS:000175373600005
J	Raychaudhuri, B; Malur, A; Bonfield, TL; Abraham, S; Schilz, RJ; Farver, CF; Kavuru, MS; Arroliga, AC; Thomassen, MJ				Raychaudhuri, B; Malur, A; Bonfield, TL; Abraham, S; Schilz, RJ; Farver, CF; Kavuru, MS; Arroliga, AC; Thomassen, MJ			The prostacyclin analogue treprostinil blocks NF kappa B nuclear translocation in human alveolar macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PRIMARY PULMONARY-HYPERTENSION; EPOPROSTENOL PROSTACYCLIN; ACTIVATION; INHIBITION; IMMUNOSUPPRESSION; EXPRESSION; THERAPY; RELEASE; GROWTH	Primary pulmonary hypertension (PPH) is characterized by increased pulmonary arterial pressure and vascular resistance. We and others have observed that inflammatory cytokines and infiltrates are present in the lung tissue, but the significance is uncertain. Treprostinil (TRE), a prostacyclin analogue with extended half-life and chemical stability, has shown promise in the treatment of PPH. We hypothesize that TRE might exert beneficial effects in PPH by antagonizing inflammatory cytokine production in the lung. Here we show that TRE dose-dependently inhibits inflammatory cytokine (tumor necrosis factor-a, interleukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) secretion and gene expression by human alveolar macrophages. TRE blocks NFkappaB activation, but IkappaB-alpha phosphorylation and degradation are unaffected. Moreover, TRE does not affect the formation of the NFkappaB-DNA complex but blocks nuclear translocation of p65. These results are the first to illustrate the anti-cytokine actions of TRE in down-regulating NTkappaB, not through its inhibitory component or by direct binding but by blocking nuclear translocation. These data indicate that inflammatory mechanisms may be important in the pathogenesis of PPH and cytokine antagonism by blocking N-FkappaB may contribute to the efficacy of TRE therapy in PPH.	Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Thomassen, MJ (corresponding author), Cleveland Clin Fdn, Dept Pulm & Crit Care Med, 9500 Euclid Ave,Desk A90, Cleveland, OH 44195 USA.	thomasm@ccf.org	Arroliga, Alejandro/AAX-3933-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; Barst RJ, 1997, HEART, V77, P299, DOI 10.1136/hrt.77.4.299; Chacon MR, 1999, AM J RESP CRIT CARE, V159, pA696; Clapp LH, 2002, AM J RESP CELL MOL, V26, P194, DOI 10.1165/ajrcmb.26.2.4695; CRUTCHLEY DJ, 1994, J PHARMACOL EXP THER, V271, P446; D'Acquisto F, 1998, FEBS LETT, V440, P76, DOI 10.1016/S0014-5793(98)01407-0; Dorfmuller P, 2002, AM J RESP CRIT CARE, V165, P534, DOI 10.1164/rccm.2012112; EISENHUT T, 1993, IMMUNOPHARMACOLOGY, V26, P259, DOI 10.1016/0162-3109(93)90042-O; Fartoukh M, 1998, CHEST, V114, p50S, DOI 10.1378/chest.114.1_Supplement.50S; HUMBERT M, 1995, AM J RESP CRIT CARE, V151, P1628, DOI 10.1164/ajrccm.151.5.7735624; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Luttmann W, 1996, PULM PHARMACOL, V9, P43, DOI 10.1006/pulp.1996.0005; Luttmann W, 1999, CYTOKINE, V11, P127, DOI 10.1006/cyto.1998.0410; Magnani B, 1996, EUR HEART J, V17, P18; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; Meja KK, 1997, BRIT J PHARMACOL, V122, P149, DOI 10.1038/sj.bjp.0701360; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Raychaudhuri B, 2000, CYTOKINE, V12, P1348, DOI 10.1006/cyto.2000.0721; Raychaudhuri B, 1999, AM J RESP CELL MOL, V21, P311, DOI 10.1165/ajrcmb.21.3.3611; Robbins IM, 2001, CHEST, V120, P1639, DOI 10.1378/chest.120.5.1639; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Shapiro SM, 1997, J AM COLL CARDIOL, V30, P343, DOI 10.1016/S0735-1097(97)00187-3; Simonneau G, 2002, AM J RESP CRIT CARE, V165, P800, DOI 10.1164/ajrccm.165.6.2106079; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMASSEN MJ, 1979, PEDIATR RES, V13, P1085, DOI 10.1203/00006450-197909000-00030; TUDER RM, 1994, AM J PATHOL, V144, P275; Voelkel NF, 1995, EUR RESPIR J, V8, P2129, DOI 10.1183/09031936.95.08122129	32	37	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33344	33348		10.1074/jbc.M203567200	http://dx.doi.org/10.1074/jbc.M203567200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082102	hybrid			2022-12-25	WOS:000177859000122
J	Wansa, KDSA; Harris, JM; Muscat, GEO				Wansa, KDSA; Harris, JM; Muscat, GEO			The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; SERUM GROWTH-FACTORS; NGFI-B; STEROID-RECEPTOR; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; REV-ERBA; BINDING; ALPHA	Nur77/NR4A1 is an "orphan member" of the nuclear hormone receptor superfamily. Nur77 and its close relatives Nurr1 and NOR-1 bind as monomers to a consensus binding site, the nerve growth factor induced protein I-B (NGFI-B)-binding response element (NBRE). The Nur77/NURR1/NOR1 nuclear receptors are classified as immediate early response genes which are induced through multiple signal transduction pathways. They have been implicated in cell proliferation, differentiation, and apoptosis. However, the mechanism of coactivation and ligand independent trans-activation remains unclear. Hence we examined the molecular basis of Nur77-mediated cofactor recruitment and activation. We observed that Nur77 trans-activates gene expression in a cell-specific manner, and operates in an activation function-1 (AF-1)-dependent manner. The AB region encodes an uncommonly potent N-terminal AF-1 domain delimited to between amino acids 50 and 160 and is essential for the ligand-independent activation of gene expression. Steroid receptor coactivator-2 (SRC-2) modulates the activity of the N-terminal AF-1 domain. Moreover, SRC-2 dramatically potentiates the retinoid induced RXR-dependent activation of the Nur77 ligand binding domain (LBD). Interestingly, the N-terminal AB region (not the LBD) facilitates coactivator recruitment and directly interacts with SRC, p300, PCAF, and DRIP-205. Consistent with this, homology modeling indicated that the Nur77 LBD coactivator binding cleft was substantially different from that of retinoic acid receptor gamma, a closely related AF-2-dependent receptor. In particular, the hydrophobic cleft characteristic of nuclear receptors was replaced with a much more hydrophilic surface with a distinct topology. This observation accounts for the inability of this nuclear receptor LBD to directly mediate cofactor recruitment. Furthermore, the AF-1 domain physically associates with the Nur77 C-terminal LBD and synergizes with the retinoid X receptor LBD. Thus, the AF-1 domain plays a major role in Nur77-mediated transcriptional activation, cofactor recruitment, and intra- and intermolecular interactions.	Univ Queensland, Ctr Mol & Cellular Biol, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Queensland Univ Technol, Ctr Mol Biotechnol, Brisbane, Qld 4001, Australia	University of Queensland; Queensland University of Technology (QUT)	Muscat, GEO (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	G.Muscat@imb.uq.edu.au	Muscat, George/A-6401-2017	Muscat, George/0000-0002-5829-5695; Harris, Jonathan/0000-0003-4209-2380				ALLEGRETTO EA, 1995, J BIOL CHEM, V270, P23906, DOI 10.1074/jbc.270.41.23906; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; Buervenich S, 2000, AM J MED GENET, V96, P808, DOI 10.1002/1096-8628(20001204)96:6<808::AID-AJMG23>3.0.CO;2-E; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen HL, 2001, SPE RESERV EVAL ENG, V4, P16, DOI 10.2118/69197-PA; Chen SL, 2000, GENE DEV, V14, P1209; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Chen YH, 2001, AM J MED GENET, V105, P753, DOI 10.1002/ajmg.10036; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dowhan DH, 1996, NUCLEIC ACIDS RES, V24, P264, DOI 10.1093/nar/24.2.264; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fernandez PM, 2000, ENDOCRINOLOGY, V141, P2392, DOI 10.1210/en.141.7.2392; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Glass CK, 2000, GENE DEV, V14, P121; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; Ishiguro H, 2002, AM J MED GENET, V114, P15, DOI 10.1002/ajmg.1620; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIM YS, 1992, LIFE SCI, V50, P397, DOI 10.1016/0024-3205(92)90374-X; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIM RW, 1995, BBA-MOL CELL RES, V1266, P91, DOI 10.1016/0167-4889(94)00226-5; LIM RW, 1995, BIOCHEM J, V308, P785, DOI 10.1042/bj3080785; MADER S, 1993, J BIOL CHEM, V268, P591; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; Sacchetti P, 1999, MOL BRAIN RES, V74, P167, DOI 10.1016/S0169-328X(99)00275-2; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Schimmel JJ, 1999, MOL BRAIN RES, V74, P1, DOI 10.1016/S0169-328X(99)00234-X; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Stocco CO, 2002, J BIOL CHEM, V277, P3293, DOI 10.1074/jbc.M110936200; SURLES MC, 1994, PROTEIN SCI, V3, P198; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Witta J, 2000, MOL BRAIN RES, V84, P67, DOI 10.1016/S0169-328X(00)00211-4; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; Yang WL, 1997, BIOCHEM J, V321, P281, DOI 10.1042/bj3210281; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656	57	117	120	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33001	33011		10.1074/jbc.M203572200	http://dx.doi.org/10.1074/jbc.M203572200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082103	Green Published, hybrid			2022-12-25	WOS:000177859000080
J	Bidere, N; Briet, M; Durrbach, A; Dumont, C; Feldmann, J; Charpentier, B; de Saint-Basile, G; Senik, A				Bidere, N; Briet, M; Durrbach, A; Dumont, C; Feldmann, J; Charpentier, B; de Saint-Basile, G; Senik, A			Selective inhibition of dipeptidyl peptidase I, not caspases, prevents the partial processing of procaspase-3 in CD3-activated human CD8(+) T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEDIAK-HIGASHI-SYNDROME; CYTOCHROME-C RELEASE; CATHEPSIN-B CONTRIBUTES; GRANZYME-B; GRANULE EXOCYTOSIS; SERINE PROTEASES; APOPTOSIS; ACTIVATION; PATHWAY; CLEAVAGE	Activation of primary human T cells by anti-CD3 and interleukin-2 resulted in partial processing of procaspase-3 in activated nonapoptotic (Deltapsi(m)(high)) CD8(+) T cells but not in CD4(+) T cells. Apical caspases-8 and -9 were not activated, and Bid was not processed to truncated Bid. Boc-D.fmk, a broad spectrum caspase inhibitor, did not prevent this process, whereas GF.dmk, a selective inhibitor of dipeptidyl peptidase I was effective. Dipeptidyl peptidase I is required for the activation of granule-associated serine proteases. It is enriched in the cytolytic granules of cytotoxic lymphocytes, where it promotes the proteolytic activation of progranzymes A and B. Inhibition of granzyme B (GrB)-like serine proteases by Z-AAD.cmk prevented partial processing of procapase-3, whereas inhibition of GrA activity by D-FPR.cmk had no effect. Specific inhibitors of other lysosomal proteases such as cathepsins B, L, and D did not interfere in this event. Patients with Chediak-Higashi syndrome or with perforin deficiency also displayed partial processing of procaspase-3, excluding the involvement of granule exocytosis for the delivery of the serine protease in cause. The p20/p12 processing pattern of procaspase-3 in our model points to GrB, the sole serine protease with aspase activity. Small amounts of GrB were indeed exported from cytolytic granules to the cytosol of a significant fraction of GrB-positive cells.	Hop Paul Brousse, Lab Greffes Epitheliums & Regulat Activat Lymphoc, Unite INSERM 542, F-94807 Villejuif, France; Hop Necker Enfants Malad, Lab Dev Normal & Pathol Syst Immunitaire, Unite INSERM 429, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Senik, A (corresponding author), Hop Paul Brousse, Lab Greffes Epitheliums & Regulat Activat Lymphoc, Unite INSERM 542, 14 Ave Paul Vaillant Couturier,Batiment Lavoisier, F-94807 Villejuif, France.		Bidère, Nicolas/K-8887-2015; Briet, Marie/K-7385-2015; de Saint Basile, Genevieve/G-9731-2017	Bidère, Nicolas/0000-0001-9177-0008; de Saint Basile, Genevieve/0000-0002-1913-5269; Briet, Marie/0000-0003-3738-5998				Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; BAETZ K, 1995, J IMMUNOL, V154, P6122; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; BROWN GR, 1993, J IMMUNOL, V150, P4733; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Certain S, 2000, BLOOD, V95, P979; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Deas O, 1998, J IMMUNOL, V161, P3375; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Feldmann J, 2002, BRIT J HAEMATOL, V117, P965, DOI 10.1046/j.1365-2141.2002.03534.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Kam CM, 2000, BBA-PROTEIN STRUCT M, V1477, P307, DOI 10.1016/S0167-4838(99)00282-4; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KUMER JA, 1996, J BIOL CHEM, V271, P9281; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Mabee CL, 1998, J IMMUNOL, V160, P5880; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Schotte P, 2001, J BIOL CHEM, V276, P21153, DOI 10.1074/jbc.M102239200; SMYTH MJ, 1995, J IMMUNOL, V154, P6299; Smyth MJ, 2001, J LEUKOCYTE BIOL, V70, P18; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Wolters PJ, 2001, J BIOL CHEM, V276, P18551, DOI 10.1074/jbc.M100223200; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916	52	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32339	32347		10.1074/jbc.M205153200	http://dx.doi.org/10.1074/jbc.M205153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080079	hybrid			2022-12-25	WOS:000177718700129
J	Gao, N; Ding, M; Zheng, JZ; Zhang, Z; Leonard, SS; Liu, KJ; Shi, XL; Jiang, BH				Gao, N; Ding, M; Zheng, JZ; Zhang, Z; Leonard, SS; Liu, KJ; Shi, XL; Jiang, BH			Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; MORPHOLOGICAL TRANSFORMATION; VANADIUM PENTOXIDE; PROLYL HYDROXYLATION; GENE-EXPRESSION; BALB/3T3 CELLS; TRANSCRIPTION; ANGIOGENESIS; ACTIVATION	Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric basic helix-loop-helix transcription factor composed of HIF-1alpha and HIF-1beta/aryl hydrocarbon nuclear translocator subunits. HIF-1 expression is induced by hypoxia, growth factors, and activation of oncogenes. In response to hypoxia, HIF-1 activates the expression of many genes including vascular endothelial growth factor (VEGF) and erythropoietin. HIF-1 and VEGF play an important role in angiogenesis and tumor progression. Vanadate is widely used in industry, and is a potent inducer of tumors in humans and animals. In this study, we demonstrate that vanadate induces HIF-1 activity through the expression of HIF-1alpha but not HIF-1beta subunit, and increases VEGF expression in DU145 human prostate carcinoma cells. We also studied the signaling pathway involved in vanadate-induced HIF-1alpha and VEGF expression and found that phosphatidylinositol 3-kinase/Akt signaling was required for HIF-1 and VEGF expression induced by vanadate, whereas mitogen-activated protein kinase pathway was not required. We also found that reactive oxygen species (ROS) were involved in vanadate-induced expression of HIF-1 and VEGF in DU145 cells. The major species of ROS responsible for the induction of HIF-1 and VEGF expression was H2O2. These results suggest that the expression of HIF-1 and VEGF induced by vanadate through PI3K/Akt may be an important signaling pathway in the vanadate-induced carcinogenesis, and ROS may play an important role.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA; Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA	West Virginia University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of New Mexico	Jiang, BH (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.		Zhang, Zhuo/B-8601-2012; Shi, Xianglin/B-8588-2012	Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER; NCRR NIH HHS [RR16440] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AltamiranoLozano M, 1996, TERATOGEN CARCIN MUT, V16, P7, DOI 10.1002/(SICI)1520-6866(1996)16:1<7::AID-TCM2>3.0.CO;2-M; Barbagallo M, 2001, HYPERTENSION, V38, P701, DOI 10.1161/hy09t1.095392; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Borgstrom P, 1996, CANCER RES, V56, P4032; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CRANS DC, 1989, BIOCHEM BIOPH RES CO, V165, P246, DOI 10.1016/0006-291X(89)91061-9; Ding M, 1999, CARCINOGENESIS, V20, P663, DOI 10.1093/carcin/20.4.663; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Goldwaser I, 2000, J INORG BIOCHEM, V80, P21, DOI 10.1016/S0162-0134(00)00035-0; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Grunstein J, 1999, CANCER RES, V59, P1592; HICKEY RJ, 1967, ARCH ENVIRON HEALTH, V15, P728, DOI 10.1080/00039896.1967.10664990; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kerckaert GA, 1996, FUND APPL TOXICOL, V34, P67, DOI 10.1006/faat.1996.0176; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; KRAUS T, 1989, ZBL HYG UMWELTMED, V188, P108; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Millauer B, 1996, CANCER RES, V56, P1615; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Minet E, 2000, INT J MOL MED, V5, P253; NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rojas E, 1996, MUTAT RES-ENVIR MUTA, V359, P77, DOI 10.1016/S0165-1161(96)90254-X; Rojas E, 1999, MUTAT RES-GEN TOX EN, V443, P157, DOI 10.1016/S1383-5742(99)00018-6; ROLDAN RE, 1990, MUTAT RES, V245, P61, DOI 10.1016/0165-7992(90)90001-Z; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; SABBIONI E, 1993, CARCINOGENESIS, V14, P2565, DOI 10.1093/carcin/14.12.2565; SABBIONI E, 1991, CARCINOGENESIS, V12, P47, DOI 10.1093/carcin/12.1.47; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; SHEU CW, 1992, FOOD CHEM TOXICOL, V30, P307, DOI 10.1016/0278-6915(92)90008-9; SHI XL, 1992, FREE RADICAL RES COM, V17, P369, DOI 10.3109/10715769209083141; SHI XL, 1990, FEBS LETT, V271, P185, DOI 10.1016/0014-5793(90)80402-5; SHI XL, 1991, ARCH BIOCHEM BIOPHYS, V289, P355, DOI 10.1016/0003-9861(91)90423-G; STOCKS P, 1960, BRIT J CANCER, V14, P397, DOI 10.1038/bjc.1960.45; Strawn LM, 1996, CANCER RES, V56, P3540; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541	64	157	165	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31963	31971		10.1074/jbc.M200082200	http://dx.doi.org/10.1074/jbc.M200082200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070140	hybrid, Green Submitted			2022-12-25	WOS:000177718700083
J	Kulinski, A; Rustaeus, S; Vance, JE				Kulinski, A; Rustaeus, S; Vance, JE			Microsomal triacylglycerol transfer protein is required for lumenal accretion of triacylglycerol not associated with ApoB, as well as for ApoB lipidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; B-CONTAINING LIPOPROTEINS; PRIMARY RAT HEPATOCYTES; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; MCA-RH7777 CELLS; DISULFIDE ISOMERASE; ABETALIPOPROTEINEMIA GENE; SECRETION	The assembly of very low density lipoproteins in hepatocytes requires the microsomal triacylglycerol transfer protein (MTP). This microsomal lumenal protein transfers lipids, particularly triacylglycerols (TG), between membranes in vitro and has been proposed to transfer TG to nascent apolipoprotein (apo) B in vivo. We examined the role of MTP in the assembly of apoB-containing lipoproteins in cultured murine primary hepatocytes using an inhibitor of MTP. The MTP inhibitor reduced TG secretion from hepatocytes by 85% and decreased the amount of apoB100 in the microsomal lumen, as well as that secreted into the medium, by 70 and 90%, respectively, whereas the secretion of apoB48 was only slightly decreased and the amount of lumenal apoB48 was unaffected. However, apoB48-containing particles formed in the presence of inhibitor were lipid-poor compared with those produced in the absence of inhibitor. We also isolated a pool of apoB-free TG from the microsomal lumen and showed that inhibition of MTP decreased the amount of TG in this pool by similar to45%. The pool of TG associated with apoB was similarly reduced. However, inhibition of MTP did not directly block TG transfer from the apoB-independent TG pool to partially lipidated apoB in the microsomal lumen. We conclude that MTP is required for TG accumulation in the microsomal lumen and as a source of TG for assembly with apoB, but normal levels of MTP are not required for transferring the bulk of TG to apoB during VLDL assembly in murine hepatocytes.	Univ Alberta, Heritage Med Res Ctr 332, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta	Vance, JE (corresponding author), Univ Alberta, Heritage Med Res Ctr 332, Dept Med, Edmonton, AB T6G 2S2, Canada.							ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1994, J BIOL CHEM, V269, P25879; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Du EZ, 1996, J LIPID RES, V37, P1309; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fleming JF, 1999, J BIOL CHEM, V274, P9509, DOI 10.1074/jbc.274.14.9509; Folch J., 1959, J BIOL CHEM, V226, P495; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Hamilton RL, 1998, J LIPID RES, V39, P1543; Hebbachi AM, 1999, J LIPID RES, V40, P1758; Hebbachi AM, 2001, J LIPID RES, V42, P1609; Hebbachi AM, 1999, BBA-MOL CELL BIOL L, V1441, P36, DOI 10.1016/S1388-1981(99)00138-9; HERBERT PN, 1985, J CLIN INVEST, V76, P403, DOI 10.1172/JCI111986; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kang S, 2000, BBA-MOL CELL BIOL L, V1529, P223, DOI 10.1016/S1388-1981(00)00151-7; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Liang JS, 2001, J BIOL CHEM, V276, P28606, DOI 10.1074/jbc.M100294200; Macri J, 2000, BIOCHEM BIOPH RES CO, V276, P1035, DOI 10.1006/bbrc.2000.3509; Macri J, 1997, J BIOL CHEM, V272, P7328, DOI 10.1074/jbc.272.11.7328; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Nicodeme E, 1999, J BIOL CHEM, V274, P1986, DOI 10.1074/jbc.274.4.1986; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Segrest JP, 1999, J LIPID RES, V40, P1401; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; Tietge UJF, 1999, J LIPID RES, V40, P2134; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; VANCE JE, 1991, J LIPID RES, V32, P1971; VANCE JE, 1988, J BIOL CHEM, V263, P5898; Wang L, 1997, J BIOL CHEM, V272, P27644, DOI 10.1074/jbc.272.44.27644; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG LY, 1995, J LIPID RES, V36, P125; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	58	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31516	31525		10.1074/jbc.M202015200	http://dx.doi.org/10.1074/jbc.M202015200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12072432	hybrid			2022-12-25	WOS:000177718700030
J	Mathiasen, IS; Sergeev, IN; Bastholm, L; Elling, F; Norman, AW; Jaattela, M				Mathiasen, IS; Sergeev, IN; Bastholm, L; Elling, F; Norman, AW; Jaattela, M			Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; ENDOPLASMIC-RETICULUM; D ANALOG; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; PHOSPHOLIPASE A(2); CYSTEINE PROTEASE; OXIDATIVE STRESS; UP-REGULATION; LNCAP CELLS	The active form of vitamin D-3 (1,25(OH)(2)D-3) induces an increase in the intracellular free calcium ([Ca2+](i)) and caspase-independent cell death in human breast cancer cells. Here we show that the treatment of MCF-7 breast cancer cells with 1,25(OH)(2)D-3 or its chemotherapeutic analog, EB 1089, releases Ca2+ from the endoplasmic reticulum. The increase in [Ca2+](i) was associated with the activation of a calcium-dependent cysteine protease, mu-calpain. Interestingly, ectopic expression of a calcium-binding protein, calbindin-D-28k, in MCF-7 cells not only attenuated the elevation in [Ca2+](i) and calpain activation, but also reduced death triggered by vitamin D compounds. Similarly, the inhibition of calpain activity by structurally unrelated chemical inhibitors increased the survival of the cells and reduces the amount of annexin V-positive cells. Despite the complete absence of effector caspase activation, transmission electron microscopy of MCF-7 cells treated with 1,25(OH)(2)D-3 or EB 1089 revealed apoptosis-like morphology characterized by the condensed cytoplasm, nuclei, and chromatin. Overall, these results suggest that calpain may take over the role of the major execution protease in apoptosis-like death induced by vitamin D compounds. Thus, these compounds may prove useful in the treatment of tumors resistant to therapeutic agents dependent on the classical caspase cascade.	Danish Canc Soc, Apoptosis Lab, DK-2100 Copenhagen O, Denmark; S Dakota State Univ, Dept Chem & Biochem, Brookings, SD 57006 USA; Univ Copenhagen, Fac Hlth Sci, Inst Mol Pathol, DK-1353 Copenhagen K, Denmark; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	Danish Cancer Society; South Dakota State University; University of Copenhagen; University of California System; University of California Riverside	Jaattela, M (corresponding author), Danish Canc Soc, Apoptosis Lab, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Jäättelä, Marja/AAT-7932-2021	Jäättelä, Marja/0000-0001-5950-7111	NCI NIH HHS [CA 67317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R15CA067317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baudet C, 1996, CANCER LETT, V100, P3, DOI 10.1016/0304-3835(95)04054-4; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Garach-Jehoshua O, 1998, BRIT J DERMATOL, V139, P950; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; Hansen CM, 2000, CURR PHARM DESIGN, V6, P803, DOI 10.2174/1381612003400371; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsieh TC, 1997, BIOCHEM BIOPH RES CO, V235, P539, DOI 10.1006/bbrc.1997.6838; Ishihara I, 2000, NEUROSCI LETT, V279, P97, DOI 10.1016/S0304-3940(99)00960-X; Jaattela M, 1996, J IMMUNOL, V156, P1166; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; James SY, 1999, GEN PHARMACOL, V32, P143, DOI 10.1016/S0306-3623(98)00098-6; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Mathiasen IS, 1999, CANCER RES, V59, P4848; MATHIASEN IS, 1993, J STEROID BIOCHEM, V46, P365, DOI 10.1016/0960-0760(93)90226-M; Mathiasen IS, 2001, INT J CANCER, V93, P224, DOI 10.1002/ijc.1325; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Narvaez CJ, 2001, J BIOL CHEM, V276, P9101, DOI 10.1074/jbc.M006876200; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pink JJ, 2000, EXP CELL RES, V255, P144, DOI 10.1006/excr.1999.4790; Pirianov G, 1999, CELL DEATH DIFFER, V6, P890, DOI 10.1038/sj.cdd.4400563; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; RHOTEN WB, 1994, ENDOCRINE, V2, P989; Sergeev I.N., 2000, VITAMIN D ENDOCRINE, P399; Sergeev IN, 1998, SUB CELL BIOCHEM, V30, P271; SERGEEV IN, 1995, ENDOCRINOLOGY, V136, P2852, DOI 10.1210/en.136.7.2852; Sergeev IN, 1996, ENDOCRINE, V5, P335, DOI 10.1007/BF02739068; Sergeev IN, 1998, ENDOCRINE, V9, P321, DOI 10.1385/ENDO:9:3:321; Squier MKT, 1997, J IMMUNOL, V158, P3690; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; VANDEWALLE B, 1995, INT J CANCER, V61, P806, DOI 10.1002/ijc.2910610611; Villa PG, 1998, J CELL SCI, V111, P713; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang Q, 2000, CANCER RES, V60, P2040; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; WILSON PW, 1988, J MOL BIOL, V200, P615, DOI 10.1016/0022-2836(88)90475-5; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267	58	176	194	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30738	30745		10.1074/jbc.M201558200	http://dx.doi.org/10.1074/jbc.M201558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12072431	hybrid			2022-12-25	WOS:000177579800044
J	Terrell, AR; Wongwisansri, S; Pilon, JL; Laybourn, PJ				Terrell, AR; Wongwisansri, S; Pilon, JL; Laybourn, PJ			Reconstitution of nucleosome positioning, remodeling, histone acetylation, and transcriptional activation on the PHO5 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; IN-VIVO; CHROMATIN TEMPLATES; YEAST; GENES; PROTEIN; SYSTEM; TRANSACTIVATION	The PHO5 gene promoter is an important model for the study of gene regulation in the context of chromatin. Upon PHO5 activation the chromatin structure is reconfigured, but the mechanism of this transition remains unclear. Using templates reconstituted into chromatin with purified recombinant yeast core histones, we have investigated the mechanism of chromatin structure reconfiguration on the PHO5 promoter, a prerequisite for transcriptional activation. Footprinting analyses show that intrinsic properties of the promoter DNA are sufficient for translational nucleosome positioning, which approximates that seen in vivo. We have found that both Pho4p and Pho2p can bind their cognate sites on chromatin-assembled templates without the aid of histone-modifying or nucleosome-remodeling factors. However, nucleosome remodeling by these transcriptional activators requires an ATP-dependent activity in a yeast nuclear extract fraction. Finally, transcriptional activation on chromatin templates requires acetyl-CoA in addition to these other activities and cofactors. The addition of acetyl-CoA results in significant core histone acetylation. These findings indicate that transcriptional activation requires Pho4p, Pho2p, nucleosome remodeling, and nucleosome acetylation. Furthermore, we find that DNA binding, nucleosome remodeling, and transcriptional activation are separable steps, facilitating biochemical analysis of the PHO5 regulatory mechanism.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Proligo, Boulder, CO 80301 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA	Colorado State University; Washington University (WUSTL)	Laybourn, PJ (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, MRB Bldg,Rm 231, Ft Collins, CO 80523 USA.							Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; Barbaric S, 1998, MOL CELL BIOL, V18, P2629, DOI 10.1128/MCB.18.5.2629; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; BERGMAN LW, 1986, MOL CELL BIOL, V6, P38, DOI 10.1128/MCB.6.1.38; BRAZAS RM, 1993, MOL CELL BIOL, V13, P5524, DOI 10.1128/MCB.13.9.5524; Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365-2958.1999.01390.x; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Haswell ES, 1999, MOL CELL BIOL, V19, P2817; Havas K, 2001, CELL MOL LIFE SCI, V58, P673, DOI 10.1007/PL00000891; HULL MW, 1991, METHOD CELL BIOL, V35, P383; JACKSON JR, 1993, NUCLEIC ACIDS RES, V21, P957, DOI 10.1093/nar/21.4.957; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Kent NA, 2001, GENE DEV, V15, P619, DOI 10.1101/gad.190301; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; Magbanua JPV, 1997, J BIOCHEM, V121, P1182; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Robinson KM, 1998, BBA-REV CANCER, V1378, pM1, DOI 10.1016/S0304-419X(98)00008-0; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; ROTH SY, 1991, METHOD CELL BIOL, V35, P289; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; Shao DL, 1996, MOL GEN GENET, V251, P358, DOI 10.1007/BF02172527; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Venditti P, 1998, NUCLEIC ACIDS RES, V26, P3657, DOI 10.1093/nar/26.16.3657; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	46	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31038	31047		10.1074/jbc.M204662200	http://dx.doi.org/10.1074/jbc.M204662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060664	hybrid			2022-12-25	WOS:000177579800082
J	Baba, D; Kashiwabara, SI; Honda, A; Yamagata, K; Wu, Q; Ikawa, M; Okabe, M; Baba, T				Baba, D; Kashiwabara, SI; Honda, A; Yamagata, K; Wu, Q; Ikawa, M; Okabe, M; Baba, T			Mouse sperm lacking cell surface hyaluronidase PH-20 can pass through the layer of cumulus cells and fertilize the egg	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE RB(6.16) TRANSLOCATION; MAMMALIAN SPERM; ZONA-PELLUCIDA; ACROSOME REACTION; MEMBRANE-PROTEIN; SPAM1 PH-20; GENE; PENETRATE; BINDING; OOCYTE	The function of glycosylphosphatidylinositol-anchored sperm hyaluronidase PH-20 in fertilization has long been believed to enable acrosome-intact sperm to pass through the layer of cumulus cells and reach the egg zona pellucida. In this study, we have produced mice carrying a null mutation in the PH-20 gene using homologous recombination. Despite the absence of sperm PH-20, the mutant male mice were still fertile. In vitro fertilization assays showed that mouse sperm lacking PH-20 possess a reduced ability to disperse cumulus cells from the cumulus mass, resulting in delayed fertilization solely at the early stages after insemination. Moreover, SDS-PAGE of sperm extracts and subsequent Western blot analysis revealed the presence of other hyaluronidase(s), except PH-20, presumably within the acrosome of mouse sperm. These data provide evidence that PH-20 is not essential for fertilization, at least in the mouse, suggesting that the other hyaluronidase(s) may play an important role in sperm penetration through the cumulus cell layer and/or the egg zona pellucida, possibly in cooperation with PH-20, although the importance of sperm motility cannot be neglected.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan	University of Tsukuba; Osaka University	Baba, T (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan.	acroman@sakura.cc.tsukuba.ac.jp	ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044				ARANHA IP, 1995, CYTOGENET CELL GENET, V69, P253, DOI 10.1159/000133975; ARANHA IP, 1991, HUM GENET, V87, P278, DOI 10.1007/BF00200904; BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1994, J BIOL CHEM, V269, P31845; BABA T, 1994, J BIOL CHEM, V269, P10133; CHAYKO CA, 1992, HUM GENET, V90, P79, DOI 10.1007/BF00210748; Cherr GN, 2001, MATRIX BIOL, V20, P515, DOI 10.1016/S0945-053X(01)00171-8; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; DANDEKAR P, 1992, HUM REPROD, V7, P391, DOI 10.1093/oxfordjournals.humrep.a137656; Frost GL, 1996, TRENDS GLYCOSCI GLYC, V8, P419, DOI 10.4052/tigg.8.419; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; GUNTENHONER MW, 1992, MATRIX, V12, P388, DOI 10.1016/S0934-8832(11)80035-1; HO YG, 1995, MOL REPROD DEV, V41, P232, DOI 10.1002/mrd.1080410214; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; Hunnicutt CR, 1996, BIOL REPROD, V55, P80, DOI 10.1095/biolreprod55.1.80; Kashiwabara S, 2000, DEV BIOL, V228, P106, DOI 10.1006/dbio.2000.9894; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; Ohmura K, 1999, J BIOL CHEM, V274, P29426, DOI 10.1074/jbc.274.41.29426; PHELPS BM, 1988, SCIENCE, V240, P1780, DOI 10.1126/science.3381102; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; PRYCEJONES RH, 1997, J PHARM PHARMACOL, V31, pP92; SILVER LM, 1985, ANNU REV GENET, V19, P179, DOI 10.1146/annurev.ge.19.120185.001143; THALER CD, 1995, BIOCHEMISTRY-US, V34, P7788, DOI 10.1021/bi00024a002; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Yamagata K, 1998, ZYGOTE, V6, P311, DOI 10.1017/S0967199498000264; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; Zheng Y, 1999, MOL REPROD DEV, V54, P8, DOI 10.1002/(SICI)1098-2795(199909)54:1&lt;8::AID-MRD2&gt;3.0.CO;2-D; Zheng Y, 2001, BIOL REPROD, V64, P1730, DOI 10.1095/biolreprod64.6.1730; Zheng Y, 2001, MAMM GENOME, V12, P822, DOI 10.1007/s00335-001-1008-3	35	140	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30310	30314		10.1074/jbc.M204596200	http://dx.doi.org/10.1074/jbc.M204596200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12065596	hybrid			2022-12-25	WOS:000177509300117
J	Fukuda, M				Fukuda, M			Vesicle-associated membrane protein-2/Synaptobrevin binding to Synaptotagmin I promotes O-glycosylation of Synaptotagmin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; CONSERVED WHXL MOTIF; SYNAPTIC VESICLES; C2B DOMAIN; PC12 CELLS; C-TERMINUS; NEUROTRANSMITTER RELEASE; ENDOPLASMIC-RETICULUM; TRANSMITTER RELEASE; MUTATIONAL ANALYSIS	Synaptotagmin I (Syt I), an evolutionarily conserved integral membrane protein of synaptic vesicles, is now known to regulate Ca2+-dependent neurotransmitter release. Syt I protein should undergo several post-translational modifications before maturation and subsequent functioning on synaptic vesicles (e.g. N-glycosylation and fatty acylation in vertebrate Syt I), because the apparent molecular weight of Syt I on synaptic vesicles (mature form, 65,000) was much higher than the calculated molecular weight (47,400) predicted from the cDNA sequences both in vertebrates and invertebrates. Common post-translational modification(s) of Syt I conserved across phylogeny, however, have never been elucidated. In the present study, I discovered that dithreonine residues (Thr-15 and Thr-16) at the intravesicular domain of mouse Syt I are post-translationally modified by a complex form of O-linked sugar (i.e. the addition of sialic acids) in PC12 cells and that the O-glycosylation of Syt I in COS-7 cells depends on the coexpression of vesicle-associated membrane protein-2 (VAMP-2)/synaptobrevin. I also showed that a transmembrane domain of Syt I directly interacts with isolated VAMP-2, but not VAMP-2, in the heterotrimeric SNARE (SNAP receptor) complex (vesicle SNARE, VAMP-2, and two target SNARES, syntaxin IA and SNAP-25). Since di-Thr or di-Ser residues are often found at the intravesicular domain of invertebrate Syt I, and VAMP-dependent O-glycosylation was also observed in squid Syt expressed in COS-7 cells, I propose that VAMP-dependent O-glycosylation of Syt I is a common modification during evolution and may have important role(s) in synaptic vesicle trafficking.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Berton F, 2000, EUR J NEUROSCI, V12, P1294, DOI 10.1046/j.1460-9568.2000.00013.x; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Craxton M, 1999, FEBS LETT, V460, P417, DOI 10.1016/S0014-5793(99)01382-4; Craxton M, 2001, GENOMICS, V77, P43, DOI 10.1006/geno.2001.6619; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Detrait E, 2000, J NEUROBIOL, V44, P382, DOI 10.1002/1097-4695(20000915)44:4<382::AID-NEU2>3.0.CO;2-Q; Detrait ER, 2000, J NEUROSCI RES, V62, P566, DOI 10.1002/1097-4547(20001115)62:4<566::AID-JNR11>3.3.CO;2-W; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; Earles CA, 2001, J CELL BIOL, V154, P1117, DOI 10.1083/jcb.200105020; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FEANY MB, 1993, J CELL BIOL, V123, P575, DOI 10.1083/jcb.123.3.575; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fukuda M, 2000, NEUROSCI LETT, V295, P33, DOI 10.1016/S0304-3940(00)01585-8; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, FEBS LETT, V482, P269, DOI 10.1016/S0014-5793(00)02064-0; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, J BIOL CHEM, V276, P41112, DOI 10.1074/jbc.M106209200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; FUKUDA M, 2000, J BIOCH, V128, P627; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jarousse N, 2001, J CELL BIOL, V154, P857, DOI 10.1083/jcb.200103040; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kabayama H, 1999, NEUROSCIENCE, V88, P999, DOI 10.1016/S0306-4522(98)00547-8; Kida Y, 2000, J CELL BIOL, V150, P719, DOI 10.1083/jcb.150.4.719; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; Lloyd TE, 2000, NEURON, V26, P45, DOI 10.1016/S0896-6273(00)81136-8; Mackler JM, 2001, J COMP NEUROL, V436, P4, DOI 10.1002/cne.1049; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; MARTIN KC, 1995, P NATL ACAD SCI USA, V92, P11307, DOI 10.1073/pnas.92.24.11307; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mochida S, 1997, NEUROSCIENCE, V77, P937; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1991, J BIOL CHEM, V266, P623; Reist NE, 1998, J NEUROSCI, V18, P7662; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; Salem N, 1998, NAT NEUROSCI, V1, P551, DOI 10.1038/2787; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thomas DM, 1998, J NEUROSCI, V18, P3511; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; von Poser C, 2001, EUR J CELL BIOL, V80, P41; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2	86	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30351	30358		10.1074/jbc.M204056200	http://dx.doi.org/10.1074/jbc.M204056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048209	hybrid			2022-12-25	WOS:000177509300121
J	Zuo, YH; Deutscher, MP				Zuo, YH; Deutscher, MP			The physiological role of RNase T can be explained by its unusual substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNASE ACTIVITY; END-TURNOVER; MATURATION; EXORIBONUCLEASES; IDENTIFICATION	Escherichia coli RNase T, the enzyme responsible for the end-turnover of tRNA and for the 3' maturation of 5 S and 23 S rRNAs and many other small, stable RNAs, was examined in detail with respect to its substrate specificity. The enzyme was found to be a single-strand-specific exoribonuclease that acts in the 3' to 5' direction in a non-processive manner. However, although other Escherichia coli exoribonucleases stop several nucleotides downstream of an RNA duplex, RNase T can digest RNA up to the first base pair. The presence of a free 3'-hydroxyl group is required for the enzyme to initiate digestion. Studies with RNA homopolymers and a variety of oligoribonucleotides revealed that RNase T displays an unusual base specificity, discriminating against pyrimidine and, particularly, C residues. Although RNase T appears to bind up to 10 nucleotides in its active site, its specificity is defined largely by the last 4 residues. A single 3'-terminal C residue can reduce RNase T action by >100-fold, and 2-terminal C residues essentially stop the enzyme. In vivo, the substrates of RNase T are similar in that they all contain a double-stranded stem followed by a single-stranded 3' overhang; yet, the action of RNase T on these substrates differs. The substrate specificity described here helps to explain why the different substrates yield different products, and why certain RNA molecules are not substrates at all.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	mdeutsch@med.miami.edu	Zuo, Yuhong/H-7392-2012	Zuo, Yuhong/0000-0003-1810-4580	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; Jones S, 2001, NUCLEIC ACIDS RES, V29, P943, DOI 10.1093/nar/29.4.943; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; Li ZW, 1996, J BIOL CHEM, V271, P1127, DOI 10.1074/jbc.271.2.1127; Li ZW, 1999, RNA, V5, P139, DOI 10.1017/S1355838299981669; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; LI ZW, 1994, J BIOL CHEM, V269, P6064; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860; Viswanathan M, 1998, J BIOL CHEM, V273, P35126, DOI 10.1074/jbc.273.52.35126; Viswanathan M, 1999, GENETICS, V151, P929; Zuo YH, 1999, NUCLEIC ACIDS RES, V27, P4077, DOI 10.1093/nar/27.20.4077	17	55	58	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29654	29661		10.1074/jbc.M204252200	http://dx.doi.org/10.1074/jbc.M204252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050169	hybrid			2022-12-25	WOS:000177509300040
J	Biroccio, A; Amodei, S; Benassi, B; Scarsella, M; Cianciulli, A; Mottolese, M; Del Bufalo, D; Leonetti, C; Zupi, G				Biroccio, A; Amodei, S; Benassi, B; Scarsella, M; Cianciulli, A; Mottolese, M; Del Bufalo, D; Leonetti, C; Zupi, G			Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones	ONCOGENE			English	Article						c-Myc; telomerase; tumorigenicity; apoptosis; melanoma	TELOMERASE REVERSE-TRANSCRIPTASE; NORMAL HUMAN-CELLS; CATALYTIC SUBUNIT; IN-VITRO; ANTISENSE OLIGODEOXYNUCLEOTIDES; HUMAN FIBROBLASTS; TRANSGENIC MICE; TUMOR-CELLS; LIFE-SPAN; GENE	c-Myc is involved in the control of telomerase activity through its ability to induce the expression of the catalytic subunit of the enzyme, the human telomerase reverse transcriptase (hTERT). Our aim was to study whether telomerase plays a critical role in c-Myc-dependent tumorigenicity of melanoma cells. By using M14-derived clones, expressing low levels of c-Myc, we demonstrated that the down-regulation of c-Myc reduced cell proliferation rate, cloning efficiency and tumorigenicity and increased the apoptotic rate. Decreased tumorigenic potential correlated with reduced hTERT gene expression, telomerase activity and telomere shortening. Introduction of wild-type hTERT into these cells increased their proliferation rate and partially re-established their tumorigenic potential, at early passages, even though the apoptotic rate of the population remained unaltered. After several in vitro passages, hTERT-mediated cell proliferation made the tumorigenic potential of the c-Myc low-expressing clones comparable to that of the M14 parental line. Over-expression of the mutant biologically inactive hTERT did not drive cells to proliferate. In conclusion, our results demonstrate that the reconstitution of high levels of telomerase activity reverses the low tumorigenicity due to low c-Myc expression.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy; Regina Elena Inst Canc Res, Clin & Pathol Labs, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy.	zupi@ifo.it	Biroccio, Annamaria/B-2861-2018; Del Bufalo, Donatella/K-8673-2016; Scarsella, Marco/AAA-1486-2020; Leonetti, Carlo/B-2860-2018; Del Bufalo, Donatella/AAC-1594-2021	Biroccio, Annamaria/0000-0003-3198-3532; Del Bufalo, Donatella/0000-0002-3148-6096; Leonetti, Carlo/0000-0002-3526-7827; Del Bufalo, Donatella/0000-0002-3148-6096; Scarsella, Marco/0000-0002-3386-9664				Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHADENEAU C, 1995, ONCOGENE, V11, P893; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Citro G, 1998, CANCER RES, V58, P283; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	48	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3011	3019		10.1038/sj.onc.1205415	http://dx.doi.org/10.1038/sj.onc.1205415			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082531				2022-12-25	WOS:000175262700008
J	Fest, T; Mougey, V; Dalstein, V; Hagerty, M; Milette, D; Silva, S; Mai, S				Fest, T; Mougey, V; Dalstein, V; Hagerty, M; Milette, D; Silva, S; Mai, S			c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis	ONCOGENE			English	Article						c-Myc; dihydrofolate reductase; genomic instability; polyploidy; apoptosis	GENE AMPLIFICATION; P53 MUTATIONS; CYCLE ARREST; TRANSFORMATION; TUMORIGENESIS; CHECKPOINT; LYMPHOMA; EXPRESSION; REDUCTASE; COOPERATE	Overexpression of c-Myc in tumors is usually associated with cell proliferation and increased susceptibility to apoptosis. Concomitantly, c-Myc contributes to tumorigenesis by its ability to destabilize the cellular genome. Here, we examined whether c-Myc induces genomic instability and apoptosis in c-Myc-activated cells. Wildtype Myc (wt-Myc) and two mutated Myc myc box II proteins (mt-Myc) were overexpressed in IL3-dependent murine Ba/F3 cells. As expected, wt-Myc triggered apoptosis in absence of IL3. Standard karyotyping, spectral karyotyping, and fluorescent in situ hybridization (FISH) were performed before and after c-Myc activation. Structural and numerical genomic instability was detected 48 h after wt-Myc activation and included gene amplification, the formation of extrachromosomal elements (EEs), chromosome breakage, deletions, increased aneuploidy, and polyploidization. Interestingly, some cells simultaneously displayed genomic instability and apoptosis. Both wt- and mt-Myc proteins were equally potent promoters of genomic instability. However, only wt-Myc simultaneously induced genomic instability and apoptosis. Mt-Myc proteins failed to induce apoptosis, thereby generating a strong imbalance towards the survival of genomically unstable cells.	CancerCare Manitoba Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag, Winnipeg, MB R3E 0V9, Canada; Inst Etud & Transfert Genes, F-25030 Besancon, France; Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden	CancerCare Manitoba Foundation; Karolinska Institutet	Mai, S (corresponding author), CancerCare Manitoba Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.		Mai, Sabine/E-5667-2017; DALSTEIN, Véronique/P-5250-2016	Mai, Sabine/0000-0002-5797-2201; fest, thierry/0000-0002-6437-4189				ASKEW DS, 1991, ONCOGENE, V6, P1915; BHATIA KG, 1992, CANCER RES, V52, P4273; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CHENG KC, 1993, ADV CANCER RES, V60, P121; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; *COMM STAND GEN NO, 1969, MOUSE NEWS LETT, V17, P481; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CELL, V65, P113; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; ORMEROD MG, 1990, PRACTICAL APPROACH, P69; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WANG HC, 1971, NATURE, V235, P52; WIENER F, 2000, TECHNICAL TIPS ONLIN, V1, P8; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410	31	34	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	2002	21	19					2981	2990		10.1038/sj/onc/1205274	http://dx.doi.org/10.1038/sj/onc/1205274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082528				2022-12-25	WOS:000175262700005
J	Serra, PA; Sciola, L; Delogu, MR; Spano, A; Monaco, G; Miele, E; Rocchitta, G; Miele, M; Migheli, R; Desole, MS				Serra, PA; Sciola, L; Delogu, MR; Spano, A; Monaco, G; Miele, E; Rocchitta, G; Miele, M; Migheli, R; Desole, MS			The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia - Relevance to nigral neuronal death and striatal neurochemical changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; RAT-BRAIN; OXIDATIVE STRESS; ASCORBIC-ACID; PC12 CELLS; IN-VIVO; NUCLEOTIDE-METABOLISM; TYROSINE-HYDROXYLASE; DOPAMINE OXIDATION	Swiss mice were given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 25 mg/kg/day, for 5 consecutive days and killed at different days after MPTP discontinuance. Decreases in striatal tyrosine hydroxylase activity and levels of dopamine and its metabolites were observed I day after MPTP discontinuance. Ascorbic acid and glutamate levels had increased, dehydroascorbic acid and GSH decreased, whereas catabolites of high-energy phosphates (inosine, hypoxanthine, xanthine, and uric acid) were unchanged. In addition, gliosis was observed in both striatum and substantia nigra compacta SNc. Sections of SNc showed some terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end labeling (TUNEL)-positive cells. Neurochemical parameters of dopaminergic activity showed a trend toward recovery 3 days after MPTP discontinuance. At this time point, TUNEL-positive cells were detected in SNc; some of them showed nuclei with neuronal morphology. A late (days 6-11) increase in striatal dopamine oxidative metabolism, ascorbic acid oxidative status, and catabolites of high-energy phosphates were observed concomitant with nigral neuron and nigrostriatal glial cell apoptotic death, as revealed by TUNEL, acridine orange, and Hoechst staining, and transmission electron microscopy. These data suggest that MPTP-induced activation/apoptotic death of glial cells plays a key role in the sequential linkage of neurochemical and cellular events leading to dopaminergic nigral neuron apoptotic death.	Univ Sassari, Fac Med, Dept Pharmacol, I-07100 Sassari, Italy; Univ Sassari, Dept Physiol Biochem & Cellular Sci, I-07100 Sassari, Italy	University of Sassari; University of Sassari	Desole, MS (corresponding author), Univ Sassari, Fac Med, Dept Pharmacol, Viale S Pietro 43B, I-07100 Sassari, Italy.	Pharmaco@ssmain.uniss.it	Rocchitta, Gaia/HHM-8002-2022	MIGHELI, Rossana/0000-0001-5520-5511; ROCCHITTA, Gaia Giovanna Maria/0000-0002-4319-4197; SPANO, Alessandra/0000-0002-2881-7413; SERRA, Pier Andrea/0000-0003-2401-5146; SCIOLA, Gian Luigi/0000-0002-9390-2278				Adams JD, 2001, CURR MED CHEM, V8, P809, DOI 10.2174/0929867013372995; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Banati RB, 1998, MOVEMENT DISORD, V13, P221, DOI 10.1002/mds.870130205; BECKER BF, 1993, FREE RADICAL BIO MED, V14, P615, DOI 10.1016/0891-5849(93)90143-I; Berger TM, 1997, J BIOL CHEM, V272, P15656, DOI 10.1074/jbc.272.25.15656; BIOLSKI BHJ, 1982, ASCORBIC ACID CHEM M, P81; BLOEM BR, 1990, J NEUROL SCI, V97, P273, DOI 10.1016/0022-510X(90)90225-C; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Brosh S, 1996, INT J BIOCHEM CELL B, V28, P319, DOI 10.1016/1357-2725(95)00134-4; Cassarino DS, 1998, J NEUROCHEM, V71, P295; CHIUEH CC, 1993, ADV NEUROL, V60, P251; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Church WH, 1999, EXP BRAIN RES, V127, P147, DOI 10.1007/s002210050784; COYLE JT, 1972, BIOCHEM PHARMACOL, V21, P1935, DOI 10.1016/0006-2952(72)90006-8; DALTON DA, 1986, P NATL ACAD SCI USA, V83, P3811, DOI 10.1073/pnas.83.11.3811; Desole MS, 2000, AGING CLIN EXP RES, V12, P470, DOI 10.1007/BF03339879; Desole MS, 1996, BRAIN RES, V723, P154, DOI 10.1016/0006-8993(96)00235-1; Desole MS, 1997, NEUROCHEM INT, V31, P169, DOI 10.1016/S0197-0186(96)00146-5; DESOLE MS, 1995, PHARMACOL BIOCHEM BE, V51, P581, DOI 10.1016/0091-3057(94)00401-4; DESOLE MS, 1993, NEUROSCI LETT, V159, P143, DOI 10.1016/0304-3940(93)90819-7; DILIBERTO EJ, 1992, J NEUROCHEM, V39, P363; DIMONTE DA, 1992, GLIA, V5, P48, DOI 10.1002/glia.440050108; Eng LF, 1998, J NEUROSCI RES, V53, P353, DOI 10.1002/(SICI)1097-4547(19980801)53:3<353::AID-JNR9>3.0.CO;2-9; Enrico P, 1997, PHARMACOL RES, V35, P577, DOI 10.1006/phrs.1997.0193; FRANCIS JW, 1995, NEUROTOXICOL TERATOL, V17, P7, DOI 10.1016/0892-0362(94)00048-I; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; German DC, 1996, NEURODEGENERATION, V5, P299, DOI 10.1006/neur.1996.0041; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Han JL, 1999, J NEUROCHEM, V73, P1683, DOI 10.1046/j.1471-4159.1999.731683.x; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; Hartmann A, 2001, ADV NEUROL, V86, P143; HILLERED L, 1991, RES EXP MED, V191, P219, DOI 10.1007/BF02576677; Jellinger KA, 1999, DRUG AGING, V14, P115, DOI 10.2165/00002512-199914020-00004; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kiyatkin EA, 1998, BRAIN RES, V812, P14, DOI 10.1016/S0006-8993(98)00814-2; Lapchak PA, 1998, MOVEMENT DISORD, V13, P49; Le WD, 2001, J NEUROSCI, V21, P8447, DOI 10.1523/JNEUROSCI.21-21-08447.2001; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu X, 2000, NEUROSCIENCE, V97, P285, DOI 10.1016/S0306-4522(00)00033-6; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; McNaught KS, 2001, ADV NEUROL, V86, P73; McNaught KSP, 2000, BIOCHEM PHARMACOL, V60, P979, DOI 10.1016/S0006-2952(00)00415-9; McNaught KSP, 1999, J NEUROCHEM, V73, P2469, DOI 10.1046/j.1471-4159.1999.0732469.x; MIELE M, 1994, NEUROSCIENCE, V62, P87, DOI 10.1016/0306-4522(94)90316-6; MIELE M, 1995, NEUROSCI LETT, V183, P155, DOI 10.1016/0304-3940(94)11138-9; Miele M, 1996, J NEUROSCI METH, V70, P15, DOI 10.1016/S0165-0270(96)00094-5; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; MRTENSSON J, 1991, P NATL ACAD SCI USA, V88, P4656, DOI 10.1073/pnas.88.11.4656; Muralikrishnan D, 1998, FASEB J, V12, P905, DOI 10.1096/fasebj.12.10.905; Noack H, 1998, GLIA, V23, P285, DOI 10.1002/(SICI)1098-1136(199808)23:4<285::AID-GLIA1>3.0.CO;2-2; OBATA T, 1992, J NEURAL TRANSM-GEN, V89, P139, DOI 10.1007/BF01245361; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Pothos EN, 1998, J NEUROSCI, V18, P5575; Rabinovic AD, 1998, J NEUROCHEM, V71, P2071; Rice ME, 1999, NEUROTOX RES, V1, P81, DOI 10.1007/BF03033272; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; SAVOLAINEN H, 1978, RES COMMUN CHEM PATH, V21, P173; Sheehan JP, 1997, J NEUROSCI RES, V48, P226, DOI 10.1002/(SICI)1097-4547(19970501)48:3<226::AID-JNR5>3.0.CO;2-H; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; Song DD, 2000, J NEUROSCI, V20, P5102; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Tatton NA, 1997, NEUROSCIENCE, V77, P1037, DOI 10.1016/S0306-4522(96)00545-3; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WESTERINK BHC, 1982, J NEUROCHEM, V38, P680, DOI 10.1111/j.1471-4159.1982.tb08685.x; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wullner U, 1996, NEUROREPORT, V7, P921; ZorefShani E, 1995, INT J DEV NEUROSCI, V13, P887, DOI 10.1016/0736-5748(95)00054-2; ZOREFSHANI E, 1992, J MOL CELL CARDIOL, V24, P183, DOI 10.1016/0022-2828(92)93154-C	82	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34451	34461		10.1074/jbc.M202099200	http://dx.doi.org/10.1074/jbc.M202099200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12084711	hybrid			2022-12-25	WOS:000177959100118
J	de la Torre-Ruiz, MA; Torres, J; Arino, J; Herrero, E				de la Torre-Ruiz, MA; Torres, J; Arino, J; Herrero, E			Sit4 is required for proper modulation of the biological functions mediated by Pkc1 and the cell integrity pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAP KINASE; WALL INTEGRITY; GENE-EXPRESSION; BUDDING YEAST; DOMINANT MUTATIONS; CATALYTIC SUBUNIT; OSMOTIC-STRESS; TOR PROTEINS; PHOSPHATASE	Maintenance of cellular integrity in Saccharomyces cerevisiae is carried out by the activation of the protein kinase C-mediated mitogen-activated protein kinase (PKC1-MAPK) pathway. Here we report that correct down-regulation of both basal and induced activity of the PKC1-MAPK pathway requires the SIT4 function. Sit4 is a protein phosphatase also required for a proper cell cycle progression. We present evidence demonstrating that the G, to S delay in the cell cycle, which occurs as a consequence of the absence of Sit4, is mediated by up-regulation of Pkc1 activity. Sit4 operates downstream of the plasma membrane sensors Mid2, Wsc1, and Wsc2 and upstream of Pkc1. Sit4 affects all known biological functions involving Pkc1, namely Mpk1 activity and cell wall integrity, actin cytoskeleton organization, and ribosomal gene transcription.	Univ Lleida, Dept Ciencies Med Bas, Fac Med, Lleida 25198, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, Bellaterra 08193, Barcelona, Spain	Universitat de Lleida; Autonomous University of Barcelona	de la Torre-Ruiz, MA (corresponding author), Univ Lleida, Dept Ciencies Med Bas, Fac Med, Rovira Roure 44, Lleida 25198, Spain.	madelatorre@cmb.udl.es	de la Torre, M Angeles/A-7357-2010; Herrero, Enrique/B-5592-2009; Arino, Joaquin/D-3756-2011; Torres-Rosell, Jordi/A-4213-2010	de la Torre, M Angeles/0000-0002-6111-1359; Herrero, Enrique/0000-0002-6763-111X; Arino, Joaquin/0000-0002-6774-2987; Torres-Rosell, Jordi/0000-0003-1308-6926; Arino Carmona, Joaquin/0000-0002-0390-4270				Andrews PD, 2000, J CELL SCI, V113, P507; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bastians H, 1996, J CELL SCI, V109, P2865; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Belli G, 2001, MOL MICROBIOL, V39, P1022, DOI 10.1046/j.1365-2958.2001.02297.x; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; Clotet J, 1999, MOL CELL BIOL, V19, P2408; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; DICOMO CJ, 1995, GENETICS, V139, P95; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOSEFF AI, 1995, GENETICS, V141, P857; Evans DRH, 1997, GENETICS, V145, P227; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goldstein AL, 1999, YEAST, V15, P507, DOI 10.1002/(SICI)1097-0061(199904)15:6<507::AID-YEA369>3.0.CO;2-P; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Johnston LH, 1997, METHOD ENZYMOL, V283, P342; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kaiser C., 1994, METHODS YEAST GENETI; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; Li Y, 2000, MOL CELL BIOL, V20, P3843, DOI 10.1128/MCB.20.11.3843-3851.2000; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; Lim YM, 1997, GENETICS, V146, P263; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; MANN DJ, 1993, EMBO J, V12, P4833, DOI 10.1002/j.1460-2075.1993.tb06173.x; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Masuda CA, 2000, J BIOL CHEM, V275, P30957, DOI 10.1074/jbc.M004869200; Mattison CP, 1999, MOL CELL BIOL, V19, P7651; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; POSAS F, 1992, J BIOL CHEM, V267, P11734; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROWLEY A, 1993, MOL CELL BIOL, V13, P1034, DOI 10.1128/MCB.13.2.1034; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; SHIMANUKI M, 1993, MOL BIOL CELL, V4, P303, DOI 10.1091/mbc.4.3.303; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Sutton A, 1997, GENETICS, V147, P57; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WANG T, 2000, MOL BIOL CELL, V6, P1011; WATANABE M, 1994, J BIOL CHEM, V269, P16829; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	63	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33468	33476		10.1074/jbc.M203515200	http://dx.doi.org/10.1074/jbc.M203515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080055	hybrid, Green Published			2022-12-25	WOS:000177859000136
J	Hu, BA; Nakata, H; Gu, C; de Beer, T; Cooper, DMF				Hu, BA; Nakata, H; Gu, C; de Beer, T; Cooper, DMF			A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN ADENYLYL-CYCLASE; CATALYTIC MECHANISM; CALCIUM; MAGNESIUM; BINDING; ENTRY; DOMAINS; CELLS; SITES; ION	Adenylyl cyclase type 5 (AC5) is sensitive to both high and low affinity inhibition by Ca2+. This property provides a sensitive feedback mechanism of the Ca2+ entry that is potentiated by cAMP in sources where AC5 is commonly expressed (e.g. myocardium). Remarkably little is known about the molecular mechanism whereby Ca2+ inhibits AC5. Because previous studies had showed that Ca2+ antagonized the activation of adenylyl cyclase brought about by Mg2+, we have now evaluated the Mg2+-binding domain in the catalytic site as the potential site of the interaction, using a number of mutations of AC5 with impaired Mg2+ activation. Mg2+ activation exerted contrasting effects on the high and low affinity Ca2+ inhibition. In both wild type and mutants, activation by Mg2+ decreased the absolute amount of high affinity inhibition without affecting the K-i value, whereas the K-i value for low affinity inhibition was decreased. These effects were directly proportional to the sensitivity of the mutants to Mg2+. Parallel changes were noted in the efficacies of Ca2+, Sr2+, and Ba2+ in the mutant species, suggesting a simple mutation in a shared domain. Strikingly, forskolin, which activates by a mechanism different from Mg2+, did not modify inhibition by Ca2+. Deletion of the N terminus and the C1b domain of AC5 and a chimera formed with AC2 confirmed that the catalytic domain alone was responsible for high affinity inhibition. We therefore conclude that both low and high affinity inhibition by Ca2+ are exerted on different conformations of the Mg2+-binding sites in the catalytic domain of AC5.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.	dmfc2@cam.ac.uk	Hu, Biao/G-6084-2010; Gu, Chen/E-3163-2011		NIGMS NIH HHS [GM 32483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano T, 2000, BRIT J PHARMACOL, V130, P731, DOI 10.1038/sj.bjp.0703361; BIRNBAUMER L, 1973, BIOCHIM BIOPHYS ACTA, V300, P129, DOI 10.1016/0304-4157(73)90002-6; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BOYAJIAN CL, 1990, CELL CALCIUM, V11, P299, DOI 10.1016/0143-4160(90)90007-H; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; COOPER DMF, 1993, TRENDS PHARMACOL SCI, V14, P34, DOI 10.1016/0165-6147(93)90027-H; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; Gu C, 2000, J BIOL CHEM, V275, P6980, DOI 10.1074/jbc.275.10.6980; Gu C, 2001, CURR BIOL, V11, P185, DOI 10.1016/S0960-9822(01)00044-6; Guillou JL, 1999, J BIOL CHEM, V274, P35539, DOI 10.1074/jbc.274.50.35539; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kato H, 1998, BRAIN RES, V779, P329, DOI 10.1016/S0006-8993(97)01232-8; Klein C, 2002, J BIOL CHEM, V277, P11859, DOI 10.1074/jbc.M108808200; LIN MC, 1975, J BIOL CHEM, V250, P4246; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Smith KE, 2002, J BIOL CHEM, V277, P6025, DOI 10.1074/jbc.M109615200; STEER ML, 1975, J BIOL CHEM, V250, P2080; SUMMERS MD, 1987, TEX AGR EXP STN B, V155, P1; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Weitmann S, 1999, BIOCHEMISTRY-US, V38, P3409, DOI 10.1021/bi982229l; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	34	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33139	33147		10.1074/jbc.M112373200	http://dx.doi.org/10.1074/jbc.M112373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12065575	hybrid			2022-12-25	WOS:000177859000096
J	Katsamba, PS; Bayramyan, M; Haworth, IS; Myszka, DG; Laird-Offringa, IA				Katsamba, PS; Bayramyan, M; Haworth, IS; Myszka, DG; Laird-Offringa, IA			Complex role of the beta(2)-beta(3) loop in the interaction of U1A with U1 hairpin II RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; BINDING DOMAINS DETERMINE; HIGH-AFFINITY; MACROMOLECULAR INTERACTIONS; MOLECULAR-DYNAMICS; RECOGNITION MOTIFS; CRYSTAL-STRUCTURE; PROTEIN COMPLEX; A-PROTEIN; IDENTIFICATION	RNA recognition motifs (RRMs) are characterized by highly conserved regions located centrally on a beta-sheet, which forms the RNA binding surface. Variable flanking regions, such as the loop connecting beta-strands 2 and 3, are thought to be important in determining the RNA-binding specificities of individual RRMs. The N-terminal RRM of the spliceosomal U1A protein mediates binding to an RNA hairpin (U1hpII) in the U1 small nuclear RNA. In this complex, the beta(2)-beta(3) loop protrudes through the 10-nucleotide RNA loop. Shortening of the RNA loop strongly perturbs binding, suggesting that an optimal "fit" of the beta(2)-beta(3) loop into the RNA loop is an important factor in complexation. To understand this interaction further, we mutated or deleted loop residues Lys(50) and Met(51), which protrude centrally into the RNA loop but do not make any direct contacts to the bases. Using BIACORE, we analyzed the ability of these U1A mutants to bind to wild type RNAs, or RNAs with shortened loops. Alanine replacement mutations only modestly affected binding to wild type U1hpII. Interestingly, simultaneous replacement of Lys(50) and Met(51) with alanine appeared to alleviate the loss of binding caused by shortening of the RNA loop. Deletion of Lys(50) or Met(51) caused a dramatic loss in stability of the U1A(.)U1hpII complex. However, deletion of both residues simultaneously was much less deleterious. Simulated annealing molecular dynamics analyses suggest this is due to the ability of this mutant to rearrange flanking amino acids to substitute for the two deleted residues. The double deletion mutant also exhibited substantially reduced negative effects of RNA loop shortening, suggesting the rearranged loop is better able to accommodate a short RNA loop. Our results indicate that one of the roles of the beta(2)-beta(3) loop is to provide a steric fit into the RNA loop, thereby stabilizing the RNA-protein complex.	Univ So Calif, Dept Surg Biochem & Mol Biol, Norris Canc Ctr, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA; Univ Utah, Sch Med, Ctr Biomol Interact Anal, Salt Lake City, UT 84132 USA	University of Southern California; University of Southern California; Utah System of Higher Education; University of Utah	Laird-Offringa, IA (corresponding author), Univ So Calif, Dept Surg Biochem & Mol Biol, Norris Canc Ctr, Keck Sch Med, MC 9176,Rm NOR 6420,1441 Eastlake Ave, Los Angeles, CA 90089 USA.		Offringa, Ite/R-4101-2019	Katsamba, Phinikoula/0000-0003-3981-1604				Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; Blakaj DM, 2001, J AM CHEM SOC, V123, P2548, DOI 10.1021/ja005538j; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P4611, DOI 10.1093/nar/19.17.4611; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; De Guzman RN, 1998, BIOPOLYMERS, V48, P181, DOI 10.1002/(SICI)1097-0282(1998)48:2<181::AID-BIP7>3.0.CO;2-L; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ginisty H, 2001, J BIOL CHEM, V276, P14338, DOI 10.1074/jbc.M011120200; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Ito T, 1999, EMBO J, V18, P4523, DOI 10.1093/emboj/18.16.4523; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; Katsamba PS, 2001, J BIOL CHEM, V276, P21476, DOI 10.1074/jbc.M101624200; Kranz JK, 1996, PROTEIN SCI, V5, P1567, DOI 10.1002/pro.5560050812; Kranz JK, 1999, J MOL BIOL, V285, P215, DOI 10.1006/jmbi.1998.2296; Kranz JK, 1998, J MOL BIOL, V275, P465, DOI 10.1006/jmbi.1997.1441; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; Luchansky SJ, 2000, J AM CHEM SOC, V122, P7130, DOI 10.1021/ja000837u; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; Mayeda A, 1998, RNA, V4, P1111, DOI 10.1017/S135583829898089X; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Myszka DG, 1998, BIOPHYS J, V75, P583, DOI 10.1016/S0006-3495(98)77549-6; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nolan SJ, 1999, J AM CHEM SOC, V121, P8951, DOI 10.1021/ja991617n; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; PEARLMAN DA, 1991, AMBER4 0; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; Shiels JC, 2002, NUCLEIC ACIDS RES, V30, P550, DOI 10.1093/nar/30.2.550; STUMP WT, 1995, RNA, V1, P55; Tang Y, 1999, BIOPHYS J, V77, P1284, DOI 10.1016/S0006-3495(99)76979-1; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Williams DJ, 1996, J MOL BIOL, V257, P265	42	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33267	33274		10.1074/jbc.M200304200	http://dx.doi.org/10.1074/jbc.M200304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082087	hybrid			2022-12-25	WOS:000177859000112
J	Baccon, J; Pellizzoni, L; Rappsilber, J; Mann, M; Dreyfuss, G				Baccon, J; Pellizzoni, L; Rappsilber, J; Mann, M; Dreyfuss, G			Identification and characterization of Gemin7, a novel component of the survival of motor neuron complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; DISEASE GENE-PRODUCT; SPLICEOSOMAL SM PROTEINS; POLYACRYLAMIDE GELS; SNRNP BIOGENESIS; COILED BODIES; 20S COMPLEX; U-SNRNP; GEMS; INTERACTS	The survival of motor neurons (SMN) protein is the product of the gene mutated or deleted in the neurodegenerative disease, spinal muscular atrophy. SMN is part of a large macromolecular complex that also contains Gemin2, Gemin3, Gemin4, Gemin5, and Gemin6. The SMN complex functions in the assembly of spliceosomal small nuclear ribonucleoproteins and probably other ribonucleoprotein particles. We have identified a novel protein component of the SMN complex termed Gemin7 using native purified SMN complexes and peptide sequencing by mass spectrometry. Coimmunoprecipitation and immunolocalization experiments demonstrate that Gemin7 is a component of the SMN complex and colocalizes with SMN in the cytoplasm and in gems. Binding experiments show that Gemin7 interacts directly with SMN and Gemin6 and mediates the association of Gemin6 with the SMN complex. The amino acid sequence of Gemin7 does not contain any recognizable motifs with the exception of several arginine and glycine repeats that are necessary for its interaction with SMN. Moreover, Gemin7 interacts with several Sm proteins of spliceosomal small nuclear ribonucleoproteins, in particular, with SmE. With the identification of Gemin7, the inventory of the core components of the SMN complex appears essentially complete.	Univ Penn, Howard Hughes Med Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Sch Med, Philadelphia, PA 19104 USA; Univ So Denmark, Prot Interact Lab, Ctr Expt Bioinformat, DK-5230 Odense, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Southern Denmark; University of Southern Denmark	Dreyfuss, G (corresponding author), Univ Penn, Howard Hughes Med Inst, Sch Med, Philadelphia, PA 19104 USA.		Mann, Matthias/A-3454-2013; Rappsilber, Juri/ABF-3328-2020; Dreyfuss, Gideon/D-1218-2013; Rappsilber, Juri/B-7265-2015	Mann, Matthias/0000-0003-1292-4799; Dreyfuss, Gideon/0000-0001-8129-8774; Rappsilber, Juri/0000-0001-5999-1310; Pellizzoni, Livio/0000-0002-9168-5628				ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401; Jones KW, 2001, J BIOL CHEM, V276, P38645, DOI 10.1074/jbc.M106161200; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Matera AG, 1998, AM J HUM GENET, V63, P317, DOI 10.1086/301992; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Miguel-Aliaga I, 2000, FEBS LETT, V486, P99, DOI 10.1016/S0014-5793(00)02243-2; Mourelatos Z, 2001, EMBO J, V20, P5443, DOI 10.1093/emboj/20.19.5443; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; Paushkin S, 2000, J BIOL CHEM, V275, P23841, DOI 10.1074/jbc.M001441200; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Rossoll W, 2002, HUM MOL GENET, V11, P93, DOI 10.1093/hmg/11.1.93; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Wang J, 2001, J BIOL CHEM, V276, P9599, DOI 10.1074/jbc.M009162200; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188; Young PJ, 2002, J BIOL CHEM, V277, P2852, DOI 10.1074/jbc.M108769200; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186	44	88	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31957	31962		10.1074/jbc.M203478200	http://dx.doi.org/10.1074/jbc.M203478200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12065586	hybrid			2022-12-25	WOS:000177718700082
J	Bikker, FJ; Ligtenberg, AJM; Nazmi, K; Veerman, ECI; van't Hof, W; Bolscher, JGM; Poustka, A; Amerongen, AVN; Mollenhauer, J				Bikker, FJ; Ligtenberg, AJM; Nazmi, K; Veerman, ECI; van't Hof, W; Bolscher, JGM; Poustka, A; Amerongen, AVN; Mollenhauer, J			Identification of the bacteria-binding peptide domain on salivary agglutinin (gp-340/DMBT1), a member of the scavenger receptor cysteine-rich superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-D; STREPTOCOCCUS-MUTANS; SRCR SUPERFAMILY; CUB DOMAIN; GLYCOPROTEIN; AGGREGATION; EXPRESSION; ANCIENT; CLONING; ANTIGEN	Salivary agglutinin is encoded by DMBT1 and identical to gp-340, a member of the scavenger receptor cysteine-rich (SRCR) superfamily. Salivary agglutinin/DMBT1 is known for its Streptococcus mutans agglutinating properties. This 300-400 kDa glycoprotein is composed of conserved peptide motifs: 14 SRCR domains that are separated by SRCR-interspersed domains (SIDs), 2 CUB (C1r/C1s Uegf Bmp1) domains, and a zona pellucida domain. We have searched for the peptide domains of agglutinin/DMBT1 responsible for bacteria binding. Digestion with endoproteinase Lys-C resulted in a protein fragment containing exclusively SRCR and SID domains that binds to S. mutans. To define more closely the S. mutans-binding domain, consensus-based peptides of the SRCR domains and SIDs were designed and synthesized. Only one of the SRCR peptides, designated SRCRP2, and none of the SID peptides bound to S. mutans. Strikingly, this peptide was also able to induce agglutination of S. mutans and a number of other bacteria. The repeated presence of this peptide in the native molecule endows agglutinin/DMBT1 with a general bacterial binding feature with a multivalent character. Moreover, our studies demonstrate for the first time that the polymorphic SRCR domains of salivary agglutinin/DMBT1 mediate ligand interactions.	Acad Ctr Dent Amsterdam, Dept Dent Basic Sci, Sect Oral Biochem, NL-1081 BT Amsterdam, Netherlands; Deutsch Krebsforschungszentrum, Div Mol Genome Anal, D-69120 Heidelberg, Germany	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ)	Bikker, FJ (corresponding author), Free Univ Amsterdam, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	fj.bikker.obc.acta@med.vu.nl	Mollenhauer, Jan/G-4452-2012; Abrams, William R/A-5782-2008; Bikker, Floris/R-1941-2019; Bolscher, Jan/ABF-6102-2021; Bikker, Floris/B-1187-2012	Bikker, Floris/0000-0002-9453-4630; Bolscher, Jan/0000-0001-5669-6164; 				Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; BANK RA, 1988, FEBS LETT, V238, P105, DOI 10.1016/0014-5793(88)80235-7; Bikker FJ, 2002, J DENT RES, V81, P134, DOI 10.1177/154405910208100210; BLEIWEIS AS, 1993, ADHESION COHESION PL, P287; Bolscher JGM, 1999, J DENT RES, V78, P1362, DOI 10.1177/00220345990780071101; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; CORONEL CE, 1992, J BIOL CHEM, V267, P20909; COURTNEY HS, 1991, INFECT IMMUN, V59, P1661, DOI 10.1128/IAI.59.5.1661-1666.1991; CROWLEY PJ, 1993, INFECT IMMUN, V61, P1547, DOI 10.1128/IAI.61.4.1547-1552.1993; DEMUTH DR, 1990, J BIOL CHEM, V265, P7120; DEMUTH DR, 1990, MICROB PATHOGENESIS, V9, P199, DOI 10.1016/0882-4010(90)90022-I; DESOET JJ, 1990, J CLIN MICROBIOL, V28, P2467, DOI 10.1128/JCM.28.11.2467-2472.1990; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ERICKSON PR, 1993, J BIOL CHEM, V268, P1646; ERICSON T, 1983, EUR J BIOCHEM, V133, P255, DOI 10.1111/j.1432-1033.1983.tb07456.x; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Gough PJ, 2000, MICROBES INFECT, V2, P305, DOI 10.1016/S1286-4579(00)00297-5; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Holmskov UL, 2000, APMIS, V108, P7; Kraal G, 2000, MICROBES INFECT, V2, P313, DOI 10.1016/S1286-4579(00)00296-3; Ligtenberg AJM, 2000, ANTON LEEUW INT J G, V77, P21, DOI 10.1023/A:1002054810170; Ligtenberg TJM, 2001, BIOCHEM J, V359, P243, DOI 10.1042/0264-6021:3590243; McAlister MSB, 1998, EUR J BIOCHEM, V257, P131, DOI 10.1046/j.1432-1327.1998.2570131.x; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 2001, CANCER RES, V61, P8880; Mollenhauer J, 2000, CANCER RES, V60, P1704; MOLLENHAUER J, 2002, IN PRESS GENES CHROM; Nagle GT, 2001, EUR J BIOCHEM, V268, P1213, DOI 10.1046/j.1432-1327.2001.01972.x; Oho T, 1998, INFECT IMMUN, V66, P115, DOI 10.1128/IAI.66.1.115-121.1998; Prakobphol A, 2000, J BIOL CHEM, V275, P39860, DOI 10.1074/jbc.M006928200; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; RUNDEGREN J, 1981, J ORAL PATHOL MED, V10, P269, DOI 10.1111/j.1600-0714.1981.tb01273.x; Sinowatz F, 2001, CELLS TISSUES ORGANS, V168, P24, DOI 10.1159/000016803; Stenudd C, 2001, J DENT RES, V80, P2005, DOI 10.1177/00220345010800111101; Tino MJ, 1999, AM J RESP CELL MOL, V20, P759, DOI 10.1165/ajrcmb.20.4.3439; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9	40	120	124	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32109	32115		10.1074/jbc.M203788200	http://dx.doi.org/10.1074/jbc.M203788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12050164	hybrid			2022-12-25	WOS:000177718700101
J	Clark, RA; Li, SL; Pearson, DW; Leidal, KG; Clark, JR; Denning, GM; Reddick, R; Krause, KH; Valente, AJ				Clark, RA; Li, SL; Pearson, DW; Leidal, KG; Clark, JR; Denning, GM; Reddick, R; Krause, KH; Valente, AJ			Regulation of calreticulin expression during induction of differentiation in human myeloid cells - Evidence for remodeling of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; RESPIRATORY BURST OXIDASE; CALCIUM-PUMP ISOFORMS; HEAT-SHOCK; CA2+ STORE; INTRACELLULAR-DISTRIBUTION; TRANSCRIPTIONAL REGULATION; FUNCTIONAL EXPRESSION; MOLECULAR CHAPERONE; CARDIAC DEVELOPMENT	Induction of differentiation of HL-60 human myeloid cells profoundly affected expression of calreticulin, a Ca2+-binding endoplasmic reticulum chaperone. Induction with Me2SO or retinoic acid reduced levels of calreticulin protein by similar to60% within 4 days. Pulse-chase studies indicated that labeled calreticulin decayed at similar rates in differentiated and undifferentiated cells (t(1/2) similar to4.6 days), but the biosynthetic rate was <10% of control after 4 days. Differentiation also induced a rapid decline in calreticulin mRNA levels (90% reduction after 1 day) without a decrease in transcript stability (t(1/2) similar to5 h). Nuclear run-on analysis demonstrated rapid down-regulation of gene transcription (21% of control at 2 h). Differentiation also greatly reduced the Ca2+ content of the cells (25% of control), although residual Ca2+ pools remained sensitive to thapsigargin, ionomycin, and inositol trisphosphate. Progressive decreases were also observed in levels of calnexin and ERp57, whereas BiP/GRP78 and protein disulfide isomerase were only modestly affected. Ultrastructural studies showed a substantial reduction in endoplasmic reticulum content of the cells. Thus, terminal differentiation of myeloid cells was associated with decreased endoplasmic reticulum content, selective reductions in molecular chaperones, and diminished intracellular Ca2+ stores, perhaps reflecting an endoplasmic reticulum remodeling program as a prominent feature of granulocytic differentiation.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Dept Pathol, San Antonio, TX 78229 USA; Iowa City Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA; Univ Geneva, Dept Med, CH-1225 Geneva, Switzerland	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Geneva	Clark, RA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	clarkra@uthscsa.edu	Clark, Robert/Q-6764-2019; Denning, Gerene M/D-1077-2009; Krause, Karl-Heinz/E-8030-2011	Clark, Robert/0000-0002-4892-3619; Krause, Karl-Heinz/0000-0002-9033-6768				BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1995, BIOCHEM BIOPH RES CO, V209, P310, DOI 10.1006/bbrc.1995.1504; BAKSH S, 1996, CALRETICULIN, P11; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Borisjuk N, 1998, PLANTA, V206, P504, DOI 10.1007/s004250050427; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; BURNS K, 1992, J BIOL CHEM, V267, P19039; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; CONWAY EM, 1995, J BIOL CHEM, V270, P17011, DOI 10.1074/jbc.270.28.17011; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Denning GM, 1997, BLOOD, V90, P372; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; ENYEDI P, 1993, CELL CALCIUM, V14, P485, DOI 10.1016/0143-4160(93)90007-S; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; Guo L, 2001, J BIOL CHEM, V276, P2797, DOI 10.1074/jbc.C000822200; GUPTA JW, 1992, CANCER RES, V52, P2530; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Johnson RJ, 1998, MOL BRAIN RES, V53, P104, DOI 10.1016/S0169-328X(97)00284-2; KHALIFE J, 1995, PARASITOLOGY, V111, P469, DOI 10.1017/S0031182000065975; Kishore U, 1997, BIOCHEM J, V322, P543, DOI 10.1042/bj3220543; Kovacs H, 1998, BIOCHEMISTRY-US, V37, P17865, DOI 10.1021/bi973197p; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; LIU NG, 1994, J BIOL CHEM, V269, P28635; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Nguyen TQ, 1996, MOL IMMUNOL, V33, P379, DOI 10.1016/0161-5890(95)00149-2; Nunez MT, 2001, J CELL BIOCHEM, V82, P660, DOI 10.1002/jcb.1194; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; PAPP B, 1993, CELL CALCIUM, V14, P531, DOI 10.1016/0143-4160(93)90074-G; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; RAMSAMOOJ P, 1995, CANCER RES, V55, P3016; Rubinstein AL, 2000, GENESIS, V26, P86, DOI 10.1002/(SICI)1526-968X(200001)26:1<86::AID-GENE11>3.0.CO;2-Q; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; Szewczenko-Pawlikowski M, 1997, MOL CELL BIOCHEM, V177, P145, DOI 10.1023/A:1006874019070; Tharin S, 1996, J CELL PHYSIOL, V166, P547, DOI 10.1002/(SICI)1097-4652(199603)166:3<547::AID-JCP9>3.0.CO;2-P; TUCKER KA, 1987, BLOOD, V70, P372; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Xu W, 2000, J BIOL CHEM, V275, P36676, DOI 10.1074/jbc.M002041200; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; Yamamoto S, 1996, J EXP ZOOL, V275, P431; Zhu N, 1998, ENDOCRINOLOGY, V139, P4337, DOI 10.1210/en.139.10.4337	65	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32369	32378		10.1074/jbc.M205269200	http://dx.doi.org/10.1074/jbc.M205269200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12065601	hybrid			2022-12-25	WOS:000177718700133
J	Garton, NJ; Gilleron, M; Brando, T; Dan, HH; Giguere, S; Puzo, G; Prescott, JF; Sutcliffe, IC				Garton, NJ; Gilleron, M; Brando, T; Dan, HH; Giguere, S; Puzo, G; Prescott, JF; Sutcliffe, IC			A novel lipoarabinomannan from the equine pathogen Rhodococcus equi - Structure and effect on marcophage cytokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-BOVIS BCG; MYO-INOSITOL ANCHOR; MANNOSE-BINDING PROTEIN; MASS-SPECTROMETRY; HUMAN MACROPHAGES; NMR-SPECTROSCOPY; BIOCHEMICAL-CHARACTERIZATION; MULTIACYLATED FORMS; LIPOTEICHOIC ACIDS; MAMMALIAN-CELLS	Rhodococcus equi is a major cause of foal morbidity and mortality. We have investigated the presence of lipoglycan in this organism as closely related bacteria, notably Mycobacterium tuberculosis, produce lipoarabinomannans (LAM) that may play multiple roles as virulence determinants. The lipoglycan was structurally characterized by gas chromatography-mass spectrometry following permethylation, capillary electrophoresis after chemical degradation, and H-1 and P-31 and two-dimensional heteronuclear nuclear magnetic resonance studies. Key structural features of the lipoglycan are a linear alpha-1,6-mannan with side chains containing one 2-linked alpha-D-Manp residue. This polysaccharidic backbone is linked to a phosphatidylinositol mannosyl anchor. In contrast to mycobacterial LAM, there are no extensive arabinan domains but single terminal alpha-D-Araf residue capping the 2-linked alpha-D-Manp. The lipoglycan binds concanavalin A and mannose-binding protein consistent with the presence of t-alpha-D-Manp residues. We studied the ability of the lipoglycans to induce cytokines from equine macrophages, in comparison to whole cells of R. equi. These data revealed patterns of cytokine mRNA induction that suggest that the lipoglycan is involved in much of the early macrophage cytokine response to R. equi infection. These studies identify a novel LAM variant that may contribute to the pathogenesis of disease caused by R. equi.	Univ Sunderland, Inst Pharm Chem & Biomed Sci, Sunderland SR2 3SD, England; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France; Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; Univ Florida, Coll Vet Med, Gainesville, FL 32610 USA	University of Sunderland; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Guelph; State University System of Florida; University of Florida	Sutcliffe, IC (corresponding author), Univ Sunderland, Inst Pharm Chem & Biomed Sci, Sunderland SR2 3SD, England.		Sutcliffe, Iain C./A-5354-2009	Sutcliffe, Iain C./0000-0002-9036-2683; GILLERON, Martine/0000-0002-2581-3302	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025147] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-25147] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSAF NA, 1993, BIOTECHNIQUES, V15, P1010; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469, DOI 10.1128/IAI.67.2.469-477.1999; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BEACHEY EH, 1979, INFECT IMMUN, V23, P618, DOI 10.1128/IAI.23.3.618-625.1979; BOX A, 1986, J AM CHEM SOC, V108, P2093; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CHUN J, 1996, J IND MICROBIOL, V16, P1; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; Darrah PA, 2000, INFECT IMMUN, V68, P3587, DOI 10.1128/IAI.68.6.3587-3593.2000; DELL A, 1994, METHOD ENZYMOL, V230, P108; Delmas C, 1997, GLYCOBIOLOGY, V7, P811, DOI 10.1093/glycob/7.6.811; Ferguson JS, 1999, J IMMUNOL, V163, P312; Flaherty C, 1996, ZBL BAKT-INT J MED M, V285, P11, DOI 10.1016/S0934-8840(96)80017-X; Flaherty C, 1999, SYST APPL MICROBIOL, V22, P530, DOI 10.1016/S0723-2020(99)80005-8; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; GAYLORD H, 1987, INFECT IMMUN, V55, P2860, DOI 10.1128/IAI.55.11.2860-2863.1987; Giguere S, 1998, INFECT IMMUN, V66, P1848; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 1997, J BIOL CHEM, V272, P117; Guttman A, 1996, ANAL BIOCHEM, V233, P234, DOI 10.1006/abio.1996.0034; Hetland G, 1998, CLIN DIAGN LAB IMMUN, V5, P211, DOI 10.1128/CDLI.5.2.211-218.1998; Hobo S, 1999, AM J VET RES, V60, P169; Hobo S, 1999, AM J VET RES, V60, P368; HONDALUS MK, 1993, INFECT IMMUN, V61, P2919, DOI 10.1128/IAI.61.7.2919-2929.1993; Hoppe HC, 1997, INFECT IMMUN, V65, P3896, DOI 10.1128/IAI.65.9.3896-3905.1997; IKEDAFUJITA T, 1987, MICROBIOL IMMUNOL, V31, P289, DOI 10.1111/j.1348-0421.1987.tb03091.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; Leutenegger CM, 1999, VET IMMUNOL IMMUNOP, V71, P291, DOI 10.1016/S0165-2427(99)00100-2; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Matsushita M, 1996, MICROBIOL IMMUNOL, V40, P887, DOI 10.1111/j.1348-0421.1996.tb01156.x; Monsarrat B, 1999, GLYCOBIOLOGY, V9, P335, DOI 10.1093/glycob/9.4.335; Mosser DM, 1996, TRENDS MICROBIOL, V4, P29, DOI 10.1016/0966-842X(96)81502-2; Nigou J, 1999, GLYCOCONJUGATE J, V16, P257, DOI 10.1023/A:1007046609341; Nigou J, 2000, J MOL BIOL, V299, P1353, DOI 10.1006/jmbi.2000.3821; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; Polotsky VY, 1996, INFECT IMMUN, V64, P380, DOI 10.1128/IAI.64.1.380-383.1996; Polotsky VY, 1997, J INFECT DIS, V175, P1159, DOI 10.1086/520354; PRESCOTT JF, 1991, CLIN MICROBIOL REV, V4, P20, DOI 10.1128/CMR.4.1.20-34.1991; SADDLER GS, 1991, J MICROBIOL METH, V14, P185, DOI 10.1016/0167-7012(91)90022-I; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0; SUTCLIFFE IC, 1994, SYST APPL MICROBIOL, V17, P321, DOI 10.1016/S0723-2020(11)80047-0; Sutcliffe IC, 1995, ARCH ORAL BIOL, V40, P1119, DOI 10.1016/0003-9969(95)00086-0; Sutcliffe IC, 2000, ANTON LEEUW INT J G, V78, P195, DOI 10.1023/A:1026562610490; Takai S, 1997, VET MICROBIOL, V56, P167, DOI 10.1016/S0378-1135(97)00085-0; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VENISSE A, 1993, J BIOL CHEM, V268, P12401; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012	62	80	84	13	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31722	31733		10.1074/jbc.M203008200	http://dx.doi.org/10.1074/jbc.M203008200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12072437	hybrid, Green Submitted			2022-12-25	WOS:000177718700053
J	Gugliucci, A; Ranzato, L; Scorrano, L; Colonna, R; Petronilli, V; Cusan, C; Prato, M; Mancini, M; Pagano, F; Bernardi, P				Gugliucci, A; Ranzato, L; Scorrano, L; Colonna, R; Petronilli, V; Cusan, C; Prato, M; Mancini, M; Pagano, F; Bernardi, P			Mitochondria are direct targets of the lipoxygenase inhibitor MK886 - A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PERMEABILITY TRANSITION PORE; 5-LIPOXYGENASE-ACTIVATING PROTEIN FLAP; ARACHIDONIC-ACID; CYTOCHROME-C; CYCLOSPORINE-A; PROSTATE-CANCER; FACTOR-ALPHA; CASPASE ACTIVATION; PHOSPHOLIPASE A(2)	We have investigated the mitochondrial and cellular effects of the lipoxygenase inhibitor MK886. Low concentrations (1 mu(M)) of MK886 selectively sensitized the permeability transition pore (PTP) to opening, whereas higher concentrations of MK886 (10 mu(M)) caused depolarization through combination of an ionophoretic effect with inhibition of respiration. MK886 killed prostate cancer PC3 cells only at the higher, toxic concentration (10 mu(M)), whereas the lower concentration (1 mu(M)) had no major effect on cell survival. However, 1 mu(M) MK886 alone demonstrably induced PTP-dependent mitochondrial dysfunction; and it caused cell death through the mitochondrial pathway when it was used in combination with the cyclooxygenase inhibitor, indomethacin, which had no effects per se. Treatment with 1 mu(M) MK886 plus indomethacin sensitized cells to killing by exogenous arachidonic acid, which induces PTP opening and cytochrome c release (Scorrano, L., Penzo, D., Petronilli, V., Pagano, F., and Bernardi, P. (2001) J. Biol. Chem. 276, 12035-12040). Combination of MK886 and cyclooxygenase inhibitors may represent a viable therapeutic strategy to force cell death through the mitochondrial pathway. This approach should be specifically useful to kill cells possessing a high flux of arachidonic acid and its metabolites like prostate and colon cancer cells.	Univ Padua, Dept Biomed Sci, Nazl Ric Inst Neurosci, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy; Univ Trieste, Dept Pharmaceut Chem, I-34127 Trieste, Italy; Univ Padua, Inst Urol, I-35128 Padua, Italy	University of Padua; Veneto Institute Molecular Medicine; University of Trieste; University of Padua	Bernardi, P (corresponding author), Univ Padua, Dept Biomed Sci, Nazl Ric Inst Neurosci, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.		Petronilli, Valeria/C-3558-2015; Bernardi, Paolo/C-3656-2008; Mancini, Mariangela/AAR-2090-2020; /GLU-4312-2022; Prato, Maurizio/G-7067-2012; Scorrano, Luca/A-6652-2008; Scorrano, Luca/K-3967-2019	Petronilli, Valeria/0000-0003-4026-6404; Bernardi, Paolo/0000-0001-9187-3736; Mancini, Mariangela/0000-0001-6766-8767; Prato, Maurizio/0000-0002-8869-8612; Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928				Anderson KM, 1996, ANTICANCER RES, V16, P2589; Anderson KM, 1995, LEUKEMIA RES, V19, P789, DOI 10.1016/0145-2126(95)00043-7; Anderson KM, 1998, PROSTATE, V37, P161, DOI 10.1002/(SICI)1097-0045(19981101)37:3<161::AID-PROS5>3.0.CO;2-D; ARA G, 1996, FATTY ACIDS, V54, P3; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chang HC, 2001, ONCOL REP, V8, P1321; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Datta K, 1999, BIOCHEM J, V340, P371, DOI 10.1042/0264-6021:3400371; Ding XZ, 2000, ANTICANCER RES, V20, P2625; Dittmann KH, 1998, LEUKEMIA RES, V22, P49, DOI 10.1016/S0145-2126(97)00132-X; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GANN PH, 1994, J NATL CANCER I, V86, P281, DOI 10.1093/jnci/86.4.281; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Ghosh J, 1997, BIOCHEM BIOPH RES CO, V235, P418, DOI 10.1006/bbrc.1997.6799; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Ikawa H, 1999, CANCER RES, V59, P360; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li M, 2001, CLIN CANCER RES, V7, P1010; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Liu XH, 1998, CANCER RES, V58, P4245; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Maccarrone M, 2001, CELL DEATH DIFFER, V8, P776, DOI 10.1038/sj.cdd.4400908; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; REID T, 1991, J BIOL CHEM, V266, P16580; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VICKERS PJ, 1995, J LIPID MEDIAT CELL, V12, P185, DOI 10.1016/0929-7855(95)00018-L; WENZEL DG, 1978, TOXICOLOGY, V11, P119, DOI 10.1016/S0300-483X(78)90839-9; Wieckowski MR, 2001, FEBS LETT, V505, P453, DOI 10.1016/S0014-5793(01)02858-7; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	61	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31789	31795		10.1074/jbc.M204450200	http://dx.doi.org/10.1074/jbc.M204450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080072	hybrid			2022-12-25	WOS:000177718700061
J	Segat, D; Comai, R; Di Marco, E; Strangio, A; Cancedda, R; Franzi, AT; Tacchetti, C				Segat, D; Comai, R; Di Marco, E; Strangio, A; Cancedda, R; Franzi, AT; Tacchetti, C			Integrins alpha(6A)beta(1) and alpha(6B)beta(1) promote different stages of chondrogenic cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CHONDROCYTE DIFFERENTIATION; EXTRACELLULAR-MATRIX; LIMB CHONDROGENESIS; LAMININ RECEPTOR; ALPHA-6 INTEGRIN; CHICK-EMBRYO; REGULATES CHONDROGENESIS; HYPERTROPHIC CARTILAGE; SIGNAL-TRANSDUCTION	The differentiation of chondrocytes and of several other cell types is associated with a switch from the alpha(6B) to the alpha(6A) isoform of the laminin alpha(6)beta(1) integrin receptor. To define whether this event plays a functional role in cell differentiation, we used an in vitro model system that allows chick chondrogenic cells to remain undifferentiated when cultured in monolayer and to differentiate into chondrocytes when grown in suspension culture. We report that: (i) upon over-expression of the human alpha(6B), adherentchondrogenic cells differentiate to stage I chondrocytes (i.e. increased type II collagen, reduced type I collagen, fibronectin, alpha(5)beta(1), and growth rate, loss of fibroblast morphology); (ii) the expression of type 11 collagen requires the activation of p38 MAP kinase; (iii) the over-expression of alpha(6A) induces an incomplete differentiation to stage I chondrocytes, whereas no differentiation was observed in alpha(5) and mock-transfected control cells; (iv) a prevalence of the alpha(6A) subunit is necessary to stabilize the differentiated phenotype when cells are transferred to suspension culture. Altogether, these results indicate a functional role for the alpha(6B) to alpha(6A) switch in chondrocyte differentiation; the former promotes chondrocyte differentiation, and the latter is necessary in stabilizing the differentiated phenotype.	Univ Genoa, Dipartimento Med Sperimentale, Sez Anat Umana, I-16100 Genoa, Italy; Univ Genoa, Dipartimento Oncol Biol & Genet, I-16100 Genoa, Italy; Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, Lab Differenziamento Cellular, I-16100 Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; IRCCS AOU San Martino IST	Tacchetti, C (corresponding author), Univ Genoa, Dipartimento Med Sperimentale, Sez Anat Umana, Via Toni,14, I-16100 Genoa, Italy.	carlo.tacchetti@unige.it		TACCHETTI, CARLO/0000-0003-4602-000X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023144] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-2-3144] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; CANCEDDA FD, 1988, J CELL BIOL, V107, P2455, DOI 10.1083/jcb.107.6.2455; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; CASTAGNOLA P, 1986, J CELL BIOL, V102, P2310, DOI 10.1083/jcb.102.6.2310; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CHANG SC, 1994, J BIOL CHEM, V269, P28227; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; Cirulli V, 2000, J CELL BIOL, V150, P1445, DOI 10.1083/jcb.150.6.1445; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DESSAU W, 1980, J EMBRYOL EXP MORPH, V57, P51; Dike LE, 1996, J CELL SCI, V109, P2855; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; Gimond C, 1998, J CELL BIOL, V143, P253, DOI 10.1083/jcb.143.1.253; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HAY ED, 1981, J CELL BIOL, V91, pS205, DOI 10.1083/jcb.91.3.205s; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; JIANG RL, 1995, EXP CELL RES, V217, P195, DOI 10.1006/excr.1995.1079; JIANG TX, 1993, DEV BIOL, V155, P545, DOI 10.1006/dbio.1993.1051; KADOYA Y, 1995, J CELL BIOL, V129, P521, DOI 10.1083/jcb.129.2.521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lin TH, 1997, J BIOL CHEM, V272, P8849; MACIEIRACOELHO A, 1973, TISSUE CULTURE METHO, P412; MACKIE EJ, 1987, J CELL BIOL, V105, P2569, DOI 10.1083/jcb.105.6.2569; MAINI PK, 1991, INT REV CYTOL, V129, P91; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Morini M, 1997, EXP CELL RES, V232, P304, DOI 10.1006/excr.1997.3528; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; SHAW LM, 1995, J BIOL CHEM, V270, P23648, DOI 10.1074/jbc.270.40.23648; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; SOLURSH M, 1980, DEV BIOL, V78, P141, DOI 10.1016/0012-1606(80)90324-3; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; SWALLA BJ, 1984, DIFFERENTIATION, V26, P42, DOI 10.1111/j.1432-0436.1984.tb01371.x; TACCHETTI C, 1989, DEV BIOL, V132, P442, DOI 10.1016/0012-1606(89)90240-6; TACCHETTI C, 1992, EUR J CELL BIOL, V57, P236; TACCHETTI C, 1987, J CELL BIOL, V105, P999, DOI 10.1083/jcb.105.2.999; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; Tavella S, 1997, J CELL SCI, V110, P2261; TAVELLA S, 1994, EXP CELL RES, V215, P354, DOI 10.1006/excr.1994.1352; Walker JL, 1999, DEV BIOL, V210, P497, DOI 10.1006/dbio.1999.9277; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115; ZHEN X, 2000, J BIOL CHEM, V29, P29; Zhu XY, 2000, J BIOL CHEM, V275, P6703, DOI 10.1074/jbc.275.10.6703	69	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31612	31622		10.1074/jbc.M203471200	http://dx.doi.org/10.1074/jbc.M203471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077132	hybrid			2022-12-25	WOS:000177718700041
J	Tian, GC; Sobotka-Briner, CD; Zysk, J; Liu, XD; Birr, C; Sylvester, MA; Edwards, PD; Scott, CD; Greenberg, BD				Tian, GC; Sobotka-Briner, CD; Zysk, J; Liu, XD; Birr, C; Sylvester, MA; Edwards, PD; Scott, CD; Greenberg, BD			Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin a methylester, L685458, sulfonamides, and benzodiazepines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ASPARTYL PROTEASE; ALZHEIMERS-DISEASE; PRESENILIN-1; CLEAVAGE; STATE; ENDOPROTEOLYSIS; SUBSTRATE; PEPTIDES	Cerebral deposition of amyloid beta-protein (abeta) is believed to play a key role in the pathogenesis of Alzheimer's disease. Because Abeta is produced from the processing of amyloid beta-protein precursor (APP) by beta- and gamma-secretases, these enzymes are considered important therapeutic targets for identification of drugs to treat Alzheimer's disease. Unlike beta-secretase, which is a monomeric aspartyl protease, gamma-secretase activity resides as part of a membrane-bound, high molecular weight, macromolecular complex. Pepstatin and L685458 are among several structural classes of gamma-secretase inhibitors identified so far. These compounds possess a hydroxyethylene dipeptide isostere of aspartyl protease transition state analogs, suggesting gamma-secretase may be an aspartyl protease. However, the mechanism of inhibition of gamma-secretase by pepstatin and L685458 has not been elucidated. In this study, we report that pepstatin A methylester and L685458 unexpectedly displayed linear non-competitive inhibition of gamma-secretase. Sulfonamides and benzodiazepines, which do not resemble transition state analogs of aspartyl proteases, also displayed potent, non-competitive inhibition of gamma-secretase. Models to rationalize how transition state analogs inhibit their targets by non-competitive inhibition are discussed.	AstraZeneca Pharmaceut, Dept Lead Discovery, Wilmington, DE 19850 USA; AstraZeneca Pharmaceut, Dept Mol Sci, Wilmington, DE 19850 USA; AstraZeneca Pharmaceut, Dept Chem, Wilmington, DE 19850 USA; AstraZeneca Phamaceut, Dept Enabling Sci & Technol Biol, Waltham, MA 02451 USA	AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca	Tian, GC (corresponding author), AstraZeneca Pharmaceut, Dept Lead Discovery, Wilmington, DE 19850 USA.							ASKIN D, 1992, J ORG CHEM, V57, P2771, DOI 10.1021/jo00036a004; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; EVANS BE, 1985, J ORG CHEM, V50, P4615, DOI 10.1021/jo00223a037; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; McWilliams JC, 1996, J AM CHEM SOC, V118, P11970, DOI 10.1021/ja962123i; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Plowman K. M., 1972, ENZYME KINETICS; Segel I.H., 1975, ENZYME KINETICS; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SMITH DW, 2001, Patent No. 0050391; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WU J, 1998, Patent No. 9828268; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	33	129	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31499	31505		10.1074/jbc.M112328200	http://dx.doi.org/10.1074/jbc.M112328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12072428	hybrid			2022-12-25	WOS:000177718700028
J	Tickenbrock, L; Cramer, J; Vetter, IR; Muller, O				Tickenbrock, L; Cramer, J; Vetter, IR; Muller, O			The coiled coil region (Amino acids 129-250) of the tumor suppressor protein adenomatous polyposis coli (APC) - Its structure and its interaction with chromosome maintenance region 1 (Crm-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; KAPPA-B-ALPHA; BETA-CATENIN; SUBCELLULAR-LOCALIZATION; FUNCTIONAL INTERACTION; SECONDARY STRUCTURE; GERMLINE MUTATIONS; DOWN-REGULATION; TRANSCRIPTION; GSK3-BETA	The APC (adenomatous polyposis coli) tumor suppressor protein has many different intracellular functions including a nuclear export activity. Only little is known about the molecular architecture of the 2843-amino acid APC protein. Guided by secondary structure predictions we identified a fragment close to the N-terminal end, termed APC-(129-250), as a soluble and protease-resistant domain. We solved the crystal structure of APC-(129-250), which is monomeric and consists of three alpha-helices forming two separate antiparallel coiled coils. APC-(129-250) includes the nuclear export signal NES-(165-174) at the C-terminal end of the first helix. Surprisingly, the conserved hydrophobic amino acids of NES-(165-174) are buried in one of the coiled coils and are thus not accessible for interaction with other proteins. We demonstrate the direct interaction of APC(129-250) with the nuclear export factor chromosome maintenance region 1 (Crm-1). This interaction is enhanced by the small GTPase Ran in its activated GTP-bound form and also by a double mutation in APC-(129250), which deletes two amino acids forming two of the major interhelical interactions within the coiled coil. These observations hint to a regulatory mechanism of the APC nuclear export activity by NES masking.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Max Planck Society	Muller, O (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.							Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Day CL, 2000, J MOL BIOL, V301, P147, DOI 10.1006/jmbi.2000.3895; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hirschl D, 1996, FEBS LETT, V383, P31, DOI 10.1016/0014-5793(96)00215-3; Holm L, 1998, PROTEINS, V33, P88, DOI 10.1002/(SICI)1097-0134(19981001)33:1<88::AID-PROT8>3.0.CO;2-H; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kohler M, 1999, EXP NEPHROL, V7, P290; Lee SH, 2001, J BIOL CHEM, V276, P23599, DOI 10.1074/jbc.M011197200; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2000, EMBO REP, V1, P519; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; OSSAREHNAZARI, 1997, SCIENCE, V278, P141; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sharma VA, 1998, CURR BIOL, V8, P823, DOI 10.1016/S0960-9822(98)70324-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; vanderLuijt RB, 1997, HUM MUTAT, V9, P7, DOI 10.1002/(SICI)1098-1004(1997)9:1<7::AID-HUMU2>3.0.CO;2-8; Walon C, 1997, HUM GENET, V100, P601, DOI 10.1007/s004390050560; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	44	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32332	32338		10.1074/jbc.M203990200	http://dx.doi.org/10.1074/jbc.M203990200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070164	hybrid			2022-12-25	WOS:000177718700128
J	Wu, WS; Xu, ZX; Chang, KS				Wu, WS; Xu, ZX; Chang, KS			The promyelocytic leukemia protein represses A20-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SUPPRESSES GROWTH; RAR-ALPHA; PML; A20; EXPRESSION; CELLS; TUMORIGENICITY; ACTIVATION; APOPTOSIS	The promyelocytic leukemia (PML) protein is a tumor suppressor that is disrupted by the chromosomal translocation t(15;17), a consistent cytogenetic feature of acute promyelocytic leukemia. A role of PML in multiple pathways of apoptosis was conclusively demonstrated using PML-/- animal and cell culture models. In a previous study, we found that PML sensitizes tumor necrosis factor-induced apoptosis in tumor necrosis factor (TNF)-resistant U2OS cells. This finding helped to explain the mechanism of PNL-induced apoptosis. The zinc finger protein A20 is a target gene of NFkappaB inducible by TNFalpha, and it is a potent inhibitor of TNF-induced apoptosis. In the this study, we demonstrated that PML is a transcriptional repressor of the A20 promoter and that PML represses A20 expression induced by TNFa. We showed that PML inhibits A20 transactivation through the NFkappaB site by interfering with its binding to the promoter. We also showed that stable overexpression of A20 inhibits apoptosis and caspase activation induced by PML/TNFalpha. The results of this study suggest that A20 is a downstream target of PML-induced apoptosis and supports a role of A20 in modulating cell death induced by PML/TNFalpha in TNF-resistant cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chang, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77030 USA.	kchang@mail.mdanderson.org	Wu, Wen-Shu/I-1258-2014	Wu, Wen-Shu/0000-0002-0225-2522	NCI NIH HHS [CA-16672, CA55577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055577, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; He DL, 1997, CANCER RES, V57, P1868; HUFFEL V, 2001, J BIOL CHEM, V276, P30216; Jaattela M, 1996, J IMMUNOL, V156, P1166; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rahman A, 1999, J IMMUNOL, V162, P5466; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stadler M, 1995, ONCOGENE, V11, P2565; TERRIS B, 1995, CANCER RES, V55, P1590; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VALLIAN S, 1998, ONCOGENE, V90, P3265; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	44	20	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31734	31739		10.1074/jbc.M201648200	http://dx.doi.org/10.1074/jbc.M201648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080044	hybrid			2022-12-25	WOS:000177718700054
J	Yan, ZJ; Kim, YS; Jetten, AM				Yan, ZJ; Kim, YS; Jetten, AM			RAP80, a novel nuclear protein that interacts with the retinoid-related testis-associated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; ORPHAN RECEPTOR; HORMONE RECEPTORS; RESPONSE ELEMENT; XENOPUS-LAEVIS; CLONING; SUPERFAMILY; EXPRESSION; REPRESSOR; GENE	In this study, we describe the characterization of a novel nuclear protein, referred to as RAP80. The RAP80 cDNA was cloned from a human testis cDNA library and encodes a 719-amino acid protein containing two potential CX2CX11HX3C-type zinc finger motifs at its carboxyl-terminal region. Analysis of its genomic structure revealed that the RAP80 gene covers more than 90 kb and consists of 15 exons and 14 introns. Fluorescence in situ hybridization mapped the RAP80 gene to human chromosome 5q35. RAP80 mRNA is expressed in many human tissues, but its expression is particularly high in testis. In situ hybridization showed that RAP80 is highly expressed in germ cells of mouse testis but is not differentially regulated during spermatogenesis. Confocal microscopy showed that RAP80 is localized to the nucleus, where it is distributed in a speckled pattern. Deletion analysis showed that a bipartite nuclear localization signal at the amino terminus is important in mediating nuclear transport of RAP80. Monohybrid analysis showed that RAP80 might function as an active repressor of transcription. Mammalian two-hybrid analysis demonstrated that RAP80 was able to interact with the retinoid-related testis-associated receptor (RTR), an orphan receptor that has been implicated in the control of embryonic development and spermatogenesis. Pull-down analysis showed that RAP80 and RTR physically interact in vitro. Deletion and point mutation analyses revealed that part of the hinge domain of RTR is required for this interaction. RAP80 is able to inhibit the interaction of RTR with the co-repressor N-CoR likely by competing with N-CoR for RTR binding. Our results suggest that RAP80 may be functioning as a modulator of RTR signaling.	NIEHS, Cell Biol Sect, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jetten, AM (corresponding author), NIEHS, Cell Biol Sect, Div Intramural Res, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025042, Z01ES101586, ZIAES101586] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agoulnik IY, 1998, FEBS LETT, V424, P73, DOI 10.1016/S0014-5793(98)00142-2; Berkovits HJ, 1999, BIOCHEMISTRY-US, V38, P16826, DOI 10.1021/bi991433l; Borgmeyer U, 1997, EUR J BIOCHEM, V244, P120, DOI 10.1111/j.1432-1033.1997.00120.x; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Braat AK, 1999, MOL REPROD DEV, V53, P369, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;369::AID-MRD1&gt;3.0.CO;2-U; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; Chung ACK, 2001, MOL CELL BIOL, V21, P663, DOI 10.1128/MCB.21.2.663-677.2001; Cooney AJ, 1998, BIOCHEM BIOPH RES CO, V245, P94, DOI 10.1006/bbrc.1998.8391; David R, 1998, MECH DEVELOP, V79, P137, DOI 10.1016/S0925-4773(98)00181-6; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Glass CK, 2000, GENE DEV, V14, P121; Greschik H, 1998, J MOL MED-JMM, V76, P800, DOI 10.1007/s001090050284; HIROSE T, 1995, GENE, V152, P247, DOI 10.1016/0378-1119(94)00656-D; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; Hummelke GC, 2001, FRONT BIOSCI, V6, pD1186, DOI 10.2741/Hummelke; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; Joos TO, 1996, MECH DEVELOP, V60, P45, DOI 10.1016/S0925-4773(96)00599-0; Kapelle M, 1997, BBA-GENE STRUCT EXPR, V1352, P13, DOI 10.1016/S0167-4781(97)00043-2; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; Lei W, 1997, J MOL ENDOCRINOL, V18, P167, DOI 10.1677/jme.0.0180167; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Mehta DV, 2002, PLACENTA, V23, P281, DOI 10.1053/plac.2001.0779; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; PEREY B, 1961, AM J ANAT, V108, P47, DOI 10.1002/aja.1001080105; Ramboarina S, 1999, BIOCHEMISTRY-US, V38, P9600, DOI 10.1021/bi9905258; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Susens U, 1996, BBA-GENE STRUCT EXPR, V1309, P179, DOI 10.1016/S0167-4781(96)00157-1; Susens U, 1997, DEV NEUROSCI-BASEL, V19, P410, DOI 10.1159/000111238; WILLY PJ, 1998, HORMONES SIGNALING, V1, P308; Yan ZH, 1998, J BIOL CHEM, V273, P10948, DOI 10.1074/jbc.273.18.10948; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yan ZJ, 2000, J BIOL CHEM, V275, P35077, DOI 10.1074/jbc.M005566200; Zhang YL, 1998, MOL REPROD DEV, V50, P93, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;93::AID-MRD12&gt;3.0.CO;2-Z	43	42	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32379	32388		10.1074/jbc.M203475200	http://dx.doi.org/10.1074/jbc.M203475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080054	hybrid			2022-12-25	WOS:000177718700134
J	Jung, D; Fried, M; Kullak-Ublick, GA				Jung, D; Fried, M; Kullak-Ublick, GA			Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE-X RECEPTOR; ACID TRANSPORTER; CHOLESTEROL 7-ALPHA-HYDROXYLASE; TRANSCRIPTION FACTORS; ULCERATIVE-COLITIS; RESPONSE ELEMENT; PPAR-ALPHA; REAL-TIME	The apical sodium-dependent bile salt transporter (ASBT/SLC10A2), also called the ileal bile acid transporter, mediates the intestinal absorption of bile salts. The efficiency of this transport process is a determinant of hepatic bile salt synthesis from cholesterol and of serum triglyceride levels. Our aim was to characterize the human ASBT gene promoter with respect to regulatory mechanisms that coordinately affect ASBT expression and hepatic lipid and bile salt metabolism. The minimal construct that confers full promoter activity contains three functional hepatocyte nuclear factor 1alpha (HNF1alpha) recognition sites, explaining the dependence of ASBT gene expression upon HNF1alpha. A nuclear receptor binding site arranged as a direct hexanucleotide repeat (DR1 motif) is localized similar to1.6 kb upstream of the transcription initiation site. Constructs containing this element were transactivated by WY14643 and ciprofibrate, ligands of the peroxisome proliferator-activated receptor alpha (PPARalpha), in Caco2 cells. The DR1 element was shown to bind the PPARalpha/9-cis-retinoic acid receptor heterodimer, and targeted mutagenesis of the DR1 motif abolished PPARalpha responsiveness. Ciprofibrate treatment of SK-ChA cholangiocytes increased ASBT mRNA levels, suggesting a physiologic role for PPARalpha-mediated ASBT gene regulation. This study identifies PPARalpha as a novel link between ileal bile salt absorption and hepatic lipid metabolism.	Univ Zurich Hosp, Div Gastroenterol & Hepatol, Lab Mol Gastroenterol & Hepatol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Kullak-Ublick, GA (corresponding author), Univ Zurich Hosp, Div Gastroenterol & Hepatol, Lab Mol Gastroenterol & Hepatol, CH-8091 Zurich, Switzerland.							Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; ANGELIN B, 1987, P NATL ACAD SCI USA, V84, P5434, DOI 10.1073/pnas.84.15.5434; ANGELIN B, 1978, J LIPID RES, V19, P1017; Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Bertolotti M, 1995, ITAL J GASTROENTEROL, V27, P446; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; CARULLI N, 1981, J CLIN PHARMACOL, V21, P436, DOI 10.1002/j.1552-4604.1981.tb01746.x; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen F, 2001, J BIOL CHEM, V276, P38703, DOI 10.1074/jbc.M104511200; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DUANE WC, 1995, J LIPID RES, V36, P96; Duane WC, 2000, J LIPID RES, V41, P1384; Gervois P, 1999, MOL ENDOCRINOL, V13, P400, DOI 10.1210/me.13.3.400; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; GRUNDY SM, 1971, J LAB CLIN MED, V78, P94; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Handschin C, 2001, MOL ENDOCRINOL, V15, P1571, DOI 10.1210/me.15.9.1571; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; Hunt MC, 2000, J BIOL CHEM, V275, P28947, DOI 10.1074/jbc.M002782200; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Jung D, 2002, GASTROENTEROLOGY, V122, P1954, DOI 10.1053/gast.2002.33583; Jung D, 2001, J BIOL CHEM, V276, P37206, DOI 10.1074/jbc.M103988200; Kajiura K, 1998, DIGESTION, V59, P69, DOI 10.1159/000007469; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; Lazaridis KN, 1997, J CLIN INVEST, V100, P2714, DOI 10.1172/JCI119816; Love MW, 2001, ARTERIOSCL THROM VAS, V21, P2039, DOI 10.1161/hq1201.100262; Marrapodi M, 2000, J LIPID RES, V41, P514; Nowicki MJ, 1997, AM J PHYSIOL-GASTR L, V273, pG197, DOI 10.1152/ajpgi.1997.273.1.G197; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269; Post SM, 2001, ARTERIOSCL THROM VAS, V21, P1840, DOI 10.1161/hq1101.098228; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; SCHEURLEN C, 1986, DIGESTION, V35, P102, DOI 10.1159/000199353; Schoonjans K, 1996, J LIPID RES, V37, P907; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; Sinal CJ, 2001, J BIOL CHEM, V276, P47154, DOI 10.1074/jbc.M107000200; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Sundaram U, 1998, AM J PHYSIOL-GASTR L, V275, pG1259, DOI 10.1152/ajpgi.1998.275.6.G1259; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Wada K, 2001, TRENDS MOL MED, V7, P329, DOI 10.1016/S1471-4914(01)02076-7; Walker NJ, 2001, J BIOCHEM MOL TOXIC, V15, P121, DOI 10.1002/jbt.8; Wang B, 2001, HEPATOLOGY, V34, P979, DOI 10.1053/jhep.2001.28885; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; WITZTUM JL, 1976, J LAB CLIN MED, V88, P1008; Xu GR, 2000, J LIPID RES, V41, P298; Zaghini I, 2002, J BIOL CHEM, V277, P1324, DOI 10.1074/jbc.M106375200	52	84	87	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30559	30566		10.1074/jbc.M203511200	http://dx.doi.org/10.1074/jbc.M203511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12055195	hybrid			2022-12-25	WOS:000177579800022
J	Yang, Z; Champoux, JJ				Yang, Z; Champoux, JJ			Reconstitution of enzymatic activity by the association of the cap and catalytic domains of human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; MECHANISM; FRAGMENT; SITE; CAMPTOTHECIN; SENSITIVITY; MODEL	When human topoisomerase I binds DNA, two opposing lobes in the enzyme, the cap region (amino acid, residues 175-433) and the catalytic domain (Deltacap, residues 433 to the COOH terminus) clamp tightly around the DNA helix to form the precleavage complex. Although Deltacap contains all of the residues known to be important for catalysis and binds DNA with an affinity similar to that of the intact enzyme, this fragment lacks catalytic activity. However, a mixture of Deltacap and topo31 (residues 175-433) reconstitutes enzymatic activity as measured by plasmid DNA relaxation and suicide cleavage assays. Although the formation of an active complex between topo31 and Deltacap is too unstable to be detected by pull-down experiments even in the presence of DNA, the association of topo31 with Deltacap persists and is detectable after the complex catalyzes the covalent attachment of the DNA to Deltacap by suicide cleavage. Removal of topo3 from Deltacap-DNA after suicide cleavage reveals that, unlike the cleavage reaction, religation does not require the cap region of the protein. These results suggest that activation of the catalytic domain of the enzyme for cleavage requires both DNA binding and the presence of the cap region of the protein.	Univ Washington, Dept Microbiol, Sch Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Dept Microbiol, Sch Med, Box 357242, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 60330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 1998, PROG NUCLEIC ACID RE, V60, P111, DOI 10.1016/S0079-6603(08)60891-0; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fleury F, 1998, BIOCHEMISTRY-US, V37, P14630, DOI 10.1021/bi9806495; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SIMONS DT, 1996, VIROLOGY, V222, P365; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Tirumalai RS, 1997, P NATL ACAD SCI USA, V94, P6104, DOI 10.1073/pnas.94.12.6104; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200	27	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30815	30823		10.1074/jbc.M205302200	http://dx.doi.org/10.1074/jbc.M205302200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12077150	hybrid			2022-12-25	WOS:000177579800054
J	Ren, SX; Cai, HR; Li, ML; Furth, PA				Ren, SX; Cai, HR; Li, ML; Furth, PA			Loss of Stat5a delays mammary cancer progression in a mouse model	ONCOGENE			English	Article						Stat5a; mammary cancer; mouse model; SV40 T antigen, apoptosis	TRANSCRIPTION FACTORS; BREAST-CANCER; GLAND DEVELOPMENT; CELL-SURVIVAL; GROWTH-FACTOR; ACTIVATION; PROLACTIN; EXPRESSION; MICE; SIGNALS	A genetic study was conducted to determine if activated Stat5a contributes to mammary carcinogenesis and to evaluate the mechanism. Similar to human breast cancers, a proportion of mammary adenocarcinomas in the WAP-TAg transgenic mouse model demonstrate constitutive Stat5a/b and Stat3 activation. Stat5a activation is linked to mammary epithelial cell survival and differentiation, and proliferation in hematopoetic cell lineages. Breeding WAP-TAg mice to mice carrying germ-line deletions of the Stat5a gene generated mice with reduced levels of Stat5a. Hemizygous loss of the Stat5a allele significantly reduced levels of Stat5a expression without altering mammary gland development or transgene expression levels. In comparison to mice carrying two wild-type Stat5a alleles, hemizygous loss of the Stat5a allele reduced the number of mice with palpable tumors at 7 months of age (67% from 100%, P<0.05), resulted in smaller tumors at 7 months of age (3.8 cm(3) from 7.6 cm(3), P=0.003), delayed first tumor appearance (208 days from 188 days, P=0.01), and increased the apoptotic index in the adenocarcinomas (4.3+0.3 from 1.2+0.2, P=0.016). Neither cell proliferation nor differentiation in the cancers was altered. Decreasing Stat5a activation levels could be a therapeutic approach for reducing survival of breast cancer cells.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore	Furth, PA (corresponding author), Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Res Bldg,E518,3970 Reservoir Rd NW, Washington, DC 20007 USA.	paf3@georgetown.edu						Berclaz G, 2001, INT J ONCOL, V19, P1155; Birkenkamp KU, 2001, LEUKEMIA, V15, P1923, DOI 10.1038/sj.leu.2402317; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Gallego MI, 2001, DEV BIOL, V229, P163, DOI 10.1006/dbio.2000.9961; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gouilleux-Gruart V, 1997, LEUKEMIA LYMPHOMA, V28, P83, DOI 10.3109/10428199709058334; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Hennighausen L, 1997, J MAMMARY GLAND BIOL, V2, P365, DOI 10.1023/A:1026347313096; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kieslinger M, 2000, GENE DEV, V14, P232; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ormandy CJ, 1997, J MAMMARY GLAND BIOL, V2, P355, DOI 10.1023/A:1026395229025; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Schaber JD, 1998, CANCER RES, V58, P1914; Shang YF, 1999, ONCOGENE, V18, P6725, DOI 10.1038/sj.onc.1203084; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162	35	94	97	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4335	4339		10.1038/sj.onc.1205484	http://dx.doi.org/10.1038/sj.onc.1205484			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082622				2022-12-25	WOS:000176174200017
J	Appl, H; Klempnauer, KH				Appl, H; Klempnauer, KH			Targeted disruption of c-myb in the chicken pre B-cell line DT40	ONCOGENE			English	Article						c-myb; DT40 cells; homologous recombination; pre B-cell; Pdcd4	V-MYB; MIM-1 GENE; C/EBP-BETA; TRANSCRIPTIONAL ACTIVATION; SYNERGISTIC ACTIVATION; MYELOMONOCYTIC CELLS; PDCD4 GENE; NF-M; EXPRESSION; ONCOGENE	The c-myb proto-oncogene is highly expressed in a wide variety of immature hematopoietic cells and plays a key role in the development of the hematopoietic system. c-myb and its retroviral counterpart v-myb encode transcription factors which have been implicated in the regulation of certain target genes. Targeting of c-myb in mouse embryonic stem cells by homologous recombination has provided clear evidence that c-myb is necessary for the proper development of most myeloid lineages of the hematopoietic system as well as of T-lymphocytes. Here we have explored the function of c-myb in the B-lymphoid lineage. We have used the chicken DT40 cells, a pre B-cell line which shows extremely high efficiencies of homologous recombination, as a model system to disrupt c-myb. DT40 cells lacking a functional c-myb gene are viable and show only minor perturbations of their growth parameters, indicating that c-myb is not an essential gene in these cells. We have used the c-myb null DT40 cells to analyse the expression of genes which have been previously been identified as myb target genes. Neither c-myc nor bcl-2, two putative myb targets, showed altered expression in the cells lacking c-myb. However, expression of the Pdcd4 gene, a myb target gene originally identified in a myelomonocytic cell line expressing a conditional form of v-myb, was diminished in the absence of c-myb. The c-myb knock-out cells described here should provide a useful model system for the identification and characterization of c-myb target genes in B-lymphoid cells.	Westfal Wilhelms Univ, Inst Biochem, D-48143 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Westfal Wilhelms Univ, Inst Biochem, Wilhelm Klemm Str 2, D-48143 Munster, Germany.	klempna@uni-muenster.de						Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PRESS RD, 1995, ONCOGENE, V11, P525; QUEVA C, 1992, DEVELOPMENT, V114, P125; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sitzmann J, 1995, ONCOGENE, V11, P2273; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Smith MR, 1997, J VIROL, V71, P6534, DOI 10.1128/JVI.71.9.6534-6540.1997; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	50	18	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3076	3081		10.1038/sj.onc.1205427	http://dx.doi.org/10.1038/sj.onc.1205427			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082539				2022-12-25	WOS:000175262700016
J	Qin, JZ; Chaturvedi, V; Denning, MF; Bacon, P; Panella, J; Choubey, D; Nickoloff, BJ				Qin, JZ; Chaturvedi, V; Denning, MF; Bacon, P; Panella, J; Choubey, D; Nickoloff, BJ			Regulation of apoptosis by p53 in UV-irradiated human epidermis, psoriatic plaques and senescent keratinocytes	ONCOGENE			English	Article						apoptosis; human skin; keratinocytes; p53; psoriasis; senescence	NF-KAPPA-B; POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL TARGET; ULTRAVIOLET-RADIATION; CELLULAR SENESCENCE; MOUSE SKIN; DNA; EXPRESSION; INDUCTION; PROTEIN	The carcinogenic effects of sunlight in human epidermis may be thwarted by either: transient growth arrest and repair of DNA photodamage in keratinocytes (KCs); elimination of KCs with damaged DNA via apoptosis; or by stimulating a senescence switch whereby KCs become irreversibly growth arrested. Using normal human skin organ cultures and living epidermal equivalents, we demonstrate that in the proliferative basal layer, removal of KCs via apoptosis had a rapid onset (beginning within 2 h) following UV-light exposure generating progressively greater numbers of KCs with thymine dimers as the dose of UV-light was increased; involved induction of Apaf-1, activation of caspase-3, and was dependent on p53 activation as addition of a p53 chemical inhibitor blocked the apoptotic response. Suprabasal layer KCs underwent apoptosis at much later time points (> 8 h). KCs in the basal layer repaired DNA damage more rapidly than KCs in suprabasal layers. Steady state levels of p53 increased in irradiated cells, and the increase was accompanied by phosphorylation of serine 9 and serine 15, but not serine 6 residues. By contrast, cultured KCs undergoing spontaneous replicative senescence were resistant to UV-induced apoptosis. Senescent KCs constitutively contained low levels of p53, which were neither increased nor phosphorylated or acetylated after UV-exposure and possessed minimal DNA binding activity, indicative of functional inactivation. Furthermore, treatment of senescent KCs with DNA damaging agent adriamycin did not result in activation of latent p53 or apoptosis. When KCs within psoriatic plaques were examined, they resembled senescent KCs in that they expressed p53, which was not phosphorylated or acetylated. Thus, UV-light induces DNA damage in human epidermal KCs triggering p53 activation, and subsequent apoptosis involving distinct cell layers and kinetics. However, the lack of p53 activation as seen in senescent KCs and psoriatic plaques, is associated with a relative resistance of KCs to UV-induced apoptosis. In conclusion, the sensitivity and resistance of KCs to apoptosis depends not only on the location within various layers of epidermis and levels of p53, but may also involve p53 activation via post-translational modifications.	Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL USA; Loyola Univ, Ctr Med, Dept Radiat Oncol, Maywood, IL USA	Loyola University Chicago; Loyola University Chicago	Nickoloff, BJ (corresponding author), Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL USA.	Bnickol@lumc.edu	Choubey, Divaker/A-4771-2008		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047307, R01AR040065] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 47307, AR 40065] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Burren R, 1998, INT J CANCER, V76, P201, DOI 10.1002/(SICI)1097-0215(19980413)76:2<201::AID-IJC6>3.0.CO;2-0; Campbell T, 1998, EXOT PET PRACT, V3, P1; Campisi J, 2000, IN VIVO, V14, P183; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1996, CANC MED, P307; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HALL PA, 1993, ONCOGENE, V8, P203; HELANDER SD, 1993, J AM ACAD DERMATOL, V29, P741, DOI 10.1016/0190-9622(93)70240-T; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kubilus J, 1996, IN VITRO TOXICOL, V9, P157; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; Li G, 1996, AM J PATHOL, V148, P1113; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris RJ, 1997, CANCER RES, V57, P3436; NAKAMURA H, 1994, DEV HYDROB, V91, P3; Nickoloff B J, 2001, J Invest Dermatol, V117, P1; Nickoloff BJ, 2001, J CUTAN PATHOL, V28, P57, DOI 10.1034/j.1600-0560.2001.280201.x; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Ponten F, 2001, JNCI-J NATL CANCER I, V93, P128, DOI 10.1093/jnci/93.2.128; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Qin JZ, 2001, J INVEST DERMATOL, V117, P898, DOI 10.1046/j.0022-202x.2001.01477.x; REES JL, 1995, J INVEST DERMATOL, V104, P883, DOI 10.1111/1523-1747.ep12606149; Robles AI, 2001, CANCER RES, V61, P6660; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; SOINI Y, 1994, BRIT J DERMATOL, V131, P514; SPANDAU DF, 1994, ONCOGENE, V9, P1861; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; Terui T, 2001, CURR OPIN ALLERGY CL, V1, P461, DOI 10.1097/01.all.0000011061.54491.2e; TORNALETTI S, 1993, ONCOGENE, V8, P2051; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; WroneSmith T, 1997, AM J PATHOL, V151, P1321; Yaar M, 1998, J Investig Dermatol Symp Proc, V3, P47; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	60	82	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2991	3002		10.1038/sj.onc.1205404	http://dx.doi.org/10.1038/sj.onc.1205404			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082529	Bronze			2022-12-25	WOS:000175262700006
J	Okada, K; Blanchoin, L; Abe, H; Chen, H; Pollard, TD; Bamburg, JR				Okada, K; Blanchoin, L; Abe, H; Chen, H; Pollard, TD; Bamburg, JR			Xenopus actin-interacting protein 1 (XAip1) enhances cofilin fragmentation of filaments by capping filament ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA ACTOPHORIN ADF/COFILIN; DEPOLYMERIZING FACTOR COFILIN; SKELETAL-MUSCLE; ARP2/3 COMPLEX; BARBED ENDS; ADP-ACTIN; F-ACTIN; PHOSPHORYLATION; PROFILIN; DYNAMICS	Xenopus actin-interacting protein 1 (XAip1) is thought to promote fragmentation of actin filaments by cofilin. To examine the mechanism of XAip1, we measured polymer lengths by fluorescence microscopy and the concentration of filament ends with an elongation assay. Cofilin creates ends by severing actin filaments. XAip1 alone does not sever actin filaments or prevent annealing/ redistribution of mechanically severed filaments and has no effect on the concentration of ends available for subunit addition. In the presence of XAip1, the apparent filament fragmentation by cofilin is enhanced, but XAip1 reduces rather than increases the concentration of ends capable of adding subunits. Electron microscopy with gold-labeled antibodies showed that a low concentration of XAip1 bound preferentially to one end of the filament. A high concentration of XAip1 bound along the length of the filament. In the presence of gelsolin-actin to cap filament barbed ends, XAip1 does not enhance cofilin activity. We conclude that XAip1 caps the barbed end of filaments severed by cofilin. This capping blocks annealing and depolymerization and allows more extensive severing by cofilin.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Chiba Univ, Fac Sci, Dept Biol, Chiba 2638522, Japan; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 444, Japan	Colorado State University; Chiba University; Salk Institute; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Bamburg, JR (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.				NIGMS NIH HHS [GM26338, GM35126, GM54004] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338, R01GM035126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Adler HJ, 1999, GENOMICS, V56, P59, DOI 10.1006/geno.1998.5672; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Aizawa H, 1999, GENES CELLS, V4, P311, DOI 10.1046/j.1365-2443.1999.00262.x; AMBERG DC, 1995, STRUCT BIOL, V2, P28; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bernstein BW, 2000, CELL MOTIL CYTOSKEL, V47, P319, DOI 10.1002/1097-0169(200012)47:4<319::AID-CM6>3.0.CO;2-I; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Blanchoin L, 2000, J MOL BIOL, V295, P203, DOI 10.1006/jmbi.1999.3336; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CASELLA JF, 1986, J BIOL CHEM, V261, P915; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; Konzok A, 1999, J CELL BIOL, V146, P453, DOI 10.1083/jcb.146.2.453; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kuhn TB, 2000, J NEUROBIOL, V44, P126, DOI 10.1002/1097-4695(200008)44:2<126::AID-NEU4>3.0.CO;2-Z; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Maciver SK, 1998, EUR J BIOCHEM, V256, P388, DOI 10.1046/j.1432-1327.1998.2560388.x; Maciver SK, 1998, CURR OPIN CELL BIOL, V10, P140, DOI 10.1016/S0955-0674(98)80097-5; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Matsumoto S, 1998, J BIOCHEM-TOKYO, V124, P326, DOI 10.1093/oxfordjournals.jbchem.a022115; MCLEOD JF, 1989, J BIOL CHEM, V264, P1260; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; Moriyama K, 1999, EMBO J, V18, P6752, DOI 10.1093/emboj/18.23.6752; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; Okada K, 1999, J CELL SCI, V112, P1553; Ono S, 2001, J CELL BIOL, V152, P1313, DOI 10.1083/jcb.152.6.1313; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Teubner A, 1998, BIOCHEMISTRY-US, V37, P7532, DOI 10.1021/bi972176s; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	45	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43011	43016		10.1074/jbc.M203111200	http://dx.doi.org/10.1074/jbc.M203111200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12055192	hybrid, Green Published			2022-12-25	WOS:000179081200077
J	Kang, HG; Evers, MR; Xia, GQ; Baenziger, JU; Schachner, M				Kang, HG; Evers, MR; Xia, GQ; Baenziger, JU; Schachner, M			Molecular cloning and characterization of chondroitin-4-O-sulfotransferase-3 - A novel member of the HNK-1 family of sulfotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-1,4-LINKED N-ACETYLGALACTOSAMINE; CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; EXPRESSION CLONING; OLIGOSACCHARIDES; RECEPTOR; PROTEIN; N-ACETYLGALACTOSAMINE-4-O-SULFOTRANSFERASE; 4-O-SULFOTRANSFERASES; GLYCOLIPIDS	We have identified and characterized an N-acetylgalactosamine-4-O-sulfotransferase designated chondroitin-4-sulfotransferase-3 (C4ST-3) (GenBank(TM) accession number AY120869) based on its homology to HNK-1 sulfotransferase (HNK-1 ST). The cDNA predicts an open reading frame encoding a type II membrane protein of 341 amino acids with a 12-amino acid cytoplasmic domain and a 311-amino acid luminal domain containing a single potential N-linked glycosylation site. C4ST-3 has the greatest amino acid sequence identity when aligned with chondroitin-4-O-sulfotransferase 1 C4ST-1) (45%) but also shows significant amino acid identity with chondroitin-4-O-sulfotransferase 2 (C4ST-2) (27%), dermatan-4-O-sulfotransferase 1 (29%), HNK-1 ST (26%), N-acetylgalactosamine-4-O-sulfotransferase 1 (26%), and N-acetylgalactosamine-4-O-sulfotransferase 2 (23%). C4ST-3 transfers sulfate to the C-4 hydroxyl of beta1,4-linked GalNAc that is substituted with a beta-linked glucuronic acid at the C-3 hydroxyl. The open reading frame of C4ST-3 is encoded by three exons located on human chromosome 3q21.3. Northern blot analysis reveals a single 2.1-kilobase transcript. C4ST-3 message is expressed in adult liver and at lower levels in adult kidney, lymph nodes, and fetal liver. Although C4ST-3 and C4ST-1 have similar specificities, the highly restricted pattern of expression seen for C4ST-3 suggests that it has a different role than C4ST-1.	Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; Washington University (WUSTL)	Schachner, M (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.		Baenziger, Jacques U/E-9430-2012; Xia, Guoqing/C-2365-2015	Xia, Guoqing/0000-0003-4492-9156	NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1994, METHOD ENZYMOL, V230, P237; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bukalo O, 2001, NEUROSCIENCE, V104, P359, DOI 10.1016/S0306-4522(01)00082-3; COLE LA, 1984, BIOCHEM BIOPH RES CO, V122, P1260, DOI 10.1016/0006-291X(84)91228-2; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Evers MR, 2001, J BIOL CHEM, V276, P36344, DOI 10.1074/jbc.M105848200; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 2001, GLYCOBIOLOGY, V11, P495, DOI 10.1093/glycob/11.6.495; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kang HG, 2001, J BIOL CHEM, V276, P10861, DOI 10.1074/jbc.M011560200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; Milanesi L, 1999, BIOINFORMATICS, V15, P612, DOI 10.1093/bioinformatics/15.7.612; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975	38	65	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34766	34772		10.1074/jbc.M204907200	http://dx.doi.org/10.1074/jbc.M204907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12080076	Green Published, hybrid			2022-12-25	WOS:000178117000017
J	Benchoua, A; Couriaud, C; Guegan, C; Tartier, L; Couvert, P; Friocourt, G; Chelly, J; Menissier-de Murcia, J; Onteniente, B				Benchoua, A; Couriaud, C; Guegan, C; Tartier, L; Couvert, P; Friocourt, G; Chelly, J; Menissier-de Murcia, J; Onteniente, B			Active caspase-8 translocates into the nucleus of apoptotic cells to inactivate poly(ADP-ribose) polymerase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX DISC; PARKINSONS-DISEASE; DEATH; CLEAVAGE; ACTIVATION; PROTEASES; NEURONS; BRAIN; RAT; EXPRESSION	Caspase-8 is the prototypic initiator of the death domain receptor pathway of apoptosis. Here, we report that caspase-8 not only triggers and amplifies the apoptotic process at cytoplasmic sites but can also act as an executioner at nuclear levels. In a murine model of acute ischemia, caspase-8 is relocated into the nucleus of apoptotic neurons, where it cleaves PARP-2, a member of the poly(ADP-ribose) polymerase family involved in DNA repair. As indicated by site-directed mutagenesis, PARP-2 cleavage occurs preferentially at the LQMD sequence mapped between the DNA binding and the catalytic domains of the protein. This is close to the cleavage sequence found in Bid, the cytoplasmic target of caspase-8. Activity assays confirm that cleavage of PARP-2 results in inactivation of its poly(ADP-ribosylation) property, proportional to the efficiency of the cleavage. Our findings add to the complexity of proteolytic caspase networks by demonstrating that caspase-8 is in turn an initiator, amplifier, and effector caspase.	Univ Paris 12, INSERM, U 421, F-94010 Creteil, France; Ecole Super Biotechnol Strasbourg, CNRS, UPR 9003, F-67400 Illkirch Graffenstaden, France; Fac Med Cochin, Lab Genet & Physiopathol Retards Mentaux, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Onteniente, B (corresponding author), Univ Paris 12, INSERM, U 421, 8 Rue Gen Sarrail, F-94010 Creteil, France.		Friocourt-Masse, Gaelle/M-8916-2017; Guegan, Christelle/AAD-5377-2020; ONTENIENTE, Brigitte/E-4921-2019	Couvert, Philippe/0000-0002-7607-2057; Friocourt, Gaelle/0000-0001-6681-7644; Benchoua, Alexandra/0000-0002-9980-6471				Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; D'Amours D, 2001, J CELL SCI, V114, P3771; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Guegan C, 2000, BRAIN RES, V856, P93, DOI 10.1016/S0006-8993(99)02347-1; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Joashi UC, 1999, EUR J NEUROSCI, V11, P91, DOI 10.1046/j.1460-9568.1999.00409.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Krupinski J, 2000, NEUROBIOL DIS, V7, P332, DOI 10.1006/nbdi.2000.0310; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakanishi K, 2001, J BIOL CHEM, V276, P41237, DOI 10.1074/jbc.M105648200; Ni BH, 1997, J NEUROSCI, V17, P1561; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; SCHREIBER V, 2002, J BIOL CHEM, V10, P10; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SHIGENO T, 1985, SURG NEUROL, V24, P47, DOI 10.1016/0090-3019(85)90063-1; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	53	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34217	34222		10.1074/jbc.M203941200	http://dx.doi.org/10.1074/jbc.M203941200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12065591	hybrid			2022-12-25	WOS:000177959100090
J	Busch, JL; Bessay, EP; Francis, SH; Corbin, JD				Busch, JL; Bessay, EP; Francis, SH; Corbin, JD			A conserved serine juxtaposed to the pseudosubstrate site of type I cGMP-dependent protein kinase contributes strongly to autoinhibition and lower cGMP affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; APPARENT CONFORMATIONAL CHANGE; SUBUNIT RII-ALPHA; REGULATORY SUBUNIT; MOLECULAR-CLONING; CYCLIC-GMP; BINDING-SITES; HUMAN TESTIS; CDNA STRUCTURE; CAMP	Serines 64 and 79 are homologous residues that are juxtaposed to the autoinhibitory pseudosubstrate site in cGMP-dependent protein kinase type Ialpha and type Ibeta (PKG-Ialpha and PKG-Ibeta), respectively. Autophosphorylation of this residue is associated with activation of type I PKGs. To determine the role of this conserved serine, point mutations have been made in PKG-Ialpha (S64A, S64T, S64D, and S64N) and PKG-Ibeta (S79A). In wild-type PKG-Ialpha, basal kinase activity ratio (-cGMP/+cGMP) is 0.11, autophosphorylation increases this ratio 3-fold, and the K. and K, values for cGMP are 127 and 36 nm, respectively. S64A PKG-Ialpha basal kinase activity ratio increases 2-fold, cGMP binding affinity increases similar to10-fold in both K-a and K-D, and activation by autophosphorylation is slight. S64D and S64N mutants are nearly constitutively active in the absence of cGMP, cGMP binding affinity in each increases 18-fold, and autophosphorylation does not affect the kinase activity of these mutants. Mutation of the homologous site in PKG-Ibeta (S79A) increases the basal kinase activity ratio 2-fold and cGMP binding affinity 5-fold over that of wild-type PKG-Ibeta. The combined results demonstrate that a conserved serine juxtaposed to the pseudosubstrate site in type I PKGs contributes importantly to enzyme function by increasing autoinhibition and decreasing cGMP binding affinity.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Corbin, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	jackie.corbin@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563, R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK 07563, DK 40029] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chu DM, 1998, J BIOL CHEM, V273, P14649, DOI 10.1074/jbc.273.23.14649; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; DOSKELAND SO, 1983, BIOCHEMISTRY-US, V22, P1094; Foss KB, 1997, BBA-GENE STRUCT EXPR, V1350, P98, DOI 10.1016/S0167-4781(96)00152-2; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; GEAHLEN RL, 1981, J BIOL CHEM, V256, P4536; GLASS DB, 1982, J BIOL CHEM, V257, P1196; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KUNKEL TA, 1994, CURRENT PROTOCOLS MO; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LINCOLN TM, 1978, J BIOL CHEM, V253, P6002; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; Poteet-Smith Celeste E., 1997, V31, P219; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; Reed RB, 1997, ADV SEC MESS PHOSPH, V31, P205; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; Stansberry J, 2001, J NEUROCHEM, V76, P1177, DOI 10.1046/j.1471-4159.2001.00131.x; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAKIO K, 1983, J BIOL CHEM, V258, P5531; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; Walter U, 1982, Prog Clin Biol Res, V102 Pt C, P173; WALTER U, 1981, EUR J BIOCHEM, V118, P339; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	46	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34048	34054		10.1074/jbc.M202761200	http://dx.doi.org/10.1074/jbc.M202761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12080049	hybrid			2022-12-25	WOS:000177959100071
J	Izsvak, Z; Khare, D; Behlke, J; Heinemann, U; Plasterk, RH; Ivics, Z				Izsvak, Z; Khare, D; Behlke, J; Heinemann, U; Plasterk, RH; Ivics, Z			Involvement of a bifunctional, paired-like DNA-binding domain and a transpositional enhancer in Sleeping Beauty transposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC COMPLEX; FUNCTIONAL DOMAINS; CRYSTAL-STRUCTURE; SEQUENCE; ELEMENT; IDENTIFICATION; REQUIREMENTS; REVEALS; ELEGANS; ORIGIN	Sleeping Beauty (SB) is the most active Tc1/mariner-like transposon in vertebrate species. Each of the terminal inverted repeats (IRs) of SB contains two transposase-binding sites (DRs). This feature, termed the IR/DR structure, is conserved in a group of Tc1-like transposons. The DNA-binding region of SB transposase, similar to the paired domain of Pax proteins, consists of two helix-turn-helix subdomains (PAI + RED = PAIRED). The N-terminal PAI subdomain was found to play a dominant role in contacting the DRs. Transposase was able to bind to mutant sites retaining the 3' part of the DRs; thus, primary DNA binding is not sufficient to determine the specificity of the transposition reaction. The PAI subdomain was also found to bind to a transpositional enhancer-like sequence within the left IR of SB, and to mediate protein-protein interactions between transposase subunits. A tetrameric form of the transposase was detected in solution, consistent with an interaction between the IR/DR structure and a transposase tetramer. We propose a model in which the transpositional enhancer and the PAI subdomain stabilize complexes formed by a transposase tetramer bound at the IR/DR. These interactions may result in enhanced stability of synaptic complexes, which might explain the efficient transposition of Sleeping Beauty in vertebrate cells.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6726 Szeged, Hungary; Free Univ Berlin, Inst Chem Crystallog, D-14195 Berlin, Germany; Hubrecht Lab Dev Biol, NL-3584 CT Utrecht, Netherlands	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Free University of Berlin; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Ivics, Z (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	zivics@mdc-berlin.de	Heinemann, Udo/S-3379-2016; Heinemann, Udo/AAH-4766-2019; Wilson, Matthew H/K-3193-2013	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850; 				Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Breitling R, 2000, DEV GENES EVOL, V210, P644, DOI 10.1007/s004270000106; COLLOMS SD, 1994, NUCLEIC ACIDS RES, V22, P5548, DOI 10.1093/nar/22.25.5548; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; Fischer SEJ, 2001, P NATL ACAD SCI USA, V98, P6759, DOI 10.1073/pnas.121569298; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Ivics Z, 1996, P NATL ACAD SCI USA, V93, P5008, DOI 10.1073/pnas.93.10.5008; Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047; Jun S, 1996, DEVELOPMENT, V122, P2639; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; Lohe AR, 1996, MOL BIOL EVOL, V13, P549, DOI 10.1093/oxfordjournals.molbev.a025615; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; Normand C, 2001, J MOL BIOL, V308, P853, DOI 10.1006/jmbi.2001.4641; Pellizzari L, 1999, BIOCHEM J, V337, P253, DOI 10.1042/0264-6021:3370253; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Poleev A, 1997, EUR J BIOCHEM, V247, P860, DOI 10.1111/j.1432-1033.1997.00860.x; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Steiniger-White M, 2000, J BIOL CHEM, V275, P23127, DOI 10.1074/jbc.M003411200; vanPouderoyen G, 1997, EMBO J, V16, P6044, DOI 10.1093/emboj/16.19.6044; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568	31	116	123	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34581	34588		10.1074/jbc.M204001200	http://dx.doi.org/10.1074/jbc.M204001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12082109	hybrid			2022-12-25	WOS:000177959100132
J	Fonseca, MV; Buan, NR; Horswill, AR; Rayment, I; Escalante-Semerena, JC				Fonseca, MV; Buan, NR; Horswill, AR; Rayment, I; Escalante-Semerena, JC			The ATP : Co(I)rrinoid adenosyltransferase (CobA) enzyme of Salmonella enterica requires the 2 '-OH group of ATP for function and yields inorganic triphosphate as its reaction byproduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; CORRINOID ADENOSYLTRANSFERASE; ESCHERICHIA-COLI; TYPHIMURIUM; BTUB; ADENOSYLCOBALAMIN; ASSIMILATION; COBALAMIN; ANALOGS; BINDING	The specificity of the ATP:corrinoid adenosyltransferase (CobA) enzyme of Salmonella enterica serovar Typhimurium LT2 for its nucleotide substrate was tested using ATP analogs and alternative nucleotide donors. The enzyme showed broad specificity for the nucleotide base and required the 2'-OH group of the ribosyl moiety of ATP for activity. P-31 NMR spectroscopy was used to identify inorganic triphosphate (PPPi) as the byproduct of the reaction catalyzed by the CobA enzyme. Cleavage of triphosphate into pyrophosphate and orthophosphate did not occur, indicating that triphosphate cleavage was not required for release of the adenosylcorrinoid product. Triphosphate was a strong inhibitor of the reaction, with 85% of CobA activity lost when the ATP/PPPi ratio present in the reaction mixture was 1:2.5.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NCRR NIH HHS [RR02301, RR02781] Funding Source: Medline; NIGMS NIH HHS [GM58281, GM40313, R01 GM040313, GM08349] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002781, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040313, R01GM040313, R01GM058281, T32GM008349] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHMAN LK, 1975, J BIOL CHEM, V250, P14; BARKER HA, 1972, ANNU REV BIOCHEM, V41, P55, DOI 10.1146/annurev.bi.41.070172.000415; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BRADY RO, 1962, J BIOL CHEM, V223, P2325; COOKE R, 1973, BIOCHEMISTRY-US, V12, P3927, DOI 10.1021/bi00744a022; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Fonseca MV, 2000, J BACTERIOL, V182, P4304, DOI 10.1128/JB.182.15.4304-4309.2000; Franklund CV, 1997, J BACTERIOL, V179, P4039, DOI 10.1128/jb.179.12.4039-4042.1997; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HORAK A, 1976, BIOCHIM BIOPHYS ACTA, V430, P135, DOI 10.1016/0005-2728(76)90229-2; Kofoid E, 1999, J BACTERIOL, V181, P5317, DOI 10.1128/JB.181.17.5317-5329.1999; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; LUNDRIGAN MD, 1987, MOL GEN GENET, V206, P401, DOI 10.1007/BF00428878; MA QF, 1990, BIOCHEMISTRY-US, V29, P1412, DOI 10.1021/bi00458a011; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; Nou XW, 2000, P NATL ACAD SCI USA, V97, P7190, DOI 10.1073/pnas.130013897; OTOOLE GA, 1993, J BACTERIOL, V175, P6328, DOI 10.1128/JB.175.19.6328-6336.1993; Reczkowski RS, 1999, BIOCHEMISTRY-US, V38, P9063, DOI 10.1021/bi990528k; ROOF DM, 1989, J BACTERIOL, V171, P3316, DOI 10.1128/jb.171.6.3316-3323.1989; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995; SUH SJ, 1993, GENE, V129, P93, DOI 10.1016/0378-1119(93)90701-4; SUH SJ, 1994, THESIS U WISCONSIN M; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALSH C, 1979, ENZYMATIC REACTION M, P851; WEISSBACH H, 1961, J BIOL CHEM, V236, pPC40	26	23	25	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33127	33131		10.1074/jbc.M203893200	http://dx.doi.org/10.1074/jbc.M203893200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080060	hybrid			2022-12-25	WOS:000177859000094
J	Mahmud, T; Bode, HB; Silakowski, B; Kroppenstedt, RM; Xu, MJ; Nordhoff, S; Hofle, G; Muller, R				Mahmud, T; Bode, HB; Silakowski, B; Kroppenstedt, RM; Xu, MJ; Nordhoff, S; Hofle, G; Muller, R			A novel biosynthetic pathway providing precursors for fatty acid biosynthesis and secondary metabolite formation in myxobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYXOCOCCUS-XANTHUS DEVELOPMENT; RIBOSOMAL PEPTIDE SYNTHETASE; STIGMATELLA-AURANTIACA; GENE-CLUSTER; IDENTIFICATION; LOCUS; ESG	Short chain carboxylic acids are well known as the precursors of fatty acid and polyketide biosynthesis. Iso-fatty acids, which are important for the control of membrane fluidity, are formed from branched chain starter units (isovaleryl-CoA and isobutyryl-CoA), which in turn are derived from the degradation of leucine and valine, respectively. Branched chain carboxylic acids are also employed as starter molecules for the biosynthesis of secondary metabolites, e.g. the therapeutically important anthelmintic agent avermectin or the electron transport inhibitor myxothiazol. During our studies on myxothiazol biosynthesis in the myxobacterium, Stigmatella aurantiaca, we detected a novel biosynthetic route to isovaleric acid. After cloning and inactivation of the branched chain keto acid dehydrogenase complex, which is responsible for the degradation of branched chain amino acids, the strain is still able to produce iso-fatty acids and myxothiazol. Incorporation studies employing deuterated leucine show that it can only serve as precursor in the wild type strain but not in the esg mutant. Feeding experiments using C-13-labeled precursors show that isovalerate is efficiently made from acetate, giving rise to a labeling pattern in myxothiazol that provides evidence for a novel branch of the mevalonate pathway involving the intermediate 3,3-dimethylacryloyl-CoA. 3,3-Dimethylacrylic acid was synthesized in deuterated form and fed to the esg mutant, resulting in strong incorporation into myxothiazol and iso-fatty acids. Similar experiments employing Myxococcus xanthus revealed that the discovered biosynthetic route described is present in other myxobacteria as well.	GBF mbH, Abt NBI MX, D-38124 Braunschweig, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Inst Pharmazeut Biol, D-38106 Braunschweig, Germany; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Deutsch Sammlung Mikroorganismen & Zellkulturen, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Braunschweig University of Technology; University of Washington; University of Washington Seattle; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ)	Muller, R (corresponding author), GBF mbH, Abt NBI MX, Mascheroder Weg 1, D-38124 Braunschweig, Germany.		Bode, Helge B/F-7022-2014; Müller, Rolf/B-1559-2008; Mahmud, Taifo/A-1492-2015	Bode, Helge B/0000-0001-6048-5909; Müller, Rolf/0000-0002-1042-5665; Mahmud, Taifo/0000-0001-9639-526X				DOWNARD J, 1993, J BACTERIOL, V175, P7762, DOI 10.1128/JB.175.24.7762-7770.1993; DOWNARD J, 1995, MOL MICROBIOL, V16, P171, DOI 10.1111/j.1365-2958.1995.tb02290.x; Dworkin M, 1996, MICROBIOL REV, V60, P70, DOI 10.1128/MMBR.60.1.70-102.1996; FUCHS G, 1999, BIOL PROKARYOTES, P110; HODGKIN J, 1977, P NATL ACAD SCI USA, V74, P2932; Ikeda H, 1997, CHEM REV, V97, P2591, DOI 10.1021/cr960023p; JANSEN R, 1983, LIEBIGS ANN CHEM, V7, P1081; KAISER D, 1979, P NATL ACAD SCI USA, V76, P5952, DOI 10.1073/pnas.76.11.5952; Kearns DB, 2001, P NATL ACAD SCI USA, V98, P13990, DOI 10.1073/pnas.251484598; Kearns DB, 2000, P NATL ACAD SCI USA, V97, P11505, DOI 10.1073/pnas.210448597; KUYKENDALL LD, 1988, INT J SYST BACTERIOL, V38, P358, DOI 10.1099/00207713-38-4-358; MICHAL G, 1999, BIOCH PATHWAYS, V1; MILLER LT, 1982, J CLIN MICROBIOL, V16, P584, DOI 10.1128/JCM.16.3.584-586.1982; Rohdich F, 2001, CURR OPIN CHEM BIOL, V5, P535, DOI 10.1016/S1367-5931(00)00240-4; Sambrook J., 2002, MOL CLONING LAB MANU; Silakowski B, 2001, CHEM BIOL, V8, P59, DOI 10.1016/S1074-5521(00)00056-9; Silakowski B, 1999, J BIOL CHEM, V274, P37391, DOI 10.1074/jbc.274.52.37391; Silakowski B, 2001, GENE, V275, P233, DOI 10.1016/S0378-1119(01)00680-1; Stamm I, 1999, ARCH MICROBIOL, V172, P175, DOI 10.1007/s002030050757; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOAL DR, 1995, MOL MICROBIOL, V16, P177, DOI 10.1111/j.1365-2958.1995.tb02291.x; TROWITZSCHKIENA.W, 1986, LIEBIGS ANN CHEM, V10, P93; Voet D., 1995, BIOCHEMISTRY; WARE JC, 1973, J BACTERIOL, V115, P253, DOI 10.1128/JB.115.1.253-261.1973	24	50	50	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32768	32774		10.1074/jbc.M205222200	http://dx.doi.org/10.1074/jbc.M205222200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084727	hybrid			2022-12-25	WOS:000177859000049
J	Sitaraman, SV; Wang, LX; Wong, M; Bruewer, M; Hobert, M; Yun, CH; Merlin, D; Madara, JL				Sitaraman, SV; Wang, LX; Wong, M; Bruewer, M; Hobert, M; Yun, CH; Merlin, D; Madara, JL			The adenosine 2b receptor is recruited to the plasma membrane and associates with E3KARP and ezrin upon agonist stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN INTESTINAL EPITHELIA; PROTEIN-KINASE-A; A(2B) RECEPTORS; MAST-CELLS; EXPRESSION; SECRETION; TRANSPORT; ORGANIZATION; TRAFFICKING	We have previously shown that adenosine is formed in the intestinal lumen during active inflammation from neutrophil-derived 5'-AMP. Acting through the adenosine A2b receptor (A2bR), the luminally derived adenosine induces vectorial chloride secretion and a polarized secretion of interleukin-6 to the intestinal lumen. Although some G protein-coupled receptors interact with anchoring or signaling molecules, not much is known in this critical area for the A2bM We used the model intestinal epithelial cell line, T84, and Caco2-BBE cells stably transfected with GFP-A2b receptor to study the intestinal A2bR. The A2bR is present in both the apical and basolateral membranes of intestinal epithelia. Apical or basolateral stimulation of the A2bR induces recruitment of the receptor to the plasma membrane and caveolar fractions. The A2bR co-inummoprecipitates with E3KARP and ezrin upon agonist stimulation. Ezrin interacts with E3KARP and PKA and the interaction between ezrin and E3KARP is enhanced by agonist stimulation. Our data suggest that the A2bR is recruited to the plasma membrane upon apical or basolateral agonist stimulation and interacts with E3KARP and ezrin. We speculate that such an interaction may not only anchor the A2bR to the plasma membrane but may also function to stabilize the receptor in a signaling complex in the plasma membrane.	Emory Univ, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Dept Pathol, Epithelial Biol Unit, Atlanta, GA 30322 USA	Emory University; Emory University	Sitaraman, SV (corresponding author), Emory Univ, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA.				NIDDK NIH HHS [DK 47662, DK 35932, K01 DK 02831, K08 DK02802] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035932, R37DK035932, R01DK047662, K01DK002831, K08DK002802] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT KE, 1989, AM J PHYSIOL, V256, pC197; BARRETT KE, 1990, AM J PHYSIOL, V258, pC902, DOI 10.1152/ajpcell.1990.258.5.C902; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Christofi FL, 2001, J COMP NEUROL, V439, P46, DOI 10.1002/cne.1334; ELLIS JA, 1992, BIOCHEM J, V283, P553, DOI 10.1042/bj2830553; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Herrera C, 2001, MOL PHARMACOL, V59, P127, DOI 10.1124/mol.59.1.127; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; JACOBSON MA, 1995, GENOMICS, V27, P374, DOI 10.1006/geno.1995.1061; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Linden J, 1998, LIFE SCI, V62, P1519, DOI 10.1016/S0024-3205(98)00100-3; Linden J, 1999, MOL PHARMACOL, V56, P705; MADARA JL, 1993, J CLIN INVEST, V91, P5716; McCormick BA, 1997, INFECT IMMUN, V65, P1414, DOI 10.1128/IAI.65.4.1414-1421.1997; Merlin D, 2001, J BIOL CHEM, V276, P39282, DOI 10.1074/jbc.M105077200; Merlin D, 2001, GASTROENTEROLOGY, V120, P1666, DOI 10.1053/gast.2001.24845; NASH S, 1991, J CLIN INVEST, V87, P1474, DOI 10.1172/JCI115156; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; Peters KW, 2000, MED CLIN N AM, V84, P633, DOI 10.1016/S0025-7125(05)70246-7; Peyot ML, 2000, CIRC RES, V86, P76, DOI 10.1161/01.RES.86.1.76; PUFFINBARGER NK, 1995, MOL PHARMACOL, V47, P1126; Ralevic V, 1998, PHARMACOL REV, V50, P413; Roman RM, 1999, GASTROENTEROLOGY, V116, P964, DOI 10.1016/S0016-5085(99)70081-8; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Sitaraman SV, 2000, AM J PHYSIOL-CELL PH, V278, pC1230, DOI 10.1152/ajpcell.2000.278.6.C1230; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; STROHMEIER GR, 1995, J BIOL CHEM, V270, P2387, DOI 10.1074/jbc.270.5.2387; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; VANBELLE H, 1987, AM J PHYSIOL, V252, pH886, DOI 10.1152/ajpheart.1987.252.5.H886; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zidek Z, 1999, EUR CYTOKINE NETW, V10, P319	40	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33188	33195		10.1074/jbc.M202522200	http://dx.doi.org/10.1074/jbc.M202522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080047	hybrid			2022-12-25	WOS:000177859000102
J	Tanoue, A; Koshimizu, T; Tsuchiya, M; Ishii, K; Osawa, M; Saeki, M; Tsujimoto, G				Tanoue, A; Koshimizu, T; Tsuchiya, M; Ishii, K; Osawa, M; Saeki, M; Tsujimoto, G			Two novel transcripts for human endothelin B receptor produced by RNA editing/alternative splicing from a single gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIRSCHSPRUNGS-DISEASE; STRUCTURAL ORGANIZATION; PROLIDASE DEFICIENCY; ADENOSINE-DEAMINASE; DNA-POLYMERASE; MUTATIONS; ENZYME; EXPRESSION; PROTEIN; DELETION	Hirschsprung disease is a heterogeneous genetic disorder, causative genes of which include the endothelin B receptor (ETB). To investigate the mutations of ETB in Hirschsprung disease, expression of the ETB gene in lymphoblastoid cells from patients and normal healthy adults was examined, and novel mutant transcripts were found. The mutant ETB gene transcripts lacked a 134-bp nucleotide sequence corresponding to exon 5, and some also contained a substitution from A to G at position 950 in exon 4, resulting in an amino acid substitution from glutamine (Q) to arginine (R). This substitution was suspected to be the result of RNA editing because it was not present in the genomic sequence. Transfection experiments using ETB minigenes containing the editing site with or without the gene for double-strand RNA deaminases (ADAR1 and ADAR2) revealed that the deaminases were involved in RNA editing. Furthermore, a c-Myc-tagged mutant ETB protein was not detected by Western blot analysis. The present results show that the mutant ETB transcripts were novel splice variants, which might not be translated, or that the products translated from splice variants might be quickly degraded, presumably because of their instability. The preferential production of this null function ETB by RNA editing/splicing could be involved in the etiology of some cases of Hirschsprung disease.	Natl Ctr Child Hlth, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548567, Japan; Inst Dev Res, Setagaya Ku, Tokyo 1548567, Japan; Tokyo Womens Med Univ, Dept Pediat, Shinjuku Ku, Tokyo 1628666, Japan; Natl Ctr Child Hlth & Dev, Dept Surg, Setagaya Ku, Tokyo 1548535, Japan	Tokyo Women's Medical University; National Center for Child Health & Development - Japan	Tsujimoto, G (corresponding author), Natl Ctr Child Hlth, Dept Mol Cell Pharmacol, Setagaya Ku, 3-35-31 Taishi Do, Tokyo 1548567, Japan.	gtsujimoto@nch.go.jp		Koshimizu, Taka-aki/0000-0001-5292-7535				ARAI H, 1993, J BIOL CHEM, V268, P3463; Ashkenas J, 1997, AM J HUM GENET, V60, P278; Auricchio A, 1996, HUM MOL GENET, V5, P351, DOI 10.1093/hmg/5.3.351; Bass BL, 1997, RNA, V3, P947; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Cappione AJ, 1997, AM J HUM GENET, V60, P305; CECCHERINI I, 1995, HUM MOL GENET, V4, P2089, DOI 10.1093/hmg/4.11.2089; DELATORRE JC, 1992, P NATL ACAD SCI USA, V89, P2531, DOI 10.1073/pnas.89.7.2531; Dembowski C, 2000, J PEDIATR SURG, V35, P480, DOI 10.1016/S0022-3468(00)90218-5; Eckert K A, 1991, PCR Methods Appl, V1, P17; EGEBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270, DOI 10.1073/pnas.91.22.10270; Elshourbagy NA, 1996, J BIOL CHEM, V271, P25300, DOI 10.1074/jbc.271.41.25300; Gariepy CE, 1998, J CLIN INVEST, V102, P1092, DOI 10.1172/JCI3702; Gath R, 2001, GUT, V48, P671, DOI 10.1136/gut.48.5.671; Gerber A, 1997, RNA, V3, P453; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Inoue M, 1998, J PEDIATR SURG, V33, P1206, DOI 10.1016/S0022-3468(98)90151-8; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; Kusafuka T, 1996, PEDIATR SURG INT, V12, P19; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Nambi P, 2000, J PHARMACOL EXP THER, V292, P247; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SHYAMALA V, 1994, CELL MOL BIOL RES, V40, P285; Skuse GR, 1996, NUCLEIC ACIDS RES, V24, P478, DOI 10.1093/nar/24.3.478; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; Tanaka H, 1998, J BIOL CHEM, V273, P11378, DOI 10.1074/jbc.273.18.11378; TANOUE A, 1990, J BIOL CHEM, V265, P11306; TANOUE A, 1990, J CLIN INVEST, V86, P351, DOI 10.1172/JCI114708	38	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33205	33212		10.1074/jbc.M203972200	http://dx.doi.org/10.1074/jbc.M203972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080062	hybrid			2022-12-25	WOS:000177859000104
J	Xiang, LK; Moore, BS				Xiang, LK; Moore, BS			Inactivation, complementation, and heterologous expression of encP, a novel bacterial phenylalanine ammonia-lyase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLIDENE-IMIDAZOLONE; STREPTOMYCES-MARITIMUS; ESCHERICHIA-COLI; BIOSYNTHESIS; HISTIDINE; CLONING; ELECTROPHILE; MUTAGENESIS; CLUSTER; SITE	The enzyme phenylalanine ammonia-lyase, which catalyzes the nonoxidative deamination of L-phenylalanine to trans-cinnamic acid, is ubiquitously distributed in plants. We now report its characterization for the first time in a bacterium. The phenylalanine ammonia-lyase homologous gene encP from the "Streptomyces maritimus" enterocin biosynthetic gene cluster was functionally characterized and shown to encode the first enzyme in the pathway to the enterocin polyketide synthase starter unit benzoyl-coenzyme A. The disruption of the encP gene completely inhibited the production of cinnamate and enterocin, whereas complementation of the mutant with benzoyl-coenzyme A pathway intermediates or with the wild-type gene encP restored the formation of the benzoate-primed polyketide antibiotic enterocin. Heterologous expression of the encP gene under the control of the ermE* promoter in Streptomyces coelicolor furthermore led to the production of cinnamic acid in the fermented cultures, confirming that the encP gene indeed encodes a novel bacterial phenylalanine ammonia-lyase.	Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Moore, BS (corresponding author), Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA.			Moore, Bradley/0000-0002-4652-1253	NIAID NIH HHS [AI47818] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI047818, R01AI047818] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEZANSON GS, 1970, CAN J MICROBIOL, V16, P147, DOI 10.1139/m70-026; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; EMES AV, 1970, CAN J BIOCHEM CELL B, V48, P613, DOI 10.1139/o70-099; Hertweck C, 2001, CHEMBIOCHEM, V2, P784, DOI 10.1002/1439-7633(20011001)2:10<784::AID-CBIC784>3.0.CO;2-K; Hertweck C, 2000, TETRAHEDRON, V56, P9115, DOI 10.1016/S0040-4020(00)00765-1; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kyndt JA, 2002, FEBS LETT, V512, P240, DOI 10.1016/S0014-5793(02)02272-X; Langer B, 1997, BIOCHEMISTRY-US, V36, P10867, DOI 10.1021/bi970699u; Langer B, 2001, ADV PROTEIN CHEM, V58, P175; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; MAZODIER P, 1989, J BACTERIOL, V171, P3583, DOI 10.1128/jb.171.6.3583-3585.1989; Moore BS, 2002, NAT PROD REP, V19, P70, DOI 10.1039/b003939j; Piel J, 2000, CHEM BIOL, V7, P943, DOI 10.1016/S1074-5521(00)00044-2; Piel J, 2000, J AM CHEM SOC, V122, P5415, DOI 10.1021/ja000445n; Poppe L, 2001, CURR OPIN CHEM BIOL, V5, P512, DOI 10.1016/S1367-5931(00)00253-2; Retey J, 1996, NATURWISSENSCHAFTEN, V83, P439; Rother R, 2001, EUR J BIOCHEM, V268, P6011; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schwede TF, 1999, BIOCHEMISTRY-US, V38, P5355, DOI 10.1021/bi982929q; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Sitachitta N, 1996, TETRAHEDRON, V52, P8073, DOI 10.1016/0040-4020(96)00391-2; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; YAMAMOTO H, 1986, J ANTIBIOT, V39, P1304, DOI 10.7164/antibiotics.39.1304; YU TW, 1995, MICROBIOL-UK, V141, P2779, DOI 10.1099/13500872-141-11-2779	24	74	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32505	32509		10.1074/jbc.M204171200	http://dx.doi.org/10.1074/jbc.M204171200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082112	hybrid			2022-12-25	WOS:000177859000016
J	Lin, DT; Lechleiter, JD				Lin, DT; Lechleiter, JD			Mitochondrial targeted cyclophilin D protects cells from cell death by peptidyl prolyl isomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCASE; DEPENDENT ANION CHANNEL; CYCLOSPORINE-A BINDING; INNER-MEMBRANE; ISOMERASE ACTIVITY; OXIDATIVE STRESS; APOPTOSIS; CA2+; MODULATION	Cyclophilin D (CyPD) is thought to sensitize opening of the mitochondrial permeability transition pore (mPTP) based on the findings that cyclosporin A (CsA), a pseudo-CyPD substrate, hyperpolarizes the mitochondrial membrane potential (Deltapsi) and inhibits apoptosis. We provide evidence that contrasts with this model. Using live cell imaging and two photon microscopy, we report that overexpression of CyPD desensitizes HEK293 and rat glioma C6 cells to apoptotic stimuli. By site-directed mutagenesis of CyPD that compromises peptidyl-prolyl cis-trans isomerase (PPIase) activity, we demonstrate that the mechanism involved in this protective effect requires PPIase activity. Furthermore, we show that, under resting conditions, Deltapsi is hyperpolarized in CyPD wild type-overexpressing cells but not in cells overexpressing mutant forms of CyPD that lack PPIase activity. Finally, in glutathione S-transferase (GST) pull-down assays, we demonstrate that CyPD binding to the adenine nucleotide translocator (ANT), which is considered to be the core component of the mPTP, is not affected by the loss of PPIase activity. Collectively, our data suggest that CyPD should be viewed as a cell survival-signaling molecule and indicate a protective role of CyPD against apoptosis that is mediated by one or more targets other than the ANT.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Lechleiter, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	lechleiter@uthscsa.edu	Lin, Da-Ting/D-1699-2018	Lin, Da-Ting/0000-0003-0538-7892	NIGMS NIH HHS [GM 48451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Boya P, 2001, EMBO J, V20, P4325, DOI 10.1093/emboj/20.16.4325; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; DAVIS ES, 1992, P NATL ACAD SCI USA, V89, P11169, DOI 10.1073/pnas.89.23.11169; Doyle V, 1999, BIOCHEM J, V341, P127, DOI 10.1042/0264-6021:3410127; Fink C, 1998, BIOPHYS J, V75, P1648, DOI 10.1016/S0006-3495(98)77607-6; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; HARDING MW, 1991, PHARMACOTHERAPY, V11, pS142; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; John LM, 2001, J PHYSIOL-LONDON, V535, P3, DOI 10.1111/j.1469-7793.2001.t01-2-00003.x; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KE HM, 1993, P NATL ACAD SCI USA, V90, P3324, DOI 10.1073/pnas.90.8.3324; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Korsmeyer S J, 1999, Harvey Lect, V95, P21; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; Santos AN, 2000, BIOL REPROD, V62, P1, DOI 10.1095/biolreprod62.1.1; Scorrano L, 1997, MOL CELL BIOCHEM, V174, P181, DOI 10.1023/A:1006887921810; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Smaili SS, 1999, CELL CALCIUM, V26, P121, DOI 10.1054/ceca.1999.0061; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Waterhouse NJ, 1999, J CLIN IMMUNOL, V19, P378, DOI 10.1023/A:1020550716138; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Woodfield KY, 1997, BBA-GENE STRUCT EXPR, V1351, P27, DOI 10.1016/S0167-4781(97)00017-1; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	56	150	160	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31134	31141		10.1074/jbc.M112035200	http://dx.doi.org/10.1074/jbc.M112035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12077116	hybrid			2022-12-25	WOS:000177579800093
J	Rocheleau, JV; Head, WS; Nicholson, WE; Powers, AC; Piston, DW				Rocheleau, JV; Head, WS; Nicholson, WE; Powers, AC; Piston, DW			Pancreatic islet beta-cells transiently metabolize pyruvate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; LACTATE-DEHYDROGENASE; GLUCOSE-METABOLISM; CYTOPLASMIC PH; B-CELLS; SHUTTLE; ACID; TRANSPORTER; MICROSCOPY; RESPONSES	Pancreatic beta-cell metabolism was followed during glucose and pyruvate stimulation of pancreatic islets using quantitative two-photon NAD(P)H imaging. The observed redox changes, spatially separated between the cytoplasm and mitochondria, were compared with whole islet insulin secretion. As expected, both NAD(P)H and insulin secretion showed sustained increases in response to glucose stimulation. In contrast, pyruvate caused a much lower NAD(P)H response an did not generate insulin secretion. Low pyruvate concentrations decreased cytoplasmic NAD(P)H without affecting mitochondrial NAD(P)H, whereas higher concentrations increased cytoplasmic and mitochondrial levels. However, the pyruvate-stimulated mitochondrial increase was transient and equilibrated to near-base-line levels. Inhibitors of the mitochondrial pyruvate-transporter and malate-aspartate shuttle were utilized to resolve the glucose- and pyruvate-stimulated NAD(P)H response mechanisms. These data showed that glucose-stimulated mitochondrial NAD(P)H and insulin secretion are independent of pyruvate transport but dependent on NAD(P)H shuttling. In contrast, the pyruvate-stimulated cytoplasmic NAD(P)H response was enhanced by both inhibitors. Surprisingly the malateaspartate shuttle inhibitor enabled pyruvate-stimulated insulin secretion. These data support a model in which glycolysis plays a dominant role in glucose-stimulated insulin secretion. Based on these data, we propose a mechanism for glucose-stimulated insulin secretion that includes allosteric inhibition of tricarboxylic acid cycle enzymes and pH dependence of mitochondrial pyruvate transport.	Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA; Tennessee Valley Vet Affairs Hlth Syst, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Piston, DW (corresponding author), Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA.			Rocheleau, Jonathan/0000-0002-1760-2564	NCI NIH HHS [CA 68485] Funding Source: Medline; NIDDK NIH HHS [DK 20593, DK 53434, DK 59737, DK 55233, DK 07061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK059737, R01DK053434, P60DK020593, R01DK055233, T32DK007061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKHAMMAR POG, 1998, METHODS CELL SCI, V18, P1; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; Bennett BD, 1996, J BIOL CHEM, V271, P3647; BEST L, 1988, BIOCHEM PHARMACOL, V37, P2019, DOI 10.1016/0006-2952(88)90550-3; BRANDT RB, 1982, METHOD ENZYMOL, V89, P35; Denton R M, 1979, Essays Biochem, V15, P37; DUKES ID, 1994, J BIOL CHEM, V269, P10979; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; HALESTRAP AP, 1976, BIOCHEM J, V156, P181, DOI 10.1042/bj1560181; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; JUNTTIBERGGREN L, 1994, J BIOL CHEM, V269, P14391; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MALAISSE WJ, 1980, DIABETES, V29, P431, DOI 10.2337/diabetes.29.6.431; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; Piston DW, 1999, METHOD ENZYMOL, V307, P351; Piston DW, 1999, TRENDS ENDOCRIN MET, V10, P413, DOI 10.1016/S1043-2760(99)00204-0; SCHARP DW, 1973, TRANSPLANTATION, V16, P686, DOI 10.1097/00007890-197312000-00028; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Shepherd RM, 1996, ENDOCRINOLOGY, V137, P677, DOI 10.1210/en.137.2.677; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; Voet D., 1993, BIOCHEMISTRY; Wang T, 1997, NAT BIOTECHNOL, V15, P358, DOI 10.1038/nbt0497-358; Zawalich WS, 1997, J BIOL CHEM, V272, P3527, DOI 10.1074/jbc.272.6.3527	29	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30914	30920		10.1074/jbc.M202314200	http://dx.doi.org/10.1074/jbc.M202314200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070148	hybrid			2022-12-25	WOS:000177579800066
J	Kim, GY; Mercer, SE; Ewton, DZ; Yan, ZF; Jin, K; Friedman, E				Kim, GY; Mercer, SE; Ewton, DZ; Yan, ZF; Jin, K; Friedman, E			The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CYCLIN-DEPENDENT KINASES; TRANSFORMING GROWTH-FACTOR-BETA-1; POTENTIAL MEDIATOR; DNA-REPLICATION; EXPRESSION; DIFFERENTIATION; P21(WAF1/CIP1); IDENTIFICATION; PROLIFERATION	Stress signals activate the SAPK/JNK and p38 MAPK classes of protein kinases, which mediate cellular responses, including steps in apoptosis and the maturation of some cell types. We now show that stress signals initiated by transforming growth factor-beta1 (TGF-beta1) induce G(1) arrest through protein stabilization of the CDK inhibitor p21(Cip1). TGF-beta1 was previously shown to increase p21 protein levels, which in turn mediated G(1) arrest through inactivation of the CDK2-cyclin E complex in HD3 cells (Yan, Z., Kim, G.-Y., Deng, X., and Friedman, E. (2002) J. Biol. Chem. 277, 9870-9879). We now demonstrate that the increase in p21 abundance is caused by a post-transcriptional, SMAD-independent mechanism. TGF-beta1 activated p38alpha and JNK1, which initiated the phosphorylation of p21. TGF-beta1 treatment increased the half-life of p21 by 3-4-fold. The increase in p21 stability was detected following activation of p38a and JNK1, and treatment of cells with the p38 inhibitor SB203580 prevented this increase in p21 stability. p38a and JNK1 phosphorylated p21 in vivo, and both p38a and JNK1 phosphorylated p21 at Ser(130) in vitro. Peptide mapping demonstrated that both TGF-beta1 and p38a induced phosphorylation of p21 at Ser(130) in vivo, and mutation of Ser(130) to alanine rendered p21 less stable than wild-type p21. TGF-beta1 increased the stability of wildtype p21, but not the p21-S130A mutant. These findings demonstrate that SAPKs can mediate cell cycle arrest through post-translational modification of p21.	Upstate Med Univ, Pathol Dept, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), Upstate Med Univ, Pathol Dept, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.	friedmae@mail.upstate.edu			NATIONAL CANCER INSTITUTE [R01CA075708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA75708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFTI A, 1997, J BIOL CHEM, V272, P1429; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Dmitrieva NI, 2002, P NATL ACAD SCI USA, V99, P184, DOI 10.1073/pnas.231623498; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Ewton DZ, 2002, INT J CANCER, V98, P665, DOI 10.1002/ijc.10229; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARPER JW, 1993, CELL, V75, P805; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; MULDER KM, 1992, J BIOL CHEM, V267, P5029; NAFTALIN RJ, 1990, FEBS LETT, V260, P187, DOI 10.1016/0014-5793(90)80100-W; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yan ZF, 2002, J BIOL CHEM, V277, P9870, DOI 10.1074/jbc.M107646200; YAN ZF, 1992, ONCOGENE, V7, P801; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	183	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29792	29802		10.1074/jbc.M201299200	http://dx.doi.org/10.1074/jbc.M201299200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058028	hybrid			2022-12-25	WOS:000177509300057
J	Vega-Agapito, V; Almeida, A; Hatzoglou, M; Bolanos, JP				Vega-Agapito, V; Almeida, A; Hatzoglou, M; Bolanos, JP			Peroxynitrite stimulates L-arginine transport system y(+) in glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; AMINO-ACID-TRANSPORT; MEDIATED MITOCHONDRIAL DAMAGE; CULTURED RAT ASTROCYTES; ANIMAL-CELLS; ACTIVATED ASTROCYTES; RELAXING FACTOR; NERVOUS-SYSTEM; NEURONS; EXPRESSION	We have reported previously that peroxynitrite stimulates L-arginine release from astrocytes, but the mechanism responsible for such an effect remains elusive. To explore this issue, we studied the regulation of L-[H-3]arginine transport by either exogenous or endogenous peroxynitrite in glial cells. A 2-fold peroxynitrite-mediated stimulation of L-arginine release in C6 cells was found to be Na+-independent, was prevented by 5 MM L-arginine and, although only in the presence of Na+, was blocked by 5 MM L-alanine or L-leucine. Peroxynitrite-mediated stimulation of L-arginine uptake was trans-stimulated by 10 MM L-arginine and was inhibited in a dose-dependent fashion (k(i) of similar to40 muM) by the system y(+) inhibitor N-ethylmaleimide in C6 cells. Endogenous production of peroxynitrite in lipopolysaccharide-treated astrocytes triggered an increased L-arginine transport activity without affecting Cat1 L-arginine transporter mRNA levels. However, Western blot analyses of peroxynitrite-treated astrocytes and C6 glial cells revealed a 3-nitrotyrosinated anti-Cat1-immunopositive band, strongly suggesting peroxynitrite-mediated Cat1 nitration. Furthermore, peroxynitrite stimulation of L-arginine release was abolished in fibroblast cells homozygous for a targeted inactivation of the Cat1 gene. Finally, peroxynitrite-triggered L-arginine released from astrocytes was efficiently taken up by neurons in an insert-based co-culture system. These results strongly suggest that peroxynitrite-mediated activation of the Cat1 transporter in glial cells may serve as a mechanism focused to replenish L-arginine in the neighboring neurons.	Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; Hosp Univ Salamance, Unidad Invest, Salamanca 37007, Spain; Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA	University of Salamanca; Case Western Reserve University	Bolanos, JP (corresponding author), Univ Salamanca, Dept Bioquim & Biol Mol, Pl Doctores Reina S-N, Salamanca 37007, Spain.		Agapito, Victoria Vega/ABH-1298-2020; Bolaños, Juan Pedro/M-9518-2019; ALMEIDA, ANGELES/B-4727-2017	Bolaños, Juan Pedro/0000-0002-3949-6862; ALMEIDA, ANGELES/0000-0003-0485-8904				AGULLO L, 1992, BIOCHEM BIOPH RES CO, V182, P1362, DOI 10.1016/0006-291X(92)91883-R; Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; AOKI E, 1991, BRAIN RES, V547, P190, DOI 10.1016/0006-8993(91)90961-T; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bolanos JP, 1997, BRAIN RES PROTOC, V1, P258, DOI 10.1016/S1385-299X(96)00039-6; Bolanos JP, 1996, FREE RADICAL BIO MED, V21, P995, DOI 10.1016/S0891-5849(96)00240-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broer A, 2000, BIOCHEM J, V349, P787, DOI 10.1042/bj3490787; BROWN GC, 1995, NEUROSCI LETT, V193, P201, DOI 10.1016/0304-3940(95)11703-Y; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cidad P, 2001, J NEUROCHEM, V79, P17, DOI 10.1046/j.1471-4159.2001.00523.x; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; CULCASI M, 1994, J BIOL CHEM, V269, P12589; Delgado-Esteban M, 2000, J NEUROCHEM, V75, P1618, DOI 10.1046/j.1471-4159.2000.0751618.x; DEVES R, 1993, J PHYSIOL-LONDON, V468, P753, DOI 10.1113/jphysiol.1993.sp019799; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Estevez AG, 1998, PROG BRAIN RES, V118, P269; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; Grima G, 1998, J NEUROCHEM, V71, P2139; Grima G, 1997, EUR J NEUROSCI, V9, P2248, DOI 10.1111/j.1460-9568.1997.tb01643.x; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Merrill JE, 1997, J NEUROSCI RES, V48, P372, DOI 10.1002/(SICI)1097-4547(19970515)48:4<372::AID-JNR9>3.0.CO;2-8; Nicholson B, 1998, J BIOL CHEM, V273, P14663, DOI 10.1074/jbc.273.24.14663; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Perkins CP, 1997, GENE DEV, V11, P914, DOI 10.1101/gad.11.7.914; RADI R, 1991, J BIOL CHEM, V266, P4244; SCHMIDLIN A, 1994, GLIA, V11, P262, DOI 10.1002/glia.440110307; SCHMIDLIN A, 1995, J NEUROCHEM, V65, P590; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Stevens BR, 1996, J BIOL CHEM, V271, P24017, DOI 10.1074/jbc.271.39.24017; STOLL J, 1993, J NEUROCHEM, V60, P1956, DOI 10.1111/j.1471-4159.1993.tb13428.x; Vega-Agapito V, 1999, J NEUROCHEM, V73, P1446, DOI 10.1046/j.1471-4159.1999.0731446.x; WESTERGAARD N, 1993, J NEUROCHEM, V61, P364, DOI 10.1111/j.1471-4159.1993.tb03579.x; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1982, J BIOL CHEM, V257, P4443; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635	47	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29753	29759		10.1074/jbc.M203728200	http://dx.doi.org/10.1074/jbc.M203728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058042	hybrid			2022-12-25	WOS:000177509300052
J	Carpentier, A; Taghibiglou, C; Leung, N; Szeto, L; Van Iderstine, SC; Uffelman, KD; Buckingham, R; Adeli, K; Lewis, GF				Carpentier, A; Taghibiglou, C; Leung, N; Szeto, L; Van Iderstine, SC; Uffelman, KD; Buckingham, R; Adeli, K; Lewis, GF			Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 DIABETES-MELLITUS; APOLIPOPROTEIN-B; PPAR-GAMMA; TYROSINE PHOSPHATASE-1B; CARDIOVASCULAR-DISEASE; LIPID AVAILABILITY; OPTIMAL SEGMENTS; CONTROLLED TRIAL; GENE-EXPRESSION; ADIPOSE-TISSUE	To determine whether reduction of insulin resistance could ameliorate fructose-induced very low density lipoprotein (VLDL) oversecretion and to explore the mechanism of this effect, fructose-fed hamsters received placebo or rosiglitazone for 3 weeks. Rosiglitazone treatment led to normalization of the blunted insulin-mediated suppression of the glucose production rate and to a similar to2-fold increase in whole body insulin-mediated glucose disappearance rate (p < 0.001). Rosiglitazone ameliorated the defect in hepatocyte insulin-stimulated tyrosine phosphorylation of the insulin receptor, IRS-1, and IRS-2 and the reduced protein mass of IRS-1 and IRS-2 induced by fructose feeding. Protein-tyrosine phosphatase 111 levels were increased with fructose feeding and were markedly reduced by rosiglitazone. Rosiglitazone treatment led to a similar to50% reduction of VLDL secretion rates (p < 0.05) in vivo and ex vivo. VLDL clearance assessed directly in vivo was not significantly different in the FR (fructose-fed + rosiglitazone-treated) versus F (fructose-fed + placebo-treated) hamsters, although there was a trend toward a lower clearance with rosiglitazone. Enhanced stability of nascent apolipoprotein B (apoB) in fructose-fed hepatocytes was evident, and rosiglitazone treatment resulted in a significant reduction in apoB stability. The increase in intracellular mass of microsomal triglyceride transfer protein seen with fructose feeding was reduced by treatment with rosiglitazone. In conclusion, improvement of hepatic insulin signaling with rosiglitazone, a peroxisome proliferator-activated receptor gamma agonist, is associated with reduced hepatic VLDL assembly and secretion due to reduced intracellular apoB stability.	Univ Toronto, Hlth Network, Dept Med, Div Endocrinol & Metab, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hosp Sick Children, Dept Lab Mad & Pathobiol, Toronto, ON M5G 2C4, Canada; GlaxoSmithKline, Clin Dev & Med Affairs, Harlow CM19 5AW, Essex, England; Heart & Stroke Fdn Canada, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); GlaxoSmithKline	Lewis, GF (corresponding author), Toronto Gen Hosp, Div Endocrinol & Metab, 200 Elizabeth St,Room EN11-229, Toronto, ON M5G 2C4, Canada.		Taghibiglou, Changiz/H-4590-2019; Adiels, Martin/C-9278-2011	Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1994, J BIOL CHEM, V269, P9166; Ahmad F, 1997, METABOLISM, V46, P1140, DOI 10.1016/S0026-0495(97)90206-7; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; BRADLEY DC, 1993, AM J PHYSIOL, V264, pE902, DOI 10.1152/ajpendo.1993.264.6.E902; Carpentier A, 2001, DIABETES, V50, P1402, DOI 10.2337/diabetes.50.6.1402; Chicco A, 2000, METABOLISM, V49, P1346, DOI 10.1053/meta.2000.9506; Edvardsson U, 1999, J LIPID RES, V40, P1177; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FINEGOOD DT, 1987, DIABETES, V36, P914, DOI 10.2337/diabetes.36.8.914; FINEGOOD DT, 1983, AM J PHYSIOL, V244, pE472, DOI 10.1152/ajpendo.1983.244.5.E472; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HIRANO T, 1988, AM J PHYSIOL, V255, pE236, DOI 10.1152/ajpendo.1988.255.3.E236; JACKSON TK, 1988, DIABETES, V37, P1234, DOI 10.2337/diabetes.37.9.1234; Kennedy BP, 2000, BIOCHEM PHARMACOL, V60, P877, DOI 10.1016/S0006-2952(00)00305-1; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kumar S, 1996, DIABETOLOGIA, V39, P701; Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756; Lemieux S, 1999, J LIPID RES, V40, P2111; LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633; Lewis GF, 1996, DIABETES METAB REV, V12, P37, DOI 10.1002/(SICI)1099-0895(199603)12:1&lt;37::AID-DMR154&gt;3.0.CO;2-Q; Lewis GF, 1997, CURR OPIN LIPIDOL, V8, P146, DOI 10.1097/00041433-199706000-00004; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Li XH, 1997, J LIPID RES, V38, P1277; LIN MCM, 1995, J LIPID RES, V36, P1073; Maggs DG, 1998, ANN INTERN MED, V128, P176, DOI 10.7326/0003-4819-128-3-199802010-00002; Malmstrom R, 1998, DIABETES, V47, P779, DOI 10.2337/diabetes.47.5.779; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; OAKES ND, 1994, DIABETES, V43, P1203, DOI 10.2337/diabetes.43.10.1203; Oakes ND, 1997, METABOLISM, V46, P935, DOI 10.1016/S0026-0495(97)90083-4; Oakes ND, 2001, DIABETES, V50, P1158, DOI 10.2337/diabetes.50.5.1158; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Park J, 1997, J LIPID RES, V38, P2529; PARK OJ, 1992, BIOCHEM J, V282, P753, DOI 10.1042/bj2820753; Ranganathan S, 1998, J BIOL CHEM, V273, P26117, DOI 10.1074/jbc.273.40.26117; Raskin P, 2000, DIABETOLOGIA, V43, P278, DOI 10.1007/s001250050045; Rieusset J, 1999, BIOCHEM BIOPH RES CO, V265, P265, DOI 10.1006/bbrc.1999.1657; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SCHWENK WF, 1990, AM J PHYSIOL, V258, P228; SREDY J, 1995, METABOLISM, V44, P1074, DOI 10.1016/0026-0495(95)90107-8; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Sunayama S, 1999, ATHEROSCLEROSIS, V146, P187, DOI 10.1016/S0021-9150(99)00138-0; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Taghibiglou C, 2000, J LIPID RES, V41, P499; Taghibiglou C, 2002, J BIOL CHEM, V277, P793, DOI 10.1074/jbc.M106737200; Yao ZM, 1997, J LIPID RES, V38, P1937	50	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28795	28802		10.1074/jbc.M204568200	http://dx.doi.org/10.1074/jbc.M204568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048212	hybrid			2022-12-25	WOS:000177342600059
J	Rottapel, R; Ilangumaran, S; Neale, C; La Rose, J; Ho, JMY; Nguyen, MHH; Barber, D; Dubreuil, P; de Sepulveda, P				Rottapel, R; Ilangumaran, S; Neale, C; La Rose, J; Ho, JMY; Nguyen, MHH; Barber, D; Dubreuil, P; de Sepulveda, P			The tumor suppressor activity of SOCS-1	ONCOGENE			English	Article						SOCS-1; Tel-Jak; KIT; BCR-ABL; tyrosine kinase	KINASE-ACTIVITY; NEGATIVE REGULATION; LYMPHOPROLIFERATIVE DISEASE; TYROSINE PHOSPHORYLATION; BOX MOTIF; C-CBL; PROTEIN; INDUCTION; DOMAIN; JAK2	SOCS-1 is an inducible SH2-containing inhibitor of Jak kinases and as such can potently suppress cytokine signaling. SOCS-1 deficient mice die within the first three weeks of life from a myeloproliferative disorder driven by excessive interferon signaling. We report here that SOCS-I inhibits proliferation signals induced by a variety of oncogenes active within the hematopoietic system. Ectopic expression of SOCS-I abolished proliferation mediated by a constitutively active form of the KIT receptor, TEL-JAK2, and v-ABL, and reduced metastasis from BCR-ABL transformed cells. SOCS-1, however, did not interfere with v-SRC or RASV12 mediated cellular transformation. A mutant form of SOCS-I unable to bind through its SH2 domain to tyrosine phosphorylated proteins could still inhibit KIT, but not TEL-JAK2, indicating multiple mechanisms for SOCS-1-mediated tumor suppression. We show that the steady state levels of TEL-JAK2 and to a greater extent v-ABL are diminished in the presence of SOCS-1. Lastly, we show that SOCS-1 -/- fibroblasts are more sensitive than wild type fibroblasts to either spontaneous or oncogene-induced transformation. These data suggest that loss-of-function of SOCS-1 may collaborate with a variety of hematopoietic oncogenes to facilitate tumor progression.	Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; INSERM, U119, F-13009 Marseille, France	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rottapel, R (corresponding author), Princess Margaret Hosp, Rm 10-116,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rottapel@oci.utoronto.ca; sepulveda@marseille.inserm.fr	De sepulveda, paulo/K-6043-2015; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	De sepulveda, paulo/0000-0001-8295-5414; Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Ilangumaran, Subburaj/0000-0002-7563-576X; Rottapel, Robert/0000-0002-6024-5558				Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mauro MJ, 2001, CURR OPIN ONCOL, V13, P3, DOI 10.1097/00001622-200101000-00002; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Nagai H, 2001, J HEPATOL, V34, P416, DOI 10.1016/S0168-8278(00)00038-6; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Rohrschneider LR, 2000, GENE DEV, V14, P505; Rottapel R, 2000, FR MOLEC B, V29, P246; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	53	108	110	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4351	4362		10.1038/sj.onc.1205537	http://dx.doi.org/10.1038/sj.onc.1205537			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080466				2022-12-25	WOS:000176317100001
J	Talukder, AH; Wang, RA; Kumar, R				Talukder, AH; Wang, RA; Kumar, R			Expression and transactivating functions of the bZIP transcription factor GADD153 in mammary epithelial cells	ONCOGENE			English	Article						HER2; heregulin; GADD153; differentiation; mammary epithelial cells	FACTOR CHOP GADD153; BINDING PROTEIN; REGULATED EXPRESSION; POINT MUTATION; GROWTH-FACTORS; DNA-BINDING; HEREGULIN; DIFFERENTIATION; STRESS; GENE	Heregulin-beta1 (HRG), a combinatorial ligand for human epidermal growth factor receptor 3 (HER3) and HER4, is a regulatory polypeptide having distinct biological effects, such as growth stimulation, differentiation, invasiveness, and migration in mammary epithelial cells. The mechanism underlying the diverse functions of HRG is not well established but is believed to depend on induced changes in the expression of specific cellular gene products, their modification, or both. Here, we identified the basic leucine zipper transcription factor, the growth-arrest and DNA-damage 153 (GADD153)/ CCAAT-enhancer binding protein (C/EBP) homologous protein (CHOP) as one of the HRG-inducible genes. We demonstrated that HRG stimulation of mammary epithetial cells induces the expression of GADD153 mRNA and protein and transcription of GADD153 promoter. The transcriptional activity of the GADD153 promoter as well as transcription from the C/EBP-activating transcription factor (ATF) composite motif in the GADD153 promoter was also stimulated by HRG-inducible ATF-4 and activated HER2 but not wild-type HER2. GADD153 expression was upregulated by the lactogenic hormones insulin and progesterone and associated with differentiation of normal mammary epithelial cells. Consistent with its role as transcriptional modifier, GADD153 stimulated transcription of beta-casein promoter activity in a STAT5a-sensitive manner in mammary epithelial cells. Analysis of mouse mammary gland development revealed that GADD153 expression was predominantly restricted in the early lactating stages. Because cyclic AMP responsive element and ATF binding sites are present in a variety of growth-regulating cellular genes, these findings suggest that stimulation of GADD153 expression and its transactivating functions may constitute an important mechanism of regulation of putative genes having diverse functions during cell growth and differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Wang, Brian/HGA-9535-2022	Wang, Rui-An/0000-0003-2320-1211	NCI NIH HHS [CA80066, CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, R01CA080066, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Krane IM, 1996, ONCOGENE, V12, P1781; Kumar R, 1996, CLIN CANCER RES, V2, P1215; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SLAMON DJ, 1987, SCIENCE, V235, P77; Talukder AH, 2001, J BIOL CHEM, V276, P5636, DOI 10.1074/jbc.M006824200; Talukder AH, 2000, CANCER RES, V60, P276; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Vadlamudi RK, 2000, MOL CELL BIOL, V20, P9092, DOI 10.1128/MCB.20.23.9092-9101.2000; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	46	24	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4289	4300		10.1038/sj.onc.1205529	http://dx.doi.org/10.1038/sj.onc.1205529			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082616				2022-12-25	WOS:000176174200011
J	Wilting, J; Papoutsi, M; Christ, B; Nicolaides, KH; von Kaisenberg, CS; Borges, J; Stark, GB; Alitalo, K; Tomarev, SI; Niemeyer, C; Rossler, J				Wilting, J; Papoutsi, M; Christ, B; Nicolaides, KH; von Kaisenberg, CS; Borges, J; Stark, GB; Alitalo, K; Tomarev, SI; Niemeyer, C; Rossler, J			The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues	FASEB JOURNAL			English	Article						human fetus; lymphedema; lymphangioma; hemangioma; lymphangiogenesis	GROWTH-FACTOR RECEPTOR-3; VASCULAR TUMORS; VEGF-C; EXPRESSION; BLOOD; GENE; LYMPHANGIOGENESIS; PROMOTES; CD31; LOCALIZATION	Detection of lymphatic endothelal cells (LECs) has been problematic because of the lack of specific markers. The homeobox transcription factor Prox1 is expressed in LECs of murine and avian embryos. We have studied expression of Prox1 in human tissues with immunofluorescence. In 19-wk-old human fetuses, Prox1 and vascular endothelial growth factor receptor-3 (VEGFR-3) are coexpressed in LECs of lymphatic trunks and lymphatic capillaries. Prox1 is located in the nucleus, and its expression is mutually exclusive with that of the blood vascular marker PAL-E. Prox1 is a constitutive marker of LECs and is found in tissues of healthy adults and lymphedema patients. Blood vascular endothelial cells (BECs) of hemangiomas express CD31 and CD34, but not Prox1. A subset of these cells is positive for VEGFR-3. Lymphatics in the periphery of hemangiomas express Prox1 and CD31, but not CD34. In lymphangiomas, LECs express Prox1, CD31, and VEGFR-3, but rarely CD34. In the stroma, spindle-shaped CD34-positive cells are present. We show that Prox1 is a reliable marker for LECs in normal and pathologic human tissues, coexpressed with VEGFR-3 and CD31. VEGFR-3 and CD34 are less reliable markers for LECs and BECs, respectively, because exceptions from their normal expression patterns are found in pathologic tissues.	Univ Freiburg, Inst Anat, D-79104 Freiburg, Germany; Kings Coll Hosp London, Harris Birthright Res Ctr Fetal Med, London, England; Univ Kiel, Frauenklin, D-24105 Kiel, Germany; Univ Freiburg, Abt Plast & Handchirurg, D-79104 Freiburg, Germany; Univ Helsinki, Mol & Canc Biol Lab, FIN-00014 Helsinki, Finland; NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Freiburg, Zentrum Kinderheilkunde & Jugendmed, D-79104 Freiburg, Germany	University of Freiburg; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Kiel; University of Freiburg; University of Helsinki; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Freiburg	Wilting, J (corresponding author), Univ Freiburg, Inst Anat, Albertstr 17, D-79104 Freiburg, Germany.	Joerg.Wilting@anat.uni-freiburg.de	von Kaisenberg, Constantin/AAR-2756-2021; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Nicolaides, Kypros/0000-0003-1266-0711; Rossler, Jochen/0000-0003-4022-4917	NATIONAL EYE INSTITUTE [Z01EY000311, ZIAEY000311] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Carreira CM, 2001, CANCER RES, V61, P8079; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Duncan GS, 1999, J IMMUNOL, V162, P3022; FOLKMAN J, 1974, CANCER RES, V34, P2109; Folpe AL, 2000, MODERN PATHOL, V13, P180, DOI 10.1038/modpathol.3880033; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KATO S, 1990, ACTA HISTOCHEM CYTOC, V23, P613, DOI 10.1267/ahc.23.613; Kinmonth JB, 1972, LYMPHATICS DIS LYMPH, V1st; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; MCNEILL GC, 1989, RADIOLOGY, V172, P495, DOI 10.1148/radiology.172.2.2748831; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; Paal E, 1998, CANCER-AM CANCER SOC, V82, P2150, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2150::AID-CNCR9>3.0.CO;2-Z; Papoutsi M, 2000, HISTOCHEM CELL BIOL, V113, P105, DOI 10.1007/s004180050013; Papoutsi M, 2001, DEV DYNAM, V222, P238, DOI 10.1002/dvdy.1187; Papoutsi M, 2000, HISTOCHEM CELL BIOL, V114, P373; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; POLKINGHORNE J, 1989, CM762; Rodriguez-Niedenfuhr M, 2001, ANAT EMBRYOL, V204, P399, DOI 10.1007/s00429-001-0214-9; Sauter B, 1998, J HISTOCHEM CYTOCHEM, V46, P165, DOI 10.1177/002215549804600205; SCHLINGEMANN RO, 1985, LAB INVEST, V52, P71; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2001, MICROSC RES TECHNIQ, V55, P61, DOI 10.1002/jemt.1157; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Tomarev SI, 1996, DEV DYNAM, V206, P354, DOI 10.1002/(SICI)1097-0177(199608)206:4<354::AID-AJA2>3.0.CO;2-H; Tomarev SI, 1998, BIOCHEM BIOPH RES CO, V248, P684, DOI 10.1006/bbrc.1998.8989; Vikkula M, 1998, TRENDS CARDIOVAS MED, V8, P281, DOI 10.1016/S1050-1738(98)00024-3; von Kaisenberg CS, 1999, HUM REPROD, V14, P823, DOI 10.1093/humrep/14.3.823; Wetterwald A, 1996, BONE, V18, P125, DOI 10.1016/8756-3282(95)00457-2; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wilting J, 1997, CELL TISSUE RES, V288, P207, DOI 10.1007/s004410050807; Wilting J, 2001, MICROSC RES TECHNIQ, V55, P81, DOI 10.1002/jemt.1159; Witte MH, 2001, MICROSC RES TECHNIQ, V55, P122, DOI 10.1002/jemt.1163; Zinovieva RD, 1996, GENOMICS, V35, P517, DOI 10.1006/geno.1996.0392	44	135	150	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1271	+		10.1096/fj.01-1010fje	http://dx.doi.org/10.1096/fj.01-1010fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060670				2022-12-25	WOS:000176683900038
J	Spankuch-Schmitt, B; Wolf, G; Solbach, C; Loibl, S; Knecht, R; Stegmuller, M; von Minckwitz, G; Kaufmann, M; Strebhardt, K				Spankuch-Schmitt, B; Wolf, G; Solbach, C; Loibl, S; Knecht, R; Stegmuller, M; von Minckwitz, G; Kaufmann, M; Strebhardt, K			Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells	ONCOGENE			English	Article						polo-like kinase; antisense; anticancer activity; xenograft	PROTEIN-KINASE; PHASE-I; SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE KINASE; PROGNOSTIC-SIGNIFICANCE; PLK EXPRESSION; C-ALPHA; CYCLE; DROSOPHILA; OLIGODEOXYNUCLEOTIDE	A central role for polo-like kinases (PLK) in regulating several stages of mitotic progression has been born out in several species. Overexpression of PLK1 is observed in the majority of hitherto analysed human tumors. PLK1 overexpression is a negative prognostic factor in patients suffering from non-small cell lung cancer, head and neck tumors, esophageal carcinomas and melanomas. In order to define the role of PLK1 for mitotic progression of human cells and for neoplastic cell growth, phosphorothioate antisense oligonucleotides (ASOs) were tested to selectively downregulate PLK1 expression in MDA-MB-435 (breast cancer), HeLa S3 (cervical carcinoma) and A549 (non-small cell lung cancer) cells. ASOs were identified which suppress PLK1 mRNA and protein in a dose-dependent and sequence-specific manner. This approach also led to reduced PLK1 serine/threonine kinase activity. Downregulation of cellular PLK1 levels in cancer cells altered cell cycle progression moderately with an elevated percentage (20-30%) of cells in G(2)/M. Furthermore, cells with reduced PLK1 protein gained a rounded phenotype with multiple centrosomes. Moreover, ASO treatment resulted in potent antiproliferative effects in cell culture. Considerable antitumor activity was observed in vivo against A549 cells. This study suggests that antisense inhibitors targeted against PLK1 at well tolerated doses may be considered as a cancer therapeutic agent.	Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, D-60596 Frankfurt, Germany; Goethe Univ Frankfurt, Sch Med, Dept Otorhinolaryngol, D-60596 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.	Stebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, pVII, DOI 10.1089/oli.1.1998.8.vii; Crooke ST, 2000, ONCOGENE, V19, P6651, DOI 10.1038/sj.onc.1204093; CROOKE ST, 1994, CLIN PHARMACOL THER, V56, P641, DOI 10.1038/clpt.1994.189; Cunningham CC, 2000, CLIN CANCER RES, V6, P1626; DIRKSEN ML, 1981, J BIOL CHEM, V256, P1569; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HARTWELL LH, 1973, GENETICS, V74, P267; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Knecht R, 1999, CANCER RES, V59, P2794; Kuss B, 1999, ANN ONCOL, V10, P495, DOI 10.1023/A:1026416314887; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; SHARON G, 1990, GENETICS, V125, P475; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yuan JP, 1997, AM J PATHOL, V150, P1165; Yuen AR, 1999, CLIN CANCER RES, V5, P3357; ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3	39	147	158	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3162	3171		10.1038/sj.onc.1205412	http://dx.doi.org/10.1038/sj.onc.1205412			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082631				2022-12-25	WOS:000175373600007
J	Hamidinia, SA; Shimelis, OI; Tan, B; Erdahl, WL; Chapman, CJ; Renkes, GD; Taylor, RW; Pfeiffer, DR				Hamidinia, SA; Shimelis, OI; Tan, B; Erdahl, WL; Chapman, CJ; Renkes, GD; Taylor, RW; Pfeiffer, DR			Monensin mediates a rapid and selective transport of Pb2+ - Possible application of monensin for the treatment of Pb2+ intoxication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-ABSORPTION-SPECTROMETRY; STANDARD BUFFER SOLUTIONS; METHANOL-WATER MIXTURES; IONOPHORES A23187; METAL-CATIONS; LEAD MOBILIZATION; COMPLEX-FORMATION; DIVALENT-CATIONS; PH-MEASUREMENTS; BLOOD-PRESSURE	The carboxylic acid ionophore monensin, known as an electroneutral Na+ ionophore, an anticoccidial agent, and a growth-promoting feed additive in agriculture, is shown to be highly efficient as an ionophore for Pb2+ and to be highly selective for Pb2+ compared with other divalent cations. Monensin transports Pb2+ by an electroneutral mechanism in which the complex PbMonOH is the transporting species. Electrogenic transport via the species PbMon(+) may also be possible. Monensin catalyzed Pb2+ transport is little affected by Ca2+, Mg2+, or K+ concentrations that are encountered in living systems. Na+ is inhibitory, but its effectiveness at 100 mm does not exceed similar to50%. The poor activity of monensin as an ionophore for divalent cations other than Pb2+ is consistent with the pattern of complex formation constants observed in the mixed solvent 80% methanol/water. This pattern also explains why Ca2+, Mg2+, and (+) are ineffective as inhibitors of Pb2+ transport, but it does not fully explain the actions of Na+, where kinetic features of the transport mechanism may also be important. When given to rats at 100 ppm in feed together with Pb2+ at 100 ppm in drinking water, monensin reduces Pb accumulation in several organs and tissues. It also accelerates the excretion of Pb that was accumulated previously and produces this effect without depleting the organs of zinc or copper. Monensin, used alone or in combination with other agents, may be useful for the treatment of Pb intoxication.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Oklahoma System; University of Oklahoma - Norman	Pfeiffer, DR (corresponding author), Ohio State Univ, Dept Biochem Med, 1645 Neil Ave,310A Hamilton Hall, Columbus, OH 43210 USA.	pfeiffer.17@osu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066206] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM66206] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baes C.F., 1976, HYDROLYSIS CATIONS, DOI 10.1002/bbpc.19770810252; BARLTROP D, 1979, ARCH ENVIRON HEALTH, V34, P280, DOI 10.1080/00039896.1979.10667414; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BOGDEN JD, 1991, J NUTR, V121, P718, DOI 10.1093/jn/121.5.718; BOGDEN JD, 1995, J NUTR, V125, P990; BRAIDE VB, 1984, GEN PHARMACOL, V15, P37, DOI 10.1016/0306-3623(84)90077-6; BriggsReed LM, 1997, MICROCHEM J, V55, P122, DOI 10.1006/mchj.1996.1424; CHAPMAN CJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P44, DOI 10.1016/0003-9861(90)90411-Q; CHAPMAN CJ, 1991, CHEM PHYS LIPIDS, V60, P201, DOI 10.1016/0009-3084(91)90042-A; CHAPMAN CJ, 1990, CHEM PHYS LIPIDS, V55, P73, DOI 10.1016/0009-3084(90)90068-3; CHAPMAN CJ, 1987, RECL TRAV CHIM PAY B, V106, P265; CHAPMAN CJ, 1987, BIOCHEMISTRY-US, V26, P5009, DOI 10.1021/bi00390a019; CORYSLECHTA DA, 1987, J PHARMACOL EXP THER, V243, P804; CORYSLECHTA DA, 1988, J PHARMACOL EXP THER, V246, P84; COX BG, 1984, J AM CHEM SOC, V106, P5965, DOI 10.1021/ja00332a035; Davies C.W., 1962, ION ASS; DELIGNY CL, 1960, RECL TRAV CHIM PAY B, V79, P699; DELIGNY CL, 1960, RECL TRAV CHIM PAY B, V79, P713; DOBLER M, 1981, IONOPHORES THEIR STR, P5; Erdahl WL, 1996, BIOCHEMISTRY-US, V35, P13817, DOI 10.1021/bi961391q; Erdahl WL, 1995, BIOPHYS J, V69, P2350, DOI 10.1016/S0006-3495(95)80104-9; ERDAHL WL, 1994, BIOPHYS J, V66, P1678, DOI 10.1016/S0006-3495(94)80959-2; Erdahl WL, 2000, J BIOL CHEM, V275, P7071, DOI 10.1074/jbc.275.10.7071; ESTRADA OS, 1968, ANTIMICROB AGENTS CH, P279; FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0; GELSEMA WJ, 1966, RECL TRAV CHIM PAY-B, V85, P647; GELSEMA WJ, 1967, RECL TRAV CHIM PAY-B, V86, P852; GRAN G, 1952, ANALYST, V77, P661, DOI 10.1039/an9527700661; Gruber HE, 1997, MINER ELECTROL METAB, V23, P65; Hamidinia SA, 2002, BIOPHYS J, V82, p562A; HAMMOND PB, 1967, J PHARMACOL EXP THER, V157, P196; HEBRANT M, 1992, NEW J CHEM, V16, P999; Hladky SB, 1995, BIOPHYS J, V69, P1758, DOI 10.1016/S0006-3495(95)80046-9; HOOGERHEIDE JG, 1979, J SOLUTION CHEM, V8, P83, DOI 10.1007/BF00646810; IVANOVA OG, 2000, THESIS U OKLAHOMA NO; IZATT RM, 1985, CHEM REV, V85, P271, DOI 10.1021/cr00068a003; KAUFFMAN RF, 1982, BIOCHEMISTRY-US, V21, P2426, DOI 10.1021/bi00539a023; Kostial K, 2000, J TRACE ELEM EXP MED, V13, P277, DOI 10.1002/1520-670X(2000)13:3<277::AID-JTRA5>3.0.CO;2-2; Martell A. E., 1977, CRITICAL STABILITY C, V3; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; MIMOUNI M, 1993, J SOLUTION CHEM, V22, P769, DOI 10.1007/BF00648581; MIMOUNI M, 1994, B SOC CHIM FR, V131, P58; MOTEKAITIS RJ, 1982, CAN J CHEM, V60, P168, DOI 10.1139/v82-029; MOTEKAITIS RJ, 1982, CAN J CHEM, V60, P2403, DOI 10.1139/v82-347; PAINTER GR, 1982, TOP CURR CHEM, P88; PAPPAS JB, 1995, TOXICOL APPL PHARM, V133, P121, DOI 10.1006/taap.1995.1133; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; PERRY HM, 1959, J CLIN INVEST, V38, P1452, DOI 10.1172/JCI103922; PFEIFFER DR, 1983, INORG CHIM A-BIOINOR, V79, P214, DOI 10.1016/S0020-1693(00)95247-2; PINKERTO.M, 1970, J MOL BIOL, V49, P533, DOI 10.1016/0022-2836(70)90279-2; POINTUD Y, 1985, J CHIM PHYS PCB, V82, P891, DOI 10.1051/jcp/1985820891; PRESSMAN BC, 1982, ANNU REV PHARMACOL, V22, P465, DOI 10.1146/annurev.pa.22.040182.002341; PROSSER BLT, 1982, POLYETHER ANTIBIOTIC, P21; QUARTERMAN J, 1976, ENVIRON RES, V12, P180, DOI 10.1016/0013-9351(76)90022-0; RAUN AP, 1976, J ANIM SCI, V43, P670, DOI 10.2527/jas1976.433670x; RORABACH.DB, 1971, ANAL CHEM, V43, P561, DOI 10.1021/ac60299a014; Ruff MD, 1982, POLYETHER ANTIBIOTIC, P303; Seaton CL, 1999, TOXICOL APPL PHARM, V159, P153, DOI 10.1006/taap.1999.8725; SHUMARD RF, 1967, ANTIMICROB AGENTS CH, P369; SHUTTLER IL, 1986, ANALYST, V111, P651, DOI 10.1039/an9861100651; Smith D, 1998, ENVIRON RES, V78, P168, DOI 10.1006/enrs.1998.3854; STILES MK, 1991, J BIOL CHEM, V266, P8336; SUZUKI K, 1988, ANAL CHEM, V60, P1714, DOI 10.1021/ac00168a016; SUZUKI K, 1987, J CHEM SOC CHEM COMM, P932, DOI 10.1039/c39870000932; Tandon SK, 1998, CLIN EXP PHARMACOL P, V25, P686, DOI 10.1111/j.1440-1681.1998.tb02277.x; TAYLOR RW, 1985, BIOCHEMISTRY-US, V24, P4852, DOI 10.1021/bi00339a019; TAYLOR RW, 1993, PURE APPL CHEM, V65, P579, DOI 10.1351/pac199365030579; TAYLOR RW, 1982, POLYETHER ANTIBIOTIC, V1, P103; TODD GC, 1984, J ANIM SCI, V58, P1512, DOI 10.2527/jas1984.5861512x; TOEPLITZ BK, 1979, J AM CHEM SOC, V101, P3344, DOI 10.1021/ja00506a035; TSUKUBE H, 1994, INORG CHEM, V33, P2984, DOI 10.1021/ic00091a043; Vogel A. I., 1961, TXB QUANTITATIVE INO, P433; Wang E, 1998, BIOPHYS J, V75, P1244, DOI 10.1016/S0006-3495(98)74044-5; Wang E, 2001, BIOPHYS J, V81, P3275, DOI 10.1016/S0006-3495(01)75961-9; Westley JW, 1982, POLYETHER ANTIBIOTIC, P1; ZINTERHOFER LJ, 1971, J LAB CLIN MED, V78, P664	77	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38111	38120		10.1074/jbc.M205590200	http://dx.doi.org/10.1074/jbc.M205590200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12080080	hybrid			2022-12-25	WOS:000178529600019
J	Grundschober, C; Malosio, ML; Astolfi, L; Giordano, T; Nef, P; Meldolesi, J				Grundschober, C; Malosio, ML; Astolfi, L; Giordano, T; Nef, P; Meldolesi, J			Neurosecretion competence - A comprehensive gene expression program identified in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEIN; INDEPENDENTLY REGULATED TRAIT; TRANSCRIPTION FACTOR; NEUROTRANSMITTER RELEASE; DIFFERENTIAL REGULATION; CHROMOGRANIN-B; MESSENGER-RNA; RAT; TRANSPORT; NEURONS	The phenotype of neurosecretory cells is characterized by clear vesicles and dense granules, both discharged by regulated exocytosis. However, these organelles are lacking completely in a few neurosecretion-incompetent clones of the pheochromocytoma PC12 line, in which other specific features are maintained (incompetent clones). In view of the heterogeneity of PC12 cells, a differential characterization of the incompetent phenotype based on the comparison of a single incompetent and a single wild-type clone would have been inconclusive. Therefore, we have compared two pairs of PC12 clones, studying in parallel the transcript levels of 4,200 genes and 19,000 express sequence tags (ESTs) by high density oligonucleotide arrays. After accurate data processing for quality control and filtration, a total of 755 transcripts, corresponding to 448 genes and 307 ESTs, was found consistently changed , with 46% up-regulated and 54% down-regulated in incompetent versus wild-type clones. Many but not all neurosecretion genes were profoundly down-regulated in incompetent cells. Expression of endocytosis genes was normal, whereas that of many nuclear and transcription factors, including some previously shown to play key roles in neurogenesis, was profoundly changed. Additional differences appeared in genes involved in signaling and metabolism. Taken together these results demonstrate for the first time that expression of neurosecretory vesicles and granules is part of a complex gene expression program that includes many other features that so far have not been recognized.	Ist Sci San Raffaele, Dept Biol & Technol Res, I-20132 Milan, Italy; F Hoffmann La Roche & Co Ltd, Cent Nervous Syst, CH-4070 Basel, Switzerland; Univ Vita Salute San Raffaele, I-20132 Milan, Italy; Ist Sci San Raffaele, Dept Neurosci, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Roche Holding; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Malosio, ML (corresponding author), Ist Sci San Raffaele, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.	malosio.marialuisa@hsr.it	Astolfi, Laura/GLU-1045-2022; Astolfi, Laura/H-2846-2012; Malosio, Maria Luisa/C-1695-2013	Astolfi, Laura/0000-0002-3291-8567; Astolfi, Laura/0000-0002-3291-8567; Malosio, Maria Luisa/0000-0003-0626-3066	Telethon [1118] Funding Source: Medline	Telethon(Fondazione Telethon)		ANTON R, 1994, EXP NEUROL, V127, P207, DOI 10.1006/exnr.1994.1097; Atouf F, 1997, J BIOL CHEM, V272, P1929, DOI 10.1074/jbc.272.3.1929; BITLER CM, 1986, J NEUROCHEM, V47, P1286; Borgonovo B, 1998, J BIOL CHEM, V273, P34683, DOI 10.1074/jbc.273.52.34683; CECCALDI PE, 1995, J CELL BIOL, V128, P905, DOI 10.1083/jcb.128.5.905; Christiansen JH, 2000, CURR OPIN CELL BIOL, V12, P719, DOI 10.1016/S0955-0674(00)00158-7; CIDON S, 1989, J BIOL CHEM, V264, P8281; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Corradi N, 1996, J BIOL CHEM, V271, P27116, DOI 10.1074/jbc.271.43.27116; Courey AJ, 2001, CURR BIOL, V11, pR250, DOI 10.1016/S0960-9822(01)00130-0; Daly C, 1997, J NEUROSCI, V17, P2365; DAY R, 1995, DNA CELL BIOL, V14, P175, DOI 10.1089/dna.1995.14.175; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; Fowler CJ, 2001, BIOCHEM PHARMACOL, V62, P517, DOI 10.1016/S0006-2952(01)00712-2; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Goridis C, 1999, CURR OPIN NEUROBIOL, V9, P47, DOI 10.1016/S0959-4388(99)80006-3; Gorr SU, 1996, J BIOL CHEM, V271, P3575; GROVES AK, 1995, DEVELOPMENT, V121, P887; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; Hirsch MR, 1998, DEVELOPMENT, V125, P599; Howard M, 1999, DEV BIOL, V215, P62, DOI 10.1006/dbio.1999.9450; Ichinose H, 1999, BIOL CHEM, V380, P1355, DOI 10.1515/BC.1999.175; ISHII K, 1990, MOL BRAIN RES, V7, P151, DOI 10.1016/0169-328X(90)90092-R; Janz R, 1998, J NEUROSCI, V18, P9269; Janz R, 1999, NEURON, V24, P1003, DOI 10.1016/S0896-6273(00)81046-6; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Leoni C, 1999, MOL BIOL CELL, V10, P2919, DOI 10.1091/mbc.10.9.2919; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Lo LC, 1998, DEVELOPMENT, V125, P609; Malosio ML, 1999, J PHYSIOL-LONDON, V520, P43, DOI 10.1111/j.1469-7793.1999.t01-1-00043.x; Martinez-Arca S, 2001, J NEUROSCI, V21, P3830, DOI 10.1523/JNEUROSCI.21-11-03830.2001; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; Meldolesi J, 2001, PROG NEUROBIOL, V65, P309, DOI 10.1016/S0301-0082(01)00004-1; MEYER TE, 1992, NUCLEIC ACIDS RES, V20, P6106, DOI 10.1093/nar/20.22.6106; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Pance A, 1999, J NEUROCHEM, V73, P21, DOI 10.1046/j.1471-4159.1999.0730021.x; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Plunkett JA, 1998, J NEUROSCI, V18, P5832; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; Rowe J, 1999, J CELL SCI, V112, P1865; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; SCHAEFER T, 1994, ANN NY ACAD SCI, V733, P279, DOI 10.1111/j.1749-6632.1994.tb17277.x; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Yamakuni T, 1998, J BIOL CHEM, V273, P27051, DOI 10.1074/jbc.273.42.27051; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200; 1997, USER B NUMBER 2 ABI, V2	64	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36715	36724		10.1074/jbc.M203777200	http://dx.doi.org/10.1074/jbc.M203777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12070162	hybrid			2022-12-25	WOS:000178275100118
J	Denning, DP; Uversky, V; Patel, SS; Fink, AL; Rexach, M				Denning, DP; Uversky, V; Patel, SS; Fink, AL; Rexach, M			The Saccharomyces cerevisiae nucleoporin Nup2p is a natively unfolded protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; GTPASE-ACTIVATING PROTEIN; RAN EXCHANGE FACTOR; YEAST NUCLEOPORIN; IMPORTIN-BETA; NUCLEOCYTOPLASMIC TRANSPORT; ARCHITECTURE; GRADIENT; BINDING; NUP153	Little is known about the structure of the individual nucleoporins that form eukaryotic nuclear pore complexes (NPCs). We report here in vitro physical and structural characterizations of a full-length nucleoporin, the Saccharomyces cerevisiae protein Nup2p. Analyses of the Nup2p structure by far-UV circular dichroism (CD) spectroscopy, Fourier transform infrared (FTIR) spectroscopy, protease sensitivity, gel filtration, and sedimentation velocity experiments indicate that Nup2p is a "natively unfolded protein," belonging to a class of proteins that exhibit little secondary structure, high flexibility, and low compactness. Nup2p possesses a very large Stokes radius (79 A) in gel filtration columns, sediments slowly in sucrose gradients as a 2.9 S particle, and is highly sensitive to proteolytic digestion by proteinase K, these characteristics suggest a structure of low compactness and high flexibility. Spectral analyses (CD and FTIR spectroscopy) provide additional evidence that Nup2p contains extensive regions of structural disorder with comparatively small contributions of ordered secondary structure. We address the possible significance of natively unfolded nucleoporins in the mechanics of nucleocytoplasmic trafficking across NPCs.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Stanford Med Sch, Canc Biol Program, Stanford, CA 94305 USA; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142290, Moscow Region, Russia	Stanford University; Stanford University; University of California System; University of California Santa Cruz; Russian Academy of Sciences	Rexach, M (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	rexach@stanford.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Patel, Samir/0000-0002-9489-5516				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; Akhtar N, 2001, MOL GENET GENOMICS, V265, P851, DOI 10.1007/s004380100480; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Dunker AK, 2001, NAT BIOTECHNOL, V19, P805, DOI 10.1038/nbt0901-805; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hood JK, 2000, J CELL SCI, V113, P1471; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Keminer O, 1999, P NATL ACAD SCI USA, V96, P11842, DOI 10.1073/pnas.96.21.11842; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; Oberg KA, 1998, ANAL BIOCHEM, V256, P92, DOI 10.1006/abio.1997.2486; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Schlaich NL, 1997, MOL BIOL CELL, V8, P33, DOI 10.1091/mbc.8.1.33; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493	58	77	80	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33447	33455		10.1074/jbc.M203499200	http://dx.doi.org/10.1074/jbc.M203499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12065587	hybrid			2022-12-25	WOS:000177859000134
J	Loo, BM; Salmivirta, M				Loo, BM; Salmivirta, M			Heparin/heparan sulfate domains in binding and signaling of fibroblast growth factor 8b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; BREAST-CANCER CELLS; HEPARAN-SULFATE; FACTOR RECEPTOR; MITOGENIC ACTIVITY; CRYSTAL-STRUCTURE; PROSTATE-CANCER; FGF RECEPTORS; TUMOR-GROWTH; EXPRESSION	The role of heparin and heparan sulfate in the binding and signaling of fibroblast growth factors (FGFs) has been subject to intense investigation, but the studies have largely been confined to two species (FGF1 and FGF2) of the family with similar to20 members. We have investigated the structural requirements for heparin/heparan sulfate in binding and activation of FGF8 (splice variant b). We present evidence that the minimal FGF8b-binding saccharide domain encompasses 5-7 monosaccharide units. The N-, 2-O-, and 6-O-sulfate substituents of heparin/heparan sulfate (HS) are all involved in the interaction, preferentially in the form of trisulfated IdoUA(2-OSO3)-GlcNSO(3)(6-OSO3) disaccharide constituents. These structural characteristics resemble those described earlier for FGFI. By contrast, the saccharide structures required for the biological activity of FGF8b differed significantly from those characteristic for FGF1 and FGF2. Experiments with cells lacking active HS indicated that extended greater than or equal to14-mer heparin domains were needed to enhance cell proliferation and Erk phosphorylation by FGF8b, whereas in cells stimulated with FGF1 or FGF2 the corresponding responses were achieved by much shorter, 6-8-mer, oligosaccharides. Furthermore, still longer domains were needed to activate FGF8b in cells with "non-optimal" FGF receptor expression. Collectively, our data suggest that the heparin/HS structures enhancing the biological activity of FGFs were influenced by the FGF species involved as well as by the cellular composition of FGF receptors.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; BioTie Therapies Corp, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University	Salmivirta, M (corresponding author), Univ Turku, Turku Ctr Biotechnol, POB 123, FIN-20520 Turku, Finland.							AIBA M, 1985, ARCH PATHOL LAB MED, V109, P357; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Borgenstrom M, 2001, EXP CELL RES, V264, P307, DOI 10.1006/excr.2000.5126; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; FLYNN EA, 1991, J CANCER RES CLIN, V117, P115, DOI 10.1007/BF01613134; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Hajihosseini MK, 1999, MOL CELL NEUROSCI, V14, P468, DOI 10.1006/mcne.1999.0800; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P452; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1999, FRONT BIOSCI, V4, P165; KOUHARA H, 1994, ONCOGENE, V9, P455; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; KUSCHE M, 1988, BIOCHEM J, V253, P885, DOI 10.1042/bj2530885; Leung HY, 1996, ONCOGENE, V12, P1833; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, J BIOL CHEM, V268, P23989; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Mattila MMT, 2001, ONCOGENE, V20, P2791, DOI 10.1038/sj.onc.1204430; NOGUCHI S, 1989, J STEROID BIOCHEM, V32, P479, DOI 10.1016/0022-4731(89)90379-8; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ruohola JK, 2001, CANCER RES, V61, P4229; RUOHOLA JK, 1995, ENDOCRINOLOGY, V136, P2179, DOI 10.1210/en.136.5.2179; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SATO B, 1993, J STEROID BIOCHEM, V47, P91, DOI 10.1016/0960-0760(93)90061-Z; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Stringer SE, 1999, J BIOL CHEM, V274, P25455, DOI 10.1074/jbc.274.36.25455; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P3658, DOI 10.1073/pnas.96.7.3658; Yano Hiroshi, 1999, Gastric Cancer, V2, P26, DOI 10.1007/s101200050017; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417	64	46	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32616	32623		10.1074/jbc.M204961200	http://dx.doi.org/10.1074/jbc.M204961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077148	hybrid			2022-12-25	WOS:000177859000030
J	Turner, RB; Liu, L; Sazonova, IY; Reed, GL				Turner, RB; Liu, L; Sazonova, IY; Reed, GL			Structural elements that govern the substrate specificity of the clot-dissolving enzyme plasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVATOR; STREPTOKINASE; ALPHA-2-ANTIPLASMIN; STAPHYLOKINASE; COMPLEX; INHIBITOR; KINETICS; PROGRAM; POTENT	There is remarkable homology between the core structures of plasmin, a fibrin clot-degrading enzyme, and factor D, a complement-activating enzyme, despite markedly different biological functions. We postulated that sequence divergence in the loop structures between these two enzymes mediated the unique substrate and inhibitor interactions of plasmin. Recombinant microplasminogens chimerized with factor D sequences at loops 3, 5, and 7 were cleaved by the plasminogen activator urokinase and developed titratable active sites. Chimerization abolished functional interactions with the plasminogen activator streptokinase but did not block complex formation. The microplasmin chimeras showed enhanced resistance (k(i) decreased up to two to three times) to inactivation of microplasmin by alpha(2)-antiplasmin. Microplasmin chimerization had minimal (similar to2 fold) effects on the catalytic efficiency for cleavage of small substrates and did not alter the cleavage of fibrin. However, microplasmin and the microplasmin chimeras showed enhanced abilities to degrade fibrin in plasma clots suspended in human plasma. These studies indicate that loop regions of the protease domain of plasmin are important for interactions with substrates, regulatory molecules, and inhibitors. Because modification of these regions affected substrate and inhibitor interactions, loop chimerization may hold promise for improving the clot dissolving properties of this enzyme.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, II-127,677 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL-58946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL058946, R01HL058946] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; Collen D, 1998, NAT MED, V4, P279, DOI 10.1038/nm0398-279; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOROI M, 1976, J BIOL CHEM, V251, P5956; MULLERTZ S, 1976, BIOCHEM J, V159, P545; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Peisach E, 1999, BIOCHEMISTRY-US, V38, P11180, DOI 10.1021/bi991130r; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; REED GL, 1990, P NATL ACAD SCI USA, V87, P1114, DOI 10.1073/pnas.87.3.1114; Sambrook J., 2002, MOL CLONING LAB MANU; Sazonova IY, 2001, J BIOL CHEM, V276, P12609, DOI 10.1074/jbc.M009265200; WANG JY, 1995, PROTEIN SCI, V4, P1768, DOI 10.1002/pro.5560040912; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WIMAN B, 1979, BIOCHIM BIOPHYS ACTA, V579, P142, DOI 10.1016/0005-2795(79)90094-1; WIMAN B, 1977, THROMB RES, V10, P213, DOI 10.1016/0049-3848(77)90003-2; WIMAN B, 1978, EUR J BIOCHEM, V87, P142; WOHL RC, 1980, J BIOL CHEM, V255, P2005	23	14	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33068	33074		10.1074/jbc.M203782200	http://dx.doi.org/10.1074/jbc.M203782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080056	hybrid			2022-12-25	WOS:000177859000087
J	Bonetto, V; Massignan, T; Chiesa, R; Morbin, M; Mazzoleni, G; Diomede, L; Angeretti, N; Colombo, L; Forloni, G; Tagliavini, F; Salmona, M				Bonetto, V; Massignan, T; Chiesa, R; Morbin, M; Mazzoleni, G; Diomede, L; Angeretti, N; Colombo, L; Forloni, G; Tagliavini, F; Salmona, M			Synthetic miniprion PrP106	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; RECOMBINANT PRION PROTEIN; CIRCULAR-DICHROISM; 106 RESIDUES; FRAGMENT; NEUROTOXICITY; PREDICTION	Elucidation of structure and biological properties of the prion protein scrapie (PrPSc) is fundamental to an understanding of the mechanism of conformational transition of cellular (PrPC) into disease-specific isoforms and the pathogenesis of prion diseases. Unfortunately, the insolubility and heterogeneity of PrPSc have limited these studies. The observation that a construct of 106 amino acids (termed PrP106 or miniprion), derived from mouse PrP and containing two deletions (Delta23-88, Delta141-176), becomes protease-resistant when expressed in scrapie-infected neuroblastoma cells and sustains prion replication when expressed in PrP0/0 mice prompted us to generate a corresponding synthetic peptide (sPrP106) to be used for biochemical and cell culture studies. sPrP106 was obtained successfully with a straightforward procedure, which combines classical stepwise solid phase synthesis with a purification strategy based on transient labeling with a lipophilic chromatographic probe. sPrP106 readily adopted a beta-sheet structure, aggregated into branched filamentous structures without ultrastructural and tinctorial properties of amyloid, exhibited a proteinase K-resistant domain spanning residues 134-217, was highly toxic to primary neuronal cultures, and induced a remarkable increase in membrane microviscosity. These features are central properties of PrPSc and make sPrP106 an excellent tool for investigating the molecular basis of the conformational conversion of PrPC into PrPSc and prion disease pathogenesis.	Dulbecco Telethon Inst, I-20157 Milan, Italy; Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy; Dept Neurosci, I-20157 Milan, Italy; Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy; Ist Neurol Carlo Besta, I-20133 Milan, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Neurologico Besta	Bonetto, V (corresponding author), Dulbecco Telethon Inst, Via Eritrea 62, I-20157 Milan, Italy.	bonetto@marionegri.it	salmona, mario/ABI-4066-2020; Diomede, Luisa/P-3417-2014; Forloni, Gianluigi/AAB-2115-2020; colombo, laura/AAA-6716-2020; salmona, mario/AAA-7116-2020; Tagliavini, Fabrizio/AAO-7891-2021; Bonetto, Valentina/I-4694-2018; Chiesa, Roberto/G-1561-2017; Bonetto, Valentina/ABB-6383-2020	Diomede, Luisa/0000-0002-2258-0531; Forloni, Gianluigi/0000-0001-5374-3914; colombo, laura/0000-0002-3243-0270; salmona, mario/0000-0002-9098-9873; Tagliavini, Fabrizio/0000-0003-1039-7315; Bonetto, Valentina/0000-0003-0456-2054; Chiesa, Roberto/0000-0002-3842-3733; Bonetto, Valentina/0000-0003-0456-2054; massignan, tania/0000-0002-6176-2696; Morbin, Michela/0000-0001-8034-3123	Telethon [466/BI] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		BALL HL, 1992, INT J PEPT PROT RES, V40, P370; Ball HL, 2001, J PEPT RES, V58, P357, DOI 10.1034/j.1399-3011.2001.00943.x; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; Diomede L, 1996, BIOCHEM J, V320, P563, DOI 10.1042/bj3200563; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kourie JI, 2001, CHEM-BIOL INTERACT, V138, P1, DOI 10.1016/S0009-2797(01)00228-9; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Salmona M, 1997, NEUROBIOL DIS, V4, P47, DOI 10.1006/nbdi.1997.0133; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Tagliavini F, 2001, ADV PROTEIN CHEM, V57, P171; Tompa P, 2001, P NATL ACAD SCI USA, V98, P4431, DOI 10.1073/pnas.071308398; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499	26	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31327	31334		10.1074/jbc.M203275200	http://dx.doi.org/10.1074/jbc.M203275200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12058037	hybrid			2022-12-25	WOS:000177718700008
J	Pineda, AO; Cantwell, AM; Bush, LA; Rose, T; Di Cera, E				Pineda, AO; Cantwell, AM; Bush, LA; Rose, T; Di Cera, E			The thrombin epitope recognizing thrombomodulin is a highly cooperative hot spot in exosite I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C ACTIVATION; BLOOD-COAGULATION; SPECIFICITY; INTERFACE; RECEPTOR; DOMAINS; SITE; LOCALIZATION; ARGININE-101; ENERGETICS	The functional epitope of thrombin recognizing thrombomodulin was mapped using Ala-scanning mutagenesis of 54 residues located around the active site, the Na+ binding loop, the 186-loop, the autolysis loop, exosite I, and exosite II. The epitope for thrombomodulin binding is shaped as a hot spot in exosite I, centered around the buried ion quartet formed by Arg(67), Lys(70), Glu(77), and Glu(80), and capped by the hydrophobic residues Tyr(76) and Ile(82). The hot spot is a much smaller subset of the structural epitope for thrombomodulin binding recently documented by x-ray crystallography. Interestingly, the contribution of each residue of the epitope to the binding free energy shows no correlation with the change in its accessible surface area upon formation of the thrombin-thrombomodulin complex. Furthermore, residues of the epitope are strongly coupled in the recognition of thrombomodulin, as seen for the interaction of human growth hormone and insulin with their receptors. Finally, the Ala substitution of two negatively charged residues in exosite II, Asp(100) and Asp(178), is found unexpectedly to significantly increase thrombomodulin binding.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.			ROSE, Thierry/0000-0001-8863-0207	NHLBI NIH HHS [HL49413, HL58141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; Di Cera E, 1998, ADV PROTEIN CHEM, V51, P59; Di Cera E, 2001, ANN NY ACAD SCI, V936, P133; Di Cera E, 1998, CHEM REV, V98, P1563, DOI 10.1021/cr960135g; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; He XH, 1997, BIOCHEMISTRY-US, V36, P8969, DOI 10.1021/bi9704717; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; Mandell JG, 2001, J MOL BIOL, V306, P575, DOI 10.1006/jmbi.2000.4416; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SRINIVASAN J, 1994, BIOCHEMISTRY-US, V33, P13553, DOI 10.1021/bi00250a007; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1992, J BIOL CHEM, V267, P11023; YE J, 1994, J BIOL CHEM, V269, P17965	28	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32015	32019		10.1074/jbc.M205009200	http://dx.doi.org/10.1074/jbc.M205009200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12068020	hybrid			2022-12-25	WOS:000177718700089
J	Fass, E; Shahar, S; Zhao, J; Zemach, A; Avivi, Y; Grafi, G				Fass, E; Shahar, S; Zhao, J; Zemach, A; Avivi, Y; Grafi, G			Phosphorylation of histone H3 at serine 10 cannot account directly for the detachment of human heterochromatin protein 1 gamma from mitotic chromosomes in plant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN STRUCTURE; HP1 PROTEINS; GENE-REGULATION; LYSINE 9; DROSOPHILA; CYCLE; TRANSCRIPTION; EUCHROMATIN; METHYLATION; CONDENSATION	Heterochromatin protein 1 (HP1) controls heterochromatin formation in animal cells, at least partly through interaction with lysine 9 (Lys-9)-methylated histone H3. We aimed to determine whether a structurally conserved human HP1 protein exhibits conserved heterochromatin localization in plant cells and studied its relation to modified histone H3. We generated transgenic tobacco plants and cycling cells expressing the human HP1gamma fused to green fluorescent protein (GFP) and followed its association with chromatin. Plants expressing GFP-HP1gamma showed no phenotypic perturbations. We found that GFP-HP1y is preferentially associated with the transcriptionally "inactive" heterochromatin fraction, a fraction enriched in Lys-9-methylated histone H3. During mitosis GFP-HP1gamma is detached from chromosomes concomitantly with phosphorylation of histone H3 at serine 10 and reassembles as cells exit mitosis. However, this phosphorylation cannot directly account for the dissociation of GFP-HP1gamma from mitotic chromosomes inasmuch as phosphorylation does not interfere with binding to HP1gamma. It is, therefore, possible that phosphorylation at serine 10 creates a "code" that is read by as yet an unknown factor(s), eventually leading to detachment of GFP-HP1gamma from mitotic chromosomes. Together, our results suggest that chromatin organization in plants and animals is conserved, being controlled at least partly by the association of HP1 proteins with methylated histone H3.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Grafi, G (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.	gideon.grafi@weizmann.ac.il		Zemach, Assaf/0000-0003-3282-4445				AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Fransz PF, 2000, CELL, V100, P367, DOI 10.1016/S0092-8674(00)80672-8; Furuta K, 1997, CHROMOSOMA, V106, P11, DOI 10.1007/s004120050219; Gaudin V, 2001, DEVELOPMENT, V128, P4847; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Horsley D, 1996, CYTOGENET CELL GENET, V73, P308, DOI 10.1159/000134363; Houben A, 1999, PLANT J, V18, P675, DOI 10.1046/j.1365-313x.1999.00496.x; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Ingram R, 1999, PLANT CELL, V11, P1047, DOI 10.1105/tpc.11.6.1047; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Jasencakova Z, 2000, PLANT CELL, V12, P2087, DOI 10.1105/tpc.12.11.2087; KAHL G, 1988, ARCHITECTURE EUKARYO, P301; KELLUM R, 1995, J CELL SCI, V108, P1407; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Losada A, 2001, BIOESSAYS, V23, P924, DOI 10.1002/bies.1133; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MAZZINI G, 1983, CYTOMETRY, V3, P443, DOI 10.1002/cyto.990030610; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pedrosa A, 2001, CHROMOSOMA, V110, P203, DOI 10.1007/s004120000125; PERRY RP, 1960, EXP CELL RES, V20, P216, DOI 10.1016/0014-4827(60)90240-8; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Remboutsika E, 1999, J CELL SCI, V112, P1671; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tang GL, 2000, PLANT J, V23, P195, DOI 10.1046/j.1365-313x.2000.00770.x; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; van Blokland R, 1997, MOL GEN GENET, V257, P1, DOI 10.1007/s004380050617; van Holde KE., 1989, SPRINGER SERIES MOL; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Williams L, 2000, TRENDS PLANT SCI, V5, P239, DOI 10.1016/S1360-1385(00)01653-8; WOLFFE A, 1992, CHROMATIN STRUCTURE; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao J, 2000, J BIOL CHEM, V275, P27494; Zhao J, 2001, J BIOL CHEM, V276, P22772, DOI 10.1074/jbc.M101756200	50	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30921	30927		10.1074/jbc.M112250200	http://dx.doi.org/10.1074/jbc.M112250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060650	hybrid			2022-12-25	WOS:000177579800067
J	Shuen, M; Avvakumov, N; Walfish, PG; Brandl, CJ; Mymryk, JS				Shuen, M; Avvakumov, N; Walfish, PG; Brandl, CJ; Mymryk, JS			The adenovirus E1A protein targets the SAGA but not the ADA transcriptional regulatory complex through multiple independent domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ONCOGENIC TRANSFORMATION; MOLECULAR-CLONING; BINDING PROTEIN; ONCOPROTEIN E1A; MESSENGER-RNA; YEAST; ACETYLTRANSFERASE; ACTIVATION; P300	Expression of the adenovirus E1A protein in the simple eukaryote Saccharomyces cerevisiae inhibits growth. We tested four regions of E1A that alter growth and transcription in mammalian cells for their effects in yeast when expressed as fusions to the Gal4p DNA binding domain. Expression of the N-terminal/conserved region (CR) 1 or CR3, but not of the CR2 or the C-terminal portion of E1A, inhibited yeast growth. Growth inhibition was relieved by deletion of the genes encoding the yGcn5p, Ngg1p, or Spt7p components of the SAGA transcriptional regulatory complex, but not the Ahc1p component of the related ADA complex, indicating that the N-terminal/CR1 and CR3 regions of E1A target the SAGA complex independently. Expression of the pCAF acetyltransferase, a mammalian homologue of yGcn5p, also suppressed growth inhibition by either portion of EIA. Furthermore, the N-terminal 29 residues and the CR3 portion of EIA interacted independently with yGcn5p and pCAF in vitro. Thus, two separate regions of E1A target the yGcn5p component of the SAGA transcriptional activation complex. A subregion of the N-terminal/CR1 fragment spanning residues 30-69 within CR1 also inhibited yeast growth in a SAGA-dependent fashion. However, this region did not interact with yGcn5p or pCAF, suggesting that it makes a third contact with another SAGA component. Our results provide a new model system to elucidate mechanisms by which EIA and the SAGA complex regulate transcription and growth.	Univ Western Ontario, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Oncol, London, ON N6A 4L6, Canada; Univ Toronto, Sch Med, Samuel Lunenfeld Res Inst, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Toronto, Sch Med, Dept Med, Div Endocrinol, Toronto, ON M5G 1X5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Mymryk, JS (corresponding author), Univ Western Ontario, London Reg Canc Ctr, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	jmymryk@uwo.ca						ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BONDESSON M, 1994, NUCLEIC ACIDS RES, V22, P3053, DOI 10.1093/nar/22.15.3053; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ENGEL DA, 1988, GENE DEV, V2, P1517, DOI 10.1101/gad.2.12a.1517; ENGEL DA, 1991, P NATL ACAD SCI USA, V88, P3957, DOI 10.1073/pnas.88.9.3957; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HANDA H, 1987, GENE, V58, P127; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kulesza CA, 2002, ONCOGENE, V21, P1411, DOI 10.1038/sj.onc.1205201; LIANG S, 1995, P NATL ACAD SCI USA, V92, P7372, DOI 10.1073/pnas.92.16.7372; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAGUIRE K, 1991, ONCOGENE, V6, P1417; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MAZZARELLI JM, 1995, ONCOGENE, V11, P1859; MILLER ME, 1995, ONCOGENE, V11, P1623; Miller ME, 1996, MOL CELL BIOL, V16, P5737; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MYMRYK JS, 1993, J GEN VIROL, V74, P2131, DOI 10.1099/0022-1317-74-10-2131; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SHENK T, 1991, ADV CANCER RES, V57, P47; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; WADA T, 1990, BIOCHEM BIOPH RES CO, V170, P470, DOI 10.1016/0006-291X(90)92115-G; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	45	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30844	30851		10.1074/jbc.M201877200	http://dx.doi.org/10.1074/jbc.M201877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070146	hybrid			2022-12-25	WOS:000177579800058
J	Morsomme, P; Chami, M; Marco, S; Nader, J; Ketchum, KA; Goffeau, A; Rigaud, JL				Morsomme, P; Chami, M; Marco, S; Nader, J; Ketchum, KA; Goffeau, A; Rigaud, JL			Characterization of a hyperthermophilic P-type ATPase from Methanococcus jannaschii expressed in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; H+-ATPASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; BIOLOGICAL MACROMOLECULES; ELECTRON-MICROSCOPY; PHOSPHORYLATED INTERMEDIATE; MOLECULAR-CLONING; GENOME SEQUENCE	We report on the biochemical and structural properties of a putative P-type H+-ATPase, MJ1226p, from the anaerobic hyperthermophilic Archaea Methanococcus jannaschii. An efficient heterologous expression system was developed in Saccharomyces cerevisiae and a four-step purification protocol, using n-dodecyl beta-D-maltoside, led to a homogenous detergent-solubilized protein fraction with a yield of over 2 mg of protein per liter of culture. The three-dimensional structure of the purified detergent-solubilized protein obtained at 2.4 nm resolution by electron microscopy showed a dimeric organization in which the size and the shape of each monomer was compatible with the reported structures of P-type ATPases. The purified MJ1226p ATPase was inactive at 40 degreesC and was active at elevated temperature reaching high specific activity, up to 180 mumol of P(i)(.)min(-1.)mg(-1) at 95 degreesC. Maximum ATPase activity was observed at pH 4.2 and required up to 200 mm monovalent salts. The ATPase activity was stable for several days upon storage at 65 degreesC and was highly resistant to urea and guanidine hydrochloride. The protein formed catalytic phosphoenzyme intermediates from MgATP or P-i, a functional characteristic specific of P-type ATPases. The highly purified, homogeneous, stable, and active MJ1226p ATPase provides a new model for further structure-function studies of P-type ATPases.	Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium; Inst Curie, UMR CNRS 168, F-75231 Paris, France; CEA, LRC, F-75231 Paris, France; Inst Genom Res, Rockville, MD 20850 USA	Universite Catholique Louvain; UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CEA; J. Craig Venter Institute	Goffeau, A (corresponding author), Catholic Univ Louvain, Unite Biochim Physiol, Pl Croix Sud 2-20, B-1348 Louvain, Belgium.	goffeau@fysa.ucl.ac.be	Morsomme, Pierre/AAD-9600-2019; marco garrido, sergio/F-5876-2013; marco, SERGIO/E-4875-2017	Morsomme, Pierre/0000-0001-7780-7230				ADDISON R, 1981, J BIOL CHEM, V256, P3165; AMORY A, 1980, J BIOL CHEM, V255, P9353; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V642, P173, DOI 10.1016/0005-2736(81)90147-4; BOUTRY M, 1989, BIOCHEM BIOPH RES CO, V162, P567, DOI 10.1016/0006-291X(89)92348-6; BOWMAN EJ, 1981, J BIOL CHEM, V256, P2336; Bukrinsky JT, 2001, FEBS LETT, V494, P6, DOI 10.1016/S0014-5793(01)02301-8; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; Degand I, 1999, MOL MICROBIOL, V31, P545, DOI 10.1046/j.1365-2958.1999.01195.x; DEMEIS L, 1987, FEBS LETT, V212, P323, DOI 10.1016/0014-5793(87)81369-8; Deppenmeier U, 1999, FEBS LETT, V457, P291, DOI 10.1016/S0014-5793(99)01026-1; dExaerde AD, 1997, MOL MICROBIOL, V25, P261, DOI 10.1046/j.1365-2958.1997.4571826.x; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; DUFOUR JP, 1980, J BIOL CHEM, V255, P591; DUFOUR JP, 1978, J BIOL CHEM, V253, P7026; DUFOUR JP, 1980, EUR J BIOCHEM, V105, P145, DOI 10.1111/j.1432-1033.1980.tb04484.x; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; HARPER JF, 1989, P NATL ACAD SCI USA, V86, P1234, DOI 10.1073/pnas.86.4.1234; Hinrichs M, 1999, BIOL CHEM, V380, P1063, DOI 10.1515/BC.1999.132; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jaenicke R, 1996, FASEB J, V10, P84, DOI 10.1096/fasebj.10.1.8566552; LANCASTER JR, 1989, J BIOENERG BIOMEMBR, V21, P717, DOI 10.1007/BF00762689; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALPARTIDA F, 1980, FEBS LETT, V111, P69, DOI 10.1016/0014-5793(80)80763-0; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; Mullick R, 1998, ANN M SOC COMP APPL; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; PEDERSEN A, 1992, ANN NY ACAD SCI, V671, P542; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Schafer G, 1999, MICROBIOL MOL BIOL R, V63, P570; Segel I.H, 1993, ENZYME KINETICS; Stokes DL, 1999, CURR BIOL, V9, P672, DOI 10.1016/S0960-9822(99)80307-8; Talla E, 1998, J BIOL CHEM, V273, P27831, DOI 10.1074/jbc.273.43.27831; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VARA F, 1983, J BIOL CHEM, V258, P5334; Vieille C, 1996, Biotechnol Annu Rev, V2, P1, DOI 10.1016/S1387-2656(08)70006-1	51	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29608	29616		10.1074/jbc.M203871200	http://dx.doi.org/10.1074/jbc.M203871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048206	hybrid			2022-12-25	WOS:000177509300035
J	Yoon, SO; Park, SJ; Yoon, SY; Yun, CH; Chung, AS				Yoon, SO; Park, SJ; Yoon, SY; Yun, CH; Chung, AS			Sustained production of H2O2 activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SUPEROXIDE-DISMUTASE; FIBROSARCOMA CELLS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; TUMOR-GROWTH; IN-VITRO; EXPRESSION; INVASION; CANCER	A rate-limiting step of tumor cell metastasis is matrix degradation by active matrix metalloproteinases (MMPs). It is known that reactive oxygen species are involved in tumor metastasis. Sustained production of H2O2 by phenazine methosulfate (PMS) induced activation of pro-MMP-2 through the induction of membrane type 1-AMP (MT1-AMP) expression in HT1080 cells. MMP-2, AMP-9, and tissue inhibitor of metalloproteinase-1 and -2 levels were changed negligibly by PMS. A one time treatment with H2O2 did not induce activation of MMPs. It was also demonstrated that superoxide anions and hydroxyl radicals were not related to PMS action. PMS-induced pro-AMP-2 activation was regulated by the receptor tyrosine kinases, especially the receptors of platelet-derived growth factor and vascular endothelial growth factor, and downstream on the phosphatidylinositol 3-kinase/NF-kappaB pathway but not Ras, cAMP-dependent protein kinase, protein kinase C, and mitogen-activated protein kinases. PMS did not induce pro-MMP-2 activation in T98G and NIH3T3 cells. This may be related to a low level of MT1-MMP, indicating a threshold level of MT1-MMP is important for pro-AMP-2 activation. Furthermore, PMS increased cell motility and invasion but decreased cell-cell interaction. Cell-matrix interaction was not affected by PMS.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Chung, AS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	aschung@mail.kaist.ac.kr						Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Copin JC, 2001, FASEB J, V15, P525, DOI 10.1096/fj.00-0330com; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Gupta S, 2001, MOL CELL BIOL, V21, P5846, DOI 10.1128/MCB.21.17.5846-5856.2001; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Kaczarek E, 1999, INT J DEV NEUROSCI, V17, P625, DOI 10.1016/S0736-5748(99)00047-7; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Liabakk NB, 1996, CANCER RES, V56, P190; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maquoi E, 2000, EXP CELL RES, V261, P348, DOI 10.1006/excr.2000.5063; MARSH JP, 1991, CANCER RES, V51, P167; Marumo T, 1997, CIRCULATION, V96, P2361; MURAMATSU H, 1995, CANCER RES, V55, P6210; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Rhee S.G., 2000, SCI STKE; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Siwik DA, 1999, CIRC RES, V85, P147, DOI 10.1161/01.RES.85.2.147; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yamamoto M, 1996, CANCER RES, V56, P384; Yoon SO, 2001, FASEB J, V15, P111, DOI 10.1096/fj.01-0398fje	38	144	147	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30271	30282		10.1074/jbc.M202647200	http://dx.doi.org/10.1074/jbc.M202647200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12058032	hybrid			2022-12-25	WOS:000177509300113
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING CASSETTE; CYSTEINE-SCANNING MUTAGENESIS; DISULFIDE CROSS-LINKING; CONDUCTANCE REGULATOR; DRUG-BINDING; ABC TRANSPORTER; CRYSTAL-STRUCTURE; FUNCTIONAL CONSEQUENCES; SECONDARY STRUCTURE; ACTIVE-SITE	The most common mutation in cystic fibrosis (deletion of phenylalanine 508 (DeltaF508) in the cystic fibrosis conductance transmembrane regulator (CFTR) gene) causes defective synthesis of CFTR protein. To understand how this deletion interferes with protein folding, we made the equivalent deletion (DeltaY490) in P-glycoprotein (P-gp). A Cys-less P-gp with cysteines in transmembrane (TM) 4 or TM5 can be cross-linked with a cysteine in TM12. Deleting Tyr(490) in P-gp resulted in an inactive and defectively processed mutant in which no cross-linking between TM4 or TM5 and TM12 was detected. Expression of the DeltaY490 mutant in the presence of a chemical chaperone corrected the processing defect and yielded active P-gp mutants that could be cross-linked between TM4 or TM5 and TM12. Cross-linking between TM4 or TM5 and TM12 was also detected when residues (483)TIAENIRYG(491) in P-gp were replaced with residues (501)TIKENHFG(509) from CFTR (P-gp/CFTR). Deleting Phe(508) in the P-gp/CFTR chimera, however, caused defective processing of the mutant protein and no detectable cross-linking between TM4 or TM5 and TM12. The processing defect was corrected with a chemical chaperone and yielded active P-gp/CFTR mutant proteins that could be cross-linked. These results show that deletion at residue 490 disrupts packing of the TM segments possibly by affecting interaction between the first nucleotide-binding domain (Tyr(490)) and the first cytoplasmic loop (Glu(184)).	Univ Toronto, Dept Med, CIHR Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, CIHR Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bianchet MA, 1997, J BIOENERG BIOMEMBR, V29, P503, DOI 10.1023/A:1022443209010; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; CHEN CJ, 1990, J BIOL CHEM, V265, P506; Chen EYJ, 2000, BIOCHEMISTRY-US, V39, P3797, DOI 10.1021/bi992620m; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOOF T, 1994, J BIOL CHEM, V269, P20575; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Ko YH, 1997, J BIOENERG BIOMEMBR, V29, P417, DOI 10.1023/A:1022402105375; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Massiah MA, 1999, BIOCHEMISTRY-US, V38, P7453, DOI 10.1021/bi9903603; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sheppard DN, 1999, PHYSIOL REV, V79, P23; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	48	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27585	27588		10.1074/jbc.C200330200	http://dx.doi.org/10.1074/jbc.C200330200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12070134	hybrid			2022-12-25	WOS:000177189800003
J	Chattopadhyay, R; Roy, S				Chattopadhyay, R; Roy, S			DnaK-Sigma 32 interaction is temperature-dependent - Implication for the mechanism of heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SECONDARY STRUCTURE; SIGMA(32); TRANSCRIPTION; DNAK; AFFINITY; PROTEIN	The heat shock response in bacteria is a complex phenomenon in which sigma 32 plays the central role. The DnaK/J chaperone system binds and promotes degradation of sigma 32 at lower temperatures. At heat shock temperatures, the DnaK/J-mediated degradation of sigma 32 is largely abolished by a mechanism, which is not yet fully understood. In this article we have shown that interaction of DnaK with sigma 32 is highly temperature-dependent. This interaction is completely abolished at 42 degreesC. To investigate the origin of such strong temperature dependence, we have monitored the structural changes that occur in the sigma 32 protein upon upshift of temperature and attempted to elucidate its functional roles. Upon a shift of temperature from 30 to 42 degreesC,the CD spectrum of sigma 32 becomes significantly more positive without significant change in either tryptophan fluorescence spectra or quenchability to external quenchers. 1,8-Anilinonaphthalene sulfonic acid binding at 42 degreesC is not significantly affected. The equilibrium guanidine hydrochloride denaturation of sigma 32 is biphasic. The first phase shifts to even lower guanidine hydrochloride concentrations at 42 degreesC, whereas the major phase remains largely unchanged. The sigma 32-core interaction remains unchanged as a function of temperature. This suggests that increased temperature destabilizes a structural element. We discuss the possible location of this temperature-sensitive structural element.	Bose Inst, Dept Biophys, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Roy, S (corresponding author), Bose Inst, Dept Biophys, P-1-12,CIT Scheme 7 M, Kolkata 700054, W Bengal, India.	sidroy@vsnl.com						Appella E, 2000, PATHOL BIOL, V48, P227; Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3; Bandyopadhyay S, 1996, BIOCHEMISTRY-US, V35, P5033, DOI 10.1021/bi952123f; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; Chattopadhyay K, 2000, BIOCHEMISTRY-US, V39, P263, DOI 10.1021/bi990729o; FARR CD, 1995, BIOCHEMISTRY-US, V34, P15574, DOI 10.1021/bi00047a024; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Haugland R.P., 1992, HDB FLUORESCENT PROB; Irun MP, 2001, J MOL BIOL, V306, P877, DOI 10.1006/jmbi.2001.4436; Joo DM, 1997, P NATL ACAD SCI USA, V94, P4907, DOI 10.1073/pnas.94.10.4907; Kanemori M, 1999, J BIOL CHEM, V274, P22002, DOI 10.1074/jbc.274.31.22002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Michele TM, 1999, ANTIMICROB AGENTS CH, V43, P218, DOI 10.1128/AAC.43.2.218; Morita M, 1999, J BACTERIOL, V181, P401, DOI 10.1128/JB.181.2.401-410.1999; Morita MT, 2000, P NATL ACAD SCI USA, V97, P5860, DOI 10.1073/pnas.080495197; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; SKOWYRA D, 1995, J BIOL CHEM, V270, P26282, DOI 10.1074/jbc.270.44.26282; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; Tatsuta T, 2000, FEBS LETT, V478, P271, DOI 10.1016/S0014-5793(00)01869-X; Yura T, 1999, CURR OPIN MICROBIOL, V2, P153, DOI 10.1016/S1369-5274(99)80027-7	21	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33641	33647		10.1074/jbc.M203197200	http://dx.doi.org/10.1074/jbc.M203197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12084715	hybrid			2022-12-25	WOS:000177959100016
J	Sonoda, H; Aoki, J; Hiramatsu, T; Ishida, M; Bandoh, K; Nagai, Y; Taguchi, R; Inoue, K; Arai, H				Sonoda, H; Aoki, J; Hiramatsu, T; Ishida, M; Bandoh, K; Nagai, Y; Taguchi, R; Inoue, K; Arai, H			A novel phosphatidic acid-selective phospholipase A(1) that produces lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC LIPASE; PERITONEAL MAST-CELLS; ACTIVATED PLATELETS; SEQUENCE SIMILARITY; HISTAMINE-RELEASE; RECEPTORS; PATHWAYS; FAMILY; VENOM; SPECTROMETRY	Lysophosphatidic acid (LPA) is a lipid mediator with diverse biological properties, although its synthetic pathways have not been completely solved. We report the cloning and characterization of a novel phosphatidic acid (PA)-selective phospholipase A(1) (PLA(1)) that produces 2-acyl-LPA. The PLA(1) was identified in the GenBank(TM) data base as a close homologue of phosphatidylserine (PS)-specific PLA(1) (PS-PILA(1)). When expressed in insect Sf9 cells, this enzyme was recovered from the Triton X-100-insoluble fraction and did not show any catalytic activity toward exogenously added phospholipid substrates. However, culture medium obtained from Sf9 cells expressing the enzyme was found to activate EDG7/LPA(3), a cellular receptor for 2-acyl-LPA. The activation of EDG7 was further enhanced when the cells were treated with phorbol ester or a bacterial phospholipase D, suggesting involvement of phospholipase D in the process. In the latter condition, an increased level of LPA(1) but not other lysophospholipids, was confirmed by mass spectrometry analyses. Expression of the enzyme is observed in several human tissues such as prostate, testis, ovary, pancreas, and especially platelets. These data show that the enzyme is a membrane-associated PA-selective PLA(1) and suggest that it has a role in LPA production.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4670027, Japan	University of Tokyo; Nagoya City University	Sonoda, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp		Sonoda, Hirofumi/0000-0003-3353-1783; Aoki, Junken/0000-0001-9435-1896				An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; BELLINI F, 1993, FEBS LETT, V316, P1, DOI 10.1016/0014-5793(93)81724-E; Carriere F, 1998, BBA-REV BIOMEMBRANES, V1376, P417, DOI 10.1016/S0304-4157(98)00016-1; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Eder AM, 2000, CLIN CANCER RES, V6, P2482; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; GASSAMADIAGNE A, 1991, METHOD ENZYMOL, V197, P316; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; Hoer A, 1998, BBA-LIPID LIPID MET, V1393, P325, DOI 10.1016/S0005-2760(98)00087-3; HOFFMAN DR, 1994, INT ARCH ALLERGY IMM, V104, P184, DOI 10.1159/000236728; Hosono H, 2001, J BIOL CHEM, V276, P29664, DOI 10.1074/jbc.M104597200; JENNENS ML, 1994, J BIOL CHEM, V269, P25470; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; KOKUSHO Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1302, DOI 10.1271/bbb.57.1302; Le Balle F, 1999, ADV ENZYME REGUL, V39, P275, DOI 10.1016/S0065-2571(98)00024-7; Lourenssen S, 1998, NEUROSCI LETT, V248, P77, DOI 10.1016/S0304-3940(98)00275-4; Marheineke K, 1998, FEBS LETT, V441, P49, DOI 10.1016/S0014-5793(98)01523-3; MARTIN TW, 1978, P NATL ACAD SCI USA, V75, P4997, DOI 10.1073/pnas.75.10.4997; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Nagai Y, 1999, J BIOL CHEM, V274, P11053, DOI 10.1074/jbc.274.16.11053; PERKINS LM, 1994, NUCLEIC ACIDS RES, V22, P450, DOI 10.1093/nar/22.3.450; Sato T, 1997, J BIOL CHEM, V272, P2192; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; SMITH GA, 1979, FEBS LETT, V105, P58, DOI 10.1016/0014-5793(79)80887-X; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; Taguchi R, 2000, J MASS SPECTROM, V35, P953, DOI 10.1002/1096-9888(200008)35:8<953::AID-JMS23>3.0.CO;2-4; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; TOKUMURA A, 1978, LIPIDS, V13, P572, DOI 10.1007/BF02533598; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Xu Y, 1995, CLIN CANCER RES, V1, P1223	48	162	171	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34254	34263		10.1074/jbc.M201659200	http://dx.doi.org/10.1074/jbc.M201659200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12063250	hybrid			2022-12-25	WOS:000177959100095
J	Atkins, WM; Lu, WYD; Cook, DL				Atkins, WM; Lu, WYD; Cook, DL			Is there a toxicological advantage for non-hyperbolic kinetics in cytochrome P450 catalysis? Functional allostery from "distributrve catalysis"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-DRUG INTERACTIONS; EVOLUTIONARY OPTIMIZATION; RISK ASSESSMENT; ENZYME; BIOACTIVATION; COOPERATIVITY; EFFICIENCY; THRESHOLDS; SITES; 3A4	The cytochrome P450s (CYPs) are the major enzymatic detoxification and drug metabolism system. Recently, it has become clear that several CYP isoforms exhibit positive and negative homotropic cooperativity. However, the toxicological implications of allosteric kinetics have not been considered, nor understood. The allosteric kinetics are particularly enigmatic in several respects. In many cases, CYPs bioactivate substrates to more toxic products, thus making it difficult to rationalize a functional advantage for positive cooperativity. Also, CYPs exhibit cooperativity with many structurally diverse ligands, in marked contrast to the specificity observed with other allosteric systems. Here, kinetic simulations are used to compare the probabilistic time-and concentration-dependent integrated toxicity function during conversion of substrate to product for CYP models exhibiting Michaelis-Menten (non-cooperative) kinetics, positive cooperativity, or negative cooperativity. The results demonstrate that, at low substrate concentrations, the slower substrate turnover afforded by cooperative CYPs compared with Michaelis-Menten enzymes can be a significant toxicological advantage, when toxic thresholds exist. When present, the advantage results from enhanced "distribution" of toxin in two pools, substrate and product, for an extended period, thus minimizing the chance that either exceeds its toxic threshold. At intermediate concentrations, the allosteric kinetics can be a modest advantage or modest disadvantage, depending on the kinetic parameters. However, at high substrate concentrations associated with a high probability of toxicity, fast turnover is desirable, and this advantage is provided also by the cooperative enzymes. For the positive homotropic cooperativity, the allosteric kinetics minimize the probability of toxicity over the widest range of system parameters. Furthermore, this apparent functional cooperativity is achieved without specific molecular recognition that is the hallmark of "traditional" allostery.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98103 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062284] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62284, GM08268-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; Atkins WM, 2001, CHEM RES TOXICOL, V14, P338, DOI 10.1021/tx0002132; BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9293, DOI 10.1021/bi00450a009; Burkart W, 2000, SCI TOTAL ENVIRON, V249, P63, DOI 10.1016/S0048-9697(99)00511-2; Cassee FR, 1998, CRIT REV TOXICOL, V28, P73, DOI 10.1080/10408449891344164; Castagnoli N, 1997, CHEM RES TOXICOL, V10, P924, DOI 10.1021/tx970096j; Cook DL, 1997, BIOCHEMISTRY-US, V36, P10801, DOI 10.1021/bi971284b; DEMONTELLANO PO, 1991, CYTOCHROME P450 STRU; Dong HJ, 2000, DRUG METAB DISPOS, V28, P1397; ELLINGTON AD, 1987, J THEOR BIOL, V127, P491, DOI 10.1016/S0022-5193(87)80145-5; Gaylor DW, 2000, TOXICOLOGY, V149, P17, DOI 10.1016/S0300-483X(00)00228-6; Gaylor DW, 1998, ENVIRON HEALTH PERSP, V106, P391, DOI 10.2307/3433944; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1999, ANN REV PHARM TOXICO, V39, P317; Hlavica P, 2001, EUR J BIOCHEM, V268, P4817, DOI 10.1046/j.1432-1327.2001.02412.x; Houston JB, 2000, DRUG METAB DISPOS, V28, P246; KLIPP E, 1994, J THEOR BIOL, V171, P309, DOI 10.1006/jtbi.1994.1234; Koley AP, 1997, J BIOL CHEM, V272, P3149, DOI 10.1074/jbc.272.6.3149; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Miller GP, 2001, BIOCHEMISTRY-US, V40, P7262, DOI 10.1021/bi010402z; PETTERSSON G, 1992, EUR J BIOCHEM, V206, P289, DOI 10.1111/j.1432-1033.1992.tb16927.x; Schrag ML, 2000, DRUG METAB DISPOS, V28, P1198; Tang W, 2001, CURR DRUG METAB, V2, P185, DOI 10.2174/1389200013338658; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; van Iersel MLPS, 1999, MUTAT RES-GEN TOX EN, V443, P259, DOI 10.1016/S1383-5742(99)00023-X; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Yost GS, 2001, ADV EXP MED BIOL, V500, P53	27	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33258	33266		10.1074/jbc.M204425200	http://dx.doi.org/10.1074/jbc.M204425200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082118	hybrid			2022-12-25	WOS:000177859000111
J	Bauerle, M; Doenecke, D; Albig, W				Bauerle, M; Doenecke, D; Albig, W			The requirement of H1 histones for a heterodimeric nuclear import receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN L5; NUCLEOCYTOPLASMIC TRANSPORT; MAMMALIAN-CELLS; CORE HISTONES; BETA; LOCALIZATION; BINDING; SEQUENCE; SIGNALS; COMPLEX	After synthesis in the cytoplasm, H1 histones are imported into the nucleus through an energy-dependent process that can be mediated by an importin beta-importin 7 (Impbeta-Imp7) heterodimer. H1 histories contain two structurally different types of nuclear localization signals (NLS). The first type of NLS resides within the unstructured C-terminal domain and is rich in basic amino acids. In contrast, the highly conserved central domain of the H1 histone contains comparatively few basic amino acids but also represents a functional NLS. The competence for the nuclear import of this globular domain seems to be based on its secondary structure. Here, we show that the Impbeta-Imp7 heterodimer is the only receptor for H1 import. Furthermore, we identified the import receptors mediating the in vitro transport of different NLS of the H1 histone. Using the digitonin-permeabilized cell import assay we show that Impbeta is the most efficient import receptor for the globular domain of H1 histones, whereas the heterodimer of Impbeta and Imp7 is the functional receptor for the entire C-terminal domain. However, short fragments of the C-terminal domain are imported in vitro by at least four different importins, which resembles the import pathway of ribosomal proteins and core histones. In addition, we show that heterodimerization of Impbeta with Imp7 is absolutely necessary for their proper function as an import receptor for H1 histories. These findings point to a chaperone-like function of the heterodimeric complex in addition to its function as an import receptor. It appears that the Impbeta-Imp7 heterodimer is specialized for NLS consisting of extended basic domains.	Univ Gottingen, Inst Biochem & Mol Zellbiol, Mol Biol Abt, D-37073 Gottingen, Germany	University of Gottingen	Albig, W (corresponding author), Univ Gottingen, Inst Biochem, Humboltallee 23, D-37073 Gottingen, Germany.							ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Albig W, 1997, GENE, V184, P141, DOI 10.1016/S0378-1119(96)00582-3; Albig W, 1998, FEBS LETT, V435, P245, DOI 10.1016/S0014-5793(98)01084-9; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; Baake M, 2001, J CELL BIOCHEM, V81, P333, DOI 10.1002/1097-4644(20010501)81:2<333::AID-JCB1048>3.3.CO;2-4; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Claussen M, 1999, J BIOL CHEM, V274, P33951, DOI 10.1074/jbc.274.48.33951; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Khadake JR, 1997, BIOCHEMISTRY-US, V36, P1041, DOI 10.1021/bi961617p; Kurz M, 1997, J CELL BIOCHEM, V64, P573; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Mosammaparast N, 2001, J CELL BIOL, V153, P251, DOI 10.1083/jcb.153.2.251; Muhlhausser P, 2001, EMBO REP, V2, P690, DOI 10.1093/embo-reports/kve168; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rosorius O, 2000, J BIOL CHEM, V275, P12061, DOI 10.1074/jbc.275.16.12061; Schwamborn K, 1998, EXP CELL RES, V244, P206, DOI 10.1006/excr.1998.4177; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; THOMA F, 1983, J MOL BIOL, V167, P619, DOI 10.1016/S0022-2836(83)80102-8; Wellman SE, 1996, BIOPOLYMERS, V39, P491, DOI 10.1002/(SICI)1097-0282(199610)39:4<491::AID-BIP2>3.3.CO;2-8; Wolffe A., 1998, CHROMATIN STRUCTURE	38	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32480	32489		10.1074/jbc.M202765200	http://dx.doi.org/10.1074/jbc.M202765200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080050	hybrid			2022-12-25	WOS:000177859000013
J	Kanamori, A; Kojima, N; Uchimura, K; Muramatsu, T; Tamatani, T; Berndt, MC; Kansas, GS; Kannagi, R				Kanamori, A; Kojima, N; Uchimura, K; Muramatsu, T; Tamatani, T; Berndt, MC; Kansas, GS; Kannagi, R			Distinct sulfation requirements of selectins disclosed using cells that support rolling mediated by all three selectins under shear flow - L-selectin prefers carbohydrate 6-sulfation to tyrosine sulfation, whereas P-selectin does not	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; SIALYL-LEWIS-X; ALPHA(1,3)FUCOSYLTRANSFERASE FUC-TVII; COBRA VENOM METALLOPROTEINASE; GLYCOPROTEIN LIGAND-1 PSGL-1; HUMAN LYMPH-NODES; LEUKOCYTE ADHESION; CAPPING GROUP; BINDING; IDENTIFICATION	L- and P-selectin are known to require sulfation in their ligand molecules. We investigated the significance of carbohydrate 6-sulfation and tyrosine sulfation in selectin-mediated cell adhesion. COS-7 cells were genetically engineered to express P-selectin glycoprotein ligand-1 (PSGL-1) or its mutant in various combinations with 6-O-sulfotransferase (6-Sul-T) and/or alpha1-->3fucosyl-transferase VII (Fuc-T VII). The cells transfected with PSGL-1, 6-Sul-T, and Fuc-T VII cDNAs supported rolling mediated by all three selectins and provided the best experimental system so far to estimate kinetic parameters in selectin-mediated cell adhesion for all three selectins using the identical rolling substrate and to compare the ligand specificity of each selectin. L-selectin-mediated rolling was drastically impaired if the cells lacked carbohydrate 6-sulfation elaborated by 6-Sul-T, but not affected when PSGL-1 was replaced with a mutant lacking three tyrosine residues at its NH2 terminus. L-selectin-mediated adhesion was also hardly affected by mocarhagin treatment of the cells, which cleaved a short peptide containing sulfated tyrosine residues from PSGL-1. In contrast, P-selectin-mediated rolling was abolished when PSGL-1 was either mutated or cleaved by mocarhagin at its NH2 terminus, whereas the cells expressing PSGL-1 and Fuc-T VII but not 6-Sul-T showed only a modest decrease in P-selectin-mediated adhesion. These results indicate that L-selectin prefers carbohydrate 6-sulfation much more than tyrosine sulfation, whereas P-selectin favors tyrosine sulfation in the PSGL-1 molecule far more than carbohydrate 6-sulfation. E-selectin-mediated adhesion was sulfation-independent requiring only Fuc-T VII, and thus the three members of the selectin family have distinct requirements for ligand sulfation.	Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan; Tokai Univ, Sch Technol, Dept Appl Chem, Kanagawa 2591292, Japan; Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Baker Med Res Inst, Hazel & Pip Appel Vasc Biol Lab, Prahran, Vic 3181, Australia; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA	Aichi Cancer Center; Tokai University; Nagoya University; University of Tokyo; Baker Heart and Diabetes Institute; Northwestern University	Kannagi, R (corresponding author), Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan.	rkannagi@aichi-cc.jp	Berndt, Michael C/D-5580-2012; Kannagi, Reiji/Q-6459-2018; Uchimura, Kenji/C-9635-2014; Uchimura, Kenji/AFV-1802-2022	Kannagi, Reiji/0000-0003-4202-2921; Uchimura, Kenji/0000-0003-3009-248X; Uchimura, Kenji/0000-0003-3009-248X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055647] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55647] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Forlow SB, 2000, BLOOD, V95, P1317, DOI 10.1182/blood.V95.4.1317.004k30_1317_1323; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; IMAI Y, 1993, NATURE, V361, P555; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LAWRENCE MB, 1987, BLOOD, V70, P1284; Levesque JP, 1999, IMMUNITY, V11, P369, DOI 10.1016/S1074-7613(00)80112-0; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Lim YC, 1998, J IMMUNOL, V161, P2501; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Moore KL, 1998, LEUKEMIA LYMPHOMA, V29, P1, DOI 10.3109/10428199809058377; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Ohmori K, 2000, BIOCHEM BIOPH RES CO, V278, P90, DOI 10.1006/bbrc.2000.3768; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; Puri KD, 1997, J IMMUNOL, V158, P405; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA M, 1993, BIOCHEM BIOPH RES CO, V193, P337, DOI 10.1006/bbrc.1993.1629; Shao JY, 1998, P NATL ACAD SCI USA, V95, P6797, DOI 10.1073/pnas.95.12.6797; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; TAKADA A, 1993, CANCER RES, V53, P354; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Tu LL, 1999, J IMMUNOL, V163, P5070; Tu LL, 1996, J IMMUNOL, V157, P3995; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Ward CM, 1996, TOXICON, V34, P1203, DOI 10.1016/0041-0101(96)00115-8; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769	62	42	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32578	32586		10.1074/jbc.M204400200	http://dx.doi.org/10.1074/jbc.M204400200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12068018	hybrid			2022-12-25	WOS:000177859000026
J	Park, KW; Kim, KJ; Howard, AJ; Stark, BC; Webster, DA				Park, KW; Kim, KJ; Howard, AJ; Stark, BC; Webster, DA			Vitreoscilla hemoglobin binds to subunit I of cytochrome bo ubiquinol oxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMERIC BACTERIAL HEMOGLOBIN; ESCHERICHIA-COLI; FLAVOHEMOGLOBIN GENE; HETEROLOGOUS EXPRESSION; OXYGEN-BINDING; NITRIC-OXIDE; GROWTH; RESPIRATION; SITE	The bacterium, Vitreoscilla, can induce the synthesis of a homodimeric hemoglobin under hypoxic conditions. Expression of VHb in heterologous bacteria often enhances growth and increases yields of recombinant proteins and production of antibiotics, especially under oxygen-limiting conditions. There is evidence that VHb interacts with bacterial respiratory membranes and cytochrome bo proteoliposomes. We have examined whether there are binding sites for VHb on the cytochrome, using the yeast two-hybrid system with VHb as the bait and testing every Vitreoscilla cytochrome bo subunit as well as the soluble domains of subunits I and II. A significant interaction was observed only between VHb and intact subunit I. We further examined whether there are binding sites for VHb on cytochrome bo from Escherichia coli and Pseudomonas aeruginosa, two organisms in which stimulatory effects of VHb have been observed. Again, in both cases a significant interaction was observed only between VHb and subunit I. Because subunit I contains the binuclear center where oxygen is reduced to water, these data support the function proposed for VHb of providing oxygen directly to the terminal oxidase; it may also explain its positive effects in Vitreoscilla as well as in heterologous organisms.	IIT, Div Biol, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA	Illinois Institute of Technology	Kim, KJ (corresponding author), IIT, Div Biol, Dept Biol Chem & Phys Sci, LS Bldg,3101 S Dearborn St, Chicago, IL 60616 USA.	kjkim@anl.gov						Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Buddenhagen RE, 1996, BIOTECHNOL LETT, V18, P695, DOI 10.1007/BF00130768; Buisson N, 1998, J BIOL CHEM, V273, P9527, DOI 10.1074/jbc.273.16.9527; Chung JW, 2001, J IND MICROBIOL BIOT, V27, P27, DOI 10.1038/sj.jim.7000156; Crawford MJ, 1998, J BIOL CHEM, V273, P34028, DOI 10.1074/jbc.273.51.34028; Dikshit KL, 1998, ARCH BIOCHEM BIOPHYS, V349, P161, DOI 10.1006/abbi.1997.0432; DIKSHIT KL, 1990, NUCLEIC ACIDS RES, V18, P4149, DOI 10.1093/nar/18.14.4149; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; EFIOK BJS, 1990, BIOCHEM BIOPH RES CO, V173, P370, DOI 10.1016/S0006-291X(05)81067-8; EFIOK BJS, 1992, ARCH BIOCHEM BIOPHYS, V292, P102, DOI 10.1016/0003-9861(92)90056-3; EFIOK BJS, 1990, BIOCHEMISTRY-US, V29, P4734, DOI 10.1021/bi00471a030; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; MAGNOLO SK, 1991, BIO-TECHNOL, V9, P473, DOI 10.1038/nbt0591-473; ORII Y, 1977, PLANT CELL PHYSIOL, V18, P521; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; RAMANDEEP, 2002, APPL ENVIRON MICROB, V68, P152; Ramirez M, 1999, MOL PLANT MICROBE IN, V12, P1008, DOI 10.1094/MPMI.1999.12.11.1008; Stevanin TM, 2000, J BIOL CHEM, V275, P35868, DOI 10.1074/jbc.M002471200; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; Tsai PS, 1996, BIOTECHNOL BIOENG, V49, P151, DOI 10.1002/(SICI)1097-0290(19960120)49:2<151::AID-BIT4>3.0.CO;2-P; Tsai PS, 1996, BIOTECHNOL BIOENG, V49, P139; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0	27	100	111	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33334	33337		10.1074/jbc.M203820200	http://dx.doi.org/10.1074/jbc.M203820200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080058	hybrid			2022-12-25	WOS:000177859000120
J	Fischer, L; Boland, G; Tuan, RS				Fischer, L; Boland, G; Tuan, RS			Wnt-3A enhances bone morphogenetic protein-2-mediated chondrogenesis of murine C3H10T1/2 mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; INTEGRIN-LINKED-KINASE; TRANSCRIPTION FACTOR LEF-1; N-CADHERIN EXPRESSION; CHICK LIMB BUD; BETA-CATENIN; SIGNALING PATHWAYS; PROTEIN-KINASE; MICROMASS CULTURES; PATTERN-FORMATION	We have recently reported the chondrogenic effect of bone morphogenetic protein-2 (BMP-2) in high density cultures of the mouse multipotent mesenchymal C3H10T1/2 cell line and have shown the functional requirement of the cell-cell adhesion molecule N-cadherin in BMP-2-induced chondrogenesis in vitro (Denker, A. E., Nicoll, S. B., and Tuan, R. S. (1995) Differentiation 59, 25-34; Haas, A. R., and Tuan, R. S. (1999) Differentiation 64, 77-89). Furthermore, BMP-2 treatment also results in an increased protein level of beta-catenin, a known N-cadherin-associated Wnt signal transducer (Fischer, L., Haas, A., and Tuan, R. S. (2001) Signal Transduction 2, 66-78), suggesting functional cross-talk between the BW-2 and Wnt signaling pathways. We have observed previously that BMP-2 treatment up-regulates expression of Wnt-3A in high density cultures of C3H10T1/2 cells. To assess the contribution of Wnt-3A to BMP-2-mediated chondrogenesis, we have generated C3H10T1/2 cell lines overexpressing Wnt-3A and various forms of glycogen synthase kinase-3beta (GSK-3beta), an immediate cytosolic component of the Wnt signaling pathway, and examined their response to BMP-2. We show that overexpression of either Wnt-3A or kinase-dead GSK-3beta enhances BMP-2-mediated chondrogenesis. Furthermore, Wnt-3A overexpression results in decreases in both N-cadherin and GSK-3beta protein levels, whereas Wnt-3A as well as kinase-dead GSK-3beta overexpression increase total and nuclear levels of both beta-catenin and LEF-1. Direct cross-talk between Wnts and BMP-2 was also indicated by the up-regulated interaction between beta-catenin and SMAD-4 in response to BMP-2. These results suggest that Wnt-3A acts in a manner opposite to that of other Wnts, such as Wnt-7A which were previously identified as inhibitory to chondrogenesis, and is the first BMP-2-regulated, chondrogenesis-enhancing member of the Writ family.	NIAMS, Cartilage Biol & Orthoped Branch, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Dept Orthoped Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Grad Programs Biochem & Mol Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cell & Tissue Engn, Philadelphia, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Jefferson University; Jefferson University; Jefferson University	Tuan, RS (corresponding author), NIAMS, Cartilage Biol & Orthoped Branch, NIH, Bldg 50,Rm 1503,50 S Dr,MSC 8022, Bethesda, MD 20892 USA.	Tuanr@mail.nih.gov	Boland, Genevieve/AAP-2767-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, Z01AR041131, R01AR045181, ZIAAR041131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012864] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 45181, AR 39740] Funding Source: Medline; NIDCR NIH HHS [DE 12864] Funding Source: Medline; NIEHS NIH HHS [ES 07005] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; ANTONIO JDS, 1986, DEV BIOL, V115, P313, DOI 10.1016/0012-1606(86)90252-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BURATOVICH MA, 1995, DEV BIOL, V168, P452, DOI 10.1006/dbio.1995.1094; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; DENKER AE, 1995, DIFFERENTIATION, V59, P25, DOI 10.1046/j.1432-0436.1995.5910025.x; Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432-0436.1999.6420067.x; Dominguez I, 2000, DEVELOPMENT, V127, P861; Emerald BS, 1998, DEV GENES EVOL, V208, P504, DOI 10.1007/s004270050209; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Fischer L, 2002, J CELL BIOCHEM, V84, P816, DOI 10.1002/jcb.10091; FISCHER L, 2001, SIGNAL TRANSDUCTION, V2, P66; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Haas AR, 1999, DIFFERENTIATION, V64, P77, DOI 10.1046/j.1432-0436.1999.6420077.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; KAPHINGST K, 1994, CELL, V78, P437, DOI 10.1016/0092-8674(94)90422-7; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; LOTY S, 1995, BIOL CELL, V83, P149, DOI 10.1016/0248-4900(96)81303-7; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; McEwen DG, 2000, CURR BIOL, V10, pR562, DOI 10.1016/S0960-9822(00)00611-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pandur P, 2001, BIOESSAYS, V23, P207, DOI 10.1002/1521-1878(200103)23:3<207::AID-BIES1029>3.0.CO;2-0; PARR BA, 1993, DEVELOPMENT, V119, P247; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shibamoto S, 1998, GENES CELLS, V3, P659; SOLER AP, 1995, HUM PATHOL, V26, P1363, DOI 10.1016/0046-8177(95)90302-X; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Tufan AC, 2001, FASEB J, V15, P1436, DOI 10.1096/fj.00-0784fje; UMANSKY R, 1966, DEV BIOL, V13, P31, DOI 10.1016/0012-1606(66)90048-0; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	65	122	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30870	30878		10.1074/jbc.M109330200	http://dx.doi.org/10.1074/jbc.M109330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12077113	hybrid			2022-12-25	WOS:000177579800061
J	Park, H; Kim, YH; Lim, YM; Han, I; Oh, ES				Park, H; Kim, YH; Lim, YM; Han, I; Oh, ES			Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HEPARAN-SULFATE PROTEOGLYCAN; N-CADHERIN; EXPRESSION; MIGRATION; PROTEIN; DOMAIN; DIFFERENTIATION; TRANSFORMATION; MORPHOLOGY	Syndecan-2 is a transmembrane heparan sulfate proteoglycan whose function at the cell surface is unclear. In this study, we examined the function of syndecan-2 in colon cancer cell lines. In several colon cancer cell lines, syndecan-2 was highly expressed compared with normal cell lines. In contrast, syndecan-1 and -4 were decreased. Cell biological studies using the extracellular domain of recombinant syndecan-2 (2E) or spreading assay with syndecan-2 antibody-coated plates showed that syndecan-2 mediated adhesion and cytoskeletal organization of colon cancer cells. This interaction was critical for the proliferation of colon carcinoma cells. Blocking with 2E or antisense syndecan-2 cDNA induced G(0)/G(1) cell cycle arrest with concomitantly increased expression of p21, p27, and p53. Furthermore, blocking of syndecan-2 through antisense syndecan-2 cDNA significantly reduced tumorigenic activity in colon carcinoma cells. Therefore, increased syndecan-2 expression appears to be a critical for colon carcinoma cell behavior, and syndecan-2 regulates tumorigenic activity through regulation of adhesion and proliferation in colon carcinoma cells.	Ewha Womans Univ, Ctr Cell Signaling Res, Seodaemoon Gu, Seoul 120750, South Korea; Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ewha Med Sch, Ewha Inst Neurosci, Seoul 120750, South Korea	Ewha Womans University; Ewha Womans University; Ewha Womans University	Oh, ES (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Seodaemoon Gu, Seoul 120750, South Korea.	OhES@mm.ewha.ac.kr						AMRKKU M, 1994, J BIOL CHEM, V269, P27795; Bayer-Garner IB, 2001, J CUTAN PATHOL, V28, P83, DOI 10.1034/j.1600-0560.2001.280204.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Carey DJ, 1997, BIOCHEM J, V327, P1; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DASSONVILLE O, 1993, J CLIN ONCOL, V11, P1873, DOI 10.1200/JCO.1993.11.10.1873; Day RM, 1999, VIRCHOWS ARCH, V434, P121, DOI 10.1007/s004280050315; Dhodapkar MV, 1997, BRIT J HAEMATOL, V99, P368, DOI 10.1046/j.1365-2141.1997.3893203.x; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ethell IM, 2000, J CELL BIOL, V151, P53, DOI 10.1083/jcb.151.1.53; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fujiya M, 2001, JPN J CANCER RES, V92, P1074, DOI 10.1111/j.1349-7006.2001.tb01062.x; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Granes F, 1999, EXP CELL RES, V248, P439, DOI 10.1006/excr.1999.4437; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; INKI P, 1994, EUR J CELL BIOL, V63, P43; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; Kaushal GP, 1999, BRIT J HAEMATOL, V104, P365, DOI 10.1046/j.1365-2141.1999.01180.x; Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Li G, 2001, CANCER RES, V61, P3819; LIEBERSBACH BF, 1994, J BIOL CHEM, V269, P20013; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Longley RL, 1999, J CELL SCI, V112, P3421; Modrowski D, 2000, J BIOL CHEM, V275, P9178, DOI 10.1074/jbc.275.13.9178; Nakanishi K, 1999, INT J CANCER, V80, P527, DOI 10.1002/(SICI)1097-0215(19990209)80:4<527::AID-IJC8>3.3.CO;2-P; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; PIGNATELLI M, 1992, BRIT J CANCER, V66, P629, DOI 10.1038/bjc.1992.328; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Sebestyen A, 1999, BRIT J HAEMATOL, V104, P412, DOI 10.1046/j.1365-2141.1999.01211.x; Tong WM, 1998, BRIT J CANCER, V77, P1792, DOI 10.1038/bjc.1998.298; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Zimmermann P, 1999, FASEB J, V13, pS91	43	132	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29730	29736		10.1074/jbc.M202435200	http://dx.doi.org/10.1074/jbc.M202435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12055189	hybrid			2022-12-25	WOS:000177509300049
J	Leaney, JL; Benians, A; Graves, FM; Tinker, A				Leaney, JL; Benians, A; Graves, FM; Tinker, A			A novel strategy to engineer functional fluorescent inhibitory G-protein alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; RECTIFYING K+-CHANNEL; ACTIVATION; EXPRESSION; RECEPTORS; DYNAMICS; PALMITOYLATION; ACYLATION; MECHANISM; MOBILITY	Signaling studies in living cells would be greatly facilitated by the development of functional fluorescently tagged G-protein a subunits. We have designed G(i/o)alpha subunits fused to the cyan fluorescent protein and assayed their function by studying the following two signal transduction pathways: the regulation of G-protein-gated inwardly rectifying K+ channels (Kir3.0 family) and adenylate cyclase. Palmitoylation and myristoylation consensus sites were removed from G(i/o) a subunits (G(i1alpha), G(i2)alpha, G(i3)alpha, and G(oA)alpha) and a mutation introduced at Cys(-4) rendering the subunit resistant to pertussis toxin. This construct was fused in-frame with cyan fluorescent protein containing a short peptide motif from GAP43 that directs palmitoylation and thus membrane targeting. Western blotting confirmed G(i/o)alpha protein expression. Confocal microscopy and biochemical fractionation studies revealed membrane localization. Each mutant G(i/o)alpha subunit significantly reduced basal current density when transiently expressed in a stable cell line expressing Kir3.1 and Kir3.2A, consistent with the sequestration of the Gbetagamma dimer by the mutant Galpha subunit. Moreover, each subunit was able to support A1-mediated and D2S-mediated channel activation when transiently expressed in pertussis toxin-treated cells. Overexpression of tagged G(i3)alpha and G(oA)alpha alpha subunits reduced receptor-mediated and forskolin-induced cAMP mobilization.	UCL, BHF Labs, London WC1E 6JJ, England; UCL, Dept Med, Ctr Clin Pharmacol, London WC1E 6JJ, England	University of London; University College London; University of London; University College London	Tinker, A (corresponding author), UCL, BHF Labs, Rom 420,4th Floor, London WC1E 6JJ, England.	a.tinker@ucl.ac.uk						Bevan N, 1999, FEBS LETT, V462, P61, DOI 10.1016/S0014-5793(99)01467-2; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; Cooper J, 1997, BRIT J PHARMACOL, V122, P546, DOI 10.1038/sj.bjp.0701401; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Giblin JP, 1999, J BIOL CHEM, V274, P22652, DOI 10.1074/jbc.274.32.22652; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; HUNT TW, 1994, J BIOL CHEM, V269, P29565; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Leaney JL, 2000, P NATL ACAD SCI USA, V97, P5651, DOI 10.1073/pnas.080572297; Leaney JL, 2000, J BIOL CHEM, V275, P921, DOI 10.1074/jbc.275.2.921; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; Milligan G, 1999, BRIT J PHARMACOL, V128, P501, DOI 10.1038/sj.bjp.0702824; Milligan G, 1997, ESSAYS BIOCHEM, V32, P49; NOMA A, 1978, PFLUG ARCH EUR J PHY, V377, P193, DOI 10.1007/BF00584272; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; Pyenta PS, 2001, BIOPHYS J, V80, P2120, DOI 10.1016/S0006-3495(01)76185-1; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Wenzel-Seifert K, 1998, BIOCHEM J, V334, P519, DOI 10.1042/bj3340519; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wise A, 1997, BIOCHEM J, V321, P721, DOI 10.1042/bj3210721; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Yamada M, 1998, PHARMACOL REV, V50, P723; Yu JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/mol.61.2.352; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	48	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28803	28809		10.1074/jbc.M204683200	http://dx.doi.org/10.1074/jbc.M204683200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048213	hybrid			2022-12-25	WOS:000177342600060
J	Wuest, T; Gerlach, E; Banerjee, D; Gerspach, J; Moosmayer, D; Pfizenmaier, K				Wuest, T; Gerlach, E; Banerjee, D; Gerspach, J; Moosmayer, D; Pfizenmaier, K			TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor	ONCOGENE			English	Article						tumor stroma targeting; tumor associated proteases; TNFR2 signaling; juxtatropic membrane TNF like action	FACTOR-ALPHA; FACTOR RECEPTOR; STROMAL FIBROBLASTS; PROTEIN; CANCER; CELLS; INVOLVEMENT; VASCULATURE; EXPRESSION; THERAPY	We describe a TNF fusion protein designated TNF-Selectokine, which is a homo-trimeric molecule comprised of a single chain antibody (scFv) targeting module, a trimerization domain and TINE TNF-Selectokine exerts high bioactivity towards the targeted and adjacent, antigen negative cells. Membrane targeting dependent immobilization of the TNF-Selectokine induced cell death in TNFR1 and TNFR2 dependent manner, thus cell bound TNF-Selectokine mimicks membrane TNF. To restrict TNF activity to the tumor, a prototype of a TNF-Selectokine prodrug was constructed by insertion of a TNFR1 fragment, separated from TNF by a protease-sensitive linker. The prodrug exerts minimal TNF activity, but can be activated in vitro several thousand-fold by proteolytic digest, showing the principal feasibility of this approach. Choice of cleavage site(s) recognized by protease(s) typically associated with a given carcinoma should allow high dose systemic application of the respective TNF prodrug that unveils its specific bioactivity only in targeted tissues.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Pfizenmaier, K (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	klaus.pfizenmaier@po.uni-stuttgart.de						BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brocks B, 2001, MOL MED, V7, P461, DOI 10.1007/BF03401851; Christ O, 2001, CLIN CANCER RES, V7, P985; CORCORAN AE, 1994, EUR J BIOCHEM, V223, P831, DOI 10.1111/j.1432-1033.1994.tb19059.x; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; De Petro G, 1998, CANCER RES, V58, P2234; DeFeo-Jones D, 2000, NAT MED, V6, P1248, DOI 10.1038/81351; Eggermont A M, 2001, Curr Oncol Rep, V3, P359, DOI 10.1007/s11912-001-0090-8; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Gasparri A, 1999, CANCER RES, V59, P2917; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Huang PS, 2001, CURR OPIN GENET DEV, V11, P104, DOI 10.1016/S0959-437X(00)00164-7; Kammerer RA, 1998, J BIOL CHEM, V273, P10602, DOI 10.1074/jbc.273.17.10602; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mersmann M, 2001, INT J CANCER, V92, P240, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1170>3.3.CO;2-L; Nooijen PTGA, 1998, CANCER RES, V58, P4880; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; ROSENBLUM MG, 1995, CANCER IMMUNOL IMMUN, V40, P322, DOI 10.1007/BF01519633; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Scherf U, 1996, CLIN CANCER RES, V2, P1523; SCHMID EF, 1995, BLOOD, V86, P1836, DOI 10.1182/blood.V86.5.1836.bloodjournal8651836; Stoelcker B, 2000, AM J PATHOL, V156, P1171, DOI 10.1016/S0002-9440(10)64986-3; Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197-1266; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9	31	24	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4257	4265		10.1038/sj.onc.1205193	http://dx.doi.org/10.1038/sj.onc.1205193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082613				2022-12-25	WOS:000176174200008
J	Weber, HO; Samuel, T; Rauch, P; Funk, JO				Weber, HO; Samuel, T; Rauch, P; Funk, JO			Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways	ONCOGENE			English	Article						INK4a/ARF; p53; p21; 14-3-3 sigma; DNA tumor virus	P19(ARF) TUMOR-SUPPRESSOR; INK4A LOCUS; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; MDM2; P14(ARF); CANCER; P21; P16(INK4A); PRODUCT	The tumor suppressor ARF is transcribed from the INK4a/ARF locus in partly overlapping reading frames with the CDK inhibitor p16(Ink4a). ARF is able to antagonize the MDM2-mediated ubiquitination and degradation of p53, leading to either cell cycle arrest or apoptosis, depending on the cellular context. However, recent data point to additional p53-independent functions of mouse p19(ARF). Little is known about the dependency of human p14(ARF) function on p53 and its downstream genes. Therefore, we analysed the mechanism of p14(ARF)-induced cell cycle arrest in several human cell types. Wild-type HCT116 colon carcinoma cells (p53(+/+)p21(CIP1+/+) 14-3-3sigma(+/+)), but not p53(-/-) counterparts, underwent G(1) and G(2) cell cycle arrest following infection with a p14(ARF)-adenovirus. In p21(CIP1-/-) cells, p14(ARF) did not induce G(1) or G(2) arrest, while 14-3-3sigma(-/-) counterparts were mainly arrested in G(1), pointing to essential roles of p21(CIP1) in G(1) and G(2) arrest and cooperative roles of p21 and 14-3-3sigma in ARF-mediated G(2) arrest. Our data demonstrate a strict p53 and p21(CIP1) dependency of p14(ARF)-induced cell cycle arrest in human cells.	Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, D-91052 Erlangen, Germany; NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA	University of Erlangen Nuremberg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Funk, JO (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, Hartmannstr 14, D-91052 Erlangen, Germany.							Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERMEKING H, 1997, MOL CELL, V1, P1; Herzinger T, 1995, ONCOGENE, V11, P2051; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Modestou M, 2001, CANCER RES, V61, P3145; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	52	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3207	3212		10.1038/sj.onc.1205429	http://dx.doi.org/10.1038/sj.onc.1205429			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082636				2022-12-25	WOS:000175373600012
J	Thin, TH; Kim, E; Yeh, S; Sampson, ER; Chen, YT; Collins, LL; Basavappa, R; Chang, CS				Thin, TH; Kim, E; Yeh, S; Sampson, ER; Chen, YT; Collins, LL; Basavappa, R; Chang, CS			Mutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of 17 beta-estradiol-induced androgen receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN INTERACTIONS; LIGAND; PROSTATE; INSENSITIVITY; ESTROGEN; BETA; COACTIVATOR; SPECIFICITY; ACTIVATION; COFACTOR	The influence of estrogen on the development of the male reproductive system may be interrupted in a subset of partial androgen insensitivity syndrome (PAIS) patients. PAIS describes a wide range of male under-masculinization resulting from mutations in the androgen receptor (AR) or steroid metabolism enzymes that perturb androgen-AR regulation of male sex organ development. In this study, we are interested in determining if PAIS-derived AR mutants that respond normally to androgen have altered responses to estrogen in the presence of ARA70, a coregulator previously shown to enhance 17beta-estradiol E2-induced AR transactivation. The wild-type AR (wtAR) and two PAIS AR mutants, AR(S703G) and AR(E709K), all bind to androgen and E2 and subsequently translocate to the nucleus. Whereas ARA70 functionally interacts with the wtAR and the PAIS AR mutants in response to androgen, E2 only promotes the functional interaction between ARA70 and the wtAR but not the PAIS AR mutants. ARA70 increases E2 competitive binding to the wtAR in the presence of low level androgen and also retards E2 dissociation from the wtAR. ARA70 is present in both the cytoplasm and the nucleus of various mouse testicular cells during early embryogenesis day 16, at postpartum day 0 during estradiol synthesis and in the Leydig cells at postpartum day 49. ARA70 may be unable to modulate the PAIS AR mutants-E2 binding, diminishing the effect of E2 via AR during male reproductive system development in patients with such mutations. Therefore, the presence of ARA70 in the testosterone and E2-producing Leydig cells may enhance the overall activity of AR during critical stages of male sex organ development.	Univ Rochester, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@URMC.rochester.edu	Basavappa, Ravi/AAF-7385-2021	Chen, Yei-Tsung/0000-0002-3891-5172; Chang, Chawnshang/0000-0001-8510-3516	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Adeyemo O, 1993, Afr J Med Med Sci, V22, P55; AGOULNIK I, 2000, KEYSTONE STEROID S; AIMAN J, 1979, NEW ENGL J MED, V300, P223, DOI 10.1056/NEJM197902013000503; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Cupp AS, 2001, REPROD TOXICOL, V15, P317, DOI 10.1016/S0890-6238(01)00124-1; FELIG P, 2001, ENDOCRINOL METAB, P779; Gao TS, 1999, MOL ENDOCRINOL, V13, P1645, DOI 10.1210/me.13.10.1645; GEORGE FW, 1982, ENDOCRINOLOGY, V111, P522, DOI 10.1210/endo-111-2-522; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; HABERT R, 1984, J STEROID BIOCHEM, V21, P193, DOI 10.1016/0022-4731(84)90383-2; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hughes IA, 2000, NEW ENGL J MED, V343, P881, DOI 10.1056/NEJM200009213431210; Jarred RA, 2000, ENDOCRINOLOGY, V141, P3471, DOI 10.1210/en.141.9.3471; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kokontis J, 1991, Receptor, V1, P271; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; Lim HN, 2001, CLIN GENET, V59, P284, DOI 10.1034/j.1399-0004.2001.590412.x; Nitsche EM, 2000, HORM RES, V54, P327, DOI 10.1159/000053282; Pelletier G, 2000, J ENDOCRINOL, V165, P359, DOI 10.1677/joe.0.1650359; Prins GS, 2001, CANCER RES, V61, P6089; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Radmayr C, 1997, J UROLOGY, V158, P1553, DOI 10.1016/S0022-5347(01)64279-4; RAJFER J, 1978, INVEST UROL, V16, P186; RIGH R, 1968, MOUSE REPROD DEV, P282; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; TANAGHO EA, 2000, SMITHS GEN UROLOGY, P813; Truica CI, 2000, CANCER RES, V60, P4709; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527; You L, 1998, ENDOCRINE, V9, P253, DOI 10.1385/ENDO:9:3:253; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	35	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36499	36508		10.1074/jbc.M202824200	http://dx.doi.org/10.1074/jbc.M202824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12068007	hybrid			2022-12-25	WOS:000178275100092
J	Veal, EA; Toone, WM; Jones, N; Morgan, BA				Veal, EA; Toone, WM; Jones, N; Morgan, BA			Distinct roles for glutathione S-transferases in the oxidative stress response in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; YEAST; CONJUGATION; PEROXIDASE; EXPRESSION; RESISTANCE; PROTEINS; SEQUENCE; VECTORS; ALPHA	We have identified three genes, gst1(+), gst2(+), and gst3(+), encoding theta-class glutathione S-transferases (GSTs) in Schizosaccharomyces pombe. The gst1(+) and gst2(+) genes encode closely related proteins (79% identical). Our analysis suggests that Gst1, Gst2, and Gst3 all have GST activity with the substrate 1-chloro-2,4-dinitrobenzene and that Gst3 has glutathione peroxidase activity. Although Gst1 and Gst2 have no detectable peroxidase activity, all three gst genes are required for normal cellular resistance to peroxides. In contrast, each mutant is more resistant to diamide than wild-type cells. The gst1Delta, gst2Delta, and gst3Delta mutants are also more sensitive to fluconazole, suggesting that GSTs may be involved in anti-fungal drug detoxification. Both gst2(+) and gst3(+) mRNA levels increase in stationary phase, and all three gst genes are induced by hydrogen peroxide. Indeed, gst1(+), gst2(+), and gst3(+) are regulated by the stress-activated protein kinase Sty1. The Gst1 and Gst2 proteins are distributed throughout the cell and can form homodimers and Gst1-Gst2 heterodimers. In contrast, Gst3 is excluded from the nucleus and forms homodimers but not complexes with either Gst1 or Gst2. Collectively, our data suggest that GSTs have separate and overlapping roles in oxidative stress and drug responses in fission yeast.	Newcastle Univ, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK Cell Regulat Grp, Manchester M20 4BX, Lancs, England	Newcastle University - UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Morgan, BA (corresponding author), Newcastle Univ, Sch Med, Sch Biochem & Genet, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	B.A.Morgan@ncl.ac.uk		Veal, Elizabeth/0000-0002-1152-5473				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ALFA CE, 1993, METHOD CELL BIOL, V37, P201, DOI 10.1016/S0091-679X(08)60251-4; Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; BOARD PG, 1995, BIOCHEM J, V311, P247, DOI 10.1042/bj3110247; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; DANIELSON UH, 1987, BIOCHEM J, V247, P707, DOI 10.1042/bj2470707; Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501; Hagan IM, 2000, PRACT APPROACH SER, V218, P179; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Henderson CJ, 2000, P NATL ACAD SCI USA, V97, P12741, DOI 10.1073/pnas.220176997; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Kim HG, 2001, BBA-GENE STRUCT EXPR, V1520, P179, DOI 10.1016/S0167-4781(01)00265-2; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Rossjohn J, 1996, PROTEIN ENG, V9, P327, DOI 10.1093/protein/9.4.327; Salinas AE, 1999, CURR MED CHEM, V6, P279; Sherratt PJ, 1998, BIOCHEM J, V335, P619, DOI 10.1042/bj3350619; Sherratt PJ, 1997, BIOCHEM J, V326, P837, DOI 10.1042/bj3260837; STRANGE RC, 1999, IARC SCI PUBL, V8148, P231; Tan KL, 1996, BIOCHEM J, V315, P727, DOI 10.1042/bj3150727; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yamada K, 1999, YEAST, V15, P1125, DOI 10.1002/(SICI)1097-0061(199908)15:11<1125::AID-YEA442>3.0.CO;2-Z; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	36	113	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35523	35531		10.1074/jbc.M111548200	http://dx.doi.org/10.1074/jbc.M111548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12063243	hybrid			2022-12-25	WOS:000178117000111
J	Kawakami, Y; Kawakami, K; Steelant, WFA; Ono, M; Baek, RC; Handa, K; Withers, DA; Hakomori, S				Kawakami, Y; Kawakami, K; Steelant, WFA; Ono, M; Baek, RC; Handa, K; Withers, DA; Hakomori, S			Tetraspanin CD9 is a "proteolipid," and its interaction with alpha(3) integrin in microdomain is promoted by GM3 ganglioside, leading to inhibition of laminin-5-dependent cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA B16 CELLS; MONOCLONAL-ANTIBODY; MEMBRANE DOMAINS; CARCINOMA CELLS; ADHESION; GLYCOSYLATION; PROTEIN; EXPRESSION; RECEPTOR; COMPLEXES	GM3 ganglioside inhibits tetraspanin CD9-facilitated cell motility in various cell lines (Ono, M., Handa, K., Sonnino, S., Withers, D. A., Nagai, H., and Hakomori, S. (2001) Biochemistry 40,6414-6421). We now report the following. (i) CD9 has the novel feature of being soluble in chloroform/methanol, and classifiable as "proteolipid"; (ii) CD9 and alpha(3) integrin were concentrated together in the low-density glycolipid-enriched microdomain (GEM) of ldlD/CD9 cells, and the alpha(3) expression ratio (value for cells grown under +Gal condition divided by the value for cells grown under -Gal condition) in GEM of ldlD/CD9 cells was higher than that in control ldlD/moc cells, suggesting that CD9 recruits alpha(3) in GEM under +Gal condition, whereby GM3 is present. (iii) Chemical levels of alpha(3) and CD9 in the total extract or membrane fractions from cells grown under +Gal versus -Gal condition were nearly identical, whereas alpha(3) expressed at the cell surface, probed by antibody binding in flow cytometry, was higher under -Gal than +Gal condition. These results suggest that GM3 synthesized under +Gal condition promotes interaction of alpha(3) with CD9, which restricts alpha(3) binding to its antibody. A concept of the alpha(3)/CD9 interaction promoted by GM3 was further supported by W co-immunoprecipitation of CD9 and alpha(3) under +Gal but not -Gal condition, (ii) enhanced co-immunoprecipitation of CD9 and alpha(3) when GM3 was added exogenously to cells under -Gal condition, and (iii) the co-localization images of CD9 with alpha(3) and of GM3 with CD9 in fluorescence laser scanning confocal microscopy. Based on the promotion of alpha(3)/CD9 interaction by GM3 and the status of laminin-5 as a true ligand for alpha(3), the laminin-5/alpha(3)-dependent motility of ldlD/CD9 cells was found to be greatly enhanced under -Gal condition, but strongly inhibited under +Gal condition. Such a motility difference under +Gal versus -Gal condition was not observed for ldlD/moc cells. The inhibitory effect observed in ldlD/CD9 cells under +Gal condition was reversed upon addition of anti-alpha(3) antibody and is therefore based on interaction between alpha(3), CD9, and GM3 in GEM.	Pacific NW Res Inst, Div Biomembrane Res, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hakomori, S (corresponding author), Pacific NW Res Inst, Div Biomembrane Res, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; Berditchevski F, 2001, J CELL SCI, V114, P4143; Cajot JF, 1997, CANCER RES, V57, P2593; CARTER WG, 1981, J BIOL CHEM, V256, P6953; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; DOHI T, 1988, CANCER RES, V48, P5680; FOLCH J, 1951, J BIOL CHEM, V191, P807; FOLCH J, 1951, J BIOL CHEM, V191, P819; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; Horvath G, 1998, J BIOL CHEM, V273, P30537, DOI 10.1074/jbc.273.46.30537; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hyuga S, 1997, BIOCHEM BIOPH RES CO, V231, P340, DOI 10.1006/bbrc.1997.6096; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; MIYAKE M, 1991, BIOCHEMISTRY-US, V30, P3328, DOI 10.1021/bi00227a023; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; NAKAJIMA M, 1989, CANCER RES, V49, P1698; Ono M, 1999, CANCER RES, V59, P2335; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Satoh M, 2001, INT J ONCOL, V19, P723; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sorice M, 1997, J LIPID RES, V38, P969; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	48	88	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34349	34358		10.1074/jbc.M200771200	http://dx.doi.org/10.1074/jbc.M200771200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12068006	hybrid			2022-12-25	WOS:000177959100107
J	Milewski, MI; Mickle, JE; Forrest, JK; Stanton, BA; Cutting, GR				Milewski, MI; Mickle, JE; Forrest, JK; Stanton, BA; Cutting, GR			Aggregation of misfolded proteins can be a selective process dependent upon peptide composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; GREEN FLUORESCENT PROTEIN; ALPHA-B-CRYSTALLIN; PDZ-INTERACTING DOMAIN; CYSTIC-FIBROSIS; AGGRESOME FORMATION; HEAT-SHOCK; CONFORMATIONAL DISEASE; HUNTINGTONS-DISEASE; INCLUSION-BODIES	Intracellular aggregation of misfolded proteins is observed in a number of human diseases, in particular, neurologic disorders in which expanded tracts of polyglutamine residues play a central role. A variety of other proteins are prone to aggregation when mutated, indicating that this process is a common pathologic mechanism for inherited disorders. However, little is known about the relationship between the sequence of aggregating peptides and the specificity of intracellular accumulation. Here we demonstrate that substitution of two residues eliminates aggregation of a 111-amino acid peptide derived from the C-terminal portion of the cystic fibrosis transmembrane conductance regulator (CFTR). We also show that fusion to a reporter protein considerably alters the subcellular distribution of aggregating peptide. When fused to green fluorescent protein, the peptide containing amino acids 1370-1480 of CFTR accumulates in large perinuclear or nuclear aggregates. The same CFTR fragment devoid of green fluorescent protein localizes predominantly to discrete accumulations associated with mitochondria. Importantly, both types of accumulation are dependent on the presence of the same two amino acids within the CFTR sequence. Co-expression studies show that both CFTR-derived proteins can co-localize in large cytoplasmic/nuclear aggregates. However, neither CFTR construct accumulates in intracellular inclusions formed by N-terminal fragment of huntingtin. In addition to unique accumulation patterns, each aggregating peptide shows differences in association with chaperone proteins. Thus, our results indicate that the process of intracellular aggregation can be a selective process determined by the composition of the aggregating peptides.	Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA; Inst Mother & Child Hlth, Dept Med Genet, PL-01211 Warsaw, Poland; Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03758 USA	Johns Hopkins University; Dartmouth College	Cutting, GR (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, 600 N Wolfe St,CMSC 9-123, Baltimore, MD 21218 USA.		Milewski, Michał/AAK-4243-2021; Milewski, Michal/C-7144-2012	Milewski, Michał/0000-0001-7982-2565; Milewski, Michal/0000-0001-7982-2565	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044003, R01DK044003] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44003] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Cardinale A, 2001, EUR J BIOCHEM, V268, P268, DOI 10.1046/j.1432-1327.2001.01876.x; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; CUTTING GR, 1997, EMERY RIMOINS PRINCI, P1561; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; Gregersen N, 2000, J INHERIT METAB DIS, V23, P441, DOI 10.1023/A:1005663728291; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Harada M, 2001, GASTROENTEROLOGY, V120, P967, DOI 10.1053/gast.2001.22543; HEAD MW, 1993, AM J PATHOL, V143, P1743; Heath CM, 2001, J CELL BIOL, V153, P449, DOI 10.1083/jcb.153.3.449; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; IWAKI T, 1993, AM J PATHOL, V143, P487; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kabore AF, 2001, J CELL SCI, V114, P293; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Koyama Y, 1999, AM J PATHOL, V154, P1563, DOI 10.1016/S0002-9440(10)65409-0; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Milewski MI, 2001, J CELL SCI, V114, P719; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Notterpek L, 1999, NEUROBIOL DIS, V6, P450, DOI 10.1006/nbdi.1999.0274; PETRESKA L, 1994, HUM MOL GENET, V3, P999, DOI 10.1093/hmg/3.6.999; Qu BH, 1997, J BIOENERG BIOMEMBR, V29, P483, DOI 10.1023/A:1022439108101; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Rappaport L, 1998, MOL CELL BIOCHEM, V184, P101, DOI 10.1023/A:1006843113166; Reiss C, 2000, TOXICOLOGY, V153, P115, DOI 10.1016/S0300-483X(00)00308-5; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Thomas CL, 2000, J GEN VIROL, V81, P1851, DOI 10.1099/0022-1317-81-7-1851; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; YI TM, 1993, J MOL BIOL, V232, P1117, DOI 10.1006/jmbi.1993.1464; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	57	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34462	34470		10.1074/jbc.M205420200	http://dx.doi.org/10.1074/jbc.M205420200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12084728	hybrid			2022-12-25	WOS:000177959100119
J	Ruiz-Velasco, R; Lanning, CC; Williams, CL				Ruiz-Velasco, R; Lanning, CC; Williams, CL			The activation of Rac1 by M-3 muscarinic acetylcholine receptors involves the translocation of Rac1 and IQGAP1 to cell junctions and changes in the composition of protein complexes containing Rac1, IQGAP1, and actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; LYSOPHOSPHATIDIC ACID; BINDING PROTEIN; TERMINAL KINASE; CDC42; ADHESION; DISSOCIATION; INVOLVEMENT; EFFECTOR; MYOSIN	The abilities of the M-3 muscarinic acetylcholine receptor (mAChR) and Rac1 to regulate similar cellular responses, including cadherin-mediated adhesion, prompted us to investigate Rac1 regulation by M-3 mAChR. We characterized changes in Rac1 induced by stimulating transfected M-3 mAChR in Chinese hamster ovary cells stably expressing hemagglutinin (HA)tagged wild-type or mutant Rac1. mAChR activation converts endogenous Rac1 to the GTP-bound form in cells expressing HA-Rac1 but not in cells expressing dominant negative HA-Rac1(Asn-17) or constitutively active HA-Rac1(Val-12). The competitive binding of endogenous IQGAP1 by HA-Rac1(Val-12) may diminish the mAChR-mediated activation of endogenous Rac1. HA-Rac1 and HA-Rac1(Val-12), but not HA-Rac1(Asn-17), accumulate with IQGAP1 at cell junctions during mAChR-induced cell-cell compaction. Co-localization studies suggest that Rac1 can accumulate at junctions without IQGAP1, but IQGAP1 cannot accumulate at junctions without Rac1. mAChR activation also induces GTP-independent changes in Rac1 because mAChR activation redistributes HA-Rac1(Asn-17), which does not bind GTP. Actin associates with complexes containing HA-Rac1 or HA-Rac1(Val-12) after prolonged mAChR activation. We also demonstrate that Rac1 participates in mAChR-induced cell-cell compaction and c-Jun phosphorylation. These results indicate that M-3 mAChR activation converts Rac1 to the GTP-bound form, alters interactions between Rac1, IQGAP1, and actin, and causes the junctional accumulation of Rac1 and IQGAP1.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, 1 Guthrie Sq, Sayre, PA 18840 USA.	cwilliam@inet.guthrie.org			NHLBI NIH HHS [R01 HL63921, R01 HL063921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER V, 1992, J BIOL CHEM, V267, P17001; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Dumontier M, 2000, J CELL SCI, V113, P2253; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Gong MC, 2001, AM J PHYSIOL-CELL PH, V281, pC257, DOI 10.1152/ajpcell.2001.281.1.C257; Hahn A, 2002, BIOCHEM J, V362, P33, DOI 10.1042/0264-6021:3620033; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Machesky LM, 1998, CURR BIOL, V8, pR202, DOI 10.1016/S0960-9822(98)70125-3; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Naarala J, 1997, LIFE SCI, V60, P1905, DOI 10.1016/S0024-3205(97)00152-5; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROGERS M, 1996, CALMODULIN GUIDEBOOK, P34; Schmitz U, 2001, J BIOL CHEM, V276, P22003, DOI 10.1074/jbc.M102450200; Shafer SH, 1999, EXP CELL RES, V248, P148, DOI 10.1006/excr.1998.4385; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Strassheim D, 1999, J BIOL CHEM, V274, P18675, DOI 10.1074/jbc.274.26.18675; Strassheim D, 2000, J BIOL CHEM, V275, P6699, DOI 10.1074/jbc.275.10.6699; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Valentin F, 2001, CELL CALCIUM, V29, P409, DOI 10.1054/ceca.2001.0203; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VANZWIETEN PA, 1995, CARDIOVASC DRUG THER, V9, P159, DOI 10.1007/BF00877757; Wassmann S, 2001, MOL PHARMACOL, V59, P646, DOI 10.1124/mol.59.3.646; WHITE MV, 1995, J ALLERGY CLIN IMMUN, V95, P1065, DOI 10.1016/S0091-6749(95)70209-1; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; WILLIAMS CL, 1993, J CELL BIOL, V121, P643, DOI 10.1083/jcb.121.3.643; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200	46	19	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33081	33091		10.1074/jbc.M202664200	http://dx.doi.org/10.1074/jbc.M202664200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12070151	hybrid			2022-12-25	WOS:000177859000089
J	Sugiyama, T; Kowalczykowski, SC				Sugiyama, T; Kowalczykowski, SC			Rad52 protein associates with replication protein a (RPA)-single-stranded DNA to accelerate Rad51-mediated displacement of RPA and presynaptic complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; COLI RECA PROTEIN; BACTERIOPHAGE-T4 RECOMBINATION PROTEINS; DEPENDENT ATPASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BINDING-PROTEIN; DUPLEX DNA; GENETIC-RECOMBINATION; SSB PROTEIN	The Rad51 nucleoprotein filament mediates DNA strand exchange, a key step of homologous recombination. This activity is stimulated by replication protein A (RPA), but only when RPA is introduced after Rad51 nucleoprotein filament formation. In contrast, RPA inhibits Rad51 nucleoprotein complex formation by prior binding to single-stranded DNA (ssDNA), but Rad52 protein alleviates this inhibition. Here we show that Rad51 filament formation is simultaneous with displacement of RPA from ssDNA. This displacement is initiated by a rate-limiting nucleation of Rad51 protein onto ssDNA complex, followed by rapid elongation of the filament. Rad52 protein accelerates RPA displacement by Rad51 protein. This acceleration probably involves direct interactions with both Rad51 protein and RPA. Detection of a Rad52-RPA-ssDNA co-complex suggests that this co-complex is an intermediate in the displacement process.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Briggs Hall, Davis, CA 95616 USA.			Sugiyama, Tomohiko/0000-0003-2942-3667				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Ando RA, 1999, BIOCHEMISTRY-US, V38, P16589, DOI 10.1021/bi991917h; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Beermann W, 1999, HERZ, V24, P369, DOI 10.1007/BF03043928; Beernink HTH, 1998, BIOCHEMISTRY-US, V37, P5673, DOI 10.1021/bi9800956; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Ivanov EL, 1996, GENETICS, V142, P693; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1981, ENZYMES, P373; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LEBOWITZ J, 1985, THESIS U HOPKINS U B; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Sweezy MA, 1999, BIOCHEMISTRY-US, V38, P936, DOI 10.1021/bi9817055; UMEZU K, 1994, J BIOL CHEM, V269, P30005	39	170	173	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31663	31672		10.1074/jbc.M203494200	http://dx.doi.org/10.1074/jbc.M203494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077133	hybrid, Green Submitted			2022-12-25	WOS:000177718700047
J	Uchida, Y; Gomi, F; Masumizu, T; Miura, Y				Uchida, Y; Gomi, F; Masumizu, T; Miura, Y			Growth inhibitory factor prevents neurite extension and the death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN-LIKE PROTEIN; ALZHEIMERS-DISEASE BRAIN; EXPRESSION; SUPEROXIDE; PROTECTION; MECHANISM; KINETICS; SIGNAL; CELLS; MICE	Growth inhibitory factor (GIF), a brain-specific member of the metallothionein family (MT-III), has been characterized as a inhibitory substance for neurotrophic factors in Alzheimer's disease brains. However, the function of GIF, other than the inhibition of neurotrophic factors, remains unknown. We demonstrate here that exogenous GIF prevents neurite extension of cortical neurons in the early period of differentiation and the death of differentiated neurons caused by high oxygen exposure. Down-regulation of GIF in cortical neurons with antisense S-oligonucleotides promoted neuronal death under high oxygen conditions. ESR spin-trapping studies demonstrated that GIF at 2-6 mum scavenged hydroxyl radicals generated by a Fenton-type reaction or the photolysis of hydrogen peroxide much more effectively than the same concentration of metallothionein I+II. GIF did not scavenge either superoxide produced by the xanthine/xanthine oxidase reaction or NO generated from 1-hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl-1-triazene. Moreover, GIF at 40-80 muM inhibited tyrosine nitration by peroxynitrite as efficiently as metallothionein I+II at the same concentration. These results indicate that GIF prevents neurite extension of neurons in the early period of differentiation and supports the survival of differentiated neurons by scavenging hydroxyl radicals.	Tokyo Metropolitan Inst Gerontol, Dept Neuropathol, Itabashi Ku, Tokyo 1730015, Japan; Tokyo Metropolitan Inst Gerontol, Dept Ultrastruct, Itabashi Ku, Tokyo 1730015, Japan; Tokyo Metropolitan Inst Gerontol, Dept Biochem & Isotopes, Itabashi Ku, Tokyo 1730015, Japan; JEOL Ltd, 3ESR Applicat Lab, Akishima, Tokyo 1968558, Japan	Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology; Jeol Ltd; JEOL Japan	Uchida, Y (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Neuropathol, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.							Akaike T, 1996, METHOD ENZYMOL, V268, P211; Amoureux MC, 1995, NEUROSCI LETT, V201, P61, DOI 10.1016/0304-3940(95)12134-P; Arai Y, 1997, PEDIATR NEUROL, V17, P134, DOI 10.1016/S0887-8994(97)00085-4; ENOKIDO Y, 1992, BRAIN RES, V599, P261, DOI 10.1016/0006-8993(92)90400-4; ERICKSON JC, 1995, NEUROCHEM INT, V27, P35, DOI 10.1016/0197-0186(94)00166-R; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Erickson JC, 1997, J NEUROSCI, V17, P1271; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; Hussain S, 1996, NEUROCHEM INT, V29, P145, DOI 10.1016/0197-0186(95)00114-X; Katoh S, 1997, BIOCHEM BIOPH RES CO, V241, P347, DOI 10.1006/bbrc.1997.7514; Kawashima T, 2000, DEMENT GERIATR COGN, V11, P251, DOI 10.1159/000017247; KENNEDY MC, 1993, BIOCHEM BIOPH RES CO, V196, P632, DOI 10.1006/bbrc.1993.2296; KOBAYASHI H, 1993, MOL BRAIN RES, V19, P188, DOI 10.1016/0169-328X(93)90025-K; Kumari MVR, 1998, FREE RADICAL RES, V29, P93, DOI 10.1080/10715769800300111; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MITSUTA K, 1990, B CHEM SOC JPN, V63, P187, DOI 10.1246/bcsj.63.187; Montoliu C, 2000, J NEUROCHEM, V75, P266, DOI 10.1046/j.1471-4159.2000.0750266.x; Nakagawa H, 2000, CHEM PHARM BULL, V48, P261; O'Brien P, 1998, ARCH TOXICOL, V72, P690, DOI 10.1007/s002040050562; SAKURAI H, 1994, BIOCHEM BIOPH RES CO, V199, P313, DOI 10.1006/bbrc.1994.1230; Suzuki KT, 1996, TOXICOL APPL PHARM, V141, P231; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UCHIDA Y, 1989, BRAIN RES, V481, P190, DOI 10.1016/0006-8993(89)90503-9; Uchida Y, 1999, J NEUROCHEM, V73, P1945; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Yoko, 1994, Biological Signals, V3, P211	27	98	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32353	32359		10.1074/jbc.M111263200	http://dx.doi.org/10.1074/jbc.M111263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12058024	hybrid			2022-12-25	WOS:000177718700131
J	Chang, W; Webster, DR; Salam, AA; Gruber, D; Prasad, A; Eiserich, JP; Bulinski, JC				Chang, W; Webster, DR; Salam, AA; Gruber, D; Prasad, A; Eiserich, JP; Bulinski, JC			Alteration of the C-terminal amino acid of tubulin specifically inhibits myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TUBULIN; MICROTUBULE DYNAMICS; DETYROSINATED MICROTUBULES; MUSCLE DIFFERENTIATION; INTERMEDIATE FILAMENTS; NITRIC-OXIDE; POSTTRANSLATIONAL MODIFICATION; CARBOXYPEPTIDASE ACTIVITY; 3-DIMENSIONAL CULTURES; SIGNAL-TRANSDUCTION	Detyrosination is an evolutionarily conserved post-translational modification of microtubule polymers that is known to be enhanced during early morphological differentiation of cultured myogenic cells (Gundersen, G. G., Khawaja, S., and Bulinski, J. C. (1989) J. Cell Biol. 109, 2275-2288). We proposed that altering the C terminus of a-tubulin by detyrosination plays a role in morphological differentiation. To test our hypothesis, we treated L6 myoblasts with 3-nitrotyrosine (Eiserich, J. P., Estevez, A. G., Bamberg, T. V., Ye, Y. Z., Chuniley, P. H., Beckman, J. S., and Freeman, B. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96,6365-6375), a nontoxic inhibitor that resulted in high level inhibition of microtubule detyrosination and low level incorporation of nitrotyrosine into microtubules. Even though microtubule stabilization or modification by acetylation still occurred normally, morphological differentiation was blocked; myoblasts neither elongated significantly nor fused. Nitrotyrosine treatment prevented synthesis or activation of markers of myogenic differentiation, including muscle-specific myosin, alpha-actin, integrin alpha(7), and myogenin. Consistent with this, myoblast integrin beta(1A) remained highly expressed. In contrast, the increase in beta-catenin level characteristic of early myogenesis was unaffected by treatment. These results show that the identity of the C-terminal residue of alpha-tubulin modulates microtubule activity, possibly because binding to or signaling from modified microtubules is required for the myogenic program.	Columbia Univ, Coll Arts & Sci, Dept Biol Sci, New York, NY 10027 USA; Columbia Univ, Coll Arts & Sci, Dept Anat & Cell Biol, New York, NY 10027 USA; Columbia Univ, Coll Arts & Sci, Dept Pathol, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Dept Biol Sci, New York, NY 10027 USA; Columbia Univ, Integrated Program Cell Mol & Biophys Studies, New York, NY 10027 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of California System; University of California Davis	Bulinski, JC (corresponding author), Columbia Univ, Coll Arts & Sci, Dept Biol Sci, MC2450,804 Sherman Fairchild Ctr,1212 Amsterdam A, New York, NY 10027 USA.	jcb4@columbia.edu	Salam, Abdul/GWC-1029-2022		NCI NIH HHS [T32 CA 09503] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008224] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; BAAS PW, 1990, J CELL BIOL, V111, P495, DOI 10.1083/jcb.111.2.495; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BULINSKI JC, 1988, J CELL BIOL, V106, P1213, DOI 10.1083/jcb.106.4.1213; BULINSKI JC, 1991, BIOESSAYS, V13, P285, DOI 10.1002/bies.950130605; BULINSKI JC, 1983, P NATL ACAD SCI-BIOL, V80, P1506, DOI 10.1073/pnas.80.6.1506; CHAPIN SJ, 1991, METHOD ENZYMOL, V196, P254; CHIU CP, 1984, CELL, V37, P879, DOI 10.1016/0092-8674(84)90423-9; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; GALELLA G, 1979, CAN J BIOCHEM CELL B, V57, P1368, DOI 10.1139/o79-182; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Gruber D, 2001, CELL MOTIL CYTOSKEL, V49, P115, DOI 10.1002/cm.1026; GUNDERSEN GG, 1989, J CELL BIOL, V109, P2275, DOI 10.1083/jcb.109.5.2275; GUNDERSEN GG, 1987, J CELL BIOL, V105, P251, DOI 10.1083/jcb.105.1.251; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; GURLAND G, 1995, J CELL BIOL, V131, P1275, DOI 10.1083/jcb.131.5.1275; HAIDER SR, 1994, EXP CELL RES, V210, P278, DOI 10.1006/excr.1994.1040; HASHIMOTO N, 1994, FEBS LETT, V352, P236, DOI 10.1016/0014-5793(94)00964-3; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KALISZ HM, 2000, BIOCHIM BIOPHYS ACTA, V1481, P1131; KAUFMAN SJ, 1985, J CELL BIOL, V100, P1977, DOI 10.1083/jcb.100.6.1977; KHAWAJA S, 1988, J CELL BIOL, V106, P141, DOI 10.1083/jcb.106.1.141; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; Lafanechere L, 2000, NEUROCHEM RES, V25, P11, DOI 10.1023/A:1007575012904; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Liao GJ, 1998, J BIOL CHEM, V273, P9797, DOI 10.1074/jbc.273.16.9797; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; Luduena RF, 1998, INT REV CYTOL, V178, P207; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Moreno RD, 2000, CELL MOTIL CYTOSKEL, V46, P235, DOI 10.1002/1097-0169(200008)46:4<235::AID-CM1>3.0.CO;2-G; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; OLMSTED JB, 1975, BIOCHEMISTRY-US, V14, P2996, DOI 10.1021/bi00684a032; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Redfield A, 1997, J CELL BIOL, V138, P1323, DOI 10.1083/jcb.138.6.1323; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; Seghatoleslami MR, 2000, J CELL BIOCHEM, V77, P252, DOI 10.1002/(SICI)1097-4644(20000501)77:2<252::AID-JCB8>3.0.CO;2-J; SHIRAISHI F, 1978, KOKURITSU KOGAI KENK, V5, P77; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; TEDESCO D, 1995, J VIROL, V69, P6947, DOI 10.1128/JVI.69.11.6947-6957.1995; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Watanabe K, 1997, CELL MOTIL CYTOSKEL, V37, P263, DOI 10.1002/(SICI)1097-0169(1997)37:3<263::AID-CM8>3.0.CO;2-7; WEBSTER DR, 1987, P NATL ACAD SCI USA, V84, P9040, DOI 10.1073/pnas.84.24.9040; Webster DR, 1996, J CELL BIOCHEM, V60, P424, DOI 10.1002/(SICI)1097-4644(19960301)60:3<424::AID-JCB13>3.0.CO;2-K; WEBSTER DR, 1992, BIOCHEMISTRY-US, V31, P5849, DOI 10.1021/bi00140a021; WEBSTER DR, 1990, J CELL BIOL, V111, P113, DOI 10.1083/jcb.111.1.113; WEHLAND J, 1987, J CELL SCI, V88, P185; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Ziober BL, 1996, J BIOL CHEM, V271, P22915, DOI 10.1074/jbc.271.37.22915	64	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30690	30698		10.1074/jbc.M204930200	http://dx.doi.org/10.1074/jbc.M204930200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070174	hybrid			2022-12-25	WOS:000177579800038
J	Nadal, A; Martell, M; Lytle, JR; Lyons, AJ; Robertson, HD; Cabot, B; Esteban, JI; Esteban, R; Guardia, J; Gomez, J				Nadal, A; Martell, M; Lytle, JR; Lyons, AJ; Robertson, HD; Cabot, B; Esteban, JI; Esteban, R; Guardia, J; Gomez, J			Specific cleavage of hepatitis C virus RNA genome by human RNase P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; STRUCTURAL ELEMENT; INTERFERON THERAPY; ESCHERICHIA-COLI; RIBONUCLEASE; IDENTIFICATION; SEQUENCES; SUBUNIT; INHIBITION; NUCLEOTIDE	We have found that RNase P from HeLa cells specifically and efficiently cleaves hepatitis C virus (HCV) transcripts in vitro. The evidence includes identification of the 5'-phosphate polarity of the newly generated termini at position A(2860) as well as immunological and biochemical assays. Active cleavage has been shown in five dominant sequences of HCV "quasispecies" differing at or near the position of cleavage, demonstrating that this is a general property of HCV RNA. During the analysis, a second cleavage event was found in the 3' domain of the internal ribosome entry site. We have found that HCV RNA competitively inhibits pre-tRNA cleavage by RNase P, suggesting that HCV RNA has structural similarities to tRNA. This finding sets HCV apart from other pathogens causing serious human diseases and represents the first description of human RNase P-viral RNA cleavage. Here we discuss the possible meaning of these RNase P-accessible structures built into the viral genome and their possible role in vivo. Moreover, such structures within the viral genome might be vulnerable to attack by therapeutic strategies.	Hosp Gen Valle Hebron, Lab Med Interna Hepatol, Area Invest Basica B, Barcelona 08035, Spain; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Hospital Universitari Vall d'Hebron; Cornell University	Gomez, J (corresponding author), Hosp Gen Valle Hebron, Lab Med Interna Hepatol, Area Invest Basica B, Paseo Vall Dhebron 119-129, Barcelona 08035, Spain.	jgomez@hg.vhebron.es	Martell, Maria/J-8191-2013; Nadal, Anna/K-3029-2017; Jordi, Gómez/L-6112-2015	Martell, Maria/0000-0002-0935-0029; Nadal, Anna/0000-0003-1917-9277; Gomez, Jordi/0000-0002-7806-1503; esteban, rafael/0000-0001-5280-392X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056424] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 56424] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS RLP, 1992, BIOCH NUCL ACIDS, P97; ALTMAN S, 1995, BIO-TECHNOL, V13, P327, DOI 10.1038/nbt0495-327; Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; BARRELL BG, 1971, PROCEDURES NUCL ACID; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; Baumstark T, 2001, RNA, V7, P1652; BRANCH AD, 1989, METHOD ENZYMOL, V180, P130; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Cabot B, 2000, J VIROL, V74, P805, DOI 10.1128/JVI.74.2.805-811.2000; Chamberlain JR, 1996, NUCLEIC ACIDS RES, V24, P3158, DOI 10.1093/nar/24.16.3158; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Domingo Esteban, 1994, P161; Eder PS, 1997, P NATL ACAD SCI USA, V94, P1101, DOI 10.1073/pnas.94.4.1101; ENOMOTO N, 1994, J GEN VIROL, V75, P1361, DOI 10.1099/0022-1317-75-6-1361; GIEGE R, 1993, BIOCHIMIE, V75, P569, DOI 10.1016/0300-9084(93)90063-X; Gomez J, 1999, J VIRAL HEPATITIS, V6, P3, DOI 10.1046/j.1365-2893.1999.t01-1-6120131.x; GUERRIERTAKADA C, 1988, CELL, V53, P267, DOI 10.1016/0092-8674(88)90388-1; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HAYASHI N, 1993, J HEPATOL, V17, pS94, DOI 10.1016/S0168-8278(05)80432-5; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Houghton Michael, 1994, V61, P1; JOSHI S, 1982, NUCLEIC ACIDS RES, V10, P1947, DOI 10.1093/nar/10.6.1947; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; Kilani AF, 2000, J BIOL CHEM, V275, P10611, DOI 10.1074/jbc.275.14.10611; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; LeGuen B, 1997, HEPATOLOGY, V25, P1250, DOI 10.1002/hep.510250531; LIU FY, 1995, GENE DEV, V9, P471, DOI 10.1101/gad.9.4.471; Lyons AJ, 2001, NUCLEIC ACIDS RES, V29, P2535, DOI 10.1093/nar/29.12.2535; Lytle JR, 2001, J VIROL, V75, P7629, DOI 10.1128/JVI.75.16.7629-7636.2001; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; Martell M, 1999, J CLIN MICROBIOL, V37, P327, DOI 10.1128/JCM.37.2.327-332.1999; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; PECKMILLER KA, 1991, J MOL BIOL, V221, P1; Plehn-Dujowich D, 1998, P NATL ACAD SCI USA, V95, P7327, DOI 10.1073/pnas.95.13.7327; Polyak SJ, 1998, J VIROL, V72, P4288, DOI 10.1128/JVI.72.5.4288-4296.1998; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; Springer M, 1998, COLD SPRING HARBOR M, P377; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WALEWSKY JL, 2001, RNA, V20, P3840; WANG CY, 1995, RNA, V1, P526; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; YUAN Y, 1995, EMBO J, V14, P159, DOI 10.1002/j.1460-2075.1995.tb06986.x	49	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30606	30613		10.1074/jbc.M203595200	http://dx.doi.org/10.1074/jbc.M203595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12060655	hybrid			2022-12-25	WOS:000177579800028
J	Bazan, NG; Lukiw, WJ				Bazan, NG; Lukiw, WJ			Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1 beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FAMILIAL ALZHEIMERS-DISEASE; TRANSCRIPTION FACTORS; INDUCIBLE FACTOR-1; OXIDATIVE STRESS; UP-REGULATION; DNA-BINDING; PRECURSOR PROTEIN; BRAIN; MODEL	Lipid messengers and amyloid beta (Abeta) peptides generated by cyclooxygenase-2 (COX-2) and presenilin-1 (PS1) mediate pro-inflammatory signaling and neural degeneration in Alzheimer's disease (AD) brain. This study provides data showing that the COX-2 and PS1 genes each transcribe rare, highly labile RNA species that display early response gene behavior in human neural (HN) cells in primary culture, down-regulation during human neural development, and up-regulation in AD neocortex and hippocampal CA1. Together, interleukin-1beta and amyloid beta42 peptide [IL-1beta+Abeta42] synergistically activated COX-2 and PS1 gene expression preceded by increases in AP1-, STAT1alpha-, and in particular NF-kappaBp50/p65- and HIF-1alpha-DNA binding. These events were markedly potentiated by hypoxia and blocked by the antioxidant alpha-phenyl-N-tent-butyl nitrone. Broad transcription profiling further indicated that hypoxia-induced, [IL-1beta+Abeta42]-treated HN cells display robust induction of COX-2 and PS1 as well as a pro-inflammatory gene family that includes NF-kappaBp50/p105, IL-1beta precursor, and cytosolic phospholipase A(2) genes. These findings indicate a novel [IL-1beta+Abeta42]-mediated, hypoxia-enhanced, free. radical-triggered gene program that drives inflammatory gene signaling and suggest a mechanism by which hypoxia during aging contributes episodically to amyloidogenesis, inflammation, and AD pathophysiology.	Louisiana State Univ, Ctr Neurosci, Hlth Sci Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Dept Ophthalmol, Hlth Sci Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lukiw, WJ (corresponding author), Louisiana State Univ, Ctr Neurosci, Hlth Sci Ctr, New Orleans, LA 70112 USA.	wlukiw@lsuhsc.edu	Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NIA NIH HHS [AG18031] Funding Source: Medline; NINDS NIH HHS [NS23002] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018031] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Andreasson KI, 2001, J NEUROSCI, V21, P8198; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Apelt J, 2001, BRAIN RES, V894, P21, DOI 10.1016/S0006-8993(00)03176-0; Bazan NG, 2001, NAT MED, V7, P414, DOI 10.1038/86477; Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Butterfield DA, 1999, LIFE SCI, V65, P1883, DOI 10.1016/S0024-3205(99)00442-7; Butterfield DA, 1998, ANN NY ACAD SCI, V854, P448, DOI 10.1111/j.1749-6632.1998.tb09924.x; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; D'Angio CT, 2000, MOL GENET METAB, V71, P371, DOI 10.1006/mgme.2000.3074; Desmond DW, 1996, CEREBROVAS BRAIN MET, V8, P296; Dewachter I, 2001, BIOCHEM SOC SYMP, V67, P203; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; Fiebich BL, 2000, J NEUROCHEM, V75, P2020, DOI 10.1046/j.1471-4159.2000.0752020.x; Fortini ME, 2001, CURR OPIN CELL BIOL, V13, P627, DOI 10.1016/S0955-0674(00)00261-1; Gitter BD, 2000, ANN NY ACAD SCI, V917, P154; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; Griffin WST, 2000, EXP GERONTOL, V35, P481, DOI 10.1016/S0531-5565(00)00110-8; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Ho L, 1999, J NEUROSCI RES, V57, P295; Honda T, 2000, NEUROSCI RES, V37, P101, DOI 10.1016/S0168-0102(00)00106-1; Hoozemans JJM, 2001, EXP GERONTOL, V36, P559, DOI 10.1016/S0531-5565(00)00226-6; Ivashkiv L B, 2000, Rev Immunogenet, V2, P220; John GR, 2001, J NEUROSCI, V21, P4134, DOI 10.1523/JNEUROSCI.21-12-04134.2001; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kitamura Y, 1997, NEUROSCI LETT, V237, P17, DOI 10.1016/S0304-3940(97)00797-0; Kuperstein F, 2001, J NEUROCHEM, V76, P758, DOI 10.1046/j.1471-4159.2001.00037.x; Li XH, 1996, J NEUROSCI, V16, P5914; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Loring JF, 2001, DNA CELL BIOL, V20, P683, DOI 10.1089/10445490152717541; Lukiw WJ, 2000, ALZHEIMERS REP, V3, P161; Lukiw WJ, 2000, NEUROCHEM RES, V25, P1173, DOI 10.1023/A:1007627725251; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; Lukiw WJ, 2001, INVEST OPHTH VIS SCI, V42, pS243; Lukiw WJ, 2001, NEUROREPORT, V12, P53, DOI 10.1097/00001756-200101220-00019; Lukiw WJ, 1998, J NEUROSCI RES, V53, P583, DOI 10.1002/(SICI)1097-4547(19980901)53:5<583::AID-JNR8>3.3.CO;2-B; LUKIW WJ, IN PRESS J NEUROSCI; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; Mattson MP, 2000, J NEUROSCI, V20, P1358; McGeer PL, 2000, J NEURAL TRANSM-SUPP, P53; Mitsuda N, 2001, J BIOL CHEM, V276, P9688, DOI 10.1074/jbc.M006153200; MORGAN JI, 1995, TRENDS NEUROSCI, V18, P66; Muller CW, 2001, CURR OPIN STRUC BIOL, V11, P26, DOI 10.1016/S0959-440X(00)00163-9; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; Rhodin J, 2000, ANN NY ACAD SCI, V903, P345, DOI 10.1111/j.1749-6632.2000.tb06385.x; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rogers J, 2000, ANN NY ACAD SCI, V924, P132; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Tong LQ, 2001, J BIOL CHEM, V276, P17301, DOI 10.1074/jbc.M010450200; Toone WM, 2001, ONCOGENE, V20, P2336, DOI 10.1038/sj.onc.1204384; Wiltfang J, 2001, J BIOL CHEM, V276, P42645, DOI 10.1074/jbc.M102790200; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2	64	91	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30359	30367		10.1074/jbc.M203201200	http://dx.doi.org/10.1074/jbc.M203201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050157	hybrid			2022-12-25	WOS:000177509300122
J	Kim, SJ; Kim, HG; Oh, CD; Hwang, SG; Song, WK; Yoo, YJ; Kang, SS; Chun, JS				Kim, SJ; Kim, HG; Oh, CD; Hwang, SG; Song, WK; Yoo, YJ; Kang, SS; Chun, JS			P38 kinase-dependent and -independent inhibition of protein kinase C xi and -alpha regulates nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ACTIVATION; SUPPRESSION; ZETA; PKC; CHONDROGENESIS; DEGRADATION; CARTILAGE; ISOFORMS; PATHWAY	In articular chondrocytes, nitric oxide (NO) production triggers dedifferentiation and apoptotic cell death that is regulated by the converse functions of two mitogen-activated protein kinase subtypes, extracellular signal-regulated kinase (ERK) and p38 kinase. Since protein kinase C (PKC) transducer signals that influence differentiation, survival, and apoptosis of various cell types, we investigated the roles and underlying molecular mechanisms of action of PKC isoforms in NO-induced dedifferentiation and apoptosis of articular chondrocytes. We report here that among the expressed isoforms, activities of PKCalpha and -zeta were reduced during NO-induced dedifferentiation and apoptosis. Inhibition of PKCalpha activity was independent of NO-induced activation of ERK or p38 kinase and occurred due to blockage of expression. On the other hand, PKCzeta activity was inhibited as a result of NO-induced p38 kinase activation and was observed prior to proteolytic cleavage by a caspase-mediated process to generate enzymatically inactive fragments. Inhibition of PKCalpha or -zeta activities potentiated NO-induced apoptosis, whereas ectopic expression of these isoforms significantly reduced the number of apoptotic cells and blocked dedifferentiation. Ectopic expression of PKCalpha or -zeta did not affect p38 kinase or ERK but inhibited the p53 accumulation and caspase-3 activation that are required for NO-induced apoptosis of chondrocytes. Therefore, our results collectively indicate that p38 kinase-independent and -dependent inhibition of PKCalpha and -zeta, respectively, regulates NO-induced apoptosis and dedifferentiation of articular chondrocytes.	Kwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Gwangju 500712, South Korea; Kyungpook Natl Univ, Dept Biol, Taegu 702701, South Korea	Gwangju Institute of Science & Technology (GIST); Kyungpook National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Gwangju 500712, South Korea.	jschun@kjist.ac.kr		Oh, Chundo/0000-0002-5419-8011				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Cao M, 1997, BIOCHEM J, V324, P305, DOI 10.1042/bj3240305; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Thonel A, 2001, BLOOD, V98, P3770, DOI 10.1182/blood.V98.13.3770; Desai DS, 1999, BIOCHEM BIOPH RES CO, V263, P28, DOI 10.1006/bbrc.1999.1307; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Foo SY, 1999, TRENDS GENET, V15, P229; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; Hoppe J, 2001, EXP CELL RES, V266, P64, DOI 10.1006/excr.2001.5211; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Leirdal M, 1999, BRIT J CANCER, V80, P1558, DOI 10.1038/sj.bjc.6690560; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Martel-Pelletier J, 1999, FRONT BIOSCI, V4, pD694; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Okuda H, 1999, ONCOGENE, V18, P5604, DOI 10.1038/sj.onc.1202946; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Poole AR, 1999, FRONT BIOSCI, V4, P662; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; TASKIRAN D, 1994, BIOCHEM BIOPH RES CO, V200, P142, DOI 10.1006/bbrc.1994.1426; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; Yatsugi N, 2000, J Orthop Sci, V5, P150, DOI 10.1007/s007760050142; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; Zhang LH, 2001, J BIOL CHEM, V276, P43534, DOI 10.1074/jbc.M104257200	52	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30375	30381		10.1074/jbc.M205193200	http://dx.doi.org/10.1074/jbc.M205193200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048219	hybrid			2022-12-25	WOS:000177509300124
J	Muhlenhoff, U; Richhardt, N; Gerber, J; Lill, R				Muhlenhoff, U; Richhardt, N; Gerber, J; Lill, R			Characterization of iron-sulfur protein assembly in isolated mitochondria - A requirement for ATP, NADH, and reduced iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; NIFS-LIKE PROTEIN; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; ESCHERICHIA-COLI; AZOTOBACTER-VINELANDII; FRIEDREICHS-ATAXIA; GENE-PRODUCT; MATURATION; BIOSYNTHESIS	To study the biochemical requirements for maturation of iron-sulfur (Fe/S) proteins, we have reconstituted the process in vitro using detergent extracts from Saccharomyces cerevisiae mitochondria. Efficient assembly of biotin synthase as a model Fe/S protein required anaerobic conditions, dithiothreitol, cysteine, ATP, and NADH. Cysteine is utilized by the cysteine desulfurase Nfs1p to release sulfan sulfur; ATP presumably reflects the function of the Hsp70 family chaperone Ssq1p; and NADH is used for reduction of the ferredoxin Yah1p involved in Fe/S protein biogenesis. Hence, our assay system faithfully reproduces the in vivo pathway. We have further investigated the involvement of various mitochondrial proteins suspected to participate in Fe/S protein biogenesis. In mitochondrial extracts depleted in Isa1p, Fe/S protein formation was severely decreased. A similar strong decline was observed with extracts from Deltayfh1 mitochondria, indicating that both Isa1p and the yeast frataxin homologue, Yfh1p, are crucial for biogenesis of mitochondrial Fe/S proteins. Conversely, the activities of mitochondrial extracts from Deltanfu1 cells were only moderately reduced, suggesting a dispensable role for Nfu1p. Finally, iron utilized for Fe/S protein formation was imported into the matrix of intact mitochondria in ferrous form in a membrane potential-dependent transport step. Our results represent the first an vitro reconstitution of the entire pathway of Fe/S protein maturation.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany	Philipps University Marburg	Lill, R (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 5, D-35033 Marburg, Germany.	Lill@mailer.uni-marburg.de		Lill, Roland/0000-0002-8345-6518				Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Clausen T, 2000, P NATL ACAD SCI USA, V97, P3856, DOI 10.1073/pnas.97.8.3856; DAUM G, 1982, J BIOL CHEM, V257, P3028; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; Floss B, 1997, PHOTOSYNTH RES, V54, P63, DOI 10.1023/A:1005823620291; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARLOW E, 1998, USING ANTIBODIES LAB; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; MEYER J, 1986, BIOCHIM BIOPHYS ACTA, V871, P243, DOI 10.1016/0167-4838(86)90205-0; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Pelzer W, 2000, FEBS LETT, V476, P134, DOI 10.1016/S0014-5793(00)01711-7; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHASHI Y, 1991, PLANT PHYSIOL, V95, P104, DOI 10.1104/pp.95.1.104; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	60	106	108	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29810	29816		10.1074/jbc.M204675200	http://dx.doi.org/10.1074/jbc.M204675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12065597	hybrid			2022-12-25	WOS:000177509300059
J	Wustner, D; Herrmann, A; Hao, MM; Maxfield, FR				Wustner, D; Herrmann, A; Hao, MM; Maxfield, FR			Rapid nonvesicular transport of sterol between the plasma membrane domains of polarized hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; HEPG2 CELLS; RAT-LIVER; DENSITY-LIPOPROTEIN; LIPID-COMPOSITION; GOLGI-APPARATUS; P-GLYCOPROTEIN; MDCK CELLS; SUBAPICAL COMPARTMENT; ENDOPLASMIC-RETICULUM	We studied the transport of the fluorescent cholesterol analog dehydroergosterol (DHE) in polarized HepG2 human hepatoma cells. DHE delivered via methyl-beta-cyclodextrin was delivered to both the apical and basolateral membranes and became concentrated in the apical membrane within 1 min. Intracellular DHE was targeted mainly to vesicles of the subapical compartment or apical recycling compartment (SAC/ARC), where it colocalized with fluorescent transferrin and fluorescent analogs of phosphatidylcholine and sphingomyelin. In contrast, transport of DHE from the plasma membrane to the trans-Golgi network was found to be very low. Vesicles containing DHE traversed the cells in both directions, but vesicular export of DHE from the SAC/ARC to the plasma membrane domains was low. Disruption of the microtubule cytoskeleton disturbed vesicular transport of DHE but not its enrichment in the apical (canalicular) membrane. Transport of DHE to the canalicular membrane after photobleaching was very rapid (t(1/2) = 1.6 min) and was largely ATP-independent in contrast to enrichment of DHE in the SAC/ARC. Release of DHE from the canalicular membrane was also ATP-independent but slower than the enrichment of sterol in the biliary canaliculus (t(1/2) = 5.4 min). Canalicular DHE could completely redistribute to the basolateral plasma membrane but could not transfer from one cell to the other cell of an HepG2 couplet. We conclude that sterol shuttles rapidly among the plasma membrane domains and other membrane organelles and that this nonvesicular pathway includes fast transbilayer migration.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Humboldt Univ, Math Nat Wissensch Fak 1, Inst Biol Biophys, D-10115 Berlin, Germany	Cornell University; Humboldt University of Berlin	Maxfield, FR (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, Rm E-215,1300 York Ave, New York, NY 10021 USA.		Eckhardt, Erik/G-1567-2010; Maxfield, Fred/A-1718-2011	Wustner, Daniel/0000-0003-4995-9709; Maxfield, Frederick/0000-0003-4396-8866	NIDDK NIH HHS [DK27083] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027083, R01DK027083] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; Cheng KH, 1999, BIOPHYS J, V77, P3108, DOI 10.1016/S0006-3495(99)77141-9; CHONG PLG, 1994, P NATL ACAD SCI USA, V91, P10069, DOI 10.1073/pnas.91.21.10069; Corvera S, 2000, J BIOL CHEM, V275, P31414, DOI 10.1074/jbc.M001708200; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; Frijters CMG, 1997, ADV DRUG DELIVER REV, V25, P201, DOI 10.1016/S0169-409X(97)00499-7; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; GEBHARDT R, 1982, EUR J CELL BIOL, V29, P68; Gheber LA, 1999, BIOPHYS J, V77, P3163, DOI 10.1016/S0006-3495(99)77147-X; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GLAUMANN H, 1975, J CELL BIOL, V64, P356, DOI 10.1083/jcb.64.2.356; GRAY MC, 1995, ANAL BIOCHEM, V224, P286, DOI 10.1006/abio.1995.1042; HALE JE, 1982, EUR J BIOCHEM, V122, P649; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Heinrich R, 1997, J THEOR BIOL, V185, P295, DOI 10.1006/jtbi.1996.0325; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Hornick CA, 1997, AM J PHYSIOL-CELL PH, V273, pC1075, DOI 10.1152/ajpcell.1997.273.3.C1075; Ihrke G, 1998, J CELL BIOL, V141, P115, DOI 10.1083/jcb.141.1.115; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; JOHN K, 2002, IN PRESS BIOPHYS J; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; KREMMER T, 1976, BIOCHIM BIOPHYS ACTA, V455, P655, DOI 10.1016/0005-2736(76)90039-0; Kuipers F, 1997, Subcell Biochem, V28, P295; LANGE Y, 1981, J BIOL CHEM, V256, P5321; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Lange Y, 1999, J LIPID RES, V40, P2264; LARKIN JM, 1985, J CELL PHYSIOL, V124, P372, DOI 10.1002/jcp.1041240303; Leventis R, 2001, BIOPHYS J, V81, P2257, DOI 10.1016/S0006-3495(01)75873-0; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Loura LMS, 1997, BIOPHYS J, V72, P2226, DOI 10.1016/S0006-3495(97)78866-0; Luxon BA, 1997, AM J PHYSIOL-CELL PH, V273, pC859, DOI 10.1152/ajpcell.1997.273.3.C859; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Matyash V, 2001, MOL BIOL CELL, V12, P1725, DOI 10.1091/mbc.12.6.1725; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Nusrat A, 2000, J CELL SCI, V113, P1771; Ohvo-Rekila H, 2000, CHEM PHYS LIPIDS, V105, P167, DOI 10.1016/S0009-3084(00)00122-5; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Robins SJ, 1999, HEPATOLOGY, V29, P1541, DOI 10.1002/hep.510290518; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; SCHROEDER F, 1991, BIOCHIM BIOPHYS ACTA, V1066, P183, DOI 10.1016/0005-2736(91)90185-B; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; Smith AJ, 1998, HEPATOLOGY, V28, P530, DOI 10.1002/hep.510280234; SORMUNEN R, 1993, LAB INVEST, V68, P652; STROEVE P, 1975, BIOCHIM BIOPHYS ACTA, V401, P157, DOI 10.1016/0005-2736(75)90300-4; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Tang Q, 2001, BIOPHYS J, V81, P196, DOI 10.1016/S0006-3495(01)75691-3; TAYLOR JA, 1984, BIOCHIM BIOPHYS ACTA, V769, P171, DOI 10.1016/0005-2736(84)90020-8; Tuma PL, 1999, J CELL BIOL, V145, P1089, DOI 10.1083/jcb.145.5.1089; van IJzendoorn SCD, 1998, J CELL BIOL, V142, P683, DOI 10.1083/jcb.142.3.683; van Ijzendoorn SCD, 1999, MOL BIOL CELL, V10, P3449, DOI 10.1091/mbc.10.10.3449; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; vanIjzendoorn SCD, 1997, J CELL BIOL, V137, P347, DOI 10.1083/jcb.137.2.347; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; Wustner D, 2001, TRAFFIC, V2, P277, DOI 10.1034/j.1600-0854.2001.9o135.x; XU XX, 1991, J BIOL CHEM, V266, P17040; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZAMBRANO F, 1975, BIOCHIM BIOPHYS ACTA, V380, P357, DOI 10.1016/0005-2760(75)90104-6	76	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30325	30336		10.1074/jbc.M202626200	http://dx.doi.org/10.1074/jbc.M202626200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050151				2022-12-25	WOS:000177509300119
J	Zhou, TH; Kim, J; Kilani, AF; Kim, K; Dunn, W; Jo, S; Nepomuceno, E; Liu, FY				Zhou, TH; Kim, J; Kilani, AF; Kim, K; Dunn, W; Jo, S; Nepomuceno, E; Liu, FY			In vitro selection of external guide sequences for directing RNase P-mediated inhibition of viral gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CATALYTIC RNA; HAMMERHEAD RIBOZYME; HAIRPIN RIBOZYMES; SUBSTRATE-BINDING; RIBONUCLEASE-P; CLEAVAGE; DNA; SUBUNIT; DIVERSITY	External guide sequences (EGSs) are small RNA molecules that bind to a target mRNA, form a complex resembling the structure of a tRNA, and render the mRNA susceptible to hydrolysis by RNase P, a tRNA processing enzyme. An in vitro selection procedure was used to select EGSs that direct human RNase P to cleave the mRNA encoding thymidine kinase (TK) of herpes simplex virus 1. One of the selected EGSs, TK17, was at least 35 times more active in directing RNase P in cleaving TK mRNA an vitro than the EGS derived from a natural tRNA sequence. TK17, when in complex with the TK mRNA sequence, resembles a portion of tRNA structure and exhibits an enhanced binding affinity to the target mRNA. Moreover, a reduction of 95 and 50% in the TK expression was found in herpes simplex virus 1-infected cells that expressed the selected EGS and the EGS derived from the natural tRNA sequence, respectively. Our study provides direct evidence that EGS molecules isolated by the selection procedure are effective in tissue culture. These results also demonstrate the potential for using the selection procedure as a general approach for the generation of highly effective EGSs for gene-targeting application.	Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Program Comparat Biochem, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Liu, FY (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Program Comparat Biochem, Berkeley, CA 94720 USA.	liu_fy@uclink4.berkeley.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014145] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43250] Funding Source: Medline; NIDCR NIH HHS [DE14145] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altman S., 1999, RNA WORLD, P351; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; Bertrand E, 1997, RNA, V3, P75; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BURKE JM, 1993, FASEB J, V7, P106, DOI 10.1096/fasebj.7.1.8422956; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DRAINAS D, 1989, FEBS LETT, V251, P84, DOI 10.1016/0014-5793(89)81433-4; Dunn W, 2001, P NATL ACAD SCI USA, V98, P14831, DOI 10.1073/pnas.261560598; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gold L., 1993, RNA WORLD, P497; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; Joyce GF, 1998, P NATL ACAD SCI USA, V95, P5845, DOI 10.1073/pnas.95.11.5845; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; Kawa D, 1998, RNA, V4, P1397, DOI 10.1017/S1355838298980918; Kilani AF, 2000, J BIOL CHEM, V275, P10611, DOI 10.1074/jbc.275.14.10611; Kim JJ, 1997, RNA, V3, P613; Kruger M, 1999, METHOD ENZYMOL, V306, P207; Lee NS, 1999, RNA, V5, P1200, DOI 10.1017/S1355838299990246; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1995, GENE DEV, V9, P471, DOI 10.1101/gad.9.4.471; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; Ma M, 2000, NAT BIOTECHNOL, V18, P58, DOI 10.1038/71924; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; NAKAMAYE KL, 1994, BIOCHEMISTRY-US, V33, P1271, DOI 10.1021/bi00171a030; Pal BK, 1998, J VIROL, V72, P8349, DOI 10.1128/JVI.72.10.8349-8353.1998; Pan T, 1996, EMBO J, V15, P2249, DOI 10.1002/j.1460-2075.1996.tb00578.x; Plehn-Dujowich D, 1998, P NATL ACAD SCI USA, V95, P7327, DOI 10.1073/pnas.95.13.7327; Putlitz JZ, 1999, J VIROL, V73, P4188, DOI 10.1128/JVI.73.5.4188-4196.1999; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; Szostak J.W., 1993, RNA WORLD, P511; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; Tang J, 1997, RNA, V3, P914; Trang P, 1999, NUCLEIC ACIDS RES, V27, P4590, DOI 10.1093/nar/27.23.4590; Trang P, 2000, P NATL ACAD SCI USA, V97, P5812, DOI 10.1073/pnas.100101797; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Yu Q, 1998, J BIOL CHEM, V273, P23524, DOI 10.1074/jbc.273.36.23524; YUAN Y, 1994, SCIENCE, V263, P1269, DOI 10.1126/science.8122108; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006	50	25	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30112	30120		10.1074/jbc.M200183200	http://dx.doi.org/10.1074/jbc.M200183200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050148	hybrid			2022-12-25	WOS:000177509300094
J	Dessauer, CW; Chen-Goodspeed, M; Chen, J				Dessauer, CW; Chen-Goodspeed, M; Chen, J			Mechanism of G alpha(i)-mediated inhibition of type V adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC DOMAINS; CATALYTIC MECHANISM; KINETIC-ANALYSIS; G(S ALPHA); SITE; FORSKOLIN; EXPRESSION; MEMBRANES; PROTEINS; SUBUNITS	The topology of mammalian adenylyl cyclase reveals an integral membrane protein composed of an alternating series of membrane and cytoplasmic domains (C-1 and C-2). The stimulatory G protein, Galpha(s), binds within a cleft in the C-2 domain of adenylyl cyclase while Galpha(i) binds within the opposite cleft in the C-2 domain. The mechanism of these two regulators also appears to be in opposition. Activation of adenylyl cyclase by Galpha(i). or forskolin results in a 100-fold increase in the apparent affinity of the two domains for one another. We show herein that Galpha(i) reduces C-1/C-2 domain interaction and thus formation of the adenylyl cyclase catalytic site. Mutants that increase the affinity of C-1 for C-2 decrease the ability of Gai to inhibit the enzyme. In addition, Galpha(i) can influence binding of molecules to the catalytic site, which resides at the C-1/C-2 interface. Adenylyl cyclase can bind substrate analogs in the presence of Galpha(i) but cannot simultaneously bind Galpha(i) and transition state analogs such as 2'd3'-AMP. Galpha(i) also cannot inhibit the membrane-bound enzyme in the presence of manganese, which increases the affinity of adenylyl cyclase for ATP and substrate analogs. Thus homologous G protein alpha-subunits promote bidirectional regulation at the domain interface of the pseudosymmetrical adenylyl cyclase enzyme.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Dessauer, CW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	Carmen.W.Dessauer@uth.tmc.edu	Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060419] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60419, R01 GM060419-03, R01 GM060419] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 2002, METHOD ENZYMOL, V345, P112; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hatley ME, 2000, J BIOL CHEM, V275, P38626, DOI 10.1074/jbc.M007148200; HILDEBRANDT JD, 1983, J BIOL CHEM, V258, P3141; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P3178; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KUNKEL MW, 1989, FASEB J, V3, P2067, DOI 10.1096/fasebj.3.9.2545497; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lin TH, 2002, J BIOL CHEM, V277, P15721, DOI 10.1074/jbc.M111537200; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LONDOS C, 1977, J BIOL CHEM, V252, P5951; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Smith MS, 1998, ANN EMERG MED, V32, P65, DOI 10.1016/S0196-0644(98)70101-5; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; WESTCOTT KR, 1980, J BIOL CHEM, V255, P8767; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 2002, METHOD ENZYMOL, V345, P231; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	39	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28823	28829		10.1074/jbc.M203962200	http://dx.doi.org/10.1074/jbc.M203962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12058044	hybrid			2022-12-25	WOS:000177342600063
J	Benvenuti, S; Cramer, R; Bruce, J; Waterfield, MD; Jat, PS				Benvenuti, S; Cramer, R; Bruce, J; Waterfield, MD; Jat, PS			Identification of novel candidates for replicative senescence by functional proteomics	ONCOGENE			English	Article						replicative senescence; proteomics; gene expression; mass spectrometry	RESPONSE MEDIATOR PROTEIN-2; LIM-DOMAIN PROTEIN; T-ANTIGEN; CELL-LINES; GENE; GELSOLIN; HOMEODOMAIN; EXPRESSION; DYNAMICS; NEURONS	To identify the underlying mechanisms that limit the mitotic potential of normal somatic cells, we have undertaken a high resolution differential proteomic analysis aimed at identifying proteins that were differentially expressed upon replicative senescence. Since replicative senescence in heterogenous primary fibroblast cultures is asynchronous, we analysed a group of conditionally immortalized rat embryo fibroblast cell lines that have previously been shown to undergo synchronous senescence upon inactivation of SV40 tsA58 T antigen. This identified 43 spots that were differentially expressed in these cell lines. Comparison of the identity of these features with those identified in a complimentary independent differential proteomic analysis of replicative senescence, directly in primary rat embryo fibroblasts upon serial passaging, identified nine features that were in common between the two studies even though they had been conducted entirely separately. None of these proteins have previously been recognized to be involved with replicative senescence. Thus, they represent novel starting points for elucidating the underlying mechanism that regulates the finite mitotic life span of somatic cells and how it can be overcome in cancer cells.	Royal Free & Univ Coll, Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Oxford GlycoSci, Abingdon OX14 3YS, Oxon, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London	Jat, PS (corresponding author), Royal Free & Univ Coll, Sch Med, Ludwig Inst Canc Res, Courtland Bldg,91 Riding House St, London W1W 7BS, England.	parmjit@ludwig.ucl.ac.uk		Benvenuti, Silvia/0000-0002-3041-4429; Cramer, Rainer/0000-0002-8037-2511				AMESS B, 1995, ELECTROPHORESIS, V16, P1255, DOI 10.1002/elps.11501601207; Asch HL, 1996, CANCER RES, V56, P4841; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bauer K, 2000, BLOOD, V96, P4236; Benvenuti S, 2002, MOL CELL PROTEOMICS, V1, P280, DOI 10.1074/mcp.M100028-MCP200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Conzen SD, 1995, ONCOGENE, V11, P2295; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Darmon Alison J., 2000, Molecular Cell Biology Research Communications, V4, P219, DOI 10.1006/mcbr.2001.0281; Dong Y, 1999, INT J CANCER, V81, P930, DOI 10.1002/(SICI)1097-0215(19990611)81:6<930::AID-IJC15>3.0.CO;2-A; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; Gotzmann J, 1999, CRIT REV EUKAR GENE, V9, P257, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.100; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RA, 2002, PROTEOMICS, V2, P212, DOI 10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Lee HK, 1999, PROSTATE, V40, P14, DOI 10.1002/(SICI)1097-0045(19990615)40:1<14::AID-PROS2>3.0.CO;2-6; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; NAKAJIMA N, 1995, FEBS LETT, V365, P108, DOI 10.1016/0014-5793(95)00453-G; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; WANG JA, 1996, J CHINA COAL SCI, V1, P16; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592	38	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4403	4413		10.1038/sj.onc.1205525	http://dx.doi.org/10.1038/sj.onc.1205525			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080471				2022-12-25	WOS:000176317100006
J	Armstrong, JS; Jones, DP				Armstrong, JS; Jones, DP			Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in HL60 cells that overexpress Bcl-2	FASEB JOURNAL			English	Article						mitochondrial permeability transition; glutathione; respiratory complex III; Bcl-2; reactive oxygen species	CYTOCHROME BC(1) COMPLEX; ADENINE-NUCLEOTIDE TRANSLOCATOR; DEPENDENT ANION CHANNEL; ENDOPLASMIC-RETICULUM; RESPIRATORY-CHAIN; PYRIDINE-NUCLEOTIDES; INNER MITOCHONDRIAL; C RELEASE; APOPTOSIS; PORE	Bcl-2, a protein that blocks apoptosis by inhibiting the mitochondrial permeability transition (MPT) and release of cytochrome c appears to affect normal mitochondrial function by altering electron flow and increasing rates of reactive oxygen species (ROS) production. In this study, we show that glutathione (GSH) depletion induces ROS production and selective toxicity in HL60 cells that overexpress Bcl-2 compared with neomycin vector control cells. Toxicity was mediated by the MPT because it was blocked with the adenine nucleotide translocator (ANT) ligand bongkrekic acid and resulted in mitochondrial cytochrome c release, caspase 3 activation, and DNA fragmentation, indicating the involvement of an apoptotic pathway. Respiratory chain inhibitors stigmatellin and antimycin A, which inhibit Qo and Qi sites of respiratory chain complex III, respectively, blocked ROS production, preserved the redox state of protein thiols, and prevented cell death. These results indicate that in the absence of GSH, endogenous ROS generated at respiratory complex III induce MPT independently of Bcl-2. The results also suggest a new model for MPT in which the central pore protein ANT is regulated by adenine nucleotide and the activity of mitochondrial respiratory complex III.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Armstrong, JS (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd,4123 Rollins Res Ctr, Atlanta, GA 30322 USA.	jeff30322@lycos.com						AKAO Y, 1994, CANCER RES, V54, P2468; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; Armstrong JS, 2001, EXP CELL RES, V262, P170, DOI 10.1006/excr.2000.5091; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BASS DA, 1983, J IMMUNOL, V130, P1910; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CAI J, BIOCH BIOPHYS ACTA, V1366, P139; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Gotow T, 2000, CELL DEATH DIFFER, V7, P666, DOI 10.1038/sj.cdd.4400694; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; KANG DC, 1983, J BIOCHEM, V94, P1301, DOI 10.1093/oxfordjournals.jbchem.a134475; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; ROST J, 1964, NATURE, V201, P185, DOI 10.1038/201185a0; Sanchez-Alcazar JA, 2000, J BIOL CHEM, V275, P13353, DOI 10.1074/jbc.275.18.13353; SATO N, 1995, J IMMUNOL, V154, P3194; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; Starkov AA, 2001, BIOCHEM BIOPH RES CO, V281, P645, DOI 10.1006/bbrc.2001.4409; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	192	200	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1263	+		10.1096/fj.02-0097fje	http://dx.doi.org/10.1096/fj.02-0097fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060676				2022-12-25	WOS:000176683900033
J	Sim, EUH; Smith, A; Szilagi, E; Rae, F; Ioannou, P; Lindsay, MH; Little, MH				Sim, EUH; Smith, A; Szilagi, E; Rae, F; Ioannou, P; Lindsay, MH; Little, MH			Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1	ONCOGENE			English	Article						Wnt-4; WT1; Denys-Drash syndrome; kidney development; expression profiling	DNA-BINDING; ORNITHINE-DECARBOXYLASE; REPRESSES TRANSCRIPTION; SUSCEPTIBILITY GENE; GROWTH-FACTOR; PROTEIN; EXPRESSION; TARGET; TRANSFORMATION; ASSOCIATION	The Wilms' tumour suppressor gene, WT1, encodes multiple nuclear protein isoforms, all containing four C-terminal zinc finger motifs. WT1 proteins can both activate and repress putative target genes in vitro, although the in vivo relevance of these putative target genes is often unverified. WT1 mutations can result in Wilms' tumour and the Denys-Drash Syndrome (DDS) of infantile nephropathy, XY pseudohermaphroditism and predisposition to Wilms' tumour. We have established stable transfectants of the mouse mesonephric cell line, M15, which express WT1 harbouring a common DDS point mutation (R394W). A comparison of the expression profiles of M15 and transfectant C2A was performed using Nylon-based arrays. Very few genes showed differential expression. However Wnt-4, a member of the Wnt gene family of secreted glycoproteins, was downregulated in C2A and other similar clones. Doxycycline induction of WT1-A or WT1-D expression in HEK293 stable transfectants also elicited an elevation in Wnt4 expression. Wnt4 is critical for the mesenchyme-to-epithetial transition during kidney development, making it an attractive putative WT1 target. We have mapped human Wnt-4 gene to chromosome 1p35-36, a region of frequent LOH in WT, have characterized the genomic structure of the human Wnt4 gene and isolated 9 kb of immediate promoter. While several potential WT1 binding sites exist within this promoter, reporter analysis does not strongly support the direct regulation of Wnt4 by WT1. We propose that Wnt-4 regulation by WT1 occurs at a more distant promoter or enhancer site, or is indirect.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	University of Queensland; University of Queensland; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Little, MH (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	M.Little@imb.uq.edu.au	Sim, Edmund Ui-Hang/J-2863-2019; Smith, Aaron/A-8329-2010; Little, Melissa Helen/A-6170-2010	Sim, Edmund Ui-Hang/0000-0001-8652-8495; Little, Melissa Helen/0000-0003-0380-2263				Bergstein I, 1997, GENOMICS, V46, P450, DOI 10.1006/geno.1997.5041; Borel F, 1996, BIOCHEMISTRY-US, V35, P12070, DOI 10.1021/bi960758o; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christiansen JH, 1996, ONCOGENE, V12, P2705; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Englert C, 1997, CANCER RES, V57, P1429; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GAVIN BJ, 1990, DEVELOPMENT, V3, P2319; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HEWITT SM, 1995, CANCER RES, V55, P5386; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kim J, 1999, MOL CELL BIOL, V19, P2289; Koesters R, 1999, CANCER RES, V59, P3880; KU M, 1993, DEVELOPMENT, V119, P1161; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; Little MH, 1996, ONCOGENE, V13, P1461; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Patek CE, 1999, P NATL ACAD SCI USA, V96, P2931, DOI 10.1073/pnas.96.6.2931; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rahman N, 1998, HUM GENET, V103, P547, DOI 10.1007/PL00008708; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SINGER RH, 1992, CURR OPIN CELL BIOL, V4, P1; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	58	69	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2948	2960		10.1038/sj.onc.1205373	http://dx.doi.org/10.1038/sj.onc.1205373			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082525	Green Accepted			2022-12-25	WOS:000175262700002
J	Gille, A; Liu, HY; Sprang, SR; Seifert, R				Gille, A; Liu, HY; Sprang, SR; Seifert, R			Distinct interactions of GTP, UTP, and CTP with G(s) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LESCH-NYHAN-SYNDROME; PURINE NUCLEOTIDE-METABOLISM; DEFICIENT TRANSGENIC MICE; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; SPLICE VARIANTS; GUANOSINE 5'-TRIPHOSPHATE; MOLECULAR ANALYSIS; BINDING PROTEINS; FUSION PROTEINS	Early studies showed that in addition to GTP, the pyrimidine nucleotides UTP and CTP support activation of the adenylyl cyclase (AC)-stimulating G(s) protein. The aim of this study was to elucidate the mechanism by which UTP and CTP support G(s) activation. As models, we used S49 wild-type lymphoma cells, representing a physiologically relevant system in which the beta(2)-adrenoreceptor (beta(2)AR) couples to G(s), and Sf9 insect cell membranes expressing beta(2)AR-Galpha(s) fusion proteins. Fusion proteins provide a higher sensitivity for the analysis of beta(2)AR-G(s) coupling than native systems. Nucleoside 5'-triphosphates (NTPs) supported agonist-stimulated AC activity in the two systems and basal AC activity in membranes from cholera toxin-treated S49 cells in the order of efficacy GTP greater than or equal to UTP > CTP > ATP (ineffective). NTPs disrupted high affinity agonist binding in beta(2)AR-Gas in the order of efficacy GTP > UTP > CTP > ATP (ineffective). In contrast, the order of efficacy of NTPs as substrates for nucleoside diphosphokinase, catalyzing the formation of GTP from GDP and NTP was ATP greater than or equal to UTP greater than or equal to CTP greater than or equal to GTP. NTPs inhibited beta(2)AR-Galpha(s)-catalyzed [gamma-P-32]GTP hydrolysis in the order of potency GTP > UTP > CTP. Molecular dynamics simulations revealed that UTP is accommodated more easily within the binding pocket of Galpha(s) than CTP. Collectively, our data indicate that GTP, UTP, and CTP interact differentially with G(s) proteins and that transphosphorylation of GDP to GTP is not involved in this G protein activation. In certain cell systems, intracellular UTP and CTP concentrations reach similar to10 nmol/mg of protein and are higher than intracellular GTP concentrations, indicating that G protein activation by UTP and CTP can occur physiologically. G protein activation by UTP and CTP could of particular importance in pathological conditions such as cholera and Lesch-Nyhan syndrome.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Kansas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Seifert, R (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, Malott Hall,Rm 5064,1251 Wescoe Hall Dr, Lawrence, KS 66045 USA.	rseifert@ku.edu	Seifert, Roland/G-3189-2013; Gille, Andreas/E-1531-2011	Gille, Andreas/0000-0001-5235-8897	NIDDK NIH HHS [R01 DK046371] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALOUSI AA, 1991, FASEB J, V5, P2300, DOI 10.1096/fasebj.5.9.1650314; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; BILEZIKIAN JP, 1974, J BIOL CHEM, V249, P157; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Brosh S, 2000, J MOL NEUROSCI, V14, P87, DOI 10.1385/JMN:14:1-2:087; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHIDIAC P, 1992, BIOCHEMISTRY-US, V31, P10908, DOI 10.1021/bi00159a035; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Ernst M, 1996, NEW ENGL J MED, V334, P1568, DOI 10.1056/NEJM199606133342403; Ernst M, 2000, NEUROPSYCHOPHARMACOL, V22, P320, DOI 10.1016/S0893-133X(99)00119-0; GIERSCHIK P, 1994, METHOD ENZYMOL, V237, P13; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; JONES DT, 1990, J BIOL CHEM, V265, P2671; KASLOW HR, 1979, MOL PHARMACOL, V15, P472; Klinker JF, 1999, EUR J BIOCHEM, V261, P72, DOI 10.1046/j.1432-1327.1999.00209.x; Klinker JF, 1999, BIOCHEM BIOPH RES CO, V262, P341, DOI 10.1006/bbrc.1999.1203; LAKE CR, 1977, SCIENCE, V196, P905, DOI 10.1126/science.860124; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; LLOYD KG, 1981, NEW ENGL J MED, V305, P1106, DOI 10.1056/NEJM198111053051902; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; MILLIGAN G, 1985, J BIOL CHEM, V260, P2057; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Nuki G, 1977, Adv Exp Med Biol, V76A, P326; Nyhan WL, 1997, J INHERIT METAB DIS, V20, P171, DOI 10.1023/A:1005348504512; ODONNELL JK, 1991, MOL PHARMACOL, V39, P702; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pelled D, 1999, J NEUROCHEM, V72, P1139, DOI 10.1046/j.1471-4159.1999.0721139.x; Piacentini L, 1996, MOL CELL BIOCHEM, V157, P59; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; ROCKSON S, 1974, SCIENCE, V186, P934, DOI 10.1126/science.186.4167.934; RODBELL M, 1971, J BIOL CHEM, V246, P1877; Saito Y, 1999, NEUROPEDIATRICS, V30, P66, DOI 10.1055/s-2007-973462; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Seifert R, 2001, J PHARMACOL EXP THER, V298, P840; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; SIDI Y, 1985, J CLIN INVEST, V76, P2416, DOI 10.1172/JCI112255; SIMMONDS HA, 1988, CLIN CHIM ACTA, V171, P197, DOI 10.1016/0009-8981(88)90145-3; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; Wenzel-Seifert K, 2000, MOL PHARMACOL, V58, P954, DOI 10.1124/mol.58.5.954; WIELAND T, 1992, MOL PHARMACOL, V42, P731; WOLFF J, 1973, J BIOL CHEM, V248, P350; ZorefShani E, 1995, INT J DEV NEUROSCI, V13, P887, DOI 10.1016/0736-5748(95)00054-2; ZOREFSHANI E, 1993, J NEUROCHEM, V61, P457	54	14	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34434	34442		10.1074/jbc.M204259200	http://dx.doi.org/10.1074/jbc.M204259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12080068	hybrid			2022-12-25	WOS:000177959100116
J	Ding, K; Mani, K; Cheng, F; Belting, M; Fransson, LA				Ding, K; Mani, K; Cheng, F; Belting, M; Fransson, LA			Copper-dependent autocleavage of glypican-1 heparan sulfate by nitric oxide derived from intrinsic nitrosothiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-UNSUBSTITUTED GLUCOSAMINE; ENDOTHELIAL-CELLS; S-NITROSYLATION; PROTEOGLYCANS; DEGRADATION; MECHANISM; PROTEIN	Cell surface heparan sulfate proteoglycans facilitate uptake of growth-promoting polyamines (Belting, M., Borsig, L., Fuster, M. M., Brown, J. R., Persson, L., Fransson, L.-Angstrom., and Esko, J. D. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 371-376). Increased polyamine uptake correlates with an increased number of positively charged N-unsubstituted glucosamine units in the otherwise polyanionic heparan sulfate chains of glypican-1. During intracellular recycling of glypican-1, there is an NO-dependent deaminative cleavage of heparan sulfate at these glucosamine units, which would eliminate the positive charges (Ding, K., Sandgren, S., Mani, K., Belting, M., and Fransson, L.-Angstrom. (2001) J. BioL Chem. 276, 46779-46791). Here, using both biochemical and microscopic techniques, we have identified and isolated S' nitrosylated forms of glypican-1 as well as slightly charged glypican-1 glycoforms containing heparan sulfate chains rich in N-unsubstituted glucosamines. These glycoforms were converted to highly charged species upon treatment of cells with 1 MM L-ascorbate, which releases NO from nitrosothiols, resulting in deaminative cleavage of heparan sulfate at the N-unsubstituted glucosamines. S-Nitrosylation and subsequent deaminative cleavage were abrogated by inhibition of a Cu2+/Cu+ redox cycle. Under cell-free conditions, purified S-nitrosylated glypican-1 was able to autocleave its heparan sulfate chains when NO release was triggered by L-ascorbate. The heparan sulfate fragments generated in cells during this autocatalytic process contained terminal anhydromannose residues. We conclude that the core protein of glypican-1 can slowly accumulate NO as nitrosothiols, whereas Cu2+ is reduced to Cu+. Subsequent release of NO results in efficient deaminative cleavage of the heparan sulfate chains attached to the same core protein, whereas Cu+ is oxidized to Cu2+.	Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, SE-22184 Lund, Sweden	Lund University	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, BMC C13, SE-22184 Lund, Sweden.	Lars-Ake.Fransson@medkem.lu.se		Mani, Katrin/0000-0002-1821-0634; Belting, Mattias/0000-0003-1585-5434				Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; Fortini ME, 2001, NAT CELL BIOL, V3, pE229, DOI 10.1038/ncb1001-e229; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; PEJLER G, 1988, J BIOL CHEM, V263, P5197; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Stubauer G, 1999, J BIOL CHEM, V274, P28128, DOI 10.1074/jbc.274.40.28128; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303	30	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33353	33360		10.1074/jbc.M203383200	http://dx.doi.org/10.1074/jbc.M203383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084716	hybrid			2022-12-25	WOS:000177859000124
J	Doe, CL; Ahn, JS; Dixon, J; Whitby, MC				Doe, CL; Ahn, JS; Dixon, J; Whitby, MC			Mus81-Eme1 and Rqh1 involvement in processing stalled and collapsed replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION RESOLVASE; DOUBLE-STRAND BREAKS; YEAST SCHIZOSACCHAROMYCES-POMBE; DNA CLEAVABLE COMPLEXES; TOPOISOMERASE-I; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BLOOMS-SYNDROME; DAMAGE TOLERANCE	The processing of stalled replication forks and the repair of collapsed replication forks are essential functions in all organisms. In fission yeast DNA junctions at stalled replication forks appear to be processed by either the Rqh1 DNA helicase or Mus81-Eme1 endonuclease. Accordingly, we show that the hypersensitivity to agents that cause replication fork stalling of mus81, eme1, and rqh1 mutants is suppressed by a Holliday junction resolvase (RusA), as is the synthetic lethality of a mus81- rqh1- double mutant. Recombinant Mus81-Eme1, purified from Escherichia coli, readily cleaves replication fork structures but cleaves synthetic Holliday junctions relatively poorly in vitro. From these data we propose that Mus81-Eme1 can process stalled replication forks before they have regressed to form a Holliday junction. We also implicate Mus81-Eme1 and Rqh1 in the repair of collapsed replication forks. Here Mus81-Eme1 and Rqh1 seem to function on different substrates because RusA can substitute for Mus81-Eme1 but not Rqh1.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Whitby, MC (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	whitby@bioch.ox.ac.uk		Whitby, Matthew/0000-0003-0951-3374				AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chan SN, 1997, J BIOL CHEM, V272, P14873, DOI 10.1074/jbc.272.23.14873; Chan SN, 1998, NUCLEIC ACIDS RES, V26, P1560, DOI 10.1093/nar/26.7.1560; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; de los Santos T, 2001, GENETICS, V159, P1511; Doe CL, 2000, EMBO J, V19, P2751, DOI 10.1093/emboj/19.11.2751; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; Haber JE, 2001, CELL, V107, P551, DOI 10.1016/S0092-8674(01)00593-1; HSIANG YH, 1989, CANCER RES, V49, P5077; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KUHN EM, 1986, CANCER GENET CYTOGEN, V22, P1, DOI 10.1016/0165-4608(86)90132-9; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; Liu LF, 1996, ANN NY ACAD SCI, V803, P44, DOI 10.1111/j.1749-6632.1996.tb26375.x; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; Mankouri HW, 2001, MECH AGEING DEV, V122, P1107, DOI 10.1016/S0047-6374(01)00253-6; McCready SJ, 2000, MUTAT RES-FUND MOL M, V451, P197, DOI 10.1016/S0027-5107(00)00050-6; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mullen JR, 2001, GENETICS, V157, P103; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Rothstein R, 2000, GENE DEV, V14, P1; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Sharples GJ, 1999, J BACTERIOL, V181, P5543, DOI 10.1128/JB.181.18.5543-5550.1999; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; TSAO YP, 1993, CANCER RES, V53, P5908; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Whitby MC, 1998, J BIOL CHEM, V273, P35063, DOI 10.1074/jbc.273.52.35063	46	198	203	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32753	32759		10.1074/jbc.M202120200	http://dx.doi.org/10.1074/jbc.M202120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084712	hybrid			2022-12-25	WOS:000177859000047
J	Kim, HT; Kim, BC; Kim, IY; Mamura, M; Seong, DH; Jang, JJ; Kim, SJ				Kim, HT; Kim, BC; Kim, IY; Mamura, M; Seong, DH; Jang, JJ; Kim, SJ			Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; ER-BETA; BH3 DOMAIN; POSTMENOPAUSAL WOMEN; SURVIVAL SIGNALS; RECEPTOR-BETA; CYTOCHROME-C; DEATH; PHOSPHORYLATION; EXPRESSION	Selective estrogen receptor modulator is a proven agent for chemoprevention and chemotherapy of cancer. Raloxifene, a mixed estrogen agonist/antagonist, was developed to prevent osteoporosis and potentially reduce the risk of breast cancer. In this study, we examined the effect of raloxifene on the TSU-PR1 cell line. This cell line was originally reported to be a prostate cancer cell line, but recently it has been shown to be a human bladder transitional cell carcinoma cell line. The TSU-PR1 cell line contains high levels of estrogen receptor P. Following treatment with raloxifene, evidence of apoptosis, including change in nuclear morphology, DNA fragmentation, and cytochrome c release, was observed in a dose-dependent manner in the TSU-PR1 cells (10(-9) to 10(-6) m range). We observed no detectable change in the steady-state levels of Bax, Bcl-2, and Bcl-X-L following raloxifene treatment. However, raloxifene induced caspase-dependent cleavage of BAD to generate a 15-kDa truncated protein. Overexpression of a double mutant BAD resistant to caspase 3 cleavage blocked raloxifene-induced apoptosis. These results demonstrate that raloxifene induces apoptosis through the cleavage of BAD in TSU-PR1 cells. This molecular mechanism of apoptosis suggests that raloxifene may be a therapeutic agent for human bladder cancer.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Rm C629,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.	Kims@mail.nih.gov	Jang, JaJune/F-6647-2011	Mamura, Mizuko/0000-0003-4531-0144				Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bryant HU, 1999, J STEROID BIOCHEM, V69, P37, DOI 10.1016/S0960-0760(98)00147-2; BRYANT HU, 1996, J SOC GYNECOL INVEST, V3, P152; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; KAUFFMAN RF, 1995, DRUG NEWS PERSPECT, V8, P531; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lau KM, 2000, CANCER RES, V60, P3175; Makela S, 2000, MOL CELL ENDOCRINOL, V164, P109, DOI 10.1016/S0303-7207(00)00233-1; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pelletier G, 2000, HISTOL HISTOPATHOL, V15, P1261, DOI 10.14670/HH-15.1261; Salomoni P, 2000, BLOOD, V96, P676; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Taylor AH, 2000, J MOL ENDOCRINOL, V24, P145, DOI 10.1677/jme.0.0240145; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; van Bokhoven A, 2001, CANCER RES, V61, P6340; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Weyant MJ, 2001, CANCER RES, V61, P2547; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	41	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32510	32515		10.1074/jbc.M202852200	http://dx.doi.org/10.1074/jbc.M202852200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084714	hybrid			2022-12-25	WOS:000177859000017
J	Welker, E; Raymond, LD; Scheraga, HA; Caughey, B				Welker, E; Raymond, LD; Scheraga, HA; Caughey, B			Intramolecular versus intermolecular disulfide bonds in prion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC RIBONUCLEASE-A; SCRAPIE; CONVERSION; CONFORMATIONS; INFECTIVITY; DISEASES; STATE	Prion protein (PrP) is the major component of the partially protease-resistant aggregate that accumulates in mammals with transmissible spongiform encephalopathies. The two cysteines of the scrapie form, PrPSc, were found to be in their oxidized (i.e. disulfide) form (Turk, E., Teplow, D. B., Hood, L. E., and Prusiner, S. B. (1988) Eur. J. Biochem. 176,21-30); however, uncertainty remains as to whether the disulfide bonds are intra- or intermolecular. It is demonstrated here that the monomers of PrPSc are not linked by intermolecular disulfide bonds. Furthermore, evidence is provided that PrPSc can induce the conversion of the oxidized, disulfide. intact form of the monomeric cellular prion protein to its protease-resistant form without the temporary breakage and subsequent re-formation of the disulfide bonds in cell-free reactions.	Cornell Univ, Baker Lab Chem & Chem Biol, Ithaca, NY 14853 USA; NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Scheraga, HA (corresponding author), Cornell Univ, Baker Lab Chem & Chem Biol, Ithaca, NY 14853 USA.		Welker, Ervin/AAC-6493-2022		NIGMS NIH HHS [GM-24893] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000580, ZIAAI000580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Feughelman M, 2000, J THEOR BIOL, V206, P313, DOI 10.1006/jtbi.2000.2112; Herrmann LM, 1998, NEUROREPORT, V9, P2457, DOI 10.1097/00001756-199808030-00006; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hope J, 2000, CURR OPIN GENET DEV, V10, P568, DOI 10.1016/S0959-437X(00)00129-5; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6294; SAFAR J, 1990, P NATL ACAD SCI USA, V87, P6373, DOI 10.1073/pnas.87.16.6373; Saito K, 2001, BIOCHEMISTRY-US, V40, P15002, DOI 10.1021/bi010781w; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Welker E, 2001, P NATL ACAD SCI USA, V98, P4334, DOI 10.1073/pnas.071066598; Welker E, 2001, P NATL ACAD SCI USA, V98, P2312, DOI 10.1073/pnas.041615798; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	32	74	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33477	33481		10.1074/jbc.M204273200	http://dx.doi.org/10.1074/jbc.M204273200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082114	hybrid			2022-12-25	WOS:000177859000137
J	Casteel, DE; Zhuang, SH; Gudi, T; Tang, J; Vuica, M; Desiderio, S; Pilz, RB				Casteel, DE; Zhuang, SH; Gudi, T; Tang, J; Vuica, M; Desiderio, S; Pilz, RB			cGMP-dependent protein kinase I beta physically and functionally interacts with the transcriptional regulator TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; C-FOS PROMOTER; REQUIRES NUCLEAR TRANSLOCATION; DNA-BINDING PROTEINS; NITRIC-OXIDE; GENE-EXPRESSION; SMOOTH-MUSCLE; PHOSPHORYLATION SITES; CREB PHOSPHORYLATION; INITIATOR ELEMENT	Transcriptional regulation of the fos promoter by nitric oxide and cGMP can occur by nuclear translocation of cGMP-dependent protein kinase I (G-kinase I) (Gudi, T., Lohmann, S. M., and Pilz, R. B. (1997) Mol Cell Biol. 17, 5244-5254). To identify nuclear targets of G-kinase I, we performed a yeast two-hybrid screen with G-kinase Ibeta as bait. We found that G-kinase Ibeta interacted specifically with TFII-I, an unusual transcriptional regulator that associates with multiple proteins to modulate both basal and signal-induced transcription. By using purified recombinant proteins, the interaction was mapped to the N-terminal 93 amino acids of G-kinase Ibeta and one of six 95-amino acid repeats found in TFII-I. In baby hamster kidney cells, cGMP analogs enhanced co-immunoprecipitation of G-kinase Ibeta and TFII-I by inducing co-localization of both proteins in the nucleus, but in other cell types containing cytoplasmic TFII-I the G-kinase-TFII-l interaction was largely cGMP-independent. G-kinase phosphorylated TFII-I in vitro and in vivo on Ser(371) and Ser(743) outside of the interaction domain. G-kinase strongly enhanced TFII-I transactivation of a serum-response element-containing promoter in COS7 cells, and this effect was lost when Ser(371) and Ser(743) of TFII-I were mutated. TFII-I by itself had little effect on a full-length fos promoter in baby hamster kidney cells, but it synergistically enhanced transcriptional activation by G-kinase Ibeta. Binding of G-kinase to TFII-I may position the kinase to phosphorylate and regulate TFII-I and/or factors that interact with TFII-I at the serum-response element.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rpilz@ucsd.edu			NIGMS NIH HHS [R01GM055586] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; Browning DD, 2001, J BIOL CHEM, V276, P13039, DOI 10.1074/jbc.M009187200; BUTT E, 1994, J BIOL CHEM, V269, P14509; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 2002, J BIOL CHEM, V277, P22798, DOI 10.1074/jbc.M202956200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Cheriyath V, 2001, J BIOL CHEM, V276, P8377, DOI 10.1074/jbc.M008411200; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; Dostmann WRG, 1999, PHARMACOL THERAPEUT, V82, P373, DOI 10.1016/S0163-7258(98)00063-1; Egloff AM, 2001, J BIOL CHEM, V276, P27806, DOI 10.1074/jbc.M103692200; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P174; FEIL R, 1993, MOL CELL BIOCHEM, V128, P71, DOI 10.1007/BF01076758; FELLEYBOSCO E, 1994, AM J RESP CELL MOL, V11, P159, DOI 10.1165/ajrcmb.11.2.7519434; GARINGO AD, 1995, J BIOL CHEM, V270, P9169, DOI 10.1074/jbc.270.16.9169; GEAHLEN RL, 1980, J BIOL CHEM, V255, P1164; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; Hofmann F, 2000, J CELL SCI, V113, P1671; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kim DW, 2000, MOL CELL BIOL, V20, P1140, DOI 10.1128/MCB.20.4.1140-1148.2000; Kim DW, 2001, MOL CELL BIOL, V21, P3387, DOI 10.1128/MCB.21.10.3387-3397.2000; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Montano MA, 1996, P NATL ACAD SCI USA, V93, P12376, DOI 10.1073/pnas.93.22.12376; NAKAZAWA K, 1993, NEUROREPORT, V4, P1275, DOI 10.1097/00001756-199309000-00017; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; OHKI K, 1995, BRAIN RES, V696, P140, DOI 10.1016/0006-8993(95)00914-C; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Thiriet N, 1997, NEUROREPORT, V8, P399, DOI 10.1097/00001756-199701200-00003; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; Tussie-Luna MI, 2001, P NATL ACAD SCI USA, V98, P7789, DOI 10.1073/pnas.141222298; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Wu J, 2000, NEUROSCIENCE, V96, P351, DOI 10.1016/S0306-4522(99)00534-5; Wu YX, 1999, J BIOL CHEM, V274, P3207, DOI 10.1074/jbc.274.5.3207; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897	71	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32003	32014		10.1074/jbc.M112332200	http://dx.doi.org/10.1074/jbc.M112332200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12082086	hybrid			2022-12-25	WOS:000177718700088
J	Athiner, L; Kindrachuk, J; Georges, F; Napper, S				Athiner, L; Kindrachuk, J; Georges, F; Napper, S			The influence of protein structure on the products emerging from succinimide hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; HISTIDINE-CONTAINING PROTEIN; ESCHERICHIA-COLI; PHOSPHOCARRIER PROTEIN; ASPARAGINYL RESIDUES; ACTIVE-SITE; SPONTANEOUS DEGRADATION; SALMONELLA-TYPHIMURIUM; TERTIARY STRUCTURE; ASPARTYL RESIDUES	Proteins are vulnerable to spontaneous, covalent modifications that may result in alterations to structure and function. Asparagines are particularly labile, able to undergo deamidation through the formation of a succinimide intermediate to produce either aspartate or isoaspartate residues. Although aspartates cannot undergo deamidation they can form a succinimide and result in the same products. Isoaspartyls are the principal product of succinimide hydrolysis, accounting for 65-85% of the emerging residues. The variability in the ratio of products emerging from succinimide hydrolysis suggests the ability of protein structure to influence succinimide outcome. In the H15D histidine-containing protein (HPr), phosphorylation of the active site aspartate catalyzes the formation of a cyclic intermediate. Resolution of this species is exclusively to aspartate residues, suggestive of either a succinimide with restrained hydrolysis, or an isoimide, from which aspartyl residues are the only possible product. Deletion of the C-terminal residue of this protein does not influence the ability for phosphorylation or ring formation, but it does allow for isoaspartyl formation, verifying a succinimide as the cyclic intermediate in H15D HPr. Isoaspartyl formation in H15D Delta85 is rationalized to occur as a consequence of elimination of steric restrictions imposed by the C terminus on the main-chain carbonyl of the succinimide, the required point of nucleophilic attack of a water molecule for isoaspartyl formation. This is the first reported demonstration of the influence of protein structure on the products emerging from succinimide hydrolysis.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E5, Canada; Natl Res Council Canada, Inst Plant Biochem, Saskatoon, SK S7N 0W9, Canada	University of Saskatchewan; University of Saskatchewan; National Research Council Canada	Napper, S (corresponding author), Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada.			Kindrachuk, Jason/0000-0002-3305-7084				ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; ANDERSON JW, 1993, J BIOL CHEM, V268, P12325; ANDERSON JW, 1994, THESIS U SASKATCHEWA; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; BRENNAN TV, 1995, INT J PEPT PROT RES, V45, P547; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; CLARKE S, 1992, STABILITY PROTEIN PH, P1; ERNI B, 1989, J BIOL CHEM, V264, P18733; GEIGER T, 1987, J BIOL CHEM, V262, P785; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; JIA ZC, 1993, J BIOL CHEM, V268, P22490; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; LI C, 1992, J BACTERIOL, V174, P355, DOI 10.1128/jb.174.2.355-361.1992; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; Nabuchi Y, 1997, PHARMACEUT RES, V14, P1685, DOI 10.1023/A:1012115426306; Napper S, 1996, BIOCHEMISTRY-US, V35, P11260, DOI 10.1021/bi9603480; Napper S, 1999, J BIOL CHEM, V274, P21776, DOI 10.1074/jbc.274.31.21776; Niewmierzycka A, 1999, ARCH BIOCHEM BIOPHYS, V364, P209, DOI 10.1006/abbi.1999.1114; OCONNOR CM, 1987, J BIOL CHEM, V262, P1404; SHARMA S, 1993, J BIOL CHEM, V268, P17695; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOMIZAWA H, 1994, BIOCHEMISTRY-US, V33, P13032, DOI 10.1021/bi00248a012; Visick JE, 1998, J BACTERIOL, V180, P2623, DOI 10.1128/JB.180.10.2623-2629.1998; WAYGOOD EB, 1984, J CELL BIOCHEM, V25, P139, DOI 10.1002/jcb.240250304; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V27, P1	33	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30502	30507		10.1074/jbc.M205314200	http://dx.doi.org/10.1074/jbc.M205314200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12068021	hybrid			2022-12-25	WOS:000177579800015
J	Ravid, T; Sweeney, C; Gee, P; Carraway, KL; Goldkorn, T				Ravid, T; Sweeney, C; Gee, P; Carraway, KL; Goldkorn, T			Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; EGF RECEPTOR; UBIQUITINATION; PATHWAY; CELLS; INTERNALIZATION; C-CBL/SLI-1; ENDOCYTOSIS; KINASES; ENZYME	Activation of the epidermal growth factor (EGF) receptor by its ligand, EGF, rapidly enhances receptor internalization and degradation, which desensitizes receptor signaling. In contrast, we have shown previously that exposure to oxidative stress in the form of hydrogen peroxide (H2O2) activated the EGF receptor but that the levels of activated receptors did not decline, which resulted in prolonged receptor signaling. This study provides mechanistic insights into these different modes of EGF receptor activation. Here we demonstrate that the pattern of receptor tyrosine phosphorylation induced by H2O2 differs from that induced by its ligand, EGF. Importantly, H2O2 generates a receptor with negligible phosphorylation at tyrosine 1045, the major docking site for the ubiquitin ligase c-Cbl. As a result, H2O2-activated receptors fail to recruit c-Cbl and do not undergo ubiquitination and endocytosis. In summary, H2O2 stimulation results in an activated receptor uncoupled from normal down-regulation, a process that may contribute to oxidant-mediated tumorigenesis.	Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Ctr Canc, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Goldkorn, T (corresponding author), Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA.	ttgoldkorn@ucdavis.edu	Gee, Peter/H-5681-2013		NHLBI NIH HHS [HL 66189] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BOSTICK DT, 1975, ANAL CHEM, V47, P447, DOI 10.1021/ac60353a039; Cooper KF, 1999, MOL CELL BIOL, V19, P3338; de Melker AA, 2001, J CELL SCI, V114, P2167; De Wit R, 2001, FASEB J, V15, P306; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ECCLES SA, 1994, INVAS METAST, V14, P337; Figueiredo-Pereira ME, 1999, MOL BIOL REP, V26, P65, DOI 10.1023/A:1006909918866; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; Huang RP, 2001, MOL CARCINOGEN, V30, P209, DOI 10.1002/mc.1030; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Tirosh A, 1999, J BIOL CHEM, V274, P10595, DOI 10.1074/jbc.274.15.10595; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VanWinkle LS, 1997, AM J PATHOL, V151, P443; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; VONBOXBERG Y, 1990, EUR J BIOCHEM, V190, P249; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	30	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31214	31219		10.1074/jbc.M204677200	http://dx.doi.org/10.1074/jbc.M204677200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063263	hybrid			2022-12-25	WOS:000177579800102
J	Plotnick, MI; Rubin, H; Schechter, NM				Plotnick, MI; Rubin, H; Schechter, NM			The effects of reactive site location on the inhibitory properties of the serpin alpha(1)-antichymotrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SHEET-A; PLASMA PROTEINASE-INHIBITORS; HUMAN NEUTROPHIL ELASTASE; CENTER LOOP; ALPHA(1)-PROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR; HUMAN CHYMASE; COMPLEX; CHYMOTRYPSIN; INSERTION	The large size of the serpin reactive site loop (RSL) suggests that the role of the RSL in protease inhibition is more complex than that of presenting the reactive site (P1 residue) to the protease. This study examines the effect on inhibition of relocating the reactive site (Leu-358) of the serpin alpha(1)-antichymotrypsin either one residue closer (P2) or further (P1') from the base of the RSL (Glu-342). alpha(1)-Antichymotrypsin variants were produced by mutation within the P4-P2' region; the sequence ITLLSA was changed to ITLSSA to relocate the reactive site to P2 (Leu-357) and to ITITLS to relocate it to P1' (Leu-359). Inhibition of the chymotrypsin-like proteases human chymase and chymotrypsin and the non-target protease human neutrophil elastase (HNE) were analyzed. The P2 variant inhibited chymase and chymotrypsin but not HNE. Relative to P1, interaction at P2 was characterized by greater complex stability, lower inhibition rate constants, and increased stoichiometry of inhibition values. In contrast, the P1' variant inhibited HNE (stoichiometry of inhibition = 4) but not chymase or chymotrypsin. However, inhibition of HNE was by interaction with Ile-357, the P2 residue. The P1' site was recognized by all proteases as a cleavage site. Covalent-complexes resistant to SDS-PAGE were observed in all inhibitory reactions, consistent with the trapping of the protease as a serpin-acyl protease complex. The complete loss in inhibitory activity associated with lengthening the Glu-342-reactive site distance by a single residue and the enhanced stability of complexes associated with shortening this distance by a single residue are compatible with the distorted-protease model of inhibition requiring full insertion of the RSL into the body of the serpin and translocation of the linked protease to the pole opposite from that of encounter.	Univ Penn, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Philadelphia Vet Affais Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Plotnick, MI (corresponding author), Hosp Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Maloney Bldg 8th Fl,36th & Spruce Sts, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003495, R01HL050523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039674] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50523, HL03495] Funding Source: Medline; NIAMS NIH HHS [AR39674] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, THROMBIN STRUCTURE F, P3; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; Cooley J, 2001, BIOCHEMISTRY-US, V40, P15762, DOI 10.1021/bi0113925; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; ELDERING E, 1992, J BIOL CHEM, V267, P7013; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P33; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LENNICK M, 1986, BIOCHEMISTRY-US, V25, P3890, DOI 10.1021/bi00361a023; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; O'Malley KM, 2001, J BIOL CHEM, V276, P6631, DOI 10.1074/jbc.M008478200; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8879; PEMBERTON PA, 1989, BIOCHEM J, V258, P193, DOI 10.1042/bj2580193; Pereira PJB, 1999, J MOL BIOL, V286, P163, DOI 10.1006/jmbi.1998.2462; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; Plotnick MI, 1997, BIOCHEMISTRY-US, V36, P14601, DOI 10.1021/bi971530j; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; Plotnick MI, 2002, BIOCHEMISTRY-US, V41, P334, DOI 10.1021/bi015650+; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; Riewald M, 1996, J BIOL CHEM, V271, P14526, DOI 10.1074/jbc.271.24.14526; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHECHTER NM, 1988, ARCH BIOCHEM BIOPHYS, V262, P232, DOI 10.1016/0003-9861(88)90185-3; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; Wang ZM, 1998, BIOL CHEM, V379, P167, DOI 10.1515/bchm.1998.379.2.167; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	51	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29927	29935		10.1074/jbc.M202374200	http://dx.doi.org/10.1074/jbc.M202374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12055188	hybrid			2022-12-25	WOS:000177509300073
J	Dover, J; Schneider, J; Tawiah-Boateng, MA; Wood, A; Dean, K; Johnston, M; Shilatifard, A				Dover, J; Schneider, J; Tawiah-Boateng, MA; Wood, A; Dean, K; Johnston, M; Shilatifard, A			Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR GENE RAD6; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; CONJUGATING ENZYME; YEAST RAD6; MECHANISM; TRITHORAX; PROTEINS; COMPLEX; EZH2	The DNA of eukaryotes is wrapped around nucleosomes and packaged into chromatin. Covalent modifications of the histone proteins that comprise the nucleosome alter chromatin structure and have major effects on gene expression. Methylation of lysine 4 of histone H3 by COMPASS is required for silencing of genes located near chromosome telomeres and within the rDNA (Krogan, N. J, Dover, J., Khorrami, S., Greenblatt, J. F., Schneider, J., Johnston, M., and Shilatifard, A. (2002) J. Biol. Chem. 277, 10753-10755; Briggs, S. D., Bryk, M., Strahl, B. D., Cheung, W. L., Davie, J. K., Dent, S. Y., Winston, F., and Allis, C. D. (2001) Genes. Dev. 15, 32863295). To learn about the mechanism of histone methylation, we surveyed the genome of the yeast Saccharomyces cerevisiae for genes necessary for this process. By analyzing similar to4800 mutant strains, each deleted for a different non-essential gene, we discovered that the ubiquitin-conjugating enzyme Rad6 is required for methylation of lysine 4 of histone H3. Ubiquitination of histone H2B on lysine 123 is the signal for the methylation of histone H3, which leads to silencing of genes located near telomeres.	St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL)	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; 	NCI NIH HHS [1R01CA089455] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089455] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hishida T, 2002, EMBO J, V21, P2019, DOI 10.1093/emboj/21.8.2019; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KANG XL, 1992, GENETICS, V130, P285; KOKEN M, 1991, P NATL ACAD SCI USA, V88, P3832, DOI 10.1073/pnas.88.9.3832; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; KUPIEC M, 1986, MOL GEN GENET, V203, P538, DOI 10.1007/BF00422083; Laible G, 1999, MAMM GENOME, V10, P311, DOI 10.1007/s003359900993; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	25	401	410	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28368	28371		10.1074/jbc.C200348200	http://dx.doi.org/10.1074/jbc.C200348200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12070136	hybrid			2022-12-25	WOS:000177342600003
J	Senyuk, V; Chakraborty, S; Mikhail, FM; Zhao, R; Chi, YQ; Nucifora, G				Senyuk, V; Chakraborty, S; Mikhail, FM; Zhao, R; Chi, YQ; Nucifora, G			The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells	ONCOGENE			English	Article						AML1; MDS1; EVI1; t(3;21); CtBP1; HDAC1	ACUTE PROMYELOCYTIC LEUKEMIA; STIMULATING FACTOR-RECEPTOR; PRIMARY MYELOID PROGENITORS; TERMINAL BINDING-PROTEIN; FUSION PROTEIN; HISTONE DEACETYLASES; MOLECULAR-CLONING; CO-REPRESSOR; AML1; GENE	The leukemia-associated fusion gene AML1/MDS1/EVI1 (AME) encodes a chimeric transcription factor that results from the (3;21)(q26;q22) translocation. This translocation is observed in patients with therapy-related myelodysplastic syndrome (MDS), with chronic myelogenous leukemia during the blast crisis (CML-BC), and with de novo or therapy-related acute myeloid leukemia (AML). AME is obtained by in-frame fusion of the AML1 and MDS1/EVI1 genes. We have previously shown that AME is a transcriptional repressor that induces leukemia in mice. In order to elucidate the role of AME in leukemic transformation, we investigated the interaction of AME with the transcription co-regulator CtBP1 and with members of the histone deacetylase (HDAC) family. In this report, we show that AME physically interacts in vivo with CtBP1 and HDACI and that these co-repressors require distinct regions of AME for interaction. By using reporter gene assays, we demonstrate that AME represses gene transcription by CtBP1-dependent and CtBP1-independent mechanisms. Finally, we show that the interaction between AME and CtBP1 is biologically important and is necessary for growth upregulation and abnormal differentiation of the murine hematopoietic precursor cell line 32Dc13 and of murine bone marrow progenitors.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Univ Alexandria, Dept Clin Pathol, Fac Med, Alexandria, Egypt	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Egyptian Knowledge Bank (EKB); Alexandria University	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, Mol Biol Res Bldg,MC 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu			NCI NIH HHS [CA 67189, CA 72675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072675, R01CA067189, R29CA067189] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; HAST R, 1989, LEUKEMIA RES, V13, P173, DOI 10.1016/0145-2126(89)90142-2; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Keller SA, 2000, MOL CELL BIOL, V20, P7247, DOI 10.1128/MCB.20.19.7247-7258.2000; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LANGENHUIJSEN MMAC, 1984, BRIT J HAEMATOL, V58, P227, DOI 10.1111/j.1365-2141.1984.tb06080.x; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; MIKHAIL FM, 2002, IN PRESS CANC GENET; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; RUBIN CM, 1990, BLOOD, V76, P2594; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Zent C, 1996, CURR TOP MICROBIOL, V211, P243; Zent C., 1997, Leukemia (Basingstoke), V11, P273; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	41	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3232	3240		10.1038/sj.onc.1205436	http://dx.doi.org/10.1038/sj.onc.1205436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082639				2022-12-25	WOS:000175373600015
J	Jin, TQ; Li, JX				Jin, TQ; Li, JX			Dynamitin controls beta(2) integrin avidity by modulating cytoskeletal constraint on integrin molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; C-KINASE SUBSTRATE; CELL-ADHESION; TYROSINE PHOSPHORYLATION; ACTIN CYTOSKELETON; SIGNAL-TRANSDUCTION; LEUKOCYTE ADHESION; CYTOPLASMIC TAIL; FOCAL ADHESIONS; MOTOR PROTEINS	Dynamitin, a subunit of the microtubule-deperident motor complex, was implicated in cell adhesion by binding to MacMARCKS (Macrophage-enriched Myristoylated alanine-rice C kinase substrate). However, how dynamitin is involved in cell adhesion is unclear despite the fact that both MacMARCKS and microtubules regulate beta(2) integrin activation. We report that dynamitin regulates beta(2) integrin avidity toward iC3b by modulating the lateral mobility of beta(2) integrin molecules. Using the single particle tracking method, we found that integrin molecular mobility in cells expressing the fusion protein CFP (cyan fluorescent protein)-dynamitin or CFP-MB (the MacMARCKS binding domain peptide of dynamitin) increased 6-fold over the control cells, suggesting that disturbing dynamitin function dramatically altered the cytoskeletal constraint on beta(2) integrin molecules. Further mechanistic studies revealed that overexpression of dynamitin stimulated the phosphorylation of endogenous MacMARCKS protein, which lead to the enhanced tyrosine phosphorylation of paxillin. This effect of dynamitin correlates with the observation that higher concentration of PKC inhibitor is required to block beta(2) integrin mobility in dynamitin-expressing cells. Although dynamitin acts at the point of MacMARCKS phosphorylation, it is upstream of RhoA, because its effect was blocked by RhoA inhibitor. Thus, we conclude that dynamitin is a part of the cytoskeletal constraint that locks beta(2) integrin in the inactive form.	Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Li, JX (corresponding author), Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60612 USA.				NIGMS NIH HHS [GM54715] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054715] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Arao T, 2000, J CLIN ENDOCR METAB, V85, P382, DOI 10.1210/jc.85.1.382; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHERESH DA, 1991, BIOCHEM SOC T, V19, P835, DOI 10.1042/bst0190835; CHEUNG HT, 1980, CELL BIOL INT REP, V4, P1125, DOI 10.1016/0309-1651(80)90050-8; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEBRABANDER M, 1977, CELL BIOL INT REP, V1, P453, DOI 10.1016/0309-1651(77)90080-7; DUSTIN ML, 1990, BIOESSAYS, V12, P421, DOI 10.1002/bies.950120905; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; IVANOVA OY, 1976, EXP CELL RES, V101, P207, DOI 10.1016/0014-4827(76)90431-6; Jin TQ, 2001, J BIOL CHEM, V276, P12879, DOI 10.1074/jbc.M010513200; Kadi A, 1998, BIOCHEM BIOPH RES CO, V246, P690, DOI 10.1006/bbrc.1998.8536; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pesce G, 2001, INT ARCH ALLERGY IMM, V125, P160, DOI 10.1159/000053810; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; Volkov Y, 2001, NAT IMMUNOL, V2, P508, DOI 10.1038/88700; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wright S D, 1986, Methods Enzymol, V132, P204; Yue LL, 1999, J CELL PHYSIOL, V181, P355, DOI 10.1002/(SICI)1097-4652(199911)181:2<355::AID-JCP17>3.0.CO;2-B; Yue LL, 2000, CELL ADHES COMMUN, V7, P359, DOI 10.3109/15419060009109018; Yue LL, 2000, J BIOL CHEM, V275, P23948, DOI 10.1074/jbc.M001845200; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	54	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32963	32969		10.1074/jbc.M201525200	http://dx.doi.org/10.1074/jbc.M201525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082093	hybrid			2022-12-25	WOS:000177859000075
J	Podyma-Inoue, KA; Yokote, H; Sakaguchi, K; Ikuta, M; Yanagishita, M				Podyma-Inoue, KA; Yokote, H; Sakaguchi, K; Ikuta, M; Yanagishita, M			Characterization of heparanase from a rat parathyroid cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; OVARIAN GRANULOSA-CELLS; SULFATE PROTEOGLYCANS; MAMMALIAN HEPARANASE; PLATELET; EXPRESSION; HEPARIN; CLONING; PURIFICATION; DEGRADATION	Cell surface heparan sulfate proteoglycans undergo unique intracellular degradation pathways after they are endocytosed from the cell surface. Heparanase, an endo-beta-glucuronidase capable of cleaving heparan sulfate, has been demonstrated to contribute to the physiological degradation of heparan sulfate proteoglycans and therefore regulation of their biological functions. A rat parathyroid cell line was found to produce heparanase with an optimal activity at neutral and slightly acidic conditions suggesting that the enzyme participates in heparan sulfate proteoglycan metabolism in extralysosomal compartments. To elucidate the detailed properties of the purified enzyme, the substrate specificity against naturally occurring heparan sulfates and chemically modified heparins was studied. Cleavage sites of rat heparanase were present in heparan sulfate chains obtained from a variety of animal organs, but their occurrence was infrequent (average, 1-2 sites per chain) requiring recognition of both undersulfated and sulfated regions of heparan sulfate. On the other hand intact and chemically modified heparins were not cleaved by heparanase. The carbohydrate structure of the newly generated reducing end region of heparan sulfate cleaved by the enzyme was determined, and it represented relatively undersulfated structures. O-Sulfation of heparan sulfate chains also played important roles in substrate recognition, implying that rat parathyroid heparanase acts near the boundary of highly sulfated and undersulfated domains of heparan sulfate proteoglycans. Further elucidation of the roles of heparanase in normal physiological processes would provide an important tool for analyzing the regulation of heparan sulfate-dependent cell functions.	Tokyo Med & Dent Univ, Div Biochem, Dept Hard Tissue Engn,Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Dept Oral Surg, Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan; Wakayama Med Coll, Dept Mol Med, Wakayama 6418509, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Wakayama Medical University	Yanagishita, M (corresponding author), Tokyo Med & Dent Univ, Div Biochem, Dept Hard Tissue Engn,Grad Sch, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.		Inoue, Katarzyna A./ABD-9622-2020					Bame KJ, 1997, J BIOL CHEM, V272, P2245; BAME KJ, 1993, J BIOL CHEM, V268, P19956; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1999, BIOCHEM J, V342, P361, DOI 10.1042/0264-6021:3420361; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; HASCALL VC, 1994, METHOD ENZYMOL, V230, P390; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V73, P569, DOI 10.1016/0006-291X(76)90848-2; Kosir MA, 1997, J SURG RES, V67, P98, DOI 10.1006/jsre.1996.4976; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKAGUCHI K, 1987, P NATL ACAD SCI USA, V84, P3269, DOI 10.1073/pnas.84.10.3269; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TAKEUCHI Y, 1992, J BIOL CHEM, V267, P14677; THUNBERG L, 1982, J BIOL CHEM, V257, P278; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Tumova S, 1999, BIOCHEM J, V337, P471, DOI 10.1042/0264-6021:3370471; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YANAGISHITA M, 1983, J BIOL CHEM, V258, P2857; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YANAGISHITA M, 1983, J BIOL CHEM, V258, P2847	33	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32459	32465		10.1074/jbc.M203282200	http://dx.doi.org/10.1074/jbc.M203282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077130	hybrid			2022-12-25	WOS:000177859000010
J	Yamaga, AK; Ou, JH				Yamaga, AK; Ou, JH			Membrane topology of the hepatitis C virus NS2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; IN-VITRO; REGION; IDENTIFICATION	The hepatitis C virus (HCV) NS2 protein is a hydrophobic protein. Previous studies indicate that this protein is an integral membrane protein, which is targeted to the membrane of the endoplasmic reticulum (ER) by the signal sequence located in its preceding p7 protein. In this report, we demonstrate that the membrane association of NS2 is p7-independent and occurs co-translationally. Further deletion-mapping studies suggest the presence of two internal signal sequences in NS2. These two internal signal sequences, which are located within amino acids 839-883 and amino acids 928-960, could target the alpha-globin reporter, a cytosolic protein, to the membrane compartments in HuH7 hepatoma cells. The presence of multiple signal sequences for its membrane association suggests that NS2 has multiple transmembrane domains. The glycosylation studies indicate that both amino and carboxyl termini of NS2 are located in the endoplasmic reticulum lumen. Based on these results, a model for the NS2 membrane topology is presented.	Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA; Univ So Calif, Dept Pediat, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Ou, JH (corresponding author), Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, 2011 Zonal Ave,HMR-401, Los Angeles, CA 90033 USA.	jamesou@hsc.usc.edu						Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; COLOMBO M, 1989, LANCET, V2, P1006; DIBISCEGLIE AM, 1991, AM J GASTROENTEROL, V86, P335; DSOUZA EDA, 1994, J GEN VIROL, V75, P3469, DOI 10.1099/0022-1317-75-12-3469; Flint M, 1999, J GEN VIROL, V80, P1943, DOI 10.1099/0022-1317-80-8-1943; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Li J, 1999, J VIROL, V73, P1239, DOI 10.1128/JVI.73.2.1239-1244.1999; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MIZUSHIMA H, 1994, J VIROL, V68, P2731, DOI 10.1128/JVI.68.4.2731-2734.1994; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SANTOLINI E, 1995, J VIROL, V69, P7461, DOI 10.1128/JVI.69.12.7461-7471.1995; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993	21	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33228	33234		10.1074/jbc.M202304200	http://dx.doi.org/10.1074/jbc.M202304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082096	hybrid			2022-12-25	WOS:000177859000107
J	Duong, DT; Waltner-Law, ME; Sears, R; Sealy, L; Granner, DK				Duong, DT; Waltner-Law, ME; Sears, R; Sealy, L; Granner, DK			Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcriptional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase II with the phosphoenolpyruvate carboxykinase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC NUCLEAR FACTOR-3; CAMP RESPONSE ELEMENT; C/EBP-BETA ISOFORMS; NF-KAPPA-B; GLUCOCORTICOID RESPONSE; ACCESSORY FACTOR; PEPCK GENE; CHROMATIN STRUCTURE; IN-VIVO; COUP-TF	Hormones regulate glucose homeostasis, in part, by controlling the expression of gluconeogenic enzymes, such as phosphoenolpyruvate carboxykinase (PEPCK). Insulin and glucocorticoids reciprocally regulate PEPCK expression primarily at the level of gene transcription. We demonstrate here that glucocorticoids promote, whereas insulin disrupts, the association of CREB-binding protein (CBP) and RNA polymerase II with the hepatic PEPCK gene promoter in vivo. We also show that accessory factors, such as CCAAT/enhancer-binding protein beta (C/EBPbeta), can recruit CBP to drive transcription. Insulin increases protein levels of liver-enriched transcriptional inhibitory protein (LIP), an inhibitory form of C/EBPbeta, in a phosphatidylinositol 3-kinase-dependent manner. LIP concomitantly replaces liver-enriched transcriptional activator protein on the PEPCK gene promoter, which can abrogate the recruitment of CBP and polymerase II, culminating in the repression of PEPCK expression and the attenuation of hepatocellular glucose production.	Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, Nashville, TN 37232 USA; Duke Univ, Med Ctr, Dept Genet, Howard Hughes Med Inst, Durham, NC 27710 USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Duke University; Howard Hughes Medical Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Granner, DK (corresponding author), Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, 707 Light Hall,21St & Garland Ave, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002887, R37DK035107, P60DK020593, T32DK007061, R01DK035107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20593, DK07061, DK02887, DK35107] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; CHU DTW, 1988, J BIOL CHEM, V263, P13007; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FABER S, 1993, J BIOL CHEM, V268, P24976; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IP YT, 1989, MOL CELL BIOL, V9, P1289, DOI 10.1128/MCB.9.3.1289; JOHNSON AC, 1988, J CELL BIOCHEM, V37, P243, DOI 10.1002/jcb.240370211; LIU JS, 1991, J BIOL CHEM, V266, P19095; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Waltner-Law M, 2000, J BIOL CHEM, V275, P31847, DOI 10.1074/jbc.M003656200; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880	41	82	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32234	32242		10.1074/jbc.M204873200	http://dx.doi.org/10.1074/jbc.M204873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070172	hybrid			2022-12-25	WOS:000177718700117
J	Haidari, M; Leung, N; Mahbub, F; Uffelman, KD; Kohen-Avramoglu, R; Lewis, GF; Adeli, K				Haidari, M; Leung, N; Mahbub, F; Uffelman, KD; Kohen-Avramoglu, R; Lewis, GF; Adeli, K			Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance - Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; VERY-LOW-DENSITY; DEPENDENT DIABETES-MELLITUS; INTIMA-MEDIA THICKNESS; MIDDLE-AGED MEN; APOLIPOPROTEIN B-48; REMNANT LIPOPROTEINS; CHOLESTEROL ACYLTRANSFERASE; ALIMENTARY LIPEMIA; GLUCOSE-TOLERANCE	Insulin-resistant states are characterized by hypertriglyceridemia, predominantly because of overproduction of hepatic very low density lipoprotein particles. The additional contribution of intestinal lipoprotein overproduction to the dyslipidemia of insulin-resistant states has not been previously appreciated. Here, we have investigated intestinal lipoprotein production in a fructose-fed hamster model of insulin resistance previously documented to have whole body and hepatic insulin resistance, and hepatic very low density lipoprotein overproduction. Chronic fructose feeding for 3 weeks induced significant oversecretion of apolipoprotein B48 (apoB48)-containing lipoproteins in the fasting state and during steady state fat feeding, based on (a) in vivo Triton WR1339 studies of apoB48 production as well as (b) ex vivo pulse-chase labeling of intestinal enterocytes from fasted and fed hamsters. ApoB48 particle overproduction was accompanied by increased intracellular apoB48 stability, enhanced lipid synthesis, higher abundance of microsomal triglyceride transfer protein mass, and a significant shift toward the secretion of larger chylomicron-like particles. ApoB48 particle overproduction was not observed with short-term fructose feeding or in vitro incubation of enterocytes with fructose. Secretion of intestinal apoB48 and triglyceride was closely linked to intestinal enterocyte de novo lipogenesis, which was up-regulated in fructose-fed hamsters. Inhibition of fatty acid synthesis by cerulenin, a fatty acid synthase inhibitor, resulted in a dose-dependent decrease in intestinal apoB48 secretion. Overall, these findings further suggest that intestinal overproduction of apoB48 lipoproteins should also be considered as a major contributor to the fasting and postprandial dyslipidemia observed in response to chronic fructose feeding and development of an insulin-resistant state.	Hosp Sick Children, Div Clin Biochem, Dept Lab Med & Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Div Endocrinol & Metab, Dept Med, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Adeli, K (corresponding author), Hosp Sick Children, Div Clin Biochem, Dept Lab Med & Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	k.adeli@utoronto.ca		Adeli, Khosrow/0000-0002-5839-5709				Abbasi F, 1999, J CLIN ENDOCR METAB, V84, P3903, DOI 10.1210/jc.84.11.3903; ARBEENY CM, 1992, J LIPID RES, V33, P843; Battula SB, 2000, METABOLISM, V49, P1049, DOI 10.1053/meta.2000.7744; Bioletto S, 2000, AM J CLIN NUTR, V71, P443; Boquist S, 1999, CIRCULATION, V100, P723, DOI 10.1161/01.CIR.100.7.723; Boquist S, 2000, DIABETOLOGIA, V43, P185, DOI 10.1007/s001250050028; Cartwright IJ, 1999, J LIPID RES, V40, P1357; CENEDELLA RJ, 1974, LIPIDS, V9, P35, DOI 10.1007/BF02533211; CHEN YDI, 1993, J CLIN ENDOCR METAB, V76, P172, DOI 10.1210/jc.76.1.172; Cohn JS, 1998, CAN J CARDIOL, V14, p18B; Curtin A, 1996, ACTA DIABETOL, V33, P205; Doi H, 2000, CIRCULATION, V102, P670, DOI 10.1161/01.CIR.102.6.670; FEINGOLD KR, 1982, DIABETES, V31, P388, DOI 10.2337/diabetes.31.5.388; FEINGOLD KR, 1989, DIABETES, V38, P141, DOI 10.2337/diabetes.38.2.141; GANGL A, 1975, J CLIN INVEST, V55, P803, DOI 10.1172/JCI107991; Gleeson A, 1999, DIABETOLOGIA, V42, P944, DOI 10.1007/s001250051252; GOULINET S, 1993, J LIPID RES, V34, P943; Harbis A, 2001, DIABETES, V50, P462, DOI 10.2337/diabetes.50.2.462; HOANG VQ, 1995, BBA-LIPID LIPID MET, V1254, P37, DOI 10.1016/0005-2760(94)00160-Z; HOLT PR, 1980, AM J PHYSIOL, V238, pG453, DOI 10.1152/ajpgi.1980.238.5.G453; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; JEPPESEN J, 1995, ARTERIOSCL THROM VAS, V15, P320, DOI 10.1161/01.ATV.15.3.320; JIAO S, 1988, DIABETES, V37, P342, DOI 10.2337/diabetes.37.3.342; JIAO S, 1989, DIABETES, V38, P604, DOI 10.2337/diabetes.38.5.604; JOHNSTON JM, 1964, BIOCHIM BIOPHYS ACTA, V84, P412, DOI 10.1016/0926-6542(64)90005-8; Karpe F, 1996, METHOD ENZYMOL, V263, P95; Karpe F, 2001, J LIPID RES, V42, P17; KRASPER H, 1970, DIGESTION, V3, P321, DOI 10.1159/000197052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemieux S, 1998, J LIPID RES, V39, P1964; LEWIS GF, 1991, J CLIN ENDOCR METAB, V72, P934, DOI 10.1210/jcem-72-4-934; LEWIS GF, 1990, J CLIN ENDOCR METAB, V71, P1041, DOI 10.1210/jcem-71-4-1041; Liao W, 2000, J BIOL CHEM, V275, P3950, DOI 10.1074/jbc.275.6.3950; LIU GL, 1991, COMP BIOCHEM PHYS A, V99, P223, DOI 10.1016/0300-9629(91)90263-C; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; MARTINS IJ, 1994, DIABETOLOGIA, V37, P238, DOI 10.1007/BF00398049; MAYES PA, 1993, AM J CLIN NUTR, V58, P754; McNamara JR, 2001, ATHEROSCLEROSIS, V154, P229, DOI 10.1016/S0021-9150(00)00484-6; Mero N, 1998, ATHEROSCLEROSIS, V141, pS53, DOI 10.1016/S0021-9150(98)00218-4; Meyer E, 1996, ATHEROSCLEROSIS, V124, P221, DOI 10.1016/0021-9150(96)05832-7; OCKNER RK, 1969, J CLIN INVEST, V48, P2079, DOI 10.1172/JCI106174; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; POPPER DA, 1985, AM J PHYSIOL, V249, pG161, DOI 10.1152/ajpgi.1985.249.2.G161; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; RISSER TR, 1978, AM J PHYSIOL, V234, pE277, DOI 10.1152/ajpendo.1978.234.3.E277; ROHEIM PS, 1966, J CLIN INVEST, V45, P297, DOI 10.1172/JCI105343; SHIAU YF, 1985, AM J PHYSIOL, V248, pG164, DOI 10.1152/ajpgi.1985.248.2.G164; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SPADY DK, 1983, J LIPID RES, V24, P303; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Taghibiglou C, 2000, J LIPID RES, V41, P499; Taghibiglou C, 2002, J BIOL CHEM, V277, P793, DOI 10.1074/jbc.M106737200; Watanabe N, 1999, DIABETES CARE, V22, P152, DOI 10.2337/diacare.22.1.152; WINDMUELLER HG, 1968, J BIOL CHEM, V243, P4878; Yu KCW, 2001, FRONT BIOSCI-LANDMRK, V6, pD332, DOI 10.2741/Yu	56	214	219	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31646	31655		10.1074/jbc.M200544200	http://dx.doi.org/10.1074/jbc.M200544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070142	hybrid			2022-12-25	WOS:000177718700045
J	Pruitt, K; Pruitt, WM; Bilter, GK; Westwick, JK; Der, CJ				Pruitt, K; Pruitt, WM; Bilter, GK; Westwick, JK; Der, CJ			Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIE-1 EPITHELIAL-CELLS; CYCLIN D1 PROMOTER; N-TERMINAL KINASE; C-JUN; MAP KINASE; TRANSCRIPTIONAL ACTIVITY; CELLULAR-TRANSFORMATION; SIGNALING PATHWAY; PHOSPHOLIPASE-C; SMALL GTPASES	Activated Ras, but not Raf, causes transformation of RIE-1 epithelial cells, supporting the importance of Raf-independent pathways in mediating Ras transformation. The p38 and JNK mitogen-activated protein kinase cascades are activated by Ras via Raf-independent effector function. Therefore, we determined whether p38 and JNK activation are involved in Ras transformation of RIE-1 epithelial cells. Rather surprisingly, we found that pharmacologic inhibition of p38, together with Raf activation of ERK, was sufficient to mimic the morphologic and growth transformation caused by oncogenic Ras. p38 inhibition together with ERK activation also caused the same alterations in cyclin D1 and p21(CIP1) expression caused by Ras and induced an autocrine growth factor loop important for transformation. Finally, in contrast to p38, we found that JNK activation promoted Ras transformation, and that Ras deregulation of p38 and JNK was not mediated by activation of the Rac small GTPase. We conclude that a key action of Raf-independent effector pathways important for Ras transformation may involve inhibition of p38 and activation of JNK.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Celgene, Signal Res Div, San Diego, CA 92121 USA	University of North Carolina; University of North Carolina Chapel Hill; Bristol-Myers Squibb; Celgene Corporation	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.			Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA63071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MURPHY GA, 2002, ONCOGNEE DIRECTED TH; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Pruitt K, 2000, J BIOL CHEM, V275, P40916, DOI 10.1074/jbc.M006682200; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; YEN A, 1994, EUR J CELL BIOL, V65, P103; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	50	70	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31808	31817		10.1074/jbc.M203964200	http://dx.doi.org/10.1074/jbc.M203964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12082106	hybrid, Green Published			2022-12-25	WOS:000177718700064
J	Bromberg, KD; Hendricks, C; Burgin, AB; Osheroff, N				Bromberg, KD; Hendricks, C; Burgin, AB; Osheroff, N			Human topoisomerase II alpha possesses an intrinsic nucleic acid specificity for DNA ligation - Use of 5 ' covalently activated oligonucleotide substrates to study enzyme mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE RELIGATION REACTION; ANTICANCER DRUGS; TARGETED DRUGS; ANTINEOPLASTIC DRUGS; SITE; SEQUENCE; BREAKPOINTS; INHIBITORS; LEUKEMIAS; POISONS	Despite the importance of topoisomerase II-mediated DNA ligation to the essential physiological functions of the enzyme, the mechanistic details of this important reaction are poorly understood. Because topoisomerase II normally does not release cleaved DNA molecules prior to ligation, it is not known whether all of the nucleic acid specificity of its cleavage/ligation cycle is embodied in DNA cleavage or whether ligation also contributes specificity to the enzyme. All currently available ligation assays require that topoisomerase II cleave the initial DNA substrate before rejoining can be monitored. Consequently, it has been impossible to examine the specificity of DNA ligation separately from that of scission. To address this issue, a cleavage-independent topoisomerase II DNA ligation assay was developed. This assay utilizes a nicked oligonucleotide whose 5'-phosphate terminus at the nick has been activated by covalent attachment to the tyrosine mimic, p-nitrophenol. Human topoisomerase IIalpha and enzymes with active-site mutations that abrogated cleavage activity ligated the activated nick by catalyzing the direct attack of the terminal X-OH on the activated 5'-phosphate. Results with different DNA sequences indicate that human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for ligation that parallels its specificity for DNA cleavage.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med Hematol Oncol, Sch Med, Nashville, TN 37232 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Emerald Biostruct, Bainbridge Isl, WA 98110 USA	Vanderbilt University; Vanderbilt University; California State University System; San Diego State University	Osheroff, N (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 654 Robinson Res Bldg, Nashville, TN 37232 USA.				NIGMS NIH HHS [GM 33944, GM 58596] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058596, R01GM033944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; Berger JM, 1998, BBA-GENE STRUCT EXPR, V1400, P3, DOI 10.1016/S0167-4781(98)00124-9; Bromberg KD, 2001, BIOCHEMISTRY-US, V40, P8410, DOI 10.1021/bi010681q; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CORBETT AH, 1992, J BIOL CHEM, V267, P683; Fass D, 1999, NAT STRUCT BIOL, V6, P322; FELIX CA, 1995, CANCER RES, V55, P4287; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; JONES DH, 1991, BIOTECHNIQUES, V10, P62; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LIU LF, 1983, J BIOL CHEM, V258, P5365; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN GH, 1993, J BIOL CHEM, V268, P3683; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; SABOURIN M, 2002, ENCY MOL MED, V5, P3192; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; Wilstermann AM, 2001, J BIOL CHEM, V276, P17727, DOI 10.1074/jbc.M100197200; Woodfield G, 2000, NUCLEIC ACIDS RES, V28, P3323, DOI 10.1093/nar/28.17.3323; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	42	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31201	31206		10.1074/jbc.M204741200	http://dx.doi.org/10.1074/jbc.M204741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12050172	hybrid			2022-12-25	WOS:000177579800100
J	Grobe, K; Esko, JD				Grobe, K; Esko, JD			Regulated translation of heparan sulfate N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes by structured 5 '-untranslated regions and internal ribosome entry sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MESSENGER-RNA; GROWTH-FACTOR; MAST-CELLS; EXPRESSION; INITIATION; MOUSE; MICE; BIOSYNTHESIS; BINDING	We report the full-length 5'-untranslated region (5'-UTR) sequences of the four vertebrate heparan sulfate/heparin GlcNAc N-deacetylase/N-sulfotransferases (NDSTs) and their role in translational regulation in vivo and in vitro. All four NDST 5'-UTR sequences are unusually long, have a high degree of predicted secondary structure, and contain multiple upstream AUG codons, which together impose a major barrier to conventional, cap-dependent ribosomal scanning. At least two alternatively spliced forms of NDST2 differing in their 5'-UTRs exist, and two forms of NDST4 arise from alternative transcriptional start sites. The 5'-UTRs do not show any significant sequence similarity between isozymes, but possess highly conserved regions between mouse and human orthologs, pointing toward evolutionarily conserved functions. Expression of bicistronic vector constructs showed that the 5'-UTRs of NDST1-4 are capable of regulating translation differentially in vivo dependent on cell type and culture conditions. In vitro translation of a reporter gene located downstream of the UTRs demonstrated the presence of internal ribosome entry sites, providing an additional, cap-independent step in fine-tuning NDST expression. Comparative studies of NDST1-3 mRNAs and protein expression in brain and embryonic extracts revealed striking differences in translational efficiency. Other genes necessary for glycosaminoglycan synthesis in addition to the NDST isozymes have long, structured 5'-UTRs. Because several growth factors and morphogens that bind heparan sulfate also contain structured 5'-UTRs, translational regulation may coordinate the action of these factors and their heparan sulfate co-receptors.	Univ Calif San Diego, Dept Cellular & Mol Biol, Glycobiol Training & Res Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Esko, JD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Biol, Glycobiol Training & Res Ctr, 9500 Gilman Dr,CMM E 1055, La Jolla, CA 92093 USA.	jesko@ucsd.edu	Grobe, Kay/F-2399-2011		NHLBI NIH HHS [P01 HL 57345] Funding Source: Medline; NIGMS NIH HHS [R37 GM 33063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BRENT R, 1997, CURRENT PROTOCOLS MO; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Conrad H. E., 1998, HEPARIN BINDING PROT; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GROBE K, 2002, IN PRESS BIOCH BIOPH; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Morii E, 2001, BLOOD, V97, P3032, DOI 10.1182/blood.V97.10.3032; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Piao Z, 1997, CANCER-AM CANCER SOC, V80, P865; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Sonenberg N, 2001, SCIENCE, V293, P818, DOI 10.1126/science.1062937; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; ZAK BM, 2002, IN PRESS BIOCH BIOPH; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	39	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30699	30706		10.1074/jbc.M111904200	http://dx.doi.org/10.1074/jbc.M111904200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070138	hybrid			2022-12-25	WOS:000177579800039
J	Klapisz, E; Sorokina, I; Lemeer, S; Pijnenburg, M; Verkleij, AJ; Henegouwen, PMPVE				Klapisz, E; Sorokina, I; Lemeer, S; Pijnenburg, M; Verkleij, AJ; Henegouwen, PMPVE			A ubiquitin-interacting motif (UIM) is essential for Eps15 and Eps15R ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST URACIL PERMEASE; CLATHRIN-COATED PITS; NUCLEAR-RECEPTOR; SELF-UBIQUITINATION; PROTEASOME PATHWAY; ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; RICH MOTIF; PHOSPHORYLATION; PROTEIN	An important negative control mechanism in the signaling of epidermal growth factor (EGF) is the endocytosis and subsequent degradation of activated EGF receptors. Eps15 and its related partner Eps15R play a key role in clathrin-mediated endocytosis of transmembrane receptors. Upon EGF stimulation of the cell, Eps15 becomes both phosphorylated on tyrosine residues and monoubiquitinated. Although tyrosine phosphorylation of Eps15 has been implicated in EGF receptor internalization, the function of Eps15 ubiquitination is not known. Using a mutational approach, we have found that the second ubiquitin-interacting motif (UIM) of Eps15 and Eps15R is essential for their ubiquitination. This UIM partially overlaps with the recently characterized nuclear export signal in Eps15. We show that these two overlapping motifs have different structural requirements with respect to nuclear export signal versus ubiquitination signal activity. Our data demonstrate that the UIM does not contain the ubiquitin acceptor site but functions as a recruitment site for the ubiquitination machinery leading to the monoubiquitination of both Eps15 and Eps15R.	Univ Utrecht, Biomembrane Inst, NL-3584 CH Utrecht, Netherlands	Utrecht University	Henegouwen, PMPVE (corresponding author), Univ Utrecht, Biomembrane Inst, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Lemeer, Simone/I-4363-2016; van Bergen en Henegouwen, Paul/B-8870-2011	van Bergen en Henegouwen, Paul/0000-0001-6050-9042				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Brickey WJ, 1999, J IMMUNOL, V163, P6622; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Carbone R, 1997, CANCER RES, V57, P5498; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hericourt F, 2000, BIOCHEM J, V349, P417, DOI 10.1042/0264-6021:3490417; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; HOU D, 1994, J BIOL CHEM, V269, P14244; Iannolo G, 1997, CANCER RES, V57, P240; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Poupon V, 2002, J BIOL CHEM, V277, P8941, DOI 10.1074/jbc.M108385200; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	47	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30746	30753		10.1074/jbc.M203004200	http://dx.doi.org/10.1074/jbc.M203004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12072436	hybrid			2022-12-25	WOS:000177579800045
J	Panda, K; Rosenfeld, RJ; Ghosh, S; Meade, AL; Getzoff, ED; Stuehr, DJ				Panda, K; Rosenfeld, RJ; Ghosh, S; Meade, AL; Getzoff, ED; Stuehr, DJ			Distinct dimer interaction and regulation in nitric-oxide synthase types I, II, and III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; ELECTRON-TRANSFER; SUBUNIT DIMERIZATION; OXYGENASE DIMER; L-ARGININE; EXPRESSIONAL CONTROL; CATALYTIC-ACTIVITY; CRYSTAL-STRUCTURE; BINDING DOMAINS; HEME INSERTION	Homodimer formation activates all nitric-oxide synthases (NOSs). It involves the interaction between two oxygenase domains (NOSoxy) that each bind heme and (6R)-tetrahydrobiopterin (H4B) and catalyze NO synthesis from L-Arg. Here we compared three NOSoxy isozymes regarding dimer strength, interface composition, and the ability of L-Arg and H4B to stabilize the dimer, promote its formation, and protect it from proteolysis. Urea dissociation studies indicated that the relative dimer strengths were NOSIIIoxy >> NOSIoxy > NOSIIoxy (endothelial NOSoxy (eNOSoxy) >> neuronal NOSOXY (nNOSoxy) > inducible NOSoxy (iNOSoxy)). Dimer strengths of the full-length NOSs had the same rank order as judged by their urea-induced loss of NO synthesis activity. NOSoxy dimers containing L-Arg plus H4B exhibited the greatest resistance to urea-induced dissociation followed by those containing either molecule and then by those containing neither. Analysis of crystallographic structures of eNOSoxy and iNOSoxy dimers showed more intersubunit contacts and buried surface area in the dimer interface of eNOSoxy than iNOSoxy, thus revealing a potential basis for their different stabilities. L-Arg plus H4B promoted dimerization of urea-generated iNOSoxy and nNOSoxy monomers, which otherwise was minimal in their absence, and also protected both dimers against trypsin proteolysis. In these respects, L-Arg alone was more effective than H4B alone for nNOSoxy, whereas for iNOSoxy the converse was true. The eNOSoxy dimer was insensitive to proteolysis under all conditions. Our results indicate that the three NOS isozymes, despite their general structural similarity, differ markedly in their strengths, interfaces, and in how L-Arg and H4B influence their formation and stability. These distinguishing features may provide a basis for selective control and likely help to regulate each NOS in its particular biologic milieu.	Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute	Stuehr, DJ (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org	; Panda, Koustubh/E-5273-2017	Ghosh, Sanjay/0000-0001-8624-1494; Panda, Koustubh/0000-0002-4783-2221	NCI NIH HHS [CA 53914] Funding Source: Medline; NHLBI NIH HHS [HL 58883-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Aoyagi M, 2001, BIOCHEMISTRY-US, V40, P12826, DOI 10.1021/bi011183k; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Blasko E, 2002, J BIOL CHEM, V277, P295, DOI 10.1074/jbc.M105691200; Blau N, 2001, MOL GENET METAB, V74, P172, DOI 10.1006/mgme.2001.3213; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; Cosentino F, 2001, ARTERIOSCL THROM VAS, V21, P496, DOI 10.1161/01.ATV.21.4.496; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Forstermann U, 1998, FASEB J, V12, P773; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; FORSTERMANN U, 1995, BIOCHEM PHARMACOL, V50, P1321, DOI 10.1016/0006-2952(95)00181-6; Geller DA, 2000, BIOCHEM BIOPH RES CO, V276, P633, DOI 10.1006/bbrc.2000.3537; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Hemmens B, 1998, METH MOL B, V100, P1; Hemmens B, 1998, BIOCHEM J, V332, P337, DOI 10.1042/bj3320337; Hemmens B, 2000, J BIOL CHEM, V275, P35786, DOI 10.1074/jbc.M005976200; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG1146, DOI 10.1152/ajpgi.1998.275.5.G1146; Iwanaga T, 2000, BIOCHEMISTRY-US, V39, P15150, DOI 10.1021/bi001806e; Iwasaki T, 1999, J BIOL CHEM, V274, P7705, DOI 10.1074/jbc.274.12.7705; Jiang HB, 2001, INT J BIOCHEM CELL B, V33, P155, DOI 10.1016/S1357-2725(00)00082-0; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; LINCOLN J, 1997, NITRIC OXIDE HLTH DI, P27; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Lowe PN, 1996, BIOCHEM J, V314, P55, DOI 10.1042/bj3140055; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Morris SM, 1998, AM J PHYSIOL-ENDOC M, V275, pE740, DOI 10.1152/ajpendo.1998.275.5.E740; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Que LG, 1998, AM J PHYSIOL-LUNG C, V275, pL96, DOI 10.1152/ajplung.1998.275.1.L96; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; SAKAI N, 1993, MOL PHARMACOL, V43, P6; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Sennequier N, 1999, J BIOL CHEM, V274, P930, DOI 10.1074/jbc.274.2.930; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1999, BIOCHIM BIOPHYS ACTA, V1411, P2146; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; TSOKOS DC, 1992, BIOCHEMISTRY-US, V31, P7155, DOI 10.1021/bi00146a018; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang Y, 1997, J BIOL CHEM, V272, P11392; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	83	108	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31020	31030		10.1074/jbc.M203749200	http://dx.doi.org/10.1074/jbc.M203749200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12048205	hybrid			2022-12-25	WOS:000177579800080
J	Kou, RQ; Greif, D; Michel, T				Kou, RQ; Greif, D; Michel, T			Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor - Implications for the vascular responses to cyclosporin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHORYLATION; ACTIVATION; CELLS; AKT; RECEPTORS; PATHWAYS; SITES	The endothelial isoform of nitric-oxide synthase (eNOS) is a key determinant of vascular tone. eNOS, a Ca2+/ camodulin-dependent enzyme, is also regulated by a variety of agonist-activated protein kinases, but the role and regulation of the protein phosphatase pathways involved in eNOS dephosphorylation are much less well understood. Treatment of endothelial cells with vascular endothelial growth factor (VEGF), a potent eNOS agonist, leads to the activation of calcineurin, a Ca2+/camodulin-dependent protein phosphatase. In these studies, we used a phosphorylation state-specific antibody to show that VEGF promotes dephosphorylation of eNOS at serine residue 116 in cultured endothelial cells. Cyclosporin A, an inhibitor of calcineurin, completely blocks VEGF-induced eNOS dephosphorylation; under identical conditions, cyclosporin A also inhibits VEGF-induced eNOS activation. VEGF-induced eNOS dephosphorylation shows an EC50 of 2 ng/ml and is maximal 30 min after agonist addition. eNOS phosphorylation at serine 116 is completely blocked by the protein kinase C inhibitor calphostin but is blocked by neither wortmannin (an inhibitor of phosphatidylinositide 3-kinase) nor the MAP kinase pathway inhibitor U0126. A phosphorylation-deficient mutant of eNOS in which serine 116 is changed to an alanine residue (S116A) shows significantly enhanced enzyme activity compared with the wild-type enzyme. Taken together, these findings indicated that VEGF-induced eNOS dephosphorylation at serine 116 leads to enzyme activation. Cyclosporin A is widely used as an immunosuppressive drug for which hypertension is an important dose-limiting side effect. Our results suggest that cyclosporin A-induced hypertension may involve, at least in part, the attenuation of endothelium-derived NO production through a calcineurin-sensitive pathway regulating eNOS dephosphorylation.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; AUCHSCHWELK W, 1993, J CARDIOVASC PHARM, V21, P435, DOI 10.1097/00005344-199303000-00013; CAIRNS HS, 1989, BRIT J PHARMACOL, V98, P463, DOI 10.1111/j.1476-5381.1989.tb12619.x; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Cifkova R, 2001, J HYPERTENS, V19, P2283, DOI 10.1097/00004872-200112000-00025; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Verheul HMW, 2000, BLOOD, V96, P4216, DOI 10.1182/blood.V96.13.4216	23	157	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29669	29673		10.1074/jbc.M204519200	http://dx.doi.org/10.1074/jbc.M204519200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050171	hybrid			2022-12-25	WOS:000177509300042
J	Leach, MR; Cohen-Doyle, MF; Thomas, DY; Williams, DB				Leach, MR; Cohen-Doyle, MF; Thomas, DY; Williams, DB			Localization of the lectin, ERp57 binding, and polypeptide binding sites of calnexin and calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; IN-VITRO; LINKED OLIGOSACCHARIDE; QUALITY-CONTROL; PROTEIN; GLYCOPROTEIN; IDENTIFICATION; MEMBRANE; ASSOCIATION	Calnexin and calreticulin are membrane-bound and soluble chaperones, respectively, of the endoplasmic reticulum (ER) which interact transiently with a broad spectrum of newly synthesized glycoproteins. In addition to sharing substantial sequence identity, both calnexin and calreticulin bind to monoglucosylated oligosaccharides of the form Glc(1)Man(5-9)GleNAc(2), interact with the thiol oxidoreductase, ERp57, and are capable of acting as chaperones in vitro to suppress the aggregation of non-native proteins. To understand how these diverse functions are coordinated, we have localized the lectin, ERp57 binding, and polypeptide binding sites of calnexin and calreticulin. Recent structural studies suggest that both proteins consist of a globular domain and an extended arm domain comprised of two sequence motifs repeated in tandem. Our results indicate that the primary lectin site of calnexin and calreticulin resides within the globular domain, but the results also point to a much weaker secondary site within the arm domain which lacks specificity for monoglucosylated oligosaccharides. For both proteins, a site of interaction with ERp57 is centered on the arm domain, which retains similar to50% of binding compared with full-length controls. This site is in addition to a Zn2+-dependent site located within the globular domain of both proteins. Finally, calnexin and calreticulin suppress the aggregation of unfolded proteins via a polypeptide binding site located within their globular domains but require the arm domain for full chaperone function. These findings are integrated into a model that describes the interaction of glycoprotein folding intermediates with calnexin and calreticulin.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 2B2, Canada	University of Toronto; McGill University	Williams, DB (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BAKSH S, 1995, FEBS LETT, V376, P53, DOI 10.1016/0014-5793(95)01246-4; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CARRENO BM, 1995, J IMMUNOL, V154, P5173; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; DAVID V, 1993, J BIOL CHEM, V268, P9585; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; Jorgensen CS, 2000, EUR J BIOCHEM, V267, P2945, DOI 10.1046/j.1432-1033.2000.01309.x; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; LEACH MR, 2002, IN PRESS CALRETICULI; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; Nair S, 1999, J IMMUNOL, V162, P6426; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Peterson JR, 1999, J CELL SCI, V112, P2775; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; REDDY AG, 1989, CYTOBIOS, V60, P21; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; Vallejo Abbe N., 1995, P603; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	47	167	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29686	29697		10.1074/jbc.M202405200	http://dx.doi.org/10.1074/jbc.M202405200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12052826	hybrid			2022-12-25	WOS:000177509300045
J	Yan, B; Raben, N; Plotz, P				Yan, B; Raben, N; Plotz, P			The human acid alpha-glucosidase gene is a novel target of the Notch-1/Hes-1 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIR CELL-DIFFERENTIATION; NEURONAL DIFFERENTIATION; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; DROSOPHILA-HAIRY; MAMMALIAN NOTCH; HUMAN HOMOLOG; LUNG-CANCER; EXPRESSION	Acid a-glucosidase (GAA) is a lysosomal enzyme that degrades glycogen. A deficiency of GAA is responsible for a recessively inherited myopathy and cardiomyopathy, glycogenosis type II. Previously, we identified an intronic repressor element in the GAA gene and demonstrated that Hes-1, a basic helix-loop-helix factor, binds to a C class E box within the element and functions as a transcriptional repressor in HepG2 cells. Hes-1 is a well studied downstream target gene in the Notch signaling pathway. In this study, over-expression and depletion of Notch-1 intracellular domain (NICD) strategies were used to investigate whether expression of the GAA gene is under the control of Notch-1/Hes-1 signaling. In cotransfection experiments, Hes-1, up-regulated by overexpressed NICD, enhanced the repressive effect of the DNA element with wild type Hes-1 binding sites but not with mutant Hes-1 binding sites. Conversely, depletion of Notch-1 with phosphorothioated antisense oligonucleotides, corresponding to the fourth ankyrin repeat within NICD, led to reduced Hes-1. Constitutively overexpressed Hes-1 and Notch-1 repressed GAA gene expression. Therefore, our data establish that the human GAA gene, encoding a lysosomal enzyme, is a downstream target of the Notch-1/Hes-1 signaling pathway.	NIAMS, Clin Ctr, NIH, Bethesda, MD 20892 USA; NIAMS, Arthritis & Rheumatism Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Plotz, P (corresponding author), NIAMS, Clin Ctr, NIH, 9000 Rockville Pike,Bldg 10,Rm 9N244, Bethesda, MD 20892 USA.	plotzp@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041099, ZIAAR041099] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Allen RD, 2001, MOL CELL BIOL, V21, P3071, DOI 10.1128/MCB.21.9.3071-3082.2001; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bessho Y, 2001, GENES CELLS, V6, P175, DOI 10.1046/j.1365-2443.2001.00409.x; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEDER JN, 1994, GENOMICS, V20, P56, DOI 10.1006/geno.1994.1126; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Grynfeld A, 2000, INT J CANCER, V88, P401, DOI 10.1002/1097-0215(20001101)88:3<401::AID-IJC12>3.3.CO;2-M; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; Hirschhorn R., 2000, METABOLIC MOL BASES, P3389; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; Koyano-Nakagawa N, 2000, DEVELOPMENT, V127, P4203; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ponce E, 1999, AM J PATHOL, V154, P1089, DOI 10.1016/S0002-9440(10)65361-8; Raben N, 2001, HUM MOL GENET, V10, P2039, DOI 10.1093/hmg/10.19.2039; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shawber C, 1996, DEVELOPMENT, V122, P3765; Sriuranpong V, 2001, CANCER RES, V61, P3200; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Umapathysivam K, 2001, CLIN CHEM, V47, P1378; Wakabayashi N, 2000, J BIOCHEM, V128, P1087, DOI 10.1093/oxfordjournals.jbchem.a022837; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Yan B, 2001, HUM GENET, V109, P186, DOI 10.1007/s004390100562; Yan B, 2001, J BIOL CHEM, V276, P1789, DOI 10.1074/jbc.M005959200; Zheng JL, 2000, DEVELOPMENT, V127, P4551; Zine A, 2000, DEVELOPMENT, V127, P3373	46	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29760	29764		10.1074/jbc.M204721200	http://dx.doi.org/10.1074/jbc.M204721200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12065598	hybrid			2022-12-25	WOS:000177509300053
J	Cunningham, SA; Rodriguez, JM; Arrate, MP; Tran, TM; Brock, TA				Cunningham, SA; Rodriguez, JM; Arrate, MP; Tran, TM; Brock, TA			JAM2 interacts with alpha(4)beta(1) - Facilitation by JAM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; COUNTER-RECEPTOR; INTEGRIN; BINDING; FIBRONECTIN; VCAM-1; VLA-4; MOTIF; MIGRATION	We have previously reported that junctional adhesion molecule 2 (JAM2) adheres to T cells through heterotypic interactions with JAM3. An examination of the cation dependence of JAM2 adhesion to HSB cells revealed a Mn2+-enhanced binding component indicative of integrin involvement. Using neutralizing integrin antibodies, we have defined an interaction between JAM2 and alpha(4)beta(1) in T cells. The interaction is readily amenable to drug intervention as demonstrated by the ability of TBC 772, an alpha(4)-specific inhibitor, to attenuate the Mn2+-enhanced component. Intriguingly, the engagement of alpha(4)beta(1) by JAM2 is only enabled following prior adhesion of JAM2 with JAMS and is not detectable in cells where JAM3 expression is absent. Supporting this observation, we show that neutralizing JAMS serum and soluble JAM3 ectodomain inhibit not only JAM2 binding to JAM3 but also prevent JAM2/alpha(4)beta(1) interactions in T cells. We further define the first Ig-like fold of JAM2 as being competent in binding both JAMS and alpha(4)beta(1) counter-receptors. Mutagenesis of the only acidic residue in the C-D loop of this Ig fold, namely Asp-82, has no bearing on alpha(4)beta(1) interactions, and thus JAM2 deviates somewhat from the mechanism used by other immunoglobulin superfamily cell adhesion molecules to engage integrin.	Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA		Cunningham, SA (corresponding author), Texas Biotechnol Corp, Dept Pharmacol, Suite 1920,7000 Fannin, Houston, TX 77030 USA.							Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Briskin MJ, 1996, J IMMUNOL, V156, P719; CHAN PY, 1993, J BIOL CHEM, V268, P24655; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; HOLNESS CL, 1994, J CELL SCI, V107, P2065; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Liu S, 2000, TRENDS CARDIOVAS MED, V10, P253, DOI 10.1016/S1050-1738(00)00073-6; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1996, J CELL SCI, V109, P2613; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SZABO MC, 1995, J IMMUNOL, V154, P2112; Vanderslice P, 1997, J IMMUNOL, V158, P1710; Viney JL, 1996, J IMMUNOL, V157, P2488; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; WU CY, 1995, J CELL SCI, V108, P821	28	151	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27589	27592		10.1074/jbc.C200331200	http://dx.doi.org/10.1074/jbc.C200331200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12070135	hybrid			2022-12-25	WOS:000177189800004
J	Berlingieri, MT; Pierantoni, GM; Giancotti, V; Santoro, M; Fusco, A				Berlingieri, MT; Pierantoni, GM; Giancotti, V; Santoro, M; Fusco, A			Thyroid cell transformation requires the expression of the HMGA1 proteins	ONCOGENE			English	Article						thyroid cell; transformation; HMGA1; AP-1 complex; differentiation	TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; HMGI(Y) PROTEINS; C GENE; NEOPLASTIC TRANSFORMATION; NUCLEAR PROTEINS; ONCOGENE; GROWTH; I(Y); PHENOTYPE	Elevated expression of HMGA1 and HMGA2 proteins is correlated with a highly malignant phenotype in several human tumors. We previously demonstrated that the block of HMGA2 protein synthesis prevented rat thyroid cell transformation by murine retroviruses. Suppression of HMGA2 synthesis was associated with lack of induction of HMGA1 proteins suggesting that both HMGA1 and HMGA2 play a role in the process of neoplastic transformation. To determine the role of the HMGA1 gene in thyroid cell transformation, we blocked HMGA1 protein synthesis by an antisense methodology. Here we report that transfection of an HMGA1 cDNA antisense construct into a normal rat thyroid cell line (FRTL-5 C12), followed by infection with Kirsten murine sarcoma virus (KiMSV), generated a transformed cell line that expresses high levels of the v-ras-Ki oncogene and that does not require thyroid-stimulating hormones for growth. However, this cell line does not show the malignant phenotype, i.e., it neither grows in soft agar nor induces tumors after injection in athymic mice. Moreover, the lack of the neoplastic phenotype in the virus-infected thyroid cells carrying the HMGA1 antisense construct correlates with the absence of induction of AP-1 transcriptional activity.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale,CNR, I-80131 Naples, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Trieste	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale,CNR, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Pierantoni, Giovanna Maria/O-7527-2015	Pierantoni, Giovanna Maria/0000-0003-4078-8528; Fusco, Alfredo/0000-0003-3332-5197				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Bandiera A, 1998, CANCER RES, V58, P426; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; Fedele M, 2001, CANCER RES, V61, P4583; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; FEDELE M, 2002, IN PRESS ONCOGENE, V21; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GACK S, 1994, J BIOL CHEM, V269, P10363; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scala S, 2001, CARCINOGENESIS, V22, P251, DOI 10.1093/carcin/22.2.251; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; TAMIMI Y, 1993, CANCER RES, V53, P5512; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood LJ, 2000, CANCER RES, V60, P4256; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	43	74	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2971	2980		10.1038/sj.onc.1205368	http://dx.doi.org/10.1038/sj.onc.1205368			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082527				2022-12-25	WOS:000175262700004
J	Taggart, CC; Greene, CM; McElvaney, NG; O'Neill, S				Taggart, CC; Greene, CM; McElvaney, NG; O'Neill, S			Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced I kappa B alpha degradation without affecting phosphorylation or ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE PROTEASE INHIBITOR; RESPIRATORY EPITHELIAL SURFACE; LEUKOPROTEASE INHIBITOR; PROTEINASE-INHIBITOR; ELASTASE; ANTILEUKOPROTEASE; INFLAMMATION; MACROPHAGES; ACTIVATION; PATHWAY	Secretory leucoprotease inhibitor (SLPI) is a non-glycosylated protein produced by epithelial cells, macrophages, and neutrophils and was initially identified as a serine protease inhibitor of the neutrophil proteases elastase and cathepsin G. In addition to its antiprotease activity, SLPI has been shown to exhibit anti-inflammatory properties including down-regulation of tumor necrosis factor-a expression by lipopolysaccharide (LPS) in monocytes, inhibition of NF-kappaB activation by IgG immune complexes in a rat model of acute lung injury, and prevention of human immunodeficiency virus infectivity in monocytic cells via as yet unidentified mechanisms. In this report we have shown that SLPI prevents LPS-induced NF-kappaB activation by inhibiting degradation of IkappaBalpha without affecting the LPS-induced phosphorylation and ubiquitination of IkappaBalpha. We have also demonstrated that SLPI prevents LPS-induced interleukin-1 receptor-associated kinase and IKBA degradation. In addition, we have demonstrated that oxidized SLPI, a variant of SLPI that has diminished antiprotease activity, cannot prevent LPS-induced NF-kappaB activation or Inhibitor kappaB alpha/beta degradation indicating that the anti-inflammatory effect of SLPI on the LPS-signaling pathway is dependent on its antiprotease activity. These results suggest that SLPI may be inhibiting proteasomal degradation of NF-kappaB regulatory proteins, an effect that is dependent on the antiprotease activity of SLPI.	Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr,Dept Med, Pulm Res Div, Dublin 9, Ireland	Royal College of Surgeons - Ireland	Taggart, CC (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr,Dept Med, Pulm Res Div, Dublin 9, Ireland.		Taggart, Clifford C/G-4492-2014; McElvaney, Noel/A-6809-2010; Greene, Catherine M/D-3513-2012	Greene, Catherine M/0000-0003-2549-2569; Taggart, Clifford/0000-0002-9930-2978; mcelvaney, Noel/0000-0002-0152-4370				ABE T, 1991, J CLIN INVEST, V87, P2207, DOI 10.1172/JCI115255; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; Gao YH, 2000, J CLIN INVEST, V106, P439, DOI 10.1172/JCI9826; GAUTHIER F, 1982, BIOCHIM BIOPHYS ACTA, V700, P178, DOI 10.1016/0167-4838(82)90095-4; Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Kikuchi T, 2000, AM J RESP CELL MOL, V23, P364, DOI 10.1165/ajrcmb.23.3.3942; LEE CH, 1993, AM REV RESPIR DIS, V147, P710, DOI 10.1164/ajrccm/147.3.710; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; Mansell A, 2001, FEBS LETT, V508, P313, DOI 10.1016/S0014-5793(01)03077-0; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149; Mihaila A, 2001, Z NATURFORSCH C, V56, P291; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Mulligan MS, 2000, AM J PATHOL, V156, P1033, DOI 10.1016/S0002-9440(10)64971-1; Sallenave JM, 1997, J LEUKOCYTE BIOL, V61, P695, DOI 10.1002/jlb.61.6.695; Sano C, 2000, CLIN EXP IMMUNOL, V121, P77, DOI 10.1046/j.1365-2249.2000.01269.x; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; Taggart CC, 2001, J BIOL CHEM, V276, P33345, DOI 10.1074/jbc.M103220200; VOGELMEIER C, 1991, J CLIN INVEST, V87, P482, DOI 10.1172/JCI115021; Zhang YH, 1997, J CLIN INVEST, V99, P894, DOI 10.1172/JCI119254	23	115	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33648	33653		10.1074/jbc.M203710200	http://dx.doi.org/10.1074/jbc.M203710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12084717	hybrid			2022-12-25	WOS:000177959100017
J	Liu, J; Shriver, Z; Pope, RM; Thorp, SC; Duncan, MB; Copeland, RJ; Raska, CS; Yoshida, K; Eisenberg, RJ; Cohen, G; Linhardt, RJ; Sasisekharan, R				Liu, J; Shriver, Z; Pope, RM; Thorp, SC; Duncan, MB; Copeland, RJ; Raska, CS; Yoshida, K; Eisenberg, RJ; Cohen, G; Linhardt, RJ; Sasisekharan, R			Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-III; FLAVOBACTERIUM-HEPARINUM; VIRAL ENTRY; OLIGOSACCHARIDES; GLYCOSAMINOGLYCANS; CELLS; SITE; TETRASACCHARIDES; PROTEOGLYCANS; PURIFICATION	Herpes simplex virus type 1 utilizes cell surface heparan sulfate as receptors to infect target cells. The unique heparan sulfate saccharide sequence offers the binding site for viral envelope proteins and plays critical roles in assisting viral infections. A specific 3-O-sulfated heparan sulfate is known to facilitate the entry of herpes simplex virus I into cells. The 3-O-sulfated heparan sulfate is generated by the heparan sulfate D-glucosaminyl-3-O-sulfotransferase isoform 3 (3-OST-3), and it provides binding sites for viral glycoprotein D (gD). Here, we report the purification and structural characterization of an oligosaccharide that binds to gD. The isolated gD-binding site is an octasaccharide, and has a binding affinity to gD around 18 muM, as determined by affinity coelectrophoresis. The octasaccharide was prepared and purified from a heparan sulfate oligosaccharide library that was modified by purified 3-OST-3 enzyme. The molecular mass of the isolated octasaccharide was determined using both nanoelectrospray ionization mass spectrometry and matrix-assisted laser desorption/ionization mass spectrometry. The results from the sequence analysis suggest that the structure of the octasaccharide is a heptasulfated octasaccharide. The proposed structure of the octasaccharide is DeltaUA-G1cNS-IdoUA2S-G1cNAc-UA2S-G1cNS-IdoUA2S-G1cNH(2)3S6S. Given that the binding of 3-O-sulfated heparan sulfate to gD can mediate viral entry, our results provide structural information about heparan sulfate-assisted viral entry.	Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; Univ N Carolina, Prote Core Facil, Dept Biochem, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Seikagaku Corp, Tokyo Res Inst, Higashiyamato, Tokyo 207, Japan; Univ Penn, Ctr Oral Hlth Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA	University of North Carolina; University of North Carolina Chapel Hill; Massachusetts Institute of Technology (MIT); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Seikagaku Corporation; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Iowa	Liu, J (corresponding author), Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Rm 309,Beard Hall,CB 7360, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA 090940] Funding Source: Medline; NHLBI NIH HHS [P01 HL 41484, R01 HL 59479] Funding Source: Medline; NIAID NIH HHS [AI50050-01] Funding Source: Medline; NIGMS NIH HHS [GM 57073] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090940] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, R01HL059479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073, R37GM057073] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Edward Conrad H, 1998, HEPARIN BINDING PROT, P7, DOI [10.1016/B978-012186060-8/50003-6, DOI 10.1016/B978-012186060-8/50003-6]; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; FREEMAN C, 1989, BIOCHEM J, V259, P209, DOI 10.1042/bj2590209; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Godavarti R, 1998, J BIOL CHEM, V273, P248, DOI 10.1074/jbc.273.1.248; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Hernaiz M, 2000, BIOCHEM BIOPH RES CO, V276, P292, DOI 10.1006/bbrc.2000.3453; Herold BC, 1996, J VIROL, V70, P3461, DOI 10.1128/JVI.70.6.3461-3469.1996; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kim YS, 1998, GLYCOBIOLOGY, V8, P869, DOI 10.1093/glycob/8.9.869; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Li JP, 2001, J BIOL CHEM, V276, P20069, DOI 10.1074/jbc.M011783200; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; METTENLEITER TC, 1989, VIROLOGY, V171, P623, DOI 10.1016/0042-6822(89)90635-1; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Pope RM, 2001, GLYCOBIOLOGY, V11, P505, DOI 10.1093/glycob/11.6.505; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P12232, DOI 10.1073/pnas.95.21.12232; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Shriver Z, 2000, P NATL ACAD SCI USA, V97, P10359, DOI 10.1073/pnas.97.19.10359; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; TRYBALA E, 1994, J GEN VIROL, V75, P743, DOI 10.1099/0022-1317-75-4-743; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; WARNICK CT, 1972, BIOCHEMISTRY-US, V11, P568, DOI 10.1021/bi00754a014; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681	47	140	151	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33456	33467		10.1074/jbc.M202034200	http://dx.doi.org/10.1074/jbc.M202034200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080045	Green Published, hybrid			2022-12-25	WOS:000177859000135
J	Liu, ZM; George-Raizen, JB; Li, SY; Meyers, KC; Chang, MY; Garrard, WT				Liu, ZM; George-Raizen, JB; Li, SY; Meyers, KC; Chang, MY; Garrard, WT			Chromatin structural analyses of the mouse Ig kappa gene locus reveal new hypersensitive sites specifying a transcriptional silencer and enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DEVELOPMENT; MURINE IMMUNOGLOBULIN-KAPPA; LIGHT-CHAIN ENHANCERS; SOMATIC HYPERMUTATION; V(D)J RECOMBINATION; SEQUENCE ELEMENTS; ANTIGEN-RECEPTOR; STABLE INTEGRATION; INTRON ENHANCER; TRANSGENIC MICE	To identify new regulatory elements within the mouse Igkappa locus, we have mapped DNase I hypersensitive sites (HSs) in the chromatin of B cell lines arrested at different stages of differentiation. We have focused on two regions encompassing 50 kilobases suspected to contain new regulatory elements based on our previous high level expression results with yeast artificial chromosome-based mouse Igkappa transgenes. This approach has revealed a cluster of HSs within the 18-kilobase intervening sequence, which we cloned and sequenced in its entirety, between the Vkappa gene closest to the Jkappa region. These HSs exhibit pro/pre-B cell-specific transcriptional silencing of a Vkappa gene promoter in transient transfection assays. We also identified a plasmacytoma cell-specific HS in the far downstream region of the locus, which in analogous transient transfection assays proved to be a powerful transcriptional enhancer. Deletional analyses reveal that for each element multiple DNA segments cooperate to achieve either silencing or enhancement. The enhancer sequence is conserved in the human Igkappa gene locus, including N-F-kappaB and E-box sites that are important for the activity. In summary, our results pinpoint the locations of presumptive regulatory elements for future knockout studies to define their functional roles in the native locus.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garrard, WT (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NIGMS NIH HHS [GM29935] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029935] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANEN A, 1989, EUR J IMMUNOL, V19, P1961, DOI 10.1002/eji.1830191031; APEL TW, 1995, GENE, V156, P191, DOI 10.1016/0378-1119(94)00901-4; Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; Bain G, 1997, IMMUNITY, V6, P145, DOI 10.1016/S1074-7613(00)80421-5; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BLASQUEZ VC, 1992, J BIOL CHEM, V267, P23888; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BRINTON BT, 1991, J BIOL CHEM, V266, P5153; BULFONEPAUS S, 1995, NUCLEIC ACIDS RES, V23, P1997, DOI 10.1093/nar/23.11.1997; Cavelier P, 1997, EUR J IMMUNOL, V27, P1626, DOI 10.1002/eji.1830270706; Cedar H, 1999, CURR OPIN IMMUNOL, V11, P64, DOI 10.1016/S0952-7915(99)80012-0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cocea L, 1999, J EXP MED, V189, P1443, DOI 10.1084/jem.189.9.1443; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DHONSTELAERE LA, 1990, J IMMUNOL, V145, P2706; Ferradini L, 1994, Semin Immunol, V6, P165, DOI 10.1006/smim.1994.1022; Ferradini L, 1996, SCIENCE, V271, P1416, DOI 10.1126/science.271.5254.1416; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; FULTON R, 1993, NUCLEIC ACIDS RES, V21, P4941, DOI 10.1093/nar/21.21.4941; FULTON R, 1994, NUCLEIC ACIDS RES, V22, P4216, DOI 10.1093/nar/22.20.4216; GARRARD WT, 1989, TISSUE SPECIFIC GENE, P13; George JB, 1995, P NATL ACAD SCI USA, V92, P12421, DOI 10.1073/pnas.92.26.12421; GEORGE JB, 1997, ANTIBODIES, V4, P41; GIANNINI SL, 1993, J IMMUNOL, V150, P1772; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; Grawunder U, 1998, CURR OPIN IMMUNOL, V10, P172, DOI 10.1016/S0952-7915(98)80246-X; Green NS, 1998, BIOESSAYS, V20, P227, DOI 10.1002/(SICI)1521-1878(199803)20:3<227::AID-BIES6>3.0.CO;2-O; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P157; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; Hale MA, 1998, MOL IMMUNOL, V35, P609, DOI 10.1016/S0161-5890(98)00060-1; HEINRICH G, 1984, J EXP MED, V159, P417, DOI 10.1084/jem.159.2.417; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; HOCHTL J, 1983, NATURE, V302, P260, DOI 10.1038/302260a0; Inlay M, 2002, NAT IMMUNOL, V3, P463, DOI 10.1038/ni790; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kirschbaum T, 1999, EUR J IMMUNOL, V29, P2057, DOI 10.1002/(SICI)1521-4141(199907)29:07<2057::AID-IMMU2057>3.0.CO;2-P; Kirschbaum T, 1998, EUR J IMMUNOL, V28, P1458, DOI 10.1002/(SICI)1521-4141(199805)28:05&lt;1458::AID-IMMU1458&gt;3.0.CO;2-5; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; Lewis SM, 1997, CELL, V88, P159, DOI 10.1016/S0092-8674(00)81833-4; Li SY, 2000, J IMMUNOL, V164, P812, DOI 10.4049/jimmunol.164.2.812; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; Liu XD, 1999, J BIOL CHEM, V274, P3285, DOI 10.1074/jbc.274.6.3285; Liu XD, 1999, MOL IMMUNOL, V36, P461, DOI 10.1016/S0161-5890(99)00065-6; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Maes J, 2001, J IMMUNOL, V167, P866, DOI 10.4049/jimmunol.167.2.866; MARTIN DJ, 1990, MOL CELL BIOL, V10, P1950, DOI 10.1128/MCB.10.5.1950; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; MULLER B, 1990, EUR J IMMUNOL, V20, P1409, DOI 10.1002/eji.1830200631; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; Nagawa F, 1998, MOL CELL BIOL, V18, P655, DOI 10.1128/MCB.18.1.655; Neuberger MS, 1998, IMMUNOL REV, V162, P107, DOI 10.1111/j.1600-065X.1998.tb01434.x; OBrien DP, 1997, MOL CELL BIOL, V17, P3477, DOI 10.1128/MCB.17.7.3477; Papavasiliou F, 1997, CURR OPIN IMMUNOL, V9, P233, DOI 10.1016/S0952-7915(97)80141-0; PARSLOW TG, 1982, NATURE, V299, P449, DOI 10.1038/299449a0; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Rada C, 2001, EMBO J, V20, P4570, DOI 10.1093/emboj/20.16.4570; REEVES RH, 1992, METHOD ENZYMOL, V216, P584; Reya T, 1998, CURR OPIN IMMUNOL, V10, P158, DOI 10.1016/S0952-7915(98)80244-6; Roque MC, 1996, MOL CELL BIOL, V16, P3138; Roschenthaler F, 1999, EUR J IMMUNOL, V29, P2065, DOI 10.1002/(SICI)1521-4141(199907)29:07<2065::AID-IMMU2065>3.0.CO;2-Z; Roth DB, 2000, CELL, V103, P699, DOI 10.1016/S0092-8674(00)00173-2; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SAMBROOK J, 1989, MOL CLONING, V2, P9; Schable KF, 1999, EUR J IMMUNOL, V29, P2082, DOI 10.1002/(SICI)1521-4141(199907)29:07&lt;2082::AID-IMMU2082&gt;3.0.CO;2-C; SCHANKE JT, 1994, J IMMUNOL, V153, P4565; Scherer DC, 1996, IMMUNITY, V5, P563, DOI 10.1016/S1074-7613(00)80271-X; Scheuermann RH, 1999, CRIT REV EUKAR GENE, V9, P295, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.140; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; Shaffer AL, 1997, IMMUNITY, V6, P131, DOI 10.1016/S1074-7613(00)80420-3; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Skok JA, 2001, NAT IMMUNOL, V2, P848, DOI 10.1038/ni0901-848; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; Storb U, 1998, IMMUNOL REV, V162, P153; STROHAL R, 1989, IMMUNOGENETICS, V30, P475, DOI 10.1007/BF02421180; Thiebe R, 1999, EUR J IMMUNOL, V29, P2072, DOI 10.1002/(SICI)1521-4141(199907)29:07&lt;2072::AID-IMMU2072&gt;3.0.CO;2-E; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; Xian J, 1998, TRANSGENICS, V2, P333; XU M, 1989, J BIOL CHEM, V264, P21190; Xu Y, 1996, IMMUNITY, V4, P377, DOI 10.1016/S1074-7613(00)80251-4; Yi M, 1999, J IMMUNOL, V162, P6029; ZACHAU HG, 1996, IMMUNOLOGIST, V0004, P00049; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zou XG, 1996, FASEB J, V10, P1227, DOI 10.1096/fasebj.10.10.8751726	90	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32640	32649		10.1074/jbc.M204065200	http://dx.doi.org/10.1074/jbc.M204065200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12080064	hybrid			2022-12-25	WOS:000177859000033
J	Xie, YH; Gibbs, TC; Mukhin, YV; Meier, KE				Xie, YH; Gibbs, TC; Mukhin, YV; Meier, KE			Role for 18 : 1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHOLIPID GROWTH-FACTORS; PROTEIN-COUPLED RECEPTORS; MASS-SPECTROMETRY; SPHINGOSINE 1-PHOSPHATE; PLATELET-AGGREGATION; LPA RECEPTORS; EDG FAMILY; ELECTROSPRAY; EXPRESSION; ANALOGS	Lysophosphatidic acid (LPA) is a lipid mediator that may play an important role in growth and survival of carcinomas. In this study, LPA production and response were characterized in two human prostate cancer (CaP) cell lines: PC-3 and Du145. Bombesin, a neuroendocrine peptide that is mitogenic for CaP cells, stimulated focal adhesion kinase phosphorylation and activated the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway. Similar responses were elicited by 18:1 LPA (oleoyl-LPA). Studies using radioisotopic labeling revealed that both PC-3 and Du145 generate LPA and that LPA production is increased by bombesin. The kinetics of bombesin-induced phospholipase D activation and LPA production were similar. Using electrospray ionization mass spectrometry, 18:1 LPA was found to be an abundant LPA species in CaP cell medium. Structure activity studies of acyl-LPAs revealed that 18:1 LPA is most efficacious for activation of extracellular signal-regulated kinase and phospholipase D in CaP cells. Incubation with 18:1 LPA caused homologous desensitization of LPA response, whereas bombesin caused heterologous desensitization. LPA was present at nanomolar levels in medium from bombesin-treated cells. LPA extracted from the medium induced calcium mobilization in CaP cells. These results demonstrate that bioactive LPA is generated by CaP cells in response to a mitogen and suggest that 18:1 LPA can act as an autocrine mediator.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Meier, KE (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave,POB 250505, Charleston, SC 29425 USA.	meierke@musc.edu			NCRR NIH HHS [S10-RR013005] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013005] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; An SZ, 1998, J CELL BIOCHEM, P147; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; BOLOGNA M, 1989, CANCER, V63, P1714; Carrier A, 2000, J CHROMATOGR A, V876, P97, DOI 10.1016/S0021-9673(00)00148-5; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Gibbs TC, 2000, J CELL PHYSIOL, V182, P77, DOI 10.1002/(SICI)1097-4652(200001)182:1<77::AID-JCP9>3.0.CO;2-B; Gibbs TC, 2000, ANN NY ACAD SCI, V905, P290; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Guo CH, 2000, J UROLOGY, V163, P1027, DOI 10.1016/S0022-5347(05)67876-7; Harrison KA, 1999, J MASS SPECTROM, V34, P330, DOI 10.1002/(SICI)1096-9888(199904)34:4<330::AID-JMS798>3.0.CO;2-#; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hiroyama M, 1998, BIOCHEM J, V336, P483, DOI 10.1042/bj3360483; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; HU VL, 2001, JNCI-J NATL CANCER I, V93, P762; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; KANOH H, 1986, J BIOL CHEM, V261, P5597; Kue PF, 2000, J UROLOGY, V164, P2162, DOI 10.1016/S0022-5347(05)66990-X; Kume K, 1997, BIOCHEM BIOPH RES CO, V237, P663, DOI 10.1006/bbrc.1997.7214; LYNCH KR, 2001, PROSTAG OTH LIPID M, V64, P3; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Markwalder R, 1999, CANCER RES, V59, P1152; MEIER KE, 1999, SIGNAL TRANSDUCTION, P301; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; Nishino H, 1998, AM J PHYSIOL-GASTR L, V274, pG525, DOI 10.1152/ajpgi.1998.274.3.G525; Pages C, 2000, ANN NY ACAD SCI, V905, P159; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Plonowski A, 2000, INT J CANCER, V88, P652, DOI 10.1002/1097-0215(20001115)88:4<652::AID-IJC21>3.0.CO;2-1; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qi C, 1998, J CELL PHYSIOL, V174, P261, DOI 10.1002/(SICI)1097-4652(199802)174:2<261::AID-JCP13>3.0.CO;2-F; Santos WL, 2000, ANN NY ACAD SCI, V905, P232; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; SINGH IN, 1995, FEBS LETT, V365, P125, DOI 10.1016/0014-5793(95)00432-9; Sugiura T, 2000, ANN NY ACAD SCI, V905, P351; Sun BD, 2000, PROSTATE, V42, P295; Svetlov SI, 1996, ARCH BIOCHEM BIOPHYS, V336, P59, DOI 10.1006/abbi.1996.0532; Swarthout JT, 2000, CELL MOL LIFE SCI, V57, P1978, DOI 10.1007/PL00000678; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tokumura A, 2000, ANN NY ACAD SCI, V905, P347; Wang DA, 2001, J BIOL CHEM, V276, P49213, DOI 10.1074/jbc.M107301200; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; XIE Y, 2001, METHOD ENZYMOL, V344, P294; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; Xu J, 2000, ANN NY ACAD SCI, V905, P81	56	78	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32516	32526		10.1074/jbc.M203864200	http://dx.doi.org/10.1074/jbc.M203864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084719	hybrid			2022-12-25	WOS:000177859000018
J	Xing, YM; Nakamura, A; Korenaga, T; Guo, ZJ; Yao, JJ; Fu, XY; Matsushita, T; Kogishi, K; Hosokawa, M; Kametani, F; Mori, M; Higuchi, K				Xing, YM; Nakamura, A; Korenaga, T; Guo, ZJ; Yao, JJ; Fu, XY; Matsushita, T; Kogishi, K; Hosokawa, M; Kametani, F; Mori, M; Higuchi, K			Induction of protein conformational change in mouse senile amyloidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; APOA-II; PRIONS; YEAST; SCRAPIE; MICE; POLYNEUROPATHY; TRANSMISSION; SENESCENCE	Aggregated amyloid fibrils can induce further polymerization of precursor proteins in vitro, thus providing a possible basis for propagation or transmission in the pathogenesis of amyloidoses. Previously, we postulated that the transmission of amyloid fibrils induces conformational. changes of endogenous amyloid protein in mouse senile amyloidosis (Xing, Y., Nakamura, A., Chiba, T., Kogishi, K., Matsushita, T., Fu, L., Guo Z., Hosokawa, M., Mori, M., and Higuchi, K. (2001) Lab. Invest. 81, 493-499). To further characterize this transmissibility, we injected amyloid fibrils (AApoAII(C)) of amyloidogenic C type apolipoprotein A-II (APOAIIC) intravenously into 2-month-old SAMR1 mice, which have B type apolipoprotein A-H (APOAIIB), and develop few if any amyloid deposits spontaneously. 10 months after amyloid injection, deposits were detected in the tongue, stomach, intestine, lungs, heart, liver, and kidneys. The intensity of deposition increased thereafter, whereas no amyloid was detected in distilled water-injected SAMR1 mice, even after 20 months. The deposited amyloid was composed of endogenous APOAIIB with a different amyloid fibril conformation. The injection of these amyloid fibrils of APOAIIB (AApoAII(B)) induced earlier and more severe amyloidosis in SAMR1 mice than the injection of AApoAII(C) amyloid fibrils. Thus, AApoAII(C) from amyloidogenic mice could induce a conformational change of less amyloidogenic APOAIIB to a different amyloid fibril structure, which could also induce amyloidosis in the less amyloidogenic strain. These results provide important insights into the pathogenesis of amyloid diseases.	Shinshu Univ, Dept Aging Angiol, Res Ctr Aging & Adaptat, Sch Med, Matsumoto, Nagano 3908621, Japan; Kyoto Univ, Inst Frontier Med Sci, Field Regenerat Control, Kyoto 6068507, Japan; Tokyo Inst Psychiat, Dept Biol Mol, Tokyo 1568585, Japan	Shinshu University; Kyoto University; Tokyo Institute of Psychiatry	Higuchi, K (corresponding author), Shinshu Univ, Dept Aging Angiol, Res Ctr Aging & Adaptat, Sch Med, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.	khiguchi@sch.md.shinshu-u.ac.jp	Kametani, Fuyuki/G-4752-2011	Kametani, Fuyuki/0000-0001-9125-7001				Asl LH, 1999, AM J PATHOL, V154, P221, DOI 10.1016/S0002-9440(10)65268-6; BAKER HF, 1994, MOL NEUROBIOL, V8, P25, DOI 10.1007/BF02778005; Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; Booth DR, 1996, J CLIN INVEST, V97, P2714, DOI 10.1172/JCI118725; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Clark A, 1996, BIOCHEM SOC T, V24, P594, DOI 10.1042/bst0240594; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Graether SP, 1996, AMYLOID, V3, P20, DOI 10.3109/13506129609014351; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HIGUCHI K, 1983, LAB INVEST, V48, P231; HIGUCHI K, 1991, BIOCHEM J, V279, P427, DOI 10.1042/bj2790427; HIGUCHI K, 1995, LAB INVEST, V72, P75; Higuchi K, 1998, LAB INVEST, V78, P1535; HIGUCHI K, 1986, J BIOL CHEM, V261, P2834; Hoshii Y, 1997, AM J PATHOL, V151, P911; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Johan K, 1998, P NATL ACAD SCI USA, V95, P2558, DOI 10.1073/pnas.95.5.2558; KELLEHER CJ, 1994, J SEX HLTH, V3, P186; KINDY MS, 1995, LAB INVEST, V73, P469; KISILEVSKY R, 1995, AMYLOID, V2, P128, DOI 10.3109/13506129509031899; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; NAIKI H, 1991, LAB INVEST, V65, P104; NICHOLS WC, 1990, GENOMICS, V8, P318, DOI 10.1016/0888-7543(90)90288-6; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRAS M, 1968, J CLIN INVEST, V47, P924; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Stangou AJ, 1998, TRANSPLANTATION, V66, P229, DOI 10.1097/00007890-199807270-00016; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Wickner RB, 1999, J BIOL CHEM, V274, P555, DOI 10.1074/jbc.274.2.555; Xing YM, 2001, LAB INVEST, V81, P493, DOI 10.1038/labinvest.3780257; Yazaki M, 2000, BIOCHEM BIOPH RES CO, V274, P702, DOI 10.1006/bbrc.2000.3203; YONEZU T, 1986, FEBS LETT, V203, P149, DOI 10.1016/0014-5793(86)80732-3	42	43	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33164	33169		10.1074/jbc.M111570200	http://dx.doi.org/10.1074/jbc.M111570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077115	hybrid			2022-12-25	WOS:000177859000099
J	Caudy, AA; Pikaard, CS				Caudy, AA; Pikaard, CS			Xenopus ribosomal RNA gene Intergenic Spacer elements conferring transcriptional enhancement and nucleolar dominance-like competition in oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I TRANSCRIPTION; SEQUENCE ORGANIZATION; LAEVIS; DNA; PROMOTER; HYBRIDS; BOREALIS	Repeated within the intergenic spacers that separate adjacent ribosomal RNA (rRNA) genes in Xenopus laevis are several distinct sequence elements. These include transcription terminators, "region 0" repeats, "region 1" repeats, duplicated spacer promoters, and 42-bp enhancer elements that are embedded within 60 or 81-bp repeats. All have been reported to stimulate RNA polymerase I transcription from an adjacent gene promoter. A greater number of 42-bp enhancers/gene have been suggested to explain the preferential transcription of X. laevis rRNA genes in X. laevis x Xenopus borealis hybrids, an epigenetic phenomenon known as nucleolar dominance. However, the possible contribution of regions 0/1 and/or spacer promoters to the preferential transcription of X. laevis (over X. borealis) rRNA genes has never been tested directly. In this study, we systematically tested the various intergenic spacer elements for their contributions to promoter strength and nucleolar dominance-like competition in oocytes. In disagreement with a previous report, region 0 and region 1 repeats do not have significant enhancer activity, nor do they play a discernible role in X. laevis-X. borealis rRNA gene competition. Minigenes containing X. laevis spacer sequences are only dominant over minigenes having complete X. borealis spacers if a spacer promoter is located upstream of the 42-bp enhancers; X. laevis enhancers alone are not sufficient. These results provide additional evidence that spacer promoters together with adjacent enhancers form a functional activating unit in Xenopus oocytes.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Pikaard, CS (corresponding author), Washington Univ, Dept Biol, Campus Box 1137,1 Brookings Dr, St Louis, MO 63130 USA.		Pikaard, Craig S/K-8772-2012	Pikaard, Craig S/0000-0001-8204-7459; Caudy, Amy/0000-0001-6307-8137	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050910, R01GM060380] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM50910, R01-GM60380] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH R, 1981, NUCLEIC ACIDS RES, V9, P5311, DOI 10.1093/nar/9.20.5311; BOSELEY P, 1979, CELL, V17, P19, DOI 10.1016/0092-8674(79)90291-5; BUSBY SJ, 1983, CELL, V34, P989, DOI 10.1016/0092-8674(83)90556-1; CASSIDY DM, 1974, DEV BIOL, V41, P84, DOI 10.1016/0012-1606(74)90285-1; DEWINTER RFJ, 1987, J MOL BIOL, V196, P813, DOI 10.1016/0022-2836(87)90407-4; DEWINTER RFJ, 1986, CELL, V44, P313, DOI 10.1016/0092-8674(86)90765-8; DUNAWAY M, 1989, GENE DEV, V3, P1768, DOI 10.1101/gad.3.11.1768; DURICA DS, 1978, GENETICS, V89, P37; DURICA DS, 1977, DEV BIOL, V59, P62, DOI 10.1016/0012-1606(77)90240-8; Frieman M, 1999, GENETICS, V152, P451; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; HONJO T, 1973, J MOL BIOL, V80, P217, DOI 10.1016/0022-2836(73)90168-X; LABHART P, 1984, CELL, V37, P285, DOI 10.1016/0092-8674(84)90324-6; LABHART P, 1987, NUCLEIC ACIDS RES, V15, P3623, DOI 10.1093/nar/15.8.3623; LABHART P, 1986, CELL, V45, P431, DOI 10.1016/0092-8674(86)90329-6; McCLINTOCK BARBARA, 1934, ZEITSCHR ZELLJORSCH U MIKROSK ANAT, V21, P294, DOI 10.1007/BF00374060; MORGAN GT, 1984, NUCLEIC ACIDS RES, V12, P6043, DOI 10.1093/nar/12.15.6043; MORGAN GT, 1983, P NATL ACAD SCI-BIOL, V80, P6490, DOI 10.1073/pnas.80.21.6490; MOSS T, 1983, NATURE, V302, P223, DOI 10.1038/302223a0; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MOSS T, 1979, NUCLEIC ACIDS RES, V6, P3733, DOI 10.1093/nar/6.12.3733; MOSS T, 1980, NUCLEIC ACIDS RES, V8, P467, DOI 10.1093/nar/8.3.467; Mougey EB, 1996, J BIOL CHEM, V271, P27138, DOI 10.1074/jbc.271.43.27138; NAVASHIN M., 1934, CYTOLOGIA, V5, P169, DOI 10.1508/cytologia.5.169; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pikaard CS, 2000, PLANT MOL BIOL, V43, P163, DOI 10.1023/A:1006471009225; Pikaard CS, 2000, TRENDS GENET, V16, P495, DOI 10.1016/S0168-9525(00)02113-2; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PIKAARD CS, 1988, MOL CELL BIOL, V8, P4282, DOI 10.1128/MCB.8.10.4282; PIKAARD CS, 1994, P NATL ACAD SCI USA, V91, P464, DOI 10.1073/pnas.91.2.464; Reeder RH, 1989, CURR OPIN CELL BIOL, V1, P466, DOI 10.1016/0955-0674(89)90007-0; REEDER RH, 1984, CELL, V38, P39, DOI 10.1016/0092-8674(84)90524-5; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; REEDER RH, 1985, J CELL BIOL, V101, P2013, DOI 10.1083/jcb.101.5.2013; REEDER RH, 1983, CELL, V35, P449, DOI 10.1016/0092-8674(83)90178-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; WALLACE H, 1966, BIOCHIM BIOPHYS ACTA, V114, P296, DOI 10.1016/0005-2787(66)90311-X	40	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31577	31584		10.1074/jbc.M202737200	http://dx.doi.org/10.1074/jbc.M202737200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080048	hybrid			2022-12-25	WOS:000177718700037
J	Gaudreau, R; Le Gouill, C; Helene, MN; Stankova, J; Rola-Pleszczynski, M				Gaudreau, R; Le Gouill, C; Helene, MN; Stankova, J; Rola-Pleszczynski, M			Threonine 308 within a putative casein kinase 2 site of the cytoplasmic tail of leukotriene B-4 receptor (BLT1) is crucial for ligand-induced, G-protein-coupled receptor-specific kinase 6-mediated desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; INOSITOL 1,4,5-TRISPHOSPHATE; CHEMOATTRACTANT RECEPTOR; PHOSPHORYLATION SITES; CALCIUM MOBILIZATION; MOLECULAR-CLONING; HUMAN NEUTROPHILS; ARACHIDONIC-ACID; HORMONE RECEPTOR; HUMAN MONOCYTES	Desensitization of G-protein-coupled receptors may involve phosphorylation of serine and threonine residues. The leukotriene B-4 (LTB4) receptor (BLT1) contains 14 intracellular serines and threonines, 8 of which are part of consensus target sequences for protein kinase C (PKC) or casein kinase 2. In this study, we investigated the importance of PKC and GPCR-specific kinase (GRK) phosphorylation in BLT1 desensitization. Pretreatment of BLT1-transfected COS-7 cells with PKC activators caused a decrease of LTB4-induced inositol phosphate (IP) accumulation. This reduction was prevented with the PKC inhibitor, staurosporine, and not observed in cells expressing a BLT1 deletion mutant (G291stop) lacking the cytoplasmic tail. Moreover LTB4- induced IP accumulation was significantly inhibited by overexpression of GRK2, GRK5, and especially GRK6, in cells expressing wild type BLT1 but not in those expressing G291stop. GRK6-mediated desensitization correlated with increased phosphorylation of BLT1. The G319stop truncated BLT1 mutant displayed functional characteristics comparable with wild type BLT1 in terms of desensitization by GRK6, but not by PKC. Substitution of Thr(308) within a putative casein kinase 2 site to proline or alanine in the full-length BLT1 receptor prevented most of GRK6-mediated inhibition of LTB4-induced IP production but only partially affected LTB4-induced BLT1 phosphorylation. Our findings thus suggest that Thr(308) is a major residue involved in GRK6-mediated desensitization of BLT1 signaling.	Univ Sherbrooke, Div Immunol, Dept Pediat, Fac Med, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rola-Pleszczynski, M (corresponding author), Univ Sherbrooke, Div Immunol, Dept Pediat, Fac Med, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	mrolaple@courrier.usherb.ca						Aiyar N, 2000, EUR J PHARMACOL, V403, P1, DOI 10.1016/S0014-2999(00)00419-2; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ANDERSSON T, 1986, BIOCHEM J, V240, P333, DOI 10.1042/bj2400333; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Chungaon KO, 1996, BRIT J PHARMACOL, V117, P1334, DOI 10.1111/j.1476-5381.1996.tb16733.x; Cunningham ML, 1999, MOL PHARMACOL, V56, P265, DOI 10.1124/mol.56.2.265; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Diviani D, 1996, J BIOL CHEM, V271, P5049; DRYDEN P, 1992, PROSTAGLANDINS, V44, P11, DOI 10.1016/0090-6980(92)90103-Z; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; GOLDMAN DW, 1986, J IMMUNOL, V136, P4631; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hanyaloglu AC, 2001, J BIOL CHEM, V276, P18066, DOI 10.1074/jbc.M009275200; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; HONDA Z, 1994, J BIOL CHEM, V269, P2307; Kamohara M, 2000, J BIOL CHEM, V275, P27000; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; LEW PD, 1984, FEBS LETT, V166, P44, DOI 10.1016/0014-5793(84)80041-1; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; MARLEAU S, 1993, J IMMUNOL, V150, P206; MONTERO M, 1994, BIOCHEM J, V303, P559, DOI 10.1042/bj3030559; Neill JD, 1998, ENDOCRINOLOGY, V139, P1781, DOI 10.1210/en.139.4.1781; OFLAHERTY JT, 1990, J CELL PHYSIOL, V142, P299, DOI 10.1002/jcp.1041420212; OFLAHERTY JT, 1986, FEBS LETT, V206, P279, DOI 10.1016/0014-5793(86)80996-6; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Owman C, 1997, BIOCHEM BIOPH RES CO, V240, P162, DOI 10.1006/bbrc.1997.7628; Patry C, 1996, PROSTAG LEUKOTR ESS, V54, P361, DOI 10.1016/S0952-3278(96)90050-2; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Richardson RM, 2000, J BIOL CHEM, V275, P9201, DOI 10.1074/jbc.275.13.9201; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; ROLAPLESZCZYNSKI M, 1985, IMMUNOL TODAY, V6, P302, DOI 10.1016/0167-5699(85)90181-1; Seibold A, 2000, MOL PHARMACOL, V58, P1162, DOI 10.1124/mol.58.5.1162; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SHEFCYK J, 1985, BIOCHEM BIOPH RES CO, V126, P1174, DOI 10.1016/0006-291X(85)90309-2; SHOWELL HJ, 1982, J IMMUNOL, V128, P811; STANKOVA J, 1993, J IMMUNOL, V150, P4041; STANKOVA J, 1992, IMMUNOLOGY, V76, P258; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; Tager AM, 2000, J EXP MED, V192, P439, DOI 10.1084/jem.192.3.439; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsuga H, 1998, J PHARMACOL EXP THER, V284, P1218; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Willets J, 2001, EUR J PHARMACOL, V431, P133, DOI 10.1016/S0014-2999(01)01360-7; WRINKLER JD, 1988, J PHARMACOL EXP THER, V246, P204; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	66	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31567	31576		10.1074/jbc.M202723200	http://dx.doi.org/10.1074/jbc.M202723200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077128	hybrid			2022-12-25	WOS:000177718700036
J	Hurne, AM; Chai, CLL; Moerman, K; Waring, P				Hurne, AM; Chai, CLL; Moerman, K; Waring, P			Influx of calcium through a redox-sensitive plasma membrane channel in thymocytes causes early necrotic cell death induced by the epipolythiodioxopiperazine toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; FUNGAL METABOLITE; DNA FRAGMENTATION; CA2+ RELEASE; GLIOTOXIN; APOPTOSIS; SPORIDESMIN; MACROPHAGES; MECHANISMS	Gliotoxin, a member of the epipolythiodioxopiperazine (ETP) class of toxins, induces both apoptotic and necrotic cell death in a concentration-dependent manner. Whereas the specific trigger for apoptotic death caused by these toxins is unclear, the reactive disulfide bond in the ETP toxins is required for biological activity. Thus it is likely that it is the interaction of this disulfide moiety with macromolecules in cells that was responsible for activity of ETP toxins. Here we present evidence that necrosis induced by gliotoxin and a simple synthetic ETP toxin is largely because of an influx of extracellular calcium through a redox-sensitive calcium channel in the plasma membrane of murine thymocytes. The calcium rises are strongly dependent on the pH of the external medium and the presence of external calcium and are abrogated and/or reversed by the presence of dithiothreitol, cell impermeant glutathione, and the calcium channel blocker Ni2+. Comparisons with thapsigargin, which indirectly causes release of calcium from internal stores, indicates that ETP toxins do not provoke calcium rises by store depletion. A mechanism of oxidation by ETP toxins of cell surface thiol groups resulting in direct entry of calcium through a redox active channel in the plasma membrane is proposed. Necrotic but not apoptotic cell death was abrogated by inhibition of calcium entry.	Australian Natl Univ, Dept Chem, The Faculties, Canberra, ACT 0200, Australia; Australian Natl Univ, Div Cell Biol & Immunol, John Curtin Sch Med Res, Canberra, ACT 0200, Australia	Australian National University; Australian National University; John Curtin School of Medical Research	Waring, P (corresponding author), Australian Natl Univ, Dept Chem, The Faculties, Canberra, ACT 0200, Australia.		Chai, Christina L/A-3133-2014	Chai, Christina/0000-0002-9199-851X				Az-ma T, 1999, BRIT J PHARMACOL, V126, P1462, DOI 10.1038/sj.bjp.0702438; BEAVER JP, 1994, IMMUNOL CELL BIOL, V72, P489, DOI 10.1038/icb.1994.73; DAVIES D, 2000, LIVING COLOUR PROTOC, P463; DOAN TN, 1994, BIOCHEM J, V297, P209, DOI 10.1042/bj2970209; EICHNER RD, 1984, AUST J EXP BIOL MED, V62, P479, DOI 10.1038/icb.1984.45; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Foster FM, 1999, CELL CALCIUM, V25, P69, DOI 10.1054/ceca.1998.0004; Green D, 2000, J MEMBRANE BIOL, V175, P223, DOI 10.1007/s002320001070; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hurne AM, 1997, BIOORG MED CHEM LETT, V7, P2645, DOI 10.1016/S0960-894X(97)10052-X; Hurne AM, 2000, J BIOL CHEM, V275, P25202, DOI 10.1074/jbc.M002278200; JORDAN TW, 1986, J CELL SCI, V85, P33; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; JUNE CH, 1994, FLOW CYTOMETRY, P149; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; KRIPPEITDREWS P, 1995, BIOCHEM BIOPH RES CO, V209, P139, DOI 10.1006/bbrc.1995.1481; MULLBACHER A, 1986, MOL IMMUNOL, V23, P231, DOI 10.1016/0161-5890(86)90047-7; MUNDAY R, 1982, CHEM-BIOL INTERACT, V41, P361, DOI 10.1016/0009-2797(82)90112-0; Nagase T, 1997, BRIT J CANCER, V76, P1001, DOI 10.1038/bjc.1997.499; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; OTTENHEIJM HCJ, 1978, J MED CHEM, V21, P799, DOI 10.1021/jm00206a016; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; RICHARD J, 1990, VET HUM TOXICOL, V32, P63; SCHWEIZER M, 1994, BIOCHEMISTRY-US, V33, P13401, DOI 10.1021/bi00249a028; Silva JP, 1997, REDOX REP, V3, P331, DOI 10.1080/13510002.1997.11747131; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WARING P, 1990, INT J IMMUNOPHARMACO, V12, P445, DOI 10.1016/0192-0561(90)90028-L; Waring P, 1999, CELL DEATH DIFFER, V6, P624, DOI 10.1038/sj.cdd.4400540; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WARING P, 1988, J BIOL CHEM, V263, P18493; Waring P, 1996, GEN PHARMACOL, V27, P1311, DOI 10.1016/S0306-3623(96)00083-3; WARING P, 1990, J BIOL CHEM, V265, P14476; WARING P, 1995, INT J IMMUNOPHARMACO, V17, P403, DOI 10.1016/0192-0561(95)00021-S; WARING P, 1995, BIOCHEM PHARMACOL, V49, P1195, DOI 10.1016/0006-2952(95)00039-3; WARING P, 1988, MED RES REV, V8, P499, DOI 10.1002/med.2610080404	36	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31631	31638		10.1074/jbc.M201699200	http://dx.doi.org/10.1074/jbc.M201699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12063251	hybrid			2022-12-25	WOS:000177718700043
J	Mansour, M; Lee, SY; Pohajdak, B				Mansour, M; Lee, SY; Pohajdak, B			The N-terminal coiled coil domain of cytohesin/ARNO family of guanine nucleotide exchange factors interacts with the scaffolding protein CASP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLECKSTRIN-HOMOLOGY DOMAINS; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATED TRANSLOCATION; CARGO SELECTION; GOLGI MEMBRANES; FACTOR GRP1; COMPLEX; BINDING	Cytohesin is a guanine nucleotide exchange factor that regulates members of the ADP-ribosylation factor (ARF) family of small GTPases. All of the members of the cytohesin family (including ARNO, ARNO3, and the newly characterized cytohesin-4) have a similar domain distribution consisting of a Sec7 homology domain, a pleckstrin homology domain, and an N-terminal coiled coil. In this study, we attempt to identify proteins that interact specifically with the coiled coil motif of cytohesin. Yeast two-hybrid screening of a B cell library using the cytohesin N terminus as bait, identified CASP, a scaffolding protein of previously unknown function, as a binding partner. CASP contains an internal coiled coil motif that is required for cytohesin binding both in vitro and in COS-1 cells. The specificity of the coiled coil of CASP is not restricted to cytohesin, however, because it is also capable of interacting with other members of the cytohesin/ARNO family, ARNO and ARNO3. In immunofluorescence experiments, CASP localizes to perinuclear tubulovesicular structures that are in close proximity to the Golgi. These structures remain relatively undisturbed when the cells are treated with brefeldin A. In epidermal growth factor-stimulated COS-1 cells over-expressing cytohesin and CASP, cytohesin recruits CASP to membrane ruffles, revealing a functional interaction between the two proteins. These observations collectively suggest that CASP is a scaffolding protein that facilitates the function of at least one member of the cytohesin/ARNO family in response to specific cellular stimuli.	Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada	Dalhousie University	Pohajdak, B (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada.	Billpoh@is.dal.ca						Allan RB, 1999, SCIENCE, V285, P63, DOI 10.1126/science.285.5424.63; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DIXON B, 1993, BIOCHIM BIOPHYS ACTA, V1216, P321, DOI 10.1016/0167-4781(93)90165-A; Drake MT, 2000, MOL BIOL CELL, V11, P3723, DOI 10.1091/mbc.11.11.3723; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Fullekrug J, 1997, FEBS LETT, V404, P75, DOI 10.1016/S0014-5793(97)00097-5; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lee SY, 2000, J CELL SCI, V113, P1883; Lee SY, 2000, EXP CELL RES, V256, P515, DOI 10.1006/excr.2000.4845; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Ogasawara M, 2000, J BIOL CHEM, V275, P3221, DOI 10.1074/jbc.275.5.3221; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; Radhakrishna H, 1999, J CELL SCI, V112, P855; Schafer DA, 2000, TRAFFIC, V1, P892; SCHWEIZER A, 1993, J CELL SCI, V104, P671; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; Venkateswarlu K, 2000, BIOCHEM J, V345, P719, DOI 10.1042/0264-6021:3450719; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	37	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32302	32309		10.1074/jbc.M202898200	http://dx.doi.org/10.1074/jbc.M202898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12052827	hybrid			2022-12-25	WOS:000177718700125
J	Niu, XL; Peters, KG; Kontos, CD				Niu, XL; Peters, KG; Kontos, CD			Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; BLOOD-VESSEL FORMATION; TUMOR ANGIOGENESIS; VENOUS MALFORMATIONS; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; GROWTH; ACTIVATION; DOMAIN; ANGIOPOIETIN-1	Tie2 is an endothelial receptor tyrosine kinase that is required for both embryonic vascular development and tumor angiogenesis. There is considerable interest in understanding the mechanisms of Tie2 activation for therapeutic purposes. The recent solution of the Tie2 crystal structure suggests that Tie2 activity is autoinhibited by its carboxyl terminus. Here we investigated the role of the C tail in Tie2 activation, signaling, and function both in vitro and in vivo by deleting the C terminus of Tie2 (DeltaCT). Compared to wild type Tie2, in vitro autophosphorylation and kinase activity were significantly enhanced by the DeltaCT mutation. In NIH 3T3 cells expressing chimeric Tie2 receptors, both basal and ligand-induced tyrosine phosphorylation were markedly enhanced compared to wild type in several independent clones of Tie2-DeltaCT. Moreover, the DeltaCT mutation enhanced basal and ligand-dependent activation of Akt and extracellular signal-regulated kinase. Enhanced Akt activation correlated with significant inhibition of staurosporine-induced apoptosis. These findings demonstrate that the Tie2 C tail performs a novel negative regulatory role in Tie2 signaling and function, and they provide important insights into the mechanisms by which the Tie2 kinase is activated.	Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Procter & Gamble Co, Hlth Care Res Ctr, Mason, OH 45040 USA	Duke University; Duke University; Procter & Gamble	Kontos, CD (corresponding author), Duke Univ, Med Ctr, Div Cardiol, Dept Med, Box 3629, Durham, NC 27710 USA.			Kontos, Christopher/0000-0002-8056-3115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070165] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070165, HL 03557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Calvert JT, 1999, HUM MOL GENET, V8, P1279, DOI 10.1093/hmg/8.7.1279; Deng SJ, 2001, COMB CHEM HIGH T SCR, V4, P525; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; HUANG LW, 1995, ONCOGENE, V11, P2097; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kontos CD, 2002, MOL CELL BIOL, V22, P1704, DOI 10.1128/MCB.22.6.1704-1713.2002; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Siemeister G, 1999, CANCER RES, V59, P3185; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	35	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31768	31773		10.1074/jbc.M203995200	http://dx.doi.org/10.1074/jbc.M203995200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12082108	hybrid			2022-12-25	WOS:000177718700058
J	Picaud, T; Desbois, A				Picaud, T; Desbois, A			Electrostatic control of the isoalloxazine environment in the two-electron reduced states of yeast glutathione reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOAMIDE DEHYDROGENASE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; ACTIVE DISULFIDE; MIXED DISULFIDE; PIG-HEART; FLAVIN; ENZYME; CATALYSIS; REDOX	The resonance Raman spectra of the oxidized and two-electron reduced forms of yeast glutathione reductase are reported. The spectra of the oxidized enzyme indicate a low electron density for the isoalloxazine ring. As far as the two-electron reduced species are concerned, the spectral comparison of the NADPH-reduced enzyme with the glutathione- or dithiothreitol-reduced enzyme shows significant frequency differences for the flavin bands II, III, and VII. The shift of band VII was correlated with a change in steric or electronic interaction of the hydroxyl group of a conserved Tyr with the N-10-C-10a portion of the isoalloxazine ring. Upward shifts of bands II and III observed for the glutathione- or dithiothreitol-reduced enzyme indicate both a slight change in isoalloxazine conformation and a hydrogen bond strengthening at the N-1 and/or N-5 site(s). The formation of a mixed disulfide intermediate tends to slightly decrease the frequency of bands II, III, X, XI, and XIV. To account for the different spectral features observed for the NADPH- and glutathione-reduced species, several possibilities have been examined. In particular, we propose a hydrogen bonding modulation at the N-5 site of FAD through a variable conformation of an ammonium group of a conserved Lys residue. Changes in N-5(flavin)-protein interaction in the two-electron reduced forms of glutathione reductase are discussed in relation to a plausible mechanism of the regulation of the enzyme activity via a variable redox potential of FAD.	CEA Saclay, Dept Biol Joliot Curie, Sect Biophys Fonct Membranaires, Commissariat Energie, F-91191 Gif Sur Yvette, France; CEA Saclay, Ctr Natl Rech Sci, Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Desbois, A (corresponding author), CEA Saclay, Dept Biol Joliot Curie, Sect Biophys Fonct Membranaires, Commissariat Energie, F-91191 Gif Sur Yvette, France.	desbois@dsvidf.cea.fr						ABE M, 1987, SPECTROCHIM ACTA A, V43, P1027, DOI 10.1016/0584-8539(87)80175-7; AKIYAMA T, 1992, J AM CHEM SOC, V114, P6613, DOI 10.1021/ja00043a002; Arscott LD, 2000, BIOCHEMISTRY-US, V39, P4711, DOI 10.1021/bi9926431; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; BOWMAN WD, 1981, BIOCHEMISTRY-US, V20, P3313, DOI 10.1021/bi00514a051; BULGER JE, 1971, J BIOL CHEM, V246, P5578; BURTON K, 1953, BIOCHEM J, V54, P86, DOI 10.1042/bj0540086; CARLBERG I, 1977, BIOCHIM BIOPHYS ACTA, V484, P268, DOI 10.1016/0005-2744(77)90083-3; Chang FC, 1999, BIOCHEMISTRY-US, V38, P7168, DOI 10.1021/bi982203u; COLLINSON LP, 1995, GENE, V156, P123, DOI 10.1016/0378-1119(95)00026-3; DESBOIS A, 1989, BIOCHEMISTRY-US, V28, P8011, DOI 10.1021/bi00446a007; DISTEFANO MD, 1989, BIOCHEMISTRY-US, V28, P1168, DOI 10.1021/bi00429a035; ENGEL PC, 1967, BIOCHEM J, V105, P691, DOI 10.1042/bj1050691; FOX B, 1982, J BIOL CHEM, V257, P2498; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; HORECKER BL, 1948, J BIOL CHEM, V175, P385; HUBER PW, 1980, BIOCHEMISTRY-US, V19, P4568, DOI 10.1021/bi00561a005; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KITAGAWA T, 1979, BIOCHEMISTRY-US, V18, P1804, DOI 10.1021/bi00576a026; Krauth-Siegel RL, 1998, BIOCHEMISTRY-US, V37, P13968, DOI 10.1021/bi980637j; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; LEONDIADIS L, 1992, INORG CHEM, V31, P4691, DOI 10.1021/ic00048a044; LIVELY CR, 1990, J PHYS CHEM-US, V94, P3980, DOI 10.1021/j100373a021; LIVELY CR, 1986, BIOCHEM BIOPH RES CO, V136, P22, DOI 10.1016/0006-291X(86)90871-5; MAEDAYORITA K, 1994, BIOCHEMISTRY-US, V33, P6213, DOI 10.1021/bi00186a022; MASSEY V, 1965, J BIOL CHEM, V240, P4470; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1993, J MOL BIOL, V230, P1200, DOI 10.1006/jmbi.1993.1236; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MCFARLAND JT, 1987, RESONANCE RAMAN SPEC, V2, P211; MITTL PRE, 1994, PROTEIN SCI, V3, P799; MORRIS MD, 1986, SPECTROSCOPY BIOL SY, P395; MULLER F, 1983, TOP CURR CHEM, V108, P71; OLSON JA, 1953, J BIOL CHEM, V202, P841; PAI EF, 1983, J BIOL CHEM, V258, P1752; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; SAHLMAN L, 1989, J BIOL CHEM, V264, P8033; SCHMIDT J, 1983, BIOCHEMISTRY-US, V22, P76, DOI 10.1021/bi00270a011; SHINKAI S, 1985, J AM CHEM SOC, V107, P6286, DOI 10.1021/ja00308a021; Tegoni M, 1997, BIOCHEMISTRY-US, V36, P8932, DOI 10.1021/bi962425x; Veine DM, 1998, BIOCHEMISTRY-US, V37, P15575, DOI 10.1021/bi9811314; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WONG KK, 1988, BIOCHEMISTRY-US, V27, P7091, DOI 10.1021/bi00418a063	46	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31715	31721		10.1074/jbc.M202273200	http://dx.doi.org/10.1074/jbc.M202273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12077126	hybrid			2022-12-25	WOS:000177718700052
J	Tseng, YH; Ueki, K; Kriauciunas, KM; Kahn, CR				Tseng, YH; Ueki, K; Kriauciunas, KM; Kahn, CR			Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; ELEMENT-BINDING PROTEIN; FACTOR-I RECEPTOR; BROWN ADIPOCYTES; SIGNALING PATHWAY; CELL-SURVIVAL; FACTOR FKHR; PHOSPHATIDYLINOSITOL 3'-KINASE; GLUCOSE-HOMEOSTASIS	Insulin-like growth factor-1 (IGF-1) and insulin are known to prevent apoptosis. The signaling network of IGF-l and insulin occurs via multiple pathways involving different insulin receptor substrates (IRSs). To define their roles in the anti-apoptotic function of IGF-1 and insulin, we established brown pre-adipocyte cell lines from wild-type and IRS knockout (KO) animals. In response to 16 h of serum deprivation, IRS-1-deficient cells showed a significant decrease in response to IGF-1 protection from apoptosis, whereas no changes were observed in the IRS-2, IRS-3, or IRS-4 KO cells. Five hours after serum withdrawal, cells already began to undergo apoptosis. At this early time point, IGF-l and insulin were able to protect both wild-type and IRS-1 KO cells from death by 85-90%. After a longer period of serum deprivation, the protective ability of insulin and IGF-1 was decreased, and this was especially reduced in the IRS-1 KO cells. Reconstitution of these cells with IRS-1, IRS-2, IRS-3, or IRS-1/IRS-2 chimeras restored the anti-apoptotic effects of IGF-1, whereas overexpression of IRS-4 had no effect at long time points and actually reduced the effect of IGF-1 at the short time point. The biochemical basis of the defect in anti-apoptosis was not dependent on phosphorylation of mitogen-activated protein kinase; whereas phosphoinositide 3-kinase activity was decreased by 30% in IRS-1 KO cells. Akt phosphorylation was slightly reduced in these cells. Phosphorylation of the transcription factors cAMP response element-binding protein and FKHR by IGF-1 and insulin was markedly reduced in IRS-1 KO cells. In addition, both IGF-1 and insulin prevented caspase-3 cleavage in the wild-type cells, and this effect was greatly reduced in the IRS-1-deficient cells. These findings suggest that the IRS proteins may play differential roles in the anti-apoptotic effects of IGF-1 and insulin in brown pre-adipocytes, with IRS-1 being predominant, possibly acting through caspase-3-, CREB-, and FKHR-dependent mechanisms.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res,Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res,Dept Med, 1 Joslin Pl, Boston, MA 02215 USA.		Tseng, Yu-Hua/AAE-6471-2021; Kahn, Ronald/AAY-2435-2021	Tseng, Yu-Hua/0000-0003-2053-9559; Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055545, R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK101183, DK55545, DK33201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Algenstaedt PM, 1997, J BIOL CHEM, V272, P23696, DOI 10.1074/jbc.272.38.23696; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chaudhary LR, 2001, J CELL BIOCHEM, V81, P304, DOI 10.1002/1097-4644(20010501)81:2<304::AID-JCB1045>3.3.CO;2-L; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Ma YC, 2002, TRENDS CARDIOVAS MED, V12, P46, DOI 10.1016/S1050-1738(01)00138-4; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; McDonald RB, 1999, J BIOENERG BIOMEMBR, V31, P507, DOI 10.1023/A:1005404708710; Minshall C, 1999, J IMMUNOL, V162, P4542; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; Valverde AM, 1999, DIABETES, V48, P2122, DOI 10.2337/diabetes.48.11.2122; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; XIE HJ, 1995, J IMMUNOL, V154, P1717; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	85	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31601	31611		10.1074/jbc.M202932200	http://dx.doi.org/10.1074/jbc.M202932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12082100	hybrid			2022-12-25	WOS:000177718700040
J	Machida, K; Hayashi, Y; Osada, H				Machida, K; Hayashi, Y; Osada, H			A novel adenine nucleotide translocase inhibitor, MT-21, induces cytochrome c release by a mitochondrial permeability transition-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; ADP/ATP CARRIER; CYCLOPHILIN-D; LIVER-MITOCHONDRIA; N-ETHYLMALEIMIDE; APOPTOSIS; PORE; MEMBRANE; BAX; PROTEIN	The release of cytochrome c from mitochondria is a critical step during apoptosis. In order to study this process, we have used a synthetic compound, MT-21, that is able to initiate release of cytochrome c from isolated mitochondria. We demonstrate that MT-21 significantly inhibits ADP transport activity in mitochondria and reduces binding of the adenine nucleotide translocase (ANT) to a phenylarsine oxide affinity matrix. These results suggest that ANT, one of the components of the mitochondrial permeability transition (PT) pore, is the molecular target for MT-21. In agreement with this, the MT-21-induced cytochrome c release was effectively inhibited in the presence of ANT ligands, and MT-21 could dissociate ANT from a complex with a glutathione S-transferase-cyclophilin D fusion protein. Interestingly, we also found that specific inhibitors of ANT such as MT-21 and atractyloside could induce cytochrome c release without mitochondrial swelling and that this event was highly dependent on the presence of Mg2+. These results suggest that although ANT resides in the mitochondrial inner membrane, specific ANT inhibitors can induce cytochrome c release without having an effect on inner membrane permeability. Therefore, MT-21 can be a powerful tool for studying the mechanism of PT-independent cytochrome c release from mitochondria.	RIKEN, Antibiot Lab, Wako, Saitama 3510198, Japan; Sci Univ Tokyo, Fac Engn, Dept Ind Chem, Shinjuku Ku, Tokyo 1628601, Japan	RIKEN; Tokyo University of Science	Osada, H (corresponding author), RIKEN, Antibiot Lab, Hirosawa 2-1, Wako, Saitama 3510198, Japan.		Osada, Hiroyuki/AAY-6254-2020; Osada, Hiroyuki/N-4305-2014					Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Belzacq AS, 2001, CANCER RES, V61, P1260; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BOULAY F, 1984, BIOCHEMISTRY-US, V23, P4807, DOI 10.1021/bi00315a042; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; DAVIDSON AM, 1990, BIOCHEM J, V268, P147, DOI 10.1042/bj2680147; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Hashimoto M, 2000, ARCH BIOCHEM BIOPHYS, V384, P163, DOI 10.1006/abbi.2000.2085; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Johnson N, 1999, EUR J BIOCHEM, V263, P353, DOI 10.1046/j.1432-1327.1999.00490.x; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kakeya H, 1997, J MED CHEM, V40, P391, DOI 10.1021/jm960719a; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Nishikimi A, 2001, BIOCHEM J, V356, P621, DOI 10.1042/0264-6021:3560621; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Watabe M, 2000, CANCER RES, V60, P5214; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	44	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31243	31248		10.1074/jbc.M204564200	http://dx.doi.org/10.1074/jbc.M204564200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063261	hybrid			2022-12-25	WOS:000177579800106
J	Sharma, M; Chuang, WW; Sun, ZJ				Sharma, M; Chuang, WW; Sun, ZJ			Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3 beta inhibition and nuclear beta-catenin accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PROSTATE-CANCER; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVITY; XENOPUS EMBRYOS; AKT PATHWAY; RECEPTOR; PHOSPHORYLATION; ACTIVATION; CELLS	PI3K/Akt plays a critical role in prostate cancer cell growth and survival. Recent studies have shown that the effect of PI3K/Akt in prostate cells is mediated through androgen signaling. The PI3K inhibitor, LY294002, and a tumor suppressor, PTEN, negatively regulate the PI3K/Akt pathway and repress AR activity. However, the molecular mechanisms whereby PI3K/Akt and PTEN regulate the androgen pathway are currently unclear. Here, we demonstrate that blocking the PI3K/Akt pathway reduces the expression of an endogenous AR target gene. Moreover, we show that the repression of AR activity by LY294002 is mediated through phosphorylation and inactivation of GSK3beta, a downstream substrate of PI3K/Akt, which results in the nuclear accumulation of beta-catenin. Given the recent evidence that beta-catenin acts as a coactivator of AR, our findings suggest a novel mechanism by which PI3K/Akt modulates androgen signaling. In a PTEN-null prostate cancer cell line, we show that PTEN expression reduces beta-catenin-mediated augmentation of AR transactivation. Using the mutants of beta-catenin, we further demonstrate that the repressive effect of PTEN is mediated by a GSK3beta-regulated degradation of beta-catenin. Our results delineate a novel link among the PI3K, wnt, and androgen pathways and provide fresh insights into the mechanisms of prostate tumor development and progression.	Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Sun, ZJ (corresponding author), Stanford Univ, Sch Med, Dept Surg, R135,Edwards Bldg, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [R01CA087767, R01CA070297, R29CA070297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061002] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA070297-07, R01 CA070297-06A1, R01 CA070297-11A2, R01 CA070297-10, CA 70297, CA 87767, R01 CA070297, R01 CA087767-03, R01 CA070297-09, R01 CA087767-02, R01 CA087767-05, R01 CA087767-01A2, R01 CA087767, R01 CA070297-12, R01 CA070297-08, R01 CA087767-04] Funding Source: Medline; NIDDK NIH HHS [R01 DK061002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Blok LJ, 1996, ENDOCR RES, V22, P197, DOI 10.3109/07435809609030508; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Hayes SA, 2001, CANCER RES, V61, P2112; Isaacs J T, 1989, Cancer Treat Res, V46, P177; Jenster G, 1999, SEMIN ONCOL, V26, P407; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Monick MM, 2001, J IMMUNOL, V167, P5977, DOI 10.4049/jimmunol.167.10.5977; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Polakis P, 2000, GENE DEV, V14, P1837; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Truica CI, 2000, CANCER RES, V60, P4709; Truica CI, 2001, AACR ANN M P, V42, P693; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; van de Wetering M, 2001, CANCER RES, V61, P278; Voeller HJ, 1998, CANCER RES, V58, P2520; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Wen Y, 2000, CANCER RES, V60, P6841; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	47	254	259	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30935	30941		10.1074/jbc.M201919200	http://dx.doi.org/10.1074/jbc.M201919200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063252	hybrid			2022-12-25	WOS:000177579800069
J	Gavrilyuk, V; Dello Russo, C; Heneka, MT; Pelligrino, D; Weinberg, G; Feinstein, DL				Gavrilyuk, V; Dello Russo, C; Heneka, MT; Pelligrino, D; Weinberg, G; Feinstein, DL			Norepinephrine increases I kappa B alpha expression in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-A; GENE-EXPRESSION; CYCLIC-AMP; RAT; PROMOTER; ACTIVATION; TRANSCRIPTION; INDUCTION; RECEPTOR	The neurotransmitter norepinephrine (NE) can inhibit inflammatory gene expression in glial cells; however, the mechanisms involved are not clear. In primary astrocytes, NE dose-dependently increased the expression of inhibitory IkappaBalpha protein accompanied by an increase in steady state levels of IkappaBalpha mRNA. Maximal increases were observed at 30-60 min for the mRNA and at 4 h for protein, and these effects were mediated by NE binding to beta-adrenergic receptors. NE activated a 1.3-kilobase IkappaBalpha promoter transfected into astrocytes or C6 glioma cells, and this activation was prevented by a beta-antagonist and by protein kinase A inhibitors but not by an NFkappaB inhibitor. NE increased IkappaBalpha protein in both the cytosolic and the nuclear fractions, suggesting an increase in nuclear uptake of IkappaBalpha. IkappaBalpha was detected in the frontal cortex of normal adult rats, and its levels were reduced if central NE levels were depleted by lesion of the locus ceruleus. The reduction of brain IkappaBalpha levels was paralleled by increased inflammatory responses to lipopolysaccharide. These results demonstrate that IkappaBalpha expression is regulated by NE at both transcriptional and post-transcriptional levels, which could contribute to the observed anti-inflammatory properties of NE in vitro and in vivo.	Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA; Univ Bonn, Dept Neurol, D-50236 Bonn, Germany; Vet Affairs Chicago Hlth Care Syst W Side Div, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Bonn	Feinstein, DL (corresponding author), 1819 W Polk St,MC519,Rm 544, Chicago, IL 60612 USA.	dlfeins@uic.edu	Dello Russo, Cinzia/K-5283-2018; Heneka, Michael/AAE-8011-2019; feinstein, doug/M-9414-2019; Heneka, Michael/E-8072-2015	Dello Russo, Cinzia/0000-0002-2538-3832; Heneka, Michael/0000-0003-4996-1630				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Ballestas ME, 1997, J NEUROCHEM, V69, P1438; Benveniste EN, 1995, BRAIN BEHAV IMMUN, V9, P304, DOI 10.1006/brbi.1995.1029; Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x; CHELMICKASCHORR E, 1989, J NEUROIMMUNOL, V25, P203, DOI 10.1016/0165-5728(89)90138-0; Chin JH, 1996, J CLIN INVEST, V97, P2316, DOI 10.1172/JCI118674; Cho S, 2001, GLIA, V33, P324, DOI 10.1002/1098-1136(20010315)33:4<324::AID-GLIA1031>3.0.CO;2-M; De Keyser J, 1999, NEUROLOGY, V53, P1628, DOI 10.1212/WNL.53.8.1628; Delerive P, 2000, J BIOL CHEM, V275, P36703, DOI 10.1074/jbc.M004045200; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; DeMeester SL, 1997, ARCH SURG-CHICAGO, V132, P1283; Dragon S, 2001, AM J PHYSIOL-REG I, V280, pR870, DOI 10.1152/ajpregu.2001.280.3.R870; Farmer P, 2000, AM J PHYSIOL-LUNG C, V279, pL675, DOI 10.1152/ajplung.2000.279.4.L675; FEINSTEIN DL, 1993, J NEUROCHEM, V60, P1945, DOI 10.1111/j.1471-4159.1993.tb13425.x; Feinstein DL, 1998, J NEUROCHEM, V70, P1484; FROHMAN EM, 1988, J NEUROIMMUNOL, V17, P89, DOI 10.1016/0165-5728(88)90017-3; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Gavrilyuk V, 2001, J NEUROCHEM, V78, P129, DOI 10.1046/j.1471-4159.2001.00375.x; Gravel M, 2000, J NEUROCHEM, V75, P1940, DOI 10.1046/j.1471-4159.2000.0751940.x; Heneka MT, 2002, J NEUROSCI, V22, P2434, DOI 10.1523/JNEUROSCI.22-07-02434.2002; Herring AC, 1998, BIOCHEM PHARMACOL, V55, P1013, DOI 10.1016/S0006-2952(97)00630-8; Imura T, 1999, J NEUROSCI, V19, P9768; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Kamthong PJ, 2001, BIOCHEM J, V356, P525, DOI 10.1042/0264-6021:3560525; Lacroix S, 1998, BRAIN PATHOL, V8, P625, DOI 10.1111/j.1750-3639.1998.tb00189.x; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lin CS, 2001, BIOCHEM BIOPH RES CO, V280, P693, DOI 10.1006/bbrc.2000.4221; MANN DMA, 1983, CLIN NEUROPATHOL, V2, P1; Manna SK, 1998, J IMMUNOL, V161, P2873; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Meng XZ, 1996, CARDIOVASC RES, V32, P374, DOI 10.1016/0008-6363(96)00078-8; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; Mustafa SB, 1998, J BIOL CHEM, V273, P5073, DOI 10.1074/jbc.273.9.5073; Nisoli E, 2001, INT J OBESITY, V25, P1421, DOI 10.1038/sj.ijo.0801788; Petrova TV, 1999, J BIOL CHEM, V274, P28823, DOI 10.1074/jbc.274.40.28823; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SERKKOLA E, 1993, FEBS LETT, V334, P327, DOI 10.1016/0014-5793(93)80704-X; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stasiolek M, 2000, J BIOL CHEM, V275, P24847, DOI 10.1074/jbc.M910284199; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; WIEGMANN K, 1995, J NEUROIMMUNOL, V56, P201, DOI 10.1016/0165-5728(94)00153-F; WILLIS SA, 1995, J IMMUNOL, V154, P1399; Woltje M, 2000, J NEUROCHEM, V74, P1355, DOI 10.1046/j.1471-4159.2000.0741355.x; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; Yan F, 1999, J BIOL CHEM, V274, P36631, DOI 10.1074/jbc.274.51.36631; Zeinstra E, 2000, NEUROSCI LETT, V289, P75, DOI 10.1016/S0304-3940(00)01254-4; Zhang Wen Ling, 2001, Kobe Journal of Medical Sciences, V47, P77	48	65	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29662	29668		10.1074/jbc.M203256200	http://dx.doi.org/10.1074/jbc.M203256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050158	hybrid			2022-12-25	WOS:000177509300041
J	Palmero, I; Murga, M; Zubiaga, A; Serrano, M				Palmero, I; Murga, M; Zubiaga, A; Serrano, M			Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2	ONCOGENE			English	Article						ARF; p53; E2F; tumour suppressor; oncogene	THYMIC NEGATIVE SELECTION; TUMOR-SUPPRESSOR; DNA-DAMAGE; TRANSCRIPTION FACTOR; INK4A LOCUS; S-PHASE; P53-DEPENDENT APOPTOSIS; CELLULAR PROLIFERATION; GROWTH-CHARACTERISTICS; UV-IRRADIATION	The ARF tumour suppressor protein (p14(ARF) in human and p19(ARF) in mouse) is a major mediator of the activation of p53 in response to oncogenic stress. Little is known about the signalling pathways connecting oncogenic stimuli to the activation of ARF. Regulation of ARF occurs primarily at the transcriptional level and several modulators of ARF transcription have been identified. Notably, ectopic expression of E2F1 upregulates ARF transcriptionally, and both E2F1 and ARF have been implicated in apoptosis and cell-cycle arrest. We have used primary mouse fibroblasts deficient for E2F1, E2F2, or both to determine the possible role of these E2F proteins as upstream regulators of ARF in response to oncogenic stimuli and other stresses. In particular, we have studied the effects of oncogenic Ras and the viral oncoprotein E1A on ARF levels, neoplastic transformation, and sensitization to apoptosis. We have also examined the behaviour of the E2F-deficient MEFs with respect to immortalization and sensitivity to DNA damage. None of the ARF-mediated responses that we have analysed is significantly affected in E2F1(-/-), E2F2(-/-) or E2F1/2(-/-) MEFs, and ARF is upregulated normally in all cases. Taken together, our results indicate that the activation of ARF in response to oncogenic stress can occur by E2F1- and E2F2-independent mechanisms. This challenges previous suggestions implicating E2F factors as key mediators in the activation of ARF by oncogenic stress.	CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Basque Country, Fac Sci, Dept Anim Biol & Genet, E-48080 Bilbao, Spain; Univ Salamanca, CSIC, Inst Mol & Cellular Biol Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Serrano, M (corresponding author), CSIC, Natl Biotechnol Ctr, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		zubiaga, ana/S-3457-2019; Palmero, Ignacio/B-4346-2013; Serrano, Manuel/H-2634-2015	zubiaga, ana/0000-0002-2132-9708; Serrano, Manuel/0000-0001-7177-9312				AMRTELLI F, 2001, P NATL ACAD SCI USA, V98, P4455; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BRUMMELKAMP TR, 2001, J BIOL CHEM, V17, P17; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARVEY M, 1993, ONCOGENE, V8, P2457; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Huang YY, 1997, CANCER RES, V57, P3640; Humbert PO, 2000, GENE DEV, V14, P690; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2000, GENE DEV, V14, P1797; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Meng RD, 1999, INT J ONCOL, V14, P5; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 2001, CELL, V106, P531, DOI 10.1016/S0092-8674(01)00486-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	88	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	2002	21	19					2939	2947		10.1038/sj/onc/1205371	http://dx.doi.org/10.1038/sj/onc/1205371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082524				2022-12-25	WOS:000175262700001
J	Saito, T; Mitsui, K; Hamada, Y; Tsurugi, K				Saito, T; Mitsui, K; Hamada, Y; Tsurugi, K			Regulation of the Gts1p level by the ubiquitination system to maintain metabolic oscillations in the continuous culture of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; UBA DOMAIN; PROTEIN; GENE; SYNCHRONIZATION; DEGRADATION; PROTEASOME; MONOUBIQUITINATION; INTERNALIZATION; ARABIDOPSIS	Yeast cells exhibit sustained ultradian oscillations of energy metabolism in coupling with cell cycle and stress resistance oscillations in continuous culture. We have reported that the rhythmic expression of Gts1p is important for the maintenance of ultradian rhythms. Structurally, Gts1p contains sequence motifs similar to N-degron and the ubiquitin association domain, raising the possibility that the Gts1p level is regulated by degradation via ubiquitination. When the lysine residue at the putative ubiquitination site of the N-degron was substituted with arginine, both the protein level and half-life of mutant Gts1p increased. During continuous culture, the protein level of the mutant Gts1p was elevated and did not fluctuate, leading to the disappearance of metabolic oscillation within a day. Furthermore, using three Gts1ps containing mutations in the ubiquitin association domain, we showed that the lower the binding activity of the mutant Gts1ps for polyubiquitin in vitro, the higher the protein level in vivo. Expression of the mutant Gts1ps in the continuous culture resulted in an increase in Gts1p and early loss of the oscillation. Therefore, Gts1p is degraded through conjugation with ubiquitin, and the UBA domain promoted the degradation of ubiquitinated Gts1p, causing a fluctuation in protein level, which is required for the maintenance of metabolic oscillations.	Yamanashi Med Univ, Dept Biochem 2, Yamanashi 4093898, Japan; Yamanashi Med Univ, Dept Orthoped, Yamanashi 4093898, Japan	University of Yamanashi; University of Yamanashi	Tsurugi, K (corresponding author), Yamanashi Med Univ, Dept Biochem 2, 1110 Shimokato, Yamanashi 4093898, Japan.							Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; CHEN CI, 1990, BIOTECHNOL BIOENG, V36, P28, DOI 10.1002/bit.260360105; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Goldbeter A., 1996, BIOCH OSCILLATIONS C, P31, DOI 10.1017/CBO9780511608193.005; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Kawabata K, 1999, EUR J BIOCHEM, V259, P112, DOI 10.1046/j.1432-1327.1999.00008.x; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lucero P, 2000, J BACTERIOL, V182, P241, DOI 10.1128/JB.182.1.241-243.2000; Maki CG, 1996, CANCER RES, V56, P2649; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Nelson DC, 2000, CELL, V101, P331, DOI 10.1016/S0092-8674(00)80842-9; NICOLIS G, 1977, SELF ORG NONEQUILIBR, P334; PARULEKAR SJ, 1986, BIOTECHNOL BIOENG, V28, P700, DOI 10.1002/bit.260280509; PORRO D, 1988, BIOTECHNOL BIOENG, V32, P411, DOI 10.1002/bit.260320402; PRIGOGIN.I, 1969, NATURE, V223, P913, DOI 10.1038/223913a0; Somers DE, 2000, CELL, V101, P319, DOI 10.1016/S0092-8674(00)80841-7; STRASSLE C, 1988, J BIOTECHNOL, V7, P299, DOI 10.1016/0168-1656(88)90042-9; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Tonozuka H, 2001, J BIOCHEM-TOKYO, V130, P589, DOI 10.1093/oxfordjournals.jbchem.a003023; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Wang JQ, 2001, FEBS LETT, V489, P81, DOI 10.1016/S0014-5793(01)02083-X; Wang JQ, 2000, FEMS MICROBIOL LETT, V189, P9, DOI 10.1111/j.1574-6968.2000.tb09198.x; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939	26	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33624	33631		10.1074/jbc.M201909200	http://dx.doi.org/10.1074/jbc.M201909200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12070147	hybrid			2022-12-25	WOS:000177959100014
J	Decraene, D; Agostinis, P; Bouillon, R; Degreef, H; Garmyn, M				Decraene, D; Agostinis, P; Bouillon, R; Degreef, H; Garmyn, M			Insulin-like growth factor-1-mediated AKT activation postpones the onset of ultraviolet B-induced apoptosis, providing more time for cyclobutane thymine dimer removal in primary human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PROTEIN-KINASE-B; NUCLEOTIDE EXCISION-REPAIR; SERINE-THREONINE KINASE; GLOBAL GENOMIC REPAIR; NF-KAPPA-B; IGF-I; RNA-POLYMERASE; FACTOR-ALPHA; DNA-DAMAGE	Insulin-like growth factor-1 (IGF-1) acts as a potent survival factor in numerous cell lines, primarily through activation of the AKT signaling pathway. Although some targets of this pathway have known antiapoptotic functions, its relationship with the improved survival of cells after exposure to environmental stresses, including UVB, remains largely unclear. We report that in growth factor-deprived keratinocytes, IGF-1 significantly and consistently delayed the onset of UVB-induced apoptosis by > 7 h. This delay allowed IGF-1-supplemented keratinocytes to repair significantly more cyclobutane thymine dimers than their growth factor-deprived counterparts. This increase in cyclobutane thymine removal resulted in enhanced survival if the amount of DNA damage was not too high. To increase cell survival after UVB irradiation, IGF-1 supplementation was required only during this initial time period in which extra repair was executed. Finally, we show that IGF-1 mediated this delay in the onset of UVB-induced apoptosis through activation of the AKT signaling pathway. We therefore believe that the AKT signaling pathway increases cell survival after a genotoxic insult such as UVB irradiation not by inhibiting the apoptotic stimulus, but only by postponing the induction of apoptosis, giving the DNA repair mechanism more time to work.	Katholieke Univ Leuven, Dept Dermatol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven	Garmyn, M (corresponding author), Univ Hosp St Raphael, Dept Dermatol, Kapucijnenvoer 33, B-3000 Louvain, Belgium.		Agostinis, Patrizia/ABI-1177-2020; Agostinis, Patrizia/AAO-2468-2020	Agostinis, Patrizia/0000-0003-1314-2115; 				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BATCH JA, 1994, J CLIN ENDOCR METAB, V79, P1444, DOI 10.1210/jc.79.5.1444; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiGiovanni J, 2000, CANCER RES, V60, P1561; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; GILCHREST BA, 1983, J INVEST DERMATOL S1, V81, P184; Girnita L, 2000, CANCER RES, V60, P5278; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KRANE JF, 1991, J INVEST DERMATOL, V96, P419, DOI 10.1111/1523-1747.ep12469799; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Ljungman M, 1996, ONCOGENE, V13, P823; McCarthy MJ, 1997, PHOTOCHEM PHOTOBIOL, V66, P356, DOI 10.1111/j.1751-1097.1997.tb03158.x; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Ozes ON, 1999, NATURE, V401, P82; Pourzand C, 1999, PHOTOCHEM PHOTOBIOL, V70, P380, DOI 10.1111/j.1751-1097.1999.tb08239.x; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	49	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32587	32595		10.1074/jbc.M111106200	http://dx.doi.org/10.1074/jbc.M111106200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12070137	hybrid			2022-12-25	WOS:000177859000027
J	Klinger, M; Kudlacek, O; Seidel, MG; Freissmuth, M; Sexl, V				Klinger, M; Kudlacek, O; Seidel, MG; Freissmuth, M; Sexl, V			MAP kinase stimulation by cAMP does not require RAP1 but SRC family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; A(2A)-ADENOSINE RECEPTOR; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; C-SRC; B-RAF; BINDING; EFFECTOR; MEMBRANE	The small G protein RAP1 and the kinase B-RAF have been proposed to link elevations of cAMP to activation of ERK/mitogen-activated protein (MAP) kinase. In order to delineate signaling pathways that link receptor. generated cAMP to the activation of MAP kinase, the human A(2A)-adenosine receptor, a prototypical G(8)-coupled receptor, was heterologously expressed in Chinese hamster ovary cells (referred as CHO-A(2A) cells). In CHO-A(2A) cells, the stimulation of the A(2A)-receptor resulted in an activation of RAP1 and formation of RAP1-B-RAF complexes. However, overexpression of a RAP1 GTPase-activating protein (RAP1GAP), which efficiently clamped cellular RAP1 in the inactive GDP-bound form, did not affect A(2A)-agonist-mediated MAP kinase stimulation. In contrast, the inhibitor of protein kinase A H89 efficiently suppressed A(2A)-agonist-mediated MAP kinase stimulation. Neither dynamin-dependent receptor internalization nor receptor-promoted shedding of matrix-bound growth factors accounted for A(2A)-receptor-dependent MAP kinase activation. PP1, an inhibitor of SRC family kinases, blunted both the A(2A)-receptor- and the forskolin-induced MAP kinase stimulation (IC50 = 50 nM); this was also seen in PC12 cells, which express the A(2A)-receptor endogenously, and in NIH3T3 fibroblasts, in which cAMP causes MAP kinase stimulation. In the corresponding murine fibroblast cell line SYF, which lacks the ubiquitously expressed SRC family kinases SRC, YES, and FYN, forskolin barely stimulated MAP kinase; this reduction was reversed in cells in which c-SRC had been reintroduced. These findings show that activation of MAP kinase by cAMP requires a SRC family kinase that lies downstream of protein kinase A. A role for RAP1, as documented for the beta(2)-adrenergic receptor, is apparently contingent on receptor endocytosis.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria	University of Vienna	Freissmuth, M (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	freissmuth@univie.ac.at	; Seidel, Markus G/N-9951-2017; Sexl, Veronika/B-8657-2016	Kudlacek, Oliver/0000-0002-3086-8551; Freissmuth, Michael/0000-0001-9398-1765; Seidel, Markus G/0000-0003-0981-8661; Klinger, Markus/0000-0001-8381-1543; Sexl, Veronika/0000-0001-9363-0412				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Arslan G, 1997, NEUROPHARMACOLOGY, V36, P1319, DOI 10.1016/S0028-3908(97)00090-7; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Klinger M, 2002, CELL SIGNAL, V14, P99, DOI 10.1016/S0898-6568(01)00235-2; Lindquist JM, 2000, J BIOL CHEM, V275, P22670, DOI 10.1074/jbc.M909093199; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PALMER TM, 1994, MOL PHARMACOL, V45, P1082; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; POLAKIS P, 1992, J BIOL CHEM, V267, P10780; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schulte G, 2000, MOL PHARMACOL, V58, P477, DOI 10.1124/mol.58.3.477; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Traxler P, 1997, J MED CHEM, V40, P3601, DOI 10.1021/jm970124v; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALKER F, 1993, J BIOL CHEM, V268, P19552; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	43	67	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32490	32497		10.1074/jbc.M200556200	http://dx.doi.org/10.1074/jbc.M200556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082090	hybrid			2022-12-25	WOS:000177859000014
J	Lee, HW; Ahn, DH; Crawley, SC; Li, JD; Gum, JR; Basbaum, CB; Fan, NQ; Szymkowski, DE; Han, SY; Lee, BH; Sleisenger, MH; Kim, YS				Lee, HW; Ahn, DH; Crawley, SC; Li, JD; Gum, JR; Basbaum, CB; Fan, NQ; Szymkowski, DE; Han, SY; Lee, BH; Sleisenger, MH; Kim, YS			Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GENE-EXPRESSION; EPITHELIAL-CELLS; SIGNALING PATHWAYS; RETINOIC ACID; COLON-CANCER; DNA-BINDING; MAP KINASE; ACTIVATION; PHOSPHORYLATION	MUC2 is a secretory mucin normally expressed by goblet cells of the intestinal epithelium. It is overexpressed in mucinous type colorectal cancers but down-regulated in colorectal adenocarcinoma. Phorbol 12-myristate 13-acetate (PMA) treatment of colon cancer cell lines increases MUC2 expression, so we have undertaken a detailed analysis of the effects of PMA on the promoter activity of the 5'-flanking region of the MUC2 gene using stably and transiently transfected promoter reporter vectors. Protein kinase C inhibitors (bisindolylmaleimide, calphostin C) and inhibitors of mitogen-activated protein/extracellular signal regulated kinase kinase (MEK) (PD98059 and U0126) suppressed up-regulation of MUC2. Sre tyrosine kinase inhibitor PP2, a protein kinase A inhibitor (KT5720), and a p38 inhibitor (SB 203580) did not affect transcription. Western blotting and reverse transcription-PCR analysis confirmed these results. In addition, co-transfections with mutants of Ras, Raf, and MEK showed that the induction of MUC2 promoter activity by PMA required these three signaling proteins. Our results demonstrate that PMA activates protein kinase C, stimulating MAP kinase through a Ras- and Raf-dependent mechanism. An important role for nuclear factor kappaB (NF-kappaB) was also demonstrated using the inhibitor caffeic acid phenethyl ester and electrophoretic mobility shift assays. Such identification of pathways involved in MUC2 upregulation by PMA in the HM3 colon cancer cell line may serve as a model for the effects of cytokines and growth factors, which regulate MUC2 expression during the progression of colorectal cancer.	Vet Affairs Med Ctr, Gastrointestinal Res Lab 151M2, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ So Calif, Gonda Dept Cell & Mol Biol, House Ear Inst, Los Angeles, CA USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA USA; Roche Biosci, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; House Research Institute; University of Southern California; University of Southern California; Roche Holding	Kim, YS (corresponding author), Vet Affairs Med Ctr, Gastrointestinal Res Lab 151M2, 4150 Clement St, San Francisco, CA 94121 USA.			Li, Jian-Dong/0000-0002-5593-050X; Szymkowski, David/0000-0002-8934-7902	NATIONAL CANCER INSTITUTE [R01CA024321] Funding Source: NIH RePORTER; NCI NIH HHS [CA24321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Mulla F, 1999, J PATHOL, V187, P433, DOI 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; Han SY, 2000, INT J ONCOL, V17, P487; Hanski C, 1997, LAB INVEST, V77, P685; HO SB, 1993, CANCER RES, V53, P641; Hong DH, 1999, AM J PHYSIOL-GASTR L, V277, pG1041, DOI 10.1152/ajpgi.1999.277.5.G1041; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koo JS, 1999, BIOCHEM J, V338, P351, DOI 10.1042/0264-6021:3380351; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li YQ, 1999, J IMMUNOL, V162, P3316; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Sambrook J., 2002, MOL CLONING LAB MANU; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sylvester PA, 2001, J PATHOL, V195, P327; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VELCICH A, 1993, J BIOL CHEM, V268, P13956; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Yoon JH, 1997, AM J RESP CELL MOL, V16, P724, DOI 10.1165/ajrcmb.16.6.9191474	40	93	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32624	32631		10.1074/jbc.M200353200	http://dx.doi.org/10.1074/jbc.M200353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12077118	hybrid			2022-12-25	WOS:000177859000031
J	Berg, P; Pongratz, I				Berg, P; Pongratz, I			Two parallel pathways mediate cytoplasmic localization of the dioxin (Aryl hydrocarbon) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HELIX-LOOP-HELIX; REGULATES INTRACELLULAR-LOCALIZATION; X-ASSOCIATED PROTEIN-2; DNA-BINDING ACTIVITY; NUCLEAR EXPORT; SUBCELLULAR-LOCALIZATION; CYTOSKELETAL NETWORKS; CORE COMPLEX; AH RECEPTOR	The dioxin receptor is a ligand-dependent transcription factor that mediates the biological effects of dioxin and related environmental pollutants. In the absence of ligand the receptor is present in the cytoplasmic compartment of the cell associated with the hsp90-dependent chaperone complex. This complex regulates several functions of the receptor such as ligand binding and nuclear import. Furthermore, intracellular localization of the receptor is modulated by multiple factors such as the export protein CRM-1 and the hsp90-associated immunophilin XAP-2. We have identified the mechanism of XAP-2-induced cytoplasmic localization of the receptor and studied the potential cross-talk between CRM-1 and XAP-2. We show that XAP-2 anchors the ligand-free receptor to cytoskeletal structures. This effect is blocked upon treatment with the actin inhibitor cytochalasin B, whereas the tubulin inhibitor colchicine had no effect on receptor localization. In addition, we show that the receptor interacts with CRM-1 both in the presence and absence of ligand. CRM-1-mediated nuclear export occurs independently of XAP-2. Our data provide evidence that CRM-1 and XAP-2 act in parallel through different mechanisms and target different interfaces of the receptor. These results suggest that two pathways cooperate to localize the non-activated receptor in the cytoplasmic compartment of the cell.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Pongratz, I (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.							ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Berg P, 2001, J BIOL CHEM, V276, P43231, DOI 10.1074/jbc.M105261200; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; DEINUM J, 1986, BIOCHIM BIOPHYS ACTA, V870, P226, DOI 10.1016/0167-4838(86)90226-8; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heid SE, 2000, MOL PHARMACOL, V57, P82; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; Ma Q, 1997, J BIOL CHEM, V272, P8878; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PERROTAPPLANAT M, 1992, J CELL BIOL, V119, P337, DOI 10.1083/jcb.119.2.337; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Pollenz RS, 2000, MOL CELL BIOL, V20, P6095, DOI 10.1128/MCB.20.16.6095-6104.2000; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; WELCH WJ, 1985, MOL CELL BIOL, V5, P1571, DOI 10.1128/MCB.5.7.1571; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	38	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32310	32319		10.1074/jbc.M203351200	http://dx.doi.org/10.1074/jbc.M203351200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12065584	hybrid			2022-12-25	WOS:000177718700126
J	Holmberg, C; Katz, S; Lerdrup, M; Herdegen, T; Jaattela, M; Aronheim, A; Kallunki, T				Holmberg, C; Katz, S; Lerdrup, M; Herdegen, T; Jaattela, M; Aronheim, A; Kallunki, T			A novel specific role for I kappa B kinase complex-associated protein in cytosolic stress signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; JUN ACTIVATION DOMAIN; NERVE GROWTH-FACTOR; C-JUN; FAMILIAL DYSAUTONOMIA; TRANSDUCTION PATHWAY; SCAFFOLD PROTEINS; INDUCED APOPTOSIS; MAP KINASES; IKK COMPLEX	We demonstrate here a novel role for the IkappaB kinase complex-associated protein (IKAP) in the regulation of activation of the mammalian stress response via the c-Jun N-terminal kinase (JNK)-signaling pathway. We cloned IKAP as a JNK-associating protein using the Ras recruitment yeast two-hybrid system. IKAP efficiently and specifically enhanced JNK activation induced by ectopic expression of MEKK1 and ASK1, upstream activators of JNK. Importantly, IKAP also enhanced JNK activation induced by ultraviolet light irradiation as well as treatments with tumor necrosis factor or epidermal growth factor. The JNK association site in IKAP was mapped to the C-terminal part of IKAP. Interestingly, this region is deleted from IKAP expressed in the autonomous nervous system of the patients affected by familial dysautonomia. Ectopic expression of this C-terminal fragment of IKAP was sufficient to support JNK activation. Taken together, our data demonstrate a novel role for IKAP in the regulation of the JNK-mediated stress signaling. Additionally, our results point to a role of JNK signaling in familial dysautonomia and, thus, further support the involvement of JNK signaling in the development, survival, and degeneration of the sensory and autonomic nervous system.	Danish Canc Soc, Apoptosis Lab, DK-2100 Copenhagen, Denmark; Technion Israel Inst Technol, Dept Mol Genet, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Christian Albrechts Univ Kiel Klinikum, Inst Pharmacol, D-24105 Kiel, Germany	Danish Cancer Society; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Kiel; Schleswig Holstein University Hospital	Kallunki, T (corresponding author), Danish Canc Soc, Apoptosis Lab, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Holmberg, Christian/L-8011-2014; herdegen, thomas/E-5135-2010; Jäättelä, Marja/AAT-7932-2021	Holmberg, Christian/0000-0001-9224-0543; Jäättelä, Marja/0000-0001-5950-7111; Aronheim, Ami/0000-0002-8575-4092; Kallunki, Tuula/0000-0002-8571-383X; Lerdrup, Mads/0000-0002-7730-8973				Anderson SL, 2001, AM J HUM GENET, V68, P753, DOI 10.1086/318808; Aronheim A, 2001, METHOD ENZYMOL, V332, P260; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BREAKEFIELD XO, 1984, P NATL ACAD SCI-BIOL, V81, P4213, DOI 10.1073/pnas.81.13.4213; BREAKEFIELD XO, 1986, MOL BIOL MED, V3, P483; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Buschmann T, 2000, CANCER RES, V60, P896; Chauhan D, 1999, CANCER RES, V59, P1192; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hawkes NA, 2002, J BIOL CHEM, V277, P3047, DOI 10.1074/jbc.M110445200; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kenney AM, 1998, J NEUROSCI, V18, P1318; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Slaugenhaupt SA, 2001, AM J HUM GENET, V68, P598, DOI 10.1086/318810; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Takeoka S, 2001, J HUM GENET, V46, P57, DOI 10.1007/s100380170109; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YAN MH, 1994, NATURE, V372, P798; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	65	89	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31918	31928		10.1074/jbc.M200719200	http://dx.doi.org/10.1074/jbc.M200719200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12058026	hybrid			2022-12-25	WOS:000177718700078
J	Simon, J; Filippov, AK; Goransson, S; Wong, YH; Frelin, C; Michel, AD; Brown, DA; Barnard, EA				Simon, J; Filippov, AK; Goransson, S; Wong, YH; Frelin, C; Michel, AD; Brown, DA; Barnard, EA			Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TYPE CA2+; PLATELET ADP RECEPTOR; ADENOSINE TRIPHOSPHATES; SYMPATHETIC NEURONS; EXTRACELLULAR ATP; MOLECULAR-BASIS; GLIOMA-CELLS; SHAPE CHANGE; CYCLIC-AMP; INHIBITION	Rat brain capillary endothelial (B10) cells express an unidentified nucleotide receptor linked to adenylyl cyclase inhibition. We show that this receptor in B10 cells is identical in sequence to the P2Y(12) ADP receptor ("P2Y(T)") of platelets. When expressed heterologously, 2-methylthio-ADP (2-MeSADP; EC50, 2 nm), ADP, and adenosine 5'-O-(2-thio)diphosphate were agonists of cAMP decrease, and 2-propylthio-D-beta,gamma-difluoromethylene-ATP was a competitive antagonist (K,, 28 nm), as in platelets. However, 2-methylthio-ATP (2-MeSATP) (EC50, 0.4 nm), ATP (1.9 mum), and 2-chloro-ATP (190 nm), antagonists in the platelet, were also agonists. 2-Me- SADP activated (EC50, 0.1 nm) GIRK1/GIRK2 inward rectifier K+ channels when co-expressed with P2Y(12) receptors in sympathetic neurons. Surprisingly, P2Y(1) receptors expressed likewise gave that response; however, a full inactivation followed, absent with P2Y(12) receptors. A new P2Y(12)-mediated transduction was found, the closing of native N-type Ca2+ channels; again both 2-MeSATP and 2-MeSADP are agonists (EC50, 0.04 and 0.1 nm, respectively). That action, like their cAMP response, was pertussis toxin-sensitive. The Ca2+ channel inhibition and K+ channel activation are mediated by betay subunit release from a heterotrimeric G-protein. Galpha subunit types in B10 cells were also identified. The presence in the brain capillary endothelial cell of the P2Y(12) receptor is a significant extension of its functional range.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Univ Cambridge, Glaxo Inst Appl Pharmacol, Cambridge CB2 1PD, England; CNRS UMR6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; UCL, Dept Pharmacol, London WC1E 6BT, England	University of Cambridge; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Hong Kong University of Science & Technology; University of London; University College London	Barnard, EA (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	eb247@cam.ac.uk	Brown, David A/J-9019-2012	Wong, Yung Hou/0000-0002-0123-7697				ABBOTT ML, 1991, ENVIRON EXP BOT, V31, P1, DOI 10.1016/0098-8472(91)90002-6; Anwar Z, 1999, BRIT J PHARMACOL, V128, P465, DOI 10.1038/sj.bjp.0702792; Barnard EA, 2001, TRENDS PHARMACOL SCI, V22, P388, DOI 10.1016/S0165-6147(00)01759-4; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; Brown DA, 2000, J AUTONOM NERV SYST, V81, P31, DOI 10.1016/S0165-1838(00)00150-8; Carruthers AM, 1999, BRIT J PHARMACOL, V126, P1221, DOI 10.1038/sj.bjp.0702401; Claes P, 2001, BRIT J PHARMACOL, V134, P402, DOI 10.1038/sj.bjp.0704271; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; CUSACK NJ, 1982, BRIT J PHARMACOL, V77, P329, DOI 10.1111/j.1476-5381.1982.tb09302.x; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; FEOLDE E, 1995, BRIT J PHARMACOL, V115, P1199, DOI 10.1111/j.1476-5381.1995.tb15025.x; Fernandez-Fernandez JM, 2001, EUR J NEUROSCI, V14, P283, DOI 10.1046/j.0953-816x.2001.01642.x; Filippov AK, 1999, BRIT J PHARMACOL, V126, P1009, DOI 10.1038/sj.bjp.0702356; Filippov AK, 2000, BRIT J PHARMACOL, V129, P1063, DOI 10.1038/sj.bjp.0703185; Filippov AK, 1998, J NEUROSCI, V18, P5170, DOI 10.1523/JNEUROSCI.18-14-05170.1998; Haley JE, 1998, J NEUROSCI, V18, P4521; Hechler B, 1998, BRIT J HAEMATOL, V103, P858, DOI 10.1046/j.1365-2141.1998.01056.x; Hechler B, 1998, MOL PHARMACOL, V53, P727, DOI 10.1124/mol.53.4.727; Hermans E, 1999, BRIT J PHARMACOL, V126, P873, DOI 10.1038/sj.bjp.0702359; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; HOYER D, 1993, TRENDS PHARMACOL SCI, V14, P270, DOI 10.1016/0165-6147(93)90129-8; HUMPHRIES RG, 1994, BRIT J PHARMACOL, V113, P1057, DOI 10.1111/j.1476-5381.1994.tb17100.x; Jantzen HM, 1999, THROMB HAEMOSTASIS, V81, P111; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Jeong SW, 2000, P NATL ACAD SCI USA, V97, P907, DOI 10.1073/pnas.97.2.907; Jin JG, 2001, BRIT J PHARMACOL, V133, P521, DOI 10.1038/sj.bjp.0704114; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kenakin T, 1999, TRENDS PHARMACOL SCI, V20, P400, DOI 10.1016/S0165-6147(99)01361-9; Kenakin T, 1996, PHARMACOL REV, V48, P413; Kenakin T., 1997, PHARMACOLOGIC ANAL D, Vsecond edition, P137, DOI DOI 10.1097/00007691-198803000-00029; King BF, 2000, J AUTONOM NERV SYST, V81, P164, DOI 10.1016/S0165-1838(00)00134-X; Kunapuli SP, 1998, TRENDS PHARMACOL SCI, V19, P391, DOI 10.1016/S0165-6147(98)01248-6; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; Mark MD, 2000, NEUROPHARMACOLOGY, V39, P2360, DOI 10.1016/S0028-3908(00)00080-0; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)90685-4; Onaran HO, 1999, TRENDS PHARMACOL SCI, V20, P274, DOI 10.1016/S0165-6147(99)01364-4; Palmer RK, 1998, MOL PHARMACOL, V54, P1118, DOI 10.1124/mol.54.6.1118; Park HS, 1999, BRIT J PHARMACOL, V127, P1359, DOI 10.1038/sj.bjp.0702690; Perroy J, 2001, J BIOL CHEM, V276, P45800, DOI 10.1074/jbc.M106876200; PIANET I, 1989, BIOCHEM BIOPH RES CO, V163, P1150, DOI 10.1016/0006-291X(89)92341-3; Savi P, 2001, BIOCHEM BIOPH RES CO, V283, P379, DOI 10.1006/bbrc.2001.4816; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; Sellers LK, 2001, J BIOL CHEM, V276, P16379, DOI 10.1074/jbc.M006617200; Simon J, 2001, BRIT J PHARMACOL, V132, P173, DOI 10.1038/sj.bjp.0703816; Takasaki J, 2001, MOL PHARMACOL, V60, P432; VALEINS H, 1992, MOL PHARMACOL, V42, P1033; Webb TE, 1996, BRIT J PHARMACOL, V119, P1385, DOI 10.1111/j.1476-5381.1996.tb16050.x; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200; Zhong HY, 1996, MOL PHARMACOL, V50, P175	59	89	91	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31390	31400		10.1074/jbc.M110714200	http://dx.doi.org/10.1074/jbc.M110714200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12080041	hybrid			2022-12-25	WOS:000177718700015
J	Tabunoki, H; Sugiyama, H; Tanaka, Y; Fujii, H; Banno, Y; Jouni, ZE; Kobayashi, M; Sato, R; Maekawa, H; Tsuchida, K				Tabunoki, H; Sugiyama, H; Tanaka, Y; Fujii, H; Banno, Y; Jouni, ZE; Kobayashi, M; Sato, R; Maekawa, H; Tsuchida, K			Isolation, characterization, and cDNA sequence of a carotenoid binding protein from the silk gland of Bombyx mori larvae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; INTRAMITOCHONDRIAL CHOLESTEROL TRANSFER; LIPID TRANSFER PARTICLE; MANDUCA-SEXTA; STAR; PURIFICATION; DOMAIN; IDENTIFICATION; LIPOPROTEIN; MECHANISM	A carotenoid binding protein (CBP) has been isolated from the silk glands of Bombyx mori larvae. The protein has an apparent molecular mass of 33 kDa and binds carotenoids in a 1:1 molar ratio. Lutein accounts for 90% of the bound carotenoids, whereas a-carotene and beta-carotene are minor components. Immunological analysis demonstrated the presence of CBP only in the yellow-colored tissues of the silk gland, midgut, testis, and ovary. Several phenotypes of B. mori mutants linked to carotenoid transport have been utilized to characterize CBP. The Y (yellow hemolymph) gene controls uptake of carotenoids from the midgut lumen into the midgut epithelium, and larvae with the +(Y) gene lack this property. Immunoblotting analysis confirmed the presence of CBP in mutants with the dominant Y gene only. Immunohistochemistry verified the localization of CBP in the villi of the midgut epithelium, indicating that CBP might be involved in absorption of carotenoids. A cDNA clone for CBP encoding a protein of 297 amino acids has been isolated from the R mori silk gland cDNA library. The deduced amino acid sequence revealed that CBP is a novel member of the steroidogenic acute regulatory (StAR) protein family with its unique structural feature of a StAR-related lipid transfer domain, known to aid in lipid transfer and recognition. Lutein-binding capacity of the recombinant CBP (rCBP) determined by incubating rCBP with lutein followed by immunoprecipitation using anti-CBP IgG conjugated to protein A-Sepharose, demonstrated the formation of a lutein-rCBP complex. Sequence analyses coupled with binding specificity suggest that CBP is a new member of the StAR protein family that binds carotenoids rather than cholesterol.	Natl Inst Infect Dis, Div Radiol Protect, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Dept Agrobiol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Kyushu Univ, Ctr Genet Resources, Fukuoka 8120053, Japan; Lion Corp, Tokyo 1320035, Japan; Natl Inst Infect Dis, Dept Parasitol, Tokyo 1628640, Japan; Tokyo Univ Agr & Technol, Koganei, Tokyo 1830054, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo; University of Arizona; Kyushu University; Lion Corporation; National Institute of Infectious Diseases (NIID); Tokyo University of Agriculture & Technology	Tsuchida, K (corresponding author), Natl Inst Infect Dis, Div Radiol Protect, Shinjuku Ku, Tokyo 1628640, Japan.		TABUNOKI, Hiroko/H-6593-2013; Sato, Ryoichi/G-1074-2013	TABUNOKI, Hiroko/0000-0003-1823-9952; 				Achermann JC, 2001, MOL GENET METAB, V73, P354, DOI 10.1006/mgme.2001.3202; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; CHINO H, 1981, J LIPID RES, V22, P1042; CHINO H, 1985, COMPREHENSIVE INSECT, V10, P115; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; DOIRA H, 1978, SILKWORM IMPORTANT L, P53; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Jouni ZE, 1996, J BIOL CHEM, V271, P14722, DOI 10.1074/jbc.271.25.14722; Nakajima M., 1963, B FAC AGR TOKYO, V8, P1; NEEDHAM H, 1978, BIOCH INSECTS, P233; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; ONG DE, 1982, J BIOL CHEM, V257, P13385; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Rao MN, 1997, J BIOL CHEM, V272, P24455, DOI 10.1074/jbc.272.39.24455; SHIMIZU I, 1981, J INSECT PHYSIOL, V27, P593, DOI 10.1016/0022-1910(81)90106-2; STARK WS, 1976, J COMP PHYSIOL, V105, P15, DOI 10.1007/BF01380050; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA K, 1990, J BIOL CHEM, V265, P5761; TSUCHIDA K, 1988, INSECT BIOCHEM, V18, P263, DOI 10.1016/0020-1790(88)90090-X; Tsuchida K, 1997, BBA-PROTEIN STRUCT M, V1337, P57, DOI 10.1016/S0167-4838(96)00149-5; Tsuchida K, 1998, INSECT BIOCHEM MOLEC, V28, P927, DOI 10.1016/S0965-1748(98)00036-8; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; WESTERMAN J, 1983, EUR J BIOCHEM, V132, P441, DOI 10.1111/j.1432-1033.1983.tb07382.x	32	68	88	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32133	32140		10.1074/jbc.M204507200	http://dx.doi.org/10.1074/jbc.M204507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12052833	hybrid			2022-12-25	WOS:000177718700104
J	Jemth, P; Kreuger, J; Kusche-Gullberg, M; Sturiale, L; Gimenez-Gallego, G; Lindahl, U				Jemth, P; Kreuger, J; Kusche-Gullberg, M; Sturiale, L; Gimenez-Gallego, G; Lindahl, U			Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs - Exploring the structural diversity by screening for fibroblast growth factor (FGF) 1 and FGF2 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMER-MODIFICATION REACTIONS; HEPARIN/HEPARAN SULFATE; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; EVOLUTION; EPIMERIZATION; PROTEOGLYCANS; 2-O-SULFATION; PURIFICATION; DOMAINS	Heparan sulfate is crucial for vital reactions in the body because of its ability to bind various proteins. The identification of protein-binding heparan sulfate sequences is essential to our understanding of heparan sulfate biology and raises the possibility to develop drugs against diseases such as cancer and inflammatory conditions. We present proof-of-principle that in vitro generated heparan sulfate oligosaccharide libraries can be used to explore interactions between heparan sulfate and proteins, and that the libraries expand the available heparan sulfate sequence space. Oligosaccharide libraries mimicking highly 6-O-sulfated domains of heparan sulfate were constructed by enzymatic O-sulfation of O-desulfated, end-group H-3-labeled heparin octasaccharides. Acceptor oligosaccharides that were 6-O-desulfated but only partially 2O-desulfated yielded oligosaccharide arrays with increased ratio of iduronyl 2-O-sulfate/glucosaminyl 6-O-sulfate. The products were probed by affinity chromatography on immobilized growth factors, fibroblast growth factor-1 (FGF1) and FGF2, followed by sequence analysis of trapped oligosaccharides. An N-sulfated octasaccharide, devoid of 2-O-sulfate but with three 6-O-sulfate groups, was unexpectedly found to bind FGF1 as well as FGF2 at physiological ionic strength. However, a single 2-O-sulfate group in the absence of 6-O-sulfation gave higher affinity for FGF2. FGF1 binding was also augmented by 2-O-sulfation, preferentially in combination with an adjacent upstream 6-O-sulfate group. These results demonstrate the potential of the enzymatically generated oligosaccharide libraries.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; G Ronzoni Inst Chem & Biochem Res, I-20133 Milan, Italy; CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Uppsala University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Lindahl, U (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, Box 582, SE-75123 Uppsala, Sweden.		Kreuger, Johan/HDM-1503-2022; Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695; STURIALE, LUISELLA/0000-0002-3996-1138				Atkins J.F, 1999, RNA WORLD; Bartolozzi A, 2001, CURR OPIN STRUC BIOL, V11, P587, DOI 10.1016/S0959-440X(00)00252-9; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Flitsch SL, 2000, CURR OPIN CHEM BIOL, V4, P619, DOI 10.1016/S1367-5931(00)00152-6; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Hagner-McWhirter A, 2000, BIOCHEM J, V347, P69, DOI 10.1042/0264-6021:3470069; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Johnston WK, 2001, SCIENCE, V292, P1319, DOI 10.1126/science.1060786; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; JUHASZ P, 1994, P NATL ACAD SCI USA, V91, P4333, DOI 10.1073/pnas.91.10.4333; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; LEVY L, 1962, P SOC EXP BIOL MED, V109, P901; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Rong JH, 2000, BIOCHEM J, V346, P463, DOI 10.1042/0264-6021:3460463; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; Varki A, 2002, P NATL ACAD SCI USA, V99, P543, DOI 10.1073/pnas.022649499; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Wu ZLL, 2002, FASEB J, V16, P539, DOI 10.1096/fj.01-0807com; ZAZO M, 1992, GENE, V113, P231, DOI 10.1016/0378-1119(92)90400-J	43	89	90	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30567	30573		10.1074/jbc.M203404200	http://dx.doi.org/10.1074/jbc.M203404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12058038	Green Published, hybrid			2022-12-25	WOS:000177579800023
J	Sarto, I; Klausberger, T; Ehya, N; Mayer, B; Fuchs, K; Sieghart, W				Sarto, I; Klausberger, T; Ehya, N; Mayer, B; Fuchs, K; Sieghart, W			A novel site on gamma(3) subunits important for assembly of GABA(A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACID(A) RECEPTORS; BENZODIAZEPINE BINDING-SITE; INTERSUBUNIT CONTACTS; ALPHA-SUBUNITS; IDENTIFICATION; STOICHIOMETRY; DETERMINANTS; PHARMACOLOGY; PERSPECTIVE; EXPRESSION	gamma-Aminobutyric acid, type A (GABA(A)) receptors are ligand-gated chloride channels and are the major inhibitory transmitter receptors in the central nervous system. The majority of these receptors is composed of two alpha, two beta, and one gamma subunits. To identify sequences important for subunit assembly, we generated C-terminally truncated and chimeric gamma(3) constructs. From their ability to associate with full-length alpha(1) and beta(3) subunits, we concluded that amino acid sequence gamma(3)(70-84) either directly interacts with alpha(1) or beta(3) subunits or stabilizes a contact site elsewhere in the protein. The observation that this sequence contains amino acid residues homologous to gamma(2) residues contributing to the benzodiazepine-binding site at the alpha(1)/gamma(2) interface suggested that in alpha(1)beta(3)gamma(3) receptors the sequence gamma(3)(70-84) is located at the alpha(1)/gamma(3) interface. In the absence of alpha(1) subunits this sequence might allow assembly of beta(3) with gamma(3) subunits. Other experiments indicated that sequences gamma(3)(86-95) and gamma(3)(94-107), which are homologous to previously identified sequences important for assembly of gamma(2) subunits, are also important for assembly of gamma(3) subunits. This indicates that during assembly of the GABA(A) receptor, more than one N-terminal sequence is important for binding to the same neighboring subunit. Whether the three sequences investigated are involved in direct interaction or stabilize other regions involved in intersubunit contacts has to be further studied.	Univ Vienna, Brain Res Inst, Div Biochem & Mol Biol, A-1090 Vienna, Austria; Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, A-1090 Vienna, Austria; Univ Vienna, Inst Theoret Chem & Mol Struct Biol, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Sieghart, W (corresponding author), Univ Vienna, Brain Res Inst, Div Biochem & Mol Biol, Spitalgasse 4, A-1090 Vienna, Austria.	werner.sieghart@univie.ac.at	Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				Baer K, 1999, P NATL ACAD SCI USA, V96, P12860, DOI 10.1073/pnas.96.22.12860; Barnard EA, 1998, PHARMACOL REV, V50, P291; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Hackam AS, 1997, J BIOL CHEM, V272, P13750, DOI 10.1074/jbc.272.21.13750; Hackam AS, 1997, NEUROREPORT, V8, P1425, DOI 10.1097/00001756-199704140-00020; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Keller SH, 1999, J GEN PHYSIOL, V113, P171, DOI 10.1085/jgp.113.2.171; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Klausberger T, 2001, J BIOL CHEM, V276, P16024, DOI 10.1074/jbc.M009508200; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mayer B, 2000, J COMPUT CHEM, V21, P270, DOI 10.1002/(SICI)1096-987X(200003)21:4<270::AID-JCC3>3.0.CO;2-V; NAYEEM N, 1994, J NEUROCHEM, V62, P815; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; Nusser Z, 1998, J NEUROSCI, V18, P1693; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Somogyi P, 1996, NEUROPHARMACOLOGY, V35, P1425, DOI 10.1016/S0028-3908(96)00086-X; Srinivasan S, 1999, J BIOL CHEM, V274, P26633, DOI 10.1074/jbc.274.38.26633; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; TOGEL M, 1994, J BIOL CHEM, V269, P12993; Tretter V, 1997, J NEUROSCI, V17, P2728; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WHITE BA, 1993, PCR PROTOCOLS, P251; WISDEN W, 1992, J NEUROSCI, V12, P1040; Zezula J, 1996, EUR J PHARMACOL, V301, P207, DOI 10.1016/0014-2999(96)00066-0	50	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30656	30664		10.1074/jbc.M203597200	http://dx.doi.org/10.1074/jbc.M203597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12065588	hybrid			2022-12-25	WOS:000177579800034
J	Gomez, I; Miranda-Rios, J; Rudino-Pinera, E; Oltean, DI; Gill, SS; Bravo, A; Soberon, M				Gomez, I; Miranda-Rios, J; Rudino-Pinera, E; Oltean, DI; Gill, SS; Bravo, A; Soberon, M			Hydropathic complementarity determines interaction of epitope (HITDTNNK876)-H-869 in Manduca sexta Bt-R-1 receptor with loop 2 of domain II of Bacillus thuringiensis Cry1A toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; DISPAR AMINOPEPTIDASE-N; DELTA-ENDOTOXIN; HELIOTHIS-VIRESCENS; INSECTICIDAL TOXIN; CRYSTAL PROTEINS; BOMBYX-MORI; IRREVERSIBLE BINDING; ARGININE RESIDUES; HIGH-AFFINITY	In susceptible insects, Cry toxin specificity correlates with receptor recognition. In previous work, we characterized an scFv antibody (scFv73) that inhibits binding of Cry1A toxins to cadherin-like receptor. The CDR3 region of scFv73 shared homology with an 8-amino acid epitope ((HITDTNNK876)-H-869) of the Manduca sexta cadherin-like receptor Bt-R-1 (Gomez, I., Oltean, D. I., Gill, S. S., Bravo, A., and Soberon, M. (2001) J. Biol. Chem. 276, 28906-28912). In this work, we show that the previous sequence of scFv73 CDR3 region was obtained from the noncoding DNA strand. However, most importantly, both scFv73 CDR3 amino acid sequences of the coding and noncoding DNA strands have similar binding capabilities to Cry1Ab toxin as Bt-R-1 (HITDTNNK876)-H-869 epitope, as demonstrated by the competition of scFv73 with binding to Cry1Ab with synthetic peptides with amino acid sequences corresponding to these regions. Using synthetic peptides corresponding to three exposed loop regions of domain II of Cry1Aa and Cry1Ab toxins, we found that loop 2 synthetic peptide competed with binding of scFv73 to Cry1A toxins in Western blot experiments. Also, loop 2 mutations that affect toxicity of Cry1Ab toxin are affected in scFv73 binding. Toxin overlay assays of Cry1A toxins to M. sexta brush border membrane proteins showed that loop 2 synthetic peptides competed with binding of Cry1A toxins to cadherin-like Bt-R-1 receptor. These experiments identified loop 2 in domain II of as the cognate binding partner of Bt-R-1 (HITDTNNK876)-H-869. Finally, 10 amino acids from beta-6-loop 2 region of Cry1Ab toxin ((SSTLYRRPFNI373)-S-363) showed hydropathic pattern complementarity to a 10-amino acid region of Bt-R-1 ((NITIHITDTNN875)-N-865), suggesting that binding of Cry1A toxins to Bt-R-1 is determined by hydropathic complementarity and that the binding epitope of Bt-R-1 may be larger than the one identified by amino acid sequence similarity to scFv73.	Univ Nacl Autonoma Mexico, Dept Mol Microbiol, Cuernavaca 62250, Morelos, Mexico; Univ Nacl Autonoma Mexico, Dept Reconocimeinto Mol & Bioestructura, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; University of California System; University of California Riverside	Soberon, M (corresponding author), Univ Nacl Autonoma Mexico, Dept Mol Microbiol, Apdo Postal 510-3, Cuernavaca 62250, Morelos, Mexico.	mario@ibt.unam.mx	Miranda Ríos, Juan/ABB-7767-2021; de la Parra, Maria Alejandra Bravo/R-6740-2017	Rudino-Pinera, Enrique/0000-0001-8170-6379; Bravo, Alejandra/0000-0002-7573-7475				Aranda E, 1996, J INVERTEBR PATHOL, V68, P203, DOI 10.1006/jipa.1996.0087; ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; BELFIORE CJ, 1994, BIOCHEM BIOPH RES CO, V200, P359, DOI 10.1006/bbrc.1994.1456; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; Blalock JE, 1999, CELL MOL LIFE SCI, V55, P513, DOI 10.1007/s000180050309; BOQUET D, 1995, MOL IMMUNOL, V32, P303, DOI 10.1016/0161-5890(95)00012-4; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P237, DOI 10.1016/0022-2011(92)90004-N; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOMA CT, 1990, EUR J BIOCHEM, V189, P523, DOI 10.1111/j.1432-1033.1990.tb15518.x; Crickmore N, 1998, MICROBIOL MOL BIOL R, V62, P807, DOI 10.1128/MMBR.62.3.807-813.1998; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; Denolf P, 1997, EUR J BIOCHEM, V248, P748, DOI 10.1111/j.1432-1033.1997.t01-1-00748.x; DILLON J, 1991, P NATL ACAD SCI USA, V88, P9726, DOI 10.1073/pnas.88.21.9726; Dillon PF, 1998, HYPERTENSION, V31, P854, DOI 10.1161/01.HYP.31.3.854; DORSCH JA, 2002, IN PRESS INSECT BIOC; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; GARCZYNSKI SF, 1995, INSECT BIOCHEM MOLEC, V25, P409, DOI 10.1016/0965-1748(94)00072-7; GILL SS, 1995, J BIOL CHEM, V270, P27277, DOI 10.1074/jbc.270.45.27277; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Heal JR, 1999, MOL IMMUNOL, V36, P1141, DOI 10.1016/S0161-5890(99)00129-7; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; Jenkins J L, 2000, Genet Eng (N Y), V22, P33; Jenkins JL, 2000, J BIOL CHEM, V275, P14423, DOI 10.1074/jbc.275.19.14423; Kay BK, 2000, FEBS LETT, V480, P55, DOI 10.1016/S0014-5793(00)01778-6; Keeton TP, 1997, APPL ENVIRON MICROB, V63, P3419, DOI 10.1128/AEM.63.9.3419-3425.1997; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; Lee MK, 2000, MOL MICROBIOL, V38, P289, DOI 10.1046/j.1365-2958.2000.02109.x; LEE MK, 1992, J BIOL CHEM, V267, P3115; Lee MK, 2001, FEBS LETT, V497, P108, DOI 10.1016/S0014-5793(01)02446-2; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; MARKUS G, 1989, ARCH BIOCHEM BIOPHYS, V272, P433, DOI 10.1016/0003-9861(89)90237-3; Morse RJ, 2001, STRUCTURE, V9, P409, DOI 10.1016/S0969-2126(01)00601-3; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; Oltean DI, 1999, APPL ENVIRON MICROB, V65, P4760; Pietrantonio P. V., 1996, P345; Rajamohan F, 1996, J BIOL CHEM, V271, P2390, DOI 10.1074/jbc.271.5.2390; RAJAMOHAN F, 1995, J BACTERIOL, V177, P2276, DOI 10.1128/jb.177.9.2276-2282.1995; Rajamohan F, 1996, J BIOL CHEM, V271, P25220, DOI 10.1074/jbc.271.41.25220; Root-Bernstein RS, 1998, J THEOR BIOL, V190, P107, DOI 10.1006/jtbi.1997.0544; RUIZOPAZO N, 1995, NAT MED, V1, P1074, DOI 10.1038/nm1095-1074; Sagot MA, 2000, MOL IMMUNOL, V37, P423, DOI 10.1016/S0161-5890(00)00060-2; THOMAS WE, 1983, J CELL SCI, V60, P181; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; VAKSER IA, 1994, PROTEINS, V20, P320, DOI 10.1002/prot.340200405; Valaitis AP, 2001, ARCH INSECT BIOCHEM, V46, P186, DOI 10.1002/arch.1028; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Yaoi K, 1999, FEBS LETT, V463, P221, DOI 10.1016/S0014-5793(99)01626-9; Yaoi K, 1997, EUR J BIOCHEM, V246, P652, DOI 10.1111/j.1432-1033.1997.t01-1-00652.x	54	51	59	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30137	30143		10.1074/jbc.M203121200	http://dx.doi.org/10.1074/jbc.M203121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12050155	hybrid			2022-12-25	WOS:000177509300097
J	Nuti, SL; Rao, US				Nuti, SL; Rao, US			Proteolytic cleavage of the linker region of the human P-glycoprotein modulates its ATPase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; HAMSTER OVARY CELLS; INSECT CELLS; NUCLEOTIDE-BINDING; CONFORMATIONAL-CHANGES; CATALYTIC CYCLE; DRUG-BINDING; KINASE-C; EXPRESSION; MUTANTS	P-glycoprotein (Pgp), an anticancer drug-translocating ATPase, is responsible for multidrug resistance in cancer. We have previously shown (Nuti, S. L., Mehdi, A., and Rao, U. S. (2000) Biochemistry 39, 3424-3432) that tryptic cleavage of Pgp results in the activation of basal and drug-stimulated ATPase functions of Pgp. To understand this phenomenon, we determined the sites cleaved by trypsin and further examined whether the modulation of Pgp function is trypsin-specific or the result of proteolysis in general. The effects of chymotrypsin and proteinase K on Pgp ATPase function were studied. The results show that proteolysis of Pgp irrespective of the protease employed resulted in the activation of basal ATPase activity. However, drug-stimulated ATPase activities were differentially modulated. Immunoblot analysis of proteolytic digests indicated that, irrespective of the protease employed, Pgp was predominantly cleaved in the middle of the molecule. N-terminal amino acid sequencing of Pgp tryptic and chymotryptic peptides indicated Arg(680) and Leu(682) as the sites of cleavage, respectively. These two cleavage sites are part of the predicted linker region that joins the two halves of Pgp. Together, these results suggest that the linker region in Pgp is primarily accessible to protease action and that cleavage of this region modulates Pgp ATPase function.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rao, US (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St,984525, Omaha, NE 68198 USA.	usrao@unmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051529, R01DK051529] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51529] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BAUMANN WK, 1970, FEBS LETT, V8, P257, DOI 10.1016/0014-5793(70)80280-0; BEREZIN IV, 1970, FEBS LETT, V8, P261, DOI 10.1016/0014-5793(70)80281-2; Berman MC, 2001, BBA-BIOMEMBRANES, V1513, P95, DOI 10.1016/S0005-2736(01)00356-X; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Germann UA, 1998, METHOD ENZYMOL, V292, P427; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GOTTESMAN MM, 1993, CANCER RES, V53, P747; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hrycyna CA, 1998, BIOCHEMISTRY-US, V37, P13660, DOI 10.1021/bi9808823; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1993, J BIOL CHEM, V268, P19965; Muller M, 1996, J BIOL CHEM, V271, P1877; Nuti SL, 2000, BIOCHEMISTRY-US, V39, P3424, DOI 10.1021/bi992392w; NUTRI SL, 2000, FASEB J, V14, pA1468; ORR GA, 1993, J BIOL CHEM, V268, P25054; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; Rao US, 2000, ANAL BIOCHEM, V286, P206, DOI 10.1006/abio.2000.4861; RAO US, 1995, J BIOL CHEM, V270, P6686; RAO US, 1994, BIOCHEM PHARMACOL, V48, P287, DOI 10.1016/0006-2952(94)90099-X; Rao US, 1998, BIOCHEMISTRY-US, V37, P14981, DOI 10.1021/bi980072r; RAO VV, 1994, J NUCL MED, V35, P510; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Senior AE, 1998, METHOD ENZYMOL, V292, P514; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Shapiro AB, 1998, ACTA PHYSIOL SCAND, V163, P227; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Shepard RL, 1998, BIOCHEM PHARMACOL, V56, P719, DOI 10.1016/S0006-2952(98)00212-3; Szabo K, 1997, J BIOL CHEM, V272, P23165, DOI 10.1074/jbc.272.37.23165; Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; WELKER E, 1995, BIOCHEM BIOPH RES CO, V216, P602, DOI 10.1006/bbrc.1995.2665	50	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29417	29423		10.1074/jbc.M204054200	http://dx.doi.org/10.1074/jbc.M204054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12055198	hybrid			2022-12-25	WOS:000177509300010
J	Stein, T; Crighton, D; Boyle, JM; Varley, JM; White, RJ				Stein, T; Crighton, D; Boyle, JM; Varley, JM; White, RJ			RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome	ONCOGENE			English	Article						E6; p53; Li-Fraumeni; mdm2; RNA polymerase III; transcription	WILD-TYPE P53; TATA-BINDING-PROTEIN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; HUMAN TUMORS; DNA-BINDING; REPRESSION; CANCER; GROWTH	RNA polymerase (pol) III synthesizes essential small RNAs, including tRNA and 5S rRNA. Wild-type p53 can repress pol III transcription both in vitro and in vivo. Many tumours carry substitutions in p53 which have selective effects on its functions. We identify tumour-derived mutations that compromise the ability of p53 to regulate pol III transcription. Furthermore, substitution R175H, the most common mutation in cancers, converts p53 from a repressor to an activator of pol III. Oncoproteins neutralize p53 in some tumours; we show that human papillomavirus E6 and cellular hdm2 can both release pol III from repression by p53. These data suggest that the restraining influence of p53 on pol III will be lost in many tumours. In addition to these features of sporadic cancers, some individuals inherit mutant forms of p53 and consequently suffer from Li-Fraumeni syndrome, showing genetic predisposition to certain malignancies. We find that pol III transcriptional activity is often highly elevated in primary fibroblasts from Li-Fraumeni patients, especially if the germline p53 mutation is followed by loss of the remaining allele. Our data suggest that p53 status can have a profound effect upon pol III transcription and hence on the biosynthetic capacity of cells.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Paterson Inst Canc Res, Canc Res UK Dept Canc Genet, Manchester M20 9BX, Lancs, England	University of Glasgow; Paterson Institute for Cancer Research	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@bio.gla.ac.uk	Stein, Torsten/G-1147-2012	Stein, Torsten/0000-0002-9946-1549				AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Boyle JM, 1998, BRIT J CANCER, V77, P2181, DOI 10.1038/bjc.1998.364; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONCHOWER LA, 1992, NATURE, V356, P215; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Eichhorn K, 2001, J BIOL CHEM, V276, P21158, DOI 10.1074/jbc.M102295200; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOH HS, 1995, CANCER RES, V55, P5217; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1996, ONCOGENE, V12, P2437; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Varley JM, 2001, ONCOGENE, V20, P2647, DOI 10.1038/sj.onc.1204369; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WANG HD, 1995, MOL CELL BIOL, V15, P6720; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhao RB, 2000, GENE DEV, V14, P981	87	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2961	2970		10.1038/sj.onc.1205372	http://dx.doi.org/10.1038/sj.onc.1205372			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082526				2022-12-25	WOS:000175262700003
J	Chavakis, T; Pixley, RA; Isordia-Salas, I; Colman, RW; Preissner, KT				Chavakis, T; Pixley, RA; Isordia-Salas, I; Colman, RW; Preissner, KT			A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOMEDIN-B DOMAIN; ENDOTHELIAL-CELLS; LIGHT CHAIN; UROKINASE RECEPTOR; THROMBOEMBOLIC DISEASE; MYOCARDIAL-INFARCTION; EXTRACELLULAR-MATRIX; PLASMA VITRONECTIN; SURFACE-BINDING; ANIONIC SURFACE	The adhesive glycoprotein vitronectin (VN) forms a function-stabilizing complex with plasminogen activator inhibitor-1 (PAI-I), the major fibrinolysis inhibitor in both plasma and vessel wall connective tissue. VN also interacts with two-chain high molecular weight kininogen (HKa) and PAI-1 was investigated. In a purified system, HKa and particularly domain 5 inhibited the binding of PAI-1 to VN. In this study the influence of HKa and domain 5 on the antifibrinolytic function of PAI-1 was investigated. In a purified system, HKa and particularly domain 5 inhibited the binding of PAI-1 displacement from both isolated VN as well as subendothelial extracellular matrix-associated VN. The sequence Gly(486)-Lys(502) of HKa domain 5 was identified as responsible for this inhibition. Although hainosaurus no direct effect on PAI-1 activity itself, HKa domain 5 or the peptide Gly(486)-Lys(502) markedly destabilized the VN.PAI-1 complex interaction, resulting in a significant reduction of PAI-1 inhibitory function on plasminogen activators, resembling the effect of VN antibodies that prevent stabilization of PAI-1. Furthermore, high affinity fibrin binding of PAI-1 in the presence of VN as well as the VN-dependent fibrin clot stabilization by the inhibitor were abrogated in the presence of the kininogen forms mentioned. Taken together, our data indicate that the peptide Gly(486)-Lys(502) derived from domain 5 HKa serves to interfere with PAI-1 function. Based on these observations potential low molecular weight PAI-1 inhibitors could be designed for the use in therapeutic interventions against thromboembolic complications.	Univ Giessen, Inst Biochem, Fachbereich Humanmed, D-35392 Giessen, Germany; Univ Giessen, Dept Internal Med 3, D-35392 Giessen, Germany; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Justus Liebig University Giessen; Justus Liebig University Giessen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Chavakis, T (corresponding author), Univ Giessen, Inst Biochem, Fachbereich Humanmed, Friedrichstr 24, D-35392 Giessen, Germany.	triantafyllos.chavakis@innere.med.uni-giessen.de	Chavakis, Triantafyllos/ABE-8845-2020					BIEMOND BJ, 1995, CIRCULATION, V91, P1175, DOI 10.1161/01.CIR.91.4.1175; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; Boncela J, 2001, J BIOL CHEM, V276, P35305, DOI 10.1074/jbc.M104028200; BRADFORD HN, 1993, J BIOL CHEM, V268, P26546; Cesari M, 1999, ARTERIOSCL THROM VAS, V19, P1378, DOI 10.1161/01.ATV.19.6.1378; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 2002, J BIOL CHEM, V277, P23157, DOI 10.1074/jbc.M202529200; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; Chikanishi T, 1999, J ANTIBIOT, V52, P797, DOI 10.7164/antibiotics.52.797; COLLEN D, 1991, BLOOD, V78, P3114; Colman RW, 1999, ARTERIOSCL THROM VAS, V19, P2245, DOI 10.1161/01.ATV.19.9.2245; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DIEVAL J, 1991, BLOOD, V77, P528; EITZMAN DT, 1995, J CLIN INVEST, V95, P2416, DOI 10.1172/JCI117937; Eitzman DT, 2000, BLOOD, V95, P577, DOI 10.1182/blood.V95.2.577; Farrehi PM, 1998, CIRCULATION, V97, P1002; FAY WP, 1994, BLOOD, V83, P351; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; JESPERSEN J, 1992, ANN NY ACAD SCI, V667, P454, DOI 10.1111/j.1749-6632.1992.tb51648.x; KEIJER J, 1991, J BIOL CHEM, V266, P10700; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Konstantinides S, 2001, CIRCULATION, V103, P576, DOI 10.1161/01.CIR.103.4.576; KOST C, 1992, J BIOL CHEM, V267, P12098; Krijanovski Y, 2001, BLOOD, V98, p530A; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; Kunapuli SP, 1996, J BIOL CHEM, V271, P11228, DOI 10.1074/jbc.271.19.11228; LAMMLE B, 1991, THROMB HAEMOSTASIS, V65, P117; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LEVI M, 1992, CIRCULATION, V85, P305, DOI 10.1161/01.CIR.85.1.305; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; Matsuno H, 1999, THROMB HAEMOSTASIS, V81, P601; MIMURO J, 1989, J BIOL CHEM, V264, P5058; NISHIKAWA K, 1992, BLOOD, V80, P1980; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1989, BLOOD, V74, P1989; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Shinohara C, 2000, J ANTIBIOT, V53, P262, DOI 10.7164/antibiotics.53.262; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TORRBROWN SR, 1993, THROMB RES, V72, P413, DOI 10.1016/0049-3848(93)90241-F; Urano T, 2001, J BIOL CHEM, V276, P24690, DOI 10.1074/jbc.M101751200; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; VON KaNEL R, 1992, BLOOD COAGUL FIBRIN, V3, P555, DOI 10.1097/00001721-199210000-00006; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; WIMAN B, 1990, SEMIN THROMB HEMOST, V16, P207, DOI 10.1055/s-2007-1002671; WU JH, 1995, THROMB HAEMOSTASIS, V74, P711; WU JH, 1995, ANAL BIOCHEM, V224, P83, DOI 10.1006/abio.1995.1011	66	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32677	32682		10.1074/jbc.M204010200	http://dx.doi.org/10.1074/jbc.M204010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082110	hybrid			2022-12-25	WOS:000177859000037
J	Chen, SC; Cao, L; Intengan, HD; Humphreys, M; Gardner, DG				Chen, SC; Cao, L; Intengan, HD; Humphreys, M; Gardner, DG			Osmoregulation of endothelial nitric-oxide synthase gene expression in inner medullary collecting duct cells - Role in activation of the type a natriuretic peptide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER PERMEABILITY; RAT; PROTEIN; MYOINOSITOL; TRANSCRIPTION; COTRANSPORTER; INSULIN; PATHWAY; CLONING; CGMP	Previously, we showed that increased extracellular tonicity promotes increased type A natriuretic peptide receptor (NPR-A) expression through a p38 MAPKbeta pathway in inner medullary collecting duct cells. The endothelial and inducible nitric-oxide synthase (eNOS and iNOS respectively) genes are also expressed in this nephron segment and are thought to play a role in regulating urinary sodium concentration. We sought to determine whether changes in tonicity might regulate NOS gene expression, and if so, whether these latter changes might be linked mechanistically to the increase in NPR-A gene expression. Increased extracellular tonicity effected a time-dependent reduction in eNOS and iNOS protein levels, eNOS mRNA levels, and eNOS gene promoter activity over the first 8 h of the incubation. Although levels of the eNOS mRNA and promoter activity had returned to normal after 24 h, eNOS protein levels remained low at 24-36 h, and recovery was not complete even at 48 h. The decrease in eNOS expression was signaled in large part through a p38 MAPK-dependent mechanism. Reduction in eNOS expression together with the concomitant decline in intracellular cyclic GMP levels appears to account for a significant portion of the p38 MAPK-dependent osmotic stimulation of NPR-A gene expression noted previously. Collectively, these findings support the existence of a complex regulatory circuitry in the cells of the inner medullary collecting duct linking two independent cyclic GMP-generating signal transduction systems involved in regulation of urinary sodium concentration.	Univ Calif San Francisco, Ctr Diabet, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Ctr Diabet, Metab Res Unit, 1109 Hlth Sci W, San Francisco, CA 94143 USA.			Anderson, Hope/0000-0001-6570-6678	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058812] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45637] Funding Source: Medline; NIDDK NIH HHS [DK58812] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; Begum N, 2000, AM J PHYSIOL-CELL PH, V278, pC81, DOI 10.1152/ajpcell.2000.278.1.C81; BURG MB, 1995, AM J PHYSIOL, V268, P983; Cai ZQ, 2000, AM J PHYSIOL-RENAL, V279, pF270, DOI 10.1152/ajprenal.2000.279.2.F270; CAO L, 1994, HYPERTENSION, V24, P329, DOI 10.1161/01.HYP.24.3.329; Cao L, 1998, AM J PHYSIOL-RENAL, V275, pF119, DOI 10.1152/ajprenal.1998.275.1.F119; CAO L, 1995, J BIOL CHEM, V270, P24891, DOI 10.1074/jbc.270.42.24891; Chan ED, 2001, AM J PHYSIOL-CELL PH, V280, pC441, DOI 10.1152/ajpcell.2001.280.3.C441; Chen SC, 2002, J BIOL CHEM, V277, P6037, DOI 10.1074/jbc.M111117200; Gardner WL, 1999, PSYCHOL SCI, V10, P321, DOI 10.1111/1467-9280.00162; GRENIER FC, 1981, AM J PHYSIOL, V241, pF94, DOI 10.1152/ajprenal.1981.241.1.F94; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KOHAN DE, 1994, AM J PHYSIOL, V266, pF291, DOI 10.1152/ajprenal.1994.266.2.F291; KOHAN DE, 1993, J CLIN INVEST, V91, P1235, DOI 10.1172/JCI116286; Kultz D, 1998, J EXP BIOL, V201, P3015; LUKE RG, 1973, AM J PHYSIOL, V224, P13, DOI 10.1152/ajplegacy.1973.224.1.13; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; NADLER SP, 1992, J CLIN INVEST, V90, P1458, DOI 10.1172/JCI116013; OISHI R, 1991, AM J PHYSIOL, V261, pF951, DOI 10.1152/ajprenal.1991.261.6.F951; OWADA A, 1994, J CLIN INVEST, V93, P556, DOI 10.1172/JCI117007; SCHARAMEK H, 1993, J AM SOC NEPHROL, V4, P206; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; THRASHER TN, 1984, AM J PHYSIOL, V247, pR76, DOI 10.1152/ajpregu.1984.247.1.R76; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; Vaziri ND, 1999, HYPERTENSION, V34, P1237, DOI 10.1161/01.HYP.34.6.1237; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WU G, 1999, AM J PHYSIOL, V276, pF874; YAMAUCHI A, 1994, J AM SOC NEPHROL, V5, P62; YOKOYAMA T, 1993, INVEST OPHTH VIS SCI, V34, P2512; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZEIDEL ML, 1993, AM J PHYSIOL, V265, pF159, DOI 10.1152/ajprenal.1993.265.2.F159; ZHOU C, 1994, INVEST OPHTH VIS SCI, V35, P1236	34	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32498	32504		10.1074/jbc.M202321200	http://dx.doi.org/10.1074/jbc.M202321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082097	hybrid			2022-12-25	WOS:000177859000015
J	Ghosh-Choudhury, N; Abboud, SL; Nishimura, R; Celeste, A; Mahimainathan, L; Choudhury, GG				Ghosh-Choudhury, N; Abboud, SL; Nishimura, R; Celeste, A; Mahimainathan, L; Choudhury, GG			Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; GLOMERULAR MESANGIAL CELLS; C-FOS; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; IN-VITRO; SURVIVAL; ACTIVATION; RECEPTORS; APOPTOSIS	The mechanism by which bone morphogenetic protein-2 (BMP-2) induces ostcoblast differentiation is not precisely known. We investigated the involvement of the phosphatidylinositol (PI) 3-kinase/Akt signal transduction pathway in modulation of this process. BMP-2 stimulated PI 3-kinase activity in osteogenic cells. Inhibition of PI 3-kinase activity with the specific inhibitor Ly-294002 prevented BNW-2-induced alkaline phosphatase, an early marker of osteoblast differentiation. Expression of dominant-negative PI 3-kinase also abolished osteoblastic induction of alkaline phosphatase in response to BMP-2, confirming the involvement of this lipid kinase in this process. BMP-2 stimulated Akt serine/threonine kinase activity in a PI 3-kinase-dependent manner in osteoblast precursor cells. Inhibition of Akt activity by a dominant-negative mutant of Akt blocked BMP-2-induced osteoblastic alkaline phosphatase activity. BMP-2 stimulates its own expression during osteoblast differentiation. Expression of dominantnegative PI 3-kinase or dominant-negative Akt inhibited BMP-2-induced BMP-2 transcription. Because all the known biological activities of BMP-2 are mediated by transcription via BMP-specific Smad proteins, we investigated the involvement of PI 3-kinase in Smad-dependent BMP-2 transcription. Smad5 stimulated BMP-2 transcription independent of addition of the ligand. Dominant-negative PI 3-kinase or dominant-negative Akt inhibited Smad5-dependent transcription of BMP-2. Furthermore dominant-negative Akt inhibited translocation of BMP-specific Smads into nucleus. Together these data provide the first evidence that activation of BMP receptor serine/threonine kinase stimulates the PI 3 kinase/Akt pathway and define a role for this signal transduction pathway in BMP-specific Smad function during osteoblast differentiation.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Osaka Univ, Fac Dent, Suita, Osaka 5650871, Japan; Genet Inst Inc, Cambridge, MA 01810 USA; S Texas Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Osaka University; Geriatric Research Education & Clinical Center	Choudhury, GG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	choudhury@uthscsa.edu		/0000-0001-5077-3552; Nishimura, Riko/0000-0001-7279-8363	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055815] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR042306, AR-42306] Funding Source: Medline; NIDDK NIH HHS [R01 DK55815] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; Choudhury GG, 2000, KIDNEY INT, V57, P908, DOI 10.1046/j.1523-1755.2000.00907.x; Choudhury GG, 2000, BIOCHEM BIOPH RES CO, V273, P1069, DOI 10.1006/bbrc.2000.3081; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIKE PT, 1994, J BIOL CHEM, V269, P16985; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; FUKUDA M, 1995, ONCOGENE, V11, P239; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Ghosh-Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; GhoshChoudhury N, 1997, BIOCHEM BIOPH RES CO, V231, P196, DOI 10.1006/bbrc.1996.5962; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756-3282(98)00053-2; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	61	249	271	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33361	33368		10.1074/jbc.M205053200	http://dx.doi.org/10.1074/jbc.M205053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12084724	hybrid			2022-12-25	WOS:000177859000125
J	Ippolito, DL; Temkin, PA; Rogalski, SL; Chavkin, C				Ippolito, DL; Temkin, PA; Rogalski, SL; Chavkin, C			N-terminal tyrosine residues within the potassium channel Kir3 modulate GTPase activity of G alpha(i).	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNELS; BETA-GAMMA-SUBUNITS; INFLAMMATORY PAIN; ACETYLCHOLINE-RECEPTOR; SIGNAL-TRANSDUCTION; ACTIVATING PROTEIN; CRYSTAL-STRUCTURE; TRANSITION-STATE; ACH CHANNEL; KINASE	trkB activation results in tyrosine phosphorylation of N-terminal Kir3 residues, decreasing channel activation. To determine the mechanism of the effect, we reconstituted Kir3, trkB, and the mu opioid receptor in Xenopus oocytes. Activation of trkB by BDNF (brain-derived neurotrophic factor) accelerated Kir3 deactivation following termination of mu opioid receptor signaling. Similarly, overexpression of RGS4, a GTpase-activating protein (GAP), accelerated Kir3 deactivation. Blocking GTPase activity with GTPgammaS also prevented Kir3 deactivation, and the GTPgammaS effect was not reversed by BDNF treatment. These results suggest that BDNF treatment did not reduce Kir3 affinity for Gbetagamma but rather acted to accelerate GTPase activity, like RGS4. Tyrosine phosphatase inhibition by peroxyvanadate pretreatment reversibly mimicked the BDNF/trkB effect, indicating that tyrosine phosphorylation of Kir3 may have caused the GTPase acceleration. Tyrosine to phenylalanine substitution in the N-terminal domain of Kir3.4 blocked the BDNF effect, supporting the hypothesis that phosphorylation of these tyrosines was responsible. Like other GAPs, Kir3.4 contains a tyrosine-arginine-glutamine motif that is thought to function by interacting with G protein catalytic domains to facilitate GTP hydrolysis. These data suggest that the N-terminal tyrosine hydroxyls in Kir3 normally mask the GAP activity and that modification by phosphorylation or phenylalanine substitution reveals the GAP domain. Thus, BDNF activation of trkB could inhibit Kir3 by facilitating channel deactivation.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Chavkin, Charles/G-2797-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007278, R01DA011672, R37DA011672] Funding Source: NIH RePORTER; NIDA NIH HHS [R37 DA011672, DA11672, T32 DA007278, R01 DA011672] Funding Source: Medline; NIGMS NIH HHS [GM07270, T32 GM007270] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alleva E, 2001, PHYSIOL BEHAV, V73, P313, DOI 10.1016/S0031-9384(01)00498-X; Bowlby MR, 1997, J GEN PHYSIOL, V110, P601, DOI 10.1085/jgp.110.5.601; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Cabot PJ, 2001, PAIN, V93, P207, DOI 10.1016/S0304-3959(01)00322-0; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1986, MOL BRAIN RES, V1, P201, DOI 10.1016/0169-328X(86)90026-4; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; GUTFREUND H, 1995, KINETICS LIFE SCI RE, P19; Haendeler J, 2000, REGUL PEPTIDES, V95, P1, DOI 10.1016/S0167-0115(00)00133-6; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Ikeda K, 2000, NEUROSCI RES, V38, P113, DOI 10.1016/S0168-0102(00)00144-9; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; Keren-Raifman T, 2001, FEBS LETT, V492, P20, DOI 10.1016/S0014-5793(01)02220-7; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Kovoor A, 2002, NEURON, V33, P6, DOI 10.1016/S0896-6273(01)00572-4; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Mannion RJ, 1999, P NATL ACAD SCI USA, V96, P9385, DOI 10.1073/pnas.96.16.9385; Mosser VA, 2002, J BIOL CHEM, V277, P922, DOI 10.1074/jbc.M104210200; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; SAKMANN B, 1983, SINGLE CHANNEL RECOR, P135; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Sprang SR, 1997, SCIENCE, V277, P329, DOI 10.1126/science.277.5324.329; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; Yi BA, 2001, P NATL ACAD SCI USA, V98, P11016, DOI 10.1073/pnas.191351798; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	46	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32692	32696		10.1074/jbc.M204407200	http://dx.doi.org/10.1074/jbc.M204407200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12082117	Green Accepted, hybrid			2022-12-25	WOS:000177859000039
J	Dahlgren, KN; Manelli, AM; Stine, WB; Baker, LK; Krafft, GA; LaDu, MJ				Dahlgren, KN; Manelli, AM; Stine, WB; Baker, LK; Krafft, GA; LaDu, MJ			Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN GENE; TRANSGENIC MICE; AGGREGATION PROPERTIES; SECONDARY STRUCTURE; DUTCH-TYPE; CONGO RED; MUTATION; NEURODEGENERATION	Genetic evidence predicts a causative role for amyloid-beta (Abeta) in Alzheimer's disease. Recent debate has focused on whether fibrils (amyloid) or soluble oligomers of Abeta are the active species that contribute to neurodegeneration and dementia. We developed two aggregation protocols for the consistent production of stable oligomeric or fibrillar preparations of Abeta-(1-42). Here we report that oligomers inhibit neuronal viability 10-fold more than fibrils and similar to40-fold more than unaggregated peptide, with oligomeric Abeta-(1-42)-induced inhibition significant at 10 nm. Under Abeta-(1-42) oligomer- and fibril-forming conditions, Abeta-(1-40) remains predominantly as unassembled monomer and had significantly less effect on neuronal viability than preparations of Abeta-(1-42). We applied the aggregation protocols developed for wild type Abeta-(1-42) to Abeta-(1-42) with the Dutch (E22Q) or Arctic (E22G) mutations. Oligomeric preparations of the mutations exhibited extensive protofibril and fibril formation, respectively, but were not consistently different from wild type Abeta-(1-42) in terms of inhibition of neuronal viability. However, fibrillar preparations of the mutants appeared larger and induced significantly more inhibition of neuronal viability than wild type Abeta-(1-42) fibril preparations. These data demonstrate that protocols developed to produce oligomeric and fibrillar Abeta-(1-42) are useful in distinguishing the structural and functional differences between Abeta-(1-42) and Abeta-(1-40) and genetic mutations of Abeta-(1-42).	Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Evanston NW Healthcare Res Inst, Dept Neurol, Evanston, IL 60201 USA; Northwestern Univ, Alzheimers Dis Core Ctr, Chicago, IL 60611 USA; Northwestern Univ, Dept Mol Pharmacol, Chicago, IL 60611 USA; Northwestern Univ, Dept Neurobiol & Physiol, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University	LaDu, MJ (corresponding author), Evanston NW Healthcare Res Inst, Dept Med, 1801 Maple Ave,Suite 6240, Evanston, IL 60201 USA.			LaDu, Mary Jo/0000-0003-2141-1450; Baker, Lorinda/0000-0002-4541-5109				Aksenova MV, 1996, NEUROSCI LETT, V211, P45, DOI 10.1016/0304-3940(96)12717-8; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; De Jonghe C, 1998, NEUROBIOL DIS, V5, P281, DOI 10.1006/nbdi.1998.0202; Demeester N, 2001, EUR J NEUROSCI, V13, P2015, DOI 10.1046/j.0953-816x.2001.01579.x; El-Agnaf OMA, 1998, EUR J BIOCHEM, V256, P560, DOI 10.1046/j.1432-1327.1998.2560560.x; Forloni G, 1997, J NEUROCHEM, V69, P2048, DOI 10.1046/j.1471-4159.1997.69052048.x; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; Haass C, 2001, NAT NEUROSCI, V4, P859, DOI 10.1038/nn0901-859; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Mbebi C, 2002, J BIOL CHEM, V277, P20979, DOI 10.1074/jbc.M107948200; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Monji A, 1999, NEUROSCI LETT, V266, P85, DOI 10.1016/S0304-3940(99)00273-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Roher AE, 2000, BBA-MOL BASIS DIS, V1502, P31, DOI 10.1016/S0925-4439(00)00030-2; Sajithlal G, 2002, J BIOL CHEM, V277, P6888, DOI 10.1074/jbc.M107627200; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sian AK, 2000, BIOCHEM J, V349, P299, DOI 10.1042/0264-6021:3490299; Small D H, 1998, Amyloid, V5, P301, DOI 10.3109/13506129809007304; SWAAB DF, 1997, CONNECTIONS COGNITIO, P83; Tagliavini F., 1999, ALZHEIMERS REP, V2, pS28; Terry RD, 2001, ANN NEUROL, V49, P684, DOI 10.1002/ana.1042; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; WHITSON JS, 1990, NEUROSCI LETT, V110, P319, DOI 10.1016/0304-3940(90)90867-9; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	69	1183	1266	1	131	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32046	32053		10.1074/jbc.M201750200	http://dx.doi.org/10.1074/jbc.M201750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12058030	hybrid			2022-12-25	WOS:000177718700093
J	Idres, N; Marill, J; Flexor, MA; Chabot, GC				Idres, N; Marill, J; Flexor, MA; Chabot, GC			Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PROMYELOCYTIC LEUKEMIA; BIOLOGICAL-ACTIVITY; NUCLEAR RECEPTOR; IDENTIFICATION; LIGAND; DIFFERENTIATION; PROLIFERATION; MATURATION	We have shown that four metabolites of all-trans-retinoic acid (ATRA) (4-oxo-, 4-OH-, 18-OH-, and 5,6-epoxy-RA) can induce maturation of NB4 promyelocytic leukemia cells (Idres, N., Benoit, G., Flexor, M. A., Lanotte, M., and Chabot, G. G. (2001) Cancer Res. 61, 700-705). To better understand the mechanism of action of ATRA metabolites and isomers, we assessed their binding to retinoic acid receptors (RARs) and activation of RAR-mediated transcription via a retinoic acid response element (RARE). Competition binding experiments with tritiated ATRA showed that all metabolites could bind to RARs with variable affinity. For transactivation studies, COS-7 cells were cotransfected with RARalpha, beta, or gamma expression vectors and the reporter plasmid RARE-tk-Luc, and the retinoid concentrations for half-maximal luciferase activity (EC50) were determined. All retinoids tested could activate the three RAR isotypes. The lowest EC50 value for RARalpha was with 9-cis-RA (13 nm), followed by 4-oxo-RA (33 nm), 5,6-epoxy-RA (77 rim), 13-cis-RA (124 nm), 18-OH-RA (162 nm), ATRA (169 nm), and 4-OH-RA (791 nm). For RARbeta, the EC50 values increased as follows: 4-oxo-RA (8 nm), ATRA (9 nm), 18-OH-RA (14 nm), 5,6-epoxy-RA (35 nm), 13-cis-RA (47 nm), 4-OH-RA (64 nm), and 9-cis-RA (173 nm). For RARgamma the EC50 values were: ATRA (2 nm), 5,6-epoxy-RA (4 nm), 18-11A (14 nm), 13-cis-RA (36 nm), 9-cis-RA (58 nm), 4-oxo-RA (89 nm), and 4-OH-RA (94 nm). By comparing the -fold induction of luciferase activity, all retinoids tested were equipotent at transactivating RARE-tk-Luc whatever the RAR considered. However, the best induction of the transcription was obtained for RARalpha, which was 5-fold higher than for RARbeta and 10-fold higher than for RARgamma. In conclusion, these data show that ATRA metabolites can bind to and activate the three RARs with variable relative affinity but with similar efficacy. These results suggest that ATRA metabolites may activate several signaling pathways and probably play an important role in cellular physiology and cancer therapy.	Inst Univ Hematol, INSERM, UMR 496, Hop St Louis,Ctr Hayem, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chabot, GC (corresponding author), Inst Univ Hematol, INSERM, UMR 496, Hop St Louis,Ctr Hayem, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		CHABOT, Guy G/F-7825-2013					ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Blaner William S., 1994, P229; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hong Waun Ki, 1994, P597; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Idres N, 2001, CANCER RES, V61, P700; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; RAMP U, 1994, BIOL CELL, V81, P31, DOI 10.1016/0248-4900(94)90052-3; REYNOLDS NJ, 1993, J PHARMACOL EXP THER, V266, P1636; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; vanderLeede BM, 1997, J BIOL CHEM, V272, P17921, DOI 10.1074/jbc.272.29.17921	25	129	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31491	31498		10.1074/jbc.M205016200	http://dx.doi.org/10.1074/jbc.M205016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12070176	hybrid			2022-12-25	WOS:000177718700027
J	Claycombe, KJ; Wu, DY; Nikolova-Karakashian, M; Palmer, H; Beharka, A; Paulson, KE; Meydani, SN				Claycombe, KJ; Wu, DY; Nikolova-Karakashian, M; Palmer, H; Beharka, A; Paulson, KE; Meydani, SN			Ceramide mediates age-associated increase in macrophage cyclooxygenase-2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CD8(+) T-CELLS; GENE-EXPRESSION; NEUTRAL SPHINGOMYELINASE; INDUCED APOPTOSIS; EPITHELIAL-CELLS; KAPPA-B; INDUCTION; LIPOPOLYSACCHARIDE; RATS	Previously, we showed that macrophages (MO) from old mice have significantly higher levels of lipopolysaccharide (LPS)-induced prostaglandin E-2 (PGE(2)) production than young mice, due to increased cyclooxygenase-2 (COX-2) mRNA levels. The aim of the current study was to determine the underlying mechanisms of age-associated increase in COX-2 gene expression. The results demonstrate that increased COX-2 mRNA expression in the old mice is due to a higher rate of transcription rather than increased stability of COX-2 mRNA. Furthermore, the results show that LPS-induced ceramide levels from the old mice are significantly higher than those of young mice, whereas there is no age-related difference in concentration of its down stream metabolite, sphingosine. The addition of ceramide in the presence or absence of LPS resulted in a significant increase in PGE2 production in a dose- and time-dependent manner. Inhibition of ceramide conversion to sphingosine had no effect on this ceramide-induced effect. The ceramide-induced up-regulation in PGE2 production was mediated through increase in COX activity and transcriptional up-regulation of COX-2 mRNA. Collectively, these data suggest that the age-associated increase in MO COX-2 mRNA is due to transcriptional up-regulation. Furthermore, this increase in transcription is mediated by higher cellular ceramide concentration in old MO compared with that of young MO.	Tufts Univ, USDA, Human Nutr Res Ctr, Nutr Immunol Lab, Boston, MA 02111 USA; Univ Kentucky, Sch Med, Dept Physiol, Lexington, KY 40536 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); University of Kentucky; Tufts University	Meydani, SN (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr, Nutr Immunol Lab, 711 Washington St, Boston, MA 02111 USA.				NIA NIH HHS [R01 AG 09140-09] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009140] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aureli T, 2000, NEUROCHEM RES, V25, P395, DOI 10.1023/A:1007501306623; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARBER SA, 1995, J IMMUNOL, V155, P2303; Barrios-Rodiles M, 1999, J IMMUNOL, V163, P963; Beharka AA, 2001, J GERONTOL A-BIOL, V56, pB81, DOI 10.1093/gerona/56.2.B81; Beharka AA, 1997, MECH AGEING DEV, V93, P59, DOI 10.1016/S0047-6374(96)01819-2; Bryl E, 2001, BLOOD, V98, P1100, DOI 10.1182/blood.V98.4.1100; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; Delion S, 1997, J LIPID RES, V38, P680; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Fagnoni FF, 2000, BLOOD, V95, P2860, DOI 10.1182/blood.V95.9.2860.009k35_2860_2868; FU JY, 1990, J BIOL CHEM, V265, P16737; FURUKAWA T, 1987, MECH AGEING DEV, V38, P107, DOI 10.1016/0047-6374(87)90071-6; Ginaldi L, 2000, GERONTOLOGY, V46, P242, DOI 10.1159/000022167; Ginaldi L, 2001, AM J HEMATOL, V67, P63, DOI 10.1002/ajh.1082; GIUSTO NM, 1992, LIPIDS, V27, P835, DOI 10.1007/BF02535859; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Harris N R., 2001, Pathophysiology, V8, P1, DOI 10.1016/S0928-4680(01)00064-5; Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V220, P681, DOI 10.1006/bbrc.1996.0464; HAYEK MG, 1994, J GERONTOL, V49, pB197, DOI 10.1093/geronj/49.5.B197; Hayek MG, 1997, J IMMUNOL, V159, P2445; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; Hsu HC, 2001, MECH AGEING DEV, V122, P305, DOI 10.1016/S0047-6374(00)00247-5; IMAKI T, 1995, J CLIN INVEST, V96, P231, DOI 10.1172/JCI118026; JENKINS KJ, 1988, J DAIRY SCI, V71, P435, DOI 10.3168/jds.S0022-0302(88)79573-9; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; Kim SS, 1997, BIOCHEM BIOPH RES CO, V237, P583, DOI 10.1006/bbrc.1997.7133; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Ma XM, 1999, MOL BRAIN RES, V68, P129, DOI 10.1016/S0169-328X(99)00080-7; MacKichan ML, 1999, J BIOL CHEM, V274, P1767, DOI 10.1074/jbc.274.3.1767; Marchell NL, 1998, J INVEST DERMATOL, V110, P383, DOI 10.1046/j.1523-1747.1998.00145.x; MASFERRER JL, 1994, J PHARMACOL EXP THER, V270, P1340; Memon RA, 2001, J LIPID RES, V42, P452; Millatt LJ, 2000, HYPERTENSION, V35, P643, DOI 10.1161/01.HYP.35.2.643; Newton R, 2000, BIOCHEM BIOPH RES CO, V277, P675, DOI 10.1006/bbrc.2000.3722; OXENKRUG GF, 1984, J PINEAL RES, V1, P181, DOI 10.1111/j.1600-079X.1984.tb00209.x; Pahlavani MA, 2000, IMMUNOPHARMACOLOGY, V49, P345, DOI 10.1016/S0162-3109(00)00254-X; Pahlavani MA, 2001, FEBS LETT, V491, P114, DOI 10.1016/S0014-5793(01)02184-6; PALESTINI P, 1993, J NEUROCHEM, V61, P955, DOI 10.1111/j.1471-4159.1993.tb03608.x; PETKOVA DH, 1988, EXP GERONTOL, V23, P19, DOI 10.1016/0531-5565(88)90016-2; Santana P, 1996, ENDOCRINOLOGY, V137, P2480, DOI 10.1210/en.137.6.2480; Sasaki T, 2001, NUCL MED BIOL, V28, P25, DOI 10.1016/S0969-8051(00)00180-3; Schneider C, 2000, LIPIDS, V35, P1259, DOI 10.1007/s11745-000-0642-7; SCHWAB R, 1985, IMMUNOLOGY, V55, P677; Selzner M, 2001, CANCER RES, V61, P1233; Shimizu N, 2000, J GERONTOL A-BIOL, V55, pB489, DOI 10.1093/gerona/55.10.B489; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Sugiki H, 2000, BRIT J DERMATOL, V143, P1154, DOI 10.1046/j.1365-2133.2000.03882.x; Uchida M, 2001, J BONE MINER RES, V16, P221, DOI 10.1359/jbmr.2001.16.2.221; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Vesper H, 1999, J NUTR, V129, P1239, DOI 10.1093/jn/129.7.1239; Vlahos R, 1999, BRIT J PHARMACOL, V126, P1315, DOI 10.1038/sj.bjp.0702424; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; Wu D, 1998, AM J PHYSIOL-CELL PH, V275, pC661, DOI 10.1152/ajpcell.1998.275.3.C661; Wu DY, 1999, AM J CLIN NUTR, V70, P536; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117; Zimmermann C, 2001, BRAIN RES, V895, P59, DOI 10.1016/S0006-8993(01)02028-5	61	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30784	30791		10.1074/jbc.M204463200	http://dx.doi.org/10.1074/jbc.M204463200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12072440	hybrid			2022-12-25	WOS:000177579800050
J	Erickson, AM; Nevarea, Z; Gipp, JJ; Mulcahy, RT				Erickson, AM; Nevarea, Z; Gipp, JJ; Mulcahy, RT			Identification of a variant antioxidant response element in the promoter of the human glutamate-cysteine ligase modifier subunit gene - Revision of the ARE consensus sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NAPHTHOFLAVONE-INDUCED EXPRESSION; HEAVY SUBUNIT; INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR; CATALYTIC SUBUNIT; LIGHT SUBUNIT; GLUTATHIONE; INDUCTION; CELLS	Constitutive and inducible expression of the gene encoding the modulator subunit of human glutamate-cysteine ligase (GCLM) is regulated by either of two regions of the promoter; an antioxidant response element (ARE) at -302:-291 and a 44-bp fragment (-346:-303) upstream of the ARE. This second region includes a consensus AP-1 site previously considered responsible for the enhancer activity of the upstream fragment. Deletion of a 165-bp fragment (-348:-183) including the ARE and upstream 44-bp fragment totally ablated t-butyl hydroquinone (tBHQ) inducibility of a GCLM promoter/luciferase transgene. Mutation analyses confirmed that both the ARE and the -346:-303 fragment could support induction following tBHQ exposure but demonstrated that induction in the latter case did not involve the AP-1 site at -341:-335. A region sharing significant homology with the consensus ARE sequence except for a single nucleotide mismatch at -330 (5'-TTACnnnGCA-3' versus 5'-TGACnnnGCA-3') was identified at the 5'-end of the 44-bp fragment immediately adjacent to the AP-1 site. A G in this position has been considered an invariant requirement of functional ARE sequences. Mutation of T -330 to A (a substitution known to ablate ARE function) or C eliminated basal and inducible expression. Substitution of a G at -330 enhanced basal expression relative to the wild-type sequence, but induction following tBHQ exposure was comparable, indicating that either sequence (5'-TTACnnnGCA-3' versus 5'-TGACnnnGCA-3') may function as an ARE, although the former sequence is less effective at directing basal expression. This possibility was confirmed by similar mutational analyses of the core sequence of hNQO1, a prototypic ARE. Electrophoretic mobility shift competition assays revealed that the 5'-TTACnnnGCA-3' sequence could compete with the hNQO1 ARE for protein binding but was less effective than a similar probe containing the 5'-TGACnnnGCA-3' motif. Probes including the T(-330)A or T(-330)C mutations were ineffective. These results reveal that the GCLM promoter includes two functional AREs, one having a variant sequence. The results indicate that the consensus ARE sequence should be revised to 5'-RTKAYnnnGCR-3'.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Mulcahy, RT (corresponding author), K4-554 CSC,600 Highland Ave, Madison, WI 53792 USA.			Barnes, Aileen/0000-0001-8021-4997	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009749] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 09749] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; Galloway DC, 1998, BIOCHEM J, V336, P535, DOI 10.1042/bj3360535; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Rahman I, 1998, FEBS LETT, V427, P129, DOI 10.1016/S0014-5793(98)00410-4; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373	23	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30730	30737		10.1074/jbc.M205225200	http://dx.doi.org/10.1074/jbc.M205225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12070177	hybrid			2022-12-25	WOS:000177579800043
J	Wu, HJ; Nash, JE; Zamorano, P; Garner, CC				Wu, HJ; Nash, JE; Zamorano, P; Garner, CC			Interaction of SAP97 with minus-end-directed actin motor myosin VI - Implications for AMPA receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; HUMAN HOMOLOG; UNCONVENTIONAL MYOSIN; POSTSYNAPTIC DENSITY; SYNAPTIC PLASTICITY; PROTEIN; MEMBRANE; ORGANIZATION; FILAMENTS; POLARITY	SAP97 is a modular protein composed of three PDZ domains, an SH3 domain, and a guanylate kinase-like domain. It has been implicated functionally in the assembly and structural stability of synaptic junctions as well as in the trafficking, recruitment, and localization of specific ion channels and neurotransmitter receptors. The N terminus of SAP97 (S97N) has been shown to play a key role in the selection of binding partners and the localization of SAP97 at adhesion sites, as well as the clustering of ion channels in heterologous cells. Using the S97N domain as bait in a yeast two-hybrid screen, we identified the minus-end-directed actin-based motor, myosin VI, as an S97N binding partner. Moreover, in light membrane fractions prepared from rat brain, we found that myosin VI and SAP97 form a trimeric complex with the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor subunit, GluR1. These data suggest that SAP97 may serve as a molecular link between GluR1 and the actin-dependent motor protein myosin VI during the dynamic translocation of AMPA receptors to and from the postsynaptic plasma membrane.	Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Garner, CC (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, 1201 Welch Rd, Palo Alto, CA 94304 USA.			Garner, Craig/0000-0003-1970-5417	NIA NIH HHS [AG 06569-09, AG 12978-02] Funding Source: Medline; NICHD NIH HHS [P50 HD 32901] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012978, P01AG006569] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Avraham KB, 1997, HUM MOL GENET, V6, P1225, DOI 10.1093/hmg/6.8.1225; Brenman JE, 1996, J NEUROSCI, V16, P7407; Budnik V, 1996, CURR OPIN NEUROBIOL, V6, P858, DOI 10.1016/S0959-4388(96)80038-9; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Man HY, 2000, CELL MOL LIFE SCI, V57, P1526, DOI 10.1007/PL00000637; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Mehta S, 2001, J BIOL CHEM, V276, P16092, DOI 10.1074/jbc.M100643200; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MOOSEKER MS, 1975, J CELL BIOL, V67, P725, DOI 10.1083/jcb.67.3.725; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; Reuver SM, 1998, J CELL SCI, V111, P1071; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SMALL JV, 1978, NATURE, V272, P638, DOI 10.1038/272638a0; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; Suter DM, 2000, J NEUROBIOL, V42, P370, DOI 10.1002/(SICI)1097-4695(20000215)42:3<370::AID-NEU8>3.3.CO;2-M; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TILNEY LG, 1980, J CELL BIOL, V86, P244, DOI 10.1083/jcb.86.1.244; TILNEY LG, 1981, J CELL BIOL, V90, P485, DOI 10.1083/jcb.90.2.485; Titus MA, 2000, CURR BIOL, V10, pR294, DOI 10.1016/S0960-9822(00)00433-4; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 1998, J CELL SCI, V111, P2365; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4	48	109	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30928	30934		10.1074/jbc.M203735200	http://dx.doi.org/10.1074/jbc.M203735200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12050163	hybrid			2022-12-25	WOS:000177579800068
J	Zamah, AM; Delahunty, M; Luttrell, LM; Lefkowitz, RJ				Zamah, AM; Delahunty, M; Luttrell, LM; Lefkowitz, RJ			Protein kinase A-mediated phosphorylation of the beta(2)-Adrenergic receptor regulates its coupling to G(s) and G(i) - Demonstration in a reconstituted system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MAMMALIAN BETA-2-ADRENERGIC RECEPTOR; ALPHA-SUBUNITS; FUNCTIONAL INTERACTIONS; ADENYLATE-CYCLASE; ACTIVATION; GS; IDENTIFICATION; BINDING; SITE	While classically viewed as a prototypic G(s) and adenylyl cyclase-coupled G protein-coupled receptor, recent studies have indicated that some aspects of beta(2)-adrenergic receptor (beta(2)-AR) signaling are inhibited by pertussis toxin, indicating that they are mediated by G(i)/G(o) proteins. These signals include activation of ERK MAPKs and Akt activation, as well as hypertrophic and antiapoptotic pathways in cardiac myocytes. Studies in cultured cells have suggested the hypothesis that protein kinase A (PKA)-mediated phosphorylation of the beta(2)-AR regulates its coupling specificity with respect to G(s) and G(i). Using a Chinese hamster ovary cell system, we show that mutant beta(2)-ARs with Ala substituted for Ser at consensus PKA sites stimulate robust cyclic AMP accumulation (G(s)) but are unable to activate ERK (G(i)). In contrast, Ser --> Asp mutants are dramatically impaired in their ability to activate adenylyl cyclase but are significantly more active than wild type receptor in activating ERK. Activation of adenylyl cyclase by wild type and Ser --> Ala mutant receptors is not altered by pertussis toxin, whereas adenylyl cyclase stimulated through the Ser --> Asp mutant is enhanced. Activation of ERK by wild type and Ser --> Asp receptors is inhibited by pertussis toxin. To further rigorously test the hypothesis, we utilized a completely reconstituted system of purified recombinant wild type and PKA phosphorylation site mutant beta(2)-ARs and heterotrimeric G(s) and G(i). G protein coupling was measured by receptor-mediated stimulation of GTPgammaS binding to the G protein. PKA-mediated phosphorylation of the beta(2)-AR significantly decreased its ability to couple to G(s), while simultaneously dramatically increasing its ability to couple to G(i). These results are reproduced when a purified recombinant Ser --> Asp mutant beta(2)-AR is tested, whereas the Ser --> Ala receptor resembles the unphosphorylated wild type. These results provide strong experimental support for the idea that PKA-mediated phosphorylation of the beta(2)-adrenergic receptor switches its predominant coupling from G(s) to G(i).	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [R01 HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; CARON MG, 1979, J BIOL CHEM, V254, P2923; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GERIONE RA, 1985, J BIOL CHEM, V269, P1493; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Lawler OA, 2001, J BIOL CHEM, V276, P33596, DOI 10.1074/jbc.M104434200; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEE E, 1994, METHOD ENZYMOL, V237, P146; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; STILES GL, 1984, PHYSIOL REV, V64, P661, DOI 10.1152/physrev.1984.64.2.661; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xiao RP, 1999, CIRC RES, V85, P1092; Xiao RP, 1999, CIRC RES, V84, P43; YUAN NY, 1994, J BIOL CHEM, V269, P23032; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	45	142	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31249	31256		10.1074/jbc.M202753200	http://dx.doi.org/10.1074/jbc.M202753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12063255	hybrid			2022-12-25	WOS:000177579800107
J	Hankeln, T; Jaenicke, V; Kiger, L; Dewilde, S; Ungerechts, G; Schmidt, M; Urban, J; Marden, MC; Moens, L; Burmester, T				Hankeln, T; Jaenicke, V; Kiger, L; Dewilde, S; Ungerechts, G; Schmidt, M; Urban, J; Marden, MC; Moens, L; Burmester, T			Characterization of Drosophila hemoglobin - Evidence for hemoglobin-mediated respiration in insects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIRONOMUS-THUMMI-THUMMI; GLOBIN GENE; MELANOGASTER; OXYGEN; NEUROGLOBIN; SEQUENCE; DIPTERA	In contrast to previous assumptions, the fruit fly Drosophila melanogaster possesses hemoglobin. This respiratory protein forms a monomer of about 17 kDa that is not exported into the hemolymph. Recombinant Drosophila hemoglobin displays a typical hexacoordinated deoxy spectrum and binds oxygen with an affinity of 0.12 torr. Four different hemoglobin transcripts have been identified, which are generated by two distinct promoters of the hemoglobin (glob1) gene but are identical in their coding regions. Putative binding sites for hypoxia-regulated transcription factors have been identified in the gene. Hemoglobin synthesis in Drosophila is mainly associated with the tracheal system and the fat body. This suggests that oxygen supply in insects may be more complex than thought previously and may depend on hemoglobin-mediated oxygen transport and storage in addition to simple diffusion.	Univ Mainz, Inst Mol Genet Biosafety Res & Consulting, D-55099 Mainz, Germany; INSERM, U473, F-94276 Le Kremlin Bicetre, France; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Univ Mainz, Genet Inst, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Antwerp; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Hankeln, T (corresponding author), Univ Mainz, Inst Mol Genet Biosafety Res & Consulting, D-55099 Mainz, Germany.		Kiger, Laurent/Q-1686-2018; Burmester, Thorsten/I-7225-2013; Marden, Michael/AAA-5923-2020; Marden, Michael C/G-3139-2012	Burmester, Thorsten/0000-0002-5772-7863; Marden, Michael C/0000-0002-5254-6385				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMICONI G, 1972, EUR J BIOCHEM, V31, P52, DOI 10.1111/j.1432-1033.1972.tb02499.x; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P1; BERGTROM G, 1976, J CELL BIOL, V69, P264, DOI 10.1083/jcb.69.2.264; BERGTROM G, 1977, INSECT BIOCHEM, V7, P313, DOI 10.1016/0020-1790(77)90031-2; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Burmester T, 1999, MOL BIOL EVOL, V16, P1809, DOI 10.1093/oxfordjournals.molbev.a026093; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dewilde S, 1998, J BIOL CHEM, V273, P32467, DOI 10.1074/jbc.273.49.32467; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Haddad GG, 1997, P NATL ACAD SCI USA, V94, P10809, DOI 10.1073/pnas.94.20.10809; Hankeln T, 1997, GENE, V205, P151, DOI 10.1016/S0378-1119(97)00518-0; Hankeln T, 1998, J MOL EVOL, V46, P589, DOI 10.1007/PL00006339; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; KEILIN D, 1946, BIOCHEM J, V40, P855, DOI 10.1042/bj0400855; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; OSMULSKI PA, 1986, COMP BIOCHEM PHYS B, V85, P701, DOI 10.1016/0305-0491(86)90166-5; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; TREWITT PM, 1986, J INSECT PHYSIOL, V32, P963, DOI 10.1016/0022-1910(86)90145-9; WEBER RE, 1985, COMP BIOCHEM PHYS B, V80, P747, DOI 10.1016/0305-0491(85)90456-0; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; WEGENER C, 1993, SURVINING HYPOXIA ME, P417; WELLS RMG, 1981, J COMP PHYSIOL, V142, P515, DOI 10.1007/BF00688984; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; WITTENBERG BA, 1965, BIOCHEM J, V96, P363, DOI 10.1042/bj0960363; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; [No title captured]	38	77	81	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29012	29017		10.1074/jbc.M204009200	http://dx.doi.org/10.1074/jbc.M204009200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048208	hybrid, Green Submitted			2022-12-25	WOS:000177342600087
J	Kanda, H; Igaki, T; Kanuka, H; Yagi, T; Miura, M				Kanda, H; Igaki, T; Kanuka, H; Yagi, T; Miura, M			Wengen, a member of the Drosophila tumor necrosis factor receptor superfamily, is required for Eiger signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH	We identified Wengen, the first member of the Drosophila tumor necrosis factor receptor (TNFR) superfamily. Wengen is a type III membrane protein with conserved cysteine-rich residues (TNFR homology domain) in the extracellular domain, a hallmark of the TNFR superfamily. wengen mRNA is expressed at all stages of Drosophila development. The small-eye phenotype caused by an eye-specific overexpression of a Drosophila TNF superfamily ligand, Eiger, was dramatically suppressed by down-regulation of Wengen using RNA interference. In addition, Wengen and Eiger physically interacted with each other through their TNFR homology domain and TNF homology domain, respectively. These results suggest that Wengen can act as a component of a functional receptor for Eiger. Our identification of Wengen and further genetic analysis should provide increased understanding of the evolutionarily conserved roles of TNF/TNFR superfamily proteins in normal development, as well as in some pathophysiological conditions.	RIKEN, Brain Sci Inst, Lab Cell Recovery Mechanisms, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Frontier Biosci, Labs Integrated Biol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan	RIKEN; Osaka University; Osaka University	Miura, M (corresponding author), RIKEN, Brain Sci Inst, Lab Cell Recovery Mechanisms, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Kanda, Hiroshi/L-1292-2013					Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; ENGELS WR, 1984, GENETICS, V107, P657; Hisahara S, 1998, J CELL SCI, V111, P667; IGKI T, 2002, EMBO J, V21, P3009; Kalderon D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	11	135	140	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28372	28375		10.1074/jbc.C200324200	http://dx.doi.org/10.1074/jbc.C200324200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12084706	hybrid			2022-12-25	WOS:000177342600004
J	Martinez-Chantar, ML; Corrales, FJ; Martinez-Cruz, LA; Garcia-Trevijano, ER; Huang, ZZ; Chen, LX; Kanel, G; Avila, MA; Mato, JM; Lu, SC				Martinez-Chantar, ML; Corrales, FJ; Martinez-Cruz, LA; Garcia-Trevijano, ER; Huang, ZZ; Chen, LX; Kanel, G; Avila, MA; Mato, JM; Lu, SC			Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A	FASEB JOURNAL			English	Article						S-adenosylmethionine; cytochrome P450 2E1; hepatocellular carcinoma; CCl4-induced hepatotoxicity	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; S-ADENOSYLMETHIONINE; RAT-LIVER; GLUTATHIONE SYNTHESIS; UNCOUPLING PROTEIN-2; CYTOCHROME-P450 2E1; GENE-EXPRESSION; HEPG2 CELLS; CYP2E1; HEPATOCYTES	In mammals, methionine metabolism occurs mainly in the liver via methionine adenosyltransferase-catalyzed conversion to S-adenosylmethionine. Of the two genes that encode methionine adenosyltransferase(MAT1A and MAT2A), MAT1A is mainly expressed in adult liver whereas MAT2A is expressed in all extrahepatic tissues. Mice lacking MAT1A have reduced hepatic S-adenosylmethionine content and hyperplasia and spontaneously develop nonalcoholic steatohepatitis. In this study, we examined whether chronic hepatic S-adenosylmethionine deficiency generates oxidative stress and predisposes to injury and malignant transformation. Differential gene expression in MAT1A knockout mice was analyzed following the criteria of the Gene Ontology Consortium. Susceptibility of MAT1A knockout mice to CCl4-induced hepatotoxicity and malignant transformation was determined in 3- and 18-month-old mice, respectively. Analysis of gene expression profiles revealed an abnormal expression of genes involved in the metabolism of lipids and carbohydrates in MAT1A knockout mice, a situation that is reminiscent of that found in diabetes, obesity, and other conditions associated with nonalcoholic steatohepatitis. This aberrant expression of metabolic genes in the knockout mice was associated with hyperglycemia, increased hepatic CYP2E1 and UCP2 expression and triglyceride levels, and reduced hepatic glutathione content. The knockout animals have increased lipid peroxidation and enhanced sensitivity to CCl4-induced liver damage, which was largely due to increased CYP2E1 expression because diallyl sulfide, an inhibitor of CYP2E1, prevented CCl4-induced liver injury. Hepatocellular carcinoma developed in more than half of the knockout mice by 18 months of age. Taken together, our findings define a critical role for S-adenosylmethionine in maintaining normal hepatic function and tumorigenesis of the liver.	Univ Navarra, Fac Med, Sch Med,Dept Med, Div Hepatol & Gene Therapy, Pamplona 31008, Spain; Univ So Calif, UCLA Res Ctr Alcohol Liver & Pancreat Dis, USC Liver Dis Res Ctr,USC Sch Med, Div Gastroenterol & Liver Dis, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA	University of Navarra; University of Southern California; University of Southern California	Mato, JM (corresponding author), Univ Navarra, Fac Med, Sch Med,Dept Med, Div Hepatol & Gene Therapy, Edificio Los Castanos, Pamplona 31008, Spain.	jmmato@unav.es; shellylu@hsc.usc.edu	Ruiz García-Trevijano, Elena R./ABE-1014-2021; Avila, Matias A/Y-6342-2019; Martinez-Cruz, Luis Alfonso/G-2285-2011; Mato, Jose/A-5187-2011; Martinez Chantar, Maria Luz/F-5190-2011	Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Avila, Matias A/0000-0001-6570-3557; Martinez-Cruz, Luis Alfonso/0000-0002-5856-9377; Mato, Jose/0000-0003-1264-3153; Lu, Shelly/0000-0003-2128-5407; Martinez Chantar, Maria Luz/0000-0002-6446-9911; Corrales, Fernando/0000-0002-0231-5159				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cai JX, 1998, CANCER RES, V58, P1444; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Carrington DB, 1998, ENVIRON ST, V2, P55; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; CHEN LS, 1994, BIOCHEM PHARMACOL, V48, P2199, DOI 10.1016/0006-2952(94)00435-8; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; DAVIS JF, 1993, J BIOL CHEM, V268, P16584; Enriquez A, 1999, BIOCHEM BIOPH RES CO, V255, P300, DOI 10.1006/bbrc.1999.0202; GARCEA R, 1989, CANCER RES, V49, P1850; Garcia-Trevijano ER, 2000, FASEB J, V14, P2511, DOI 10.1096/fj.00-0121com; Garcia-Trevijano ER, 2002, GASTROENTEROLOGY, V122, P1355, DOI 10.1053/gast.2002.33020; Gerard-Monnier D, 1998, CHEM RES TOXICOL, V11, P1176, DOI 10.1021/tx9701790; Huang ZZ, 2000, BBA-GENE STRUCT EXPR, V1493, P48, DOI 10.1016/S0167-4781(00)00156-1; Huang ZZ, 2001, FASEB J, V15, P19, DOI 10.1096/fj.00-0445fje; Kim ND, 1997, BIOCHEM PHARMACOL, V53, P261, DOI 10.1016/S0006-2952(96)00647-8; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; LATASA MU, 2001, FASEB J, DOI DOI 10.1096/FJ.00-0056FJE; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; LU SC, 1994, BIOCHEM PHARMACOL, V47, P859, DOI 10.1016/0006-2952(94)90486-3; Lu SC, 1999, HEPATOLOGY, V30, P209, DOI 10.1002/hep.510300134; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Majano PL, 2001, J HEPATOL, V35, P692, DOI 10.1016/S0168-8278(01)00208-2; Mari M, 2001, J BIOMED SCI, V8, P52, DOI 10.1159/000054013; Mari R, 2000, J BIOL CHEM, V275, P15563; MARTINDUCE C, 1988, HEPATOLOGY, V8, P65; Mato JM, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P47; Newberne P M, 1986, Adv Exp Med Biol, V206, P223; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; Robertson Graham, 2001, American Journal of Physiology, V281, pG1135; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; Weltman MD, 1996, GASTROENTEROLOGY, V111, P1645, DOI 10.1016/S0016-5085(96)70028-8; Wu CC, 2001, FOOD CHEM TOXICOL, V39, P563, DOI 10.1016/S0278-6915(00)00171-X; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799	38	207	216	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1292	+		10.1096/fj.02-0078fje	http://dx.doi.org/10.1096/fj.02-0078fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060674				2022-12-25	WOS:000176683900036
